PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Goetzl, EJ				Goetzl, Edward J.			Diverse pathways for nuclear signaling by G protein-coupled receptors and their ligands	FASEB JOURNAL			English	Article						signal transduction; lipid mediators; receptor downregulation; MAP kinases; peroxisome proliferator-activated receptor; transcription	TRANSLOCATION; ACID; ENDOCYTOSIS; LOCALIZATION; ACTIVATION; WINGLESS; PEA-15	Recent realization that plasma membrane G protein-coupled receptors (GPCRs) may translocate and establish ligand-responsive signaling complexes in other cellular structures has motivated studies of site-specific differences in transductional pathways. GPCRs and their ligands may signal transcription and other nuclear events by two basic mechanisms. The first consists of GPCR-complex activation of messengers that enter the nucleus and there initiate cell-modifying processes without the GPCR leaving the plasma membrane. The second encompasses entry into the nuclear membranes or matrix of either GPCR ligands, which bind to non-GPCR nuclear signaling proteins, proteolytic fragments of GPCRs capable of ligand-independent signaling, or intact GPCRs with transduction-competent factors that directly initiate or regulate transcriptional events. With the second mechanism, often concurrent down-regulation of plasma membrane GPCRs terminates signaling from the cell-surface and moves it into the nuclear domain. Site-dependent differences in signals from the same GPCR provide potentials for unique cellular abnormalities attributable to defective intracellular movement and distribution of a GPCR, site-specific alterations in ligand concentration, and limited intracellular bioavailability of pharmacological agents that can interact specifically with both nuclear and plasma membrane forms of a GPCR. Goetzl, E. J. Diverse pathways for nuclear signaling by G Protein-coupled receptors and their ligands.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol Microbiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), UC Box 0711,533 Parnassus Ave & 4th Ave, San Francisco, CA 94143 USA.	edward.goetzl@ucsf.edu						Ajenjo N, 2004, J BIOL CHEM, V279, P32813, DOI 10.1074/jbc.M313656200; Bkaily G, 2003, CAN J PHYSIOL PHARM, V81, P274, DOI 10.1139/Y03-007; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gaumont-Leclerc MF, 2004, J BIOL CHEM, V279, P46802, DOI 10.1074/jbc.M403893200; Gayral S, 2006, CIRC RES, V99, P132, DOI 10.1161/01.RES.0000232323.86227.8b; Gobeil F, 2003, J BIOL CHEM, V278, P38875, DOI 10.1074/jbc.M212481200; Gobeil F, 2006, J BIOL CHEM, V281, P16058, DOI 10.1074/jbc.M602219200; GOGOLAK P, 2006, IN PRESS BLOOD; Gripentrog JM, 2005, CELL SIGNAL, V17, P1300, DOI 10.1016/j.cellsig.2005.01.006; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Jafri F, 2006, J BIOL CHEM, V281, P19346, DOI 10.1074/jbc.M512643200; Kobayashi H, 2005, CELL SIGNAL, V17, P1248, DOI 10.1016/j.cellsig.2004.12.014; Ledeen RW, 2006, BBA-MOL CELL BIOL L, V1761, P588, DOI 10.1016/j.bbalip.2006.04.010; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIAO JJ, IN PRESS J BIOL CHEM; Mathew D, 2005, SCIENCE, V310, P1344, DOI 10.1126/science.1117051; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Packard M, 2002, CELL, V111, P319, DOI 10.1016/S0092-8674(02)01047-4; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Rosenfeldt HM, 2003, FASEB J, V17, P1789, DOI 10.1096/fj.02-0836com; Tsukahara T, 2006, J BIOL CHEM, V281, P3398, DOI 10.1074/jbc.M510843200; Waters CM, 2006, BIOCHEM J, V398, P55, DOI 10.1042/BJ20060155; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619; Zhao M, 2006, MOL PHARMACOL, V69, P66, DOI 10.1124/mol.105.016923	30	31	34	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					638	642		10.1096/fj.06-6624hyp	http://dx.doi.org/10.1096/fj.06-6624hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17194692				2022-12-28	WOS:000244686400002
J	Ptasinska, A; Wang, SB; Zhang, JH; Wesley, RA; Danner, RL				Ptasinska, Anetta; Wang, Shuibang; Zhang, Jianhua; Wesley, Robert A.; Danner, Robert L.			Nitric oxide activation of peroxisome proliferator-activated receptor gamma through a p38 MAPK signaling pathway	FASEB JOURNAL			English	Article						endothelial cells; gene expression; inflammation; peroxisome proliferator response element; vascular homeostasis	VASCULAR ENDOTHELIAL-CELLS; PPAR-GAMMA; HUMAN NEUTROPHILS; EXPRESSION; INHIBITION; KINASE; TRANSDUCTION; SUPEROXIDE; MECHANISMS; SYNTHASE	Both nitric oxide (NO center dot) and peroxisome proliferator-activated receptors (PPARs) protect the endothelium and regulate its function. Here, we tested for crosstalk between these signaling pathways. Human umbilical vein and hybrid EA.hy926 endothelial cells were exposed to S-nitrosoglutathione (GSNO) or diethylenetriamine NONOate (DETA NONOate). Electrophoretic mobility shift assays using PPAR-response element (PPRE) probe showed that NO center dot caused a rapid dose-dependent increase in PPAR gamma binding, an effect that was confirmed in vivo by chromatin inummoprecipitation. Conversely, N-G-monomethyl-L-arginine, a NOS inhibitor, decreased PPAR gamma binding. NO center dot-mediated PPAR gamma binding and NO center dot induction of cyclooxygenase-2 (COX-2), diacylglycerol (DAG) kinase alpha (DGK alpha), and heme oxygenase-1 (HO-1), genes with well-characterized PPRE motifs, were cGMP independent. NO center dot dose dependently activated p38 MAPK, and p38 MAPK inhibition with SB202190 or knockdown with siRNA was shown to block NO center dot activation of PPAR gamma. Likewise, p38 MAPK and PPAR gamma inhibitors or knockdown of either transcript all significantly blocked NO center dot induction of PPRE-regulated genes. PPAR gamma activation by p38 MAPK may contribute to the anti-inflammatory and cytoprotective effects of NO center dot in the vasculature. This crosstalk mechanism suggests new strategies for preventing and treating vascular dysfunction.	Ctr Clin, Crit Care Med Dept, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Danner, RL (corresponding author), Ctr Clin, Crit Care Med Dept, NIH, Bethesda, MD 20892 USA.	rdanner@cc.nih.gov			Intramural NIH HHS Funding Source: Medline; CLINICAL CENTER [ZIACL001164, Z01CL001158, Z01CL000188, ZIACL001158, ZIACL000188, Z01CL001164] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CLINICAL CENTER		AZUMA H, 1986, BRIT J PHARMACOL, V88, P411, DOI 10.1111/j.1476-5381.1986.tb10218.x; Beckman JS, 1999, CIRC RES, V85, P870, DOI 10.1161/01.RES.85.9.870; Bolego C, 2006, BIOCHEM BIOPH RES CO, V339, P188, DOI 10.1016/j.bbrc.2005.11.017; Caballero AE, 2003, METABOLISM, V52, P173, DOI 10.1053/meta.2003.50023; Chen YQE, 2003, VITAM HORM, V66, P157, DOI 10.1016/S0083-6729(03)01005-7; Cines DB, 1998, BLOOD, V91, P3527; Cobb JP, 1996, JAMA-J AM MED ASSOC, V275, P1192, DOI 10.1001/jama.275.15.1192; Corriveau CC, 1998, J INFECT DIS, V177, P116, DOI 10.1086/513829; Cui XL, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-151; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Estevez AG, 1998, J NEUROSCI, V18, P923; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02-06-0356; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Inoue I, 2001, METABOLISM, V50, P3, DOI 10.1053/meta.2001.19415; Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; Kota BP, 2005, PHARMACOL RES, V51, P85, DOI 10.1016/j.phrs.2004.07.012; KUBES P, 1993, FASEB J, V7, P1293, DOI 10.1096/fasebj.7.13.8405815; Ma PL, 2004, J LEUKOCYTE BIOL, V76, P278, DOI 10.1189/jlb.1203653; Marx N, 2004, CIRC RES, V94, P1168, DOI 10.1161/01.RES.0000127122.22685.0A; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; Marx N, 2000, J IMMUNOL, V164, P6503, DOI 10.4049/jimmunol.164.12.6503; MONCADA S, 1991, PHARMACOL REV, V43, P109; Pang LH, 2003, J IMMUNOL, V170, P1043, DOI 10.4049/jimmunol.170.2.1043; Patel RP, 2000, CARDIOVASC RES, V47, P465, DOI 10.1016/S0008-6363(00)00086-9; Pawliczak R, 2002, J BIOL CHEM, V277, P33153, DOI 10.1074/jbc.M200246200; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Polikandriotis JA, 2005, ARTERIOSCL THROM VAS, V25, P1810, DOI 10.1161/01.ATV.0000177805.65864.d4; Pontsler AV, 2002, J BIOL CHEM, V277, P13029, DOI 10.1074/jbc.M109546200; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Schopfer FJ, 2005, P NATL ACAD SCI USA, V102, P2340, DOI 10.1073/pnas.0408384102; Semple RK, 2006, J CLIN INVEST, V116, P581, DOI 10.1172/JCI28003; Takata Y, 2002, CIRC RES, V91, P427, DOI 10.1161/01.RES.0000031271.20771.4F; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; Verrier E, 2004, CIRC RES, V94, P1515, DOI 10.1161/01.RES.0000130527.92537.06; von Knethen A, 2002, J IMMUNOL, V169, P2619, DOI 10.4049/jimmunol.169.5.2619; Wang NP, 2002, J BIOL CHEM, V277, P34176, DOI 10.1074/jbc.M203436200; Wang SB, 1997, J BIOL CHEM, V272, P5959, DOI 10.1074/jbc.272.9.5959; Wang SB, 2006, NUCLEIC ACIDS RES, V34, P3044, DOI 10.1093/nar/gkl386; Wang WH, 2001, AM J PHYSIOL-CELL PH, V281, pC544, DOI 10.1152/ajpcell.2001.281.2.C544; Wever RMF, 1998, CIRCULATION, V97, P108, DOI 10.1161/01.CIR.97.1.108; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Zhang JH, 2003, J BIOL CHEM, V278, P29192, DOI 10.1074/jbc.M213043200; Zingarelli B, 2003, J IMMUNOL, V171, P6827, DOI 10.4049/jimmunol.171.12.6827	48	66	67	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					950	961		10.1096/fj.06-6822com	http://dx.doi.org/10.1096/fj.06-6822com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197391				2022-12-28	WOS:000244686400031
J	Su, Y; Zhang, L; Gao, X; Meng, FW; Wen, J; Zhou, H; Meng, AM; Chen, YG				Su, Ying; Zhang, Long; Gao, Xia; Meng, Fanwei; Wen, Jun; Zhou, Hu; Meng, Anming; Chen, Ye-Guang			The evolutionally conserved activity of Dapper2 in antagonizing TGF-beta signaling	FASEB JOURNAL			English	Article						receptor degradation; embryonic expression	ONE-EYED PINHEAD; MESODERM; ZEBRAFISH; IDENTIFICATION; SMAD7; INHIBITOR; REGULATOR; INTERACTS; RECEPTOR; PROTEIN	Dapper1 and Dapper2, two divergent members of the Dapper family, have been suggested to modulate Wnt and TGF-beta/Nodal signaling in Xenopus and zebrafish. To get a better understanding of Dapper function in mammals, we have cloned the mouse ortholog of zebrafish Dapper2, mDpr2 and investigated its function in regulating TGF-beta signaling activity. Here, we showed that, like zebrafish Dapper2, overexpression of mDpr2 inhibited the TGF-beta-induced expression of the Smad-responsive reporters and targeted TGF-beta type I receptor ALK5 for degradation in mammalian cells. Overexpression of mBpr2 in the zebrafish embryos led to a decrease in expression of the mesoderm marker no tail and goosecoid at the shield stage and eye fusion later, implying that mDpr2 may have an intrinsic in vivo activity similar to fish Dapper2 activity. The expression of mDpr2 was detected throughout the epiblast around the onset of gastrulation and in somites, the neural tube and gut at later stages in mouse embryos, implying a role in early embryonic development. Our data indicate that the function of Dpr2 as a negative regulator of the TGF-beta/Nodal signal pathway is evolutionally conserved, at least in part, in fish and mammals.	Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China	Tsinghua University	Meng, AM (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	mengam@mail.tsinghua.edu.cn; ygchen@tsinghua.edu.cn	Chen, Ye-Guang/L-6998-2019; Zhang, Long/AAT-6571-2021; Meng, Anming/A-4785-2012; Su, Ying/ABA-8545-2021; Su, Ying/M-5825-2013	Zhang, Long/0000-0001-8139-0474; Su, Ying/0000-0002-8466-0043; Su, Ying/0000-0002-8466-0043; Meng, Anming/0000-0001-7228-3431				Brott BK, 2005, DEV CELL, V8, P703, DOI 10.1016/j.devcel.2005.02.012; Chen YG, 2004, CELL RES, V14, P441, DOI 10.1038/sj.cr.7290246; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Correia KM, 2001, METHODS, V23, P335, DOI 10.1006/meth.2000.1145; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Gillhouse M, 2004, DEV DYNAM, V230, P403, DOI 10.1002/dvdy.20060; Gloy J, 2002, NAT CELL BIOL, V4, P351, DOI 10.1038/ncb784; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hikasa H, 2004, DEVELOPMENT, V131, P4725, DOI 10.1242/dev.01369; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Katoh M, 2005, INT J MOL MED, V15, P1045; Katoh M, 2003, INT J ONCOL, V22, P907; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schier AF, 1997, DEVELOPMENT, V124, P327; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Thisse C, 1999, DEVELOPMENT, V126, P229; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Waxman JS, 2004, DEVELOPMENT, V131, P5909, DOI 10.1242/dev.01520; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200; Zhang LX, 2004, SCIENCE, V306, P114, DOI 10.1126/science.1100569; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	34	52	59	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					682	690		10.1096/fj.06-6246com	http://dx.doi.org/10.1096/fj.06-6246com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197390				2022-12-28	WOS:000244686400007
J	Ferrand, N; Demange, C; Prunier, C; Seo, SR; Atfi, A				Ferrand, Nathalie; Demange, Christine; Prunier, Celine; Seo, Su Ryeon; Atfi, Azeddine			A mechanism for mutational inactivation of the homeodomain protein TGIF in holoprosencephaly	FASEB JOURNAL			English	Article						nuclear aggregates; severe forebrain and craniofacial malformations; transcriptional repression; ubiquitin-dependent degradation	SMAD2 TRANSCRIPTIONAL ACTIVITY; TGF-BETA RECEPTOR; DEGRADATION; COREPRESSOR; COMPLEX; GENE; MICE	The homeodomain protein TGIF functions as a negative modulator for multiple classes of transcription factors. Loss of function mutations in a single copy of TGIF result in holoprosencephaly, a developmental anomaly leading to severe forebrain and craniofacial malformations. However, the mechanisms by which these mutations disrupt the functions of TGIF remain to be elucidated. Here we show that a holoprosencephaly mutation (P63R) interferes with the ability of TGIF to act as a corepressor for c-Jun and Smad2, suggesting that this holoprosencephaly mutation may lead to a general defect in the TGIF protein. In fact, we observed that the P63R mutation affects folding of the TGIF protein, resulting in the disruption of the diffuse nuclear staining pattern characteristic of wild-type (WT) TGIF and the accumulation of TGIF in nuclear aggregates. We also show that the mutant TGIF.P63R is degraded more rapidly when compared with WT TGIF and that this degradation occurs through the ubiquitin-proteasome pathway. Furthermore, we observed that TGIF.P63R homodimerizes with WT TGIF to sequester it into nuclear aggregates and to enhance its ubiquitin-dependent degradation. These results reveal an important mechanism for the degradation of TGIF through the ubiquitin-proteasome pathway, whose deregulation might contribute to the development of human holoprosencephaly.	Hop St Antoine, INSERM, U 673, F-75571 Paris 12, France; Lerner Res Inst, Dept Cell Biol, Cleveland, OH USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Cleveland Clinic Foundation	Atfi, A (corresponding author), Hop St Antoine, INSERM, U 673, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	atfi@st-antoine.inserm.fr	Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273				Bartholin L, 2006, MOL CELL BIOL, V26, P990, DOI 10.1128/MCB.26.3.990-1001.2006; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 2000, J CELL BIOCHEM, P40; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Gripp KW, 2000, NAT GENET, V25, P205, DOI 10.1038/76074; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Mar L, 2006, MOL CELL BIOL, V26, P4302, DOI 10.1128/MCB.02156-05; Massague J, 2000, GENE DEV, V14, P627; Pessah M, 2002, J BIOL CHEM, V277, P29094, DOI 10.1074/jbc.M202831200; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Shen J, 2005, MOL CELL BIOL, V25, P3639, DOI 10.1128/MCB.25.9.3639-3647.2005; Wallis D, 2000, HUM MUTAT, V16, P99, DOI 10.1002/1098-1004(200008)16:2<99::AID-HUMU2>3.0.CO;2-0; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1	27	10	11	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					488	496		10.1096/fj.06-6423com	http://dx.doi.org/10.1096/fj.06-6423com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158784				2022-12-28	WOS:000244686300022
J	Lee, SY; Patton, SM; Henderson, RJ; Connor, JR				Lee, Sang Y.; Patton, Stephanie M.; Henderson, Rebecca J.; Connor, James R.			Consequences of expressing mutants of the hemochromatosis gene (HFE) into a human neuronal cell line lacking endogenous HFE	FASEB JOURNAL			English	Article						gene expression; iron-responsive elements; iron regulatory proteins; quantitative real-time polymerase chain reaction; oxidative stress	AMYOTROPHIC-LATERAL-SCLEROSIS; REGULATORY PROTEIN-ACTIVITY; LABILE IRON POOL; TRANSFERRIN RECEPTOR; ALZHEIMERS-DISEASE; INTRACELLULAR IRON; MUTATIONS; ASSOCIATION; C282Y; SYSTEM	HFE mutations have traditionally been associated with the iron overload disorder known as hemochromatosis. Recently, it has become clear that the two most common mutations in the HFE gene, H63D and C282Y, may be genetic modifiers for risk of neurodegenerative disorders and cancer, respectively. We developed human neuroblastoma stable cell lines that express either wild-type (WT) or mutant HFE to determine the cellular consequences of the mutant forms of HFE. The presence of the C282Y mutation was associated with relatively higher labile iron pool and iron regulatory protein activity than WT or H63D HFE. Targeted gene arrays revealed that the signal transduction pathway was up-regulated in the C282Y cells. H63D cells had higher levels of lipid peroxidation, protein oxidation, and lower mitochondrial membrane potential, suggesting higher baseline stress. This cell fine was also more vulnerable to exposure to oxidative stress agents and more responsive to iron chelation than the C282Y cells. These data demonstrate that the different mutations in the HFE gene have unique effects on the cells and provide insights into how the different mutations may have different clinical consequences. The results also raise multiple novel questions for future study about the function of the HFE protein.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Neurosurg,GM Leader Family Lab Alzheimers Di, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Connor, JR (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Neurosurg,GM Leader Family Lab Alzheimers Di, H110,500 Univ Dr,H110, Hershey, PA 17033 USA.	jconnor@psu.edu		Lee, Sang/0000-0003-3911-8316				Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; Berlin D, 2004, NEUROBIOL AGING, V25, P465, DOI 10.1016/j.neurobiolaging.2003.06.008; Best LG, 2001, CLIN GENET, V60, P68, DOI 10.1034/j.1399-0004.2001.600111.x; Byrnes V, 2001, GENET TEST, V5, P127, DOI 10.1089/109065701753145583; Cabantchik ZI, 1996, ANAL BIOCHEM, V233, P221, DOI 10.1006/abio.1996.0032; Candore G, 2003, MECH AGEING DEV, V124, P525, DOI 10.1016/S0047-6374(03)00031-9; Cauza E, 2003, AM J GASTROENTEROL, V98, P442, DOI 10.1016/S0002-9270(02)05890-2; Combarros O, 2003, DEMENT GERIATR COGN, V15, P151, DOI 10.1159/000068480; CONNNOR JR, 2006, IN PRESS J ALZHEIMER; Connor JR, 2001, J ALZHEIMERS DIS, V3, P471, DOI 10.3233/JAD-2001-3506; CONNOR JR, 1994, J NEUROSCI RES, V37, P461, DOI 10.1002/jnr.490370405; Corsi B, 1999, FEBS LETT, V460, P149, DOI 10.1016/S0014-5793(99)01330-7; Drakesmith H, 2002, P NATL ACAD SCI USA, V99, P15602, DOI 10.1073/pnas.242614699; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; Esteller M, 2002, CANCER RES, V62, P5902; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feeney GP, 2001, BBA-MOL CELL RES, V1538, P242, DOI 10.1016/S0167-4889(01)00075-1; Floor E, 2000, CELL MOL BIOL, V46, P709; Goodall EF, 2005, NEUROLOGY, V65, P934, DOI 10.1212/01.wnl.0000176032.94434.d4; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Hellerbrand C, 2003, CLIN GASTROENTEROL H, V1, P279, DOI 10.1016/S1542-3565(03)00132-0; Henderson RJ, 2005, BBA-MOL CELL RES, V1743, P162, DOI 10.1016/j.bbamcr.2004.09.032; Jason J, 2001, CLIN EXP IMMUNOL, V126, P466, DOI 10.1046/j.1365-2249.2001.01707.x; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Kallianpur AR, 2004, CANCER EPIDEM BIOMAR, V13, P205, DOI 10.1158/1055-9965.EPI-03-0188; Lee SY, 2005, NEUROBIOL AGING, V26, P803, DOI 10.1016/j.neurobiolaging.2004.08.006; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Li PA, 2004, MOL BRAIN RES, V120, P115, DOI 10.1016/j.molbrainres.2003.10.013; Lucotte G, 2001, BLOOD CELL MOL DIS, V27, P892, DOI 10.1006/bcmd.2001.0451; Malaspina A, 2001, J NEUROCHEM, V77, P132, DOI 10.1046/j.1471-4159.2001.t01-1-00231.x; Merryweather-Clarke AT, 2000, GENET TEST, V4, P183, DOI 10.1089/10906570050114902; Moalem S, 2000, AM J MED GENET, V95, P189, DOI 10.1002/1096-8628(20001113)95:2<189::AID-AJMG21>3.0.CO;2-7; Murphy S, 1998, TISSUE ANTIGENS, V52, P484, DOI 10.1111/j.1399-0039.1998.tb03076.x; Niederau Claus, 1999, Journal of Hepatology, V30, P6; Nonn L, 2003, MOL CANCER RES, V1, P682; Pantopoulos K, 2004, ANN NY ACAD SCI, V1012, P1, DOI 10.1196/annals.1306.001; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Powell LW, 2000, J HEPATOL, V32, P48, DOI 10.1016/S0168-8278(00)80415-8; Pulliam JF, 2003, AM J MED GENET B, V119B, P48, DOI 10.1002/ajmg.b.10069; Riedel HD, 1999, BLOOD, V94, P3915, DOI 10.1182/blood.V94.11.3915.423k27_3915_3921; Robb SJ, 1999, J NEUROSCI RES, V56, P166, DOI 10.1002/(SICI)1097-4547(19990415)56:2<166::AID-JNR6>3.0.CO;2-S; Robb SJ, 1998, BRAIN RES, V788, P125, DOI 10.1016/S0006-8993(97)01543-6; Robb SJ, 1999, J NEUROSCI RES, V55, P674, DOI 10.1002/(SICI)1097-4547(19990315)55:6<674::AID-JNR3>3.0.CO;2-J; Robson KJH, 2004, J MED GENET, V41, P261, DOI 10.1136/jmg.2003.015552; Roy CN, 2000, FEBS LETT, V484, P271, DOI 10.1016/S0014-5793(00)02173-6; Roy CN, 2002, J CELL PHYSIOL, V190, P218, DOI 10.1002/JCP.10056; Ryan E, 1998, BLOOD CELL MOL DIS, V24, P428, DOI 10.1006/bcmd.1998.0211; Ryan F, 2000, BRIT J BIOMED SCI, V57, P315; Sampietro M, 2001, NEUROBIOL AGING, V22, P563, DOI 10.1016/S0197-4580(01)00219-6; Shaheen NJ, 2003, JNCI-J NATL CANCER I, V95, P154, DOI 10.1093/jnci/95.2.154; Syrjakoski K, 2006, INT J CANCER, V118, P518, DOI 10.1002/ijc.21331; Wang J, 2003, BIOCHEM J, V370, P891, DOI 10.1042/BJ20021607; Wang XS, 2004, J NEUROL SCI, V227, P27, DOI 10.1016/j.jns.2004.08.003; Ye Z, 1999, BIOCHEM BIOPH RES CO, V264, P709, DOI 10.1006/bbrc.1999.1554; Yen AA, 2004, NEUROLOGY, V62, P1611, DOI 10.1212/01.WNL.0000123114.04644.CC; Zhang XS, 2005, GLIA, V52, P199, DOI 10.1002/glia.20235	58	52	53	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					564	576		10.1096/fj.06-6397com	http://dx.doi.org/10.1096/fj.06-6397com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17194693				2022-12-28	WOS:000244686300029
J	Furst, R; Schroeder, T; Eilken, HM; Bubik, MF; Kiemer, AK; Zahler, S; Vollmar, AM				Fuerst, Robert; Schroeder, Timm; Eilken, Hanna M.; Bubik, Martin F.; Kiemer, Alexandra K.; Zahler, Stefan; Vollmar, Angelika M.			MAPK phosphatase-1 represents a novel anti-inflammatory target of glucocorticoids in the human endothelium	FASEB JOURNAL			English	Article						inflammation	E-SELECTIN EXPRESSION; FACTOR-KAPPA-B; KINASE PHOSPHATASE-1; SIGNALING PATHWAYS; P38 MAPK; C-KIT; CELLS; RECEPTOR; ALPHA; ADHESION	Glucocorticoids are well-established anti-inflammatory drugs thought to mainly act by inhibition of proinflammatory transcription factors like NF-kappa B. In recent years, however, transcription factor-independent mechanisms of glucocorticoid action have been proposed, namely the influence on MAPK pathways. Here we identify MAPK phosphatase-1 ( MKP-1) as a pivotal mediator of the anti-inflammatory action of glucocorticoids in the human endothelium. We applied dexamethasone ( Dex) to TNF-alpha-activated human endothelial cells and used the adhesion molecule E-selectin as inflammatory read-out parameter. Dex is known to reduce the expression of E-selectin, which is largely regulated by NF-kappa B. Here, we communicate that Dex at low concentrations ( 1 - 100 nM) markedly attenuates E-selectin expression without affecting NF-kappa B. Importantly, Dex is able to increase the expression of MKP-1, which causes an inactivation of TNF-alpha-induced p38 MAPK and mediates inhibition of E-selectin expression. In endothelial MKP-1(-/-) cells differentiated from MKP-1(-/-) embryonic stem cells and in MKP-1-silenced human endothelial cells, Dex did not inhibit TNF-alpha-evoked E-selectin expression. Thus, our findings introduce MKP-1 as a novel and crucial mediator of the anti-inflammatory action of glucocorticoids at low concentrations in the human endothelium and highlight MKP-1 as an important and promising anti-inflammatory drug target.	Univ Munich, Dept Pharm, D-81377 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Stem Cell Res, Neuherberg, Germany; Univ Saarland, Inst Pharmaceut Biol, D-6600 Saarbrucken, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Saarland University	Furst, R (corresponding author), Univ Munich, Dept Pharm, Butenandtstr 5-13, D-81377 Munich, Germany.	robert.fuerst@cup.uni-muenchen.de	Fuerst, Robert/B-5815-2011; Schroeder, Timm/F-8448-2010; Kiemer, Alexandra K./I-9300-2012	Schroeder, Timm/0000-0001-9320-0252; Kiemer, Alexandra K./0000-0002-7224-9900; Furst, Robert/0000-0002-9926-7578; Zahler, Stefan/0000-0002-5140-7287				Brostjan C, 1997, J IMMUNOL, V158, P3836; CHEN CC, 1995, AGENT ACTION SUPPL, V47, P135; Clark AR, 2003, CURR OPIN PHARMACOL, V3, P404, DOI 10.1016/S1471-4892(03)00073-0; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; Dorfman K, 1996, ONCOGENE, V13, P925; Furst R, 2005, CIRC RES, V96, P43, DOI 10.1161/01.RES.0000151983.01148.06; Galley HF, 2004, BRIT J ANAESTH, V93, P105, DOI 10.1093/bja/aeh163; Gonzalez MV, 1999, FEBS LETT, V459, P272, DOI 10.1016/S0014-5793(99)01257-0; Hammer M, 2006, J EXP MED, V203, P15, DOI 10.1084/jem.20051753; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3; KODAMA H, 1994, EXP HEMATOL, V22, P979; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Ley K, 1998, CIRC RES, V83, P287, DOI 10.1161/01.RES.83.3.287; Limbourg FP, 2003, J MOL MED-JMM, V81, P168, DOI 10.1007/s00109-003-0418-y; Pelaia G, 2001, BIOCHEM PHARMACOL, V62, P1719, DOI 10.1016/S0006-2952(01)00791-2; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Schroeder T, 2003, P NATL ACAD SCI USA, V100, P4018, DOI 10.1073/pnas.0438008100; Weber NC, 2003, J LEUKOCYTE BIOL, V74, P932, DOI 10.1189/jlb.0603254; Zhao Q, 2006, J EXP MED, V203, P131, DOI 10.1084/jem.20051794	24	72	75	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2007	21	1					74	80		10.1096/fj.06-6752com	http://dx.doi.org/10.1096/fj.06-6752com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17099067	Green Submitted			2022-12-28	WOS:000243130200009
J	Xiao, ZX; Ehrlich, E; Luo, K; Xiong, Y; Yu, XF				Xiao, Zuoxiang; Ehrlich, Elana; Luo, Kun; Xiong, Yong; Yu, Xiao-Fang			Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G	FASEB JOURNAL			English	Article						HIV-1 virion; lentiviral Vif proteins; TPEN; zinc binding motif	E3 UBIQUITIN LIGASE; SOCS-BOX; ENZYME APOBEC3G; BINDING DOMAIN; DEGRADATION; COMPLEX; PROTEIN; PROTEASOME; ASSEMBLE; RECONSTITUTE	APOBEC3 proteins are cellular antiviral proteins that are targeted for proteasomal degradation by primate lentiviral Vif proteins. Vif acts as a substrate receptor for the Cullin5 (Cul5) E3 ubiquitin ligase, specifically interacting with Cul5 through a novel H-(x5)-C-(x17-18)-C-(x3-5)-H zinc binding motif. Using the membranepermeable zinc chelator, N,N,N',N'-tetrakis-(2-pyridylmethyl) ethylenediamine ( TPEN), we demonstrated a requirement for zinc for Vif function in vivo. Treatment with TPEN at an IC50 of 1.79 mu M inhibits Cul5 recruitment and APOBEC3G (A3G) degradation. Zinc chelation prevented Vif function in infectivity assays, allowing the virus to become sensitive to the antiviral activity of A3G. Zinc chelation had no effect on cellular Cul5-SOCS3 E3 ligase assembly, suggesting that zinc-dependent E3 ligase assembly may be unique to HIV-1 Vif, representing a new target for novel drug design.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Zhejiang Univ, Sch Med, Affiliated Hosp 2, Zhejiang, Peoples R China	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Zhejiang University	Yu, XF (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.	xfyu@jhsph.edu		xiong, yong/0000-0003-0678-4064	PHS HHS [A1062644] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bieniasz PD, 2004, NAT IMMUNOL, V5, P1109, DOI 10.1038/ni1125; Boyer JL, 2000, J BIOL CHEM, V275, P14969, DOI 10.1074/jbc.M000566200; Brower CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI 10.1073/pnas.162424199; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Goff SP, 2003, CELL, V114, P281, DOI 10.1016/S0092-8674(03)00602-0; Harris RS, 2004, NAT REV IMMUNOL, V4, P868, DOI 10.1038/nri1489; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kobayashi M, 2005, J BIOL CHEM, V280, P18573, DOI 10.1074/jbc.C500082200; Liu BD, 2005, J VIROL, V79, P9579, DOI 10.1128/JVI.79.15.9579-9587.2005; Liu BD, 2004, J VIROL, V78, P2072, DOI 10.1128/JVI.78.4.2072-2081.2004; Luo K, 2005, P NATL ACAD SCI USA, V102, P11444, DOI 10.1073/pnas.0502440102; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Navarro F, 2004, CURR OPIN IMMUNOL, V16, P477, DOI 10.1016/j.coi.2004.05.006; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rose KM, 2004, TRENDS MOL MED, V10, P291, DOI 10.1016/j.molmed.2004.04.008; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Turelli P, 2005, SCIENCE, V307, P1061, DOI 10.1126/science.1105964; Xiao ZX, 2006, VIROLOGY, V349, P290, DOI 10.1016/j.virol.2006.02.002; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204	29	79	88	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					217	222		10.1096/fj.06-6773com	http://dx.doi.org/10.1096/fj.06-6773com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135358				2022-12-28	WOS:000243130200023
J	Park, CH; Kang, JS; Shin, YH; Chang, MY; Chung, S; Koh, HC; Zhu, MH; Oh, SB; Lee, YS; Panagiotakos, G; Tabar, V; Studer, L; Lee, SH				Park, Chang-Hwan; Kang, Jin Sun; Shin, Yeon Ho; Chang, Mi-Yoon; Chung, Seungsoo; Koh, Hyun-Chul; Zhu, Mei Hong; Oh, Seog Bae; Lee, Yong-Sung; Panagiotakos, Georgia; Tabar, Vivian; Studer, Lorenz; Lee, Sang-Hun			Acquisition of in vitro and in vivo functionality of Nurr1-induced dopamine neurons	FASEB JOURNAL			English	Article						Parkinson's disease; neural precursor cell; transplantation; dopaminergic differentiation; dopamine neuron; Bcl-XL; Sonic hedgehog; Mash1	NEURAL PROGENITOR CELLS; LOOP-HELIX FACTORS; STEM-CELLS; NIGRAL TRANSPLANTS; PRECURSOR CELLS; PRONEURAL GENES; GROWTH-FACTOR; DIFFERENTIATION; NURR1; INDUCTION	Neural precursor cells provide an expandable source of neurons and glia for basic and translational applications. However, little progress has been made in directing naive neural precursors toward specific neuronal fates such as midbrain dopamine (DA) neurons. We have recently demonstrated that transgenic expression of the nuclear orphan receptor Nurr1 is sufficient to drive dopaminergic differentiation of forebrain embryonic rat neural precursors in vitro. However, Nurr1-induced DA neurons exhibit immature neuronal morphologies and functional properties and are unable to induce behavioral recovery in rodent models of Parkinson's disease (PD). Here, we report on the identification of key genetic factors that drive morphological and functional differentiation of Nurr1-derived DA neurons. We show that coexpression of Nurr1, Bcl-XL, and Sonic hedgehog (SHH) or Nurr1 and the proneural bHLH factor Mash1 is sufficient to drive naive rat forebrain precursors into neurons exhibiting the biochemical, electrophysiological, and functional properties of DA neuron in vitro. On transplantation into the striatum of Parkinsonian rats, precursor cells engineered with Nurr1/SHH/Bcl-XL or Nurr1/Mash1 survived in vivo and differentiated into mature DA neurons that can reverse the behavioral deficits in the grafted animals.-Park, C.-H., Kang, J. S., Shin, Y. H., Chang, M.-Y., Chung, S., Koh, H.-C., Zhu, M. H., Oh, S. B., Lee, Y.-S., Panagiotakos, G., Tabar, V., Studer, L., and Lee, S.-H. Acquisition of in vitro and in vivo functionality of Nurr1-induced dopamine neurons.	Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Dept Pharmacol, Seoul 133791, South Korea; Hanyang Univ, Inst Mental Hlth, Seoul 133791, South Korea; Yonsei Univ, Coll Med, Dept Physiol, Seoul 120749, South Korea; Seoul Natl Univ, Coll Dent, Dept Physiol, Seoul 151, South Korea; Seoul Natl Univ, Dent Res Inst, Seoul 151, South Korea; Sloan Kettering Canc Inst, Lab Stem Cell & Tumor Biol, New York, NY USA	Hanyang University; Hanyang University; Hanyang University; Hanyang University; Yonsei University; Yonsei University Health System; Seoul National University (SNU); Seoul National University (SNU); Memorial Sloan Kettering Cancer Center	Lee, SH (corresponding author), Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, 17 Haengdang Dong, Seoul 133791, South Korea.	leesh@hanyang.ac.kr	Studer, Lorenz/ABH-1491-2021; lee, sang hun/Q-4650-2019; Zhu, Mei Hong/E-7786-2012; OH, Seog Bae/AAQ-2478-2020	Studer, Lorenz/0000-0003-0741-7987; lee, sang hun/0000-0002-9005-5966; Chung, Seungsoo/0000-0002-3119-9628; PANAGIOTAKOS, GEORGIA/0000-0001-9444-2480				Andersson E, 2006, DEVELOPMENT, V133, P507, DOI 10.1242/dev.02224; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Campos-Ortega JA, 1998, INT J DEV BIOL, V42, P291; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; Chang MY, 2004, DEV BRAIN RES, V153, P89, DOI 10.1016/j.devbrainres.2004.08.003; Chang MY, 2003, MOL CELL NEUROSCI, V23, P414, DOI 10.1016/S1044-7431(03)00068-X; Charron F, 2003, CELL, V113, P11, DOI 10.1016/S0092-8674(03)00199-5; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Dass B, 2005, J NEURAL TRANSM, V112, P763, DOI 10.1007/s00702-004-0227-7; Holm KH, 2001, NEUROSCIENCE, V104, P397, DOI 10.1016/S0306-4522(01)00098-7; Hynes M, 2000, NAT NEUROSCI, V3, P41, DOI 10.1038/71114; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Jonas EA, 2003, J NEUROSCI, V23, P8423; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kele J, 2006, DEVELOPMENT, V133, P495, DOI 10.1242/dev.02223; Kim JY, 2003, J NEUROCHEM, V85, P1443, DOI 10.1046/j.1471-4159.2003.01780.x; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Lee JY, 2003, NEUROREPORT, V14, P1401, DOI 10.1097/01.wnr.0000078542.07662.4b; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Miao NN, 1997, J NEUROSCI, V17, P5891; Modolell J, 1997, PERSPECT DEV NEUROBI, V4, P285; Oh YJ, 1996, NEUROSCI LETT, V202, P161, DOI 10.1016/0304-3940(95)12235-4; OLSSON M, 1995, J NEUROSCI, V15, P3863; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Park CH, 2005, J NEUROCHEM, V92, P1265, DOI 10.1111/j.1471-4159.2004.03006.x; Park CH, 2006, J CELL SCI, V119, P2310, DOI 10.1242/jcs.02955; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; Quinn SM, 1999, J NEUROSCI RES, V57, P590, DOI 10.1002/(SICI)1097-4547(19990901)57:5<590::AID-JNR2>3.0.CO;2-X; Rafuse VF, 2005, NEUROSCIENCE, V131, P899, DOI 10.1016/j.neuroscience.2004.11.048; RAYPORT S, 1992, J NEUROSCI, V12, P4264; Rohrbacher J, 2000, NEUROSCIENCE, V97, P703, DOI 10.1016/S0306-4522(00)00046-4; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Shim JW, 2004, J NEUROSCI, V24, P843, DOI 10.1523/JNEUROSCI.3977-03.2004; So PL, 2006, DEV BIOL, V298, P167, DOI 10.1016/j.ydbio.2006.06.027; Thibert C, 2003, SCIENCE, V301, P843, DOI 10.1126/science.1085405; Tsuboi K, 2002, EXP NEUROL, V173, P95, DOI 10.1006/exnr.2001.7825; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Yan J, 2001, J NEUROCHEM, V76, P307, DOI 10.1046/j.1471-4159.2001.00073.x; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	43	40	44	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2553	+		10.1096/fj.06-6159fje	http://dx.doi.org/10.1096/fj.06-6159fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077287				2022-12-28	WOS:000242490700021
J	Tian, LJ; Chen, L; McClafferty, H; Sailer, CA; Ruth, P; Knaus, HG; Shipston, MJ				Tian, Lijun; Chen, Lie; McClafferty, Heather; Sailer, Claudia A.; Ruth, Peter; Knaus, Hans-Guenther; Shipston, Michael J.			A noncanonical SH3 domain binding motif links BK channels to the actin cytoskeleton via the SH3 adapter cortactin	FASEB JOURNAL			English	Article						KCNMA1; Src homology 3 domain; macromolecular signaling complex	CA2+-ACTIVATED K+ CHANNELS; ACTIVATED POTASSIUM CHANNEL; DEPENDENT PROTEIN-KINASE; RAT HIPPOCAMPAL-NEURONS; LARGE-CONDUCTANCE; TRANSMITTER RELEASE; SIGNALING COMPLEX; ALPHA-SUBUNITS; ION CHANNELS; MICE LACKING	Calcium-activated potassium (BK) channels play a central role in regulating multiple physiological processes, from the control of blood flow to neuronal excitability. Coordinated regulation of BK channel activity by changes in actin cytoskeleton dynamics has been implicated in several of these processes and related disease states such as epilepsy and stroke. However, how BK channels interact with the actin cytoskeleton is essentially unknown. Here we demonstrate noncanonical Src homology domain 3 (SH3) binding site motifs in the intracellular C terminus of the BK channel pore-forming alpha-subunit that are conserved from fish to humans. These noncanonical motifs target multiple SH3 domain cellular signaling proteins to BK channels, including the SH3 adapter protein cortactin (EMS1). We demonstrate that cortactin provides a molecular bridge between BK channels and the cortical actin cytoskeleton in cells. Disruption of the SH3-mediated interaction prevents the regulation of BK channel activity controlled by changes in actin cytoskeletal dynamics. Targeting of cortactin to BK channels via a novel, noncanonical SH3 domain binding motif has important implications for the coordination of BK channel function in normal physiology and disease.	Univ Edinburgh, Sch Biomed Sci, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland; Med Univ Innsbruck, Div Mol & Cellular Pharmacol, Innsbruck, Austria; Univ Tubingen, Inst Pharmazeut, Tubingen, Germany	University of Edinburgh; Medical University of Innsbruck; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Shipston, MJ (corresponding author), Univ Edinburgh, Sch Biomed Sci, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland.	mike.shipston@ed.ac.uk	Shipston, Mike/C-7309-2013	Shipston, Mike/0000-0001-7544-582X; Chen, Lie/0000-0001-9764-4299	Wellcome Trust [067683] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANKER G, 1988, NATURE, V336, P185, DOI 10.1038/336185a0; Berry DM, 2002, CURR BIOL, V12, P1336, DOI 10.1016/S0960-9822(02)01038-2; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Brainard AM, 2005, AM J PHYSIOL-CELL PH, V289, pC49, DOI 10.1152/ajpcell.00399.2004; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Carre-Pierrat M, 2006, J MOL BIOL, V358, P387, DOI 10.1016/j.jmb.2006.02.037; Chen L, 2005, J BIOL CHEM, V280, P33599, DOI 10.1074/jbc.M505383200; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737; Du W, 2005, NAT GENET, V37, P733, DOI 10.1038/ng1585; Edgerton JR, 2003, J PHYSIOL-LONDON, V548, P53, DOI 10.1113/jphysiol.2002.027854; Ehrhardt AG, 1996, J PHYSIOL-LONDON, V496, P663, DOI 10.1113/jphysiol.1996.sp021717; Endres M, 1999, J CLIN INVEST, V103, P347, DOI 10.1172/JCI4953; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Gribkoff VK, 2001, NEUROSCIENTIST, V7, P166, DOI 10.1177/107385840100700211; Gribkoff VK, 2001, NAT MED, V7, P471, DOI 10.1038/86546; Grunnet M, 2004, J BIOL CHEM, V279, P36445, DOI 10.1074/jbc.M402254200; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Harvey J, 2000, J PHYSIOL-LONDON, V527, P95, DOI 10.1111/j.1469-7793.2000.00095.x; Hegle AP, 2006, P NATL ACAD SCI USA, V103, P2886, DOI 10.1073/pnas.0505909103; Hu H, 2001, J NEUROSCI, V21, P9585, DOI 10.1523/JNEUROSCI.21-24-09585.2001; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Knaus HG, 1996, J NEUROSCI, V16, P955; Kraft R, 2000, J MEMBRANE BIOL, V175, P25, DOI 10.1007/s002320001052; LANCASTER B, 1991, J NEUROSCI, V11, P23; Lesage F, 2004, P NATL ACAD SCI USA, V101, P671, DOI 10.1073/pnas.0307681100; Levitan IB, 2006, NAT NEUROSCI, V9, P305, DOI 10.1038/nn1647; Levitan IB, 1999, ADV SEC MESS PHOSPH, V33, P3; Li CY, 2005, PHARMACOL THERAPEUT, V108, P208, DOI 10.1016/j.pharmthera.2005.04.004; Liu GX, 2004, EMBO J, V23, P2196, DOI 10.1038/sj.emboj.7600228; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Lu R, 2006, J PHYSIOL-LONDON, V570, P65, DOI 10.1113/jphysiol.2005.098913; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; Mayer BJ, 2001, J CELL SCI, V114, P1253; McCartney CE, 2005, P NATL ACAD SCI USA, V102, P17870, DOI 10.1073/pnas.0505270102; Meredith AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200; O'Malley D, 2005, FASEB J, V19, P1917, DOI 10.1096/fj.05-4166fje; Park SM, 2004, FEBS LETT, V570, P143, DOI 10.1016/j.febslet.2004.06.037; Petrecca K, 2000, J NEUROSCI, V20, P8736; Piao L, 2003, PFLUG ARCH EUR J PHY, V446, P523, DOI 10.1007/s00424-003-1079-y; Raffaelli G, 2004, J PHYSIOL-LONDON, V557, P147, DOI 10.1113/jphysiol.2004.062661; Rezzonico R, 2002, J BONE MINER RES, V17, P869, DOI 10.1359/jbmr.2002.17.5.869; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Sailer CA, 2006, EUR J NEUROSCI, V24, P442, DOI 10.1111/j.1460-9568.2006.04936.x; Sausbier M, 2005, CIRCULATION, V112, P60, DOI 10.1161/01.CIR.0000156448.74296.FE; Schubert R, 2001, TRENDS PHARMACOL SCI, V22, P505, DOI 10.1016/S0165-6147(00)01775-2; Shanley LJ, 2002, J PHYSIOL-LONDON, V545, P933, DOI 10.1113/jphysiol.2002.029488; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Tang XD, 2004, NAT STRUCT MOL BIOL, V11, P171, DOI 10.1038/nsmb725; Tian L, 2004, P NATL ACAD SCI USA, V101, P11897, DOI 10.1073/pnas.0402590101; Tian LJ, 2003, J BIOL CHEM, V278, P8669, DOI 10.1074/jbc.M211661200; Tian LJ, 2001, J BIOL CHEM, V276, P7717, DOI 10.1074/jbc.C000741200; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wang XL, 2005, J BIOL CHEM, V280, P11656, DOI 10.1074/jbc.M410987200; Wang ZR, 2004, AM J PHYSIOL-HEART C, V286, pH749, DOI 10.1152/ajpheart.00398.2003; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Werner ME, 2005, J PHYSIOL-LONDON, V567, P545, DOI 10.1113/jphysiol.2005.093823; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; Zhou Q, 2001, P NATL ACAD SCI USA, V98, P1261, DOI 10.1073/pnas.031573798	61	65	66	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2588	+		10.1096/fj.06-6152fje	http://dx.doi.org/10.1096/fj.06-6152fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065230				2022-12-28	WOS:000242490700033
J	Riou, P; Saffroy, R; Chenailler, C; Franc, B; Gentile, C; Rubinstein, E; Resink, T; Debuire, B; Piatier-Tonneau, D; Lemoine, A				Riou, Philippe; Saffroy, Raphael; Chenailler, Catherine; Franc, Brigitte; Gentile, Carla; Rubinstein, Eric; Resink, Therese; Debuire, Brigitte; Piatier-Tonneau, Dominique; Lemoine, Antoinette			Expression of T-cadherin in tumor cells influences invasive potential of human hepatocellular carcinoma	FASEB JOURNAL			English	Article						primary tumors; cadherin switch; cell invasion; hepatoma cell lines; RNA interference	EPITHELIAL-MESENCHYMAL TRANSITION; ADHESION MOLECULE; TRANSENDOTHELIAL MIGRATION; N-CADHERIN; IDENTIFICATION; POLARIZATION; ASSOCIATION; PROGRESSION; DOMAINS; CATENIN	Overexpression of T-cadherin (T-cad) transcripts occurs in approximate to 50% of human hepatocellular carcinomas (HCCs). To elucidate T-cad functions in HCC, we examined T-cad protein expression in normal and tumoral human livers and hepatoma cell lines and investigated its influence on invasive potential of HCC using RNA interference silencing of T-cad expression in Mahlavu cells. Whereas T-cad expression was restricted to endothelial cells (EC) from large blood vessels in normal livers, it was up-regulated in sinusoidal EC from 8/15 invasive HCCs. Importantly, in three of them (38%) T-cad was detected in tumor cells within regions in which E-cadherin expression was absent. Among six hepatoma cell lines, only Mahlavu expressed T-cad but not E-cadherin. T-cad exhibited a globally punctuate distribution in quiescent Mahlavu and additionally it concentrated at the leading edge of migrating cells. Matrigel invasion assay revealed that Mahlavu possess a high invasive potential that was significantly inhibited by T-cad silencing. Wound healing and random motility assays demonstrated that inhibition of T-cad expression in Mahlavu significantly reduced their motility. We propose that T-cad expression in tumor cells might occur by cadherin-switching during epithelial-mesenchymal transition and may represent an additional mechanism contributing to HCC metastasis.	Univ Paris 11, AP HP, Serv Biochim & Biol Mol, Hop Univ Paul Brousse, F-94804 Villejuif, France; Univ Paris 11, INSERM, U602, F-94804 Villejuif, France; Univ Paris 06, CNRS, UMR 7091, Villejuif, France; Univ Versailles, AP HP, Hop Ambroise Pare, Serv Anat Pathol, Boulogne, France; Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; University of Basel	Lemoine, A (corresponding author), Univ Paris 11, AP HP, Serv Biochim & Biol Mol, Hop Univ Paul Brousse, 14 Ave Paul Vaillant Couturier, F-94804 Villejuif, France.	antoinette.lemoine@pbr.ap-hop-paris.fr	Rubinstein, Eric/B-4650-2019; Gentile, Carla/AAB-1540-2020	Rubinstein, Eric/0000-0001-7623-9665; Gentile, Carla/0000-0001-5861-3342; SAFFROY, RAPHAEL/0000-0002-9878-3669				Adachi Y, 2006, VIRCHOWS ARCH, V448, P311, DOI 10.1007/s00428-005-0098-9; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Fiorentino M, 2004, CLIN CANCER RES, V10, P1789, DOI 10.1158/1078-0432.CCR-1149-3; Gomez-Mouton C, 2004, J CELL BIOL, V164, P759, DOI 10.1083/jcb.200309101; GUGUENGUILLOUZO C, 1982, CELL BIOL INT REP, V6, P625, DOI 10.1016/0309-1651(82)90187-4; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hu L, 2004, ONCOGENE, V23, P298, DOI 10.1038/sj.onc.1206483; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Ivanov D, 2004, CARDIOVASC RES, V64, P132, DOI 10.1016/j.cardiores.2004.06.010; Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexcr.2003.09.030; Ivanov D, 2001, HISTOCHEM CELL BIOL, V115, P231; Ivanov DB, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1174, DOI 10.1023/A:1012445316415; Kozyraki R, 1996, GASTROENTEROLOGY, V110, P1137, DOI 10.1053/gast.1996.v110.pm8613003; Kudrjashova E, 2002, HISTOCHEM CELL BIOL, V118, P281, DOI 10.1007/s00418-002-0463-6; Kuzmenko YS, 1998, BIOCHEM BIOPH RES CO, V246, P489, DOI 10.1006/bbrc.1998.8645; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Niermann T, 2003, BIOCHEM BIOPH RES CO, V300, P943, DOI 10.1016/S0006-291X(02)02970-4; Oshima RG, 2004, CANCER RES, V64, P169, DOI 10.1158/0008-5472.CAN-03-1944; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Philippova M, 2005, FASEB J, V19, P588, DOI 10.1096/fj.04-2430fje; Philippova M, 2003, HISTOCHEM CELL BIOL, V120, P353, DOI 10.1007/s00418-003-0584-6; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; Riou P, 2002, CLIN CANCER RES, V8, P3178; Saffroy R, 2002, EUR J HUM GENET, V10, P239, DOI 10.1038/sj.ejhg.5200795; Sala M, 2004, LIVER TRANSPLANT, V10, P1294, DOI 10.1002/lt.20202; Sandig M, 1997, CELL MOTIL CYTOSKEL, V38, P351, DOI 10.1002/(SICI)1097-0169(1997)38:4<351::AID-CM5>3.3.CO;2-Z; Stambolsky DV, 1999, BBA-BIOMEMBRANES, V1416, P155, DOI 10.1016/S0005-2736(98)00218-1; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Toyooka S, 2002, CANCER RES, V62, P3382; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; Voura EB, 1998, MICROSC RES TECHNIQ, V43, P265, DOI 10.1002/(SICI)1097-0029(19981101)43:3<265::AID-JEMT9>3.0.CO;2-Z; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wyder L, 2000, CANCER RES, V60, P4682	43	44	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2291	2301		10.1096/fj.06-6085com	http://dx.doi.org/10.1096/fj.06-6085com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077306				2022-12-28	WOS:000241702600014
J	Borthwick, GM; Johnson, AS; Partington, M; Burn, J; Wilson, R; Arthur, HM				Borthwick, Gillian M.; Johnson, A. Sarah; Partington, Matthew; Burn, John; Wilson, Robert; Arthur, Helen M.			Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism	FASEB JOURNAL			English	Article						endothelial cells; Celecoxib; SC560; cancer	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE-2 GENE-EXPRESSION; NF-KAPPA-B; SODIUM-SALICYLATE; UP-REGULATION; COLORECTAL ADENOMAS; TUMOR ANGIOGENESIS; ENDOTHELIAL-CELLS; RANDOMIZED-TRIAL; CANCER	A range of antineoplastic properties is attributed to aspirin, thought to be due to inhibition of cyclooxygenase (Cox) enzymes in tumor cells. One important outcome is that by reducing angiogenic factor secretion by cancer cells, aspirin also inhibits angiogenesis, thereby restricting tumor growth. However, aspirin may also have direct effects on endothelial cells to regulate angiogenesis. Our aim was to quantitate these effects and determine whether they occurred through inhibiting Cox enzymes. The effects of aspirin, salicylate (the natural deacetylated form of aspirin), and the selective Cox inhibitors SC560 and Celecoxib on endothelial cell proliferation, viability, and angiogenesis were compared. Therapeutic aspirin concentrations (0.5 mM) had no detectable effect on endothelial cell viability or proliferation but caused a striking reduction in tubule formation in a three-dimensional collagen angiogenesis assay. This was also seen with equimolar concentrations of salicylate, while selective Cox inhibitors did not inhibit angiogenesis in this assay either alone or in combination. Furthermore, high doses of aspirin or salicylate (5 mM), well above therapeutic plasma concentrations, lead to endothelial cell apoptosis. We conclude that aspirin, at therapeutic concentrations, directly inhibits angiogenesis via a Cox-independent mechanism, which may significantly contribute to its neoplastic protective effects.	Newcastle Univ, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; Univ Durham, James Cook Hosp, Dept Surg, Durham, England	Newcastle University - UK; Durham University; James Cook University	Arthur, HM (corresponding author), Newcastle Univ, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	helen.arthur@ncl.ac.uk	Arthur, Helen/C-7808-2009	Burn, John/0000-0002-9823-2322; Arthur, Helen/0000-0001-6522-1363	MRC [G0100496] Funding Source: UKRI; Medical Research Council [G0100496] Funding Source: Medline; Wellcome Trust [VS/02/NEW/3/CH/TH/FH] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Abdelrahim M, 2005, MOL PHARMACOL, V68, P317, DOI 10.1124/mol.105.011825; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Baatout S, 1997, ANTICANCER RES, V17, P451; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Bell SE, 2001, J CELL SCI, V114, P2755; Benamouzig R, 2003, GASTROENTEROLOGY, V125, P328, DOI 10.1016/S0016-5085(03)00887-4; Botting R, 2005, PROSTAG LEUKOTR ESS, V72, P85, DOI 10.1016/j.plefa.2004.10.005; Buchanan FG, 2004, GASTROENTEROLOGY, V127, P1391, DOI 10.1053/j.gastro.2004.07.025; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chapple KS, 2002, J PATHOL, V198, P435, DOI 10.1002/path.1223; CHARO IF, 1984, J CLIN INVEST, V74, P914, DOI 10.1172/JCI111509; Chen JX, 2004, AM J PHYSIOL-HEART C, V287, pH187, DOI 10.1152/ajpheart.01058.2003; Cianchi F, 2001, GASTROENTEROLOGY, V121, P1339, DOI 10.1053/gast.2001.29691; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; FU JY, 1990, J BIOL CHEM, V265, P16737; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gately S, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.040; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hurwitz H, 2005, ONCOLOGY-BASEL, V69, P17, DOI 10.1159/000088480; JONES DA, 1993, J BIOL CHEM, V268, P9049; Jones MK, 1999, NAT MED, V5, P1418; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Koehne CH, 2004, SEMIN ONCOL, V31, P12, DOI 10.1053/j.seminoncol.2004.03.041; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Lanas A, 2001, EUR J GASTROEN HEPAT, V13, P623, DOI 10.1097/00042737-200106000-00001; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; Leahy KM, 2002, CANCER RES, V62, P625; Mann JR, 2004, CANCER J, V10, P145, DOI 10.1097/00130404-200405000-00001; Masferrer JL, 2000, CANCER RES, V60, P1306; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; Masunaga R, 2000, CLIN CANCER RES, V6, P4064; Meadows KN, 2004, ONCOGENE, V23, P192, DOI 10.1038/sj.onc.1206921; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; Premzl A, 2006, J CELL BIOCHEM, V97, P1230, DOI 10.1002/jcb.20720; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Sheehan KM, 2004, EUR J GASTROEN HEPAT, V16, P619, DOI 10.1097/00042737-200406000-00017; Shtivelband MI, 2003, J THROMB HAEMOST, V1, P2225, DOI 10.1046/j.1538-7836.2003.00446.x; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; Wang DZ, 2004, P NATL ACAD SCI USA, V101, P415, DOI 10.1073/pnas.0307640100; Williams A, 1999, HEALTH ECON, V8, P1; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yang S, 1999, AM J PATHOL, V155, P887, DOI 10.1016/S0002-9440(10)65188-7; Yoshida S, 2003, LAB INVEST, V83, P1385, DOI 10.1097/01.LAB.0000090159.53224.B9; Zhang Y, 1997, J PHARMACOL EXP THER, V283, P1069	58	91	98	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2009	2016		10.1096/fj.06-5987com	http://dx.doi.org/10.1096/fj.06-5987com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012253				2022-12-28	WOS:000241156900009
J	Davoust, N; Vuaillat, C; Cavillon, G; Domenget, C; Hatterer, E; Bernard, A; Dumontel, C; Jurdic, P; Malcus, C; Confavreux, C; Belin, MF; Nataf, S				Davoust, N.; Vuaillat, C.; Cavillon, G.; Domenget, C.; Hatterer, E.; Bernard, A.; Dumontel, C.; Jurdic, P.; Malcus, C.; Confavreux, C.; Belin, M. F.; Nataf, S.			Bone marrow CD34+/B220+ progenitors target the inflamed brain and display in vitro differentiation potential toward microglia	FASEB JOURNAL			English	Article						glial cell; bone marrow; stem cells; cell transfer	CENTRAL-NERVOUS-SYSTEM; CELLS; RECRUITMENT; EXPRESSION	Recent evidence indicates that microglial cells may not derive from blood circulating mature monocytes as they express features of myeloid progenitors. Here, we observed that a subpopulation of microglial cells expressed CD34 and B220 antigens during brain development. We thus hypothesized that microglia, or a subset of microglial cells, originate from blood circulating CD34(+)/B220(+) myeloid progenitors, which could target the brain under developmental or neuroinflammatory conditions. Using experimental allergic encephalomyelitis (EAE) as a model of chronic neuroinflammation, we found that a discrete population of CD34(+)/B220(+) cells expands in both blood and brain of diseased animals. In EAE mice, intravenous transfer experiments showed that macrophage-colony stimulating factor (M-CSF)-expanded CD34(+) myeloid progenitors target the inflamed central nervous system (CNS) while keeping their immature phenotype. Based on these results, we then assessed whether CD34(+)/B220(+) cells display in vitro differentiation potential toward microglia. For this purpose, CD34(+)/B220(+) cells were sorted from M-CSF-stimulated bone marrow (BM) cultures and exposed to a glial cell conditioned medium. Under these experimental conditions, CD34(+)/B220(+) cells were able to differentiate into microglial-like cells showing the morphological and phenotypic features of native microglia. Overall, our data suggest that under developmental or neuroinflammatory conditions, a subpopulation of microglial cells derive from CNS-invading CD34(+)/B220(+) myeloid progenitors.	Fac Med Laennec, INSERM U433, IFR Neurosci Lyon, F-69372 Lyon, France; ENS, CNR 5161, Labs Biol Mol Cellule, Lyon, France; Hop Neurol, Immunol Lab, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON); CHU Lyon	Nataf, S (corresponding author), Fac Med Laennec, INSERM U433, IFR Neurosci Lyon, 07 Rue Guillaume Paradin, F-69372 Lyon, France.	nataf@lyon.inserm.fr	Davoust, Nathalie/S-5676-2017					Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; ALLIOT F, 1991, P NATL ACAD SCI USA, V88, P1541, DOI 10.1073/pnas.88.4.1541; Asheuer M, 2004, P NATL ACAD SCI USA, V101, P3557, DOI 10.1073/pnas.0306431101; Camelo S, 2000, J NEUROVIROL, V6, P507, DOI 10.3109/13550280009091951; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Davoust N, 1999, J IMMUNOL, V163, P6551; del Hoyo GM, 2002, NATURE, V415, P1043, DOI 10.1038/4151043a; Flugel A, 2001, J NEUROSCI RES, V66, P74, DOI 10.1002/jnr.1198; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; GIULIAN D, 1995, J NEUROSCI, V15, P7712; HUITINGA I, 1990, J EXP MED, V172, P1025, DOI 10.1084/jem.172.4.1025; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Kennedy DW, 1998, P NATL ACAD SCI USA, V95, P14944, DOI 10.1073/pnas.95.25.14944; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Ladeby R, 2005, GLIA, V50, P121, DOI 10.1002/glia.20159; Lesniak MS, 2005, NEUROL RES, V27, P820, DOI 10.1179/016164105X49454; Lima FRS, 2001, J NEUROSCI, V21, P2028, DOI 10.1523/JNEUROSCI.21-06-02028.2001; Malm TM, 2005, NEUROBIOL DIS, V18, P134, DOI 10.1016/j.nbd.2004.09.009; MILES JM, 1988, J NEUROPATH EXP NEUR, V47, P579, DOI 10.1097/00005072-198811000-00001; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; Nguyen MD, 2004, J NEUROSCI, V24, P1340, DOI 10.1523/JNEUROSCI.4786-03.2004; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Ohsawa K, 2000, J CELL SCI, V113, P3073; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; Peterson JW, 2002, J NEUROPATH EXP NEUR, V61, P539, DOI 10.1093/jnen/61.6.539; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Rakic S, 2003, GLIA, V41, P117, DOI 10.1002/glia.10140; Santambrogio L, 2001, P NATL ACAD SCI USA, V98, P6295, DOI 10.1073/pnas.111152498; Tabatabai G, 2005, BRAIN, V128, P2200, DOI 10.1093/brain/awh563; Udani V, 2005, NEUROL RES, V27, P801, DOI 10.1179/016164105X49319; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2	33	45	48	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2081	2092		10.1096/fj.05-5593com	http://dx.doi.org/10.1096/fj.05-5593com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012260				2022-12-28	WOS:000241156900016
J	Yamagata, M; Rook, SL; Sassa, Y; Ma, RC; Geraldes, P; Goddard, L; Clermont, A; Gao, B; Salti, H; Gundel, R; White, M; Feener, EP; Aiello, LP; King, GL				Yamagata, Michiko; Rook, Susan L.; Sassa, Yukio; Ma, Ronald C.; Geraldes, Pedro; Goddard, Lucy; Clermont, Allen; Gao, Benbo; Salti, Haytham; Gundel, Robert; White, Mark; Feener, Edward P.; Aiello, Lloyd Paul; King, George L.			Bactericidal/permeability-increasing protein's signaling pathways and its retinal trophic and anti-angiogenic effects	FASEB JOURNAL			English	Article						ERK; Akt; diabetic retinopathy; age-related macular degeneration; glypican 4	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY; IN-VIVO; BPI; NEOVASCULARIZATION; RETINOPATHY; EXPRESSION; APOPTOSIS; FRAGMENT; CELLS	Bactericidal/permeability-increasing protein (BPI) was originally identified as a lipopolysaccharide (LPS) binding protein with Gram-negative bactericidal activity in the leukocytes. In this study, we characterized the previously unknown effects of BPI in the eye and the molecular mechanisms involved in its action. BPI mRNA was detected in bovine retina; retinal pigment epithelium; and primary cultures of bovine retinal pigment epithelial cells (RPE), pericytes (RPC), and endothelial cells (REC); while BPI protein was measured in human vitreous and plasma. BPI, but not control protein thaumatin, activated extracellular regulated kinase (ERK) and AKT, and increased DNA synthesis in RPE and RPC but not in REC. A human recombinant 21 kDa modified amino-terminal fragment of BPI (rBPI(21)) reduced H2O2-induced apoptosis in RPE and inhibited vascular endothelial growth factor (VEGF)-stimulated ERK phosphorylation in REC when preincubated with VEGF. Intraperitoneal (i.p.)-injected rBPI21 reduced ischemia-induced retinal neovascularization and diabetes-induced retinal permeability. Since BPI has unusual dual properties of promoting RPC and RPE growth while suppressing VEGF-induced REC growth and vascular permeability, the mechanistic understanding of BPI's action may provide novel therapeutic opportunities for diabetic retinopathy and age-related macular degeneration.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA; XOMA US LLC, Dept Preclin Res & Cellular, Berkeley, CA USA; XOMA US LLC, Dept Analyt Dev, Berkeley, CA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	King, GL (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	george.king@joslin.harvard.edu	Ma, Ronald/C-2788-2009; Sassa, Yukio/H-6339-2012	Ma, Ronald/0000-0002-1227-803X; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x; Canny G, 2002, P NATL ACAD SCI USA, V99, P3902, DOI 10.1073/pnas.052533799; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007; Harkin DW, 2001, ANN SURG, V234, P233, DOI 10.1097/00000658-200108000-00014; KING GL, 1987, DIABETES, V36, P1460, DOI 10.2337/diabetes.36.12.1460; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013; Levine KB, 2002, BIOCHEMISTRY-US, V41, P12629, DOI 10.1021/bi0258997; LITTLE RG, 1994, J BIOL CHEM, V269, P1865; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NAYAK RC, 1988, J EXP MED, V167, P1003, DOI 10.1084/jem.167.3.1003; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408; Rauniyar RK, 2002, INVEST OPHTH VIS SCI, V43, P503; SHAFER WM, 1984, INFECT IMMUN, V45, P29, DOI 10.1128/IAI.45.1.29-35.1984; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Takahashi M, 2004, EXP DERMATOL, V13, P55, DOI 10.1111/j.0906-6705.2004.00116.x; van der Schaft DWJ, 2000, BLOOD, V96, P176, DOI 10.1182/blood.V96.1.176.013k32_176_181; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WEISS J, 1992, J CLIN INVEST, V90, P1122, DOI 10.1172/JCI115930; WEISS J, 1978, J BIOL CHEM, V253, P2664	32	19	27	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2058	2067		10.1096/05-5662com	http://dx.doi.org/10.1096/05-5662com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012258				2022-12-28	WOS:000241156900014
J	Tunnemann, G; Martin, RM; Haupt, S; Patsch, C; Edenhofer, F; Cardoso, MC				Tuennemann, Gisela; Martin, Robert M.; Haupt, Simone; Patsch, Christoph; Edenhofer, Frank; Cardoso, M. Cristina			Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells	FASEB JOURNAL			English	Article						cell-penetrating peptide; protein transduction; PCNA; PBD; Cre recombinase	DNA-LIGASE I; CELLULAR UPTAKE; PENETRATING PEPTIDES; CRE RECOMBINASE; FUSION PROTEINS; REPLICATION FACTORIES; TRANSDUCTION DOMAINS; NUCLEAR ANTIGEN; ENTERS CELLS; MECHANISM	Cell-penetrating peptides (CPPs) are capable of introducing a wide range of cargoes into living cells. Descriptions of the internalization process vary from energy-independent cell penetration of membranes to endocytic uptake. To elucidate whether the mechanism of entry of CPP constructs might be influenced by the properties of the cargo, we used time lapse confocal microscopy analysis of living mammalian cells to directly compare the uptake of the well-studied CPP TAT fused to a protein (> 50 amino acids) or peptide (< 50 amino acids) cargo. We also analyzed various constructs for their subcellular distribution and mobility after the internalization event. TAT fusion proteins were taken up largely into cytoplasmic vesicles whereas peptides fused to TAT entered the cell in a rapid manner that was dependent on membrane potential. Despite their accumulation in the nucleolus, photobleaching of TAT fusion peptides revealed their mobility. The bioavailability of internalized TAT peptides was tested and confirmed by the strong inhibitory effect on cell cycle progression of two TAT fusion peptides derived from the tumor suppressor p21(WAF/Cip) and DNA Ligase I measured in living cells.-Tunnemann, G., Martin, R. M., Haupt, S., Patsch, C., Edenhofer, F., Cardoso, M. C. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Univ Bonn, Inst Reconstruct Neurobiol, Stem Cell Engn Grp, Life & Brain Ctr, D-5300 Bonn, Germany; Hertie Fdn, Bonn, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Bonn	Tunnemann, G (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	cardoso@mdc-berlin.de	Edenhofer, Frank/ABG-9458-2020; Cardoso, M. Cristina/F-5215-2011	Edenhofer, Frank/0000-0002-6489-714X; Martin, Robert/0000-0001-5600-7525; Lattig, Gisela/0000-0001-6485-1136				Aidley D.J., 1996, ION CHANNELS MOL ACT; Cardoso MC, 1997, J CELL BIOL, V139, P579, DOI 10.1083/jcb.139.3.579; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Cardoso MC, 2002, BIOL CHEM, V383, P1593, DOI 10.1515/BC.2002.180; Caron NJ, 2004, BIOCHEM BIOPH RES CO, V319, P12, DOI 10.1016/j.bbrc.2004.04.180; Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279; Choi M, 2003, BLOOD, V102, P2259, DOI 10.1182/blood-2002-09-2960; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; Dom G, 2003, NUCLEIC ACIDS RES, V31, P556, DOI 10.1093/nar/gkg160; Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; FLANAGAN MD, 1980, J BIOL CHEM, V255, P835; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; GODDETTE DW, 1986, J BIOL CHEM, V261, P5970; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Ho A, 2001, CANCER RES, V61, P474; Jo DW, 2001, NAT BIOTECHNOL, V19, P929, DOI 10.1038/nbt1001-929; Joshi SK, 2002, GENESIS, V33, P48, DOI 10.1002/gene.10089; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200; Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; NOLDEN L, 2006, IN PRESS NAT METHODS; Peitz M, 2002, P NATL ACAD SCI USA, V99, P4489, DOI 10.1073/pnas.032068699; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003; Scheller A, 2000, EUR J BIOCHEM, V267, P6043, DOI 10.1046/j.1432-1327.2000.01681.x; SEEWALD N, 2002, PEPTIDES CHEM BIOL; Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636; Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Watanabe Y, 2004, GENE DEV, V18, P889, DOI 10.1101/gad.1179004; Will E, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf059; Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604; Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805	43	318	336	1	74	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1775	1784		10.1096/fj.05-5523com	http://dx.doi.org/10.1096/fj.05-5523com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940149				2022-12-28	WOS:000240267000005
J	Browne, RO; Ben Moyal-Segal, L; Zumsteg, D; David, Y; Kofman, O; Berger, A; Soreq, H; Friedman, A				Browne, R. Orie; Ben Moyal-Segal, Liat; Zumsteg, Dominik; David, Yaron; Kofman, Ora; Berger, Andrea; Soreq, Hermona; Friedman, Alon			Coding region paraoxonase polymorphisms dictate accentuated neuronal reactions in chronic, sub-threshold pesticide exposure	FASEB JOURNAL			English	Article						acetylcholinesterase; electroencephalography; LORETA; organophosphates; subthreshold exposure	CORTICAL CHOLINERGIC INPUTS; ELECTROMAGNETIC TOMOGRAPHY; BASAL FOREBRAIN; ORGANOPHOSPHATE PESTICIDES; CARDIOVASCULAR-DISEASE; ATTENTIONAL FUNCTIONS; AFFERENT-PROJECTIONS; PON1 POLYMORPHISMS; SERUM PARAOXONASE; OXIDATIVE STRESS	Organophosphate pesticides (OPs), known inhibitors of acetylcholinesterase (AChE), are used extensively throughout the world. Recent studies have focused on the ACHE/PON1 locus as a determinant of inherited susceptibility to environmental OP exposure. To explore the relationship of the corresponding gene-environment interactions with brain activity, we integrated neurophysiologic, neuropsychological, biochemical, and genetic methods. Importantly, we found that subthreshold OP exposure leads to discernible physiological consequences that are significantly influenced by inherited factors. Cortical EEG analyses by LORETA revealed significantly decreased theta activity in the hippocampus, parahippocampal regions, and the cingulate cortex, as well as increased beta activity in the prefrontal cortex of exposed individuals-areas known to play a role in cholinergic-associated cognitive functions. Through neuropsychological testing, we identified an appreciable deficit in the visual recall in exposed individuals. Other neuropsychological tests revealed no significant differences between exposed and non-exposed individuals, attesting to the specificity of our findings. Biochemical analyses of blood samples revealed increases in paraoxonase and arylesterase activities and reduced serum acetylcholinesterase activity in chronically exposed individuals. Notably, specific paraoxonase genotypes were found to be associated with these exposure-related changes in blood enzyme activities and abnormal EEG patterns. Thus, gene-environment interactions involving the ACHE/PON1 locus may be causally involved in determining the physiological response to OP exposure.	Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Dept Behav Sci, IL-84105 Beer Sheva, Israel; Hebrew Univ Jerusalem, Soroka Univ Med Ctr, Dept Physiol, IL-91905 Jerusalem, Israel; Hebrew Univ Jerusalem, Soroka Univ Med Ctr, Dept Neurosurg, IL-91905 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91905 Jerusalem, Israel; Univ Toronto, Toronto Western Hosp, Krembil Neurosci Ctr, Toronto, ON M4X 1K9, Canada	Ben Gurion University; Ben Gurion University; Soroka Medical Center; Hebrew University of Jerusalem; Ben Gurion University; Soroka Medical Center; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Krembil Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Friedman, A (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, IL-84105 Beer Sheva, Israel.	alonf@bgu.ac.il	Berger, Andrea/F-1427-2012	Berger, Andrea/0000-0001-5557-4114; Soreq, Hermona/0000-0002-0955-526X				Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Aharoni A, 2004, P NATL ACAD SCI USA, V101, P482, DOI 10.1073/pnas.2536901100; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; Benmoyal-Segal L, 2005, FASEB J, V19, P452, DOI 10.1096/fj.04-2106fje; BESWICK FW, 1987, OXFORD TXB MED; BOWERS MB, 1964, J NERV MENT DIS, V138, P383; Brophy VH, 2001, AM J HUM GENET, V68, P1428, DOI 10.1086/320600; Brown MA, 1998, J APPL TOXICOL, V18, P393, DOI 10.1002/(SICI)1099-1263(199811/12)18:6<393::AID-JAT528>3.0.CO;2-0; Bryk B, 2005, J NEUROCHEM, V92, P1216, DOI 10.1111/j.1471-4159.2004.02959.x; Bucci DJ, 1998, J NEUROSCI, V18, P8038; BURCHFIEL JL, 1982, NEUROBEH TOXICOL TER, V4, P767; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; Chiba AA, 1999, NEUROREPORT, V10, P3119, DOI 10.1097/00001756-199909290-00044; Costa LG, 2003, ANNU REV MED, V54, P371, DOI 10.1146/annurev.med.54.101601.152421; Dale AM, 2000, NEURON, V26, P55, DOI 10.1016/S0896-6273(00)81138-1; Davies HG, 1996, NAT GENET, V14, P334, DOI 10.1038/ng1196-334; DUBOIS KP, 1949, J PHARMACOL EXP THER, V95, P79; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Fiedler N, 1997, AM J IND MED, V32, P487, DOI 10.1002/(SICI)1097-0274(199711)32:5&lt;487::AID-AJIM8&gt;3.0.CO;2-P; FURLONG CE, 1989, ANAL BIOCHEM, V180, P242, DOI 10.1016/0003-2697(89)90424-7; Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134; Gill TM, 2000, J NEUROSCI, V20, P4745, DOI 10.1523/JNEUROSCI.20-12-04745.2000; GLICK D, 2003, BUTYRYLCHOLINESTERAS, P55; Hernandez AF, 2004, J TOXICOL ENV HEAL A, V67, P1095, DOI 10.1080/15287390490452371; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kaufer D, 1999, CURR OPIN NEUROL, V12, P739, DOI 10.1097/00019052-199912000-00014; Kocsis B, 2001, EUR J NEUROSCI, V13, P381, DOI 10.1046/j.0953-816X.2000.01392.x; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kozak R, 2006, CEREB CORTEX, V16, P9, DOI 10.1093/cercor/bhi079; LEVIN HS, 1976, ARCH GEN PSYCHIAT, V33, P225; Lezak M.D., 2012, NEUROPSYCHOLOGICAL A; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; Martinez V, 2004, BEHAV NEUROSCI, V118, P984, DOI 10.1037/0735-7044.118.5.984; McGaughy J, 2002, J NEUROSCI, V22, P1905, DOI 10.1523/JNEUROSCI.22-05-01905.2002; McGaughy J, 2000, BEHAV BRAIN RES, V115, P251, DOI 10.1016/S0166-4328(00)00262-X; MESULAM MM, 1983, J COMP NEUROL, V214, P170, DOI 10.1002/cne.902140206; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; Metcalf D R, 1969, Ann N Y Acad Sci, V160, P357, DOI 10.1111/j.1749-6632.1969.tb15857.x; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P91; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; PASCUALMARQUI RD, 1994, INT J PSYCHOPHYSIOL, V18, P49, DOI 10.1016/0167-8760(84)90014-X; Pavlovsky L, 2005, J NEUROL, V252, P42, DOI 10.1007/s00415-005-0596-3; Ray DE, 2001, TOXICOL LETT, V120, P343, DOI 10.1016/S0378-4274(01)00266-1; RICHTER ED, 1992, ISRAEL J MED SCI, V28, P584; RODNITZKY RL, 1975, ARCH ENVIRON HEALTH, V30, P98, DOI 10.1080/00039896.1975.10666651; Rodrigo L, 2001, CHEM-BIOL INTERACT, V137, P123, DOI 10.1016/S0009-2797(01)00225-3; Sarter M, 1999, ANN NY ACAD SCI, V877, P368, DOI 10.1111/j.1749-6632.1999.tb09277.x; Sarter M, 2005, BRAIN RES REV, V48, P98, DOI 10.1016/j.brainresrev.2004.08.006; Sarter M, 1997, BRAIN RES REV, V23, P28, DOI 10.1016/S0165-0173(96)00009-4; Schmidt R, 2002, CEREBROVASC DIS, V13, P16, DOI 10.1159/000049145; Shapira M, 2000, HUM MOL GENET, V9, P1273, DOI 10.1093/hmg/9.9.1273; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Sklan EH, 2004, P NATL ACAD SCI USA, V101, P5512, DOI 10.1073/pnas.0307659101; SOREQ H, 2005, ENCY STRESS; Steenland K, 2000, ENVIRON HEALTH PERSP, V108, P293, DOI 10.2307/3454346; STEWART M, 1990, TRENDS NEUROSCI, V13, P163, DOI 10.1016/0166-2236(90)90040-H; Strik WK, 1998, EVOKED POTENTIAL, V108, P406, DOI 10.1016/S0168-5597(98)00021-5; Sukov W, 1998, J NEUROPHYSIOL, V79, P2875, DOI 10.1152/jn.1998.79.6.2875; Talairach J., 1988, COPLANAR STEREOTAXIC; TAYLOR P, 2001, GOODMAN GILMANS PHAR, P131; Turchi J, 2000, EUR J NEUROSCI, V12, P4505, DOI 10.1111/j.1460-9568.2000.01347.x; Vertes Robert P, 2004, Behav Cogn Neurosci Rev, V3, P173, DOI 10.1177/1534582304273594; Vertes RP, 1997, NEUROSCIENCE, V81, P893; VINOGRADOVA OS, 1995, PROG NEUROBIOL, V45, P523, DOI 10.1016/0301-0082(94)00051-I; WEINER L, 1994, BIOCHEM BIOPH RES CO, V198, P915, DOI 10.1006/bbrc.1994.1130	67	39	40	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1733	+		10.1096/fj.05-5576fje	http://dx.doi.org/10.1096/fj.05-5576fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807370				2022-12-28	WOS:000240266600031
J	Nakayama, H; Wilkin, BJ; Bodi, I; Molkentin, JD				Nakayama, Hiroyuki; Wilkin, Benjamin J.; Bodi, Ilona; Molkentin, Jeffery D.			Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart	FASEB JOURNAL			English	Article						signaling; calcium; store-operated; NFAT	CAPACITATIVE CALCIUM-ENTRY; NUCLEAR TRANSLOCATION; CARDIAC-HYPERTROPHY; SKELETAL-MUSCLE; CELLS; CHANNELS; NFAT; CARDIOMYOCYTES; INHIBITION; EXPRESSION	The manner in which Ca2+-sensitive signaling proteins are activated in contracting cardiomyocytes is an intriguing theoretical problem given that the cytoplasm is continually bathed with systolic Ca2+ concentrations that should maximally activate most Ca2+-sensitive signaling kinases and phosphatases. Store-operated Ca2+ entry, partially attributed to transient receptor potential (TRP) proteins, can mediate activation of the Ca2+-sensitive phosphatase calcineurin in nonexcitable cells. Here we investigated the gain-of-function phenotype associated with TRPC3 expression in the mouse heart using transgenesis to examine the potential role of store-operated Ca2+ entry in regulating cardiac calcineurin activation and ensuing hypertrophy/ myopathy. Adult myocytes isolated from TRPC3 transgenic mice showed abundant store-operated Ca2+ entry that was inhibited with SKF96365 but not verapamil or KB-R7943. Associated with this induction in store-operated Ca2+ entry, TRPC3 transgenic mice showed increased calcineurin-nuclear factor of activated T cells (NFAT) activation in vivo, cardiomyopathy, and increased hypertrophy after neuroendocrine agonist or pressure overload stimulation. The cardiomyopathic phenotype and increased hypertrophy after pressure overload stimulation were blocked by targeted disruption of the calcineurin A beta gene. Thus, enhanced store-operated Ca2+ entry in the heart can regulate calcineurin-NFAT signaling in vivo, which could secondarily the hypertrophic response and cardiomyopathy.	Univ Cincinnati, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati Childrens Hosp,Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Surg, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Molkentin, JD (corresponding author), Univ Cincinnati, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati Childrens Hosp,Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org	Tuluc, Petronel/C-2527-2011	Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL069779, P50HL077101, R01HL062927, R01HL081104, R01HL060562] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [P01 HL069779-06A10003, P01 HL069779, R01 HL060562, P50 HL077101, R01 HL081104, R01 HL062927-10A1, R01 HL062927, R01 HL060562-11, R01 HL081104-04, P50 HL077101-050004] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bikah G, 2000, NAT IMMUNOL, V1, P402, DOI 10.1038/80841; Brochet DXP, 2005, P NATL ACAD SCI USA, V102, P3099, DOI 10.1073/pnas.0500059102; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Eisner DA, 2000, CIRC RES, V87, P1087, DOI 10.1161/01.RES.87.12.1087; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Freichel M, 1999, CELL PHYSIOL BIOCHEM, V9, P270, DOI 10.1159/000016321; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; HUANG J, 2006, AM J PHYSL      0118; Hunton DL, 2004, AM J PHYSIOL-HEART C, V286, pH1124, DOI 10.1152/ajpheart.00162.2003; Hunton DL, 2002, J BIOL CHEM, V277, P14266, DOI 10.1074/jbc.M107167200; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Kiriazis H, 2002, CARDIOVASC RES, V53, P372, DOI 10.1016/S0008-6363(01)00487-4; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Liu YW, 2005, J CELL BIOL, V168, P887, DOI 10.1083/jcb.200408128; Liu YW, 2001, J CELL BIOL, V155, P27, DOI 10.1083/jcb.200103020; Mignen O, 2003, J BIOL CHEM, V278, P40088, DOI 10.1074/jbc.M306365200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; Ohki G, 2000, J BIOL CHEM, V275, P39055, DOI 10.1074/jbc.M003606200; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Rosenberg P, 2004, P NATL ACAD SCI USA, V101, P9387, DOI 10.1073/pnas.0308179101; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Uehara A, 2002, CELL CALCIUM, V31, P89, DOI 10.1054/ceca.2001.0257; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wu X, 2006, J CLIN INVEST, V116, P675, DOI 10.1172/JCI27374	34	217	234	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1660	1670		10.1096/fj.05-5560com	http://dx.doi.org/10.1096/fj.05-5560com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873889	Green Accepted			2022-12-28	WOS:000240266600011
J	Laflamme, K; Roberge, CJ; Grenier, G; Remy-Zolghadri, M; Pouliot, S; Baker, K; Labbe, R; D'Orleans-Juste, P; Auger, FA; Germain, L				Laflamme, Karina; Roberge, Charles J.; Grenier, Guillaume; Remy-Zolghadri, Murielle; Pouliot, Stephanie; Baker, Kathleen; Labbe, Raymond; D'Orleans-Juste, Pedro; Auger, Francois A.; Germain, Lucie			Adventitia contribution in vascular tone: insights from adventitia-derived cells in a tissue-engineered human blood vessel	FASEB JOURNAL			English	Article						adventitia; contraction; media; endothelin; blood vessel	NITRIC-OXIDE; RAT AORTA; ENDOTHELIN; EXPRESSION; INHIBITOR; PATHOPHYSIOLOGY; GENERATION; REACTIVITY; PHYSIOLOGY; RECEPTORS	Whether the adventitia component of blood vessels directly participates in the regulation of vascular tone remains to be demonstrated. We have recently developed a human tissue-engineered blood vessel comprising the three tunicae of a native blood vessel using the self-assembly approach. To investigate the role of the adventitia in the modulation of vascular tone, this tissue-engineering method was used to produce three vascular constructs from cells explanted and proliferated from donor vessel tunicae 1) an adventitia + a media, or only 2) an adventitia, or 3) a media. The vasoconstriction responses of these 3 constructs to endothelin, the most potent vasopressor known up-to-date, as well as to nonselective and selective agonists and antagonists, were compared. The adventitia contracted to endothelin-1, -2, whereas the media and the media+adventitia contracted to all three endothelins. Endothelin-induced contraction of the adventitia was dependent on ETA receptors, whereas that of the media and the adventitia+media was ETA and ETB receptor-dependent. RT-PCR studies corroborated these results. SNP induced a dose-dependent relaxation of the three tissue constructs. We also demonstrated that the endothelin-converting enzyme, responsible for the formation of the active endothelin peptides, was present and functional in the adventitia. In conclusion, this is the first direct demonstration that the adventitia has the capacity to contract and relax in response to vasoactive factors. The present study suggests that the adventitia of a blood vessel could play a greater role than expected in the modulation of blood vessel tone.-Laflamme, K., Roberge, C. J., Grenier, G., Remy-Zolghadri, M., Pouliot, S., Baker, K., Labbe, R., D'Orleans-Juste, P., Auger, F. A., Germain, L. Adventitia contribution in vascular tone: insights from adventitia-derived cells in a tissue-engineered human blood vessel.	Univ Quebec, CHA, Lab Organogenese Expt, LOEXl,Hop St Sacrement, Ste Foy, PQ G1S 4L8, Canada; Univ Laval, Dept Surg, Quebec City, PQ, Canada; Univ Sherbrooke, Sch Med, Inst Pharmacol, Sherbrooke, PQ J1K 2R1, Canada	Laval University; University of Quebec; Laval University; University of Sherbrooke	Germain, L (corresponding author), Univ Quebec, CHA, Lab Organogenese Expt, LOEXl,Hop St Sacrement, 1050 Chemin, Ste Foy, PQ G1S 4L8, Canada.	lucie.germain@chg.ulaval.ca		Germain, Lucie/0000-0001-8883-6491				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARNAL JF, 1994, AM J PHYSIOL-HEART C, V267, pH1777, DOI 10.1152/ajpheart.1994.267.5.H1777; BARRA JA, 1986, J THORAC CARDIOV SUR, V92, P330; BATES JN, 1991, BIOCHEM PHARMACOL, V42, pS157, DOI 10.1016/0006-2952(91)90406-U; BATTLE T, 1994, TISSUE CELL, V26, P943, DOI 10.1016/0040-8166(94)90043-4; BAX WA, 1993, EUR J PHARMACOL, V239, P267, DOI 10.1016/0014-2999(93)91010-K; D'Orleans-Juste P, 2003, CAN J PHYSIOL PHARM, V81, P503, DOI 10.1139/Y03-032; DELOMBAERT S, 1994, BIOCHEM BIOPH RES CO, V204, P407, DOI 10.1006/bbrc.1994.2473; Ergul A, 1998, J PHARMACOL EXP THER, V285, P511; Gonzalez MC, 2001, AM J PHYSIOL-HEART C, V280, pH2876, DOI 10.1152/ajpheart.2001.280.6.H2876; Grenier G, 2003, IN VITRO CELL DEV-AN, V39, P131; Hachiya A, 2002, J BIOL CHEM, V277, P5395, DOI 10.1074/jbc.M105874200; HAYNES WG, 1994, LANCET, V344, P852, DOI 10.1016/S0140-6736(94)92827-4; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Jeng AY, 2002, CAN J PHYSIOL PHARM, V80, P440, DOI 10.1139/y02-025; Kemler MA, 1997, PLAST RECONSTR SURG, V99, P1626, DOI 10.1097/00006534-199705010-00024; Korth P, 1999, J HISTOCHEM CYTOCHEM, V47, P447, DOI 10.1177/002215549904700403; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; L'Heureux N, 2001, FASEB J, V15, P515, DOI 10.1096/fj.00-0283com; Laflamme K, 2005, CIRCULATION, V111, P459, DOI 10.1161/01.CIR.0000153850.53419.50; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; LOHMAN R, 1995, ANN PLAS SURG, V35, P60, DOI 10.1097/00000637-199507000-00012; MCMAHON EG, 1993, AM J HYPERTENS, V6, P667, DOI 10.1093/ajh/6.8.667; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; MONCADA S, 1991, PHARMACOL REV, V43, P109; Olson LJ, 1997, HYPERTENSION, V29, P254, DOI 10.1161/01.HYP.29.1.254; RHODIN JAG, 1980, HDB PHYSL 2, V2, P1, DOI DOI 10.1002/CPHY.CP020201; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; SCHWARTZ CJ, 1962, CIRCULATION, V26, P73, DOI 10.1161/01.CIR.26.1.73; Scotland R, 1999, CARDIOVASC RES, V41, P237, DOI 10.1016/S0008-6363(98)00223-5; Scotland R, 1999, BRIT J PHARMACOL, V128, P1229, DOI 10.1038/sj.bjp.0702930; SHIMADA K, 1995, BIOCHEM BIOPH RES CO, V207, P807, DOI 10.1006/bbrc.1995.1258; Spratt JCS, 2001, BRIT J PHARMACOL, V134, P648, DOI 10.1038/sj.bjp.0704304; vanderLoo B, 1997, INT J MICROCIRC, V17, P280, DOI 10.1159/000179240; Wang HD, 1999, HYPERTENSION, V33, P1225, DOI 10.1161/01.HYP.33.5.1225; WHITE DG, 1994, EUR J PHARMACOL, V257, P307, DOI 10.1016/0014-2999(94)90144-9; Wilcox JN, 1996, INT J CARDIOL, V54, pS21, DOI 10.1016/S0167-5273(96)02811-2; WILLIAMS JK, 1988, AM J PHYSIOL, V254, pH126, DOI 10.1152/ajpheart.1988.254.1.H126; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zurbrugg HR, 2000, ANN THORAC SURG, V70, P1536, DOI 10.1016/S0003-4975(00)01997-4	41	42	47	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1245	+		10.1096/fj.05-4702fje	http://dx.doi.org/10.1096/fj.05-4702fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16611833				2022-12-28	WOS:000240210300040
J	Schlueter, PJ; Royer, T; Farah, MH; Laser, B; Chan, SJ; Steiner, DF; Duan, CM				Schlueter, Peter J.; Royer, Tricia; Farah, Mohamed H.; Laser, Benjamin; Chan, Shu Jin; Steiner, Donald F.; Duan, Cunming			Gene duplication and functional divergence of the zebrafish insulin-like growth factor 1 receptors	FASEB JOURNAL			English	Article						IGF signaling; growth; developmental timing; retina; inner ear; heart; muscle	GROWTH-FACTOR RECEPTOR; IGF-I; INSULIN; MAP; INTRAUTERINE; EXPRESSION; DISTINCT; MUTATIONS	Insulin-like growth factor (IGF) 1 receptor (IGF1R)-mediated signaling plays key roles in growth, development, and physiology. Recent studies have shown that there are two distinct igf1r genes in zebrafish, termed igf1ra and igf1rb. In this study, we tested the hypothesis that zebrafish igf1ra and igf1rb resulted from a gene duplication event at the igf1r locus and that this has led to their functional divergence. The genomic structures of zebrafish igf1ra and igf1rb were determined and their loci mapped. While zebrafish igf1ra has 21 exons and is located on linkage group (LG) 18, zebrafish igf1rb has 22 exons and mapped to LG 7. There is a strong syntenic relationship between the two zebrafish genes and the human IG F1R gene. Using a MO-based loss-of-function approach, we show that both Igf1ra and Igf1rb are required for zebrafish embryo viability and proper growth and development. Although Igf1ra and Igf1rb demonstrated a large degree of functional overlap with regard to cell differentiation in the developing eye, inner ear, heart, and muscle, they also exhibited functional distinction involving a greater requirement for Igf1rb in spontaneous muscle contractility. These findings suggest that the duplicated zebrafish igf1r genes play largely overlapping but not identical functional roles in early development and provide novel insight into the functional evolution of the IGF1R/insulin receptor gene family.-Schlueter, P. J., Royer, T., Mohamed, H. F., Laser, B., Chan, S. J., Steiner, D. F., Duan, C. Gene duplication and functional divergence of the zebrafish insulin-like growth factor 1 receptors.	Univ Michigan, Dept MCDB, Ann Arbor, MI 48109 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Chicago	Schlueter, PJ (corresponding author), Univ Michigan, Dept MCDB, Kraus Nat Sci Bldg, Ann Arbor, MI 48109 USA.	cduan@umich.edu						Abuzzahab MJ, 2003, NEW ENGL J MED, V349, P2211, DOI 10.1056/NEJMoa010107; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Ayaso E, 2002, MOL CELL ENDOCRINOL, V191, P137, DOI 10.1016/S0303-7207(02)00083-7; Barbazuk WB, 2000, GENOME RES, V10, P1351, DOI 10.1101/gr.144700; Chan SJ, 1997, P NATL ACAD SCI USA, V94, P12446, DOI 10.1073/pnas.94.23.12446; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; Denley A, 2005, MOL ENDOCRINOL, V19, P711, DOI 10.1210/me.2004-0409; Drapeau P, 2002, PROG NEUROBIOL, V68, P85, DOI 10.1016/S0301-0082(02)00075-8; Duan CM, 1999, P NATL ACAD SCI USA, V96, P15274, DOI 10.1073/pnas.96.26.15274; Easter SS, 2002, RES PRO CEL, V40, P346; Efstratiadis A, 1998, INT J DEV BIOL, V42, P955; Eivers E, 2004, INT J DEV BIOL, V48, P1131, DOI 10.1387/ijdb.041913ee; Ekker SC, 2000, YEAST, V17, P302, DOI 10.1002/1097-0061(200012)17:4<302::AID-YEA53>3.0.CO;2-#; Ekker SC, 2001, GENESIS, V30, P89, DOI 10.1002/gene.1038; Force A, 1999, GENETICS, V151, P1531; Gates MA, 1999, GENOME RES, V9, P334; Geisler R, 1999, NAT GENET, V23, P86, DOI 10.1038/12692; He XL, 2005, GENETICS, V169, P1157, DOI 10.1534/genetics.104.037051; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hu M, 1999, DEV BIOL, V207, P309, DOI 10.1006/dbio.1998.9031; Hukriede NA, 1999, P NATL ACAD SCI USA, V96, P9745, DOI 10.1073/pnas.96.17.9745; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kawashima Y, 2005, J CLIN ENDOCR METAB, V90, P4679, DOI 10.1210/jc.2004-1947; Kim JJ, 2002, GROWTH HORM IGF RES, V12, P84, DOI 10.1054/ghir.2002.0265; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Klinghoffer RA, 2002, DEV CELL, V2, P103, DOI 10.1016/S1534-5807(01)00103-4; Klinghoffer RA, 2001, MOL CELL, V7, P343, DOI 10.1016/S1097-2765(01)00182-4; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Maures T, 2002, ENDOCRINOLOGY, V143, P1858, DOI 10.1210/en.143.5.1858; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Neumann CJ, 2000, SCIENCE, V289, P2137, DOI 10.1126/science.289.5487.2137; Neumann CJ, 2001, SEMIN CELL DEV BIOL, V12, P485, DOI 10.1006/scdb.2001.0272; Ohno S., 1970, P1; Pera EM, 2001, DEV CELL, V1, P655, DOI 10.1016/S1534-5807(01)00069-7; Pera EM, 2003, GENE DEV, V17, P3023, DOI 10.1101/gad.1153603; Pozios KC, 2001, AM J PHYSIOL-REG I, V280, pR1230, DOI 10.1152/ajpregu.2001.280.4.R1230; Richard-Parpaillon L, 2002, DEV BIOL, V244, P407, DOI 10.1006/dbio.2002.0605; Walenkamp MJE, 2005, J CLIN ENDOCR METAB, V90, P2855, DOI 10.1210/jc.2004-1254; Whitfield TT, 2002, DEV DYNAM, V223, P427, DOI 10.1002/dvdy.10073; Wood AW, 2005, INT REV CYTOL, V243, P215, DOI 10.1016/S0074-7696(05)43004-1; Wood AW, 2005, MOL ENDOCRINOL, V19, P1024, DOI 10.1210/me.2004-0392; Woods IG, 2000, GENOME RES, V10, P1903, DOI 10.1101/gr.10.12.1903; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Zhang JZ, 2003, TRENDS ECOL EVOL, V18, P292, DOI 10.1016/S0169-5347(03)00033-8	47	56	61	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1230	+		10.1096/fj.05-3882fje	http://dx.doi.org/10.1096/fj.05-3882fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16705083	Green Submitted			2022-12-28	WOS:000240210300035
J	Shaked, GM; Kummer, MP; Lu, DC; Galvan, V; Bredesen, DE; Koo, EH				Shaked, G. M.; Kummer, M. P.; Lu, D. C.; Galvan, V.; Bredesen, D. E.; Koo, E. H.			A beta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624)	FASEB JOURNAL			English	Article						C31; YENPTY region; APP homo-oligomerization	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; CASPASE CLEAVAGE; NUCLEAR RECEPTOR; IDENTIFICATION; HOMOLOG; FAMILY; ACCUMULATION; APOPTOSIS; TOXICITY	Amyloid beta-peptide (A beta) is postulated to play a central role in the pathogenesis of Alzheimer's disease. We recently proposed a pathway of A beta-induced toxicity that is APP dependent and involves the facilitation of APP complex formation by A beta. The APP-dependent component requires cleavage of APP at position 664 in the cytoplasmic domain, presumably by caspases or caspase-like proteases, with release of a potentially cytotoxic C31 peptide. In this study we show that A beta interacted directly and specifically with membrane-bound APP to facilitate APP homo-oligomerization. Using chimeric APP molecules, this interaction was shown to take place between A beta and its homologous sequence on APP. Consistent with this finding, we demonstrated that A beta also facilitated the oligomerization of beta-secretase cleaved APP C-terminal fragment (C99). We found that the YENPTY domain in the APP cytoplasmic tail and contained within C31 is critical for this cell death pathway. Deletion or alanine- scanning mutagenesis through this domain significantly attenuated cell death apparently without affecting either APP dimerization or cleavage at position 664. This indicated that sequences within C31 are required after its release from APP. As the YENPTY domain has been shown to interact with a number of cytosolic adaptor molecules, it is possible that the interaction of APP, especially dimeric forms of APP, with these molecules contribute to cell death.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Buck Inst Age Res, Novato, CA USA	University of California System; University of California San Diego; Buck Institute for Research on Aging	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci, 9500 Gilman Dr,Mail Code 0691, La Jolla, CA 92093 USA.	edkoo@ucsd.edu	Kummer, Markus/A-3860-2009	Kummer, Markus P./0000-0002-0993-2918	NATIONAL INSTITUTE ON AGING [P50AG005131] Funding Source: NIH RePORTER; NIA NIH HHS [AG05131, P50 AG005131] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Dumanchin-Njock C, 2001, J NEUROCHEM, V78, P1153, DOI 10.1046/j.1471-4159.2001.00513.x; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; Galvan V, 2002, J NEUROCHEM, V82, P283, DOI 10.1046/j.1471-4159.2002.00970.x; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heredia L, 2004, NEUROBIOL DIS, V16, P617, DOI 10.1016/j.nbd.2004.04.015; Kim CM, 2003, VECTOR-BORNE ZOONOT, V3, P17, DOI 10.1089/153036603765627424; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Klein WL, 2004, NEUROBIOL AGING, V25, P569, DOI 10.1016/j.neurobiolaging.2004.02.010; Klein WL, 2002, NEUROBIOL AGING, V23, P231, DOI 10.1016/S0197-4580(01)00312-8; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Levites Y, 2006, J CLIN INVEST, V116, P193, DOI 10.1172/JCI25410; Lorenzo A, 2000, NAT NEUROSCI, V3, P460, DOI 10.1038/74833; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Lu DC, 2003, ANN NEUROL, V54, P781, DOI 10.1002/ana.10761; Lu DC, 2003, J NEUROCHEM, V87, P733, DOI 10.1046/j.1471-4159.2003.02059.x; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Melchor JP, 2000, J BIOL CHEM, V275, P9782, DOI 10.1074/jbc.275.13.9782; Paliga K, 1997, EUR J BIOCHEM, V250, P354, DOI 10.1111/j.1432-1033.1997.0354a.x; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Schwartz CJE, 2001, EMBO J, V20, P510, DOI 10.1093/emboj/20.3.510; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Soriano S, 2001, J BIOL CHEM, V276, P29045, DOI 10.1074/jbc.M102456200; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; Su JH, 2002, ACTA NEUROPATHOL, V104, P1, DOI 10.1007/s00401-002-0548-2; Van Nostrand WE, 2002, J BIOL CHEM, V277, P36392, DOI 10.1074/jbc.M204676200; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wang YC, 2004, MOL CELL, V15, P343, DOI 10.1016/j.molcel.2004.06.037; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Zhao M, 2003, NEUROBIOL DIS, V14, P391, DOI 10.1016/j.nbd.2003.07.006	43	98	103	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1254	+		10.1096/fj.05-5032fje	http://dx.doi.org/10.1096/fj.05-5032fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636103	Green Accepted			2022-12-28	WOS:000240210300043
J	Huang, YC; Laval, SH; van Remoortere, A; Baudier, J; Benaud, C; Anderson, LVB; Straub, V; Deelder, A; Frants, RR; den Dunnen, JT; Bushby, K; van der Maarel, SM				Huang, Yanchao; Laval, Steven H.; van Remoortere, Alexandra; Baudier, Jacques; Benaud, Chriselle; Anderson, Louise V. B.; Straub, Volker; Deelder, Andre; Frants, Rune R.; den Dunnen, Johan T.; Bushby, Kate; van der Maarel, Silvere M.			AHNAR, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration	FASEB JOURNAL			English	Article						protein interaction; dysferlinopathies; membrane repair; LGMD2B; MM	GIRDLE MUSCULAR-DYSTROPHY; CALCIUM-CHANNEL; GENE; MYOPATHY; CELLS; CAVEOLIN-3; EXPRESSION; DESMOYOKIN; INTERACTS; MUTATION	Mutations in dysferlin cause limb girdle muscular dystrophy 2B, Miyoshi myopathy and distal anterior compartment myopathy. Dysferlin is proposed to play a role in muscle membrane repair. To gain functional insight into the molecular mechanisms of dysferlin, we have searched for dysferlin-interacting proteins in skeletal muscle. By coimmunoprecipitation coupled with mass spectrometry, we demonstrate that AHNAK interacts with dysferlin. We defined the binding sites in dysferlin and AHNAK as the C2A domain in dysferlin and the carboxyterminal domain of AHNAK by glutathione S-transferase (GST)-pull down assays. As expected, the N-terminal domain of myoferlin also interacts with the carboxyterminal domain of AHNAK In normal skeletal muscle, dysferlin and AHNAK colocalize at the sarcolemmal membrane and T-tubules. In dysferlinopathies, reduction or absence of dysferlin correlates with a secondary muscle-specific loss of AHNAK. Moreover, in regenerating rat muscle, dysferlin and AHNAK showed a marked increase and cytoplasmic localization, consistent with the direct interaction between them. Our data suggest that dysferlin participates in the recruitment and stabilization of AHNAK to the sarcolemma and that AHNAK plays a role in dysferlin membrane repair process. It may also have significant implications for understanding the biology of AHNAK-containing exocytotic vesicles, "enlargosomes," in plasma membrane remodeling and repair.	Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Dept Human Genet, NL-2333 ZA Leiden, Netherlands; Int Ctr Life, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England; Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 RA Leiden, Netherlands; CEA, INSERM, DRDC, EMI104, Grenoble, France	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Newcastle University - UK; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	van der Maarel, SM (corresponding author), Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Dept Human Genet, Hlbinusdreef 2, NL-2333 ZA Leiden, Netherlands.	maarel@lumc.nl	dunnen, johan den/ABH-4228-2020; van der Maarel, Silvere/X-3631-2018; Baudier, Jacques/O-2183-2016; Benaud, Christelle/M-1178-2018; jacques, baudier/T-3300-2019	dunnen, johan den/0000-0002-6304-1710; van der Maarel, Silvere/0000-0001-8103-711X; jacques, baudier/0000-0001-8427-4444; Straub, Volker/0000-0001-9046-3540	NIAMS NIH HHS [R21-AR48327-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR048327] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Achanzar WE, 1997, J CELL SCI, V110, P1073; Ampong Beryl N, 2005, Acta Myol, V24, P134; Anderson LVB, 1999, HUM MOL GENET, V8, P855, DOI 10.1093/hmg/8.5.855; Anderson LVB, 1999, AM J PATHOL, V154, P1017, DOI 10.1016/S0002-9440(10)65354-0; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098; Borgonovo B, 2002, NAT CELL BIOL, V4, P955, DOI 10.1038/ncb888; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; Gentil BJ, 2003, J HISTOCHEM CYTOCHEM, V51, P339, DOI 10.1177/002215540305100309; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HASHIMOTO T, 1993, J CELL SCI, V105, P275; Hernandez-Deviez DJ, 2006, HUM MOL GENET, V15, P129, DOI 10.1093/hmg/ddi434; Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0855com; Huang YC, 2005, EUR J HUM GENET, V13, P721, DOI 10.1038/sj.ejhg.5201414; Illa I, 2001, ANN NEUROL, V49, P130, DOI 10.1002/1531-8249(200101)49:1<130::AID-ANA22>3.0.CO;2-0; Illarioshkin SN, 2000, NEUROLOGY, V55, P1931, DOI 10.1212/WNL.55.12.1931; Komuro A, 2004, P NATL ACAD SCI USA, V101, P4053, DOI 10.1073/pnas.0308619101; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; MASUNAGA T, 1995, J INVEST DERMATOL, V104, P941, DOI 10.1111/1523-1747.ep12606213; Matsuda C, 2005, J NEUROPATH EXP NEUR, V64, P334, DOI 10.1093/jnen/64.4.334; Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761; Piccolo F, 2000, ANN NEUROL, V48, P902, DOI 10.1002/1531-8249(200012)48:6<902::AID-ANA11>3.3.CO;2-Q; Salani S, 2004, MUSCLE NERVE, V30, P366, DOI 10.1002/mus.20106; Schneider MF, 2004, J MUSCLE RES CELL M, V25, P587; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; Shevchenko A, 1996, BIOCHEM SOC T, V24, P893, DOI 10.1042/bst0240893	29	108	115	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					732	742		10.1096/fj.06-6628com	http://dx.doi.org/10.1096/fj.06-6628com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17185750				2022-12-28	WOS:000244686400012
J	Martini, L; Waldhoer, M; Pusch, M; Kharazia, V; Fong, J; Lee, JH; Freissmuth, C; Whistler, JL				Martini, Lene; Waldhoer, Maria; Pusch, Margareta; Kharazia, Viktor; Fong, Jamie; Lee, Josephine H.; Freissmuth, Clarissa; Whistler, Jennifer L.			Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1	FASEB JOURNAL			English	Article						degradation; GPCR; postendocytic sorting; tolerance	MESSENGER-RNA LEVELS; RAT-BRAIN; CB1 RECEPTORS; BASAL GANGLIA; MOUSE-BRAIN; DELTA(9)-TETRAHYDROCANNABINOL; BINDING; MICE; INTERNALIZATION; LOCALIZATION	The cannabinoid 1 receptor (CB1R) is one of the most abundant seven transmembrane (7TM) spanning/G-protein-coupled receptors in the central nervous system and plays an important role in pain transmission, feeding, and the rewarding effects of cannabis. Tolerance to cannabinoids has been widely observed after long-term use, with concomitant receptor desensitization and/or down-regulation depending on the brain region studied. Several CB1R agonists promote receptor internalization after activation, but the postendocytic sorting of the receptor has not been studied in detail. Utilizing human embryonic kidney (HEK293) cells stably expressing the CB1R and primary cultured neurons expressing endogenous CB1R, we show that treatment with cannabinoid agonists results in CBIR degradation after endocytosis and that the G-protein-coupled receptor-associated sorting protein GASP1 plays a major role in the postendocytic sorting process. Thus, these results may identify a molecular mechanism underlying tolerance and receptor down-regulation after long-term use of cannabinoids.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Oakland, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Whistler, JL (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, 5858 Horton St,Ste 200, Oakland, CA 94608 USA.	jennifer.whistler@ucsf.edu	Waldhoer, Maria/HDO-0619-2022	Waldhoer, Maria/0000-0003-3534-1959; Kharazia, Viktor/0000-0003-0642-6080	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015232] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA15232] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Baker D, 2006, TRENDS PHARMACOL SCI, V27, P1, DOI 10.1016/j.tips.2005.11.003; Bartlett SE, 2005, P NATL ACAD SCI USA, V102, P11521, DOI 10.1073/pnas.0502418102; Beardsley PM, 2005, BEHAV PHARMACOL, V16, P275, DOI 10.1097/00008877-200509000-00003; Breivogel CS, 2001, MOL PHARMACOL, V60, P155, DOI 10.1124/mol.60.1.155; Breivogel CS, 1999, J NEUROCHEM, V73, P2447, DOI 10.1046/j.1471-4159.1999.0732447.x; Corchero J, 2002, J PSYCHOPHARMACOL, V16, P283, DOI 10.1177/026988110201600401; Coutts AA, 2001, J NEUROSCI, V21, P2425; De Vry J, 2004, BEHAV PHARMACOL, V15, P1, DOI 10.1097/00008877-200402000-00001; DEFONSECA FR, 1994, PHARMACOL BIOCHEM BE, V47, P33, DOI 10.1016/0091-3057(94)90108-2; Di Marzo V, 2000, J NEUROCHEM, V74, P1627, DOI 10.1046/j.1471-4159.2000.0741627.x; Di Marzo V, 2005, NAT NEUROSCI, V8, P585, DOI 10.1038/nn1457; Fan F, 1996, BRAIN RES, V706, P13, DOI 10.1016/0006-8993(95)01113-7; Gear RW, 1999, PAIN, V83, P339, DOI 10.1016/S0304-3959(99)00119-0; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Heydorn A, 2004, J BIOL CHEM, V279, P54291, DOI 10.1074/jbc.M406169200; Howard AD, 2001, TRENDS PHARMACOL SCI, V22, P132, DOI 10.1016/S0165-6147(00)01636-9; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Hsieh C, 1999, J NEUROCHEM, V73, P493, DOI 10.1046/j.1471-4159.1999.0730493.x; HUNTER SA, 1986, NEUROCHEM RES, V11, P1273, DOI 10.1007/BF00966122; Leterrier C, 2006, J NEUROSCI, V26, P3141, DOI 10.1523/JNEUROSCI.5437-05.2006; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; Martin BR, 2004, TRENDS PHARMACOL SCI, V25, P325, DOI 10.1016/j.tips.2004.04.005; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Matyas F, 2006, NEUROSCIENCE, V137, P337, DOI 10.1016/j.neuroscience.2005.09.005; OVIEDO A, 1993, BRAIN RES, V616, P293, DOI 10.1016/0006-8993(93)90220-H; Romero J, 1998, J MOL NEUROSCI, V11, P109, DOI 10.1385/JMN:11:2:109; Romero J, 1999, NEUROCHEM INT, V34, P473, DOI 10.1016/S0197-0186(99)00020-0; Romero J, 1998, SYNAPSE, V30, P298, DOI 10.1002/(SICI)1098-2396(199811)30:3<298::AID-SYN7>3.0.CO;2-6; Romero J, 1997, MOL BRAIN RES, V46, P100, DOI 10.1016/S0169-328X(96)00277-X; RUBINO T, 1994, NEUROREPORT, V5, P2493, DOI 10.1097/00001756-199412000-00022; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Sim LJ, 1996, J NEUROSCI, V16, P8057; Sim-Selley LJ, 2006, MOL PHARMACOL, V70, P986, DOI 10.1124/mol.105.019612; Sim-Selley LJ, 2002, J PHARMACOL EXP THER, V303, P36, DOI 10.1124/jpet.102.035618; Simonin F, 2004, J NEUROCHEM, V89, P766, DOI 10.1111/j.1471-4159.2004.02411.x; Song ZH, 1996, MOL PHARMACOL, V49, P891; Suyama M, 1999, NUCLEIC ACIDS RES, V27, P338, DOI 10.1093/nar/27.1.338; Tang Stephanie L, 2005, J Am Osteopath Assoc, V105, P26; Thanos PK, 2005, BEHAV BRAIN RES, V164, P206, DOI 10.1016/j.bbr.2005.06.021; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Walker JM, 2005, HANDB EXP PHARMACOL, V168, P509; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Willoughby KA, 1997, J PHARMACOL EXP THER, V282, P243	43	111	114	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					802	811		10.1096/fj.06-7132com	http://dx.doi.org/10.1096/fj.06-7132com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197383				2022-12-28	WOS:000244686400018
J	Lokmic, Z; Stillaert, F; Morrison, WA; Thompson, EW; Mitchell, GM				Lokmic, Zerina; Stillaert, Filip; Morrison, Wayne A.; Thompson, Erik W.; Mitchell, Geraldine M.			An arteriovenous loop in a protected space generates a permanent, highly vascular, tissue-engineered construct	FASEB JOURNAL			English	Article						chamber space; macrovascular loop; angiogenesis; growth and remodeling; in vivo tissue engineering	ENDOTHELIAL GROWTH-FACTOR; EXTRACELLULAR-MATRIX; IN-VIVO; GRANULATION-TISSUE; CELL-PROLIFERATION; CONTROLLED-RELEASE; ANGIOGENESIS; HYPOXIA; MODEL; APOPTOSIS	A major obstacle to 3-dimensional tissue engineering is incorporation of a functional vascular supply to support the expanding new tissue. This is overcome in an in vivo intrinsic vascularization model where an arteriovenous loop (AVL) is placed in a noncollapsible space protected by a polycarbonate chamber. Vascular development and hypoxia were examined from 3 days to 112 days by vascular casting, morphometric, and morphological techniques to understand the model's vascular growth and remodeling parameters for tissue engineering purposes. At 3 days a fibrin exudate surrounded the AVL, providing a scaffold to migrating inflammatory, endothelial, and mesenchymal cells. Capillaries formed between 3 and 7 days. Hypoxia and cell proliferation were maximal at 7 days, followed by a peak in percent vascular volume at 10 days (23.20 +/- 3.14% compared with 3.59 +/- 2.68% at 3 days, P < 0.001). Maximal apoptosis was observed at 112 days. The protected space and spontaneous microcirculatory development in this model suggest it would be applicable for in vivo tissue engineering. A temporal window in a period of intense angiogenesis at 7 to 10 days is optimal for exogenous cell seeding and survival in the chamber, potentially enabling specific tissue outcomes to be achieved.	Bernard OBrien Inst Microsurg, Melbourne, Vic 3065, Australia; Univ Melbourne, St Vincent Hosp, Dept Surg, Melbourne, Vic, Australia; Univ Hosp Gent, UZ Gent, Dept Plast, Ghent, Belgium; Univ Hosp Gent, UZ Gent, Reconstruct Surg Unit, Ghent, Belgium	St Vincent's Hospital Melbourne; University of Melbourne; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Mitchell, GM (corresponding author), Bernard OBrien Inst Microsurg, 42 Fitzroy St, Melbourne, Vic 3065, Australia.	mitcg@unimelb.edu.au	Thompson, Erik/GPK-2067-2022; Thompson, Erik W/A-1425-2009; Lokmic-Tomkins, Zerina/AAC-6962-2022	Thompson, Erik/0000-0002-9723-4924; Thompson, Erik W/0000-0002-9723-4924; Lokmic-Tomkins, Zerina/0000-0003-0266-9536				Alenghat Francis J, 2002, Sci STKE, V2002, ppe6, DOI 10.1126/stke.2002.119.pe6; Auger FA, 2004, BIOTECHNOL APPL BIOC, V39, P263; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; Darby IA, 2002, J PATHOL, V197, P117, DOI 10.1002/path.1074; Egginton S, 2003, MICROCIRCULATION, V10, P45, DOI 10.1038/sj.mn.7800174; Elcin YM, 2001, ARTIF ORGANS, V25, P558, DOI 10.1046/j.1525-1594.2001.025007558.x; EXCELL L, 2004, AUSTR NZ ORG DON REG; Frerich B, 2001, INT J ORAL MAX SURG, V30, P414, DOI 10.1054/ijom.2001.0130; Hewitson TD, 2000, METH MOL B, V123, P157; Hossler FE, 2001, MICROSC MICROANAL, V7, P253, DOI 10.1017/S1431927601010261; Howard C, 1998, UNBIASED STEREOLOGY; Ichioka S, 1997, J SURG RES, V72, P29, DOI 10.1006/jsre.1997.5170; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Lee KY, 2003, J CONTROL RELEASE, V87, P49, DOI 10.1016/S0168-3659(02)00349-8; Levenberg S, 2005, NAT BIOTECHNOL, V23, P879, DOI 10.1038/nbt1109; LOKMIC Z, 2004, ENCY BIOMATERIALS BI, P1750; Lokmic Z, 2006, WOUND REPAIR REGEN, V14, P277, DOI 10.1111/j.1743-6109.2006.00122.x; Lu YX, 2001, CIRCULATION, V104, P594, DOI 10.1161/hc3101.092215; McIntire LV, 2002, ANN NY ACAD SCI, V961, P246, DOI 10.1111/j.1749-6632.2002.tb03092.x; Mian RW, 2000, TISSUE ENG, V6, P595, DOI 10.1089/10763270050199541; Muskhelishvili L, 2003, J HISTOCHEM CYTOCHEM, V51, P1681, DOI 10.1177/002215540305101212; OEHMICHEN M, 1982, Z RECHTSMED, V88, P285; Paige K T, 1995, Tissue Eng, V1, P97, DOI 10.1089/ten.1995.1.97; Park KD, 2000, YONSEI MED J, V41, P780, DOI 10.3349/ymj.2000.41.6.780; Ratcliffe A, 2000, MATRIX BIOL, V19, P353, DOI 10.1016/S0945-053X(00)00080-9; Rinsch C, 2001, GENE THER, V8, P523, DOI 10.1038/sj.gt.3301436; SCHERLE W, 1970, Mikroskopie, V26, P57; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stupack DG, 2003, ONCOGENE, V22, P9022, DOI 10.1038/sj.onc.1207110; Tabata Y, 2000, TISSUE ENG, V6, P279, DOI 10.1089/10763270050044452; Tanaka Y, 2003, PLAST RECONSTR SURG, V112, P1636, DOI 10.1097/01.PRS.0000086140.49022.AB; van Hinsbergh VWM, 2001, ANN NY ACAD SCI, V936, P426	38	139	143	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					511	522		10.1096/fj.06-6614com	http://dx.doi.org/10.1096/fj.06-6614com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17172640	Green Published			2022-12-28	WOS:000244686300024
J	Kim, YS; Choi, DH; Block, ML; Lorenzl, S; Yang, LC; Kim, YJ; Sugama, S; Cho, BP; Hwang, O; Browne, SE; Kim, SY; Hong, JS; Beal, MF; Joh, TH				Kim, Yoon Seong; Choi, Dong Hee; Block, Michelle L.; Lorenzl, Stefan; Yang, Lichuan; Kim, Youn Jung; Sugama, Shuei; Cho, Byung Pil; Hwang, Onyou; Browne, Susan E.; Kim, Soo Yul; Hong, Jau-Shyong; Beal, M. Flint; Joh, Tong H.			A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation	FASEB JOURNAL			English	Article						dopamine neuron protection	SUBSTANTIA-NIGRA; NADPH OXIDASE; REACTIVE MICROGLIA; PARKINSONS; APOPTOSIS; BRAIN; MODEL; MPTP; PHAGOCYTOSIS; MITOCHONDRIA	Recent studies have demonstrated that activated microglia play an important role in dopamine (DA) neuronal degeneration in Parkinson disease (PD) by generating NADPH-oxidase (NADPHO)-derived superoxide. However, the molecular mechanisms that underlie microglial activation in DA cell death are still disputed. We report here that matrix metalloproteinase-3 (MMP-3) was newly induced and activated in stressed DA cells, and the active form of MMP-3 (actMMP-3) was released into the medium. The released actMMP-3, as well as catalytically active recombinant MMP-3 ( cMMP-3) led to microglial activation and superoxide generation in microglia and enhanced DA cell death. cMMP-3 caused DA cell death in mesencephalic neuron-glia mixed culture of wild-type (WT) mice, but this was attenuated in the culture of NADPHO subunit null mice (gp9(1phox-/-)), suggesting that NADPHO mediated the cMMP-3-induced microglial production of superoxide and DA cell death. Furthermore, in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- injected animal model of PD, nigrostriatal DA neuronal degeneration, microglial activation, and superoxide generation were largely attenuated in MMP-3-/- mice. These results indicate that actMMP-3 released from stressed DA neurons is responsible for microglial activation and generation of NADPHO-derived superoxide and eventually enhances nigrostriatal DA neuronal degeneration. Our results could lead to a novel therapeutic approach to PD.	Cornell Univ, Weill Med Coll, Burke Med Res Inst, White Plains, NY USA; Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, White Plains, NY USA; Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea; NIEHS, Res Triangle Pk, NC 27709 USA; Kyung Hee Univ, Coll Oriental Med, Seoul, South Korea	Cornell University; Cornell University; University of Ulsan; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Kyung Hee University	Joh, TH (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, Rm F610,1300 York Ave, New York, NY 10021 USA.	thjoh@med.cornell.edu	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Block, Michelle/0000-0001-8303-7914				Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Brown SB, 1999, J IMMUNOL, V162, P480; Burke RE, 1998, ANN NEUROL, V44, pS126, DOI 10.1002/ana.410440719; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; Cho BP, 2003, CELL MOL NEUROBIOL, V23, P551, DOI 10.1023/A:1025024129946; Chun HS, 2002, EXP NEUROL, V173, P235, DOI 10.1006/exnr.2001.7842; DiezRoux G, 1997, DEVELOPMENT, V124, P3633; DIPASQUALE B, 1991, BIOCHEM BIOPH RES CO, V181, P1442, DOI 10.1016/0006-291X(91)92101-O; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Gao HM, 2003, FASEB J, V17, P1957, DOI 10.1096/fj.03-0203fje; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Kim YS, 2005, J NEUROSCI, V25, P3701, DOI 10.1523/JNEUROSCI.4346-04.2005; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Liu B, 2001, J NEUROCHEM, V77, P182, DOI 10.1046/j.1471-4159.2001.t01-1-00216.x; Lorenzl S, 2004, NEUROMOL MED, V5, P119, DOI 10.1385/NMM:5:2:119; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; McGeer PL, 2003, ANN NEUROL, V54, P599, DOI 10.1002/ana.10728; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V134, P743, DOI 10.1016/S0006-291X(86)80483-1; Stuart LM, 2002, J IMMUNOL, V168, P1627, DOI 10.4049/jimmunol.168.4.1627; Sugama S, 2003, BRAIN RES, V964, P288, DOI 10.1016/S0006-8993(02)04085-4; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100	27	158	167	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					179	187		10.1096/fj.06-5865com	http://dx.doi.org/10.1096/fj.06-5865com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17116747				2022-12-28	WOS:000243130200019
J	Gonzalez-Periz, A; Planaguma, A; Gronert, K; Miquel, R; Lopez-Parra, M; Titos, E; Horrillo, R; Ferre, N; Deulofeu, R; Arroyo, V; Rodes, J; Claria, J				Gonzalez-Periz, Ana; Planaguma, Anna; Gronert, Karsten; Miquel, Rosa; Lopez-Parra, Marta; Titos, Esther; Horrillo, Raquel; Ferre, Natalia; Deulofeu, Ramon; Arroyo, Vicente; Rodes, Juan; Claria, Joan			Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA	FASEB JOURNAL			English	Article						inflammation; liver cells; omega-3 essential fatty acids	POLYUNSATURATED FATTY-ACIDS; FISH-OIL; ANTIINFLAMMATORY ACTIONS; HEPATIC STEATOSIS; COX-2 EXPRESSION; CELL APOPTOSIS; MECHANISMS; FIBROSIS; MODEL; OMEGA-3-FATTY-ACIDS	Docosahexaenoic acid (DHA) is a omega-3 essential fatty acid that reduces the incidence and severity of a number of diseases. Recently, a novel series of DHA-derived lipid mediators with potent protective actions has been identified. In this study we demonstrate that dietary amplification of these DHA-derived products protects the liver from necroinflammatory injury. In vitro, supplementation of hepatocytes with DHA significantly reduced hydrogen peroxide-induced DNA damage, evaluated by the "comet assay," and oxidative stress, determined by measurement of malondialdehyde levels. In vivo, dietary supplementation of mice with DHA ameliorated carbon tetrachloride-induced necroinflammatory damage. In addition, hepatic cyclooxygenase-2 expression and PGE(2) levels were significantly reduced in mice fed DHA-enriched diets. In these animals, increased hepatic formation of DHA-derived lipid mediators (i.e., 17S-hydroxy- DHA (17S-HDHA) and protectin D1) was detected by HPLC-gas chromatography/mass spectrometry analysis. Consistent with these findings, synthetic 17-HDHA abrogated genotoxic and oxidative damage in hepatocytes and decreased TNF-alpha release and 5-lipoxygenase expression in macrophages. In a transactivation assay, 17-HDHA acted in a concentration-dependent manner as a PPAR gamma agonist. Taken together, these findings identify a potential role for DHA-derived products, specifically 17S-HDHA and protectin D1, in mediating the protective effects of dietary DHA in necroinflammatory liver injury.-Gonzalez-Periz, A., Planaguma, A., Gronert, K., Miquel, R., Lopez- Parra, M., Titos, E., Horrillo, R., Ferre, N., Deulofeu, R., Arroyo, V., Rodes, J., Claria, J. Docosahexaenoic acid ( DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxyDHA.	Univ Barcelona, Sch Med, Hosp Clin Barcelona,IDIBAPS, Dept Biochem & Mol Genet, E-08036 Barcelona, Spain; Univ Barcelona, Sch Med, Hosp Clin Barcelona,IDIBAPS, Pathol Lab, E-08036 Barcelona, Spain; Univ Barcelona, Sch Med, Hosp Clin Barcelona,IDIBAPS, Liver Unit, E-08036 Barcelona, Spain; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; New York Medical College	Claria, J (corresponding author), Univ Barcelona, Sch Med, Hosp Clin Barcelona,IDIBAPS, Dept Biochem & Mol Genet, Villarroel 170, E-08036 Barcelona, Spain.	jclaria@clinic.ub.es	Ferré, Natalia/ABE-5700-2020; Titos, Esther/AAA-5394-2019; Arroyo, Vicente/F-9189-2015; Horrillo, Raquel/B-4348-2009; Claria, Joan/M-7772-2019	Ferré, Natalia/0000-0002-2838-1525; Titos, Esther/0000-0002-2543-2243; Arroyo, Vicente/0000-0002-2728-1848; Claria, Joan/0000-0003-4333-7749	NATIONAL EYE INSTITUTE [R01EY016136] Funding Source: NIH RePORTER; NEI NIH HHS [EY016136, R01 EY016136-03, R01 EY016136] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alwayn IPJ, 2005, TRANSPLANTATION, V79, P606, DOI 10.1097/01.TP.0000150023.86487.44; Ariel A, 2005, J BIOL CHEM, V280, P43079, DOI 10.1074/jbc.M509796200; Arita M, 2005, P NATL ACAD SCI USA, V102, P7671, DOI 10.1073/pnas.0409271102; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Aronson AJ, 2001, UROLOGY, V58, P283, DOI 10.1016/S0090-4295(01)01116-5; Bagga D, 2003, P NATL ACAD SCI USA, V100, P1751, DOI 10.1073/pnas.0334211100; BALDIE G, 1993, BIOCHIM BIOPHYS ACTA, V1179, P125, DOI 10.1016/0167-4889(93)90133-A; BILLIAR TR, 1988, SURGERY, V104, P343; Cabre E, 1999, NUTRITION, V15, P322; Cabre E, 1996, NUTRITION, V12, P542, DOI 10.1016/S0899-9007(96)00122-0; Calder PC, 2002, P NUTR SOC, V61, P345, DOI 10.1079/PNS2002166; Curtis CL, 2000, J BIOL CHEM, V275, P721, DOI 10.1074/jbc.275.2.721; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; Diehl AM, 2000, IMMUNOL REV, V174, P160, DOI 10.1034/j.1600-0528.2002.017411.x; Du CY, 2004, J NUTR BIOCHEM, V15, P273, DOI 10.1016/j.jnutbio.2003.11.005; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Gronert K, 2005, J BIOL CHEM, V280, P15267, DOI 10.1074/jbc.M410638200; Gronert K, 1999, METH MOL B, V120, P119; HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1; Llor X, 2003, CLIN NUTR, V22, P71, DOI 10.1054/clnu.2002.0627; Lotersztajn S, 2005, ANNU REV PHARMACOL, V45, P605, DOI 10.1146/annurev.pharmtox.45.120403.095906; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Miyamoto A, 1997, J GASTROEN HEPATOL, V12, P644, DOI 10.1111/j.1440-1746.1997.tb00528.x; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; Nanji AA, 2001, J PHARMACOL EXP THER, V299, P638; Narayanan BA, 2003, CANCER RES, V63, P972; OWEN JS, 1982, J LIPID RES, V23, P124; OWEN JS, 1981, J LIPID RES, V22, P423; Pawlosky RJ, 2004, ALCOHOL CLIN EXP RES, V28, P1569, DOI 10.1097/01.ALC.0000141810.22855.4E; Planaguma A, 2005, FASEB J, V19, P1120, DOI 10.1096/fj.04-2753fje; Rousseau D, 2003, AM J PHYSIOL-HEART C, V285, pH1294, DOI 10.1152/ajpheart.00651.2002; Rousseau D, 2001, MOL CELL BIOCHEM, V225, P109, DOI 10.1023/A:1012266005428; Sekiya M, 2003, HEPATOLOGY, V38, P1529, DOI 10.1016/j.hep.2003.09.028; Serhan CN, 2006, J IMMUNOL, V176, P1848, DOI 10.4049/jimmunol.176.3.1848; Serhan CN, 2004, PROSTAG OTH LIPID M, V73, P155, DOI 10.1016/j.prostaglandins.2004.03.005; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Thomas EL, 1997, HEPATOLOGY, V25, P178, DOI 10.1002/hep.510250133; Titos E, 2005, J LEUKOCYTE BIOL, V78, P871, DOI 10.1189/jlb.1204747; Titos E, 2003, FASEB J, V17, P1745, DOI 10.1096/fj.02-1157fje; Titos E, 2000, GASTROENTEROLOGY, V119, P794, DOI 10.1053/gast.2000.17831; Vecchini A, 2004, J LIPID RES, V45, P308, DOI 10.1194/jlr.M300396-JLR200; Wallace FA, 2000, CYTOKINE, V12, P1374, DOI 10.1006/cyto.2000.0735; Watanabe A, 1999, NUTRITION, V15, P284, DOI 10.1016/S0899-9007(99)00004-0	50	177	189	2	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2537	+		10.1096/fj.06-6250fje	http://dx.doi.org/10.1096/fj.06-6250fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17056761				2022-12-28	WOS:000242490700015
J	Karabina, SA; Brocheriou, I; Le Naour, G; Agrapart, M; Durand, H; Gelb, M; Lambeau, G; Ninio, E				Karabina, Sonia-Athina; Brocheriou, Isabelle; Le Naour, Gilles; Agrapart, Monique; Durand, Herve; Gelb, Michael; Lambeau, Gerard; Ninio, Ewa			Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function	FASEB JOURNAL			English	Article						low-density lipoprotein; adhesion molecules; lipid mediators; inflammation	LOW-DENSITY-LIPOPROTEIN; ARACHIDONIC-ACID RELEASE; GROUP-V; POTENTIAL ROLE; GROUP-IIA; EICOSANOID PRODUCTION; A(2) MODIFICATION; ENZYMES; BINDING; MACROPHAGES	Increasing evidence suggests that secreted phospholipases A2 (sPLA2s) play an important role in the pathophysiology of atherosclerosis. Among sPLA2s, the human group X (hGX) enzyme has the highest catalytic activity toward phosphatidylcholine, one of the major phospholipid species of cell membranes and low-density lipoprotein (LDL). Our study examined the presence of hGX sPLA2 in human atherosclerotic lesions and investigated the ability of hGX modified LDL to alter human endothelial cell (HUVEC) function. Our results show that hGX sPLA2 is present in human atherosclerotic lesions and that the hydrolysis of LDL by hGX sPLA2 results in a modified particle that induces lipid accumulation in human monocyte-derived macrophages. Acting on endothelial cells, hGX-modified LDL activates the MAP kinase pathway, which leads to increased arachidonic acid release, increased expression of adhesion molecules on the surface of HUVEC, and increased adhesion of monocytes to HUVEC monolayers. Together, our data suggest that LDL modified by hGX, rather than hGX itself may have strong proinflammatory and proatherogenic properties, which could play an important role in the propagation of atherosclerosis.-Karabina, S. A., Brocheriou, I., Le Naour, G., Agrapart, M., Durand, H., Gelb, M., Lambeau, G., Ninio, E. Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function.	Fac Med Pierre & Marie Curie, F-75634 Paris, France; Univ Paris 06, Inst Federatif CMV, F-75252 Paris 05, France; INSERM, UMR 525, Paris, France; Grp Hosp Pitie Salpetriere, Lab Cent Anat Pathol, F-75634 Paris, France; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; IPMC, CNRS UMR 6097, Valbonne, France	UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Karabina, SA (corresponding author), Fac Med Pierre & Marie Curie, 91 Blvd Hop, F-75634 Paris, France.	akarampi@chups.jussieu.fr	Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X; Durand, Herve/0000-0002-8167-4693; gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL-36235] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036235, R01HL036235, R37HL036235] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bezzine S, 2002, J BIOL CHEM, V277, P48523, DOI 10.1074/jbc.M203137200; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bobryshev YV, 1996, ATHEROSCLEROSIS, V127, P283, DOI 10.1016/S0021-9150(96)05946-1; Boyanovsky BB, 2005, J BIOL CHEM, V280, P32746, DOI 10.1074/jbc.M502067200; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Dentan C, 1996, EUR J BIOCHEM, V236, P48, DOI 10.1111/j.1432-1033.1996.00048.x; El-Hariry I, 1997, Expert Opin Investig Drugs, V6, P1465, DOI 10.1517/13543784.6.10.1465; Esterbauer H, 1996, REV PHYSIOL BIOCH P, V127, P31, DOI 10.1007/BFb0048264; Flood C, 2004, ARTERIOSCL THROM VAS, V24, P564, DOI 10.1161/01.ATV.0000117174.19078.85; Gesquiere L, 2002, BIOCHEMISTRY-US, V41, P4911, DOI 10.1021/bi015757x; Ghesquiere SAI, 2005, CARDIOVASC TOXICOL, V5, P161, DOI 10.1385/CT:5:2:161; Granata F, 2005, J IMMUNOL, V174, P464, DOI 10.4049/jimmunol.174.1.464; Gudmundsdottir IJ, 2001, ATHEROSCLEROSIS, V156, P81, DOI 10.1016/S0021-9150(00)00631-6; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Hevonoja T, 2000, BBA-MOL CELL BIOL L, V1488, P189, DOI 10.1016/S1388-1981(00)00123-2; Houliston RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1266, DOI 10.1152/ajpcell.2001.281.4.C1266; Hurt-Camejo E, 2000, CURR OPIN LIPIDOL, V11, P465, DOI 10.1097/00041433-200010000-00004; Hurt-Camejo E, 2001, CIRC RES, V89, P298, DOI 10.1161/hh1601.095598; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; Ishimoto Y, 2003, BBA-MOL CELL RES, V1642, P129, DOI 10.1016/S0167-4889(03)00120-4; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KLEINMAN Y, 1988, J LIPID RES, V29, P729; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Meller M, 2005, PLACENTA, V26, P601, DOI 10.1016/j.placenta.2004.09.009; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Murakami M, 2004, BIOL PHARM BULL, V27, P1158, DOI 10.1248/bpb.27.1158; Murakami M, 2003, CURR OPIN LIPIDOL, V14, P431, DOI 10.1097/00041433-200310000-00003; Natarajan R, 2004, ARTERIOSCL THROM VAS, V24, P1542, DOI 10.1161/01.ATV.0000133606.69732.4c; Niessen HWM, 2003, CARDIOVASC RES, V60, P68, DOI 10.1016/S0008-6363(03)00324-9; Packard C, 2000, INT J CARDIOL, V74, pS17, DOI 10.1016/S0167-5273(99)00107-2; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; Pruzanski W, 2005, BBA-MOL CELL BIOL L, V1736, P38, DOI 10.1016/j.bbalip.2005.07.005; PUHL H, 1994, METHOD ENZYMOL, V233, P425; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; Saiga A, 2005, PROSTAG OTH LIPID M, V75, P79, DOI 10.1016/j.prostaglandins.2004.10.001; SANTANAM N, 1995, J CLIN INVEST, V95, P2594, DOI 10.1172/JCI117961; Sartipy P, 2002, ADV EXP MED BIOL, V507, P3; Sartipy P, 1999, J BIOL CHEM, V274, P25913, DOI 10.1074/jbc.274.36.25913; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Smart BP, 2006, J MED CHEM, V49, P2858, DOI 10.1021/jm060136t; SOMMER A, 1992, J BIOL CHEM, V267, P24217; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Webb NR, 2005, CURR OPIN LIPIDOL, V16, P341, DOI 10.1097/01.mol.0000169355.20395.55; Wong JT, 1998, J BIOL CHEM, V273, P6830, DOI 10.1074/jbc.273.12.6830; Wooton-Kee CR, 2004, ARTERIOSCL THROM VAS, V24, P762, DOI 10.1161/01.ATV.0000122363.02961.c1; Zalewski A, 2002, CIRC RES, V91, P652, DOI 10.1161/01.RES.0000038996.97287.9A	57	77	79	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2547	+		10.1096/fj.06-6018fje	http://dx.doi.org/10.1096/fj.06-6018fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077289				2022-12-28	WOS:000242490700019
J	Chen, HW; Su, SF; Chien, CT; Lin, WH; Yu, SL; Chou, CC; Chen, JJW; Yang, PC				Chen, Huei-Wen; Su, Sheng-Fang; Chien, Chiang-Ting; Lin, Wei-Hsiang; Yu, Sung-Liang; Chou, Cheng-Chung; Chen, Jeremy J. W.; Yang, Pan-Chyr			Titanium dioxide nanoparticles induce emphysema-like lung injury in mice	FASEB JOURNAL			English	Article						nanotechnology; chemokines; placenta growth factor; microarray; pulmonary emphysema	PLACENTAL GROWTH-FACTOR; EPITHELIAL-CELLS; GENE-EXPRESSION; ALVEOLAR MACROPHAGES; RAT LUNG; PULMONARY; PARTICLES; INFLAMMATION; COMPLEMENT; PATHOPHYSIOLOGY	Titanium dioxide nanoparticles (nanoTiO(2)) have been widely used as a photocatalyst in air and water cleaning. However, these nanoparticles inhalation can induce pulmonary toxicity and its mechanism is not fully understood. In this study we investigated the pulmonary toxicity of nanoTiO(2) and its molecular pathogenesis. The adult male ICR mice were exposed to intratracheal single dose of 0.1 or 0.5 mg nanoTiO(2) (19 - 21 nm) and lung tissues were collected at 3rd day, 1st wk, and 2nd wk for morphometric, microarray gene expression, and pathway analyses. NanoTiO(2) can induce pulmonary emphysema, macrophages accumulation, extensive disruption of alveolar septa, type II pneumocyte hyperplasia, and epithelial cell apoptosis. NanoTiO2 induced differential expression of hundreds of genes include activation of pathways involved in cell cycle, apoptosis, chemokines, and complement cascades. In particular, nanoTiO(2) up-regulates placenta growth factor ( PlGF) and other chemokines (CXCL1, CXCL5, and CCL3) expressions that may cause pulmonary emphysema and alveolar epithelial cell apoptosis. Cultured human THP-1 cell-derived macrophages treated with nanoTiO2 in vitro also resulted in upregulations of PlGF, CXCL1, CXCL5, and CCL3. These results indicated that nanoTiO2 can induce severe pulmonary emphysema, which may be caused by activation of PlGF and related inflammatory pathways.	Natl Yang Ming Univ, Sch Med, Dept Pharmacol, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan; Natl Taiwan Univ, Ctr Genom Med, Taipei 10764, Taiwan; Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan; Natl Chung Hsing Univ, Coll Life Sci, Inst Life Sci, Taichung 40227, Taiwan; Natl Chung Hsing Univ, Coll Life Sci, Inst Biomed Sci & Mol Biol, Taichung 40227, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Chung Hsing University; National Chung Hsing University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Yang, PC (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan S Rd, Taipei 100, Taiwan.	pcyang@ha.mc.ntu.edu.tw	Yang, Pan-Chyr/B-8808-2009; Tsou, YY/H-4160-2011; Su, Sheng-Fang/AAT-3642-2021	Tsou, YY/0000-0003-3345-4351; Su, Sheng-Fang/0000-0002-1624-5745; CHEN, HUEI-WEN/0000-0001-5051-9896; Chen, Jeremy J.W./0000-0003-1049-3825; YANG, PAN-CHYR/0000-0001-6330-6048; YU, SUNG-LIANG/0000-0003-4535-9036				Afaq F, 1998, J APPL TOXICOL, V18, P307, DOI 10.1002/(SICI)1099-1263(1998090)18:5<307::AID-JAT508>3.0.CO;2-K; *AM THOR SOC PAT I, 2005, AM J RESP CRIT CARE, V171, P3; Barnes PJ, 2003, ANNU REV MED, V54, P113, DOI 10.1146/annurev.med.54.101601.152209; Borders CW, 2005, SCAND J IMMUNOL, V62, P123, DOI 10.1111/j.1365-3083.2005.01643.x; Borm PJA, 2004, J NANOSCI NANOTECHNO, V4, P521, DOI 10.1166/jnn.2004.081; Chellat F, 2005, BIOMATERIALS, V26, P961, DOI 10.1016/j.biomaterials.2004.04.006; Chen HW, 2005, HUM REPROD, V20, P2492, DOI 10.1093/humrep/dei084; Chen HW, 2004, HEART, V90, P927, DOI 10.1136/hrt.2002.006734; Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311, DOI 10.1165/ajrcmb/8.3.311; Golpon HA, 2004, AM J RESP CELL MOL, V31, P595, DOI 10.1165/rcmb.2004-0008OC; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; Hohr D, 2002, INT J HYG ENVIR HEAL, V205, P239, DOI 10.1078/1438-4639-00123; Hoyle GW, 1999, AM J PATHOL, V154, P1763, DOI 10.1016/S0002-9440(10)65432-6; Jeyaseelan S, 2005, AM J RESP CELL MOL, V32, P531, DOI 10.1165/rcmb.2005-0063OC; Jeyaseelan S, 2004, INFECT IMMUN, V72, P7247, DOI 10.1128/IAI.72.12.7247-7256.2004; Kader HA, 2005, AM J GASTROENTEROL, V100, P414, DOI 10.1111/j.1572-0241.2005.40819.x; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; Lam CW, 2004, TOXICOL SCI, V77, P126, DOI 10.1093/toxsci/kfg243; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Leong BKJ, 1998, J APPL TOXICOL, V18, P149, DOI 10.1002/(SICI)1099-1263(199803/04)18:2<149::AID-JAT490>3.3.CO;2-C; Levine RJ, 2005, JAMA-J AM MED ASSOC, V293, P77, DOI 10.1001/jama.293.1.77; Linde K, 2001, BMC Complement Altern Med, V1, P3; Londhe Vedang A, 2005, J Inflamm (Lond), V2, P4, DOI 10.1186/1476-9255-2-4; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Luttun A, 2002, BIOCHEM BIOPH RES CO, V295, P428, DOI 10.1016/S0006-291X(02)00677-0; Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev; MORGAN BP, 1995, CRIT REV CL LAB SCI, V32, P265, DOI 10.3109/10408369509084686; MUTASA HCF, 1988, HISTOCHEM J, V20, P558, DOI 10.1007/BF01002610; Negoescu A, 1996, J HISTOCHEM CYTOCHEM, V44, P959, DOI 10.1177/44.9.8773561; Oberdorster G, 2000, Res Rep Health Eff Inst, P5; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Oberdorster G, 1996, PARTICLE OVERLOAD IN THE RAT LUNG AND LUNG CANCER, P73; Oura H, 2003, BLOOD, V101, P560, DOI 10.1182/blood-2002-05-1516; Perelman N, 2003, BLOOD, V102, P1506, DOI 10.1182/blood-2002-11-3422; Peters K, 2004, J MATER SCI-MATER M, V15, P321, DOI 10.1023/B:JMSM.0000021095.36878.1b; Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423; Steerenberg PA, 1998, EXP LUNG RES, V24, P85, DOI 10.3109/01902149809046056; Sun D, 2004, WATER SCI TECHNOL, V49, P103, DOI 10.2166/wst.2004.0030; THURLBEC.WM, 1967, AM REV RESPIR DIS, V95, P752; Tsao PN, 2004, AM J RESP CRIT CARE, V169, P505, DOI 10.1164/rccm.200306-774OC; VANBUCHEM MA, 1993, LEUKEMIA, V7, P1608; Walrath E, 2005, AM J RESP CELL MOL, V33, P48, DOI 10.1165/rcmb.2005-0060OC; Wottrich R, 2004, INT J HYG ENVIR HEAL, V207, P353, DOI 10.1078/1438-4639-00300; Yao PL, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-89; Yu SL, 2004, AM J RESP CRIT CARE, V169, P1135, DOI 10.1164/rccm.200211-1278OC	46	229	248	3	55	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2393	+		10.1096/fj.06-6485fje	http://dx.doi.org/10.1096/fj.06-6485fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023518				2022-12-28	WOS:000241702600031
J	Kioi, M; Seetharam, S; Puri, RK				Kioi, Mitomu; Seetharam, Saraswathy; Puri, Raj K.			N-linked glycosylation of IL-13R alpha 2 is essential for optimal IL-13 inhibitory activity	FASEB JOURNAL			English	Article						type I cytokine receptor; ECD; allergic and inflammatory diseases; cancer	INTERLEUKIN-13 RECEPTOR; SIGNAL-TRANSDUCTION; EXTRACELLULAR DOMAIN; GLIOMA-CELLS; BINDING; PROTEIN; ALPHA; COMPONENT; CLONING; IDENTIFICATION	A high-affinity receptor for interleukin (IL)-13 (interleukin-13R alpha 2) is over-expressed in disease-related fibroblasts and neoplastic cells and is involved in cancer, allergic, and inflammatory diseases. The extracellular domain of IL-13R alpha 2 (ECD alpha 2) could be cleaved, which serves as a decoy receptor. We have expressed and purified ECD alpha 2 in both Escherichia coli ( E. coli) and mammalian systems as a soluble fragment and studied its biological activities. Although both products of ECD alpha 2 showed IL-13 inhibitory activities, mammalian cell-derived ECD alpha 2 appeared to be superior compared with purified protein from E. coli. When expressed in E. coli, ECD alpha 2 appeared to be a monomer of 42 but a 60 kDa protein when purified from mammalian cells due to heavy glycosylation. The purified glycosylated ECD alpha 2 efficiently inhibited IL-13-induced STAT6 phosphorylation in immune and Hodgkin's lymphoma cell lines, IL-13 binding, and cytotoxicity of IL-13 cytotoxin in various cancer cell lines. The improved potency of mammalian cell-derived ECD alpha 2 was shown over ECD alpha 2/Fc fusion protein. The N-linked glycosylation of ECD alpha 2 was found to be essential for optimal IL-13 inhibitory activity as deglycosylation by PNGase F showed lower activity. ECD alpha 2 did not inhibit IL-4-induced STAT6 phosphorylation, indicating that inhibitory effects of ECD alpha 2 are receptor specific. These results indicate that glycosylated ECD alpha 2 can serve as a potent inhibitor of IL-13 in a variety of conditions in which IL-13 is a key mediator, e. g., pulmonary, allergic, fibrotic, and neoplastic diseases.	US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Tumor Vaccines & Biotechnol Branch, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Puri, RK (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Tumor Vaccines & Biotechnol Branch, NIH Bldg 29B,Rm 2NN20,29 Lincoln Dr, Bethesda, MD 20892 USA.	raj.puri@fda.hhs.gov		Kioi, Mitomu/0000-0002-7981-3340				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; BASTIAN W, 1993, DIABETES, V42, P966, DOI 10.2337/diabetes.42.7.966; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; Cole AR, 1999, J BIOL CHEM, V274, P7207, DOI 10.1074/jbc.274.11.7207; Daines MO, 2002, J BIOL CHEM, V277, P10387, DOI 10.1074/jbc.M108109200; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Debinski W, 1995, CLIN CANCER RES, V1, P1253; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; DING DXH, 1995, J BIOL CHEM, V270, P24580, DOI 10.1074/jbc.270.41.24580; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Gonzalez-Moreno O, 2005, INT J CANCER, V114, P870, DOI 10.1002/ijc.20789; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Husain SR, 2000, BLOOD, V95, P3506, DOI 10.1182/blood.V95.11.3506.011k47_3506_3513; Jakubzick C, 2004, J CLIN PATHOL, V57, P477, DOI 10.1136/jcp.2003.012799; Jakubzick C, 2003, J IMMUNOL, V171, P2684, DOI 10.4049/jimmunol.171.5.2684; Joshi BH, 2000, CANCER RES, V60, P1168; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Kawakami K, 2001, J BIOL CHEM, V276, P25114, DOI 10.1074/jbc.M100936200; Kawakami K, 2001, CANCER RES, V61, P6194; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; Kioi M, 2004, CELL IMMUNOL, V229, P41, DOI 10.1016/j.cellimm.2004.06.005; Kioi M, 2004, CLIN CANCER RES, V10, P6231, DOI 10.1158/1078-0432.CCR-04-0700; KITAMURA T, 1989, BLOOD, V73, P375; LEFORT S, 1995, FEBS LETT, V366, P122, DOI 10.1016/0014-5793(95)00512-8; Logsdon NJ, 2004, J MOL BIOL, V342, P503, DOI 10.1016/j.jmb.2004.07.069; Mentink-Kane MM, 2004, P NATL ACAD SCI USA, V101, P586, DOI 10.1073/pnas.0305064101; Murad AM, 1997, CLIN DRUG INVEST, V13, P90, DOI 10.2165/00044011-199713020-00005; Niu LH, 2000, BLOOD, V95, P3357, DOI 10.1182/blood.V95.11.3357.011k43_3357_3362; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; Oshima Y, 2001, J BIOL CHEM, V276, P15185, DOI 10.1074/jbc.M010159200; Rahaman SO, 2005, CANCER RES, V65, P2956, DOI 10.1158/0008-5472.CAN-04-3592; Rahaman SO, 2002, CANCER RES, V62, P1103; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Yoshikawa M, 2003, BIOCHEM BIOPH RES CO, V312, P1248, DOI 10.1016/j.bbrc.2003.11.077; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	41	24	26	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2378	+		10.1096/fj.06-5995fje	http://dx.doi.org/10.1096/fj.06-5995fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023392				2022-12-28	WOS:000241702600026
J	McCormick, J; Barry, SP; Sivarajah, A; Stefanutti, G; Townsend, PA; Lawrence, KM; Eaton, S; Knight, RA; Thiemermann, C; Latchman, DS; Stephanou, A				McCormick, James; Barry, Sean P.; Sivarajah, Ahila; Stefanutti, Giorgio; Townsend, Paul A.; Lawrence, Kevin M.; Eaton, Simon; Knight, Richard A.; Thiemermann, Christoph; Latchman, David S.; Stephanou, Anastasis			Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury	FASEB JOURNAL			English	Article						tempol; heart; rat	CARDIAC MYOCYTES; INDUCED APOPTOSIS; ISCHEMIA; EXPRESSION; INDUCTION; PROTECTS; PATHWAY; ATM	The signal transducer and activator of transcription (STAT) family are latent transcription factors involved in a variety of signal transduction pathways, including cell death cascades. STAT1 has been shown to have a crucial role in regulating cardiac cell apoptosis in the myocardium exposed to ischemia/reperfusion (I/R) injury. The free radical scavenger, tempol, is known to have cardioprotective properties, although little is known about the molecular mechanism(s) by which it acts. In the present study, we assessed the levels of phosphorylated STAT1 and STAT3 and examined whether tempol was able to affect STAT activation after in vivo cardiac I/R injury. We observed a reperfusion time-dependent increase in the tyrosine phosphorylation of STAT1 and STAT3 at residues 701 and 705, respectively. Here we show for the first time that tempol dramatically reduced STAT1 and 3 phosphorylation. The reduction in STAT1 and 3 phosphorylation was accompanied by a concomitant decrease in cellular malondialdehyde (MDA) levels. To verify the role of STAT1 in modulating the cardioprotective effect of tempol, rats were injected with the STAT1 activator, IFN-gamma, and tempol during I/R injury. We found that the presence of IFN-gamma abrogated the protective effects of tempol, suggesting that the protective effects of tempol may partly operate by decreasing the phosphorylation of STAT1. This study demonstrates that careful dissection of the molecular mechanisms that underpin I/R injury may reveal cardioprotective targets for future therapy.	UCL, Inst Child Hlth, Dept Med Mol Biol, London WC1N 1EH, England; UCL, Inst Child Hlth, Dept Surg, London WC1N 1EH, England; Queen Mary Univ London, Ctr Expt Med Nephrol & Crit Care, William Harvey Res Inst, St Bartholomews & Royal London Sch Med & Dent, London E1 4NS, England; Univ Southampton, Southampton Gen Hosp, Div Human Genet, Southampton, Hants, England	University of London; University College London; University of London; University College London; University of London; Queen Mary University London; University of Southampton	Stephanou, A (corresponding author), UCL, Inst Child Hlth, Dept Med Mol Biol, 30 Guilford St, London WC1N 1EH, England.	a.stephanou@ich.ucl.ac.uk	Eaton, Simon/C-4942-2008; Townsend, Paul/AAF-8234-2020	Eaton, Simon/0000-0003-0892-9204; Thiemermann, Christoph/0000-0003-4228-9722; Townsend, Paul/0000-0001-8956-9508				Decker T, 2002, J CLIN INVEST, V109, P1271, DOI 10.1172/JCI200215770; Eefting F, 2004, CARDIOVASC RES, V61, P414, DOI 10.1016/j.cardiores.2003.12.023; FLAHERTY JT, 1991, AM J MED S3C, V91, P79; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; Hilfiker-Kleiner D, 2004, CIRC RES, V95, P187, DOI 10.1161/01.RES.0000134921.50377.61; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; Maxwell SRJ, 1997, INT J CARDIOL, V58, P95, DOI 10.1016/S0167-5273(96)02854-9; McDonald MC, 1999, FREE RADICAL BIO MED, V27, P493, DOI 10.1016/S0891-5849(99)00100-8; Menegazzi M, 2001, FASEB J, V15, P1309, DOI 10.1096/fj.00-0519fje; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Scarabelli TM, 2002, CIRC RES, V90, P745, DOI 10.1161/01.RES.0000015224.07870.9A; Shen YH, 2005, BIOCHEM BIOPH RES CO, V330, P305, DOI 10.1016/j.bbrc.2005.02.154; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Stefanutti G, 2005, SHOCK, V24, P159, DOI 10.1097/01.shk.0000168871.60531.6f; Stephanou A, 2004, J CELL MOL MED, V8, P519, DOI 10.1111/j.1582-4934.2004.tb00476.x; Stephanou A, 2002, FASEB J, V16, P1841, DOI 10.1096/fj.02-0150fje; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Stephanou A, 2001, CELL DEATH DIFFER, V8, P434, DOI 10.1038/sj.cdd.4400846; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; Townsend PA, 2005, J CELL SCI, V118, P1629, DOI 10.1242/jcs.01728; Townsend PA, 2004, FASEB J, V18, P1612, DOI 10.1096/fj.04-1716fje	25	61	62	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2115	+		10.1096/fj.06-6188fje	http://dx.doi.org/10.1096/fj.06-6188fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935931				2022-12-28	WOS:000241156900021
J	Hunt, MC; Rautanen, A; Westin, MAK; Svensson, LT; Alexson, SEH				Hunt, Mary C.; Rautanen, Anna; Westin, Maria A. K.; Svensson, L. Thomas; Alexson, Stefan E. H.			Analysis of the mouse and human acyl-CoA thioesterase (ACOT) gene clusters shows that convergent, functional evolution results in a reduced number of human peroxisomal ACOTs	FASEB JOURNAL			English	Article						beta-oxidation; acyl-coenzyme A; peroxisome; fatty acids	ACTIVATED RECEPTORS ALPHA; LONG-CHAIN; FATTY-ACIDS; RAT-LIVER; MOLECULAR-CLONING; IDENTIFICATION; ESTERS; INHIBITION; OXIDASE; PROTEIN	The maintenance of cellular levels of free fatty acids and acyl-CoAs, the activated form of free fatty acids, is extremely important, as imbalances in lipid metabolism have serious consequences for human health. Acyl-coenzyme A (CoA) thioesterases (ACOTs) hydrolyze acyl-CoAs to the free fatty acid and CoASH, and thereby have the potential to regulate intracellular levels of these compounds. We previously identified and characterized a mouse ACOT gene cluster comprised of six genes that apparently arose by gene duplications encoding acyl-CoA thioesterases with localizations in cytosol (ACOT1), mitochondria (ACOT2), and peroxisomes (ACOT3 - 6). However, the corresponding human gene cluster contains only three genes (ACOT1, ACOT2, and ACOT4) coding for full-length thioesterase proteins, of which only one is peroxisomal (ACOT4). We therefore set out to characterize the human genes, and we show here that the human ACOT4 protein catalyzes the activities of three mouse peroxisomal ACOTs (ACOT3, 4, and 5), being active on succinyl-CoA and medium to long chain acyl-CoAs, while ACOT1 and ACOT2 carry out similar functions to the corresponding mouse genes. These data strongly suggest that the human ACOT4 gene has acquired the functions of three mouse genes by a functional convergent evolution that also provides an explanation for the unexpectedly low number of human genes. - Hunt, M. C., Rautanen, A., Westin, M. A. K., Svensson, L. T., Alexson, S. E. H. Analysis of the mouse and human acyl-CoA thioesterase (ACOT) gene clusters shows that convergent, functional evolution results in a reduced number of human peroxisomal ACOTs.	Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Chem C1 74, SE-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Hunt, MC (corresponding author), Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Chem C1 74, SE-14186 Stockholm, Sweden.	mary.hunt@ki.se		Svensson, Thomas/0000-0002-9190-2979; Watter, Maria/0000-0001-9047-5517; Hunt, Mary/0000-0001-6415-2992				Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; Branstrom R, 2004, DIABETOLOGIA, V47, P277, DOI 10.1007/s00125-003-1299-x; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Hirotsune S, 2003, NATURE, V423, P91, DOI 10.1038/nature01535; Hostetler HA, 2005, J BIOL CHEM, V280, P18667, DOI 10.1074/jbc.M412062200; Huhtinen K, 2002, J BIOL CHEM, V277, P3424, DOI 10.1074/jbc.M109040200; Hunt MC, 2005, J LIPID RES, V46, P2029, DOI 10.1194/jlr.E500003-JLR200; Hunt MC, 2005, EUR J CLIN INVEST, V35, P38, DOI 10.1111/j.1365-2362.2005.01447.x; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Jones JM, 2000, BIOCHEM BIOPH RES CO, V275, P233, DOI 10.1006/bbrc.2000.3285; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; OGIWARA H, 1978, EUR J BIOCHEM, V89, P33, DOI 10.1111/j.1432-1033.1978.tb20893.x; Pawar A, 2003, J BIOL CHEM, V278, P35931, DOI 10.1074/jbc.M306238200; SCHEPERS L, 1990, J BIOL CHEM, V265, P5242; SRERE PA, 1965, BIOCHIM BIOPHYS ACTA, V106, P445, DOI 10.1016/0005-2760(65)90061-5; Suga Tetsuya, 2003, Drug Metab Pharmacokinet, V18, P155, DOI 10.2133/dmpk.18.155; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; TAN H, 1990, EUR J BIOCHEM, V190, P107, DOI 10.1111/j.1432-1033.1990.tb15552.x; Taylor EB, 2005, AM J PHYSIOL-ENDOC M, V288, pE1055, DOI 10.1152/ajpendo.00516.2004; Thompson AL, 2000, DIABETES, V49, P1761, DOI 10.2337/diabetes.49.11.1761; VANHOVE GF, 1993, J BIOL CHEM, V268, P10335; Wanders RJA, 2004, MOL GENET METAB, V83, P16, DOI 10.1016/j.ymgme.2004.08.016; Wanders RJA, 2004, AM J MED GENET A, V126A, P355, DOI 10.1002/ajmg.a.20661; Westin MAK, 2005, J BIOL CHEM, V280, P38125, DOI 10.1074/jbc.M508479200; Westin MAK, 2004, J BIOL CHEM, V279, P21841, DOI 10.1074/jbc.M313863200; Yamada J, 2005, AMINO ACIDS, V28, P273, DOI 10.1007/s00726-005-0181-1	35	75	82	2	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1855	1864		10.1096/fj.06-6042com	http://dx.doi.org/10.1096/fj.06-6042com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940157	Green Submitted			2022-12-28	WOS:000240267000013
J	Cole, JN; McArthur, JD; McKay, FC; Sanderson-Smith, ML; Cork, AJ; Ranson, M; Rohde, M; Itzek, A; Sun, HM; Ginsburg, D; Kotb, M; Nizet, V; Chhatwal, GS; Walker, MJ				Cole, Jason N.; McArthur, Jason D.; McKay, Fiona C.; Sanderson-Smith, Martina L.; Cork, Amanda J.; Ranson, Marie; Rohde, Manfred; Itzek, Andreas; Sun, Hongmin; Ginsburg, David; Kotb, Malak; Nizet, Victor; Chhatwal, G. S.; Walker, Mark J.			Trigger for group A streptococcal M1T1 invasive disease	FASEB JOURNAL			English	Article						Streptococcus pyogenes; SpeB; plasminogen	HYALURONIC-ACID CAPSULE; CYSTEINE PROTEASE; PLASMINOGEN-BINDING; VIRULENCE FACTORS; SKIN INFECTION; IN-VIVO; PYOGENES; SURFACE; EXPRESSION; FIBRINOGEN	The globally disseminated Streptococcus pyogenes M1T1 clone causes a number of highly invasive human diseases. The transition from local to systemic infection occurs by an unknown mechanism; however invasive M1T1 clinical isolates are known to express significantly less cysteine protease SpeB than M1T1 isolates from local infections. Here, we show that in comparison to the M1T1 strain 5448, the isogenic mutant Delta speB accumulated 75-fold more human plasmin activity on the bacterial surface following incubation in human plasma. Human plasminogen was an absolute requirement for M1T1 strain 5448 virulence following subcutaneous (s.c.) infection of humanized plasminogen transgenic mice. S. pyogenes M1T1 isolates from the blood of infected humanized plasminogen transgenic mice expressed reduced levels of SpeB in comparison with the parental 5448 used as inoculum. We propose that the human plasminogen system plays a critical role in group A streptococcal M1T1 systemic disease initiation. SpeB is required for S. pyogenes M1T1 survival at the site of local infection, however, SpeB also disrupts the interaction of S. pyogenes M1T1 with the human plasminogen activation system. Loss of SpeB activity in a subpopulation of S. pyogenes M1T1 at the site of infection results in accumulation of surface plasmin activity thus triggering systemic spread.	Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; German Natl Ctr Biotechnol, Dept Microbial Pathogenesis & Vaccine Dev, Braunschweig, Germany; Univ Michigan, Dept Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Tennessee, Dept Mol Sci, Knoxville, TN 37996 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA	University of Wollongong; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Tennessee System; University of Tennessee Knoxville; University of California System; University of California San Diego	Walker, MJ (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mwalker@uow.edu.au	Sanderson-Smith, Martina L/H-9614-2013; Walker, Mark J./F-6940-2011; Ranson, Marie/GRO-5792-2022; Ranson, Marie/AAC-4468-2019; Ranson, Marie/A-6324-2008; Nizet, Victor/AAF-3190-2019; Cork, Amanda/C-3830-2012; Sanderson-Smith, Martina/O-9387-2019	Sanderson-Smith, Martina L/0000-0002-6366-4993; Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Cork, Amanda/0000-0003-2207-6877; Nizet, Victor/0000-0003-3847-0422; McKay, Fiona Catherine/0000-0002-9610-0668; Walker, Mark/0000-0001-7423-2769	NHLBI NIH HHS [P01HL057346] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057346] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashbaugh CD, 1998, J CLIN INVEST, V102, P550, DOI 10.1172/JCI3065; Aziz RK, 2004, MOL MICROBIOL, V51, P123, DOI 10.1046/j.1365-2958.2003.03797.x; BERGE A, 1993, J BIOL CHEM, V268, P25417; Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cole JN, 2005, INFECT IMMUN, V73, P3137, DOI 10.1128/IAI.73.5.3137-3146.2005; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Gillen CM, 2002, MICROBIOL-SGM, V148, P169, DOI 10.1099/00221287-148-1-169; Herwald H, 2004, CELL, V116, P367, DOI 10.1016/S0092-8674(04)00057-1; Hynes W, 2004, FRONT BIOSCI-LANDMRK, V9, P3399, DOI 10.2741/1491; Hytonen J, 2001, MOL MICROBIOL, V39, P512, DOI 10.1046/j.1365-2958.2001.02269.x; Johnson DR, 2002, J INFECT DIS, V185, P1586, DOI 10.1086/340576; Kansal RG, 2000, INFECT IMMUN, V68, P6362, DOI 10.1128/IAI.68.11.6362-6369.2000; Kansal RG, 2003, J INFECT DIS, V187, P398, DOI 10.1086/368022; Kazmi SU, 2001, INFECT IMMUN, V69, P4988, DOI 10.1128/IAI.69.8.4988-4995.2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTENBERG R, 1992, J BACTERIOL, V174, P5204, DOI 10.1128/JB.174.16.5204-5210.1992; McKay FC, 2004, INFECT IMMUN, V72, P364, DOI 10.1128/IAI.72.1.364-370.2004; McMillan DJ, 2004, FEMS IMMUNOL MED MIC, V40, P249, DOI 10.1016/S0928-8244(04)00003-3; Musser JM, 1996, INFECT IMMUN, V64, P1913, DOI 10.1128/IAI.64.6.1913-1917.1996; Nyberg P, 2004, J BIOL CHEM, V279, P52820, DOI 10.1074/jbc.C400485200; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; Raeder R, 1998, RES MICROBIOL, V149, P539, DOI 10.1016/S0923-2508(99)80001-1; Rezcallah MS, 2004, MICROBIOL-SGM, V150, P365, DOI 10.1099/mic.0.26826-0; Ringdahl U, 2000, MOL MICROBIOL, V37, P1318, DOI 10.1046/j.1365-2958.2000.02062.x; Rosch J, 2004, SCIENCE, V304, P1513, DOI 10.1126/science.1097404; Schrager HM, 1996, J CLIN INVEST, V98, P1954, DOI 10.1172/JCI118998; STEVENS DL, 1992, CLIN INFECT DIS, V14, P2, DOI 10.1093/clinids/14.1.2; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Svensson MD, 2000, MOL MICROBIOL, V38, P242, DOI 10.1046/j.1365-2958.2000.02144.x; Walker MJ, 2005, TRENDS MICROBIOL, V13, P308, DOI 10.1016/j.tim.2005.05.006; WANG H, 1995, MICROB PATHOGENESIS, V18, P153, DOI 10.1016/S0882-4010(95)90013-6; WANG H, 1994, J INFECT DIS, V169, P143, DOI 10.1093/infdis/169.1.143; WANG H, 1995, J INFECT DIS, V171, P85, DOI 10.1093/infdis/171.1.85; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8	36	120	121	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1745	+		10.1096/fj.06-5804fje	http://dx.doi.org/10.1096/fj.06-5804fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790522	Green Submitted			2022-12-28	WOS:000240266600035
J	Shepherd, BR; Enis, DR; Wang, FY; Suarez, Y; Pober, JS; Schechner, JS				Shepherd, Benjamin R.; Enis, David R.; Wang, Feiya; Suarez, Yajaira; Pober, Jordan S.; Schechner, Jeffrey S.			Vascularization and engraftment of a human skin substitute using circulating progenitor cell-derived endothelial cells	FASEB JOURNAL			English	Article						endothelial progenitor cell; umbilical cord blood; leukapheresis; angiogenesis; tissue engineering	GROWTH; DIFFERENTIATION; TRANSPLANTATION; MICROVESSELS; FIBROBLASTS; EQUIVALENT; SIROLIMUS; APOPTOSIS; GRAFTS; ORIGIN	We seeded tissue engineered human skin substitutes with endothelial cells (EC) differentiated in vitro from progenitors from umbilical cord blood (CB-EC) or adult peripheral blood (AB-EC), comparing the results to previous work using cultured human umbilical vein EC (HUVEC) with or without Bcl-2 transduction. Vascularized skin substitutes were prepared by seeding Bcl-2-transduced or nontransduced HUVEC, CB-EC, or AB- EC on the deep surface of decellularized human dermis following keratinocyte coverage of the epidermal surface. These skin substitutes were transplanted onto C. B-17 SCID/beige mice receiving systemic rapamycin or vehicle control and were analyzed 21 d later. CB-EC and Bcl-2-HUVEC formed more human EC-lined vessels than AB- EC or control HUVEC; CB-EC, Bcl-2-HUVEC, and AB- EC but not control HUVEC promoted ingrowth of mouse EC-lined vessels. Bcl-2 transduction increased the number of human and mouse EC-lined vessels in grafts seeded with HUVEC but not with CB-EC or AB- EC. Both CB-EC and AB-EC-induced microvessels became invested by smooth muscle cell-specific alpha-actin-positive mural cells, indicative of maturation. Rapamycin inhibited ingrowth of mouse EC-lined vessels but did not inhibit formation of human EC-lined vessels. We conclude that EC differentiated from circulating progenitors can be utilized to vascularize human skin substitutes even in the setting of compromised host angiogenesis/vasculogenesis.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Dermatol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Immunobiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdept Program Vasc Biol & Transplantat, New Haven, CT 06510 USA	Yale University; Yale University; Yale University; Yale University	Pober, JS (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, 295 Congress Ave,Rm 454, New Haven, CT 06510 USA.	jordan.pober@yale.edu		Suarez, Yajaira/0000-0003-4549-2953	NHLBI NIH HHS [T32 HL07950, R01 HL551014] Funding Source: Medline; NIAMS NIH HHS [P30 AR41942] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041942] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BOYCE ST, 1995, ANN SURG, V222, P743, DOI 10.1097/00000658-199512000-00008; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; Curran MP, 2002, BIODRUGS, V16, P439, DOI 10.2165/00063030-200216060-00005; DEMARCHEZ M, 1992, TRANSPLANTATION, V54, P317, DOI 10.1097/00007890-199208000-00023; Drosou A, 2005, J AM ACAD DERMATOL, V52, P854, DOI 10.1016/j.jaad.2004.11.069; Enis DR, 2005, P NATL ACAD SCI USA, V102, P425, DOI 10.1073/pnas.0408357102; Gehling UM, 2000, BLOOD, V95, P3106; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Greenberg S, 2004, METH MOL B, V289, P425; Guilbeau JM, 2002, ANN PHARMACOTHER, V36, P1391; Harraz M, 2001, STEM CELLS, V19, P304, DOI 10.1634/stemcells.19-4-304; Hristov M, 2003, TRENDS CARDIOVAS MED, V13, P201, DOI 10.1016/S1050-1738(03)00077-X; Kearney JN, 2001, BURNS, V27, P545, DOI 10.1016/S0305-4179(01)00020-1; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; KREJCI NC, 1991, J INVEST DERMATOL, V97, P843, DOI 10.1111/1523-1747.ep12491522; Kuypers DRJ, 2005, DRUG SAFETY, V28, P153, DOI 10.2165/00002018-200528020-00006; LAMBERT PB, 1971, NATURE, V232, P279, DOI 10.1038/232279a0; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Marston WA, 2004, EXPERT REV MED DEVIC, V1, P21, DOI 10.1586/17434440.1.1.21; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; MORHENN VB, 1987, J INVEST DERMATOL, V89, P464, DOI 10.1111/1523-1747.ep12460913; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Phillips T, 2002, ARCH DERMATOL, V138, P1079, DOI 10.1001/archderm.138.8.1079; POBER JS, 1983, NATURE, V305, P726, DOI 10.1038/305726a0; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Schechner JS, 2003, FASEB J, V17, P2250, DOI 10.1096/fj.03-0257com; Sivan-Loukianova E, 2003, J VASC RES, V40, P368, DOI 10.1159/000072701; Supp DM, 2000, J INVEST DERMATOL, V114, P5, DOI 10.1046/j.1523-1747.2000.00824.x; Supp DM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0868com; THOMSON AW, 1989, LANCET, V2, P443; Tremblay PL, 2005, AM J TRANSPLANT, V5, P1002, DOI 10.1111/j.1600-6143.2005.00790.x; Wu X, 2004, AM J PHYSIOL-HEART C, V287, pH480, DOI 10.1152/ajpheart.01232.2003; Young D. M., 1996, Journal of Burn Care and Rehabilitation, V17, P305, DOI 10.1097/00004630-199607000-00005; Zheng L, 2000, J IMMUNOL, V164, P4665, DOI 10.4049/jimmunol.164.9.4665; Zheng L, 2004, J IMMUNOL, V173, P3020, DOI 10.4049/jimmunol.173.5.3020	39	102	112	2	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1739	+		10.1096/fj.05-5682fje	http://dx.doi.org/10.1096/fj.05-5682fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807367				2022-12-28	WOS:000240266600033
J	Abdel-Malek, ZA; Kadekaro, AL; Kavanagh, RJ; Todorovic, A; Koikov, LN; McNulty, JC; Jackson, PJ; Millhauser, GL; Schwemberger, S; Babcock, G; Haskell-Luevano, C; Knittel, JJ				Abdel-Malek, Zalfa A.; Kadekaro, Ana Luisa; Kavanagh, Renny J.; Todorovic, Aleksandar; Koikov, Leonid N.; McNulty, Joseph C.; Jackson, Pilgrim J.; Millhauser, Glenn L.; Schwemberger, Sandy; Babcock, George; Haskell-Luevano, Carrie; Knittel, James J.			Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity	FASEB JOURNAL			English	Article						melanocortins; photoprotection; melanogenesis; DNA repair; melanomagenesis	NONMELANOMA SKIN-CANCER; MINIMAL ACTIVE SEQUENCE; MELANOCORTIN RECEPTORS; MELANOTROPIN; RISK; STIMULATION; MUTATIONS; VARIANTS; PEPTIDES; AGONISTS	Melanoma is the deadliest form of skin cancer, with no cure for advanced disease. We propose a strategy for melanoma prevention based on using analogs of alpha-melanocyte stimulating hormone (alpha-MSH) that function as melanocortin 1 receptor (MC1R) agonists. Treatment of human melanocytes with alpha-MSH results in stimulation of eumelanin synthesis, reduction of apoptosis that is attributable to reduced hydrogen peroxide generation and enhanced repair of DNA photoproducts. These effects should contribute to genomic stability of human melanocytes, thus preventing their malignant transformation to melanoma. Based on these findings, we synthesized and tested the effects of 3 tetrapeptide alpha-MSH analogs, Ac-His-D-Phe-Arg-Trp-NH2, n-Pentadecanoyl- and 4-Phenylbutyryl-His-D-Phe-Arg-Trp-NH2, on cultured human melanocytes. The latter two analogs were more potent than the former, or alpha-MSH, in stimulating the activity of tyrosinase, thus melanogenesis, reducing apoptosis and release of hydrogen peroxide and enhancing repair of DNA photoproducts in melanocytes exposed to UV radiation (UVR). The above analogs are MC1R agonists, as their effects were abrogated by an analog of agouti signaling protein, the physiological MC1R antagonist, and were absent in melanocytes expressing loss-of-function MC1R. Analogs, such as 4-Phenylbutyryl-His-D-Phe-Arg-Trp-NH2 with prolonged and reversible effects, can potentially be developed into topical agents to prevent skin photocarcinogenesis, particularly melanoma.	Univ Cincinnati, Coll Med, Dept Dermatol, Cincinnati, OH 45267 USA; Univ Florida, Coll Pharm, Dept Med Chem, Gainesville, FL 32611 USA; Univ Cincinnati, Coll Pharm, Cincinnati, OH 45221 USA; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Univ Cincinnati, Dept Surg, Coll Med, Cincinnati, OH 45221 USA; Shriners Burn Hosp, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; State University System of Florida; University of Florida; University System of Ohio; University of Cincinnati; University of California System; University of California Santa Cruz; University System of Ohio; University of Cincinnati	Abdel-Malek, ZA (corresponding author), Univ Cincinnati, Coll Med, Dept Dermatol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	abdelmza@email.uc.edu		JACKSON, PILGRIM/0000-0002-2796-5297	NIDDK NIH HHS [DK 57080, DK 064265] Funding Source: Medline; NIEHS NIH HHS [R01 ES-09110] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK057080, R01DK057080, R01DK064265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009110] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdel-Malek ZA, 2001, CELL MOL LIFE SCI, V58, P434, DOI 10.1007/PL00000868; ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ABDELMALEK Z, 1998, PIGMENTARY SYSTEM PH, P115; *AM CANC SOC, 2005, FACTS FIG; BARKER D, 1995, CANCER RES, V55, P4041; Bastiaens MT, 2001, AM J HUM GENET, V68, P884, DOI 10.1086/319500; CASTRUCCI AML, 1989, GEN COMP ENDOCR, V73, P157, DOI 10.1016/0016-6480(89)90066-X; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Geschwind I.I., 1972, Recent Progress Hormone Res, V28, P91; GREEN A, 1985, BRIT J CANCER, V51, P393, DOI 10.1038/bjc.1985.53; Hadley M.E., 1996, ENDOCRINOLOGY; HRUBY VJ, 1987, J MED CHEM, V30, P2126, DOI 10.1021/jm00394a033; HUNT G, 1994, PIGM CELL RES, V7, P217, DOI 10.1111/j.1600-0749.1994.tb00052.x; Im SB, 1998, CANCER RES, V58, P47; JOSEPH M, 1988, FEBS LETT, V238, P411, DOI 10.1016/0014-5793(88)80522-2; Kadekaro AL, 2005, CANCER RES, V65, P4292, DOI 10.1158/0008-5472.CAN-04-4535; Koikov LN, 2003, BIOORG MED CHEM LETT, V13, P2647, DOI 10.1016/S0960-894X(03)00552-3; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; Krishnan V, 1999, BIOORG MED CHEM LETT, V9, P3363, DOI 10.1016/S0960-894X(99)00604-6; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; LAN EL, 1994, J PHARM SCI, V83, P1081, DOI 10.1002/jps.2600830805; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MARWAN MM, 1985, MOL CELL ENDOCRINOL, V41, P171, DOI 10.1016/0303-7207(85)90020-6; McNulty JC, 2005, J MOL BIOL, V346, P1059, DOI 10.1016/j.jmb.2004.12.030; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; Sander CS, 2004, INT J DERMATOL, V43, P326, DOI 10.1111/j.1365-4632.2004.02222.x; Sarkar-Agrawal P, 2004, JNCI-J NATL CANCER I, V96, P1790, DOI 10.1093/jnci/djh307; SAWYER TK, 1982, J MED CHEM, V25, P1022, DOI 10.1021/jm00351a004; Scott MC, 2002, J CELL SCI, V115, P2349; SLEPNEV VI, 1995, BIOCONJUGATE CHEM, V6, P608, DOI 10.1021/bc00035a016; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; Suzuki I, 1997, J INVEST DERMATOL, V108, P838, DOI 10.1111/1523-1747.ep12292572; Thomas RK, 2003, MARK HEALTH SERV, V23, P38; Todorovic A, 2005, J MED CHEM, V48, P3328, DOI 10.1021/jm0490843; Tucker MA, 2003, ONCOGENE, V22, P3042, DOI 10.1038/sj.onc.1206444; Veuillez F, 1999, EUR J PHARM BIOPHARM, V48, P21, DOI 10.1016/S0939-6411(99)00025-9; Wei QY, 2003, J NATL CANCER I, V95, P308, DOI 10.1093/jnci/95.4.308	40	60	64	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1561	+		10.1096/fj.05-5655fje	http://dx.doi.org/10.1096/fj.05-5655fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723376				2022-12-28	WOS:000240266000051
J	Nemchinov, LG; Paape, MJ; Sohn, EJ; Bannerman, DD; Zarlenga, DS; Hammond, RW				Nemchinov, Lev G.; Paape, Max J.; Sohn, Eun J.; Bannerman, Douglas D.; Zarlenga, Dante S.; Hammond, Rosemarie W.			Bovine CD14 receptor produced in plants reduces severity of intramammary bacterial infection	FASEB JOURNAL			English	Article						potato virus X; plant-derived therapeutic; coliform mastitis; apoptosis; LPS	ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE; ENDOTOXIN; COWS; EXPRESSION; PROTEINS; MASTITIS; VACCINES; MICE	CD14 is a high-affinity receptor protein for the complex of bacterial LPS (LPS) and LPS binding protein in animals. Binding of the soluble form of CD14 (sCD14) to LPS, found in the outer membrane of Escherichia coli and other Gram-negative bacteria, enhances host innate immune responses, reduces the severity of mastitis, and facilitates clearance and neutralization of LPS, thus protecting against an excessive immune response to LPS and development of endotoxic shock. A truncated form of sCD14, carrying a histidine residue affinity tag for purification, was incorporated into Potato virus X for transient expression in Nicotiana benthamiana plants. Western blots probed with CD14-specific antibodies demonstrated that crude plant extracts and affinity-purified samples contained immunoreactive sCD14. Biological activity of plant-derived recombinant bovine sCD14 (PrbosCD14) was demonstrated in vitro by LPS-induced apoptosis and interleukin (IL) -8 production in bovine endothelial cells, and in vivo by enhancement of LPS-induced neutrophil recruitment. Finally, in PrbosCD14-infused glands subsequently infected with E. coli, lower numbers of viable bacteria were recovered and there was an absence of clinical symptoms, demonstrating prophylactic efficacy of PrbosCD14. This is the first report of a functionally active animal receptor protein made in plants and the prophylactic use of a plant-derived protein to reduce the severity of bacterial infections in animals.	USDA ARS, Mol Plant Pathol Lab, Beltsville, MD 20705 USA; USDA ARS, Beltsville Agr Res Ctr, Beltsville, MD 20705 USA; Bovine Funct Genom Lab, Beltsville, MD USA	United States Department of Agriculture (USDA); United States Department of Agriculture (USDA)	Hammond, RW (corresponding author), USDA ARS, Mol Plant Pathol Lab, Rm 214 ,Bldg 004 BARC W, Beltsville, MD 20705 USA.	hammondr@ba.ars.usda.gov						BANKS KL, 1985, AM J VET RES, V46, P1568; Bannerman DD, 2004, CLIN DIAGN LAB IMMUN, V11, P463, DOI 10.1128/CDLI.11.3.463-472.2004; Bannerman DD, 2003, J DAIRY SCI, V86, P3128, DOI 10.3168/jds.S0022-0302(03)73914-9; Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002; Bannerman DD, 2002, J BIOL CHEM, V277, P8048, DOI 10.1074/jbc.M111249200; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; BRAMLEY AJ, 1976, J DAIRY SCI, V79, P3094; CHAPMAN S, 1992, PLANT J, V2, P549; Lee JW, 2003, VET RES, V34, P307, DOI 10.1051/vetres:2003006; Lee JW, 2003, INFECT IMMUN, V71, P4034, DOI 10.1128/IAI.71.7.4034-4039.2003; LOPPNOW H, 1995, INFECT IMMUN, V63, P1020, DOI 10.1128/IAI.63.3.1020-1026.1995; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; Ma JKC, 2000, NAT BIOTECHNOL, V18, P1141, DOI 10.1038/81113; Ma JKC, 2003, NAT REV GENET, V4, P794, DOI 10.1038/nrg1177; MILLER RH, 1986, J DAIRY SCI, V69, P1942, DOI 10.3168/jds.S0022-0302(86)80621-X; NACIONAL MASTITIS COUNCIL, 1996, CURRENT CONCEPTS BOV, V4; Paape MJ, 1996, AM J VET RES, V57, P477; Pugin J, 1995, Prog Clin Biol Res, V392, P369; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Shuster DE, 1996, AM J VET RES, V57, P1569; Sohn EJ, 2004, VET RES, V35, P597, DOI 10.1051/vetres:2004035; Streatfield SJ, 2003, INT J PARASITOL, V33, P479, DOI 10.1016/S0020-7519(03)00052-3; Wall RJ, 2005, NAT BIOTECHNOL, V23, P445, DOI 10.1038/nbt1078; Wang Y, 2002, VET IMMUNOL IMMUNOP, V86, P115, DOI 10.1016/S0165-2427(02)00021-1; WANG Y, 1997, J CELL BIOL MED BI S, V8, pA85	25	12	13	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1345	1351		10.1096/fj.05-5295com	http://dx.doi.org/10.1096/fj.05-5295com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816109				2022-12-28	WOS:000240266000011
J	Locke, D; Koreen, IV; Harris, AL				Locke, Darren; Koreen, Irina V.; Harris, Andrew L.			Isoelectric points and post-translational modifications of connexin26 and connexin32	FASEB JOURNAL			English	Article						gap junction; hemichannel; IEF; mass spectrometry; Rotofor	GAP-JUNCTION CHANNELS; PROTEIN-KINASE-C; LIPID RAFTS; PHOSPHORYLATION; PURIFICATION; CELL; LIVER; SOLUBILIZATION; IDENTIFICATION; CHROMATOGRAPHY	The isoelectric points of the gap junction proteins connexin26 (Cx26) and connexin32 (Cx32) were determined by isoelectric focusing in free fluids. The isoelectric points were significantly more acidic than predicted from amino acid sequences and different from each other, allowing homomeric channels to be resolved separately. The isoelectric points of the homomeric channels bracketed the isoelectric points of heteromeric Cx26/Cx32 channels. For heteromeric channels, Cx26 and Cx32 were found in overlapping, pH-focused fractions, indicating quaternary structure was retained. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was used to identify post-translational modifications of Cx26 and Cx32 cytoplasmic domains, including the first reported post-translational modifications of Cx26. Suspected modifications were hydroxylation and/or phosphorylation near the amino terminus of both connexins, gamma-carboxyglutamate residues in the cytoplasmic loop of both connexins, phosphorylation in the carboxyl-terminal domain of Cx32, and palmitoylation at the carboxyl-terminus of Cx32. These modifications contribute to the measured acidic isoelectric points of Cx26 and Cx32, whereas their low molecular masses would not appreciably change connexin SDS-PAGE mobility. Most of these modifications have not previously been identified for connexins and may be instrumental in guiding and understanding novel aspects of channel trafficking and molecular mechanisms of channel regulation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Locke, D (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave, Newark, NJ 07103 USA.	lockeda@umdnj.edu		Harris, Andrew/0000-0002-3782-0550	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061406, R01GM036044] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61406, GM36044] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad S, 2001, EUR J BIOCHEM, V268, P4544, DOI 10.1046/j.1432-1327.2001.02380.x; Amini A, 2000, J CHROMATOGR A, V894, P345, DOI 10.1016/S0021-9673(00)00798-6; Ayad WA, 2006, J BIOL CHEM, V281, P16727, DOI 10.1074/jbc.M600136200; Ayala A, 1998, APPL BIOCHEM BIOTECH, V69, P11, DOI 10.1007/BF02786017; Bandyopadhyay PK, 2002, P NATL ACAD SCI USA, V99, P1264, DOI 10.1073/pnas.022637099; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Bier M, 1998, ELECTROPHORESIS, V19, P1057, DOI 10.1002/elps.1150190703; BUEHLER LK, 1995, BIOPHYS J, V68, P1767, DOI 10.1016/S0006-3495(95)80353-X; Cottrell GT, 2005, BBA-BIOMEMBRANES, V1711, P126, DOI 10.1016/j.bbamem.2004.11.013; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; Herbert B, 1999, ELECTROPHORESIS, V20, P660, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<660::AID-ELPS660>3.0.CO;2-Q; Hertzberg EL, 2004, MOL BIOL CELL, V15, p185A; Huang Y, 2005, J NEUROSCI, V25, P7111, DOI 10.1523/JNEUROSCI.1319-05.2005; Issaq HJ, 2002, ELECTROPHORESIS, V23, P3048, DOI 10.1002/1522-2683(200209)23:17<3048::AID-ELPS3048>3.0.CO;2-L; Kashino Y, 2003, J CHROMATOGR B, V797, P191, DOI 10.1016/S1570-0232(03)00428-8; KONIG N, 1995, J CELL SCI, V108, P3091; Koreen IV, 2004, BIOCHEM J, V383, P111, DOI 10.1042/BJ20040806; Korovkina VP, 2002, CLIN EXP PHARMACOL P, V29, P317, DOI 10.1046/j.1440-1681.2002.03651.x; Krutchinsky AN, 2001, ANAL CHEM, V73, P5066, DOI 10.1021/ac010682o; Kumar Y, 2004, PROTEOMICS, V4, P1672, DOI 10.1002/pmic.200300778; Laird DW, 2005, BBA-BIOMEMBRANES, V1711, P172, DOI 10.1016/j.bbamem.2004.09.009; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Linke S, 2004, J BIOL CHEM, V279, P14391, DOI 10.1074/jbc.M313614200; Locke D, 2005, BIOCHEMISTRY-US, V44, P13027, DOI 10.1021/bi050495a; Locke D, 2004, EXP CELL RES, V298, P643, DOI 10.1016/j.yexcr.2004.05.003; MAZET F, 1990, EXP CELL RES, V188, P312, DOI 10.1016/0014-4827(90)90175-A; Moreno AP, 2005, BBA-BIOMEMBRANES, V1711, P164, DOI 10.1016/j.bbamem.2005.02.016; Muller DJ, 2002, EMBO J, V21, P3598, DOI 10.1093/emboj/cdf365; Nelsestuen GL, 2000, VITAM HORM, V58, P355, DOI 10.1016/S0083-6729(00)58031-5; O'Connell KMS, 2004, TRENDS CARDIOVAS MED, V14, P37, DOI 10.1016/j.tcm.2003.10.002; Peracchia C, 2000, J BIOL CHEM, V275, P26220, DOI 10.1074/jbc.M004007200; Presnell SR, 2001, BIOCHEMISTRY-US, V40, P11723, DOI 10.1021/bi010332w; Purnick PEM, 2000, ARCH BIOCHEM BIOPHYS, V381, P181, DOI 10.1006/abbi.2000.1989; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; Righetti PG, 2003, PROTEOMICS, V3, P1397, DOI 10.1002/pmic.200300472; Rucker P, 1997, PROTEIN ENG, V10, P967, DOI 10.1093/protein/10.8.967; SAEZ JC, 1990, EUR J BIOCHEM, V192, P263, DOI 10.1111/j.1432-1033.1990.tb19223.x; SIKERWAR SS, 1983, CELL BIOL INT REP, V7, P897, DOI 10.1016/0309-1651(83)90208-4; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Solan JL, 2005, BBA-BIOMEMBRANES, V1711, P154, DOI 10.1016/j.bbamem.2004.09.013; Sosinsky GE, 2001, METH MOL B, V154, P57; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; Stockert RJ, 1999, HEPATOLOGY, V30, P740, DOI 10.1002/hep.510300304; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; Thaler F, 2003, ANAL BIOANAL CHEM, V376, P366, DOI 10.1007/s00216-003-1919-9; Thimm J, 2005, J BIOL CHEM, V280, P10646, DOI 10.1074/jbc.M412749200; Tillman TS, 2003, CELL BIOCHEM BIOPHYS, V38, P161, DOI 10.1385/CBB:38:2:161; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; Wei CJ, 2004, ANNU REV CELL DEV BI, V20, P811, DOI 10.1146/annurev.cellbio.19.111301.144309; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILLECKE K, 1988, GAP JUNCTIONS, V7, P41; Zhang N, 2004, J PROTEOME RES, V3, P719, DOI 10.1021/pr034116g	57	37	40	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1221	+		10.1096/fj.05-5309fje	http://dx.doi.org/10.1096/fj.05-5309fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16645047				2022-12-28	WOS:000240210300032
J	Zhang, YM; Bo, J; Taffet, GE; Chang, J; Shi, J; Reddy, AK; Michael, LH; Schneider, MD; Entman, ML; Schwartz, RJ; Wei, L				Zhang, Ying-Min; Bo, Jacqueline; Taffet, George E.; Chang, Jiang; Shi, Jianjian; Reddy, Anilkumar K.; Michael, Lloyd H.; Schneider, Michael D.; Entman, Mark L.; Schwartz, Robert J.; Wei, Lei			Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis	FASEB JOURNAL			English	Article						Rho kinase; pressure overload; fibrosis; hypertrophy; fibrogenic cytokines	TISSUE GROWTH-FACTOR; LEFT-VENTRICULAR HYPERTROPHY; LONG-TERM INHIBITION; RHO-KINASE; CARDIAC-HYPERTROPHY; ANGIOTENSIN-II; MYOCARDIAL HYPERTROPHY; IN-VIVO; FAILURE; MICE	Ventricular myocyte hypertrophy is an important compensatory growth response to pressure overload. However, pathophysiological cardiac hypertrophy is accompanied by reactive fibrosis and remodeling. The Rho kinase family, consisting of ROCK1 and ROCK2, has been implicated in cardiac hypertrophy and ventricular remodeling. However, these previous studies relied heavily on pharmacological inhibitors, and not on gene deletion. Here we used ROCK1 knockout (ROCK1(-/-)) mice to investigate role of ROCK1 in the development of ventricular remodeling induced by transverse aortic banding. We observed that ROCK1 deletion did not impair compensatory hypertrophic response induced by pressure overload. However, ROCK1(-/-) mice exhibited reduced perivascular and interstitial fibrosis, which was observed at 3 wk but not at 1 wk after the banding. The reduced fibrosis in the myocardium of ROCK1(-/-) mice was closely associated with reduced expression of a variety of extracellular matrix (ECM) proteins and fibrogenic cytokines such as TGF beta 2 and connective tissue growth factor. This inhibitory effect of ROCK1 deletion on pathophysiological induction of fibrogenic cytokines was further confirmed in the myocardium of transgenic mice with cardiomyocyte-specific overexpression of G alpha q. Thus, these results indicate that ROCK1 contributes to the development of cardiac fibrosis and induction of fibrogenic cytokines in cardiomyocytes in response to pathological stimuli.	Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Baylor Coll Med, Cardiovasc Sci Sect, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA	Indiana University System; Indiana University-Purdue University Indianapolis; Baylor College of Medicine; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wei, L (corresponding author), Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, R4 Bldg,Rm 370,1044 W Walnut St, Indianapolis, IN 46202 USA.	lewei@iupui.edu	Reddy, Anilkumar/GLS-1391-2022	Schneider, Michael/0000-0001-9645-1938; Chang, Jiang/0000-0003-3707-7557	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953, P01HL042550, R01HL064356, R01HL072897, P01HL085098] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL072897-04, R01-HL72897, P01 HL085098, R01 HL072897, P01-HL42550, P01-HL49953, P01 HL085098-01A10002, R01-HL64356] Funding Source: Medline; NIA NIH HHS [R01-AG18599] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Ahmed MS, 2005, ACTA PHYSIOL SCAND, V184, P27, DOI 10.1111/j.1365-201X.2005.01416.x; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Barker TH, 2004, EXP CELL RES, V295, P488, DOI 10.1016/j.yexcr.2004.01.026; Begum R, 2004, EXP MOL MED, V36, P358, DOI 10.1038/emm.2004.47; Breitenlechner C, 2003, STRUCTURE, V11, P1595, DOI 10.1016/j.str.2003.11.002; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dean RG, 2005, J HISTOCHEM CYTOCHEM, V53, P1245, DOI 10.1369/jhc.4A6560.2005; Dorn GW, 2003, CIRC RES, V92, P1171, DOI 10.1161/01.RES.0000077012.11088.BC; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; Frey N, 2004, CIRCULATION, V109, P1580, DOI 10.1161/01.CIR.0000120390.68287.BB; Hattori T, 2004, CIRCULATION, V109, P2234, DOI 10.1161/01.CIR.0000127939.16111.58; He ZH, 2005, J BIOL CHEM, V280, P15719, DOI 10.1074/jbc.M413493200; Higashi M, 2003, CIRC RES, V93, P767, DOI 10.1161/01.RES.0000096650.91688.28; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Kallapur S, 1999, MOL REPROD DEV, V52, P341, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;341::AID-MRD2&gt;3.0.CO;2-N; Kannel W B, 1972, N Engl J Med, V287, P781, DOI 10.1056/NEJM197210192871601; Kemp TJ, 2004, J MOL CELL CARDIOL, V37, P603, DOI 10.1016/j.yjmcc.2004.04.022; Kobayashi N, 2002, CARDIOVASC RES, V55, P757, DOI 10.1016/S0008-6363(02)00457-1; Landerholm TE, 1999, DEVELOPMENT, V126, P2053; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Lorell BH, 2000, CIRCULATION, V102, P470; Matsui Y, 2004, J MOL CELL CARDIOL, V37, P477, DOI 10.1016/j.yjmcc.2004.05.012; Nakamura A, 2001, AM J PHYSIOL-HEART C, V281, pH1104, DOI 10.1152/ajpheart.2001.281.3.H1104; Nicoletti A, 1999, CARDIOVASC RES, V41, P532, DOI 10.1016/S0008-6363(98)00305-8; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rikitake Y, 2005, CIRCULATION, V112, P2959, DOI 10.1161/CIRCULATIONAHA.105.584623; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Satoh S, 2003, J MOL CELL CARDIOL, V35, P59, DOI 10.1016/S0022-2828(02)00278-X; Shimizu Y, 2005, J CELL BIOL, V168, P941, DOI 10.1083/jcb.200411179; Taffet GE, 1996, AM J PHYSIOL-HEART C, V270, pH2204; Takaoka H, 2002, AM J PHYSIOL-HEART C, V282, pH2190, DOI 10.1152/ajpheart.00759.2001; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van Wamel AJET, 2001, MOL CELL BIOCHEM, V218, P113, DOI 10.1023/A:1007279700705; Wakatsuki T, 2004, TRENDS BIOCHEM SCI, V29, P609, DOI 10.1016/j.tibs.2004.09.002; Wang YX, 2005, EUR J PHARMACOL, V512, P215, DOI 10.1016/j.ejphar.2005.02.024; Weber KT, 1995, EUR HEART J, V16, P12, DOI 10.1093/eurheartj/16.suppl_N.12; Wei L, 2004, FASEB J, V18, P857, DOI 10.1096/fj.03-0664fje; Wei L, 2004, J MOL CELL CARDIOL, V36, P465, DOI 10.1016/j.yjmcc.2004.02.006; Wei L, 2002, DEVELOPMENT, V129, P1705; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Zhan GD, 2003, NAT MATER, V2, P38, DOI 10.1038/nmat793; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037	46	165	174	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					916	925		10.1096/fj.05-5129com	http://dx.doi.org/10.1096/fj.05-5129com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675849				2022-12-28	WOS:000240157700014
J	Goldman, J; Rutkowski, JM; Shields, JD; Pasquier, MC; Cui, YJ; Schmokel, HG; Willey, S; Hicklin, DJ; Pytowski, B; Swartz, MA				Goldman, Jeremy; Rutkowski, Joseph M.; Shields, Jacqueline D.; Pasquier, Miriella C.; Cui, Yingjie; Schmoekel, Hugo G.; Willey, Stephen; Hicklin, Daniel J.; Pytowski, Bronislaw; Swartz, Melody A.			Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis	FASEB JOURNAL			English	Article						VEGF-C; mouse; in vitro wound healing; vasculogenesis	ENDOTHELIAL GROWTH-FACTOR; FACTOR-C; LYMPHATIC REGENERATION; FACTOR RECEPTOR-3; TYROSINE KINASES; TRANSGENIC MICE; HYPERPLASIA; METASTASIS; ACTIVATION; ANTIBODY	Activation of vascular endothelial growth factor ( VEGF) receptor-3 (VEGFR-3) by VEGF-C initiates lymphangiogenesis by promoting lymphatic proliferation and migration. However, it is unclear whether VEGFR-3 signaling is required beyond these initial stages, namely during the organization of new lymphatic endothelial cells (LECs) into functional capillaries. Furthermore, the role of VEGFR-2, which is also expressed on LECs and binds VEGF-C, is unclear. We addressed these questions by selectively neutralizing VEGFR-3 and/or VEGFR-2 for various time periods in an adult model of lymphangiogenesis in regenerating skin. While blocking either VEGFR-2 or VEGFR-3 with specific antagonist mAbs (DC101 and mF4-31C1, respectively) prior to lymphatic migration prevented lymphangiogenesis, blocking VEGFR-3 subsequent to migration did not affect organization into functional capillaries, and VEGFR-2 blocking had only a small hindrance on organization. These findings were confirmed in vitro using human LECs and anti-human antagonist mAbs (IMC-1121a and hF4-3C5): both VEGFR-2 and VEGFR-3 signaling were required for migration and proliferation, but tubulogenesis in 3D cultures was unaffected by VEGFR-3 blocking and partially hindered by VEGFR-2 blocking. Furthermore, both in vitro and in vivo, while VEGFR-3 blocking had no effect on LEC organization, coneutralization of VEGFR-2, and VEGFR- 3 completely prevented lymphatic organization. Our findings demonstrate that cooperative signaling of VEGFR-2 and -3 is necessary for lymphatic migration and proliferation, but VEGFR-3 is redundant with VEGFR-2 for LEC organization into functional capillaries.	Ecole Polytech Fed Lausanne, Inst Bioengn, Sch Life Sci, LMBM, CH-1015 Lausanne, Switzerland; Tumor Biol ImClone Syst, New York, NY USA; ImClone Syst, Expt Therapeut, New York, NY USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Eli Lilly; Eli Lilly	Swartz, MA (corresponding author), Ecole Polytech Fed Lausanne, Inst Bioengn, Sch Life Sci, LMBM, Stn 15, CH-1015 Lausanne, Switzerland.	melody.swartz@epfl.ch	Swartz, Melody A./F-9563-2011; Swartz, Melody/B-7633-2009	Rutkowski, Joseph/0000-0002-4197-0236	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075217] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL075217-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Alam A, 2004, BIOCHEM BIOPH RES CO, V324, P909, DOI 10.1016/j.bbrc.2004.08.237; Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Aoki Y, 2005, JNCI-J NATL CANCER I, V97, P2, DOI 10.1093/jnci/dji015; Boardman KC, 2003, CIRC RES, V92, P801, DOI 10.1161/01.RES.0000065621.69843.49; Dixelius J, 2003, J BIOL CHEM, V278, P40973, DOI 10.1074/jbc.M304499200; Goldman J, 2005, CIRC RES, V96, P1193, DOI 10.1161/01.RES.0000168918.27576.78; He YL, 2005, CANCER RES, V65, P4739, DOI 10.1158/0008-5472.CAN-04-4576; Hong YK, 2004, FASEB J, V18, P1111, DOI 10.1096/fj.03-1179fje; Isaka N, 2004, CANCER RES, V64, P4400, DOI 10.1158/0008-5472.CAN-04-0752; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; Karpanen T, 2001, CANCER RES, V61, P1786; Kunstfeld R, 2004, BLOOD, V104, P1048, DOI 10.1182/blood-2003-08-2964; Lin JM, 2005, CANCER RES, V65, P6901, DOI 10.1158/0008-5472.CAN-05-0408; Maruyama K, 2005, J CLIN INVEST, V115, P2363, DOI 10.1172/JCI23874; Mimura T, 2001, EXP EYE RES, V72, P71, DOI 10.1006/exer.2000.0925; Moriyama T, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-3; Oliver G, 2005, ANNU REV CELL DEV BI, V21, P457, DOI 10.1146/annurev.cellbio.21.012704.132338; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Persaud K, 2004, J CELL SCI, V117, P2745, DOI 10.1242/jcs.01138; Podgrabinska S, 2002, P NATL ACAD SCI USA, V99, P16069, DOI 10.1073/pnas.242401399; Pytowski B, 2005, JNCI-J NATL CANCER I, V97, P14, DOI 10.1093/jnci/dji003; Roberts N, 2006, CANCER RES, V66, P2650, DOI 10.1158/0008-5472.CAN-05-1843; Rutkowski JM, 2006, AM J PHYSIOL-HEART C, V291, pH1402, DOI 10.1152/ajpheart.00038.2006; Saaristo A, 2004, FASEB J, V18, P1707, DOI 10.1096/fj.04-1592fje; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Su JL, 2006, CANCER CELL, V9, P209, DOI 10.1016/j.ccr.2006.02.018; Swartz MA, 2001, MICROSC RES TECHNIQ, V55, P92, DOI 10.1002/jemt.1160; Szuba A, 2002, FASEB J, V16, P1985, DOI 10.1096/fj.02-0401fje; Tammela T, 2005, BLOOD, V105, P4642, DOI 10.1182/blood-2004-08-3327; WITTE K, 1998, HLTH RISK COMMUNICAT, V2, P1; Yoon Y, 2003, J CLIN INVEST, V111, P717, DOI 10.1172/JCI200315830; Yuan L, 2002, DEVELOPMENT, V129, P4797	37	112	123	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1003	1012		10.1096/fj.06-6656com	http://dx.doi.org/10.1096/fj.06-6656com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17210781				2022-12-28	WOS:000245650400005
J	Liu, Q; Zhang, J; Zhu, H; Qin, C; Chen, Q; Zhao, BL				Liu, Qiang; Zhang, Jie; Zhu, Hua; Qin, Chuan; Chen, Qi; Zhao, Baolu			Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model	FASEB JOURNAL			English	Article						AD; alpha 7nAChRs; signal pathway	AMYLOID PRECURSOR PROTEIN; PROGRESSIVE SUPRANUCLEAR PALSY; ACETYLCHOLINE-RECEPTOR; INDUCED NEUROTOXICITY; CELL-DEATH; NEURODEGENERATIVE DISEASES; MICROGLIAL ACTIVATION; INHIBITS APOPTOSIS; TEMPORAL CORTEX; PICKS-DISEASE	Nicotine has a therapeutic benefit in treating Alzheimer's disease ( AD). In the present study we show that nicotine decreases accumulation of beta-amyloid ( A beta) in the cortex and hippocampus of APP ( V717I) transgenic mice. Nicotine prevents activation of NF-kappa B and c-Myc by inhibiting the activation of MAP kinases ( MAPKs). As a result, the activity of inducible NOS and the production of NO are down-regulated. RNA interference experiments show that the above nicotine-mediated process requires alpha 7 nAChR. Nicotine decreases A beta via the activation of alpha 7nAChRs through MAPK, NF-kappa B, and c-myc pathways. Nicotine also inhibits apoptosis and cell cycle progression in this mouse line. The dissected signaling pathway of nicotine-mediated neuroprotection in the present study provides a mechanistic basis for the potential development of drug targets for treating AD.	Acad Sinica, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100101, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; Chinese Acad Sci, Inst Lab Anim Sci, Beijing, Peoples R China; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Shanghai Univ Tradit Chinese Med, E Inst NO & Inflammat, Shanghai, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Laboratory Animal Science - CAMS; Chinese Academy of Sciences; Salk Institute; Shanghai University of Traditional Chinese Medicine	Zhao, BL (corresponding author), Acad Sinica, Inst Biophys, State Key Lab Brain & Cognit Sci, 15 Datun Rd, Beijing 100101, Peoples R China.	zhaobl@sun5.ibp.ac.cn	Liu, Qiang/E-9245-2011; Zhang, Jie/A-5426-2010					Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Arendt T, 1996, NEUROREPORT, V7, P3047; Arendt T, 1998, J NEURAL TRANSM, V105, P949, DOI 10.1007/s007020050104; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; Chen L, 2006, NEUROPHARMACOLOGY, V50, P254, DOI 10.1016/j.neuropharm.2005.09.018; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; Dasgupta P, 2006, P NATL ACAD SCI USA, V103, P6332, DOI 10.1073/pnas.0509313103; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Emilien G, 2000, ARCH NEUROL-CHICAGO, V57, P454, DOI 10.1001/archneur.57.4.454; FEDDERSEN RM, 1992, NEURON, V9, P955, DOI 10.1016/0896-6273(92)90247-B; Ferrer I, 2001, NEUROPATH APPL NEURO, V27, P343, DOI 10.1046/j.1365-2990.2001.00348.x; Ferrer I, 2001, BRAIN PATHOL, V11, P144; Gahtan E, 1999, NEUROSCI BIOBEHAV R, V23, P615, DOI 10.1016/S0149-7634(98)00058-X; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hellstrom-Lindahl E, 2004, EUR J NEUROSCI, V19, P2703, DOI 10.1111/j.1460-9568.2004.03377.x; Hensley K, 1996, ANN NY ACAD SCI, V786, P120, DOI 10.1111/j.1749-6632.1996.tb39057.x; HERRUP K, 1995, DEVELOPMENT, V121, P2385; Ibach B, 2004, CURR PHARM DESIGN, V10, P231, DOI 10.2174/1381612043386509; Kihara T, 1997, ANN NEUROL, V42, P159, DOI 10.1002/ana.410420205; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Liu Q, 2004, BRIT J PHARMACOL, V141, P746, DOI 10.1038/sj.bjp.0705653; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; MARK RJ, 1995, J NEUROSCI, V15, P6239; Martin-Ruiz CM, 1999, J NEUROCHEM, V73, P1635, DOI 10.1046/j.1471-4159.1999.0731635.x; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Mihailescu S, 2000, ARCH MED RES, V31, P131, DOI 10.1016/S0188-4409(99)00087-9; Nagele RG, 2002, NEUROSCIENCE, V110, P199, DOI 10.1016/S0306-4522(01)00460-2; Nordberg A, 2002, J NEUROCHEM, V81, P655, DOI 10.1046/j.1471-4159.2002.00874.x; O'Neill MJ, 2002, CNS NEUROL DISORD-DR, V1, P399, DOI 10.2174/1568007023339166; Ono K, 2002, BIOL PSYCHIAT, V52, P880, DOI 10.1016/S0006-3223(02)01417-8; Pei JJ, 2002, MOL BRAIN RES, V109, P45, DOI 10.1016/S0169-328X(02)00488-6; Rezvani AH, 2001, BIOL PSYCHIAT, V49, P258, DOI 10.1016/S0006-3223(00)01094-5; ROWELL PP, 1983, J PHARMACOL METHOD, V9, P249, DOI 10.1016/0160-5402(83)90064-5; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; SIMS NR, 1983, J NEUROCHEM, V40, P503, DOI 10.1111/j.1471-4159.1983.tb11311.x; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Sugano N, 1998, BIOCHEM BIOPH RES CO, V252, P25, DOI 10.1006/bbrc.1998.9599; Suzuki T, 2006, J NEUROSCI RES, V83, P1461, DOI 10.1002/jnr.20850; Tan J, 2000, J NEUROSCI, V20, P7587; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vincent I, 1997, J NEUROSCI, V17, P3588; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; WILCOCK GK, 1982, J NEUROL SCI, V57, P407, DOI 10.1016/0022-510X(82)90045-4; Xie YX, 2005, J BIOL CHEM, V280, P32405, DOI 10.1074/jbc.M504664200; Xie ZC, 2005, J BIOL CHEM, V280, P15413, DOI 10.1074/jbc.M414353200; Yu WF, 2005, EXP NEUROL, V192, P215, DOI 10.1016/j.expneurol.2004.12.015; Zamani MR, 1997, NEUROREPORT, V8, P513, DOI 10.1097/00001756-199701200-00027; Zhang J, 2006, FASEB J, V20, P1212, DOI 10.1096/fj.05-5214fje; Zhang YT, 2002, BRAIN RES BULL, V58, P385, DOI 10.1016/S0361-9230(02)00808-0; Zhu XW, 2000, J NEUROPATH EXP NEUR, V59, P880, DOI 10.1093/jnen/59.10.880; Zhu XW, 2001, MECH AGEING DEV, V123, P39, DOI 10.1016/S0047-6374(01)00342-6	57	95	114	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					61	73		10.1096/fj.06-5841com	http://dx.doi.org/10.1096/fj.06-5841com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135361				2022-12-28	WOS:000243130200008
J	Brunori, M; Vallone, B				Brunori, M.; Vallone, B.			A globin for the brain	FASEB JOURNAL			English	Review						neuroprotection; O-2/ NO binding; structure	NITRIC-OXIDE; HUMAN NEUROGLOBIN; LIGAND-BINDING; PROTEIN; OXYGEN; HEMOGLOBIN; EXPRESSION; MECHANISM; OXIDATION; PATHWAYS	The discovery that a myoglobin-like hemeprotein (called neuroglobin) is expressed in our brain raised considerable curiosity from the standpoints of biochemistry and pathophysiology alike. Neuroglobin is involved in neuroprotection from damage due to hypoxia or ischemia in vitro and in vivo; overexpression of neuroglobin ameliorates the recovery from stroke in experimental animals. The mechanism underlying this remarkable effect is still mysterious. Structural studies revealed that neuroglobin has a typical globin fold, and despite being hexacoordinated, it binds reversibly O-2, CO, and NO, undergoing a substantial conformational change of the heme and of the protein. The possible mechanisms involved in neuroprotection are briefly reviewed. Neuroglobin is unlikely to be involved in O-2 transport (like myoglobin), although it seems to act as a sensor of the O-2/NO ratio in the cell, possibly regulating the GDP/GTP exchange rate forming a specific complex with the G(alpha beta gamma)-protein when oxidized but not when bound to a gaseous ligand. Thus it appears that neuroglobin is a stress-responsive sensor for signal transduction in the brain, mediated by a ligand-linked conformational change of the protein.	Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy	Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome	Brunori, M (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	maurizio.brunori@uniroma1.it	Vallone, Beatrice/F-4174-2012	Brunori, Maurizio/0000-0002-7795-1635; VALLONE, Beatrice/0000-0003-0058-9049				Ascenzi P, 2004, BIOCHEM MOL BIOL EDU, V32, P305, DOI 10.1002/bmb.2004.494032050386; Brunori M, 2005, P NATL ACAD SCI USA, V102, P8483, DOI 10.1073/pnas.0408766102; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P21, DOI 10.1016/S0968-0004(00)01698-4; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Burmester T, 2004, NEWS PHYSIOL SCI, V19, P110, DOI 10.1152/nips.01513.2003; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GOODMAN M, 1975, NATURE, V253, P603, DOI 10.1038/253603a0; Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; JENSEN EO, 1981, NATURE, V291, P677, DOI 10.1038/291677a0; Kriegl JM, 2002, P NATL ACAD SCI USA, V99, P7992, DOI 10.1073/pnas.082244399; Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Uzan J, 2004, BIOPHYS J, V87, P1196, DOI 10.1529/biophysj.104.042168; Vallone B, 2004, PROTEINS, V56, P85, DOI 10.1002/prot.20113; Vallone B, 2004, P NATL ACAD SCI USA, V101, P17351, DOI 10.1073/pnas.0407633101; Van Doorslaer S, 2003, J BIOL CHEM, V278, P4919, DOI 10.1074/jbc.M210617200; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; Wakasugi K, 2005, BIOCHEMISTRY-US, V44, P2943, DOI 10.1021/bi0477539; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9; Zhu YH, 2002, BLOOD, V100, P2494, DOI 10.1182/blood-2002-01-0280	35	73	78	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2192	2197		10.1096/fj.06-6643rev	http://dx.doi.org/10.1096/fj.06-6643rev			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077295				2022-12-28	WOS:000241702600003
J	Giacco, F; Perruolo, G; D'Agostino, E; Fratellanza, G; Perna, E; Misso, S; Saldalamacchia, G; Oriente, F; Fiory, F; Miele, C; Formisano, S; Beguinot, F; Formisano, P				Giacco, Ferdinando; Perruolo, Giuseppe; D'Agostino, Elio; Fratellanza, Giorgio; Perna, Enzo; Misso, Saverio; Saldalamacchia, Gennaro; Oriente, Francesco; Fiory, Francesca; Miele, Claudia; Formisano, Salvatore; Beguinot, Francesco; Formisano, Pietro			Thrombin-activated platelets induce proliferation of human skin fibroblasts by stimulating autocrine production of insulin-like growth factor-1	FASEB JOURNAL			English	Article						tyrosine kinase; growth factor receptors; Akt/PKB; ERK; diabetic foot	DIABETIC FOOT ULCERS; RICH PLASMA; IGF-I; RECEPTOR; PHOSPHORYLATION; ENHANCEMENT; COMPONENTS; THERAPY; EGF; AKT	Platelet components have found successful clinical utilization to initiate or to accelerate tissue-repair mechanisms. However, the molecular pathways by which platelet factors contribute to tissue regeneration have not been fully elucidated. We have studied the effect of thrombin-activated platelets (TAPs) on cell growth in vivo and in cultured cell systems. Application of TAPs to ulcerative skin lesions of diabetic patients induced local activation of ERK1/2 and Akt/PKB. Moreover, when applied to cultured human skin fibroblasts, TAPs promoted cell growth and DNA synthesis and activated platelet-derived growth factor ( PDGF) and insulin-like growth factor (IGF)-1 receptor tyrosine kinases. PDGF was released by TAPs and rapidly achieved a plateau. At variance, the release of IGF-1 was mainly provided by the TAPs-stimulated fibroblasts and progressively increased up to 48 h. The PDGF-R blocker Ag1296 reduced the activation of Akt/PKB and, at a lesser extent, of ERK1/2. Conversely, inhibition of IGF-1 signaling by Ag1024 and expression of a dominant-negative IGF-1R mutant selectively reduced the stimulation of ERK1/ 2 by TAPs and fibroblast-released factors, with minor changes of Akt/PKB activity. Thus, platelet factors promote fibroblast growth by acutely activating Akt/PKB and ERK1/2. Sustained activation of ERK1/ 2, however, requires autocrine production of IGF-1 by TAPs-stimulated fibroblasts.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Med Clin & Sperimentale, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II	Formisano, P (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	fpietro@unina.it	giuseppe, perruolo/AAW-3869-2021; Formisano, Pietro/J-4237-2018; ORIENTE, Francesco/J-6652-2018	Perruolo, Giuseppe/0000-0003-0479-8729; Formisano, Pietro/0000-0001-7020-6870; ORIENTE, Francesco/0000-0003-4375-4526	Telethon [GGP04041] Funding Source: Medline	Telethon(Fondazione Telethon)		Anitua E, 2004, THROMB HAEMOSTASIS, V91, P4, DOI 10.1160/TH03-07-0440; BENNETT JS, 1992, DM-DIS MON, V38, P579; Bennett SP, 2003, BRIT J SURG, V90, P133, DOI 10.1002/bjs.4019; Bhanot Sumeet, 2002, Facial Plast Surg, V18, P27, DOI 10.1055/s-2002-19824; Borzini P, 2005, TRANSFUSION, V45, P1759, DOI 10.1111/j.1537-2995.2005.00600.x; Chaudhary LR, 2001, J CELL BIOCHEM, V81, P304, DOI 10.1002/1097-4644(20010501)81:2<304::AID-JCB1045>3.3.CO;2-L; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; DAWES KE, 1993, EUR J CELL BIOL, V61, P126; Diegelmann RF, 2004, FRONT BIOSCI-LANDMRK, V9, P283, DOI 10.2741/1184; Doucet C, 2005, J CELL PHYSIOL, V205, P228, DOI 10.1002/jcp.20391; Eldor R, 2004, DIABETIC MED, V21, P1161, DOI 10.1111/j.1464-5491.2004.01358.x; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KNIGHTON DR, 1986, ANN SURG, V204, P322, DOI 10.1097/00000658-198609000-00011; KOVALENKO M, 1994, CANCER RES, V54, P6106; Loots MAM, 2002, EUR J CELL BIOL, V81, P153, DOI 10.1078/0171-9335-00228; Margolis DJ, 2001, DIABETES CARE, V24, P483, DOI 10.2337/diacare.24.3.483; Marx RE, 2004, J ORAL MAXIL SURG, V62, P489, DOI 10.1016/j.joms.2003.12.003; Marx RE, 1998, ORAL SURG ORAL MED O, V85, P638, DOI 10.1016/S1079-2104(98)90029-4; Miller MC, 2005, BIODRUGS, V19, P363, DOI 10.2165/00063030-200519060-00004; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; O'Neill EM, 2001, VOX SANG, V81, P172, DOI 10.1046/j.1423-0410.2001.00099.x; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; PIERCE GF, 1995, ANNU REV MED, V46, P467; PIERCE GF, 1991, J CELL BIOCHEM, V45, P319, DOI 10.1002/jcb.240450403; Saldalamacchia G, 2004, NUTR METAB CARDIOVAS, V14, P395, DOI 10.1016/S0939-4753(04)80029-2; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Sly W S, 1979, Methods Enzymol, V58, P444; Snyder EL, 2001, TRANSFUSION, V41, P1186, DOI 10.1046/j.1537-2995.2001.41101186.x; STEED DL, 1992, DIABETES CARE, V15, P1598, DOI 10.2337/diacare.15.11.1598; Stefani C M, 2000, Implant Dent, V9, P126, DOI 10.1097/00008505-200009020-00004; Strawn LM, 1996, CANCER RES, V56, P3540; Tao JC, 2001, J BIOL CHEM, V276, P29520, DOI 10.1074/jbc.M103721200; Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003; Wagner F W Jr, 1984, Compr Ther, V10, P29; Weibrich G, 2002, J CRANIO MAXILL SURG, V30, P97, DOI 10.1054/jcms.2002.0285; Zimmermann R, 2001, TRANSFUSION, V41, P1217, DOI 10.1046/j.1537-2995.2001.41101217.x	37	29	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13								10.1096/fj.06-6104fje	http://dx.doi.org/10.1096/fj.06-6104fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17015410				2022-12-28	WOS:000241702600034
J	Okkenhaug, H; Weylandt, KH; Carmena, D; Wells, DJ; Higgins, CF; Sardini, A				Okkenhaug, Hanneke; Weylandt, Karsten-Henrich; Carmena, David; Wells, Dominic J.; Higgins, Christopher F.; Sardini, Alessandro			The human ClC-4 protein, a member of the CLC chloride channel/transporter family, is localized to the endoplasmic reticulum by its N-terminus	FASEB JOURNAL			English	Article						CLC family proteins; targeting motif; sarcoplasmic reticulum	SKELETAL-MUSCLE; MOLECULAR-BASIS; CHANNEL; MEMBRANE; GENE; ACIDIFICATION; COLOCALIZES; EXPRESSION; MUTATIONS; TRANSPORT	Despite considerable similarity in their amino acid sequences and structural features, the mammalian members of the CLC chloride channel/transporter family have different subcellular locations. The subcellular location and function of one of these members, hClC-4, is controversial. To characterize its cellular function, we investigated its tissue distribution and subcellular location. Expression was high in excitable tissues such as the nervous system and skeletal muscle. When heterologously expressed in HEK293 cells and in skeletal muscle fibers, hClC-4 localizes to the endoplasmic/sarcoplasmic reticulum (ER/SR) membranes, in contrast to hClC-3, which localizes to vesicular structures. This location was confirmed by identification of endogenous ClC-4 in membrane fractions from mouse brain homogenate enriched for the sarco-endoplasmic reticulum ATPase SERCA2, an ER/SR marker. To identify the motif responsible for ER localization of hClC-4, we generated hClC-4 truncations and chimeras between hClC-4 and hClC-3 or the unrelated plasma membrane protein Ly49E. A stretch of amino acids, residues 14-63, at the N-terminus constitutes a novel motif both necessary and sufficient for targeting hClC-4 and other membrane proteins to the ER.	Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Ctr Clin Sci, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Cellular & Mol Neurosci, Div Neurosci & Psychol Med,Gene Targeting Unit, London, England	Imperial College London; Imperial College London	Sardini, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Ctr Clin Sci, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	a.sardini@csc.mrc.ac.uk	Carmena, David/S-4049-2019	Carmena, David/0000-0002-4015-8553; Okkenhaug, Hanneke/0000-0003-0669-4069; Wells, Dominic/0000-0002-1425-6344				Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Buyse G, 1998, BIOCHEM J, V330, P1015, DOI 10.1042/bj3301015; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Gays F, 2005, J IMMUNOL, V175, P2938, DOI 10.4049/jimmunol.175.5.2938; Guerini D, 2002, FASEB J, V16, P519, DOI 10.1096/fj.01-0362com; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Haug K, 2003, NAT GENET, V33, P527, DOI 10.1038/ng1121; Hebeisen S, 2003, BIOPHYS J, V84, P2306, DOI 10.1016/S0006-3495(03)75036-X; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hui D, 2000, J BIOL CHEM, V275, P2713, DOI 10.1074/jbc.275.4.2713; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; JONASSEN I, 1995, PROTEIN SCI, V4, P1587, DOI 10.1002/pro.5560040817; Kawasaki Masanobu, 1999, American Journal of Physiology, V277, pC948; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Kuwana T, 1998, P NATL ACAD SCI USA, V95, P1056, DOI 10.1073/pnas.95.3.1056; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Ludwig M, 2004, AM J MED GENET A, V128A, P434, DOI 10.1002/ajmg.a.30204; McMahon JM, 2001, GENE THER, V8, P1264, DOI 10.1038/sj.gt.3301522; Mohammad-Panah R, 2003, J BIOL CHEM, V278, P29267, DOI 10.1074/jbc.M304357200; Mohammad-Panah R, 2002, J BIOL CHEM, V277, P566, DOI 10.1074/jbc.M106968200; Newton T, 2003, BIOCHEM J, V371, P775, DOI 10.1042/BJ20021477; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; Ryan MM, 1999, AM J HUM GENET, V65, P1104, DOI 10.1086/302588; Salazar G, 2004, J BIOL CHEM, V279, P25430, DOI 10.1074/jbc.M402331200; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; SchmidtRose T, 1997, J BIOL CHEM, V272, P20515, DOI 10.1074/jbc.272.33.20515; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Suzuki T, 2006, J CELL PHYSIOL, V206, P792, DOI 10.1002/jcp.20516; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Toomey JA, 1998, EUR J IMMUNOL, V28, P47, DOI 10.1002/(SICI)1521-4141(199801)28:01<47::AID-IMMU47>3.0.CO;2-A; Vanoye CG, 2002, J PHYSIOL-LONDON, V539, P373, DOI 10.1113/jphysiol.2001.013115; VANSLEGTENHORST MA, 1994, HUM MOL GENET, V3, P547; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Wang T, 2004, GASTROENTEROLOGY, V126, P1157, DOI 10.1053/j.gastro.2004.01.015; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang AH, 2005, GENE, V350, P25, DOI 10.1016/j.gene.2005.01.019	49	25	26	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2390	+		10.1096/fj.05-5588fje	http://dx.doi.org/10.1096/fj.05-5588fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023393				2022-12-28	WOS:000241702600030
J	Xu, DS; Buehner, A; Xu, JP; Lambert, T; Nekl, C; Nielsen, MK; Zhou, Y				Xu, Dongsheng; Buehner, Angela; Xu, Jianping; Lambert, Travis; Nekl, Casey; Nielsen, Merlyn K.; Zhou, You			A polymorphic glucocorticoid receptor in a mouse population may explain inherited altered stress response and increased anxiety-type behaviors	FASEB JOURNAL			English	Article						corticosterone response; polyglutamine track; mouse model; open field assessment; elevated plus maze	HEAT-LOSS; POLYGLUTAMINE DISEASE; DIVERGENT SELECTION; TRANSGENIC MICE; 15 GENERATIONS; DNA-BINDING; GENE; CHAPERONES; PROTEIN; HSP70	A polymorphic glucocorticoid receptor (GRQn) with an expanded CAG track and two silent mutations, when compared with the sequence of other isoform (GRwt), is found in two outbred mouse lines that were produced by selection for high (SH) or low (SL) stress response from high or low heat loss lines of mice, respectively. The GRQn allele, which is also found in 5 of 16 commonly used inbred mouse lines, had a much higher frequency in SL mice; the GRwt/wt was found only in the SH line. Both GRQn/Qn and GRwt/Qn mice had a much weaker corticosterone response to stress than the GRwt/wt mice. Assessment of open field activity revealed that GRQn/Qn and GRwt/Qn mice exhibited significantly lower velocity and locomotor activity, less time in the center, and much longer duration in corner zones than the GRwt/wt mice. The increased anxiety-type behaviors of the GRQn/Qn and GRwt/Qn mice were confirmed by the "elevated plus maze" test in which GRQn/Qn and GRwt/Qn mice spent significantly less time in the "open arm" and longer duration in the "closed arm," than GRwt/wt mice. These results suggest this GR polymorphism plays a role in complex mechanisms leading to lower corticosterone response to stress, and may also be associated with decreased locomotive and increased anxiety-type behaviors in mice.	Univ Nebraska, Beadle Ctr, Dept Vet & Biomed Sci, Lincoln, NE 68588 USA; Univ Nebraska, Dept Anim Sci, Lincoln, NE 68588 USA; Univ Nebraska, Ctr Biotechnol, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Zhou, Y (corresponding author), Univ Nebraska, Beadle Ctr, Dept Vet & Biomed Sci, Rm E117,1901 Vine St, Lincoln, NE 68588 USA.	yzhou2@unl.edu						BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blalock EM, 2003, J NEUROSCI, V23, P3807; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chai YH, 1999, J NEUROSCI, V19, P10338; Dallman MF, 2004, ENDOCRINOLOGY, V145, P2633, DOI 10.1210/en.2004-0037; Diamond MI, 2000, P NATL ACAD SCI USA, V97, P657, DOI 10.1073/pnas.97.2.657; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Heeley RP, 2002, ENDOCR RES, V28, P217, DOI 10.1081/ERC-120015060; Heeley RP, 1998, MAMM GENOME, V9, P198, DOI 10.1007/s003359900725; Holmes A, 2000, PHYSIOL BEHAV, V71, P509, DOI 10.1016/S0031-9384(00)00373-5; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Karolyi IJ, 1999, P NATL ACAD SCI USA, V96, P11595, DOI 10.1073/pnas.96.20.11595; Kgwatalala PM, 2004, J ANIM SCI, V82, P2876; Kitchener P, 2004, EUR J NEUROSCI, V19, P1837, DOI 10.1111/j.1460-9568.2004.03267.x; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; McEwen BS, 2000, BRAIN RES, V886, P172, DOI 10.1016/S0006-8993(00)02950-4; MONTKOWSKI A, 1995, J NEUROENDOCRINOL, V7, P841, DOI 10.1111/j.1365-2826.1995.tb00724.x; Mousel MR, 2001, J ANIM SCI, V79, P861; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Nielsen MK, 1997, J ANIM SCI, V75, P1469; Nielsen MK, 1997, J ANIM SCI, V75, P1461; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; ROYCE JR, 1971, J COMP PHYSIOL PSYCH, V76, P353, DOI 10.1037/h0031387; Southwick C. H., 1968, Communications in Behavioral Biology, VA1, P49; Steckler T, 2001, BEHAV NEUROSCI, V115, P207, DOI 10.1037//0735-7044.115.1.207; STORER JB, 1966, J GERONTOL, V21, P404, DOI 10.1093/geronj/21.3.404; Toyoshima I, 2002, J NEUROSCI RES, V68, P442, DOI 10.1002/jnr.10233; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Veenema AH, 2003, J NEUROENDOCRINOL, V15, P256, DOI 10.1046/j.1365-2826.2003.00986.x; Wei Q, 2004, P NATL ACAD SCI USA, V101, P11851, DOI 10.1073/pnas.0402208101; Wesolowski SR, 2003, PHYSIOL GENOMICS, V13, P129, DOI 10.1152/physiolgenomics.00184.2002; Wust S, 2004, J CLIN ENDOCR METAB, V89, P565, DOI 10.1210/jc.2003-031148; Yalcin B, 2004, NAT GENET, V36, P1197, DOI 10.1038/ng1450; Yudt MR, 2002, MOL ENDOCRINOL, V16, P1719, DOI 10.1210/me.2002-0106; Zhou Y, 1998, BRAIN RES, V788, P151, DOI 10.1016/S0006-8993(97)01533-3	35	20	20	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2414	+		10.1096/fj.06-5926fje	http://dx.doi.org/10.1096/fj.06-5926fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17012242				2022-12-28	WOS:000241702600038
J	Giroux, V; Iovanna, J; Dagorn, JC				Giroux, Valentin; Iovanna, Juan; Dagorn, Jean-Charles			Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance	FASEB JOURNAL			English	Article						apoptosis; pancreatic; adenocarcinoma; chemotherapy	FACTOR-KAPPA-B; PROTEIN-KINASE; INHIBITION; EXPRESSION; APOPTOSIS; ADENOCARCINOMA; REGULATOR; CARCINOMA; THERAPY; SUBUNIT	Except for gemcitabine, chemotherapeutic agents are ineffective with pancreatic adenocarcinoma because this cancer is resistant to apoptosis induction. Involvement of specific kinases in such resistance is likely. We developed a systematic strategy to screen the human kinome and select kinases whose inhibition in pancreatic cancer cells can increase 1) spontaneous apoptosis or 2) gemcitabine-induced apoptosis. The pancreatic adenocarcinoma cell line MiaPaCa-2 was transfected with 645 pairs of siRNAs directed to all human kinases. The same experiment was conducted in cells treated with 150 mu M gemcitabine. Apoptosis was measured after 2 days and the results were normalized for cell viability. A panel of 56 kinases whose inhibition increased spontaneous apoptosis by at least 50% was established. Ten of them gave similar results on Panc1 and BxPC3 pancreatic adenocarcinoma cell lines. A panel of 83 kinases whose inhibition increased gemcitabine-induced apoptosis by 50% or more was also established. Twelve kinases appeared in both panels. A cumulative increase in apoptosis was observed when inhibiting simultaneously several kinases. Such a systematic approach allowed characterization of all kinases involved in pancreatic cancer cell survival and resistance to gemcitabine. Inhibitors of these kinases, used alone or in combination, might improve the treatment of pancreatic adenocarcinoma.	INSERM Unite 624, Ctr Rech, F-13288 Marseille 9, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Dagorn, JC (corresponding author), INSERM Unite 624, Ctr Rech, Parc Sci & Technol Luminy,Case 915, F-13288 Marseille 9, France.	dagorn@marseille.inserm.fr	Iovanna, Juan/M-9805-2017	Iovanna, Juan/0000-0003-1822-2237				Bondar VM, 2002, MOL CANCER THER, V1, P989; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Clark DE, 2005, CANCER RES, V65, P3108; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Cotteret S, 2003, MOL CELL BIOL, V23, P5526, DOI 10.1128/MCB.23.16.5526-5539.2003; Demols A, 2006, BRIT J CANCER, V94, P481, DOI 10.1038/sj.bjc.6602966; Duxbury MS, 2004, CLIN CANCER RES, V10, P2307, DOI 10.1158/1078-0432.CCR-1183-3; Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602; Friberg Gregory, 2005, Curr Oncol Rep, V7, P186, DOI 10.1007/s11912-005-0072-3; Giroux V, 2006, CLIN CANCER RES, V12, P235, DOI 10.1158/1078-0432.CCR-05-1700; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jia L, 2005, CANCER RES, V65, P8003, DOI 10.1158/0008-5472.CAN-04-3679; Katoh M, 2005, ONCOL REP, V14, P1583; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Metaye T, 2002, J CLIN ENDOCR METAB, V87, P3279, DOI 10.1210/jc.87.7.3279; Morgan-Lappe S, 2006, ONCOGENE, V25, P1340, DOI 10.1038/sj.onc.1209169; Ng SSW, 2000, CANCER RES, V60, P5451; Richards DA, 2005, SEMIN ONCOL, V32, pS9, DOI 10.1053/j.seminoncol.2005.06.024; Semba S, 2002, CLIN CANCER RES, V8, P3824; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Siu LL, 2006, CLIN CANCER RES, V12, P144, DOI 10.1158/1078-0432.CCR-05-1571; Sun CL, 2001, ONCOL REP, V8, P89; Taylor JM, 1999, J CELL SCI, V112, P231; Yokoi K, 2005, CANCER RES, V65, P10371, DOI 10.1158/0008-5472.CAN-05-1698; Zhang YX, 2006, CANCER RES, V66, P1025, DOI 10.1158/0008-5472.CAN-05-2968	31	76	80	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					1982	1991		10.1096/fj.06-6239com	http://dx.doi.org/10.1096/fj.06-6239com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012250				2022-12-28	WOS:000241156900006
J	Nahirney, PC; Forbes, JG; Morris, HD; Chock, SC; Wang, K				Nahirney, Patrick C.; Forbes, Jeffrey G.; Morris, H. Douglas; Chock, Susanne C.; Wang, Kuan			What the buzz was all about: superfast song muscles rattle the tymbals of male periodical cicadas	FASEB JOURNAL			English	Article						multimodal imaging; Z-band lattice; myofilament length regulation; sarcomere proportion; supercontraction	FISH PORICHTHYS-NOTATUS; SKELETAL-MUSCLE; SOUND-PRODUCTION; MOTOR SYSTEM; Z-BAND; FILAMENTS; PROTEIN; FIBERS; ORGANIZATION; ARCHITECTURE	Male cicadas produce mating calls by oscillating a pair of superfast tymbal muscles in their anterior abdominal cavity that pull on and buckle stiff-ribbed cuticular tymbal membranes located beneath the folded wings. The functional anatomy and rattling of the tymbal organ in 17 yr periodical cicada, Magicicada cassini (Brood X), were revealed by high-resolution microcomputed tomography, magnetic resonance imaging, electron microscopy, and laser vibrometry to understand the mechanism of sound production in these insects. Each 50 Hz muscle contraction yielded five to six stages of rib buckling in the tymbal, and a small release of muscle tension resulted in a rapid recovery due to the spring-loaded nature of the stiff ribs in the resilin-rich tymbal. The tymbal muscle sarcomeres have thick and thin filaments that are 30% shorter than those in flight muscles, with Z-bands that were thicker and configured into novel perforated hexagonal lattices. Caffeine-treated fibers supercontracted by allowing thick filaments to traverse the Z-band through its open lattice. This superfast sonic muscle illustrates design features, especially the matching hexagonal symmetry of the myofilaments and the perforated Z-band that contribute to high-speed contractions, long endurance, and potentially supercontraction needed for producing enduring mating songs and choruses.	NIAMSD, Muscle Proteom & Nanotechnol Sect, Muscle Biol Lab, NIH, Bethesda, MD 20892 USA; NINDS, NIH, Magnet Resonance Imaging Res Facil, NIH, Bethesda, MD 20892 USA; Dept Hlth & Human Serv, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Wang, K (corresponding author), NIAMSD, Muscle Proteom & Nanotechnol Sect, Muscle Biol Lab, NIH, Bldg 50,Rm 1140, Bethesda, MD 20892 USA.	wangk@exchange.nih.gov		Morris, H. Douglas/0000-0002-7942-3748	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		APPELT D, 1991, J MUSCLE RES CELL M, V12, P543, DOI 10.1007/BF01738442; BASS AH, 1989, J COMP NEUROL, V286, P141, DOI 10.1002/cne.902860202; BASS AH, 1989, J COMP NEUROL, V286, P154, DOI 10.1002/cne.902860203; Conley KE, 2002, J EXP BIOL, V205, P2175; Conley KE, 1996, NATURE, V383, P71, DOI 10.1038/383071a0; EISENBERG BR, 1976, J ULTRA MOL STRUCT R, V54, P76, DOI 10.1016/S0022-5320(76)80010-X; EPSTEIN HF, 1985, J CELL BIOL, V100, P904, DOI 10.1083/jcb.100.3.904; FRANZINI.C, 1973, J CELL BIOL, V58, P630, DOI 10.1083/jcb.58.3.630; Gronenberg W, 1997, CELL TISSUE RES, V289, P347, DOI 10.1007/s004410050882; HEATH JE, 1968, AM MIDL NAT, V80, P440, DOI 10.2307/2423537; Hoyle G., 1983, MUSCLES THEIR NEURAL; Jasanoff A, 2002, J MAGN RESON, V158, P79, DOI 10.1016/S1090-7807(02)00063-0; Josephson RK, 2000, J EXP BIOL, V203, P2713; Knupp C, 2002, J MOL BIOL, V322, P731, DOI 10.1016/S0022-2836(02)00819-7; Kovacic-Milivojevic B, 2001, MOL BIOL CELL, V12, P2290, DOI 10.1091/mbc.12.8.2290; Kulke M, 2001, J CELL BIOL, V154, P1045, DOI 10.1083/jcb.200104016; Lewis MK, 2003, J STRUCT BIOL, V143, P56, DOI 10.1016/S1047-8477(03)00121-7; Lindstedt SL, 1998, COMP BIOCHEM PHYS B, V120, P35, DOI 10.1016/S0305-0491(98)00021-2; LLOYD M, 1966, EVOLUTION, V20, P466, DOI 10.1111/j.1558-5646.1966.tb03381.x; Mardahl-Dumesnil M, 2001, J CELL BIOL, V155, P1043, DOI 10.1083/jcb.200108026; Michaelis T, 2005, NEUROIMAGE, V24, P596, DOI 10.1016/j.neuroimage.2004.08.048; PRINGLE JWS, 1953, NATURE, V172, P248, DOI 10.1038/172248b0; Qiu F, 2005, J CELL SCI, V118, P1527, DOI 10.1242/jcs.02281; REID KH, 1971, SCIENCE, V172, P949, DOI 10.1126/science.172.3986.949; Rome LC, 1996, P NATL ACAD SCI USA, V93, P8095, DOI 10.1073/pnas.93.15.8095; Schaeffer PJ, 1996, J EXP BIOL, V199, P351; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; SZENTGYORGYI AG, 1971, J MOL BIOL, V56, P239, DOI 10.1016/0022-2836(71)90462-1; van der Ven PFM, 2000, J CELL SCI, V113, P1405; VIGOREAUX JO, 1994, J MUSCLE RES CELL M, V15, P237; Wang K, 1996, J BIOL CHEM, V271, P4304; Wang K, 1996, ADV BIOPHYS, V33, P123; Wecker S, 2002, MAGN RESON IMAGING, V20, P105, DOI 10.1016/S0730-725X(01)00445-3; Weins A, 2001, J CELL BIOL, V155, P393, DOI 10.1083/jcb.200012039; WEISFOGH T, 1960, J EXP BIOL, V37, P889; WILLIAMS KS, 1995, ANNU REV ENTOMOL, V40, P269, DOI 10.1146/annurev.en.40.010195.001413; Wirkner CS, 2004, MICROSC RES TECHNIQ, V64, P250, DOI 10.1002/jemt.20076; YAMAGUCHI M, 1985, J MOL BIOL, V184, P621, DOI 10.1016/0022-2836(85)90308-0; YOUNG D, 1983, J COMP PHYSIOL, V152, P197, DOI 10.1007/BF00611184; YOUNG D, 1972, J COMP PHYSIOL, V79, P343, DOI 10.1007/BF00696251; YOUNG D, 1983, J COMP PHYSIOL, V152, P183, DOI 10.1007/BF00611183	41	12	14	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2017	2026		10.1096/fj.06-5991com	http://dx.doi.org/10.1096/fj.06-5991com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012254				2022-12-28	WOS:000241156900010
J	Cheng, S; Pollock, AS; Mahimkar, R; Olson, JL; Lovett, DH				Cheng, Sunfa; Pollock, Allan S.; Mahimkar, Rajeev; Olson, Jean L.; Lovett, David H.			Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury	FASEB JOURNAL			English	Article						epithelial-mesenchymal transition; chronic kidney disease; tubular atrophy; interstitial fibrosis	MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASES; TRANSFORMING GROWTH-FACTOR-BETA-1; TUBULOINTERSTITIAL FIBROSIS; MYOFIBROBLAST TRANSITION; DIABETIC-NEPHROPATHY; KIDNEY-DISEASE; IV COLLAGENASE; EXPRESSION; INHIBITION	Chronic kidney disease (CKD) and failure are problems of increasing importance. Regardless of the primary etiology, CKD is characterized by tubular atrophy, interstitial fibrosis, and glomerulosclerosis. It has been assumed that diminished matrix metalloproteinase (MMP) activity is responsible for the accumulation of the extracellular matrix (ECM) proteins and collagens that typify the fibrotic kidney. Here we demonstrate that transgenic renal proximal tubular epithelial expression of a specific enzyme, MMP-2, is sufficient to generate the entire spectrum of pathological and functional changes characteristic of human CKD. At the earliest point, MMP-2 leads to structural alterations in the tubular basement membrane, a process that triggers tubular epithelial-mesenchymal transition, with resultant tubular atrophy, fibrosis and renal failure. Inhibition of MMP-2, specifically in the early, prefibrotic stages of disease may offer an additional approach for treatment of these disabling disorders.	Univ Calif San Francisco, Med Serv 111J, SFVAMC, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lovett, DH (corresponding author), Univ Calif San Francisco, Med Serv 111J, SFVAMC, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA.	david.lovett@med.va.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039776, K08DK059383] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08 DK 59383, R01 DK39776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergman MR, 2003, BIOCHEM J, V369, P485, DOI 10.1042/BJ20020707; Cheng SF, 2003, AM J PATHOL, V162, P1937, DOI 10.1016/S0002-9440(10)64327-1; Eknoyan G, 2004, KIDNEY INT, V66, P1310, DOI 10.1111/j.1523-1755.2004.00894.x; Fan WH, 2002, J BIOL CHEM, V277, P9800, DOI 10.1074/jbc.M111213200; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; Huang YF, 2003, J CLIN INVEST, V112, P379, DOI 10.1172/JCI200318038; Inkinen KA, 2005, TRANSPLANT INT, V18, P506, DOI 10.1111/j.1432-2277.2004.00053.x; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Jinde K, 2001, AM J KIDNEY DIS, V38, P761, DOI 10.1053/ajkd.2001.27693; JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772; Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x; Li YJ, 2003, J CLIN INVEST, V112, P503, DOI 10.1172/JCI200317913; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Lutz J, 2005, TRANSPLANTATION, V79, P655, DOI 10.1097/01.TP.0000151644.85832.B5; Ma LJ, 2005, J AM SOC NEPHROL, V16, P966, DOI 10.1681/ASN.2004060492; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MARTI HP, 1994, AM J PATHOL, V144, P82; McLennan SV, 2002, DIABETOLOGIA, V45, P268, DOI 10.1007/s00125-001-0730-4; McLennan SV, 2000, KIDNEY INT, V58, pS81, DOI 10.1046/j.1523-1755.2000.07713.x; Mook ORF, 2003, J HISTOCHEM CYTOCHEM, V51, P821, DOI 10.1177/002215540305100613; Murakami S, 2001, ATHEROSCLEROSIS, V157, P361, DOI 10.1016/S0021-9150(00)00743-7; Ng YY, 1998, KIDNEY INT, V54, P864, DOI 10.1046/j.1523-1755.1998.00076.x; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; PORTIKDOBOS V, 2005, IN PRESS AM J PHYSL; RAIJ L, 1984, KIDNEY INT, V26, P137, DOI 10.1038/ki.1984.147; Rastaldi MP, 2002, KIDNEY INT, V62, P137, DOI 10.1046/j.1523-1755.2002.00430.x; Reisdorff J, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015617.39974.FB; Ru Y., 2003, Journal of Submicroscopic Cytology and Pathology, V35, P147; Sato N, 2003, AM J NEPHROL, V23, P334, DOI 10.1159/000072915; SCHAFFNER DL, 1993, AM J PATHOL, V142, P1051; Seomun Y, 2001, BIOCHEM J, V358, P41, DOI 10.1042/0264-6021:3580041; Sinniah R, 1999, ULTRASTRUCT PATHOL, V23, P359, DOI 10.1080/019131299281329; Song WM, 2000, DEV BIOL, V227, P606, DOI 10.1006/dbio.2000.9919; Tang WW, 1997, KIDNEY INT, V51, P926, DOI 10.1038/ki.1997.131; Terzi F, 2000, J CLIN INVEST, V106, P225, DOI 10.1172/JCI8315; Thomasset N, 1998, AM J PATHOL, V153, P457, DOI 10.1016/S0002-9440(10)65589-7; Ward C, 2005, TRANSPL P, V37, P977, DOI 10.1016/j.transproceed.2004.12.203; YANG C, 2000, CANCER RES, V63, P8312; Yang JW, 2002, J CLIN INVEST, V110, P1525, DOI 10.1172/JC1200216219; Yang JW, 2002, J AM SOC NEPHROL, V13, P96, DOI 10.1681/ASN.V13196; Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3; Zeisberg M, 2003, AM J PHYSIOL-RENAL, V285, pF1060, DOI 10.1152/ajprenal.00191.2002; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7; Zeisberg M, 2002, AM J PATHOL, V160, P2001, DOI 10.1016/S0002-9440(10)61150-9	44	186	202	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1898	+		10.1096/fj.06-5898fje	http://dx.doi.org/10.1096/fj.06-5898fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16891619				2022-12-28	WOS:000240267000023
J	Rouzaud, F; Costin, GE; Yamaguchi, Y; Valencia, JC; Berens, WF; Chen, KG; Hoashi, T; Bohm, M; Abdel-Malek, ZA; Hearing, VJ				Rouzaud, Francois; Costin, Gertrude-E.; Yamaguchi, Yuji; Valencia, Julio C.; Berens, Werner F.; Chen, Kevin G.; Hoashi, Toshihiko; Boehm, Markus; Abdel-Malek, Zalfa A.; Hearing, Vincent J.			Regulation of constitutive and UVR-induced skin pigmentation by melanocortin 1 receptor isoforms	FASEB JOURNAL			English	Article						splice variant; melanocyte; UVR	PROTEIN-COUPLED RECEPTORS; HUMAN MELANOCYTES; CYTOPLASMIC TAIL; MSH RECEPTOR; DNA-DAMAGE; EXPRESSION; VARIANTS; GENE; MC1R; PALMITOYLATION	Melanin synthesized by epidermal melanocytes protects the skin against UVR-induced DNA damage and skin cancer. Exposure to UVR increases the synthesis of the photoprotective eumelanin on activation of MC1R, a melanoma susceptibility gene. We studied the expression of MC1R under UVR and alpha-MSH stimulation in skin of different ethnic origins and in melanocytes of various pigmentary levels. This study identifies and characterizes a novel MC1R isoform (MC1R350) generated by alternative splicing of the classically known MC1R (MC1R317). We demonstrate that the melanin content of melanocytes shows a significant positive correlation with MC1R317 levels but correlates inversely with the amount of MC1R350, suggesting that this latter isoform could act as a negative regulator of melanin synthesis. We confirmed that hypothesis by showing that while MC1R317 signaling significantly increases the expression of MITF and tyrosinase, two key factors in the melanin synthesis pathway, MC1R350 dramatically hampers their expression. In the skin, we show that UVR does not increase MC1R350 expression but does significantly increase MC1R317. Taken together, our results strongly suggest that MC1R350 acts as a negative regulator of skin pigmentation and demonstrate for the first time that MC1R isoform-specific expression is closely related to skin pigmentation and photoprotection.	Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Munster, Dept Dermatol, D-4400 Munster, Germany; Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-4400 Munster, Germany; Univ Cincinnati, Coll Med, Dept Dermatol, Cincinnati, OH USA	State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Munster; University of Munster; University System of Ohio; University of Cincinnati	Rouzaud, F (corresponding author), Univ Florida, Dept Med Chem, Rm P5-26,1600 SW Archer Rd, Gainesville, FL 32610 USA.	frouzaud@ufl.edu	Yamaguchi, Yuji/B-9312-2008; Yamaguchi, Yuji/X-6681-2019; Chen, Kevin G/D-6769-2011; Chen, Kevin/GYU-8963-2022	Chen, Kevin G/0000-0003-2983-6330; Yamaguchi, Yuji/0000-0003-4338-2662	DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009110] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 NS999999] Funding Source: Medline; NIEHS NIH HHS [R01 ES009110] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bohm M, 1999, EXP DERMATOL, V8, P453, DOI 10.1111/j.1600-0625.1999.tb00303.x; Bohm M, 1999, ANN NY ACAD SCI, V885, P372; Bonilla C, 2005, HUM GENET, V116, P402, DOI 10.1007/s00439-004-1251-2; Box NF, 2001, J INVEST DERMATOL, V116, P224, DOI 10.1046/j.1523-1747.2001.01224.x; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; Chakraborty AK, 1999, ANN NY ACAD SCI, V885, P100; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; DONATIEN PD, 1992, ARCH DERMATOL RES, V284, P424, DOI 10.1007/BF00372074; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; Everts RE, 2000, ANIM GENET, V31, P194, DOI 10.1046/j.1365-2052.2000.00639.x; Frandberg PA, 1998, BIOCHEM BIOPH RES CO, V245, P490, DOI 10.1006/bbrc.1998.8459; HALDER RM, 1995, CANCER, V75, P667, DOI 10.1002/1097-0142(19950115)75:2+<667::AID-CNCR2820751409>3.0.CO;2-I; HARRISON GA, 1973, J INVEST DERMATOL, V60, P418, DOI 10.1111/1523-1747.ep12702616; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Im SB, 1998, CANCER RES, V58, P47; Imoto K, 2002, J INVEST DERMATOL, V119, P1177, DOI 10.1046/j.1523-1747.2002.19514.x; Irani BG, 2004, CURR PHARM DESIGN, V10, P3443, DOI 10.2174/1381612043382891; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; Jimenez-Cervantes C, 2001, FEBS LETT, V508, P44, DOI 10.1016/S0014-5793(01)03025-3; Jimenez-Cervantes C, 2001, J INVEST DERMATOL, V117, P156, DOI 10.1046/j.0022-202x.2001.01393.x; John PR, 2002, HUM MUTAT, V19, DOI 10.1002/humu.9030; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KLUNGLAND H, 1995, MAMM GENOME, V6, P636, DOI 10.1007/BF00352371; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; Little C., 1957, INHERITANCE COAT COL; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Mandrika I, 2005, BIOCHEM BIOPH RES CO, V326, P349, DOI 10.1016/j.bbrc.2004.11.036; Milligan G, 2004, MOL PHARMACOL, V66, P1, DOI 10.1124/mol.104.000497.; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Newton JM, 2000, MAMM GENOME, V11, P24, DOI 10.1007/s003350010005; PAWELEK JM, 1992, PIGM CELL RES, V5, P348, DOI 10.1111/j.1600-0749.1992.tb00561.x; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; Rana BK, 1999, GENETICS, V151, P1547; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Rouzaud F, 2000, GENET SEL EVOL, V32, P511, DOI 10.1051/gse:2000102; Rouzaud F, 2005, MUTAT RES-FUND MOL M, V571, P133, DOI 10.1016/j.mrfmmm.2004.09.014; Rouzaud F, 2003, FASEB J, V17, P2154, DOI 10.1096/fj.03-0206fje; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Sanchez-Laorden BL, 2006, J INVEST DERMATOL, V126, P172, DOI 10.1038/sj.jid.5700036; Schioth HB, 1999, BIOCHEM BIOPH RES CO, V260, P488, DOI 10.1006/bbrc.1999.0935; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Scott MC, 2002, J CELL SCI, V115, P2349; Scott MC, 2002, PIGM CELL RES, V15, P433, DOI 10.1034/j.1600-0749.2002.02051.x; Searle A.G., 1968, COMP GENETICS COAT C; SIEGRIST W, 1986, ANAL BIOCHEM, V159, P191, DOI 10.1016/0003-2697(86)90327-1; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; Smith R, 1998, J INVEST DERMATOL, V111, P119, DOI 10.1046/j.1523-1747.1998.00252.x; Sturm RA, 2001, GENE, V277, P49, DOI 10.1016/S0378-1119(01)00694-1; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; Tadokoro T, 2005, J INVEST DERMATOL, V124, P1326, DOI 10.1111/j.0022-202X.2005.23760.x; Tadokoro T, 2003, FASEB J, V17, P1177, DOI 10.1096/fj.02-0865fje; Tan CP, 1999, FEBS LETT, V451, P137, DOI 10.1016/S0014-5793(99)00525-6; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; Wilson S, 1998, BRIT J PHARMACOL, V125, P1387, DOI 10.1038/sj.bjp.0702238	58	35	38	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1927	+		10.1096/fj.06-5922fje	http://dx.doi.org/10.1096/fj.06-5922fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877522				2022-12-28	WOS:000240267000033
J	Xu, RJ; Jin, JF; Hu, W; Sun, W; Bielawski, J; Szulc, Z; Taha, T; Obeid, LM; Mao, CG				Xu, Ruijuan; Jin, Junfei; Hu, Wei; Sun, Wei; Bielawski, Jacek; Szulc, Zdzislaw; Taha, Tarek; Obeid, Lina M.; Mao, Cungui			Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P	FASEB JOURNAL			English	Article						placenta; rate-limiting step; serum deprivation; S1P receptor; sphingolipid	MOLECULAR-CLONING; NEUTRAL CERAMIDASE; FUNCTIONAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; EDG-1 FAMILY; GENE FAMILY; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; EXPRESSION; IDENTIFICATION	Sphingosine-1-phosphate (S1P), a sphingolipid metabolite, promotes cell proliferation and survival whereas its precursor, sphingosine, has the opposite effects. However, much remains unknown about their regulation. Here we identify a novel human ceramidase (haCER2) that regulates the levels of both sphingosine and S1P by controlling the hydrolysis of ceramides. haCER2 is localized to the Golgi complex and is highly expressed in the placenta. High ectopic expression of haCER2 caused fragmentation of the Golgi complex and growth arrest in HeLa cells due to sphingosine accumulation. Low ectopic expression of haCER2 increased S1P without sphingosine accumulation, promoting cell proliferation in serum-free medium. This proliferative effect was suppressed by dimethylsphingosine, an inhibitor of the S1P formation, or by the RNA interference (RNAi) - mediated inhibition of S1P(1), a G-protein-coupled receptor for S1P. The RNAi-mediated down-regulation of haCER2 enhanced the serum deprivation-induced growth arrest and apoptosis of HeLa cells, which was inhibited by addition of exogenous S1P. Serum deprivation up-regulated both haCER2 mRNA and activity in HeLa cells. haCER2 mRNA is also up-regulated in some tumors. Taken together, these results suggest that haCER2 is important for the generation of S1P and S1P-mediated cell proliferation and survival, but that its overexpression may cause cell growth arrest due to an accumulation of sphingosine. - Xu, R., Jin, J., Hu, W., Sun, W., Bielawski, J., Szulc, Z., Taha, T., Obeid, L. M., Mao, C. Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Mao, CG (corresponding author), 114 Doughty St,Rm 646,STB,POB 250779, Charleston, SC 29425 USA.	maoc@musc.edu	xu, rui/GRX-5734-2022	obeid, lina/0000-0002-0734-0847; Jin, Junfei/0000-0002-9237-9024	NATIONAL CANCER INSTITUTE [R01CA104834] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104834] Funding Source: Medline; NCRR NIH HHS [P20RR017677] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BIELAWSKI J, 2006, IN PRESS METHODS; Boquet I, 2000, J NEUROBIOL, V42, P33; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; el Bawab Samer, 2002, Subcell Biochem, V36, P187; English D, 2001, CARDIOVASC RES, V49, P588, DOI 10.1016/S0008-6363(00)00230-3; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Graveel CR, 2001, ONCOGENE, V20, P2704, DOI 10.1038/sj.onc.1204391; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Hla T, 2000, ANN NY ACAD SCI, V905, P16; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Hong GY, 1999, FEBS LETT, V460, P513, DOI 10.1016/S0014-5793(99)01400-3; Hu W, 2005, MOL BIOL CELL, V16, P1555, DOI 10.1091/mbc.E04-07-0594; Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200; Jolly PS, 2005, BLOOD, V105, P4736, DOI 10.1182/blood-2004-12-4686; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Mandala SM, 2001, PROSTAG OTH LIPID M, V64, P143, DOI 10.1016/S0090-6980(01)00111-3; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2003, J BIOL CHEM, V278, P31184, DOI 10.1074/jbc.M303875200; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005; Mizutani Y, 2004, FEBS LETT, V563, P93, DOI 10.1016/S0014-5793(04)00274-1; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Nikolova-Karakashian M, 2000, METHOD ENZYMOL, V311, P194; Obeid L.M., 2001, J BIOL CHEM, V16, P16; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Rotolo JA, 2005, J BIOL CHEM, V280, P26425, DOI 10.1074/jbc.M414569200; Ruwisch L, 2001, N-S ARCH PHARMACOL, V363, P358, DOI 10.1007/s002100000365; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2000, ANN NY ACAD SCI, V905, P54; Sullards M C, 2001, Sci STKE, V2001, ppl1; Tani M, 2005, J BIOL CHEM, V280, P36592, DOI 10.1074/jbc.M506827200; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Usta J, 2001, BIOCHEMISTRY-US, V40, P9657, DOI 10.1021/bi010535k; Van Veldhoven PP, 2000, BBA-MOL CELL BIOL L, V1487, P128, DOI 10.1016/S1388-1981(00)00079-2; Xu Y, 2001, J SOC GYNECOL INVEST, V8, P1, DOI 10.1016/S1071-5576(00)00092-7; Zhou JH, 1998, BIOCHEM BIOPH RES CO, V242, P502, DOI 10.1006/bbrc.1997.7993	48	108	118	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1813	1825		10.1096/fj.05-5689com	http://dx.doi.org/10.1096/fj.05-5689com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940153				2022-12-28	WOS:000240267000009
J	Bon, M; McGowan, SJ; Cook, PR				Bon, Michael; McGowan, Simon J.; Cook, Peter R.			Many expressed genes in bacteria and yeast are transcribed only once per cell cycle	FASEB JOURNAL			English	Article						database; nascent RNA; transcription rate; transcriptomics	RNA-POLYMERASE-II; ESCHERICHIA-COLI; VISUALIZATION; UNITS; STRAND	The steady-state levels of all mature transcripts expressed in bacteria and yeast have been cataloged, but we do not yet know the numbers of nascent transcripts and so RNA polymerases engaged on all genes. Such catalogs are presented here. As mRNA levels depend on the balance between synthesis and degradation, we use published data to calculate the numbers of engaged polymerases required to maintain these levels in the face of the known rate of degradation. Most genes, including essential ones, prove not to be transcribed most of the time, and many produce only one message per cell cycle. Some cells even fail to produce an essential message during a cycle, and so must depend on their mother's messages and/or proteins for survival. We speculate that evolution sets the rate of message production so low to conserve energy, minimize transcription-induced mutation, and permit regulation over the widest range.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Cook, PR (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	peter.cook@path.ox.ac.uk		Cook, Peter/0000-0002-6639-188X; McGowan, Simon/0000-0001-9720-1914				Beletskii A, 1996, P NATL ACAD SCI USA, V93, P13919, DOI 10.1073/pnas.93.24.13919; Bernstein JA, 2002, P NATL ACAD SCI USA, V99, P9697, DOI 10.1073/pnas.112318199; BEYER AL, 1981, J MOL BIOL, V147, P269, DOI 10.1016/0022-2836(81)90441-1; Bremer H, 1996, ESCHERICHIA COLI SAL; CONDON C, 1995, J BACTERIOL, V177, P4152, DOI 10.1128/jb.177.14.4152-4156.1995; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; Femino A, 1998, SCIENCE, V280, P585, DOI 10.1126/science.280.5363.585; FRENCH SL, 1989, J BACTERIOL, V171, P4207, DOI 10.1128/JB.171.8.4207-4216.1989; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hsu LM, 2002, BBA-GENE STRUCT EXPR, V1577, P191, DOI 10.1016/S0167-4781(02)00452-9; Jackson DA, 2000, FASEB J, V14, P242, DOI 10.1096/fasebj.14.2.242; Jackson DA, 1998, MOL BIOL CELL, V9, P1523, DOI 10.1091/mbc.9.6.1523; Kimura H, 2002, J CELL BIOL, V159, P777, DOI 10.1083/jcb.200206019; LAIRD CD, 1976, CHROMOSOMA, V58, P193, DOI 10.1007/BF00701359; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; MCKNIGHT SL, 1979, CELL, V17, P551; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WOLGEMUTH DJ, 1981, J MOL BIOL, V147, P247, DOI 10.1016/0022-2836(81)90440-X	27	34	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1721	+		10.1096/fj.06-6087fje	http://dx.doi.org/10.1096/fj.06-6087fje			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16818468				2022-12-28	WOS:000240266600027
J	Falagas, ME; Zarkadoulia, EA; Samonis, G				Falagas, Matthew E.; Zarkadoulia, Effie A.; Samonis, George			Arab science in the golden age (750-1258 CE) and today	FASEB JOURNAL			English	Editorial Material									Alfa Inst Biomed Sci, Maroussi 15123, Greece; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Univ Crete, Sch Med, Dept Med, Iraklion, Crete, Greece	Alfa Institute Of Biomedical Sciences; Tufts University; University of Crete	Falagas, ME (corresponding author), Alfa Inst Biomed Sci, 9 Neapoleos St, Maroussi 15123, Greece.	m.falagas@aibs.gr						Bliziotis IA, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-16; HADDAD FS, 1993, B SOC LIBAN HIST MED, V1, P21; HADDAD FS, 1993, B SOC LIBAN HIST MED, V3, P74; HEAD HA, HIST ISLAMIC SCI, V2; *HOR MANN AC MIDDL, SCI CULT MED ISL C 1; *HOR MANN AC MIDDL, SCI CULT MED ISL C 4; *NAT LIB MED, 1998, ISL CULT MED ARTS; *OSW CIT SCH DISTR, GOLD AG ISL; Shaban SF, 2003, SAUDI MED J, V24, P294; Soteriades ES, 2005, BRIT MED J, V331, P192, DOI 10.1136/bmj.331.7510.192; SYED IB, ISLAMIC MED; Tadmouri GO, 2004, SAUDI MED J, V25, P7; *WORLD BANK, 2004, WORLD DEV IND 2002; Zetterstrom R, 2002, ACTA PAEDIATR, V91, P1020, DOI 10.1080/080352502760311467; ISLAM ISLAMIC HIST A	15	25	25	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1581	1586		10.1096/fj.06-0803ufm	http://dx.doi.org/10.1096/fj.06-0803ufm			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873881				2022-12-28	WOS:000240266600003
J	Lesnefsky, EJ; He, DC; Moghaddas, S; Hoppel, CL				Lesnefsky, Edward J.; He, DingChao; Moghaddas, Shadi; Hoppel, Charles L.			Reversal of mitochondrial defects before ischemia protects the aged heart	FASEB JOURNAL			English	Article						oxidative phosphorylation; reperfusion; cytochrome oxidase; ubiquinol-cytochrome c oxidoreductase (complex III)	ACETYL-L-CARNITINE; PROPIONYL-L-CARNITINE; ELECTRON-TRANSPORT; COMPLEX-III; REPERFUSION INJURY; LIPID-PEROXIDATION; CYTOCHROME-OXIDASE; RAT HEARTS; TRANSCRIPTION; DYSFUNCTION	Myocardial injury is increased in the aged heart during ischemia and reperfusion. Aging decreases oxidative metabolism in interfibrillar mitochondria (IFM) located between the myofibrils. We asked whether reversal of aging defects in IFM before ischemia would decrease injury in the aged heart following ischemia and reperfusion. Treatment with acetylcarnitine (AcCN) increases the activity of cytochrome oxidase in the aged heart. Aged (24 months) and adult ( 6 months) Fischer 344 rats were treated with AcCN (300 mg/ kg i. p. 3 h before excision of the heart) or served as controls. AcCN restored oxidative phosphorylation and the activity of complexes III and IV in IFM from aged hearts to rates present in adults. Isolated hearts underwent 25 min global ischemia and 30 min reperfusion without additional treatment. Contractile recovery during reperfusion improved in hearts from AcCN-treated aged rats compared to aged controls and were similar to adults in recovery. AcCN-treated aged hearts sustained less damage, indicated by decreased lactate dehydrogenase (LDH) release during reperfusion. AcCN treatment did not alter functional recovery or LDH release in adults. Restoration of mitochondrial function in the aged heart before ischemia was accompanied by enhanced contractile recovery and decreased tissue injury following ischemia and reperfusion.	Louis Stokes VA Med Ctr, Med Serv, Cardiol Sect, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Div Cardiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Div Clin Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Lesnefsky, EJ (corresponding author), Louis Stokes VA Med Ctr, Med Serv, Cardiol Sect, 111W,10701 E Blvd, Cleveland, OH 44106 USA.	EXL9@cwru.edu			NIA NIH HHS [1K04AG00676, 1P01AG15885, 1R01AG12447] Funding Source: Medline; NIDDK NIH HHS [1R01DK36069] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K04AG000676, R01AG012447, P01AG015885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; ATAKA K, 1992, CIRCULATION, V86, P371; BAHL JJ, 1987, ANNU REV PHARMACOL, V27, P257, DOI 10.1146/annurev.pa.27.040187.001353; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; CARREA FP, 1991, CIRC RES, V68, P1652, DOI 10.1161/01.RES.68.6.1652; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Demin OV, 1998, MOL CELL BIOCHEM, V184, P21, DOI 10.1023/A:1006849920918; DILISA F, 1994, AM J PHYSIOL, V267, pH455, DOI 10.1152/ajpheart.1994.267.2.H455; DUAN J, 1989, BRIT J PHARMACOL, V98, P1319, DOI 10.1111/j.1476-5381.1989.tb12680.x; Fannin SW, 1999, ARCH BIOCHEM BIOPHYS, V372, P399, DOI 10.1006/abbi.1999.1508; FERRARI R, 1991, CARDIOVASC DRUG THER, V5, P57, DOI 10.1007/BF00128244; FROLKIS VV, 1991, GERONTOLOGY, V37, P233; GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x; GADALETA MN, 1994, ANN NY ACAD SCI, V717, P150, DOI 10.1111/j.1749-6632.1994.tb12082.x; Hagen TM, 2002, P NATL ACAD SCI USA, V99, P7184; HEARSE DJ, 1980, THORAC CARDIOV SURG, V28, P253, DOI 10.1055/s-2007-1022090; Horwitz LD, 1999, J CARDIOVASC PHARM, V33, P19, DOI 10.1097/00005344-199901000-00004; Kadenbach B, 2000, FREE RADICAL BIO MED, V29, P211, DOI 10.1016/S0891-5849(00)00305-1; Lesnefsky EJ, 1996, J AM COLL CARDIOL, V28, P331, DOI 10.1016/0735-1097(96)00148-9; Lesnefsky EJ, 2003, ARCH BIOCHEM BIOPHYS, V420, P287, DOI 10.1016/j.abb.2003.09.046; Lesnefsky EJ, 2003, FASEB J, V17, pA518; Lesnefsky EJ, 1997, AM J PHYSIOL-HEART C, V273, pH1544, DOI 10.1152/ajpheart.1997.273.3.H1544; LESNEFSKY EJ, 1994, J LAB CLIN MED, V124, P843; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P37, DOI 10.1006/jmcc.2000.1273; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; Lesnefsky EJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P117, DOI 10.1006/abbi.2000.2066; Liu LX, 1998, AM J PHYSIOL-REG I, V275, pR315, DOI 10.1152/ajpregu.1998.275.1.R315; Loster H, 1998, MOL CELL BIOCHEM, V185, P65, DOI 10.1023/A:1006891208220; Lucas DT, 1998, P NATL ACAD SCI USA, V95, P510, DOI 10.1073/pnas.95.2.510; Moghaddas S, 2003, ARCH BIOCHEM BIOPHYS, V414, P59, DOI 10.1016/S0003-9861(03)00166-8; Moghaddas S, 2002, J GERONTOL A-BIOL, V57, pB22, DOI 10.1093/gerona/57.1.B22; PALMER JW, 1977, J BIOL CHEM, V252, P8731; PARADIES G, 1993, ARCH GERONTOL GERIAT, V16, P263, DOI 10.1016/0167-4943(93)90037-I; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; PARADIES G, 1992, BIOCHIM BIOPHYS ACTA, V1103, P324, DOI 10.1016/0005-2736(92)90103-S; Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0; PARADIES G, 1994, FEBS LETT, V350, P213, DOI 10.1016/0014-5793(94)00763-2; PARADIES G, 1994, ANN NY ACAD SCI, V717, P233, DOI 10.1111/j.1749-6632.1994.tb12093.x; ROUSLIN W, 1983, AM J PHYSIOL, V244, pH743, DOI 10.1152/ajpheart.1983.244.6.H743; Steel R.G., 1980, PRINCIPLES PROCEDURE, P481; SUGIOKA K, 1988, BIOCHIM BIOPHYS ACTA, V936, P377, DOI 10.1016/0005-2728(88)90014-X; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VIK SB, 1977, BIOCHEMISTRY-US, V16, P5755, DOI 10.1021/bi00645a016	43	46	48	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1543	+		10.1096/fj.05-4535fje	http://dx.doi.org/10.1096/fj.05-4535fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16793872				2022-12-28	WOS:000240266000045
J	Vilcek, J; Cronstein, BN				Vilcek, Jan; Cronstein, Bruce N.			A prize for the foreign-born	FASEB JOURNAL			English	Biographical-Item									NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY USA	New York University; New York University	Vilcek, J (corresponding author), NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.	jan.vilcek@med.nyu.edu	Cronstein, Bruce N/D-4678-2011	Cronstein, Bruce N/0000-0002-4295-7383					0	4	4	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1281	1283		10.1096/fj.06-0702ufm	http://dx.doi.org/10.1096/fj.06-0702ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816100				2022-12-28	WOS:000240266000002
J	Sanz, A; Caro, P; Ayala, V; Portero-Otin, M; Pamplona, R; Barja, G				Sanz, Alberto; Caro, Pilar; Ayala, Victoria; Portero-Otin, Manuel; Pamplona, Reinald; Barja, Gustavo			Methionine restriction decreases mitochondrial oxygen radical generation and leak as well as oxidative damage to mitochondrial DNA and proteins	FASEB JOURNAL			English	Article						mitochondria; methionine restriction; caloric restriction; free radicals; aging; DNA damage; oxidative damage	LOW-DENSITY-LIPOPROTEIN; MAXIMUM LIFE-SPAN; CALORIC RESTRICTION; RAT-HEART; SULFOXIDE REDUCTASE; DIETARY-PROTEIN; COMPLEX-I; INCREASES; STRESS; HOMOCYSTEINE	Previous studies have consistently shown that caloric restriction (CR) decreases mitochondrial reactive oxygen species (ROS) (mitROS) generation and oxidative damage to mtDNA and mitochondrial proteins, and increases maximum longevity, although the mechanisms responsible for this are unknown. We recently found that protein restriction ( PR) also produces these changes independent of energy restriction. Various facts link methionine to aging, and methionine restriction (MetR) without energy restriction increases, like CR, maximum longevity. We have thus hypothesized that MetR is responsible for the decrease in mitROS generation and oxidative stress in PR and CR. In this investigation we subjected male rats to exactly the same dietary protocol of MetR that is known to increase their longevity. We have found, for the first time, that MetR profoundly decreases mitROS production, decreases oxidative damage to mtDNA, lowers membrane unsaturation, and decreases all five markers of protein oxidation measured in rat heart and liver mitochondria. The concentration of complexes I and IV also decreases in MetR. The decrease in mitROS generation occurs in complexes I and III in liver and in complex I in heart mitochondria, and is due to an increase in efficiency of the respiratory chain in avoiding electron leak to oxygen. These changes are strikingly similar to those observed in CR and PR, suggesting that the decrease in methionine ingestion is responsible for the decrease in mitochondrial ROS production and oxidative stress, and possibly part of the decrease in aging rate, occurring during caloric restriction.	Univ Complutense, Fac Ciencias Biol, Dept Fisiol Anim 2, E-28040 Madrid, Spain; Univ Lleida, Dept Basic Med Sci, Lleida, Spain	Complutense University of Madrid; Universitat de Lleida	Barja, G (corresponding author), Univ Complutense, Fac Ciencias Biol, Dept Fisiol Anim 2, C Antonio Novais 2, E-28040 Madrid, Spain.	gbarja@bio.ucm.es	Portero-Otin, Manuel/B-7122-2009; Ayala, Maria Victoria/A-7391-2010; Barja, Gustavo/AAA-5903-2019; Pamplona, Reinald/A-7359-2010; Gustavo, Barja/B-5591-2012; Sanz, Alberto/O-2329-2015; SANZ, ALBERTO/F-8432-2011	Portero-Otin, Manuel/0000-0002-1823-0299; Ayala, Maria Victoria/0000-0002-1496-966X; Barja, Gustavo/0000-0001-5736-4735; Pamplona, Reinald/0000-0003-4337-6107; Sanz, Alberto/0000-0003-2149-1753; Caro, Pilar/0000-0002-7531-3234				Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; ASUNCION JG, 1996, FASEB J, V10, P333; Barja G, 2004, BIOL REV, V79, P235, DOI 10.1017/S1464793103006213; Barja G, 2002, J BIOENERG BIOMEMBR, V34, P227, DOI 10.1023/A:1016039604958; Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005; BARROWS CH, 1975, GROWTH, V39, P525; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Chang L, 2004, CLIN EXP PHARMACOL P, V31, P237, DOI 10.1111/j.1440-1681.2004.03983.x; FAU D, 1988, J NUTR, V118, P128, DOI 10.1093/jn/118.1.128; GOODRICK CL, 1978, J GERONTOL, V33, P184, DOI 10.1093/geronj/33.2.184; Gredilla R, 2005, ENDOCRINOLOGY, V146, P3713, DOI 10.1210/en.2005-0378; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; Gredilla R, 2001, J BIOENERG BIOMEMBR, V33, P279, DOI 10.1023/A:1010603206190; Hidiroglou N, 2004, J NUTR BIOCHEM, V15, P730, DOI 10.1016/j.jnutbio.2004.04.009; KNECHT KJ, 1991, DIABETES, V40, P190, DOI 10.2337/diabetes.40.2.190; LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649; LETO S, 1976, J GERONTOL, V31, P144, DOI 10.1093/geronj/31.2.144; Loft S, 1999, METHOD ENZYMOL, V300, P166; Mair W, 2005, PLOS BIOL, V3, P1305, DOI 10.1371/journal.pbio.0030223; Matthias D, 1996, ATHEROSCLEROSIS, V122, P201, DOI 10.1016/0021-9150(95)05740-4; Miller RA, 2005, AGING CELL, V4, P119, DOI 10.1111/j.1474-9726.2005.00152.x; Mitsui A, 2002, ANTIOXID REDOX SIGN, V4, P693, DOI 10.1089/15230860260220201; Mori N, 2000, J NUTR, V130, P2349, DOI 10.1093/jn/130.9.2349; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; Ninomiya T, 2004, AM J KIDNEY DIS, V44, P437, DOI 10.1053/j.ajkd.2004.05.024; Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200; Pamplona R, 2002, ANN NY ACAD SCI, V959, P475, DOI 10.1111/j.1749-6632.2002.tb02118.x; Pamplona R, 2002, MECH AGEING DEV, V123, P1437, DOI 10.1016/S0047-6374(02)00076-3; Pamplona R, 2002, FREE RADICAL RES, V36, P47, DOI 10.1080/10715760210165; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Requena JR, 2001, P NATL ACAD SCI USA, V98, P69, DOI 10.1073/pnas.011526698; RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743; ROSS MH, 1961, J NUTR, V75, P197, DOI 10.1093/jn/75.2.197; Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199; Ruiz MC, 2005, MECH AGEING DEV, V126, P1106, DOI 10.1016/j.mad.2005.04.005; Sanz A, 2004, J BIOENERG BIOMEMBR, V36, P545, DOI 10.1007/s10863-004-9001-7; SANZ A, 2006, IN PRESS ANN NY ACAD; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Uthus EO, 2003, EXP GERONTOL, V38, P491, DOI 10.1016/S0531-5565(03)00008-1; Zimmerman JA, 2003, EXP GERONTOL, V38, P47, DOI 10.1016/S0531-5565(02)00149-3	40	165	177	3	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1064	1073		10.1096/fj.05-5568com	http://dx.doi.org/10.1096/fj.05-5568com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770005				2022-12-28	WOS:000240210300006
J	Fernando, P; Megeney, LA				Fernando, Pasan; Megeney, Lynn A.			Is caspase-dependent apoptosis only cell differentiation taken to the extreme?	FASEB JOURNAL			English	Review							DNA STRAND BREAKS; SKELETAL-MUSCLE; TERMINAL DIFFERENTIATION; MONOCYTE DIFFERENTIATION; MYOGENIC DIFFERENTIATION; REGULATES APOPTOSIS; NEURONAL APOPTOSIS; ESCHERICHIA-COLI; NUCLEAR EXPORT; CYTOCHROME-C	The benefits of apoptosis for a multicellular organism are obvious and fit the current dogma that the maintenance and viability of such organisms are dependent on the selective elimination of unneeded or deleterious cell types. However, self destruction at the level of the individual cell defies the most basic precepts of biology ( sustaining life). If apoptosis is viewed through this construct then one question becomes paramount, i.e., why would an individual cell and its progeny develop, retain, or evolve a mechanism the sole purpose of which is to eliminate itself? In consideration of such a paradox, it is reasonable to postulate that prospective apoptotic pathways co-evolved with and or were co-opted from another basic cell function( s) that did not involve the death of the cell per se. In the following article, we present the hypothesis that the conserved biochemical pathways of apoptosis are integral components of terminal cell differentiation and it is the time of engagement and activity level of these pathways that ultimately determines the choice between cell death or cell maturation.	Ottawa Hosp, Ottawa Hlth Res Inst, Program Mol Med, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; StemPath Inc, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Megeney, LA (corresponding author), Ottawa Hosp, Ottawa Hlth Res Inst, Program Mol Med, Gen Campus, Ottawa, ON K1H 8L6, Canada.	lmegeney@ohri.ca		Megeney, Lynn/0000-0002-6824-8569; Fernando, Pasan/0000-0001-8792-9637				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Ameisen JC, 1996, SCIENCE, V272, P1278, DOI 10.1126/science.272.5266.1278; Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; Black S, 2004, CELL DEATH DIFFER, V11, P90, DOI 10.1038/sj.cdd.4401307; Boyce M, 2004, CELL DEATH DIFFER, V11, P29, DOI 10.1038/sj.cdd.4401339; Budihardjo II, 1998, MOL CELL BIOCHEM, V178, P245, DOI 10.1023/A:1006808001462; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CATHELIN S, 2006, J BIOL CHEM; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; CHASIS JA, 1989, BLOOD, V74, P2562; Chen SE, 2005, AM J PHYSIOL-CELL PH, V289, pC1179, DOI 10.1152/ajpcell.00062.2005; Chew SK, 2004, DEV CELL, V7, P897, DOI 10.1016/j.devcel.2004.09.016; Chomarat P, 2003, J IMMUNOL, V171, P2262, DOI 10.4049/jimmunol.171.5.2262; COULTON GR, 1992, J CELL SCI, V102, P653; DAWSON BA, 1988, DEV BIOL, V127, P362, DOI 10.1016/0012-1606(88)90322-3; Demontis S, 2006, CELL DEATH DIFFER, V13, P335, DOI 10.1038/sj.cdd.4401744; Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200; FARZANEH F, 1982, NATURE, V300, P362, DOI 10.1038/300362a0; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; FERNANDO P, 2005, FASEB J; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Furusawa C, 2002, ANAT RECORD, V268, P327, DOI 10.1002/ar.10164; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020; Gotz R, 2000, HUM MOL GENET, V9, P2479, DOI 10.1093/hmg/9.17.2479; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; GUDE NM, 2004, 11 INT C ANT ANT, V114, P397; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hay BA, 2004, NAT REV GENET, V5, P911, DOI 10.1038/nrg1491; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Hossain MS, 2003, DIFFERENTIATION, V71, P271, DOI 10.1046/j.1432-0436.2003.7104504.x; Huh JR, 2004, PLOS BIOL, V2, P43, DOI 10.1371/journal.pbio.0020015; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Joza N, 2005, MOL CELL BIOL, V25, P10261, DOI 10.1128/MCB.25.23.10261-10272.2005; Kaiser D, 1999, TRENDS GENET, V15, P273, DOI 10.1016/S0168-9525(99)01740-0; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kanuka H, 2005, EMBO J, V24, P3793, DOI 10.1038/sj.emboj.7600822; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khan MAS, 2005, P NATL ACAD SCI USA, V102, P17326, DOI 10.1073/pnas.0508120102; KHAN Z, 1987, BLOOD, V69, P1114; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liu F, 2004, J BIOL CHEM, V279, P34537, DOI 10.1074/jbc.M402475200; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; MCMAHON G, 1984, P NATL ACAD SCI-BIOL, V81, P7461, DOI 10.1073/pnas.81.23.7461; Mejat A, 2005, NAT NEUROSCI, V8, P313, DOI 10.1038/nn1408; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427; Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Oomman S, 2005, DEV BRAIN RES, V160, P130, DOI 10.1016/j.devbrainres.2005.07.010; Pirrotta V, 2004, CELL, V119, P735, DOI 10.1016/j.cell.2004.12.002; Plenchette S, 2004, BLOOD, V104, P2035, DOI 10.1182/blood-2004-01-0065; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Qu G, 1997, J CELL BIOCHEM, V67, P514, DOI 10.1002/(SICI)1097-4644(19971215)67:4<514::AID-JCB9>3.3.CO;2-I; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rimondi E, 2006, J CELL PHYSIOL, V206, P647, DOI 10.1002/jcp.20512; Rohn TT, 2004, EXP CELL RES, V295, P215, DOI 10.1016/j.yexcr.2003.12.029; RUBIOLO C, 2006, BLOOD; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; SIEGEL RM, 2006, CASPASES CROSSROADS, V6, P308; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Tang XL, 2005, J NEUROSCI, V25, P4823, DOI 10.1523/JNEUROSCI.1331-05.2005; Torrente Y, 2003, CELL TRANSPLANT, V12, P91, DOI 10.3727/000000003783985115; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Vachova L, 2005, J CELL BIOL, V169, P711, DOI 10.1083/jcb.200410064; van den Eijnde SM, 2001, J CELL SCI, V114, P3631; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Weber GF, 2005, J BIOL CHEM, V280, P22135, DOI 10.1074/jbc.M414270200; Wedhas N, 2005, FASEB J, V19, P1986, DOI 10.1096/fj.05-4198com; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Willis S, 2003, J CELL SCI, V116, P4053, DOI 10.1242/jcs.00754; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Wride MA, 2000, APOPTOSIS, V5, P203, DOI 10.1023/A:1009653326511; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yang JY, 2004, MOL CELL BIOL, V24, P10425, DOI 10.1128/MCB.24.23.10425-10436.2004; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zandy AJ, 2005, J BIOL CHEM, V280, P30263, DOI 10.1074/jbc.M504007200; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247	104	75	79	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2007	21	1					8	17		10.1096/fj.06-5912hyp	http://dx.doi.org/10.1096/fj.06-5912hyp			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17093139				2022-12-28	WOS:000243130200002
J	Rittner, HL; Labuz, D; Schaefer, M; Mousa, SA; Schulz, S; Schafer, M; Stein, C; Brack, A				Rittner, Heike L.; Labuz, Dominika; Schaefer, Michael; Mousa, Shaaban A.; Schulz, Stefan; Schaefer, Michael; Stein, Christoph; Brack, Alexander			Pain control by CXCR2 ligands through Ca2(+)-regulated release of opioid peptides from polymorphonuclear cells	FASEB JOURNAL			English	Article						chemokine; analgesia; inflammation; secretion; neutrophil	NEUTROPHIL ACTIVATION; INFLAMMATORY PAIN; BETA-ENDORPHIN; CALCIUM-ENTRY; IMMUNE CELLS; BONE-MARROW; CHEMOKINE; RECEPTOR; RECRUITMENT; INHIBITION	Leukocytes counteract inflammatory pain by releasing opioid peptides, which bind to opioid receptors on peripheral sensory neurons. In the early phase of inflammation, polymorphonuclear cells (PMN) are the major source of opioids. Their recruitment is governed by ligands at the chemokine receptor CXCR2. Here, we examined whether chemokines can also induce opioid peptide secretion from PMN and thus inhibit inflammatory pain. In rats with hindpaw inflammation, intraplantar injection of CXCL2/3, but not of the CXCR4 ligand CXCL12, elicited naloxone-reversible (i.e., opioid receptor mediated) mechanical and thermal analgesia, which was abolished by systemic PMN depletion. Both CXCR1/2-and CXCR4-ligands induced PMN chemotaxis, but only CXCR1/2 ligands triggered opioid release from human and rat PMN in vitro. This release was unaltered by extracellular Ca2+ chelation, was mimicked by thapsigargin and was blocked by inhibitors of the inositol 1,4,5-triphosphate receptor (IP3) and by intracellular Ca2+ chelation, indicating that it required Ca2+ from intracellular but not extracellular sources. Furthermore, release was partially reduced by phosphoinositol-3-kinase (PI3K) inhibitors. Adoptive transfer of allogenic PMN into PMN-depleted rats reconstituted CXCL2/3-induced analgesia, which was inhibited by prior ex vivo chelation of intracellular Ca2+. These findings demonstrate that, beyond cell recruitment, CXCR2 ligands induce Ca2+-regulated opioid release from PMN and thereby inhibit inflammatory pain in vivo.	Charite Univ Med Berlin, Klin Anaesthesiol & Operat Intens Med, D-12200 Berlin, Germany; Charite Univ Med Berlin, Inst Pharmakol, D-12200 Berlin, Germany; Otto Von Guericke Univ, Dept Pharmacol, Magdeburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Otto von Guericke University	Rittner, HL (corresponding author), Charite Univ Med Berlin, Klin Anaesthesiol & Operat Intens Med, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	heike.rittner@charite.de	Schulz, Stefan/A-6928-2017; RIttner, Heike/AAC-6523-2019; Schäfer, Michael/AAB-1395-2020	Schulz, Stefan/0000-0002-5997-8885; RIttner, Heike/0000-0003-4867-0188; Schaefer, Michael/0000-0002-1581-706X; Stein, Christoph/0000-0001-5240-6836				Bertini R, 2004, P NATL ACAD SCI USA, V101, P11791, DOI 10.1073/pnas.0402090101; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Brack A, 2004, PAIN, V108, P67, DOI 10.1016/j.pain.2003.12.008; Brack A, 2004, ANESTHESIOLOGY, V100, P149, DOI 10.1097/00000542-200401000-00024; Brack A, 2004, ANESTHESIOLOGY, V101, P204, DOI 10.1097/00000542-200407000-00031; Brack A, 2004, PAIN, V112, P229, DOI 10.1016/j.pain.2004.08.029; Bras JMA, 2001, NEUROSCIENCE, V103, P1073, DOI 10.1016/S0306-4522(01)00034-3; Briones Michael A, 2003, Curr Hematol Rep, V2, P522; Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506; Cabot PJ, 2001, PAIN, V93, P207, DOI 10.1016/S0304-3959(01)00322-0; Cerchiaro GA, 2001, BIOCHEM PHARMACOL, V62, P357, DOI 10.1016/S0006-2952(01)00672-4; Cunha TM, 2005, P NATL ACAD SCI USA, V102, P1755, DOI 10.1073/pnas.0409225102; DEWALD B, 1988, J BIOL CHEM, V263, P16179; Fan GH, 2003, BLOOD, V101, P2115, DOI 10.1182/blood-2002-07-1965; FREVERT CW, 1995, INFLAMMATION, V19, P133, DOI 10.1007/BF01534386; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Heveker N, 2001, MOL PHARMACOL, V59, P1418, DOI 10.1124/mol.59.6.1418; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Inngjerdingen M, 2003, J IMMUNOL, V171, P2889, DOI 10.4049/jimmunol.171.6.2889; Itagaki K, 2002, J IMMUNOL, V168, P4063, DOI 10.4049/jimmunol.168.8.4063; Ito N, 2002, J BIOL CHEM, V277, P44898, DOI 10.1074/jbc.M208051200; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; Kalso E, 2002, PAIN, V98, P269, DOI 10.1016/S0304-3959(02)00019-2; KANKAANRANTA H, 1995, BIOCHEM PHARMACOL, V50, P197, DOI 10.1016/0006-2952(95)00126-K; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Lenoir M, 2004, J IMMUNOL, V172, P7136, DOI 10.4049/jimmunol.172.11.7136; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; LEW PD, 1986, J CELL BIOL, V102, P2197, DOI 10.1083/jcb.102.6.2197; Lin TJ, 2000, J IMMUNOL, V165, P211, DOI 10.4049/jimmunol.165.1.211; Lorenzetti BB, 2002, EUR CYTOKINE NETW, V13, P456; Lyons PD, 1997, J NEUROIMMUNOL, V78, P47, DOI 10.1016/S0165-5728(97)00081-7; Machelska H, 1998, NAT MED, V4, P1425, DOI 10.1038/4017; Machelska H, 2003, J NEUROIMMUNOL, V141, P30, DOI 10.1016/S0165-5728(03)00213-3; Machelska H, 2004, BRIT J PHARMACOL, V142, P772, DOI 10.1038/sj.bjp.0705837; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; Mousa SA, 2003, PAIN, V106, P297, DOI 10.1016/S0304-3959(03)00302-6; Mousa SA, 2004, ENDOCRINOLOGY, V145, P1331, DOI 10.1210/en.2003-1287; Oh SB, 2001, J NEUROSCI, V21, P5027, DOI 10.1523/JNEUROSCI.21-14-05027.2001; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Remick DG, 2001, AM J PATHOL, V159, P1149, DOI 10.1016/S0002-9440(10)61791-9; Rittner HL, 2006, J LEUKOCYTE BIOL, V79, P1022, DOI 10.1189/jlb.0805452; Rittner HL, 2005, J LEUKOCYTE BIOL, V78, P1215, DOI 10.1189/jlb.0405223; Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036; Sadhu C, 2003, BIOCHEM BIOPH RES CO, V308, P764, DOI 10.1016/S0006-291X(03)01480-3; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; Schorr W, 1999, EUR J IMMUNOL, V29, P897, DOI 10.1002/(SICI)1521-4141(199903)29:03<897::AID-IMMU897>3.3.CO;2-X; SENGELOV H, 1993, J IMMUNOL, V150, P1535; SMITH RJ, 1992, J LEUKOCYTE BIOL, V52, P17, DOI 10.1002/jlb.52.1.17; STEIN C, 1993, LANCET, V342, P321, DOI 10.1016/0140-6736(93)91471-W; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; STEIN C, 1988, PHARMACOL BIOCHEM BE, V31, P445, DOI 10.1016/0091-3057(88)90372-3; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Stumm RK, 2002, J NEUROSCI, V22, P5865; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; VINDROLA O, 1990, J CLIN INVEST, V86, P531, DOI 10.1172/JCI114740; Vocks A, 2003, CELL PHYSIOL BIOCHEM, V13, P165, DOI 10.1159/000071867; Wenk HN, 2006, J NEUROPHYSIOL, V95, P2083, DOI 10.1152/jn.00394.2005; Zhuang ZY, 2004, J NEUROSCI, V24, P8300, DOI 10.1523/JNEUROSCI.2893-04.2004; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	62	91	100	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2627	+		10.1096/fj.06-6077fje	http://dx.doi.org/10.1096/fj.06-6077fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17060402				2022-12-28	WOS:000242490700046
J	Shibata, N; Jishage, KI; Arita, M; Watanabe, M; Kawase, Y; Nishikawa, K; Natori, Y; Inoue, H; Shimano, H; Yamada, N; Tsujimoto, M; Arai, H				Shibata, Norihito; Jishage, Kou-ichi; Arita, Makoto; Watanabe, Miho; Kawase, Yosuke; Nishikawa, Kiyotaka; Natori, Yasuhiro; Inoue, Hiroyasu; Shimano, Hitoshi; Yamada, Nobuhiro; Tsujimoto, Masafumi; Arai, Hiroyuki			Regulation of hepatic cholesterol synthesis by a novel protein (SPF) that accelerates cholesterol biosynthesis	FASEB JOURNAL			English	Article						squalene monooxygenase; peroxisome proliferator-activated receptor alpha; fasting; fibrate	HMG-COA REDUCTASE; FASTING RESPONSE; ACID SYNTHESIS; MICE LACKING; PPAR-ALPHA; RAT-LIVER; SQUALENE; GEMFIBROZIL; METABOLISM; EXPRESSION	Supernatant protein factor (SPF) is a novel cholesterol biosynthesis- accelerating protein expressed in liver and small intestine. Here, we report on the physiological role of SPF by using Spf-deficient mice. Although plasma cholesterol levels were similar in chow-fed Spf(-/-) and wild-type (WT) mice, fasting significantly decreased plasma cholesterol levels in Spf(-/-) mice but not in WT mice. While fasting reduced hepatic cholesterol synthesis rate in WT mice, a more pronounced reduction was observed in Spf(-/-) mice. The expression of cholesterogenic enzymes was dramatically suppressed by fasting both in WT and Spf(-/-) mice. In contrast, hepatic SPF expression of WT mice was up-regulated by fasting in peroxisome proliferator-activated receptor alpha (PPAR-alpha)-dependent manner. These results indicate that in WT mice, the decrease of hepatic cholesterol synthesis under fasting conditions is at least in part compensated by SPF up-regulation. Fibrates, which function as a PPAR-alpha agonist and are widely used as hypotriglycemic drugs, reduced hepatic cholesterol synthesis and plasma cholesterol levels by approximately one-half in Spf(-/-) mice but not in WT mice. These findings suggest that co-administration of fibrates and an SPF inhibitor may reduce not only plasma triglyceride but also cholesterol levels, indicating that SPF is a promising hypocholesterolemic drug target.	Univ Tokyo, Dept Hlth Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Lab Cellular Biochem, Saitama, Japan; Chugai Res Inst Med Sci Inc, Pharmacol & Pathol Res Ctr, Shizuoka, Japan; Int Med Ctr Japan, Dept Clin Pharmacol, Res Inst, Tokyo, Japan; Nara Womens Univ, Dept Food Sci & Nutr, Fac Human Life & Environm, Nara 630, Japan; Univ Tsukuba, Dept Internal Med, Inst Clin Med, Tsukuba, Ibaraki 305, Japan	University of Tokyo; RIKEN; Chugai Pharmaceutical Co., Ltd.; Chugai Research Institute for Medical Science, Inc.; National Center for Global Health & Medicine - Japan; Nara Womens University; University of Tsukuba	Arai, H (corresponding author), Univ Tokyo, Dept Hlth Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	harai@mol.f.u-tokyo.ac.jp	Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020	Shimano, Hitoshi/0000-0002-5562-5572; SHIBATA, NORIHITO/0000-0001-5792-8510; Arita, Makoto/0000-0001-9902-0463				BAHNSEN M, 1984, AM J PHYSIOL, V247, pE173, DOI 10.1152/ajpendo.1984.247.2.E173; Bankir L, 1997, KIDNEY INT, pS50; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; Brown AS, 1998, J AM COLL CARDIOL, V32, P665, DOI 10.1016/S0735-1097(98)00300-3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chang JT, 2004, PHARMACOEPIDEM DR S, V13, P417, DOI 10.1002/pds.977; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; COHEN BI, 1974, BIOCHIM BIOPHYS ACTA, V369, P79; DIETSCHY JM, 1967, J LIPID RES, V8, P97; Engelking LJ, 2004, J CLIN INVEST, V113, P1168, DOI 10.1172/JCI200420978; FERGUSON JB, 1977, J BIOL CHEM, V252, P5381; FRIEDLANDER EJ, 1980, J BIOL CHEM, V255, P8042; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUNDY SM, 1987, AM J MED, V83, P9, DOI 10.1016/0002-9343(87)90866-7; Haas MJ, 2000, METABOLISM, V49, P1572, DOI 10.1053/meta.2000.18554; Hiyoshi H, 2000, J LIPID RES, V41, P1136; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; ISHIKAWA T, 1979, J LIPID RES, V20, P254; Kaempf-Rotzoll DE, 2003, PLACENTA, V24, P439, DOI 10.1053/plac.2002.0966; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kok T, 2003, GASTROENTEROLOGY, V124, P160, DOI 10.1053/gast.2003.50007; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; LISCUM L, 1983, J BIOL CHEM, V258, P8450; Mardones P, 2003, J BIOL CHEM, V278, P7884, DOI 10.1074/jbc.M211627200; Mokashi V, 2005, ARCH BIOCHEM BIOPHYS, V435, P175, DOI 10.1016/j.abb.2004.11.030; Mokashi V, 2005, ARCH BIOCHEM BIOPHYS, V433, P474, DOI 10.1016/j.abb.2004.10.002; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; Nwokoro NA, 2001, MOL GENET METAB, V74, P105, DOI 10.1006/mgme.2001.3226; Ohashi K, 2003, J BIOL CHEM, V278, P42936, DOI 10.1074/jbc.M307228200; OLIVIER P, 1988, ATHEROSCLEROSIS, V70, P107, DOI 10.1016/0021-9150(88)90104-9; Ozdemir O, 2000, ANGIOLOGY, V51, P695; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Schwarz M, 1998, J LIPID RES, V39, P1833; Shek A, 2001, ANN PHARMACOTHER, V35, P908, DOI 10.1345/aph.10315; Shibata N, 2001, P NATL ACAD SCI USA, V98, P2244, DOI 10.1073/pnas.041620398; Singh DK, 2003, J BIOL CHEM, V278, P5646, DOI 10.1074/jbc.M211750200; SOBEL AE, 1945, J BIOL CHEM, V157, P255; SPERRY WM, 1950, J BIOL CHEM, V187, P97; TCHEN TT, 1957, J BIOL CHEM, V226, P921; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; VANDENBERGHE G, 1991, J INHERIT METAB DIS, V14, P407, DOI 10.1007/BF01797914; WISS O, 1976, BIOCHEM BIOPH RES CO, V68, P353, DOI 10.1016/0006-291X(76)91151-7; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; Yokota T, 2001, P NATL ACAD SCI USA, V98, P15185, DOI 10.1073/pnas.261456098	46	22	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2642	+		10.1096/fj.06-6368fje	http://dx.doi.org/10.1096/fj.06-6368fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077281				2022-12-28	WOS:000242490700051
J	Kim, S; Kim, H; Chang, B; Ahn, N; Hwang, S; Di Paolo, G; Chang, S				Kim, Sunyun; Kim, Hyunmyung; Chang, Belle; Ahn, Namhui; Hwang, Suha; Di Paolo, Gilbert; Chang, Sunghoe			Regulation of transferrin recycling kinetics by PtdIns[4,5]P-2 availability	FASEB JOURNAL			English	Article						endocytosis; membrane recycling	PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PLASMA-MEMBRANE; ACTIN; VESICLES; BINDING; ENDOSOMES; MOLECULES; DOMAIN; LIPIDS	Phosphatidylinositol 4,5-bisphosphate (PtdIns[4,5]P-2) is a phosphoinositide involved in a variety of cellular functions, including signal transduction, organelle trafficking, and actin dynamics. Although the role of PtdIns[4,5]P-2 in endocytosis is well established, the precise trafficking steps relying on normal PtdIns[4,5]P-2 balance in the endosomal pathway have not yet been elucidated. Here we show that decrease in intracellular PtdIns[4,5]P-2 levels achieved by the overexpression of the 5-phosphatase domain of synaptojanin 1 or by siRNA knock-down of PIP5Ks expression lead to severe defects in the internalization of transferrin as well as in the recycling of internalized transferrin back to the cell surface in COS-7 cells. These defects suggest that PtdIns[4,5]P-2 participates in multiple trafficking and/or sorting events during endocytosis. Coexpression of the PtdIns[4,5]P-2 synthesizing enzyme, PIP5KI gamma, was able to rescue these endocytic defects. Furthermore, decreased levels of PtdIns[4,5]P-2 caused delays in rapid and slow membrane recycling pathways as well as a severe backup of endocytosed membrane. Taken together, our results demonstrate that PtdIns[4,5]P-2 availability regulates multiple steps in the endocytic cycle in non-neuronal cells.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju, South Korea; Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Pathol, New York, NY USA	Gwangju Institute of Science & Technology (GIST); Columbia University	Chang, S (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju, South Korea.	sunghoe@gist.ac.kr	Chang, Sunghoe/J-2784-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD047733] Funding Source: NIH RePORTER; NICHD NIH HHS [HD047733-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Chang S, 2001, NAT NEUROSCI, V4, P787, DOI 10.1038/90489; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Gruenberg J, 2003, CURR OPIN CELL BIOL, V15, P382, DOI 10.1016/S0955-0674(03)00078-4; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Harris TW, 2000, J CELL BIOL, V150, P589, DOI 10.1083/jcb.150.3.589; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kim WT, 2002, P NATL ACAD SCI USA, V99, P17143, DOI 10.1073/pnas.222657399; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Micheva KD, 2001, J CELL BIOL, V154, P355, DOI 10.1083/jcb.200102098; Nasuhoglu C, 2002, ANAL BIOCHEM, V301, P243, DOI 10.1006/abio.2001.5489; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sechi AS, 2000, J CELL SCI, V113, P3685; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Taunton J, 2001, CURR OPIN CELL BIOL, V13, P85, DOI 10.1016/S0955-0674(00)00178-2; Verstreken P, 2003, NEURON, V40, P733, DOI 10.1016/S0896-6273(03)00644-5; Wang Z, 2004, J HYDROMETEOROL, V5, P3, DOI 10.1175/1525-7541(2004)005<0003:UMBAAD>2.0.CO;2; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	33	24	24	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2399	+		10.1096/fj.05-4621fje	http://dx.doi.org/10.1096/fj.05-4621fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17012244				2022-12-28	WOS:000241702600033
J	Koo, BC; Kwon, MS; Choi, BR; Kim, JH; Cho, SK; Sohn, SH; Cho, EJ; Lee, HT; Chang, W; Jeon, I; Park, JK; Park, JB; Kim, T				Koo, Bon Chul; Kwon, Mo Sun; Choi, Bok Ryul; Kim, Jin-Hoi; Cho, Seong-Keun; Sohn, Sea Hwan; Cho, Eun Jung; Lee, Hoon Taek; Chang, Wonkyung; Jeon, Iksoo; Park, Jin-Ki; Park, Jae Bok; Kim, Teoan			Production of germline transgenic chickens expressing enhanced green fluorescent protein using a MoMLV-based retrovirus vector	FASEB JOURNAL			English	Article						Moloney murine leukemia virus	GENE-TRANSFER; LENTIVIRAL VECTORS; EGG-WHITE; LINE TRANSMISSION; LEUKEMIA-VIRUS; GENERATION; IDENTIFICATION; INJECTION; OOCYTES; CELLS	The Moloney murine leukemia virus (MoMLV)-based retrovirus vector system has been used most often in gene transfer work, but has been known to cause silencing of the imported gene in transgenic animals. In the present study, using a MoMLV-based retrovirus vector, we successfully generated a new transgenic chicken line expressing high levels of enhanced green fluorescent protein (eGFP). The level of eGFP expression was conserved after germline transmission and as much as 100 mu g of eGFP could be detected per 1 mg of tissue protein. DNA sequencing showed that the transgene had been integrated at chromosome 26 of the G(1) and G(2) generation transgenic chickens. Owing to the stable integration of the transgene, it is now feasible to produce G(3) generation of homozygous eGFP transgenic chickens that will provide 100% transgenic eggs. These results will help establish a useful transgenic chicken model system for studies of embryonic development and for efficient production of transgenic chickens as bioreactors.	Catholic Univ Daegu, Sch Med, Dept Physiol, Taegu, South Korea; Catholic Univ Daegu, Sch Med, Dept Pathol, Taegu, South Korea; GyeongSang Natl Univ, Dept Appl Life Sci, Jinju, South Korea; GyeongSang Natl Univ, Dept Appl Life Sci, Jinju, South Korea; Konkuk Univ, Anim Resources Res Ctr, Seoul, South Korea; Natl Livestock Res Inst, RDA, Suwon, South Korea	Catholic University of Daegu; Catholic University of Daegu; Gyeongsang National University; Gyeongsang National University; Konkuk University; Rural Development Administration (RDA)	Kim, T (corresponding author), Catholic Univ Daegu, Sch Med, Dept Physiol, Taegu, South Korea.	takim@cu.ac.kr		kim, jin-hoi/0000-0003-1232-5307				BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Chan AWS, 2001, SCIENCE, V291, P309, DOI 10.1126/science.291.5502.309; Chapman SC, 2005, DEVELOPMENT, V132, P935, DOI 10.1242/dev.01652; Cui XS, 2005, MOL REPROD DEV, V70, P278, DOI 10.1002/mrd.20210; EYALGILADI H, 1976, DEV BIOL, V49, P321, DOI 10.1016/0012-1606(76)90178-0; GORDON JW, 1981, SCIENCE, V214, P1244, DOI 10.1126/science.6272397; Harvey AJ, 2002, NAT BIOTECHNOL, V20, P396, DOI 10.1038/nbt0402-396; Hofmann A, 2004, BIOL REPROD, V71, P405, DOI 10.1095/biolreprod.104.028472; Hofmann A, 2003, EMBO REP, V4, P1054, DOI 10.1038/sj.embor.7400007; Ivarie R, 2003, TRENDS BIOTECHNOL, V21, P14, DOI 10.1016/S0167-7799(02)00009-4; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Kamihira M, 2005, J VIROL, V79, P10864, DOI 10.1128/JVI.79.17.10864-10874.2005; Kim T., 2002, TRANSGENIC ANIMAL TE, P173; Kwon MS, 2004, BIOCHEM BIOPH RES CO, V320, P442, DOI 10.1016/j.bbrc.2004.05.197; Lillico SG, 2005, DRUG DISCOV TODAY, V10, P191, DOI 10.1016/S1359-6446(04)03317-3; McGrew MJ, 2004, EMBO REP, V5, P728, DOI 10.1038/sj.embor.7400171; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mizuarai S, 2001, BIOCHEM BIOPH RES CO, V286, P456, DOI 10.1006/bbrc.2001.5422; Mozdziak PE, 2006, CELL TISSUE RES, V324, P41, DOI 10.1007/s00441-005-0060-9; Mozdziak PE, 2004, DEV DYNAM, V229, P414, DOI 10.1002/dvdy.10461; OFF SP, 2001, FIELDS VIROLOGY, P1871; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; Park M, 2005, J EUKARYOT MICROBIOL, V52, P223, DOI 10.1111/j.1550-7408.2005.00027.x; Perry ACF, 1999, SCIENCE, V284, P1180, DOI 10.1126/science.284.5417.1180; PETITTE JN, 2002, TRANSGENIC ANIMAL TE, P279, DOI DOI 10.1016/B978-0-08-057480-6.50015-0; Polites H.G., 2002, TRANSGENIC ANIMAL TE, P15; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; Rapp JC, 2003, TRANSGENIC RES, V12, P569, DOI 10.1023/A:1025854217349; Sang H, 2004, MECH DEVELOP, V121, P1179, DOI 10.1016/j.mod.2004.05.012; SAVATIER P, 1990, DEVELOPMENT, V109, P655; Scott BB, 2005, P NATL ACAD SCI USA, V102, P16443, DOI 10.1073/pnas.0508437102; Speksnijder G, 2000, POULTRY SCI, V79, P1430, DOI 10.1093/ps/79.10.1430; TEMIN HM, 1987, GENE TRANSFER, P149; Whitelaw CBA, 2004, FEBS LETT, V571, P233, DOI 10.1016/j.febslet.2004.06.076; Zhu L, 2005, NAT BIOTECHNOL, V23, P1159, DOI 10.1038/nbt1132; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	38	43	50	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2251	2260		10.1096/fj.06-5866com	http://dx.doi.org/10.1096/fj.06-5866com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077302				2022-12-28	WOS:000241702600010
J	Carrotta, R; Di Carlo, M; Manno, M; Montana, G; Picone, P; Romancino, D; San Biagio, PL				Carrotta, R.; Di Carlo, M.; Manno, M.; Montana, G.; Picone, P.; Romancino, D.; San Biagio, P. L.			Toxicity of recombinant beta-amyloid prefibrillar oligomers on the morphogenesis of the sea urchin Paracentrotus lividus	FASEB JOURNAL			English	Article						A beta 42; light scattering; toxicity	LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; COMMON MECHANISM; PROTEIN; AGGREGATION; PEPTIDE; FIBRILLOGENESIS; NEUROTOXICITY; PATHOGENESIS; HYPOTHESIS	A distinctive feature of Alzheimer's disease is the deposition of amyloid beta-protein (A beta) in senile or diffuse plaques. The 42 residue beta-peptide (A beta 42) is the predominant form found in plaques. In the present work we report a high-yield expression and purification method of production of a recombinant A beta 42. The purified recombinant peptide shows characteristics similar to the synthetic human peptide. Different size aggregates, either small oligomers or larger aggregates, were obtained upon dissolving the recombinant A beta 42 peptide under different conditions at pH 7.2 or pH 3, respectively. We report a new toxicity assay on the morphogenic development of the sea urchin Paracentrotus lividus and study the toxicity of the two kinds of aggregates. Despite the difference between the ionic strength of human extracellular fluid (0.154 mol/l) and artificial sea water (0.48 mol/l), toxicity data collected in this system have an intrinsic relevance. The different ionic strength, in fact, could change the kinetics of oligomer formation, but the effect of morphogenic development reported here is related to the final oligomer sizes. Results of the toxicity assay of A beta 42 on sea urchin development also show a dose-dependent effect. After only 4 h of embryo development, one can note morphological defects in the cell membrane. Retardation of the embryo's development, along with cellular disorders visible inside the blastocoele, can be observed after 1 day of development. Cellular degeneration in two different pathological phenotypes the occluded blastulae and the occluded prism - is present after 48 h of development. Results show that a greater effect on cell death is induced by the small oligomers stabilized under physiological conditions than at acid pH. In this case only occluded blastulae are found after 48 h of development.	CNR, IBF, UO Palermo, I-90146 Palermo, Italy; CNR, Ist Biomed & Immunol Mol, I-90146 Palermo, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR)	San Biagio, PL (corresponding author), CNR, IBF, UO Palermo, Via Ugo La Malfa,153, I-90146 Palermo, Italy.	pierluigi.sanbiagio@pa.ibf.cnr.it	Manno, Mauro/F-1385-2010; Romancino, Daniele/C-3031-2015; Picone, Pasquale/AAX-3158-2020	Manno, Mauro/0000-0001-9843-0428; Romancino, Daniele/0000-0003-2041-0122; Carrotta, Rita/0000-0003-4628-2819; Picone, Pasquale/0000-0001-7127-2183; Di Carlo, Marta/0000-0002-7934-1275; SAN BIAGIO, PIER LUIGI/0000-0002-4622-7361; Montana, Giovanna/0000-0003-3368-4114				BERNE B. J., 1976, DYNAMIC LIGHT SCATTE; Bitan G, 2004, ACCOUNTS CHEM RES, V37, P357, DOI 10.1021/ar000214l; Bitan G, 2005, AMYLOID, V12, P88, DOI 10.1080/13506120500106958; Bondos SE, 2003, ANAL BIOCHEM, V316, P223, DOI 10.1016/S0003-2697(03)00059-9; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURDICK D, 1992, J BIOL CHEM, V267, P546; Carrotta R, 2005, J BIOL CHEM, V280, P30001, DOI 10.1074/jbc.M500052200; Carter J., 2001, Current Molecular Medicine (Hilversum), V1, P733, DOI 10.2174/1566524013363177; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Crescenzi O, 2002, EUR J BIOCHEM, V269, P5642, DOI 10.1046/j.1432-1033.2002.03271.x; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; DiCarlo M, 1996, BIOCHEM BIOPH RES CO, V229, P511; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fezoui Y, 2000, AMYLOID, V7, P166, DOI 10.3109/13506120009146831; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; Giudice G., 1973, DEV BIOL SEA URCHIN; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Huang THJ, 2000, J BIOL CHEM, V275, P36436, DOI 10.1074/jbc.M005698200; Huglin M. B., 1972, LIGHT SCATTERING POL; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kammerer RA, 2004, P NATL ACAD SCI USA, V101, P4435, DOI 10.1073/pnas.0306786101; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Marchesi VT, 2005, P NATL ACAD SCI USA, V102, P9093, DOI 10.1073/pnas.0503181102; Matsubara K, 2003, PROTEIN EXPRES PURIF, V30, P55, DOI 10.1016/S1046-5928(03)00069-X; Nakajima Y, 2004, EVOL DEV, V6, P95, DOI 10.1111/j.1525-142X.2004.04011.x; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; Romancino DP, 2001, DEV BIOL, V234, P107, DOI 10.1006/dbio.2001.0233; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SHEN CL, 1994, BIOPHYS J, V67, P1238, DOI 10.1016/S0006-3495(94)80593-4; STEPANEK P, 1993, DYNAMIC LIGHT SCATTE; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Wilquet V, 2004, CURR OPIN NEUROBIOL, V14, P582, DOI 10.1016/j.conb.2004.08.001	41	40	41	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1916	+		10.1096/fj.06-5716fje	http://dx.doi.org/10.1096/fj.06-5716fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16818470				2022-12-28	WOS:000240267000029
J	Pan, YL; Zhao, LN; Liang, J; Liu, J; Shi, YQ; Liu, N; Zhang, GY; Jin, HF; Gao, J; Xie, HH; Wang, J; Liu, ZG; Fan, DM				Pan, Yanglin; Zhao, Lina; Liang, Jie; Liu, Jie; Shi, Yongquan; Liu, Na; Zhang, Guoyun; Jin, Haifeng; Gao, Juan; Xie, Huahong; Wang, Jun; Liu, Zhiguo; Fan, Daiming			Cellular prion protein promotes invasion and metastasis of gastric cancer	FASEB JOURNAL			English	Article						PrPc; extracellular matrix	TRUNCATED PRP; HUMAN NEURONS; EXPRESSION; STROMELYSIN-3; TUMOR; ADHESION; CELLS; DEATH; LINE; OVEREXPRESSION	Cellular prion protein (PrPc) is a glycosylphosphatidylinositol (GPI) - anchored membrane protein that is highly conserved in mammalian species. PrPc has the characteristics of adhesive molecules and is thought to play a role in cell adhesion and membrane signaling. Here we investigated the possible role of PrPc in the process of invasiveness and metastasis in gastric cancers. PrPc was found to be highly expressed in metastatic gastric cancers compared to nonmetastatic ones by immunohistochemical staining. PrPc significantly promoted the adhesive, invasive, and in vivo metastatic abilities of gastric cancer cell lines SGC7901 and MKN45. PrPc also increased promoter activity and the expression of MMP11 by activating phosphorylated ErK1/2 in gastric cancer cells. MEK inhibitor PD98059 and MMP11 antibody (Ab) significantly inhibited in vitro invasive and in vivo metastatic abilities induced by PrPc. N-terminal fragment (amino acid 24 - 90) was suggested to be an indispensable region for signal transduction and invasion-promoting function of PrPc. Taken together, the present work revealed a novel function of PrPc that the existence of N-terminal region of PrPc could promote the invasive and metastatic abilities of gastric cancer cells at least partially through activation of MEK/ERK pathway and consequent transactivation of MMP11. - Pan, Y., Zhao, L., Liang, J., Liu, J., Shi, Y., Liu, N., Zhang, G., Jin, H., Gao, J., Xie, H., Wang, J., Liu, Z., Fan, D. Cellular prion protein promotes invasion and metastasis of gastric cancer.	Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian 710032, Shaanxi Provi, Peoples R China; Fourth Mil Med Univ, Xijing Hosp, Inst Digest Dis, Xian 710032, Shaanxi Provi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Fan, DM (corresponding author), Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, 17 Changle Western Rd, Xian 710032, Shaanxi Provi, Peoples R China.	fandaim@fmmu.edu.cn	Shi, Yongquan/AAE-3954-2020; liu, na/W-7939-2019; Zhao, Lina/GVR-7716-2022; gao, juan/GXV-1381-2022	liu, zhiguo/0000-0002-8485-7356				Andarawewa KL, 2003, CANCER RES, V63, P5844; Boulay A, 2001, CANCER RES, V61, P2189; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brown DR, 1998, EUR J CELL BIOL, V75, P29, DOI 10.1016/S0171-9335(98)80043-5; Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Delany AM, 2001, ENDOCRINOLOGY, V142, P1561, DOI 10.1210/en.142.4.1561; Delebecq TJ, 2000, CLIN CANCER RES, V6, P1086; Deng H, 2005, BIOCHEM BIOPH RES CO, V326, P274, DOI 10.1016/j.bbrc.2004.11.027; Diarra-Mehrpour M, 2004, CANCER RES, V64, P719, DOI 10.1158/0008-5472.CAN-03-1735; Du JP, 2005, INT J CANCER, V113, P213, DOI 10.1002/ijc.20570; Flechsig E, 2004, CURR MOL MED, V4, P337, DOI 10.2174/1566524043360645; Flechsig E, 2003, EMBO J, V22, P3095, DOI 10.1093/emboj/cdg285; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Graner E, 2000, MOL BRAIN RES, V76, P85, DOI 10.1016/S0169-328X(99)00334-4; Hundt C, 2003, BIOL CHEM, V384, P791, DOI 10.1515/BC.2003.088; Hynes RO, 2003, CELL, V113, P821, DOI 10.1016/S0092-8674(03)00468-9; Khasigov PZ, 2003, BIOCHEMISTRY-MOSCOW+, V68, P711, DOI 10.1023/A:1025051214001; Kim BH, 2004, MOL BRAIN RES, V124, P40, DOI 10.1016/j.molbrainres.2004.02.005; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Li RL, 2001, CELL IMMUNOL, V207, P49, DOI 10.1006/cimm.2000.1751; Liu N, 2004, CLIN CANCER RES, V10, P6239, DOI 10.1158/1078-0432.CCR-04-0242; Lysek DA, 2004, BIOCHEMISTRY-US, V43, P10393, DOI 10.1021/bi0494828; Mange A, 2002, FEBS LETT, V514, P159, DOI 10.1016/S0014-5793(02)02338-4; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Nakopoulou L, 2002, MODERN PATHOL, V15, P1154, DOI 10.1097/01.MP.0000037317.84782.CD; Nunziante M, 2003, J BIOL CHEM, V278, P3726, DOI 10.1074/jbc.M206313200; Pammer J, 2000, VIRCHOWS ARCH, V436, P466, DOI 10.1007/s004280050474; Pammer J, 1998, AM J PATHOL, V153, P1353, DOI 10.1016/S0002-9440(10)65720-3; Pan T, 2002, BIOCHEM J, V368, P81, DOI 10.1042/BJ20020773; Pan YL, 2004, BIOCHEM BIOPH RES CO, V315, P686, DOI 10.1016/j.bbrc.2004.01.108; Perret AG, 2002, CANCER-AM CANCER SOC, V94, P765, DOI 10.1002/cncr.10270; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Roucou X, 2005, CELL DEATH DIFFER, V12, P783, DOI 10.1038/sj.cdd.4401629; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Satoh J, 2000, AM J PATHOL, V157, P59, DOI 10.1016/S0002-9440(10)64517-8; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; SCNEIDER B, 2003, P NALT ACAD SCI US, P13326; Selvey S, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-40; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Skoglund J, 2004, ONCOLOGY-BASEL, V67, P67, DOI 10.1159/000080288; Thamilselvan V, 2004, GASTROENTEROLOGY, V126, P8, DOI 10.1053/j.gastro.2003.10.078; Vassallo N, 2003, J NEUROCHEM, V86, P538, DOI 10.1046/j.1471-4159.2003.01882.x; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Walmsley AR, 2003, J BIOL CHEM, V278, P37241, DOI 10.1074/jbc.M302036200; WANG F, 2005, CANC LETT, V11; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Zhang CC, 2006, P NATL ACAD SCI USA, V103, P2184, DOI 10.1073/pnas.0510577103	49	92	101	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1886	+		10.1096/fj.06-6138fje	http://dx.doi.org/10.1096/fj.06-6138fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877520				2022-12-28	WOS:000240267000019
J	West, MB; Hill, BG; Xuan, YT; Bhatnagar, A				West, Matthew B.; Hill, Bradford G.; Xuan, Yu-Ting; Bhatnagar, Aruni			Protein glutathiolation by nitric oxide: an intracellular mechanism regulating redox protein modification	FASEB JOURNAL			English	Article						iNOS-TG mice; aortic rings; endothelium-dependent relaxation; posttranslational modification; rat aortic smooth muscle cells	MITOCHONDRIAL PERMEABILITY TRANSITION; VASCULAR SMOOTH-MUSCLE; ADENINE-NUCLEOTIDE TRANSLOCASE; THIOL-DISULFIDE EXCHANGE; CYTOCHROME-C-OXIDASE; S-GLUTATHIONYLATION; RESPIRATORY BURST; ALDOSE REDUCTASE; MIXED DISULFIDES; OXIDATIVE STRESS	This study was designed to examine whether NO regulates protein glutathiolation. Exposure to NO donors increased protein glutathiolation in COS-7 or rat aortic smooth muscle cells as detected by anti-protein glutathione (GSH) antibodies. This process was reversible and saturable. Stimulation with acetylcholine (ACh) increased protein glutathiolation in isolated rat aortic rings. This was prevented by inhibiting endothelial NO synthase (eNOS). In ACh-treated rings, proteins showing positive immunoreactivity with the anti-PSSG antibody (Ab) were identified by matrix assisted laser desorption-time-of-flight mass spectrometry to be actin, vimentin, and heat shock protein 70. Purified actin was more readily glutathiolated by S-nitrosoglutathione than by oxidized GSH as determined by electrospray-ionization mass spectrometry, and nitrosylated actin was glutathiolated by reduced GSH. Relative to wild-type (WT) mice, increased protein glutathiolation was observed in hearts of mice with cardiac-specific expression of inducible NO synthase (iNOS). Proteins immunoprecipitated from transgenic hearts revealed GSH-adducted peptides corresponding to adenine nucleotide translocator and the alpha-subunit of F(1)F(0)ATPase. These data suggest that exogenous NO or NO generated by eNOS or iNOS regulates protein adduction with GSH. This could be due to a direct reaction of proteins with S-nitrosoglutathione or deni-trosylation of S-nitrosylated proteins by reduced GSH. Glutathiolation of cytoskeletal and mitochondrial proteins may be a significant feature of NO bioreactivity.	Univ Louisville, Dept Biochem & Mol Biol, Div Cardiol, Louisville, KY 40202 USA; Univ Louisville, Inst Mol Cardiol, Louisville, KY 40202 USA	University of Louisville; University of Louisville	Bhatnagar, A (corresponding author), Univ Louisville, Dept Med, Div Cardiol, Delia Baxter Bldg,580 S Preston St,Rm 421F, Louisville, KY 40202 USA.	aruni@louisville.edu	Hill, Bradford/F-9228-2011; Bhatnagar, Aruni/H-7791-2013; Hill, Bradford/I-4154-2013	Hill, Bradford/0000-0001-5332-8286	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059378, R01HL065660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011860] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-59378, HL-65660] Funding Source: Medline; NIEHS NIH HHS [ES-11860] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Adachi T, 2004, NAT MED, V10, P1200, DOI 10.1038/nm1119; Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Chandra A, 1997, BIOCHEMISTRY-US, V36, P15801, DOI 10.1021/bi9714722; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Craghill J, 2004, BIOCHEM J, V379, P595, DOI 10.1042/BJ20031367; Dalle-Donne I, 2003, FREE RADICAL BIO MED, V35, P1185, DOI 10.1016/S0891-5849(03)00504-5; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Fratelli M, 2003, PROTEOMICS, V3, P1154, DOI 10.1002/pmic.200300436; FURCHGOTT RF, 1995, ANNU REV PHARMACOL, V35, P1; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; Giuffre A, 1996, J BIOL CHEM, V271, P33404, DOI 10.1074/jbc.271.52.33404; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Heger J, 2002, CIRC RES, V90, P93, DOI 10.1161/hh0102.102757; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; HILL B, 1992, IONIC CHANNELS EXCIT; Hoppe G, 2004, EXP EYE RES, V78, P1085, DOI 10.1016/j.exer.2004.02.001; Ignarro L., 1995, NITRIC OXIDE BIOCH M; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Jensen ON, 1999, METH MOL B, V112, P513; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mawatari S, 2004, ARCH BIOCHEM BIOPHYS, V421, P108, DOI 10.1016/j.abb.2003.10.012; McStay GP, 2002, BIOCHEM J, V367, P541, DOI 10.1042/BJ20011672; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; MURAD F, 1994, RECENT PROG HORM RES, V49, P239; Padgett Christine M., 1995, Cell Biochemistry and Biophysics, V27, P157; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Pastore A, 2003, J BIOL CHEM, V278, P42588, DOI 10.1074/jbc.M301872200; Percival MD, 1999, BIOCHEMISTRY-US, V38, P13574, DOI 10.1021/bi991028u; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; RADI R, 1991, J BIOL CHEM, V266, P4244; Ramana KV, 2003, FASEB J, V17, P417, DOI 10.1096/fj.02-0722com; ROKUTAN K, 1994, AM J PHYSIOL, V266, P247; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; Seres T, 1996, J IMMUNOL, V156, P1973; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; Srivastava S, 2001, BIOCHEM J, V358, P111, DOI 10.1042/0264-6021:3580111; SRIVASTAVA SK, 1973, EXP EYE RES, V17, P33, DOI 10.1016/0014-4835(73)90165-6; STADLER J, 1994, P NATL ACAD SCI USA, V91, P3559, DOI 10.1073/pnas.91.9.3559; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; Tao LM, 2004, BIOCHEMISTRY-US, V43, P4028, DOI 10.1021/bi035924o; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Townsend DM, 2006, MOL PHARMACOL, V69, P501, DOI 10.1124/mol.105.018523; Wang GW, 2005, AM J PHYSIOL-HEART C, V288, pH1290, DOI 10.1152/ajpheart.00796.2004; West MB, 2004, FASEB J, V18, pC276; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016; Xian M, 2000, J BIOL CHEM, V275, P20467, DOI 10.1074/jbc.M001054200; Yang Y, 2005, P NATL ACAD SCI USA, V102, P117, DOI 10.1073/pnas.0405989102; Zech B, 1999, J BIOL CHEM, V274, P20931, DOI 10.1074/jbc.274.30.20931; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	71	92	95	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1715	+		10.1096/fj.06-5843fje	http://dx.doi.org/10.1096/fj.06-5843fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16809435				2022-12-28	WOS:000240266600025
J	Brenneis, C; Maier, TJ; Schmidt, R; Hofacker, A; Zulauf, L; Jakobsson, PJ; Scholich, K; Geisslinger, G				Brenneis, Christian; Maier, Thorsten J.; Schmidt, Ronald; Hofacker, Annette; Zulauf, Lars; Jakobsson, Per-Johan; Scholich, Klaus; Geisslinger, Gerd			Inhibition of prostaglandin E-2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition	FASEB JOURNAL			English	Article						PGE2; cyclooxygenase; TNF alpha	E SYNTHASE; PROINFLAMMATORY CYTOKINES; MECHANICAL ALLODYNIA; MACROPHAGES; EXPRESSION; PROTEIN; PAIN; INFLAMMATION	Prostaglandin E-2 (PGE(2)) produced by cyclooxygenase-2 (COX-2) and microsomal prostaglandin E-2 synthase-1 (mPGES-1) plays an important role in the pathophysiology of inflammation, pain, and fever. We investigated the actions of TNF alpha toward stimulation of PGE2 synthesis in primary spinal cord neurons. TNF alpha induced COX-2 and mPGES-1 expression in neurons, followed by formation of PGE(2), which was blocked by a selective COX-2 inhibitor. Surprisingly, the "selective COX-1" inhibitor SC-560 completely inhibited TNF alpha-induced PGE(2) synthesis in neurons at nanomolar concentrations. Moreover, SC-560 inhibited PGE(2) and thromboxane A(2) synthesis in human monocytes and platelets with IC50 of 1.8 nM and 2.5 nM, respectively. SC-560 treatment neither altered TNF alpha-induced COX-2 or mPGES-1 expression nor did the addition of the calcium ionophore A23187 or arachidonic acid reverse the inhibition by SC-560. Moreover, no influence of SC-560 on PGE(2) synthase activities or PGE(2) transport was seen. Most importantly, SC-560 blocked TNF alpha-induced PGE(2) synthesis in COX-1-deficient spinal cord neurons, demonstrating a COX-1-independent inhibition of PGE(2) synthesis. Although SC-560 inhibited LPS-induced PGE(2) synthesis in neurons and RAW264.7 macrophages in whole cell assays, no inhibition was observed in lysates of the same cells. Taken together our data demonstrate that SC-560 acts at least in some cell types as an unselective COX inhibitor despite its selectivity toward COX-1 under cell-free conditions.	Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, ZAFES, D-60590 Frankfurt, Germany; Karolinska Hosp, S-10401 Stockholm, Sweden	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Karolinska Institutet; Karolinska University Hospital	Geisslinger, G (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, ZAFES, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	geisslinger@em.uni-frankfurt.de	Jakobsson, Per-Johan/ABC-5594-2021					DeLeo JA, 2000, NEUROREPORT, V11, P599, DOI 10.1097/00001756-200002280-00033; Demasi M, 2000, INFLAMM RES, V49, P737, DOI 10.1007/s000110050655; Ehnert C, 2004, J NEUROCHEM, V88, P948, DOI 10.1046/j.1471-4159.2003.02229.x; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; Garavito RM, 2002, PROSTAG OTH LIPID M, V68-9, P129; Gierse JK, 2005, J PHARMACOL EXP THER, V312, P1206, DOI 10.1124/jpet.104.076877; Graham Garry G, 2005, Am J Ther, V12, P46, DOI 10.1097/00045391-200501000-00008; Hinz B, 2000, BIOCHEM BIOPH RES CO, V272, P744, DOI 10.1006/bbrc.2000.2859; Ivanov AI, 2004, FRONT BIOSCI-LANDMRK, V9, P1977, DOI 10.2741/1383; Kojima F, 2004, ARTHRITIS RES THER, V6, pR355, DOI 10.1186/ar1195; Kojima F, 2003, ARTHRITIS RHEUM, V48, P2819, DOI 10.1002/art.11261; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; Murakami M, 2002, PROSTAG OTH LIPID M, V68-9, P383, DOI 10.1016/S0090-6980(02)00043-6; Palomer A, 2002, J MED CHEM, V45, P1402, DOI 10.1021/jm010458r; Reid G, 2003, P NATL ACAD SCI USA, V100, P9244, DOI 10.1073/pnas.1033060100; Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558; Rouzer CA, 2004, J BIOL CHEM, V279, P34256, DOI 10.1074/jbc.M402594200; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Schafers M, 2003, J NEUROSCI, V23, P2517; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Tanioka T, 2003, BIOCHEM BIOPH RES CO, V303, P1018, DOI 10.1016/S0006-291X(03)00470-4; Thoren S, 2000, EUR J BIOCHEM, V267, P6428, DOI 10.1046/j.1432-1327.2000.01735.x; Trebino CE, 2005, J BIOL CHEM, V280, P16579, DOI 10.1074/jbc.M412075200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Vanegas HN, 2001, PROG NEUROBIOL, V64, P327, DOI 10.1016/S0301-0082(00)00063-0; Walker MC, 2001, BIOCHEM J, V357, P709, DOI 10.1042/0264-6021:3570709; Warner TD, 2006, FASEB J, V20, P542, DOI 10.1096/fj.05-4434fje; Watkins LR, 2003, ADV EXP MED BIOL, V521, P1	29	66	68	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1352	1360		10.1096/fj.05-5346com	http://dx.doi.org/10.1096/fj.05-5346com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816110				2022-12-28	WOS:000240266000012
J	Fischer, TW; Sweatman, TW; Semak, I; Sayre, RM; Wortsman, J; Slominski, A				Fischer, Tobias W.; Sweatman, Trevor W.; Semak, Igor; Sayre, Robert M.; Wortsman, Jacobo; Slominski, Andrzej			Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems	FASEB JOURNAL			English	Article						AFMK; 2-hydroxymelatonin; 4-hydroxymelatonin; melatonin; skin; UVR	TANDEM MASS-SPECTROMETRY; INDUCED DNA-DAMAGE; INDUCED ERYTHEMA; BONE-MARROW; OXIDATION; SKIN; N-1-ACETYL-N-2-FORMYL-5-METHOXYKYNURAMINE; ANTIOXIDANT; IDENTIFICATION; EXPRESSION	Melatonin, which can be produced in the skin, exerts a protective effect against damage induced by UV radiation (UVR). We have investigated the effect of UVB, the most damaging component of UVR, on melatonin metabolism in HaCaT keratinocytes and in a cell-free system. Four metabolites were identified by HPLC and LC-MS: 6-hydroxymelatonin, N-1-acetyl-N-2-formyl- 5-methoxykynuramine (AFMK), 2-hydroxymelatonin (the main intermediate between melatonin and AFMK), and 4-hydroxymelatonin. Concentrations of these photoproducts were directly proportional to UVR-dose and to melatonin substrate content, and their accumulation was time-dependent. The UVR-dependent increase of AFMK and 2-hydroxymelatonin was also detected in keratinocytes, where it was accompanied by simultaneous consumption of intracellular melatonin. Of note, melatonin and its two major metabolites, 2-hydroxymelatonin and AFMK, were also detected in untreated keratinocytes, neither irradiated nor preincubated with melatonin. Thus, intracellular melatonin metabolism is enhanced under exposure to UVR. The additional biological activity of these individual melatonin metabolites increases the spectrum of potential actions of the recently identified cutaneous melatoninergic system.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Div Dermatol, Memphis, TN 38163 USA; Med Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Dermatol, D-23538 Lubeck, Germany; Belarusian State Univ, Dept Biochem, Minsk 220050, BELARUS; So Illinois Univ, Dept Internal Med, Springfield, IL 62708 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Kiel; Schleswig Holstein University Hospital; University of Lubeck; Belarusian State University; Southern Illinois University System; Southern Illinois University	Slominski, A (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, 930 Madison Ave, Memphis, TN 38163 USA.	aslominski@utmem.edu	Semak, Igor/AAT-9273-2020	Semak, Igor/0000-0001-9430-8492; Slominski, Andrzej/0000-0001-8963-3995				Almeida EA, 2004, J PINEAL RES, V36, P64, DOI 10.1046/j.1600-079X.2003.00098.x; ARENDT J, 1988, CLIN ENDOCRINOL, V29, P205, DOI 10.1111/j.1365-2265.1988.tb00263.x; Bangha E, 1997, DERMATOLOGY, V195, P248, DOI 10.1159/000245953; Berman B, 2001, INT J DERMATOL, V40, P573, DOI 10.1046/j.1365-4362.2001.01280.x; Bubenik GA, 1999, J PINEAL RES, V26, P56, DOI 10.1111/j.1600-079X.1999.tb00567.x; Bubenik GA, 2002, DIGEST DIS SCI, V47, P2336, DOI 10.1023/A:1020107915919; CAHILL GM, 1992, VISUAL NEUROSCI, V8, P487, DOI 10.1017/S0952523800005009; Carrillo-Vico A, 2004, FASEB J, V18, P537, DOI 10.1096/fj.03-0694fje; Collier M, 2004, PLOUGHSHARES, V30, P23; Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600-079X.2000.280401.x; Costa EJX, 1995, J PINEAL RES, V19, P123, DOI 10.1111/j.1600-079X.1995.tb00180.x; de Almeida EA, 2003, J PINEAL RES, V35, P131; de Vries E, 2004, EUR J CANCER PREV, V13, P387, DOI 10.1097/00008469-200410000-00006; Dellegar SM, 1999, BIOCHEM BIOPH RES CO, V257, P431, DOI 10.1006/bbrc.1999.0438; Dreher F, 1998, BRIT J DERMATOL, V139, P332, DOI 10.1046/j.1365-2133.1998.02447.x; FINOCCHIARO LME, 1991, BIOCHEM J, V280, P727, DOI 10.1042/bj2800727; Fischer TW, 2006, J PINEAL RES, V40, P18, DOI 10.1111/j.1600-079X.2005.00273.x; Fischer TW, 2004, SKIN PHARMACOL PHYS, V17, P190, DOI 10.1159/000078822; Fischer TW, 2004, J PINEAL RES, V37, P107, DOI 10.1111/j.1600-079X.2004.00142.x; Fischer TW, 2001, J PINEAL RES, V31, P39, DOI 10.1034/j.1600-079X.2001.310106.x; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; HARDELAND R, 2005, INT J BIOCHEM CELL B, DOI DOI 10.1016/JBIOCEL.2005.1008.1020; Hasse S, 2004, J INVEST DERMATOL, V122, P307, DOI 10.1046/j.0022-202X.2004.22230.x; Hipler UC, 2003, SKIN PHARMACOL APPL, V16, P379, DOI 10.1159/000072933; Horstman JA, 2002, BIOORG CHEM, V30, P371, DOI 10.1016/S0045-2068(02)00511-4; Itoh MT, 1999, MOL HUM REPROD, V5, P402, DOI 10.1093/molehr/5.5.402; Iuvone PM, 2005, PROG RETIN EYE RES, V24, P433, DOI 10.1016/j.preteyeres.2005.01.003; Kadekaro AL, 2004, J PINEAL RES, V36, P204, DOI 10.1111/j.1600-079X.2004.00119.x; Karasek M, 2002, NEUROENDOCRINOL LETT, V23, P1; Karbownik M, 2002, NEUROENDOCRINOL LETT, V23, P39; KELLY RW, 1984, BIOCHEM BIOPH RES CO, V121, P372, DOI 10.1016/0006-291X(84)90732-0; Kim YO, 1999, ARCH PHARM RES, V22, P143, DOI 10.1007/BF02976538; Kobayashi H, 2005, FASEB J, V19, P1710, DOI 10.1096/fj.04-2293fje; Krutmann J, 2001, EUR J DERMATOL, V11, P170; LERNER AB, 1958, J AM CHEM SOC, V80, P2587, DOI 10.1021/ja01543a060; LERNER AB, 1978, J NEURAL TRANSM, P339; Lisby S, 2005, EXP DERMATOL, V14, P349, DOI 10.1111/j.0906-6705.2005.00282.x; Ma XC, 2005, DRUG METAB DISPOS, V33, P489, DOI 10.1124/dmd.104.002410; Maestroni GJM, 2001, EXPERT OPIN INV DRUG, V10, P467, DOI 10.1517/13543784.10.3.467; Maharaj DS, 2002, J PINEAL RES, V32, P257, DOI 10.1034/j.1600-079X.2002.01866.x; Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002; Nickel A, 2000, ARCH DERMATOL RES, V292, P366, DOI 10.1007/s004030000141; Onuki J, 2005, J PINEAL RES, V38, P107, DOI 10.1111/j.1600-079X.2004.00180.x; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Reiter RJ, 2005, J PINEAL RES, V39, P215, DOI 10.1111/j.1600-079X.2005.00261.x; Reiter RJ, 2002, ANN NY ACAD SCI, V957, P341, DOI 10.1111/j.1749-6632.2002.tb02938.x; Reiter RJ, 2003, J PINEAL RES, V34, P79, DOI 10.1034/j.1600-079X.2003.2e114.x; REITER RJ, 1994, ANN NY ACAD SCI, V719, P1, DOI 10.1111/j.1749-6632.1994.tb56817.x; Ressmeyer AR, 2003, REDOX REP, V8, P205, DOI 10.1179/135100003225002709; Rozov SV, 2003, J PINEAL RES, V35, P245, DOI 10.1034/j.1600-079X.2003.00081.x; SCHALLREUTER KU, 1994, SCIENCE, V263, P1444, DOI 10.1126/science.8128228; Schallreuter KU, 2001, J PHOTOCH PHOTOBIO B, V64, P179, DOI 10.1016/S1011-1344(01)00235-4; Schwarz A, 2002, NAT CELL BIOL, V4, P26, DOI 10.1038/ncb717; Semak I, 2005, BIOCHEMISTRY-US, V44, P9300, DOI 10.1021/bi050202d; Silva SO, 2004, J NEUROIMMUNOL, V156, P146, DOI 10.1016/j.jneuroim.2004.07.015; Silva SO, 2004, J PINEAL RES, V37, P171, DOI 10.1111/j.1600-079X.2004.00149.x; Skinner DC, 1999, ENDOCRINOLOGY, V140, P4399, DOI 10.1210/endo.140.10.7074; Slominski A, 1994, Exp Dermatol, V3, P45, DOI 10.1111/j.1600-0625.1994.tb00265.x; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; Slominski A, 1996, J BIOL CHEM, V271, P12281, DOI 10.1074/jbc.271.21.12281; Slominski A, 2005, ENDOCRINE, V27, P137, DOI 10.1385/ENDO:27:2:137; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2004, BBA-GENE STRUCT EXPR, V1680, P67, DOI 10.1016/j.bbaexp.2004.09.002; Slominski A, 2003, BBA-MOL BASIS DIS, V1639, P80, DOI 10.1016/S0925-4439(03)00124-8; Slominski A, 2003, EUR J BIOCHEM, V270, P3335, DOI 10.1046/j.1432-1033.2003.03708.x; Slominski A, 2003, J CELL PHYSIOL, V196, P144, DOI 10.1002/jcp.10287; Slominski A, 2002, FEBS LETT, V511, P102, DOI 10.1016/S0014-5793(01)03319-1; SLOMINSKI A, 1993, EXP CELL RES, V206, P189, DOI 10.1006/excr.1993.1137; Stasica P, 2000, J PINEAL RES, V29, P125, DOI 10.1034/j.1600-079X.2000.290209.x; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Tan DX, 1999, LIFE SCI, V65, P2523, DOI 10.1016/S0024-3205(99)00519-6; Tan DX, 1999, BBA-GEN SUBJECTS, V1472, P206, DOI 10.1016/S0304-4165(99)00125-7; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tesoriere L, 2001, FREE RADICAL RES, V35, P633, DOI 10.1080/10715760100301161; VAKKURI O, 1987, ENDOCRINOLOGY, V120, P2453, DOI 10.1210/endo-120-6-2453; Wong PSH, 1999, RAPID COMMUN MASS SP, V13, P407, DOI 10.1002/(SICI)1097-0231(19990315)13:5<407::AID-RCM500>3.0.CO;2-I; XIMENES VF, 2005, J BIOL CHEM	79	134	144	2	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1564	+		10.1096/fj.05-5227fje	http://dx.doi.org/10.1096/fj.05-5227fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16793870				2022-12-28	WOS:000240266000052
J	Garcia, P; Ucurum, Z; Bucher, R; Svergun, DI; Huber, T; Lustig, A; Konarev, PV; Marino, M; Mayans, O				Garcia, Pilar; Ucurum, Zohre; Bucher, Rainer; Svergun, Dmitri I.; Huber, Thomas; Lustig, Ariel; Konarev, Petr V.; Marino, Marco; Mayans, Olga			Molecular insights into the self-assembly mechanism of dystrophia myotonica kinase	FASEB JOURNAL			English	Article						kinase; coiled-coil; protein assembly; protein structure; X-ray crystallography; multiangle static light scattering; small angle X-ray scattering	RAY SOLUTION SCATTERING; HELICAL COILED COILS; GCN4 LEUCINE-ZIPPER; PROTEIN-KINASE; CYTOSKELETAL REORGANIZATION; BIOLOGICAL MACROMOLECULES; MYOSIN PHOSPHATASE; SALT BRIDGE; RHO-KINASE; PROGRAM	Self-assembly via coiled-coil domains (CC) is crucial for the regulation of the dystrophia myotonica kinase ( DMPK)-related family of kinases. These CC domains are thought to form dimeric arrangements and thus to mediate dimerization in these enzymes. Using size exclusion chromatography combined with multiangle static light scattering, we analyzed the oligomeric state of DMPK as well as that of a truncated variant lacking the CC fraction. Remarkably, both forms were found to assemble into robust dimers. In contrast, the CC domain in isolation yielded trimeric assemblies, indicating that the oligomerization properties of CC domains from this kinase family are more diversified than anticipated. The crystal structure of this CC has been elucidated to 1.6 angstrom resolution and its properties in solution established using sedimentation equilibrium and thermal denaturation. These data show that, contrary to expectations, the self-assembly of DMPK is not dictated by the association properties of its CC domain. Instead, it appears to be driven by sequence segments flanking both N and C termini of the catalytic kinase fraction, as suggested by models of head-to-head dimers based on small angle X-ray scattering data. Our findings support a shared pattern of assembly across DMPK, ROCKs, and MRCK members of this family.	Univ Basel, Biozentrum, Div Struct Biol, CH-4056 Basel, Switzerland; DESY, Hamburg Outstn, European Mol Biol Lab, D-2000 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow, Russia; Univ Zurich, Inst Biochem, CH-8006 Zurich, Switzerland	University of Basel; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; University of Zurich	Mayans, O (corresponding author), Univ Basel, Biozentrum, Div Struct Biol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	olga.mayans@unibas.ch	Konarev, Petr V/W-1380-2017; Mayans, Olga/A-3954-2008	Mayans, Olga/0000-0001-6876-8532; Svergun, Dmitri/0000-0003-0830-5696; Konarev, Petr/0000-0002-5606-1596				Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Burkhard P, 2002, J MOL BIOL, V318, P901, DOI 10.1016/S0022-2836(02)00114-6; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; Di Cunto F, 1998, J BIOL CHEM, V273, P29706, DOI 10.1074/jbc.273.45.29706; Doran JD, 2004, BIOCHEM J, V384, P255, DOI 10.1042/BJ20040344; Dvorsky R, 2004, J BIOL CHEM, V279, P7098, DOI 10.1074/jbc.M311911200; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Garcia P, 2004, ACTA CRYSTALLOGR D, V60, P2336, DOI 10.1107/S0907444904026873; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P1011, DOI 10.1038/nsb1296-1011; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Harper P.S., 1989, MYOTONIC DYSTROPHY; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JACOBS MD, 2005, J BIOL CHEM     1024; Jiang H, 2004, HUM MOL GENET, V13, P3079, DOI 10.1093/hmg/ddh327; Jin S, 2000, CELL MOTIL CYTOSKEL, V45, P133, DOI 10.1002/(SICI)1097-0169(200002)45:2<133::AID-CM5>3.0.CO;2-S; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kammerer RA, 2001, J BIOL CHEM, V276, P13685, DOI 10.1074/jbc.M010492200; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee HC, 2003, PHYSIOL GENOMICS, V12, P147, DOI 10.1152/physiolgenomics.00095.2002; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; Luo LQ, 1997, P NATL ACAD SCI USA, V94, P12963, DOI 10.1073/pnas.94.24.12963; Lupas AN, 2005, ADV PROTEIN CHEM, V70, P37, DOI 10.1016/S0065-3233(04)70003-0; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Meier M, 2002, J STRUCT BIOL, V137, P65, DOI 10.1006/jsbi.2002.4467; Mounsey JP, 2000, HUM MOL GENET, V9, P2313, DOI 10.1093/oxfordjournals.hmg.a018923; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petoukhov MV, 2005, BIOPHYS J, V89, P1237, DOI 10.1529/biophysj.105.064154; Petoukhov MV, 2002, BIOPHYS J, V83, P3113, DOI 10.1016/S0006-3495(02)75315-0; Piekny AJ, 2002, J CELL SCI, V115, P2271; Porod G., 1982, SMALL ANGLE XRAY SCA; Schulz PE, 2003, J NEUROPHYSIOL, V89, P1177, DOI 10.1152/jn.00504.2002; Shimizu M, 2000, FEBS LETT, V475, P273, DOI 10.1016/S0014-5793(00)01692-6; Shimizu T, 2003, J BIOL CHEM, V278, P46046, DOI 10.1074/jbc.M306458200; Strelkov SV, 2002, J STRUCT BIOL, V137, P54, DOI 10.1006/jsbi.2002.4454; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; Walshaw J, 2001, J MOL BIOL, V307, P1427, DOI 10.1006/jmbi.2001.4545; Wissmann A, 1997, GENE DEV, V11, P409, DOI 10.1101/gad.11.4.409; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zhang RX, 2003, FEBS LETT, V546, P281, DOI 10.1016/S0014-5793(03)00601-X	55	18	19	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1142	1151		10.1096/fj.05-5262com	http://dx.doi.org/10.1096/fj.05-5262com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770013				2022-12-28	WOS:000240210300014
J	Li, AQ; Guo, H; Luo, XY; Sheng, JS; Yang, S; Yin, YQ; Zhou, JW; Zhou, JW				Li, Aiqun; Guo, Hong; Luo, Xiaoying; Sheng, Jiansong; Yang, Shuo; Yin, Yanqing; Zhou, Jianwei; Zhou, Jiawei			Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons	FASEB JOURNAL			English	Article						striatum; neurotrophic factor; PD; signal transduction	FIBROBLAST-GROWTH-FACTOR; BINDING PROTEIN-PHOSPHORYLATION; PARKINSONS-DISEASE; ENDOTHELIAL-CELLS; DEPLETED STRIATUM; FACTOR-2 ISOFORMS; GENE-EXPRESSION; RAT-BRAIN; C-FOS; RELEASE	Apomorphine (APO), a potent D1/D2 dopamine receptor agonist, is currently used as an antiparkinsonian drug. We have shown previously that APO stimulates synthesis and release of multiple trophic factors, such as brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), in both mesencephalic and striatal neurons, thereby effectively preventing dopaminergic neuron loss in vitro. The present study was designed to investigate the effects of APO on fibroblast growth factor-2 (FGF-2) expression and regulation in astrocytes, and furthermore, to identify signaling mechanisms underlying these effects. Here, we show that FGF-2 expression is robustly induced in cultured astrocytes in response to APO. FGF-2 expression was proportional to APO concentration and time-dependent. Conversely, treatment with S-APO, a derivative of R-APO lacking DA receptor agonist activity, did not alter FGF-2 levels. APO treatment resulted in enhanced cytosol FGF-2 immunoreactivity, export of high MW forms of FGF-2 to the cytoplasm from the nucleus and increased extracellular release of FGF-2. Interestingly, both high and low MW forms of FGF-2 were detectable in conditioned medium of APO-treated cultures. This APO-induced effect was correlated with activation of D1 and D2 receptors, as it could be either mimicked by dopamine receptor agonists (SKF38393, quinpirole) or partially blocked by antagonists (SCH23390, SKF83566, haloperidol). Activation of the D1 receptor preferentially increased PKA activity, whereas activation of the D2 receptor only promoted phosphorylation of MAPK. Importantly, APO-modulated FGF-2 expression was independent of Akt/phosphoinositide 3-kinase signaling. These data suggest that APO can enhance biosynthesis and release of FGF-2 through activation of dopamine receptors in striatal astrocytes. Both cAMP/PKA and MEK/MAPK signaling cascades are major steps mediating this process. -Li, A., Guo, H., Luo, X., Sheng, J., Yang, S., Yin, Y., Zhou, J., and Zhou, J. Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons.	Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China; Nanjing Med Univ, Inst Publ Hlth, Nanjing, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Nanjing Medical University	Zhou, JW (corresponding author), Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	jwzhou@sibs.ac.cn	SHENG, JIANSONG/K-1914-2013	Zhou, Jiawei/0000-0002-1844-9178				BAL A, 1994, MOL BRAIN RES, V23, P204, DOI 10.1016/0169-328X(94)90227-5; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; Claus P, 2004, NEUROSCI LETT, V360, P117, DOI 10.1016/j.neulet.2004.01.046; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Gerfen CR, 2002, J NEUROSCI, V22, P5042, DOI 10.1523/JNEUROSCI.22-12-05042.2002; Girault JA, 2004, ARCH NEUROL-CHICAGO, V61, P641, DOI 10.1001/archneur.61.5.641; Grothe C, 2000, NEUROSCIENCE, V100, P73, DOI 10.1016/S0306-4522(00)00247-5; Grunblatt E, 2001, J NEUROCHEM, V78, P1, DOI 10.1046/j.1471-4159.2001.00397.x; Guo H, 2002, EUR J NEUROSCI, V16, P1861, DOI 10.1046/j.1460-9568.2002.02256.x; Jang CG, 2002, ARCH PHARM RES, V25, P370, DOI 10.1007/BF02976641; Keefe KA, 1996, J COMP NEUROL, V367, P165, DOI 10.1002/(SICI)1096-9861(19960401)367:2<165::AID-CNE1>3.0.CO;2-3; KEEFE KA, 1995, NEUROSCIENCE, V66, P903, DOI 10.1016/0306-4522(95)00024-D; Kyriazis M, 2003, J ANTI-AGING MED, V6, P21, DOI 10.1089/109454503765361551; Lee HT, 2004, J BIOL CHEM, V279, P32325, DOI 10.1074/jbc.M405208200; Liu FC, 1996, NEURON, V17, P1133, DOI 10.1016/S0896-6273(00)80245-7; Manson AJ, 2001, BRAIN, V124, P331, DOI 10.1093/brain/124.2.331; Maragnoli ME, 2004, BIOL PSYCHIAT, V55, P1095, DOI 10.1016/j.biopsych.2004.02.003; Menet V, 2001, J NEUROSCI, V21, P6147; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Miyazaki I, 2004, BRAIN RES, V1029, P120, DOI 10.1016/j.brainres.2004.09.014; Moffett J, 1998, MOL BIOL CELL, V9, P2269, DOI 10.1091/mbc.9.8.2269; Ohta M, 2000, BIOCHEM BIOPH RES CO, V272, P18, DOI 10.1006/bbrc.2000.2732; OMALLEY EK, 1994, BRAIN RES, V647, P83, DOI 10.1016/0006-8993(94)91401-X; OTTO D, 1993, EUR J NEUROSCI, V5, P927, DOI 10.1111/j.1460-9568.1993.tb00943.x; OTTO D, 1993, J NEUROSCI RES, V34, P382, DOI 10.1002/jnr.490340403; PAUL ML, 1992, J NEUROSCI, V12, P3729, DOI 10.1523/jneurosci.12-10-03729.1992; Peng H, 2001, MOL BIOL CELL, V12, P449, DOI 10.1091/mbc.12.2.449; Piotrowicz RS, 1999, J CELL PHYSIOL, V178, P144, DOI 10.1002/(SICI)1097-4652(199902)178:2<144::AID-JCP3>3.0.CO;2-Z; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; Reuss B, 2003, CELL TISSUE RES, V313, P139, DOI 10.1007/s00441-003-0756-7; Sheng JS, 2004, EUR J NEUROSCI, V20, P873, DOI 10.1111/j.1460-9568.2004.03567.x; Smith GM, 1997, J NEUROSCI, V17, P9624; Taverna S, 2003, J BIOL CHEM, V278, P51911, DOI 10.1074/jbc.M304192200; TOOYAMA I, 1993, NEUROLOGY, V43, P372, DOI 10.1212/WNL.43.2.372; UBEDA A, 1993, FREE RADICAL BIO MED, V15, P159, DOI 10.1016/0891-5849(93)90055-Y; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Vincent SR, 1998, SYNAPSE, V29, P29, DOI 10.1002/(SICI)1098-2396(199805)29:1<29::AID-SYN3>3.3.CO;2-T; Wakisaka N, 2002, CANCER RES, V62, P6337; WOODWARD WR, 1992, J NEUROSCI, V12, P142; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Yan Z, 1999, P NATL ACAD SCI USA, V96, P11607, DOI 10.1073/pnas.96.20.11607; Zanassi P, 1999, J NEUROSCI RES, V58, P544, DOI 10.1002/(SICI)1097-4547(19991115)58:4<544::AID-JNR7>3.0.CO;2-9; Zeng ZZ, 2002, J BIOL CHEM, V277, P41213, DOI 10.1074/jbc.M204508200	47	47	54	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8								10.1096/fj.05-5510fje	http://dx.doi.org/10.1096/fj.05-5510fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636101				2022-12-28	WOS:000240210300046
J	Shukla, A; Barrett, TF; Nakayama, KI; Nakayama, K; Mossman, BT; Lounsbury, KM				Shukla, Arti; Barrett, Trisha F.; Nakayama, Keiichi I.; Nakayama, Kieko; Mossman, Brooke T.; Lounsbury, Karen M.			Transcriptional up-regulation of MMP12 and MMP13 by asbestos occurs via a PKC delta-dependent pathway in murine lung	FASEB JOURNAL			English	Article						TIMP; fibrosis; lung cancer; lung epithelium	PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; IDIOPATHIC PULMONARY-FIBROSIS; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; TISSUE INHIBITORS; CIGARETTE-SMOKE; ACTIVATION; MICE; PROLIFERATION	Asbestos is a known inflammatory, carcinogenic, and fibrotic agent, but the mechanisms leading to asbestos-induced lung diseases are unclear. Using a murine inhalation model of fibrogenesis, we show that asbestos causes significant increases in mRNA levels of lung matrix metalloproteinases (MMPs 12 and 13) and tissue inhibitor of metalloproteinases (TIMP1), as well as increased activities of MMP 2, 9, and 12 in bronchoalveolar lavage fluids (BALF). Asbestos-exposed PKC delta knockout (PKC delta-/-) mice exhibited decreased expression of lung MMP12 and MMP13 compared with asbestos-exposed wild-type mice. Studies using small molecule inhibitors in murine alveolar epithelial type II cells (C10) and primary lung fibroblasts confirmed that asbestos transcriptionally upregulates MMPs via an EGFR (or other growth factor receptors)/PI3K/PKC delta/ERK1/2 pathway. Moreover, use of a broad-spectrum MMP inhibitor showed that MMPs play an important role in further enhancing asbestos-induced signaling events by activating EGFR. These data reveal a potentially important link between asbestos signaling and integrity of the extracellular matrix (ECM) that likely contributes to asbestos-induced lung remodeling and diseases.	Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA; Kyushu Univ, Dept Mol Genet, Med Inst Bioregulat, Fukuoka 812, Japan	University of Vermont; University of Vermont; Kyushu University	Lounsbury, KM (corresponding author), Univ Vermont, Coll Med, Dept Pharmacol, 89 Beaumont Ave, Burlington, VT 05405 USA.	karen.lounsbury@uvm.edu			NCI NIH HHS [P30CA22435] Funding Source: Medline; NHLBI NIH HHS [P01 HL067004, P01HL67004] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA022435] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067004] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Burch PM, 2004, MOL CELL BIOL, V24, P4696, DOI 10.1128/MCB.24.11.4696-4709.2004; Corbel M, 2001, J PATHOL, V193, P538, DOI 10.1002/path.826; Ellerbroek SM, 2001, CANCER RES, V61, P1855; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Fukuda Y, 1998, LAB INVEST, V78, P687; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hayashi T, 1996, AM J PATHOL, V149, P1241; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Lavigne MC, 2005, BIOCHEM BIOPH RES CO, V330, P194, DOI 10.1016/j.bbrc.2005.02.144; Lemjabbar H, 1999, AM J RESP CELL MOL, V20, P903, DOI 10.1165/ajrcmb.20.5.3260; Lounsbury KM, 2002, AM J PATHOL, V160, P1991, DOI 10.1016/S0002-9440(10)61149-2; Lucchesi PA, 2004, CIRCULATION, V110, P3587, DOI 10.1161/01.CIR.0000148780.36121.47; Malkinson AM, 1997, TOXICOLOGY, V123, P53, DOI 10.1016/S0300-483X(97)00108-X; Manning CB, 2002, CANCER RES, V62, P4169; Manning CB, 2002, INT IMMUNOPHARMACOL, V2, P191, DOI 10.1016/S1567-5769(01)00172-2; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141; MOSSMAN BT, 1989, NEW ENGL J MED, V320, P1721, DOI 10.1056/NEJM198906293202604; MOSSMAN BT, 1990, AM REV RESPIR DIS, V141, P1266, DOI 10.1164/ajrccm/141.5_Pt_1.1266; Muscella A, 2003, J CELL PHYSIOL, V195, P234, DOI 10.1002/jcp.10242; Ortiz LA, 2001, AM J RESP CRIT CARE, V163, P244, DOI 10.1164/ajrccm.163.1.2002123; Perez-Ramos J, 1999, AM J RESP CRIT CARE, V160, P1274, DOI 10.1164/ajrccm.160.4.9808006; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Robledo RF, 2000, AM J PATHOL, V156, P1307, DOI 10.1016/S0002-9440(10)65001-8; Sabo-Attwood T, 2005, AM J PATHOL, V167, P1243, DOI 10.1016/S0002-9440(10)61212-6; Scapoli L, 2004, ONCOGENE, V23, P805, DOI 10.1038/sj.onc.1207163; Selman M, 2000, AM J PHYSIOL-LUNG C, V279, pL562, DOI 10.1152/ajplung.2000.279.3.L562; Shapiro SD, 1999, THROMB HAEMOSTASIS, V82, P846; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; Shapiro SD, 1999, AM J RESP CELL MOL, V20, P1100, DOI 10.1165/ajrcmb.20.6.f151; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Shukla A, 2005, FASEB J, V19, pA491; Shukla A, 2003, AM J RESP CELL MOL, V29, P198, DOI 10.1165/rcmb.2002-0248OC; Shukla A, 2003, FREE RADICAL BIO MED, V34, P1117, DOI 10.1016/S0891-5849(03)00060-1; Shukla A, 2001, CANCER RES, V61, P1791; Shukla A, 2000, AM J RESP CELL MOL, V23, P182, DOI 10.1165/ajrcmb.23.2.4035; Shum JKS, 2002, J BIOL CHEM, V277, P42830, DOI 10.1074/jbc.M205094200; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Vincenti MP, 2000, METH MOL B, V151, P121, DOI 10.1385/1-59259-046-2:121; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Winkler MK, 2002, AM J PHYSIOL-LUNG C, V283, pL1, DOI 10.1152/ajplung.00489.2001; Woo JH, 2004, ONCOGENE, V23, P1845, DOI 10.1038/sj.onc.1207307; Wylie AG, 1997, TOXICOL APPL PHARM, V147, P143, DOI 10.1006/taap.1997.8276; Yoshisue H, 2004, BIOSCI BIOTECH BIOCH, V68, P2024, DOI 10.1271/bbb.68.2024; Zanella CL, 1996, CANCER RES, V56, P5334; Zanella CL, 1999, AM J PHYSIOL-LUNG C, V277, pL684, DOI 10.1152/ajplung.1999.277.4.L684; Zhang Q, 2005, AM J RESP CELL MOL, V32, P72, DOI 10.1165/rcmb.2004-0198OC; Zuo FR, 2002, P NATL ACAD SCI USA, V99, P6292, DOI 10.1073/pnas.092134099	51	33	33	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					997	+		10.1096/fj.05-4554fje	http://dx.doi.org/10.1096/fj.05-4554fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571779				2022-12-28	WOS:000240157700034
J	Louis, E; Boschi, CDE; Ortega, GJ; Fernandez, E				Louis, E.; Boschi, C. Degli Esposti; Ortega, G. J.; Fernandez, E.			Role of transport performance for neuron cell morphology	FASEB JOURNAL			English	Article						compartmental model; passive properties	JUNCTION-CONNECTED CELLS; ELECTRICAL-PROPERTIES; RETINA; NETWORKS; MODELS	The compartmental model is a basic tool for studying signal propagation in neurons; if the model parameters are adequately redefined, it can also be helpful in the study of electrical or fluid transport in other biological systems. Here we show that the input resistance in different networks that simulate the morphology of neurons is the result of the interplay between the relevant conductances, neuron morphology, and neuron size. The results suggest that neurons may grow in such a way that facilitates the current How to the synapses, concurrently minimizing power consumption.	Univ Miguel Hernandez, Fac Med, Dept Histol, Alicante 03550, Spain; Univ Miguel Hernandez, Fac Med, Inst Bioengn, Alicante 03550, Spain; Univ Alicante, Inst Univ Mat, IUMA, Dept Fis Aplicada, E-03080 Alicante, Spain; Univ Alicante, CSIC, Unidad Asociada, E-03080 Alicante, Spain; CNR, INFM, Unita Ric, CNISM Bologna, I-40126 Bologna, Italy; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fis, FCEN, RA-1428 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina	Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche; Universitat d'Alacant; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat d'Alacant; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Fernandez, E (corresponding author), Univ Miguel Hernandez, Fac Med, Dept Histol, Alicante 03550, Spain.	e.fernandez@umh.es	Fernandez, Eduardo/S-8206-2016; Degli Esposti Boschi, Cristian/AAF-8855-2020; Degli Esposti Boschi, Cristian/P-1559-2014	Fernandez, Eduardo/0000-0002-7052-6011; Degli Esposti Boschi, Cristian/0000-0002-3190-2985; Degli Esposti Boschi, Cristian/0000-0002-3190-2985; louis, enrique/0000-0001-8631-0189				Andreu E, 1997, J PHYSIOL-LONDON, V498, P753, DOI 10.1113/jphysiol.1997.sp021899; Andreu E, 2000, PFLUG ARCH EUR J PHY, V439, P789, DOI 10.1007/s004249900190; Bejan A, 1997, FRACTALS, V5, P685, DOI 10.1142/S0218348X97000553; Bejan A., 2000, SHAPE STRUCTURE ENG; CHERNIAK C, 1994, J NEUROSCI, V14, P2418; Chklovskii DB, 2000, J NEUROPHYSIOL, V83, P2113, DOI 10.1152/jn.2000.83.4.2113; Duijnhouwer J, 2001, NEUROCOMPUTING, V38, P183, DOI 10.1016/S0925-2312(01)00502-1; Fernandez E, 2001, METHODS, V24, P309, DOI 10.1006/meth.2001.1201; Fernandez-Ballesteros R, 1999, EUR J PSYCHOL ASSESS, V15, P1, DOI 10.1027//1015-5759.15.1.1; GARCIARUIZ JM, 1993, NATO ASI SERIES; Hageman L.A., 1981, APPL ITERATIVE METHO; Haldane JB., 1985, BEING RIGHT SIZE OTH; Hille B., 1991, IONIC CHANNELS EXCIT; JAMES T, 1963, MATH THEORY ELECT MA; Jelinek HF, 1998, J NEUROSCI METH, V81, P9, DOI 10.1016/S0165-0270(98)00021-1; KOCH C, 1999, BIOPHYS COMPUTATION; LAMB TD, 1976, J PHYSIOL-LONDON, V263, P257, DOI 10.1113/jphysiol.1976.sp011631; Laughlin SB, 2003, SCIENCE, V301, P1870, DOI 10.1126/science.1089662; Louis E, 2002, NEUROSCI LETT, V323, P21, DOI 10.1016/S0304-3940(02)00115-5; PANICO J, 1995, J COMP NEUROL, V361, P479, DOI 10.1002/cne.903610311; Poznanski RR, 1997, PROG NEUROBIOL, V53, P273, DOI 10.1016/S0301-0082(97)00037-3; QIAN HH, 1993, VISUAL NEUROSCI, V10, P287, DOI 10.1017/S0952523800003680; RALL W, 1959, EXP NEUROL, V1, P491, DOI 10.1016/0014-4886(59)90046-9; Rall W, 1998, METHODS NEURONAL MOD, P27; Ramon y Cajal S, 1995, HISTOLOGY NERVOUS SY; RAPP M, 1994, J PHYSIOL-LONDON, V474, P101, DOI 10.1113/jphysiol.1994.sp020006; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; SEGEV I, 1992, TRENDS NEUROSCI, V15, P414, DOI 10.1016/0166-2236(92)90003-Q; Surkis A, 1996, NEUROSCIENCE, V74, P375, DOI 10.1016/0306-4522(96)00139-X; THOMPSON WD, 2000, GROWTH FORM ABRIGED; UMINO O, 1994, VISUAL NEUROSCI, V11, P533, DOI 10.1017/S0952523800002443; Valiunas V, 1997, CIRC RES, V80, P708, DOI 10.1161/01.RES.80.5.708; Vicsek T, 1992, FRACTAL GROWTH PHENO; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122	34	1	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					866	871		10.1096/fj.06-5977com	http://dx.doi.org/10.1096/fj.06-5977com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17194694	Green Submitted			2022-12-28	WOS:000244686400023
J	Robinson, P; Lipscomb, S; Preston, LC; Altin, E; Watkins, H; Ashley, CC; Redwood, CS				Robinson, Paul; Lipscomb, Simon; Preston, Laura C.; Altin, Elissa; Watkins, Hugh; Ashley, Christopher C.; Redwood, Charles S.			Mutations in fast skeletal troponin I, troponin T, and beta-tropomyosin that cause distal arthrogryposis all increase contractile function	FASEB JOURNAL			English	Article						contractility; muscle disease	THIN FILAMENT REGULATION; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; MYOSIN-ACTIN INTERACTIONS; ALPHA-TROPOMYOSIN; COILED-COIL; DILATED CARDIOMYOPATHY; COOPERATIVE REGULATION; REGULATORY PROPERTIES; MULTIPLEX CONGENITA; CLINICAL ANALYSIS	Distal arthrogryposes (DAs) are a group of disorders characterized by congenital contractures of distal limbs without overt neurological or muscle disease. Unexpectedly, mutations in genes encoding the fast skeletal muscle regulatory proteins troponin T (TnT), troponin I (TnI), and beta-tropomyosin (beta-TM) have been shown to cause autosomal dominant DA. We tested how these mutations affect contractile function by comparing wild-type (WT) and mutant proteins in actomyosin ATPase assays and in troponin-replaced rabbit psoas fibers. We have analyzed all four reported mutants: Arg63His TnT, Arg91Gly beta-TM, Arg174GIn TnI, and a TnI truncation mutant (Arg156ter). Thin filaments, reconstituted using actin and WT troponin and beta-TM, activated myosin subfragment-1 ATPase in a calcium-dependent, cooperative manner. Thin filaments containing either a troponin or beta-TM DA mutant produced significantly enhanced ATPase rates at all calcium concentrations without alternating calcium-sensitivity or cooperativity. In troponin-exchanged skinned fibers, each mutant caused a significant increase in Ca2+ sensitivity, and Arg156ter TnI generated significantly higher maximum force. Arg91Gly beta-TM was found to have a lower actin affinity than WT and forma less stable coiled coil. We propose the mutations cause increased contractility of developing fast-twitch skeletal muscles, thus causing muscle contractures and the development of the observed limb deformities.	Univ Oxford, Dept Cardiovasc Med, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, Dept Physiol, Oxford, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Redwood, CS (corresponding author), Univ Oxford, Dept Cardiovasc Med, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.	credwood@well.ox.ac.uk		Watkins, Hugh/0000-0002-5287-9016				ASHLEY CC, 1993, ADV EXP MED BIOL, V332, P97; ASHLEY CC, 1993, ADV EXP MED BIOL, V332, P114; BAMSHAD M, 1994, AM J HUM GENET, V55, P1153; Bamshad M, 1996, AM J MED GENET, V65, P277, DOI 10.1002/(SICI)1096-8628(19961111)65:4<277::AID-AJMG6>3.0.CO;2-M; Bamshad M, 1996, AM J MED GENET, V65, P282, DOI 10.1002/(SICI)1096-8628(19961111)65:4<282::AID-AJMG7>3.0.CO;2-R; Beals RK, 2005, CLIN ORTHOP RELAT R, P203; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Bing W, 1997, BIOCHEM BIOPH RES CO, V236, P760, DOI 10.1006/bbrc.1997.7045; Bottinelli R, 1998, CIRC RES, V82, P106; Brenner B, 1999, BIOPHYS J, V77, P2677, DOI 10.1016/S0006-3495(99)77102-X; BRONSON DD, 1982, J BIOL CHEM, V257, P3937; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Craig R, 2001, J MOL BIOL, V311, P1027, DOI 10.1006/jmbi.2001.4897; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Gordon N, 1998, BRAIN DEV-JPN, V20, P507, DOI 10.1016/S0387-7604(98)00037-0; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; GRIFFITHS PJ, 1994, J PHYSL, V438, pB146; Hall JG, 1997, J PEDIATR ORTHOP B, V6, P159, DOI 10.1097/01202412-199707000-00002; HALL JG, 1982, AM J MED GENET, V11, P185, DOI 10.1002/ajmg.1320110208; Heller MJ, 2003, J BIOL CHEM, V278, P41742, DOI 10.1074/jbc.M303408200; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; Hitchcock-DeGregori SE, 2002, BIOCHEMISTRY-US, V41, P15036, DOI 10.1021/bi026519k; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; Krakowiak PA, 1998, AM J MED GENET, V76, P93, DOI 10.1002/(SICI)1096-8628(19980226)76:1<93::AID-AJMG17>3.0.CO;2-K; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; LEHRER SS, 1991, BIOCHEMISTRY-US, V30, P5682, DOI 10.1021/bi00237a007; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; Lipscomb S, 2005, BIOCHEM J, V388, P905, DOI 10.1042/BJ20041841; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; Mirza M, 2005, J BIOL CHEM, V280, P28498, DOI 10.1074/jbc.M412281200; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Palm T, 2001, BIOPHYS J, V81, P2827, DOI 10.1016/S0006-3495(01)75924-3; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PERRY SV, 1985, J EXP BIOL, V115, P31; Ramos CHI, 1999, J BIOL CHEM, V274, P18189, DOI 10.1074/jbc.274.26.18189; Rarick HM, 1997, J BIOL CHEM, V272, P26887, DOI 10.1074/jbc.272.43.26887; Redwood C, 2000, CIRC RES, V86, P1146; Robinson P, 2002, J BIOL CHEM, V277, P40710, DOI 10.1074/jbc.M203446200; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; She MD, 2000, J MUSCLE RES CELL M, V21, P737, DOI 10.1023/A:1010300802980; Singh A, 2006, STRUCTURE, V14, P43, DOI 10.1016/j.str.2005.09.016; Singh A, 2003, BIOCHEMISTRY-US, V42, P14114, DOI 10.1021/bi0348462; SMITH DA, 1995, BIOPHYS J, V69, P524, DOI 10.1016/S0006-3495(95)79926-X; Smith DA, 2003, BIOPHYS J, V84, P3155, DOI 10.1016/S0006-3495(03)70040-X; Smith DA, 2003, BIOPHYS J, V84, P3168, DOI 10.1016/S0006-3495(03)70041-1; Smith R. M., 1974, CRITICAL STABILITY C, P1; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sung SS, 2003, AM J HUM GENET, V73, P212, DOI 10.1086/376418; Sung SS, 2003, AM J HUM GENET, V72, P681, DOI 10.1086/368294; Varnava A, 1999, HEART, V82, P621, DOI 10.1136/hrt.82.5.621; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x	58	74	83	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					896	905		10.1096/fj.06-6899com	http://dx.doi.org/10.1096/fj.06-6899com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17194691				2022-12-28	WOS:000244686400026
J	Yung, HW; Korolchuk, S; Tolkovsky, AM; Charnock-Jones, DS; Burton, GJ				Yung, Hong-Wa; Korolchuk, Svitlana; Tolkovsky, Aviva M.; Charnock-Jones, D. Stephen; Burton, Graham J.			Endoplasmic reticulum stress exacerbates ischemia-reperfusion-induced apoptosis through attenuation of Akt protein synthesis in human choriocarcinoma cells	FASEB JOURNAL			English	Article						unfolded protein response; placenta; oxidative stress; trophoblast; CHOP	P70 S6 KINASE; OXIDATIVE STRESS; GENE-EXPRESSION; TRANSLATION INITIATION; CEREBRAL-ISCHEMIA; ALPHA-TOCOPHEROL; BRAIN ISCHEMIA; ER STRESS; PHOSPHORYLATION; ACTIVATION	Oxidative stress is central to ischemia-reperfusion injury. The role of the endoplasmic reticulum (ER) in this process is uncertain. In ER signaling, PERK-Nrf2 and Ire-CHOP are two pathways that determine cell fate under stress. PERK-Nrf2 up-regulates antioxidant enzyme expression whereas Ire-CHOP promotes apoptosis. We have identified a novel pathway in ER stress-induced apoptosis after ischemia-reperfusion in vitro involving translational suppression of the survival kinase PKB/Akt (Akt), and elucidated an alternative protective role of antioxidants in the regulation of Akt activity. Using human choriocarcinoma JEG-3 cells, we found that sustained activation of ER stress by tunicamycin or thapsigargin exacerbated apoptosis in oxygen-glucose-deprived cells during reoxygenation. This was mediated via a reduction in phosphorylated Akt secondary to down-regulation of protein translation rather than suppression of phosphorylation. Transient overexpression of wild-type Akt, but not kinase-dead Akt, in JEG-3 cells diminished tunicamycin-OGD reoxygenation-induced apoptosis. The antioxidants Trolox and Edaravone reduced apoptosis, but the protective effect of Trolox was abrogated by the PI3K inhibitor, LY294002. We speculate that sustained ER stress may contribute to the placental dysfunction seen in human pregnancy complications.	Univ Cambridge, Dept Physiol Dev & Neurosci, Physiol Lab, Cambridge CB2 3EG, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Cambridge, Dept Obstet & Gynaecol, Cambridge CB2 1QW, England	University of Cambridge; University of Cambridge; University of Cambridge	Burton, GJ (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Physiol Lab, Downing St, Cambridge CB2 3EG, England.	gjb2@cam.ac.uk	Charnock-Jones, D. Stephen/B-3743-2009; Charnock-Jones, D. Stephen/AAE-3391-2020	Charnock-Jones, D. Stephen/0000-0002-2936-4890; Charnock-Jones, D. Stephen/0000-0002-2936-4890	Wellcome Trust [069027/Z/02/Z, 069027] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Althausen S, 2001, J NEUROCHEM, V78, P779, DOI 10.1046/j.1471-4159.2001.00462.x; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Benavides A, 2005, GLIA, V52, P261, DOI 10.1002/glia.20242; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brosens JJ, 2002, AM J OBSTET GYNECOL, V187, P1416, DOI 10.1067/mob.2002.127305; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Burns DM, 1998, SENSOR ACTUAT A-PHYS, V70, P6, DOI 10.1016/S0924-4247(98)00106-X; Burton GJ, 2004, J SOC GYNECOL INVEST, V11, P342, DOI 10.1016/j.jsgi.2004.03.003; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Clement S, 1997, EUR J BIOCHEM, V246, P745, DOI 10.1111/j.1432-1033.1997.t01-2-00745.x; Cullinan SB, 2006, INT J BIOCHEM CELL B, V38, P317, DOI 10.1016/j.biocel.2005.09.018; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de la Vega CM, 2001, BIOCHEM J, V357, P819; DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x; DeGracia DJ, 2004, J NEUROSCI RES, V77, P771, DOI 10.1002/jnr.20225; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; DEL PL, 1997, SCIENCE, V278, P687; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hayashi T, 2005, J CEREBR BLOOD F MET, V25, P41, DOI 10.1038/sj.jcbfm.9600005; Hayashi T, 2004, NEUROBIOL DIS, V15, P229, DOI 10.1016/j.nbd.2003.10.005; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; HOSSMANN KA, 1993, PROG BRAIN RES, V96, P161; Hung TH, 2002, CIRC RES, V90, P1274, DOI 10.1161/01.RES.0000024411.22110.AA; Hyoda K, 2006, BIOCHEM BIOPH RES CO, V340, P286, DOI 10.1016/j.bbrc.2005.12.007; Ishihara N, 2002, AM J OBSTET GYNECOL, V186, P158, DOI 10.1067/mob.2002.119176; Jan E, 2001, COLD SPRING HARB SYM, V66, P285, DOI 10.1101/sqb.2001.66.285; KIMBALL SR, 1992, AM J PHYSIOL, V263, pE958, DOI 10.1152/ajpendo.1992.263.5.E958; Kumar R, 2003, J CEREBR BLOOD F MET, V23, P462, DOI 10.1097/01.WCB.0000056064.25434.CA; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; MARTIN CB, 1964, AM J OBSTET GYNECOL, V90, P819, DOI 10.1016/0002-9378(64)90948-2; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Qi X, 2004, J PHARMACOL EXP THER, V311, P388, DOI 10.1124/jpet.104.069088; Rajesh KG, 2003, AM J PHYSIOL-HEART C, V285, pH2171, DOI 10.1152/ajpheart.00143.2003; Ricciarelli R, 1998, BIOCHEM J, V334, P243, DOI 10.1042/bj3340243; Rimbach G, 2002, P NUTR SOC, V61, P415, DOI 10.1079/PNS2002183; Roberts JM, 1999, LANCET, V354, P788, DOI 10.1016/S0140-6736(99)80002-6; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shang J, 2004, BIOCHEM BIOPH RES CO, V317, P390, DOI 10.1016/j.bbrc.2004.03.058; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Srinivasan S, 2005, DIABETES, V54, P968, DOI 10.2337/diabetes.54.4.968; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; Virdee K, 1999, BRAIN RES, V837, P127, DOI 10.1016/S0006-8993(99)01643-1; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yoneda Y, 2003, STROKE, V34, P718, DOI 10.1161/01.STR.0000056171.55342.FF; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2001, J INVEST DERM SYMP P, V6, P1, DOI 10.1046/j.0022-202x.2001.00006.x; Yung HW, 2003, J NEUROCHEM, V86, P1281, DOI 10.1046/j.1471-4159.2003.01946.x	56	97	101	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					872	884		10.1096/fj.06-6054com	http://dx.doi.org/10.1096/fj.06-6054com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17167073	Green Accepted			2022-12-28	WOS:000244686400024
J	Janovick, JA; Brothers, SP; Knollman, PE; Conn, PM				Janovick, Jo Ann; Brothers, Shaun P.; Knollman, Paul E.; Conn, P. Michael			Specializations of a G-protein-coupled receptor that appear to aid with detection of frequency-modulated signals from its ligand	FASEB JOURNAL			English	Article						quality control system; pharmacoperone; pharmacological chaperone; protein routing; receptor evolution	PLASMA-MEMBRANE EXPRESSION; HORMONE GNRH RECEPTOR; HYPOGONADOTROPIC HYPOGONADISM; PHARMACOLOGICAL CHAPERONES; GONADOTROPIN-SECRETION; DISEASE ETIOLOGY; MOLECULAR-BASIS; MUTANTS; RESCUE; IDENTIFICATION	The primate GnRH receptor (GnRHR) is a GPCR (G-protein-coupled receptor) that transduces both amplitude- and frequency-modulated signals; each modality conveys information that regulates primate reproduction. Slower GnRH pulses favor release (and higher circulating levels) of pituitary FSH, while faster pulses favor LH release. We used radioligand binding and inositol phosphate production (a measure of G-protein coupling) in association with mutational analysis to identify the impact of evolved sequence specializations that regulate receptor concentration at the plasma membrane and K-d in primate GnRHRs. Our results show that mutations appear to provide a mechanism that allows independent adjustment of response sensitivity and squelching (suppression) of low-level signals (noise), both desirable features for recognition of frequency-modulated signals. We identify specific amino acid residues that appear to be involved in these processes. This investigation occurred in light of recent observations that restriction of GnRHR plasma membrane expression developed under strong convergent pressure and concurrently with the complex pattern of cyclicity associated with primate reproduction. The findings present an evolved means for increased effectiveness of detection of a frequency-m modulated signal and provide a strategy to identify similar mechanisms in other receptors.	Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Reprod Sci, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Beaverton, OR 97006 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University	Conn, PM (corresponding author), Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	connm@ohsu.edu	Brothers, Shaun/G-8690-2012	Brothers, Shaun/0000-0003-2184-4037	NCRR NIH HHS [RR-00163] Funding Source: Medline; NICHD NIH HHS [TW/HD-00668, HD-18185, HD-19899] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019899, R37HD019899] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Brothers SP, 2004, MOL ENDOCRINOL, V18, P1787, DOI 10.1210/me.2004-0091; Castro-Fernandez C, 2005, ENDOCR REV, V26, P479, DOI 10.1210/er.2004-0010; Conn P Michael, 2002, Mol Interv, V2, P308, DOI 10.1124/mi.2.5.308; CONN PM, 2006, IN PRESS MOL ENDOCRI; CONN PM, IN PRESS J ENDOCRINO; Corrada Y, 2006, THERIOGENOLOGY, V66, P1599, DOI 10.1016/j.theriogenology.2006.01.003; Crofford LJ, 2004, BRAIN BEHAV IMMUN, V18, P314, DOI 10.1016/j.bbi.2003.12.011; Cui JS, 2000, MOL ENDOCRINOL, V14, P671, DOI 10.1210/me.14.5.671; Darzy KH, 2006, J CLIN ENDOCR METAB, V91, P987, DOI 10.1210/jc.2005-2145; Gavrila A, 2003, J CLIN ENDOCR METAB, V88, P2838, DOI 10.1210/jc.2002-021721; Ikemoto T, 2004, MOL CELL ENDOCRINOL, V214, P137, DOI 10.1016/j.mce.2003.10.062; Janovick JA, 2006, J BIOL CHEM, V281, P8417, DOI 10.1074/jbc.M510601200; Janovick JA, 2003, J PHARMACOL EXP THER, V305, P608, DOI 10.1124/jpet.102.048454; Janovick JA, 2002, J CLIN ENDOCR METAB, V87, P3255, DOI 10.1210/jc.87.7.3255; Knollman PE, 2005, J BIOL CHEM, V280, P24506, DOI 10.1074/jbc.M501978200; Koutkia P, 2004, AM J PHYSIOL-ENDOC M, V287, pE506, DOI 10.1152/ajpendo.00548.2003; Leanos-Miranda A, 2003, J CLIN ENDOCR METAB, V88, P3360, DOI 10.1210/jc.2003-030084; Leanos-Miranda A, 2002, J CLIN ENDOCR METAB, V87, P4825, DOI 10.1210/jc.2002-020961; Lin XW, 1998, MOL ENDOCRINOL, V12, P161, DOI 10.1210/me.12.2.161; Maya-Nunez G, 2000, ENDOCRINE, V13, P401, DOI 10.1385/ENDO:13:3:401; McCartney CR, 2002, J CLIN ENDOCR METAB, V87, P2194, DOI 10.1210/jc.87.5.2194; MCNATTY KP, 1991, J REPROD FERTIL, V91, P583, DOI 10.1530/jrf.0.0910583; Misra M, 2005, AM J PHYSIOL-ENDOC M, V289, pE373, DOI 10.1152/ajpendo.00041.2005; Mogi K, 2004, J VET MED SCI, V66, P1071, DOI 10.1292/jvms.66.1071; Natalucci G, 2005, EUR J ENDOCRINOL, V152, P845, DOI 10.1530/eje.1.01919; Pawson AJ, 1998, J ENDOCRINOL, V156, pR9, DOI 10.1677/joe.0.156R009; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Petrovska R, 2005, BRIT J PHARMACOL, V144, P651, DOI 10.1038/sj.bjp.0706087; SCHEEN A, 2005, DIABETES METAB SPEC, V2, P27; Uberti MA, 2005, J PHARMACOL EXP THER, V313, P16, DOI 10.1124/jpet.104.079541; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Ulloa-Aguirre A, 2003, EXPERT OPIN THER TAR, V7, P175, DOI 10.1517/eott.7.2.175.23780; Vandenberghe W, 2005, J NEUROSCI, V25, P1095, DOI 10.1523/JNEUROSCI.3568-04.2005; WILDT L, 1981, ENDOCRINOLOGY, V109, P376, DOI 10.1210/endo-109-2-376; Winters SJ, 2004, REPRODUCTION, V128, P13, DOI 10.1530/rep.1.00195	35	10	10	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					384	392		10.1096/fj.06-6901com	http://dx.doi.org/10.1096/fj.06-6901com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17172315				2022-12-28	WOS:000244686300012
J	Kessler, SP; Senanayake, PD; Gaughan, C; Sen, GC				Kessler, Sean P.; deS. Senanayake, Preenie; Gaughan, Christina; Sen, Ganes C.			Vascular expression of germinal ACE fails to maintain normal blood pressure in ACE-/- mice	FASEB JOURNAL			English	Article						ANG-converting enzyme; transgenic mice; renin-angiotensin system	ANGIOTENSIN-CONVERTING ENZYME; MALE-FERTILITY; IMMUNOHISTOCHEMICAL LOCALIZATION; CLEAVAGE-SECRETION; CELL-SURFACE; SOMATIC ACE; 2 ISOFORMS; C-DOMAIN; GENE; TRANSCRIPTION	Maintenance of normal blood pressure is critical for preserving the integrity of the cardiovascular system. Angiotensin 1-converting enzyme ( ACE) regulates normal blood pressure and fluid homeostasis through its action in the renin-angiotensin-aldosterone system ( RAAS) and the renal tubuloglomerular feedback response. Although the two structurally related isozymic forms of ACE both generate the vasoactive octapeptide angiotensin II ( Ang II) with equal efficiency, both are expressed in a nonoverlapping tissue-restricted fashion. To discriminate the precise physiological role of each ACE in its requisite tissue in vivo, we expressed one ACE isoform exclusively in a single cell type of an Ace null mouse. Previously, we demonstrated that vascular endothelial cell-specific expression of transgenic somatic ACE ( sACE) could restore normal blood pressure of Ace-null mice. In this current study, we expressed germinal ACE ( gACE) in the vascular endothelial cells of the Ace null mouse. These mice exhibited correct renal structure, renal function, and normal growth rates. Although the mice had elevated levels of gACE bound to vascular endothelial cells and high levels of gACE and Ang II in the circulating serum, blood pressure was restored only partially. This study demonstrated that gACE, even when expressed in the vasculature, could not functionally substitute for sACE.	Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Cleveland Clin, Cole Eye Inst, Dept Ophthalm Res, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Senanayake, PD (corresponding author), Lerner Res Inst, Dept Mol Genet, NE20,9500 Euclid Ave, Cleveland, OH 44195 USA.	seng@ccf.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48258] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balyasnikova IV, 2003, TISSUE ANTIGENS, V61, P49, DOI 10.1034/j.1399-0039.2003.610104.x; BERG T, 1986, J HISTOCHEM CYTOCHEM, V34, P753, DOI 10.1177/34.6.3009604; BRUNEVAL P, 1986, HISTOCHEMISTRY, V85, P73, DOI 10.1007/BF00508656; CALDWELL PRB, 1976, SCIENCE, V191, P1050, DOI 10.1126/science.175444; Corradi HR, 2006, J MOL BIOL, V357, P964, DOI 10.1016/j.jmb.2006.01.048; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; Esther CR, 1996, LAB INVEST, V74, P953; FRIEDLAND J, 1978, BIOCHEM BIOPH RES CO, V83, P843, DOI 10.1016/0006-291X(78)91471-7; Fuchs S, 2005, NAT MED, V11, P1140, DOI 10.1038/nm1105-1140; Houard X, 1998, EUR J BIOCHEM, V257, P599, DOI 10.1046/j.1432-1327.1998.2570599.x; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; Isaac RE, 1997, BIOCHEM J, V328, P587, DOI 10.1042/bj3280587; JASPARD E, 1995, BIOCHEM BIOPH RES CO, V211, P528, DOI 10.1006/bbrc.1995.1845; Kessler SP, 2000, J BIOL CHEM, V275, P26259, DOI 10.1074/jbc.M004006200; Kessler SP, 2003, J BIOL CHEM, V278, P21105, DOI 10.1074/jbc.M3023472000; Kessler SP, 2002, J BIOL CHEM, V277, P4271, DOI 10.1074/jbc.M109474200; Kondoh G, 2005, NAT MED, V11, P160, DOI 10.1038/nm1179; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; LANGFORD KG, 1993, BIOL REPROD, V48, P1210, DOI 10.1095/biolreprod48.6.1210; Leisle L, 2005, NAT MED, V11, P1139, DOI 10.1038/nm1105-1139; Meier Pascal, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P15, DOI 10.2174/1568006053004994; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Natesh R, 2004, BIOCHEMISTRY-US, V43, P8718, DOI 10.1021/bi049480n; Ramaraj P, 1998, J CLIN INVEST, V102, P371, DOI 10.1172/JCI3545; ROUSSEAU A, 1995, J BIOL CHEM, V270, P3656, DOI 10.1074/jbc.270.8.3656; SAAVEDRA JM, 1982, NEUROSCI LETT, V29, P123, DOI 10.1016/0304-3940(82)90340-8; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; Safer R. L., 1981, BIOCH REGULATION BLO, P123; Santhamma KR, 2004, J BIOL CHEM, V279, P40227, DOI 10.1074/jbc.M407176200; SEN I, 1991, J BIOL CHEM, V266, P21985; Senanayake PD, 1998, PEPTIDES, V19, P1685, DOI 10.1016/S0196-9781(98)00123-5; SIBONY M, 1993, HYPERTENSION, V21, P827, DOI 10.1161/01.HYP.21.6.827; van Esch JHM, 2005, HYPERTENSION, V45, P120, DOI 10.1161/01.HYP.0000151323.93372.f5; WILLIAMS TA, 1992, BIOCHEM J, V288, P875, DOI 10.1042/bj2880875	37	3	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2007	21	1					156	166		10.1096/fj.06-6678com	http://dx.doi.org/10.1096/fj.06-6678com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135368				2022-12-28	WOS:000243130200017
J	Liu, L; Liu, HZ; Visner, G; Fletcher, BS				Liu, Li; Liu, Hanzhong; Visner, Gary; Fletcher, Bradley S.			Sleeping Beauty-mediated eNOS gene therapy attenuates monocrotaline-induced pulmonary hypertension in rats	FASEB JOURNAL			English	Article						NOS; vasculature; remodeling; transposon	NITRIC-OXIDE SYNTHASE; LONG-TERM EXPRESSION; SMOOTH-MUSCLE-CELLS; IN-VIVO; TRANSPOSON SYSTEM; ARTERIAL-HYPERTENSION; HEMOPHILIC MICE; VIRAL VECTORS; LUNG; NO	Pulmonary hypertension (PH) is a life-threatening disorder with high mortality rates and limited treatment options. Gene therapy is an alternative treatment strategy, yet viral vectors have inherent disadvantages including immune activation. The Sleeping Beauty (SB) transposon is a nonviral method of gene delivery that overcomes some of these drawbacks. A SB-based transposon harboring a constitutively active endothelial nitric oxide synthase (eNOS) gene was administered to Sprague-Dawley rats via tail vein injection using the carrier polyethylenimine. Two days after transposon delivery, monocrotaline (MCT) was administered to induce PH. Hemodynamic, histological, and molecular measurements were performed four weeks later. Animals coinjected with transposase showed a significant reduction in pulmonary arterial pressure (PABP, 31.67 +/- 6.03 mmHg, P < 0.01), an attenuation of right ventricle (RV) to whole heart (WH) wt ratios (0.227 +/- 0.0252, P < 0.05) and a decrease in the pulmonary vessel wall thickness index (36.87%, P < 0.001), compared with those animals receiving the eNOS transposon and a nonfunctional transposase (PABP 44.33 +/- 4.04 mmHg; RV/WH ratio 0.280 +/- 0.01; wall thickness index 62.14%) or control animals receiving MCT injection alone (PABP 49.67 +/- 3.22 mmHg; RV/WH ratio 0.290 +/- 0.0265; wall thickness index 71.99%). The physiological improvements correlated with therapeutic gene expression, suggesting that transposon-based genetic approaches have utility in the treatment of PH.	Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA; Med Res Serv, Dept Vet Affairs Med Ctr, Gainesville, FL USA	State University System of Florida; University of Florida; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Fletcher, BS (corresponding author), Univ Florida, Coll Med, Dept Pharmacol & Therapeut, 1600 SW Archer Rd,Box 100267, Gainesville, FL 32610 USA.	bsf@pharmacology.ufl.edu						Baus J, 2005, MOL THER, V12, P1148, DOI 10.1016/j.ymthe.2005.06.484; Belur LR, 2003, MOL THER, V8, P501, DOI 10.1016/S1525-0016(03)00211-9; Budts W, 2000, CIRCULATION, V102, P2880; Campbell AIM, 2001, CIRCULATION, V104, P2242, DOI 10.1161/hc4201.097838; Champion HC, 1999, CIRC RES, V84, P1422; Champion HC, 2000, CIRCULATION, V101, P923, DOI 10.1161/01.CIR.101.8.923; Champion HC, 2002, P NATL ACAD SCI USA, V99, P13248, DOI 10.1073/pnas.182225899; Chen LH, 1998, CIRC RES, V82, P862; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dupuy AJ, 2002, P NATL ACAD SCI USA, V99, P4495, DOI 10.1073/pnas.062630599; Galie N, 2004, CARDIOVASC RES, V61, P227, DOI 10.1016/j.cardiores.2003.11.026; Galie Nazzareno, 2003, Am J Respir Med, V2, P123; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Gong FQ, 2005, PEDIATR INT, V47, P242, DOI 10.1111/j.1442-200x.2005.02060.x; Goula D, 2000, GENE THER, V7, P499, DOI 10.1038/sj.gt.3301113; Goula D, 1998, GENE THER, V5, P1291, DOI 10.1038/sj.gt.3300717; Guignabert C, 2005, CIRCULATION, V111, P2812, DOI 10.1161/CIRCULATIONAHA.104.524926; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Hampl V, 2000, PHYSIOL REV, V80, P1337, DOI 10.1152/physrev.2000.80.4.1337; Ichinose F, 2004, CIRCULATION, V109, P3106, DOI 10.1161/01.CIR.0000134595.80170.62; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324; KOUYOUMDJIAN C, 1994, J CLIN INVEST, V94, P578, DOI 10.1172/JCI117372; Liu L, 2004, MOL THER, V10, P97, DOI 10.1016/j.ymthe.2004.04.006; LIU L, 2006, MOL THER, V3, P3; Louzier V, 2001, HUM GENE THER, V12, P503, DOI 10.1089/104303401300042401; Machado RD, 2001, AM J HUM GENET, V68, P92, DOI 10.1086/316947; Michelakis EA, 2003, HEART FAIL REV, V8, P5, DOI 10.1023/A:1022150819223; MILLER OI, 1995, LANCET, V346, P51, DOI 10.1016/S0140-6736(95)92681-X; Montini E, 2002, MOL THER, V6, P759, DOI 10.1006/mthe.2002.0812; Niidome T, 2002, GENE THER, V9, P1647, DOI 10.1038/sj.gt.3301923; Ohana P., 2004, GENE THER MOL BIOL, V8, P181; Ohlfest JR, 2005, BLOOD, V105, P2691, DOI 10.1182/blood-2004-09-3496; Partovian C, 2000, AM J RESP CELL MOL, V23, P762, DOI 10.1165/ajrcmb.23.6.4106; Patel JM, 1996, AM J RESP CELL MOL, V15, P410, DOI 10.1165/ajrcmb.15.3.8810647; Pilane CM, 2004, J CELL PHYSIOL, V199, P310, DOI 10.1002/jcp.10464; Roberts JD, 2000, CIRC RES, V87, P140, DOI 10.1161/01.RES.87.2.140; Rudolph C, 2000, J GENE MED, V2, P269, DOI 10.1002/1521-2254(200007/08)2:4<269::AID-JGM112>3.0.CO;2-F; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Strange JW, 2002, CLIN SCI, V102, P253, DOI 10.1042/CS20010212; Tahara N, 2004, HUM GENE THER, V15, P1270, DOI 10.1089/hum.2004.15.1270; Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066; Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001; Tyler RC, 1999, AM J PHYSIOL-LUNG C, V276, pL297, DOI 10.1152/ajplung.1999.276.2.L297; von der Leyen HE, 2001, CIRCULATION, V103, P2760; Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Yew NS, 2002, MOL THER, V5, P731, DOI 10.1006/mthe.2002.0598; Zhao YD, 2003, CIRC RES, V92, P984, DOI 10.1161/01.RES.0000070587.79937.F0; ZHAO YD, 2006, AM J RESP CELL MOL B, V16, P16; Zhou HL, 2006, LAB INVEST, V86, P62, DOI 10.1038/labinvest.3700361	52	48	51	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2594	+		10.1096/fj.06-6254fje	http://dx.doi.org/10.1096/fj.06-6254fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065228				2022-12-28	WOS:000242490700035
J	Cottet, S; Michaut, L; Boisset, G; Schlecht, U; Gehring, W; Schorderet, DF				Cottet, Sandra; Michaut, Lydia; Boisset, Gaeelle; Schlecht, Ulrich; Gehring, Walter; Schorderet, Daniel F.			Biological characterization of gene response in Rpe65(-/-) mouse model of Leber's congenital amaurosis during progression of the disease	FASEB JOURNAL			English	Article						microarray; LCA; apoptosis	ALPHA-B-CRYSTALLIN; RETINAL-PIGMENT EPITHELIUM; HEAT-SHOCK-PROTEIN; A-CRYSTALLIN; PROTECTIVE ACTIVITY; BINDING-PROTEIN; DOWN-REGULATION; VISUAL-PIGMENT; MESSENGER-RNA; VITAMIN-A	RPE65 is the retinal isomerase essential for conversion of all-trans-retinyl ester to 11-cis-retinol in the visual cycle. Leber's congenital amaurosis (LCA), an autosomal recessive form of RP resulting in blindness, is commonly caused by mutations in the Rpe65 gene. Whereas the molecular mechanisms by which these mutations contribute to retinal disease remain largely unresolved, affected patients show marked RPE damage and photoreceptor degeneration. We evaluated gene expression in Rpe65(-/-) mouse model of LCA before and at the onset of photoreceptor cell death in 2, 4, and 6 month old animals. Microarray analysis demonstrates altered expression of genes involved in phototransduction, apoptosis regulation, cytoskeleton organization, and extracellular matrix (ECM) constituents. Cone-specific phototransduction genes are strongly decreased, reflecting early loss of cones. In addition, remaining rods show modified expression of genes encoding components of the cytoskeleton and ECM. This may affect rod physiology and interaction with the adjacent RPE and lead to loss of survival signals, as reflected by the alteration of apoptosis-related genes Together, these results suggest that RPE65 defect triggers an overall remodeling of the neurosensitive retina that may, in turn, disrupt photoreceptor homeostasis and induce apoptosis signaling cascade toward retinal cell death.	Inst Res Ophthalmol, Sion, Switzerland; Univ Basel, Biozentrum, Basel, Switzerland; Univ Lausanne, Lausanne, Switzerland; Ecole Polytech Fed Lausanne, Lausanne, Switzerland	University of Basel; University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Cottet, S (corresponding author), Av Grand Champsec 64, CH-1950 Sion 4, Switzerland.	sandra.cottet@iro.vsnet.ch						Ablonczy Z, 2002, J BIOL CHEM, V277, P40491, DOI 10.1074/jbc.M205507200; Acharya S, 1998, J BIOL CHEM, V273, P31599, DOI 10.1074/jbc.273.47.31599; Aguirre G D, 1998, Mol Vis, V4, P23; ANDERSON DH, 1986, INVEST OPHTH VIS SCI, V27, P168; Andley UP, 2000, J BIOL CHEM, V275, P36823, DOI 10.1074/jbc.M004233200; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Cavusoglu N, 2003, MOL CELL PROTEOMICS, V2, P494, DOI 10.1074/mcp.M300029-MCP200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; D'Alessio G, 2002, EUR J BIOCHEM, V269, P3122, DOI 10.1046/j.1432-1033.2002.03004.x; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DERETIC D, 1994, J BIOL CHEM, V269, P16853; Dirks RPH, 1998, EXP EYE RES, V66, P267, DOI 10.1006/exer.1997.0439; DOW KE, 1994, EXP NEUROL, V128, P233, DOI 10.1006/exnr.1994.1132; Dufour EM, 2003, NEUROBIOL DIS, V14, P166, DOI 10.1016/S0969-9961(03)00102-5; Eckmiller MS, 2004, PROG RETIN EYE RES, V23, P495, DOI 10.1016/j.preteyeres.2004.04.005; Eckmiller MS, 1998, ACTA ANAT, V162, P133; El Matri L, 2006, GRAEF ARCH CLIN EXP, V244, P1104, DOI 10.1007/s00417-005-0096-2; Felbor U, 1998, CYTOGENET CELL GENET, V81, P12, DOI 10.1159/000015001; FITZGERALD PG, 1991, CURR EYE RES, V10, P417, DOI 10.3109/02713689109001750; FUKUCHI T, 1994, EXP EYE RES, V58, P231, DOI 10.1006/exer.1994.1012; Galvin JA, 2005, OPHTHALMOLOGY, V112, P349, DOI 10.1016/j.ophtha.2004.08.023; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P11824, DOI 10.1021/bi035227w; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Hanein S, 2004, HUM MUTAT, V23, P306, DOI 10.1002/humu.20010; Hasson T, 1999, CURR BIOL, V9, pR838, DOI 10.1016/S0960-9822(00)80040-8; HEAD MW, 1995, EXP EYE RES, V61, P423, DOI 10.1016/S0014-4835(05)80137-X; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hollyfield JG, 1999, INVEST OPHTH VIS SCI, V40, P2767; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Inatani M, 2002, PROG RETIN EYE RES, V21, P429, DOI 10.1016/S1350-9462(02)00009-5; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Johnson EC, 1996, EXP EYE RES, V62, P663, DOI 10.1006/exer.1996.0077; Jones SE, 1999, INVEST OPHTH VIS SCI, V40, P3017; Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; Kapphahn RJ, 2003, BIOCHEMISTRY-US, V42, P15310, DOI 10.1021/bi034774e; Kelsell RE, 1998, AM J HUM GENET, V63, P274, DOI 10.1086/301905; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Kusaka S, 1998, JPN J OPHTHALMOL, V42, P218, DOI 10.1016/S0021-5155(97)00136-6; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; LIEM ATA, 1994, OPHTHALMOLOGY, V101, P1945; Lorenz B, 2000, INVEST OPHTH VIS SCI, V41, P2735; Magabo KS, 2000, INVEST OPHTH VIS SCI, V41, P3056; Manes G, 1998, FEBS LETT, V423, P133, DOI 10.1016/S0014-5793(98)00081-7; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200; Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Narfstrom K., 1999, Veterinary Ophthalmology, V2, P75; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; Porto FBO, 2002, J GENE MED, V4, P390, DOI 10.1002/jgm.278; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Sakaguchi H, 2003, EXP EYE RES, V76, P131, DOI 10.1016/S0014-4835(02)00249-X; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; Selles-Navarro I, 2001, EXP NEUROL, V167, P282, DOI 10.1006/exnr.2000.7573; Sinha D, 1998, Mol Vis, V4, P8; Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Williams DS, 2002, VISION RES, V42, P455, DOI 10.1016/S0042-6989(01)00228-0; Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246; WRIGSTAD A, 1992, EXP EYE RES, V55, P805, DOI 10.1016/0014-4835(92)90007-F; Xi JH, 2003, MOL VIS, V9, P410; Xue LL, 2004, CELL, V117, P761, DOI 10.1016/j.cell.2004.05.016; Yoshimura N, 2003, INVEST OPHTH VIS SCI, V44, P2211, DOI 10.1167/iovs.02-0704; Znoiko SL, 2005, INVEST OPHTH VIS SCI, V46, P1473, DOI 10.1167/iovs.04-0653; Znoiko SL, 2002, INVEST OPHTH VIS SCI, V43, P1604	84	38	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2036	2049		10.1096/fj.06-6211com	http://dx.doi.org/10.1096/fj.06-6211com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012256				2022-12-28	WOS:000241156900012
J	Arad, S; Konnikov, N; Goukassian, DA; Gilchrest, BA				Arad, Simin; Konnikov, Nellie; Goukassian, David A.; Gilchrest, Barbara A.			T-oligos augment UV-induced protective responses in human skin	FASEB JOURNAL			English	Article						NER; oligonucleotides; melanin content; CPD	DNA-REPAIR CAPACITY; TRANSCRIPTION-COUPLED REPAIR; P53 MUTATIONS; 6-4 PHOTOPRODUCTS; HUMAN MELANOCYTES; CELL CARCINOMA; DAMAGE; MELANOGENESIS; CANCER; GENE	We have shown that DNA oligonucleotides substantially homologous to the telomere 3-prime overhang sequence (T-oligos) increase DNA repair capacity (DRC) in cultured human cells and decrease UV-induced mutation rate and photocarcinogenesis in mouse skin. To investigate the protective effects of T-oligos in intact human skin, paired skin explants obtained from adult donors were treated with T-oligos or diluent alone for 24 h, then UVB-or sham-irradiated, and processed after 6, 24, 48, 72, and 96 h for histological analysis. After UV irradiation apoptotic epidermal cells were comparable in diluent-and T-oligo-treated skin. Proliferating (Ki67+) cells were sparse in sham-irradiated skin and for 24 h after UV in both diluent-and T-oligo-treated specimens. However, compared to diluent controls, at 48 and 72 h T-oligos significantly inhibited UV-induced rebound hyperproliferation. Maximum and comparable cyclobutane pyrimidine dimers (CPDs) were detected immediately after UV irradiation in diluent- and T-oligo-treated skin, but CPDs were strikingly reduced in T-oligo-vs. diluent-treated skin at 24, 48, and 72 h. Total and activated p53 protein was increased in T-oligo-vs. diluent-pretreated skin at the time of irradiation, and up to 3-fold increases persisted for 24 h post-UV. Over 5 days, UV irradiation and T-oligo comparably increased expression of melanogenic proteins and each increased epidermal melanin content 3-to 5-fold, with distinct nuclear capping in many keratinocytes. In combination, these findings predict that T-oligo treatment will increase melanogenesis, prolong epidermal arrest, and increase DNA repair rate after UV irradiation, thus decreasing the severity of acute and chronic photodamage in human skin. Moreover, the data document an inducible SOS-like response consisting of increased melanogenesis and increased DNA repair capacity in human skin following UV-induced damage that is also produced by T-oligos in the absence of initial damage.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Goukassian, DA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.	dgoukass@bu.edu; bgilchre@bu.edu		Goukassian, David/0000-0001-5270-5270	NCI NIH HHS [R0I CA 10515-02] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baba T, 1996, J DERMATOL SCI, V12, P18, DOI 10.1016/0923-1811(95)00452-1; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bhawan J, 1999, AM J DERMATOPATH, V21, P225, DOI 10.1097/00000372-199906000-00003; BOHR VA, 1995, MUTAT RES-DNAGING G, V338, P25, DOI 10.1016/0921-8734(95)00008-T; Botchkareva NV, 2001, FASEB J, V15, P645, DOI 10.1096/fj.00-0368com; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Bykov VJ, 2000, J INVEST DERMATOL, V114, P40, DOI 10.1046/j.1523-1747.2000.00821.x; CARR AH, 1995, TRENDS CELL BIOL, P32; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; Coultas L, 2000, APOPTOSIS, V5, P491, DOI 10.1023/A:1009617727938; Cruz PD, 2000, J INVEST DERMATOL, V114, P253, DOI 10.1046/j.1523-1747.2000.00866.x; Drouin R, 1997, PHOTOCHEM PHOTOBIOL, V66, P719, DOI 10.1111/j.1751-1097.1997.tb03213.x; Einspahr JG, 2003, RECENT RESULTS CANC, V163, P151; Eller MS, 2003, FASEB J, V17, P152, DOI 10.1096/fj.02-0197com; Eller MS, 2002, EXP CELL RES, V276, P185, DOI 10.1006/excr.2002.5531; ELLER MS, 1994, NATURE, V372, P413, DOI 10.1038/372413a0; Eller MS, 1996, P NATL ACAD SCI USA, V93, P1087, DOI 10.1073/pnas.93.3.1087; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; FITZPATRICK TB, 2003, FITZPATRICKS DERMATO, P819; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Francis MA, 1999, CARCINOGENESIS, V20, P19, DOI 10.1093/carcin/20.1.19; FREEDBERG IM, 1999, FITZPATRICKS DERMATO, P1555; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gilchrest BA, 1999, J INVEST DERM SYMP P, V4, P35, DOI 10.1038/sj.jidsp.5640178; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; Gilchrest BA, 1997, FASEB J, V11, P322, DOI 10.1096/fasebj.11.5.9141498; Goukassian D, 2000, FASEB J, V14, P1325, DOI 10.1096/fj.14.10.1325; Goukassian DA, 2004, P NATL ACAD SCI USA, V101, P3933, DOI 10.1073/pnas.0306389101; Goukassian DA, 2002, FASEB J, V16, P754, DOI 10.1096/fj.01-0829fje; Grossman D, 1997, ARCH DERMATOL, V133, P1263, DOI 10.1001/archderm.133.10.1263; Hadshiew IM, 2001, J DERMATOL SCI, V25, P127, DOI 10.1016/S0923-1811(00)00125-0; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Khlgatian MK, 2002, J INVEST DERMATOL, V118, P126, DOI 10.1046/j.0022-202x.2001.01667.x; LANE DP, 1992, NATURE, V358, P16; Li GZ, 2003, P NATL ACAD SCI USA, V100, P527, DOI 10.1073/pnas.0235444100; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MARWAHA V, 2005, J BIOL CHEM; Moriwaki SI, 1996, MUTAT RES-DNA REPAIR, V364, P117, DOI 10.1016/0921-8777(96)00029-8; Nylander K, 2000, J PATHOL, V190, P39, DOI 10.1002/(SICI)1096-9896(200001)190:1<39::AID-PATH492>3.0.CO;2-V; OLSEN WM, 1990, J INVEST DERMATOL, V94, P101, DOI 10.1111/1523-1747.ep12873961; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; Perkins JL, 2005, J CLIN ONCOL, V23, P3733, DOI 10.1200/JCO.2005.06.237; Petrocelli T, 1996, ONCOGENE, V12, P1387; Puri N, 2004, FASEB J, V18, P1373, DOI 10.1096/fj.04-1774com; Radman M, 1975, Basic Life Sci, V5A, P355; RADMAN M, 1970, J MOL BIOL, V49, P203, DOI 10.1016/0022-2836(70)90386-4; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; Smit NPM, 2001, PHOTOCHEM PHOTOBIOL, V74, P424, DOI 10.1562/0031-8655(2001)074<0424:MOPAIO>2.0.CO;2; Spatz A, 2001, CANCER RES, V61, P2480; Tadokoro T, 2005, J INVEST DERMATOL, V124, P1326, DOI 10.1111/j.0022-202X.2005.23760.x; WALKER SL, 2003, DERMATOLOGY GEN MED, P1275; WEI QY, 1995, J INVEST DERMATOL, V104, P933, DOI 10.1111/1523-1747.ep12606207; WEI Z, 1993, P NATL ACAD SCI USA, V90, P1614; WERNINGHAUS K, 1991, PHOTODERMATOL PHOTO, V8, P236; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Young AR, 1996, J INVEST DERMATOL, V106, P1307, DOI 10.1111/1523-1747.ep12349031; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	60	47	49	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1895	+		10.1096/fj.06-5964fje	http://dx.doi.org/10.1096/fj.06-5964fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877521				2022-12-28	WOS:000240267000022
J	Broderick, KE; Feala, J; McCulloch, A; Paternostro, G; Sharma, VS; Pilz, RB; Boss, GR				Broderick, Kate E.; Feala, Jake; McCulloch, Andrew; Paternostro, Giovanni; Sharma, Vijay S.; Pilz, Renate B.; Boss, Gerry R.			The nitric oxide scavenger cobinamide profoundly improves survival in a Drosophila melanogaster model of bacterial sepsis	FASEB JOURNAL			English	Article						septic shock; cobalamin; cardiac function	IMMUNE-DEFICIENCY IMD; COBALAMIN ANALOGS; ANTIBACTERIAL DEFENSE; INDUCED HYPOTENSION; SYNTHASE ACTIVITY; INHIBITION; SYSTEM; HOST; DYSFUNCTION; MECHANISMS	Septic shock has an extremely high mortality rate, with similar to 200,000 people dying from sepsis annually in the U. S. The high mortality results in part from severe hypotension secondary to high serum NO concentrations. Reducing NO levels should be beneficial in sepsis, but NOS inhibitors have had a checkered history in animal models, and one such agent increased mortality in a clinical trial. An alternative approach to reduce NO levels in sepsis is to use an NO scavenger, which should leave sufficient free NO for normal physiological functions. Using a well-established model of bacterial sepsis in Drosophila melanogaster, we found that cobinamide, a B-12 analog and an effective NO scavenger in vitro, dramatically improved fly survival. Cobinamide augmented the effect of an antibiotic and was beneficial even in immune-deficient flies. Cobinamide's mechanism of action appeared to be from reducing NO levels and improving cardiac function. Broderick, K. E., Feala, J., McCulloch, A., Paternostro, G., Sharma, V. S., Pilz, R. B., Boss, G. R. The nitric oxide scavenger cobinamide profoundly improves survival in a Drosophila melanogaster model of bacterial sepsis.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Burnham Inst Med Res, La Jolla, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gboss@ucsd.edu		Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [R01CA090932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051300] Funding Source: NIH RePORTER; NCI NIH HHS [CA90932] Funding Source: Medline; NIAMS NIH HHS [AR051300] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aboy M, 2005, IEEE T BIO-MED ENG, V52, P1662, DOI 10.1109/TBME.2005.855725; Agrawal N, 2005, P NATL ACAD SCI USA, V102, P3777, DOI 10.1073/pnas.0500055102; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bier E, 2004, GENE, V342, P1, DOI 10.1016/j.gene.2004.07.018; BOMAN HG, 1972, NATURE, V237, P232, DOI 10.1038/237232a0; Broderick KE, 2005, J BIOL CHEM, V280, P8678, DOI 10.1074/jbc.M410498200; CLANCY RM, 1995, P SOC EXP BIOL MED, V210, P93; COATES ME, 1956, BIOCHEM J, V64, P682, DOI 10.1042/bj0640682; COBB JP, 1992, J EXP MED, V176, P1175, DOI 10.1084/jem.176.4.1175; Danishpajooh IO, 2001, J BIOL CHEM, V276, P27296, DOI 10.1074/jbc.M104043200; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; Fedosov SN, 2002, J BIOL CHEM, V277, P9989, DOI 10.1074/jbc.M111399200; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Gonzalez BE, 2003, J PERINAT MED, V31, P60, DOI 10.1515/JPM.2003.009; GREENBERG SS, 1995, J PHARMACOL EXP THER, V273, P257; Heneka MT, 1997, J CLIN INVEST, V99, P47, DOI 10.1172/JCI119132; Ichinose F, 2003, AM J PHYSIOL-HEART C, V285, pH2524, DOI 10.1152/ajpheart.00530.2003; Johnson E, 2002, J COMP PHYSIOL B, V172, P227, DOI 10.1007/s00360-001-0246-8; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; Kim HW, 2002, SHOCK, V17, P423, DOI 10.1097/00024382-200205000-00014; KOLHOUSE JF, 1978, NEW ENGL J MED, V299, P785, DOI 10.1056/NEJM197810122991501; KOLHOUSE JF, 1977, J CLIN INVEST, V60, P1381, DOI 10.1172/JCI108899; KONDO H, 1980, P NATL ACAD SCI-BIOL, V77, P817, DOI 10.1073/pnas.77.2.817; KONDO H, 1992, INT J HEMATOL, V56, P167; KONDO H, 1982, J CLIN INVEST, V70, P889, DOI 10.1172/JCI110685; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; Marshall JC, 2003, NAT REV DRUG DISCOV, V2, P391, DOI 10.1038/nrd1084; McGettigan J, 2005, INSECT BIOCHEM MOLEC, V35, P741, DOI 10.1016/j.ibmb.2005.02.017; Miller A., 1950, BIOL DROSOPHILA, P420; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Needham AJ, 2004, MICROBIOL-SGM, V150, P2347, DOI 10.1099/mic.0.27116-0; Paternostro G, 2001, CIRC RES, V88, P1053, DOI 10.1161/hh1001.090857; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; Poon BY, 2003, CIRCULATION, V108, P1107, DOI 10.1161/01.CIR.0000086321.04702.AC; Price S, 2003, EUR J PHARMACOL, V472, P111, DOI 10.1016/S0014-2999(03)01826-0; Regulski M, 2004, CURR BIOL, V14, pR881, DOI 10.1016/j.cub.2004.09.068; Sharma VS, 2003, BIOCHEMISTRY-US, V42, P8900, DOI 10.1021/bi034469t; SPAIN DA, 1994, J TRAUMA, V36, P720, DOI 10.1097/00005373-199405000-00021; STABLER SP, 1991, J CLIN INVEST, V87, P1422, DOI 10.1172/JCI115148; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; Tickoo S, 2002, CURR OPIN PHARMACOL, V2, P555, DOI 10.1016/S1471-4892(02)00206-0; Vincent JL, 2000, AM J RESP CRIT CARE, V161, P1781, DOI 10.1164/ajrccm.161.6.9812004; Weinberg JB, 1998, BIOCHEM BIOPH RES CO, V246, P393, DOI 10.1006/bbrc.1998.8629; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48	47	26	26	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1865	1873		10.1096/fj.06-5780com	http://dx.doi.org/10.1096/fj.06-5780com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940158				2022-12-28	WOS:000240267000014
J	Moffatt, JD; Lever, R; Page, CP				Moffatt, James D.; Lever, Rebecca; Page, Clive P.			Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice	FASEB JOURNAL			English	Article						urocortin; airway; neutrophil; smooth muscle; epithelium	MOUSE ISOLATED TRACHEA; EPITHELIUM; PEPTIDE; RELAXATION; LIGANDS; HYPERREACTIVITY; UROCORTIN-2; ENDOTOXIN; AIRWAYS; FAMILY	Urocortins are members of the corticotropin-releasing factor (CRF) family of peptides that bind to two receptors, CRF1 and CRF2. While CRF1 is a high-affinity receptor for CRF, urocortin III binds with much greater affinity to CRF2. In the present study we investigated the effect of CRF2 receptor activation with urocortin III on airway smooth muscle tone in vitro and in an acute model of airway inflammation in mice. Urocortin III caused relaxation of methacholine-precontracted mouse tracheal segments. CRF caused similar relaxation, but with reduced potency compared to urocortin III, consistent with the CRF2 receptor subtype. Relaxation induced by urocortin III was concentration-dependently inhibited by the CRF2 antagonist, astressin 2B, with an IC50 in the nanomolar range. These relaxations were potentiated by inhibition of phosphodiesterases but unaffected by inhibition of cyclooxygenase and NO or by removal of the epithelium. Finally, the number of neutrophils retrieved by bronchoalveolar lavage after administration of bacterial LPS (LPS) was reduced by prior intraperitoneal (i. p.) injection of urocortin III. This effect was also suppressed by astressin 2B, implicating CRF2 receptors. Therefore, CRF2 agonists appear to have both bronchorelaxant and anti-inflammatory activities and might represent an interesting therapeutic approach to the treatment of inflammatory lung diseases.-Moffatt, J. D., Lever, R., Page, C. P. Activation of corticotropinreleasing factor receptor-2 (CRF2) causes bronchorelaxation and inhibits pulmonary inflammation in mice.	Kings Coll London, Sackler Inst Pulm Pharmacol, London SE1 1UL, England; Univ London, Sch Pharm, London WC1N 1AX, England	University of London; King's College London; University of London; University College London; University of London School of Pharmacy	Moffatt, JD (corresponding author), Kings Coll London, Sackler Inst Pulm Pharmacol, 5th Floor,Hodgkin Bldg,Guys Campus, London SE1 1UL, England.	james.moffatt@kcl.ac.uk		Page, Clive Peter/0000-0002-9358-3799				AGNELLO D, 1998, AM J PHYSIOL, V275, pF757; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Dautzenberg FM, 2002, TRENDS PHARMACOL SCI, V23, P71, DOI 10.1016/S0165-6147(02)01946-6; Deleuze V, 2004, AM J PHYSIOL-LUNG C, V286, pL98, DOI 10.1152/ajplung.00053.2003; deMoraes VLG, 1996, BRIT J PHARMACOL, V117, P1792; Hauger RL, 2003, PHARMACOL REV, V55, P21, DOI 10.1124/pr.55.1.3; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; Kao J, 1999, AM J PHYSIOL-LUNG C, V277, pL264, DOI 10.1152/ajplung.1999.277.2.L264; KNOWLES MR, 1995, AM J RESP CRIT CARE, V151, pS65, DOI 10.1164/ajrccm/151.3_Pt_2.S65; Kornerup KN, 2005, BRIT J PHARMACOL, V144, P1011, DOI 10.1038/sj.bjp.0706133; la Fleur SE, 2005, P NATL ACAD SCI USA, V102, P7647, DOI 10.1073/pnas.0408531102; Lan RS, 2001, BRIT J PHARMACOL, V132, P93, DOI 10.1038/sj.bjp.0703776; Lefort J, 2001, AM J RESP CELL MOL, V24, P345, DOI 10.1165/ajrcmb.24.3.4289; Lefort J, 1998, J IMMUNOL, V161, P474; Lewis K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/pnas.121165198; Moffatt JD, 2004, BRIT J PHARMACOL, V141, P1159, DOI 10.1038/sj.bjp.0705720; Moffatt JD, 2002, AM J RESP CELL MOL, V26, P680, DOI 10.1165/ajrcmb.26.6.4693; Porcher C, 2005, AM J PHYSIOL-GASTR L, V288, pG1091, DOI 10.1152/ajpgi.00302.2004; Rivier J, 2002, J MED CHEM, V45, P4737, DOI 10.1021/jm0202122; Sashinami H, 2005, ENDOCRINOLOGY, V146, P5003, DOI 10.1210/en.2005-0439; Schlemper V, 2005, BRIT J PHARMACOL, V145, P740, DOI 10.1038/sj.bjp.0706222; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; Suda T, 2004, PEPTIDES, V25, P1689, DOI 10.1016/j.peptides.2004.03.027; Wiley KE, 2004, BRIT J PHARMACOL, V143, P508, DOI 10.1038/sj.bjp.0705985	24	21	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1877	+		10.1096/fj.05-5315fje	http://dx.doi.org/10.1096/fj.05-5315fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16855006				2022-12-28	WOS:000240267000016
J	Barre, L; Venkatesan, N; Magdalou, J; Netter, P; Fournel-Gigleux, S; Ouzzine, M				Barre, Lydia; Venkatesan, Narayanan; Magdalou, Jacques; Netter, Patrick; Fournel-Gigleux, Sylvie; Ouzzine, Mohamed			Evidence of calcium-dependent pathway in the regulation of human beta 1,3-glucuronosyltransferase-1 (GlcAT-I) gene expression: a key enzyme in proteoglycan synthesis	FASEB JOURNAL			English	Article						glycosyltransferase; glycosaminoglycan; promoter activation	HEPARAN-SULFATE PROTEOGLYCANS; GRANULOSA-CELLS INVITRO; GLUCURONOSYLTRANSFERASE-I; CAENORHABDITIS-ELEGANS; ENDOPLASMIC-RETICULUM; SIGNAL SEQUENCE; MOLECULAR-BASIS; SP1 BINDING; DNA-BINDING; TRANSCRIPTION	The importance of heparan-and chondroitinsulfate proteoglycans in physiological and pathological processes led to the investigation of the regulation of beta 1,3-glucuronosyltransferase I (GlcAT-I), responsible for the completion of glycosaminoglycan-protein linkage tetrasaccharide, a key step prior to polymerization of chondroitin-and heparan-sulfate chains. We have cloned and functionally characterized GlcAT-I 5'-flanking regulatory region. Mutation analysis and electrophoretic mobility shift assays demonstrated the importance of Sp1 motif located at -65/-56 position in promoter activity. Furthermore, we found that elevation of intracellular calcium concentration by the calcium ionophore ionomycin stimulated GlcAT-I gene expression as well as glycosaminoglycan chain synthesis in HeLa cells. Bisanthracycline, an anti-Sp1 compound, inhibited GlcAT-I basal promoter activity and suppressed ionomycin induction, suggesting the importance of Sp1 in calcium induction of GlcAT-I gene expression. Nuclear protein extracts from ionomycin-induced cells exhibited an increased DNA binding of Sp1 factor to the consensus sequence at position -65/-56. Signaling pathway analysis and MEK inhibition studies revealed the important role of p42/p44 MAPK in the stimulation of GlcAT-I promoter activity by ionomycin. The present study identifies, for the first time, GlcAT-I as a target of calcium-dependent signaling pathway and evidences the critical role of Sp1 transcription factor in the activation of GlcAT-I expression.	Univ Nancy 1, CNRS, UMR 7561, Fac Med, F-54505 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Ouzzine, M (corresponding author), Univ Nancy 1, CNRS, UMR 7561, Fac Med, BP 184, F-54505 Vandoeuvre Les Nancy, France.	ouzzine@medecine.uhp-nancy.fr	Ouzzine, Mohamed/G-4368-2013	OUZZINE, Mohamed/0000-0003-0058-4950				Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; BELLIN ME, 1983, MOL CELL ENDOCRINOL, V29, P51, DOI 10.1016/0303-7207(83)90004-7; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; Bontemps Y, 2003, J BIOL CHEM, V278, P21566, DOI 10.1074/jbc.M209366200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chu SJ, 2005, GENE, V348, P1, DOI 10.1016/j.gene.2005.01.013; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Daidouji K, 2002, DIGEST DIS SCI, V47, P331, DOI 10.1023/A:1013718021713; DEVRIES BJ, 1986, RHEUMATOL INT, V6, P273, DOI 10.1007/BF00541319; DITTMER J, 1994, J BIOL CHEM, V269, P21428; Dittmer J, 2003, MOL CANCER, V2, P1; Fagnen G, 2000, J CELL BIOCHEM, V76, P322; Hapgood JP, 2001, CELL BIOL INT, V25, P17, DOI 10.1006/cbir.2000.0674; Heegaard AM, 2004, J CELL BIOCHEM, V93, P463, DOI 10.1002/jcb.20189; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Kang-Park S, 2001, BIOCHEM BIOPH RES CO, V283, P303, DOI 10.1006/bbrc.2001.4767; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 2001, BIOCHEM J, V358, P539, DOI 10.1042/0264-6021:3580539; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kopp JL, 2004, J BIOL CHEM, V279, P19407, DOI 10.1074/jbc.M314115200; LATTARD V, 2005, IN PRESS PROTEIN EXP; LENZ RW, 1982, ENDOCRINOLOGY, V110, P1052, DOI 10.1210/endo-110-3-1052; Martin B, 1999, NUCLEIC ACIDS RES, V27, P3402, DOI 10.1093/nar/27.17.3402; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; McCormick C, 1999, MOL MED TODAY, V5, P481, DOI 10.1016/S1357-4310(99)01593-2; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Mukaratirwa S, 2004, J COMP PATHOL, V131, P259, DOI 10.1016/j.jcpa.2004.04.007; Okajima T, 1999, J BIOL CHEM, V274, P28841, DOI 10.1074/jbc.274.41.28841; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Ouzzine M, 1999, FEBS LETT, V454, P187, DOI 10.1016/S0014-5793(99)00797-8; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Prydz K, 2000, J CELL SCI, V113, P193; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Valhmu WB, 1998, J BIOL CHEM, V273, P6196, DOI 10.1074/jbc.273.11.6196; VANDEWALLE B, 1994, J CANCER RES CLIN, V120, P389, DOI 10.1007/BF01240136; Venkatesan N, 2004, P NATL ACAD SCI USA, V101, P18087, DOI 10.1073/pnas.0404504102; Vijayagopal P, 2001, ATHEROSCLEROSIS, V157, P353, DOI 10.1016/S0021-9150(00)00742-5; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wegrowski Y, 2004, CRIT REV ONCOL HEMAT, V49, P259, DOI 10.1016/j.critrevonc.2003.10.005; Wendt CH, 2000, J BIOL CHEM, V275, P41396, DOI 10.1074/jbc.M004759200; Wight TN, 2004, CIRC RES, V94, P1158, DOI 10.1161/01.RES.0000126921.29919.51; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6; Zhuang Y, 2000, J BIOL CHEM, V275, P24173, DOI 10.1074/jbc.M002953200	54	19	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1692	+		10.1096/fj.05-5073fje	http://dx.doi.org/10.1096/fj.05-5073fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807373				2022-12-28	WOS:000240266600017
J	Jia, XM; Olson, DJH; Ross, ARS; Wu, LY				Jia, Xuming; Olson, Douglas J. H.; Ross, Andrew R. S.; Wu, Lingyun			Structural and functional changes in human insulin induced by methylglyoxal	FASEB JOURNAL			English	Article						MG-insulin adduct; mass spectrometry; glucose uptake; insulin release	GLYCATION END-PRODUCTS; RESISTANCE; PROTEINS; PREVENTION; GLUCOSE; OBESITY	Elevated methylglyoxal (MG) levels have been reported in insulin-resistance syndrome. The present study investigated whether MG, a highly reactive metabolite of glucose, induced structural and functional changes of insulin. Incubation of human insulin with MG in vitro yielded MG-insulin adducts, as evidenced by additional peaks observed on mass spectrometric (MS) analysis of the incubates. Tandem MS analysis of insulin B-chain adducts confirmed attachment of MG at an arginine residue. [H-3]-2-deoxyglucose uptake by 3T3-L1 adipocytes was significantly and concentration-dependently decreased after the treatment with MG-insulin adducts, in comparison with the effect of native insulin at the same concentrations. A significant decrease of glucose uptake induced by MG-insulin adducts was also observed in L8 skeletal muscle cells. MG alone had no effect on glucose uptake or the transcriptional expression of insulin receptor. Unlike native insulin, MG-insulin adducts did not inhibit insulin release from pancreatic beta-cells. The degradation of MG-insulin through liver cells was also decreased. In conclusion, MG modifies insulin by attaching to internal arginine residue in beta-chain of insulin. The formation of this MG-insulin adduct decreases insulin-mediated glucose uptake, impairs autocrine control of insulin secretion, and decreases insulin clearance. These structural and functional abnormalities of insulin molecule may contribute to the pathogenesis of insulin resistance.	Univ Saskatchewan, Coll Med, Dept Pharmacol, Saskatoon, SK S7N 5E5, Canada; Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada	University of Saskatchewan; National Research Council Canada	Wu, LY (corresponding author), Univ Saskatchewan, Coll Med, Dept Pharmacol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	liw070@duke.usask.ca						Ahmed N, 2002, BIOCHEM J, V364, P1; Alzaid AA, 1996, ACTA DIABETOL, V33, P87; Babaei-Jadidi R, 2003, DIABETES, V52, P2110, DOI 10.2337/diabetes.52.8.2110; Bradley M, 1999, Health Technol Assess, V3, P1; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; DEFRONZO RA, 1979, AM J PHYSIOL, V236, pE328, DOI 10.1152/ajpendo.1979.236.4.E328; Du J, 2003, J CELL BIOCHEM, V88, P1235, DOI 10.1002/jcb.10478; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; GORDEN P, 1978, SCIENCE, V200, P782, DOI 10.1126/science.644321; Iezzi M, 1999, MOL ENDOCRINOL, V13, P202, DOI 10.1210/me.13.2.202; Jana CK, 2002, ARCH BIOCHEM BIOPHYS, V397, P433, DOI 10.1006/abbi.2001.2690; Jones CNO, 2000, AM J PHYSIOL-ENDOC M, V278, pE501, DOI 10.1152/ajpendo.2000.278.3.E501; Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; Li YM, 1996, P NATL ACAD SCI USA, V93, P3902, DOI 10.1073/pnas.93.9.3902; LiCalzi S, 1997, AM J PHYSIOL-ENDOC M, V273, pE801, DOI 10.1152/ajpendo.1997.273.4.E801; LO TWC, 1994, J BIOL CHEM, V269, P32299; Mizutani K, 1999, J HYPERTENS, V17, P481, DOI 10.1097/00004872-199917040-00005; Nagaraj RH, 2002, ARCH BIOCHEM BIOPHYS, V402, P110, DOI 10.1016/S0003-9861(02)00067-X; OLEFSKY JM, 1981, AM J MED, V70, P151, DOI 10.1016/0002-9343(81)90422-8; Permutt MA, 2005, J CLIN INVEST, V115, P1431, DOI 10.1172/JCI24758; Poggioli S, 2002, EXP GERONTOL, V37, P1207, DOI 10.1016/S0531-5565(02)00145-6; Portero-Otin M, 2002, DIABETES, V51, P1535, DOI 10.2337/diabetes.51.5.1535; Rett K, 1999, DIABETES OBES METAB, V1, pS8, DOI 10.1046/j.1463-1326.1999.0010s1008.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; THORNALLEY PJ, 1989, DIABETES RES CLIN PR, V7, P115, DOI 10.1016/0168-8227(89)90101-0; VanderJagt DL, 1997, BIOCHEM PHARMACOL, V53, P1133, DOI 10.1016/S0006-2952(97)00090-7; Wang XX, 2005, J HYPERTENS, V23, P1565, DOI 10.1097/01.hjh.0000173778.85233.1b; Wang XX, 2004, KIDNEY INT, V66, P2315, DOI 10.1111/j.1523-1755.2004.66034.x; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wu LY, 2002, HYPERTENSION, V39, P809, DOI 10.1161/hy0302.105207; Wu LY, 2005, CAN J PHYSIOL PHARM, V83, P63, DOI 10.1139/Y04-112; [No title captured]	34	88	94	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1555	+		10.1096/fj.05-5478fje	http://dx.doi.org/10.1096/fj.05-5478fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723378				2022-12-28	WOS:000240266000049
J	Li, B; Sharpe, EE; Maupin, AB; Teleron, AA; Pyle, AL; Carmeliet, P; Young, PP				Li, Bin; Sharpe, Emerson E.; Maupin, Amanda B.; Teleron, Amylynn A.; Pyle, Amy L.; Carmeliet, Peter; Young, Pampee P.			VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization	FASEB JOURNAL			English	Article						VEGF receptors; BM transplant models; angiogenesis; placental growth factor	ENDOTHELIAL PROGENITOR CELLS; GROWTH-FACTOR RECEPTOR-1; BETA-GLUCURONIDASE; MURINE MODEL; MOBILIZATION; ANGIOGENESIS; MUCOPOLYSACCHARIDOSIS; REVASCULARIZATION; PROLIFERATION; HEMATOPOIESIS	There are growing data to suggest that tissue hypoxia represents a critical force that drives adult vasculogenesis. Vascular endothelial growth factor (VEGF) expression is dramatically up-regulated by hypoxia and results in enhanced neovascularization. Although the role of VEGF in angiogenesis has been well characterized, its role in adult vasculogenesis remains poorly understood. We used two distinct murine bone marrow transplantation (BMT) models to demonstrate that increased VEGF levels at the site of tumor growth promoted vasculogenesis in vivo. This effect of VEGF was downstream of its effect to enhance either mobilization or survival of circulating endothelial progenitor cells (EPCs). Both VEGFR1 (flt1) and VEGFR2 (flk1) are expressed on culture expanded human EPCs. Previous studies suggest that the effect of VEGF on endothelial cell migration is primarily mediated via VEGFR2; however, VEGF-induced EPC migration in vitro was mediated by both receptors, suggesting that VEGF-VEGFR1 interactions in EPCs are distinct from differentiated endothelial cells. We used specific blocking antibodies to these receptors to demonstrate that VEGFR1 plays an important role in human EPC recruitment to tumors. These findings were further supported by our finding that tumor-associated placental growth factor (PlGF), a VEGFR1-specific agonist, increased tumor vasculogenesis in a murine BMT model. We further showed that both VEGF receptors were necessary for the formation of functional vessels derived from exogenously administered human ex vivo expanded EPCs. Our data suggest local VEGF and/or PlGF expression promote vasculogenesis; VEGF plays a role in EPC recruitment and subsequent formation of functional vessels.	Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Internal Med, Nashville, TN USA; Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium	Vanderbilt University; Vanderbilt University; Flanders Institute for Biotechnology (VIB); KU Leuven	Young, PP (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, 1161 21st Ave S,C2217 MCN, Nashville, TN 37232 USA.	pampee.young@vanderbilt.edu	Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821	NHLBI NIH HHS [KO8HL84020] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL084020] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Argraves WS, 2002, DEV DYNAM, V225, P298, DOI 10.1002/dvdy.10162; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Asaumi N, 2001, ANN HEMATOL, V80, P387, DOI 10.1007/s002770100309; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bautch VL, 2000, BLOOD, V95, P1979, DOI 10.1182/blood.V95.6.1979; Boyer M, 2000, J VASC SURG, V31, P181, DOI 10.1016/S0741-5214(00)70080-2; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Conejo-Garcia JR, 2005, BLOOD, V105, P679, DOI 10.1182/blood-2004-05-1906; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423; Drake CJ, 2000, DEV BIOL, V224, P178, DOI 10.1006/dbio.2000.9744; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; Feng D, 2000, MICROVASC RES, V59, P24, DOI 10.1006/mvre.1999.2207; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FISHMAN WH, 1967, NATURE, V213, P457, DOI 10.1038/213457a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fragoso R, 2006, BLOOD, V107, P1608, DOI 10.1182/blood-2005-06-2530; Freeman BJ, 1999, BLOOD, V94, P2142, DOI 10.1182/blood.V94.6.2142.418k16_2142_2150; Gill M, 2001, CIRC RES, V88, P167; GLASER JH, 1973, J LAB CLIN MED, V82, P969; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Hofling AA, 2004, MOL THER, V9, P856, DOI 10.1016/j.ymthe.2004.03.013; Hofling AA, 2003, BLOOD, V101, P2054, DOI 10.1182/blood-2002-08-2597; Hristov M, 2004, J CELL MOL MED, V8, P498, DOI 10.1111/j.1582-4934.2004.tb00474.x; Ii M, 2005, CIRCULATION, V111, P1114, DOI 10.1161/01.CIR.0000157144.24888.7E; Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673; Jiang SG, 2004, P NATL ACAD SCI USA, V101, P16891, DOI 10.1073/pnas.0404398101; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Moore MAS, 2001, ANN NY ACAD SCI, V938, P36; Moore XL, 2004, GENE THER, V11, P811, DOI 10.1038/sj.gt.3302151; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Parr C, 2005, EUR J CANCER, V41, P2819, DOI 10.1016/j.ejca.2005.07.022; Poole TJ, 2001, DEV DYNAM, V220, P1, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1087>3.0.CO;2-2; RABELINK TJ, 2004, ARTERIOSCL THROM VAS, V24, P1; Rafii S, 2002, GENE THER, V9, P631, DOI 10.1038/sj.gt.3301723; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Rumpold H, 2004, J CELL MOL MED, V8, P509, DOI 10.1111/j.1582-4934.2004.tb00475.x; Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Solanilla A, 2003, BRIT J HAEMATOL, V120, P782, DOI 10.1046/j.1365-2141.2003.04155.x; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Teleron AA, 2005, TRANSFUSION, V45, P21, DOI 10.1111/j.1537-2995.2005.04191.x; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; Thomas J, 2002, CURR OPIN HEMATOL, V9, P183, DOI 10.1097/00062752-200205000-00002; Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Vincent L, 2005, CANCER RES, V65, P3185, DOI 10.1158/0008-5472.CAN-04-3598; Xie KP, 2004, CYTOKINE GROWTH F R, V15, P297, DOI 10.1016/j.cytogfr.2004.04.003; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Young PP, 2005, CIRCULATION, V111, P2382, DOI 10.1161/01.CIR.0000164235.26339.78; Young PP, 2003, MOL THER, V7, P52, DOI 10.1016/S1525-0016(02)00016-5; Young PP, 2002, P NATL ACAD SCI USA, V99, P11951, DOI 10.1073/pnas.182215799; Zhang Lijian, 2005, World J Surg Oncol, V3, P68, DOI 10.1186/1477-7819-3-68	67	272	310	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1495	+		10.1096/fj.05-5137fje	http://dx.doi.org/10.1096/fj.05-5137fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16754748				2022-12-28	WOS:000240266000029
J	Zhang, J; Liu, Q; Chen, Q; Liu, NQ; Li, FL; Lu, ZB; Qin, C; Zhu, H; Huang, YY; He, W; Zhao, BL				Zhang, Jie; Liu, Qiang; Chen, Qi; Liu, Nian-Qing; Li, Fu-ang Li; Lu, Zhong-Bing; Qin, Chuan; Zhu, Hua; Huang, Yu-Ying; He, Wei; Zhao, Bao-Lu			Nicotine attenuates beta-amyloid-induced neurotoxicity by regulating metal homeostasis	FASEB JOURNAL			English	Article						Alzheimer's disease; A beta; copper	ALZHEIMER A-BETA; COPPER CHAPERONE; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; DISEASE; PROTEIN; EXPRESSION; BINDING; BRAIN; IRON	Nicotine reduces beta-amyloidosis and has a beneficial effect against Alzheimer's disease (AD), but the underlying mechanism is not clear. The abnormal interactions of beta-amyloid (A beta) with metal ions such as copper and zinc are implicated in the process of A beta deposition in AD brains. In the present study, we investigated the effect of nicotine on metal homeostasis in the hippocampus and cortex of APP(V717I) ( London mutant form of APP) transgenic mice. A significant reduction in the metal contents of copper and zinc in senile plaques and neuropil is observed after nicotine treatment. The densities of copper and zinc distributions in a subfield of the hippocampus CA1 region are also reduced after nicotine treatment. We further studied the mechanism of nicotine-mediated effect on metal homeostasis by using SH-SY5Y cells overexpressing the Swedish mutant form of human APP (APPsw). Nicotine treatment decreases the intracellular copper concentration and attenuates A beta-mediated neurotoxicity facilitated by the addition of copper, and these effects are independent of the activation of nicotinic acetylcholine-receptor. These data suggest that the effect of nicotine on reducing beta-amyloidosis is partly mediated by regulating metal homeostasis.	Acad Sinica, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100101, Peoples R China; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Acad Sinica, Lab Nucl Analyt Tech, Inst High Energy Phys, Beijing 100101, Peoples R China; Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing 100037, Peoples R China; Acad Sinica, Inst High Energy Phys, Sychrotron Radiat Lab, Beijing 100101, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Salk Institute; Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Laboratory Animal Science - CAMS; Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Zhao, BL (corresponding author), Acad Sinica, Inst Biophys, State Key Lab Brain & Cognit Sci, 15 Datun Rd, Beijing 100101, Peoples R China.	zhaobl@sun5.ibp.ac.cn	Liu, Qiang/E-9245-2011; Zhang, Jie/A-5426-2010	Lu, Zhongbing/0000-0002-2717-4698				Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; Bertinato J, 2003, J BIOL CHEM, V278, P35071, DOI 10.1074/jbc.M302242200; Bertinato J, 2003, J NUTR, V133, P28, DOI 10.1093/jn/133.1.28; Borchardt T, 1999, BIOCHEM J, V344, P461, DOI 10.1042/0264-6021:3440461; Bush AI, 2002, NAT NEUROSCI, V5, P919, DOI 10.1038/nn1002-919a; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2002, NEUROBIOL AGING, V23, P1031, DOI 10.1016/S0197-4580(02)00120-3; Cerpa WF, 2004, FASEB J, V18, P1701, DOI 10.1096/fj.03-1349fje; Ektessabi A, 2001, X-RAY SPECTROM, V30, P44, DOI 10.1002/xrs.466; ESPEN PV, 1987, CHEM INTELL LAB SYST, V1, P109; HAENDLER HM, 1990, ACTA CRYSTALLOGR C, V46, P2054, DOI 10.1107/S0108270190001950; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Haugabook SJ, 2001, FASEB J, V15, P16; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Ishihara R, 2002, NEUROREPORT, V13, P1817, DOI 10.1097/00001756-200210070-00026; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; LEBECH B, 1990, NEUTRON NEWS, V2, P7; Liu NQ, 2004, SPECTROCHIM ACTA B, V59, P255, DOI 10.1016/j.sab.2003.12.006; Liu Q, 2004, BRIT J PHARMACOL, V141, P746, DOI 10.1038/sj.bjp.0705653; Liu Q, 2003, APPL MAGN RESON, V24, P105, DOI 10.1007/BF03166682; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Lynch T, 2000, EXP GERONTOL, V35, P445, DOI 10.1016/S0531-5565(00)00112-1; Maritz GS, 2000, REPROD FERT DEVELOP, V12, P97, DOI 10.1071/RD98127; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; MCARDLE HJ, 1988, J CELL PHYSIOL, V134, P509, DOI 10.1002/jcp.1041340326; MORITA A, 1994, BIOL TRACE ELEM RES, V42, P165, DOI 10.1007/BF02785387; Multhaup G, 2002, FREE RADICAL BIO MED, V33, P45, DOI 10.1016/S0891-5849(02)00806-7; Newhouse PA, 2001, BIOL PSYCHIAT, V49, P268, DOI 10.1016/S0006-3223(00)01069-6; Nordberg A, 2002, J NEUROCHEM, V81, P655, DOI 10.1046/j.1471-4159.2002.00874.x; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Paxinos G., 1996, RAT BRAIN STEREOTAXI; Rogers SW, 1998, J NEUROSCI, V18, P4825; Salomon AR, 1996, BIOCHEMISTRY-US, V35, P13568, DOI 10.1021/bi9617264; Sayre LM, 2000, J NEUROCHEM, V74, P270, DOI 10.1046/j.1471-4159.2000.0740270.x; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Strausak D, 2001, BRAIN RES BULL, V55, P175, DOI 10.1016/S0361-9230(01)00454-3; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; VEKEMANS B, 1994, X-RAY SPECTROM, V23, P278, DOI 10.1002/xrs.1300230609; Vickers JC, 2000, PROG NEUROBIOL, V60, P139, DOI 10.1016/S0301-0082(99)00023-4; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; Zamani MR, 2001, BIOL PSYCHIAT, V49, P221, DOI 10.1016/S0006-3223(00)01108-2; Zanardi A, 2002, TOXICOL LETT, V127, P207, DOI 10.1016/S0378-4274(01)00502-1; Zeng H, 2001, BIOL PSYCHIAT, V49, P248, DOI 10.1016/S0006-3223(00)01111-2	48	52	70	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1212	+		10.1096/fj.05-5214fje	http://dx.doi.org/10.1096/fj.05-5214fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16627626				2022-12-28	WOS:000240210300029
J	Silvertown, JD; Symes, JC; Neschadim, A; Nonaka, T; Kao, JCH; Summerlee, AJS; Medin, JA				Silvertown, Josh D.; Symes, Juliane C.; Neschadim, Anton; Nonaka, Takahiro; Kao, Jessica C. H.; Summerlee, Alastair J. S.; Medin, Jeffrey A.			Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth	FASEB JOURNAL			English	Article						lentivirus; LGR7; blood vessel; MMP-9	RECEPTOR-BINDING SITE; EXPRESSION; PEPTIDES; ACTIVATION; BENIGN; INSL3; MICE	Hormone antagonists can be effective tools to delineate receptor signaling pathways and their resulting downstream physiological actions. Mutation of the receptor binding domain (RBD) of human H2 relaxin (Delta H2) impaired its biological function as measured by cAMP signaling. In a competition assay, Delta H2 exhibited antagonistic activity by blocking recombinant H2 relaxin from binding to receptors on THP-1 cells. In a flow cytometry-based binding assay, Delta H2 demonstrated weak binding to 293T cells expressing the LGR7 receptor in the presence of biotinylated H2 relaxin. When human prostate cancer cell lines (PC-3 and LNCaP) were engineered to overexpress eGFP, wildtype (WT) H2, or Delta H2, and subsequently implanted into NOD/SCID mice, tumor xenografts overexpressing Delta H2 displayed smaller volumes compared to H2 and eGFP controls. Plasma osmolality readings and microvessel density and area assessment suggest that Delta H2 modulates physiological parameters in vivo. In a second murine model, intratumoral injections of lentivectors engineered to express Delta H2/eGFP led to suppressed tumor growth compared to controls. This study provides further evidence supporting a role for H2 relaxin in prostate tumor growth. More importantly, we report how mutation of the H2 relaxin RBD confers the hormone derivative with antagonistic properties, offering a novel reagent for relaxin research.	Univ Toronto, Hlth Network, Ontario Canc Inst, Div Stem Cell & Dev Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Guelph; University of Toronto	Medin, JA (corresponding author), Univ Toronto, Hlth Network, Ontario Canc Inst, Div Stem Cell & Dev Biol, Canadian Blood Serv Bldg,67 Coll St,Rm 406, Toronto, ON M5G 2M1, Canada.	jmedin@uhnres.utoronto.ca	Neschadim, Anton/G-3041-2011	Neschadim, Anton/0000-0003-1750-9703				Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bathgate RA, 2006, PHARMACOL REV, V58, P7, DOI 10.1124/pr.58.1.9; Bathgate RA, 2005, ANN NY ACAD SCI, V1041, P61, DOI 10.1196/annals.1282.010; Bathgate RAD, 2003, TRENDS ENDOCRIN MET, V14, P207, DOI 10.1016/S1043-2760(03)00081-X; BULLESBACH EE, 1992, J BIOL CHEM, V267, P22957; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; Bullesbach EE, 2005, J BIOL CHEM, V280, P14586, DOI 10.1074/jbc.M414443200; Danielson LA, 1999, J CLIN INVEST, V103, P525, DOI 10.1172/JCI5630; Del Borgo MP, 2006, J BIOL CHEM, V281, P13068, DOI 10.1074/jbc.M600472200; Halls ML, 2005, J PHARMACOL EXP THER, V313, P677, DOI 10.1124/jpet.104.080655; Hombach-Klonisch S, 2006, AM J PATHOL, V169, P617, DOI 10.2353/ajpath.2006.050876; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Kamat AA, 2006, CANCER BIOL THER, V5, P71, DOI 10.4161/cbt.5.1.2289; Klonisch T, 2005, INT J ONCOL, V27, P307; Lee HY, 2005, ENDOCRINOLOGY, V146, P511, DOI 10.1210/en.2004-0796; McGuane Jonathan T., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009944; Parsell DA, 1996, J BIOL CHEM, V271, P27936, DOI 10.1074/jbc.271.44.27936; Samuel CS, 2003, LAB INVEST, V83, P1055, DOI 10.1097/01.LAB.0000079784.81186.B9; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Silvertown JD, 2005, ANN NY ACAD SCI, V1041, P216, DOI 10.1196/annals.1282.033; Silvertown JD, 2006, INT J CANCER, V118, P62, DOI 10.1002/ijc.21288; Silvertown JD, 2003, INT J CANCER, V107, P513, DOI 10.1002/ijc.11424; Silvertown JD, 2003, ENDOCRINOLOGY, V144, P3683, DOI 10.1210/en.2003-0248; Silvertown JD, 2006, ENDOCRINOLOGY, V147, P3797, DOI 10.1210/en.2006-0028; TASHIMA LS, 1994, J MOL ENDOCRINOL, V12, P351, DOI 10.1677/jme.0.0120351; Thompson HJ, 2002, CARCINOGENESIS, V23, P847, DOI 10.1093/carcin/23.5.847; Thompson VC, 2006, PROSTATE, V66, P1698, DOI 10.1002/pros.20423; WEISINGER RS, 1993, J ENDOCRINOL, V137, P505, DOI 10.1677/joe.0.1370505; Yoshimitsu M, 2004, P NATL ACAD SCI USA, V101, P16909, DOI 10.1073/pnas.0407572101; Zhao L, 1999, ENDOCRINOLOGY, V140, P445, DOI 10.1210/en.140.1.445	30	49	53	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					754	765		10.1096/fj.06-6847com	http://dx.doi.org/10.1096/fj.06-6847com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197386				2022-12-28	WOS:000244686400014
J	Patchev, AV; Fischer, D; Wolf, SS; Herkenham, M; Gotz, F; Gehin, M; Chambon, P; Patchev, VK; Almeida, OFX				Patchev, Alexandre V.; Fischer, Dieter; Wolf, Siegmund S.; Herkenham, Miles; Goetz, Franziska; Gehin, Martine; Chambon, Pierre; Patchev, Vladimir K.; Almeida, Osborne F. X.			Insidious adrenocortical insufficiency underlies neuroendocrine dysregulation in TIF-2 deficient mice	FASEB JOURNAL			English	Article						stress; adrenal cortex; steroidogenesis; hypothalamus; hippocampus	RECEPTOR MESSENGER-RNA; STEROIDOGENIC FACTOR-I; GLUCOCORTICOID-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; EXPRESSION; SRC-1; PROTEIN; STRESS; BRAIN; GENE	C The transcription-intermediary-factor-2 (TIF-2) is a coactivator of the glucocorticoid receptor (GR),and its disruption would be expected to influence glucocorticoid-mediated control of the hypothalamo-pituitary-adrenal (HPA) axis. Here, we show that its targeted deletion in mice is associated with altered expression of several glucocorticoid-dependent components of HPA regulation ( e. g., corticotropin-releasing hormone, vasopressin, ACTH, glucocorticoid receptors), suggestive of hyperactivity under basal conditions. At the same time, TIF-2(-/-) mice display significantly lower basal corticosterone levels and a sluggish and blunted initial secretory response to brief emotional and prolonged physical stress. Subsequent analysis revealed this discrepancy to result from pronounced aberrations in the structure and function of the adrenal gland, including the cytoarchitectural organization of the zona fasciculata and basal and stress-induced expression of key elements of steroid hormone synthesis, such as the steroidogenic acute regulatory ( StAR) protein and 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD). In addition, altered expression levels of two nuclear receptors, DAX-1 and steroidogenic factor 1 (SF-1), in the adrenal cortex strengthen the view that TIF-2 deletion disrupts adrenocortical development and steroid biosynthesis. Thus, hyperactivity of the hypothalamo-pituitary unit is ascribed to insidious adrenal insufficiency and impaired glucocorticoid feedback.	Humboldt Univ, Charite, Sch Med, Inst Expt Endocrinol, D-10117 Berlin, Germany; Max Planck Inst Psychiat, Neuroadaptat Grp, D-80804 Munich, Germany; Schering AG, Corp Res Gynecol & Androl, Jena, Germany; NIMH, Funct Neuroanat Sect, NIH, Bethesda, MD 20892 USA; IGBMC, Illkirch Graffenstaden, France	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Schering AG; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Institut National de la Sante et de la Recherche Medicale (Inserm)	Patchev, AV (corresponding author), Humboldt Univ, Charite, Sch Med, Inst Expt Endocrinol, Schumannstr 20-21, D-10117 Berlin, Germany.	alexandre.patchev@charite.de	Almeida, Osborne F.X. F/E-8402-2010	Almeida, Osborne F.X. F/0000-0001-7331-6928; Herkenham, Miles/0000-0003-2228-4238	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH001090, ZIAMH001090] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aguilera G, 2001, PEPTIDES, V22, P769, DOI 10.1016/S0196-9781(01)00390-4; Aguilera G, 2000, EXP PHYSIOL, V85, p19S, DOI 10.1111/j.1469-445X.2000.tb00004.x; Akana SF, 1997, ENDOCRINOLOGY, V138, P3249, DOI 10.1210/en.138.8.3249; Babu PS, 2002, ENDOCRINOLOGY, V143, P665, DOI 10.1210/en.143.2.665; Bland ML, 2000, P NATL ACAD SCI USA, V97, P14488, DOI 10.1073/pnas.97.26.14488; Borud B, 2002, MOL ENDOCRINOL, V16, P757, DOI 10.1210/me.16.4.757; BRADY LS, 1990, NEUROENDOCRINOLOGY, V52, P441, DOI 10.1159/000125626; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; Coirini H, 2002, NEUROSCIENCE, V113, P883, DOI 10.1016/S0306-4522(02)00224-5; Condon J, 1998, J CLIN ENDOCR METAB, V83, P4490, DOI 10.1210/jc.83.12.4490; De Arrieta CM, 2000, ENDOCRINOLOGY, V141, P1693, DOI 10.1210/en.141.5.1693; de Kloet ER, 2005, NAT REV NEUROSCI, V6, P463, DOI 10.1038/nrn1683; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Gehin M, 2002, MOL CELL BIOL, V22, P5923, DOI 10.1128/MCB.22.16.5923-5937.2002; Glass CK, 2000, GENE DEV, V14, P121; Hammer GD, 2005, ENDOCRINOLOGY, V146, P1018, DOI 10.1210/en.2004-1385; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Herman JP, 1998, J NEUROSCI, V18, P7462; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Lalli E, 2003, MOL ENDOCRINOL, V17, P1445, DOI 10.1210/me.2003-0159; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Mark M, 2004, P NATL ACAD SCI USA, V101, P4453, DOI 10.1073/pnas.0400234101; Marti O, 1999, BRAIN RES, V821, P1, DOI 10.1016/S0006-8993(98)01212-8; Meijer OC, 2000, ENDOCRINOLOGY, V141, P2192, DOI 10.1210/en.141.6.2192; Mitev YA, 2003, FASEB J, V17, P518, DOI 10.1096/fj.02-0513fje; Nishi R, 1999, BRAIN RES BULL, V50, P47, DOI 10.1016/S0361-9230(99)00082-9; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PATCHEV VK, 1994, MOL CELL ENDOCRINOL, V103, P57, DOI 10.1016/0303-7207(94)90069-8; Paust HJ, 2006, EXP CLIN ENDOCR DIAB, V114, P6, DOI 10.1055/s-2005-873007; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; PicardHagen N, 1997, J MOL ENDOCRINOL, V19, P29, DOI 10.1677/jme.0.0190029; Puustinen R, 2001, EUR J ENDOCRINOL, V145, P323, DOI 10.1530/eje.0.1450323; Sandhoff TW, 1998, ENDOCRINOLOGY, V139, P4820, DOI 10.1210/en.139.12.4820; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Weidenfeld J, 2000, BRAIN RES, V877, P73, DOI 10.1016/S0006-8993(00)02532-4; WEISS L, 1970, Journal of Medical Genetics, V7, P27, DOI 10.1136/jmg.7.1.27; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; Winnay JN, 2006, ENDOCRINOLOGY, V147, P1322, DOI 10.1210/en.2005-0751; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922	42	20	21	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					231	238		10.1096/fj.06-6952com	http://dx.doi.org/10.1096/fj.06-6952com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135362				2022-12-28	WOS:000243130200025
J	Smith, CC; Taylor, HS				Smith, Caroline C.; Taylor, Hugh S.			Xenoestrogen exposure imprints expression of genes (Hoxa10) required for normal uterine development	FASEB JOURNAL			English	Article						bisphenol A; BPA; endocrine disruption; HOX	BISPHENOL-A CONCENTRATIONS; ESTROGEN-RECEPTOR-ALPHA; IN-UTERO; PERINATAL EXPOSURE; MATERNAL HOXA10; MOUSE; DIETHYLSTILBESTROL; SERUM; ADENOCARCINOMA; ENDOMETRIUM	The developing reproductive tract is sensitive to endocrine perturbation. Bisphenol A (BPA), a xenoestrogen, is a common component of food storage plastics and dental composites. We tested the ability of BPA to alter expression of HOXA10, a gene necessary for uterine development. A dose-response increase in HOXA10 mRNA expression was demonstrated in Ishikawa cells treated with 0.1 nM to 25 mu M BPA. To determine whether in utero BPA exposure resulted in a lasting alteration of uterine HOXA10 expression, mice were treated with 0.5-5.0 mg/ kg BPA on gestational days 9-16. A dose-responsive increase was seen in stromal cell HOXA10 expression in 2- and 6-week-old mice exposed in utero. To discern the mechanism of BPA action, the HOXA10 estrogen response element ( ERE) and autoregulatory element ( ARE) were tested for BPA responsiveness. BPA drove luciferase expression from HOXA10-ERE and ARE reporter constructs. HOXA10 ERE mediated induction was blocked by ER antagonist ICI, while HOXA10 ARE induction was blocked by either ICI or HOXA10 antisense. BPA affects HOXA10 expression through the HOXA10 ERE and indirectly through the ARE. BPA initially alters HOXA10 expression through the ERE, however, the response is imprinted and uncoupled from estrogen stimulation in the adult. Several xenoestrogens alter HOX gene expression, indicating that HOX genes are a common target of endocrine disruption. In utero exposure to a xenoestrogen produces reproductive tract alterations by imprinting essential developmental regulatory genes.	Yale Univ, Sch Med, Div Reprod Endocrinol, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Taylor, HS (corresponding author), Yale Univ, Sch Med, Div Reprod Endocrinol, Dept Epidemiol & Publ Hlth, 333 Cedar St,POB 208063, New Haven, CT 06520 USA.	hugh.taylor@yale.edu			NIEHS NIH HHS [ES10610] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010610] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akbas GE, 2004, J MOL BIOL, V340, P1013, DOI 10.1016/j.jmb.2004.05.052; Al-Hiyasat AS, 2004, EUR J ORAL SCI, V112, P267, DOI 10.1111/j.1600-0722.2004.00136.x; Al-Hiyasat AS, 2002, EUR J ORAL SCI, V110, P163, DOI 10.1034/j.1600-0722.2002.11201.x; Ashby J, 1998, HUM EXP TOXICOL, V17, P598, DOI 10.1191/096032798678908080; Bagot CN, 2001, DEV DYNAM, V222, P538, DOI 10.1002/dvdy.1209; Bagot CN, 2000, GENE THER, V7, P1378, DOI 10.1038/sj.gt.3301245; Block K, 2000, FASEB J, V14, P1101, DOI 10.1096/fasebj.14.9.1101; BUDWITNOVOTNY DA, 1986, CANCER RES, V46, P5419; Cermik D, 2003, J CLIN ENDOCR METAB, V88, P238, DOI 10.1210/jc.2002-021072; Coldham NG, 1997, ENVIRON HEALTH PERSP, V105, P734, DOI 10.1289/ehp.97105734; Couse JF, 2001, DEV BIOL, V238, P224, DOI 10.1006/dbio.2001.0413; Daftary GS, 2004, MOL REPROD DEV, V67, P8, DOI 10.1002/mrd.20013; Daftary GS, 2002, FERTIL STERIL, V78, P577, DOI 10.1016/S0015-0282(02)03306-X; Darmani H, 2006, DENT MATER, V22, P353, DOI 10.1016/j.dental.2005.04.029; Darmani H, 2004, J BIOMED MATER RES A, V69A, P637, DOI 10.1002/jbm.a.30029; Fei XL, 2005, ENDOCRINOLOGY, V146, P3445, DOI 10.1210/en.2005-0341; Guillette LJ, 1999, ARCH ENVIRON CON TOX, V36, P447, DOI 10.1007/PL00006617; HERBST AL, 1975, J REPROD MED, V15, P5; Hiroi H, 2004, ENDOCR J, V51, P595, DOI 10.1507/endocrj.51.595; Howdeshell KL, 1999, NATURE, V401, P763, DOI 10.1038/44517; Howdeshell KL, 2000, AM ZOOL, V40, P429, DOI 10.1668/0003-1569(2000)040[0429:DETBAI]2.0.CO;2; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; Kelly M, 2006, AM J OBSTET GYNECOL, V194, P1100, DOI 10.1016/j.ajog.2005.12.025; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lemmen JG, 2004, ENVIRON HEALTH PERSP, V112, P1544, DOI 10.1289/ehp.7155; Lessey BA, 1996, J STEROID BIOCHEM, V59, P31, DOI 10.1016/S0960-0760(96)00103-3; LESSEY BA, 1988, J CLIN ENDOCR METAB, V67, P334, DOI 10.1210/jcem-67-2-334; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Li SF, 2001, MOL CARCINOGEN, V32, P213, DOI 10.1002/mc.10015; LITTLEFIELD BA, 1990, ENDOCRINOLOGY, V127, P2757, DOI 10.1210/endo-127-6-2757; Ma L, 1998, DEV BIOL, V197, P141, DOI 10.1006/dbio.1998.8907; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301; Markey CM, 2001, BIOL REPROD, V65, P1215, DOI 10.1093/biolreprod/65.4.1215; Markey CM, 2001, ENVIRON HEALTH PERSP, V109, P55, DOI 10.2307/3434921; Milligan SR, 1998, GEN COMP ENDOCR, V112, P89, DOI 10.1006/gcen.1998.7146; Morrison AG, 2003, DOMEST ANIM ENDOCRIN, V25, P329, DOI 10.1016/j.domaniend.2003.06.004; Munoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.2307/3433065; Pottenger LH, 2000, TOXICOL SCI, V54, P3, DOI 10.1093/toxsci/54.1.3; REIJNDERS PJH, 1986, NATURE, V324, P456, DOI 10.1038/324456a0; Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783; Sakkas D, 2003, FERTIL STERIL, V80, P1169, DOI 10.1016/S0015-0282(03)02163-0; Salih SM, 2004, AM J OBSTET GYNECOL, V190, P1404, DOI 10.1016/j.ajog.2004.01.066; Sarno JL, 2005, J CLIN ENDOCR METAB, V90, P522, DOI 10.1210/jc.2004-0817; SATOKATA I, 1995, NATURE, V374, P460, DOI 10.1038/374460a0; Schonfelder G, 2004, NEOPLASIA, V6, P584, DOI 10.1593/neo.04217; Schonfelder G, 2002, NEOPLASIA, V4, P98, DOI 10.1038/sj.neo.7900212; Spencer F, 2002, INT J HYG ENVIR HEAL, V204, P353, DOI 10.1078/1438-4639-00115; Steinmetz R, 1998, ENDOCRINOLOGY, V139, P2741, DOI 10.1210/en.139.6.2741; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Suzuki A, 2002, REPROD TOXICOL, V16, P107, DOI 10.1016/S0890-6238(02)00005-9; Taylor HS, 1999, J CLIN ENDOCR METAB, V84, P1129, DOI 10.1210/jc.84.3.1129; Taylor HS, 1999, HUM REPROD, V14, P1328, DOI 10.1093/humrep/14.5.1328; Taylor HS, 1997, BIOL REPROD, V57, P1338, DOI 10.1095/biolreprod57.6.1338; Taylor WJ, 1998, J BACK MUSCULOSKELET, V10, P101, DOI 10.3233/BMR-1998-10207; Tinwell H, 2000, REGUL TOXICOL PHARM, V32, P118, DOI 10.1006/rtph.2000.1412; Troy PJ, 2003, MOL CELL BIOL, V23, P1, DOI 10.1128/MCB.23.1.1-13.2003; Tsutsumi O, 2005, J STEROID BIOCHEM, V93, P325, DOI 10.1016/j.jsbmb.2004.12.008; Yamada H, 2002, REPROD TOXICOL, V16, P735, DOI 10.1016/S0890-6238(02)00051-5	61	61	63	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					239	246		10.1096/fj.06-6635com	http://dx.doi.org/10.1096/fj.06-6635com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17093138				2022-12-28	WOS:000243130200026
J	Schmidt, S; Irving, JAE; Minto, L; Matheson, E; Nicholson, L; Ploner, A; Parson, W; Kofler, A; Amort, M; Erdel, M; Hall, A; Kofler, R				Schmidt, Stefan; Irving, Julie A. E.; Minto, Lynne; Matheson, Elizabeth; Nicholson, Lindsay; Ploner, Andreas; Parson, Walther; Kofler, Anita; Amort, Melanie; Erdel, Martin; Hall, Andy; Kofler, Reinhard			Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor	FASEB JOURNAL			English	Article						apoptosis; mutation; mismatch repair; CCRF-CEM cell line; PreB 697 cell line	NF-KAPPA-B; INDUCED APOPTOSIS; BINDING DOMAIN; CELL-LINES; IN-VITRO; GENE; MECHANISMS; EXPRESSION; REPAIR; IDENTIFICATION	Glucocorticoids (GCs) specifically induce apoptosis in malignant lymphoblasts and are thus pivotal in the treatment of acute lymphoblastic leukemia (ALL). However, GC-resistance is a therapeutic problem with an unclear molecular mechanism. We generated similar to 70 GC-resistant sublines from a GC-sensitive B- and a T-ALL cell line and investigated their mechanisms of resistance. In response to GCs, all GC-resistant subclones analyzed by real-time polymerase chain reaction (PCR) showed a deficient up-regulation of the GC-receptor (GR) and its downstream target, GC-induced leucine zipper. This deficiency in GR up-regulation was confirmed by Western blotting and on retroviral overexpression of GR in resistant subclones GC-sensitivity was restored. All GC-resistant subclones were screened for GR mutations using denaturing high-pressure liquid chromatography (DHPLC), DNA-fingerprinting, and fluorescence in situ hybridization (FISH). Among the identified mutations were some previously not associated with GC resistance: A484D, P515H, L756N, Y663H, L680P, and R714W. This approach revealed three genotypes, complete loss of functional GR in the mismatch repair deficient T-ALL model, apparently normal GR genes in B-ALLs, and heterozygosity in both. In the first genotype, deficiency in GR up-regulation was fully explained by mutational events, in the second by a putative regulatory defect, and in the third by a combination thereof. In all instances, GC-resistance occurred at the level of the GR in both models.	Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; No Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England; Innsbruck Med Univ, Inst Legal Med, Innsbruck, Austria; Innsbruck Med Univ, Div Human Genet, Innsbruck, Austria; Innsbruck Med Univ, Div Mol Pathophysiol, Bioctr, Innsbruck, Austria	Newcastle University - UK; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Schmidt, S (corresponding author), Tyrolean Canc Res Inst, Innrain 66, A-6020 Innsbruck, Austria.	stefan.schmidt@i-med.ac.at	Hall, Andy/AAD-8622-2020; Hall, Andrew G/B-3485-2009; Parson, Walther/AAD-6845-2020	Parson, Walther/0000-0002-5692-2392	Austrian Science Fund FWF [P 18571] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		ASHRAF J, 1993, MOL ENDOCRINOL, V7, P631, DOI 10.1210/me.7.5.631; Bachmann PS, 2005, BLOOD, V105, P2519, DOI 10.1182/blood-2004-05-2023; Bar W, 1997, INT J LEGAL MED, V110, P175, DOI 10.1007/s004140050061; BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; Campbell MR, 2006, ONCOGENE, V25, P2531, DOI 10.1038/sj.onc.1209277; Cannarile L, 2001, CELL DEATH DIFFER, V8, P201, DOI 10.1038/sj.cdd.4400798; Chen J, 2004, BIOCHEM BIOPH RES CO, V321, P893, DOI 10.1016/j.bbrc.2004.07.047; CLOUSTON HJ, 2005, HUMAN CYTOGENETICS C, P33; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; FINDLEY HW, 1982, BLOOD, V60, P1305; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Geley S, 1996, CANCER RES, V56, P5033; GOMI M, 1990, CANCER RES, V50, P1873; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Gu LY, 2002, ONCOGENE, V21, P5758, DOI 10.1038/sj.onc.1205695; Haarman EG, 2003, BRIT J HAEMATOL, V120, P919, DOI 10.1046/j.1365-2141.2003.04189.x; Hala M, 1996, INT J CANCER, V68, P663, DOI 10.1002/(SICI)1097-0215(19961127)68:5<663::AID-IJC17>3.0.CO;2-2; Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747; Hillmann AG, 2000, CANCER RES, V60, P2056; Irving JAE, 2005, CANCER RES, V65, P9712, DOI 10.1158/0008-5472.CAN-05-1227; KASPERS GJL, 1994, LEUKEMIA LYMPHOMA, V13, P187, DOI 10.3109/10428199409056282; Kassel O, 2004, GENE DEV, V18, P2518, DOI 10.1101/gad.322404; KLUMPER E, 1995, BLOOD, V86, P3861, DOI 10.1182/blood.V86.10.3861.bloodjournal86103861; Kofler R, 2003, J ENDOCRINOL, V178, P19, DOI 10.1677/joe.0.1780019; Laudet V., 2002, NUCL RECEPTOR FACTS; Martinez ED, 2005, EXP CELL RES, V308, P320, DOI 10.1016/j.yexcr.2005.03.040; Matheson EC, 2003, CARCINOGENESIS, V24, P31, DOI 10.1093/carcin/24.1.31; MOALLI PA, 1994, LEUKEMIA LYMPHOMA, V15, P363, DOI 10.3109/10428199409049738; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; NORMAN MR, 1977, CANCER RES, V37, P3785; Parson W, 2005, FASEB J, V19, P434, DOI 10.1096/fj.04-3062fje; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pedersen KB, 2004, BIOCHEMISTRY-US, V43, P10851, DOI 10.1021/bi049458u; Pedersen KB, 2003, BIOCHEMISTRY-US, V42, P10978, DOI 10.1021/bi034651u; POWERS JH, 1993, CANCER RES, V53, P4059; *PRESS SYND U CAMB, 1999, CHILDH LEUK; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Ramdas J, 1999, CANCER RES, V59, P1378; Riml S, 2004, CELL DEATH DIFFER, V11, pS65, DOI 10.1038/sj.cdd.4401413; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; Schmidt S, 2006, BLOOD, V107, P2061, DOI 10.1182/blood-2005-07-2853; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Smets LA, 1996, LEUKEMIA LYMPHOMA, V20, P199, DOI 10.3109/10428199609051608; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TISSING WJ, 2006, BLOOD; Tissing WJE, 2005, CLIN CANCER RES, V11, P6050, DOI 10.1158/1078-0432.CCR-04-2097; Tissing WJE, 2003, LEUKEMIA, V17, P17, DOI 10.1038/sj.leu.2402733; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430	52	58	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2600	+		10.1096/fj.06-6214fje	http://dx.doi.org/10.1096/fj.06-6214fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077285				2022-12-28	WOS:000242490700037
J	Zhang, W; Shin, EJ; Wang, TG; Lee, PH; Pang, H; Wie, MB; Kim, WK; Kim, SJ; Huang, WH; Wang, YJ; Zhang, WQ; Hong, JS; Kim, HC				Zhang, Wei; Shin, Eun-Joo; Wang, Tongguang; Lee, Phil Ho; Pang, Hao; Wie, Myung-Bok; Kim, Won-Ki; Kim, Seong-Jin; Huang, Wen-Hsin; Wang, Yongjun; Zhang, Wanqin; Hong, Jau-Shyong; Kim, Hyoung-Chun			3-hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro	FASEB JOURNAL			English	Article						PD; substantia nigra pars compacta (SNpc); striatum; astroglia; neurotrophic factors; microglia; ROS	NIGRAL DOPAMINERGIC-NEURONS; PARKINSONS-DISEASE; NEUROTROPHIC FACTOR; MICROGLIAL ACTIVATION; NADPH OXIDASE; HISTONE DEACETYLASE; SUBSTANTIA-NIGRA; VALPROIC ACID; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MODEL; MESENCEPHALIC NEURONS	We investigated the neuroprotective property of analogs of dextromethorphan (DM) in lipopolysaccharide (LPS) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) models to identify neuroprotective drugs for Parkinson's disease (PD). In vivo studies showed that daily injections with DM analogs protected dopamine (DA) neurons in substantia nigra pars compacta and restored DA levels in striatum using two different models for PD. Of the five analogs studied, 3-hydroxymorphinan (3-HM), a metabolite of DM, was the most potent, and restored DA neuronal loss and DA depletion up to 90% of the controls. Behavioral studies showed an excellent correlation between potency for preventing toxin-induced decrease in motor activities and neuroprotective effects among the DM analogs studied, of which 3-HM was the most potent in attenuating behavioral damage. In vitro studies revealed two glia-dependent mechanisms for the neuroprotection by 3-HM. First, astroglia mediated the 3-HM-induced neurotrophic effect by increasing the gene expression of neurotrophic factors, which was associated with the increased acetylation of histone H3. Second, microglia participated in 3-HM-mediated neuroprotection by reducing MPTP-elicited reactive microgliosis as evidenced by the decreased production of reactive oxygen species. In summary, we show the potent neuroprotection by 3-HM in LPS and MPTP PD models investigated. With its high efficacy and low toxicity, 3-HM may be a novel therapy for PD.-Zhang, W., Shin, E-J., Wang, T., Lee, P. H., Pang, H., Wie, M-B., Kim, W-K., Kim, S-J., Huang, W-H., Wang, Y., Zhang, W., Hong, J-S., Kim, H-C. 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; Capital Univ Med Sci, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China; Kangwon Natl Univ, Coll Pharm, Neuropsychopharmacol & Toxicol Program, Chunchon, South Korea; Kangwon Natl Univ, Dept Chem, Chunchon 200701, South Korea; Kangwon Natl Univ, Dept Vet Med, Chunchon 200701, South Korea; NCI, Lab Cell Regulat & Carcinogensis, NIH, Bethesda, MD 20892 USA; Dalian Med Univ, Dept Physiol, Dalian, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Capital Medical University; Kangwon National University; Kangwon National University; Kangwon National University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Dalian Medical University	Kim, HC (corresponding author), Kangwon Natl Univ, Coll Pharm, Neuropsychopharmacol & Toxicol Program, Chunchon 200701, South Korea.	kimhc@kangwon.ac.kr	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090082, Z01ES090082] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALI SF, 1994, BRAIN RES, V658, P33, DOI 10.1016/S0006-8993(09)90007-5; Basu A, 2002, J NEUROSCI, V22, P6071; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Blum H, 1998, NAT NEUROSCI, V1, P374, DOI 10.1038/1584; BRIZARD M, 2005, NEUROBIOL DIS; Canudas AM, 2005, MOL BRAIN RES, V134, P147, DOI 10.1016/j.molbrainres.2004.11.012; Chang KT, 2002, AGEING RES REV, V1, P313, DOI 10.1016/S1568-1637(02)00003-X; Chen Y, 2005, EXP NEUROL, V196, P87, DOI 10.1016/j.expneurol.2005.07.010; Cleren C, 2005, J NEUROCHEM, V94, P995, DOI 10.1111/j.1471-4159.2005.03253.x; Cutillas B, 2002, NEUROSCI LETT, V329, P165, DOI 10.1016/S0304-3940(02)00614-6; Datla KP, 2004, J PHARM PHARMACOL, V56, P649, DOI 10.1211/0022357023222; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Eberhardt O, 2000, J NEUROSCI, V20, P9126; Erickson JT, 2001, J NEUROSCI, V21, P581, DOI 10.1523/JNEUROSCI.21-02-00581.2001; Farkas LM, 2003, J NEUROSCI, V23, P5178; Feng ZH, 2002, NEUROSCI LETT, V329, P354, DOI 10.1016/S0304-3940(02)00704-8; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Gao HM, 2003, FASEB J, V17, P1957, DOI 10.1096/fj.03-0203fje; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Hows MEP, 2004, J NEUROSCI METH, V137, P221, DOI 10.1016/j.jneumeth.2004.02.011; Inden M, 2005, J PHARMACOL SCI, V97, P203, DOI 10.1254/jphs.FP0040525; Jaumotte JD, 2005, MOL BRAIN RES, V134, P139, DOI 10.1016/j.molbrainres.2004.11.018; Jeong MR, 2003, FEBS LETT, V542, P74, DOI 10.1016/S0014-5793(03)00350-8; Kim HC, 2003, LIFE SCI, V72, P1883, DOI 10.1016/S0024-3205(02)02505-5; Kim HC, 2001, BIOORG MED CHEM LETT, V11, P1651, DOI 10.1016/S0960-894X(01)00262-1; Kim HC, 2000, BRAIN RES, V862, P247, DOI 10.1016/S0006-8993(00)02085-0; Kobori N, 2004, J BIOL CHEM, V279, P2182, DOI 10.1074/jbc.M310734200; Krieglstein K, 2002, J PHYSIOLOGY-PARIS, V96, P25, DOI 10.1016/S0928-4257(01)00077-8; Li FQ, 2003, EXP NEUROL, V179, P28, DOI 10.1006/exnr.2002.8049; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Liu B, 2003, ENVIRON HEALTH PERSP, V111, P1065, DOI 10.1289/ehp.6361; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu J, 2005, BIOCHEM PHARMACOL, V70, P144, DOI 10.1016/j.bcp.2005.03.034; Liu YX, 2003, J PHARMACOL EXP THER, V305, P212, DOI 10.1124/jpet.102.043166; Liu YX, 2002, J PHARMACOL EXP THER, V302, P1212, DOI 10.1124/jpet.102.035956; McGeer PL, 2003, ANN NEUROL, V54, P599, DOI 10.1002/ana.10728; MULLER HW, 1995, PHARMACOL THERAPEUT, V65, P1, DOI 10.1016/0163-7258(94)00047-7; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Peng J, 2005, J BIOL CHEM, V280, P29194, DOI 10.1074/jbc.M500984200; Peskin AV, 2000, CLIN CHIM ACTA, V293, P157, DOI 10.1016/S0009-8981(99)00246-6; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; ROSENKRANZ AR, 1992, J IMMUNOL METHODS, V156, P39, DOI 10.1016/0022-1759(92)90008-H; Roussa E, 2004, NEUROSCI LETT, V361, P52, DOI 10.1016/j.neulet.2003.12.106; Roussa E, 2004, NEUROBIOL DIS, V16, P300, DOI 10.1016/j.nbd.2004.03.006; Shin EJ, 2005, BRIT J PHARMACOL, V144, P908, DOI 10.1038/sj.bjp.0705998; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; Sun ZH, 2004, CELL BIOL INT, V28, P323, DOI 10.1016/j.cellbi.2004.01.006; Tan AS, 2000, J IMMUNOL METHODS, V238, P59, DOI 10.1016/S0022-1759(00)00156-3; Teismann P, 2003, ANN NY ACAD SCI, V991, P272; Tunnicliff G, 1999, J PHYSIOL PHARMACOL, V50, P347; Urbanics R, 2001, IDrugs, V4, P820; Wang TG, 2004, J PHARMACOL EXP THER, V308, P975, DOI 10.1124/jpet.103.059683; Wang TG, 2005, FASEB J, V19, P1134, DOI 10.1096/fj.04-2457fje; Wood TK, 2005, J NEUROSCI RES, V80, P759, DOI 10.1002/jnr.20507; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Yasuhara T, 2005, BRAIN RES, V1053, P10, DOI 10.1016/j.brainres.2005.05.027; Zhang ML, 2005, CHINA OCEAN ENG, V19, P395; Zhang W, 2004, FASEB J, V18, P589, DOI 10.1096/fj.03-0983fje; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com; Zhou HF, 2005, NEUROBIOL DIS, V18, P441, DOI 10.1016/j.nbd.2004.12.005	65	69	74	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2496	2511		10.1096/fj.06-6006com	http://dx.doi.org/10.1096/fj.06-6006com			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17142799	Green Submitted			2022-12-28	WOS:000242490700010
J	Zhang, XC; Shan, PY; Jiang, G; Zhang, SSM; Otterbein, LE; Fu, XY; Lee, PJ				Zhang, Xuchen; Shan, Peiying; Jiang, Ge; Zhang, Samuel S-M.; Otterbein, Leo E.; Fu, Xin-Yuan; Lee, Patty J.			Endothelial STAT3 is essential for the protective effects of HO-1 in oxidant-induced lung injury	FASEB JOURNAL			English	Article						signal transduction; oxygen	INDUCED CELL-DEATH; HEME OXYGENASE-1; SIGNAL TRANSDUCER; THERAPY PROTECTS; HYPEROXIA; KINASE; TRANSCRIPTION; ACTIVATION; ISCHEMIA; PATHWAY	Administering high levels of inspired oxygen, or hyperoxia, is commonly used as a life-sustaining measure in critically ill patients. Unfortunately, the oxidant stress generated by prolonged hyperoxia can lead to respiratory failure, multiorgan failure, and death. Although the endothelial cell is known to be a target for hyperoxia-induced injury, its precise role is unclear. Heme oxygenase-1 (HO-1) and "signal transducer and activator of transcription 3" (STAT3) have been found to confer protection against endothelial cell injury. We sought to elucidate the specific roles of HO-1 and STAT3 in hyperoxic lung and endothelial cell injury. Mice or murine lung endothelial cells (MLEC) administered HO-1 siRNA exhibited marked injury and death compared with nonspecific siRNA. Overexpression of either HO-1 or STAT3 confers protection. However, HO-1 and its reaction product carbon monoxide (CO) lose their protective effects in the presence of STAT3 siRNA in MLEC or in endothelial-specific, STAT3-deficient mice. STAT3 overexpression is able to partially rescue HO-1-deficient MLEC from hyperoxia-induced cell death. Our results demonstrate 1) the importance of the endothelium in lethal hyperoxic injury, 2) HO-1 and CO require endothelial STAT3 for their protective effects, and 3) STAT3 confers endothelial cell protection via both HO-1-dependent and independent mechanisms.	Yale Univ, Sch Med, Sect Pulm & Crit Care Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Surg, Sch Med, Boston, MA 02215 USA; Indiana Univ, Dept Microbiol & Immunol, Indianapolis, IN 46204 USA	Yale University; Yale University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Indiana University System; Indiana University-Purdue University Indianapolis	Lee, PJ (corresponding author), Yale Univ, Sch Med, Sect Pulm & Crit Care Med, POB 208057, New Haven, CT 06520 USA.	patty.lee@yale.edu	zhang, xu/GYE-3558-2022	Zhang, Xuchen/0000-0002-1484-4672	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071595] Funding Source: Medline; NIAID NIH HHS [R01 AI034522] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMSON IYR, 1970, ARCH PATHOL, V90, P463; Ahmad A, 2006, FREE RADICAL BIO MED, V40, P1108, DOI 10.1016/j.freeradbiomed.2005.10.045; Alam J, 2002, ANTIOXID REDOX SIGN, V4, P559, DOI 10.1089/15230860260220049; Barazzone C, 2000, AM J RESP CELL MOL, V22, P517, DOI 10.1165/ajrcmb.22.5.f180; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; Dennery PA, 2003, FREE RADICAL BIO MED, V34, P124, DOI 10.1016/S0891-5849(02)01295-9; Deramaudt TB, 1999, P SOC EXP BIOL MED, V222, P185, DOI 10.1046/j.1525-1373.1999.d01-130.x; FISHER AB, 1980, AM REV RESPIR DIS, V122, P61, DOI 10.1164/arrd.1980.122.5P2.61; Fondevila C, 2004, HEPATOLOGY, V40, P1333, DOI 10.1002/hep.20480; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; Hammerman C, 2002, J PEDIATR GASTR NUTR, V35, P344, DOI 10.1097/00005176-200209000-00020; Hokuto I, 2004, J CLIN INVEST, V113, P28, DOI 10.1172/JCI200419491; Jacoby JJ, 2003, P NATL ACAD SCI USA, V100, P12929, DOI 10.1073/pnas.2134694100; Jin Y, 2005, AM J RESP CELL MOL, V33, P297, DOI 10.1165/rcmb.2005-0144OC; Kaizu T, 2005, SURGERY, V138, P229, DOI 10.1016/j.surg.2005.06.015; Kano A, 2003, J EXP MED, V198, P1517, DOI 10.1084/jem.20030077; Kuhlencordt PJ, 2004, AM J PHYSIOL-CELL PH, V286, pC1195, DOI 10.1152/ajpcell.00546.2002; Kunisada K, 2000, P NATL ACAD SCI USA, V97, P315, DOI 10.1073/pnas.97.1.315; Langouche L, 2005, J CLIN INVEST, V115, P2277, DOI 10.1172/JCI25385; Lee PJ, 2005, HEME OXYGENASE: THE ELEGANT ORCHESTRATION OF ITS PRODUCTS IN MEDICINE, P211; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; Lu YB, 2001, J EXP MED, V193, P545, DOI 10.1084/jem.193.4.545; Mantell LL, 2000, MOL GENET METAB, V71, P359, DOI 10.1006/mgme.2000.3046; Nakao A, 2004, GASTROENTEROLOGY, V127, P595, DOI 10.1053/j.gastro.2004.05.059; Nakao A, 2003, AM J PATHOL, V163, P1587, DOI 10.1016/S0002-9440(10)63515-8; Negoro S, 2001, CIRCULATION, V104, P979, DOI 10.1161/hc3401.095947; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; Neto JS, 2006, AM J PHYSIOL-RENAL, V290, pF324, DOI 10.1152/ajprenal.00026.2005; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Podewski EK, 2003, CIRCULATION, V107, P798, DOI 10.1161/01.CIR.0000057545.82749.FF; Quan S, 2002, J CELL BIOCHEM, V85, P410, DOI 10.1002/jcb.10147; Ricchetti GA, 2004, J LEUKOCYTE BIOL, V76, P719, DOI 10.1189/jlb.0104046; Song RP, 2003, AM J PATHOL, V163, P231, DOI 10.1016/S0002-9440(10)63646-2; Stephanou A, 1999, GENE EXPRESSION, V7, P311; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Tsan MF, 2001, INT J MOL MED, V7, P13; VanKlaveren RJ, 1997, AM J PHYSIOL-LUNG C, V273, pL548, DOI 10.1152/ajplung.1997.273.3.L548; Yamashita K, 2004, FASEB J, V18, P765, DOI 10.1096/fj.03-0839fje; Zhang XC, 2005, J BIOL CHEM, V280, P8714, DOI 10.1074/jbc.M408092200; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200; Zhou ZH, 2005, AM J PATHOL, V166, P27, DOI 10.1016/S0002-9440(10)62229-8	47	84	85	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2156	+		10.1096/fj.06-5668fje	http://dx.doi.org/10.1096/fj.06-5668fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16971418				2022-12-28	WOS:000241156900049
J	Reiter, B; Kraft, R; Gunzel, D; Zeissig, S; Schulzke, JD; Fromm, M; Harteneck, C				Reiter, Bettina; Kraft, Robert; Guenzel, Dorothee; Zeissig, Sebastian; Schulzke, Joerg-Dieter; Fromm, Michael; Harteneck, Christian			TRPV4-mediated regulation of epithelial permeability	FASEB JOURNAL			English	Article						transepithelial electrical resistance; paracellular pathway; transcellular pathway; calcium homeostasis; BK channel	CANINE KIDNEY-CELLS; CATION CHANNEL; 2-AMINOETHOXYDIPHENYL BORATE; TIGHT JUNCTIONS; TRPV4 CHANNELS; ACTIVATE TRPV4; ION-CHANNEL; EXPRESSION; RECEPTOR; PROTEIN	TRPV4 is a calcium-permeable channel activated by extracellular hypotonicity, polyunsaturated fatty acids, phorbol esters, and heat. We show that TRPV4 is localized in the basolateral membrane of the mouse mammary cell line HC11. Activation of TRPV4 caused an increase in the intracellular Ca2+ concentration through influx of extracellular Ca2+, triggering two independent chains of events: 1) a rapid increase in transcellular conductance through the activation of apical large conductance calcium-activated (BK) potassium channels that were blockable by paxilline; 2) a slow increase in paracellular permeability for small solutes. The latter effect was accompanied by a down-regulation of the tight junctional proteins claudin -1, -3, -4, -5, -7, and -8 and by dramatic changes in tight junction morphology, including frequent large breaks in the tight junction strands. This dual modulation of epithelial permeability after TRPV4 activation may be involved in regulating the tonicity across mammary gland epithelia. TRPV4 activation may also be responsible for exudation and edema formation during inflammation processes. - Reiter, B., Kraft, R., Gunzel, D., Zeissig, S., Schulzke, J-D., Fromm, M., Harteneck, C. TRPV4-mediated regulation of epithelial permeability.	Inst Pharmakol, D-14195 Berlin, Germany; Free Univ Berlin, Fachbereich Biol Chem Pharm, D-1000 Berlin, Germany; Inst Klin Physiol, Berlin, Germany; Med Klin I Gastroenterol Infektiol & Rheumatol, Berlin, Germany	Free University of Berlin	Harteneck, C (corresponding author), Inst Pharmakol, Charite Campus Benjamin Franklin,Thielallee 69-73, D-14195 Berlin, Germany.	christian.harteneck@charite.de	Fromm, Michael/K-6203-2013; Kraft, Robert/E-9199-2011; Zeissig, Sebastian/B-6297-2012	Fromm, Michael/0000-0003-4497-7983; Kraft, Robert/0000-0002-5774-6001; Zeissig, Sebastian/0000-0001-5124-0897; Gunzel, Dorothee/0000-0002-7998-7164				Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Arniges M, 2004, J BIOL CHEM, V279, P54062, DOI 10.1074/jbc.M409708200; Bravo-Zehnder M, 2000, P NATL ACAD SCI USA, V97, P13114, DOI 10.1073/pnas.240455697; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chung MK, 2004, J NEUROSCI, V24, P5177, DOI 10.1523/JNEUROSCI.0934-04.2004; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; den Dekker E, 2003, CELL CALCIUM, V33, P497, DOI 10.1016/S0143-4160(03)00065-4; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Grimm C, 2003, J BIOL CHEM, V278, P21493, DOI 10.1074/jbc.M300945200; Gross GJ, 2005, CARDIOVASC RES, V68, P18, DOI 10.1016/j.cardiores.2005.06.007; Grunnet M, 2005, BBA-BIOMEMBRANES, V1714, P114, DOI 10.1016/j.bbamem.2005.05.012; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; KREUSEL KM, 1991, AM J PHYSIOL, V261, pC574, DOI 10.1152/ajpcell.1991.261.4.C574; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; MULLIN M, 2004, SCI STKE, pPE2; Muraki K, 2003, CIRC RES, V93, P829, DOI 10.1161/01.RES.0000097263.10220.0C; Natarajan R, 2003, CURR OPIN PHARMACOL, V3, P198, DOI 10.1016/S1471-4892(03)00015-8; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Nguyen DAD, 1998, J MAMMARY GLAND BIOL, V3, P233, DOI 10.1023/A:1018707309361; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; SCHIFFERDECKER E, 1978, PFLUG ARCH EUR J PHY, V377, P125, DOI 10.1007/BF00582842; SCHULZKE JD, 1992, GASTROENTEROLOGY, V102, P497, DOI 10.1016/0016-5085(92)90096-H; Stelwagen K, 1999, MOL CELL ENDOCRINOL, V156, P55, DOI 10.1016/S0303-7207(99)00145-8; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Tian W, 2004, AM J PHYSIOL-RENAL, V287, pF17, DOI 10.1152/ajprenal.00397.2003; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Yu ASL, 2003, J BIOL CHEM, V278, P17350, DOI 10.1074/jbc.M213286200	36	87	90	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1802	1812		10.1096/fj.06-5772com	http://dx.doi.org/10.1096/fj.06-5772com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940152				2022-12-28	WOS:000240267000008
J	Mazzone, M; Comoglio, PM				Mazzone, Massimiliano; Comoglio, Paolo M.			The Met pathway: master switch and drug target in cancer progression	FASEB JOURNAL			English	Review						HGF; invasive growth; microenvironment; crosstalk; inhibitors	EPITHELIAL-MESENCHYMAL TRANSITIONS; HEPATOCYTE GROWTH-FACTOR; FOCAL-ADHESION KINASE; TRANSCRIPTION FACTOR SNAIL; BETA-CATENIN EXPRESSION; SCATTER-FACTOR; E-CADHERIN; C-MET; SOMATIC MUTATIONS; INVASIVE GROWTH	It has been recognized for more than a century that most tumors tend to become more aggressive in clinical behavior over time, although this time course may be variable. This phenomenon has been termed "cancer progression," a process that appears to develop in a stepwise fashion through qualitatively different stages. Cancer progression relies on the ability of neoplastic cells to abandon their primary site of accretion, trespass tissue boundaries, and penetrate into the vasculature to colonize and repopulate distant sites. Among the various properties associated with cancer progression, the acquisition by neoplastic cells of the capacity to invade locally and to metastasize is of great clinical significance, and is still the fundamental definition of malignancy. This process represents the aberrant counterpart of a physiological morphogenetic program, known as invasive growth, occurring during embryo development and, in some instances, in adulthood for the generation and maintenance of normal organ complexity and architecture. Here we summarize some of the strategies adopted to inhibit cancer cell growth and spreading. We also review the current findings about cancer and metastasis inhibitors. As we suggest possible directions for drug development, we propose the receptor for the hepatocyte growth factor, Met, as an ideal target for tackling cancer progression.	Univ Turin, Sch Med, Div Mol Oncol, Inst Canc Res & Treatment IRCC, I-10060 Candiolo, Torino, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Mazzone, M (corresponding author), Univ Turin, Sch Med, Div Mol Oncol, Inst Canc Res & Treatment IRCC, Strada Prov 142,Km 3-95, I-10060 Candiolo, Torino, Italy.	massimiliano.mazzone@ircc.it		Mazzone, Massimiliano/0000-0001-8824-4015; Comoglio, Paolo/0000-0002-7056-5328				Adjei AA, 2005, J CLIN ONCOL, V23, P5386, DOI 10.1200/JCO.2005.23.648; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; Barker N, 2001, TRENDS MOL MED, V7, P535, DOI 10.1016/S1471-4914(01)02215-8; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bertotti A, 2005, CANCER RES, V65, P10674, DOI 10.1158/0008-5472.CAN-05-2827; Bertotti A, 2003, TRENDS BIOCHEM SCI, V28, P527, DOI 10.1016/j.tibs.2003.09.001; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 2005, CANCER RES, V65, P8579, DOI 10.1158/0008-5472.CAN-05-2277; Boccaccio C, 2005, NATURE, V434, P396, DOI 10.1038/nature03357; Boon EMJ, 2002, CANCER RES, V62, P5126; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Bottaro DP, 2003, NATURE, V423, P593, DOI 10.1038/423593a; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chiara F, 2003, J BIOL CHEM, V278, P29352, DOI 10.1074/jbc.M302404200; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; CHRISTENSEN JG, 2006, CANCER RES, V63, P7345; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Cortesina G, 2000, INT J CANCER, V89, P286, DOI 10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.3.CO;2-L; Cristofanilli M, 2002, NAT REV DRUG DISCOV, V1, P415, DOI 10.1038/nrd819; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Date K, 1998, ONCOGENE, V17, P3045, DOI 10.1038/sj.onc.1202231; de Rooij J, 2005, J CELL BIOL, V171, P153, DOI 10.1083/jcb.200506152; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Durand R E, 1994, In Vivo, V8, P691; Eccles SA, 2004, INT J DEV BIOL, V48, P583, DOI 10.1387/ijdb.041820se; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Golubovskaya VM, 2003, MOL CANCER RES, V1, P755; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; ILLC D, 1995, NATURE, V377, P539; Jagadeeswaran R, 2006, CANCER RES, V66, P352, DOI 10.1158/0008-5472.CAN-04-4567; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kirchner T, 2000, AM J PATHOL, V157, P1113, DOI 10.1016/S0002-9440(10)64626-3; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Kung AL, 2004, CANCER CELL, V6, P33, DOI 10.1016/j.ccr.2004.06.009; Lee HO, 2003, DEV BIOL, V259, P162, DOI 10.1016/S0012-1606(03)00160-X; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Lin JM, 2005, CANCER RES, V65, P6901, DOI 10.1158/0008-5472.CAN-05-0408; Lorenzato A, 2002, CANCER RES, V62, P7025; MATSUMOTO K, 2006, INT J CANC; Mazzone M, 2004, J CLIN INVEST, V114, P1418, DOI 10.1172/JCI200422235; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Monga SPS, 2002, CANCER RES, V62, P2064; Montemurro F, 2004, EXPERT OPIN PHARMACO, V5, P81, DOI 10.1517/eoph.5.1.81.25499; Morello S, 2001, J CELL PHYSIOL, V189, P285, DOI 10.1002/jcp.10010; Morotti A, 2002, ONCOGENE, V21, P4885, DOI 10.1038/sj.onc.1205622; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nieto MA, 2001, MECH DEVELOP, V105, P27, DOI 10.1016/S0925-4773(01)00394-X; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; PAGET S, 1989, CANCER METAST REV, V8, P98; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PETRELLI A, 2006, IN PRESS P NATL ACAD; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Sattler M, 2003, CANCER RES, V63, P5462; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Stella MC, 2005, MOL CELL BIOL, V25, P3982, DOI 10.1128/MCB.25.10.3982-3996.2005; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tanaka T, 2005, CANCER SCI, V96, P317, DOI 10.1111/j.1349-7006.2005.00059.x; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tozer GM, 2005, NAT REV CANCER, V5, P423, DOI 10.1038/nrc1628; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Yanagida H, 2006, J SURG RES, V130, P38, DOI 10.1016/j.jss.2005.08.002; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang LY, 2004, WORLD J GASTROENTERO, V10, P3569, DOI 10.3748/wjg.v10.i24.3569; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327	123	108	112	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1611	1621		10.1096/fj.06-5947rev	http://dx.doi.org/10.1096/fj.06-5947rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873884	Green Accepted			2022-12-28	WOS:000240266600006
J	Mercado, ML; Amenta, AR; Hagiwara, H; Rafii, MS; Lechner, BE; Owens, RT; McQuillan, DJ; Froehner, SC; Fallon, JR				Mercado, Mary Lynn; Amenta, Alison R.; Hagiwara, Hiroki; Rafii, Michael S.; Lechner, Beatrice E.; Owens, Rick T.; McQuillan, David J.; Froehner, Stanley C.; Fallon, Justin R.			Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS	FASEB JOURNAL			English	Article						dystrophin-associated protein complex; alpha-dystrobrevin-2; sarcoglycans; beta 1-syntrophin	NITRIC-OXIDE SYNTHASE; LEUCINE-RICH PROTEOGLYCANS; MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; TARGETED DISRUPTION; ALPHA-DYSTROBREVIN; DEFICIENT MUSCLE; DECORIN; COMPLEX; MICE	The dystrophin-associated protein complex (DAPC) provides a linkage between the cytoskeleton and the extracellular matrix (ECM) and is also a scaffold for a host of signaling molecules. The constituents of the DAPC must be targeted to the sarcolemma in order to properly function. Biglycan is an ECM molecule that associates with the DAPC. Here, we show that biglycan null mice exhibit a mild dystrophic phenotype and display a selective reduction in the localization of alpha-dystrobrevin-1 and -2, alpha- and beta 1-syntrophin, and nNOS at the sarcolemma. Purified biglycan induces nNOS redistribution to the plasma membrane in cultured muscle cells. Biglycan protein injected into muscle becomes stably associated with the sarcolemma and ECM for at least 2 wk. This injected biglycan restores the sarcolemmal expression of alpha-dystrobrevin-1 and -2, and beta 1- and beta 2-syntrophin in biglycan null mice. We conclude that biglycan is important for the maintenance of muscle cell integrity and plays a direct role in regulating the expression and sarcolemmal localization of the intracellular signaling proteins dystrobrevin-1 and -2, alpha- and beta 1-syntrophin and nNOS.	Brown Univ, Dept Neurosci, Providence, RI 02912 USA; LifeCell Corp, Branchburg, NJ USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	Brown University; University of Washington; University of Washington Seattle	Fallon, JR (corresponding author), Brown Univ, Dept Neurosci, 190 Thayer St,Box 1953, Providence, RI 02912 USA.	Justin_Fallon@brown.edu			NCRR NIH HHS [RR15578, P20 RR015578] Funding Source: Medline; NIAMS NIH HHS [AR42826, R01 AR042826] Funding Source: Medline; NICHD NIH HHS [R01 HD023924-14S1, R01 HD023924-14, HD23924, R01 HD023924, R01 HD023924-13A1, R01 HD023924-17, R01 HD023924-15, R01 HD023924-12, R01 HD023924-16] Funding Source: Medline; NIMH NIH HHS [T32 MH020068, T32 MH020068-02, T32MH20068, T32 MH020068-03, T32 MH020068-01, T32 MH020068-05, T32 MH020068-04] Funding Source: Medline; NINDS NIH HHS [R01 NS033145, NS4678, NS33145, R44 NS045432] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023924] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH020068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033145, R44NS045432] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abdelmoity A, 2000, FEBS LETT, V482, P65, DOI 10.1016/S0014-5793(00)02038-X; Adams ME, 2000, J CELL BIOL, V150, P1385, DOI 10.1083/jcb.150.6.1385; AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Bowe MA, 2000, J CELL BIOL, V148, P801, DOI 10.1083/jcb.148.4.801; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Casar JC, 2004, DEV BIOL, V268, P358, DOI 10.1016/j.ydbio.2003.12.025; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Compton AG, 2005, J NEUROPATH EXP NEUR, V64, P350, DOI 10.1093/jnen/64.4.350; Crawford GE, 2000, J CELL BIOL, V150, P1399, DOI 10.1083/jcb.150.6.1399; Crosbie RH, 2002, FASEB J, V16, P1786, DOI 10.1096/fj.02-0519com; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Goldberg M, 2005, CALCIFIED TISSUE INT, V77, P297, DOI 10.1007/s00223-005-0026-7; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; Hack AA, 2000, MICROSC RES TECHNIQ, V48, P167, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<167::AID-JEMT5>3.0.CO;2-T; Hayashi Y, 2005, DEV BIOL, V277, P222, DOI 10.1016/j.ydbio.2004.09.022; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; Marchand S, 2001, EUR J NEUROSCI, V13, P221, DOI 10.1046/j.1460-9568.2001.01373.x; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; Metzinger L, 1997, HUM MOL GENET, V6, P1185, DOI 10.1093/hmg/6.7.1185; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Peters MF, 1998, J CELL BIOL, V142, P1269, DOI 10.1083/jcb.142.5.1269; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Rees SG, 2000, BIOCHEM J, V350, P181, DOI 10.1042/0264-6021:3500181; SAXON DW, 1994, NEUROREPORT, V5, P809, DOI 10.1097/00001756-199403000-00018; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Yoshida M, 2000, HUM MOL GENET, V9, P1033, DOI 10.1093/hmg/9.7.1033	32	48	52	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1724	+		10.1096/fj.05-5124fje	http://dx.doi.org/10.1096/fj.05-5124fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807372	Green Accepted			2022-12-28	WOS:000240266600028
J	Wang, Y; Levy, DE				Wang, Yaming; Levy, David E.			C-elegans STAT: evolution of a regulatory switch	FASEB JOURNAL			English	Article						transcription factors; domain accretion; nuclear accumulation; DNA binding factor; nematodes; tyrosine phosphorylation; SH2 domain	DNA-BINDING DOMAIN; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; DICTYOSTELIUM STAT; PROTEIN; GENE; TRANSCRIPTION; SEQUENCE; KINASES; GROWTH	STAT transcription factors have been implicated in many biological processes, particularly host immune defense and development. Here we characterize a STAT orthologue from the nematode, C. elegans. We show that this protein, termed STA-1, is structurally and functionally related to other vertebrate and invertebrate STAT proteins, recognizing a cis DNA element conserved through phylogeny. Unexpectedly, STA-1 lacks the conserved amino-terminal oligomerization domain found in vertebrate and other invertebrate STAT proteins, a feature also lacking in orthologues from a distantly related nematode species and from the slime mold, Dictyostelium discoideum. This absence suggests that a primordial STAT protein lacked this domain, which was accreted later in evolution to provide further regulatory control of STAT signaling. Derivation of null mutants demonstrated that STA-1 is not required for nematode viability, despite its widespread expression in multiple tissues of the worm. However, mutant STA-1 proteins that lack functional coiled-coil and DNA binding domains could still be activated and accumulated in the nucleus, suggesting that DNA binding is not a necessary prerequisite for nuclear retention of activated STAT proteins. Our results shed new light on the evolution and function of the STAT signaling pathway and on the structural requirements for STAT activation.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, NYU Canc Inst, New York, NY 10016 USA	New York University; New York University; New York University	Levy, DE (corresponding author), NYU, Sch Med, Dept Pathol, 550 1St Ave,MSB548, New York, NY 10016 USA.	del243@med.nyu.edu	Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022	Levy, David/0000-0002-7320-7788; 	NIAID NIH HHS [AI28900] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adler K, 1996, FEBS LETT, V395, P286, DOI 10.1016/0014-5793(96)01053-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BACH EA, 2003, SIGNAL TRANSDUCERS A, P87; Barillas-Mury C, 1999, EMBO J, V18, P959, DOI 10.1093/emboj/18.4.959; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; BRENNER S, 1974, GENETICS, V77, P71; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; da Graca LS, 2004, DEVELOPMENT, V131, P435, DOI 10.1242/dev.00922; Darnell JE, 1997, P NATL ACAD SCI USA, V94, P11767, DOI 10.1073/pnas.94.22.11767; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dearolf CR, 1999, CELL MOL LIFE SCI, V55, P1578, DOI 10.1007/s000180050397; Edgley M, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf051; Fields S, 1999, P NATL ACAD SCI USA, V96, P8825, DOI 10.1073/pnas.96.16.8825; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Fukuzawa M, 2001, MOL CELL, V7, P779, DOI 10.1016/S1097-2765(01)00222-2; Henriksen MA, 2002, GENE DEV, V16, P2379, DOI 10.1101/gad.1020702; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Hombria JCG, 2002, CURR BIOL, V12, pR569, DOI 10.1016/S0960-9822(02)01057-6; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Levy DE, 1999, CELL MOL LIFE SCI, V55, P1559, DOI 10.1007/s000180050395; Levy DE, 1998, METHODS, V15, P167, DOI 10.1006/meth.1998.0621; Lin CC, 2004, J BIOL CHEM, V279, P3308, DOI 10.1074/jbc.M309749200; Lodige I, 2005, J BIOL CHEM, V280, P43087, DOI 10.1074/jbc.M509180200; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Meyer T, 2004, EUR J BIOCHEM, V271, P4606, DOI 10.1111/j.1432-1033.2004.04423.x; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Oates AC, 1999, DEV DYNAM, V215, P352, DOI 10.1002/(SICI)1097-0177(199908)215:4<352::AID-AJA7>3.0.CO;2-J; Ortmann RA, 2000, ARTHRITIS RES, V2, P16, DOI 10.1186/ar66; Ota N, 2004, NAT IMMUNOL, V5, P208, DOI 10.1038/ni1032; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Plasterk RHA, 1995, METHOD CELL BIOL, V48, P59; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Schindler C, 2000, ADV PHARMACOL, V47, P113; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Wang YM, 2006, CURR BIOL, V16, P89, DOI 10.1016/j.cub.2005.11.061; Williams JG, 1999, TRENDS BIOCHEM SCI, V24, P333, DOI 10.1016/S0968-0004(99)01443-7; Williams JG, 2000, CURR OPIN GENET DEV, V10, P503, DOI 10.1016/S0959-437X(00)00119-2; WILLIAMS JG, 2003, SIGNAL TRANSDUCERS A, P105; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zeidler MP, 2000, ONCOGENE, V19, P2598, DOI 10.1038/sj.onc.1203482; Zhang Y, 2002, NATURE, V418, P331, DOI 10.1038/nature00891; Zhukovskaya NV, 2004, DEVELOPMENT, V131, P447, DOI 10.1242/dev.00927	58	23	23	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1641	1652		10.1096/fj.06-6051com	http://dx.doi.org/10.1096/fj.06-6051com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873887				2022-12-28	WOS:000240266600009
J	Sun, XL; Tong, YG; Qing, H; Chen, CH; Song, WH				Sun, Xiulian; Tong, Yigang; Qing, Hong; Chen, Chia-Hsiung; Song, Weihong			Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome	FASEB JOURNAL			English	Article						amyloid beta; Alzheimer's disease pathogenesis	AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE ACTIVITY; CLEAVING ENZYME; ASPARTYL PROTEASE; TRANSCRIPTIONAL REGULATION; EXPRESSION; SITE; GENERATION; CLEAVAGE; FAMILY	Almost all Down syndrome (DS) patients develop characteristic Alzheimer's disease (AD) neuropathology, including neuritic plaques and neurofibrillary tangles, after middle age. The mechanism underlying AD neuropathology in DS has been unknown. A beta is the central component of neuritic plaques and is generated from APP by cleavage by the beta- and gamma-secretases. Here we show that beta-secretase activity is markedly elevated in DS. The ratio of mature to immature forms of BACE1 is altered in DS. DS has significantly higher levels of mature BACE1 proteins in Golgi than normal controls. Time-lapse live image analysis showed that BACE1 proteins were predominantly immobile in Golgi in DS cells, while they underwent normal trafficking in controls. Thus, overproduction of A beta in DS is caused by abnormal BACE1 protein trafficking and maturation. Our results provide a novel molecular mechanism by which AD develops in DS and support the therapeutic potential of inhibiting BACE1 in AD and DS.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Grad Program Neurosci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Song, WH (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	weihong@interchange.ubc.ca	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X; Tong, Yigang/0000-0002-8503-8045				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Charlwood J, 2001, J BIOL CHEM, V276, P16739, DOI 10.1074/jbc.M009361200; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Cruts M, 2001, NEUROSCI LETT, V313, P105, DOI 10.1016/S0304-3940(01)02234-0; Down J. T., 1866, LONDON HOSP REPORTS, V3, P259; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2003, J BIOL CHEM, V278, P17141, DOI 10.1074/jbc.M213303200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; JACOBS PA, 1959, LANCET, V1, P710; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; KITAZUME S, 2004, GLYCOCONJ J, V20, P59; Lammich S, 2004, EMBO REP, V5, P620, DOI 10.1038/sj.embor.7400166; LEJEUNE J., 1959, BULL ACAD NATL MED [PARIS], V143, P256; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Li Y, 2006, FASEB J, V20, P285, DOI 10.1096/fj.05-4986com; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Mutton D, 1996, J MED GENET, V33, P387, DOI 10.1136/jmg.33.5.387; Nicolaou M, 2001, NEUROGENETICS, V3, P203; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Pastorino L, 2004, MOL CELL NEUROSCI, V25, P642, DOI 10.1016/j.mcn.2003.12.013; PODLISNY MB, 1987, SCIENCE, V238, P669, DOI 10.1126/science.2960019; Qing H, 2004, FASEB J, V18, P1571, DOI 10.1096/fj.04-1994fje; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Rogers GW, 2004, P NATL ACAD SCI USA, V101, P2794, DOI 10.1073/pnas.0308576101; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; Schmechel A, 2004, J BIOL CHEM, V279, P39710, DOI 10.1074/jbc.M402785200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Solans A, 2000, CYTOGENET CELL GENET, V89, P177, DOI 10.1159/000015608; Sun XL, 2006, FASEB J, V20, P1369, DOI 10.1096/FJ.05-5632COM; Sun XL, 2005, FASEB J, V19, P739, DOI 10.1096/fj.04-3426com; Tonelli DD, 2004, NUCLEIC ACIDS RES, V32, P1808, DOI 10.1093/nar/gkh348; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Westmeyer GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/jbc.M410378200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; ZHOU W, 2006, IN PRESS MOL CELL BI, V26	57	51	59	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1361	1368		10.1096/fj.05-5628com	http://dx.doi.org/10.1096/fj.05-5628com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816111				2022-12-28	WOS:000240266000013
J	Du, QY; Jovanovic, S; Clelland, A; Sukhodub, A; Budas, G; Phelan, K; Murray-Tait, V; Malone, L; Jovanovic, A				Du, Qingyou; Jovanovic, Sofija; Clelland, Allyson; Sukhodub, Andrey; Budas, Grant; Phelan, Karen; Murray-Tait, Victoria; Malone, Lorraine; Jovanovic, Aleksandar			Overexpression of SUR2A generates a cardiac phenotype resistant to ischemia	FASEB JOURNAL			English	Article						SUR2A; K-ATP channel; cardioprotection; hypoxia; heart	K-ATP CHANNELS; SENSITIVE POTASSIUM CHANNEL; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; VENTRICULAR MYOCYTES; H9C2 CELLS; HYPOXIA; HEART; CARDIOMYOCYTES; EXPRESSION; PROTECTION	ATP-sensitive K+ (K-ATP) channels are present in the sarcolemma of cardiac myocytes where they link membrane excitability with the cellular bioenergetic state. These channels are in vivo composed of Kir6.2, a pore-forming subunit, SUR2A, a regulatory subunit, and at least four accessory proteins. In the present study, real-time RT-PCR has demonstrated that of all six sarcolemmal K-ATP channel-forming proteins, SUR2A was probably the least expressed protein. We have generated mice where the SUR2A was under the control of a cytomegalovirus promoter, a promoter that is more efficient than the native promoter. These mice had an increase in SUR2A mRNA/protein levels in the heart whereas levels of mRNAs of other channel-forming proteins were not affected at all. Imunoprecipitation/ Western blot and patch clamp electrophysiology has shown an increase in K-ATP channel numbers in the sarcolemma of transgenic mice. Cardiomyocytes from transgenic mice responded to hypoxia with shortening of action membrane potential and were significantly more resistant to this insult than cardiomyocytes from the wild-type. The size of myocardial infarction in response to ischemia-reperfusion was much smaller in hearts from transgenic mice compared to those in wild-type. We conclude that overexpression of SUR2A generates cardiac phenotype resistant to hypoxia/ischemia/reperfusion injury due at least in part to increase in levels of sarcolemmal K-ATP channels.	Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Jovanovic, A (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.	a.jovanovic@dundee.ac.uk	Jovanovic, Aleksandar/A-4482-2008	Jovanovic, Aleksandar/0000-0002-1214-9318; Clelland, Allyson/0000-0003-3637-8497	Biotechnology and Biological Sciences Research Council [S18744] Funding Source: Medline; British Heart Foundation [PG/02/091/14227] Funding Source: Medline; Medical Research Council [G0400608(71317), G0400608] Funding Source: Medline; Wellcome Trust [059528/Z/99/Z/JMW/CP/JF] Funding Source: Medline; MRC [G0400608] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Babiker FA, 2002, CARDIOVASC RES, V53, P709, DOI 10.1016/S0008-6363(01)00526-0; BILLMAN GE, 1994, CARDIOVASC RES, V28, P762, DOI 10.1093/cvr/28.6.762; Budas GR, 2004, FASEB J, V18, P1046, DOI 10.1096/fj.04-1602fje; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; Crawford RM, 2003, J BIOL CHEM, V278, P31444, DOI 10.1074/jbc.M303051200; Crawford RM, 2002, EMBO J, V21, P3936, DOI 10.1093/emboj/cdf388; Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje; Dhar-Chowdhury P, 2005, J BIOL CHEM, V280, P38464, DOI 10.1074/jbc.M508744200; Gogelein H, 2001, N-S ARCH PHARMACOL, V364, P33, DOI 10.1007/s002100000391; Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117; Hanley PJ, 2005, J MOL CELL CARDIOL, V39, P17, DOI 10.1016/j.yjmcc.2005.04.002; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Jovanovic S, 2006, BIOCHEM BIOPH RES CO, V341, P57, DOI 10.1016/j.bbrc.2005.12.147; Jovanovic S, 2005, DIABETES, V54, P383, DOI 10.2337/diabetes.54.2.383; Jovanovic S, 2005, EMBO REP, V6, P848, DOI 10.1038/sj.embor.7400489; Kane GC, 2005, J MOL CELL CARDIOL, V38, P937, DOI 10.1016/j.yjmcc.2005.02.026; Kang YH, 2004, J BIOL CHEM, V279, P47125, DOI 10.1074/jbc.M404954200; Kloner RA, 2004, J AM COLL CARDIOL, V44, P276, DOI 10.1016/j.jacc.2004.03.068; Kloner RA, 2001, CIRCULATION, V104, P3158, DOI 10.1161/hc5001.100039; Kolar F, 2004, PHYSIOL RES, V53, pS3; Lacza Z, 2003, J MOL CELL CARDIOL, V35, P1339, DOI 10.1016/S0022-2828(03)00249-9; Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Ranki HJ, 2002, J AM COLL CARDIOL, V40, P367, DOI 10.1016/S0735-1097(02)01947-2; Ranki HJ, 2002, MECH AGEING DEV, V123, P695, DOI 10.1016/S0047-6374(01)00415-8; Ranki HJ, 2001, J AM COLL CARDIOL, V38, P906, DOI 10.1016/S0735-1097(01)01428-0; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Shibasaki T, 2004, DIABETES, V53, pS59, DOI 10.2337/diabetes.53.suppl_3.S59; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Singh H, 2003, J MOL CELL CARDIOL, V35, P445, DOI 10.1016/S0022-2828(03)00041-5; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; van Bever L, 2004, AM J PHYSIOL-HEART C, V287, pH850, DOI 10.1152/ajpheart.00054.2004; Verkerk AO, 1996, J MOL CELL CARDIOL, V28, P2443, DOI 10.1006/jmcc.1996.0237; Zingman LV, 2002, P NATL ACAD SCI USA, V99, P13278, DOI 10.1073/pnas.212315199	34	74	77	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1131	1141		10.1096/fj.05-5483com	http://dx.doi.org/10.1096/fj.05-5483com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770012	Green Accepted			2022-12-28	WOS:000240210300013
J	Voss, C; Eyol, E; Frank, M; von der Lieth, CW; Berger, MR				Voss, Cristina; Eyol, Ergul; Frank, Martin; von der Lieth, Claus-W.; Berger, Martin R.			Identification and characterization of riproximin, a new type II ribosome-inactivating protein with antineoplastic activity from Ximenia americana	FASEB JOURNAL			English	Article						anticancer agent; plant protein; lectin; peroral activity; liver metastasis model	RAT-LIVER METASTASIS; RICIN-A-CHAIN; ENDOPLASMIC-RETICULUM; AVISCUMINE RVISCUMIN; CRYSTAL-STRUCTURE; SOLID TUMORS; CELL-LINES; PHASE-I; LECTIN; BINDING	The aim of this study was to identify and characterize the active component(s) of Ximenia americana plant material used to treat cancer in African traditional medicine. By a combination of preextraction, extraction, ion exchange and affinity chromatography, a mixture of two cytotoxic proteins was isolated. Using degenerated primers designed on the de novo sequence of two tryptic peptides from one of these proteins, a DNA fragment was amplified and the sequence obtained was used to determine the complete cDNA sequence by the RACE method. Sequence analysis and molecular modeling showed that the new protein, riproximin, belongs to the family of type II ribosome inactivating proteins. These results are in good agreement with the ability of riproximin to inhibit protein synthesis in a cell-free system, as well as with the cytotoxicity of riproximin, as demonstrated by its IC50 value of 0.5 pM in MCF7, 1.1 pM in HELA and 0.6 pM in CC531-lacZ cells. To assess the antineoplastic efficacy of the purified riproximin in vivo, the CC531-lacZ colorectal cancer rat metastasis model was used. Significant anticancer activity was found after administration of total dosages of 100 (perorally) and 10 (intraperitoneally) pmol riproximin/kg. These results suggest that riproximin has distinct potential for cancer treatment.	Deutsch Krebsforschungszentrum, Toxicol & Chemotherapy Unit, D-69120 Heidelberg, Germany; German Canc Res Ctr, Cent Spectroscop Dept, D-6900 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Berger, MR (corresponding author), Deutsch Krebsforschungszentrum, Toxicol & Chemotherapy Unit, E100,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.berger@dkfz.de		Frank, Martin/0000-0002-1006-6746				ADAM KP, 2000, ANAL BIOGENER ARZNEI, P470; Barbieri L, 2004, FEBS LETT, V563, P219, DOI 10.1016/S0014-5793(04)00286-8; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Battelli MG, 2004, MINI-REV MED CHEM, V4, P513, DOI 10.2174/1389557043403819; Battelli MG, 2004, CELL MOL LIFE SCI, V61, P1975, DOI 10.1007/s00018-004-4171-3; CITORES L, 2003, CELL MOL BIOL, P49; Deeks ED, 2002, BIOCHEMISTRY-US, V41, P3405, DOI 10.1021/bi011580v; Eck J, 1999, EUR J BIOCHEM, V264, P775, DOI 10.1046/j.1432-1327.1999.00638.x; Girbes T, 2003, CELL MOL BIOL, V49, P537; Girbes T, 1996, CELL MOL BIOL, V42, P461; Hartley MR, 2004, MINI-REV MED CHEM, V4, P487, DOI 10.2174/1389557043403828; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; KINTER M, 1952, PROTEIN SEQUENCING I, P81; Kinter M, 2000, PROTEIN SEQUENCING I, V1st, P152; Konstantinov SM, 1998, INT J CANCER, V77, P778, DOI 10.1002/(SICI)1097-0215(19980831)77:5<778::AID-IJC18>3.0.CO;2-Y; Krauspenhaar R, 1999, BIOCHEM BIOPH RES CO, V257, P418, DOI 10.1006/bbrc.1999.0470; Kreitman RJ, 2003, CURR OPIN MOL THER, V5, P44; Langer M, 1996, ANAL BIOCHEM, V243, P150, DOI 10.1006/abio.1996.0493; LIN JY, 1970, NATURE, V227, P292, DOI 10.1038/227292a0; Lord JM, 2003, BIOCHEM SOC T, V31, P1260; Lord Michael J., 2003, Toxicological Reviews, V22, P53, DOI 10.2165/00139709-200322010-00006; Marsden CJ, 2004, EUR J BIOCHEM, V271, P153, DOI 10.1046/j.1432-1033.2003.03914.x; Mishra V, 2005, J BIOL CHEM, V280, P20712, DOI 10.1074/jbc.M500735200; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Munoz R, 2001, CANCER LETT, V167, P163, DOI 10.1016/S0304-3835(01)00477-3; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; Pryme IF, 2004, CANCER DETECT PREV, V28, P52, DOI 10.1016/j.cdp.2003.10.003; Pusztai A, 1998, J NUTR BIOCHEM, V9, P31, DOI 10.1016/S0955-2863(97)00164-2; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P240, DOI 10.1002/prot.340100308; Saenger J, 2004, J CANCER RES CLIN, V130, P203, DOI 10.1007/s00432-003-0523-x; Schoffski P, 2005, EUR J CANCER, V41, P1431, DOI 10.1016/j.ejca.2005.03.019; Schoffski P, 2004, ANN ONCOL, V15, P1816, DOI 10.1093/annonc/mdh469; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Stirpe F, 2004, TOXICON, V44, P371, DOI 10.1016/j.toxicon.2004.05.004; VOSS C, 2005, TOXICOL APPL PHARM; Wittmer A, 1999, CLIN EXP METASTAS, V17, P369, DOI 10.1023/A:1006643831825	39	37	37	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1194	+		10.1096/fj.05-5231fje	http://dx.doi.org/10.1096/fj.05-5231fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16641197				2022-12-28	WOS:000240210300023
J	Lopez-Lazaro, M				Lopez-Lazaro, Miguel			HIF-1: hypoxia-inducible factor or dysoxia-inducible factor?	FASEB JOURNAL			English	Article						oxygen; ATP; glycolysis; hydrogen peroxide; cancer	MITOCHONDRIAL COMPLEX-III; HEPATIC STELLATE CELLS; INTRACELLULAR PH; HYDROGEN-PEROXIDE; NA+/H+ EXCHANGER; GROWTH-FACTOR; CANCER; ACTIVATION; EXPRESSION; HIF-1-ALPHA	Hypoxia-inducible factor 1 (HIF-1) activates the transcription of genes involved in diverse aspects of cellular and integrative physiology, including energy metabolism, cell growth, survival, invasion, migration or angiogenesis. The activity of this transcription factor is known to be increased by hypoxia, but also by a growing number of apparently unrelated factors that can activate it even in nonhypoxic conditions. Here I propose a model in which an alteration in oxygen metabolism is the key cellular event involved in HIF-1 activation under hypoxic and nonhypoxic conditions. This new perspective unifies previously unrelated observations and predicts cellular processes and therapeutic strategies that may modify HIF-1 activity. This may have relevance, for instance, to cancer, as HIF-1 overexpression is observed in many human cancers and has been associated with increased patient mortality.	Univ Seville, Fac Pharm, Dept Pharmacol, Seville 41011, Spain	University of Sevilla	Lopez-Lazaro, M (corresponding author), Univ Seville, Fac Pharm, Dept Pharmacol, C Prof Garcia Gonzalez, Seville 41011, Spain.	mlopezlazaro@us.es						Alberts B., 2008, MOL BIOL CEL, V5th ed.; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cao Q, 2004, J BIOL CHEM, V279, P4292, DOI 10.1074/jbc.M308351200; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chou WC, 2004, P NATL ACAD SCI USA, V101, P4578, DOI 10.1073/pnas.0306687101; Cuezva JM, 2002, CANCER RES, V62, P6674; Dalgard CL, 2004, BIOCHEM J, V380, P419, DOI 10.1042/BJ20031647; Di Sario A, 2001, J HEPATOL, V34, P378, DOI 10.1016/S0168-8278(00)00062-3; DiGiammarino EL, 2002, NAT STRUCT BIOL, V9, P12, DOI 10.1038/nsb730; ERECINSKA M, 1995, J NEUROCHEM, V65, P2765; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; Harguindey S, 2005, BBA-REV CANCER, V1756, P1, DOI 10.1016/j.bbcan.2005.06.004; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Isidoro A, 2004, BIOCHEM J, V378, P17, DOI 10.1042/BJ20031541; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kamat CD, 2005, TOXICOL SCI, V86, P248, DOI 10.1093/toxsci/kfi190; Kim M, 2005, CARCINOGENESIS, V26, P1553, DOI 10.1093/carcin/bgi104; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200; LU H, 2005, J BIOL CHEM; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; Mekhail K, 2004, NAT CELL BIOL, V6, P642, DOI 10.1038/ncb1144; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; Pirkebner D, 2004, J CELL PHYSIOL, V198, P295, DOI 10.1002/jcp.10408; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; ROTHENBERG P, 1983, J BIOL CHEM, V258, P2644; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SIMCHOWITZ L, 1985, J CLIN INVEST, V76, P1079, DOI 10.1172/JCI112061; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Thomas R, 2005, BIOCHEM BIOPH RES CO, V334, P543, DOI 10.1016/j.bbrc.2005.06.114; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; van der Logt EMJ, 2005, FREE RADICAL BIO MED, V39, P182, DOI 10.1016/j.freeradbiomed.2005.03.003; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang FS, 2004, J BIOL CHEM, V279, P10331, DOI 10.1074/jbc.M308013200; Xu RH, 2005, CANCER RES, V65, P613; Zhong H, 2002, CANCER LETT, V181, P233, DOI 10.1016/S0304-3835(02)00053-8	47	68	79	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					828	832		10.1096/fj.05-5168hyp	http://dx.doi.org/10.1096/fj.05-5168hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675839				2022-12-28	WOS:000240157700004
J	MacRitchie, AN; Gardner, AA; Prescott, SM; Stafforini, DM				MacRitchie, Amy N.; Gardner, Alison A.; Prescott, Stephen M.; Stafforini, Diana M.			Molecular basis for susceptibility of plasma platelet-activating factor acetylhydrolase to oxidative inactivation	FASEB JOURNAL			English	Article						PAF acetylhydrolase; phospholipase A(2); oxidant stress; peroxynitrite; reactive oxygen species; protein oxidation	APOLIPOPROTEIN-A-I; NITRIC-OXIDE; CARDIOVASCULAR-DISEASE; PHOSPHOLIPASE A(2); REPERFUSION INJURY; LIPID MEDIATORS; PAF-AH; PEROXYNITRITE; NITRATION; LIPOPROTEIN	Platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A(2) that inactivates potent lipid messengers, such as PAF and modified phospholipids generated in settings of oxidant stress. The catalytic activity of PAF-AH is sensitive to oxidants, a feature that may have pathological consequences. We report that peroxynitrite, an oxidant species generated after cellular activation, mediates oxidative inactivation of PAF-AH. We found that peroxynitrite inactivated and derivatized the recombinant protein and obtained evidence supporting a role for a methionine and two tyrosine residues in this process. We employed inter-species comparisons and site-directed mutagenesis and identified a role for M-117, and a smaller contribution of Y-307 and Y-335 as targets of oxidant attack using free and lipoprotein-associated recombinant proteins. M-117 is adjacent to W-115 and L-116, which are essential for association of PAF-AH with LDL. Oxidation of LDL-associated PAF-AH partially dissociated the enzyme from the particles. Similarly, oxidation of the purified enzyme in the absence of lipoproteins prevented subsequent association with LDL. These results provide new insights into the molecular mechanisms that mediate inactivation of PAF-AH in settings of oxidant stress and the consequences of oxidation on the ability of this enzyme to associate with LDL.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Stafforini, DM (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Cir Hope, Salt Lake City, UT 84112 USA.	diana.stafforini@hci.utah.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akarasereenont Pravit, 2001, Journal of the Medical Association of Thailand, V84, pS730; AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; Arai H, 2002, J BIOCHEM, V131, P635, DOI 10.1093/oxfordjournals.jbchem.a003145; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491; Bielicki JK, 2001, ATHEROSCLEROSIS, V155, P71, DOI 10.1016/S0021-9150(00)00539-6; Blankenberg S, 2003, J LIPID RES, V44, P1381, DOI 10.1194/jlr.M300086-JLR200; Boyle J. J., 2005, Current Vascular Pharmacology, V3, P63, DOI 10.2174/1570161052773861; Caplan Michael S, 2005, Semin Pediatr Surg, V14, P145, DOI 10.1053/j.sempedsurg.2005.05.002; Caslake MJ, 2005, NAT CLIN PRACT CARD, V2, P529, DOI 10.1038/ncpcardio0321; Caslake MJ, 2003, CURR OPIN LIPIDOL, V14, P347, DOI 10.1097/00041433-200308000-00002; Chen CH, 2004, CURR OPIN LIPIDOL, V15, P337, DOI 10.1097/00041433-200406000-00015; Clements MK, 2003, J LEUKOCYTE BIOL, V73, P344, DOI 10.1189/jlb.0802401; DENTAN C, 1994, ARTERIOSCLER THROMB, V14, P353, DOI 10.1161/01.ATV.14.3.353; Ducrocq C, 1999, CELL MOL LIFE SCI, V55, P1068, DOI 10.1007/s000180050357; Forman Henry Jay, 2001, Molecular Aspects of Medicine, V22, P189; Gaston Benjamin M, 2003, Mol Interv, V3, P253, DOI 10.1124/mi.3.5.253; Gaylord MS, 1996, AM J MED SCI, V312, P149, DOI 10.1097/00000441-199610000-00001; Godecke A, 2003, CARDIOVASC RES, V60, P215, DOI 10.1016/j.cardiores.2003.09.005; Grzelak A, 2000, SCAND J CLIN LAB INV, V60, P253, DOI 10.1080/003655100750046413; Hardy P, 2005, PROSTAG LEUKOTR ESS, V72, P301, DOI 10.1016/j.plefa.2005.02.004; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Holvoet P, 1999, Expert Opin Investig Drugs, V8, P527, DOI 10.1517/13543784.8.5.527; Honda Z, 2002, J BIOCHEM, V131, P773, DOI 10.1093/oxfordjournals.jbchem.a003164; IMAIZUMI T-A, 1990, Heart and Vessels, V5, P81, DOI 10.1007/BF02058322; Ji YB, 2006, J BIOL CHEM, V281, P1986, DOI 10.1074/jbc.M509480200; Kuhn DM, 2002, J BIOL CHEM, V277, P14336, DOI 10.1074/jbc.M200290200; LASKIN DL, 1994, J LEUKOCYTE BIOL, V56, P751, DOI 10.1002/jlb.56.6.751; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Marathe GK, 2001, TRENDS CARDIOVAS MED, V11, P139, DOI 10.1016/S1050-1738(01)00100-1; MIYAURA S, 1992, CIRC RES, V70, P341, DOI 10.1161/01.RES.70.2.341; Moriel P, 2002, BRAZ J MED BIOL RES, V35, P1301, DOI 10.1590/S0100-879X2002001100007; MULLER E, 1993, P NATL ACAD SCI USA, V90, P5818, DOI 10.1073/pnas.90.12.5818; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; RABINOVICI R, 1993, J APPL PHYSIOL, V74, P1791, DOI 10.1152/jappl.1993.74.4.1791; Rohn TT, 1998, EUR J PHARMACOL, V353, P329, DOI 10.1016/S0014-2999(98)00399-9; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763, DOI 10.1164/ajrccm.155.5.9154889; SHAO B, 2006, J BIOL CHEM; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; Souza DG, 2003, BRIT J PHARMACOL, V139, P733, DOI 10.1038/sj.bjp.0705296; STAFFORINI DM, 1989, P NATL ACAD SCI USA, V86, P2393, DOI 10.1073/pnas.86.7.2393; Stafforini DM, 2006, J BIOL CHEM, V281, P4616, DOI 10.1074/jbc.M507340200; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344; Stafforini DM, 1999, J BIOL CHEM, V274, P7018, DOI 10.1074/jbc.274.11.7018; Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693; STAFFORINI DM, 1992, T ASSOC AM PHYSICIAN, V105, P44; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; Suckling Keith E, 2002, Expert Opin Ther Targets, V6, P309; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Tjoelker LW, 2000, BBA-MOL CELL BIOL L, V1488, P102, DOI 10.1016/S1388-1981(00)00114-1; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Tsukahara Y, 1996, J SURG RES, V66, P43, DOI 10.1006/jsre.1996.0370; Vassalle C, 2002, CLIN CHEM LAB MED, V40, P802, DOI 10.1515/CCLM.2002.139; Wu B, 2003, FASEB J, V17, P1156, DOI 10.1096/fj.02-0499fje; Yamada Y, 2000, ATHEROSCLEROSIS, V150, P209, DOI 10.1016/S0021-9150(99)00385-8; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	58	30	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1164	1176		10.1096/fj.06-6743com	http://dx.doi.org/10.1096/fj.06-6743com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17210780				2022-12-28	WOS:000245650400021
J	Oberholzer, M; Marti, G; Baresic, M; Kunz, S; Hemphill, A; Seebeck, T				Oberholzer, Michael; Marti, Gabriela; Baresic, Mario; Kunz, Stefan; Hemphill, Andrew; Seebeck, Thomas			The Trypanosoma brucei cAMP phosphodiesterases TbrPDEB1 and TbrPDEB2: flagellar enzymes that are essential for parasite virulence	FASEB JOURNAL			English	Article						African sleeping sickness; PDE inhibitor; cytokinesis; life cycle stages; paraflagellar rod structure	PROTEIN-KINASE-A; PARAFLAGELLAR ROD; SCHIZOSACCHAROMYCES-POMBE; ADENYLYL-CYCLASE; PATHWAY; CRUZI; ISOFORMS; CLONING; BINDING; SIGNAL	Cyclic nucleotide specific phosphodiesterases (PDEs) are pivotal regulators of cellular signaling. They are also important drug targets. Besides catalytic activity and substrate specificity, their subcellular localization and interaction with other cell components are also functionally important. In contrast to the mammalian PDEs, the significance of PDEs in protozoal pathogens remains mostly unknown. The genome of Trypanosoma brucei, the causative agent of human sleeping sickness, codes for five different PDEs. Two of these, TbrPDEB1 and TbrPDEB2, are closely similar, cAMP-specific. PDEs containing two GAF-domains in their N-terminal regions. Despite their similarity, these two PDEs exhibit different subcellular localizations. TbrPDEB1 is located in the flagellum, whereas TbrPDEB2 is distributed between flagellum and cytoplasm. RNAi against the two mRNAs revealed that the two enzymes can complement each other but that a simultaneous ablation of both leads to cell death in bloodstream form trypanosomes. RNAi against TbrPDEB1 and TbrPDEB2 also functions in vivo where it completely prevents infection and eliminates ongoing infections. Our data demonstrate that TbrPDEB2 and TbrPDEB2 are essential for virulence, making them valuable potential targets for new PDE-inhibitor based trypanocidal drugs. Furthermore, they are compatible with the notion that the flagellum of T. brucei is an important site of cAMP signaling.	Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland; Univ Bern, Inst Parasitol, CH-3012 Bern, Switzerland	University of Bern; University of Bern	Seebeck, T (corresponding author), Univ Bern, Inst Cell Biol, Baltzerstr 4, CH-3012 Bern, Switzerland.	thomas.seebeck@izb.unibe.ch		Hemphill, Andrew/0000-0002-0622-2128				Bastin P, 1999, J CELL SCI, V112, P3769; Bastin P, 2000, J CELL SCI, V113, P3321; Beavo J.A., 2006, CYCLIC NUCLEOTIDE PH; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; Bradley J, 2005, CURR OPIN NEUROBIOL, V15, P343, DOI 10.1016/j.conb.2005.05.014; Broadhead R, 2006, NATURE, V440, P224, DOI 10.1038/nature04541; Bruder S, 2005, P NATL ACAD SCI USA, V102, P3088, DOI 10.1073/pnas.0409917102; BRUN R, 1979, ACTA TROP, V36, P289; Cann MJ, 2004, IUBMB LIFE, V56, P529, DOI 10.1080/15216540400013861; D'Angelo M, 2002, J BIOL CHEM, V277, P35025, DOI 10.1074/jbc.M204696200; D'Angelo MA, 2004, BIOCHEM J, V378, P63, DOI 10.1042/BJ20031147; Diaz-Benjumea R, 2006, BIOCHEM J, V399, P305, DOI 10.1042/BJ20060757; Eisenbach M, 2006, NAT REV MOL CELL BIO, V7, P276, DOI 10.1038/nrm1893; Fevre EM, 2006, ADV PARASIT, V61, P167, DOI 10.1016/S0065-308X(05)61005-6; Friebe A, 2003, CIRC RES, V93, P96, DOI 10.1161/01.RES.0000082524.34487.31; Gull K, 1999, ANNU REV MICROBIOL, V53, P629, DOI 10.1146/annurev.micro.53.1.629; Hatanaka M, 2001, YEAST, V18, P207, DOI 10.1002/1097-0061(200102)18:3<207::AID-YEA661>3.0.CO;2-I; HESSE F, 1995, MOL BIOCHEM PARASIT, V70, P157, DOI 10.1016/0166-6851(95)00027-X; Hoffman CS, 2005, BIOCHEM SOC T, V33, P257, DOI 10.1042/BST0330257; Houslay MD, 2003, BIOCHEM SOC T, V31, P1186; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; Johner A, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-25; Kimmel AR, 2003, SCIENCE, V300, P1525, DOI 10.1126/science.1085439; Kunz S, 2006, MOL BIOCHEM PARASIT, V145, P133, DOI 10.1016/j.molbiopara.2005.09.018; Laxman S, 2005, J BIOL CHEM, V280, P3771, DOI 10.1074/jbc.M408111200; Lerner A, 2000, LEUKEMIA LYMPHOMA, V37, P39, DOI 10.3109/10428190009057627; Maga JA, 1999, TRENDS CELL BIOL, V9, P409, DOI 10.1016/S0962-8924(99)01635-9; Manallack DT, 2005, J MED CHEM, V48, P3449, DOI 10.1021/jm040217u; Masciarelli S, 2004, J CLIN INVEST, V114, P196, DOI 10.1172/JCI2004210804; Millar JK, 2005, SCIENCE, V310, P1187, DOI 10.1126/science.1112915; Mongillo M, 2006, CIRC RES, V98, P226, DOI 10.1161/01.RES.0000200178.34179.93; O'Beirne C, 1998, MOL BIOCHEM PARASIT, V91, P165, DOI 10.1016/S0166-6851(97)00191-6; Oberholzer M, 2006, MOL BIOCHEM PARASIT, V145, P117, DOI 10.1016/j.molbiopara.2005.09.002; Ott A, 2000, EMBO J, V19, P5782, DOI 10.1093/emboj/19.21.5782; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; Park JI, 2005, BIOCHEM BIOPH RES CO, V327, P311, DOI 10.1016/j.bbrc.2004.12.019; Parsons M, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-127; Pays E, 2001, MOL BIOCHEM PARASIT, V114, P1, DOI 10.1016/S0166-6851(01)00242-0; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Rascon A, 2002, P NATL ACAD SCI USA, V99, P4714, DOI 10.1073/pnas.002031599; Rehmann H, 2006, NATURE, V439, P625, DOI 10.1038/nature04468; Rochais F, 2006, CIRC RES, V98, P1081, DOI 10.1161/01.RES.0000218493.09370.8e; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SCHLAEPPI K, 1989, J CELL BIOL, V109, P1695, DOI 10.1083/jcb.109.4.1695; SCHNEIDER A, 1987, J CELL BIOL, V104, P431, DOI 10.1083/jcb.104.3.431; Seebeck T, 2004, CURR MOL MED, V4, P585, DOI 10.2174/1566524043360113; Shalaby T, 2001, EUR J BIOCHEM, V268, P6197, DOI 10.1046/j.0014-2956.2001.02564.x; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Vassella E, 1997, J CELL SCI, V110, P2661; WENTZINGER L, 2006, CYCLIC NUCLEOTIDE PH; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Zoraghi R, 2005, J BIOL CHEM, V280, P12051, DOI 10.1074/jbc.M413611200; Zoraghi R, 2002, P NATL ACAD SCI USA, V99, P4343, DOI 10.1073/pnas.062716599	54	104	104	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					720	731		10.1096/fj.06-6818com	http://dx.doi.org/10.1096/fj.06-6818com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17167070				2022-12-28	WOS:000244686400011
J	Silva, AP; Lourenco, J; Xapelli, S; Ferreira, R; Kristiansen, H; Woldbye, DPD; Oliveira, CR; Malva, JO				Silva, Ana P.; Lourenco, Joana; Xapelli, Sara; Ferreira, Raquel; Kristiansen, Heidi; Woldbye, David P. D.; Oliveira, Catarina R.; Malva, Joao O.			Protein kinase C activity blocks neuropeptide Y-mediated inhibition of glutamate release and contributes to excitability of the hippocampus in status epilepticus	FASEB JOURNAL			English	Article						Y-2 receptor; nerve terminal; seizures; phosphorylation	ACID-INDUCED SEIZURES; PRESYNAPTIC INHIBITION; RAT HIPPOCAMPUS; IN-VITRO; SYNAPTIC-TRANSMISSION; PHORBOL ESTERS; MESSENGER-RNAS; GRANULE CELLS; UP-REGULATION; PEPTIDE YY	The unbalanced excitatory/inhibitory neurotransmitter function in the neuronal network afflicted by seizures is the main biochemical and biophysical hallmark of epilepsy. The aim of this work was to identify changes in the signaling mechanisms associated with neuropeptide Y (NPY)-mediated inhibition of glutamate release that may contribute to hyperexcitability. Using isolated rat hippocampal nerve terminals, we showed that the KCl-evoked glutamate release is inhibited by NPY Y-2 receptor activation and is potentiated by the stimulation of protein kinase C (PKC). Moreover, we observed that immediately after status epilepticus (6 h postinjection with kainate, 10 mg/kg), the functional inhibition of glutamate release by NPY Y-2 receptors was transiently blocked concomitantly with PKC hyperactivation. The pharmacological blockade of seizure-activated PKC revealed again the Y-2 receptor-mediated inhibition of glutamate release. The functional activity of PKC immediately after status epilepticus was assessed by evaluating phosphorylation of the AMPA receptor subunit GluR1 (Ser-831), a substrate for PKC. Moreover, NPY-stimulated [S-35]GTP gamma S autoradiographic binding studies indicated that the common target for Y-2 receptor and PKC on the inhibition/potentiation of glutamate release was located downstream of the Y-2 receptor, or its interacting G-protein, and involves voltage-gated calcium channels.	Univ Coimbra, Fac Med, Inst Biochem, Ctr Neurosci & Cell Biol, P-3004504 Coimbra, Portugal; Univ Coimbra, Fac Med, Inst Pharmacol & Therapeut, P-3004504 Coimbra, Portugal; Univ Coimbra, Ctr Neurosci & Cell Biol, P-3000 Coimbra, Portugal; Univ Copenhagen, Rigshosp, Univ Hosp, Lab Neuropsychiat, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Dept Pharmacol, DK-2100 Copenhagen, Denmark	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Rigshospitalet; University of Copenhagen; University of Copenhagen	Malva, JO (corresponding author), Univ Coimbra, Fac Med, Inst Biochem, Ctr Neurosci & Cell Biol, P-3004504 Coimbra, Portugal.	jomalva@fmed.uc.pt	Silva, Ana Paula/L-4184-2014; Ferreira, Raquel/AAA-7401-2021; Oliveira, Catarina R./F-3685-2010; Malva, Joao/L-3557-2014	Silva, Ana Paula/0000-0002-7802-8690; Ferreira, Raquel/0000-0003-1014-0499; Xapelli, Sara/0000-0001-6854-2509; Oliveira, Catarina/0000-0001-6942-4328; Malva, Joao/0000-0002-5438-4447; Woldbye, David/0000-0002-6321-3850				Baraban SC, 1997, J NEUROSCI, V17, P8927, DOI 10.1523/jneurosci.17-23-08927.1997; Berglund MM, 2003, EXP BIOL MED, V228, P217, DOI 10.1177/153537020322800301; Bijak M, 1999, NEUROSCI LETT, V268, P115, DOI 10.1016/S0304-3940(99)00381-X; BLACKSTONE C, 1994, J NEUROSCI, V14, P7585; BLEAKMAN D, 1992, BRIT J PHARMACOL, V107, P334, DOI 10.1111/j.1476-5381.1992.tb12747.x; CAMBRAYDEAKIN MA, 1990, DEV BRAIN RES, V53, P40, DOI 10.1016/0165-3806(90)90122-F; CAMPENOT RB, 1994, J NEUROCHEM, V63, P868; Chow KBS, 2003, EUR J PHARMACOL, V474, P7, DOI 10.1016/S0014-2999(03)02006-5; COFFEY ET, 1993, J BIOL CHEM, V268, P21060; COLMERS WF, 1991, BRIT J PHARMACOL, V102, P41, DOI 10.1111/j.1476-5381.1991.tb12129.x; Colmers William F., 2003, Epilepsy Curr, V3, P53, DOI 10.1046/j.1535-7597.2003.03208.x; Dumont Y, 2000, BRIT J PHARMACOL, V129, P1075, DOI 10.1038/sj.bjp.0703162; El Bahh B, 2005, EUR J NEUROSCI, V22, P1417, DOI 10.1111/j.1460-9568.2005.04338.x; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; FELIPO V, 1993, BRAIN RES, V604, P192, DOI 10.1016/0006-8993(93)90368-W; GANDHI VC, 1992, NEUROPHARMACOLOGY, V31, P1101, DOI 10.1016/0028-3908(92)90005-A; Garcia-Sainz JA, 2001, BIOCHEM J, V353, P603, DOI 10.1042/0264-6021:3530603; Gobbi M, 1998, J NEUROCHEM, V70, P1615; GREBER S, 1994, BRIT J PHARMACOL, V113, P737, DOI 10.1111/j.1476-5381.1994.tb17055.x; Guglielmetti F, 1997, MOL BRAIN RES, V49, P188, DOI 10.1016/S0169-328X(97)00142-3; HERRERO I, 1992, J NEUROCHEM, V59, P1574, DOI 10.1111/j.1471-4159.1992.tb08478.x; Hoffman DA, 1998, J NEUROSCI, V18, P3521; Hori T, 1999, J NEUROSCI, V19, P7262, DOI 10.1523/JNEUROSCI.19-17-07262.1999; Hussain RJ, 2003, BRAIN RES, V990, P28, DOI 10.1016/S0006-8993(03)03381-X; KLAPSTEIN GJ, 1992, BRIT J PHARMACOL, V105, P470, DOI 10.1111/j.1476-5381.1992.tb14277.x; Klapstein GJ, 1997, J NEUROPHYSIOL, V78, P1651, DOI 10.1152/jn.1997.78.3.1651; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; Malva JO, 1996, NEUROREPORT, V7, P1330, DOI 10.1097/00001756-199605170-00023; Marsh DJ, 1999, P NATL ACAD SCI USA, V96, P13518, DOI 10.1073/pnas.96.23.13518; MCMAHON HT, 1992, J BIOL CHEM, V267, P21338; McNamara RK, 2000, J NEUROSCI RES, V62, P416, DOI 10.1002/1097-4547(20001101)62:3<416::AID-JNR12>3.0.CO;2-V; Michel MC, 1998, PHARMACOL REV, V50, P143; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; PARFITT KD, 1993, J PHYSIOL-LONDON, V471, P245, DOI 10.1113/jphysiol.1993.sp019900; Parker RMC, 1999, EUR J NEUROSCI, V11, P1431, DOI 10.1046/j.1460-9568.1999.00553.x; PARROW V, 1995, J NEUROSCI RES, V41, P782, DOI 10.1002/jnr.490410609; Pinheiro PS, 2005, NEUROCHEM INT, V47, P309, DOI 10.1016/j.neuint.2005.05.007; REDMAN RS, 1997, J PHYSL, V15, P41; Rhim H, 1997, J NEUROSCI, V17, P2980; Richichi C, 2004, J NEUROSCI, V24, P3051, DOI 10.1523/JNEUROSCI.4056-03.2004; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SanchezPrieto J, 1996, TRENDS NEUROSCI, V19, P235, DOI 10.1016/0166-2236(96)10031-X; Silva AP, 2005, CNS NEUROL DISORD-DR, V4, P331, DOI 10.2174/1568007054546153; Silva AP, 2005, J NEUROCHEM, V93, P163, DOI 10.1111/j.1471-4159.2004.03005.x; Silva AP, 2001, J NEUROCHEM, V79, P286, DOI 10.1046/j.1471-4159.2001.00560.x; Silva AP, 2003, NEUROPHARMACOLOGY, V44, P282, DOI 10.1016/S0028-3908(02)00382-9; SIM LJ, 1995, P NATL ACAD SCI USA, V92, P7242, DOI 10.1073/pnas.92.16.7242; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPERK G, 1985, BRAIN RES, V338, P289, DOI 10.1016/0006-8993(85)90159-3; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; Tang FR, 2004, HIPPOCAMPUS, V14, P87, DOI 10.1002/hipo.10156; TOTH PT, 1993, NATURE, V364, P635, DOI 10.1038/364635a0; Vezzani A, 2002, NEUROSCIENCE, V110, P237, DOI 10.1016/S0306-4522(01)00581-4; Vezzani A, 1999, TRENDS NEUROSCI, V22, P25, DOI 10.1016/S0166-2236(98)01284-3; WAHLESTEDT C, 1993, ANNU REV PHARMACOL, V33, P309, DOI 10.1146/annurev.pa.33.040193.001521; Wang SJ, 2006, NEUROCHEM INT, V48, P181, DOI 10.1016/j.neuint.2005.10.006; WETTSTEIN JG, 1995, PHARMACOL THERAPEUT, V65, P397, DOI 10.1016/0163-7258(95)98598-K; Whittaker E, 1999, BRAIN RES, V827, P229, DOI 10.1016/S0006-8993(99)01302-5; Whittaker V.P., 1984, HDB NEUROCHEMISTRY, V7, P1; Woldbye DPD, 2005, NEUROBIOL DIS, V20, P760, DOI 10.1016/j.nbd.2005.05.010; Woldbye DPD, 1997, NAT MED, V3, P761, DOI 10.1038/nm0797-761; Woldbye DPD, 2004, NEUROPEPTIDES, V38, P253, DOI 10.1016/j.npep.2004.07.001; Wu YF, 2005, ACTA PHARMACOL SIN, V26, P63, DOI 10.1111/j.1745-7254.2005.00011.x	66	32	32	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					671	681		10.1096/fj.06-6163com	http://dx.doi.org/10.1096/fj.06-6163com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17167071	Green Submitted			2022-12-28	WOS:000244686400006
J	Levin, MH; de la Fuente, R; Verkman, AS				Levin, Marc H.; de la Fuente, Ricardo; Verkman, A. S.			Urearetics: a small molecule screen yields nanomolar potency inhibitors of urea transporter UT-B	FASEB JOURNAL			English	Article						urea transport; UT-B; kidney; diuretic; drug discovery; small-molecule discovery; aquaporin	URINARY CONCENTRATING ABILITY; MICE LACKING AQUAPORIN-1; WATER CHANNEL; KNOCKOUT MICE; ERYTHROCYTES; HYPONATREMIA; PROTEIN; DEFECT	Functional studies in knockout mice indicate a critical role for urea transporters (UTs) in the urinary concentrating mechanism and in renal urea clearance. However, potent and specific urea transport blockers have not been available. Here, we used high-throughput screening to discover high-affinity, small molecule inhibitors of the UT-B urea transporter. A collection of 50,000 diverse, drug like compounds was screened using a human erythrocyte lysis assay based on UT-B-facilitated acetamide transport. Primary screening yielded similar to 30 UT-B inhibitors belonging to the phenylsulfoxyoxazole, benzenesulfonanilide, phthalazinamine, and aminobenzimidazole chemical classes. Screening of similar to 700 structurally similar analogs gave many active compounds, the most potent of which inhibited UT-B urea transport with an EC50 of similar to 10 nM, and similar to 100% inhibition at higher concentrations. Phenyl-sulfoxyoxazoles and phthalazinamines also blocked rodent UT-B and had good UT-B vs. UT-A specificity. The UT-B inhibitors did not reduce aquaporin-1 (AQP1)-facilitated water transport. In AQP1-null erythrocytes, "chemical UT-B knockout" by UT-B inhibitors reduced by similar to 3-fold UT-B-mediated water transport, supporting an aqueous pore pathway through UT-B. UT-B inhibitors represent a new class of diuretics, "urearetics," which are predicted to increase renal water and solute clearance in water-retaining states.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, Grad Grp Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, Grad Grp Biophys, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124, DK72517] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574, P30EY002162] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517, R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagnasco SM, 2003, AM J PHYSIOL-RENAL, V284, pF3, DOI 10.1152/ajprenal.00260.2002; BANKIR L, 2000, KIDNEY; Cohn JV, 2003, MOL BIOCHEM PARASIT, V132, P27, DOI 10.1016/j.molbiopara.2003.08.001; Fenton RA, 2005, J AM SOC NEPHROL, V16, P1583, DOI 10.1681/ASN.2005010031; Fenton RA, 2004, P NATL ACAD SCI USA, V101, P7469, DOI 10.1073/pnas.0401704101; FROEHLICH O, 2006, AM J PHYSIOL, V291, pC600; Frohlich O, 2004, AM J PHYSIOL-CELL PH, V286, pC1264, DOI 10.1152/ajpcell.00499.2003; Goldsmith SR, 2005, AM J CARDIOL, V95, p14B, DOI 10.1016/j.amjcard.2005.03.004; Klein JD, 2004, J AM SOC NEPHROL, V15, P1161, DOI 10.1097/01.ASN.0000125617.19799.72; Lucien N, 1998, J BIOL CHEM, V273, P12973, DOI 10.1074/jbc.273.21.12973; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; MARTIAL S, 1993, PFLUG ARCH EUR J PHY, V423, P51, DOI 10.1007/BF00374960; MASILAMANI S, 2000, KIDNEY; MAYRAND RR, 1983, J GEN PHYSIOL, V81, P221, DOI 10.1085/jgp.81.2.221; Mazeron P, 2000, PHOTOCHEM PHOTOBIOL, V72, P172, DOI 10.1562/0031-8655(2000)072<0172:ATAOTM>2.0.CO;2; Miller M, 2006, J AM GERIATR SOC, V54, P345, DOI 10.1111/j.1532-5415.2005.00609.x; OLDENBURG KR, 2001, HDB DRUG SCREENING; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; Sands JM, 2004, CURR OPIN NEPHROL HY, V13, P525, DOI 10.1097/00041552-200409000-00008; Shayakul C, 2004, PFLUG ARCH EUR J PHY, V447, P603, DOI 10.1007/s00424-003-1124-x; Sidoux-Walter F, 1999, J BIOL CHEM, V274, P30228, DOI 10.1074/jbc.274.42.30228; Tsukaguchi H, 1997, J CLIN INVEST, V99, P1506, DOI 10.1172/JCI119313; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; Yang B, 2002, J BIOL CHEM, V277, P10633, DOI 10.1074/jbc.M200207200; Yang BX, 1998, J BIOL CHEM, V273, P9369, DOI 10.1074/jbc.273.16.9369; Yang BX, 2002, J BIOL CHEM, V277, P36782, DOI 10.1074/jbc.M206948200	26	51	57	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					551	563		10.1096/fj.06-6979com	http://dx.doi.org/10.1096/fj.06-6979com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17202246				2022-12-28	WOS:000244686300028
J	Machowetz, A; Poulsen, HE; Gruendel, S; Weimann, A; Fito, M; Marrugat, J; de la Torre, R; Salonen, JT; Nyyssonen, K; Mursu, J; Nascetti, S; Gaddi, A; Kiesewetter, H; Baumler, H; Selmi, H; Kaikkonen, J; Zunft, HJF; Covas, MI; Koebnick, C				Machowetz, Anja; Poulsen, Henrik E.; Gruendel, Sindy; Weimann, Allan; Fito, Montserrat; Marrugat, Jaume; de la Torre, Rafael; Salonen, Jukka T.; Nyyssonen, Kristiina; Mursu, Jaakko; Nascetti, Simona; Gaddi, Antonio; Kiesewetter, Holger; Baeumler, Hans; Selmi, Hany; Kaikkonen, Jari; Zunft, Hans-Joachim F.; Covas, Maria-Isabel; Koebnick, Corinna			Effect of olive oils on biomarkers of oxidative DNA stress in Northern and Southern Europeans	FASEB JOURNAL			English	Article						phenolic compounds; DNA and RNA damage	MASS-SPECTROMETRY; HUMAN URINE; FOOD GROUPS; DAMAGE; CANCER; ANTIOXIDANT; RISK; EXCRETION; SMOKING; REPAIR	High consumption of olive oil in the Mediterranean diet has been suggested to protect DNA against oxidative damage and to reduce cancer incidence. We investigated the impact of the phenolic compounds in olive oil, and the oil proper, on DNA and RNA oxidation in North, Central, and South European populations. In a multicenter, double-blind, randomized, controlled crossover intervention trial, the effect of olive oil phenolic content on urinary oxidation products of guanine ( 8-oxo-guanine, 8-oxo-guanosine and 8-oxo-deoxyguanosine) was investigated. Twenty-five mililiters of three olive oils with low, medium, and high phenolic content were administered to healthy males ( n = 182) daily for 3 wk. At study baseline the urinary excretion of 8-oxo-guanosine ( RNA oxidation) and 8-oxo-deoxyguanosine ( DNA oxidation) was higher in the Northern regions of Europe compared with Central and Southern European regions ( P = 0.035). Urinary excretion of the 8 hydroxylated forms of guanine, guanosine, deoxyguanosine and their nonoxidized forms were not different when comparing olive oils with low, medium, and high phenolic content given for 2 wk. Testing the effect of oil from urinary 8-oxo-deoxyguanosine changes from baseline to post-treatment showed a reduction of DNA oxidation by 13% ( P = 0.008). These findings support the idea that ingestion of olive oil is beneficial and can reduce the rate of oxidation of DNA. This effect is not due to the phenolic content in the olive oil. The higher DNA and RNA oxidation in Northern European regions compared with that in Central and Southern regions supports the contention that olive oil consumption may explain some of the North-South differences in cancer incidences in Europe.	Rigshosp, Dept Clin Pharmacol, DK-2100 Copenhagen, Denmark; German Inst Human Nutr Potsdam Rehbrucke, Nuthetal, Germany; Inst Municipal Invest Med, Lipids & Cardiovasc Epidemiol Unit, E-08003 Barcelona, Spain; Inst Municipal Invest Med, Pharmacol Res Unit, Barcelona, Spain; Univ Kuopio, Publ Hlth Res Inst, FIN-70211 Kuopio, Finland; Policlin S Orsola, Ctr Studio Arteriosclerosi & Malattie Dismetab GC, Dipartimento Med Clin & Biotecnol Applicata, Bologna, Italy; Charite Univ Med Berlin, Inst Transfus Med, Berlin, Germany; Oy Jurilab, Kuopio, Finland	Rigshospitalet; University of Copenhagen; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); University of Eastern Finland; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Poulsen, HE (corresponding author), Univ Copenhagen Hosp, Rigshosp, Dept Clin Pharmacol, Q7642,9 Blegdamsvej, DK-2100 Copenhagen, Denmark.	hepo@rh.dk	, Bäumler/N-1902-2019; de la Torre, Rafael/D-3561-2018; Koebnick, Corinna/P-4767-2016; Fito, Montserrat/C-1822-2012; Nascetti, Simona/GPF-8232-2022	, Bäumler/0000-0002-2573-2289; de la Torre, Rafael/0000-0002-6765-1866; Koebnick, Corinna/0000-0001-8274-0309; Fito, Montserrat/0000-0002-1817-483X; Poulsen, Henrik Enghusen/0000-0003-4242-9924; Marrugat, Jaume/0000-0003-3320-554X				Bosetti C, 2000, INT J CANCER, V87, P289, DOI 10.1002/1097-0215(20000715)87:2&lt;289::AID-IJC22&gt;3.0.CO;2-9; Braga C, 1998, CANCER-AM CANCER SOC, V82, P448, DOI 10.1002/(SICI)1097-0142(19980201)82:3&lt;448::AID-CNCR4&gt;3.0.CO;2-L; Cooke MS, 2002, FREE RADICAL BIO MED, V33, P1601, DOI 10.1016/S0891-5849(02)01146-2; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Deiana M, 1999, FREE RADICAL BIO MED, V26, P762, DOI 10.1016/S0891-5849(98)00231-7; Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001; Fito M, 2000, LIPIDS, V35, P633, DOI 10.1007/s11745-000-0567-1; Franceschi S, 1999, BRIT J CANCER, V80, P614, DOI 10.1038/sj.bjc.6690400; Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776; Hoffmann JS, 1998, INT J ONCOL, V12, P377; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; LAVECCHIA C, 1995, CANCER CAUSE CONTROL, V6, P545, DOI 10.1007/BF00054164; Lipworth L, 1997, PREV MED, V26, P181, DOI 10.1006/pmed.1996.9977; LOFT S, 1992, CARCINOGENESIS, V13, P2241, DOI 10.1093/carcin/13.12.2241; Marrugat J, 2004, EUR J NUTR, V43, P140, DOI 10.1007/s00394-004-0452-8; Miro-Casas E, 2001, ANAL BIOCHEM, V294, P63, DOI 10.1006/abio.2001.5160; Poulsen HE, 2005, EXP TOXICOL PATHOL, V57, P161, DOI 10.1016/j.etp.2005.05.015; Poulsen HE, 1998, EUR J CANCER PREV, V7, P9; Prieme H, 1998, CARCINOGENESIS, V19, P347, DOI 10.1093/carcin/19.2.347; Prieme H, 1997, AM J CLIN NUTR, V65, P503, DOI 10.1093/ajcn/65.2.503; Quiles JL, 2004, EXP GERONTOL, V39, P1189, DOI 10.1016/j.exger.2004.05.002; Quiles JL, 2002, BRIT J NUTR, V88, P225, DOI 10.1079/BJN2002620; Sanders TAB, 2001, INT J VITAM NUTR RES, V71, P179, DOI 10.1024/0300-9831.71.3.179; VANPOPPEL G, 1995, J NATL CANCER I, V87, P310, DOI 10.1093/jnci/87.4.310; Visioli F, 2002, MED RES REV, V22, P65, DOI 10.1002/med.1028; Weimann A, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e7; Whiteman M, 2002, BIOCHEM BIOPH RES CO, V296, P883, DOI 10.1016/S0006-291X(02)02018-1; [No title captured]; [No title captured]; [No title captured]; [No title captured]	33	110	111	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					45	52		10.1096/fj.06-6328com	http://dx.doi.org/10.1096/fj.06-6328com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17110467				2022-12-28	WOS:000243130200006
J	Wan, HC; Melo, RCN; Jin, Z; Dvorak, AM; Weller, PF				Wan, Hsiao-Ching; Melo, Rossana C. N.; Jin, Zhoung; Dvorak, Ann M.; Weller, Peter F.			Roles and origins of leukocyte lipid bodies: proteomic and ultrastructural studies	FASEB JOURNAL			English	Article						eosinophils; neutrophils; lipid bodies; lipid droplets; endoplasmic reticulum; U937 cells	ENDOPEROXIDE SYNTHASE CYCLOOXYGENASE; ENDOPLASMIC-RETICULUM; BODY FORMATION; IMMUNOGOLD LOCALIZATION; INTRACELLULAR DOMAINS; CA2+-BINDING PROTEIN; EICOSANOID FORMATION; HUMAN EOSINOPHILS; ARACHIDONIC-ACID; SURFACE-LAYER	Lipid bodies (LBs), multifunctional organelles present in most eukaryotic cells, are sites of eicosanoid formation in leukocytes; but little is known about the composition of leukocyte LBs or the biogenesis and internal structures of LBs from mammalian cells. Proteomic analyses of LBs purified from human monocytic U937 cells detected, common to LBs in other cells, proteins involved in cholesterol and triglyceride metabolism, Rab GTPases, and many membrane and endoplasmic reticulum (ER)-associated proteins. Newly lipid body (LB)-associated proteins included MRP-14, potentially involved in arachidonate transport, and ribosomal subunit proteins and translation regulatory proteins. Ultrastructurally, in U937 cells as well as human neutrophils and eosinophils, ribosomes are attached to and distributed within LBs, and LBs contain extensive ER-like membranes. The presence of ribosomes, ER-like membranes and many membrane-associated and ER luminal proteins within LBs, supports a new model by which enveloped ER-membranes and domains form LBs and indicates that LBs may be sites of protein synthesis.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA; Univ Fed Juiz de Fora, Dept Biol, Juiz de Fora, MG, Brazil	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Universidade Federal de Juiz de Fora	Weller, PF (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, DA-617,330 Brookline Ave, Boston, MA 02215 USA.	pweller@bidmc.harvard.edu	Melo, Rossana C. N./B-8248-2013	Melo, Rossana C. N./0000-0003-1736-0806	NHLBI NIH HHS [R01 HL070270, HL70270] Funding Source: Medline; NIAID NIH HHS [R01 AI022571-17, AI20241, R37 AI020241, AI22571, R01 AI022571-21A2, R01 AI020241, AI33372, R01 AI022571, R01 AI022571-19, R01 AI033372, R01 AI022571-20, R01 AI022571-18] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033372, R01AI022571, R37AI020241, R01AI020241] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrade J, 2004, BIOCHEM J, V384, P327, DOI 10.1042/BJ20040622; Andrade J, 2004, MOL BIOL CELL, V15, P481, DOI 10.1091/mbc.E03-07-0500; Arend A, 2004, PROSTAG OTH LIPID M, V74, P1, DOI 10.1016/j.prostaglandins.2004.05.002; Bandeira-Melo C, 2002, J ALLERGY CLIN IMMUN, V109, P393, DOI 10.1067/mai.2002.121529; Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; BEIL WJ, 1995, J LEUKOCYTE BIOL, V58, P284, DOI 10.1002/jlb.58.3.284; Beller M, 2006, MOL CELL PROTEOMICS, V5, P1082, DOI 10.1074/mcp.M600011-MCP200; Berthier S, 2003, J BIOL CHEM, V278, P25499, DOI 10.1074/jbc.M209755200; Binns D, 2006, J CELL BIOL, V173, P719, DOI 10.1083/jcb.200511125; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Blum R, 1996, J BIOL CHEM, V271, P17183, DOI 10.1074/jbc.271.29.17183; Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909; Bozza PT, 1996, P NATL ACAD SCI USA, V93, P11091, DOI 10.1073/pnas.93.20.11091; Bozza PT, 1996, J EXP MED, V183, P1515, DOI 10.1084/jem.183.4.1515; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Caldas H, 2003, HUM MOL GENET, V12, P2981, DOI 10.1093/hmg/ddg321; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; D'Avila H, 2006, J IMMUNOL, V176, P3087, DOI 10.4049/jimmunol.176.5.3087; Dvorak AM, 2003, HISTOL HISTOPATHOL, V18, P943, DOI 10.14670/HH-18.943; Dvorak AM, 2001, HISTOCHEM J, V33, P397, DOI 10.1023/A:1013771827069; DVORAK AM, 1994, INT ARCH ALLERGY IMM, V105, P245; DVORAK AM, 1992, J HISTOCHEM CYTOCHEM, V40, P759, DOI 10.1177/40.6.1316915; Dvorak Ann M, 2005, Chem Immunol Allergy, V85, P252; Fong TH, 2001, BIOCHEM BIOPH RES CO, V289, P1168, DOI 10.1006/bbrc.2001.6080; Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018; Hayess K, 1998, J CELL BIOCHEM, V69, P304, DOI 10.1002/(SICI)1097-4644(19980601)69:3<304::AID-JCB8>3.3.CO;2-U; Kerkhoff C, 1999, J BIOL CHEM, V274, P32672, DOI 10.1074/jbc.274.46.32672; Lefevre C, 2001, AM J HUM GENET, V69, P1002, DOI 10.1086/324121; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Londos C, 2005, BIOCHIMIE, V87, P45, DOI 10.1016/j.biochi.2004.12.010; Marshall KR, 2005, J BIOL CHEM, V280, P30735, DOI 10.1074/jbc.M414018200; Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912; Martin S, 2005, J BIOL CHEM, V280, P42325, DOI 10.1074/jbc.M506651200; Martin S, 2005, SEMIN CELL DEV BIOL, V16, P163, DOI 10.1016/j.semcdb.2005.01.007; Meadows JW, 2005, J CLIN ENDOCR METAB, V90, P2344, DOI 10.1210/jc.2004-1199; Melo RCN, 2005, TRAFFIC, V6, P866, DOI 10.1111/j.1600-0854.2005.00322.x; Melo RCN, 2003, TISSUE CELL, V35, P59, DOI 10.1016/S0040-8166(02)00105-2; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Ohashi M, 2003, J BIOL CHEM, V278, P36819, DOI 10.1074/jbc.M301408200; Ozeki S, 2005, J CELL SCI, V118, P2601, DOI 10.1242/jcs.02401; Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498; Paciga M, 2003, J BIOL CHEM, V278, P49549, DOI 10.1074/jbc.M307302200; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Prattes S, 2000, J CELL SCI, V113, P2977; Robenek H, 2005, J LIPID RES, V46, P1331, DOI 10.1194/jlr.M400323-JLR200; Robenek H, 2005, J BIOL CHEM, V280, P5789, DOI 10.1074/jbc.M407194200; Robenek MJ, 2004, FASEB J, V18, P866, DOI 10.1096/fj.03-0782fje; Roulin K, 1999, EXP CELL RES, V247, P410, DOI 10.1006/excr.1998.4382; Sato S, 2006, J BIOCHEM, V139, P921, DOI 10.1093/jb/mvj104; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Smirnova E, 2006, EMBO REP, V7, P106, DOI 10.1038/sj.embor.7400559; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Subramanian V, 2004, J BIOL CHEM, V279, P42062, DOI 10.1074/jbc.M407462200; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Than NG, 2003, EUR J BIOCHEM, V270, P1176, DOI 10.1046/j.1432-1033.2003.03475.x; TRIGGIANI M, 1995, J EXP MED, V182, P1181, DOI 10.1084/jem.182.5.1181; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; van Manen HJ, 2005, P NATL ACAD SCI USA, V102, P10159, DOI 10.1073/pnas.0502746102; WELLER PF, 1991, AM J PATHOL, V138, P141; WELLER PF, 1989, AM J PATHOL, V135, P947; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Wolins NE, 2003, J BIOL CHEM, V278, P37713, DOI 10.1074/jbc.M304025200; Wu CC, 2000, ELECTROPHORESIS, V21, P3470, DOI 10.1002/1522-2683(20001001)21:16<3470::AID-ELPS3470>3.3.CO;2-7; Yamaguchi T, 2004, J BIOL CHEM, V279, P30490, DOI 10.1074/jbc.M403920200; Yamaguchi T, 2006, MOL CELL BIOCHEM, V284, P167, DOI 10.1007/s11010-005-9045-y; Yu WG, 1998, AM J PATHOL, V152, P759; Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	73	159	164	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					167	178		10.1096/fj.06-6711com	http://dx.doi.org/10.1096/fj.06-6711com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135363	Green Accepted			2022-12-28	WOS:000243130200018
J	Shan, Y; Lambrecht, RW; Donohue, SE; Bonkovsky, HL				Shan, Ying; Lambrecht, Richard W.; Donohue, Susan E.; Bonkovsky, Herbert L.			Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin	FASEB JOURNAL			English	Article						HO-1; siRNA	EMBRYO LIVER-CELLS; TRANSCRIPTION FACTOR NF-E2; PORTAL HYPERTENSIVE-RATS; LEUCINE ZIPPER PROTEIN; LOCUS-CONTROL REGION; OXIDATIVE STRESS; WEIGHT-LOSS; EPITHELIAL-CELLS; PRIMARY CULTURES; MEDIATED INDUCTION	Heme oxygenase (HO) catalyzes the conversion of heme to biliverdin with the release of iron and carbon monoxide. HO-1 is highly inducible by a large number of physical and chemical factors. CoPP is known to be a potent and effective inducer of HO-1 activity in many tissues. Here we report that CoPP up-regulates HO-1 via Bach1 and Nrf2 in human liver cells. CoPP did not influence hepatic Bach1 or Nrf2 mRNA levels, but markedly reduced Bach1 protein levels by increasing degradation of Bach1 protein (t(1/2) from 19 h to 2.8 h), and increased Nrf2 by decreasing degradation of Nrf2 protein (t(1/2) from 2.5 h to 9 h). Silencing Bach1 by Bach1-siRNA significantly increased levels of HO-1 mRNA and protein, and addition of CoPP up-regulated HO-1 mRNA and protein further. However, silencing Nrf2 mRNA by Nrf2-siRNA did not significantly change baseline HO-1 mRNA or protein levels, but significantly decreased 5-10 mu M CoPP-mediated up-regulation of HO-1 mRNA levels compared with CoPP alone. Transfection with equal amounts of non-Bach1 or non-Nrf2 related control siRNA did not reduce Bach1 or Nrf2 mRNA or protein, confirming the specificity of Bach1-and Nrf2-siRNA in Huh-7 cells. We conclude that the pathway of CoPP-mediated induction of HO-1 involves the repression of Bach1 and up-regulation of the Nrf2 protein by post-transcriptional site(s) of action. Because CoPP, unlike heme, is neither a prooxidant nor a substrate for HO-1, it might be considered as a potential therapeutic agent in situations where up-regulation of HO-1 is desired.	Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA; Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Dept Pharmacol, Farmington, CT USA; Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Dept Mol Microbial & Struct Biol, Farmington, CT USA	University of Connecticut; University of Connecticut; University of Connecticut	Shan, Y (corresponding author), 263 Farmington Ave,MC-1119, Farmington, CT 06030 USA.	shan@uchc.edu	Bonkovsky, Herbert L./AAH-1892-2021	Bonkovsky, Herbert L./0000-0001-7387-3230	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038825, N01DK092326, U01DK065193] Funding Source: NIH RePORTER; NIDDK NIH HHS [N0-1 DK92326, R01-DK38825, U0-1 DK065193] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; Abraham NG, 2002, CELL MOL BIOL, V48, P895; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Alam J, 2003, AM J PHYSIOL-RENAL, V284, pF743, DOI 10.1152/ajprenal.00376.2002; ALAM J, 1989, J BIOL CHEM, V264, P6371; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Belcher JD, 2006, J CLIN INVEST, V116, P808, DOI 10.1172/JCI26857; Bonkovsky H. L., 2002, OXIDATIVE STRESS AGI, P690; Cable EE, 1997, MOL CELL BIOCHEM, V169, P13, DOI 10.1023/A:1006817207166; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Di Noia MA, 2006, J BIOL CHEM, V281, P15687, DOI 10.1074/jbc.M510595200; DRUMMOND GS, 1982, P NATL ACAD SCI-BIOL, V79, P2384, DOI 10.1073/pnas.79.7.2384; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Fernandez M, 1999, HEPATOLOGY, V29, P1672, DOI 10.1002/hep.510290621; Fernandez M, 2001, J HEPATOL, V34, P812, DOI 10.1016/S0168-8278(01)00010-1; Fu SH, 2004, TRANSPL P, V36, P2205, DOI 10.1016/j.transproceed.2004.06.050; GALBRAITH RA, 1987, PHARMACOLOGY, V34, P241, DOI 10.1159/000138275; GALBRAITH RA, 1990, PHARMACOLOGY, V41, P292, DOI 10.1159/000138738; GALBRAITH RA, 1991, PHARMACOLOGY, V43, P96, DOI 10.1159/000138834; GALBRAITH RA, 1991, AM J PHYSIOL, V261, pR1388, DOI 10.1152/ajpregu.1991.261.6.R1388; GALBRAITH RA, 1992, AM J PHYSIOL, V263, pR805, DOI 10.1152/ajpregu.1992.263.4.R805; GALBRAITH RA, 1992, MOL BRAIN RES, V15, P298, DOI 10.1016/0169-328X(92)90121-Q; GARDNER FH, 1953, J LAB CLIN MED, V41, P182; Gildemeister OS, 2001, MOL CELL BIOCHEM, V226, P17; Glanemann M, 2005, TRANSPLANT P, V37, P3223, DOI 10.1016/j.transproceed.2005.07.002; Hill-Kapturczak N, 2002, DNA CELL BIOL, V21, P307, DOI 10.1089/104454902753759726; Hsu BRS, 2005, TRANSPL P, V37, P1826, DOI 10.1016/j.transproceed.2005.02.085; Hsu BRS, 2004, TRANSPL P, V36, P1181, DOI 10.1016/j.transproceed.2004.04.037; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Lambrecht RW, 2005, ASCITES AND RENAL DYSFUNCTION IN LIVER DISEASE: PATHOGENESIS, DIAGNOSIS, AND TREATMENT, 2ND EDITION, P125, DOI 10.1002/9780470987476.ch10; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; LINCOLN BC, 1988, BIOCHEM J, V250, P189, DOI 10.1042/bj2500189; Lu TH, 1997, BBA-GENE STRUCT EXPR, V1352, P293, DOI 10.1016/S0167-4781(97)00028-6; Lu TH, 1998, GENE, V207, P177, DOI 10.1016/S0378-1119(97)00623-9; Lu TH, 2000, MOL CELL BIOCHEM, V209, P17, DOI 10.1023/A:1007025505842; MITANI K, 1991, BIOCHEM J, V277, P895, DOI 10.1042/bj2770895; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; Numazawa S, 1997, EXP CELL RES, V237, P434, DOI 10.1006/excr.1997.3825; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PETERS LL, 1993, NATURE, V362, P768, DOI 10.1038/362768a0; Sachan DS, 2005, J AM COLL NUTR, V24, P172, DOI 10.1080/07315724.2005.10719462; Shan Y, 2004, J BIOL CHEM, V279, P51769, DOI 10.1074/jbc.M409463200; Shan Y, 1999, HEPATOLOGY, V30, p512A; Shan Y, 2004, BBA-GENE STRUCT EXPR, V1679, P87, DOI 10.1016/j.bbaexp.2004.05.003; Shan Y, 2002, ARCH BIOCHEM BIOPHYS, V399, P159, DOI 10.1006/abbi.2001.2742; Shan Y, 1999, ARCH BIOCHEM BIOPHYS, V372, P224, DOI 10.1006/abbi.1999.1490; Shan Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P219, DOI 10.1006/abbi.2000.1921; SRIVASTAVA KK, 1993, EUR J BIOCHEM, V213, P909, DOI 10.1111/j.1432-1033.1993.tb17835.x; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Sun JY, 2004, P NATL ACAD SCI USA, V101, P1461, DOI 10.1073/pnas.0308083100; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; TYRRELL RM, 1994, METHOD ENZYMOL, V234, P224; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165	66	130	142	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2651	+		10.1096/fj.06-6346fje	http://dx.doi.org/10.1096/fj.06-6346fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065227				2022-12-28	WOS:000242490700054
J	Samardzija, M; Wenzel, A; Aufenberg, S; Thiersch, M; Reme, C; Grimm, C				Samardzija, Marijana; Wenzel, Andreas; Aufenberg, Svenja; Thiersch, Markus; Reme, Charlotte; Grimm, Christian			Differential role of Jak-STAT signaling in retinal degenerations	FASEB JOURNAL			English	Article						apoptosis; neuroprotection; photoreceptor	CILIARY NEUROTROPHIC FACTOR; FIBRILLARY ACIDIC PROTEIN; EPITHELIUM-DERIVED FACTOR; APOPTOTIC CELL-DEATH; LIGHT-INDUCED DAMAGE; MOUSE RETINA; RAT RETINA; PHOTORECEPTOR APOPTOSIS; UP-REGULATION; MULLER CELLS	Retinal degeneration is a major cause of severe visual impairment or blindness. Understanding the underlying molecular mechanisms is a prerequisite to develop therapeutic approaches for human patients. We show in three mouse models that induced and inherited retinal degeneration induces LIF and CLC as members of the interleukin (IL)-6 family of proteins, activates proteins of the Jak-STAT signaling pathway, and up-regulates suppressors of cytokine signaling as a negative feedback loop. Inhibition of Jak2 leads to protection of photoreceptors in a model of induced but not in a model of inherited retinal degeneration. Differential activation of Akt suggests alternative pathways for cell death and/or survival in different models. Proteins induced during photoreceptor degeneration are not mainly expressed in photoreceptors but in cells of other retinal layers. This suggests a model in which photoreceptor injury is signaled to cells of the inner retina, which in turn initiate a response either to support viability or accelerate death of injured cells.	Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, CIHP, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, ZNZ, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Grimm, C (corresponding author), Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, CIHP, Frauenklinikstr 24, CH-8091 Zurich, Switzerland.	cgrimm@opht.unizh.ch	Samardzija, Marijana/B-9245-2008; Thiersch, Markus/AGN-3176-2022	Samardzija, Marijana/0000-0003-0991-4653; Thiersch, Markus/0000-0002-9118-8285; Grimm, Christian/0000-0001-9318-4352				Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Beltran WA, 2005, MOL VIS, V11, P232; BOWES C, 1993, P NATL ACAD SCI USA, V90, P2955, DOI 10.1073/pnas.90.7.2955; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Burdelya L, 2002, MOL CANCER THER, V1, P893; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cao W, 1997, EXP EYE RES, V65, P241, DOI 10.1006/exer.1997.0328; Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646; Carballo M, 1999, J BIOL CHEM, V274, P17580, DOI 10.1074/jbc.274.25.17580; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Casson RJ, 2004, INVEST OPHTH VIS SCI, V45, P685, DOI 10.1167/iovs.03-0674; Chun MH, 2000, BRAIN RES, V868, P358, DOI 10.1016/S0006-8993(00)02305-2; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; deRaad S, 1996, OPHTHALMIC RES, V28, P99, DOI 10.1159/000267881; Dikdan GS, 2004, SURGERY, V136, P677, DOI 10.1016/j.surg.2004.02.005; Graham DR, 2005, INVEST OPHTH VIS SCI, V46, P2601, DOI 10.1167/iovs.05-0129; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Harada C, 2003, NEUROSCIENCE, V122, P229, DOI 10.1016/S0306-4522(03)00599-2; Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002; Harada T, 2000, NEURON, V26, P533, DOI 10.1016/S0896-6273(00)81185-X; Ikeda K, 2004, CURR EYE RES, V29, P349, DOI 10.1080/02713680490516279; Imai D, 2005, J CELL PHYSIOL, V202, P570, DOI 10.1002/jcp.20155; Ji JZ, 2004, EUR J NEUROSCI, V19, P265, DOI 10.1111/j.0953-816X.2003.03107.x; Johnson LE, 2005, CELL TISSUE RES, V320, P213, DOI 10.1007/s00441-004-1046-8; Jomary C, 2006, INVEST OPHTH VIS SCI, V47, P1620, DOI 10.1167/iovs.05-1176; Kaldi I, 2003, EXP EYE RES, V76, P453, DOI 10.1016/S0014-4835(02)00334-2; Krebs DL, 2000, J CELL SCI, V113, P2813; Kueng-Hitz N, 2000, INVEST OPHTH VIS SCI, V41, P909; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Murray P, 2001, DIFFERENTIATION, V68, P227, DOI 10.1046/j.1432-0436.2001.680410.x; Naash MI, 1996, J NEUROSCI, V16, P7853; Neophytou C, 1997, DEVELOPMENT, V124, P2345; Nir I, 1999, INVEST OPHTH VIS SCI, V40, P2383; Organisciak DT, 1999, PHOTOCHEM PHOTOBIOL, V70, P261, DOI 10.1562/0031-8655(1999)070<0261:LIDITR>2.3.CO;2; Peterson WM, 2000, J NEUROSCI, V20, P4081; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Ranchon I, 2001, INVEST OPHTH VIS SCI, V42, P1375; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; Rhee KD, 2003, MOL VIS, V9, P715; Samardzija M, 2006, EUR J NEUROSCI, V23, P1028, DOI 10.1111/j.1460-9568.2006.04639.x; Sherry DM, 2005, J NEUROSCI RES, V82, P316, DOI 10.1002/jnr.20619; Song Y, 2003, INVEST OPHTH VIS SCI, V44, P4069, DOI 10.1167/iovs.02-1130; Stephanou A, 2004, J CELL MOL MED, V8, P519, DOI 10.1111/j.1582-4934.2004.tb00476.x; Strettoi E, 2003, VISION RES, V43, P867, DOI 10.1016/S0042-6989(02)00594-1; Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292; Valter K, 2005, INVEST OPHTH VIS SCI, V46, P1748, DOI 10.1167/iovs.04-0657; Walsh N, 2001, EXP EYE RES, V72, P495, DOI 10.1006/exer.2000.0984; Wang LH, 1999, J IMMUNOL, V162, P3897; Wang Y, 2002, CURR EYE RES, V24, P305, DOI 10.1076/ceyr.24.4.305.8408; WEN R, 1995, J NEUROSCI, V15, P7377; Wenzel A, 2003, INVEST OPHTH VIS SCI, V44, P2798, DOI 10.1167/iovs.02-1134; Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002; Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653; Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001; Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798; Yamauchi K, 2006, J NEUROCHEM, V96, P1060, DOI 10.1111/j.1471-4159.2005.03559.x; Yu DY, 2004, INVEST OPHTH VIS SCI, V45, P2013, DOI 10.1167/iovs.03-0845; Zhang C, 2004, INVEST OPHTH VIS SCI, V45, P2753, DOI 10.1167/iovs.03-1344; Zhang SSM, 2003, EXP EYE RES, V76, P421, DOI 10.1016/S0014-4835(03)00002-2	67	100	103	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2411	+		10.1096/fj.06-5895fje	http://dx.doi.org/10.1096/fj.06-5895fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	16966486				2022-12-28	WOS:000241702600037
J	Klucken, J; Outeiro, TF; Nguyen, P; McLean, PJ; Hyman, BT				Klucken, Jochen; Outeiro, Tiago F.; Nguyen, Paul; McLean, Pamela J.; Hyman, Bradley T.			Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging	FASEB JOURNAL			English	Article						Parkinson's disease; Lewy body disease; chaperone; protein aggregation	PARKINSONS-DISEASE; DROSOPHILA MODEL; IN-VITRO; PROTEIN; AGGREGATION; DYNAMICS; SUPPRESSION; PHOSPHOLIPIDS; NEUROTOXICITY; GELDANAMYCIN	Oligomerization and aggregation of alpha-synuclein molecules are believed to play a major role in neuronal dysfunction and loss in Parkinson's disease (PD) and dementia with Lewy bodies. However, alpha-synuclein oligomerization and aggregation have been detected only indirectly in cells using detergent extraction methods. Here, we show for the first time intracellular alpha-synuclein oligomerization using fluorescence lifetime imaging (FLIM). Two forms of alpha-synuclein homomeric interactions were detected: an antiparallel amino terminus-carboxyl terminus interaction between alpha-synuclein molecules, and a close amino terminus-carboxy terminus interaction within single alpha-synuclein molecules. Coexpression of the chaperone protein Hsp70, which can block alpha-synuclein toxicity in several systems, causes alpha-synuclein to adopt a different, open conformation, but Hsp70 does not alter alpha-synuclein-alpha-synuclein interactions. Thus, the neuroprotective effect of Hsp70 can be explained by its chaperone activity on alpha-synuclein molecules, rather than alteration of alpha-synuclein-alpha-synuclein interactions.	Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Alzheimers Dis Res Unit, Charlestown, MA 02129 USA; Univ Regensburg, Dept Neurol, D-8400 Regensburg, Germany	Harvard University; Massachusetts General Hospital; University of Regensburg	McLean, PJ (corresponding author), Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Alzheimers Dis Res Unit, 114 16th St, Charlestown, MA 02129 USA.	pmclean@partners.org	Outeiro, Tiago/L-7351-2019; Outeiro, Tiago/M-8106-2019; Outeiro, Tiago F/C-1067-2008	Outeiro, Tiago/0000-0003-1679-1727; Outeiro, Tiago F/0000-0003-1679-1727; McLean, Pamela/0000-0003-4870-5715	NINDS NIH HHS [5P50 NS38372A-06] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038372] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auluck PK, 2005, J BIOL CHEM, V280, P2873, DOI 10.1074/jbc.M412106200; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Berezovska O, 2003, J NEUROSCI, V23, P4560; Bertoncini CW, 2005, P NATL ACAD SCI USA, V102, P1430, DOI 10.1073/pnas.0407146102; Bertoncini CW, 2005, J BIOL CHEM, V280, P30649, DOI 10.1074/jbc.C500288200; Bussell R, 2005, PROTEIN SCI, V14, P862, DOI 10.1110/ps.041255905; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Dedmon MM, 2005, J BIOL CHEM, V280, P14733, DOI 10.1074/jbc.m413024200; Dedmon MM, 2005, J AM CHEM SOC, V127, P476, DOI 10.1021/ja044834j; Del Mar C, 2005, P NATL ACAD SCI USA, V102, P15477, DOI 10.1073/pnas.0507405102; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fernandez CO, 2004, EMBO J, V23, P2039, DOI 10.1038/sj.emboj.7600211; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; Gosavi N, 2002, J BIOL CHEM, V277, P48984, DOI 10.1074/jbc.M208194200; Heise H, 2005, P NATL ACAD SCI USA, V102, P15871, DOI 10.1073/pnas.0506109102; Hoyer W, 2004, BIOCHEMISTRY-US, V43, P16233, DOI 10.1021/bi048453u; Kamp F, 2006, J BIOL CHEM, V281, P9251, DOI 10.1074/jbc.M512292200; Kaylor J, 2005, J MOL BIOL, V353, P357, DOI 10.1016/j.jmb.2005.08.046; Kirik D, 2003, P NATL ACAD SCI USA, V100, P2884, DOI 10.1073/pnas.0536383100; Klucken J, 2004, BIOCHEM BIOPH RES CO, V325, P367, DOI 10.1016/j.bbrc.2004.10.037; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Kubo S, 2005, J BIOL CHEM, V280, P31664, DOI 10.1074/jbc.M504894200; Lee HJ, 2004, J NEUROSCI, V24, P1888, DOI 10.1523/JNEUROSCI.3809-03.2004; Lee JC, 2004, P NATL ACAD SCI USA, V101, P16466, DOI 10.1073/pnas.0407307101; Leng Y, 2001, J BIOL CHEM, V276, P28212, DOI 10.1074/jbc.M011121200; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2004, BIOCHEM BIOPH RES CO, V321, P665, DOI 10.1016/j.bbrc.2004.07.021; McLean PJ, 2002, J NEUROCHEM, V83, P846, DOI 10.1046/j.1471-4159.2002.01190.x; McLean PJ, 2002, NEUROSCI LETT, V323, P219, DOI 10.1016/S0304-3940(02)00154-4; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Trostchansky A, 2006, BIOCHEM J, V393, P343, DOI 10.1042/BJ20051277; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Zhu M, 2003, J BIOL CHEM, V278, P40186, DOI 10.1074/jbc.M305326200	47	67	71	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2050	2057		10.1096/fj.05-5422com	http://dx.doi.org/10.1096/fj.05-5422com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012257				2022-12-28	WOS:000241156900013
J	Moussa, CEH; Fu, QH; Kumar, P; Shtifman, A; Lopez, JR; Allen, PD; LaFerla, F; Weinberg, D; Magrane, J; Aprahamian, T; Walsh, K; Rosen, KM; Querfurth, HW				Moussa, Charbel E-H.; Fu, Qinghao; Kumar, Pravir; Shtifman, Alexander; Lopez, Jose R.; Allen, Paul D.; LaFerla, Frank; Weinberg, David; Magrane, Jordi; Aprahamian, Tamar; Walsh, Kenneth; Rosen, Kenneth M.; Querfurth, Henry W.			Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology	FASEB JOURNAL			English	Article							INCLUSION-BODY MYOSITIS; AMYOTROPHIC-LATERAL-SCLEROSIS; SUPEROXIDE-DISMUTASE; ALPHA-SYNUCLEIN; MOUSE-MODELS; PROTEIN; MUTATION; ACCUMULATION; MYOPATHIES; DISEASES	Intracellular deposition of the beta-amyloid (A beta) peptide is an increasingly recognized pathological hallmark associated with neurodegeneration and muscle wasting in Alzheimer's disease (AD) and inclusion body myositis (IBM), respectively. Previous reports have implicated dysregulation of beta-amyloid precursor protein (beta APP) expression in IBM. Accumulation of full-length beta APP, its various proteolytic derivatives including A beta, and phospho-tau into vacuolated inclusions is an early pathogenic event. We previously reported on a statistical tendency favoring fast twitch fiber involvement in IBM, reminiscent of the tissue specific patterns of misfolded protein deposition seen in neurodegenerative diseases. To test this principle, we generated an animal model in which human wildtype (WT) beta APP expression was limited to postnatal type II skeletal muscle. Hemizygous transgenic mice harboring increased levels of holo beta APP751 and A beta in skeletal muscle fibers became significantly weaker with age compared with nontransgenic littermates and exhibited typical myopathic features. A subpopulation of dissociated muscle fibers from transgenic mice exhibited a 2-fold increase in resting calcium and membrane depolarization compared with nontransgenic littermates. Taken together, these data indicate that overexpression of human beta APP in fast twitch skeletal muscle of transgenic mice is sufficient for the development of some features characteristic of IBM, including abnormal tau histochemistry. The increase in resting calcium and depolarization are novel findings, suggesting both a mechanism for the weakness and an avenue for therapeutic intervention in IBM.	Tufts Univ, Sch Med, Dept Neurol, Caritas St Elizabeths Med Ctr, Boston, MA 02111 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA	St. Elizabeth's Medical Center; Tufts University; University of California System; University of California Irvine; Boston University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Querfurth, HW (corresponding author), Tufts Univ, Sch Med, Dept Neurol, Caritas St Elizabeths Med Ctr, 736 Cambridge St,CBR419, Boston, MA 02111 USA.	henry.querfurth@tufts.edu	Kumar, Pravir/AAR-1207-2020; Kumar, Pravir/B-2164-2015; Magrané, Jordi/AAJ-2967-2020	Kumar, Pravir/0000-0001-7444-2344; Magrané, Jordi/0000-0002-6785-2166; Aprahamian, Tamar/0000-0001-9295-5995	PHS HHS [41373] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARISPE N, 1994, MOL CELL BIOCHEM, V140, P119, DOI 10.1007/BF00926750; Arnardottir S, 2004, J NEUROL NEUROSUR PS, V75, P917, DOI 10.1136/jnnp.2003.018994; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; ASKANAS V, 1992, AM J PATHOL, V141, P31; Askanas V, 2002, CURR OPIN NEUROL, V15, P525, DOI 10.1097/00019052-200210000-00002; Askanas V, 1996, P NATL ACAD SCI USA, V93, P1314, DOI 10.1073/pnas.93.3.1314; Askanas V, 1997, NEUROREPORT, V8, P2155, DOI 10.1097/00001756-199707070-00012; Askanas V, 1998, ARCH NEUROL-CHICAGO, V55, P915, DOI 10.1001/archneur.55.7.915; ASKANAS V, 1998, INCLUSION BODY MYOSI, P3; Becher MW, 1997, NEUROBIOL DIS, V4, P1; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Bornemann KD, 2000, ANN NY ACAD SCI, V908, P260; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Carpenter S, 1996, J NEUROPATH EXP NEUR, V55, P1105, DOI 10.1097/00005072-199611000-00001; Christensen RA, 2004, J BIOL CHEM, V279, P53524, DOI 10.1074/jbc.M408473200; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dirksen RT, 2002, TRENDS CARDIOVAS MED, V12, P189, DOI 10.1016/S1050-1738(02)00163-9; Emilien G, 2000, ARCH NEUROL-CHICAGO, V57, P176, DOI 10.1001/archneur.57.2.176; Fukuchi K, 1998, AM J PATHOL, V153, P1687, DOI 10.1016/S0002-9440(10)65682-9; Gouras GK, 2005, NEUROBIOL AGING, V26, P1235, DOI 10.1016/j.neurobiolaging.2005.05.022; Gu YJ, 1996, J NEUROCHEM, V67, P1235; IMBERT N, 1995, CELL CALCIUM, V18, P177, DOI 10.1016/0143-4160(95)90062-4; Jin LW, 1998, AM J PATHOL, V153, P1679, DOI 10.1016/S0002-9440(10)65681-7; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kunst CB, 1997, NAT GENET, V15, P91, DOI 10.1038/ng0197-91; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; McFerrin J, 1998, NEUROREPORT, V9, P3201, DOI 10.1097/00001756-199810050-00013; Mufson EJ, 1999, EXP NEUROL, V158, P469, DOI 10.1006/exnr.1999.7086; Neville C, 1996, DEV GENET, V19, P157, DOI 10.1002/(SICI)1520-6408(1996)19:2<157::AID-DVG7>3.0.CO;2-8; PETTE D, 1986, FED PROC, V45, P2910; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rizzuto R, 2003, NAT GENET, V34, P135, DOI 10.1038/ng0603-135; ROSENBERG NL, 1985, ARCH NEUROL-CHICAGO, V42, P973, DOI 10.1001/archneur.1985.04060090055014; SARKOZI E, 1993, NEUROREPORT, V4, P815, DOI 10.1097/00001756-199306000-00055; SELKOE DJ, 2001, PHYSIOL REV, V81, P751; SERRATRICE G, 1998, INCLUSION BODY MYOST, P81; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; STALBERG E, 1995, ELECTROMYOGR MOTOR C, V97, P145, DOI 10.1016/0924-980X(95)00007-8; Sugarman MC, 2006, NEUROBIOL AGING, V27, P423, DOI 10.1016/j.neurobiolaging.2005.02.011; Sugarman MC, 2002, P NATL ACAD SCI USA, V99, P6334, DOI 10.1073/pnas.082545599; Tawil R, 2002, CURR OPIN RHEUMATOL, V14, P653, DOI 10.1097/00002281-200211000-00004; TESCH P, 1978, ACTA PHYSIOL SCAND, V103, P40, DOI 10.1111/j.1748-1716.1978.tb06188.x; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Weaver CL, 2000, NEUROBIOL AGING, V21, P719, DOI 10.1016/S0197-4580(00)00157-3; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133	47	29	32	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2165	+		10.1096/fj.06-5763fje	http://dx.doi.org/10.1096/fj.06-5763fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16940437				2022-12-28	WOS:000241156900055
J	Rajasingh, J; Bord, E; Luedemann, C; Asai, J; Hamada, H; Thorne, T; Qin, GJ; Goukassian, D; Zhu, Y; Losordo, DW; Kishore, R				Rajasingh, Johnson; Bord, Evelyn; Luedemann, Corinne; Asai, Jun; Hamada, Hiromichi; Thorne, Tina; Qin, Gangjian; Goukassian, David; Zhu, Yan; Losordo, Douglas W.; Kishore, Raj			IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression	FASEB JOURNAL			English	Article						mRNA stability; AU-rich elements	NECROSIS-FACTOR-ALPHA; AU-RICH ELEMENTS; IN-VIVO BLOCKADE; PROTEIN-KINASE; TRANSCRIPTIONAL REPRESSION; CHRONIC ETHANOL; KAPPA-B; INTERLEUKIN-10; BINDING; MICE	Inflammation plays an essential role in vascular injury and repair. Mononuclear phagocytes are important contributors in these processes, in part, via adhesive interactions and secretion of proinflammatory cytokines. The antiinflammatory cytokine interleukin (IL)-10 suppresses such responses via deactivation of monocytes/macrophages and repression of inflammatory cytokine expression. The mechanisms of IL-10's suppressive action are, however, incompletely characterized. Here, we report that systemic IL-10 treatment after carotid artery denudation in mice blunts inflammatory cell infiltration and arterial tumor necrosis factor (TNF) expression. At the molecular level, in a human monocytic cell line, U937 IL-10 suppressed LPS-induced mRNA expression of a number of inflammatory cytokines, mainly via posttranscriptional mRNA destabilization. Detailed studies on IL-10 regulation of TNF-alpha mRNA expression identified AU-rich elements (ARE) in the 3' untranslated region as a necessary determinant of IL-10-mediated TNF-alpha mRNA destabilization. IL-10 sensitivity to TNF depends on the ability of IL-10 to inhibit the expression and mRNA-stabilizing protein HuR and via IL-10 mediated repression of p38 mitogen-activated protein (MAP) kinase activation. Because IL-10 function and signaling are important components for control of inflammatory responses, these results may provide insights necessary to develop strategies for modulating vascular repair and other accelerated arteriopathies, including transplant vasculopathy and vein graft hyperplasia.	Tufts Univ, Div Cardiovasc Res, Caritas St Elizabeths Med Ctr, Sch Med, Brighton, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University	Kishore, R (corresponding author), Tufts Univ, Div Cardiovasc Res, Caritas St Elizabeths Med Ctr, Sch Med, 736 Cambridge St, Brighton, MA 02135 USA.	raj.kishore@tufts.edu	Losordo, Douglas W/F-9782-2011; Asai, Jun/AAD-4796-2020; Rajasingh, Johnson/AAT-1985-2021	Asai, Jun/0000-0002-7610-0820; Rajasingh, Johnson/0000-0002-6172-4083; Goukassian, David/0000-0001-5270-5270; Losordo, Douglas/0000-0002-6857-7506				Beck ARP, 1996, NUCLEIC ACIDS RES, V24, P3829, DOI 10.1093/nar/24.19.3829; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Brown CY, 1996, J BIOL CHEM, V271, P20108, DOI 10.1074/jbc.271.33.20108; Caligiuri G, 2003, MOL MED, V9, P10, DOI 10.1007/BF03402102; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CLAUSELL N, 1994, CIRCULATION, V89, P2768, DOI 10.1161/01.CIR.89.6.2768; CLAUSELL N, 1995, BRIT HEART J, V73, P534; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Colombo A, 2004, J AM COLL CARDIOL, V43, P24, DOI 10.1016/j.jacc.2003.10.015; Denys A, 2002, J IMMUNOL, V168, P4837, DOI 10.4049/jimmunol.168.10.4837; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Donners MMPC, 2003, ANN MED, V35, P523, DOI 10.1080/07853890310014876; Feldman LJ, 2000, CIRCULATION, V101, P908, DOI 10.1161/01.CIR.101.8.908; Fukuda D, 2004, J AM COLL CARDIOL, V43, P18, DOI 10.1016/j.jacc.2003.08.026; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HANCOCK WW, 1994, AM J PATHOL, V145, P1008; Iwakura A, 2003, CIRCULATION, V108, P3115, DOI 10.1161/01.CIR.0000106906.56972.83; Kamimura M, 2005, CIRC RES, V97, P305, DOI 10.1161/01.RES.0000177893.24574.13; Kishore R, 2005, J CLIN INVEST, V115, P1785, DOI 10.1172/JCI22849; Kishore R, 1999, J IMMUNOL, V162, P2457; Kishore R, 2002, CIRC RES, V91, P307, DOI 10.1161/01.RES.0000031744.06353.D3; Kishore R, 2001, J BIOL CHEM, V276, P41930, DOI 10.1074/jbc.M107181200; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Krasinski K, 2001, CIRCULATION, V104, P1754, DOI 10.1161/hc4001.098046; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LIBBY P, 1992, NOUV REV FR HEMATOL, V34, pS47; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; McMullen MR, 2003, J BIOL CHEM, V278, P38333, DOI 10.1074/jbc.M304566200; Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; Nagano S, 2002, INT IMMUNOL, V14, P733, DOI 10.1093/intimm/dxf038; Namiki M, 2004, ATHEROSCLEROSIS, V172, P21, DOI 10.1016/j.atherosclerosis.2003.08.032; Pinderski LJ, 2002, CIRC RES, V90, P1064, DOI 10.1161/01.RES.0000018941.10726.FA; RENNICK D, 1995, CLIN IMMUNOL IMMUNOP, V76, pS174, DOI 10.1016/S0090-1229(95)90144-2; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Wang EH, 1997, CANCER RES, V57, P5426; Wang YJ, 1999, POLYM-PLAST TECHNOL, V38, P533, DOI 10.1080/03602559909351598; Ward C, 2005, EUR J IMMUNOL, V35, P2728, DOI 10.1002/eji.200425561; WEIEL JE, 1986, J IMMUNOL, V136, P3012	43	125	128	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2112	+		10.1096/fj.06-6084fje	http://dx.doi.org/10.1096/fj.06-6084fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935932				2022-12-28	WOS:000241156900019
J	Borniquel, S; Valle, I; Cadenas, S; Lamas, S; Monsalve, M				Borniquel, Sara; Valle, Inmaculada; Cadenas, Susana; Lamas, Santiago; Monsalve, Maria			Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1 alpha	FASEB JOURNAL			English	Article						NO; endothelium; mitochondria	SOLUBLE GUANYLYL CYCLASE; ENDOTHELIAL-CELLS; LIFE-SPAN; GENE; EXPRESSION; RECEPTOR; ANTIOXIDANT; BIOGENESIS; MECHANISMS; DISEASE	Nitric oxide (NO) has both prooxidant and antioxidant activities in the endothelium; however, the molecular mechanisms involved are still a matter of controversy. PGC-1 alpha [peroxisome proliferators-activated receptor (PPAR) gamma coactivator 1-alpha] induces the expression of several members of the mitochondrial reactive oxygen species (ROS) detoxification system. Here, we show that NO regulates this system through the modulation of PGC-1 alpha expression. Short-term (< 12 h) treatment of endothelial cells with NO donors down-regulates PGC-1 alpha expression, whereas long-term (> 24 h) treatment up-regulates it. Treatment with the NOS inhibitor L-NAME has the opposite effect. Downregulation of PGC-1 alpha by NO is mediated by protein kinase G (PKG). It is blocked by the soluble guanylate cyclase (sGC) inhibitor ODQ and the PKG inhibitor KT5823, and mimicked by the cGMP analog 8-BrcGMP. Changes in PGC-1 alpha expression are in all cases paralleled by corresponding variations in the mitochondrial ROS detoxification system. Cells that transiently overexpress PGC-1 alpha from the cytomeglovirus (CMV) promoter respond poorly to NO donors. Analysis of tissues from eNOS(-/-) mice showed reduced levels of PGC-1 alpha and the mitochondrial ROS detoxification system. These data suggest that NO can regulate the mitochondrial ROS detoxification system both positively and negatively through PGC-1 alpha. -Borniquel, S., Valle, I., Cadenas, S., Lamas, S., and Monsalve, M. Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1 alpha.	Ctr Nacl Invest Cardiovasc, Madrid 28029, Spain; CSIC, Ctr Invest Biol, Madrid, Spain; CSIC, Inst Reina Sofia Invest Nefrol, Madrid, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC)	Monsalve, M (corresponding author), Ctr Nacl Invest Cardiovasc, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mmonsalve@cnic.es	Monsalve, Maria/K-4416-2014; Lamas, Santiago/G-7308-2015; Cadenas, Susana/D-1523-2016	Monsalve, Maria/0000-0003-2796-1453; Lamas, Santiago/0000-0001-5166-4155; Cadenas, Susana/0000-0003-0726-0369				Al-Sa'doni HH, 2005, MINI-REV MED CHEM, V5, P247, DOI 10.2174/1389557053175399; Albrecht EWJA, 2003, J PATHOL, V199, P8, DOI 10.1002/path.1250; Aliev G, 2003, NEUROL RES, V25, P665, DOI 10.1179/016164103101201977; Banmeyer I, 2005, FEBS LETT, V579, P2327, DOI 10.1016/j.febslet.2005.03.027; Bellamy TC, 2001, J BIOL CHEM, V276, P4287, DOI 10.1074/jbc.M006677200; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; Bruckdorfer Richard, 2005, Molecular Aspects of Medicine, V26, P3, DOI 10.1016/j.mam.2004.09.002; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Calabrese V, 2005, J NEUROL SCI, V233, P145, DOI 10.1016/j.jns.2005.03.012; Chang TS, 2004, J BIOL CHEM, V279, P41975, DOI 10.1074/jbc.M407707200; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; Duchen Michael R., 2004, Molecular Aspects of Medicine, V25, P365, DOI 10.1016/j.mam.2004.03.001; Duncan Andrew J., 2005, Molecular Aspects of Medicine, V26, P67, DOI 10.1016/j.mam.2004.09.004; Fariss MW, 2005, MOL INTERV, V5, P94, DOI 10.1124/mi.5.2.7; Ferrari R, 2004, CURR PHARM DESIGN, V10, P1699, DOI 10.2174/1381612043384718; Fridell YWC, 2005, CELL METAB, V1, P145, DOI 10.1016/j.cmet.2005.01.005; Galle J, 2003, KIDNEY INT, V63, pS45, DOI 10.1046/j.1523-1755.63.s84.12.x; Gewaltig MT, 2002, CARDIOVASC RES, V55, P250, DOI 10.1016/S0008-6363(02)00327-9; Goth Laszlo, 2004, Mol Diagn, V8, P141; Green K, 2004, DIABETES, V53, pS110, DOI 10.2337/diabetes.53.2007.S110; Griess P., 1879, BER DTSCH CHEM GES, V12, P426, DOI [DOI 10.2147/DDDT.S165440, 10.1002/cber.187901201117., DOI 10.1002/CBER.187901201117]; Harrison D, 2003, AM J CARDIOL, V91, p7A; Heinemann U, 2002, PROG BRAIN RES, V135, P197; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Huang H, 2004, FRONT BIOSCI-LANDMRK, V9, P1100, DOI 10.2741/1298; Imai H, 2003, FREE RADICAL BIO MED, V34, P145, DOI 10.1016/S0891-5849(02)01197-8; Jenner P, 2001, TRENDS NEUROSCI, V24, P245, DOI 10.1016/S0166-2236(00)01789-6; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Kietzmann T, 2005, SEMIN CELL DEV BIOL, V16, P474, DOI 10.1016/j.semcdb.2005.03.010; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Larrouy D, 1999, INT J OBESITY, V23, P1327, DOI 10.1038/sj.ijo.0801106; Lopez-Ongil S, 1998, BRIT J PHARMACOL, V124, P447, DOI 10.1038/sj.bjp.0701847; Loscalzo J, 2003, BIOCHEM SOC T, V31, P1059; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; Moellering D, 1998, ARCH BIOCHEM BIOPHYS, V358, P74, DOI 10.1006/abbi.1998.0854; Mohanakumar KP, 2002, ANN NY ACAD SCI, V962, P389, DOI 10.1111/j.1749-6632.2002.tb04083.x; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; Ogita H, 2004, ENDOTHELIUM-J ENDOTH, V11, P123, DOI 10.1080/10623320490482664; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Pasupathy S, 2005, EUR J VASC ENDOVASC, V29, P106, DOI 10.1016/j.ejvs.2004.11.005; Patel RP, 2000, CARDIOVASC RES, V47, P465, DOI 10.1016/S0008-6363(00)00086-9; Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Rahman I, 2004, BIOCHEM PHARMACOL, V68, P1255, DOI 10.1016/j.bcp.2004.05.042; Rivero-Vilches FJ, 2003, AM J PHYSIOL-CELL PH, V285, pC891, DOI 10.1152/ajpcell.00590.2002; Russwurm M, 2002, J BIOL CHEM, V277, P24883, DOI 10.1074/jbc.M110570200; Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9; Scandalios JG, 2005, BRAZ J MED BIOL RES, V38, P995, DOI 10.1590/S0100-879X2005000700003; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Suh SH, 1999, PFLUG ARCH EUR J PHY, V438, P612, DOI 10.1007/s004240051084; Tanaka T, 2002, EMBO J, V21, P1695, DOI 10.1093/emboj/21.7.1695; Ungvari Zoltan, 2005, Current Vascular Pharmacology, V3, P221, DOI 10.2174/1570161054368607; Valle I, 2005, CARDIOVASC RES, V66, P562, DOI 10.1016/j.cardiores.2005.01.026; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	67	121	130	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1889	+		10.1096/fj.05-5189fje	http://dx.doi.org/10.1096/fj.05-5189fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16891621				2022-12-28	WOS:000240267000020
J	Garrison, HH; Palazzo, RE				Garrison, Howard H.; Palazzo, Robert E.			What's happening to the new investigator?	FASEB JOURNAL			English	Article									Federat Amer Soc Expt Biol, Bethesda, MD USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; Rensselaer Polytech Inst, Troy, NY USA	State University of New York (SUNY) System; Wadsworth Center; Rensselaer Polytechnic Institute	Garrison, HH (corresponding author), Federat Amer Soc Expt Biol, Bethesda, MD USA.	hgarrison@faseb.org		Garrison, Howard/0000-0001-9455-3527				*FASEB OFF PUBL AF, 2006, NIH RES FUND TRENDS; National Research Council, 2005, BRIDG IND FOST IND N; *NIH, 2006, NIH ANN PROGR FOST I; *REP STUD COMM, 2006, RSC FY 2007 BUDG CON; ZERHOUNI EA, 2006, FISCAL YEAR 2006 BUD	5	4	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1288	1289		10.1096/fj.06-0704ufm	http://dx.doi.org/10.1096/fj.06-0704ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816102				2022-12-28	WOS:000240266000004
J	Cohen, B				Cohen, Bernard			Inner ear troubles: the roar in the forest?	FASEB JOURNAL			English	Editorial Material							PAROXYSMAL POSITIONAL VERTIGO; EYE MOVEMENTS; STIMULATION		Mt Sinai Sch Med, Dept Neurol, New York, NY USA	Icahn School of Medicine at Mount Sinai	Cohen, B (corresponding author), Mt Sinai Sch Med, Dept Neurol, New York, NY USA.	bernard.cohen@mssm.edu						Bladin PF, 1998, EPILEPSIA, V39, P442, DOI 10.1111/j.1528-1157.1998.tb01398.x; BRANDT T, 1991, BRAIN, V114, P2159, DOI 10.1093/brain/114.5.2159; Clarke AH, 2005, J VESTIBUL RES-EQUIL, V15, P65; COHEN B, 1964, ANN OTO RHINOL LARYN, V73, P153, DOI 10.1177/000348946407300116; Desai SS, 2005, J NEUROPHYSIOL, V93, P251, DOI 10.1152/jn.00746.2003; EPLEY JM, 1992, OTOLARYNG HEAD NECK, V107, P399, DOI 10.1177/019459989210700310; Gizzi M, 1998, ACTA OTO-LARYNGOL, V118, P774, DOI 10.1080/00016489850182422; GRAF W, 1984, J COMP NEUROL, V227, P569, DOI 10.1002/cne.902270408; Janensch W, 1935, PALAEONTOGRAPHICA S, V7, P145; Koehler P J, 2001, J Hist Neurosci, V10, P253, DOI 10.1076/jhin.10.3.253.9089; Nunn JF, 1996, ANCIENT EGYPTIAN MED; Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504; PARNES LS, 1990, ANN OTO RHINOL LARYN, V99, P330, DOI 10.1177/000348949009900502; RAPHAN T, 1979, EXP BRAIN RES, V35, P229; ROSS MD, 1976, ANN OTO RHINOL LARYN, V85, P310, DOI 10.1177/000348947608500302; SCHUCKNECHT HF, 1991, PATHOLOGY EAR, P529; SEMONT A, 1989, ANN OTOLARYNGOL CHIR, V105, P473; SPIELBERG S, 1992, JURASSIC PARK; SUZUKI J, 1964, EXP NEUROL, V9, P137, DOI 10.1016/0014-4886(64)90013-5; SUZUKI JI, 1964, EXP NEUROL, V10, P393, DOI 10.1016/0014-4886(64)90031-7; TOKUMASU K, 1965, ARCH OPHTHALMOL-CHIC, V73, P851; Weissmann G, 2005, FASEB J, V19, P1581, DOI 10.1096/fj.05-1001ufm	22	0	0	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					806	808		10.1096/fj.06-0502ufm	http://dx.doi.org/10.1096/fj.06-0502ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675836				2022-12-28	WOS:000240157700002
J	Limaye, A; Koya, V; Samsam, M; Daniell, H				Limaye, Arati; Koya, Vijay; Samsam, Mohtashem; Daniell, Henry			Receptor-mediated oral delivery of a bioencapsulated green fluorescent protein expressed in transgenic chloroplasts into the mouse circulatory system	FASEB JOURNAL			English	Article						transmucosal carrier; furin; ganglioside receptors; genetically modified crops	TOXIN B-SUBUNIT; CHOLERA-TOXIN; PROPROTEIN CONVERTASE; PROTECTIVE ANTIGEN; CRYSTAL-STRUCTURE; GOLGI-APPARATUS; FURIN; INSULIN; VACCINE; GENE	Oral delivery of biopharmaceutical proteins expressed in plant cells should reduce their cost of production, purification, processing, cold storage, transportation, and delivery. However, poor intestinal absorption of intact proteins is a major challenge. To overcome this limitation, we investigate here the concept of receptor-mediated oral delivery of chloroplast-expressed foreign proteins. Therefore, the transmucosal carrier cholera toxin B-subunit and green fluorescent protein (CTB-GFP), separated by a furin cleavage site, was expressed via the tobacco chloroplast genome. Polymerase chain reaction (PCR) and Southern blot analyses confirmed site-specific transgene integration and homoplasmy. Immunoblot analysis and ELISA confirmed expression of monomeric and pentameric forms of CTB-GFP, up to 21.3% of total soluble proteins. An in vitro furin cleavage assay confirmed integrity of the engineered furin cleavage site, and a GM(1) binding assay confirmed the functionality of CTB-GFP pentamers. Following oral administration of CTB-GFP expressing leaf material to mice, GFP was observed in the mice intestinal mucosa, liver, and spleen in fluorescence and immunohistochemical studies, while CTB remained in the intestinal cell. This report of receptor-mediated oral delivery of a foreign protein into the circulatory system opens the door for low-cost production and delivery of human therapeutic proteins.	Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA	State University System of Florida; University of Central Florida	Daniell, H (corresponding author), Univ Cent Florida, Dept Mol Biol & Microbiol, 4000 Cent Florida Blvd,Bldg 20,Rm 336, Orlando, FL 32816 USA.	daniell@mail.ucf.edu	Daniell, Henry/L-3655-2019	Daniell, Henry/0000-0003-4485-1176	NIGMS NIH HHS [R01 GM063879, R01GM63879] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063879] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alisky JM, 2002, EXP NEUROL, V178, P139, DOI 10.1006/exnr.2002.8031; Arakawa T, 1998, NAT BIOTECHNOL, V16, P934, DOI 10.1038/nbt1098-934; Arntzen C, 2005, VACCINE, V23, P1753, DOI 10.1016/j.vaccine.2005.01.090; Badizadegan K, 2000, INT J MED MICROBIOL, V290, P403; Berghoff M, 2005, MOL CELL NEUROSCI, V28, P118, DOI 10.1016/j.mcn.2004.09.001; Boonyarattanakalin S, 2004, J AM CHEM SOC, V126, P16379, DOI 10.1021/ja046663o; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Daniell H, 2005, VACCINE, V23, P1779, DOI 10.1016/j.vaccine.2004.11.004; Daniell H, 2005, METH MOL B, V286, P111; Daniell H, 2005, TRENDS BIOTECHNOL, V23, P238, DOI 10.1016/j.tibtech.2005.03.008; Daniell H, 2001, J MOL BIOL, V311, P1001, DOI 10.1006/jmbi.2001.4921; Daniell H, 2002, NAT BIOTECHNOL, V20, P581, DOI 10.1038/nbt0602-581; Daniell H, 2004, MOL FARMING, P113; DANIELL H, 1997, METHOD MOL BIOL, V62, P453; De Cosa B, 2001, NAT BIOTECHNOL, V19, P71, DOI 10.1038/83559; DeGray G, 2001, PLANT PHYSIOL, V127, P852, DOI 10.1104/pp.010233; Feng Y, 2004, EMBO REP, V5, P596, DOI 10.1038/sj.embor.7400152; Fernandez-San Millan A, 2003, PLANT BIOTECHNOL J, V1, P71, DOI 10.1046/j.1467-7652.2003.00008.x; Fujinaga Y, 2003, MOL BIOL CELL, V14, P4783, DOI 10.1091/mbc.E03-06-0354; Giddings G, 2000, NAT BIOTECHNOL, V18, P1151, DOI 10.1038/81132; GRANGER DN, 1997, ESSENTIAL MED PHYSL, P217; Grevich JJ, 2005, CRIT REV PLANT SCI, V24, P83, DOI 10.1080/07352680590935387; GROSKREUTZ DJ, 1994, J BIOL CHEM, V269, P6241; Hagemann R, 2004, MOLECULAR BIOLOGY AND BIOTECHNOLOGY OF PLANT ORGANELLES: CHLOROPLASTS AND MITOCHONDRIA, P93, DOI 10.1007/978-1-4020-3166-3_4; Hamman JH, 2005, BIODRUGS, V19, P165, DOI 10.2165/00063030-200519030-00003; Hay CW, 2003, J MOL ENDOCRINOL, V31, P597, DOI 10.1677/jme.0.0310597; Heath JP, 1996, CELL BIOL INT, V20, P139, DOI 10.1006/cbir.1996.0018; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Ito M, 2005, DIABETOLOGIA, V48, P1614, DOI 10.1007/s00125-005-1825-0; Jepson MA, 1998, TRENDS MICROBIOL, V6, P359, DOI 10.1016/S0966-842X(98)01337-7; Kong QX, 2001, P NATL ACAD SCI USA, V98, P11539, DOI 10.1073/pnas.191617598; Koya V, 2005, INFECT IMMUN, V73, P8266, DOI 10.1128/IAI.73.12.8266-8274.2005; Kumar S, 2004, PLANT PHYSIOL, V136, P2843, DOI 10.1104/pp.104.045187; Kumar Shashi, 2004, Methods Mol Biol, V267, P365; Leelavathi S, 2003, MOL BREEDING, V11, P49, DOI 10.1023/A:1022114427971; Lelivelt CLC, 2005, PLANT MOL BIOL, V58, P763, DOI 10.1007/s11103-005-7704-8; LENCER WI, 1995, P NATL ACAD SCI USA, V92, P10094, DOI 10.1073/pnas.92.22.10094; Lencer WI, 2001, AM J PHYSIOL-GASTR L, V280, pG781, DOI 10.1152/ajpgi.2001.280.5.G781; Ling H, 1998, BIOCHEMISTRY-US, V37, P1777, DOI 10.1021/bi971806n; Mason HS, 2002, TRENDS MOL MED, V8, P324, DOI 10.1016/S1471-4914(02)02360-2; Mason HS, 1998, VACCINE, V16, P1336, DOI 10.1016/S0264-410X(98)80020-0; Mayer G, 2004, CELL TISSUE RES, V316, P55, DOI 10.1007/s00441-004-0866-x; MERRITT EA, 1994, PROTEIN SCI, V3, P166; MERRITT EA, 1995, CURR OPIN STRUC BIOL, V5, P165, DOI 10.1016/0959-440X(95)80071-9; Molina A, 2005, VIROLOGY, V342, P266, DOI 10.1016/j.virol.2005.08.009; Molina A, 2004, PLANT BIOTECHNOL J, V2, P141, DOI 10.1046/j.1467-7652.2004.00057.x; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nishigori T, 1996, PEPTIDES, V17, P789, DOI 10.1016/0196-9781(96)00077-0; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PETRIDES D, 1995, BIOTECHNOL BIOENG, V48, P529, DOI 10.1002/bit.260480516; Quesada-Vargas T, 2005, PLANT PHYSIOL, V138, P1746, DOI 10.1104/pp.105.063040; Ruiz ON, 2005, PLANT PHYSIOL, V138, P1232, DOI 10.1104/pp.104.057729; RUIZ ON, 2003, PLANT PHYSIOL, V132, P1; Samsam M, 2003, J NEUROSCI, V23, P2833; Shaw JAM, 2002, J ENDOCRINOL, V172, P653, DOI 10.1677/joe.0.1720653; Short DK, 1998, AM J PHYSIOL-ENDOC M, V275, pE748, DOI 10.1152/ajpendo.1998.275.5.E748; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Watson J, 2004, VACCINE, V22, P4374, DOI 10.1016/j.vaccine.2004.01.069; YANAGITA M, 1992, FEBS LETT, V311, P55, DOI 10.1016/0014-5793(92)81366-T	62	73	91	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					959	+		10.1096/fj.05-5134fje	http://dx.doi.org/10.1096/fj.05-5134fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16603603	Green Accepted, Green Submitted			2022-12-28	WOS:000240157700021
J	Liu, ZJ; Xiao, M; Balint, K; Soma, A; Pinnix, CC; Capobianco, AJ; Velazquez, OC; Herlyn, M				Liu, Zhao-Jun; Xiao, Min; Balint, Klara; Soma, Akinobu; Pinnix, Chelsea C.; Capobianco, Anthony J.; Velazquez, Omaida C.; Herlyn, Meenhard			Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1	FASEB JOURNAL			English	Article						cell growth; cell signaling; angiogensis	GROWTH-FACTOR; CYCLE ARREST; PHOSPHATIDYLINOSITOL 3-KINASE; NEOPLASTIC TRANSFORMATION; EMBRYONIC LETHALITY; IN-VITRO; EXPRESSION; LIGAND; GENE; TRANSCRIPTION	The requirement for Notch signaling in vasculogenesis and angiogenesis is well documented. In a previous study, we showed that activation of the Notch pathway in endothelial cells induces differentiation-associated growth arrest; however, the underlying mechanism remains to be elucidated. Here, we show that activation of the Notch pathway by either stimulation of cell surface Notch receptors with crosslinked soluble Delta-like 4 (sDll4)/Jagged1 (sJag1) or constitutive expression of the Notch1 intracellular domain (N(IC)) suppresses endothelial cell proliferation. This suppression is mediated by the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt pathways. Following Notch1 activation, both pathways were suppressed in endothelial cells, and alterations in MAPK or PI3K/Akt pathway activity reversed Notch1-induced growth inhibition. Furthermore, we found the effect of Notch1 on endothelial cells to require Mastermind-like (MAML). Overexpression of a dominant-negative mutant of MAML1 antagonized the effects of activated Notch1 on the MAPK and PI3K/Akt pathways. Ectopic expression of Hairy/Enhancer of Split 1 (HES1) consistently reproduced the inhibitory effect of NIC on endothelial cell proliferation. Together, our data demonstrate that the Notch/MAML-HES signaling cascade can regulate both MAPK and PI3K/Akt pathways, which suggests a molecular mechanism for the inhibitory effect of Notch signaling on endothelial cell proliferation.	Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; Univ Penn, Dept Surg, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.org	Balint, Klara/ABB-8816-2021	Capobianco, Anthony/0000-0002-3706-6797; Pinnix, Chelsea/0000-0003-3982-3664	NATIONAL CANCER INSTITUTE [P30CA010815, R01CA076674, P01CA025874, R01CA047159] Funding Source: NIH RePORTER; NCI NIH HHS [CA76674, CA47159, CA10815, CA25874] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Brennan K, 2002, BIOESSAYS, V24, P405, DOI 10.1002/bies.10089; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kobinger GP, 2001, NAT BIOTECHNOL, V19, P225, DOI 10.1038/85664; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Krebs LT, 2000, GENE DEV, V14, P1343; Leimeister C, 2000, MECH DEVELOP, V98, P175, DOI 10.1016/S0925-4773(00)00459-7; Limbourg FP, 2005, CIRCULATION, V111, P1826, DOI 10.1161/01.CIR.0000160870.93058.DD; Liu ZJ, 2003, FASEB J, V17, P1931, DOI 10.1096/fj.02-1171fje; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Liu ZJ, 2001, P NATL ACAD SCI USA, V98, P7289, DOI 10.1073/pnas.121171998; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813-8822.2004; OGATA M, 1995, J BIOL CHEM, V270, P2337, DOI 10.1074/jbc.270.25.15076; Pear WS, 2003, SEMIN IMMUNOL, V15, P69, DOI 10.1016/S1044-5323(03)00003-4; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Qi RZ, 2003, CANCER RES, V63, P8323; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Shou JY, 2001, CANCER RES, V61, P7291; Shutter JR, 2000, GENE DEV, V14, P1313; Sriuranpong V, 2001, CANCER RES, V61, P3200; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Tsai S, 2000, BLOOD, V96, P950, DOI 10.1182/blood.V96.3.950.015k43_950_957; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Velazquez OC, 2002, FASEB J, V16, P1316, DOI 10.1096/fj.01-1011fje; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	49	84	93	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					1009	+		10.1096/fj.05-4880fje	http://dx.doi.org/10.1096/fj.05-4880fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571776				2022-12-28	WOS:000240157700038
J	Xi, JH; Bai, F; McGaha, R; Andley, UP				Xi, Jing-Hua; Bai, Fang; McGaha, Rebecca; Andley, Usha P.			Alpha-crystallin expression affects microtubule assembly and prevents their aggregation	FASEB JOURNAL			English	Article						tubulin; lens; cytoskeleton; chaperone	LENS EPITHELIAL-CELLS; B-CRYSTALLIN; A-CRYSTALLIN; CHAPERONE; TUBULIN; PROTEIN; HYPERPROLIFERATION; TAU	The molecular chaperones alpha A- and alpha B-crystallins are important for cell survival and genomic stability and associate with the tubulin cytoskeleton. The mitotic spindle is abnormally assembled in a number of alpha A-/- and alpha B-/- lens epithelial cells. However, no report to date has studied the effect of alpha-crystallin expression on tubulin/microtubule assembly in lens epithelial cells. In the current work we tested the hypothesis that the absence of alpha A- and alpha B-crystallins alters microtubule assembly. Microtubules were reconstituted from freshly dissected explants of wildtype, alpha A-/-, alpha B-/-, and alpha(A/B) -/- (DKO) mouse lens epithelia and examined by electron microscopic and biochemical analyses. The wild-type microtubules were 4 mu m long and similar to 25 nm wide and had a characteristic protofilament structure, but alpha B-/- microtubules were 2.5-fold longer. Microtubule-associated proteins (MAPs) extracted from microtubules by washing with salt included transketolase, alpha-enolase, and beta B2-crystallin. In DKO lens epithelial microtubules but not in wild-type, alpha A-/- or alpha B-/- microtubules, extraction of the MAPs gave very long (14 - 20 mu m) "polyfilament" assemblies that were tightly bundled. Addition of exogenous alpha-crystallin (alpha A+ alpha B) was ineffective in preventing polyfilament formation. However, normal microtubule structure could be restored by including MAPs derived from wild-type lens epithelial cells during microtubule reconstitution. Intriguingly, these data suggest that alpha-crystallin may interact with MAPs to inhibit aggregation of microtubules in lens epithelial cells. Sedimentation analysis and 90 degrees light scattering measurements showed that alpha-crystallin suppressed tubulin assembly in vitro. alpha-Crystallin did not have a strong effect on the GTPase activity of purified tubulin. SDS-PAGE analysis showed that alpha-crystallin prevented heat-induced aggregation of tubulin, suggesting that alpha-crystallin may affect microtubule assembly by maintaining the pool of unassembled tubulin.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Andley, UP (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.	andley@vision.wustl.edu		Andley, Usha/0000-0001-7049-7591	NATIONAL EYE INSTITUTE [R01EY005681, P30EY002687] Funding Source: NIH RePORTER; NEI NIH HHS [EY05681, EY02687] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Andley UP, 1998, J BIOL CHEM, V273, P31252, DOI 10.1074/jbc.273.47.31252; Andley UP, 2002, J BIOL CHEM, V277, P10178, DOI 10.1074/jbc.M109211200; Andley UP, 2001, FASEB J, V15, P221, DOI 10.1096/fj.00-0296com; Bai F, 2004, MOL CELL BIOCHEM, V265, P115, DOI 10.1023/B:MCBI.0000044365.48900.82; Bai F, 2003, J BIOL CHEM, V278, P36876, DOI 10.1074/jbc.M304010200; BEEBE DC, 1979, SCIENCE, V206, P836, DOI 10.1126/science.493982; Bhat SP, 2001, BIOSCIENCE REP, V21, P537, DOI 10.1023/A:1017952128502; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; Bluhm WF, 1998, AM J PHYSIOL-HEART C, V275, pH2243, DOI 10.1152/ajpheart.1998.275.6.H2243; Boyle Daniel L, 2003, BMC Ophthalmol, V3, P3, DOI 10.1186/1471-2415-3-3; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Dammermann A, 2003, CURR BIOL, V13, pR614, DOI 10.1016/S0960-9822(03)00530-X; Das KP, 1999, J BIOL CHEM, V274, P33209, DOI 10.1074/jbc.274.47.33209; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Downing KH, 1998, CURR OPIN STRUC BIOL, V8, P785, DOI 10.1016/S0959-440X(98)80099-7; Downing KH, 1998, CURR OPIN CELL BIOL, V10, P16, DOI 10.1016/S0955-0674(98)80082-3; Dunn AY, 2001, J STRUCT BIOL, V135, P176, DOI 10.1006/jsbi.2001.4380; Fujita Y, 2004, J CELL SCI, V117, P1719, DOI 10.1242/jcs.01021; GOPALAKRISHNAN S, 1992, CURR EYE RES, V11, P929, DOI 10.3109/02713689209033490; Haeusser DP, 2004, MOL MICROBIOL, V52, P801, DOI 10.1111/j.1365-2958.2004.04016.x; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Inaguma Y, 2001, EUR J CELL BIOL, V80, P741, DOI 10.1078/0171-9335-00203; Kato K, 1996, J BIOL CHEM, V271, P26989, DOI 10.1074/jbc.271.43.26989; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Liang P, 1997, J CELL SCI, V110, P1431; Lim JN, 2005, BBA-MOL BASIS DIS, V1739, P311, DOI 10.1016/j.bbadis.2004.10.003; Lo WK, 2003, EXP EYE RES, V77, P615, DOI 10.1016/S0014-4835(03)00176-3; MACCIONI RB, 1983, BIOCHEM BIOPH RES CO, V110, P463, DOI 10.1016/0006-291X(83)91172-5; Martin JL, 1997, CIRCULATION, V96, P4343; Muchowski PJ, 1999, INVEST OPHTH VIS SCI, V40, P951; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; Piatigorsky Joram, 2003, Journal of Structural and Functional Genomics, V3, P131; PRESCOTT AR, 1991, EXP EYE RES, V52, P743, DOI 10.1016/0014-4835(91)90026-B; Quinlan Roy, 2002, Prog Mol Subcell Biol, V28, P219; Rusan NM, 2001, MOL BIOL CELL, V12, P971, DOI 10.1091/mbc.12.4.971; Sakurai T, 2005, FASEB J, V19, P1199, DOI 10.1096/fj.04-3060fje; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x; Weart RB, 2005, MOL MICROBIOL, V57, P238, DOI 10.1111/j.1365-2958.2005.04673.x; Westermann S, 2005, MOL CELL, V17, P277, DOI 10.1016/j.molcel.2004.12.019; Xi JH, 2003, J CELL SCI, V116, P1073, DOI 10.1242/jcs.00325; Xu ZP, 2002, MOL CELL BIOL, V22, P6142, DOI 10.1128/MCB.22.17.6142-6147.2002; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	49	65	67	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					846	857		10.1096/fj.05-5532com	http://dx.doi.org/10.1096/fj.05-5532com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675842				2022-12-28	WOS:000240157700007
J	Jeng, W; Ramkissoon, A; Parman, T; Wells, PG				Jeng, Winnie; Ramkissoon, Annmarie; Parman, Toufan; Wells, Peter G.			Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration	FASEB JOURNAL			English	Article; Proceedings Paper	43rd Annual Meeting of the Society-of-Toxicology	MAR 21-25, 2004	Baltimore, MD	Soc Toxicol		MDMA; methamphetamine; brainstem; DNA oxidation	RAT-BRAIN; CHEMICAL TERATOGENESIS; METHAMPHETAMINE ABUSERS; ALZHEIMERS-DISEASE; MITOCHONDRIAL-DNA; KNOCKOUT MICE; COLON-CANCER; DOPAMINE; ECSTASY; DAMAGE	Reactive oxygen species (ROS) are implicated in amphetamine-initiated neurodegeneration, but the mechanism is unclear. Here, we show that amphetamines are bioactivated by CNS prostaglandin H synthase (PHS) to free radical intermediates that cause ROS formation and neurodegenerative oxidative DNA damage. In vitro incubations of purified PHS-1 with 3,4-methylenedioxyamphetamine (MDA) and methamphetamine ( METH) demonstrated PHS-catalyzed time- and concentration-dependent formation of an amphetamine carbon- and/or nitrogen-centered free radical intermediate, and stereoselective oxidative DNA damage, evidenced by 8-oxo-2'-deoxyguanosine (8-oxo-dG) formation. Similarly in vivo, MDA and METH caused dose- and time- dependent DNA oxidation in multiple brain regions, remarkably dependent on the regional PHS levels, including the striatum and substantia nigra, wherein neurodegeneration of dopaminergic nerve terminals was evidenced by decreased immunohistochemical staining of tyrosine hydroxylase. Motor impairment using the rotarod test was evident within 3 wk after the last drug dose, and persisted for at least 6 months. Pretreatment with the PHS inhibitor acetylsalicylic acid blocked MDA-initiated DNA oxidation and protected against functional motor impairment for at least 1.5 months after drug treatment. This is the first direct evidence for PHS-catalyzed bioactivation of amphetamines causing temporal and regional differences in CNS oxidative DNA damage directly related to structural and functional neurodegenerative consequences. - Jeng, J., Ramkissoon, A., Parman, T., Wells, P. G. Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration.	Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 2S2, Canada	University of Toronto; University of Toronto	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.	pg.wells@utoronto.ca						Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; Bolla KI, 1998, NEUROLOGY, V51, P1532, DOI 10.1212/WNL.51.6.1532; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; COLADO MI, 1995, BRIT J PHARMACOL, V115, P1281, DOI 10.1111/j.1476-5381.1995.tb15037.x; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; ELING TE, 1990, ANNU REV PHARMACOL, V30, P1, DOI 10.1146/annurev.pa.30.040190.000245; Feng ZH, 2002, NEUROSCI LETT, V329, P354, DOI 10.1016/S0304-3940(02)00704-8; Frederick DL, 1997, NEUROSCI BIOBEHAV R, V21, P67, DOI 10.1016/0149-7634(95)00064-X; FREEMAN BA, 1982, LAB INVEST, V47, P412; Gluck MR, 2001, J NEUROCHEM, V79, P152, DOI 10.1046/j.1471-4159.2001.00549.x; Guilarte TR, 2001, NEUROTOXICOLOGY, V22, P725, DOI 10.1016/S0161-813X(01)00046-8; HALLIWELL B, 1999, FREEE RADICALS BIOL; Jeng W, 2003, TOXICOL SCI, V72, P72; JENG W, 2004, TOXICOL SCI, V78, P413; JOHNSON M, 1988, J PHARMACOL EXP THER, V244, P977; JOHNSON MP, 1986, EUR J PHARMACOL, V132, P269, DOI 10.1016/0014-2999(86)90615-1; KALANT H, 2001, CMAJ, V165, P915; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kita T, 2000, NEUROPHARMACOLOGY, V39, P399, DOI 10.1016/S0028-3908(99)00175-6; Laposa RR, 2004, FASEB J, V18, P896, DOI 10.1096/fj.03-0903fje; Launer LJ, 2003, DRUGS, V63, P731, DOI 10.2165/00003495-200363080-00001; LIM HK, 1988, CHEM RES TOXICOL, V1, P370, DOI 10.1021/tx00006a008; Lin LY, 1997, DRUG METAB DISPOS, V25, P1059; LIU L, 1995, FREE RADICAL BIO MED, V19, P639, DOI 10.1016/0891-5849(95)00082-9; Markwell M A, 1981, Methods Enzymol, V72, P296; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; MARNETT LJ, 1983, REV BIOCHEM TOXICOL, P135; MARNETT LJ, 1995, PREV MED, V24, P103, DOI 10.1006/pmed.1995.1017; MARQUARDT GM, 1978, TOXICOL APPL PHARM, V45, P675, DOI 10.1016/0041-008X(78)90161-8; MARQUARDT GM, 1978, PSYCHOPHARMACOLOGY H, P84; McGuire P, 2000, TOXICOL LETT, V112, P153, DOI 10.1016/S0378-4274(99)00219-2; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Mecocci P, 1996, NEUROSCI LETT, V207, P129, DOI 10.1016/0304-3940(96)12509-X; Mintzer S, 1999, NEW ENGL J MED, V340, P1443, DOI 10.1056/NEJM199905063401817; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Nicol CJ, 2000, FASEB J, V14, P111, DOI 10.1096/fasebj.14.1.111; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; NICOL CJ, 1995, IN PRESS NAT GENET, V11, P104; Obrocki J, 1999, BRIT J PSYCHIAT, V175, P186, DOI 10.1192/bjp.175.2.186; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; Oka A, 1997, NEUROREPORT, V8, P1161, DOI 10.1097/00001756-199703240-00020; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Parman T, 1998, J BIOL CHEM, V273, P25079, DOI 10.1074/jbc.273.39.25079; Parman T, 2002, FASEB J, V16, P1001, DOI 10.1096/fj.01-0140com; Parrott AC, 2002, HUM PSYCHOPHARM CLIN, V17, P309, DOI 10.1002/hup.415; Pelkonen O, 1998, XENOBIOTICA, V28, P1203, DOI 10.1080/004982598238886; Pompl PN, 2003, FASEB J, V17, P725, DOI 10.1096/fj.02-0876fje; Ricaurte GA, 2000, NEUROPSYCHOBIOLOGY, V42, P5, DOI 10.1159/000026664; ROBERTS LJ, 2001, PHARMACOL BASIS THER, P689; SASAME HA, 1977, BIOCHEM BIOPH RES CO, V78, P919, DOI 10.1016/0006-291X(77)90510-1; SCHMIDT CJ, 1987, EUR J PHARMACOL, V136, P81, DOI 10.1016/0014-2999(87)90782-5; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; SPRAGUE JE, 1995, J PHARMACOL EXP THER, V273, P667; Teismann P, 2001, SYNAPSE, V39, P167, DOI 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U; Thomas DM, 2005, J PHARMACOL EXP THER, V313, P870, DOI 10.1124/jpet.104.080242; TUCKER GT, 1994, BIOCHEM PHARMACOL, V47, P1151, DOI 10.1016/0006-2952(94)90386-7; Valyi-Nagy T, 1999, J NEUROPATH EXP NEUR, V58, P1269, DOI 10.1097/00005072-199912000-00008; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Volkow ND, 2001, AM J PSYCHIAT, V158, P377, DOI 10.1176/appi.ajp.158.3.377; Volkow ND, 2001, J NEUROSCI, V21, P9414, DOI 10.1523/JNEUROSCI.21-23-09414.2001; Walsh DT, 2000, GLIA, V29, P392, DOI 10.1002/(SICI)1098-1136(20000215)29:4<392::AID-GLIA10>3.0.CO;2-C; Warner M, 1997, MUTAT RES-FUND MOL M, V376, P79, DOI 10.1016/S0027-5107(97)00053-5; WARNER M, 1994, P NATL ACAD SCI USA, V91, P1019, DOI 10.1073/pnas.91.3.1019; Wells Peter G, 2005, Toxicol Appl Pharmacol, V207, P354, DOI 10.1016/j.taap.2005.01.061; Wells PG, 1996, CRIT REV BIOCHEM MOL, V31, P1, DOI 10.3109/10409239609110574; Wells PG, 1997, MUTAT RES-FUND MOL M, V396, P65, DOI 10.1016/S0027-5107(97)00175-9; WELLS PG, 1997, HANDB EXP PHARM I, V124, P453; White SR, 1996, PROG NEUROBIOL, V49, P455, DOI 10.1016/0301-0082(96)00027-5; Winn LM, 1997, FREE RADICAL BIO MED, V22, P607, DOI 10.1016/S0891-5849(96)00340-1; Winn LM, 1999, FREE RADICAL BIO MED, V26, P266, DOI 10.1016/S0891-5849(98)00193-2; Wong A., 2004, TOXICOL SCI, V78, P380	77	39	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2006	20	6					638	650		10.1096/fj.05-5271com	http://dx.doi.org/10.1096/fj.05-5271com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581972				2022-12-28	WOS:000240130900010
J	Klitzman, R				Klitzman, Robert			Antoni Van Leeuwenhoek, FRS on Vermeer: a figment of the imagination	FASEB JOURNAL			English	Editorial Material									Columbia Univ, Coll Phys & Surg, Mailman Sch Publ Hlth, New York, NY 10032 USA	Columbia University	Klitzman, R (corresponding author), Columbia Univ, Coll Phys & Surg, Mailman Sch Publ Hlth, New York, NY 10032 USA.	rlk2@columbia.edu						GASKELL I, 1998, VERMEER STUDIES; Gowing Lawrence, 1952, VERMEER; Liedtke Walter, 2001, VERMEER DELFT SCH; Montias John Michael, 1982, ARTISTS ARTISANS DEL; SCHAMA S, 1996, EMBARRASSMENT RICHES; Snow Edward, 1994, A STUDY OF VERMEER, V2nd; WHEELOCK AK, 1998, VERMEER	7	1	2	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					591	594		10.1096/fj.06-0403ufm	http://dx.doi.org/10.1096/fj.06-0403ufm			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581963				2022-12-28	WOS:000240130900002
J	Collis, LP; Meyers, MB; Zhang, J; Phoon, CKL; Sobie, EA; Coetzee, WA; Fishman, GI				Collis, Leon P.; Meyers, Marian B.; Zhang, Jie; Phoon, Colin K. L.; Sobie, Eric A.; Coetzee, William A.; Fishman, Glenn I.			Expression of a sorcin missense mutation in the heart modulates excitation-contraction coupling	FASEB JOURNAL			English	Article						ryanodine receptor; transgenic; mouse model	MYOCARDIAL PERFORMANCE INDEX; CALCIUM SPARKS; IN-VIVO; VENTRICULAR MYOCYTES; RYANODINE RECEPTORS; CA2+ CURRENT; PROTEIN; RELEASE; OVEREXPRESSION; KINASE	Sorcin is a Ca2+ binding protein implicated in the regulation of intracellular Ca2+ cycling and cardiac excitation-contraction coupling. Structural and human genetic studies suggest that a naturally occurring sequence variant encoding L112-sorcin disrupts an E-F hand Ca2+ binding domain and may be responsible for a heritable form of hypertension and hypertrophic heart disease. We generated transgenic mice overexpressing L112-sorcin in the heart and characterized the effects on Ca2+ regulation and cardiac function both in vivo and in dissociated cardiomyocytes. Hearts of sorcin(F112L) transgenic mice were mildly dilated but ventricular function was preserved and systemic blood pressure was normal. Sorcin(F112L) myocytes were smaller than control cells and displayed complex alterations in Ca2+ regulation and contractility, including a slowed inactivation of L-type Ca2+ current, enhanced Ca2+ spark width, duration, and frequency, and increased Na+-Ca2+ exchange activity. In contrast, mice with cardiac-specific overexpression of wild-type sorcin displayed directionally opposite effects on L-type Ca2+ channel function and Ca2+ spark behavior. These data further define the role of sorcin in cardiac excitation-contraction coupling and highlight its negative regulation of SR calcium release. Our results also suggest that additional factors may be responsible for the development of cardiac hypertrophy and hypertension in humans expressing the L112-sorcin sequence variant.	NYU, Div Pediat Cardiol, Sch Med, New York, NY 10016 USA; NYU, Leon H Charney Div Cardiol, Sch Med, New York, NY 10016 USA	New York University; New York University	Fishman, GI (corresponding author), NYU, Div Cardiol, Sch Med, 550 1St Ave,OBV A-615, New York, NY 10016 USA.	glenn.fishman@med.nyu.edu	Phoon, Colin K/C-9270-2009	Coetzee, William/0000-0003-1522-8326; Fishman, Glenn/0000-0002-2366-8527	NHLBI NIH HHS [R01 HL076230-03, R01 HL076230] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076230] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854; Bers DM, 2005, ANN NY ACAD SCI, V1047, P86, DOI 10.1196/annals.1341.008; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bers DM, 2004, J MOL CELL CARDIOL, V37, P417, DOI 10.1016/j.yjmcc.2004.05.026; Bondarenko VE, 2004, AM J PHYSIOL-HEART C, V287, pH1378, DOI 10.1152/ajpheart.00185.2003; Broberg CS, 2003, J AM SOC ECHOCARDIOG, V16, P814, DOI 10.1067/S0894-7317(03)00399-7; Cheng H, 1999, BIOPHYS J, V76, P606, DOI 10.1016/S0006-3495(99)77229-2; Chu GX, 2002, CARDIOVASC RES, V54, P105, DOI 10.1016/S0008-6363(02)00230-4; Farrell EF, 2004, BIOL RES, V37, P609, DOI 10.4067/s0716-97602004000400015; Farrell EF, 2003, J BIOL CHEM, V278, P34660, DOI 10.1074/jbc.M305931200; Ferrier GR, 2003, AM J PHYSIOL-HEART C, V285, pH1495, DOI 10.1152/ajpheart.00802.2002; Frank KF, 2005, J MOL CELL CARDIOL, V38, P607, DOI 10.1016/j.yjmcc.2005.01.011; GULICK J, 1991, J BIOL CHEM, V266, P9180; Gutstein DE, 2001, CIRC RES, V88, P333, DOI 10.1161/01.RES.88.3.333; Hansen C, 2003, FEBS LETT, V545, P151, DOI 10.1016/S0014-5793(03)00518-0; IIARI A, 2002, J MOL BIOL, V317, P447; Jegger D, 2006, AM J PHYSIOL-HEART C, V290, pH1540, DOI 10.1152/ajpheart.00935.2005; Kerfant BG, 2001, CIRC RES, V88, pE59, DOI 10.1161/hh0701.090462; Li YX, 2002, CIRC RES, V90, P309, DOI 10.1161/hh0302.105660; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; Matsumoto T, 2005, BASIC RES CARDIOL, V100, P250, DOI 10.1007/s00395-005-0518-7; MATSUOKA S, 1992, J GEN PHYSIOL, V100, P963, DOI 10.1085/jgp.100.6.963; Mella M, 2003, J BIOL CHEM, V278, P24921, DOI 10.1074/jbc.M213276200; Meyers MB, 2003, J BIOL CHEM, V278, P28865, DOI 10.1074/jbc.M302009200; Meyers MB, 1998, J BIOL CHEM, V273, P18930, DOI 10.1074/jbc.273.30.18930; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; MEYERS MB, 2005, AFCS NATURE MOL PAGE, DOI DOI 10.1038/MP.A002208.002201; Mohiddin SA, 2002, CIRCULATION, V106, P319; Pack-Chung E, 2000, J BIOL CHEM, V275, P14440, DOI 10.1074/jbc.M909882199; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; Seidler T, 2003, CIRC RES, V93, P132, DOI 10.1161/01.RES.0000081596.90205.E2; Sobie EA, 2002, BIOPHYS J, V83, P59, DOI 10.1016/S0006-3495(02)75149-7; Song LS, 1998, J PHYSIOL-LONDON, V512, P677, DOI 10.1111/j.1469-7793.1998.677bd.x; Stern MD, 2004, CELL CALCIUM, V35, P591, DOI 10.1016/j.ceca.2004.01.013; Suarez J, 2004, AM J PHYSIOL-HEART C, V286, pH68, DOI 10.1152/ajpheart.00245.2003; Takeda T, 2005, FASEB J, V19, P2069, DOI 10.1096/fj.05-3744fje; Terentyev D, 2002, CIRC RES, V91, P414, DOI 10.1161/01.RES.0000032490.04207.BD; Valdivia HH, 2004, J MUSCLE RES CELL M, V25, P605; Valkova N, 2005, MOL CELL PROTEOMICS, V4, P1009, DOI 10.1074/mcp.M500091-MCP200; Wang ZY, 2001, J BIOL CHEM, V276, P17706, DOI 10.1074/jbc.M100544200; Wu YJ, 2001, J PHYSIOL-LONDON, V535, P679, DOI 10.1111/j.1469-7793.2001.t01-1-00679.x; Xie XL, 2001, PROTEIN SCI, V10, P2419, DOI 10.1110/ps.ps.36701; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429	44	18	18	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					475	487		10.1096/fj.06-6292com	http://dx.doi.org/10.1096/fj.06-6292com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17130302				2022-12-28	WOS:000244686300021
J	Rexhepaj, R; Grahammer, F; Volkl, H; Remy, C; Wagner, CA; Sandulache, D; Artunc, F; Henke, G; Nammi, S; Capasso, G; Alessi, DR; Lang, F				Rexhepaj, Rexhep; Grahammer, Florian; Voelkl, Harald; Remy, Christine; Wagner, Carsten A.; Sandulache, Diana; Artunc, Ferruh; Henke, Guido; Nammi, Srinivas; Capasso, Giovambattista; Alessi, Dario R.; Lang, Florian			Reduced intestinal and renal amino acid transport in PDK1 hypomorphic mice	FASEB JOURNAL			English	Article						aminoaciduria; PI3 kinase; growth factors; SGK; PKB	UBIQUITIN LIGASE NEDD4-2; INDUCIBLE KINASE ISOFORMS; NF-KAPPA-B; PROTEIN-KINASE; GROWTH-RETARDATION; MOLECULAR-CLONING; PLASMA-MEMBRANE; CELL-VOLUME; PHOSPHOINOSITIDE 3-KINASE; SURFACE EXPRESSION	The phosphoinositide-dependent kinase PDK1 activates the serum- and glucocorticoid-inducible kinase isoforms SGK1, SGK2, and SGK3 and protein kinase B, which in turn are known to up-regulate a variety of sodium-coupled transporters. The present study was performed to explore the role of PDK1 in amino acid transport. As mice completely lacking functional PDK1 are not viable, mice expressing 10-25% of PDK1 (pdk1(hm)) were compared with their wild-type (WT) littermates ( pdk1(wt)). Body weight was significantly less in pdk1hm than in pdk1(wt)mice. Despite lower body weight of pdk1(hm)mice, food and water intake were similar in pdk1(hm) and pdk1(wt)mice. According to Ussing chamber experiments, electrogenic transport of phenylalanine, cysteine, glutamine, proline, leucine, and tryptophan was significantly smaller in jejunum of pdk1(hm)mice than in pdk1(wt)mice. Similarly, electrogenic transport of phenylalanine, glutamine, and proline was significantly decreased in isolated perfused proximal tubules of pdk1(hm)mice. The urinary excretion of proline, valine, guanidinoacetate, methionine, phenylalanine, citrulline, glutamine/ glutamate, and tryptophan was significantly larger in pdk1(hm) than in pdk1(wt)mice. According to immunoblotting of brush border membrane proteins prepared from kidney, expression of the Na+-dependent neutral amino acid transporter B(0)AT1 (SLC6A19), the glutamate transporter EAAC1/EAAT3 (SLC1A1), and the transporter for cationic amino acids and cystine b(0), (+)AT (SLC7A9) was decreased but the Na+/proline cotransporter SIT (SLC6A20) was increased in pdk1(hm)mice. In conclusion, reduction of functional PDK1 leads to impairment of intestinal absorption and renal reabsorption of amino acids. The combined intestinal and renal loss of amino acids may contribute to the growth defect of PDK1-deficient mice.	Univ Tubingen, Dept Physiol 1, D-72076 Tubingen, Germany; Med Univ Innsbruck, Dept Physiol, Innsbruck, Austria; Univ Zurich, Inst Physiol, CH-8006 Zurich, Switzerland; Univ Zurich, Ctr Integrat Human Physiol, CH-8006 Zurich, Switzerland; Second Univ Napolis, Chair Nephrol, Naples, Italy; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	Eberhard Karls University of Tubingen; Medical University of Innsbruck; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); Universita della Campania Vanvitelli; University of Dundee	Lang, F (corresponding author), Univ Tubingen, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de	Nammi, Srinivas/I-2983-2013; Grahammer, Florian/ABB-7775-2021	Nammi, Srinivas/0000-0002-4735-2789; Capasso, Giovambattista/0000-0003-3469-8614; Alessi, Dario/0000-0002-2140-9185	MRC [MC_U127015387] Funding Source: UKRI; Medical Research Council [MC_U127015387] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; AWRICH AE, 1975, J PEDIATR-US, V87, P731, DOI 10.1016/S0022-3476(75)80296-4; BIBER J, 1981, BIOCHIM BIOPHYS ACTA, V647, P169, DOI 10.1016/0005-2736(81)90243-1; Boehmer C, 2006, J NEUROCHEM, V97, P911, DOI 10.1111/j.1471-4159.2006.03629.x; Boehmer C, 2005, BIOCHEM BIOPH RES CO, V329, P738, DOI 10.1016/j.bbrc.2005.02.035; Boehmer C, 2004, BIOCHEM BIOPH RES CO, V313, P998, DOI 10.1016/j.bbrc.2003.12.011; Boehmer C, 2003, J NEUROCHEM, V86, P1181, DOI 10.1046/j.1471-4159.2003.01937.x; Boehmer C, 2003, BIOCHEM BIOPH RES CO, V306, P156, DOI 10.1016/S0006-291X(03)00921-5; BOEHMER C, 2005, IN PRESS BIOCH BIOPH; Boulos M, 2001, Rev Med Suisse Romande, V121, P205; Broer A, 2004, J BIOL CHEM, V279, P24467, DOI 10.1074/jbc.M400904200; Broer S, 2002, PFLUG ARCH EUR J PHY, V444, P457, DOI 10.1007/s00424-002-0840-y; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURG M, 1966, AM J PHYSIOL, V210, P1293, DOI 10.1152/ajplegacy.1966.210.6.1293; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Coffer PJ, 1998, BIOCHEM J, V335, P1; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Connor KM, 2005, J BIOL CHEM, V280, P16916, DOI 10.1074/jbc.M410690200; Dieter M, 2004, OBES RES, V12, P862, DOI 10.1038/oby.2004.104; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Embark HM, 2003, PFLUG ARCH EUR J PHY, V445, P601, DOI 10.1007/s00424-002-0982-y; Fellman V, 1998, LANCET, V351, P490, DOI 10.1016/S0140-6736(97)09272-6; Firestone GL, 2003, CELL PHYSIOL BIOCHEM, V13, P1, DOI 10.1159/000070244; Font M, 2001, HUM MOL GENET, V10, P305, DOI 10.1093/hmg/10.4.305; Gamper N, 2002, PFLUG ARCH EUR J PHY, V443, P625, DOI 10.1007/s00424-001-0741-5; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; GREGER R, 1981, PFLUG ARCH EUR J PHY, V389, P175, DOI 10.1007/BF00582110; GREGER R, 1981, PFLUG ARCH EUR J PHY, V390, P30, DOI 10.1007/BF00582707; HAUSSINGER D, 1992, TRENDS PHARMACOL SCI, V13, P371, DOI 10.1016/0165-6147(92)90114-L; HAUSSINGER D, 1994, AM J PHYSIOL, V267, pE343, DOI 10.1152/ajpendo.1994.267.3.E343; Henke G, 2004, J CELL PHYSIOL, V199, P194, DOI 10.1002/jcp.10430; Jung F, 2000, CARDIOVASC RES, V48, P148, DOI 10.1016/S0008-6363(00)00152-8; Kaur S, 2005, J INTERF CYTOK RES, V25, P780, DOI 10.1089/jir.2005.25.780; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kleta R, 2004, NAT GENET, V36, P999, DOI 10.1038/ng1405; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Kowalczuk S, 2005, BIOCHEM J, V386, P417, DOI 10.1042/BJ20050100; LANG F, 1992, PHYSIOL REV, V72, P1, DOI 10.1152/physrev.1992.72.1.1; LANG F, 1986, AM J PHYSIOL, V250, pF953, DOI 10.1152/ajprenal.1986.250.6.F953; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 2003, CELL PHYSIOL BIOCHEM, V13, P41, DOI 10.1159/000070248; Lang F, 2001, Sci STKE, V2001, pre17, DOI 10.1126/stke.2001.108.re17; LANG F, 1995, NEWS PHYSIOL SCI, V10, P18; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Liu ZJ, 2003, FASEB J, V17, P1931, DOI 10.1096/fj.02-1171fje; Loffing J, 2006, ANNU REV PHYSIOL, V68, P461, DOI 10.1146/annurev.physiol.68.040104.131654; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Palacin M, 2005, PHYSIOLOGY, V20, P112, DOI 10.1152/physiol.00051.2004; Palmada M, 2006, DIABETES, V55, P421, DOI 10.2337/diabetes.55.02.06.db05-0720; Palmada M, 2005, BIOCHEM BIOPH RES CO, V331, P272, DOI 10.1016/j.bbrc.2005.03.159; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Peghini P, 1997, EMBO J, V16, P3822, DOI 10.1093/emboj/16.13.3822; Pineda M, 2004, BIOCHEM J, V377, P665, DOI 10.1042/BJ20030956; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Romeo E, 2006, AM J PHYSIOL-RENAL, V290, pF376, DOI 10.1152/ajprenal.00286.2005; Schniepp R, 2004, INVEST OPHTH VIS SCI, V45, P1442, DOI 10.1167/iovs.03-0062; SCHULTZ SG, 1981, AM J PHYSIOL, V241, pF579, DOI 10.1152/ajprenal.1981.241.6.F579; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; Seow HF, 2004, NAT GENET, V36, P1003, DOI 10.1038/ng1406; Setiawan I, 2002, PFLUG ARCH EUR J PHY, V444, P426, DOI 10.1007/s00424-002-0823-z; Shojaiefard M, 2005, BIOCHEM BIOPH RES CO, V334, P742, DOI 10.1016/j.bbrc.2005.06.164; SIMELL O, 1975, AM J MED, V59, P229, DOI 10.1016/0002-9343(75)90358-7; Stokoe David, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009361; Tapodi A, 2005, J BIOL CHEM, V280, P35767, DOI 10.1074/jbc.M507075200; Vallon V, 2005, P NATL ACAD SCI USA, V102, P17864, DOI 10.1073/pnas.0505860102; Vallon V, 2001, J AM SOC NEPHROL, V12, P2003, DOI 10.1681/ASN.V12102003; Verrey F, 2003, ANN NY ACAD SCI, V986, P554, DOI 10.1111/j.1749-6632.2003.tb07253.x; Verrey F, 2005, ANNU REV PHYSIOL, V67, P557, DOI 10.1146/annurev.physiol.67.031103.153949; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Wulff P, 2002, J CLIN INVEST, V110, P1263, DOI 10.1172/JCI200215696; Yeung MY, 2003, BIOL NEONATE, V84, P1, DOI 10.1159/000071438; Zecevic M, 2004, PFLUG ARCH EUR J PHY, V448, P29, DOI 10.1007/s00424-003-1222-9; Zhu QS, 2006, BLOOD, V107, P1847, DOI 10.1182/blood-2005-04-1612	80	24	25	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2214	2222		10.1096/fj.05-5676com	http://dx.doi.org/10.1096/fj.05-5676com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077298	Green Accepted			2022-12-28	WOS:000241702600006
J	Rumbaugh, J; Turchan-Cholewo, J; Galey, D; Hillaire, CS; Anderson, C; Conant, K; Nath, A				Rumbaugh, J.; Turchan-Cholewo, J.; Galey, D.; Hillaire, C. St.; Anderson, C.; Conant, K.; Nath, A.			Interaction of HIV Tat and matrix metalloproteinase in HIV neuropathogenesis: a new host defense mechanism	FASEB JOURNAL			English	Article						human; immunodeficiency diseases; neuroimmunology; neurotoxicity; viral	IMMUNODEFICIENCY-VIRUS TYPE-1; BLOOD-BRAIN-BARRIER; SYNERGISTIC NEUROTOXICITY; PROTEIN; EXPRESSION; APOPTOSIS; AIDS; METHAMPHETAMINE; ACTIVATION; DEMENTIA	Tat, the HIV transactivating protein, and matrix metalloproteinases ( MMPs), a family of extracellular matrix (ECM) endopeptidases, have been implicated in the pathogenesis of HIV-associated dementia. However, the possibility that MMPs interact with viral proteins has remained unexplored. We therefore treated mixed human fetal neuronal cultures with recombinant Tat and select MMPs. Neurotoxicity was determined by measuring mitochondrial membrane potential and neuronal cell death. Previous studies have shown that Tat and MMP independently cause neurotoxicity. Surprisingly, we found the combination of Tat and MMP produced significant attenuation of neurotoxicity. To determine whether there was a physical interaction between Tat and MMP, we used protein electrophoresis and Western blot techniques, and found that MMP-1 can degrade Tat. This effect was blocked by MMP inhibitors. Furthermore, MMP-1 decreased Tat-mediated transactivation of the HIV long terminal repeat region, and this functionality was restored when MMP-1 activity was inhibited. These results suggest that the decrease in Tat-induced neurotoxicity and HIV transactivation is due to Tat's enzymatic cleavage by MMP-1. The direct interaction of human MMPs with viral proteins has now been demonstrated, with resultant modulation of Tat-mediated neurotoxicity and transactivation. This study elucidates a unique viral-host interaction that may serve as an innate host defense mechanism.	Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21218 USA; Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40506 USA	Johns Hopkins University; Johns Hopkins University; University of Kentucky	Nath, A (corresponding author), 600 N Wolfe St,Pathol 509, Baltimore, MD 21287 USA.	anath1@jhmi.edu						Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Banks WA, 2005, EXP NEUROL, V193, P218, DOI 10.1016/j.expneurol.2004.11.019; Bansal AK, 2000, BRAIN RES, V879, P42, DOI 10.1016/S0006-8993(00)02725-6; Bozzo C, 1997, EXP CELL RES, V237, P326, DOI 10.1006/excr.1997.3777; Chauhan A, 2003, J BIOL CHEM, V278, P13512, DOI 10.1074/jbc.M209381200; Checler F, 2002, TRENDS NEUROSCI, V25, P616, DOI 10.1016/S0166-2236(02)02263-4; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; Chung KKK, 2001, TRENDS NEUROSCI, V24, pS7, DOI 10.1016/S0166-2236(00)01998-6; Conant K, 2004, J BIOL CHEM, V279, P8056, DOI 10.1074/jbc.M307051200; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Culley FJ, 2000, J IMMUNOL, V165, P6447, DOI 10.4049/jimmunol.165.11.6447; Dore GJ, 2003, AIDS, V17, P1539, DOI 10.1097/00002030-200307040-00015; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Flora G, 2003, EXP NEUROL, V179, P60, DOI 10.1006/exnr.2002.8048; Fox L, 1997, J NEUROPATH EXP NEUR, V56, P360, DOI 10.1097/00005072-199704000-00004; Gartner S, 2000, SCIENCE, V287, P602, DOI 10.1126/science.287.5453.602; Gelbard HA, 1999, ANN NY ACAD SCI, V890, P312, DOI 10.1111/j.1749-6632.1999.tb08008.x; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gurwell JA, 2001, NEUROSCIENCE, V102, P555, DOI 10.1016/S0306-4522(00)00461-9; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Johnston JB, 2001, ANN NEUROL, V49, P230, DOI 10.1002/1531-8249(20010201)49:2<230::AID-ANA43>3.0.CO;2-O; Kim TA, 2003, J IMMUNOL, V170, P2629, DOI 10.4049/jimmunol.170.5.2629; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; Kutsch O, 2000, J VIROL, V74, P9214, DOI 10.1128/JVI.74.19.9214-9221.2000; Langford D, 2002, J NEUROIMMUNOL, V127, P115, DOI 10.1016/S0165-5728(02)00068-1; LEVY RM, 1985, J NEUROSURG, V62, P475, DOI 10.3171/jns.1985.62.4.0475; Libby RT, 1999, J NEUROSCI, V19, P9399; Liu XJ, 2002, J BIOL CHEM, V277, P39312, DOI 10.1074/jbc.M205107200; Liu YQ, 2001, PLANT PHYSIOL, V127, P1788, DOI 10.1104/pp.010593; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; Ma MH, 1997, J VIROL, V71, P2495, DOI 10.1128/JVI.71.3.2495-2499.1997; MAGNAN A, 1995, ENFANCE, V1, P37; MALISSA H, 1991, MIKROCHIM ACTA, V1, P1; Maragos WF, 2002, J NEUROCHEM, V83, P955, DOI 10.1046/j.1471-4159.2002.01212.x; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618; MASLIAH E, 1992, J NEUROPATH EXP NEUR, V51, P585; McArthur JC, 2003, J NEUROVIROL, V9, P205, DOI 10.1080/13550280390194109; MCARTHUR JC, 1993, NEUROLOGY, V43, P2245, DOI 10.1212/WNL.43.11.2245; McManus CM, 2000, AM J PATHOL, V156, P1441, DOI 10.1016/S0002-9440(10)65013-4; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Montaner J, 2001, STROKE, V32, P2762, DOI 10.1161/hs1201.99512; Nath A, 2000, ANN NEUROL, V47, P186, DOI 10.1002/1531-8249(200002)47:2<186::AID-ANA8>3.3.CO;2-V; Nath A, 1998, PROG NEUROBIOL, V54, P19, DOI 10.1016/S0301-0082(97)00053-1; Nath A, 1999, SEMIN NEUROL, V19, P113, DOI 10.1055/s-2008-1040830; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; Nath A, 2002, JAIDS-J ACQ IMM DEF, V31, pS62, DOI 10.1097/00126334-200210012-00006; Nath A, 2002, J INFECT DIS, V186, pS193, DOI 10.1086/344528; Neuenburg JK, 2002, JAIDS-J ACQ IMM DEF, V31, P171, DOI 10.1097/00126334-200210010-00007; New DR, 1997, J NEUROVIROL, V3, P168, DOI 10.3109/13550289709015806; NICHOL KA, 1995, BRAIN RES, V697, P1, DOI 10.1016/0006-8993(95)00695-M; Olsen C, 1999, BRAIN RES, V850, P144, DOI 10.1016/S0006-8993(99)02115-0; Patton BL, 1998, NATURE, V393, P698, DOI 10.1038/31502; Polazzi E, 1999, J NEUROPATH EXP NEUR, V58, P825, DOI 10.1097/00005072-199908000-00005; Sacktor N, 2002, J NEUROVIROL, V8, P115, DOI 10.1080/13550280290101094; SASAGURI Y, 1994, LAB INVEST, V71, P261; SATO H, 1993, ONCOGENE, V8, P395; TARDIEU M, 1992, ANN NEUROL, V32, P11, DOI 10.1002/ana.410320104; Tikhonov I, 2004, FEBS LETT, V565, P89, DOI 10.1016/j.febslet.2004.03.079; Turchan J, 2003, NEUROLOGY, V60, P307, DOI 10.1212/01.WNL.0000042048.85204.3D; Turchan J, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-3; Vos CMP, 2000, EXP NEUROL, V163, P324, DOI 10.1006/exnr.2000.7388; Wang P, 1999, NEUROSCIENCE, V88, P585, DOI 10.1016/S0306-4522(98)00242-5; Weiss JM, 1999, J IMMUNOL, V163, P2953; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127	66	38	41	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1736	+		10.1096/fj.05-5619fje	http://dx.doi.org/10.1096/fj.05-5619fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807369				2022-12-28	WOS:000240266600032
J	Arck, PC; Overall, R; Spatz, K; Liezman, C; Handjiski, B; Klapp, BF; Birch-Machin, MA; Peters, EMJ				Arck, Petra Clara; Overall, Rupert; Spatz, Katharina; Liezman, Christiane; Handjiski, Bori; Klapp, Burghard F.; Birch-Machin, Mark A.; Peters, Eva Milena Johanne			Towards a "free radical theory of graying": melanocyte apoptosis in the aging human hair follicle is an indicator of oxidative stress induced tissue damage	FASEB JOURNAL			English	Article						gray hair; premature aging	MITOCHONDRIAL-DNA; STEM-CELLS; MELANOGENESIS; MICE; SKIN; DIFFERENTIATION; INVOLVEMENT; DISRUPTION; REGRESSION; DELETIONS	Oxidative stress is generated by a multitude of environmental and endogenous challenges such as radiation, inflammation, or psychoemotional stress. It also speeds the aging process. Graying is a prominent but little understood feature of aging. Intriguingly, the continuous melanin synthesis in the growing (anagen) hair follicle generates high oxidative stress. We therefore hypothesize that hair bulb melanocytes are especially susceptible to free radical-induced aging. To test this hypothesis, we subjected human scalp skin anagen hair follicles from graying individuals to macroscopic and immunohistomorphometric analysis and organ culture. We found evidence of melanocyte apoptosis and increased oxidative stress in the pigmentary unit of graying hair follicles. The "common" deletion, a marker mitochondrial DNA-deletion for accumulating oxidative stress damage, occurred most prominently in graying hair follicles. Cultured unpigmented hair follicles grew better than pigmented follicles of the same donors. Finally, cultured pigmented hair follicles exposed to exogenous oxidative stress (hydroquinone) showed increased melanocyte apoptosis in the hair bulb. We conclude that oxidative stress is high in hair follicle melanocytes and leads to their selective premature aging and apoptosis. The graying hair follicle, therefore, offers a unique model system to study oxidative stress and aging and to test antiaging therapeutics in their ability to slow down or even stop this process.	Humboldt Univ, Ctr Biomed Res, Cutaneous Neuroimmunol, D-13353 Berlin, Germany; Humboldt Univ, Ctr Biomed Res, Psychoneuroimmunol, D-13353 Berlin, Germany; Univ Newcastle, Sch Med, Newcastle, NSW 2308, Australia	Humboldt University of Berlin; Humboldt University of Berlin; University of Newcastle	Arck, PC (corresponding author), Humboldt Univ, Ctr Biomed Res, Cutaneous Neuroimmunol, Rm Nr 2-0549,Univ Med Charite,Virchow Campus,Augu, D-13353 Berlin, Germany.	eva.peters@charite.de	Overall, Rupert W/P-3102-2016; Arck, Petra C/D-7094-2013	Overall, Rupert W/0000-0002-3882-6073; Arck, Petra/0000-0002-2932-926X				Akar A, 2002, J DERMATOL SCI, V29, P85, DOI 10.1016/S0923-1811(02)00015-4; Bahmer FA, 2002, HAUTARZT, V53, P492, DOI 10.1007/s00105-002-0375-3; Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016; Birch-Machin MA, 2000, CLIN EXP DERMATOL, V25, P141, DOI 10.1046/j.1365-2230.2000.00605.x; BOTCHKAREVA NV, 2001, FASEB J, V15, P3; Bowers RR, 1999, CELL MOL BIOL, V45, P1065; Brierley EJ, 1997, MOL CELL BIOCHEM, V174, P325, DOI 10.1023/A:1006847319162; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Cernak I, 2000, MAGNESIUM RES, V13, P29; Commo S, 2004, BRIT J DERMATOL, V150, P435, DOI 10.1046/j.1365-2133.2004.05787.x; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; DAWBER R, 1995, HAIR SCALP DISORDERS; Emerit I, 2004, PHOTOCHEM PHOTOBIOL, V80, P579, DOI 10.1562/2004-06-22-RA-212.1; Epel ES, 2004, P NATL ACAD SCI USA, V101, P17312, DOI 10.1073/pnas.0407162101; FLUGEL B, 1971, Z ALTERNSFORSCHUNG, V23, P397; Fuchs J, 2001, FREE RADICAL BIO MED, V30, P337, DOI 10.1016/S0891-5849(00)00482-2; Gould L, 1996, AM HEART J, V132, P1317, DOI 10.1016/S0002-8703(96)90496-2; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Irie M, 2001, JPN J CANCER RES, V92, P367, DOI 10.1111/j.1349-7006.2001.tb01104.x; Irie M, 2001, INT ARCH OCC ENV HEA, V74, P153, DOI 10.1007/s004200000209; Ito M, 2004, DIFFERENTIATION, V72, P548, DOI 10.1111/j.1432-0436.2004.07209008.x; Jimenez-Cervantes C, 2001, J CELL SCI, V114, P2335; Kadekaro AL, 2003, PIGM CELL RES, V16, P434, DOI 10.1034/j.1600-0749.2003.00088.x; Kao SH, 1997, BIOCHEM MOL BIOL INT, V42, P285; KLIGMAN AM, 1959, J INVEST DERMATOL, V33, P307, DOI 10.1038/jid.1959.156; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; Lee JW, 2005, MECH AGEING DEV, V126, P79, DOI 10.1016/j.mad.2004.09.011; Legue E, 2005, DEVELOPMENT, V132, P4143, DOI 10.1242/dev.01975; Lindner G, 1997, AM J PATHOL, V151, P1601; Liu CS, 2001, NEPHROL DIAL TRANSPL, V16, P561, DOI 10.1093/ndt/16.3.561; Lu CY, 1999, MUTAT RES-FUND MOL M, V423, P11, DOI 10.1016/S0027-5107(98)00220-6; Melov S, 2002, INT J BIOCHEM CELL B, V34, P1395, DOI 10.1016/S1357-2725(02)00086-9; Meyskens FL, 1999, CLIN CANCER RES, V5, P1197; Moller P, 1996, CHEM-BIOL INTERACT, V102, P17, DOI 10.1016/0009-2797(96)03729-5; MOSLEY JG, 1996, BR MED J, V313; Muller-Rover S, 1999, J INVEST DERM SYMP P, V4, P272, DOI 10.1038/sj.jidsp.5640228; Muller-Rover S, 2000, AM J PATHOL, V156, P1395, DOI 10.1016/S0002-9440(10)65008-0; NAGL W, 1995, BRIT J DERMATOL, V132, P94, DOI 10.1111/j.1365-2133.1995.tb08631.x; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Nappi AJ, 1996, MELANOMA RES, V6, P341, DOI 10.1097/00008390-199610000-00001; Nishimura EK, 2005, SCIENCE, V307, P720, DOI 10.1126/science.1099593; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; NORDLUND JJ, 1998, PIGMENTARY SYSTEM, P1106; OrrWalker BJ, 1997, J CLIN ENDOCR METAB, V82, P3580, DOI 10.1210/jc.82.11.3580; PAUS R, 1993, YALE J BIOL MED, V66, P541; Paus R, 1999, J INVEST DERM SYMP P, V4, P338, DOI 10.1038/sj.jidsp.5640241; PAVEL S, 1993, J INVEST DERMATOL, V100, pS162, DOI 10.1111/1523-1747.ep12465095; Peters EMJ, 2002, J HISTOCHEM CYTOCHEM, V50, P751, DOI 10.1177/002215540205000602; Philpott M, 1999, Exp Dermatol, V8, P317; PHILPOTT MP, 1990, J CELL SCI, V97, P463; Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x; RILEY PA, 1988, ANN NY ACAD SCI, V551, P111, DOI 10.1111/j.1749-6632.1988.tb22325.x; ROSEN CJ, 1994, J CLIN ENDOCR METAB, V79, P854, DOI 10.1210/jc.79.3.854; Slominski A, 2005, J INVEST DERMATOL, V124, P13, DOI 10.1111/j.0022-202X.2004.23528.x; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; SPERLING LC, 1991, J AM ACAD DERMATOL, V25, P1, DOI 10.1016/0190-9622(91)70167-Z; Sun LQ, 2004, GENE DEV, V18, P1035, DOI 10.1101/gad.1176104; Tobin DJ, 2000, J PATHOL, V191, P407; Tobin DJ, 2001, EXP GERONTOL, V36, P29, DOI 10.1016/S0531-5565(00)00210-2; Tobin DJ, 1999, J INVEST DERM SYMP P, V4, P323, DOI 10.1038/sj.jidsp.5640239; TOBIN DJ, 2000, ATLAS HAIR NAILS, P157; Van Neste D, 2004, MICRON, V35, P193, DOI 10.1016/j.micron.2003.11.006; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Yamamura K, 1996, CANCER RES, V56, P3546; YANG JH, 1994, ARCH DERMATOL RES, V286, P386, DOI 10.1007/BF00371798; YOHN JJ, 1991, J INVEST DERMATOL, V97, P405, DOI 10.1111/1523-1747.ep12480983; Zhai S, 1996, EXP CELL RES, V224, P335, DOI 10.1006/excr.1996.0143	68	145	156	2	45	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1567	+		10.1096/fj.05-4039fje	http://dx.doi.org/10.1096/fj.05-4039fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723385				2022-12-28	WOS:000240266000053
J	Aung, HT; Schroder, K; Himes, SR; Brion, K; van Zuylen, W; Trieu, A; Suzuki, H; Hayashizaki, Y; Hume, DA; Sweet, MJ; Ravasi, T				Aung, Hnin Thanda; Schroder, Kate; Himes, Stewart R.; Brion, Kristian; van Zuylen, Wendy; Trieu, Angela; Suzuki, Harukazu; Hayashizaki, Yoshihide; Hume, David A.; Sweet, Matthew J.; Ravasi, Timothy			LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression	FASEB JOURNAL			English	Article						transcriptional regulatory networks; epigenetic; histone code; innate immunity; inflammation	NF-KAPPA-B; INNATE IMMUNE-SYSTEM; TOLL-LIKE RECEPTORS; CYCLOOXYGENASE-2 GENE; MURINE MACROPHAGES; DNA METHYLATION; CHROMATIN; PROMOTER; LIPOPOLYSACCHARIDE; TRANSCRIPTION	Bacterial LPS triggers dramatic changes in gene expression in macrophages. We show here that LPS regulated several members of the histone deacetylase (HDAC) family at the mRNA level in murine bone marrow-derived macrophages (BMM). LPS transiently repressed, then induced a number of HDACs (Hdac-4, 5, 7) in BMM, whereas Hdac-1 mRNA was induced more rapidly. Treatment of BMM with trichostatin A (TSA), an inhibitor of HDACs, enhanced LPS-induced expression of the Cox-2, Cxcl2, and Ifit2 genes. In the case of Cox-2, this effect was also apparent at the promoter level. Overexpression of Hdac-8 in RAW264 murine macrophages blocked the ability of LPS to induce Cox-2 mRNA. Another class of LPS-inducible genes, which included Ccl2, Ccl7, and Edn1, was suppressed by TSA, an effect most likely mediated by PU.1 degradation. Hence, HDACs act as potent and selective negative regulators of proinflammatory gene expression and act to prevent excessive inflammatory responses in macrophages.	Univ Calif San Diego, Dept Bioengn, San Diego, CA 92103 USA; Univ Queensland, Cooperat Res Ctr Chron Inflammatory Dis, St Lucia, Qld 4067, Australia; Univ Queensland, Australian Res Council Special Res Ctr Funct & Ap, Inst Mol Biosci, St Lucia, Qld 4067, Australia; RIKEN, Lab Genome Explorat Res Grp, Genom Sci Ctr, Yokohama Inst,Tsurumi Ku, Yokohama, Kanagawa, Japan	University of California System; University of California San Diego; University of Queensland; University of Queensland; RIKEN	Ravasi, T (corresponding author), Univ Calif San Diego, Dept Bioengn, San Diego, CA 92103 USA.	travasi@bioeng.ucsd.edu	Hume, David A/C-7695-2013; Hayashizaki, Yoshihide/N-6590-2015; Schroder, Kate/C-6132-2008; Sweet, Matthew J/F-2229-2011; Ravasi, Timothy/B-8777-2008	Schroder, Kate/0000-0001-9261-3805; Sweet, Matthew J/0000-0002-0406-8139; Hume, David/0000-0002-2615-1478; Ravasi, Timothy/0000-0002-9950-465X				Akira S, 2003, SCAND J INFECT DIS, V35, P555, DOI 10.1080/00365540310015683; Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Boekhoudt GH, 2003, J IMMUNOL, V170, P4139, DOI 10.4049/jimmunol.170.8.4139; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Chang S, 1999, J LEUKOCYTE BIOL, V66, P528, DOI 10.1002/jlb.66.3.528; Cosgrove MS, 2005, BIOCHEM CELL BIOL, V83, P468, DOI 10.1139/O05-137; Costelloe EO, 1999, J LEUKOCYTE BIOL, V66, P172, DOI 10.1002/jlb.66.1.172; Dean Ann, 2004, Briefings in Functional Genomics & Proteomics, V2, P344, DOI 10.1093/bfgp/2.4.344; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Duroux M, 2004, PLANT J, V40, P660, DOI 10.1111/j.1365-313X.2004.02242.x; Giacca Mauro, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P277, DOI 10.2174/1568008043339767; Greene Warner C, 2004, Novartis Found Symp, V259, P208; Himes SR, 2001, J LEUKOCYTE BIOL, V70, P812; Hume D A, 2001, BMC Immunol, V2, P11, DOI 10.1186/1471-2172-2-11; Joo M, 2004, J BIOL CHEM, V279, P6658, DOI 10.1074/jbc.M306267200; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Laribee RN, 2001, J IMMUNOL, V167, P5160, DOI 10.4049/jimmunol.167.9.5160; Lee JY, 2003, J LEUKOCYTE BIOL, V73, P862, DOI 10.1189/jlb.1202618; MADONNA GS, 1985, J IMMUNOL, V135, P3763; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; Marwick JA, 2004, AM J RESP CELL MOL, V31, P633, DOI 10.1165/rcmb.2004-0006OC; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Mellor J, 2005, MOL CELL, V19, P147, DOI 10.1016/j.molcel.2005.06.023; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Murakami K, 1997, DNA CELL BIOL, V16, P173, DOI 10.1089/dna.1997.16.173; MUSIKACHAROEN T, 2004, BLOOD; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Park GY, 2004, AM J PHYSIOL-LUNG C, V286, pL956, DOI 10.1152/ajplung.00338.2003; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Ram C Venkata S, 2003, Am J Ther, V10, P396, DOI 10.1097/00045391-200311000-00004; Ravasi T, 2002, J IMMUNOL, V168, P44, DOI 10.4049/jimmunol.168.1.44; Rehli M, 1999, J IMMUNOL, V162, P1559; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179; Stacey KJ, 1996, J IMMUNOL, V157, P2116; Suuronen T, 2003, J NEUROCHEM, V87, P407, DOI 10.1046/j.1471-4159.2003.02004.x; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Sweet MJ, 2002, J IMMUNOL, V168, P392, DOI 10.4049/jimmunol.168.1.392; Thiel G, 2004, EUR J BIOCHEM, V271, P2855, DOI 10.1111/j.1432-1033.2004.04174.x; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wells CA, 2003, GENOME RES, V13, P1360, DOI 10.1101/gr.1056103; Wells Christine A, 2003, BMC Immunol, V4, P5, DOI 10.1186/1471-2172-4-5; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; Zaidi SK, 2005, EMBO REP, V6, P128, DOI 10.1038/sj.embor.7400337; Zhou WS, 2004, P NATL ACAD SCI USA, V101, P2440, DOI 10.1073/pnas.0306002101	50	177	184	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1315	1327		10.1096/fj.05-5360com	http://dx.doi.org/10.1096/fj.05-5360com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816106				2022-12-28	WOS:000240266000008
J	Wang, S; Teschemacher, AG; Paton, JFR; Kasparov, S				Wang, Sheng; Teschemacher, Anja G.; Paton, Julian F. R.; Kasparov, Sergey			Mechanism of nitric oxide action on inhibitory GABAergic signaling within the nucleus tractus solitarii	FASEB JOURNAL			English	Article						ryanodine; cADPR; [Ca2+](i); patch clamp	CYCLIC ADP-RIBOSE; CA2+-INDUCED CA2+ RELEASE; CALCIUM-RELEASE; ANGIOTENSIN-II; INTRACELLULAR CALCIUM; VENTROLATERAL MEDULLA; BARORECEPTOR REFLEX; GLUTAMATE RELEASE; HEART-RATE; NEURONS	The cellular mechanisms mediating nitric oxide (NO) modulation of the inhibitory transmission in the nucleus tractus solitarii (NTS) remain unclear, even though this could be extremely important for various physiological and pathological processes. Specifically, in the NTS NO-evoked glutamate and gamma-aminobutyric acid (GABA) release might contribute to pathological hypertension. In cultured rat brainstem slices, NTS GABAergic neurons were targeted using an adenoviral vector to express enhanced green fluorescent protein and studied with a combination of patch clamp and confocal microscopy. Low nanomolar concentrations of NO increased intracellular Ca2+ concentration ([Ca2+](i)) in somata, dendrites, and putative axons of GABAergic neurons, with axons being the most sensitive compartment. This effect was cGMP mediated and not related to depolarization or indirect presynaptic effects on glutamatergic transmission. Blockade of the cyclic adenosine diphosphate ribose (cADPR)/ryanodine-sensitive stores but not the inositol triphosphate-sensitive stores, inhibited NO effect. Since cADPR/ryanodine-sensitive stores are implicated in the Ca2+-induced Ca2+ release, NO can be expected to potentiate GABA release. In support of this notion, a cADPR antagonist abolished the NO-induced potentiation of GABAergic inhibitory postsynaptic potentials in the NTS. Thus, the NO-cGMP-cADPR-Ca2+ pathway, previously described in sea urchin eggs, also operates in mammalian GABAergic neurons. Potentiation of GABA release by NO may have implications for numerous brain functions.	Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England	University of Bristol; University of Bristol	Kasparov, S (corresponding author), Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England.	sergey.kasparov@bristol.ac.uk	Paton, Julian/AAM-2121-2020; Kasparov, Sergey/AAH-5286-2019; Kasparov, Sergey/C-4932-2014	Kasparov, Sergey/0000-0002-1824-1764; Kasparov, Sergey/0000-0002-1824-1764; Wang, Sheng/0000-0001-9579-4808; Paton, Julian/0000-0001-7410-2913	Wellcome Trust [069061] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abudara V, 2002, J NEUROPHYSIOL, V88, P497, DOI 10.1152/jn.2002.88.1.497; ANDRESEN MC, 1990, AM J PHYSIOL, V259, pH1307, DOI 10.1152/ajpheart.1990.259.4.H1307; Bains JS, 1997, NEUROSCIENCE, V79, P149, DOI 10.1016/S0306-4522(96)00670-7; Bellamy TC, 2001, J BIOL CHEM, V276, P4287, DOI 10.1074/jbc.M006677200; BROOKS PA, 1992, J PHYSIOL-LONDON, V457, P115, DOI 10.1113/jphysiol.1992.sp019367; Bruzzone S, 2003, BIOCHEM J, V375, P395, DOI 10.1042/BJ20030556; Butcher JW, 1999, J AUTONOM NERV SYST, V77, P90, DOI 10.1016/S0165-1838(99)00036-3; Chini EN, 2005, BIOCHEM J, V389, P269, DOI 10.1042/BJ20041971; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; Cohen AS, 1997, J PHYSIOL-LONDON, V499, P315, DOI 10.1113/jphysiol.1997.sp021929; Dias ACR, 2005, AM J PHYSIOL-HEART C, V288, pH256, DOI 10.1152/ajpheart.01149.2003; Empson RM, 1997, J BIOL CHEM, V272, P20967, DOI 10.1074/jbc.272.34.20967; Esplugues JV, 2002, BRIT J PHARMACOL, V135, P1079, DOI 10.1038/sj.bjp.0704569; Fernandez SF, 2003, HYPERTENSION, V41, P56, DOI 10.1161/01.HYP.0000047513.75459.7E; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Griffiths C, 2002, EUR J NEUROSCI, V15, P962, DOI 10.1046/j.1460-9568.2002.01930.x; Guse AH, 2004, CURR MOL MED, V4, P239, DOI 10.2174/1566524043360771; Hashii M, 2000, BIOCHEM J, V345, P207, DOI 10.1042/0264-6021:3450207; Hirooka Y, 2003, J CARDIOVASC PHARM, V42, pS111, DOI 10.1097/00005344-200312001-00023; Horn TFW, 2002, FASEB J, V16, P1611, DOI 10.1096/fj.02-0126com; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; Huang CC, 2003, MOL PHARMACOL, V64, P521, DOI 10.1124/mol.64.2.521; Kasparov S, 2004, PROG BIOPHYS MOL BIO, V84, P251, DOI 10.1016/j.pbiomolbio.2003.11.011; Kasparov S, 1999, J PHYSIOL-LONDON, V521, P227, DOI 10.1111/j.1469-7793.1999.00227.x; Kishi T, 2001, HYPERTENSION, V38, P896, DOI 10.1161/hyp.38.4.896; Koh HY, 2001, EUR J NEUROSCI, V13, P553, DOI 10.1046/j.0953-816x.2000.01416.x; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Li Y, 2003, NEUROSCIENCE, V118, P585, DOI 10.1016/S0306-4522(03)00042-3; Lin HC, 2000, EUR J PHARMACOL, V407, P83, DOI 10.1016/S0014-2999(00)00684-1; LINDEN DJ, 1995, J NEUROSCI, V15, P5098; Llano I, 2000, NAT NEUROSCI, V3, P1256, DOI 10.1038/81781; Looms DK, 2001, BIOCHEM J, V355, P87, DOI 10.1042/bj3550087; Lu YF, 2002, J NEUROPHYSIOL, V88, P1270, DOI 10.1152/jn.2002.88.3.1270; Maeda M, 1999, NEUROREPORT, V10, P1957, DOI 10.1097/00001756-199906230-00030; Matsumura K, 1998, BRAIN RES, V798, P232, DOI 10.1016/S0006-8993(98)00420-X; Matsuo I, 2001, AM J PHYSIOL-REG I, V280, pR1285, DOI 10.1152/ajpregu.2001.280.5.R1285; MORRISSETTE J, 1993, FEBS LETT, V330, P270, DOI 10.1016/0014-5793(93)80886-Y; Ohkuma S, 1996, MOL BRAIN RES, V36, P137, DOI 10.1016/0169-328X(95)00256-R; OHKUMA S, 1995, J NEUROCHEM, V65, P1109; OHTA H, 1994, AM J PHYSIOL-REG I, V267, pR1065, DOI 10.1152/ajpregu.1994.267.4.R1065; Oliva AA, 2000, J NEUROSCI, V20, P3354, DOI 10.1523/JNEUROSCI.20-09-03354.2000; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; Paton JFR, 2002, TRENDS NEUROSCI, V25, P626, DOI 10.1016/S0166-2236(02)02261-0; Paton JFR, 2001, J PHYSIOL-LONDON, V531, P445, DOI 10.1111/j.1469-7793.2001.0445i.x; PATON JFR, 2005, ADV VAGAL AFFERENT N, P209; Pontieri V, 1998, J HYPERTENS, V16, P1993, DOI 10.1097/00004872-199816121-00021; Reyes-Harde M, 1999, J NEUROPHYSIOL, V82, P1569, DOI 10.1152/jn.1999.82.3.1569; Sistiaga A, 1997, EUR J PHARMACOL, V321, P247, DOI 10.1016/S0014-2999(96)00937-5; Stern JE, 2005, J PHYSIOL-LONDON, V562, P725, DOI 10.1113/jphysiol.2004.077735; Talman WT, 2004, HYPERTENSION, V43, P820, DOI 10.1161/01.HYP.0000120848.76987.ef; Talman WT, 2001, ANN NY ACAD SCI, V940, P169; Teggatz EG, 2005, MICROVASC RES, V70, P65, DOI 10.1016/j.mvr.2005.06.004; Teschemacher AG, 2005, EXP PHYSIOL, V90, P61, DOI 10.1113/expphysiol.2004.028191; Trabace L, 2000, J NEUROCHEM, V75, P1664, DOI 10.1046/j.1471-4159.2000.0751664.x; Vacher CM, 2003, EUR J NEUROSCI, V17, P455, DOI 10.1046/j.1460-9568.2003.02467.x; Verkhratsky A, 2005, PHYSIOL REV, V85, P201, DOI 10.1152/physrev.00004.2004; Waki H, 2003, J PHYSIOL-LONDON, V546, P233, DOI 10.1113/jphysiol.2002.030270; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; Willmott N, 1996, J BIOL CHEM, V271, P3699; Willmott NJ, 2000, J NEUROSCI, V20, P1767; Yusufi ANK, 2002, EXP BIOL MED, V227, P36, DOI 10.1177/153537020222700107; ZANZINGER J, 1995, NEUROSCI LETT, V197, P199, DOI 10.1016/0304-3940(95)11929-Q	66	36	37	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1537	+		10.1096/fj.05-5547fje	http://dx.doi.org/10.1096/fj.05-5547fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720728				2022-12-28	WOS:000240266000043
J	Hennige, AM; Stefan, N; Kapp, K; Lehmann, R; Weigert, C; Beck, A; Moeschel, K; Mushack, J; Schleicher, E; Haring, HU				Hennige, Anita M.; Stefan, Norbert; Kapp, Katja; Lehmann, Rainer; Weigert, Cora; Beck, Alexander; Moeschel, Klaus; Mushack, Joanne; Schleicher, Erwin; Haering, Hans-Ulrich			Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1	FASEB JOURNAL			English	Article						protein kinase C; obesity; Irs protein; insulin resistance	PROTEIN-KINASE-C; SKELETAL-MUSCLE CELLS; RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; C2C12 MYOTUBES; JANUS KINASE-2; GLUCOSE-UPTAKE; FATTY-ACIDS; RESISTANCE	Insulin resistance in skeletal muscle is found in obesity and type 2 diabetes. A mechanism for impaired insulin signaling in peripheral tissues is the inhibition of insulin action through serine phosphorylation of insulin receptor substrate (Irs) proteins that abolish the coupling of Irs proteins to the activated insulin receptor. Recently, we described serine-318 as a protein kinase C (PKC)-dependent phosphorylation site in Irs1 (Ser-318) activated by hyperinsulinemia. Here we show in various cell models that the adipose hormone leptin, a putative mediator in obesity-related insulin resistance, promotes phosphorylation of Ser318 in Irs1 by a janus kinase 2, Irs2, and PKC-dependent pathway. Mutation of Ser-318 to alanine abrogates the inhibitory effect of leptin on insulin-induced Irs1 tyrosine phosphorylation and glucose uptake in L6 myoblasts. In C57Bl/6 mice, Ser-318 phosphorylation levels in muscle tissue were enhanced by leptin and insulin administration in lean animals while in diet-induced obesity Ser-318 phosphorylation levels were already up-regulated in the basal state, and further stimulation was diminished. In analogy, in lymphocytes of obese hyperleptinemic human subjects basal Ser-318 phosphorylation levels were increased compared to lean individuals. During a hyperinsulinemic euglycemic clamp, the increment in Ser-318 phosphorylation observed in lean individuals was absent in obese. In summary, these data suggest that phosphorylation of Ser-318 in Irs1 mediates the inhibitory signal of leptin on the insulin-signaling cascade in obese subjects.	Univ Tubingen, Dept Internal Med 4, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Haring, HU (corresponding author), Univ Tubingen, Dept Internal Med 4, Morgenstelle 1, D-72076 Tubingen, Germany.	hans-ulrich.haering@med.uni-tuebingen.de		Stefan, Norbert/0000-0002-2186-9595				Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Argiles JM, 2005, MED RES REV, V25, P49, DOI 10.1002/med.20010; Beck A, 2003, J AM SOC MASS SPECTR, V14, P401, DOI 10.1016/S1044-0305(03)00122-3; Berti L, 1997, DIABETOLOGIA, V40, P606, DOI 10.1007/s001250050722; Bjorbaek C, 2004, RECENT PROG HORM RES, V59, P305, DOI 10.1210/rp.59.1.305; Boden G, 2002, CURR OPIN CLIN NUTR, V5, P545, DOI 10.1097/00075197-200209000-00014; Boden G, 1997, J CLIN INVEST, V100, P1107, DOI 10.1172/JCI119621; Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; Brabant G, 2005, FASEB J, V19, P1048, DOI 10.1096/fj.04-2846fje; Cardenas C, 2004, J BIOL CHEM, V279, P39122, DOI 10.1074/jbc.M401044200; Carlson CJ, 2004, BIOCHEM BIOPH RES CO, V316, P533, DOI 10.1016/j.bbrc.2004.02.082; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Ceddia RB, 2002, FASEB J, V16, DOI 10.1096/fj.02-0158rev; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Eiras S, 2004, J CELL PHYSIOL, V201, P214, DOI 10.1002/jcp.20046; Facchinetti MM, 1999, CELL SIGNAL, V11, P39, DOI 10.1016/S0898-6568(98)00029-1; FULOP T, 1995, FEBS LETT, V375, P69, DOI 10.1016/0014-5793(95)01179-I; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Ignatoski KMW, 2003, MOL CANCER RES, V1, P551; Itani SI, 2000, DIABETES, V49, P1353, DOI 10.2337/diabetes.49.8.1353; Javor ED, 2005, DIABETES, V54, P1994, DOI 10.2337/diabetes.54.7.1994; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kellerer M, 1997, DIABETOLOGIA, V40, P1358, DOI 10.1007/s001250050832; Kellerer M, 2001, DIABETOLOGIA, V44, P1125, DOI 10.1007/s001250100614; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Lazar MA, 2005, SCIENCE, V307, P373, DOI 10.1126/science.1104342; Liu YF, 2004, MOL CELL BIOL, V24, P9668, DOI 10.1128/MCB.24.21.9668-9681.2004; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Moeschel K, 2004, J BIOL CHEM, V279, P25157, DOI 10.1074/jbc.M402477200; Perez C, 2004, DIABETES, V53, P347, DOI 10.2337/diabetes.53.2.347; Pirola L, 2004, DIABETOLOGIA, V47, P170, DOI 10.1007/s00125-003-1313-3; ROTH RA, 1994, HORM RES, V41, P51, DOI 10.1159/000183961; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Sahu A, 2004, ENDOCRINOLOGY, V145, P2613, DOI 10.1210/en.2004-0032; Sahu A, 1998, ENDOCRINOLOGY, V139, P795, DOI 10.1210/en.139.2.795; Sahu A, 2002, J NEUROENDOCRINOL, V14, P796, DOI 10.1046/j.1365-2826.2002.00840.x; Sanchez-Margalet V, 2003, CLIN EXP IMMUNOL, V133, P11, DOI 10.1046/j.1365-2249.2003.02190.x; Schwartz MW, 2001, J CLIN INVEST, V108, P963, DOI 10.1172/JCI200114127; Serrano R, 2005, J MOL ENDOCRINOL, V34, P153, DOI 10.1677/jme.1.01635; Smith U, 2002, INT J OBESITY, V26, P897, DOI 10.1038/sj.ijo.0802028; Sweeney G, 2001, ENDOCRINOLOGY, V142, P4806, DOI 10.1210/en.142.11.4806; Szanto I, 2000, P NATL ACAD SCI USA, V97, P2355, DOI 10.1073/pnas.050580497; Tajmir P, 2003, J CELL PHYSIOL, V197, P122, DOI 10.1002/jcp.10351; Ueno M, 2005, DIABETOLOGIA, V48, P506, DOI 10.1007/s00125-004-1662-6; Vollenweider P, 2002, DIABETES, V51, P1052, DOI 10.2337/diabetes.51.4.1052; Weigert C, 2005, J BIOL CHEM, V280, P37393, DOI 10.1074/jbc.M506134200; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; ZICK Y, 2005, SCI STKE, pE4; Zimmet PZ, 1998, INT J OBESITY, V22, P171, DOI 10.1038/sj.ijo.0800559	56	73	77	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1206	+		10.1096/fj.05-4635fje	http://dx.doi.org/10.1096/fj.05-4635fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16611834				2022-12-28	WOS:000240210300027
J	Liu, W; Cao, DZ; Oh, SF; Serhan, CN; Kulmacz, RJ				Liu, Wen; Cao, Dazhe; Oh, Sungwhan F.; Serhan, Charles N.; Kulmacz, Richard J.			Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases	FASEB JOURNAL			English	Article						cyclooxygenase substrate specificity; cyclooxygenase activation by peroxide; aspirin-induced lipoxygenase catalysis	TURBOT SCOPHTHALMUS-MAXIMUS; SALMON SALMO-SALAR; ACTIVE-SITE RESIDUES; RAINBOW-TROUT; ONCORHYNCHUS-MYKISS; EICOSANOID PRODUCTION; LIPID HYDROPEROXIDES; ARACHIDONIC-ACID; EXPRESSION; PLASMA	Prostanoid synthesis in mammalian tissues is regulated at the level of prostaglandin H synthase ( PGHS) cyclooxygenase catalysis by the availability and structure of substrate fatty acid and the availability of peroxide activator. Two major PGHS isoforms, with distinct pathophysiological functions and catalytic regulation, have been characterized in mammals; a functionally homologous PGHS isoform pair has been cloned from an evolutionarily distant vertebrate, brook trout. The cyclooxygenase activities of recombinant brook trout PGHS-1 and -2 were characterized to test the generality of mammalian regulatory paradigms for substrate specificity, peroxide activation, and product shifting by aspirin. Both trout cyclooxygenases had much more restrictive substrate specificities than their mammalian counterparts, with pronounced discrimination toward arachidonate ( 20: 4n-6) and against eicosapentaenoate (20: 5n-3) and docosahexaenoate ( 22: 6n-3), the latter two prominent in trout tissue lipids. Aspirin treatment did not increase lipoxygenase-type catalysis by either trout enzyme. Both trout enzymes had higher requirements for peroxide activator than their mammalian counterparts, though the preferential peroxide activation of PGHS-2 over PGHS-1 seen in mammals was conserved in the fish enzymes. The divergence in cyclooxygenase characteristics between the trout and mammalian PGHS proteins may reflect accomodations to differences among vertebrates in tissue lipid composition and general redox state.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77030 USA; Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Texas System; University of Texas Health Science Center Houston; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Kulmacz, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, 6431 Fannin St, Houston, TX 77030 USA.	kulmacz@uth.tmc.edu		Cao, Dazhe/0000-0003-2775-8527	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038765, R37GM038765, R01GM052170, R01GM038765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 074448] Funding Source: Medline; NIGMS NIH HHS [GM 52170, GM 38765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKMAN RG, 1967, COMP BIOCHEM PHYSIOL, V22, P907, DOI 10.1016/0010-406X(67)90781-5; Bambai B, 2000, J BIOL CHEM, V275, P27608; Bambai B, 2004, J BIOL CHEM, V279, P4084, DOI 10.1074/jbc.M304762200; BELL JG, 1995, PROSTAG LEUKOTR ESS, V53, P279, DOI 10.1016/0952-3278(95)90128-0; BELL JG, 1994, BBA-LIPID LIPID MET, V1211, P335, DOI 10.1016/0005-2760(94)90158-9; Bell JG, 1996, LIPIDS, V31, P1163, DOI 10.1007/BF02524291; Bell JG, 1997, LIPIDS, V32, P515, DOI 10.1007/s11745-997-0066-4; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Brubacher JL, 2000, DEV COMP IMMUNOL, V24, P565, DOI 10.1016/S0145-305X(00)00019-7; Buonocore F, 2005, AQUACULTURE, V245, P301, DOI 10.1016/j.aquaculture.2004.11.015; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; Frein D, 2005, BIOCHEM PHARMACOL, V70, P811, DOI 10.1016/j.bcp.2005.04.012; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Ghioni C, 1997, PROSTAG LEUKOTR ESS, V56, P479, DOI 10.1016/S0952-3278(97)90603-7; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Gorog DA, 2002, CARDIOVASC PATHOL, V11, P153, DOI 10.1016/S1054-8807(02)00103-5; Grosser T, 2002, P NATL ACAD SCI USA, V99, P8418, DOI 10.1073/pnas.112217799; GUNTHER SJ, 2003, THESIS U GUELPH GUEL; HENDERSON RJ, 1987, PROG LIPID RES, V26, P281, DOI 10.1016/0163-7827(87)90002-6; Henderson RJ, 1996, BBA-LIPID LIPID MET, V1299, P289, DOI 10.1016/0005-2760(95)00213-8; HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Holland JW, 2003, PARASITOLOGY, V126, pS95, DOI 10.1017/S0031182003003767; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Holub DJ, 2004, MOL CELL BIOCHEM, V263, P217, DOI 10.1023/B:MCBI.0000041863.11248.8d; Jarving R, 2004, J BIOL CHEM, V279, P13624, DOI 10.1074/jbc.M313258200; Kaewsrithong J, 2000, FISHERIES SCI, V66, P768, DOI 10.1046/j.1444-2906.2000.00125.x; Kovacs IB, 1997, AM HEART J, V134, P572, DOI 10.1016/S0002-8703(97)70097-8; Kozak KR, 2001, J BIOL CHEM, V276, P36993, DOI 10.1074/jbc.M105854200; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KULMACZ RJ, 1985, PROSTAGLANDINS, V29, P175, DOI 10.1016/0090-6980(85)90200-X; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; Kulmacz RJ, 1998, FEBS LETT, V430, P154, DOI 10.1016/S0014-5793(98)00657-7; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; LANDS WEM, 1973, ADV BIOSCI, V9, P15; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MELNIKOVA VI, 1983, BIOMED MASS SPECTROM, V10, P399, DOI 10.1002/bms.1200100703; MIYAZAWA T, 1989, FREE RADICAL BIO MED, V7, P209, DOI 10.1016/0891-5849(89)90017-8; Mori Trevor A, 2004, Curr Atheroscler Rep, V6, P461, DOI 10.1007/s11883-004-0087-5; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; Ornberg RL, 1999, ADV EXP MED BIOL, V469, P131; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PENDLETON R, 1990, THESIS U ILLINOIS UR; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Roberts SB, 2000, MOL CELL ENDOCRINOL, V160, P89, DOI 10.1016/S0303-7207(99)00252-X; Rowley AF, 1997, THROMB HAEMOSTASIS, V77, P227; Rowlinson SW, 2000, J BIOL CHEM, V275, P6586, DOI 10.1074/jbc.275.9.6586; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Sakamoto H, 2000, J BIOL CHEM, V275, P40028, DOI 10.1074/jbc.M003191200; Schneider C, 2004, J BIOL CHEM, V279, P4404, DOI 10.1074/jbc.M307431200; Schneider C, 2002, J BIOL CHEM, V277, P478, DOI 10.1074/jbc.M107471200; SECOMBES CJ, 1994, VET IMMUNOL IMMUNOP, V42, P367, DOI 10.1016/0165-2427(94)90080-9; SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002; Serhan CN, 2001, J CLIN INVEST, V107, P1481, DOI 10.1172/JCI13375; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; Smith WL, 2005, CURR OPIN CELL BIOL, V17, P174, DOI 10.1016/j.ceb.2005.02.005; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sorbera LA, 2001, BIOL REPROD, V64, P382, DOI 10.1095/biolreprod64.1.382; SPRECHER H, 1982, J BIOL CHEM, V257, P3912; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; Tocher DR, 1996, COMP BIOCHEM PHYS B, V115, P215, DOI 10.1016/0305-0491(96)00113-7; Tocher DR, 1997, PROSTAG LEUKOTR ESS, V57, P125, DOI 10.1016/S0952-3278(97)90002-8; UENO R, 1982, J BIOL CHEM, V257, P5584; WADE MG, 1994, BIOL REPROD, V51, P131, DOI 10.1095/biolreprod51.1.131; WATANABE T, 1982, COMP BIOCHEM PHYS B, V73, P3, DOI 10.1016/0305-0491(82)90196-1; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; Yang TX, 1998, AM J PHYSIOL-RENAL, V274, pF481, DOI 10.1152/ajprenal.1998.274.3.F481; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181; ZAMBURLINI A, 1995, ANAL BIOCHEM, V232, P107, DOI 10.1006/abio.1995.9953; Zou J, 1999, BIOCHEM J, V340, P153, DOI 10.1042/bj3400153	80	33	33	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1097	1108		10.1096/fj.05-5273com	http://dx.doi.org/10.1096/fj.05-5273com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770009				2022-12-28	WOS:000240210300010
J	Novac, N; Baus, D; Dostert, A; Heinzel, T				Novac, Natalia; Baus, Daniela; Dostert, Anja; Heinzel, Thorsten			Competition between glucocorticoid receptor and NF kappa B for control of the human FasL promoter	FASEB JOURNAL			English	Article						nGRE; AICD; inflammation; glucocorticoid receptor; cis-repression	INDUCED APOPTOSIS; NUCLEAR FACTOR; T-LYMPHOCYTES; LIGAND GENE; CD95 LIGAND; CELL-DEATH; INHIBITION; ACTIVATION; REPRESSION; DNA	Glucocorticoids mediate a variety of biological effects via binding their intracellular receptor. Ligand-bound glucocorticoid receptor (GR) translocates to the nucleus and regulates gene transcription in a DNA binding-dependent or independent manner. The predominant biological effect of glucocorticoids on peripheral T cells is immunosupression via transcriptional repression of genes induced during T cell activation. Glucocorticoids have been implicated in the inhibition of activation-induced T cell apoptosis by virtue of their down-regulation of Fas ligand (fasL) expression. It is believed that FasL, similar to other cytokines, is repressed by glucocorticoids via GR interaction with other transcription factors, interfering with their transactivation ability. Here, we show that human fasL is directly regulated by GR in a DNA binding-dependent manner. A negative GR element found at position -990 in the fasL promoter binds GR in vitro as well as in the chromatin context. This negative glucocorticoid response element overlaps with a known NF kappa B binding site. GR down- regulates fasL promoter by competing with NF kappa B for binding to the common response element. Thus, fasL is the first gene described whose repression by GR is mediated by sterical occlusion of NF kappa B DNA binding. This type of repression represents an additional mechanism for the GR-NF kappa B mutual antagonism.	Univ Jena, Inst Biochem & Biophys, D-07743 Jena, Germany; Biomed Res Inst, Frankfurt, Germany	Friedrich Schiller University of Jena	Heinzel, T (corresponding author), Univ Jena, Inst Biochem & Biophys, Philosophenweg 12, D-07743 Jena, Germany.	t.heinzel@uni-jena.de	Heinzel, Thorsten/B-1013-2015					Baumann S, 2005, BLOOD, V106, P617, DOI 10.1182/blood-2004-11-4390; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Buttgereit F, 2005, LANCET, V365, P801; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Devitt A., 2004, METH MOL B, V282, P207; Dostert A, 2004, CURR PHARM DESIGN, V10, P2807; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kavurma MM, 2003, CELL DEATH DIFFER, V10, P36, DOI 10.1038/sj.cdd.4401179; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Lucas M, 2003, J IMMUNOL, V171, P2610, DOI 10.4049/jimmunol.171.5.2610; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Meyer T, 1997, DNA CELL BIOL, V16, P919, DOI 10.1089/dna.1997.16.919; NAKAI Y, 1991, J STEROID BIOCHEM, V40, P301, DOI 10.1016/0960-0760(91)90195-B; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Okabe T, 1998, J ENDOCRINOL, V156, P169, DOI 10.1677/joe.0.1560169; PALIOGIANNI F, 1993, J IMMUNOL, V151, P4081; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2004, CURR PHARM DESIGN, V10, P2797, DOI 10.2174/1381612043383575; Schacke Heike, 2005, Curr Opin Investig Drugs, V6, P503; Schleimer Robert P., 2000, Journal of Allergy and Clinical Immunology, V106, pS270; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; Smoak KA, 2004, MECH AGEING DEV, V125, P697, DOI 10.1016/j.mad.2004.06.010; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Umland SP, 2002, PULM PHARMACOL THER, V15, P35, DOI 10.1006/pupt.2001.0312; WYLLIE AH, 1985, ANTICANCER RES, V5, P131; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; Yerramasetti R, 2002, J CLIN IMMUNOL, V22, P37, DOI 10.1023/A:1014256603539; Zipp F, 2000, J NEUROIMMUNOL, V110, P214, DOI 10.1016/S0165-5728(00)00337-4	37	46	47	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1074	1081		10.1096/fj.05-5457com	http://dx.doi.org/10.1096/fj.05-5457com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770006				2022-12-28	WOS:000240210300007
J	Ahmad, ST; Natochin, M; Artemyev, NO; O'Tousa, JE				Ahmad, Syed Tariq; Natochin, Michael; Artemyev, Nikolai O.; O'Tousa, Joseph E.			The Drosophila rhodopsin cytoplasmic tail domain is required for maintenance of rhabdomere structure	FASEB JOURNAL			English	Article						bovine rhodopsin; microvillus; retinal degeneration	RETINAL DEGENERATION; PHOTORECEPTOR CELLS; TERMINAL DOMAIN; PROTEIN; MEMBRANES; MUTANTS; GENE; MELANOGASTER; MATURATION; TRANSPORT	The ninaE-encoded Rh1 rhodopsin is the major light-sensitive pigment expressed in Drosophila R1-6 photoreceptor cells. Rh1 rhodopsin localizes to and is essential for the development and maintenance of the rhabdomere, the specialized membrane-rich organelle that serves as the site of phototransduction. We showed previously that the vertebrate bovine rhodopsin (Rho) is expressed and properly localized in Drosophila photoreceptor cells. Drosophila photoreceptors expressing only Rho have normal rhabdomere structure at young ages, but the rhabdomeres are not maintained and show extensive disorganization by 7-10 days of age. A series of Rho-Rh1 opsin chimeric rhodopsins were used to identify Rh1 domains required for maintenance of rhabdomeric structure. The results show that the Rh1 rhodopsin cytoplasmic tail domain, positioned to interact with cytoplasmic structural components, plays a major role in promoting rhabdomeric organization.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Notre Dame; University of Iowa	O'Tousa, JE (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.	jotousa@nd.edu		O'Tousa, Joseph/0000-0001-9754-6816; Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY12682, R01 EY010843, EY06808, R01 EY012682] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012682] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahmad ST, 2006, INVEST OPHTH VIS SCI, V47, P3722, DOI 10.1167/iovs.06-0281; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; Concepcion F, 2002, VISION RES, V42, P417, DOI 10.1016/S0042-6989(01)00195-X; Davies A, 2001, J MOL BIOL, V314, P455, DOI 10.1006/jmbi.2001.5167; FUKUDA MN, 1979, J BIOL CHEM, V254, P8201; Green ES, 2000, INVEST OPHTH VIS SCI, V41, P1546; Iakhine R, 2004, J NEUROSCI, V24, P2516, DOI 10.1523/JNEUROSCI.5426-03.2004; Katanosaka K, 1998, FEBS LETT, V424, P149, DOI 10.1016/S0014-5793(98)00160-4; Kumar JP, 1995, DEVELOPMENT, V121, P4359; Kurada P, 1998, VISUAL NEUROSCI, V15, P693, DOI 10.1017/S0952523898154093; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; MATSUMOTO H, 1987, P NATL ACAD SCI USA, V84, P985, DOI 10.1073/pnas.84.4.985; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; Nakagawa M, 1999, P NATL ACAD SCI USA, V96, P6189, DOI 10.1073/pnas.96.11.6189; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAULSEN R, 1979, BIOCHIM BIOPHYS ACTA, V557, P385, DOI 10.1016/0005-2736(79)90336-5; PORTER JA, 1992, J CELL BIOL, V116, P683, DOI 10.1083/jcb.116.3.683; Seki T, 1998, EUR J BIOCHEM, V257, P522, DOI 10.1046/j.1432-1327.1998.2570522.x; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Sung CH, 2000, INT REV CYTOL, V195, P215; Tam BM, 2000, J CELL BIOL, V151, P1369, DOI 10.1083/jcb.151.7.1369; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; VENIENBRYAN C, 1995, FEBS LETT, V359, P45, DOI 10.1016/0014-5793(94)01449-B; WASHBURN T, 1989, J BIOL CHEM, V264, P15464; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	27	8	40	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					449	455		10.1096/fj.06-6530com	http://dx.doi.org/10.1096/fj.06-6530com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158966				2022-12-28	WOS:000244686300018
J	Donn, R; Berry, A; Stevens, A; Farrow, S; Betts, J; Stevens, R; Clayton, C; Wang, JX; Warnock, L; Worthington, J; Scott, L; Graham, S; Ray, D				Donn, Rachelle; Berry, Andy; Stevens, Adam; Farrow, Stuart; Betts, Joanna; Stevens, Richard; Clayton, Chris; Wang, Jixian; Warnock, Linda; Worthington, Jane; Scott, Laurie; Graham, Simon; Ray, David			Use of gene expression profiling to identify a novel glucocorticoid sensitivity determining gene, BMPRII	FASEB JOURNAL			English	Article						network; signaling; microarray; dexamethasone	NF-KAPPA-B; RECEPTOR GENE; RESISTANT ASTHMA; DOCKING PROTEIN; IN-VIVO; CELLS; MECHANISMS; DIFFERENTIATION; RECRUITMENT; MUTATIONS	Wide variation in glucocorticoid (Gc) sensitivity exists between individuals which may influence susceptibility to, and treatment response of, inflammatory diseases. To determine a genetic fingerprint of Gc sensitivity 100 healthy human volunteers were polarized into the 10% most Gc-sensitive and 10% most Gc-resistant following a low dose dexamethasone (0.25mg) suppression test. Gene expression profiling of primary lymphocytes identified the 98 most significantly Gc regulated genes. These genes were used to build a subnetwork of Gc signaling, with 54 genes mapping as nodes, and 6 non-Gc regulated genes inferred as signaling nodes. Twenty four of the 98 genes showed a difference in Gc response in vitro dependent on the Gc sensitivity of their donor individuals in vivo. A predictive model was built using both partial least squares discriminate analysis and support vector machines that predicted donor glucocorticoid sensitivity with 87% accuracy. Discriminating genes included bone morphogenetic protein receptor, type II (BMPRII). Transfection studies showed that BMPRII modulated Gc action. These studies reveal a broad base of gene expression that predicts Gc sensitivity and determine a Gc signaling network in human primary T lymphocytes. Furthermore, this combined gene profiling, and functional analysis approach has identified BMPRII as a modulator of Gc signaling.	Univ Manchester, Ctr Mol Med, Fac Med, Manchester M13 9PT, Lancs, England; Univ Manchester, Arthrit Res Campaign Epidemiol Unit, Manchester M13 9PT, Lancs, England; GlaxoSmithKline Res & Dev Ltd, Stevenage, Herts, England	University of Manchester; University of Manchester; GlaxoSmithKline	Ray, D (corresponding author), Univ Manchester, Ctr Mol Med, Fac Med, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	david.w.ray@manchester.ac.uk	Stevens, Adam/AAB-6301-2020; Worthington, Jane/M-9770-2014; Stevens, Adam/D-6476-2012	Stevens, Adam/0000-0002-1950-7325; Worthington, Jane/0000-0003-0544-042X; Stevens, Adam/0000-0002-1950-7325; Donn, Rachelle/0000-0001-6976-9828; Ray, David/0000-0002-4739-6773				ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; Aligianis IA, 2005, NAT GENET, V37, P221, DOI 10.1038/ng1517; Ambroise C, 2002, P NATL ACAD SCI USA, V99, P6562, DOI 10.1073/pnas.102102699; Boden SD, 1996, ENDOCRINOLOGY, V137, P3401, DOI 10.1210/en.137.8.3401; Boden SD, 1997, ENDOCRINOLOGY, V138, P2820, DOI 10.1210/en.138.7.2820; Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.1007/BF00058655; Crown A, 2005, CLIN ENDOCRINOL, V63, P483, DOI 10.1111/j.1365-2265.2005.02320.x; Falkenauer E., 1997, GENETIC ALGORITHMS G; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797; Hakonarson H, 2005, P NATL ACAD SCI USA, V102, P14789, DOI 10.1073/pnas.0409904102; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; Huizenga NATM, 2000, J CLIN ENDOCR METAB, V85, P2076, DOI 10.1210/jc.85.5.2076; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kano Y, 2005, ENDOCRINOLOGY, V146, P5332, DOI 10.1210/en.2005-0474; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Kino T, 2001, J ENDOCRINOL, V169, P437, DOI 10.1677/joe.0.1690437; Kolchanov NA, 2002, NUCLEIC ACIDS RES, V30, P312, DOI 10.1093/nar/30.1.312; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; Law SF, 1996, MOL CELL BIOL, V16, P3327; Leung DYM, 1998, ANN NY ACAD SCI, V840, P735, DOI 10.1111/j.1749-6632.1998.tb09612.x; Lu NZ, 2004, ANN NY ACAD SCI, V1024, P102, DOI 10.1196/annals.1321.008; Luecke HF, 2005, GENE DEV, V19, P1116, DOI 10.1101/gad.1297105; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Rajagopalan D, 2005, BIOINFORMATICS, V21, P788, DOI 10.1093/bioinformatics/bti069; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; Seckl JR, 2004, ANN NY ACAD SCI, V1032, P63, DOI 10.1196/annals.1314.006; Sierra DA, 2002, GENOMICS, V79, P177, DOI 10.1006/geno.2002.6693; Smoak KA, 2004, MECH AGEING DEV, V125, P697, DOI 10.1016/j.mad.2004.06.010; Stevens A, 2004, CLIN ENDOCRINOL, V61, P327, DOI 10.1111/j.1365-2265.2004.02097.x; Stevens A, 2004, J CLIN ENDOCR METAB, V89, P892, DOI 10.1210/jc.2003-031235; Stevens A, 2003, MOL ENDOCRINOL, V17, P845, DOI 10.1210/me.2002-0320; van Rossum EFC, 2002, DIABETES, V51, P3128, DOI 10.2337/diabetes.51.10.3128; van Rossum EFC, 2005, TRENDS ENDOCRIN MET, V16, P445, DOI 10.1016/j.tem.2005.10.009; van Rossum EFC, 2003, CLIN ENDOCRINOL, V59, P585, DOI 10.1046/j.1365-2265.2003.01888.x; Vapnik V., 1998, STAT LEARNING THEORY; Wang JC, 2006, GENE DEV, V20, P689, DOI 10.1101/gad.1400506; Wang JC, 2004, P NATL ACAD SCI USA, V101, P15603, DOI 10.1073/pnas.0407008101; Waters CE, 2004, J ENDOCRINOL, V183, P375, DOI 10.1677/joe.1.05804; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759	47	59	60	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					402	414		10.1096/fj.06-7236com	http://dx.doi.org/10.1096/fj.06-7236com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17185747				2022-12-28	WOS:000244686300014
J	Taniguchi, F; Couse, JF; Rodriguez, KF; Emmen, JMA; Poirier, D; Korach, KS				Taniguchi, Fuminori; Couse, John F.; Rodriguez, Karina F.; Emmen, Judith M. A.; Poirier, Donald; Korach, Kenneth S.			Estrogen receptor-alpha mediates an intraovarian negative feedback loop on thecal cell steroidogenesis via modulation of Cyp17a1 (cytochrome P450, steroid 17 alpha-hydroxylase/17,20 lyase) expression	FASEB JOURNAL			English	Article						hydroxysteroid (17 beta) dehydrogenase; hyperandrogenemia; folliculogenesis; aromatase	POLYCYSTIC-OVARY-SYNDROME; ANDROGEN PRODUCTION; 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE-1; TESTOSTERONE PRODUCTION; AUTOREGULATORY PROCESS; LUTEINIZING-HORMONE; SEX REVERSAL; MOUSE; FOLLICLES; ENZYMES	Excess androgen synthesis by thecal cells is invariably detrimental to preovulatory follicles in the ovary and is considered a fundamental characteristic of polycystic ovary syndrome in women. Investigators have long postulated that granulosa cell-derived estrogens modulate thecal cell steroidogenesis via a short negative-feedback loop within the follicle. To test this hypothesis, we assessed the steroidogenic capacity of individual wild-type (WT) and estrogen receptor-alpha (ER alpha-)-null follicles when cultured in vitro under comparable conditions. Late-stage ER alpha-null follicles exhibited markedly increased expression of the thecal cell enzyme CYP17A1 and secreted much greater amounts of its end product, androstenedione. This phenotype was reproduced in WT follicles when exposed to an aromatase inhibitor or ER-antagonist, and prevented when the former treatment was supplemented with an ER alpha-specific agonist. ER alpha-null follicles also exhibited increased testosterone synthesis due to ectopic expression of hydroxysteroid (17 beta) dehydrogenase type 3 (HSD17B3), a testis-specific androgenic enzyme. These data indicate that ER alpha functions within thecal cells to negatively modulate the capacity for androgen synthesis by repressing Cyp17a1 expression, and the biological activity of androgens produced by inhibiting Hsd17b3 expression. Hence, these findings provide novel evidence of an intraovarian ER alpha function that may be critical to the latter stages of folliculogenesis and overall ovarian function.	NIEHS, Reprod & Dev Toxicol Lab, Receptor Biol Sect, NIH, Res Triangle Pk, NC 27709 USA; Tottori Univ Hosp, Dept Obstet & Gynecol, Yonago, Tottori, Japan; CHUQ, Oncol & Mol Endocrinol Res Ctr, Div Med Chem, Quebec City, PQ, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Tottori University; Laval University	Korach, KS (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, Receptor Biol Sect, NIH, MD B3-02,POB 12233, Res Triangle Pk, NC 27709 USA.	korach@nichs.nih.gov		Korach, Kenneth/0000-0002-7765-418X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES070065, ZIAES070065] Funding Source: NIH RePORTER; Intramural NIH HHS [NIH0010047172] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Akingbemi BT, 2003, ENDOCRINOLOGY, V144, P84, DOI 10.1210/en.2002-220292; Azziz R, 2003, FERTIL STERIL, V80, P252, DOI 10.1016/S0015-0282(03)00735-0; BANKS PK, 1991, ENDOCRINOLOGY, V129, P1295, DOI 10.1210/endo-129-3-1295; Chaturvedi G, 2004, ENDOCRINE, V25, P147, DOI 10.1385/ENDO:25:2:147; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; Couse JF, 2003, MOL ENDOCRINOL, V17, P1039, DOI 10.1210/me.2002-0398; Couse JF, 2004, ENDOCRINOLOGY, V145, P4693, DOI 10.1210/en.2004-0548; Couse JF, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P593; Couse JF, 2006, ENDOCRINOLOGY, V147, P3666, DOI 10.1210/en.2006-0276; EHRMANN DA, 1995, ENDOCR REV, V16, P322, DOI 10.1210/er.16.3.322; Emmen JMA, 2005, ENDOCRINOLOGY, V146, P2817, DOI 10.1210/en.2004-1108; ERICKSON GF, 1985, ENDOCR REV, V6, P371, DOI 10.1210/edrv-6-3-371; EVANS G, 1981, BIOL REPROD, V25, P290, DOI 10.1095/biolreprod25.2.290; Gore-Langton Robert E., 1994, P571; Govoroun M, 2001, ENDOCRINOLOGY, V142, P1841, DOI 10.1210/en.142.5.1841; Greenwald Gilbert S., 1994, P629; Heikkila M, 2005, ENDOCRINOLOGY, V146, P4016, DOI 10.1210/en.2005-0463; HERNANDEZ ER, 1990, ENDOCRINOLOGY, V127, P2804, DOI 10.1210/endo-127-6-2804; Jakimiuk AJ, 2002, J CLIN ENDOCR METAB, V87, P5532, DOI 10.1210/jc.2002-020323; JOHNSON DC, 1984, MOL CELL ENDOCRINOL, V35, P199, DOI 10.1016/0303-7207(84)90017-0; Kobayashi S, 2004, J MOL ENDOCRINOL, V32, P69, DOI 10.1677/jme.0.0320069; LEUNG PCK, 1980, ANNU REV PHYSIOL, V42, P71, DOI 10.1146/annurev.ph.42.030180.000443; Liakos P, 2003, J ENDOCRINOL, V176, P69, DOI 10.1677/joe.0.1760069; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MAGOFFIN DA, 1982, MOL CELL ENDOCRINOL, V28, P81, DOI 10.1016/0303-7207(82)90042-9; MAGOFFIN DA, 1991, SEMIN REPROD ENDOCR, V9, P321, DOI 10.1055/s-2007-1019424; MAGOFFIN DA, 1981, ENDOCRINOLOGY, V108, P962, DOI 10.1210/endo-108-3-962; MAGOFFIN DA, 1995, BIOL REPROD, V53, P627, DOI 10.1095/biolreprod53.3.627; Mellgren G, 2003, MOL CELL ENDOCRINOL, V203, P91, DOI 10.1016/S0303-7207(03)00097-2; NAYUDU PL, 1992, J REPROD FERTIL, V95, P349, DOI 10.1530/jrf.0.0950349; Nelson VL, 1999, MOL ENDOCRINOL, V13, P946, DOI 10.1210/me.13.6.946; Nelson-Degrave VL, 2005, MOL ENDOCRINOL, V19, P379, DOI 10.1210/me.2004-0178; Ngatcha BT, 2005, J MED CHEM, V48, P5257, DOI 10.1021/jm058179h; Nokelainen P, 1996, EUR J BIOCHEM, V236, P482, DOI 10.1111/j.1432-1033.1996.00482.x; PAYNE AH, 1995, BIOL REPROD, V52, P217, DOI 10.1095/biolreprod52.2.217; Payne AH, 2004, ENDOCR REV, V25, P947, DOI 10.1210/er.2003-0030; Pencharz RI, 1940, SCIENCE, V91, P554, DOI 10.1126/science.91.2371.554; Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281; PERRIN A, 1991, ENDOCRINOLOGY, V128, P357, DOI 10.1210/endo-128-1-357; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Puranen T, 1997, ENDOCRINOLOGY, V138, P3532, DOI 10.1210/en.138.8.3532; Recanatini M, 2001, J MED CHEM, V44, P672, DOI 10.1021/jm000955s; Sakaue M, 2002, J VET MED SCI, V64, P107, DOI 10.1292/jvms.64.107; SIMONE DA, 1993, BIOL REPROD, V48, P46, DOI 10.1095/biolreprod48.1.46; SIMONE DA, 1993, BIOL REPROD, V49, P1190, DOI 10.1095/biolreprod49.6.1190; WELSH TH, 1984, CANCER RES, V44, P885; Wickenheisser JK, 2005, J CLIN ENDOCR METAB, V90, P1720, DOI 10.1210/jc.2004-1860; Wickenheisser JK, 2004, MOL ENDOCRINOL, V18, P588, DOI 10.1210/me.2003-0090; Wickenheisser JK, 2000, J CLIN ENDOCR METAB, V85, P2304, DOI 10.1210/jc.85.6.2304; Williams PC, 1940, NATURE, V145, P388, DOI 10.1038/145388c0; Zofkova I, 2002, STEROIDS, V67, P815, DOI 10.1016/S0039-128X(02)00034-X	51	52	57	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					586	595		10.1096/fj.06-6681com	http://dx.doi.org/10.1096/fj.06-6681com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158782	Green Accepted			2022-12-28	WOS:000244686300031
J	Ji, SR; Wu, Y; Zhu, L; Potempa, LA; Sheng, FL; Lu, W; Zhao, J				Ji, Shang-Rong; Wu, Yi; Zhu, Li; Potempa, Lawrence A.; Sheng, Fen-Ling; Lu, Wei; Zhao, Jing			Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m)	FASEB JOURNAL			English	Article						inflammation; cardiovascular disease; protein-membrane interaction	LOW-DENSITY-LIPOPROTEIN; FC-GAMMA-RI; CARDIOVASCULAR-DISEASE; COMPLEMENT ACTIVATION; PENTAMERIC SYMMETRY; ENDOTHELIAL-CELLS; HUMAN NEUTROPHILS; BINDING; ATHEROSCLEROSIS; IDENTIFICATION	Emerging evidence indicates that C-reactive protein (CRP) has at least two conformationally distinct isoforms, i.e., pentameric CRP (pCRP) and monomeric CRP (mCRP or CRP subunit). Both CRP isoforms are proposed to play roles in inflammation and may participate in the pathogenesis of cardiovascular disease. However, the origin of mCRP in situ and the interplay between the two CRP isoforms under physiological/ pathological circumstances remain elusive. Herein, by probing conformational alteration, neoepitope expression, and direct visualization using electron-microscopy, we have shown that calcium-dependent binding of pCRP to membranes, including liposomes and cell membranes, led to a rapid but partial structural change, producing molecules that express CRP subunit antigenicity but with retained native pentameric conformation. This hybrid molecule is herein termed mCRP(m). The formation of mCRPm was associated with significantly enhanced complement fixation. mCRP(m) can further detach from membrane to form the well-recognized mCRP isoform converted in solution (mCRP(s)) and exert potent stimulatory effects on endothelial cells. The membrane-induced pCRP dissociation not only provides a physiologically relevant scenario for mCRP formation but may represent an important mechanism for regulating CRP function.	Lanzhou Univ, Inst Biophys, MOE Key Lab Arid & Grassland Ecol, Lanzhou 730000, Peoples R China; Lanzhou Univ, Inst Cell Biol, Lanzhou 730000, Peoples R China; Lanzhou Univ, Instrumental Anal Res Ctr, Lanzhou 730000, Peoples R China; Immtech Pharmaceut Inc, Vernon Hills, IL USA	Lanzhou University; Lanzhou University; Lanzhou University	Wu, Y (corresponding author), Lanzhou Univ, Inst Biophys, MOE Key Lab Arid & Grassland Ecol, Life Sci Bldg,Rm 227, Lanzhou 730000, Peoples R China.	wuy@lzu.edu.cn		Ji, Shang-Rong/0000-0001-8595-3756; Wu, Yi/0000-0003-0365-5590				Agrawal A, 2001, J IMMUNOL, V166, P3998, DOI 10.4049/jimmunol.166.6.3998; Bang R, 2005, J BIOL CHEM, V280, P25095, DOI 10.1074/jbc.M504782200; Bhakdi S, 2004, CIRCULATION, V109, P1870, DOI 10.1161/01.CIR.0000124228.08972.26; Bharadwaj D, 1999, J EXP MED, V190, P585, DOI 10.1084/jem.190.4.585; Ciubotaru I, 2005, EXP BIOL MED, V230, P762, DOI 10.1177/153537020523001010; CROWELL RE, 1991, J IMMUNOL, V147, P3445; Devaraj S, 2005, ARTERIOSCL THROM VAS, V25, P1359, DOI 10.1161/01.ATV.0000168573.10844.ae; Diehl EE, 2000, AM J MED SCI, V319, P79, DOI 10.1097/00000441-200002000-00002; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Ji SR, 2006, ARTERIOSCL THROM VAS, V26, P935, DOI 10.1161/01.ATV.0000206211.21895.73; Ji SR, 2006, INT J BIOCHEM CELL B, V38, P648, DOI 10.1016/j.biocel.2005.11.004; Jialal I, 2004, HYPERTENSION, V44, P6, DOI 10.1161/01.HYP.0000130484.20501.df; Khreiss T, 2005, CIRC RES, V97, P690, DOI 10.1161/01.RES.0000183881.11739.CB; Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68; Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Pepys MB, 2006, NATURE, V440, P1217, DOI 10.1038/nature04672; POTEMPA LA, 1987, MOL IMMUNOL, V24, P531, DOI 10.1016/0161-5890(87)90028-9; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Schwedler SB, 2006, AM J KIDNEY DIS, V47, P212, DOI 10.1053/j.ajkd.2005.10.028; Schwedler SB, 2005, CIRCULATION, V112, P1016, DOI 10.1161/CIRCULATIONAHA.105.556530; Sepulveda JL, 2005, CURR OPIN CARDIOL, V20, P407; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Szalai Alexander J, 2004, Clin Dev Immunol, V11, P221, DOI 10.1080/17402520400001751; Tabas I, 2005, ARTERIOSCL THROM VAS, V25, P2255, DOI 10.1161/01.ATV.0000184783.04864.9f; Taskinen S, 2002, BIOCHEM J, V367, P403, DOI 10.1042/BJ20020492; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9; TUCCI A, 1983, J IMMUNOL, V131, P2416; Verma S, 2004, CIRCULATION, V109, P1914, DOI 10.1161/01.CIR.0000127085.32999.64; VIGUSHIN DM, 1993, J CLIN INVEST, V91, P1351, DOI 10.1172/JCI116336; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; VOLANAKIS JE, 1979, NATURE, V281, P155, DOI 10.1038/281155a0; Wang HW, 2001, BIOCHEM BIOPH RES CO, V288, P75, DOI 10.1006/bbrc.2001.5733; Wilson AM, 2006, INT J CARDIOL, V106, P291, DOI 10.1016/j.ijcard.2005.01.068; Wu Y, 2003, ACTA CRYSTALLOGR D, V59, P922, DOI 10.1107/S0907444903004414; Wu Y, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1377, DOI 10.1023/A:1021862027061; Wu Y, 2003, P NATL ACAD SCI USA, V100, P2082, DOI 10.1073/pnas.0435872100; Yasojima K, 2001, AM J PATHOL, V158, P1039, DOI 10.1016/S0002-9440(10)64051-5; Yeh ETH, 2005, CIRC RES, V97, P609, DOI 10.1161/01.RES.0000186188.38344.13; YING SC, 1989, J IMMUNOL, V143, P221; Zouki C, 2001, J IMMUNOL, V167, P5355, DOI 10.4049/jimmunol.167.9.5355	44	148	158	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2007	21	1					284	294		10.1096/fj.06-6722com	http://dx.doi.org/10.1096/fj.06-6722com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17116742				2022-12-28	WOS:000243130200031
J	Cui, H; Cai, F; Belsham, DD				Cui, Hong; Cai, Fang; Belsham, Denise D.			Leptin signaling in neurotensin neurons involves STAT, MAP kinases ERK1/2, and p38 through c-Fos and ATF1	FASEB JOURNAL			English	Article						leptin receptor; gene expression; hypothalamus; neurotensin/neuromedin N gene	ACTIVATED PROTEIN-KINASE; NEUROMEDIN-N-GENE; MESSENGER-RNA; DOWN-REGULATION; EXPRESSION; INSULIN; RECEPTOR; ALPHA; STIMULATION; ISOFORMS	The adipokine leptin signals energy status to the hypothalamus, which triggers a network of neuropeptide responses. Each hypothalamic cell type expresses a unique complement of neuropeptides, receptors, and second messengers; thus each likely responds specifically to peripheral hormones. We describe here the analysis of leptin signaling in a clonal population of mouse neurotensin (NT)-expressing hypothalamic neurons, N-39. Leptin induced phosphorylation of STAT3 and MAPK ERK1/2, but not the downstream effector of PI3K, Akt, and also induced c-Fos protein. We found activation of p38 MAPK by leptin, accompanied by phosphorylation of its downstream effector ATF-1. Phosphorylation of ATF-1 is blocked by the p38 MAPK inhibitor SB 203580. We linked this signaling directly to NT transcription. Protein binding analysis indicates that both ATF-1 and c-Fos are capable of binding to the mouse NT/ N gene predominantly at physiological or high concentrations of leptin. The evidence indicates activation of distinct leptin signal transduction pathways that directly result in changes in NT gene expression and links these specific neurons to the control of energy homeostasis.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Hlth Network, Toronto Gen Hosp Res Inst, Div Cellular & Mol Biol, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Belsham, DD (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg,3247A,1 Kings Coll Cir, Toronto, ON M5S 1A8, Canada.	d.belsham@utoronto.ca						Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Baskin DG, 1999, HORM METAB RES, V31, P345, DOI 10.1055/s-2007-978751; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Beck B, 1998, BIOCHEM BIOPH RES CO, V252, P634, DOI 10.1006/bbrc.1998.9712; Belsham DD, 2004, ENDOCRINOLOGY, V145, P393, DOI 10.1210/en.2003-0946; Benomar Y, 2005, BIOCHEM J, V388, P929, DOI 10.1042/BJ20041621; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Bouloumie A, 1999, FASEB J, V13, P1231, DOI 10.1096/fasebj.13.10.1231; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Catalano S, 2004, J BIOL CHEM, V279, P19908, DOI 10.1074/jbc.M313191200; Catalano S, 2003, J BIOL CHEM, V278, P28668, DOI 10.1074/jbc.M301695200; Cui H, 2005, J NEUROSCI, V25, P9497, DOI 10.1523/JNEUROSCI.2269-05.2005; Elias CF, 2000, J COMP NEUROL, V423, P261; Elmquist JK, 1998, J COMP NEUROL, V395, P535; EVERS BM, 1995, MOL CELL BIOL, V15, P3870; HARRISON RJ, 1995, MOL ENDOCRINOL, V9, P981, DOI 10.1210/me.9.8.981; Harvey J, 2000, J BIOL CHEM, V275, P4660, DOI 10.1074/jbc.275.7.4660; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; KISLAUSKIS E, 1990, NEURON, V4, P783, DOI 10.1016/0896-6273(90)90205-T; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Maroni P, 2005, CELL BIOL INT, V29, P542, DOI 10.1016/j.cellbi.2005.03.008; Maroni P, 2003, MOL CELL ENDOCRINOL, V201, P109, DOI 10.1016/S0303-7207(02)00427-6; MISTRY AM, 1994, BRAIN RES, V666, P53, DOI 10.1016/0006-8993(94)90281-X; Morikawa Y, 2004, J NEUROENDOCRINOL, V16, P105, DOI 10.1111/j.0953-8194.2004.01135.x; Morrison CD, 2005, AM J PHYSIOL-ENDOC M, V289, pE1051, DOI 10.1152/ajpendo.00094.2005; Munzberg H, 2003, ENDOCRINOLOGY, V144, P2121, DOI 10.1210/en.2002-221037; Myers MG, 2004, RECENT PROG HORM RES, V59, P287, DOI 10.1210/rp.59.1.287; Niswender KD, 2003, FRONT NEUROENDOCRIN, V24, P1, DOI 10.1016/S0091-3022(02)00105-X; Niswender KD, 2003, DIABETES, V52, P227, DOI 10.2337/diabetes.52.2.227; Richy S, 2000, BRAIN RES, V862, P276, DOI 10.1016/S0006-8993(00)02125-9; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; Russo VC, 2004, ENDOCRINOLOGY, V145, P4103, DOI 10.1210/en.2003-1767; Sahu A, 2001, BRAIN RES, V888, P343, DOI 10.1016/S0006-8993(00)03107-3; Sahu A, 1998, ENDOCRINOLOGY, V139, P795, DOI 10.1210/en.139.2.795; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Shen JH, 2005, LIFE SCI, V77, P1502, DOI 10.1016/j.lfs.2005.04.004; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Shimizu-Albergine M, 2001, J NEUROSCI, V21, P1238; Shin HJ, 2005, BIOCHEM BIOPH RES CO, V329, P18, DOI 10.1016/j.bbrc.2004.12.195; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Sweeney G, 2002, CELL SIGNAL, V14, P655, DOI 10.1016/S0898-6568(02)00006-2; Takekoshi K, 2001, ENDOCRINOLOGY, V142, P4861, DOI 10.1210/en.142.11.4861; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; van den Brink Gijs R., 2000, Molecular Cell Biology Research Communications, V4, P144, DOI 10.1006/mcbr.2001.0270; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348; Zhao AZ, 2002, NAT NEUROSCI, V5, P727, DOI 10.1038/nn885	50	61	64	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2654	+		10.1096/fj.06-5989fje	http://dx.doi.org/10.1096/fj.06-5989fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077290				2022-12-28	WOS:000242490700055
J	Blocki, FA; Radhakrishnan, S; Van Keulen, VP; Heckman, KL; Ciric, B; Howe, CL; Rodriguez, M; Kwon, E; Pease, LR				Blocki, Frank A.; Radhakrishnan, Suresh; Van Keulen, Virginia P.; Heckman, Karin L.; Ciric, Bogoljub; Howe, Charles L.; Rodriguez, Moses; Kwon, Eugene; Pease, Larry R.			RETRACTED: Induction of a gene expression program in dendritic cells with a cross-linking IgM antibody to the co-stimulatory molecule B7-DC (Retracted Article. See vol 24, pg 2135, 2010)	FASEB JOURNAL			English	Article; Retracted Publication						cellular activation; gene regulation; immune regulation; immune modulation; immunotherapy	NF-KAPPA-B; VOL. 184; C-JUN; FOS; REMYELINATION; IMMUNE; AP-1; TRANSCRIPTION; STIMULATION; GENERATION	While bivalent antibodies can block ligand-receptor interactions, IgM pentamers efficiently cross-link cell surface targets and evoke physiological responses. We have described one such interaction between an IgM antibody (Ab) and the B7-DC costimulatory molecule expressed by dendritic cells that induces strong antitumor immunity and modulates pathogenic responses associated with allergic asthma. Progressive changes in gene expression in dendritic cells activated by an IgM B7-DC cross-linking Ab resulted in the increased expression in 350 genes and decreased expression of more than 200 genes over the course of 24 h following Ab treatment. In particular, up-regulation of the caspase inhibitor FLIP and the chemokine receptor CCR7, and the down-regulation of the CXCR4 receptor provide a mechanistic basis of Ab-induced survival and enhanced migration into draining lymph nodes. Increased expression of both cell surface and secreted molecules known to be mediators of the immunomodulatory properties of dendritic cells was detected at both the levels of RNA and protein expression. This analysis documents the ability of IgM Ab to activate a gene expression cascade leading to important biological changes in cellular function and provides mechanistic insight into the potent immunomodulatory properties attributed to this Ab.	Mayo Clin & Mayo Fdn, Coll Med, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Urol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Pease, LR (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.	pease.larry@mayo.edu	Howe, Charles/B-4945-2009	Howe, Charles/0000-0002-3889-8739; Rodriguez, Moses/0000-0001-6328-6497	NCI NIH HHS [R01 CA096859, R01 CA104996, R01 CA105138] Funding Source: Medline; NIAMS NIH HHS [T32 AR007610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105138, R01CA096859, R01CA104996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Banchereau J, 2001, CANCER RES, V61, P6451; Bieber AJ, 2001, TRENDS NEUROSCI, V24, pS39, DOI 10.1016/S0166-2236(00)01991-3; Chang CCJ, 2000, J IMMUNOL, V165, P3584, DOI 10.4049/jimmunol.165.7.3584; Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Howe CL, 2004, NEUROBIOL DIS, V15, P120, DOI 10.1016/j.nbd.2003.09.002; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Kaisho T, 2003, CURR MOL MED, V3, P373, DOI 10.2174/1566524033479726; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kim TW, 2004, CANCER RES, V64, P400, DOI 10.1158/0008-5472.CAN-03-1475; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587; Mann J, 2002, J BIOL CHEM, V277, P17125, DOI 10.1074/jbc.M109250200; Medema JP, 2001, J EXP MED, V194, P657, DOI 10.1084/jem.194.5.657; Nguyen LT, 2002, J EXP MED, V196, P1393, DOI 10.1084/jem.20021466; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Radhakrishnan S, 2005, J ALLERGY CLIN IMMUN, V116, P668, DOI 10.1016/j.jaci.2005.04.038; Radhakrishnan S, 2005, P NATL ACAD SCI USA, V102, P11438, DOI 10.1073/pnas.0501420102; Radhakrishnan S, 2004, J IMMUNOL, V173, P1360, DOI 10.4049/jimmunol.173.2.1360; Radhakrishnan S, 2004, CANCER RES, V64, P4965, DOI 10.1158/0008-5472.CAN-03-3025; Radhakrishnan S, 2003, J IMMUNOL, V170, P1830, DOI 10.4049/jimmunol.170.4.1830; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RODRIGUEZ M, 1990, ANN NEUROL, V27, P12, DOI 10.1002/ana.410270104; Roncarolo MG, 2001, J EXP MED, V193, pF5, DOI 10.1084/jem.193.2.F5; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; Soldan MMP, 2003, MOL CELL NEUROSCI, V22, P14, DOI 10.1016/S1044-7431(02)00018-0; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Steinman RM, 2001, INT J CANCER, V94, P459, DOI 10.1002/ijc.1503; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Tanaka H, 2000, J EXP MED, V192, P405, DOI 10.1084/jem.192.3.405; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Turley SJ, 2002, CURR OPIN IMMUNOL, V14, P765, DOI 10.1016/S0952-7915(02)00399-0; Van Keulen VP, 2006, CLIN EXP IMMUNOL, V143, P314, DOI 10.1111/j.1365-2249.2005.02992.x; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zhu C, 2001, J BIOL CHEM, V276, P18519, DOI 10.1074/jbc.M100440200	39	16	16	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2408	+		10.1096/fj.06-6171fje	http://dx.doi.org/10.1096/fj.06-6171fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023390				2022-12-28	WOS:000241702600036
J	Chansel, D; Ciroldi, M; Vandermeersch, S; Jackson, LF; Gomez, AM; Henrion, D; Lee, DC; Coffman, TM; Richard, S; Dussaule, JC; Tharaux, PL				Chansel, Dominique; Ciroldi, Magali; Vandermeersch, Sophie; Jackson, Leslie F.; Gomez, Ana-Maria; Henrion, Daniel; Lee, David C.; Coffman, Thomas M.; Richard, Sylvain; Dussaule, Jean-Claude; Tharaux, Pierre-Louis			Heparin binding EGF is necessary for vasospastic response to endothelin	FASEB JOURNAL			English	Article						EGF receptor; calcium; HB-EGF; transactivation; PI3-kinase; human	EPIDERMAL-GROWTH-FACTOR; INDEPENDENT CA2+ CHANNELS; DIPHTHERIA-TOXIN RECEPTOR; ANGIOTENSIN-II; PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASE; HB-EGF; METALLOPROTEINASE CLEAVAGE; EXPRESSION CLONING; BLOOD-PRESSURE	Endothelin-1 (ET-1), a powerful vasoconstrictor, is involved in vasospastic diseases such as coronary artery disease and subarachnoidal hemorrhage, as well as in renal and cardiovascular fibrotic remodeling. Transactivation of the epidermal growth factor receptor (EGFR) mediates ET-1 signaling in vascular smooth muscle cells (VSMCs) and isolated arteries. Moreover, EGFR is required for a full constrictive response to ET-1. However, the relevant mechanisms mediating EGFR transactivation in response to ET-1 have not been identified. The present study used isolated arteries and VSMCs to investigate the role of the EGFR ligand heparin binding-epidermal growth factor (HB-EGF) in ET-1-induced transactivation of EGFR, intracellular calcium mobilization, and VSMCs contraction. While baseline blood pressures were similar in HB-EGF-deficient and in wild-type littermate mice, the vasoconstrictor actions of ET-1 were attenuated in HB-EGF-/- animals. In isolated mouse carotid artery segments mounted in an arteriograph, ET-1 caused only a weak increase in isovolumetric tone in HB-EGF-deficient vessels, and this effect was mimicked by inhibition of EGFR tyrosine kinase or phosphoinositide 3-kinase (PI3K) in wild-type arteries with or without endothelium, indicating a specific role in VSMCs. EGFR or PI3K inhibitors had no effect on KCl-induced contraction, which was normal in HB-EGF-deficient mice. To confirm that the abnormal responses in HB-EGF-deficient mice were due to impaired EGFR signaling, we studied VSMCs from waved-2 (wa2) mice; these animals have a mutation causing a partial loss of function of EGFR tyrosine kinase activity. The ET-1induced calcium peak was reduced by 30% in VSMCs from wa2 mice and from HB-EGF-/- mice. This effect was reproduced by preincubation of wild-type VSMCs with EGFR inhibitor AG1478 and PI3K inhibitors LY294002 and wortmannin. ProHB-EGF is bound to the cell membrane and released after cleavage by metalloproteinases; its action may contribute to effects of GPCR agonists on cell growth. Pretreatment of mouse VSMCs with batimastat, a metalloproteinase inhibitor, significantly attenuated ET-1-induced [Ca2+](i) response in wild-type cells. Human proHB-EGF has been shown to be the endogenous receptor for Corynebacterium diphteriae toxin (DT). Mutated DT toxin (CRM197) is devoid of toxicity but it neutralizes HB-EGF binding to EGFR. Pretreatment of human VSMCs from internal mammary arteries with CRM197 significantly blunted ET-1-stimulated calcium transients. In conclusion, these findings suggest that the mechanism of ET-1-induced vasoconstriction involves HB-EGF-mediated transactivation of the EGFR. This functional cascade requires modulation of agonist-induced calcium transient by EGFR and PI3K with extremely fast kinetics, suggesting a novel paradigm for GPCR-mediated calcium signaling, which may offer future therapeutic targets.	Univ Paris 06, Hop Tenon, INSERM U702, F-75020 Paris, France; Univ N Carolina, Dept Biochem & Biophys, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC USA; Univ Montpellier I, INSERM U637, Montpellier, France; Univ Angers, Fac Med, CNRS, UMR 6188, Angers, France; Duke Univ, Div Nephrol, Dept Med, Durham, NC USA; Durham Vet Affairs Med Ctr, Durham, NC USA; Univ Paris 06, APHP, Sch Med St Antoine, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite d'Angers; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Sorbonne Universite	Tharaux, PL (corresponding author), Univ Paris 06, Hop Tenon, INSERM U702, 4 Rue Chine, F-75020 Paris, France.	pierre-louis.tharaux@chusa.jussieu.fr	Henrion, Daniel/N-7023-2015; Gomez, Ana M./B-5376-2013; Tharaux, Pierre-Louis/A-9155-2009; Henrion, Daniel/J-8141-2015; Richard, Sylvain/C-9695-2016; Henrion, Daniel/AAK-1995-2021	Henrion, Daniel/0000-0003-1094-0285; Gomez, Ana M./0000-0003-0009-2884; Tharaux, Pierre-Louis/0000-0002-6062-5905; Henrion, Daniel/0000-0003-1094-0285; Henrion, Daniel/0000-0003-1094-0285; Richard, Sylvain/0000-0001-9460-6705; VANDERMEERSCH, sophie/0000-0001-6021-1334	NCI NIH HHS [CA43793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asakawa H, 1996, CELL BIOCHEM FUNCT, V14, P181; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BALDI E, 1994, AM J PHYSIOL, V266, pF957, DOI 10.1152/ajprenal.1994.266.6.F957; BUKOSKI RD, 1994, J HYPERTENS, V12, P15; Chansel D, 2001, EUR J PHARMACOL, V414, P165, DOI 10.1016/S0014-2999(01)00791-9; Che Q, 2002, HYPERTENSION, V40, P700, DOI 10.1161/01.HYP.0000035524.10948.93; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DAY R, 1995, AM J HYPERTENS, V8, P294, DOI 10.1016/0895-7061(95)96213-4; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Ferri C, 1997, CLIN SCI, V93, P35, DOI 10.1042/cs0930035; Flamant M, 2002, FASEB J, V16, P327, DOI 10.1096/fj.02-0115fje; Florian JA, 1999, AM J PHYSIOL-HEART C, V276, pH976, DOI 10.1152/ajpheart.1999.276.3.H976; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Gomez AM, 1996, J PHYSIOL-LONDON, V496, P575, DOI 10.1113/jphysiol.1996.sp021708; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hao L, 2004, CIRC RES, V94, P68, DOI 10.1161/01.RES.0000109413.57726.91; Henrion D, 1996, HYPERTENSION, V28, P361, DOI 10.1161/01.HYP.28.3.361; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Igura T, 1996, ARTERIOSCL THROM VAS, V16, P1524, DOI 10.1161/01.ATV.16.12.1524; Ikeda T, 1999, HYPERTENSION, V34, P514, DOI 10.1161/01.HYP.34.3.514; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kawanabe Y, 2004, BIOCHEM PHARMACOL, V68, P215, DOI 10.1016/j.bcp.2004.03.025; Kawanabe Y, 2002, MOL PHARMACOL, V62, P756, DOI 10.1124/mol.62.3.756; Kawanabe Y, 2002, AM J PHYSIOL-HEART C, V283, pH2671, DOI 10.1152/ajpheart.00350.2002; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Le Blanc C, 2004, CIRC RES, V95, P300, DOI 10.1161/01.RES.0000138017.76125.8b; LIU Y, 1992, AM J PHYSIOL, V262, pC941, DOI 10.1152/ajpcell.1992.262.4.C941; Loufrani L, 2001, CIRCULATION, V103, P864, DOI 10.1161/01.CIR.103.6.864; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Masui H, 2000, LIFE SCI, V68, P363, DOI 10.1016/S0024-3205(00)00942-5; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Northcott CA, 2004, HYPERTENSION, V43, P885, DOI 10.1161/01.HYP.0000118518.20331.e8; Northcott CA, 2002, CIRC RES, V91, P360, DOI 10.1161/01.RES.0000030861.13850.F1; POLLOCK DM, 1995, FASEB J, V9, P1196, DOI 10.1096/fasebj.9.12.7672512; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Quignard JF, 1997, J CLIN INVEST, V99, P185, DOI 10.1172/JCI119146; Reynolds CM, 2002, HYPERTENSION, V39, P525, DOI 10.1161/hy0202.103076; Richard S, 1998, METHOD ENZYMOL, V293, P71; Rossi GP, 1999, CIRCULATION, V99, P1147, DOI 10.1161/01.CIR.99.9.1147; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schiffrin EL, 1999, HYPERTENSION, V34, P876, DOI 10.1161/01.HYP.34.4.876; Shah BH, 2004, TRENDS ENDOCRIN MET, V15, P241, DOI 10.1016/j.tem.2004.06.011; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tharaux PL, 1999, CIRCULATION, V99, P2185, DOI 10.1161/01.CIR.99.16.2185; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685; Wang ZF, 2003, J AM SOC NEPHROL, V14, P3147, DOI 10.1097/01.ASN.0000098681.56240.1A; WILKES BM, 1991, AM J PHYSIOL, V260, pF579, DOI 10.1152/ajprenal.1991.260.4.F579; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zhang H, 2004, CIRC RES, V95, P989, DOI 10.1161/01.RES.0000147962.01036.bb	60	50	51	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1936	+		10.1096/fj.05-5328fje	http://dx.doi.org/10.1096/fj.05-5328fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877529				2022-12-28	WOS:000240267000036
J	Asikainen, TM; Chang, LY; Coalson, JJ; Schneider, BK; Waleh, NS; Ikegami, M; Shannon, JM; Winter, VT; Grubb, P; Clyman, RI; Yoder, BA; Crapo, JD; White, CW				Asikainen, Tiina M.; Chang, Ling-Yi; Coalson, Jacqueline J.; Schneider, Barbara K.; Waleh, Nahid S.; Ikegami, Machiko; Shannon, John M.; Winter, Vicki T.; Grubb, Peter; Clyman, Ronald I.; Yoder, Bradley A.; Crapo, James D.; White, Carl W.			Improved lung growth and function through hypoxia-inducible factor in primate chronic lung disease of prematurity	FASEB JOURNAL			English	Article						bronchopulmonary dysplasia; preterm neonate; angiogenesis; alveolization; lung development	BRONCHOPULMONARY DYSPLASIA; RESPIRATORY-DISTRESS; VASCULAR DEVELOPMENT; DUCTUS-ARTERIOSUS; IMMATURE BABOONS; NITRIC-OXIDE; MICE; VEGF; ANGIOGENESIS; ALVEOLARIZATION	Bronchopulmonary dysplasia (BPD), a chronic lung disease affecting preterm neonates, is associated with significant childhood and adult health problems. Histopathologic features of BPD include impaired vascular and distal airway development. We previously showed that activation of hypoxia-inducible factors (HIFs) by inhibition of prolyl hydroxylase domain-containing proteins (PHDs) is feasible and that it stimulates vascular endothelial growth factor (VEGF)-dependent angiogenesis in vitro. We tested the hypothesis that enhancement of angiogenesis by activation of HIFs improves lung growth and function in prematurely born neonates in vivo. Preterm baboons (125 day + 14 day pro re nata O(2) model, corresponding to 27 human gestational weeks) were treated for 14 days with intravenous (i. v.) FG-4095, a PHD inhibitor. Notably, 77% of diminished total alveolar surface area in untreated controls was recovered by FG-4095 treatment. Functional significance of the structural changes was indicated by improved oxygenation and lung compliance in FG-4095-treated newborns. Surfactant proteins B and C and saturated phosphatidylcholine were unchanged. Incidence of spontaneous ductus arteriosus closure was increased, likely contributing to lower ratio of pulmonary to systemic blood flow in FG-4095 group. These findings indicate that HIF stimulation by PHD inhibition ameliorates pathological and physiological consequences of BPD.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA; SW Fdn Biomed Res, San Antonio, TX 78284 USA; Univ Calif San Francisco, SRI Int, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH USA; Vanderbilt Univ, Med Ctr, Div Neonatol, Nashville, TN USA	National Jewish Health; University of Texas System; University of Texas Health San Antonio; Texas Biomedical Research Institute; SRI International; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Vanderbilt University	White, CW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St,Rm J-318, Denver, CO 80206 USA.	whitec@njc.org			NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR013986] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL052636, U10HL052636, U01HL056263, R10HL052636, U01HL063397] Funding Source: NIH RePORTER; NCRR NIH HHS [P51RR13986] Funding Source: Medline; NHLBI NIH HHS [HL63397, U01 HL56263, HL52636] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Afshar S, 2003, AM J PHYSIOL-LUNG C, V284, pL749, DOI 10.1152/ajplung.00334.2002; Asikainen TM, 2005, PEDIATR PULM, V40, P538, DOI 10.1002/ppul.20321; Asikainen TM, 2005, P NATL ACAD SCI USA, V102, P10212, DOI 10.1073/pnas.0504520102; Asikainen TM, 2005, FREE RADICAL BIO MED, V38, P1002, DOI 10.1016/j.freeradbiomed.2004.12.004; ASIKAINEN TM, 2006, AM J PHYSL LUNG CELL; ASIKAINEN TM, 2005, LUNG INJURY MECH PAT, V196, P665; Bhatt AJ, 2001, AM J RESP CRIT CARE, V164, P1971, DOI 10.1164/ajrccm.164.10.2101140; Bland RD, 2005, BIOL NEONATE, V88, P181, DOI 10.1159/000087581; Bourbon J, 2005, PEDIATR RES, V57, p38R, DOI 10.1203/01.PDR.0000159630.35883.BE; BURRI PH, 1984, ANNU REV PHYSIOL, V46, P617, DOI 10.1146/annurev.ph.46.030184.003153; Clark JC, 1997, AM J RESP CELL MOL, V16, P46, DOI 10.1165/ajrcmb.16.1.8998078; Clyman RI, 2002, AM J PHYSIOL-REG I, V282, pR199, DOI 10.1152/ajpregu.00298.2001; Coalson JJ, 1999, AM J RESP CRIT CARE, V160, P1333, DOI 10.1164/ajrccm.160.4.9810071; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; De Paepe ME, 2006, AM J RESP CRIT CARE, V173, P204, DOI 10.1164/rccm.200506-927OC; Dulak J, 2003, ANTIOXID REDOX SIGN, V5, P123, DOI 10.1089/152308603321223612; Ehrenkranz RA, 2005, PEDIATRICS, V116, P1353, DOI 10.1542/peds.2005-0249; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Gebb SA, 2000, DEV DYNAM, V217, P159, DOI 10.1002/(SICI)1097-0177(200002)217:2<159::AID-DVDY3>3.0.CO;2-9; GUNZLER V, 2006, KEYST S HYP DEV PHYS, pA216; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Ikegami M, 2005, AM J PHYSIOL-LUNG C, V289, pL34, DOI 10.1152/ajplung.00407.2004; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jakkula M, 2000, AM J PHYSIOL-LUNG C, V279, pL600, DOI 10.1152/ajplung.2000.279.3.L600; Jobe AJ, 1999, PEDIATR RES, V46, P641, DOI 10.1203/00006450-199912000-00001; KLAUS S, 2006, KEYST S HYP DEV PHYS, pA241; Kunig AM, 2005, AM J PHYSIOL-LUNG C, V289, pL529, DOI 10.1152/ajplung.00336.2004; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Lassus P, 2001, AM J RESP CRIT CARE, V164, P1981, DOI 10.1164/ajrccm.164.10.2012036; Le Cras TD, 2004, AM J PHYSIOL-LUNG C, V287, pL134, DOI 10.1152/ajplung.00050.2004; Levin M, 2006, AM J PHYSIOL-REG I, V290, pR359, DOI 10.1152/ajpregu.00629.2005; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Maniscalco WM, 2002, AM J PHYSIOL-LUNG C, V282, pL811, DOI 10.1152/ajplung.00325.2001; MASON RJ, 1976, J LIPID RES, V17, P281; McCurnin DC, 2005, AM J RESP CRIT CARE, V172, P1569, DOI 10.1164/rccm.200502-230OC; McCurnin DC, 2005, AM J PHYSIOL-LUNG C, V288, pL450, DOI 10.1152/ajplung.00347.2004; NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357, DOI 10.1056/NEJM196702162760701; Ohlsson A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003481.pub2; Peyssonnaux C, 2005, J CLIN INVEST, V115, P1806, DOI 10.1172/JCI23865; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Schreiber MD, 2003, NEW ENGL J MED, V349, P2099, DOI 10.1056/NEJMoa031154; Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266; Stenmark KR, 2005, ANNU REV PHYSIOL, V67, P623, DOI 10.1146/annurev.physiol.67.040403.102229; Thebaud B, 2005, CIRCULATION, V112, P2477, DOI 10.1161/CIRCULATIONAHA.105.541524; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tschanz SA, 2002, EXP LUNG RES, V28, P457, DOI 10.1080/01902140290096719; van Tuyl M, 2005, AM J PHYSIOL-LUNG C, V288, pL167, DOI 10.1152/ajplung.00185.2004; Waleh N, 2004, CIRCULATION, V110, P2326, DOI 10.1161/01.CIR.0000145159.16637.5D; Walisser JA, 2004, J BIOL CHEM, V279, P16326, DOI 10.1074/jbc.M400784200; Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624; Yoder BA, 2002, PEDIATR RES, V51, P426, DOI 10.1203/00006450-200204000-00006	51	62	69	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1698	+		10.1096/fj.06-5887fje	http://dx.doi.org/10.1096/fj.06-5887fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807366				2022-12-28	WOS:000240266600019
J	Mainieri, D; Summermatter, S; Seydoux, J; Montani, JP; Rusconi, S; Russell, AP; Boss, O; Buchala, AJ; Dulloo, AG				Mainieri, Davide; Summermatter, Serge; Seydoux, Josiane; Montani, Jean-Pierre; Rusconi, Sandro; Russell, Aaron P.; Boss, Olivier; Buchala, Antony J.; Dulloo, Abdul G.			A role for skeletal muscle stearoyl-CoA desaturase 1 in control of thermogenesis	FASEB JOURNAL			English	Article						obesity; weight cycling; catch-up growth; low birth weight; insulin resistance	DE-NOVO LIPOGENESIS; CATCH-UP FAT; DIRECTLY STIMULATES THERMOGENESIS; WEIGHT-LOSS; ENERGY-EXPENDITURE; LIPID OXIDATION; UNCOUPLING PROTEIN-3; METABOLIC EFFICIENCY; INSULIN-RESISTANCE; ADIPOSE-TISSUE	An enhanced metabolic efficiency for accelerating the recovery of fat mass (or catch-up fat) is a characteristic feature of body weight regulation after weight loss or growth retardation and is the outcome of an "adipose-specific" suppression of thermogenesis, i.e., a feedback control system in which signals from the depleted adipose tissue fat stores exert a suppressive effect on thermogenesis. Using a previously described rat model of semistarvation-refeeding in which catch-up fat results from suppressed thermogenesis per se, we report here that the gene expression of stearoyl-coenzyme A desaturase 1 (SCD1) is elevated in skeletal muscle after 2 wk of semistarvation and remains elevated in parallel to the phase of suppressed thermogenesis favoring catch-up fat during refeeding. These elevations in the SCD1 transcript are skeletal muscle specific and are associated with elevations in microsomal Delta 9 desaturase enzyme activity, in the Delta 9 desaturation index, and in the relative content of SCD1-derived monounsaturates in several lipid fractions extracted from skeletal muscle. An elevated skeletal muscle SCD1, by desaturating the products of de novo lipogenesis and diverting them away from mitochondrial oxidation, would inhibit substrate cycling between de novo lipogenesis and lipid oxidation, thereby leading to a state of suppressed thermogenesis that regulates the body's fat stores.	Univ Fribourg, Fac Sci, Div Physiol, Dept Med, CH-1700 Fribourg, Switzerland; Univ Fribourg, Fac Sci, Div Biochem, Dept Med, CH-1700 Fribourg, Switzerland; SUVA Care, Clin Readaptat, Sion, Switzerland; Endocrinol Energy Metab, Boston, MA USA; Univ Fribourg, Fac Sci, Dept Biol, CH-1700 Fribourg, Switzerland	University of Fribourg; University of Fribourg; University of Fribourg	Dulloo, AG (corresponding author), Univ Fribourg, Fac Sci, Div Physiol, Dept Med, Chemin Musee 5, CH-1700 Fribourg, Switzerland.	abdul.dulloo@unifr.ch	Buchala, Antony/A-2656-2012	Summermatter, Serge/0000-0003-4870-0148; DULLOO, Abdul/0000-0003-3877-6149; Russell, Aaron/0000-0002-7323-9501; MAINIERI, DAVIDE/0000-0003-0797-5794				ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; BOYLE PC, 1978, PHYSIOL BEHAV, V21, P261, DOI 10.1016/0031-9384(78)90050-1; Cettour-Rose P, 2005, DIABETES, V54, P751, DOI 10.2337/diabetes.54.3.751; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Crescenzo R, 2003, FEBS LETT, V544, P138, DOI 10.1016/S0014-5793(03)00491-5; Crescenzo R, 2003, DIABETES, V52, P1090, DOI 10.2337/diabetes.52.5.1090; Dobrzyn A, 2005, AM J PHYSIOL-ENDOC M, V288, pE599, DOI 10.1152/ajpendo.00439.2004; Dulloo AG, 1998, AM J CLIN NUTR, V68, P599, DOI 10.1093/ajcn/68.3.599; DULLOO AG, 1988, AM J PHYSIOL, V255, pE180, DOI 10.1152/ajpendo.1988.255.2.E180; Dulloo AG, 2005, ACTA PHYSIOL SCAND, V184, P295, DOI 10.1111/j.1365-201X.2005.01466.x; Dulloo AG, 2004, INT J OBESITY, V28, pS29, DOI 10.1038/sj.ijo.0802861; DULLOO AG, 1990, AM J CLIN NUTR, V52, P415, DOI 10.1093/ajcn/52.3.415; Dulloo AG, 2001, INT J OBESITY, V25, pS22, DOI 10.1038/sj.ijo.0801907; Dulloo AG, 2002, INT J OBESITY, V26, pS46, DOI 10.1038/sj.ijo.0802127; Dulloo AG, 2002, FEBS LETT, V515, P109, DOI 10.1016/S0014-5793(02)02449-3; DULLOO AG, 1995, AM J PHYSIOL-REG I, V269, pR365, DOI 10.1152/ajpregu.1995.269.2.R365; DULLOO AG, 1993, INT J OBESITY, V17, P115; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; Evans SA, 2005, AM J PHYSIOL-REG I, V288, pR1468, DOI 10.1152/ajpregu.00602.2004; Harper ME, 2001, BIOCHEM SOC T, V29, P768, DOI 10.1042/bst0290768; HARRIS RBS, 1984, J NUTR, V114, P1143, DOI 10.1093/jn/114.6.1143; HILL JO, 1984, AM J PHYSIOL, V247, pR318, DOI 10.1152/ajpregu.1984.247.2.R318; Houdali B, 2003, DIABETOLOGIA, V46, P203, DOI 10.1007/s00125-002-1015-2; Hulver MW, 2005, CELL METAB, V2, P251, DOI 10.1016/j.cmet.2005.09.002; Jiang GQ, 2005, J CLIN INVEST, V115, P1030, DOI 10.1172/JCI200523962; Keys A, 1950, BIOL HUMAN STARVATIO; LANDSBERG L, 1984, AM J PHYSIOL, V247, pE181, DOI 10.1152/ajpendo.1984.247.2.E181; LUNZER MA, 1977, J BIOL CHEM, V252, P5483; MA SWY, 1986, CAN J PHYSIOL PHARM, V64, P1252, DOI 10.1139/y86-211; MacLean PS, 2004, AM J PHYSIOL-REG I, V287, pR1306, DOI 10.1152/ajpregu.00463.2004; Maxwell MA, 2005, J BIOL CHEM, V280, P12573, DOI 10.1074/jbc.M409580200; MORRISON WR, 1964, J LIPID RES, V5, P600; Nakamura MT, 2004, ANNU REV NUTR, V24, P345, DOI 10.1146/annurev.nutr.24.121803.063211; Ntambi JM, 2004, LIPIDS, V39, P1061, DOI 10.1007/s11745-004-1331-2; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Ong KK, 2004, EUR J ENDOCRINOL, V151, pU131, DOI 10.1530/eje.0.151U131; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rahman SM, 2003, P NATL ACAD SCI USA, V100, P11110, DOI 10.1073/pnas.1934571100; Russell AP, 2003, FEBS LETT, V551, P104, DOI 10.1016/S0014-5793(03)00875-5; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Simonides WS, 2001, BIOSCIENCE REP, V21, P139, DOI 10.1023/A:1013692023449; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Smith WS, 2002, BIOCHEM J, V361, P277, DOI 10.1042/0264-6021:3610277; Solinas G, 2006, ENDOCRINOLOGY, V147, P31, DOI 10.1210/en.2005-1033; Solinas G, 2004, FEBS LETT, V577, P539, DOI 10.1016/j.febslet.2004.10.066; Verca MSB, 1998, BIOTECHNIQUES, V24, P374, DOI 10.2144/98243bm08; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Weyer C, 2000, AM J CLIN NUTR, V72, P946; Wylie AA, 2000, GENOME RES, V10, P1711, DOI 10.1101/gr.161600; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	57	28	29	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1751	+		10.1096/fj.06-5934fje	http://dx.doi.org/10.1096/fj.06-5934fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16809433	Green Submitted			2022-12-28	WOS:000240266600037
J	Semkova, I; Fauser, S; Lappas, A; Smyth, N; Kociok, N; Kirchhof, B; Paulsson, M; Poulaki, V; Joussen, AM				Semkova, Irina; Fauser, Sascha; Lappas, Alexandra; Smyth, Neil; Kociok, Norbert; Kirchhof, Bernd; Paulsson, Mats; Poulaki, Vassiliki; Joussen, Antonia M.			Overexpression of FasL in retinal pigment epithelial cells reduces choroidal neovascularization	FASEB JOURNAL			English	Article						choroidal neovascularization; apoptosis; inflammation	ENDOTHELIAL GROWTH-FACTOR; DISCIFORM MACULAR DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TARGETED DISRUPTION; IMMUNE PRIVILEGE; APOPTOSIS; LIGAND; MEMBRANES; EXPRESSION; RETINOPATHY	Choroidal neovascularization (CNV) is responsible for the severe visual loss in age-related macular degeneration. CNV formation is considered to be due to an imbalance between pro-and antiangiogenic factors that lead to neovascular growth from the choriocapillaris into the subretinal space. To define whether FasL overexpression in retinal pigment epithelial cells (RPE) can inhibit choroidal neovascularization through Fas-FasL-mediated apoptosis, we examined the role of this pathway in a mouse model of laser-induced choroidal neovascularization. FasL was expressed in the retinal pigment epithelium of transgenic mice. Polymerase chain reaction (PCR), immunoblot, and immunohistochemistry confirmed that the transgene FasL was specifically expressed in RPE. The established laser model was used to induce choroidal neovascularization (CNV) in wild-type (WT) and transgenic mice. CNV formation was compared with respect to fluorescein angiographic leakage (at days 0 and 14 after laser injury) and histological appearance. The lesions were assessed on RPE-choroidal flatmounts after CD31-labeling and with confocal microscopy after perfusion with rhodamine-labeled concanavalin A (Con A). Apoptosis was quantified by TUNEL positivity and caspase activation. FasL mRNA and protein were highly expressed in the RPE of the transgenic mice before and after laser photocoagulation. In contrast, FasL was only weakly expressed in the RPE layer of WT C57BL/ 6J mice. While ruptures of Bruch's membrane and CNV formation were observed histologically two weeks after laser photocoagulation in transgenic as well as control eyes, the shape and size of CNV lesions were reduced in the transgenic mice. The area of leakage was decreased by 70% in FasL transgenic mice compared with WT mice (P < 0.005). The number of TUNEL-positive cells was greater in FasL-overexpressing mice and correlated with the expression of activated caspases. Th expression of other antiangiogenic factors such as PEDF remained unchanged. The specific overexpression of FasL in RPE layer reduced CNV formation in our laser model. Our results strongly point to the FasL-Fas pathway as a potential therapeutic target in controlling pathological choroidal neovascularization.	Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany; Univ Southampton, Ctr Biochem, Southampton, Hants, England; Univ Southampton, Sch Biol Sci, Southampton, Hants, England; Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA	University of Cologne; University of Cologne; University of Southampton; University of Southampton; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Joussen, AM (corresponding author), Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Joseph Stelzmannstr 9, D-50931 Cologne, Germany.	joussena@googlemail.com	Joussen, Antonia/AAA-6901-2022	Smyth, Neil/0000-0002-3734-2149				ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; Barnhart BC, 2003, ONCOGENE, V22, P8634, DOI 10.1038/sj.onc.1207103; Barreiro R, 2003, INVEST OPHTH VIS SCI, V44, P1282, DOI 10.1167/iovs.02-0478; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397; CHANDRA SR, 1974, AM J OPHTHALMOL, V78, P579, DOI 10.1016/S0002-9394(14)76293-2; Chang CW, 1997, INVEST OPHTH VIS SCI, V38, P1082; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974; DAS A, 1992, OPHTHALMOLOGY, V99, P1368; Davies MH, 2003, INVEST OPHTH VIS SCI, V44, P3202, DOI 10.1167/iovs.03-0050; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907; FERGUSON TA, 1997, IMMUNOL REV, V156, P176; FINE SL, 1976, AM J OPHTHALMOL, V82, P352, DOI 10.1016/0002-9394(76)90483-9; Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5; GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206; GRAGOUDAS ES, 1976, ARCH OPHTHALMOL-CHIC, V94, P755, DOI 10.1001/archopht.1976.03910030365003; Gratas C, 1997, BRAIN PATHOL, V7, P863, DOI 10.1111/j.1750-3639.1997.tb00889.x; Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180; GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HERIOT WJ, 1984, OPHTHALMOLOGY, V91, P1603; Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203; HOLZ FG, 1995, Z PRAKT AUGENHEILKUN, V16, P87; Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jorgensen A, 1998, INVEST OPHTH VIS SCI, V39, P1590; Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509; Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; LEIBOWITZ H, 1984, SURV OPHTHALMOL S, V25, P335; LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; Lucas R, 1998, BLOOD, V92, P4730; Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466; MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899; Murata T, 1996, LAB INVEST, V74, P68; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Neff TA, 2005, AM J PATHOL, V166, P685, DOI 10.1016/S0002-9440(10)62290-0; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1; Semkova I, 2003, INVEST OPHTH VIS SCI, V44, P5349, DOI 10.1167/iovs.02-0732; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Stuart PM, 1997, J CLIN INVEST, V99, P396, DOI 10.1172/JCI119173; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TEETERS VW, 1973, AM J OPHTHALMOL, V76, P1; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walsh K, 1999, MOL MED TODAY, V5, P61, DOI 10.1016/S1357-4310(98)01415-4; Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467; Wigginton JM, 2001, J CLIN INVEST, V108, P51	63	33	38	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1689	+		10.1096/fj.05-5653fje	http://dx.doi.org/10.1096/fj.05-5653fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807368				2022-12-28	WOS:000240266600016
J	Godzich, M; Hodnett, M; Frank, JA; Su, G; Pespeni, M; Angel, A; Howard, MB; Matthay, MA; Pittet, JF				Godzich, M.; Hodnett, M.; Frank, J. A.; Su, G.; Pespeni, M.; Angel, A.; Howard, M. B.; Matthay, M. A.; Pittet, J. F.			Activation of the stress protein response prevents the development of pulmonary edema by inhibiting VEGF cell signaling in a model of lung ischemia-reperfusion injury in rats	FASEB JOURNAL			English	Article							ENDOTHELIAL GROWTH-FACTOR; UP-REGULATION; ISCHEMIA/REPERFUSION INJURY; HEMORRHAGIC-SHOCK; EXPRESSION; MEDIATORS; CADHERIN; SWITCH; DAMAGE	Lung endothelial damage is a characteristic morphological feature of ischemia-reperfusion (I/R) injury, although the molecular steps involved in the loss of endothelial integrity are still poorly understood. We tested the hypothesis that the activation of vascular endothelial growth factor (VEGF) cell signaling would be responsible for the increase in lung vascular permeability seen early after the onset of I/R in rats. Furthermore, we hypothesized that the I/R-induced pulmonary edema would be significantly attenuated in rats by the activation of the stress protein response. Pretreatment with Ad Flk-1, an adenovirus encoding for the soluble VEGF receptor type II, prevented I/R-mediated increase in lung vascular permeability in rats. Furthermore, the I/R-induced lung injury was significantly decreased by prior activation of the stress protein response with geldanamycin or pyrrolidine dithiocarbamate. In vitro studies demonstrated that VEGF caused an increase in protein permeability across primary cultures of bovine macro- and microvascular lung endothelial cell monolayers that were associated with a phosphorylation of VE- and E-cadherin and the formation of actin stress fibers. Activation of the stress protein response prevented the VEGF-mediated changes in protein permeability across these cell monolayers and reduced the phosphorylation of VE- and E-cadherins, as well as the formation of actin stress fibers in these cells.	Univ Calif San Francisco, Surg Res Lab, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Calif San Francisco, Surg Res Lab, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Surg Res Lab, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Pittet, JF (corresponding author), San Francisco Gen Hosp, Div Anesthesia, Rm 3C-38,1001 Potrero Ave, San Francisco, CA 94110 USA.	pittetj@anesthesia.ucsf.edu	Frank, Joseph/W-2021-2019		NHLBI NIH HHS [K08 HL069900, HL-51854, R56 HL088440, K08 HL069900-05, P50HL74005] Funding Source: Medline; NIGMS NIH HHS [GM-62188] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL088440, P50HL074005, R01HL051854, K08HL069900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062188] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Becker PM, 2000, AM J RESP CELL MOL, V22, P272, DOI 10.1165/ajrcmb.22.3.3814; Belotti D, 2003, CANCER RES, V63, P5224; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; de Perrot M, 2003, AM J RESP CRIT CARE, V167, P490, DOI 10.1164/rccm.200207-670SO; EPPINGER MJ, 1995, J SURG RES, V58, P713, DOI 10.1006/jsre.1995.1112; Eppinger MJ, 1997, AM J PATHOL, V150, P1773; Esser S, 1998, J CELL SCI, V111, P1853; Farivar AS, 2004, J HEART LUNG TRANSPL, V23, P585, DOI 10.1016/S1053-2498(03)00300-0; Fehrenbach A, 2003, J HEART LUNG TRANSPL, V22, P967, DOI 10.1016/S1053-2498(02)01157-9; Fujita T, 2004, J CLIN INVEST, V113, P1615, DOI 10.1172/JCI200419225; Hedge Ramanujan S., 1995, Journal of Cellular Physiology, V165, P186; Hiratsuka M, 1998, J HEART LUNG TRANSPL, V17, P1238; Hiratsuka M, 1999, ANN THORAC SURG, V67, P1421, DOI 10.1016/S0003-4975(99)00164-2; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ito K, 2003, SHOCK, V19, P462, DOI 10.1097/01.shk.0000055240.25446.16; Javadpour M, 1998, BRIT J SURG, V85, P943; Kanellis J, 2002, KIDNEY INT, V61, P1696, DOI 10.1046/j.1523-1755.2002.00329.x; Kaner RJ, 2001, MOL MED, V7, P240, DOI 10.1007/BF03401843; Kaner RJ, 2000, AM J RESP CELL MOL, V22, P657, DOI 10.1165/ajrcmb.22.6.3779; Kazi AA, 2000, AM J PHYSIOL-LUNG C, V279, pL460, DOI 10.1152/ajplung.2000.279.3.L460; Long SM, 2003, J SURG RES, V112, P12, DOI 10.1016/S0022-4804(03)00139-2; McCormick PH, 2003, J SURG RES, V109, P24, DOI 10.1016/S0022-4804(02)00035-5; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; Modelska K, 1999, AM J PHYSIOL-LUNG C, V276, pL844, DOI 10.1152/ajplung.1999.276.5.L844; Modelska K, 1997, AM J PHYSIOL-LUNG C, V273, pL305, DOI 10.1152/ajplung.1997.273.2.L305; Morimoto RI, 1990, STRESS PROTEINS BIOL; Mura M, 2004, J APPL PHYSIOL, V97, P1605, DOI 10.1152/japplphysiol.00202.2004; Pittet JF, 2005, J IMMUNOL, V174, P384, DOI 10.4049/jimmunol.174.1.384; Pittet JF, 2002, J PHYSIOL-LONDON, V538, P583, DOI 10.1113/jphysiol.2001.013102; Pittet JF, 2001, J IMMUNOL, V166, P6301, DOI 10.4049/jimmunol.166.10.6301; Rollin S, 2004, BLOOD, V103, P3789, DOI 10.1182/blood-2003-07-2272; Safdar Z, 2003, J CLIN INVEST, V112, P1541, DOI 10.1172/JCI200318370; Sakuma T, 1999, AM J PHYSIOL-LUNG C, V276, pL137, DOI 10.1152/ajplung.1999.276.1.L137; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Serraf A, 2003, J THORAC CARDIOV SUR, V125, P1050, DOI 10.1067/mtc.2003.402; Soccal PM, 2004, AM J TRANSPLANT, V4, P41, DOI 10.1046/j.1600-6135.2003.00277.x; Tseng JF, 2002, SURGERY, V132, P857, DOI 10.1067/msy.2002.127680; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Wang J, 2002, J CELL PHYSIOL, V190, P238, DOI 10.1002/JCP.10059; Ware LB, 2005, EUR RESPIR J, V26, P101, DOI 10.1183/09031936.05.00106604; Wright TJ, 2002, EXP CELL RES, V280, P159, DOI 10.1006/excr.2002.5636; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168	44	37	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1519	+		10.1096/fj.05-4708fje	http://dx.doi.org/10.1096/fj.05-4708fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16793871				2022-12-28	WOS:000240266000037
J	Hsieh, YC; Choudhry, MA; Yu, HP; Shimizu, T; Yang, SL; Suzuki, T; Chen, JG; Bland, KI; Chaudry, IH				Hsieh, Ya-Ching; Choudhry, Mashkoor A.; Yu, Huang-Ping; Shimizu, Tomoharu; Yang, Shaolong; Suzuki, Takao; Chen, Jianguo; Bland, Kirby I.; Chaudry, Irshad H.			Inhibition of cardiac PGC-1 alpha expression abolishes ER beta agonist-mediated cardioprotection following trauma-hemorrhage	FASEB JOURNAL			English	Article						hemorrhagic shock; heart; estrogen receptor; mitochondria	PROLIFERATOR-ACTIVATED RECEPTOR; ESTROGEN-RECEPTORS; UP-REGULATION; PPAR-ALPHA; MECHANISM; LIVER; SHOCK; PHOSPHORYLATION; COACTIVATOR; LIGANDS	PGC-1 alpha (peroxisome proliferator-activated receptor [PPAR gamma] coactivator-1 alpha) activates PPAR alpha and mitochondrial transcription factor A ( Tfam), which regulate proteins, fatty acid and ATP metabolism (i.e., FAT/CD36, MCAD, and COX I). Recently we found that the salutary effects of estradiol (E2) on cardiac function following trauma-hemorrhage (T-H) are mediated via estrogen receptor (ER)beta. In this study we tested the hypothesis that ER beta-mediated cardioprotection is induced via up-regulation of PGC-1 alpha through PPAR alpha or Tfam-dependent pathway. Male rats underwent T-H and received ER alpha agonist propylpyrazole-triol (PPT), ER beta agonist diarylpropionitrile (DPN), E2, or vehicle. Another group was treated with antisense PGC-1 alpha oligonucleotides prior to administration of DPN. E2 and DPN treatments attenuated the decrease in cardiac mitochondrial ATP, abrogated the T-H-induced lipid accumulation, and normalized PGC-1 alpha, PPAR alpha, FAT/CD36, MCAD, Tfam, and COX I after T-H. In contrast, PPT administration did not abrogate lipid accumulation. Moreover, in PPT-treated animals mitochondrial ATP remained significantly lower than those observed in DPN- or E2-treated animals. Prior administration of antisense PGC-1 alpha prevented DPN- mediated cardioprotection and increase in ATP levels and Tfam but not in PPAR alpha following T-H. These findings suggest that the salutary effects of E2 on cardiac function following T-H are mediated via ER beta up-regulation of PGC-1 alpha through Tfam-dependent pathway.	Univ Alabama Birmingham, Surg Res Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Chaudry, IH (corresponding author), Univ Alabama Birmingham, Surg Res Ctr, 1670 Univ Blvd,Volker Hall,Rm G094, Birmingham, AL 35294 USA.	ichaudry@surg.uab.edu			NIGMS NIH HHS [R37 GM-39519] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM039519] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexaki VI, 2004, FASEB J, V18, P1594, DOI 10.1096/fj.04-1495fje; Asano Goro, 2003, Journal of Nippon Medical School, V70, P384, DOI 10.1272/jnms.70.384; Ba ZF, 2000, CRIT CARE MED, V28, P2837, DOI 10.1097/00003246-200008000-00026; Choi YC, 2004, FUND CLIN PHARMACOL, V18, P547, DOI 10.1111/j.1472-8206.2004.00284.x; Cobb JP, 2001, SHOCK, V15, P165; De Souza CT, 2005, DIABETOLOGIA, V48, P1860, DOI 10.1007/s00125-005-1866-4; De Souza CT, 2003, DIABETOLOGIA, V46, P1522, DOI 10.1007/s00125-003-1222-5; Duval C, 2002, TRENDS MOL MED, V8, P422, DOI 10.1016/S1471-4914(02)02385-7; Erol E, 2003, FASEB J, V17, P347, DOI 10.1096/fj.03-0330fje; Gabel Scott A, 2005, J Mol Cell Cardiol, V38, P289, DOI 10.1016/j.yjmcc.2004.11.013; HAUPTMAN JG, 1989, AM J PHYSIOL, V257, pR439, DOI 10.1152/ajpregu.1989.257.2.R439; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hsieh YC, 2005, AM J PHYSIOL-HEART C, V289, pH2665, DOI 10.1152/ajpheart.00682.2005; Huss JM, 2004, CIRC RES, V95, P568, DOI 10.1161/01.RES.0000141774.29937.e3; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Ihionkhan CE, 2002, CIRC RES, V91, P814, DOI 10.1161/01.RES.0000038304.62046.4C; Jarrar D, 2000, SURGERY, V128, P246, DOI 10.1067/msy.2000.107376; Jarrar D, 2000, AM J PHYSIOL-HEART C, V279, pH1015, DOI 10.1152/ajpheart.2000.279.3.H1015; Jeschke MG, 2005, ANN SURG, V241, P759, DOI 10.1097/01.sla.0000161028.43338.cd; Junger WG, 1997, SHOCK, V8, P235, DOI 10.1097/00024382-199710000-00001; Kanda N, 2004, J INVEST DERMATOL, V123, P319, DOI 10.1111/j.0022-202X.2004.12645.x; Kher A, 2005, SHOCK, V23, P1, DOI 10.1097/01.shk.0000148055.12387.15; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; McCloskey CA, 2003, SHOCK, V20, P316, DOI 10.1097/01.shk.0000084341.58020.c5; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Mizushima Y, 2000, ANN SURG, V232, P673, DOI 10.1097/00000658-200011000-00009; Moore FA, 2004, LANCET, V363, P1988, DOI 10.1016/S0140-6736(04)16415-5; Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com; Oliveira RLGS, 2004, AM J PHYSIOL-ENDOC M, V287, pE686, DOI 10.1152/ajpendo.00103.2004; Patten RD, 2004, CIRC RES, V95, P692, DOI 10.1161/01.RES.0000144126.57786.89; Pelzer T, 2005, CIRCULATION, V111, P1492, DOI 10.1161/01.CIR.0000159262.18512.46; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Remmers DE, 1997, AM J PHYSIOL-HEART C, V273, pH2919, DOI 10.1152/ajpheart.1997.273.6.H2919; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Skavdahl M, 2005, AM J PHYSIOL-HEART C, V288, pH469, DOI 10.1152/ajpheart.00723.2004; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; van Raalte DH, 2004, PHARM RES-DORDR, V21, P1531, DOI 10.1023/B:PHAM.0000041444.06122.8d; Wade CNB, 2003, ENDOCRINOLOGY, V144, P832, DOI 10.1210/en.2002-220899; Wu LL, 2001, AM J PHYSIOL-REG I, V281, pR408, DOI 10.1152/ajpregu.2001.281.2.R408; Yu HP, 2006, J MOL CELL CARDIOL, V40, P185, DOI 10.1016/j.yjmcc.2005.10.001; Zuckerbraun BS, 2005, SHOCK, V23, P527, DOI 10.1097/01.shk.0000163206.22032.a1	42	64	66	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1109	1117		10.1096/fj.05-5549com	http://dx.doi.org/10.1096/fj.05-5549com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770010				2022-12-28	WOS:000240210300011
J	Vigetti, D; Moretto, P; Viola, M; Genasetti, A; Rizzi, M; Karousou, E; Pallotti, F; De Luca, G; Passi, A				Vigetti, Davide; Moretto, Paola; Viola, Manuela; Genasetti, Anna; Rizzi, Manuela; Karousou, Evgenia; Pallotti, Francesco; De Luca, Giancarlo; Passi, Alberto			Matrix metalloproteinase 2 and tissue inhibitors of metalloproteinases regulate human aortic smooth muscle cell migration during in vitro aging	FASEB JOURNAL			English	Article						senescence; extracellular matrix (ECM); siRNA; gene expression	TYPE-1 MATRIX-METALLOPROTEINASE; IV COLLAGENASE ACTIVITY; AGE-RELATED-CHANGES; GELATINASE-A; EXTRACELLULAR-MATRIX; TIMP-2; PROTEOGLYCANS; BINDING; MMP-2; PROLIFERATION	As a direct correlation between aging and the risk of onset of vascular disease has been universally accepted, we prepared an in vitro aging model consisting in sequential passages of human aortic smooth muscle cells (AoSMC) in order to evaluate the cell behavior changes during aging. Because matrix metalloproteinases (MMP) are actively involved in matrix remodeling and disease outcome, in our model we found active MMP-2 only in the conditioned medium of young AoSMCs, whereas aged cells showed only the inactive zymogen form of MMP-2 (pro-MMP2). We ascribed the pro-MMP-2 activation in young cells to an increase in membrane type 1 matrix metalloproteinase (MT1-MMP) content. Furthermore, we found that transcripts coding for tissue inhibitor of metalloproteinases (TIMPs) were up-regulated in aged cells, and this increase of TIMPs could also prevent pro-MMP-2 activation in aged cells. Moreover, we demonstrated that young AoSMCs possess higher migratory capabilities than aged cells. The young AoSMC migration can be inhibited by adding TIMP-1 and TIMP-2 to the cells reproducing aged AoSMC migratory behavior. Finally, the role of MMP-2 and TIMP-2 in AoSMC migration was confirmed silencing MMP-2 and TIMP-2 in young and aged AoSMCs, respectively; therefore, in this study we showed that these enzymes play a pivotal role in the regulation of the AoSMC migration during in vitro aging.	Univ Insubria, Dipartimento Sci Biomed Sperimentali & Clin, I-21100 Varese, Italy	University of Insubria	Passi, A (corresponding author), Univ Insubria, Dipartimento Sci Biomed Sperimentali & Clin, Via JH Dunant 5, I-21100 Varese, Italy.	alberto.passi@uninsubria.it	Viola, Manuela/B-7120-2011; passi, alberto g/A-1752-2018; Rizzi, Manuela/AAE-9202-2021; Vigetti, Davide/C-9861-2010	Viola, Manuela/0000-0002-0634-6390; passi, alberto g/0000-0003-3328-3089; Rizzi, Manuela/0000-0002-6174-7111; Vigetti, Davide/0000-0002-6339-8453; Pallotti, Francesco/0000-0001-9946-8516				Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Cheng L, 1998, CIRCULATION, V98, P2195, DOI 10.1161/01.CIR.98.20.2195; Cheng XW, 2004, CARDIOVASC RES, V62, P594, DOI 10.1016/j.cardiores.2004.01.023; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; Galis ZS, 1997, ARTERIOSCL THROM VAS, V17, P483, DOI 10.1161/01.ATV.17.3.483; Giannelli G, 2002, HISTOL HISTOPATHOL, V17, P339, DOI 10.14670/HH-17.339; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Halayko AJ, 2001, J APPL PHYSIOL, V90, P358, DOI 10.1152/jappl.2001.90.1.358; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Iannone F, 2003, AGING CLIN EXP RES, V15, P364, DOI 10.1007/BF03327357; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Johnson C, 2004, ARTERIOSCL THROM VAS, V24, P54, DOI 10.1161/01.ATV.0000100402.69997.C3; Kadoglou NP, 2004, CURR MED RES OPIN, V20, P419, DOI 10.1185/030079904125003143; Kanda S, 2000, ARTERIOSCL THROM VAS, V20, P998, DOI 10.1161/01.ATV.20.4.998; Katsuda Shogo, 2003, J Atheroscler Thromb, V10, P267; Kim H, 2002, BIOCHEM J, V365, P765, DOI 10.1042/BJ20011848; Kipling D, 2004, SCIENCE, V305, P1426, DOI 10.1126/science.1102587; Kuzuya M, 2003, CIRCULATION, V108, P1375, DOI 10.1161/01.CIR.0000086463.15540.3C; Lambert E, 2004, CRIT REV ONCOL HEMAT, V49, P187, DOI 10.1016/j.critrevonc.2003.09.008; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li ZH, 1997, EXP MOL PATHOL, V64, P1, DOI 10.1006/exmp.1997.2204; Li ZH, 1999, HYPERTENSION, V33, P116, DOI 10.1161/01.HYP.33.1.116; Lijnen HR, 2003, PATHOPHYSIOL HAEMO T, V33, P275, DOI 10.1159/000083814; Liu SQ, 1998, ANN BIOMED ENG, V26, P86, DOI 10.1114/1.52; Lundberg MS, 1999, EXP GERONTOL, V34, P549, DOI 10.1016/S0531-5565(99)00036-4; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; MARTIN GM, 1983, AM J PATHOL, V110, P236; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MCCAFFREY TA, 1988, J EXP MED, V167, P163, DOI 10.1084/jem.167.1.163; McNulty M, 2005, AM J HYPERTENS, V18, P504, DOI 10.1016/j.amjhyper.2004.11.011; Myers JE, 2005, HYPERTENS PREGNANCY, V24, P103, DOI 10.1081/PRG-200059836; Newby AC, 2005, PHYSIOL REV, V85, P1, DOI 10.1152/physrev.00048.2003; Nour N, 2005, MOL BIOL CELL, V16, P5215, DOI 10.1091/mbc.E05-06-0504; Oliver GW, 1997, ANAL BIOCHEM, V244, P161, DOI 10.1006/abio.1996.9895; Partridge L, 2002, CURR BIOL, V12, pR544, DOI 10.1016/S0960-9822(02)01048-5; Passi A, 1997, FEBS LETT, V402, P286, DOI 10.1016/S0014-5793(97)00008-2; Passi A, 1999, FEBS LETT, V456, P93, DOI 10.1016/S0014-5793(99)00929-1; PAULY RR, 1994, CIRC RES, V75, P41, DOI 10.1161/01.RES.75.1.41; Perez-Martinez L, 2005, J NEUROSCI, V25, P4917, DOI 10.1523/JNEUROSCI.5066-04.2005; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruiz-Torres A, 2003, J GERONTOL A-BIOL, V58, P1074; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Sounni NE, 2003, MATRIX BIOL, V22, P55, DOI 10.1016/S0945-053X(03)00003-9; SPERTI G, 1992, CIRC RES, V71, P385, DOI 10.1161/01.RES.71.2.385; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Troen BR, 2003, MT SINAI J MED, V70, P3; van der Loo B, 1998, EXP CELL RES, V241, P309, DOI 10.1006/excr.1998.4035; van Oostrom O, 2005, CARDIOVASC PATHOL, V14, P126, DOI 10.1016/j.carpath.2005.03.002; Wang WG, 2005, EMBO REP, V6, P158, DOI 10.1038/sj.embor.7400346; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Whatling C, 2004, ARTERIOSCL THROM VAS, V24, P10, DOI 10.1161/01.ATV.0000100562.63144.C1; Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573	57	41	45	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1118	1130		10.1096/fj.05-4504com	http://dx.doi.org/10.1096/fj.05-4504com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770011	Green Submitted			2022-12-28	WOS:000240210300012
J	Wegener, JW; Schulla, V; Koller, A; Klugbauer, N; Feil, R; Hofmann, F				Wegener, Joerg W.; Schulla, Verena; Koller, Angela; Klugbauer, Norbert; Feil, Robert; Hofmann, Franz			Control of intestinal motility by the Ca(v)1.2 L-type calcium channel in mice	FASEB JOURNAL			English	Article						intestinal contraction; constipation; SKF96365; store-operated channels	LONGITUDINAL SMOOTH-MUSCLE; CAPACITATIVE CA2+ ENTRY; ENTERIC MOTOR-NEURONS; INTERSTITIAL-CELLS; GUINEA-PIG; ELECTRICAL RHYTHMICITY; C-KIT; CAJAL; CONTRACTIONS; STIMULATION	The Ca(v)1.2 L-type Ca2+ channel is the dominant voltage- activated Ca2+ channel in heart and smooth muscle. The functional significance of this channel was studied in intestinal smooth muscle from mice carrying a smooth muscle-specific, conditional inactivation of the Ca(v)1.2 gene (Ca(v)1.2(SMACKO) mice). Inactivation was complete within 4 wk after tamoxifen treatment and confirmed by RT-PCR, Western blot and functional analysis. Ca(v)1.2(SMACKO) mice show reduced feces excretion, absence of rhythmic contractions in small and large intestinal muscle and signs of paralytic ileus. Extracellular field stimulation evoked smaller contractions in jejunum muscles from Ca(v)1.2(SMACKO) than from CTR mice, whereas carbachol-induced contractions of similar magnitude in both muscles. The Ca2+ needed for contraction in jejunum was provided mainly by Cav1.2 channels and by store-operated channels in muscles from CTR and Ca(v)1.2(SMACKO) mice, respectively. In conclusion, the Cav1.2 channel is essential for electromechanical coupling and important for pharmaco-mechanical coupling in intestinal smooth muscle and cannot be substituted functionally by other Ca2+ entry pathways.-Wegener, J. W., Schulla, V., Koller, A., Klugbauer, N., Feil, R., Hofmann, F. Control of intestinal motility by the Ca(v)1.2 L-type calcium channel in mice.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Technical University of Munich	Wegener, JW (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.	wegener@ipt.med.tu-muenchen.de	Feil, Robert/B-8918-2014	Feil, Robert/0000-0002-7335-4841; Wegener, Jorg/0000-0002-8129-1537				BLACKWOOD AM, 1993, BRIT J PHARMACOL, V109, P1029, DOI 10.1111/j.1476-5381.1993.tb13725.x; BRADING AF, 1980, BRIT J PHARMACOL, V70, P229, DOI 10.1111/j.1476-5381.1980.tb07928.x; Cousins HM, 2003, J PHYSIOL-LONDON, V550, P829, DOI 10.1113/jphysiol.2003.042176; Daniel EE, 2004, AM J PHYSIOL-GASTR L, V286, pG253, DOI 10.1152/ajpgi.00221.2003; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; Dietrich A, 2005, MOL CELL BIOL, V25, P6980, DOI 10.1128/MCB.25.16.6980-6989.2005; Gibson A, 1998, TRENDS PHARMACOL SCI, V19, P266; Hansen MB, 2003, PHYSIOL RES, V52, P1; Horowitz B, 1999, ANNU REV PHYSIOL, V61, P19, DOI 10.1146/annurev.physiol.61.1.19; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Kim TW, 2003, J PHYSIOL-LONDON, V546, P415, DOI 10.1113/jphysiol.2002.028977; Kim YC, 2002, J PHYSIOL-LONDON, V541, P797, DOI 10.1113/jphysiol.2002.018796; Kuhbandner S, 2000, GENESIS, V28, P15, DOI 10.1002/1526-968X(200009)28:1<15::AID-GENE20>3.0.CO;2-C; Lecci A, 2002, CURR OPIN PHARMACOL, V2, P630, DOI 10.1016/S1471-4892(02)00225-4; MAEDA H, 1992, DEVELOPMENT, V116, P369; MASON MJ, 1993, AM J PHYSIOL, V264, pC654, DOI 10.1152/ajpcell.1993.264.3.C654; Matsui M, 2002, J NEUROSCI, V22, P10627; McDaniel SS, 2001, AM J PHYSIOL-LUNG C, V280, pL870, DOI 10.1152/ajplung.2001.280.5.L870; McFadzean I, 2002, BRIT J PHARMACOL, V135, P1, DOI 10.1038/sj.bjp.0704468; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; PRESTWICH SA, 1995, BRIT J PHARMACOL, V114, P119, DOI 10.1111/j.1476-5381.1995.tb14915.x; Sanders KM, 2006, ANNU REV PHYSIOL, V68, P307, DOI 10.1146/annurev.physiol.68.040504.094718; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; Uchiyama Toshimitsu, 2004, Journal of Smooth Muscle Research, V40, P237, DOI 10.1540/jsmr.40.237; Unno T, 2005, BRIT J PHARMACOL, V146, P98, DOI 10.1038/sj.bjp.0706300; Wang XY, 2000, CELL TISSUE RES, V302, P331, DOI 10.1007/s004410000272; Wang XY, 1999, CELL TISSUE RES, V295, P247, DOI 10.1007/s004410051231; Wang XY, 2003, NEUROGASTROENT MOTIL, V15, P531, DOI 10.1046/j.1365-2982.2003.00429.x; Wang XY, 2003, AM J PHYSIOL-GASTR L, V285, pG593, DOI 10.1152/ajpgi.00421.2002; WARD SM, 1994, J PHYSIOL-LONDON, V480, P91, DOI 10.1113/jphysiol.1994.sp020343; Ward SM, 2000, J NEUROSCI, V20, P1393; Ward SM, 1998, GASTROENTEROLOGY, V115, P314, DOI 10.1016/S0016-5085(98)70198-2; Wegener JW, 2004, FASEB J, V18, P1159, DOI 10.1096/fj.04-1516fje; Xu M, 2003, J BIOL CHEM, V278, P40837, DOI 10.1074/jbc.M307598200; Zholos AV, 1997, BRIT J PHARMACOL, V122, P885, DOI 10.1038/sj.bjp.0701438	36	38	43	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1260	+		10.1096/fj.05-5292fje	http://dx.doi.org/10.1096/fj.05-5292fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636102				2022-12-28	WOS:000240210300045
J	Carnevale, R; Pignatelli, P; Lenti, L; Buchetti, B; Sanguigni, V; Di Santo, S; Violi, F				Carnevale, R.; Pignatelli, P.; Lenti, L.; Buchetti, B.; Sanguigni, V.; Di Santo, S.; Violi, F.			LDL are oxidatively modified by platelets via GP91(phox) and accumulate in human monocytes	FASEB JOURNAL			English	Article						X-linked chronic granulomatous disease; ROS; gp91phox activation	LOW-DENSITY-LIPOPROTEIN; CHRONIC GRANULOMATOUS-DISEASE; SMOOTH-MUSCLE CELLS; CHOLESTERYL ESTERS; ENDOTHELIAL-CELLS; SUPEROXIDE ANION; DEGRADATION; MACROPHAGES; ACTIVATION; CLEAVAGE	Oxidative stress-mediated LDL modification has a key role in initiation of the atherosclerotic process. Platelets produce reactive oxidant species (ROS) upon stimulation with agonist, but it is uncertain whether they are able to oxidatively modify LDL. Human platelets taken from healthy subjects were incubated with LDL, then stimulated with collagen. Compared with unstimulated platelets, collagen-stimulated platelets induced LDL modification as shown by enhanced conjugated dienes and lysophosphatidylcholine formation, electrophoretic mobility, Apo B-100 degradation, and monocyte LDL uptake. Activated platelets also induced a marked reduction of vitamin E contained in LDL. A significant inhibition of LDL oxidation was observed in platelets treated with arachidonyl trifluomethyl ketone (AACOCF3), an inhibitor of phospolipase A2. The experiments reported above were also conducted in patients with hereditary deficiency of gp91phox, the central core of NADPH oxidase, and in patients with hypercholesterolemia. Platelets from gp91 phox-deficient patients produced a small amount of ROS and weakly modified LDL. Conversely, platelets from hypercholesterolemic patients showed enhanced ROS formation and oxidized LDL more than platelets from healthy subjects. This study provides evidence that platelets modify LDL via NADPH oxidase-mediated oxidative stress, a phenomenon that could be dependent on arachidonic acid activation. This finding suggests a role for platelets in favoring LDL accumulation within atherosclerotic plaque.	Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Policlin Umberto, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med, Rome, Italy	Sapienza University Rome; University Hospital Sapienza Rome; University of Rome Tor Vergata	Violi, F (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Policlin Umberto, I-00185 Rome, Italy.	francesco.violi@uniroma1.it	Carnevale, Roberto/K-1472-2016; Sanguigni, Valerio/AAH-2515-2020; Violi, Francesco/K-1509-2016; pignatelli, pasquale/K-2116-2016	Carnevale, Roberto/0000-0002-6216-9595; Violi, Francesco/0000-0002-6610-7068; pignatelli, pasquale/0000-0002-2265-7455				Aust O, 2001, J CHROMATOGR A, V936, P83, DOI 10.1016/S0021-9673(01)01269-9; Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P7; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; Burger PC, 2003, BLOOD, V101, P2661, DOI 10.1182/blood-2002-07-2209; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; FOLCH J, 1957, J BIOL CHEM, V226, P497; FONG LG, 1987, J LIPID RES, V28, P1466; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; JULIANO L, 2000, CIRCULATION, V101, P1249; Krotz F, 2002, BLOOD, V100, P917, DOI 10.1182/blood.V100.3.917; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leo R, 1997, CIRCULATION, V95, P885; MARCUS AJ, 1977, J CLIN INVEST, V59, P149, DOI 10.1172/JCI108613; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; NOBLE RP, 1968, J LIPID RES, V9, P693; Pignatelli P, 1998, BLOOD, V91, P484, DOI 10.1182/blood.V91.2.484.484_484_490; Pignatelli P, 2004, CIRCULATION, V110, P1326, DOI 10.1161/01.CIR.0000134963.77201.55; PIGNATELLI P, 2002, AM J PHYSIOL-HEART C, V284, P41; PUHL H, 1994, METHOD ENZYMOL, V233, P425; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Rae J, 1998, AM J HUM GENET, V62, P1320, DOI 10.1086/301874; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SKIPSKI VP, 1957, METHOD ENZYMOL, V35, P395; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Wagner DD, 2003, ARTERIOSCL THROM VAS, V23, P2131, DOI 10.1161/01.ATV.0000095974.95122.EC; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200	32	49	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					927	934		10.1096/fj.06-6908com	http://dx.doi.org/10.1096/fj.06-6908com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17194695				2022-12-28	WOS:000244686400029
J	Fitzpatrick, JM; Hirai, Y; Hirai, H; Hoffmann, KF				Fitzpatrick, Jennifer M.; Hirai, Yuriko; Hirai, Hirohisa; Hoffmann, Karl F.			Schistosome egg production is dependent upon the activities of two developmentally regulated tyrosinases	FASEB JOURNAL			English	Article						helminth; schistosoma; kojic acid; developmental regulation	EGGSHELL FORMATION; PHENOL OXIDASE; GENE-EXPRESSION; REPRODUCTIVE-SYSTEM; CRYSTAL-STRUCTURE; CATECHOL OXIDASE; MANSONI; PRAZIQUANTEL; JAPONICUM; INFECTIONS	Egg production is responsible for life cycle progression and host immunopathology during schistosomiasis, with the associated parasite molecules being investigated as potential novel chemotherapeutic targets. Here, we characterize two Schistosoma mansoni products, tyrosinase I and tyrosinase 2 (SmTYR1/SmTYR2) and show that their diphenol oxidase enzyme activities are critical for eggshell formation and production. The genes encoding these bifunctional enzymes (monophenol and diphenol oxidases) result from a duplication event that likely occurred before speciation and exist in the parasite's genome as multiple copies, which are linked and localized to chromosomes 4 and W. SmTYR1/SmTYR2 transcription and diphenol oxidase action are developmentally regulated with most enzyme activity localized to the eggshell-producing cells contained within the vitellaria of adult female worms. Importantly, kojic-acid mediated inhibition (IC50=0.5 mu M) of SmTYR1/SmTYR2's diphenol oxidase activity during in vitro culture of sexually mature adult worms resulted in a significant decrease in the production of phenotypically normal eggs. Therefore our data suggest that SmTYR1/2 inhibition represents a novel and potentially effective strategy for combating schistosomiasis and furthermore, it may point to new methods for combinatorial control of immunopathology and egg transmission during platyhelminth infection.	Univ Cambridge, Dept Pathol, Cambridge CB1 1QP, England; Kyoto Univ, Primate Res Inst, Inuyama, Aichi 484, Japan	University of Cambridge; Kyoto University	Hoffmann, KF (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB1 1QP, England.	kfh24@cam.ac.uk		Hoffmann, Karl/0000-0002-3932-5502	Wellcome Trust [RG35177] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alverson J, 2003, J INVERTEBR PATHOL, V83, P60, DOI 10.1016/S0022-2011(03)00040-5; Bergquist NR, 1998, PARASITOL TODAY, V14, P99, DOI 10.1016/S0169-4758(97)01207-6; Boonanuntanasarn S, 2004, PIGM CELL RES, V17, P413, DOI 10.1111/j.1600-0749.2004.00166.x; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Cioli D, 2003, PARASITOL RES, V90, pS3, DOI 10.1007/s00436-002-0751-z; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Colhoun LM, 1998, PARASITOLOGY, V116, P555, DOI 10.1017/S0031182098002662; Doenhoff MJ, 2002, T ROY SOC TROP MED H, V96, P465, DOI 10.1016/S0035-9203(02)90405-0; Ebersberger I, 2005, DEV GENES EVOL, V215, P261, DOI 10.1007/s00427-005-0467-z; ERASMUS DA, 1973, PARASITOLOGY, V67, P165, DOI 10.1017/S0031182000046394; ESHETE F, 1993, J PARASITOL, V79, P309, DOI 10.2307/3283563; Fitzpatrick JM, 2006, INT J PARASITOL, V36, P1081, DOI 10.1016/j.ijpara.2006.06.007; Fitzpatrick JM, 2005, MOL BIOCHEM PARASIT, V141, P1, DOI 10.1016/j.molbiopara.2005.01.007; Fitzpatrick JM, 2004, MOL BIOCHEM PARASIT, V136, P191, DOI 10.1016/j.molbiopara.2004.03.014; Garcia-Borron JC, 2002, PIGM CELL RES, V15, P162, DOI 10.1034/j.1600-0749.2002.02012.x; GAYKEMA WPJ, 1986, J MOL BIOL, V187, P255, DOI 10.1016/0022-2836(86)90233-0; Greenberg RM, 2005, INT J PARASITOL, V35, P1, DOI 10.1016/j.ijpara.2004.09.004; Hagan P, 2004, TRENDS PARASITOL, V20, P92, DOI 10.1016/j.pt.2003.11.010; Hill DE, 1997, J PARASITOL, V83, P938, DOI 10.2307/3284293; HIRAI H, 1995, PARASITOL TODAY, V11, P310, DOI 10.1016/0169-4758(95)80048-4; Hoffmann KF, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-8-research0041; Hoffmann KF, 2002, ADV PARASIT, V52, P265, DOI 10.1016/S0065-308X(02)52014-5; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Kabatereine NB, 1999, PARASITOLOGY, V118, P101, DOI 10.1017/S0031182098003576; Kim YJ, 2005, BIOL PHARM BULL, V28, P323, DOI 10.1248/bpb.28.323; King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; Lei TC, 2002, ANAL BIOCHEM, V305, P260, DOI 10.1006/abio.2002.5665; Neves R, 2005, PARASITOL RES, V95, P43, DOI 10.1007/s00436-004-1241-2; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Olds GR, 1996, AM J TROP MED HYG, V55, P121; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; Ribeiro-dos-Santos G, 2006, PARASITOL RES, V99, P505, DOI 10.1007/s00436-006-0175-2; RIBEIROPAES JT, 1995, COMP BIOCHEM PHYS B, V111, P69, DOI 10.1016/0305-0491(94)00231-I; Sambrook J., 2002, MOL CLONING LAB MANU; SEED JL, 1980, EXP PARASITOL, V50, P33, DOI 10.1016/0014-4894(80)90005-3; SEED JL, 1980, EXP PARASITOL, V49, P430, DOI 10.1016/0014-4894(80)90077-6; SEED JL, 1978, J PARASITOL, V64, P283, DOI 10.2307/3279674; SHAW MK, 1987, J HELMINTHOL, V61, P253, DOI 10.1017/S0022149X00010117; SMYTH J. D., 1959, EXPTL PARASITOL, V8, P286, DOI 10.1016/0014-4894(59)90027-X; STURROCK RF, 1966, T ROY SOC TROP MED H, V60, P139, DOI 10.1016/0035-9203(66)90214-8; WANG FL, 1986, MOL BIOCHEM PARASIT, V18, P69, DOI 10.1016/0166-6851(86)90051-4; WELLS KE, 1991, EXP PARASITOL, V73, P295, DOI 10.1016/0014-4894(91)90101-2; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x	47	56	59	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					823	835		10.1096/fj.06-7314com	http://dx.doi.org/10.1096/fj.06-7314com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17167065				2022-12-28	WOS:000244686400020
J	Kapoor, M; Kojima, F; Qian, M; Yang, LH; Crofford, LJ				Kapoor, Mohit; Kojima, Fumiaki; Qian, Min; Yang, Lihua; Crofford, Leslie J.			Shunting of prostanoid biosynthesis in microsomal prostaglandin E synthase-1 null embryo fibroblasts: regulatory effects on inducible nitric oxide synthase expression and nitrite synthesis	FASEB JOURNAL			English	Article						arachidonic acid (AA); cyclooxygenase (COX); L-arginine	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLLAGEN-INDUCED ARTHRITIS; RHEUMATOID SYNOVIAL-CELLS; E-2 PRODUCTION; MICE LACKING; CYCLOOXYGENASE-2 INHIBITORS; PROINFLAMMATORY CYTOKINES; SELECTIVE INHIBITOR; PROSTACYCLIN; IDENTIFICATION	Microsomal postaglandin (PG) E synthase (mPGES)-1 is an inducible enzyme that acts downstream of cyclooxygenase (COX) and specifically catalyzes the conversion of prostaglandin (PG)H-2 to PGE(2), most prominently in inflammatory conditions. Specific inhibitors of mPGES-1 are not yet available, however, mice with genetic deletion of mPGES-1 have been generated that have given insight into the specific role of mPGES-1 in eicosanoid biosynthesis in vivo and in peritoneal macrophages. We created mouse embryo fibroblast (MEF) cell lines that would facilitate investigation of the effect of mPGES-1 genetic deletion on prostanoid biosynthesis in fibroblast lineage cells and its subsequent effect on the expression of inducible NOS ( iNOS) and nitrite biosynthesis using cells derived from mPGES-1 wild-type (WT), heterozygous (Het), and null mice. The results show that genetic deletion of mPGES-1 results in a dramatic decrease in PGE2 production in Het and null MEFs under basal conditions and after stimulation with interleukin (IL)-1 beta, suggesting that mPGES-1 is critically important for PGE2 production. Furthermore, we show that mPGES-1 gene deletion results in diversion of prostanoid production from PGE(2) to 6-keto PGF(1 alpha) (the stable metabolic product of PGI(2); prostacyclin) in a gene dose-dependent manner in Het and null MEFs compared with their WT counterparts, suggesting a shunting phenomenon within the arachidonic acid ( AA) metabolic pathway. In addition, we show that mPGES-1 gene deletion and subsequent decrease in PGE2 levels results in a differential induction profile of iNOS and nitrite levels ( the stable breakdown product of nitric oxide (NO) in mPGES-1 WT MEFs compared with null MEFs. These results provide important information regarding the therapeutic potential for pharmacologic inhibition of mPGES-1 in inflammatory conditions.	Univ Kentucky, Dept Internal Med, Div Rheumatol, Kentucky Clin, Lexington, KY 40536 USA; Univ Michigan, Sch Med, Ann Arbor, MI USA	University of Kentucky; University of Michigan System; University of Michigan	Kapoor, M (corresponding author), Univ Kentucky, Dept Internal Med, Div Rheumatol, Kentucky Clin, Rm J-509, Lexington, KY 40536 USA.	lcrofford@email.uky.edu	Crofford, Leslie J/J-8010-2013	Crofford, Leslie J/0000-0002-6347-5738	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049010] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049010, AR 049010] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Boulet L, 2004, J BIOL CHEM, V279, P23229, DOI 10.1074/jbc.M400443200; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; BUNTING S, 1983, BRIT MED BULL, V39, P271, DOI 10.1093/oxfordjournals.bmb.a071832; Crofford LJ, 2003, ARTHRITIS RES THER, V5, P25, DOI 10.1186/ar620; Crofford LJ, 2002, CURR OPIN RHEUMATOL, V14, P225, DOI 10.1097/00002281-200205000-00005; Cuzzocrea S, 2002, EUR J PHARMACOL, V453, P119, DOI 10.1016/S0014-2999(02)02338-5; Gibbons GH, 1997, AM J CARDIOL, V79, P3, DOI 10.1016/S0002-9149(97)00122-7; Gomez-Hernandez A, 2006, J CARDIOVASC PHARM, V47, P60; Griffon B, 1998, HEPATOLOGY, V28, P1300, DOI 10.1002/hep.510280519; Honda T, 2006, J EXP MED, V203, P325, DOI 10.1084/jem.20051310; Ikeda-Matsuo Y, 2005, J NEUROCHEM, V94, P1546, DOI 10.1111/j.1471-4159.2005.03302.x; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200; Kawai S, 1998, INFLAMM RES, V47, pS102; Kino Y, 2005, PROSTAG LEUKOTR ESS, V73, P103, DOI 10.1016/j.plefa.2005.04.014; Kojima F, 2005, FUND CLIN PHARMACOL, V19, P255, DOI 10.1111/j.1472-8206.2005.00316.x; Kojima F, 2004, ARTHRITIS RES THER, V6, pR355, DOI 10.1186/ar1195; Kojima F, 2003, ARTHRITIS RHEUM, V48, P2819, DOI 10.1002/art.11261; Kojima F, 2002, J RHEUMATOL, V29, P1836; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MONCADA S, 1989, BIOCHEM SOC T, V17, P642, DOI 10.1042/bst0170642; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; Olschewski H, 1996, ANN INTERN MED, V124, P820, DOI 10.7326/0003-4819-124-9-199605010-00006; Pang LH, 1997, BIOCHEM PHARMACOL, V53, P493, DOI 10.1016/S0006-2952(96)00737-X; Patel R, 1999, J IMMUNOL, V162, P4191; Pelletier JP, 2001, J RHEUMATOL, V28, P2509; Prast H, 2001, PROG NEUROBIOL, V64, P51, DOI 10.1016/S0301-0082(00)00044-7; Saha S, 2005, AM J PHYSIOL-REG I, V288, pR1100, DOI 10.1152/ajpregu.00872.2004; Satoh K, 2000, NEUROSCI LETT, V283, P221, DOI 10.1016/S0304-3940(00)00926-5; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; STEWART AG, 1994, MICROSURG, V15, P693, DOI 10.1002/micr.1920151006; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Trebino CE, 2005, J BIOL CHEM, V280, P16579, DOI 10.1074/jbc.M412075200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Westman M, 2004, ARTHRITIS RHEUM-US, V50, P1774, DOI 10.1002/art.20286; White WB, 2003, AM J CARDIOL, V92, P411, DOI 10.1016/S0002-9149(03)00659-3	47	28	28	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2387	+		10.1096/fj.06-6366fje	http://dx.doi.org/10.1096/fj.06-6366fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023389	Green Accepted, Green Submitted			2022-12-28	WOS:000241702600029
J	Lamounier-Zepter, V; Ehrhart-Bornstein, M; Karczewski, P; Haase, H; Bornstein, SR; Morano, I				Lamounier-Zepter, Valeria; Ehrhart-Bornstein, Monika; Karczewski, Peter; Haase, Hannelore; Bornstein, Stefan R.; Morano, Ingo			Human adipocytes attenuate cardiomyocyte contraction: characterization of an adipocyte-derived negative inotropic activity	FASEB JOURNAL			English	Article						cardiodepressant activity; calcium transient; obesity; heart failure	ADIPOSE-TISSUE; HEART-FAILURE; RAT CARDIOMYOCYTES; ANGIOTENSIN-II; RISK-FACTORS; FOLLOW-UP; OBESITY; PATHOPHYSIOLOGY; INHIBITION; MEDIATORS	The causal relationship between obesity and heart failure is broadly acknowledged; however, the pathophysiological mechanisms involved remain unclear. In this study we investigated whether human adipocytes secrete cardioactive substances that may affect cardiomyocyte contractility. We cultivated adipocytes obtained from human white adipose tissue and incubated isolated rat adult cardiomyocytes with adipocyte-conditioned or control medium. This is the first report to demonstrate that human adipocytes exhibit cardiodepressant activity with a direct and acute effect on cardiomyocyte contraction. This adipocyte-derived negative inotropic activity directly depresses shortening amplitude as well as intracellular systolic peak Ca2+ in cardiomyocytes within a few minutes. The adipocyte-derived cardiodepressant activity was dose-dependent and was completely blunted by heating or by trypsin digestion. Filtration of adipocyte-conditioned medium based on molecular mass characterized the cardiodepressant activity at between 10 and 30 kDa. In summary, adipose tissue exerts highly potent activity with an acute depressant effect directly on cardiomyocytes, which may well contribute to increased heart failure risk in overweight patients	Univ Dresden, Med Clin 3, D-01307 Dresden, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	Technische Universitat Dresden; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Lamounier-Zepter, V (corresponding author), Univ Dresden, Med Clin 3, Fetscherstr 74, D-01307 Dresden, Germany.	Valeria.Zepter@uniklinikum-dresden.de						Alpert MA, 2001, AM J MED SCI, V321, P225, DOI 10.1097/00000441-200104000-00003; Amadou A, 2002, AM J PHYSIOL-CELL PH, V282, pC1339, DOI 10.1152/ajpcell.00471.2001; Cao CM, 2003, J PHARMACOL EXP THER, V306, P572, DOI 10.1124/jpet.102.048264; Ehrhart-Bornstein M, 2003, P NATL ACAD SCI USA, V100, P14211, DOI 10.1073/pnas.2336140100; Engeli S, 2000, HYPERTENSION, V35, P1270, DOI 10.1161/01.HYP.35.6.1270; Haber EP, 2003, J CELL PHYSIOL, V194, P1, DOI 10.1002/jcp.10187; Hauner H, 2004, PHYSIOL BEHAV, V83, P653, DOI 10.1016/j.physbeh.2004.09.016; He J, 2001, ARCH INTERN MED, V161, P996, DOI 10.1001/archinte.161.7.996; Holycross Bethany J, 2002, Mol Interv, V2, P424, DOI 10.1124/mi.2.7.424; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Krug AW, 2005, CELL MOL LIFE SCI, V62, P1359, DOI 10.1007/s00018-005-4555-z; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; LAUER MS, 1991, JAMA-J AM MED ASSOC, V266, P231, DOI 10.1001/jama.266.2.231; Lefroy DC, 1996, AM J PHYSIOL-HEART C, V270, pH2060, DOI 10.1152/ajpheart.1996.270.6.H2060; Lohn M, 2002, FASEB J, V16, P1057, DOI 10.1096/fj.02-0024com; Massie BM, 2002, NEW ENGL J MED, V347, P358, DOI 10.1056/NEJMe020065; Nickola MW, 2000, HYPERTENSION, V36, P501, DOI 10.1161/01.HYP.36.4.501; Shah AM, 1997, CIRC RES, V80, P688, DOI 10.1161/01.RES.80.5.688; Sharma Vijay, 2005, Current Vascular Pharmacology, V3, P169, DOI 10.2174/1570161053586868; Staiger H, 2005, EXP CLIN ENDOCR DIAB, V113, P67, DOI 10.1055/s-2004-830555; Stangl V, 2002, CARDIOVASC RES, V53, P12, DOI 10.1016/S0008-6363(01)00420-5; Stein B, 1996, J MOL CELL CARDIOL, V28, P1631, DOI 10.1006/jmcc.1996.0153; Wajchenberg BL, 2000, ENDOCR REV, V21, P697, DOI 10.1210/er.21.6.697; Watanabe A, 1998, CARDIOVASC RES, V37, P524, DOI 10.1016/S0008-6363(97)00287-3; Wilhelmsen L, 2001, J INTERN MED, V249, P253, DOI 10.1046/j.1365-2796.2001.00801.x; Wong CY, 2004, CIRCULATION, V110, P3081, DOI 10.1161/01.CIR.0000147184.13872.0F; Yang ZK, 1999, AM J PHYSIOL-HEART C, V276, pH623, DOI 10.1152/ajpheart.1999.276.2.H623; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	31	35	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1653	1659		10.1096/fj.05-5436com	http://dx.doi.org/10.1096/fj.05-5436com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873888				2022-12-28	WOS:000240266600010
J	Johar, S; Cave, AC; Narayanapanicker, A; Grieve, DJ; Shah, AM				Johar, Sofian; Cave, Alison C.; Narayanapanicker, Anilkumar; Grieve, David J.; Shah, Ajay M.			Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase	FASEB JOURNAL			English	Article						oxidative stress; matrix metalloproteinase; mineralocorticoid receptor	FACTOR-KAPPA-B; MESSENGER-RNA EXPRESSION; TISSUE GROWTH-FACTOR; MYOCARDIAL FIBROSIS; OXIDATIVE STRESS; HEART-FAILURE; CARDIOVASCULAR INJURY; SUPEROXIDE GENERATION; PRESSURE-OVERLOAD; CONVERTING-ENZYME	Angiotensin (ANG) II (AngII) and aldosterone contribute to the development of interstitial cardiac fibrosis. We investigated the potential role of a Nox2-containing NADPH oxidase in aldosterone-induced fibrosis and the involvement of this mechanism in AngII-induced effects. Nox2(-/-) mice were compared with matched wild-type controls (WT). In WT mice, subcutaneous (s.c.) AngII (1.1 mg/kg/day for 2 wk) significantly increased NADPH oxidase activity, interstitial fibrosis (11.5 +/- 1.0% vs. 7.2 +/- 0.7%; P < 0.05), expression of fibronectin, procollagen I, and connective tissue growth factor mRNA, MMP-2 activity, and NF-kB activation. These effects were all inhibited in Nox(-/-) hearts. The mineralocorticoid receptor antagonist spironolactone inhibited AngII-induced increases in NADPH oxidase activity and the increase in interstitial fibrosis. In a model of mineralocorticoiddependent hypertension involving chronic aldosterone infusion (0.2 mg/kg/day) and a 1% Na Cl diet ("ALDO"), WT animals exhibited increased NADPH oxidase activity, pro-fibrotic gene expression, MMP-2 activity, NF-kB activation, and significant interstitial cardiac fibrosis (12.0 +/- 1.7% with ALDO vs. 6.3 +/- 0.3% without; P < 0.05). These effects were inhibited in Nox2(-/-) ALDO mice (e.g., fibrosis 6.8 +/- 0.8% with ALDO vs. 5.8 +/- 1.0% without ALDO; P=NS). These results suggest that aldosterone-dependent activation of a Nox2-containing NADPH oxidase contributes to the profibrotic effect of AngII in the heart as well as the fibrosis seen in mineralocorticoid-dependent hypertension.	Kings Coll London, Sch Med, Div Cardiovasc, London SE5 9PJ, England	University of London; King's College London	Shah, AM (corresponding author), Kings Coll London, Sch Med, Div Cardiovasc, New Med Sch Bldg,Bessemer Rd, London SE5 9PJ, England.	ajay.shah@kcl.ac.uk	Grieve, David/F-5035-2010; Johar, Sofian/AAX-7450-2021	Johar, Sofian/0000-0002-5962-6492; Shah, Ajay/0000-0002-6547-0631				Ahmed MS, 2004, J MOL CELL CARDIOL, V36, P393, DOI 10.1016/j.yjmcc.2003.12.004; Bataller R, 2003, J CLIN INVEST, V112, P1383, DOI 10.1172/JCI200318212; Bendall JK, 2002, CIRCULATION, V105, P293, DOI 10.1161/hc0302.103712; BRILLA CG, 1993, J MOL CELL CARDIOL, V25, P563, DOI 10.1006/jmcc.1993.1066; Brilla CG, 2000, CIRCULATION, V102, P1388, DOI 10.1161/01.CIR.102.12.1388; BRILLA CG, 1990, CIRC RES, V67, P1355, DOI 10.1161/01.RES.67.6.1355; Byrne JA, 2003, CIRC RES, V93, P802, DOI 10.1161/01.RES.0000099504.30207.F5; Callera GE, 2005, HYPERTENSION, V45, P773, DOI 10.1161/01.HYP.0000154365.30593.d3; Chen K, 2004, HYPERTENSION, V44, P655, DOI 10.1161/01.HYP.0000144400.49062.6b; Chen K, 2004, CIRC RES, V95, P1167, DOI 10.1161/01.RES.0000150369.68826.2f; Diez J, 2002, CIRCULATION, V105, P2512, DOI 10.1161/01.CIR.0000017264.66561.3D; Ferri N, 2003, J BIOL CHEM, V278, P19757, DOI 10.1074/jbc.M212714200; Fiebeler A, 2001, HYPERTENSION, V37, P787, DOI 10.1161/01.HYP.37.2.787; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Griendling KK, 2004, HEART, V90, P491, DOI 10.1136/hrt.2003.029397; Griendling KK, 2003, CIRCULATION, V108, P2034, DOI 10.1161/01.CIR.0000093661.90582.c4; Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C; Gunaruwan P, 2005, AM J CARDIOL, V95, P412, DOI 10.1016/j.amjcard.2004.09.047; Haendeler J, 2000, REGUL PEPTIDES, V95, P1, DOI 10.1016/S0167-0115(00)00133-6; Harada E, 2001, CIRCULATION, V104, P137, DOI 10.1161/01.CIR.104.2.137; Jayasankar V, 2004, CIRCULATION, V110, pII180, DOI 10.1161/01.CIR.0000138946.29375.49; Kawano H, 2000, CIRCULATION, V101, P1130, DOI 10.1161/01.CIR.101.10.1130; Keidar S, 2004, CIRCULATION, V109, P2213, DOI 10.1161/01.CIR.0000127949.05756.9D; Landmesser U, 2002, CIRCULATION, V106, P3073, DOI 10.1161/01.CIR.0000041431.57222.AF; Li JM, 2003, J BIOL CHEM, V278, P12094, DOI 10.1074/jbc.M209793200; Li LX, 2003, CIRCULATION, V107, P1053, DOI 10.1161/01.CIR.0000051459.74466.46; Lijnen P, 2000, J MOL CELL CARDIOL, V32, P865, DOI 10.1006/jmcc.2000.1129; Lu L, 2004, BIOCHEM BIOPH RES CO, V321, P879, DOI 10.1016/j.bbrc.2004.07.048; Manoury B, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-11; Maytin M, 2004, CIRCULATION, V109, P1168, DOI 10.1161/01.CIR.0000117229.60628.2F; Mazak I, 2004, CIRCULATION, V109, P2792, DOI 10.1161/01.CIR.0000131860.80444.AB; McEwan PE, 1998, CIRCULATION, V98, P2765, DOI 10.1161/01.CIR.98.24.2765; Meiners S, 2004, HYPERTENSION, V44, P471, DOI 10.1161/01.HYP.0000142772.71367.65; Mulrow PJ, 1999, REGUL PEPTIDES, V80, P27, DOI 10.1016/S0167-0115(99)00004-X; Neumann S, 2002, HYPERTENSION, V39, P756, DOI 10.1161/hy0302.105295; Ogata T, 2004, J AM COLL CARDIOL, V43, P1481, DOI 10.1016/j.jacc.2003.11.043; Pagano PJ, 1998, HYPERTENSION, V32, P331, DOI 10.1161/01.HYP.32.2.331; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pu Q, 2003, HYPERTENSION, V42, P49, DOI 10.1161/01.HYP.0000078357.92682.EC; Ramires FJA, 1998, J MOL CELL CARDIOL, V30, P475, DOI 10.1006/jmcc.1997.0612; Robert V, 1999, HYPERTENSION, V33, P981, DOI 10.1161/01.HYP.33.4.981; Ruperez M, 2003, CIRCULATION, V108, P1499, DOI 10.1161/01.CIR.0000089129.51288.BA; Schwartzkopff B, 2000, HYPERTENSION, V36, P220, DOI 10.1161/01.HYP.36.2.220; Silvestre JS, 1998, J BIOL CHEM, V273, P4883, DOI 10.1074/jbc.273.9.4883; Stockand JD, 2003, AM J PHYSIOL-HEART C, V284, pH176, DOI 10.1152/ajpheart.00421.2002; Sun Y, 2002, AM J PATHOL, V161, P1773, DOI 10.1016/S0002-9440(10)64454-9; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; Touyz RM, 2003, ARTERIOSCL THROM VAS, V23, P981, DOI 10.1161/01.ATV.0000069236.27911.68; Vellaichamy E, 2005, J BIOL CHEM, V280, P19230, DOI 10.1074/jbc.M411373200; Wang TL, 2004, J MOL CELL CARDIOL, V37, P785, DOI 10.1016/j.yjmcc.2004.06.016; Weber KT, 1997, CIRCULATION, V96, P4065	53	240	246	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1546	+		10.1096/fj.05-4642fje	http://dx.doi.org/10.1096/fj.05-4642fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720735				2022-12-28	WOS:000240266000046
J	Smulski, C; Labovsky, V; Levy, G; Hontebeyrie, M; Hoebeke, J; Levin, MJ				Smulski, C.; Labovsky, V.; Levy, G.; Hontebeyrie, M.; Hoebeke, J.; Levin, M. J.			Structural basis of the cross-reaction between an antibody to the Trypanosoma cruzi ribosomal P2 beta protein and the human beta(1) adrenergic receptor	FASEB JOURNAL			English	Article						ribosomal P proteins; single-chain Fv fragments (scFv); paratope-epitope modeling	CHAGAS HEART-DISEASE; HUMAN BETA-1-ADRENERGIC RECEPTOR; MONOCLONAL-ANTIBODY; VARIABLE FRAGMENT; P-PROTEINS; EPITOPE; AGONIST; COMPLEX; AUTOANTIBODIES; ARRHYTHMIAS	Antibodies from patients with Chagas heart disease and monoclonal antibodies (or mAb) to the carboxy-terminal end (B cell epitope R13) of the ribosomal P2 beta protein of Trypanosoma cruzi (TcP2 beta) cross-react with the beta(1) adrenergic receptor (beta(1)-AR). Two single-chain Fv fragments (scFv) C5 and B7 derived from the variable regions of the anti-R13 mAb 17.2 were expressed. scFv C5 was a dimer and bound to TcP2 beta with an affinity of K-d = 8 nM, whereas scFv B7 was monomeric and had less affinity than scFv C5 for TcP2 beta, K-d = 46 nM. The affinity constant of scFv C5 to the second extracellular loop of the human beta(1)-AR was of 10 mu M. Moreover, scFv C5 induced an increase in cAMP levels of CHO-K cells transfected with the human beta(1)-AR; scFv B7 had no effect but blocked isoproterenol stimulation. The agonist-like activity of scFv C5 and the antagonist activity of scFv B7 were both confirmed in vivo on heart beating frequency after their passive transfer to mice. Molecular modeling of the variable region of mAb 17.2 indicated which amino acids were likely to be involved in recognizing both peptide EDDDMGFGLF, derived from the R13 epitope of TcP2 beta, and peptide ESDEARRCYN from the second extracellular loop of the human beta(1)-AR. It is plausible that the recently described cross-reaction of mAb 17.2 with rhodopsin can also be explained by this model. The physiological effects of this type of anti-T. cruzi antibodies may increase the liability of patients with Chagas disease.	Consejo Nacl Invest Cient & Tecn, INGEBI, Inst Invest Ingn Genet & Biol Mol, LaBMECh,Natl Res Council, RA-1428 Buenos Aires, DF, Argentina; Inst Pasteur, Paris, France; CNRS, IBMC, UPR 9021, Strasbourg, France; INSERM, U567, Inst Cochin Genet Mol, Dept Malad Infect, Paris, France	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Levin, MJ (corresponding author), Consejo Nacl Invest Cient & Tecn, INGEBI, Inst Invest Ingn Genet & Biol Mol, LaBMECh,Natl Res Council, Vta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	mlevin@dna.uba.ar		Levy, Gabriela Vanesa/0000-0002-7638-3509; Smulski, Cristian/0000-0003-4186-8116				Asano R, 2002, J BIOCHEM, V132, P903, DOI 10.1093/oxfordjournals.jbchem.a003303; Ayub MJ, 2005, GENE, V357, P129, DOI 10.1016/j.gene.2005.06.006; Bergami PL, 1997, FEMS IMMUNOL MED MIC, V18, P75, DOI 10.1016/S0928-8244(97)00026-6; Bergami PL, 2005, CLIN EXP IMMUNOL, V142, P140, DOI 10.1111/j.1365-2249.2005.02885.x; Chiale PA, 2001, CIRCULATION, V103, P1765, DOI 10.1161/01.CIR.103.13.1765; Elies R, 1996, J IMMUNOL, V157, P4203; ELIZARI MV, 1993, J CARDIOVASC ELECTR, V4, P596, DOI 10.1111/j.1540-8167.1993.tb01247.x; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; Giordanengo L, 2000, EUR J IMMUNOL, V30, P3181, DOI 10.1002/1521-4141(200011)30:11&lt;3181::AID-IMMU3181&gt;3.0.CO;2-A; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HALPERIN C, 2000, ARRHYTHMIA MANAGEMEN, P83; Hernandez-Munain Cristina, 1993, Biological Research, V26, P209; HERNANDEZMUNAIN C, 1992, J EXP MED, V175, P1473, DOI 10.1084/jem.175.6.1473; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; Kaplan D, 1997, P NATL ACAD SCI USA, V94, P10301, DOI 10.1073/pnas.94.19.10301; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Kortt AA, 1997, PROTEIN ENG, V10, P423, DOI 10.1093/protein/10.4.423; KORTT AA, 1994, EUR J BIOCHEM, V221, P151, DOI 10.1111/j.1432-1033.1994.tb18724.x; LEVIN MJ, 1993, PARASITOL TODAY, V9, P381, DOI 10.1016/0169-4758(93)90088-W; LEVITUS G, 1991, CLIN EXP IMMUNOL, V85, P413, DOI 10.1111/j.1365-2249.1991.tb05741.x; LOPEZBERGAMI P, 2001, FASEB J, V15, P2602; Mahler E, 2004, CLIN EXP IMMUNOL, V136, P527, DOI 10.1111/j.1365-2249.2004.02480.x; Mahler E, 2001, EUR J IMMUNOL, V31, P2210, DOI 10.1002/1521-4141(200107)31:7&lt;2210::AID-IMMU2210&gt;3.0.CO;2-J; Matsumoto SC, 2006, FASEB J, V20, P550, DOI 10.1096/fj.05-4654fje; MESRI EA, 1990, J CLIN MICROBIOL, V28, P1219, DOI 10.1128/JCM.28.6.1219-1224.1990; Mijares A, 2000, MOL PHARMACOL, V58, P373, DOI 10.1124/mol.58.2.373; Mousli M, 1999, FEBS LETT, V442, P183, DOI 10.1016/S0014-5793(98)01647-0; MULLER S, 1985, BIOCHIM BIOPHYS ACTA, V827, P235, DOI 10.1016/0167-4838(85)90208-0; Peter JC, 2004, J BIOL CHEM, V279, P55697, DOI 10.1074/jbc.M407213200; Peter JC, 2003, J BIOL CHEM, V278, P36740, DOI 10.1074/jbc.M306877200; RichaletSecordel PM, 1997, ANAL BIOCHEM, V249, P165, DOI 10.1006/abio.1997.2183; ROSENBAUM MB, 1994, J CARDIOVASC ELECTR, V5, P367, DOI 10.1111/j.1540-8167.1994.tb01174.x; Sepulveda P, 2000, INFECT IMMUN, V68, P5114, DOI 10.1128/IAI.68.9.5114-5119.2000; SNARY D, 1983, CLIN EXP IMMUNOL, V54, P617; STERINBORDA L, 1986, INT J IMMUNOPHARMACO, V8, P581, DOI 10.1016/0192-0561(86)90029-9	35	29	33	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1396	1406		10.1096/fj.05-5699com	http://dx.doi.org/10.1096/fj.05-5699com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816115				2022-12-28	WOS:000240266000017
J	Razeghi, P; Buksinska-Lisik, M; Palanichamy, N; Stepkowski, S; Frazier, OH; Taegtmeyer, H				Razeghi, Peter; Buksinska-Lisik, Malgorzata; Palanichamy, Nanthini; Stepkowski, Stanislaw; Frazier, O. Howard; Taegtmeyer, Heinrich			Transcriptional regulators of ribosomal biogenesis are increased in the unloaded heart	FASEB JOURNAL			English	Article						failing human heart; LVAD; reverse remodeling c-myc	C-MYC; INCREASED EXPRESSION; RNA; HYPERTROPHY; ACTIVATION; GROWTH; GENES; UBF; DNA	Mechanical unloading of the rat heart increases both protein synthesis and protein degradation. The transcriptional mechanism underlying increased protein synthesis during atrophic remodeling is not known. The aim of this study was to identify transcriptional regulators and the gene expression profile regulating protein synthesis in the unloaded rat heart and in the unloaded failing human heart. We measured DNA binding activity, transcript levels, and protein expression of transcriptional regulators of protein synthesis in a model of atrophic remodeling induced by heterotopic transplantation of the rat heart ( duration 1 and 7 days). Using microarray analysis and quantitative RT-polymerase chain reaction, we found an increase in c-myc-regulated gene expression including an induction of ribosomal subunit messenger RNA's (RPS 10, RPL 21) and rRNA (18S). Consistent with the gene expression profile, DNA binding activity of c-myc and the nuclear protein concentration of its coactivator, upstream binding factor (UBF), increased in the atrophied heart whereas protein levels of the c-myc inhibitor MAD1 decreased. We found the same increase of ribosomal subunit messenger RNA and rRNA in 21 paired samples of failing human hearts obtained before and after left ventricular assist device treatment ( mean duration: 157 +/- 31 days). In summary, mechanical unloading increases c-myc activity and c-myc regulated gene expression in the rat heart. Changes in transcript levels of genes regulating ribosomal biogenesis in the unloaded rat heart resemble those found in the unloaded failing human heart. We concluded c-myc and c-myc-regulated gene expression are transcriptional regulators of protein synthesis during atrophic remodeling of the heart.	Univ Texas, Houston Med Sch, Div Cardiol, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Div Organ Transplantat, Houston, TX 77030 USA; St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Saint Lukes Episcopal Hospital; Texas Heart Institute	Taegtmeyer, H (corresponding author), Univ Texas, Houston Med Sch, Div Cardiol, Dept Internal Med, 6431 Fannin,MSB 1-222, Houston, TX 77030 USA.	heinrich.taegtmeyer@uth.tmc.edu		Buksinska-Lisik, Malgorzata/0000-0001-7738-1049	NHLBI NIH HHS [R01-HL 61483] Funding Source: Medline; NIA NIH HHS [R01-AG 61483] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061483] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Barton PJR, 2005, CIRCULATION, V112, pI46, DOI 10.1161/01.CIRCULATIONAHA.105.525873; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brandenburger Y, 2001, FASEB J, V15, P2051, DOI 10.1096/fj.00-0853fje; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; MCCARTHY PM, 1995, ANN THORAC SURG, V59, P609, DOI 10.1016/0003-4975(94)00953-8; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Nader GA, 2005, AM J PHYSIOL-CELL PH, V289, pC1457, DOI 10.1152/ajpcell.00165.2005; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Razeghi P, 2005, CIRC RES, V97, P964, DOI 10.1161/01.RES.0000193563.53859.3e; Razeghi P, 2003, CIRCULATION, V108, P2536, DOI 10.1161/01.CIR.0000096481.45105.13; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SCHEININ SA, 1992, ASAIO J, V38, pM271, DOI 10.1097/00002480-199207000-00035; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Schnabel P, 2000, BIOCHEM BIOPH RES CO, V275, P1, DOI 10.1006/bbrc.2000.3255; Sharma S, 2006, CARDIOLOGY, V105, P128, DOI 10.1159/000090550; Uray IP, 2002, J HEART LUNG TRANSPL, V21, P771, DOI 10.1016/S1053-2498(02)00390-X; Xiao GS, 2001, CIRC RES, V89, P1122, DOI 10.1161/hh2401.100742	20	16	16	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1090	1096		10.1096/fj.06-5718com	http://dx.doi.org/10.1096/fj.06-5718com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770008				2022-12-28	WOS:000240210300009
J	Szegedi, V; Juhasz, G; Rozsa, E; Juhasz-Vedres, G; Datki, Z; Fulop, L; Bozso, Z; Lakatos, A; Laczko, I; Farkas, T; Kis, Z; Toth, G; Soos, K; Zarandi, M; Denes, B; Toldi, J; Penke, B				Szegedi, Viktor; Juhasz, Gabor; Rozsa, Eva; Juhasz-Vedres, Gabriella; Datki, Zsolt; Fulop, Livia; Bozso, Zsolt; Lakatos, Andrea; Laczko, Ilona; Farkas, Tamas; Kis, Zsolt; Toth, Geza; Soos, Katalin; Zarandi, Marta; Denes, Budai; Toldi, Jozsef; Penke, Botond			Endomorphin-2, an endogenous tetrapeptide, protects against A beta 1-42 in vitro and in vivo	FASEB JOURNAL			English	Article						Alzheimer's disease; fibrillogenesis; circular dichroism; single-unit; transmission electronmicroscopy; rat	MU-OPIOID RECEPTORS; BETA-AMYLOID PEPTIDES; ALZHEIMERS-DISEASE; NEUROTOXICITY; ENHANCEMENT; INHIBITION; REDUCTION; PREVENTS; NEURONS; GENES	The underlying cause of Alzheimer's disease ( AD) is thought to be the beta-amyloid aggregates formed mainly by A beta 1-42 peptide. Protective pentapeptides [ e. g., Leu-Pro-Phe-Phe-Asp (LPFFD)] have been shown to prevent neuronal toxicity of A beta 1-42 by arresting and reversing fibril formation. Here we report that an endogenous tetrapeptide, endomorphin-2 (End-2, amino acid sequence: YPFF), defends against A beta 1-42 induced neuromodulatory effects at the cellular level. Although End-2 does not interfere with the kinetics of A beta fibrillogenesis according to transmission electron microscopic studies and quasielastic light scattering measurements, it binds to A beta 1-42 during aggregation, as revealed by tritium-labeled End-2 binding assay and circular dichroism measurements. The tetrapeptide attenuates the inhibitory effect on cellular redox activity of A beta 1-42 in a dose-dependent manner, as measured by 3-(4,5-dimethylthiazolyl-2)-2,-5-diphenyltetrazolium bromide (MTT) assay. In vitro and in vivo electrophysiological experiments show that End-2 also protects against the field excitatory postsynaptic potential attenuating and the NMDA-evoked responseenhancing effect of A beta 1-42. Studies using [D-Ala ( 2), N-Me-Phe (4), Gly (5)-ol]-enkephalin (DAMGO), a mu-opioid receptor agonist, show that the protective effects of the tetrapeptide are not mu-receptor modulated. The endogenous tetrapeptide End-2 may serve as a lead compound for the drug development in the treatment of AD.	Univ Szeged, Dept Med Chem, H-6720 Szeged, Hungary; Univ Szeged, Dept Comparat Physiol, H-6720 Szeged, Hungary; Univ Szeged, Dept Analyt & Inorgan Chem, H-6720 Szeged, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Biophys, H-1051 Budapest, Hungary; Univ Szeged, Juhasz Gyula Coll, Dept Biol, H-6720 Szeged, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Biochem, H-6701 Szeged, Hungary	Szeged University; Szeged University; Szeged University; Hungarian Academy of Sciences; Hungarian Biological Research Center; Szeged University; Hungarian Academy of Sciences; Hungarian Biological Research Center	Szegedi, V (corresponding author), Univ Szeged, Dept Med Chem, Dom Sq 8, H-6720 Szeged, Hungary.	szegv@mdche.szote.u-szeged.hu	Fülöp, Livia/E-2543-2011; Toldi, József/M-4858-2018; Farkas, Tamas/B-7193-2008; Kis, Zsolt/A-4583-2009; Fülöp, Livia/GRX-8140-2022; Szegedi, Viktor/A-3549-2008	Toldi, József/0000-0001-7355-0503; Kis, Zsolt/0000-0002-6896-5883; Szegedi, Viktor/0000-0003-4191-379X; Juhasz, Gabor/0000-0001-6912-5109; Fulop, Livia/0000-0002-8010-0129				Barghorn S, 2005, J NEUROCHEM, V95, P834, DOI 10.1111/j.1471-4159.2005.03407.x; Bores GM, 1998, BRAIN RES BULL, V46, P423, DOI 10.1016/S0361-9230(97)00382-1; Budai Denes, 2004, Acta Biologica Szegediensis, V48, P13; Chacon MA, 2004, MOL PSYCHIATR, V9, P953, DOI 10.1038/sj.mp.4001516; Chen QS, 2000, J NEUROSCI RES, V60, P65, DOI 10.1002/(SICI)1097-4547(20000401)60:1<65::AID-JNR7>3.0.CO;2-Q; Datki Z, 2004, NEUROBIOL DIS, V17, P507, DOI 10.1016/j.nbd.2004.08.007; Datki Z, 2003, BRAIN RES BULL, V62, P223, DOI 10.1016/j.brainresbull.2003.09.011; Drake CT, 2002, HIPPOCAMPUS, V12, P119, DOI 10.1002/hipo.1107; Drake CT, 1999, BRAIN RES, V849, P203, DOI 10.1016/S0006-8993(99)01910-1; ElKhoury J, 1996, NATURE, V382, P716; FUKUYAMA R, 1994, BRAIN RES, V667, P269, DOI 10.1016/0006-8993(94)91505-9; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; Harkany T, 2000, EUR J NEUROSCI, V12, P2735, DOI 10.1046/j.1460-9568.2000.00164.x; Hertel C, 1996, J NEUROCHEM, V67, P272; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Iglesias M, 2003, NEUROPHARMACOLOGY, V44, P482, DOI 10.1016/S0028-3908(03)00024-8; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; JOACHIM C, 1991, AM J PATHOL, V138, P373; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Lahiri DK, 2003, CURR DRUG TARGETS, V4, P97, DOI 10.2174/1389450033346957; LAMBERT MP, 1994, J NEUROSCI RES, V39, P377, DOI 10.1002/jnr.490390404; Liao SL, 2003, NEUROSCI LETT, V345, P169, DOI 10.1016/S0304-3940(03)00540-8; Lin X, 2003, BBA-MOL BASIS DIS, V1639, P195, DOI 10.1016/j.bbadis.2003.09.007; Liu YB, 1997, J NEUROCHEM, V69, P2285; Louzada PR, 2004, FASEB J, V18, P511, DOI 10.1096/fj.03-0739com; Luhrs T, 2005, P NATL ACAD SCI USA, V102, P17342, DOI 10.1073/pnas.0506723102; Malmo C, 2005, FASEB J, V19, P346, DOI 10.1096/fj.05-4652je; Martin-Schild S, 1999, J COMP NEUROL, V405, P450, DOI 10.1002/(SICI)1096-9861(19990322)405:4<450::AID-CNE2>3.0.CO;2-#; McQuiston AR, 2003, J NEUROPHYSIOL, V90, P1936, DOI 10.1152/jn.01150.2002; Molnar Z, 2004, NEUROREPORT, V15, P1649, DOI 10.1097/01.wnr.0000134471.06244.d2; Muehlhauser F, 2001, CLIN CHEM LAB MED, V39, P313, DOI 10.1515/CCLM.2001.048; Nitta A, 1997, JPN J PHARMACOL, V73, P51, DOI 10.1254/jjp.73.51; Palotas A, 2002, BRAIN RES BULL, V58, P203, DOI 10.1016/S0361-9230(02)00773-6; Pappolla M, 1998, J BIOL CHEM, V273, P7185, DOI 10.1074/jbc.273.13.7185; Permanne B, 2002, FASEB J, V16, P860, DOI 10.1096/fj.01-0841fje; Phinney AL, 2003, NEUROL RES, V25, P590, DOI 10.1179/016164103101202020; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Rocchi A, 2003, BRAIN RES BULL, V61, P1, DOI 10.1016/S0361-9230(03)00067-4; Savvateeva E V, 1999, Ross Fiziol Zh Im I M Sechenova, V85, P167; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Soto C, 1999, MOL MED TODAY, V5, P343, DOI 10.1016/S1357-4310(99)01508-7; Stephan A, 2001, J NEUROSCI, V21, P5703, DOI 10.1523/JNEUROSCI.21-15-05703.2001; Szegedi V, 2005, BRAIN RES, V1062, P120, DOI 10.1016/j.brainres.2005.09.014; Szegedi V, 2005, NEUROBIOL DIS, V18, P499, DOI 10.1016/j.nbd.2004.12.008; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Trommer BL, 2005, NEUROBIOL DIS, V18, P75, DOI 10.1016/j.nbd.2004.08.011; Vass E, 2003, CHEM REV, V103, P1917, DOI 10.1021/cr000100n; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Wogulis M, 2005, J NEUROSCI, V25, P1071, DOI 10.1523/JNEUROSCI.2381-04.2005; Yao PJ, 2003, NEUROBIOL DIS, V12, P97, DOI 10.1016/S0969-9961(02)00009-8; Yu SP, 1998, NEUROBIOL DIS, V5, P81, DOI 10.1006/nbdi.1998.0186; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0; Zadina JE, 1999, ANN NY ACAD SCI, V897, P136, DOI 10.1111/j.1749-6632.1999.tb07885.x	57	23	25	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1191	+		10.1096/fj.05-4891fje	http://dx.doi.org/10.1096/fj.05-4891fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636106				2022-12-28	WOS:000240210300022
J	Wang, RS; Zhang, YW; Zhang, X; Liu, RZ; Zhang, X; Hong, SG; Xia, K; Xia, JH; Zhang, ZH; Xu, HX				Wang, Ruishan; Zhang, Yun-Wu; Zhang, Xian; Liu, Runzhong; Zhang, Xue; Hong, Shuigen; Xia, Kun; Xia, Jiahui; Zhang, Zhuohua; Xu, Huaxi			Transcriptional regulation of APH-1A and increased gamma-secretase cleavage of APP and Notch by HIF-1 and hypoxia	FASEB JOURNAL			English	Article						Alzheimer's disease; AP4; promoter	AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; PROTEOLYTIC RELEASE; MISSENSE MUTATIONS; GENE-EXPRESSION; SPLICE VARIANT; BETA-APP; NICASTRIN; PRESENILIN-1	The proteolytic cleavage of Alzheimer beta-amyloid precursor protein (APP) and signaling receptor Notch is mediated by the PS/gamma-secretase complex, which consists of presenilins, nicastrin, APH-1, and PEN-2. Although the four components are known to coordinately regulate each other at the protein level, information regarding their transcription regulation is scarce. Here we characterized the 5'-flanking region of the human APH-1A gene and identified a 271-bp fragment containing the transcription initiation site for the promoter activity. Sequence analysis, mutagenesis, and gel shift studies revealed a binding of AP4 and HIF-1 to the promoter, which affects the promoter activity. Activation of HIF-1 by short- term NiCl2 treatments ( a condition of chemical hypoxia) dramatically increased APH-1A mRNA and protein expression, accompanied by increased secretion of A beta and decreased APP CTFs formation, indicative of an increase in gamma-secretase activity. NiCl2 treatments had little effect on APP and the other three components of the gamma-secretase complex. The cellular concentration of Notch intracellular domain (NICD) was also increased by the hypoxic treatment. Our results demonstrate that APH-1A expression and the gamma-secretase mediated A beta and Notch NICD generation are regulated by HIF-1, and the specific control of APH-1A expression may imply physiological functions uniquely assigned to APH-1A. Wang, R., Zhang, Y-w., Zhang, X., Liu, R., Zhang, X., Hong, S., Xia, K., Xia, J., Zhang, Z., Xu, H. Transcriptional regulation of APH-1A and increased gamma-secretase cleavage of APP and Notch by HIF-1 and hypoxia.	Cent S Univ, Xiang Ya Hosp, Natl Lab Med Genet China, Changsha 410078, Hunan, Peoples R China; Xiamen Univ, Mol & Cellular Neurosci Lab, Sch Life Sci, Xiamen, Peoples R China; Xiamen Univ, Biomed Res Inst, Xiamen, Peoples R China; Burnham Inst Med Res, Ctr Neurosci & Aging, La Jolla, CA USA	Central South University; Xiamen University; Xiamen University; Sanford Burnham Prebys Medical Discovery Institute	Xu, HX (corresponding author), Cent S Univ, Xiang Ya Hosp, Natl Lab Med Genet China, Changsha 410078, Hunan, Peoples R China.	xuh@burnham.org	Liu, Runzhong/B-8217-2012; Zhang, Xian/AAV-7491-2021; Zhang, YW/G-3999-2010; XIA, KUN/AAO-3525-2020; Xu, Huaxi/AAV-7177-2021	Zhang, Yun-wu/0000-0002-7152-7630	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG024895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006497] Funding Source: NIH RePORTER; NIA NIH HHS [F32 AG024895, R01 AG024895] Funding Source: Medline; NIDCD NIH HHS [R01 DC006497] Funding Source: Medline; NINDS NIH HHS [R01 NS046673] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bazan NG, 2002, J BIOL CHEM, V277, P30359, DOI 10.1074/jbc.M203201200; Cheng CK, 2003, MOL ENDOCRINOL, V17, P1175, DOI 10.1210/me.2002-0418; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; CHUNG SL, 2001, W PAC EARTH SCI, V1, P1; Costa M, 2005, MUTAT RES-FUND MOL M, V592, P79, DOI 10.1016/j.mrfmmm.2005.06.008; DE SB, 1999, NATURE, V398, P518; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Golde TE, 2005, BRAIN PATHOL, V15, P84, DOI 10.1111/j.1750-3639.2005.tb00104.x; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Greenfield JP, 2000, FRONT BIOSCI, V5, pD72, DOI 10.2741/Greenfield; Greenfield JP, 2002, J BIOL CHEM, V277, P12128, DOI 10.1074/jbc.M110009200; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Kang DE, 2005, J BIOL CHEM, V280, P31537, DOI 10.1074/jbc.M500833200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 2003, J BIOL CHEM, V278, P33445, DOI 10.1074/jbc.M301288200; Li T, 2003, J NEUROSCI, V23, P3272; Lu HT, 2005, MOL CELL BIOCHEM, V279, P45, DOI 10.1007/s11010-005-8215-2; Lu S, 2002, BBA-GENE STRUCT EXPR, V1574, P152, DOI 10.1016/S0167-4781(01)00359-1; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Ma GJ, 2005, J NEUROSCI, V25, P192, DOI 10.1523/JNEUROSCI.3814-04.2005; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Maxwell P, 2004, CANCER BIOL THER, V3, P29, DOI 10.4161/cbt.3.1.547; Mitsuda N, 2001, J BIOL CHEM, V276, P9688, DOI 10.1074/jbc.M006153200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Pastorcic M, 2004, EUR J BIOCHEM, V271, P4485, DOI 10.1111/j.1432-1033.2004.04453.x; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rogaev EI, 1997, GENOMICS, V40, P415, DOI 10.1006/geno.1996.4523; Saito S, 2005, BIOCHEM BIOPH RES CO, V330, P1068, DOI 10.1016/j.bbrc.2005.03.096; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seta K, 2002, ANN NY ACAD SCI, V971, P379, DOI 10.1111/j.1749-6632.2002.tb04500.x; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shirotani K, 2004, J BIOL CHEM, V279, P41340, DOI 10.1074/jbc.M405768200; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Sisodia SS, 1999, AM J HUM GENET, V65, P7, DOI 10.1086/302475; Smith MJ, 2004, MOL BRAIN RES, V127, P128, DOI 10.1016/j.molbrainres.2004.05.019; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Thinakaran G, 2004, PHARMACOL RES, V50, P411, DOI 10.1016/j.phrs.2003.12.026; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Wang H, 2004, J BIOL CHEM, V279, P40560, DOI 10.1074/jbc.M404345200; Wang RS, 2006, MOL CELL BIOL, V26, P1347, DOI 10.1128/MCB.26.4.1347-1354.2006; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Xu HX, 1996, P NATL ACAD SCI USA, V93, P4081, DOI 10.1073/pnas.93.9.4081; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang YW, 2005, J BIOL CHEM, V280, P17020, DOI 10.1074/jbc.M409467200	55	81	86	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1275	+		10.1096/fj.06-5839fje	http://dx.doi.org/10.1096/fj.06-5839fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16645044				2022-12-28	WOS:000240210300050
J	Chauhan, A; Hahn, S; Gartner, S; Pardo, CA; Netesan, SK; McArthur, J; Nath, A				Chauhan, Ashok; Hahn, Sven; Gartner, Suzanne; Pardo, Carlos A.; Netesan, Senthil Kumar; McArthur, Justin; Nath, Avindra			Molecular programming of endothelin-1 in HIV-infected brain: role of Tat in up-regulation of ET-1 and its inhibition by statins	FASEB JOURNAL			English	Article						HIV-neuropathogenesis; nuclear Tat; ET-1 transcriptional regulation; NF-kappa B; simvastatin	HUMAN-IMMUNODEFICIENCY-VIRUS; FACTOR-KAPPA-B; HUMAN FETAL ASTROCYTES; NITRIC-OXIDE SYNTHASE; GENE-EXPRESSION; CEREBROSPINAL-FLUID; PROTEIN-KINASE; GLIAL-CELLS; FACTOR-I; ACTIVATION	Human Immune Deficiency Virus-1 (HIV-1) infection can induce severe and debilitating neurological problems, including behavioral abnormalities, motor dysfunction, and dementia. HIV can persistently infect astrocytes, during which viral accessory proteins are produced that are unaffected by current antiretroviral therapy. The effect of these proteins on astrocyte function remains unknown. Astrocytes are the predominant cells within the brain; thus, disruption of astrocyte function could influence the neuropathogenesis of HIV infection. To explore further these effects, we constitutively expressed HIV-Tat protein in astrocytes. Since the nuclear presence of Tat protein leads to alteration of host gene expression, we further analyzed the effects of Tat on host gene transcripts. Endothelin-1 (ET-1) was a significantly elevated transcript as verified by reverse transcription-polymerase chain reaction (RT-PCR), and it was subsequently released extracellularly in Tat-expressing and HIV-infected astrocytes. ET-I expression was also prominent in reactive astrocytes and neurons in brain tissues from basal ganglia and frontal lobes of HfV encephalitic patients. HIV-Tat regulated ET-I at the transcriptional level through NF-kappa B (NF-kappa B)-responsive sites in the ET-1 promoter. Intriguingly, simvastatin (10 mu M) down-regulated HIV-Tat-induced ET-1 and also inhibited activation of NF-kappa B in astrocytes. Our findings suggest that ET-1 may be critical in mediating the neuropathogenesis of HIV dementia and that statins may have therapeutic potential in these patients.	Johns Hopkins Univ, Dept Neurol, Richard Johnson Div Neuroimmunol & Neurol Infect, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Chauhan, A (corresponding author), Johns Hopkins Univ, Dept Neurol, Richard Johnson Div Neuroimmunol & Neurol Infect, 509 Pathol,600 N Wolfe St, Baltimore, MD 21287 USA.	achauha1@jhmi.edu	Pardo, Carlos A./A-5192-2008	Pardo, Carlos A./0000-0002-4128-5335	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH070306, P01MH070056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039253, R01NS050064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K08DA016160] Funding Source: NIH RePORTER; NIDA NIH HHS [K08DA16160, K08 DA016160-04, K08 DA016160] Funding Source: Medline; NIMH NIH HHS [P01MH070306, P01MH070056, P01 MH070056, P01 MH070306] Funding Source: Medline; NINDS NIH HHS [R01 NS050064, R01NS039253, R01 NS039253, R01 NS050064-02, R01NS050064] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson CE, 2003, NEUROPATH APPL NEURO, V29, P378, DOI 10.1046/j.1365-2990.2003.00475.x; Braun-Moscovici Y, 2004, SEMIN ARTHRITIS RHEU, V34, P442, DOI 10.1016/j.semarthrit.2003.11.003; Bruce-Keller AJ, 2003, J NEUROSCI, V23, P8417; Chauhan A, 2003, J BIOL CHEM, V278, P13512, DOI 10.1074/jbc.M209381200; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CHOWDHURY M, 1992, J VIROL, V66, P7355, DOI 10.1128/JVI.66.12.7355-7361.1992; Conant K, 1996, J VIROL, V70, P1384, DOI 10.1128/JVI.70.3.1384-1389.1996; del Real G, 2004, J EXP MED, V200, P541, DOI 10.1084/jem.20040061; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; DEWHURST S, 1987, FEBS LETT, V213, P138, DOI 10.1016/0014-5793(87)81479-5; Didier N, 2002, NEUROREPORT, V13, P1179, DOI 10.1097/00001756-200207020-00022; Doi M, 2000, HYPERTENS RES, V23, P643, DOI 10.1291/hypres.23.643; EHRENREICH H, 1993, J IMMUNOL, V150, P4601; EPSTEIN L G, 1984, AIDS Research, V1, P447; FARRE AL, 1993, CIRCULATION, V88, P1166, DOI 10.1161/01.CIR.88.3.1166; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Gorry P, 1998, J NEUROVIROL, V4, P377, DOI 10.3109/13550289809114536; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hery C, 1997, NEUROPATH APPL NEURO, V23, P352, DOI 10.1111/j.1365-2990.1997.tb01307.x; Ho MCY, 2001, FASEB J, V15, P618, DOI 10.1096/fj.99-1022com; Hughes PM, 2003, J NEUROPATH EXP NEUR, V62, P1276, DOI 10.1093/jnen/62.12.1276; INOUE A, 1989, J BIOL CHEM, V264, P14954; Inoue I, 2002, BIOCHEM BIOPH RES CO, V290, P131, DOI 10.1006/bbrc.2001.6141; Ishizawa K, 2004, HYPERTENS RES, V27, P433, DOI 10.1291/hypres.27.433; Lin R, 2005, BIOL PHARM BULL, V28, P1630, DOI 10.1248/bpb.28.1630; Liu CA, 2004, ONCOGENE, V23, P8731, DOI 10.1038/sj.onc.1208106; Madonna R, 2005, J BIOL CHEM, V280, P13503, DOI 10.1074/jbc.M411859200; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; Matsuura S, 2002, GLIA, V37, P178, DOI 10.1002/glia.10020; Mattart M, 2003, BIORHEOLOGY, V40, P289; McArthur JC, 2004, ARCH NEUROL-CHICAGO, V61, P1687, DOI 10.1001/archneur.61.11.1687; Messam CA, 2000, J NEUROVIROL, V6, pS90; MINAMI M, 1995, PROG NEURO-PSYCHOPH, V19, P509, DOI 10.1016/0278-5846(95)00031-P; MOSQUEDAGARCIA R, 1993, CIRC RES, V72, P20, DOI 10.1161/01.RES.72.1.20; Mraiche F, 2005, BRIT J PHARMACOL, V144, P715, DOI 10.1038/sj.bjp.0706114; Naidoo V, 2004, J CHEM NEUROANAT, V27, P87, DOI 10.1016/j.jchemneu.2003.12.002; Narushima I, 2003, PHARMACOL TOXICOL, V92, P21, DOI 10.1034/j.1600-0773.2003.920104.x; NATH A, 1995, J NEUROPATH EXP NEUR, V54, P320, DOI 10.1097/00005072-199505000-00005; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; Nie XJ, 1996, REV NEUROSCIENCE, V7, P177; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Quehenberger P, 2000, DIABETES, V49, P1561, DOI 10.2337/diabetes.49.9.1561; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; RIECKMANN P, 1995, RES EXP MED, V195, P17, DOI 10.1007/BF02576770; Rolinski B, 1999, INFECTION, V27, P244, DOI 10.1007/s150100050020; Sabri F, 1999, VIROLOGY, V264, P370, DOI 10.1006/viro.1999.9998; Sacktor N, 2002, J NEUROVIROL, V8, P115, DOI 10.1080/13550280290101094; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; Sironi L, 2006, NEUROBIOL DIS, V22, P445, DOI 10.1016/j.nbd.2005.12.004; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; TENCE M, 1992, EUR J NEUROSCI, V4, P993, DOI 10.1111/j.1460-9568.1992.tb00125.x; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TORNATORE C, 1994, J VIROL, V68, P93, DOI 10.1128/JVI.68.1.93-102.1994; Tsang MCS, 2001, NEUROREPORT, V12, P2265, DOI 10.1097/00001756-200107200-00044; Wei CY, 2006, MOL PHARMACOL, V69, P960, DOI 10.1124/mol.105.017368; WESSELINGH SL, 1994, ADV NEUROIMMUNOL, V4, P199, DOI 10.1016/S0960-5428(06)80258-5; Woods M, 2003, MOL PHARMACOL, V64, P923, DOI 10.1124/mol.64.4.923; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; Yeung AC, 2002, CIRCULATION, V105, P2937, DOI 10.1161/01.CIR.0000023397.12047.03; Yoon SS, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-4; Zhang GuiChang, 1997, Recent Research Developments in Plant Physiology, V1, P75	61	35	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					777	789		10.1096/fj.06-7054com	http://dx.doi.org/10.1096/fj.06-7054com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197385	Green Accepted			2022-12-28	WOS:000244686400016
J	Harris, JE; Femandez-Vilaseca, M; Elkington, PTG; Horncastle, DE; Graeber, MB; Friedland, JS				Harris, James E.; Femandez-Vilaseca, Marc; Elkington, Paul T. G.; Horncastle, Donna E.; Graeber, Manuel B.; Friedland, Jon S.			IFN-gamma synergizes with IL-1 beta to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis	FASEB JOURNAL			English	Article						astrocyle; Mycobacterium; tuberculosis; monocyte; gelatinase B; AMP kinase; JAK-STAT	NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; CEREBROSPINAL-FLUID; MATRIX-METALLOPROTEINASE; GENE-EXPRESSION; MYCOBACTERIUM-TUBERCULOSIS; HUMAN CHONDROCYTES; EPITHELIAL-CELLS; GELATINASE-B; ONCOSTATIN-M	Matrix metalloproteinase-9 (MMP-9) activity is implicated in pathogenesis of central nervous system tuberculosis (CNS-TB). IFN gamma, a key cytokine in TB, usually inhibits MMP-9 secretion. Addition of IFN gamma to conditioned media from M. tb-infected monocytes (CoMTB) resulted in a 7-fold increase in MMP-9 activity detected by gelatin zymography (P < 0.01). In contrast, tissue inhibitor of metalloproteinase (TIMP)-1 and -2 secretion, measured by ELISA, was suppressed. Dexamethasone abolished the synergistic increase in MMP-9 activity. Interleukin (IL)-1 beta in CoMTB is a critical mediator of synergy with IFN gamma, and IL-beta alone synergizes with IFN gamma to increase MMP-9 secretion from 51 +/- 31 to 762 +/- 136 U. IL-1 beta activity is dependent on p38 mitogen-activated protein (MAPK) kinase, which was found to be phosphorylated in tissue specimens from patients with CNS-TB. Extracellular signal regulated kinase (Erk) and p38 MAPK activation did not affect IFN gamma signaling pathways. Inhibition of janus-activated kinase (JAK)-2 by 50 mu M AG540 decreased MMP-9 secretion to 124 +/- 11.1 from 651 +/- 229 U of activity (P < 0.01). However, signal transducer and activator of transcription (STAT)-3 but not STAT-1 phosphorylation was synergistically up-regulated by IFN gamma and CoMTB. In summary, synergy between Il-1 beta and STAT-3 dependent IFN gamma signaling is key in control of up-regulation of MMP-9 activity in CNS-TB and may be a significant mechanism of brain tissue destruction.	Univ London Imperial Coll Sci & Technol, Dept Infect Dis & Immun, London W12 0NN, England; Univ London Imperial Coll Sci & Technol, Dept Histopathol, London W12 0NN, England; Univ London Imperial Coll Sci & Technol, Dept Neuropathol, London, England	Imperial College London; Imperial College London; Imperial College London	Friedland, JS (corresponding author), Univ London Imperial Coll Sci & Technol, Dept Infect Dis & Immun, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	j.friedland@imperial.ac.uk	Graeber, Manuel/H-3224-2011	Elkington, Paul/0000-0003-0390-0613; Friedland, Jonathan S/0000-0001-7789-9649; Harris, James/0000-0002-8542-3189	Department of Health [DHCS/06/05/012] Funding Source: Medline; National Institute for Health Research [DHCS/06/05/012] Funding Source: researchfish	Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; AKALIN H, 1994, SCAND J INFECT DIS, V26, P667, DOI 10.3109/00365549409008634; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Asahina M, 2001, CLIN NEUROPATHOL, V20, P60; Bartholome EJ, 2001, J INTERF CYTOK RES, V21, P495, DOI 10.1089/10799900152434367; Bianchini F, 2006, ONCOL REP, V15, P709; Cagatay T, 2005, RESPIROLOGY, V10, P290, DOI 10.1111/j.1440-1843.2005.00711.x; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Catterall JB, 2001, ARTHRITIS RHEUM-US, V44, P2296, DOI 10.1002/1529-0131(200110)44:10<2296::AID-ART392>3.0.CO;2-9; Ceyhan M, 1997, TURKISH J PEDIATR, V39, P177; DASTUR DK, 1995, RADIOL CLIN N AM, V33, P733; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Dinney CPN, 1998, CANCER RES, V58, P808; DONALD PR, 1995, CLIN INFECT DIS, V21, P924, DOI 10.1093/clinids/21.4.924; Elkington PTG, 2006, THORAX, V61, P259, DOI 10.1136/thx.2005.051979; Elkington PTG, 2006, J IMMUNOL METHODS, V309, P115, DOI 10.1016/j.jim.2005.11.010; Elkington PTG, 2005, J IMMUNOL, V175, P5333, DOI 10.4049/jimmunol.175.8.5333; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; Fairbanks LD, 2004, NUCLEOS NUCLEOT NUCL, V23, P1185, DOI 10.1081/NCN-200027451; Fassbender K, 1999, NEUROLOGY, V53, P1104, DOI 10.1212/WNL.53.5.1104; Giannopoulou M, 2006, AM J PHYSIOL-RENAL, V290, pF1234, DOI 10.1152/ajprenal.00388.2005; GOTTSCHALL PE, 1995, J NEUROSCI RES, V42, P335, DOI 10.1002/jnr.490420307; Graeber MB, 1990, BRAIN PATHOL, V1, P2, DOI 10.1111/j.1750-3639.1990.tb00630.x; Helbecque N, 2003, NEUROSCI LETT, V350, P181, DOI 10.1016/S0304-3940(03)00905-4; Hickey WF, 2001, GLIA, V36, P118, DOI 10.1002/glia.1101; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Ivanoff A, 1999, CLIN EXP METASTAS, V17, P695, DOI 10.1023/A:1006749304315; Kaur N, 2003, J NEUROCHEM, V87, P437, DOI 10.1046/j.1471-4159.2003.02012.x; Koshy PJT, 2002, ARTHRITIS RHEUM, V46, P961, DOI 10.1002/art.10212; Kurisaki H, 2000, Rinsho Shinkeigaku, V40, P209; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Levin M, 1999, P ASSOC AM PHYSICIAN, V111, P308, DOI 10.1046/j.1525-1381.1999.99242.x; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Ma ZD, 2005, J LEUKOCYTE BIOL, V78, P515, DOI 10.1189/jlb.0205112; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Mastroianni CM, 1997, CLIN IMMUNOL IMMUNOP, V84, P171, DOI 10.1006/clin.1997.4367; Matsuura E, 2000, J NEUROL SCI, V173, P45, DOI 10.1016/S0022-510X(99)00303-2; New L, 2003, MOL BIOL CELL, V14, P2603, DOI 10.1091/mbc.E02-08-0538; Novak U, 2000, J CLIN NEUROSCI, V7, P280, DOI 10.1054/jocn.1999.0212; OHGA S, 1994, ARCH DIS CHILD, V70, P123, DOI 10.1136/adc.70.2.123; Pereira CB, 2004, MICROBES INFECT, V6, P25, DOI 10.1016/j.micinf.2003.10.007; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Price NM, 2001, J IMMUNOL, V166, P4223, DOI 10.4049/jimmunol.166.6.4223; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Rivera S, 2004, M S-MED SCI, V20, P55, DOI 10.1051/medsci/200420155; Rock RB, 2005, J INFECT DIS, V192, P2054, DOI 10.1086/498165; Roy SK, 2002, P NATL ACAD SCI USA, V99, P7945, DOI 10.1073/pnas.122075799; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; Seternes OM, 2002, MOL CELL BIOL, V22, P6931, DOI 10.1128/MCB.22.20.6931-6945.2002; Shin KY, 2000, CANCER LETT, V159, P127, DOI 10.1016/S0304-3835(00)00522-X; Simmons CP, 2005, J IMMUNOL, V175, P579, DOI 10.4049/jimmunol.175.1.579; Svendsen CN, 2002, NATURE, V417, P29, DOI 10.1038/417029a; Thwaites G, 2000, J NEUROL NEUROSUR PS, V68, P289, DOI 10.1136/jnnp.68.3.289; Thwaites GE, 2004, NEW ENGL J MED, V351, P1741, DOI 10.1056/NEJMoa040573; Thwaites GE, 2005, LANCET NEUROL, V4, P160, DOI 10.1016/S1474-4422(05)01013-6; Uhm JH, 1998, GLIA, V22, P53, DOI 10.1002/(SICI)1098-1136(199801)22:1<53::AID-GLIA5>3.0.CO;2-9; Wu CY, 2004, J NEUROCHEM, V90, P1477, DOI 10.1111/j.1471-4159.2004.02682.x; Yong V W, 1999, Expert Opin Investig Drugs, V8, P255, DOI 10.1517/13543784.8.3.255; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhou M, 2003, J BIOL CHEM, V278, P45406, DOI 10.1074/jbc.M309075200	63	37	41	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					356	365		10.1096/fj.06-6925com	http://dx.doi.org/10.1096/fj.06-6925com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158965				2022-12-28	WOS:000244686300009
J	Cuzzocrea, S; Ronchetti, S; Genovese, T; Mazzon, E; Agostini, M; Di Paola, R; Esposito, E; Muia, C; Nocentini, G; Riccardi, C				Cuzzocrea, Salvatore; Ronchetti, Simona; Genovese, Tiziana; Mazzon, Emanuela; Agostini, Massimiliano; Di Paola, Rosanna; Esposito, Emanuela; Muia, Carmelo; Nocentini, Giuseppe; Riccardi, Carlo			Genetic and pharmacological inhibition of GITR-GITRL interaction reduces chronic lung injury induced by bleomycin instillation	FASEB JOURNAL			English	Article						TNFR superfamily; mice; inflammation; fusion protein	IDIOPATHIC PULMONARY-FIBROSIS; NF-KAPPA-B; T-CELLS; RECEPTOR SUPERFAMILY; FACTOR FAMILY; ACTIVATION; LIGAND; IDENTIFICATION; EXPRESSION; PROTEINS	We have recently identified a gene named GITR ( glucocorticoid-induced TNF receptor related gene). GITR is expressed in different cells and tissues such as T lymphocytes from thymus and spleen and lymph nodes, and also in the lung. GITR ligand ( GITRL) is expressed in several cells including macrophages, B cells, denditric cells, and endothelial cells. In the present study, by comparing the responses in wild-type ( WT) mice ( GITR(+/+)) and GITR-deficient mice ( GITR(-/-)), we investigated the role played by GITR-GITRL interaction in the development of chronic lung injury caused by bleomycin instillation. When compared with bleomycin-treated GITR(+/+) mice, bleomycin-treated GITR(+/+) mice exhibited a reduced degree of i) lung infiltration with polymorphonuclear neutrophils ( MPO activity); ii) edema formation; iii) histological evidence of lung injury; iv) TNF-alpha and interleukin ( IL)-1 beta production; v) nitrotyrosine formation; and vi) NF-kappa B activation. The cotreatment of GITR(+/+) mice with Fc-GITR fusion protein ( 6.25 mu g/mouse) also significantly attenuated all of the above indicators of lung damage and inflammation. Our results clearly demonstrate that GITR-GITRL interaction plays an important role in the chronic lung injury induced by bleomycin in the mice.	Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Policlin Univ, I-98100 Messina, Italy; IRCCS, Ctr Neurol Bonino Pulejo, Messina, Italy; Univ Perugia, Dept Clin & Expt Med & Pharmacol, Sect Pharmacol Tossicol & Chemioterapy, I-06100 Perugia, Italy; Polo Sci & Didatt, Terni, Italy; Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy	AOU Policlinico Gaetano Martino; University of Messina; IRCCS Bonino Pulejo; University of Perugia; University of Naples Federico II	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Policlin Univ, Via C Valeria, I-98100 Messina, Italy.	salvator@unime.it	di paola, rosanna/U-4356-2019; Nocentini, Giuseppe/B-9412-2013; Mazzon, Emanuela/AAL-4334-2020; Nocentini, Giuseppe/GZB-0146-2022; Riccardi, Carlo/N-4610-2014; Agostini, Massimiliano/AAE-7971-2019; Ronchetti, Simona/L-2325-2013; Agostini, Massimiliano/G-9579-2014	di paola, rosanna/0000-0001-6725-8581; Nocentini, Giuseppe/0000-0002-5209-0488; Riccardi, Carlo/0000-0001-9257-3997; Agostini, Massimiliano/0000-0003-3124-2072; Ronchetti, Simona/0000-0002-5639-4243; Agostini, Massimiliano/0000-0003-3124-2072; mazzon, emanuela/0000-0002-5073-717X; GENOVESE, Tiziana/0000-0002-3335-7327; Esposito, Emanuela/0000-0002-2663-6387				Agostini M, 2005, INFECT IMMUN, V73, P7502, DOI 10.1128/IAI.73.11.7502-7508.2005; *AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; ASHCROFT T, 1988, J CLIN PATHOL, V41, P467, DOI 10.1136/jcp.41.4.467; Atarashi K, 2005, J IMMUNOL, V174, P1424, DOI 10.4049/jimmunol.174.3.1424; Bowler RP, 2002, AM J PHYSIOL-LUNG C, V282, pL719, DOI 10.1152/ajplung.00058.2001; CHANDLER DB, 1983, AM J PATHOL, V112, P170; Cuzzocrea S, 2004, J LEUKOCYTE BIOL, V76, P933, DOI 10.1189/jlb.0204110; Cuzzocrea S, 2005, FASEB J, V19, P1253, DOI 10.1096/fj.04-3556com; CUZZOCREA S, 2006, IN PRESS J IMMUNOL; Di Paola R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-66; Douglas WW, 1997, MAYO CLIN PROC, V72, P201, DOI 10.4065/72.3.201; Esparza EM, 2006, FRONT BIOSCI-LANDMRK, V11, P1448, DOI 10.2741/1895; GOLDSTEIN RH, 1995, CHEST, V108, P848, DOI 10.1378/chest.108.3.848; GREEN FH, 2002, CHEST, V122; Gurney AL, 1999, CURR BIOL, V9, P215, DOI 10.1016/S0960-9822(99)80093-1; JOHNSON MA, 1989, THORAX, V44, P280, DOI 10.1136/thx.44.4.280; Kakkar AK, 2004, CURR OPIN PHARMACOL, V4, P154, DOI 10.1016/j.coph.2004.01.003; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Kim JD, 2003, GENES IMMUN, V4, P564, DOI 10.1038/sj.gene.6364026; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; LAZENBY AJ, 1990, AM REV RESPIR DIS, V142, P206, DOI 10.1164/ajrccm/142.1.206; Lee HS, 2003, J CELL BIOCHEM, V88, P1048, DOI 10.1002/jcb.10456; Mapel DW, 1996, CHEST, V110, P1058, DOI 10.1378/chest.110.4.1058; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Nocentini G, 2005, EUR J IMMUNOL, V35, P1016, DOI 10.1002/eji.200425818; Nomura Y, 2001, LIFE SCI, V68, P1695, DOI 10.1016/S0024-3205(01)00967-5; Oury TD, 2001, AM J RESP CELL MOL, V25, P164, DOI 10.1165/ajrcmb.25.2.4235; Pan LH, 1996, PATHOL INT, V46, P91, DOI 10.1111/j.1440-1827.1996.tb03584.x; Pardo A, 2002, FRONT BIOSCI-LANDMRK, V7, pD1743, DOI 10.2741/pardo; Prasse A, 2006, AM J RESP CRIT CARE, V173, P781, DOI 10.1164/rccm.200509-1518OC; RAGHU G, 1991, AM REV RESPIR DIS, V144, P291, DOI 10.1164/ajrccm/144.2.291; Ronchetti S, 2002, BLOOD, V100, P350, DOI 10.1182/blood-2001-12-0276; Ronchetti S, 2004, EUR J IMMUNOL, V34, P613, DOI 10.1002/eji.200324804; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Shin HH, 2002, FEBS LETT, V514, P275, DOI 10.1016/S0014-5793(02)02379-7; Shin HH, 2005, BONE, V36, P832, DOI 10.1016/j.bone.2005.02.014; Suvas S, 2005, J VIROL, V79, P11935, DOI 10.1128/JVI.79.18.11935-11942.2005; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Verma IM, 2004, ANN RHEUM DIS, V63, P57, DOI 10.1136/ard.2004.028266; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; WALSH J, 1993, AM J RESP CELL MOL, V9, P637, DOI 10.1165/ajrcmb/9.6.637; WHITE DA, 1987, CANCER, V59, P1582, DOI 10.1002/1097-0142(19870501)59:9<1582::AID-CNCR2820590909>3.0.CO;2-#; Wu KK, 2005, PROSTAG LEUKOTR ESS, V72, P89, DOI 10.1016/j.plefa.2004.11.001; Yu KY, 2003, BIOCHEM BIOPH RES CO, V310, P433, DOI 10.1016/j.bbrc.2003.09.024	47	37	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					117	129		10.1096/fj.06-6611com	http://dx.doi.org/10.1096/fj.06-6611com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135359				2022-12-28	WOS:000243130200014
J	Lecuona, E; Dada, LA; Sun, HY; Butti, ML; Zhou, GF; Chew, TL; Sznajder, JI				Lecuona, Emilia; Dada, Laura A.; Sun, Haiying; Butti, Maria L.; Zhou, Guofei; Chew, Teng-Leong; Sznajder, Jacob I.			Na,K-ATPase alpha 1-subunit dephosphorylation by protein phosphatase 2A is necessary for its recruitment to the plasma membrane	FASEB JOURNAL			English	Article						alveolar epithelial cells; G-protein-coupled receptor agonists; intracellular trafficking	NA+-K+-ATPASE; LUNG EDEMA CLEARANCE; KINASE-C; NA+,K+-ATPASE ACTIVITY; ALPHA-SUBUNIT; INDUCED ENDOCYTOSIS; LIQUID CLEARANCE; DOPAMINE; PHOSPHORYLATION; MECHANISMS	In alveolar epithelial cells, G-protein coupled-receptors agonists (GPCR) induce the recruitment of the Na, K-ATPase to the plasma membrane. Here we report that for the recruitment of the Na, K-ATPase to occur, dephosphorylation of its alpha 1-subunit at serine 18 is necessary, as demonstrated by in vitro phosphorylation, mutation of the serine 18 to alanine, and use of a specific phospho-antibody. Several approaches strongly suggest dephosphorylation to be mediated by protein phosphatase 2A (PP2A): 1) Na, K-ATPase dephosphorylation and recruitment were prevented by okadaic acid (OA); 2) the Na, K-ATPase alpha 1-subunit is an in vitro substrate for PP2A; and 3) glutathione S-transferase (GST)-fusion proteins binding assays demonstrate a direct interaction between the catalytic subunit of PP2A and the first 90 amino acids of the Na, K-ATPase alpha 1-subunit. Finally, GPCR agonists induced a rapid translocation of PP2A from the cytosol to the membrane fraction, which corresponded with increased coimmunoprecipitation and colocalization of PP2A and the Na, K-ATPase. Accordingly, we provide evidence that GPCR agonists promote PP2A translocation to the membrane fraction, leading to the dephosphorylation of the Na, K-ATPase alpha 1-subunit at the serine 18 residue and its recruitment to the cell plasma membrane, which is of biological and physiological importance.	Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Cell Imaging Facil, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University	Lecuona, E (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Dept Med, 240 E Huron,McGaw M410, Chicago, IL 60611 USA.	e-lecuona@northwestern.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065161, R37HL048129, R01HL048129] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48129, HL65161] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adir Y, 2003, ISR MED ASSOC J, V5, P47; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; Barnard ML, 1997, AM J RESP CRIT CARE, V156, P709, DOI 10.1164/ajrccm.156.3.9610013; Barnard ML, 1999, AM J RESP CRIT CARE, V160, P982, DOI 10.1164/ajrccm.160.3.9812003; Bertorello AM, 2005, AM J RESP CELL MOL, V33, P432, DOI 10.1165/rcmb.2005-0297TR; Bertorello AM, 2003, MOL BIOL CELL, V14, P1149, DOI 10.1091/mbc.E02-06-0367; Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; Bertuccio CA, 2003, PFLUG ARCH EUR J PHY, V447, P87, DOI 10.1007/s00424-003-1144-6; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; BlotChabaud M, 1996, J MEMBRANE BIOL, V153, P233, DOI 10.1007/s002329900126; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brismar H, 2000, CLIN EXP HYPERTENS, V22, P303, DOI 10.1081/CEH-100100079; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; Chibalin AV, 2001, ENDOCRINOLOGY, V142, P3474, DOI 10.1210/en.142.8.3474; Chibalin AV, 1997, AM J PHYSIOL-CELL PH, V273, pC1458, DOI 10.1152/ajpcell.1997.273.5.C1458; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; Clausen T, 2003, PHYSIOL REV, V83, P1269, DOI 10.1152/physrev.00011.2003; Correa-Meyer E, 2002, AM J PHYSIOL-LUNG C, V282, pL883, DOI 10.1152/ajplung.00203.2001; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Djelidi S, 2001, J AM SOC NEPHROL, V12, P1805, DOI 10.1681/ASN.V1291805; Dunbar LA, 2001, J BIOL CHEM, V276, P29617, DOI 10.1074/jbc.R100023200; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; Feschenko MS, 1997, J BIOL CHEM, V272, P17726, DOI 10.1074/jbc.272.28.17726; Groshaus HE, 2004, CRIT CARE, V8, P234, DOI 10.1186/cc2875; Holst J, 2002, MOL BIOL CELL, V13, P1083, DOI 10.1091/mbc.01-12-0587; Ibarra FR, 2002, ACTA PHYSIOL SCAND, V175, P165, DOI 10.1046/j.1365-201X.2002.00984.x; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lecuona E, 2000, FEBS LETT, V481, P217, DOI 10.1016/S0014-5793(00)02009-3; Lecuona E, 2003, MOL BIOL CELL, V14, P3888, DOI 10.1091/mbc.E02-12-0781; Lu Q, 2003, J BIOL CHEM, V278, P4639, DOI 10.1074/jbc.M210949200; Ludowyke RI, 2000, J BIOL CHEM, V275, P6144, DOI 10.1074/jbc.275.9.6144; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mallick BN, 2000, J NEUROCHEM, V74, P1574, DOI 10.1046/j.1471-4159.2000.0741574.x; Marmorstein LY, 2002, J BIOL CHEM, V277, P30591, DOI 10.1074/jbc.M204269200; McAuley DF, 2004, CRIT CARE MED, V32, P1470, DOI 10.1097/01.CCM.0000129489.34416.0E; Morgan A, 2004, CURR BIOL, V14, pR968, DOI 10.1016/j.cub.2004.10.045; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Pagel P, 2003, ANN NY ACAD SCI, V986, P360, DOI 10.1111/j.1749-6632.2003.tb07215.x; Pedemonte CH, 2005, SEMIN NEPHROL, V25, P322, DOI 10.1016/j.semnephrol.2005.03.007; Pedemonte CH, 2001, J BIOENERG BIOMEMBR, V33, P439, DOI 10.1023/A:1010675708820; Ragolia L, 1997, J BIOL CHEM, V272, P23653, DOI 10.1074/jbc.272.38.23653; Ridge KM, 2002, MOL BIOL CELL, V13, P1381, DOI 10.1091/mbc.01-07-0323; Ridge KM, 1997, AM J PHYSIOL-LUNG C, V273, pL246, DOI 10.1152/ajplung.1997.273.1.L246; Saldias FJ, 1999, AM J RESP CRIT CARE, V159, P626, DOI 10.1164/ajrccm.159.2.9805016; Saldias FJ, 2002, AM J PHYSIOL-LUNG C, V283, pL136, DOI 10.1152/ajplung.00089.2000; Schapiro FB, 2004, MOL BIOL CELL, V15, P2884, DOI 10.1091/mbc.E03-09-0653; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Sweeney G, 2001, AM J PHYSIOL-CELL PH, V281, pC1797, DOI 10.1152/ajpcell.2001.281.6.C1797; Sznajder JI, 2002, J APPL PHYSIOL, V93, P1860, DOI 10.1152/japplphysiol.00022.2002; Teixeira VL, 2003, ANN NY ACAD SCI, V986, P587, DOI 10.1111/j.1749-6632.2003.tb07257.x; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Vastiau A, 2005, FEBS LETT, V579, P3392, DOI 10.1016/j.febslet.2005.04.079; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	56	39	39	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2618	+		10.1096/fj.06-6503fje	http://dx.doi.org/10.1096/fj.06-6503fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065225				2022-12-28	WOS:000242490700043
J	Levites, Y; Smithson, LA; Price, RW; Dakin, RS; Yuan, B; Sierks, MR; Kim, J; McGowan, E; Reed, DK; Rosenberry, TL; Das, P; Golde, TE				Levites, Yona; Smithson, Lisa A.; Price, Robert W.; Dakin, Rachel S.; Yuan, Bin; Sierks, Michael R.; Kim, Jungsu; McGowan, Eileen; Reed, Dana Kim; Rosenberry, Terrone L.; Das, Pritam; Golde, Todd E.			Insights into the mechanisms of action of anti-A beta antibodies in Alzheimer's disease mouse models	FASEB JOURNAL			English	Article						immune complex; amyloid deposits	CENTRAL-NERVOUS-SYSTEM; APP TRANSGENIC MICE; BLOOD-BRAIN-BARRIER; AMYLOID DEPOSITION; IN-VIVO; A-BETA-42 IMMUNIZATION; MICROGLIAL ACTIVATION; MEMORY DEFICITS; HALF-LIFE; PEPTIDE	A number of hypotheses regarding how anti-A beta antibodies alter amyloid deposition have been postulated, yet there is no consensus as to how A beta immunotherapy works. We have examined the in vivo binding properties, pharmacokinetics, brain penetrance, and alterations in A beta levels after a single peripheral dose of anti-A beta antibodies to both wild-type (WT) and young non-A beta depositing APP and BRI-A beta 42 mice. The rapid rise in plasma A beta observed after antibody (Ab) administration is attributable to prolongation of the half-life of A beta bound to the Ab. Only a miniscule fraction of Ab enters the brain, and despite dramatic increases in plasma A beta, we find no evidence that total brain A beta levels are significantly altered. Surprisingly, cerebral spinal fluid A beta levels transiently rise, and when Ab:A beta complex is directly injected into the lateral ventricles of mice, it is rapidly cleared from the brain into the plasma where it remains stable. When viewed in context of daily turnover of A beta, these data provide a framework to evaluate proposed mechanisms of A beta attenuation mediated by peripheral administration of an anti-A beta monoclonal antibody (mAb) effective in passive immunization paradigm. Such quantitative data suggest that the mAbs are either indirectly enhancing clearance of A beta or targeting a low abundance aggregation intermediate.	Mayo Clin Jacksonville, Dept Neurosci, Coll Med, Jacksonville, FL 32224 USA; Mayo Clin Jacksonville, Dept Pharmacol, Coll Med, Jacksonville, FL 32224 USA; Arizona State Univ, Dept Chem & Mat Engn, Tempe, AZ USA	Mayo Clinic; Mayo Clinic; Arizona State University; Arizona State University-Tempe	Golde, TE (corresponding author), Mayo Clin Jacksonville, Dept Neurosci, Coll Med, Birdsall 210,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	tgolde@mayo.edu	Kim, Jungsu/F-2457-2012; Kim, Jungsu/A-1372-2009	Kim, Jungsu/0000-0002-6931-8581; Dakin, Rachel/0000-0002-3697-8516	NIA NIH HHS [AG022595-01, AG18454] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018454, R01AG022595] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bacskai BJ, 2002, J NEUROSCI, V22, P7873; Banks WA, 2005, PEPTIDES, V26, P287, DOI 10.1016/j.peptides.2004.09.016; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Randall JB, 2006, NAT MED, V12, P856, DOI 10.1038/nm1438; Biere AL, 1996, J BIOL CHEM, V271, P32916, DOI 10.1074/jbc.271.51.32916; Brendza RP, 2005, J CLIN INVEST, V115, P428, DOI 10.1172/JCI200523269; Bussiere T, 2004, AM J PATHOL, V165, P987, DOI 10.1016/S0002-9440(10)63360-3; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chauhan VPS, 1999, BIOCHEM BIOPH RES CO, V258, P241, DOI 10.1006/bbrc.1999.0623; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Das P, 2003, J NEUROSCI, V23, P8532; Das P, 2002, NEUROBIOL AGING, V23, P671, DOI 10.1016/S0197-4580(02)00031-3; Das P, 2001, NEUROBIOL AGING, V22, P721, DOI 10.1016/S0197-4580(01)00245-7; Deane R, 2005, J NEUROSCI, V25, P11495, DOI 10.1523/JNEUROSCI.3697-05.2005; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Dodel RC, 2004, J NEUROL NEUROSUR PS, V75, P1472, DOI 10.1136/jnnp.2003.033399; DOVEY H, 2000, J NEUROCHEM, V76, P1; Fox NC, 2005, NEUROLOGY, V64, P1563, DOI 10.1212/01.WNL.0000159743.08996.99; Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102; Ghiso J, 2004, J BIOL CHEM, V279, P45897, DOI 10.1074/jbc.M407668200; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Golde TE, 2003, J CLIN INVEST, V111, P11, DOI 10.1172/JCI200317527; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hock C, 2002, NAT MED, V8, P1270, DOI 10.1038/nm783; Hone E, 2003, J ALZHEIMERS DIS, V5, P1, DOI 10.3233/JAD-2003-5101; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kuo YM, 2000, BIOCHEM BIOPH RES CO, V268, P750, DOI 10.1006/bbrc.2000.2222; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lanz TA, 2005, J PHARMACOL EXP THER, V312, P399, DOI 10.1124/jpet.104.073965; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Lee M, 2005, ANN NEUROL, V58, P430, DOI 10.1002/ana.20592; Levites Y, 2006, J CLIN INVEST, V116, P193, DOI 10.1172/JCI25410; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; Masliah E, 2005, NEUROLOGY, V64, P129, DOI 10.1212/01.WNL.0000148590.39911.DF; Matsuoka Y, 2003, J NEUROSCI, V23, P29; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; O'Toole M, 2005, ARCH NEUROL-CHICAGO, V62, P1531, DOI 10.1001/archneur.62.10.1531; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Paris D, 2000, ANN NY ACAD SCI, V903, P446, DOI 10.1111/j.1749-6632.2000.tb06397.x; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Siemers E, 2005, CLIN NEUROPHARMACOL, V28, P126, DOI 10.1097/01.wnf.0000167360.27670.29; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Su GC, 1999, BRAIN RES, V818, P105, DOI 10.1016/S0006-8993(98)01143-3; Tamura Y, 2005, NEUROBIOL DIS, V20, P541, DOI 10.1016/j.nbd.2005.04.007; Taylor BM, 2003, J PROTEIN CHEM, V22, P31, DOI 10.1023/A:1023063626770; VIEIRA P, 1986, EUR J IMMUNOL, V16, P871, DOI 10.1002/eji.1830160727; VOGELWEID CM, 1988, LAB ANIM SCI, V38, P91; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Wilcock DM, 2004, J NEUROSCI, V24, P6144, DOI 10.1523/JNEUROSCI.1090-04.2004; Wilcock DM, 2003, J NEUROSCI, V23, P3745, DOI 10.1523/jneurosci.23-09-03745.2003; Wilcock DM, 2001, DNA CELL BIOL, V20, P731, DOI 10.1089/10445490152717596	60	98	105	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2576	+		10.1096/fj.06-6463fje	http://dx.doi.org/10.1096/fj.06-6463fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17068112				2022-12-28	WOS:000242490700029
J	Frantz, S; Hu, K; Bayer, B; Gerondakis, S; Strotmann, J; Adamek, A; Ertl, G; Bauersachs, J				Frantz, Stefan; Hu, Kai; Bayer, Barbara; Gerondakis, Steve; Strotmann, Joerg; Adamek, Anna; Ertl, Georg; Bauersachs, Johann			Absence of NF-kappa B subunit p50 improves heart failure after myocardial infarction	FASEB JOURNAL			English	Article						inflammation; NF kappa B; interleukins; collagen	LEFT-VENTRICULAR ENLARGEMENT; CARDIAC MYOCYTES; TARGETED DELETION; ANGIOTENSIN-II; IN-VIVO; MICE; ACTIVATION; CARDIOMYOPATHY; INFLAMMATION; HYPERTROPHY	Background: NF kappa B (NF-kappa B) is a ubiquitous transcription factor activated by various stimuli implicated in heart failure progression including reactive oxygen species (ROS), hypoxia, and inflammatory cytokines. Although NF-kappa B is involved in ischemic preconditioning, unstable angina pectoris, and atherogenesis, its role in heart failure has not been determined. Therefore, we investigated left ventricular remodeling in mice with a targeted deletion of the NF-kappa B subunit p50/ NF-kappa B1 after myocardial infarction. Methods and results: p50 knockout (KO) and wild-type (WT) animals underwent coronary artery ligation. Transthoracic echocardiography was performed at days 0, 21, and 56 at midpapillary levels. Early mortality was significantly lower in KO than in WT animals. Moreover, p50 KOs exhibited significantly reduced ventricular dilatation over 8 wk compared to WT controls (end-systolic diameters by transthoracic echocardiography, WT vs. KO, 0.55 +/- 0.04 vs. 0.34 +/- 0.03 cm) and preserved left ventricular contractility. Collagen content and matrixmetalloproteinase (MMP) -9 expression were significantly lower in KO mice after myocardial infarction and may account for improved left ventricular remodeling. Conclusions: Absence of the NF-kappa B subunit p50 improves early survival and reduces left ventricular dilatation after myocardial infarction. NF-kappa B might therefore be an attractive target to treat heart failure.	Univ Wurzburg, Med Klin & Poliklin 1, Herzkreislauf Zentrum, D-97080 Wurzburg, Germany; Walter & Eliza Hall Inst Med Res, Parcville, Vic, Australia	University of Wurzburg; Walter & Eliza Hall Institute	Frantz, S (corresponding author), Univ Wurzburg, Med Klin & Poliklin 1, Herzkreislauf Zentrum, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	frantz_s@medizin.uni-wuerzburg.de	Frantz, Stefan/G-1723-2012					Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BOURCIER T, 1999, METHODS MOL MED VASC, P159; Buttner C, 2004, J CELL PHYSIOL, V198, P248, DOI 10.1002/jcp.10395; Chatterjee PK, 2004, CARDIOVASC RES, V61, P630, DOI 10.1016/j.cardiores.2003.10.024; Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768; Frantz S, 2004, BRIT J PHARMACOL, V141, P9, DOI 10.1038/sj.bjp.0705585; Frantz S, 2003, J MOL CELL CARDIOL, V35, P685, DOI 10.1016/S0022-2828(03)00113-5; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; Frantz S, 2001, J BIOL CHEM, V276, P5197, DOI 10.1074/jbc.M009160200; Freund C, 2005, CIRCULATION, V111, P2319, DOI 10.1161/01.CIR.0000164237.58200.5A; Kawamura N, 2005, CARDIOVASC RES, V66, P520, DOI 10.1016/j.cardiores.2005.02.007; Kawano S, 2005, CARDIOVASC RES, V67, P689, DOI 10.1016/j.cardiores.2005.04.030; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Misra A, 2003, CIRCULATION, V108, P3075, DOI 10.1161/01.CIR.0000108929.93074.0B; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Nahrendorf M, 2006, CIRCULATION, V113, P1196, DOI 10.1161/CIRCULATIONAHA.105.602094; Norman DAM, 1998, CARDIOVASC RES, V39, P434, DOI 10.1016/S0008-6363(98)00118-7; Nwogu JI, 2001, CIRCULATION, V104, P2216, DOI 10.1161/hc4301.097193; Rohde LE, 1999, CIRCULATION, V99, P3063, DOI 10.1161/01.CIR.99.23.3063; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Vanhoutte D, 2006, CARDIOVASC RES, V69, P604, DOI 10.1016/j.cardiores.2005.10.002; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664	23	111	124	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1918	+		10.1096/fj.05-5133fje	http://dx.doi.org/10.1096/fj.05-5133fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16837548				2022-12-28	WOS:000240267000030
J	Hu, J; Verkman, AS				Hu, Jie; Verkman, A. S.			Increased migration and metastatic potential of tumor cells expressing aquaporin water channels	FASEB JOURNAL			English	Article						aquaporin; water channel; tumor metastasis; cell migration; cancer	PERMEABILITY; MICE; REDISTRIBUTION; ANGIOGENESIS; LOCALIZATION; DIVERSITY; NEOPLASMS; OVARY	Aquaporin (AQP) water channels are expressed in high-grade tumor cells of different tissue origins. Based on the involvement of AQPs in angiogenesis and cell migration, we tested whether AQP expression in tumor cells might enhance their migration and metastatic potential. Transfection of B16F10 and 4T1 tumor cells with AQP1 did not affect their appearance, size, growth, or substrate adherence but increased their plasma membrane osmotic water permeability by 5- to 10-fold. In vitro analysis of cell migration by transwell assay, wound healing and video microscopy showed a 2- to 3-fold accelerated migration of the AQP1-expressing tumor cells compared to control cells. In mice, AQP1 expression increased tumor cell extravasation by > 1.5-fold as quantified by counting tumor cells in lung at 6 h after tail vein injection of a mixture of fluorescently tagged AQP1-expressing and control tumor cells. AQP1 expression also increased by 3-fold the number of lung metastases 14 days after tail vein injection of tumor cells, with alveolar wall infiltration seen with AQP1-expressing tumor cells. Our results provide evidence for AQP-facilitated tumor cell migration and spread, suggesting a novel function for AQP expression in high-grade tumors. AQP inhibition may thus reduce the metastatic potential of some tumors.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med, 1246 Hlth Sci E, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, P30DK072517, R01DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK72517, DK35124] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Boon K, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-39; Endo M, 1999, MICROVASC RES, V58, P89, DOI 10.1006/mvre.1999.2158; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Hara M, 2003, P NATL ACAD SCI USA, V100, P7360, DOI 10.1073/pnas.1230416100; Hara-Chikuma M, 2005, J BIOL CHEM, V280, P15493, DOI 10.1074/jbc.C500028200; Hara-Chikuma M, 2006, J AM SOC NEPHROL, V17, P39, DOI 10.1681/ASN.2005080846; Kafe H, 2004, VIRCHOWS ARCH, V445, P637, DOI 10.1007/s00428-004-1124-z; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MA TH, 1993, J BIOL CHEM, V268, P22756; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Mazal PR, 2005, MODERN PATHOL, V18, P535, DOI 10.1038/modpathol.3800320; Mobasheri A, 2005, INT J ONCOL, V26, P1149; Moon C, 2003, ONCOGENE, V22, P6699, DOI 10.1038/sj.onc.1206762; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Oshio K, 2005, NEUROSURGERY, V56, P375, DOI 10.1227/01.NEU.0000148904.57841.6B; Oshio K, 2003, ACTA NEUROCHIR SUPPL, V86, P499; Padmawar P, 2005, NAT METHODS, V2, P825, DOI 10.1038/NMETH801; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Schwab A, 2001, AM J PHYSIOL-RENAL, V280, pF739, DOI 10.1152/ajprenal.2001.280.5.F739; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Thiagarajah JR, 2002, J BIOL CHEM, V277, P19139, DOI 10.1074/jbc.M202071200; Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519; Warth A, 2005, ACTA NEUROPATHOL, V109, P418, DOI 10.1007/s00401-005-0984-x; Warth A, 2004, ACTA NEUROPATHOL, V107, P311, DOI 10.1007/s00401-003-0812-0; Yang JH, 2006, GYNECOL ONCOL, V100, P294, DOI 10.1016/j.ygyno.2005.08.054	31	251	299	0	38	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1892	+		10.1096/fj.06-5930fje	http://dx.doi.org/10.1096/fj.06-5930fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16818469				2022-12-28	WOS:000240267000021
J	Lin, HY; Lansing, L; Merillon, JM; Davis, FB; Tang, HY; Shih, A; Vitrac, X; Krisa, S; Keating, T; Cao, HJ; Bergh, J; Quackenbush, S; Davis, PJ				Lin, Hung-Yun; Lansing, Lawrence; Merillon, Jean-Michel; Davis, Faith B.; Tang, Heng-Yuan; Shih, Ai; Vitrac, Xavier; Krisa, Stephanie; Keating, Travis; Cao, H. James; Bergh, Joel; Quackenbush, Steven; Davis, Paul J.			Integrin alpha V beta 3 contains a receptor site for resveratrol	FASEB JOURNAL			English	Article						resveratrol; integrin alpha V beta 3; apoptosis; breast cancer cell; extracellular-regulated kinases 1 and 2	ACTIVATED PROTEIN-KINASE; THYROID-HORMONE; GROWTH-FACTOR; APOPTOSIS; CANCER; P53; PHOSPHORYLATION; CELLS	Resveratrol is a naturally occurring polyphenol, which causes apoptosis in cultured cancer cells. We describe a cell surface resveratrol receptor on the extracellular domain of hetero-dimeric alpha V beta 3 integrin in MCF-7 human breast cancer cells. This receptor is linked to induction by resveratrol of extracellular-regulated kinases 1 and 2 (ERK1/2)- and serine-15-p53-dependent phosphorylation leading to apoptosis. The integrin receptor is near the Arg-Gly-Asp (RGD) recognition site on the integrin; an integrin-binding RGD peptide inhibits induction by resveratrol of ERK1/2 and p53-dependent apoptosis. Antibody (Ab) to integrin alpha V beta 3, but not to alpha V beta 5, inhibits activation by resveratrol of ERK1/2 and p53 and consequent apoptosis in estrogen receptor-alpha (ER alpha) positive MCF-7, and ER alpha-negative MDA-MB231 cells. Resveratrol is displaced from the purified integrin by an RGD, but not RGE, peptide, and by alpha V beta 3 integrin-specific Ab. Resveratrol action is blocked by siRNA beta 3, but not by siRNA alpha V. [C-14]-Resveratrol binds to commercially purified integrin alpha V beta 3 and to alpha V beta 3 prepared from MCF-7 cells; binding of [C-14]- resveratrol to the beta 3, but not to the alpha V monomer, is displaced by unlabeled resveratrol. In conclusion, binding of resveratrol to integrin alpha V beta 3, principally to the beta 3 monomer, is essential for transduction of the stilbene signal into p53-dependent apoptosis of breast cancer cells.	Ordway Res Inst, Albany, NY 12208 USA; Stratton Vet Affairs Med Ctr, Albany, NY 12208 USA; Univ Bordeaux 1, Lab Mycol & Biotechnol Vegetale, F-33405 Talence, France; New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA	Ordway Research Institute; UDICE-French Research Universities; Universite de Bordeaux; State University of New York (SUNY) System; Wadsworth Center	Davis, PJ (corresponding author), Ordway Res Inst, 150 New Scotland Ave, Albany, NY 12208 USA.	fdavis@ordwayresearch.org						Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; Belvisi L, 2005, MOL CANCER THER, V4, P1670, DOI 10.1158/1535-7163.MCT-05-0120; Bergh JJ, 2005, ENDOCRINOLOGY, V146, P2864, DOI 10.1210/en.2005-0102; Bhat KPL, 2001, CANCER RES, V61, P6137; Castro MR, 1999, J CLIN ENDOCR METAB, V84, P2957, DOI 10.1210/jc.84.8.2957; Gao ZB, 2005, BRAIN RES, V1056, P68, DOI 10.1016/j.brainres.2005.07.013; Hattangadi DK, 2004, BIOCHEM PHARMACOL, V68, P1699, DOI 10.1016/j.bcp.2004.06.033; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Kanamori M, 2004, CANCER RES, V64, P2751, DOI 10.1158/0008-5472.CAN-03-3354; Li YB, 2006, PHARMACOL RES, V53, P6, DOI 10.1016/j.phrs.2005.08.002; Lin HY, 2002, J UROLOGY, V168, P748, DOI 10.1016/S0022-5347(05)64739-8; Lin HY, 1999, AM J PHYSIOL-CELL PH, V276, pC1014, DOI 10.1152/ajpcell.1999.276.5.C1014; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Reynolds AR, 2004, CANCER RES, V64, P8643, DOI 10.1158/0008-5472.CAN-04-2760; She QB, 2002, MOL CARCINOGEN, V33, P244, DOI 10.1002/mc.10041; Shih A, 2004, MOL CANCER THER, V3, P1355; Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017; Tang HY, 2004, ENDOCRINOLOGY, V145, P3265, DOI 10.1210/en.2004-0308; Tsan MF, 2000, BRIT J HAEMATOL, V109, P405, DOI 10.1046/j.1365-2141.2000.01980.x; Vitrac X, 2002, J BIOTECHNOL, V95, P49, DOI 10.1016/S0168-1656(01)00441-2; Zhang S, 2004, BRIT J CANCER, V91, P178, DOI 10.1038/sj.bjc.6601902	21	114	128	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1742	+		10.1096/fj.06-5743fje	http://dx.doi.org/10.1096/fj.06-5743fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790523				2022-12-28	WOS:000240266600034
J	Yu, JZ; Rasenick, MM				Yu, Jiang-Zhou; Rasenick, Mark M.			Tau associates with actin in differentiating PC12 cells	FASEB JOURNAL			English	Article						microtubule-associated protein; cytoskeleton; growth cone; nerve growth factor; neurite outgrowth and tubulin	MICROTUBULE-ASSOCIATED PROTEINS; NERVE GROWTH-FACTOR; FILAMENTS; PHOSPHORYLATION; LOCALIZATION; BINDING; DOMAIN; CONES; INHIBITION; INTERACTS	The microtubule-associated protein tau may be involved in cell morphogenesis and axonal maintenance. In addition to microtubules, tau has been shown to interact with actin in vitro. In the present study interaction of tau and actin was investigated in PC12 cells. No interaction between tau and actin was observed without NGF treatment. Under NGF stimulation, tau distributed at ends of cellular extensions, where it associated with actin in a microtubule-independent manner. F-actin disruption revealed that relocalization and assembly of F-actin at the ends of cellular extensions were necessary for NGF-induced tau reorganization and association with actin. A truncated tau-GFP (tau(1-186)-GFP, N-terminal of tau) did not associate with actin. However, tau23(174-352)-GFP (carboxyl-terminal of Tau23) did associate with actin and the requirement for NGF was lost. Nevertheless, NGF boosted tau23(174-352)-GFP interaction with actin and promoted colocalization at the ends of cellular extensions. This suggests that the C-terminal of tau is required for associating with actin and the tau N-terminal may play a regulatory role in this process. A possible role for tau-actin interaction in neurite outgrowth is postulated.	Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Yu, JZ (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys, 835 S Wolcott Ave MC 901, Chicago, IL 60612 USA.	yujz64@uic.edu; raz@uic.edu			NIA NIH HHS [AG 15482] Funding Source: Medline; NIMH NIH HHS [MH 39595, MH57391] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039595, R01MH057391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015482] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARREGUI CO, 1994, J NEUROSCI, V14, P6967; Biernat J, 1999, MOL BIOL CELL, V10, P727, DOI 10.1091/mbc.10.3.727; Black MM, 1996, J NEUROSCI, V16, P3601; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; Bunker JM, 2004, MOL BIOL CELL, V15, P2720, DOI 10.1091/mbc.E04-01-0062; CORREAS I, 1990, BIOCHEM J, V269, P61, DOI 10.1042/bj2690061; CROSS D, 1993, J CELL SCI, V105, P51; Dawson HN, 2001, J CELL SCI, V114, P1179; DITELLA M, 1994, CELL MOTIL CYTOSKEL, V29, P117, DOI 10.1002/cm.970290204; DRUBIN D, 1988, J CELL BIOL, V106, P1583, DOI 10.1083/jcb.106.5.1583; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; Farias GA, 2002, J CELL BIOCHEM, V85, P315, DOI 10.1002/jcb.10133; FERREIRA A, 1989, DEV BRAIN RES, V49, P215, DOI 10.1016/0165-3806(89)90023-0; GRIFFITH LM, 1982, J BIOL CHEM, V257, P9143; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Hely TA, 1998, P ROY SOC B-BIOL SCI, V265, P1801, DOI 10.1098/rspb.1998.0505; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; Jenkins SM, 1998, NEUROREPORT, V9, P67, DOI 10.1097/00001756-199801050-00014; Kempf M, 1996, J NEUROSCI, V16, P5583; Lee G, 1998, J CELL SCI, V111, P3167; LEGER JG, 1994, J CELL SCI, V107, P3403; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; Lohse K, 1996, DEV BRAIN RES, V96, P83, DOI 10.1016/0165-3806(96)00076-4; LOPRESTI P, 1995, P NATL ACAD SCI USA, V92, P10369, DOI 10.1073/pnas.92.22.10369; Maas T, 2000, J BIOL CHEM, V275, P15733, DOI 10.1074/jbc.M000389200; MORAGA DM, 1993, J NEUROCHEM, V61, P979, DOI 10.1111/j.1471-4159.1993.tb03611.x; PAVES H, 1990, EXP CELL RES, V186, P218, DOI 10.1016/0014-4827(90)90299-P; Pigino G, 2003, J NEUROSCI, V23, P4499; Planel E, 2001, J BIOL CHEM, V276, P34298, DOI 10.1074/jbc.M102780200; Posern G, 2000, J CELL PHYSIOL, V183, P416, DOI 10.1002/(SICI)1097-4652(200006)183:3<416::AID-JCP15>3.0.CO;2-R; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roger B, 2004, CURR BIOL, V14, P363, DOI 10.1016/j.cub.2004.01.058; Samsonov A, 2004, J CELL SCI, V117, P6129, DOI 10.1242/jcs.01531; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SELDEN SC, 1986, ANN NY ACAD SCI, V466, P803, DOI 10.1111/j.1749-6632.1986.tb38464.x; TISCHLER AS, 1983, CELL TISSUE RES, V228, P641; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; YAMAUCHI PS, 1993, BIOCHEM BIOPH RES CO, V190, P710, DOI 10.1006/bbrc.1993.1107; Yu JZ, 2002, J NEUROSCI RES, V67, P625, DOI 10.1002/jnr.10152; Zmuda JF, 2000, J CELL SCI, V113, P2797	42	45	45	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1452	1461		10.1096/fj.05-5206com	http://dx.doi.org/10.1096/fj.05-5206com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816120				2022-12-28	WOS:000240266000022
J	Guan, XL; He, X; Ong, WY; Yeo, WK; Shui, GH; Wenk, MR				Guan, Xue Li; He, Xin; Ong, Wei-Yi; Yeo, Wee Kiang; Shui, Guanghou; Wenk, Markus R.			Non-targeted profiling of lipids during kainate-induced neuronal injury	FASEB JOURNAL			English	Article						lipidomics; neurotoxicity; mass spectrometry; ceramide; N-acylated phosphatidylethanolamine	PHOSPHOLIPASE A(2) INHIBITORS; IONIZATION MASS-SPECTROMETRY; FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; RAT HIPPOCAMPUS; CELL-DEATH; BRAIN; LIPIDOMICS; INVOLVEMENT; PATHOPHYSIOLOGY	Kainate is a glutamate analog that has been widely used in pharmacological studies of neuronal injury related to ischemic conditions and epilepsy. While altered lipid metabolism has been implicated in kainate action, no study has yet investigated the associated changes in lipid metabolites on a systems scale. Here we describe a mass spectrometry-based approach for profiling of lipid mixtures in a nontargeted fashion. Combined with tandem mass spectrometry, this method aims to identify lipids that are altered between two conditions, the kainate-treated and the control hippocampal tissues. In addition to reductions in major phospholipids with mainly polyunsaturated fatty acyl chains, we find elevated levels of ions that correspond to acylated forms of phosphatidylethanolamines and ceramides. Acylated phosphatidylethanolamines are neuroprotective lipids and precursors for anandamide, which signals via cannabinoid receptors. Quantitative analysis of ceramides shows that many molecular species with different acyl compositions are increased during kainate treatment. This increase is mainly restricted to neurons rather than other brain cells in the hippocampus as revealed by immunohistochemistry of brain slices.	Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117548, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biol Sci, Singapore 117548, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117548, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Wenk, MR (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, 8 Med Dr,Block MD7, Singapore 117548, Singapore.	antongwy@nus.edu.sg; bchmrw@nus.edu.sg	Yeo, Wee Kiang/A-4566-2009; Guan, Xue Li/D-2935-2014	Guan, Xue Li/0000-0002-5189-8178; Shui, Guanghou/0000-0002-1621-9643; Yeo, Wee Kiang/0000-0002-5329-1062				Adibhatla RM, 2003, ANTIOXID REDOX SIGN, V5, P647, DOI 10.1089/152308603770310329; Balazy M, 2004, PROSTAG OTH LIPID M, V73, P173, DOI 10.1016/j.prostaglandins.2004.03.003; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; Berger C, 2004, J NEUROCHEM, V88, P1159, DOI 10.1046/j.1471-4159.2003.02244.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cole-Edwards KK, 2005, NEUROCHEM RES, V30, P847, DOI 10.1007/s11064-005-6878-4; Cowart LA, 2002, J LIPID RES, V43, P2042, DOI 10.1194/jlr.M200241-JLR200; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Farooqui AA, 2004, NEUROCHEM RES, V29, P1961, DOI 10.1007/s11064-004-6871-3; Farooqui AA, 2004, PROSTAG LEUKOTR ESS, V71, P161, DOI 10.1016/j.plefa.2004.03.004; Farooqui AA, 2001, BRAIN RES REV, V38, P61, DOI 10.1016/S0169-328X(01)00214-5; Farooqui AA, 2000, CHEM PHYS LIPIDS, V106, P1, DOI 10.1016/S0009-3084(00)00128-6; Farooqui Akhlaq A, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P85, DOI 10.2174/1568006043481239; Forrester JS, 2004, MOL PHARMACOL, V65, P813, DOI 10.1124/mol.65.4.813; Han XL, 2004, ANAL BIOCHEM, V330, P317, DOI 10.1016/j.ab.2004.04.004; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HH, 1999, J MASS SPECTROM, V34, P761, DOI 10.1002/(SICI)1096-9888(199907)34:7<761::AID-JMS832>3.0.CO;2-R; Hisaki H, 2004, BRAIN RES, V1018, P73, DOI 10.1016/j.brainres.2004.05.042; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Kunz T, 2001, EUR J NEUROSCI, V13, P569, DOI 10.1046/j.1460-9568.2001.01420.x; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lu XR, 2001, FREE RADICAL BIO MED, V30, P1263, DOI 10.1016/S0891-5849(01)00528-7; McKinney MK, 2005, ANNU REV BIOCHEM, V74, P411, DOI 10.1146/annurev.biochem.74.082803.133450; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; Nakane M, 2000, NEUROSCI LETT, V296, P89, DOI 10.1016/S0304-3940(00)01655-4; Nielsen NPV, 1998, J CHROMATOGR A, V805, P17, DOI 10.1016/S0021-9673(98)00021-1; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ong WY, 2003, BRAIN PATHOL, V13, P250; Ong WY, 2003, EXP BRAIN RES, V148, P521, DOI 10.1007/s00221-002-1315-2; Rao AM, 2000, J NEUROCHEM, V75, P2528, DOI 10.1046/j.1471-4159.2000.0752528.x; Rapaka RS, 2005, PROSTAG OTH LIPID M, V77, P223, DOI 10.1016/j.prostaglandins.2005.06.005; Rohrbough J, 2005, NAT REV NEUROSCI, V6, P139, DOI 10.1038/nrn1608; Schaub TM, 2003, ANAL CHEM, V75, P2172, DOI 10.1021/ac020627v; Serhan CN, 2005, PROSTAG OTH LIPID M, V77, P4, DOI 10.1016/j.prostaglandins.2004.09.016; Sturley SL, 2004, BBA-MOL CELL BIOL L, V1685, P83, DOI 10.1016/j.bbalip.2004.08.014; SULLARDS MC, 2001, SCI STKE; Thwin MM, 2003, EXP BRAIN RES, V150, P427, DOI 10.1007/s00221-003-1476-7; Ueda N, 2005, CURR MED CHEM, V12, P1413, DOI 10.2174/0929867054020918; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101; Wenk MR, 2003, NAT BIOTECHNOL, V21, P813, DOI 10.1038/nbt837; Wenk MR, 2005, NAT REV DRUG DISCOV, V4, P594, DOI 10.1038/nrd1776; Wolozin B, 2004, CNS DRUG REV, V10, P127	42	72	79	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1152	1161		10.1096/fj.05-5362com	http://dx.doi.org/10.1096/fj.05-5362com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770014				2022-12-28	WOS:000240210300015
J	Zhang, X; Li, F; Bulloj, A; Zhang, YW; Tong, G; Zhang, ZH; Liao, FF; Xu, HX				Zhang, Xue; Li, Feng; Bulloj, Ayelen; Zhang, Yun-wu; Tong, Gang; Zhang, Zhuohua; Liao, Francesca-Fang; Xu, Huaxi			Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules	FASEB JOURNAL			English	Article						Alzheimer's disease; tauopathy; PIP3/Akt	GLYCOGEN-SYNTHASE KINASE-3; GROWTH-FACTOR-I; DISEASE-LIKE PHOSPHORYLATION; ALZHEIMERS-DISEASE; PROTEIN-TAU; ABNORMAL PHOSPHORYLATION; CELL-SURVIVAL; FETAL-TAU; INSULIN; GENE	Neurofibrillary tangles (NFTs), consisting of abnormally hyperphosphorylated tau, are implicated in the pathogenesis of several neurodegenerative diseases including Alzheimer's disease (AD). The molecular mechanisms underlying the regulation of tau phosphorylation are largely unknown. While the PI3K/ Akt pathway has been shown to regulate multiple cellular events pertinent to AD pathogenesis, potential functions of tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) in AD pathogenesis have not been explored. Here, we examine the effects of PTEN on tau phosphorylation, its microtubule association and formation of aggregates, and consequentially neuronal morphology. In cultured cells, overexpression of wild-type (WT) PTEN alters tau phosphorylation at several sites, increases tau-microtubule association and decreases formation of tau aggregates. In addition, the phosphatase-null PTEN increases tau aggregation and impairs tau binding to microtubule and neurite outgrowth of neurons expressing the mutant PTEN. We also found a significant loss of PTEN in AD patient brains correlated with a dramatically increased concentration of phospho-tau at Ser-214 in NFTs. Together, our results demonstrate that PTEN regulates tau phosphorylation, binding to micro-tubules and formation of aggregates and neurite outgrowth. These findings suggest a link between malfunction of PTEN and tauopathy, and imply PTEN as a therapeutic target for tauopathy.-Zhang, X., Li, F., Bulloj, A., Zhang, Y.-w., Tong, G., Zhang, Z., Liao, F.-F., Xu, H. Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules.	Burnham Med Res Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Xu, HX (corresponding author), Burnham Med Res Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA.	xuh@burnham.org	Xu, Huaxi/AAV-7177-2021	Zhang, Yun-wu/0000-0002-7152-7630	NIA NIH HHS [R01 AG024895, AG05131, K12-AG00975] Funding Source: Medline; NIDCD NIH HHS [R01 DC006497] Funding Source: Medline; NINDS NIH HHS [R01 NS046673] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG024895, K12AG000975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006497] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Bondy CA, 2004, EUR J PHARMACOL, V490, P25, DOI 10.1016/j.ejphar.2004.02.042; Carro E, 2004, EUR J PHARMACOL, V490, P127, DOI 10.1016/j.ejphar.2004.02.050; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; Derkinderen P, 2005, J NEUROSCI, V25, P6584, DOI 10.1523/JNEUROSCI.1487-05.2005; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Ducruet AP, 2005, ANNU REV PHARMACOL, V45, P725, DOI 10.1146/annurev.pharmtox.45.120403.100040; Fraser MM, 2004, CANCER RES, V64, P7773, DOI 10.1158/0008-5472.CAN-04-2487; Gasparini L, 2003, TRENDS NEUROSCI, V26, P404, DOI 10.1016/S0166-2236(03)00163-2; Gouras GK, 1998, J NEUROCHEM, V71, P1920; Griffin RJ, 2005, J NEUROCHEM, V93, P105, DOI 10.1111/j.1471-4159.2004.02949.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; Imahori K, 1998, NEUROBIOL AGING, V19, pS93, DOI 10.1016/S0197-4580(98)00025-6; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; KENESSEY A, 1993, BRAIN RES, V629, P40, DOI 10.1016/0006-8993(93)90478-6; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Ksiezak-Reding H, 2003, BBA-MOL BASIS DIS, V1639, P159, DOI 10.1016/j.bbadis.2003.09.001; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Lesort M, 2000, NEUROSCIENCE, V99, P305, DOI 10.1016/S0306-4522(00)00200-1; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; Michikawa M, 2003, MOL NEUROBIOL, V27, P1, DOI 10.1385/MN:27:1:1; MORENO FJ, 1995, FEBS LETT, V372, P65, DOI 10.1016/0014-5793(95)00934-2; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pei JJ, 2003, ACTA NEUROPATHOL, V105, P381, DOI 10.1007/s00401-002-0657-y; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Pyo HK, 2004, NEUROSCIENCE, V127, P649, DOI 10.1016/j.neuroscience.2004.05.036; Rickle A, 2004, NEUROREPORT, V15, P955, DOI 10.1097/00001756-200404290-00005; Schubert M, 2003, J NEUROSCI, V23, P7084, DOI 10.1523/JNEUROSCI.23-18-07084.2003; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008; Stokoe D, 2001, CURR BIOL, V11, pR502, DOI 10.1016/S0960-9822(01)00303-7; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687	58	52	52	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1272	+		10.1096/fj.06-5721fje	http://dx.doi.org/10.1096/fj.06-5721fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16645045				2022-12-28	WOS:000240210300049
J	Jacquard, C; Trioulier, Y; Cosker, F; Escartin, C; Bizat, N; Hantraye, P; Cancela, JM; Bonvento, G; Brouillet, E				Jacquard, Carine; Trioulier, Yael; Cosker, Francois; Escartin, Carole; Bizat, Nicolas; Hantraye, Philippe; Cancela, Jose Manuel; Bonvento, Gilles; Brouillet, Emmanuel			Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation	FASEB JOURNAL			English	Article						3-nitropropionic acid; calpain; striatum; Huntington's disease	D-ASPARTATE RECEPTOR; HUNTINGTONS-DISEASE; SUCCINATE-DEHYDROGENASE; 3-NITROPROPIONIC ACID; COMPLEX-II; PERMEABILITY TRANSITION; STRIATAL DEGENERATION; CALCIUM ACCUMULATION; NEURONAL DEATH; IN-VIVO	According to the "indirect" excitotoxicity hypothesis, mitochondrial defects increase Ca2+ entry into neurons by rendering NMDA-R hypersensitive to glutamate. We tested this hypothesis by investigating in the rat striatum and cultured striatal cells how partial mitochondrial complex II inhibition produced by 3-nitropropionic acid (3NP) modifies the toxicity of the NMDA-R agonist quinolinate (QA). We showed that nontoxic 3NP treatment, leading to partial inhibition of complex II activity, greatly exacerbated striatal degeneration produced by slightly toxic QA treatment through an "all-or-nothing" process. The potentiation of QA-induced cell death by 3NP was associated with increased calpain activity and massive calpain-mediated cleavage of several postsynaptic proteins, suggesting major neuronal Ca2+ deregulation in the striatum. However, Ca2+ anomalies probably do not result from NMDA-R hypersensitivity. Indeed, brain imaging experiments using [F-18] fluorodeoxyglucose indirectly showed that 3NP did not increase QA-induced ionic perturbations at the striatal glutamatergic synapses in vivo. Consistent with this, the exacerbation of QA toxicity by 3NP was not related to an increase in the QA-induced entry of Ca-45(2+) into striatal neurons. The present results demonstrate that the potentiation of NMDA-R-mediated excitotoxicity by mitochondrial defects involves primarily intracellular Ca2+ deregulation, in the absence of NMDA-R hypersensitivity.	CEA, CNRS, URA 2210, Serv Hosp Frederic Joliot,DRM,DSV, F-91401 Orsay, France; CNRS, Lab Neurobiol Cellulaire & Mol, UPR 9040, Gif Sur Yvette, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Brouillet, E (corresponding author), CEA, CNRS, URA 2210, Serv Hosp Frederic Joliot,DRM,DSV, 4 Pl Gen Leclerc, F-91401 Orsay, France.	brouille@shfj.cea.fr	Brouillet, Emmanuel/B-4784-2014; Bonvento, Gilles/F-6023-2013; Escartin, Carole/A-1952-2010	Brouillet, Emmanuel/0000-0001-6322-7403; Bonvento, Gilles/0000-0002-2886-4228; Escartin, Carole/0000-0003-3613-4118; Cancela, Jose-Manuel/0000-0002-6234-1500; Jacquard, Carine/0000-0003-0972-8455				ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; Alexi T, 1998, EXP NEUROL, V153, P74, DOI 10.1006/exnr.1998.6842; ALSTON TA, 1977, P NATL ACAD SCI USA, V74, P3767, DOI 10.1073/pnas.74.9.3767; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Beal M F, 1992, Curr Opin Neurobiol, V2, P657, DOI 10.1016/0959-4388(92)90035-J; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; BEAL MF, 1992, FASEB J, V6, P3338, DOI 10.1096/fasebj.6.15.1464368; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bezprozvanny I, 2004, BIOCHEM BIOPH RES CO, V322, P1310, DOI 10.1016/j.bbrc.2004.08.035; Bizat N, 2003, J NEUROSCI, V23, P5020; Blum D, 2003, J NEUROSCI, V23, P5361; Bonvento G, 2002, TRENDS NEUROSCI, V25, P359, DOI 10.1016/S0166-2236(02)02168-9; Bordelon YM, 1998, NEUROSCIENCE, V83, P459, DOI 10.1016/S0306-4522(97)00421-1; Brouillet E, 1998, J NEUROCHEM, V70, P794; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Brustovetsky N, 2000, J NEUROSCI, V20, P103, DOI 10.1523/JNEUROSCI.20-01-00103.2000; Calabresi P, 2001, J NEUROSCI, V21, P5110, DOI 10.1523/JNEUROSCI.21-14-05110.2001; Cepeda C, 2001, J NEUROSCI RES, V66, P525, DOI 10.1002/jnr.1244; Choo YS, 2004, HUM MOL GENET, V13, P1407, DOI 10.1093/hmg/ddh162; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; COLES CJ, 1979, J BIOL CHEM, V254, P5161; Dautry W, 2000, J CEREBR BLOOD F MET, V20, P789, DOI 10.1097/00004647-200005000-00005; EIMERL S, 1994, J NEUROCHEM, V62, P1223; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Galas MC, 2004, NEUROBIOL DIS, V15, P152, DOI 10.1016/j.nbd.2003.09.013; Greene JG, 1998, NEUROSCIENCE, V84, P503, DOI 10.1016/S0306-4522(97)00389-8; GREENE JG, 1995, J NEUROCHEM, V64, P430; Greene JG, 1996, PROG NEUROBIOL, V48, P613, DOI 10.1016/0301-0082(96)00006-8; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Laforet GA, 2001, J NEUROSCI, V21, P9112, DOI 10.1523/JNEUROSCI.21-23-09112.2001; LUST WD, 1981, ANAL BIOCHEM, V110, P258, DOI 10.1016/0003-2697(81)90144-5; Maciel EN, 2004, J NEUROCHEM, V90, P1025, DOI 10.1111/j.1471-4159.2004.02565.x; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; MUNUJOS P, 1993, ANAL BIOCHEM, V212, P506, DOI 10.1006/abio.1993.1360; Nasr P, 2003, NEUROCHEM INT, V43, P89, DOI 10.1016/S0197-0186(02)00229-2; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; RIDDLE D, 1992, J NEUROSCI, V12, P3509; Saulle E, 2004, MOL CELL NEUROSCI, V25, P9, DOI 10.1016/j.mcn.2003.09.013; Sibson NR, 1998, P NATL ACAD SCI USA, V95, P316, DOI 10.1073/pnas.95.1.316; SIMPSON JR, 1993, EXP NEUROL, V121, P57, DOI 10.1006/exnr.1993.1071; Song C, 2003, J BIOL CHEM, V278, P33364, DOI 10.1074/jbc.M304240200; Sun Y, 2001, J BIOL CHEM, V276, P24713, DOI 10.1074/jbc.M103501200; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Ward MW, 2005, J NEUROCHEM, V92, P1081, DOI 10.1111/j.1471-4159.2004.02928.x; WELLISZ T, 1993, J LONG-TERM EFF MED, V3, P223; White RJ, 1996, J NEUROSCI, V16, P5688; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3	60	51	53	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					1021	+		10.1096/fj.05-5085fje	http://dx.doi.org/10.1096/fj.05-5085fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571773				2022-12-28	WOS:000240157700042
J	Wang, TG; Zhang, W; Pei, Z; Block, M; Wilson, B; Reece, JM; Miller, DS; Hong, JS				Wang, Tongguang; Zhang, Wei; Pei, Zhong; Block, Michelle; Wilson, Belinda; Reece, Jeffrey M.; Miller, David S.; Hong, Jau-Shyong			Reactive microgliosis participates in MPP+-induced dopaminergic neurodegeneration: role of 67 kDa laminin receptor	FASEB JOURNAL			English	Article						laminin receptor; extracellular matrix; microglia; neuron; MPP; Parkinson's disease	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; PARKINSONS-DISEASE; EXTRACELLULAR-MATRIX; ALPHA-6-BETA-1 INTEGRIN; NADPH OXIDASE; ACTIVATION; CELLS; INFLAMMATION; EXPRESSION; PROTEIN	It has been reported that extracellular matrix (ECM) molecules regulate monocyte activation by binding with a 67 kDa nonintegrin laminin receptor (LR). As microgliosis is a pivotal factor in propelling the progress of chronic neurodegeneration in the brain, we hypothesized that LR may regulate the microgliosis and subsequent neurotoxicity. Using 1-methyl-4-phenylpyridinium (MPP+)- treated C57 mice primary mesencephalic neuron-glia cultures as an in vitro Parkinson's disease (PD) model, we observed that MPP+ treatment increased LR expression only in the mixed neuron-glia but not in microglia-enriched or microglia-depleted cultures, indicating that MPP+-induced increase of LR expression is associated with neuron-microglia interaction. Using confocal microscopic examination, we found that LR was localized in the microglia, which were F4/80 positive. Treatment with the antibody ( Ab) against LR (LR-Ab) or YIGSR, a synthetic pentapeptide inhibitor for LR, significantly attenuated the MPP+-increased F4/80 immunoreactivity ( 24 h) and dopaminergic (DA) neurotoxicity. LR-Ab also attenuated MPP+-increased microglial phagocytotic activity ( 48 h) and the superoxide production ( 4 days). Further study demonstrated that exogenous laminin (1 - 10 mu g/ml) treatment induced microglial activation and DA neurotoxicity, in a dose-dependent manner, which was partially attenuated by the LR-Ab. We concluded that by regulating cell-ECM interaction, LR plays important roles in mediating microgliosis and subsequent DA neurotoxicity. Laminin is a potential ligand for activating this LR receptor. This study also suggests that laminin/LR is a potential target for developing new therapeutic drugs against neurodegenerative disorders such as PD.	Natl Inst Environm Hlth Sci, Neuropharmacol Sect, Lab Pharmacol & Chem, Natl Inst Hlth, Res Triangle Pk, NC USA; Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Hand Surg, Union Hosp, Wuhan 430074, Peoples R China; Natl Inst Environm Hlth Sci, Conofocal Microscopy Ctr, Lab Signal Transduct, Natl Inst Hlth, Res Triangle Pk, NC USA; Natl Inst Environm Hlth Sci, Lab Pharmacol & Chem, Natl Inst Hlth, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Huazhong University of Science & Technology; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wang, TG (corresponding author), Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA.	twang40@jhmi.edu	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Block, Michelle/0000-0001-8303-7914	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090082, ZIAES080060, ZIAES080048, Z01ES080060, Z01ES080048, Z01ES090082] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ardini E, 1997, J BIOL CHEM, V272, P2342; Ardini E, 2002, CANCER RES, V62, P1321; Baloui H, 2004, EUR J NEUROSCI, V20, P2605, DOI 10.1111/j.1460-9568.2004.03728.x; Canfield SM, 1999, J IMMUNOL, V163, P3430; CHAMAK B, 1991, NEUROSCIENCE, V45, P513, DOI 10.1016/0306-4522(91)90267-R; Chen J, 2003, P NATL ACAD SCI USA, V100, P14000, DOI 10.1073/pnas.2334584100; Cherepanova O A, 2003, Tsitologiia, V45, P271; Cho BP, 2003, CELL MOL NEUROBIOL, V23, P551, DOI 10.1023/A:1025024129946; Conant K, 1999, ANN NEUROL, V46, P391, DOI 10.1002/1531-8249(199909)46:3<391::AID-ANA15>3.0.CO;2-0; Donaldson Elaine A., 2000, Molecular Cell Biology Research Communications, V3, P53, DOI 10.1006/mcbr.2000.0191; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kohutnicka M, 1998, IMMUNOPHARMACOLOGY, V39, P167, DOI 10.1016/S0162-3109(98)00022-8; Liu B, 2000, NEUROSCIENCE, V97, P749, DOI 10.1016/S0306-4522(00)00057-9; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Lorenzl S, 2002, EXP NEUROL, V178, P13, DOI 10.1006/exnr.2002.8019; MARTIGNONE S, 1993, J NATL CANCER I, V85, P398, DOI 10.1093/jnci/85.5.398; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; McGeer PL, 2001, ADV NEUROL, V86, P83; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; Milner R, 2003, J IMMUNOL, V170, P3850, DOI 10.4049/jimmunol.170.7.3850; Milner R, 2002, J NEUROSCI, V22, P1562, DOI 10.1523/JNEUROSCI.22-05-01562.2002; MONNING U, 1995, J BIOL CHEM, V270, P7104, DOI 10.1074/jbc.270.13.7104; Montuori N, 1999, CLIN CANCER RES, V5, P1465; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Peterszegi G, 1997, ATHEROSCLEROSIS, V135, P103, DOI 10.1016/S0021-9150(97)00155-X; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ringheim GE, 2004, J NEUROIMMUNOL, V147, P43, DOI 10.1016/j.jneuroim.2003.10.013; ROMANOV V, 1994, CELL ADHES COMMUN, V2, P201, DOI 10.3109/15419069409004438; Schneider B, 2003, P NATL ACAD SCI USA, V100, P13326, DOI 10.1073/pnas.2235648100; Simoneau S, 2003, BIOL CHEM, V384, P243, DOI 10.1515/BC.2003.027; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; Tan AS, 2000, J IMMUNOL METHODS, V238, P59, DOI 10.1016/S0022-1759(00)00156-3; Wang TG, 2004, J NEUROIMMUNOL, V147, P68, DOI 10.1016/j.jneuroim.2003.10.040; Wang TG, 2004, J PHARMACOL EXP THER, V308, P975, DOI 10.1124/jpet.103.059683; Wang TG, 2004, J NEUROCHEM, V88, P939, DOI 10.1046/j.1471-4159.2003.02242.x; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com	40	30	33	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					906	915		10.1096/fj.05-5053com	http://dx.doi.org/10.1096/fj.05-5053com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675848				2022-12-28	WOS:000240157700013
J	Yang, XP; Doser, TA; Fang, CX; Nunn, JM; Janardhanan, R; Zhu, MJ; Sreejayan, N; Quinn, MT; Ren, J				Yang, Xiaoping; Doser, Thomas A.; Fang, Cindy X.; Nunn, Jennifer M.; Janardhanan, Rajiv; Zhu, Meijun; Sreejayan, Nair; Quinn, Mark T.; Ren, Jun			Metallothionein prolongs survival and antagonizes senescence-associated cardiomyocyte diastolic dysfunction: role of oxidative stress	FASEB JOURNAL			English	Article						contraction; oxidative stress; antioxidant; longevity	MITOCHONDRIAL NADP(+)-ISOCITRATE DEHYDROGENASE; CARDIAC CONTRACTILE DYSFUNCTION; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; DIABETIC MICE; EXPRESSION; TARGETS; DAMAGE; HEART; OVEREXPRESSION	Senescence is accompanied by oxidative stress and cardiac dysfunction, although the link between the two remains unclear. This study examined the role of antioxidant metallothionein on cardiomyocyte function, superoxide generation, the oxidative stress biomarker aconitase activity, cytochrome c release, and expression of oxidative stress-related proteins, such as the GTPase RhoA and NADPH oxidase protein p47(phox) in young (5-6 mo) and aged (26-28 mo) FVB wild-type (WT) and cardiac-specific metallothionein transgenic mice. Metallothionein mice showed a longer life span (by similar to 4 mo) than FVB mice evaluated by the Kaplan-Meier survival curve. Compared with young cardiomyocytes, aged myocytes displayed prolonged TR90, reduced tolerance to high stimulus frequency, and slowed intracellular Ca2+ decay, all of which were nullified by metallothionein. Aging increased superoxide generation, active RhoA abundance, cytochrome c release, and p47(phox) expression and suppressed aconitase activity without affecting protein nitrotyrosine formation in the hearts. These aging-induced changes in oxidative stress and related protein biomarkers were attenuated by metallothionein. Aged metallothionein mouse myocytes were more resistant to the superoxide donor pyrogallol-induced superoxide generation and apoptosis. In addition, aging-associated prolongation in TR90 was blunted by the Rho kinase inhibitor Y-27632. Collectively, our data demonstrated that metallothionein may alleviate aging-induced cardiac contractile defects and oxidative stress, which may contribute to prolonged life span in metallothionein transgenic mice.	Univ Wyoming, Div Pharmaceut Sci, Laramie, WY 82071 USA; Univ Wyoming, Ctr Cardiovasc Res & Alternat Med, Laramie, WY 82071 USA; Univ Wyoming, Dept Anim Sci, Laramie, WY 82071 USA; Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA	University of Wyoming; University of Wyoming; University of Wyoming; Montana State University System; Montana State University Bozeman	Ren, J (corresponding author), Univ Wyoming, Div Pharmaceut Sci, Laramie, WY 82071 USA.	jren@uwyo.edu	Zhu, Mei-Jun/A-4248-2013; Ren, Jun/ACG-5366-2022	Ren, Jun/0000-0002-0275-0783; Quinn, Mark/0000-0001-8114-5073	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG021324] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66575] Funding Source: Medline; NIA NIH HHS [AG21324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alexeyev MF, 2004, CLIN SCI, V107, P355, DOI 10.1042/CS20040148; Benderdour M, 2004, AM J PHYSIOL-HEART C, V287, pH2122, DOI 10.1152/ajpheart.00378.2004; Benderdour M, 2003, J BIOL CHEM, V278, P45154, DOI 10.1074/jbc.M306285200; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Cai H, 2003, TRENDS PHARMACOL SCI, V24, P471, DOI 10.1016/S0165-6147(03)00233-5; Cai L, 2005, DIABETES, V54, P1829, DOI 10.2337/diabetes.54.6.1829; Cai L, 2001, Cardiovasc Toxicol, V1, P181, DOI 10.1385/CT:1:3:181; Ceconi C, 2003, ARCH BIOCHEM BIOPHYS, V420, P217, DOI 10.1016/j.abb.2003.06.002; Chung L, 2006, BBA-MOL BASIS DIS, V1762, P103, DOI 10.1016/j.bbadis.2005.08.003; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; Dhalla N S, 2001, Expert Opin Ther Targets, V5, P205, DOI 10.1517/14728222.5.2.205; Dhalla NS, 2000, J HYPERTENS, V18, P655, DOI 10.1097/00004872-200018060-00002; Dong F, 2005, CLIN SCI, V109, P277, DOI 10.1042/CS20040278; Dong F, 2005, BRIT J PHARMACOL, V145, P323, DOI 10.1038/sj.bjp.0706193; Duan JH, 2003, AM J PHYSIOL-ENDOC M, V284, pE366, DOI 10.1152/ajpendo.00254.2002; Esberg Lucy B, 2004, Cardiovasc Toxicol, V4, P375, DOI 10.1385/CT:4:4:375; Fang CX, 2005, DIABETOLOGIA, V48, P2412, DOI 10.1007/s00125-005-1940-y; Fridovich I, 2004, AGING CELL, V3, P13, DOI 10.1046/j.1474-9728.2003.00075.x; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Hool LC, 2005, CARDIOVASC RES, V67, P624, DOI 10.1016/j.cardiores.2005.04.025; Jin LM, 2004, AM J PHYSIOL-HEART C, V287, pH1495, DOI 10.1152/ajpheart.01006.2003; KANDA T, 2005, IN PRESS FASEB J; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; Kasapoglu M, 2001, EXP GERONTOL, V36, P209, DOI 10.1016/S0531-5565(00)00198-4; Kawamura H, 2004, ARTERIOSCL THROM VAS, V24, P276, DOI 10.1161/01.ATV.0000112012.33770.2a; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58; Li SY, 2005, AGING CELL, V4, P57, DOI 10.1111/j.1474-9728.2005.00146.x; Luo JD, 2003, CURR MED CHEM, V10, P1593, DOI 10.2174/0929867033457205; Matsuoka Y, 2001, NEUROSCIENCE, V104, P609, DOI 10.1016/S0306-4522(01)00115-4; Miao LY, 2001, MECH AGEING DEV, V122, P1757, DOI 10.1016/S0047-6374(01)00297-4; Monahan KD, 2004, AM J PHYSIOL-HEART C, V286, pH2113, DOI 10.1152/ajpheart.01054.2003; Ren J, 2005, ACTA PHARMACOL SIN, V26, P279, DOI 10.1111/j.1745-7254.2005.00059.x; Rikitake Y, 2005, CIRCULATION, V111, P3261, DOI 10.1161/CIRCULATIONAHA.105.534024; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Song Y, 2005, AM J PATHOL, V167, P17, DOI 10.1016/S0002-9440(10)62949-5; Sowers JR, 2004, AM J PHYSIOL-HEART C, V286, pH1597, DOI 10.1152/ajpheart.00026.2004; Stadtman E R, 1992, EXS, V62, P64; Wang GW, 1999, AM J PHYSIOL-HEART C, V276, pH167, DOI 10.1152/ajpheart.1999.276.1.H167; Xu Y, 2004, AM J PHYSIOL-HEART C, V287, pH165, DOI 10.1152/ajpheart.00037.2004; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; Yang XP, 2005, ENDOCRINE, V26, P127, DOI 10.1385/ENDO:26:2:127; Yarian CS, 2005, BIOCHEM BIOPH RES CO, V330, P151, DOI 10.1016/j.bbrc.2005.02.135; Ye G, 2003, DIABETES, V52, P777, DOI 10.2337/diabetes.52.3.777	47	110	117	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					1024	+		10.1096/fj.05-5288fje	http://dx.doi.org/10.1096/fj.05-5288fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585059				2022-12-28	WOS:000240157700043
J	Yeung, D; Zablocki, K; Lien, CF; Jiang, TW; Arkle, S; Brutkowski, W; Brown, J; Lochmuller, H; Simon, J; Barnard, EA; Gorecki, DC				Yeung, Davy; Zablocki, Krzysztof; Lien, Chun-Fu; Jiang, Taiwen; Arkle, Stephen; Brutkowski, Wojciech; Brown, James; Lochmuller, Hanns; Simon, Joseph; Barnard, Eric A.; Gorecki, Dariusz C.			Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells	FASEB JOURNAL			English	Article						Duchenne muscular dystrophy; ATP; P2X receptor; myoblast; mdx mouse	MAMMALIAN SKELETAL-MUSCLE; MUSCULAR-DYSTROPHY; EXTRACELLULAR ATP; EXPRESSION; PURINOCEPTOR; ACTIVATION; MECHANISMS; MEMBRANE; CLONING; RELEASE	Pathological cellular hallmarks of Duchenne muscular dystrophy (DMD) include, among others, abnormal calcium homeostasis. Changes in the expression of specific receptors for extracellular ATP in dystrophic muscle have been recently documented: here, we demonstrate that at the earliest, myoblast stage of developing dystrophic muscle a purinergic dystrophic phenotype arises. In myoblasts of a dystrophin-negative muscle cell line established from the mdx mouse model of DMD but not in normal myoblasts, exposure to extracellular ATP triggered a strong increase in cytoplasmic Ca2+ concentrations. Influx of extracellular Ca2+ was stimulated by ATP and BzATP and inhibited by zinc, Coomassie Brilliant Blue-G, and KN-62, demonstrating activation of P2X7 receptors. Significant expression of P2X4 and P2X7 proteins was immunodetected in dystrophic myoblasts. Therefore, full-length dystrophin appears, surprisingly, to play an important role in myoblasts in controlling responses to ATP. Our results suggest that altered function of P2X receptors may be an important contributor to pathogenic Ca2+ entry in dystrophic mouse muscle and may have implications for the pathogenesis of muscular dystrophies. Treatments aiming at inhibition of specific ATP receptors could be of a potential therapeutic benefit. - Yeung, D., Zablocki, K., Lien, C.-F., Jiang, T., Arkle, S., Brutkowski, W., Brown, J., Lochmuller, H., Simon, J., Barnard, E. A., Gorecki, D. C. Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells.	Inst Biomed & Biomol Sci, Sch Pharm & Biomed Sci, Portsmouth PO1 2DT, Hants, England; M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; Univ Munich, Friedrich Baur Inst, Dept Neurol, Munich, Germany; Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England	University of Portsmouth; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; University of Munich; University of Cambridge	Gorecki, DC (corresponding author), Inst Biomed & Biomol Sci, Sch Pharm & Biomed Sci, St Michaels Bldg,White Swan Rd, Portsmouth PO1 2DT, Hants, England.	darek.gorecki@port.ac.uk	; Zablocki, Krzysztof/R-4181-2016	Gorecki, Dariusz/0000-0003-3584-1654; Brown, James/0000-0002-3901-6814; Zablocki, Krzysztof/0000-0002-9987-1257; Lochmuller, Hanns/0000-0003-2324-8001	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; Araya R, 2004, BRAIN RES REV, V47, P174, DOI 10.1016/j.brainresrev.2004.06.003; Atkinson L, 2004, NEUROSCIENCE, V123, P761, DOI 10.1016/j.neuroscience.2003.08.065; Betto R, 1999, J BIOL CHEM, V274, P7907, DOI 10.1074/jbc.274.12.7907; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Brun C, 2003, CELL MOL LIFE SCI, V60, P557, DOI 10.1007/s000180300047; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Chakfe Y, 2002, J NEUROSCI, V22, P3061, DOI 10.1523/JNEUROSCI.22-08-03061.2002; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Chessell IP, 1998, FEBS LETT, V439, P26, DOI 10.1016/S0014-5793(98)01332-5; Chessell IP, 1997, BRIT J PHARMACOL, V121, P1429, DOI 10.1038/sj.bjp.0701278; Choi RCY, 2003, J NEUROSCI, V23, P4445; Collet C, 2002, PFLUG ARCH EUR J PHY, V443, P771, DOI 10.1007/s00424-001-0758-9; Collo G, 1996, J NEUROSCI, V16, P2495; Cox JA, 2001, GENE, V270, P145, DOI 10.1016/S0378-1119(01)00484-X; Cseri J, 2002, PFLUG ARCH EUR J PHY, V443, P731, DOI 10.1007/s00424-001-0757-x; Dalkilic I, 2003, CURR OPIN GENET DEV, V13, P231, DOI 10.1016/S0959-437X(03)00048-0; De Man JG, 2003, BRIT J PHARMACOL, V140, P1108, DOI 10.1038/sj.bjp.0705536; Ekokoski E, 2001, J CELL PHYSIOL, V187, P166, DOI 10.1002/jcp.1070; Feng YH, 2005, AM J PHYSIOL-CELL PH, V288, pC1342, DOI 10.1152/ajpcell.00315.2004; FERRARI D, 1994, AM J PHYSIOL-CELL PH, V267, pC886, DOI 10.1152/ajpcell.1994.267.4.C886; Freedman BD, 1999, EUR J IMMUNOL, V29, P1635, DOI 10.1002/(SICI)1521-4141(199905)29:05<1635::AID-IMMU1635>3.3.CO;2-2; Geng Y, 1991, Neuromuscul Disord, V1, P125, DOI 10.1016/0960-8966(91)90060-6; HAGGBLAD J, 1988, FEBS LETT, V235, P133, DOI 10.1016/0014-5793(88)81248-1; Henning RH, 1997, PHARMACOL THERAPEUT, V74, P115, DOI 10.1016/S0163-7258(97)00015-6; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hibell AD, 2000, BRIT J PHARMACOL, V130, P167, DOI 10.1038/sj.bjp.0703302; Humphreys BD, 1998, MOL PHARMACOL, V54, P22, DOI 10.1124/mol.54.1.22; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; Jiang TW, 2005, NEUROMUSCULAR DISORD, V15, P225, DOI 10.1016/j.nmd.2004.11.008; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEDERFEIN D, 1993, HUM MOL GENET, V2, P1883, DOI 10.1093/hmg/2.11.1883; LOVE DR, 1989, NATURE, V4, P55; LU Z, 1991, J PHYSIOL-LONDON, V436, P45, DOI 10.1113/jphysiol.1991.sp018538; Mallouk N, 2000, P NATL ACAD SCI USA, V97, P4950, DOI 10.1073/pnas.97.9.4950; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Munroe SH, 2004, J CELL BIOCHEM, V93, P664, DOI 10.1002/jcb.20252; Noguchi S, 1999, BIOCHEM BIOPH RES CO, V262, P88, DOI 10.1006/bbrc.1999.1163; Noguchi S, 2000, EUR J BIOCHEM, V267, P640, DOI 10.1046/j.1432-1327.2000.00998.x; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Papp L, 2004, NEUROREPORT, V15, P2387, DOI 10.1097/00001756-200410250-00017; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Pulido SM, 1998, FEBS LETT, V439, P357, DOI 10.1016/S0014-5793(98)01399-4; Robert V, 2001, J BIOL CHEM, V276, P4647, DOI 10.1074/jbc.M006337200; Ruegg Urs T., 1999, Trends in Pharmacological Sciences, V20, P351, DOI 10.1016/S0165-6147(99)01377-2; Ryten M, 2004, FASEB J, V18, P1404, DOI 10.1096/fj.03-1175fje; Ryten M, 2002, J CELL BIOL, V158, P345, DOI 10.1083/jcb.200202025; Ryten M, 2001, DEV DYNAM, V221, P331, DOI 10.1002/dvdy.1147; Sandona D, 2005, FASEB J, V19, P1184, DOI 10.1096/fj.04-3333fje; Sandona D, 2004, BIOCHEM J, V381, P105, DOI 10.1042/BJ20031644; SHIVERS RR, 1984, AM J PATHOL, V116, P482; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Sim JA, 2004, J NEUROSCI, V24, P6307, DOI 10.1523/JNEUROSCI.1469-04.2004; Sneddon P, 1999, PROG BRAIN RES, V120, P11; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Sperlagh B, 2001, NEUROCHEM RES, V26, P951, DOI 10.1023/A:1012336601854; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Tsim KWK, 2002, NEUROSIGNALS, V11, P58, DOI 10.1159/000057322; Tung EKK, 2004, MOL PHARMACOL, V66, P794, DOI 10.1124/mol.104.003269; Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X; Yeung D, 2004, NEUROBIOL DIS, V15, P212, DOI 10.1016/j.nbd.2003.10.014	64	43	43	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					610	620		10.1096/fj.05-4022com	http://dx.doi.org/10.1096/fj.05-4022com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581969				2022-12-28	WOS:000240130900007
J	De Souza, CT; Araujo, EP; Stoppiglia, LF; Pauli, JR; Ropelle, E; Rocco, SA; Marin, RM; Franchini, KG; Carvalheira, JB; Saad, MJ; Boschero, AC; Carneiro, EM; Velloso, LA				De Souza, Claudio T.; Araujo, Eliana P.; Stoppiglia, Luiz F.; Pauli, Jose R.; Ropelle, Eduardo; Rocco, Silvana A.; Marin, Rodrigo M.; Franchini, Kleber G.; Carvalheira, Jose B.; Saad, Mario J.; Boschero, Antonio C.; Carneiro, Everardo M.; Velloso, Licio A.			Inhibition of UCP2 expression reverses diet-induced diabetes mellitus by effects on both insulin secretion and action	FASEB JOURNAL			English	Article						short-term inhibition of UCP2; antisense oligonucleotide; ATP synthase; anti-UCP2 antibody	BETA-CELL DYSFUNCTION; UNCOUPLING PROTEINS UCP2; PANCREATIC-ISLETS; RECEPTOR SUBSTRATE-1; OXIDATIVE STRESS; OBESITY; RESISTANCE; MICE; OVEREXPRESSION; HYPERINSULINEMIA	Recent characterization of the ability of uncoupling protein 2 (UCP2) to reduce ATP production and inhibit insulin secretion by pancreatic beta-cells has placed this mitochondrial protein as a candidate target for therapeutics in diabetes mellitus. In the present study we evaluate the effects of short-term treatment of two animal models of type 2 diabetes mellitus with an antisense oligonucleotide to UCP2. In both models, Swiss mice ( made obese and diabetic by a hyperlipidic diet) and ob/ob mice, the treatment resulted in a significant improvement in the hyperglycemic syndrome. This effect was due not only to an improvement of insulin secretion, but also to improved peripheral insulin action. In isolated pancreatic islets, the partial inhibition of UCP2 increased ATP content, followed by increased glucose-stimulated insulin secretion. This was not accompanied by increased expression of enzymes involved in protection against oxidative stress. The evaluation of insulin action in peripheral tissues revealed that the inhibition of UCP2 expression significantly improved insulin signal transduction in adipose tissue. In conclusion, short-term inhibition of UCP2 expression ameliorates the hyperglycemic syndrome in two distinct animal models of obesity and diabetes. Metabolic improvement is due to a combined effect on insulin-producing pancreatic islets and in at least one peripheral tissue that acts as a target for insulin.	Univ Estadual Campinas, Dept Internal Med, Campinas, SP, Brazil; Univ Estadual Campinas, Dept Phys & Biophys, Campinas, SP, Brazil	Universidade Estadual de Campinas; Universidade Estadual de Campinas	Velloso, LA (corresponding author), Univ Estadual Campinas, Dept Clin Med, Fac Ciencias Med, Campinas, SP, Brazil.	lavelloso@fcm.unicamp.br	Carvalheira, Jose Barreto Campello/E-8562-2013; Marin, Rodrigo Miguel/M-5687-2013; Carneiro, Everardo/D-4758-2012; Velloso, Licio/AAJ-3778-2020; Araujo, EP/D-9231-2013; Pauli, José Rdrigo/AAD-2763-2021; Rocco, Silvana Aparecida/Q-3828-2019; Boschero, Antonio/O-7525-2014; Carvalheira, Jose B/H-8405-2012; Stoppiglia, Luiz F/C-4963-2015; Rocco, Silvana Aparecida/H-6300-2014; Ropelle, Eduardo R/C-3977-2012; Saad, Mario/ABD-8262-2020	Carvalheira, Jose Barreto Campello/0000-0002-0136-0943; Araujo, EP/0000-0002-7539-8477; Pauli, José Rdrigo/0000-0002-6129-1521; Rocco, Silvana Aparecida/0000-0003-4551-3443; Boschero, Antonio/0000-0003-3829-8570; Stoppiglia, Luiz F/0000-0002-5202-5395; Rocco, Silvana Aparecida/0000-0003-4551-3443; Ropelle, Eduardo R/0000-0003-1655-9557; 				ANDERSSON A, 1978, DIABETOLOGIA, V14, P397, DOI 10.1007/BF01228134; Araujo EP, 2006, CURR CANCER DRUG TAR, V6, P77, DOI 10.2174/156800906775471734; Araujo EP, 2005, ENDOCRINOLOGY, V146, P1428, DOI 10.1210/en.2004-0778; Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Babinet C, 2000, J AM SOC NEPHROL, V11, pS88; BONORA E, 1987, DIABETES METAB, V13, P116; BORG LAH, 1992, ENDOCRINOLOGY, V130, P2851, DOI 10.1210/en.130.5.2851; Branchi I, 2002, GENES BRAIN BEHAV, V1, P135, DOI 10.1034/j.1601-183X.2002.10301.x; Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002; Cannon B, 2006, BBA-BIOENERGETICS, V1757, P449, DOI 10.1016/j.bbabio.2006.05.016; Carvalho MA, 2005, DIABETES, V54, P959, DOI 10.2337/diabetes.54.4.959; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Crooke ST, 2004, ANNU REV MED, V55, P61, DOI 10.1146/annurev.med.55.091902.104408; De Souza CT, 2005, ENDOCRINOLOGY, V146, P4192, DOI 10.1210/en.2004-1520; De Souza CT, 2003, DIABETOLOGIA, V46, P1522, DOI 10.1007/s00125-003-1222-5; Esteves TC, 2005, BBA-BIOENERGETICS, V1709, P35, DOI 10.1016/j.bbabio.2005.06.002; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Fujikawa T, 2005, ENDOCRINOLOGY, V146, P3471, DOI 10.1210/en.2004-1528; Hong Y, 2001, ENDOCRINOLOGY, V142, P249, DOI 10.1210/en.142.1.249; Jiang GQ, 2005, J CLIN INVEST, V115, P1030, DOI 10.1172/JCI200523962; Joseph JW, 2002, DIABETES, V51, P3211, DOI 10.2337/diabetes.51.11.3211; Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3; Nandi A, 2004, PHYSIOL REV, V84, P623, DOI 10.1152/physrev.00032.2003; Nicholls DG, 2006, BBA-BIOENERGETICS, V1757, P459, DOI 10.1016/j.bbabio.2006.02.005; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837; OPALINSKA JB, 2003, SCI STKE; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Porte D, 2001, DIABETES, V50, pS160, DOI 10.2337/diabetes.50.2007.S160; Robertson JA, 2002, INT J SYST EVOL MICR, V52, P587, DOI 10.1099/00207713-52-2-587; Robertson RP, 2004, J BIOL CHEM, V279, P42351, DOI 10.1074/jbc.R400019200; Ronner P, 1999, ANAL BIOCHEM, V275, P208, DOI 10.1006/abio.1999.4317; Rossmeisl M, 2003, DIABETES, V52, P1958, DOI 10.2337/diabetes.52.8.1958; Rydstrom J, 2006, TRENDS BIOCHEM SCI, V31, P355, DOI 10.1016/j.tibs.2006.05.003; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SCOTT AM, 1981, DIABETOLOGIA, V21, P470; Simoneau JA, 1998, FASEB J, V12, P1739, DOI 10.1096/fasebj.12.15.1739; Sluse FE, 2006, BBA-BIOENERGETICS, V1757, P480, DOI 10.1016/j.bbabio.2006.02.004; Smith RA, 2006, J CLIN INVEST, V116, P2290, DOI 10.1172/JCI25424; Tonkonogi M, 1997, ACTA PHYSIOL SCAND, V161, P345, DOI 10.1046/j.1365-201X.1997.00222.x; TRINDER P, 1969, J CLIN PATHOL, V22, P158, DOI 10.1136/jcp.22.2.158; Zhang CY, 2006, CELL METAB, V3, P417, DOI 10.1016/j.cmet.2006.04.010; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	45	71	72	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2007	21	4					1153	1163		10.1096/fj.06-7148com	http://dx.doi.org/10.1096/fj.06-7148com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17209127				2022-12-28	WOS:000245650400020
J	Tohami, T; Drucker, L; Shapiro, H; Radnay, J; Lishner, M				Tohami, Tali; Drucker, Liat; Shapiro, Hava; Radnay, Judith; Lishner, Michael			Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential	FASEB JOURNAL			English	Article						CD82; CD81; CAG; RPMI 8226	MICRODOMAINS; EXPRESSION; PROTEINS; CD82; ADHESION; GROWTH; AKT; CD9; METASTASIS; ACTIVATION	Cellular interactions with microenvironmental components are critical in multiple myeloma (MM) and impede effective disease treatment. Membranal-embedded tetraspanins, associated with metastasis suppression, are underexpressed in MM. We aimed to investigate the consequences of CD81/CD82 tetraspanins over-expression in MM cell lines. CAG and RPMI 8226 were transfected with pEGFP-N1/C1 fusion vectors of CD81/CD82. Employing flow cytometry, immunocytochemistry, and activity assays we assessed transfected cells for: morphology, survival, death, caspases, cell cycle, proliferation, oxidative stress, adhesion, motility and invasion. Overexpressed CD81/CD82 pEGFP-N1 vectors reduced survival without elevation of pre-G1 or AnnexinV+/7AAD- and independently of caspases. Decreased Ki67 and elevated intracellular glutathione were detected. No perturbations in cell cycle distribution were observed. The pEGFP-C1 vectors of CD81/CD82 caused reduction of MM cell adherence with/without fibronectin, insulin-like growth factor (IGF)-I, and matrigel. They also reduced cell motility and attenuated invasion potential, expressed by reduced secreted MMP-9 activity. These novel findings delineate the significance of CD81/CD82 expression to MM cell survival and their negative effects on cell adhesion, motility, and invasion thus, supporting their role as tumor metastasis suppressors.	Meir Med Ctr, Oncogenet Lab, IL-44281 Kefar Sava, Israel; Meir Med Ctr, Hematol Lab, IL-44281 Kefar Sava, Israel; Tel Aviv Univ, Meir Med Ctr, Dept Internal Med, IL-44281 Kefar Sava, Israel; Tel Aviv Univ, Kfar Saba, IL-44281 Kefar Sava, Israel; Tel Aviv Univ, Sackler Fac Med, IL-44281 Kefar Sava, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Drucker, L (corresponding author), Meir Med Ctr, Oncogenet Lab, IL-44281 Kefar Sava, Israel.	druckerl@clalit.org.il						Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Boucheix C., 2001, EXPERT REV MOL MED, V2001, P1; Bruno B, 2005, LEUKEMIA, V19, P1729, DOI 10.1038/sj.leu.2403905; Cacciotti P, 2005, CANCER RES, V65, P5256, DOI 10.1158/0008-5472.CAN-05-0127; Csordas A, 2006, EXP CELL RES, V312, P1753, DOI 10.1016/j.yexcr.2006.02.005; Delaguillaumie A, 2004, J CELL SCI, V117, P5269, DOI 10.1242/jcs.01380; Drucker L, 2006, CARCINOGENESIS, V27, P197, DOI 10.1093/carcin/bgi209; Epstein Joshua, 2003, Hematol J, V4, P310, DOI 10.1038/sj.thj.6200313; Guo XZ, 2005, ONCOL REP, V14, P59; He B, 2005, J BIOL CHEM, V280, P3346, DOI 10.1074/jbc.M406680200; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hong IK, 2005, EXP MOL MED, V37, P230, DOI 10.1038/emm.2005.31; Kanavaros P, 2000, ANTICANCER RES, V20, P4619; Kelly T, 2000, LEUKEMIA LYMPHOMA, V37, P273, DOI 10.3109/10428190009089428; Mazzocca A, 2005, J BIOL CHEM, V280, P11329, DOI 10.1074/jbc.M410161200; OCONNOR JE, 1988, CYTOMETRY, V9, P529, DOI 10.1002/cyto.990090604; Oliver L, 2005, DRUG RESIST UPDATE, V8, P163, DOI 10.1016/j.drup.2005.05.001; Ono M, 1999, CANCER RES, V59, P2335; Rinaldi R, 2002, DRUG METAB DISPOS, V30, P1053, DOI 10.1124/dmd.30.10.1053; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Schoenfeld N, 2004, FASEB J, V18, P158, DOI 10.1096/fj.03-0420fje; Tai YT, 2003, CANCER RES, V63, P5850; Teoh G, 1997, HEMATOL ONCOL CLIN N, V11, P27, DOI 10.1016/S0889-8588(05)70413-5; Tohami T, 2004, TISSUE ANTIGENS, V64, P235, DOI 10.1111/j.1399-0039.2004.00271.x; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; Wright MD, 2004, TISSUE ANTIGENS, V64, P533, DOI 10.1111/j.1399-0039.2004.00321.x; Yu YJ, 2002, J VIROL, V76, P3731, DOI 10.1128/JVI.76.8.3731-3738.2002; Yuan H, 2002, J VIROL, V76, P10685, DOI 10.1128/JVI.76.21.10685-10691.2002; Yunta M, 2003, CELL SIGNAL, V15, P559, DOI 10.1016/S0898-6568(02)00147-X; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	30	45	48	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					691	699		10.1096/fj.06-6610com	http://dx.doi.org/10.1096/fj.06-6610com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17210782				2022-12-28	WOS:000244686400008
J	Mulder, WJM; van der Schaft, DWJ; Hautvast, PAI; Strijkers, GJ; Koning, GA; Storm, G; Mayo, KH; Griffioen, AW; Nicolay, K				Mulder, Willem J. M.; van der Schaft, Daisy W. J.; Hautvast, Petra A. I.; Strijkers, Gustav J.; Koning, Gerben A.; Storm, Gert; Mayo, Kevin H.; Griffioen, Aijan W.; Nicolay, Klaas			Early in vivo assessment of angiostatic therapy efficacy by molecular MRI	FASEB JOURNAL			English	Article						molecular imaging; tumor angiogenesis; a nu beta 3-integrin	TUMOR-GROWTH; ANGIOGENESIS INHIBITORS; 1.5 TESLA; ENDOSTATIN; ANGINEX; NANOPARTICLE; MICROSCOPY; PEPTIDE; TARGETS; CANCER	Noninvasive diagnostic imaging methods to establish the efficacy of angiostatic therapies are becoming increasingly important with the first Food and Drug Administration approvals of such agents. Magnetic resonance molecular imaging is an imaging technique that allows the visualization of pathological processes in vivo with a better spatial resolution as compared with nuclear methods, such as photon emission tomography and single photon emission computed tomography. In this study, we used alpha v beta 3 targeted bimodal liposomes to quantitate angiogenesis in a tumor mouse model with magnetic resonance imaging (MRI) and to evaluate the therapeutic efficacy of the angiogenesis inhibitors anginex and endostatin. The MRI findings were validated with fluorescence microscopy and showed a very good correlation with the microvessel density. In conclusion, this study provides evidence that molecular MRI can be used to noninvasively measure the efficacy of angiogenesis inhibitors during the course of therapy.	Eindhoven Univ Technol, Biomed NMR, Dept Biomed Engn, NL-5600 MB Eindhoven, Netherlands; Maastricht Univ, Angiogenesis Lab, Res Inst Growth & Dev, Dept Pathol Internal Med, Maastricht, Netherlands; Univ Hosp Maastricht, Maastricht, Netherlands; Delft Univ Technol, Dept Radiat Radioisotopes & Reactors, Fac Sci Appl, Delft, Netherlands; Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Utrecht, Netherlands; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN USA	Eindhoven University of Technology; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Delft University of Technology; Utrecht University; University of Minnesota System; University of Minnesota Twin Cities	Mulder, WJM (corresponding author), Eindhoven Univ Technol, Biomed NMR, Dept Biomed Engn, POB 513, NL-5600 MB Eindhoven, Netherlands.	w.j.m.mulder@tue.nl	Nicolay, Klaas/F-4192-2010; Storm, Gerrit/O-8696-2016; Mulder, Willem J.M./B-7232-2009; Koning, Gerben A/K-2326-2012; Strijkers, Gustav J/H-3158-2011	Mulder, Willem J.M./0000-0001-8665-3878; Koning, Gerben A/0000-0003-3090-2403; Strijkers, Gustav/0000-0001-6700-5058; Nicolay, Klaas/0000-0002-4179-616X				Abdollahi A, 2005, DRUG RESIST UPDATE, V8, P59, DOI 10.1016/j.drup.2005.03.001; Beliveau R, 2002, CLIN CANCER RES, V8, P1242; Benezra R, 2004, CANCER CELL, V5, P205, DOI 10.1016/S1535-6108(04)00057-1; Dafni H, 2002, CANCER RES, V62, P6731; de Lussanet QG, 2004, EUR J CANCER, V40, P1262, DOI 10.1016/j.ejca.2004.01.020; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Griffioen AW, 2001, BIOCHEM J, V354, P233, DOI 10.1042/0264-6021:3540233; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kracht LW, 2003, EUR J NUCL MED MOL I, V30, P868, DOI 10.1007/s00259-003-1148-7; MATTHEWS K, 2006, NAT CLIN PRACT ONCOL, V3, P119; Moulton K S, 2001, Curr Atheroscler Rep, V3, P225, DOI 10.1007/s11883-001-0065-0; Mulder WJM, 2005, FASEB J, V19, P2008, DOI 10.1096/fj.05-4145fje; Mulder WJM, 2004, BIOCONJUGATE CHEM, V15, P799, DOI 10.1021/bc049949r; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; ROCCARO AM, 2005, ALLERGY, V4, P27; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; van der Schaft DWJ, 2002, FASEB J, V16, P1991, DOI 10.1096/fj.02-0509fje; Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701; Weissleder R, 2001, RADIOLOGY, V219, P316, DOI 10.1148/radiology.219.2.r01ma19316; Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219; Winter PM, 2003, CANCER RES, V63, P5838; Winter PM, 2003, CIRCULATION, V108, P2270, DOI 10.1161/01.CIR.0000093185.16083.95; Zhao M, 2001, NAT MED, V7, P1241, DOI 10.1038/nm1101-1241	25	73	77	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					378	383		10.1096/fj.06-6791com	http://dx.doi.org/10.1096/fj.06-6791com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17202248				2022-12-28	WOS:000244686300011
J	Thompson, K; Molina, RM; Donaghey, T; Schwob, JE; Brain, JD; Wessling-Resnick, M				Thompson, Khristy; Molina, Ramon M.; Donaghey, Thomas; Schwob, James E.; Brain, Joseph D.; Wessling-Resnick, Marianne			Olfactory uptake of manganese requires DMT1 and is enhanced by anemia	FASEB JOURNAL			English	Article						Belgrade rat; iron deficiency	BELGRADE LABORATORY RAT; METAL-ION TRANSPORTER; IRON-DEFICIENCY; TRICARBONYL MMT; NERVOUS-SYSTEM; DRINKING-WATER; DIETARY IRON; NASAL-MUCOSA; BASAL-CELLS; BRAIN	Manganese, an essential nutrient, can also elicit toxicity in the central nervous system (CNS). The route of exposure strongly influences the potential neurotoxicity of manganese-containing compounds. Recent studies suggest that inhaled manganese can enter the rat brain through the olfactory system, but little is known about the molecular factors involved. Divalent metal transporter-1 (DMT1) is the major transporter responsible for intestinal iron absorption and its expression is regulated by body iron status. To examine the potential role of this transporter in uptake of inhaled manganese, we studied the Belgrade rat, since these animals display significant defects in both iron and manganese metabolism due to a glycine-to-arginine substitution (G185R) in their DMT1 gene product. Absorption of intranasally instilled Mn-54 was significantly reduced in Belgrade rats and was enhanced in iron-deficient rats compared to iron-sufficient controls. Immunohistochemical experiments revealed that DMT1 was localized to both the lumen microvilli and end feet of the sustentacular cells of the olfactory epithelium. Importantly, we found that DMT1 protein levels were increased in anemic rats. The apparent function of DMT1 in olfactory manganese absorption suggests that the neurotoxicity of the metal can be modified by iron status due to the iron-responsive regulation of the transporter.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University	Wessling-Resnick, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	wessling@hsph.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES014638, P01ES012874] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK060528-02, R01 DK060528, R01 DK060528-01A1, DK60528/ES014638] Funding Source: Medline; NIEHS NIH HHS [R01 ES014638-03A1, R01 ES014638, P01 ES012874, R01 ES014638-04] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andersen ME, 1999, NEUROTOXICOLOGY, V20, P161; Aschner M, 2005, CRIT REV TOXICOL, V35, P1, DOI 10.1080/10408440590905920; BARBEAU A, 1984, NEUROTOXICOLOGY, V5, P13; Barbeau A, 1976, Adv Neurol, V14, P339; Beard JL, 2003, ANNU REV NUTR, V23, P41, DOI 10.1146/annurev.nutr.23.020102.075739; BOWEN BJ, 1987, BLOOD, V70, P38; Brenneman KA, 2000, TOXICOL APPL PHARM, V169, P238, DOI 10.1006/taap.2000.9073; Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; CHANDRA SV, 1976, ARCH TOXICOL, V35, P319, DOI 10.1007/BF00570272; Chua ACG, 1997, J COMP PHYSIOL B, V167, P361, DOI 10.1007/s003600050085; Chua ACG, 1996, BIOL TRACE ELEM RES, V55, P39, DOI 10.1007/BF02784167; COLLIPP PJ, 1983, ANN NUTR METAB, V27, P488, DOI 10.1159/000176724; Conrad ME, 2000, AM J PHYSIOL-GASTR L, V279, pG767, DOI 10.1152/ajpgi.2000.279.4.G767; COTZIAS GC, 1958, PHYSIOL REV, V38, P503, DOI 10.1152/physrev.1958.38.3.503; Crinella FM, 1998, NEUROTOXICOLOGY, V19, P468; Crossgrove JS, 2004, NEUROTOXICOLOGY, V25, P451, DOI 10.1016/j.neuro.2003.10.005; DAVIS CD, 1992, AM J CLIN NUTR, V56, P926, DOI 10.1093/ajcn/56.5.926; Ding XX, 2003, ANNU REV PHARMACOL, V43, P149, DOI 10.1146/annurev.pharmtox.43.100901.140251; Dobson AW, 2003, BIOL TRACE ELEM RES, V93, P113, DOI 10.1385/BTER:93:1-3:113; DONALDSON J, 1987, NEUROTOXICOLOGY, V8, P451; EDWARDS J, 1986, BLOOD, V67, P623; EDWARDS JA, 1980, BLOOD, V55, P645; Ellingsen DG, 2003, J APPL TOXICOL, V23, P239, DOI 10.1002/jat.913; Finley JW, 1999, AM J CLIN NUTR, V70, P37; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Forbes JR, 2003, BLOOD, V102, P1884, DOI 10.1182/blood-2003-02-0425; Frieden C.L, 1984, BIOCH ESSENTIAL ULTR, P97, DOI 10.1007/978-1-4684-4775-0; Garrick M, 1997, BIOMETALS, V10, P65, DOI 10.1023/A:1018370804882; Garrick Michael D, 2002, Methods Mol Biol, V196, P147; Goldstein BJ, 1996, J NEUROSCI, V16, P4005; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gunshin H, 2001, FEBS LETT, V509, P309, DOI 10.1016/S0014-5793(01)03189-1; HINDERER RK, 1979, AM IND HYG ASSOC J, V40, P164, DOI 10.1080/15298667991429462; HOLBROOK EH, 1995, J COMP NEUROL, V363, P129, DOI 10.1002/cne.903630111; Iwema CL, 2003, J COMP NEUROL, V459, P209, DOI 10.1002/cne.10583; JAFEK BW, 1983, LARYNGOSCOPE, V93, P1576, DOI 10.1288/00005537-198312000-00011; JOSELOW MM, 1978, AM J PUBLIC HEALTH, V68, P557, DOI 10.2105/AJPH.68.6.557; Kaiser J, 2003, SCIENCE, V300, P926, DOI 10.1126/science.300.5621.926; Kimbell JS, 1997, TOXICOL APPL PHARM, V145, P388, DOI 10.1006/taap.1997.8206; KONDAKIS XG, 1989, ARCH ENVIRON HEALTH, V44, P175, DOI 10.1080/00039896.1989.9935883; KulkarniNarla A, 1996, EXP NEUROL, V140, P115, DOI 10.1006/exnr.1996.0122; Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186; Lynam DR, 1999, NEUROTOXICOLOGY, V20, P145; MELLERT TK, 1992, OTOLARYNG HEAD NECK, V106, P181, DOI 10.1177/019459989210600221; MENA I, 1969, NEUROLOGY, V19, P1000, DOI 10.1212/WNL.19.10.1000; MENA I, 1974, ANN CLIN LAB SCI, V4, P487; Mergler D, 1999, NEUROTOXICOLOGY, V20, P327; MERGLER D, 1994, ENVIRON RES, V64, P151, DOI 10.1006/enrs.1994.1013; Moy RJD, 1999, J ROY SOC MED, V92, P234, DOI 10.1177/014107689909200505; PIHL RO, 1977, SCIENCE, V198, P204, DOI 10.1126/science.905825; Ressler T, 1999, J SYNCHROTRON RADIAT, V6, P656, DOI 10.1107/S0909049598015623; Roels H, 1997, ARCH TOXICOL, V71, P223, DOI 10.1007/s002040050380; Roth JA, 2003, BIOCHEM PHARMACOL, V66, P1, DOI 10.1016/S0006-2952(03)00145-X; Tjalve H, 1996, PHARMACOL TOXICOL, V79, P347; Tjalve H, 1999, NEUROTOXICOLOGY, V20, P181; Trinder D, 2000, GUT, V46, P270, DOI 10.1136/gut.46.2.270; Wasserman GA, 2006, ENVIRON HEALTH PERSP, V114, P124, DOI 10.1289/ehp.8030; Woolf A, 2002, ENVIRON HEALTH PERSP, V110, P613, DOI 10.1289/ehp.02110613; Wright RO, 2006, NEUROTOXICOLOGY, V27, P210, DOI 10.1016/j.neuro.2005.10.001; YOKOI K, 1991, BIOL TRACE ELEM RES, V29, P257, DOI 10.1007/BF03032682; Zayed J, 1999, INT ARCH OCC ENV HEA, V72, P7, DOI 10.1007/s004200050327	61	99	101	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					223	230		10.1096/fj.06-6710com	http://dx.doi.org/10.1096/fj.06-6710com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17116743	Green Accepted			2022-12-28	WOS:000243130200024
J	Mitchell, JA; Lucas, R; Vojnovic, I; Hasan, K; Pepper, JR; Warner, TD				Mitchell, Jane A.; Lucas, Ruth; Vojnovic, Ivana; Hasan, Kamrul; Pepper, John R.; Warner, Timothy D.			Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events	FASEB JOURNAL			English	Article						prostacyclin; thromboxane A2; thrombosis; cyclooxygenase-2	NITRIC-OXIDE SYNTHASE; LOW-DOSE ASPIRIN; CLINICAL PHARMACOKINETICS; RHEUMATOID-ARTHRITIS; SHEAR-STRESS; CYCLO-OXYGENASE-2 INHIBITORS; GASTROINTESTINAL TOXICITY; PROSTACYCLIN SYNTHESIS; MYOCARDIAL-INFARCTION; RANDOMIZED-TRIALS	Recent data have suggested that regular consumption of nonsteroid anti-inflammatory drugs (NSAIDs), particularly selective inhibitors of cyclooxygenase-2 (COX-2), is associated with an increased risk of thrombotic events. It has been suggested that this is due to NSAIDs reducing the release from the endothelium of the antithrombotic mediator prostaglandin I-2 as a result of inhibition of endothelial COX-2. Here, however, we show that despite normal human vessels and endothelial cells containing cyclooxygenase-1 (COX-1) without any detectable COX-2, COX-1 in vessels or endothelial cells is more readily inhibited by NSAIDs and COX-2-selective drugs than COX-1 in platelets (e. g., log IC50 +/- SEM values for endothelial cells vs. platelets: naproxen -5.59 +/- 0.07 vs. -4.81 +/- 0.04; rofecoxib -4.93 +/- 0.04 vs. -3.75 +/- 0.03; n = 7). In broken cell preparations, the selectivities of the tested drugs toward endothelial cell over platelet COX-1 were lost. These observations suggest that variations in cellular conditions, such as endogenous peroxide tone and substrate supply, and not the isoform of cyclo-oxygenase present, dictate the effects of NSAIDs on endothelial cells vs. platelets. This may well be because the platelet is not a good representative of COX-1 activity within the body as it produces prostanoids in an explosive burst that does not reflect tonic release from other cells. The results reported here can offer an explanation for the apparent ability of NSAIDs and COX-2-selective inhibitors to increase the risk of myocardial infarction and stroke.-Mitchell, J. A., Lucas, R., Vojnovic, I., Hasan, K., Pepper, J. R., Warner, T. D. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events.	Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England; Imperial Coll Sch Med, Royal Brompton Hosp, Unit Crit Care Med, London, England	University of London; Queen Mary University London; Imperial College London; Royal Brompton Hospital	Warner, TD (corresponding author), Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	j.a.mitchell@imperial.ac.uk; t.d.warner@qmul.ac.uk	Warner, Timothy D/A-1980-2009; hasan, kamrul/HGV-0910-2022; Lucas, Rut/H-6050-2015; Mitchell, Jane A/A-1991-2009	Warner, Timothy D/0000-0003-3988-4408; Lucas, Rut/0000-0002-4697-7832; 				Andersohn F, 2006, CIRCULATION, V113, P1950, DOI 10.1161/CIRCULATIONAHA.105.602425; Baber SR, 2003, CIRCULATION, V108, P896, DOI 10.1161/01.CIR.0000084536.87322.BB; Benedek IH, 1995, J CLIN PHARMACOL, V35, P1181, DOI 10.1002/j.1552-4604.1995.tb04044.x; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Boutaud O, 2002, P NATL ACAD SCI USA, V99, P7130, DOI 10.1073/pnas.102588199; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540; Costa C, 2002, J CLIN PATHOL, V55, P429, DOI 10.1136/jcp.55.6.429; Davidge ST, 2001, CIRC RES, V89, P650, DOI 10.1161/hh2001.098351; Davies NM, 1998, CLIN PHARMACOKINET, V34, P101, DOI 10.2165/00003088-199834020-00002; Davies NM, 2000, CLIN PHARMACOKINET, V38, P225, DOI 10.2165/00003088-200038030-00003; Davies NM, 2003, CLIN PHARMACOKINET, V42, P545, DOI 10.2165/00003088-200342060-00004; Davies NM, 1997, CLIN PHARMACOKINET, V32, P268, DOI 10.2165/00003088-199732040-00002; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Dogne JM, 2005, TRENDS PHARMACOL SCI, V26, P639, DOI 10.1016/j.tips.2005.10.001; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264-6021:3390607; GISLASON GH, 2006, IN PRESS CIRCULATION; Gonzalez-Correa JA, 2005, PLATELETS, V16, P171, DOI 10.1080/09537100400016797; Graupera M, 2003, HEPATOLOGY, V37, P172, DOI 10.1053/jhep.2003.50004; GREEN K, 1989, PROSTAG OTH LIPID M, V37, P311, DOI 10.1016/0090-6980(89)90001-4; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Hippisley-Cox J, 2005, BMJ-BRIT MED J, V330, P1366, DOI 10.1136/bmj.330.7504.1366; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Johnson ES, 1999, ARCH INTERN MED, V159, P1248, DOI 10.1001/archinte.159.11.1248; Kang RY, 1996, BRIT J RHEUMATOL, V35, P711; Kearney PM, 2006, BMJ-BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302; Komhoff M, 1997, AM J PHYSIOL-RENAL, V272, pF460, DOI 10.1152/ajprenal.1997.272.4.F460; KYRLE PA, 1987, CIRCULATION, V75, P1025, DOI 10.1161/01.CIR.75.5.1025; Lazzaroni M, 2004, ALIMENT PHARM THER, V20, P48, DOI 10.1111/j.1365-2036.2004.02037.x; Lucas R, 2005, FASEB J, V19, P635, DOI 10.1096/fj.04-2437fje; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Mitchell JA, 2006, NAT REV DRUG DISCOV, V5, P75, DOI 10.1038/nrd1929; O'Grady A, 2004, HUM PATHOL, V35, P1549, DOI 10.1016/j.humpath.2004.08.010; Okahara K, 1998, ARTERIOSCL THROM VAS, V18, P1922, DOI 10.1161/01.ATV.18.12.1922; PEDERSEN AK, 1984, NEW ENGL J MED, V311, P1206, DOI 10.1056/NEJM198411083111902; Riendeau D, 1997, BRIT J PHARMACOL, V121, P105, DOI 10.1038/sj.bjp.0701076; Sanmuganathan PS, 2001, HEART, V85, P265, DOI 10.1136/heart.85.3.265; Singh G, 2003, J RHEUMATOL, V30, P714; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Sonis ST, 2004, ORAL ONCOL, V40, P170, DOI 10.1016/S1368-8375(03)00148-9; Tabernero A, 2003, INTENS CARE MED, V29, P262, DOI 10.1007/s00134-002-1617-7; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Wallace JL, 1996, CAN J GASTROENTEROL, V10, P451, DOI 10.1155/1996/850710; Wang WZ, 2005, CLIN CANCER RES, V11, P3250, DOI 10.1158/1078-0432.CCR-04-2405; Warner TD, 2006, FASEB J, V20, P542, DOI 10.1096/fj.05-4434fje; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Yu HG, 2003, CANCER LETT, V195, P43, DOI 10.1016/S0304-3835(03)00153-8	51	56	57	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2468	2475		10.1096/fj.06-6615com	http://dx.doi.org/10.1096/fj.06-6615com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17142796				2022-12-28	WOS:000242490700007
J	Getting, SJ; Lam, CW; Chen, AS; Grieco, P; Perretti, M				Getting, Stephen J.; Lam, Connie W.; Chen, Airu S.; Grieco, Paolo; Perretti, Mauro			Melanocortin 3 receptors control crystal-induced inflammation	FASEB JOURNAL			English	Article						neutrophil trafficking; macrophage activation; anti-inflammation; drug discovery	MELANOCYTE-STIMULATING HORMONE; NF-KAPPA-B; ALPHA-MSH; ANTIINFLAMMATORY ACTIONS; TYPE-3 RECEPTOR; PEPTIDES; MACROPHAGES; MODULATION; ACTIVATION; MECHANISMS	In this study we have characterized the anti-inflammatory profile of a selective melanocortin type 3 receptor (MC3-R) ligand [D-Trp(8)]-gamma-MSH, validating in vitro results with analyses in mice deficient for this receptor subtype. In wild-type (WT) macrophages, [D-Trp(8)]-gamma-MSH activated MC3-R (as tested by accumulation of cyclic AMP) and inhibited (similar to 50%) the release of interleukin (IL)-1 and the chemokine KC (CXCL1), but was ineffective in cells taken from MC3-R null mice. In vivo, administration of 3-30 mu g [D-Trp(8)]-gamma-MSH significantly inhibited leukocyte influx and cytokine production in a model of crystal-induced peritonitis, and these effects were absent in MC3-R null mice or blocked by coadministration of an MC3-R antagonist. Finally, in a model of gouty arthritis, direct injection of urate crystals into the rat joint provoked a marked inflammatory reaction that was significantly inhibited (similar to 70%) by systemic or local administration of [D-Trp(8)]-gamma-MSH. In conclusion, using an integrated transgenic and pharmacological approach, we provide strong proof of concept for the development of selective MC3-R agonists as novel anti-inflammatory therapeutics. - Getting, S. J., Lam, C. W., Chen, A. S., Grieco, P., Perretti, M. Melanocortin 3 receptors control crystal-induced inflammation.	Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England; Merck Res Labs, Rahway, NJ USA; Univ Naples Federico II, Dept Pharmaceut Chem & Toxicol, Naples, Italy	University of London; Queen Mary University London; Merck & Company; University of Naples Federico II	Perretti, M (corresponding author), Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	m.perretti@qmul.ac.uk	Grieco, Paolo/AAB-9034-2019	Grieco, Paolo/0000-0002-6854-8123				Abdel-Malek ZA, 2001, J CELL SCI, V114, P1019; Adachi S, 1999, J IMMUNOL, V163, P3363; BRANDT KD, 1995, CURR OPIN RHEUMATOL, V7, P343; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Catania A, 2004, PHARMACOL REV, V56, P1, DOI 10.1124/pr.56.1.1; Catania A, 2000, TRENDS ENDOCRIN MET, V11, P304, DOI 10.1016/S1043-2760(00)00296-4; Catania A, 1996, PEPTIDES, V17, P675, DOI 10.1016/0196-9781(96)00037-X; Ceriani Giuliana, 1994, Neuroimmunomodulation, V1, P28, DOI 10.1159/000097087; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Ellacott KLJ, 2004, RECENT PROG HORM RES, V59, P395, DOI 10.1210/rp.59.1.395; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Gantz I, 2003, AM J PHYSIOL-ENDOC M, V284, pE468, DOI 10.1152/ajpendo.00434.2002; GEBOREK P, 1990, RHEUMATOL INT, V9, P265, DOI 10.1007/BF00541322; Getting SJ, 2004, J LEUKOCYTE BIOL, V76, P845, DOI 10.1189/jlb.0306175; Getting SJ, 1997, J PHARMACOL EXP THER, V283, P123; Getting SJ, 2002, ARTHRITIS RHEUM, V46, P2765, DOI 10.1002/art.10526; Getting SJ, 2002, TRENDS PHARMACOL SCI, V23, P447, DOI 10.1016/S0165-6147(02)02103-X; Getting SJ, 1999, J IMMUNOL, V162, P7446; Getting SJ, 2003, J IMMUNOL, V170, P3323, DOI 10.4049/jimmunol.170.6.3323; Getting SJ, 2001, J LEUKOCYTE BIOL, V69, P98; Grieco P, 2000, J MED CHEM, V43, P4998, DOI 10.1021/jm000211e; Guarini S, 2002, N-S ARCH PHARMACOL, V366, P177, DOI 10.1007/s00210-002-0572-8; GUTMAN AB, 1950, AM J MED, V9, P24, DOI 10.1016/0002-9343(50)90004-0; HENCH PS, 1949, P STAFF M MAYO CLIN, V24, P181; HRUBY VJ, 1995, J MED CHEM, V38, P3454, DOI 10.1021/jm00018a005; Kalden DH, 1999, ANN NY ACAD SCI, V885, P254; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; Lam CW, 2006, PEPTIDES, V27, P404, DOI 10.1016/j.peptides.2005.01.031; Lam CW, 2005, J IMMUNOL, V174, P2297, DOI 10.4049/jimmunol.174.4.2297; Lipton JM, 1997, IMMUNOL TODAY, V18, P140, DOI 10.1016/S0167-5699(97)01009-8; Manna SK, 1998, J IMMUNOL, V161, P2873; Martin WJ, 2004, EUR UROL, V45, P706, DOI 10.1016/j.eururo.2003.03.001; Mioni C, 2003, EUR J PHARMACOL, V477, P227, DOI 10.1016/S0014-2999(03)02184-8; PENHOAT A, 1989, P NATL ACAD SCI USA, V86, P4978, DOI 10.1073/pnas.86.13.4978; Raap U, 2003, J IMMUNOL, V171, P353, DOI 10.4049/jimmunol.171.1.353; Rajora N, 1997, PEPTIDES, V18, P381, DOI 10.1016/S0196-9781(96)00345-2; RITTER J, 1994, J RHEUMATOL, V21, P696; Schiller M, 2004, J INVEST DERMATOL, V122, P468, DOI 10.1046/j.0022-202X.2004.22239.x; Schioth HB, 1998, BRIT J PHARMACOL, V124, P75, DOI 10.1038/sj.bjp.0701804; Scholzen TE, 2005, EXP DERMATOL, V14, P158, DOI 10.1111/j.0906-6705.2005.0266r.x; Taherzadeh S, 1999, AM J PHYSIOL-REG I, V276, pR1289, DOI 10.1152/ajpregu.1999.276.5.R1289; Wikberg JES, 2000, PHARMACOL RES, V42, P393, DOI 10.1006/phrs.2000.0725; Yang YH, 1997, INFLAMMATION, V21, P583, DOI 10.1023/A:1027330021479	43	57	58	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2234	2241		10.1096/fj.06-6339com	http://dx.doi.org/10.1096/fj.06-6339com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077300				2022-12-28	WOS:000241702600008
J	Palazuelos, J; Aguado, T; Egia, A; Mechoulam, R; Guzman, M; Galve-Roperh, I				Palazuelos, Javier; Aguado, Tania; Egia, Ainara; Mechoulam, Raphael; Guzman, Manuel; Galve-Roperh, Ismael			Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation	FASEB JOURNAL			English	Article						signaling systems; hippocampus; neurogenesis	RECEPTOR; BRAIN; NEUROGENESIS; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; LOCALIZATION; INVOLVEMENT; ACTIVATION; MIGRATION	Cannabinoids, the active components of marijuana and their endogenous counterparts, act on the brain and many other organs through the widely expressed CB1 cannabinoid receptor. In contrast, the CB2 cannabinoid receptor is abundant in the immune system and shows a restricted expression pattern in brain cells. CB2-selective agonists are, therefore, very attractive therapeutic agents as they do not cause CB1-mediated psychoactive effects. CB2 receptor expression in brain has been partially examined in differentiated cells, while its presence and function in neural progenitor cells remain unknown. Here we show that the CB2 receptor is expressed, both in vitro and in vivo, in neural progenitors from late embryonic stages to adult brain. Selective pharmacological activation of the CB2 receptor in vitro promotes neural progenitor cell proliferation and neurosphere generation, an action that is impaired in CB2-deficient cells. Accordingly, in vivo experiments evidence that hippocampal progenitor proliferation is increased by administration of the CB2-selective agonist HU-308. Moreover, impaired progenitor proliferation was observed in CB2-deficient mice both in normal conditions and on kainate-induced excitotoxicity. These findings provide a novel physiological role for the CB2 cannabinoid receptor and open a novel therapeutic avenue for manipulating neural progenitor cell fate.	Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; Hebrew Univ Jerusalem, Sch Pharm, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel	Complutense University of Madrid; Hebrew University of Jerusalem	Guzman, M (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain.	mgp@bbm1.ucm.es; igr@quim.ucm.es	PALAZUELOS, JAVIER/D-1211-2013; PALAZUELOS, JAVIER/AAD-7313-2020; Aguado, Tania/AAE-3972-2019; AGUADO SANCHEZ, TANIA/ABD-6975-2021; Galve-Roperh, Ismael/AAG-2369-2020	PALAZUELOS, JAVIER/0000-0002-0409-1398; AGUADO SANCHEZ, TANIA/0000-0003-4339-0443; Guzman, Manuel/0000-0001-7475-118X				Aguado T, 2005, FASEB J, V19, P1704, DOI 10.1096/fj.05-3995fje; Aguado T, 2006, J NEUROSCI, V26, P1551, DOI 10.1523/JNEUROSCI.3101-05.2006; Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Ashton JC, 2006, NEUROSCI LETT, V396, P113, DOI 10.1016/j.neulet.2005.11.038; Berghuis P, 2005, P NATL ACAD SCI USA, V102, P19115, DOI 10.1073/pnas.0509494102; Bernard C, 2005, P NATL ACAD SCI USA, V102, P9388, DOI 10.1073/pnas.0409641102; Bilkei-Gorzo A, 2005, P NATL ACAD SCI USA, V102, P15670, DOI 10.1073/pnas.0504640102; BOUABOULA M, 1995, J BIOL CHEM, V270, P13973, DOI 10.1074/jbc.270.23.13973; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Carayon P, 1998, BLOOD, V92, P3605, DOI 10.1182/blood.V92.10.3605.422k05_3605_3615; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Eljaschewitsch E, 2006, NEURON, V49, P67, DOI 10.1016/j.neuron.2005.11.027; Fernandez-Ruiz J, 2000, TRENDS NEUROSCI, V23, P14, DOI 10.1016/S0166-2236(99)01491-5; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Gong JP, 2006, BRAIN RES, V1071, P10, DOI 10.1016/j.brainres.2005.11.035; Gotz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968-0896(99)00219-9; Ibrahim MM, 2005, P NATL ACAD SCI USA, V102, P3093, DOI 10.1073/pnas.0409888102; Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509; Jorda MA, 2004, BLOOD, V104, P526, DOI 10.1182/blood-2003-12-4257; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nunez E, 2004, SYNAPSE, V53, P208, DOI 10.1002/syn.20050; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Rueda D, 2002, J BIOL CHEM, V277, P46645, DOI 10.1074/jbc.M206590200; Sanchez C, 2001, CANCER RES, V61, P5784; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sinha D, 1998, J NEUROIMMUNOL, V82, P13, DOI 10.1016/S0165-5728(97)00181-1; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Villa A, 2000, EXP NEUROL, V161, P67, DOI 10.1006/exnr.1999.7237; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667	40	166	173	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2405	+		10.1096/fj.06-6164fje	http://dx.doi.org/10.1096/fj.06-6164fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17015409				2022-12-28	WOS:000241702600035
J	van Driel, M; Koedam, M; Buurman, CJ; Hewison, M; Chiba, H; Uitterlinden, AG; Pols, HAP; van Leeuwen, JPTM				van Driel, M.; Koedam, M.; Buurman, C. J.; Hewison, M.; Chiba, H.; Uitterlinden, A. G.; Pols, H. A. P.; van Leeuwen, J. P. T. M.			Evidence for auto/paracrine actions of vitamin D in bone: 1 alpha-hydroxylase expression and activity in human bone cells	FASEB JOURNAL			English	Article						calcium homeostasis; PBMCs; osteoblasts; osteoclasts	PROSTATE-CANCER CELLS; 25-HYDROXYVITAMIN D-3-1-ALPHA-HYDROXYLASE; 1,25-DIHYDROXYVITAMIN D-3; HUMAN KERATINOCYTES; D METABOLISM; D-RECEPTOR; D-1-ALPHA-HYDROXYLASE; HYPERPARATHYROIDISM; HYPERCALCEMIA; SARCOIDOSIS	Vitamin D is an important regulator of mineral homeostasis and bone metabolism. 1 alpha-Hydroxylation of 25-(OH)D-3 to form the bioactive vitamin D hormone, 1 alpha, 25-(OH)(2)D-3, is classically considered to take place in the kidney. However, 1 alpha-hydroxylase has been reported at extrarenal sites. Whether bone is a 1 alpha,25-(OH)(2)D-3 synthesizing tissue is not univocal. The aim of this study was to investigate an autocrine/paracrine function for 1 alpha,25-(OH)(2)D-3 in bone. We show that 1 alpha-hydroxlase is expressed in human osteoblasts, as well as the vitamin D binding protein receptors megalin and cubilin. Functional analyses demonstrate that after incubation with the 1 alpha-hydoxylase substrate 25-(OH)D-3, the osteoblasts can produce sufficient 1 alpha,25-(OH)(2)D-3 to modulate osteoblast activity, resulting in induced alkaline phosphatase ( ALP) activity, osteocalcin (OC) and CYP24 mRNA expression, and mineralization. The classical renal regulators of 1-hydroxylase, parathyroid hormone, and ambient calcium do not regulate 1 alpha-hydroxylase in osteoblasts. In contrast, interleukin (IL)-1 alpha strongly induces 1 alpha-hydroxylase. Besides the bone-forming cells, we demonstrate 1 alpha-hydroxylase activity in the bone resorbing cells, the osteoclasts. This is strongly dependent on osteoclast inducer RANKL. This study showing expression, activity, and functionality of 1 alpha-hydoxylase unequivocally demonstrates that vitamin D can act in an auto/paracrine manner in bone.	Erasmus MC, Dept Internal Med, NL-3015 GE Rotterdam, Netherlands; Univ Birmingham, Div Med Sci, Birmingham, W Midlands, England; Sapporo Med Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido, Japan	Erasmus University Rotterdam; Erasmus MC; University of Birmingham; Sapporo Medical University	van Leeuwen, JPTM (corresponding author), Erasmus MC, Dept Internal Med, Rm Ee526,Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.	j.vanleeuwen@erasmusmc.nl	van Driel, Marjolein/K-6745-2019; van Leeuwen, Johannes/D-5015-2014	van Leeuwen, Johannes/0000-0002-2282-4006				ADAMS JS, 1985, J EXP MED, V161, P755, DOI 10.1084/jem.161.4.755; Anderson PH, 2005, BONE, V36, P654, DOI 10.1016/j.bone.2005.01.012; BARBOUR GL, 1981, NEW ENGL J MED, V305, P440, DOI 10.1056/NEJM198108203050807; Bareis P, 2001, BIOCHEM BIOPH RES CO, V285, P1012, DOI 10.1006/bbrc.2001.5289; BIKLE DD, 1986, J CLIN INVEST, V78, P557, DOI 10.1172/JCI112609; Bland R, 1999, ENDOCRINOLOGY, V140, P2027, DOI 10.1210/en.140.5.2027; Bland R, 2004, J STEROID BIOCHEM, V89-90, P121, DOI 10.1016/j.jsbmb.2004.03.115; Bland R, 2001, KIDNEY INT, V60, P1277, DOI 10.1046/j.1523-1755.2001.00966.x; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; Chen TC, 2003, J CELL BIOCHEM, V88, P315, DOI 10.1002/jcb.10342; Christakos S, 2003, J CELL BIOCHEM, V88, P695, DOI 10.1002/jcb.10423; Correa P, 2002, J CLIN ENDOCR METAB, V87, P5826, DOI 10.1210/jc.2002-021356; Cross HS, 2001, STEROIDS, V66, P287, DOI 10.1016/S0039-128X(00)00153-7; Ebert R, 2004, MOL ENDOCRINOL, V18, P2440, DOI 10.1210/me.2002-0441; Evans KN, 2004, AM J PATHOL, V165, P807, DOI 10.1016/S0002-9440(10)63343-3; Friedrich M, 2003, RECENT RES CANCER, V164, P239; HENRY HL, 1992, J STEROID BIOCHEM, V41, P401, DOI 10.1016/0960-0760(92)90365-P; Hewison M, 2004, MOL CELL ENDOCRINOL, V215, P31, DOI 10.1016/j.mce.2003.11.017; Hewison M, 2003, J IMMUNOL, V170, P5382, DOI 10.4049/jimmunol.170.11.5382; Hewison M, 2000, J MOL ENDOCRINOL, V25, P141, DOI 10.1677/jme.0.0250141; Hilpert J, 2002, KIDNEY INT, V62, P1672, DOI 10.1046/j.1523-1755.2002.00634.x; HOWARD GA, 1981, J BIOL CHEM, V256, P7738; Hsu JY, 2001, CANCER RES, V61, P2852; Jones G, 1999, ENDOCRINOLOGY, V140, P3303, DOI 10.1210/en.140.7.3303; KARSTEN U, 1977, ANAL BIOCHEM, V77, P464, DOI 10.1016/0003-2697(77)90259-7; Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477; LOWRY OH, 1954, J BIOL CHEM, V207, P19; Ma JF, 2004, MOL CELL ENDOCRINOL, V221, P67, DOI 10.1016/j.mce.2004.03.003; Miyahara T, 2002, CALCIFIED TISSUE INT, V70, P488, DOI 10.1007/s00223-001-1039-5; Nykjaer A, 2001, P NATL ACAD SCI USA, V98, P13895, DOI 10.1073/pnas.241516998; POLS HAP, 1984, BIOCHEM BIOPH RES CO, V125, P265, DOI 10.1016/S0006-291X(84)80363-0; Prosser DE, 2004, TRENDS BIOCHEM SCI, V29, P664, DOI 10.1016/j.tibs.2004.10.005; Schuessler M, 2001, STEROIDS, V66, P399, DOI 10.1016/S0039-128X(00)00229-4; Schwartz GG, 1998, CANCER EPIDEM BIOMAR, V7, P391; Schwartz GG, 2004, CARCINOGENESIS, V25, P1015, DOI 10.1093/carcin/bgh086; Segersten U, 2002, J CLIN ENDOCR METAB, V87, P2967, DOI 10.1210/jc.87.6.2967; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; TURNBULL AP, 1980, NEW DIRECTIONS EXCEP, V1, P25; van der Eerden BCJ, 2005, P NATL ACAD SCI USA, V102, P17507, DOI 10.1073/pnas.0505789102; van Leeuwen JPTM, 2001, CRIT REV EUKAR GENE, V11, P199; Vanhooke JL, 2006, P NATL ACAD SCI USA, V103, P75, DOI 10.1073/pnas.0509734103; VANLEEUWEN JPTM, 1994, BBA-MOL CELL RES, V1221, P167, DOI 10.1016/0167-4889(94)90009-4; Whitlatch LW, 2002, J STEROID BIOCHEM, V81, P135, DOI 10.1016/S0960-0760(02)00053-5; Willnow TE, 2002, CURR OPIN LIPIDOL, V13, P255, DOI 10.1097/00041433-200206000-00004; Zehnder D, 1999, J AM SOC NEPHROL, V10, P2465; Zehnder D, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133621; Zehnder D, 2002, AM J PATHOL, V161, P105, DOI 10.1016/S0002-9440(10)64162-4; Zehnder D, 2001, J CLIN ENDOCR METAB, V86, P888, DOI 10.1210/jc.86.2.888	48	154	159	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2417	+		10.1096/fj.06-6374fje	http://dx.doi.org/10.1096/fj.06-6374fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023519				2022-12-28	WOS:000241702600039
J	Zhan, J; Deng, RS; Tang, JM; Zhang, B; Tang, Y; Wang, JK; Li, F; Anderson, VM; McNutt, MA; Gu, J				Zhan, Jun; Deng, Ruishu; Tang, Junmin; Zhang, Bo; Tang, Yan; Wang, Jeffrey K.; Li, Feng; Anderson, Virginia M.; McNutt, Michael A.; Gu, Jiang			The spleen as a target in severe acute respiratory syndrome	FASEB JOURNAL			English	Article						immunodeficiency; T lymphocytes; B lymphocytes; SARS	A H5N1 VIRUS; SARS-CORONAVIRUS; DENDRITIC CELLS; HUMAN-DISEASE; INFECTION; IDENTIFICATION; PATHOGENESIS; MACROPHAGES; CYTOKINES; PATHOLOGY	It has been proposed that immune injury is the central mechanism of pathogenesis of the infectious disease, severe acute respiratory syndrome (SARS). To gain a better understanding of immune injury in the spleen, we investigated the number and distribution of various immune cell types in the spleens of SARS patients. We performed autopsies on six confirmed SARS cases, with six normal subjects as controls; spleen samples from these autopsies were examined with hematoxylin and eosin (H&E) sections, in situ hybridization for SARS virus genomic sequences, and immunohistochemistry with seven monoclonal antibodies to five cell types. The number and distribution of these cells were measured and analyzed using an image analysis system. SARS genomic sequences were detected in all SARS spleens. The SARS spleens all had severe damage to the white pulp and showed an alteration of the normal distribution of various cell types. Immunocytes in the red pulp were decreased by 68.0-90.7% except for CD68(+) macrophages and human leukocyte antigen (HLA)-DR positive antigen-presenting cells (APC), which were decreased to a lesser degree. On average, CD68(+) macrophages were increased in size by 2.21-fold. We hypothesize that the collapse of the splenic immune system plays a key role in the clinical outcome of these patients.	Peking Univ, Ctr Infect Dis, Sch Basic Med Sci, Dept Pathol,Hlth Sci Ctr, Beijing 100083, Peoples R China; Peking Univ, Hlth Sci Ctr, Dept Histol & Embryol, Beijing 100083, Peoples R China; Univ So Calif, Keck Sch Med, Los Angeles, CA USA; SUNY Hlth Sci Ctr Brooklyn, Dept Pathol, Brooklyn, NY USA	Peking University; Peking University; University of Southern California; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Gu, J (corresponding author), Peking Univ, Ctr Infect Dis, Sch Basic Med Sci, Dept Pathol,Hlth Sci Ctr, 38 Xueyan Rd, Beijing 100083, Peoples R China.	jianggu@bjmu.edu.cn	Zhan, Jun/AAH-5499-2020	Gu, Jiang/0000-0002-0706-8329				Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P241; Chan MHM, 2004, J INTERN MED, V255, P512, DOI 10.1111/j.1365-2796.2004.01323.x; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; Enserink M, 2003, SCIENCE, V301, P299, DOI 10.1126/science.301.5631.299; Fisman DN, 2000, EMERG INFECT DIS, V6, P601, DOI 10.3201/eid0606.000608; Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828; Gu J, 2003, APPL IMMUNOHISTO M M, V11, P281; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; LI L, 2005, IN PRESS J INFECT DI; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Lin Y, 2003, CELL RES, V13, P141, DOI 10.1038/sj.cr.7290158; Nacife VP, 2004, CELL STRUCT FUNCT, V29, P27, DOI 10.1247/csf.29.27; PEI F, 2005, J ZHONGHUA BING LI X, V34, P656; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Shi XY, 2005, AM J GASTROENTEROL, V100, P169, DOI 10.1111/j.1572-0241.2005.40377.x; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; SUN S, 2005, J ZHONGHUA YI XUE ZA, V85, P667; To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; Tuosto L, 1994, EUR J IMMUNOL, V24, P1061, DOI 10.1002/eji.1830240508; Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x; Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358; World Health Organization, CUM NUMB REP PROB CA; Xu J, 2006, BIOL REPROD, V74, P410, DOI 10.1095/biolreprod.105.044776; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; ZHANG QL, 2003, APPL IMMUNOHISTOL MO, V11, P285; Zhong Yan-feng, 2003, Zhonghua Yi Xue Za Zhi, V83, P2137	32	28	31	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2321	2328		10.1096/fj.06-6324com	http://dx.doi.org/10.1096/fj.06-6324com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077309				2022-12-28	WOS:000241702600017
J	Yakovleva, T; Bazov, I; Cebers, G; Marinova, Z; Hara, Y; Ahmed, A; Vlaskovska, M; Johansson, BR; Hochgeschwender, U; Singh, IN; Bruce-Keller, AJ; Hurd, YL; Kaneko, T; Terenius, L; Ekstrom, TJ; Hauser, KF; Pickel, VM; Bakalkin, G				Yakovleva, Tatiana; Bazov, Igor; Cebers, Gvido; Marinova, Zoya; Hara, Yuko; Ahmed, Aisha; Vlaskovska, Mila; Johansson, Bjo Rn; Hochgeschwender, Ute; Singh, Indrapal N.; Bruce-Keller, Annadora J.; Hurd, Yasmin L.; Kaneko, Takeshi; Terenius, Lars; Ekstrom, Tomas J.; Hauser, Kurt F.; Pickel, Virginia M.; Bakalkin, Georgy			Prodynorphin storage and processing in axon terminals and dendrites	FASEB JOURNAL			English	Article							TRANS-GOLGI NETWORK; MESSENGER-RNA EXPRESSION; RAT NUCLEUS-ACCUMBENS; SECRETORY GRANULES; BIG DYNORPHIN; IMMUNOCYTOCHEMISTRY; CLEAVAGE; NEURONS; CELL; PROOPIOMELANOCORTIN	The classical view postulates that neuropeptide precursors in neurons are processed into mature neuropeptides in the somatic trans-Golgi network (TGN) and in secretory vesicles during axonal transport. Here we show that prodynorphin (PDYN), precursor to dynorphin opioid peptides, is predominantly located in axon terminals and dendrites in hippocampal and striatal neurons. The molar content of unprocessed PDYN was much greater than that of dynorphin peptides in axon terminals of PDYN-containing neurons projecting to the CA3 region of the hippocampus and in the striatal projections to the ventral tegmental area. Electron microscopy showed coexistence of PDYN and dynorphins in the same axon terminals with occasional codistribution in individual dense core vesicles. Thus, the precursor protein is apparently stored at presynaptic sites. In comparison with the hippocampus and striatum, PDYN and dynorphins were more equally distributed between neuronal somata and processes in the amygdala and cerebral cortex, suggesting regional differences in the regulation of trafficking and processing of the precursor protein. Potassium-induced depolarization activated PDYN processing and secretion of opioid peptides in neuronal cultures and in a model cell line. Regulation of PDYN storage and processing at synapses by neuronal activity or extracellular stimuli may provide a local mechanism for regulation of synaptic transmission.	Karolinska Inst, Expt Alcohol & Drug Addict Res Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden; Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK USA; Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA; Kyoto Univ, Dept Morphol Brain Sci, Kyoto, Japan	Karolinska Institutet; Cornell University; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Kentucky; Kyoto University	Bakalkin, G (corresponding author), Karolinska Inst, Expt Alcohol & Drug Addict Res Sect, Dept Clin Neurosci, CMM L8-01, S-17176 Stockholm, Sweden.	georgy.bakalkin@ki.se	Bruce-Keller, Annadora/N-1954-2017; Hara, Yuko/B-9172-2012; Ekström, Tomas/B-7764-2013; Hauser, Kurt/AAX-8361-2020; Ahmed, Aisha S/J-4619-2012	Hara, Yuko/0000-0001-5828-442X; Ahmed, Aisha/0000-0002-8483-5309; Hauser, Kurt/0000-0001-7886-0332; Bazov, Igor/0000-0003-4388-1656; Bakalkin, Georgy/0000-0002-8074-9833	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004600] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-313312, DA-004600, DA-13278] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BAKALKIN GY, 1993, MOL BRAIN RES, V20, P137, DOI 10.1016/0169-328X(93)90119-A; Berman Y, 2000, J NEUROCHEM, V75, P1763, DOI 10.1046/j.1471-4159.2000.0751763.x; Cawley NX, 2000, FEBS LETT, V481, P37, DOI 10.1016/S0014-5793(00)01961-X; CHAN J, 1990, J NEUROSCI METH, V33, P113, DOI 10.1016/0165-0270(90)90015-8; CHRISTENSSONNYLANDER I, 1985, REGUL PEPTIDES, V11, P65, DOI 10.1016/0167-0115(85)90032-1; Costigan M, 2002, CELL, V108, P297, DOI 10.1016/S0092-8674(02)00640-2; Creemers JWM, 1998, SEMIN CELL DEV BIOL, V9, P3, DOI 10.1006/scdb.1997.0195; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; DAY R, 1989, ENDOCRINOLOGY, V124, P2392, DOI 10.1210/endo-124-5-2392; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; De Vries TJ, 2002, J NEUROSCI, V22, P3321; delaCruz IP, 1996, J BIOL CHEM, V271, P22736, DOI 10.1074/jbc.271.37.22736; DRAKE CT, 1994, J NEUROSCI, V14, P3736; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; FALLON JH, 1986, J COMP NEUROL, V249, P293, DOI 10.1002/cne.902490302; GAINER H, 1977, SCIENCE, V195, P1354, DOI 10.1126/science.65791; GAINER H, 1977, J CELL BIOL, V73, P366, DOI 10.1083/jcb.73.2.366; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Hara Y, 2006, SYNAPSE, V60, P1, DOI 10.1002/syn.20273; Hokfelt T, 2000, NEUROPHARMACOLOGY, V39, P1337, DOI 10.1016/S0028-3908(00)00010-1; Hopkins KJ, 2000, BRAIN RES, V864, P69, DOI 10.1016/S0006-8993(00)02137-5; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hurd YL, 1996, NEUROSCIENCE, V72, P767, DOI 10.1016/0306-4522(96)00002-4; Hurd YL, 2002, MOL PSYCHIATR, V7, P75, DOI 10.1038/sj/mp/4000930; Josefsen K, 1998, ENDOCRINOLOGY, V139, P4329, DOI 10.1210/en.139.10.4329; KHACHATURIAN H, 1982, PEPTIDES, V3, P941, DOI 10.1016/0196-9781(82)90063-8; Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4; Kreek MJ, 2001, ANN NY ACAD SCI, V937, P27; Kuzmin A, 2006, NEUROPSYCHOPHARMACOL, V31, P1928, DOI 10.1038/sj.npp.1300959; Lee T, 1997, J COMP NEUROL, V386, P229, DOI 10.1002/(SICI)1096-9861(19970922)386:2<229::AID-CNE5>3.0.CO;2-3; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; LERANTH C, 1989, NEUROANATOMICAL TRAC, V2, P29; LEWIS RV, 1980, SCIENCE, V208, P1459, DOI 10.1126/science.7384787; Ludwig M, 1998, J NEUROENDOCRINOL, V10, P881; MANSOUR A, 1994, MOL CELL NEUROSCI, V5, P124, DOI 10.1006/mcne.1994.1015; Merg F, 2006, J NEUROCHEM, V97, P292, DOI 10.1111/j.1471-4159.2006.03732.x; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Morris JF, 1998, PROG BRAIN RES, V119, P21; MORRISON JH, 1984, BRAIN RES, V292, P269, DOI 10.1016/0006-8993(84)90763-7; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nguyen XV, 2005, BEHAV BRAIN RES, V161, P254, DOI 10.1016/j.bbr.2005.02.010; NYBERG F, 1986, BRAIN RES, V371, P278, DOI 10.1016/0006-8993(86)90363-X; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PELLETIER G, 1981, BRAIN RES, V210, P356, DOI 10.1016/0006-8993(81)90909-4; PETERS A, 1991, FINE STRUCTURE NERVO, P1; Pierce JP, 1999, HIPPOCAMPUS, V9, P255, DOI 10.1002/(SICI)1098-1063(1999)9:3<255::AID-HIPO6>3.3.CO;2-J; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEI CA, 1992, MOL ENDOCRINOL, V6, P309, DOI 10.1210/me.6.3.309; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Sharifi N, 2001, MOL BRAIN RES, V86, P70, DOI 10.1016/S0169-328X(00)00264-3; Svensson P, 1998, MOL BRAIN RES, V56, P162, DOI 10.1016/S0169-328X(98)00041-2; Swanson L. W., 1992, BRAIN MAPS STRUCTURE; Tanaka S, 1997, J HISTOCHEM CYTOCHEM, V45, P425, DOI 10.1177/002215549704500310; Thureson-Klein A K, 1990, Int Rev Cytol, V121, P67, DOI 10.1016/S0074-7696(08)60659-2; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; VANBOCKSTAELE EJ, 1994, J COMP NEUROL, V341, P1, DOI 10.1002/cne.903410102; Vlaskovska M, 1997, J NEUROCHEM, V68, P517; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Winsky-Sommerer P, 2000, J COMP NEUROL, V424, P439, DOI 10.1002/1096-9861(20000828)424:3<439::AID-CNE4>3.0.CO;2-1; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; Zhang BF, 1997, J APPL POULTRY RES, V6, P94, DOI 10.1093/japr/6.1.94; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	63	42	44	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2124	+		10.1096/fj.06-6174fje	http://dx.doi.org/10.1096/fj.06-6174fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16966485				2022-12-28	WOS:000241156900027
J	Finnson, KW; Tam, BYY; Liu, K; Marcoux, A; Lepage, P; Roy, S; Bizet, AA; Philip, A				Finnson, Kenneth W.; Tam, Betty Y. Y.; Liu, Kai; Marcoux, Anne; Lepage, Pierre; Roy, Stephane; Bizet, Albane A.; Philip, Anie			Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes	FASEB JOURNAL			English	Article						TGF-beta; receptor; CD109; signaling; keratinocyte	GROWTH-FACTOR-BETA; LIGAND-BINDING; II RECEPTORS; EXPRESSION; PROTEINS; CELLS; BETAGLYCAN; TGF-BETA-1; COMPLEXES; EPIDERMIS	We have previously reported that keratinocytes defective in glycosylphosphatidylinositol (GPI)-anchor biosynthesis display enhanced TGF-beta responses. These studies implicated the involvement of a 150 kDa GPI-anchored TGF-beta 1 binding protein, r150, in modulating TGF-beta signaling. Here, we sought to determine the molecular identity of r150 by affinity purification and microsequencing. Our results identify r150 as CD109, a novel member of the alpha 2-macroglobulin (alpha 2M)/complement superfamily, whose function has remained obscure. In addition, we have identified a novel CD109 isoform that occurs in the human placenta but not keratinocytes. Biochemical studies show that r150 contains an internal thioester bond, a defining feature of the alpha 2M/complement family. Loss and gain of function studies demonstrate that CD109 is a component of the TGF-beta receptor system, and a negative modulator of TGF-beta responses in keratinocytes, as implicated for r150. Our data suggest that CD109 can inhibit TGF-beta signaling independently of ligand sequestration and may exert its effect on TGF-beta signaling by direct modulation of receptor activity. Together, our results linking CD109 function to regulation of TGF-beta signaling suggest that CD109 plays a unique role in the regulation of isoform-specific TGF-beta signaling in keratinocytes.	McGill Univ, Dept Surg, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Stomatol, Montreal, PQ H3G 1A4, Canada; Genome Quebec Innovat Ctr, Montreal, PQ, Canada	McGill University; McGill University	Philip, A (corresponding author), McGill Univ, Montreal Gen Hosp, 1650 Cedar Ave,Rm C9-177, Montreal, PQ H3G 1A4, Canada.	anie.philip@mcgill.ca	; Bizet, Albane/L-2622-2017	Finnson, Kenneth/0000-0003-2930-0595; Bizet, Albane/0000-0003-4187-9659				BALVAY L, 1993, BIOESSAYS, V15, P165, DOI 10.1002/bies.950150304; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Choi ME, 1999, AM J PHYSIOL-RENAL, V276, pF88, DOI 10.1152/ajprenal.1999.276.1.F88; Cowin AJ, 2001, J INVEST DERMATOL, V117, P1282, DOI 10.1046/j.0022-202x.2001.01501.x; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Dodds AW, 1998, IMMUNOL REV, V166, P15; DUMONT N, 1995, MOL CELL ENDOCRINOL, V111, P57, DOI 10.1016/0303-7207(95)03548-L; Ferguson MWJ, 2004, PHILOS T R SOC B, V359, P839, DOI 10.1098/rstb.2004.1475; FURLEY AJ, 1986, BLOOD, V68, P1101; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Guo BQ, 2004, ANTICANCER RES, V24, P1337; HAREGEWOIN A, 1994, CELL IMMUNOL, V156, P357, DOI 10.1006/cimm.1994.1181; Hashimoto M, 2004, ONCOGENE, V23, P3716, DOI 10.1038/sj.onc.1207418; Hussein MR, 2005, J CUTAN PATHOL, V32, P389, DOI 10.1111/j.0303-6987.2005.00356.x; KANE CJM, 1991, J CELL PHYSIOL, V148, P157, DOI 10.1002/jcp.1041480119; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li AG, 2004, EMBO J, V23, P1770, DOI 10.1038/sj.emboj.7600183; Lin M, 2002, BLOOD, V99, P1683, DOI 10.1182/blood.V99.5.1683; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MACKAY K, 1991, J BIOL CHEM, V266, P9907; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; Philip A, 1999, EUR J BIOCHEM, V261, P618, DOI 10.1046/j.1432-1327.1999.00298.x; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; SCHMID P, 1993, J PATHOL, V171, P191, DOI 10.1002/path.1711710307; Schuh AC, 2002, BLOOD, V99, P1692, DOI 10.1182/blood.V99.5.1692; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SMITH JW, 1995, BLOOD, V86, P2807; Solomon KR, 2004, GENE, V327, P171, DOI 10.1016/j.gene.2003.11.025; SUTHERLAND DR, 1991, BLOOD, V77, P84; Tam BYY, 2003, J BIOL CHEM, V278, P49610, DOI 10.1074/jbc.M308492200; Tam BYY, 1998, J CELL BIOCHEM, V70, P573, DOI 10.1002/(SICI)1097-4644(19980915)70:4<573::AID-JCB13>3.0.CO;2-I; Tam BYY, 2001, J CELL BIOCHEM, V83, P494, DOI 10.1002/jcb.1074; Tam BYY, 1998, J CELL PHYSIOL, V176, P553, DOI 10.1002/(SICI)1097-4652(199809)176:3<553::AID-JCP12>3.3.CO;2-A; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wong SH, 2000, EUR J BIOCHEM, V267, P5550, DOI 10.1046/j.1432-1327.2000.01621.x; WRANA JL, 1992, COLD SPRING HARB SYM, V57, P81, DOI 10.1101/SQB.1992.057.01.011; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	50	108	116	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1525	+		10.1096/fj.05-5229fje	http://dx.doi.org/10.1096/fj.05-5229fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16754747				2022-12-28	WOS:000240266000039
J	Kosaka, N; Kodama, M; Sasaki, H; Yamamoto, Y; Takeshita, F; Takahama, Y; Sakamoto, H; Kato, T; Terada, M; Ochiya, T				Kosaka, Nobuyoshi; Kodama, Maho; Sasaki, Hideo; Yamamoto, Yusuke; Takeshita, Fumitaka; Takahama, Yasushi; Sakamoto, Hiromi; Kato, Takashi; Terada, Masaaki; Ochiya, Takahiro			FGF-4 regulates neural progenitor cell proliferation and neuronal differentiation	FASEB JOURNAL			English	Article						FGF-4; neural progenitor cell; neurogenesis; self-renewal	ADENOVIRUS-MEDIATED TRANSFER; GROWTH-FACTOR 2; STEM-CELLS; GENE-EXPRESSION; LIMB; PRECURSORS; EGF; REGIONALIZATION; DEMONSTRATE; GENERATION	The FGF-4 (fibroblast growth factor 4, known as HST-1) protein is an important mitogen for a variety of cell types. However, only limited information is available concerning tissue distribution and the biological role of FGF-4 in the brain. In situ hybridization analysis revealed localization of mouse Fgf-4 mRNA in the normal postnatal mouse hippocampus, subventricular zone (SVZ), and the rostral migratory stream where new neurons generate, migrate, and become incorporated into the functional circuitry of the brain. We also investigated whether FGF-4 could promote both proliferation and differentiation of the neural progenitor cells by using an in vitro neurosphere assay. The addition of recombinant FGF-4 generated large proliferative spheres that have a multipotent differentiation ability. Furthermore, recombinant FGF-4 significantly promotes neuronal differentiation in attached clonal neurosphere culture. These findings suggest that FGF-4 has an ability to promote neural stem cell proliferation and neuronal differentiation in the postnatal brain.	Natl Canc Ctr, Res Inst, Sect Studies Metastasis, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Genet, Tokyo 1040045, Japan; Waseda Univ, Sch Educ, Dept Biol, Tokyo, Japan; Waseda Univ, Grad Sch Sci & Engn, Tokyo, Japan; Nara Med Univ, Dept Surg 1, Nara, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Waseda University; Waseda University; Nara Medical University	Ochiya, T (corresponding author), Natl Canc Ctr, Res Inst, Sect Studies Metastasis, Chuo Ku, 5-1-1, Tokyo 1040045, Japan.	tochiya@ncc.go.jp	Kato, Takashi/AFO-2557-2022; Ochiya, Takahiro/AAH-7585-2019	Kato, Takashi/0000-0003-0384-7971; 				Amoh Y, 2005, P NATL ACAD SCI USA, V102, P5530, DOI 10.1073/pnas.0501263102; Arsenijevic Y, 1998, J NEUROSCI, V18, P2118; Avecilla ST, 2004, NAT MED, V10, P64, DOI 10.1038/nm973; Basilico C, 1997, J CELL PHYSIOL, V173, P227, DOI 10.1002/(SICI)1097-4652(199711)173:2<227::AID-JCP26>3.0.CO;2-B; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; Ciccolini F, 1998, J NEUROSCI, V18, P7869; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Kratochwil K, 2002, GENE DEV, V16, P3173, DOI 10.1101/gad.1035602; McGrew LL, 1997, MECH DEVELOP, V69, P105, DOI 10.1016/S0925-4773(97)00160-3; Moon AM, 2000, DEVELOPMENT, V127, P989; Nakayama EE, 2000, GENES IMMUN, V1, P293, DOI 10.1038/sj.gene.6363672; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, MOL REPROD DEV, V39, P83, DOI 10.1002/mrd.1080390113; OCHIYA T, 1995, J CELL BIOL, V130, P997, DOI 10.1083/jcb.130.4.997; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; Ray J, 1997, P NATL ACAD SCI USA, V94, P7047, DOI 10.1073/pnas.94.13.7047; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Shamim H, 1999, DEVELOPMENT, V126, P945; Shimozaki K, 2003, DEVELOPMENT, V130, P2505, DOI 10.1242/dev.00476; Sun X, 2000, NAT GENET, V25, P83, DOI 10.1038/75644; Suzuki K, 2001, VIRCHOWS ARCH, V439, P616, DOI 10.1007/s004280100437; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yamamoto H, 2002, ONCOGENE, V21, P899, DOI 10.1038/sj.onc.1205135; Yamamoto H, 2000, ONCOGENE, V19, P3805, DOI 10.1038/sj.onc.1203752; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; YOSHIDA T, 1991, ANN NY ACAD SCI, V638, P27, DOI 10.1111/j.1749-6632.1991.tb49015.x; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zappone MV, 2000, DEVELOPMENT, V127, P2367	39	48	53	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1484	+		10.1096/fj.05-5293fje	http://dx.doi.org/10.1096/fj.05-5293fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723380				2022-12-28	WOS:000240266000025
J	Haase, H; Dobbernack, G; Tuennemann, G; Karczewski, P; Cardoso, C; Petzhold, D; Schlegel, WP; Lutter, S; Pierschalek, P; Behlke, J; Morano, I				Haase, Hannelore; Dobbernack, Gisela; Tuennemann, Gisela; Karczewski, Peter; Cardoso, Cristina; Petzhold, Daria; Schlegel, Wolfgang-Peter; Lutter, Steffen; Pierschalek, Petra; Behlke, Joachim; Morano, Ingo			Minigenes encoding N-terminal domains of human cardiac myosin light chain-1 improve heart function of transgenic rats	FASEB JOURNAL			English	Article						myosin light chain; actin; heart; contractility; rat	SKELETAL-MUSCLE MYOSIN; SUBFRAGMENT-1 ISOENZYMES; CHROMOSOMAL LOCATION; FAILURE MANAGEMENT; ACTIN; BINDING; CONTRACTION; SEQUENCE; REGION; GENE	In this study we investigated whether the expression of N-terminal myosin light chain-1 (MLC-1) peptides could improve the intrinsic contractility of the whole heart. We generated transgenic rats (TGR) that overexpressed minigenes encoding the N-terminal 15 amino acids of human atrial MLC-1 (TGR/hALC-1/1-15, lines 7475 and 3966) or human ventricular MLC-1 (TGR/hVLC-1/1-15, lines 6113 and 6114) isoforms in cardiomyocytes. Synthetic N-terminal peptides revealed specific actin binding, with a significantly (P < 0.01) lower dissociation constant (K(D)) for the hVLC-1/1-15-actin complex compared with the KD value of the hALC-1/1-15-actin complex. Using synthetic hVLC-1/1-15 as a TAT fusion peptide labeled with the fluorochrome TAMRA, we observed specific accumulation of the N-terminal MLC-1 peptide at the sarcomere predominantly within the actin-containing I-band, but also within the actin-myosin overlap zone (A-band) in intact adult cardiomyocytes. For the first time we show that the expression of N-terminal human MLC-1 peptides in TGR ( range: 3-6 mu M) correlated positively with significant (P < 0.001) improvements of the intrinsic contractile state of the isolated perfused heart (Langendorff mode): systolic force generation, as well as the rates of both force generation and relaxation, rose in TGR lines that expressed the transgenic human MLC-1 peptide, but not in a TGR line with undetectable transgene expression levels. The positive inotropic effect of MLC-1 peptides occurred in the absence of a hypertrophic response. Thus, expression of N-terminal domains of MLC-1 represent a valuable tool for the treatment of the failing heart.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Charite Univ Med, Johannes Muller Inst Physiol, Berlin, Germany; Franz Volhard Clin, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Franz-Volhard Clinical Research Center	Morano, I (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	imorano@mdc-berlin.de	Cardoso, M. Cristina/F-5215-2011	Lattig, Gisela/0000-0001-6485-1136				Abdelaziz AI, 2004, J MOL MED-JMM, V82, P265, DOI 10.1007/s00109-004-0525-4; ABILLON E, 1990, BIOCHIM BIOPHYS ACTA, V1037, P394, DOI 10.1016/0167-4838(90)90042-E; Abraham WT, 1997, CIRCULATION, V96, P2755, DOI 10.1161/01.CIR.96.9.2755; Behlke J, 1997, BIOCHEMISTRY-US, V36, P5149, DOI 10.1021/bi962755h; BHANDARI DG, 1986, EUR J BIOCHEM, V160, P349, DOI 10.1111/j.1432-1033.1986.tb09978.x; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P341, DOI 10.1113/jphysiol.1994.sp020254; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; CHALOVICH JM, 1984, BIOCHEMISTRY-US, V23, P4885, DOI 10.1021/bi00316a011; FODOR WL, 1989, J BIOL CHEM, V264, P2143; Fujita H, 1962, MATH THEORY SEDIMENT; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; HAYASHIBARA T, 1994, BIOCHEMISTRY-US, V33, P12821, DOI 10.1021/bi00209a013; HENRY GD, 1985, EUR J BIOCHEM, V148, P75, DOI 10.1111/j.1432-1033.1985.tb08809.x; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Konstam MA, 2000, CIRCULATION, V102, P1076, DOI 10.1161/01.CIR.102.10.1076; LABBE JP, 1986, BIOCHEMISTRY-US, V25, P8325, DOI 10.1021/bi00373a029; LOWEY S, 1993, J BIOL CHEM, V268, P20414; Moore JR, 2000, BIOPHYS J, V78, P1431, DOI 10.1016/S0006-3495(00)76696-3; MORANO I, 1995, CIRC RES, V76, P720, DOI 10.1161/01.RES.76.5.720; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; Nieznanski K, 2003, ARCH BIOCHEM BIOPHYS, V417, P153, DOI 10.1016/S0003-9861(03)00382-5; Patchell VB, 2002, EUR J BIOCHEM, V269, P5088, DOI 10.1046/j.1432-1033.2002.03227.x; PRINCE HP, 1981, EUR J BIOCHEM, V121, P213, DOI 10.1111/j.1432-1033.1981.tb06451.x; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ruegg J., 1986, CALCIUM MUSCLE ACTIV; SEHARASEYON J, 1990, GENOMICS, V7, P289, DOI 10.1016/0888-7543(90)90554-8; STEPKOWSKI D, 1995, FEBS LETT, V374, P6, DOI 10.1016/0014-5793(95)01049-K; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; Sweeney H. L., 1995, BIOPHYS J, V68, p112S; Timson DJ, 1999, J BIOL CHEM, V274, P18271, DOI 10.1074/jbc.274.26.18271; Timson DJ, 1998, EUR J BIOCHEM, V255, P654, DOI 10.1046/j.1432-1327.1998.2550654.x; TRAYER HR, 1985, FEBS LETT, V180, P170, DOI 10.1016/0014-5793(85)81065-6; TRAYER IP, 1987, EUR J BIOCHEM, V164, P259, DOI 10.1111/j.1432-1033.1987.tb11019.x; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WINSTANLEY MA, 1977, FEBS LETT, V77, P239, DOI 10.1016/0014-5793(77)80242-1	36	24	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					865	873		10.1096/fj.05-5414com	http://dx.doi.org/10.1096/fj.05-5414com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675844				2022-12-28	WOS:000240157700009
J	Papp, E; Szaraz, P; Korcsmaros, T; Csermely, P				Papp, Eszter; Szaraz, Peter; Korcsmaros, Tamas; Csermely, Peter			Changes of endoplasmic reticulum chaperone complexes, redox state, and impaired protein disulfide reductase activity in misfolding alpha 1-antitrypsin transgenic mice	FASEB JOURNAL			English	Article						glucose regulated proteins; heat shock proteins; oxidative stress; protein aggregation; redox imbalance	OXIDATIVE STRESS; MUTANT ALPHA(1)-ANTITRYPSIN-Z; PIZ ALPHA-1-ANTITRYPSIN; RAT-LIVER; ACCUMULATION; DEGRADATION; PROTEASOME; ISOMERASE; GLUTATHIONE; DEFICIENCY	alpha 1-antitrypsin (AAT) deficiency is characterized by the accumulation of the misfolded mutant, Z form of alpha 1-antitrypsin (PiZ) inside the lumen of the hepatic endoplasmic reticulum (ER). Both human patients and PiZ transgenic mice have similar symptoms of hepatic failure culminating in cirrhosis and hepatocellular carcinoma. The involvement of molecular chaperones, as well as the relevance of oxidative stress in this disease is not characterized well yet. Here, we show that, in the PiZ transgenic mice, the 58-kDa protein disulfide isomerase (PDI), the most important oxidoreductase and chaperone of the endoplasmic reticulum, is in a complex with PiZ, which is accompanied by a decrease of protein disulfide reductase activity of the ER. PiZ transgenic mice have a shift toward a more reduced ER environment and an elevation of cytoplasmic chaperones and antioxidant enzymes. Our data suggest that lower availability of PDI and a decreased protein disulfide reductase activity of the ER along with a cytoplasmic stress may contribute to the toxic effects of PiZ aggregation.	Semmelweis Univ, Dept Med Chem, H-1444 Budapest 8, Hungary	Semmelweis University	Csermely, P (corresponding author), Semmelweis Univ, Dept Med Chem, POB 260, H-1444 Budapest 8, Hungary.	Csermely@puskin.sote.hu	Korcsmaros, Tamas/C-3526-2015; Csermely, Peter/J-2067-2017	Korcsmaros, Tamas/0000-0003-1717-996X; Csermely, Peter/0000-0001-9234-0659				Ahner A, 2004, TRENDS CELL BIOL, V14, P474, DOI 10.1016/j.tcb.2004.07.013; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Barrett MJ, 2004, J NEUROSCI RES, V78, P420, DOI 10.1002/jnr.20249; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cabral CM, 2002, MOL BIOL CELL, V13, P2639, DOI 10.1091/mbc.E02-02-0068; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; Conconi M, 1998, BIOCHEM J, V333, P407, DOI 10.1042/bj3330407; CRESTEIL D, 1990, FEBS LETT, V267, P277, DOI 10.1016/0014-5793(90)80944-E; Demasi M, 2003, FEBS LETT, V542, P89, DOI 10.1016/S0014-5793(03)00353-3; DYCAICO MJ, 1988, SCIENCE, V242, P1409, DOI 10.1126/science.3264419; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Frand AR, 2000, MOL BIOL CELL, V11, P2833, DOI 10.1091/mbc.11.9.2833; GELLER SA, 1994, HEPATOLOGY, V19, P389; Gillece P, 1999, J CELL BIOL, V147, P1443, DOI 10.1083/jcb.147.7.1443; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020; HAGERTY DT, 1995, J IMMUNOL, V155, P2993; HENNE V, 1986, FEBS LETT, V202, P267, DOI 10.1016/0014-5793(86)80699-8; Heuck AP, 1997, J BIOCHEM BIOPH METH, V34, P213, DOI 10.1016/S0165-022X(97)00014-6; Hidvegi T, 2005, J BIOL CHEM, V280, P39002, DOI 10.1074/jbc.M508652200; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Kern JC, 2005, FRONT BIOSCI-LANDMRK, V10, P1727, DOI 10.2741/1656; Lawless MW, 2004, J IMMUNOL, V172, P5722, DOI 10.4049/jimmunol.172.9.5722; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Lomas DA, 2004, THORAX, V59, P529, DOI 10.1136/thx.2003.006528; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Nardai G, 2005, BIOCHEM BIOPH RES CO, V334, P787, DOI 10.1016/j.bbrc.2005.06.172; Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200; Papp E, 2003, BIOFACTORS, V17, P249, DOI 10.1002/biof.5520170124; Perlmutter DH, 2002, J CLIN INVEST, V110, P1579, DOI 10.1172/JCI200216787; PERLMUTTER DH, 1989, J CLIN INVEST, V84, P1555, DOI 10.1172/JCI114332; Petropoulos I, 2000, J GERONTOL A-BIOL, V55, pB220, DOI 10.1093/gerona/55.5.B220; Rudnick DA, 2004, HEPATOLOGY, V39, P1048, DOI 10.1002/hep.20118; Schmidt BZ, 2005, AM J PHYSIOL-GASTR L, V289, pG444, DOI 10.1152/ajpgi.00237.2004; Sideraki V, 2000, BIOCHEMISTRY-US, V39, P1180, DOI 10.1021/bi992246q; SITIA R, 2004, SCI STKE, V239, pPE27; Smith JD, 2004, BIOTECHNOL BIOENG, V85, P340, DOI 10.1002/bit.10853; Sreedhar AS, 2004, FEBS LETT, V562, P11; Sreekumar PG, 2005, BIOCHEM BIOPH RES CO, V334, P245, DOI 10.1016/j.bbrc.2005.06.081; Teckman JH, 2002, AM J PHYSIOL-GASTR L, V283, pG1156, DOI 10.1152/ajpgi.00041.2002; Teckman JH, 2001, J BIOL CHEM, V276, P44865, DOI 10.1074/jbc.M103703200; TECKMAN JH, 2003, AM J PHYSIOL-GASTR L, V286, pG815; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Varsanyi M, 2004, J BIOL CHEM, V279, P3370, DOI 10.1074/jbc.M307783200; Vincent AM, 2004, ENDOCR REV, V25, P612, DOI 10.1210/er.2003-0019; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100	48	30	30	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					1018	+		10.1096/fj.05-5065fje	http://dx.doi.org/10.1096/fj.05-5065fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571774				2022-12-28	WOS:000240157700041
J	Malorni, W; Fiorentini, C				Malorni, Walter; Fiorentini, Carla			Is the Rac GTPase-activating toxin CNF1 a smart hijacker of host cell fate?	FASEB JOURNAL			English	Article						mitotic catastrophe; multipolar mitosis; Rac GT-Pase; CNF1; autophagy	MITOTIC CATASTROPHE; RHO-GTPASES; APOPTOSIS; DEATH; AUTOPHAGY; KINASE-1; CANCER; BCL-2; CYCLE	The term mitotic catastrophe ( MC) was coined to describe the mammalian cell death caused by aberrant mitosis. MC occurs with features that are fundamentally different from those typifying other forms of cell death, including apoptosis. We report here for the first time that the Rac-activating toxin CNF1 interferes with the occurrence of MC and leads to aneuploidy and multinucleation. This seems to be in line with the anti-apoptotic activity of the toxin and consistent with the hypothesis that points at CNF1 as a toxin bearing a carcinogenic potential. - Malorni, W., Fiorentini, C. Is the Rac GTPase- activating toxin CNF1 a smart hijacker of host cell fate?.	Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Malorni, W (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	malorni@iss.it	Fiorentini, Carla/Q-2088-2015; FIORENTINI, CARLA/AAG-8005-2019; Malorni, Walter/G-5874-2016	Fiorentini, Carla/0000-0003-1707-6282; FIORENTINI, CARLA/0000-0003-1707-6282; malorni, walter/0000-0002-1223-7000				Boyer L, 2004, MOL BIOL CELL, V15, P1124, DOI 10.1091/mbc.E03-05-0301; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; D'Amato G, 1998, CRIT REV ONCOGENESIS, V9, P275; Eskelinen EL, 2005, CELL DEATH DIFFER, V12, P1468, DOI 10.1038/sj.cdd.4401721; Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057; Fiorentini C, 2003, CELL DEATH DIFFER, V10, P147, DOI 10.1038/sj.cdd.4401151; Fiorentini C, 1998, CELL DEATH DIFFER, V5, P921, DOI 10.1038/sj.cdd.4400422; Fiorentini C, 2001, MOL BIOL CELL, V12, P2061, DOI 10.1091/mbc.12.7.2061; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Lax AJ, 2005, NAT REV MICROBIOL, V3, P343, DOI 10.1038/nrmicro1130; Lock RB, 1996, CANCER RES, V56, P4006; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Malorni W, 2003, J IMMUNOL, V171, P4195, DOI 10.4049/jimmunol.171.8.4195; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Quimby BB, 2003, CURR OPIN CELL BIOL, V15, P338, DOI 10.1016/S0955-0674(03)00046-2; Sato N, 2000, ONCOGENE, V19, P5281, DOI 10.1038/sj.onc.1203902; Travaglione S, 2005, CELL DEATH DIFFER, V12, P78, DOI 10.1038/sj.cdd.4401522	26	28	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					606	609		10.1096/fj.05-4706hyp	http://dx.doi.org/10.1096/fj.05-4706hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581968				2022-12-28	WOS:000240130900006
J	Warraich, RS; Griffiths, E; Falconar, A; Pabbathi, V; Bell, C; Angelini, G; Suleiman, MS; Yacoub, MH				Warraich, Rahat S.; Griffiths, Elinor; Falconar, Andrew; Pabbathi, Vijay; Bell, Chris; Angelini, Gianni; Suleiman, M. -Saadeh; Yacoub, Magdi H.			Human cardiac myosin autoantibodies impair myocyte contractility: a cause-and-effect relationship	FASEB JOURNAL			English	Article						dilated cardiomyopathy; antimyosin autoantibodies; myocyte contractility	DILATED CARDIOMYOPATHY; CALCIUM; HEART; ANTIBODIES; IMMUNOGLOBULINS; DYSFUNCTION; INHIBITION; PROTEINS; FAILURE; SERA	The functional relevance of autoantibodies (Abs) against cardiac myosin ( CM) in clinical idiopathic dilated cardiomyopathy (DCM) remains controversial. The study sought to determine effects of human Abs affinity-purified (AF) by immunoaffinity column chromotography on excitation-contraction coupling in isolated myocytes. Effects of CM-Abs from heart failure patients with DCM (n = 19) and ischemic heart disease (IHD, n = 19) on contractility, L-type Ca2+ current, and Ca2+ transients in continuously perfused rat ventricular myocytes were studied. Immunofluorescence studies using confocal microscopy were carried out to determine whether Abs were internalized. AF-Abs from either group did not differ in IgG titer but differed in their elution profiles. The IgG3 subclass response was higher in AF fractions from DCM (21%) than IHD (5%) patients. The Abs reduced the capacity of field-stimulated myocytes to contract in a dose-dependent manner. Inhibition of contraction, as a percentage of untreated cells, was greater with DCM than IHD-Abs ( P = 0.004), and the effect was independent of Ab titer. An increase in frequency of the beating myocytes (0.2 to 3.0 Hz) raised peak systolic and diastolic levels of [Ca2+](i) of cells treated with DCM but not IHD-Abs ( P < 0.005). The AF-Abs were not internalized by myocytes and had no effect on L-type Ca2+ currents. The altered sensitivity of the myofilaments to [Ca2+](i) by CM-Abs may represent a potential mechanism of autoantibody-mediated impairment in clinical DCM. -Warraich, R. S., Griffiths, E., Falconar, A., Pabbathi, V., Bell, C., Angelini, G., Suleiman, M.-S., Yacoub, M. H. Human cardiac myosin autoantibodies impair myocyte contractility: a cause-and-effect relationship.	Harefield Hosp, Royal Brompton & Harefield Trust, Imperial Coll Sch Med, Natl Heart & Lung Inst,Dept Cardiothorac Surg, Harefield UB9 6JH, Middx, England; Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; London Sch Hyg & Trop Med, London WC1, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Bristol Royal Infirmary; University of Bristol; University of London; London School of Hygiene & Tropical Medicine	Warraich, RS (corresponding author), Harefield Hosp, Royal Brompton & Harefield Trust, Imperial Coll Sch Med, Natl Heart & Lung Inst,Dept Cardiothorac Surg, Harefield UB9 6JH, Middx, England.	rwarraich@lycos.com	Suleiman, M.-Saadeh/AAF-2946-2019	Suleiman, M.-Saadeh/0000-0001-6080-480X; angelini, gianni/0000-0002-1753-3730				ANSARI AA, 1994, J IMMUNOL, V153, P4754; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; CAFORIO ALP, 1992, CIRCULATION, V85, P1734, DOI 10.1161/01.CIR.85.5.1734; Caforio ALP, 1997, HEART, V77, P62, DOI 10.1136/hrt.77.1.62; Caforio ALP, 1995, EUR HEART J, V16, P68, DOI 10.1093/eurheartj/16.suppl_O.68; DESCHEERDER IK, 1991, EUR HEART J, V12, P88, DOI 10.1093/eurheartj/12.suppl_D.88; GOLDMAN JH, 1995, BRIT HEART J, V74, P598; Griffiths EJ, 1999, FEBS LETT, V453, P400, DOI 10.1016/S0014-5793(99)00726-7; Griffiths EJ, 1997, AM J PHYSIOL-CELL PH, V273, pC37, DOI 10.1152/ajpcell.1997.273.1.C37; Harding SE, 1998, ANN MED, V30, P14; Jana CK, 1999, J IMMUNOL METHODS, V225, P95, DOI 10.1016/S0022-1759(99)00032-0; Knowlton AA, 1998, J MOL CELL CARDIOL, V30, P811, DOI 10.1006/jmcc.1998.0646; LAUER B, 1994, J AM COLL CARDIOL, V23, P146, DOI 10.1016/0735-1097(94)90513-4; Li M, 2002, FEBS LETT, V513, P247, DOI 10.1016/S0014-5793(02)02322-0; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; Mandi Y, 2000, PATHOBIOLOGY, V68, P150, DOI 10.1159/000055916; NEUMANN DA, 1990, J AM COLL CARDIOL, V16, P839; Owen VJ, 1999, CIRCULATION, V99, P2565, DOI 10.1161/01.CIR.99.19.2565; Ravens U, 1996, MOL CELL BIOCHEM, V157, P245; Schultheiss H P, 1985, Adv Myocardiol, V6, P311; SCHULTHEISS HP, 1988, J EXP MED, V168, P2105, DOI 10.1084/jem.168.6.2105; SHARAF AR, 1994, CIRCULATION, V89, P1217, DOI 10.1161/01.CIR.89.3.1217; Tabakyan EA, 2002, KARDIOLOGIYA, V42, P42; WAGNER JA, 1986, SCIENCE, V232, P515, DOI 10.1126/science.3008330; Warraich RS, 1999, BIOCHEM BIOPH RES CO, V259, P255, DOI 10.1006/bbrc.1999.0761; Warraich RS, 2005, AM HEART J, V150, P263, DOI 10.1016/j.ahj.2004.09.008; Warraich RS, 2002, AM HEART J, V143, P1076, DOI 10.1067/mhj.2002.124406; Warraich RS, 2000, TRANSPLANTATION, V69, P1609; Witchel HJ, 2002, FEBS LETT, V512, P59, DOI 10.1016/S0014-5793(01)03320-8	29	26	28	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					651	660		10.1096/fj.04-3001com	http://dx.doi.org/10.1096/fj.04-3001com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581973				2022-12-28	WOS:000240130900011
J	Baskar, R; Li, L; Moore, PK				Baskar, Rajamanickam; Li, Ling; Moore, Philip Keith			Hydrogen sulfide-induces DNA damage and changes in apoptotic gene expression in human lung fibroblast cells	FASEB JOURNAL			English	Article						cell cycle; p53; mitochondria; cytochrome c translocation	CYTOCHROME-C; BCL-2 FAMILY; MITOCHONDRIA; REPLICATION; ACTIVATION; RAT; BAX; MEDIATOR; RELEASE; P53	Hydrogen sulfide (H2S) has been shown previously to exert proapoptotic activity. However, the mechanism(s) by which H2S affects cell growth and function have not been addressed adequately. In this study, cultured human lung fibroblasts were treated with the H2S donor NaHS (10-75 mu M; 12-48 h). NaHS caused a concentration-dependent increase in micronuclei formation ( indicating DNA damage) and cell cycle arrest (G(1) phase). NaHS increased expression of ku 70 and ku 80 but did not affect the expression of other DNA repair proteins such as proliferating cell nuclear antigen ( PCNA) or replication protein A (rNase protection assay). NaHS treatment also resulted in stabilization of p53 coupled with induction of downstream proteins such as p21, Bax, and cytochrome c, as well as translocation of Bax from the cytosol to the mitochondria and release of cytochrome c from mitonchondria. NaHS did not up-regulate cell levels of the antiapoptotic protein, Bcl-2. We propose that the genotoxic action of H2S propels the cell toward apoptotic death triggered initially by stabilization of p53 and subsequently involving a cascade of downstream products. These results are of significance as they uncover a hitherto unknown and very fundamental role for H2S in determining cell fate.	Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Cardiovasc Biol Res Grp, Singapore 117597, Singapore	National University of Singapore	Moore, PK (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Cardiovasc Biol Res Grp, Bldg MD2,18 Med Dr, Singapore 117597, Singapore.	phchead@nus.edu.sg						Abe K, 1996, J NEUROSCI, V16, P1066; AJMANI AK, 1995, J EXP MED, V181, P2049, DOI 10.1084/jem.181.6.2049; Attene-Ramos MS, 2006, MOL CANCER RES, V4, P9, DOI 10.1158/1541-7786.MCR-05-0126; Balajee AS, 2004, RADIAT RES, V162, P677, DOI 10.1667/RR3269; BEAUCHAMP RO, 1984, CRC CR REV TOXICOL, V13, P25, DOI 10.3109/10408448409029321; Bhatia M, 2005, FASEB J, V19, P623, DOI 10.1096/fj.04-3023fje; Bian JS, 2006, J PHARMACOL EXP THER, V316, P670, DOI 10.1124/jpet.105.092023; Bouchier-Hayes L, 2005, J CLIN INVEST, V115, P2640, DOI 10.1172/JCI26274; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAO Y, 2006, IN PRESS AM J PHYSL; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Deplancke B, 2003, FASEB J, V17, P1310, DOI 10.1096/fj.02-0883fje; FENECH M, 1989, MUTAGENESIS, V4, P98, DOI 10.1093/mutage/4.2.98; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Goldstein JC, 2005, CELL DEATH DIFFER, V12, P453, DOI 10.1038/sj.cdd.4401596; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; Kaneko Y, 2006, DIABETES, V55, P1391, DOI 10.2337/db05-1082; KASTAN MB, 1991, CANCER RES, V51, P6304; Kimura H, 2002, MOL NEUROBIOL, V26, P13, DOI 10.1385/MN:26:1:013; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li L, 2005, FASEB J, V19, P1196, DOI 10.1096/fj.04-3583fje; McLaughlin LM, 2005, CANCER RES, V65, P6097, DOI 10.1158/0008-5472.CAN-04-4254; MIYASHITA T, 1995, CELL, V80, P293; Moore PK, 2003, TRENDS PHARMACOL SCI, V24, P609, DOI 10.1016/j.tips.2003.10.007; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; SAVAGE JRK, 1989, MUTAT RES, V225, P171, DOI 10.1016/0165-7992(89)90115-2; SCHMID W, 1975, MUTAT RES, V31, P9, DOI 10.1016/0165-1161(75)90058-8; Solomon DA, 2004, J CELL BIOL, V166, P455, DOI 10.1083/jcb.200312048; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang R, 2003, ANTIOXID REDOX SIGN, V5, P493, DOI 10.1089/152308603768295249; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang G, 2006, FASEB J, V20, P553, DOI 10.1096/fj.05-4712fje; Yang GD, 2004, FASEB J, V18, P1782, DOI 10.1096/fj.04-2279fje; Yusuf M, 2005, BIOCHEM BIOPH RES CO, V333, P1146, DOI 10.1016/j.bbrc.2005.06.021; Zhao WM, 2002, AM J PHYSIOL-HEART C, V283, pH474, DOI 10.1152/ajpheart.00013.2002	39	127	145	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					247	255		10.1096/fj.06-6255com	http://dx.doi.org/10.1096/fj.06-6255com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17116745				2022-12-28	WOS:000243130200027
J	Brockway, LM; Furcht, LT				Brockway, Laura M.; Furcht, Leo T.			Conflicts of interest in biomedical research - the FASEB guidelines	FASEB JOURNAL			English	Article						industry; policy; consulting; scientists; integrity		The rise in academia-industry relationships has been accompanied by increasing concerns about financial conflicts of interest. To date, policy recommendations addressing financial conflicts of interest have focused on the role of academic institutions in reviewing and overseeing investigator relationships with industry. However, investigators as a group determine the effectiveness of policies and practices. Therefore, there is a clear need for a consensus statement of standards for academia-industry interactions from the scientists' perspective. To meet that need, we propose conflict of interest guidelines for individual biomedical investigators to address the critical challenges faced when financial relationships with industry exist. Brockway, L. M., Furcht, L. T. Conflicts of interest in biomedical research-the FASEB guidelines.	FASEB Off Publ Affairs, Bethesda, MD 20814 USA; Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Brockway, LM (corresponding author), FASEB Off Publ Affairs, 9650 Rockville Pike, Bethesda, MD 20814 USA.	lbrockway@faseb.org						*ASS AM MED COLL T, 2001, PROT SUBJ PRES TRUST; *ASS AM U TASK FOR, 2001, REP IND I FIN CONFL; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Blumenthal D, 2003, NEW ENGL J MED, V349, P2452, DOI 10.1056/NEJMhpr035460; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; CAMPBELL EG, 2004, TRIPLE HELIX U GOVT; *CTR DRUG EV RES, 1996, GUID IND E6 GOOD CLI; *DEP HHS, 2003, FIN REL INT RES INV; Korn D, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010001; SHAYWITZ DA, 2005, BOSTON GLOBE; Slaughter S, 2002, SCI TECHNOL HUM VAL, V27, P282, DOI 10.1177/016224390202700205	11	12	12	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2435	2438		10.1096/fj.06-6723LSF	http://dx.doi.org/10.1096/fj.06-6723LSF			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17142792				2022-12-28	WOS:000242490700003
J	Chastain, PD; Nakamura, J; Swenberg, J; Kaufman, D				Chastain, Paul D., II; Nakamura, Jun; Swenberg, James; Kaufman, David			Nonrandom AP site distribution in highly proliferative cells	FASEB JOURNAL			English	Article						abasic; apurinic/apyrimidinic; electron microscopy; oxidative damage; reactive oxygen species; methoxyamine; isolated DNA fibers	BASE-EXCISION-REPAIR; OXIDATIVE DNA-DAMAGE; APURINIC/APYRIMIDINIC SITES; ELECTRON-MICROSCOPY; IONIZING-RADIATION; MAMMALIAN-CELLS; LESIONS; CHROMATIN; DISEASE; ASSAY	Reactive oxygen species (ROS) and the oxidative DNA damage they produce [e. g., 8-oxo-guanine and apurinic/apyrimidinic (AP) sites] have been linked to the pathogenesis of several age-related and chronic diseases. The basal number of AP sites measured in DNA by immuno-slot-blot analysis ranges from 70,000 to 100,000 per genome. We used electron microscopy to determine how AP sites were distributed in isolated DNA fibers from fresh calf thymus and HeLa cell cultures. We observed that AP sites were not equally distributed throughout all the fibers. A small percentage of the analyzed DNA fibers contained a disproportionate amount of the total AP sites in nonrandom groups of 10 to > 30 closely spaced in a small region (e. g., 20 AP sites in a 6 kb length of DNA). This finding suggests that genomic sites may differ in their vulnerability to ROS damage, perhaps because of local chromatin structure. Nonrandom AP site formation also suggests that the detrimental effects of ROS in the development of disease may be related not simply to the total number of AP sites present but to how AP sites are distributed along a DNA fiber and, perhaps, to the genomic sites affected.	Univ N Carolina, Sch Med, Dept Pathol & Lab, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Chastain, PD (corresponding author), Univ N Carolina, Sch Med, Dept Pathol & Lab, Chapel Hill, NC 27599 USA.	pchastai@med.unc.edu	Chastain, Paul/AAN-2692-2020	Chastain, Paul/0000-0001-6782-6788; Nakamura, Jun/0000-0002-1756-7199	NATIONAL CANCER INSTITUTE [P30CA016086, R01CA084493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES005948, P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NCI NIH HHS [CA16086, CA-084493] Funding Source: Medline; NIEHS NIH HHS [P42-ES05948, ES07017, P30-ES10126] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYLAWSKI BP, 1989, CARCINOGENESIS, V10, P199, DOI 10.1093/carcin/10.1.199; BRYLAWSKI BP, 1991, MOL CARCINOGEN, V4, P315, DOI 10.1002/mc.2940040410; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; De Bont R, 2004, MUTAGENESIS, V19, P169, DOI 10.1093/mutage/geh025; Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001; Friedberg ECW GC, 1995, DNA REPAIR MUTAGENES, P19; Georgakilas AG, 2002, NUCLEIC ACIDS RES, V30, P2800, DOI 10.1093/nar/gkf393; GRIFFITH JD, 1978, SCIENCE, V201, P525, DOI 10.1126/science.663672; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; LIUZZI M, 1985, J BIOL CHEM, V260, P5252; MACLEOD MC, 1995, CARCINOGENESIS, V16, P2009, DOI 10.1093/carcin/16.9.2009; Nakamura J, 2003, NUCLEIC ACIDS RES, V31, P1790, DOI 10.1093/nar/gkg263; Nakamura J, 2000, J BIOL CHEM, V275, P5323, DOI 10.1074/jbc.275.8.5323; Nakamura J, 1999, CANCER RES, V59, P2522; Nakamura J, 1998, CANCER RES, V58, P222; TALPAERTBORLE M, 1983, BIOCHIM BIOPHYS ACTA, V740, P410, DOI 10.1016/0167-4781(83)90089-1; Tian KG, 2002, DNA REPAIR, V1, P1039, DOI 10.1016/S1568-7864(02)00163-5; Yang N, 2004, DNA REPAIR, V3, P1323, DOI 10.1016/j.dnarep.2004.04.014; Zielinska-Park J, 2004, CARCINOGENESIS, V25, P1727, DOI 10.1093/carcin/bgh174	20	22	23	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2612	+		10.1096/fj.06-6145fje	http://dx.doi.org/10.1096/fj.06-6145fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17068113				2022-12-28	WOS:000242490700041
J	Stagi, M; Gorlovoy, P; Larionov, S; Takahashi, K; Neumann, H				Stagi, Massimiliano; Gorlovoy, Philipp; Larionov, Sergey; Takahashi, Kazuya; Neumann, Harald			Unloading kinesin transported cargoes from the tubulin track via the inflammatory c-Jun N-terminal kinase pathway	FASEB JOURNAL			English	Article						neuroinflammation; tumor necrosis factor-alpha; synaptophysin; mitochondria	TUMOR-NECROSIS-FACTOR; DYNEIN SUPERFAMILY PROTEINS; VESICLE PRECURSOR TRANSPORT; CENTRAL-NERVOUS-SYSTEM; AXONAL-TRANSPORT; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; SCAFFOLD PROTEIN; ORGANELLE TRANSPORT; NITRIC-OXIDE	Axonal transport of mitochondria and synaptic vesicle precursors via kinesin motor proteins is essential to keep integrity of axons and synapses. Disturbance of axonal transport is an early sign of neuroinflammatory and neurodegenerative diseases. Treatment of cultured neurons by the inflammatory cytokine tumor necrosis factor-alpha (TNF) stimulated phosphorylation of c-Jun N-terminal kinase (JNK) in neurites. TNF treatment induced dissociation of the heavy chain kinesin family-5B (KIF5B) protein from tubulin in axons but not cell bodies as determined by lifetime-based Forster resonance energy transfer (FRET) analysis. Dissociation of KIF5B from tubulin after TNF treatment was dependent on JNK activity. Furthermore, TNF inhibited axonal transport of mitochondria and synaptophysin by reducing the mobile fraction via JNK. Thus, TNF produced by activated glial cells in inflammatory or degenerative neurological diseases acts on neurites by acting on the kinesin-tubulin complex and inhibits axonal mitochondria and synaptophysin transport via JNK.-Stagi, M., Gorlovoy, P., Larionov, S., Takahashi, K., and Neumann, H. Unloading kinesin transported cargoes from the tubulin track via the inflammatory c-Jun N-terminal kinase pathway.	Univ Bonn, Life & Brain Ctr, Neural Regenerat Unit, Inst Reconstruct Neurobiol, D-53127 Bonn, Germany; Univ Bonn, Hertie Fdn, D-53127 Bonn, Germany; Univ Gottingen, Inst Multiple Sclerosis Res, D-3400 Gottingen, Germany; Hertie Fdn, Gottingen, Germany; European Neurosci Inst Gottingen, Neuroimmunol Unit, Gottingen, Germany; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT USA	University of Bonn; University of Bonn; University of Gottingen; Yale University	Neumann, H (corresponding author), Univ Bonn, Life & Brain Ctr, Neural Regenerat Unit, Inst Reconstruct Neurobiol, Sigmund Freud Str 25, D-53127 Bonn, Germany.	hneuman1@uni-bonn.de	Stagi, Massimiliano/ABF-5894-2020; Neumann, Harald/A-9718-2010; Takahashi, Kazuya/R-3499-2019	Stagi, Massimiliano/0000-0002-5827-902X; Neumann, Harald/0000-0002-5071-5202; 				Aboul-Enein F, 2006, ACTA NEUROPATHOL, V111, P539, DOI 10.1007/s00401-006-0047-y; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Byrd DT, 2001, NEURON, V32, P787, DOI 10.1016/S0896-6273(01)00532-3; Cavalli V, 2005, J CELL BIOL, V168, P775, DOI 10.1083/jcb.200410136; Chen YE, 2004, MICROSC RES TECHNIQ, V63, P72, DOI 10.1002/jemt.10430; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; De Vos K, 2000, J CELL BIOL, V149, P1207, DOI 10.1083/jcb.149.6.1207; Dreyer J, 2004, J NEUROSCI, V24, P10454, DOI 10.1523/JNEUROSCI.2265-04.2004; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goldstein LSB, 2003, NEURON, V40, P415, DOI 10.1016/S0896-6273(03)00630-5; Goldstein LSB, 2001, SCIENCE, V291, P2102, DOI 10.1126/science.1059766; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Horiuchi D, 2005, CURR BIOL, V15, P2137, DOI 10.1016/j.cub.2005.10.047; Iliev AI, 2003, FASEB J, V17, P412, DOI 10.1096/fj.03-0670fje; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kenney AM, 1998, J NEUROSCI, V18, P1318; KOLLNER M, 1992, CHEM PHYS LETT, V200, P199, DOI 10.1016/0009-2614(92)87068-Z; Martin M, 1999, MOL BIOL CELL, V10, P3717, DOI 10.1091/mbc.10.11.3717; MCGLADEMCCULLOH E, 1989, P NATL ACAD SCI USA, V86, P1093, DOI 10.1073/pnas.86.3.1093; Medana IM, 2002, AM J PATHOL, V160, P655, DOI 10.1016/S0002-9440(10)64885-7; Muresan Z, 2005, J NEUROSCI, V25, P3741, DOI 10.1523/JNEUROSCI.0152-05.2005; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Pendlebury ST, 2000, MAGN RESON IMAGING, V18, P369, DOI 10.1016/S0730-725X(00)00115-6; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Pilling AD, 2006, MOL BIOL CELL, V17, P2057, DOI 10.1091/mbc.E05-06-0526; Puig B, 2004, NEUROPATH APPL NEURO, V30, P491, DOI 10.1111/j.1365-2990.2004.00569.x; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Savage MJ, 2002, J NEUROSCI, V22, P3376; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Stagi M, 2005, J NEUROSCI, V25, P352, DOI 10.1523/JNEUROSCI.3887-04.2005; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wallrabe H, 2005, CURR OPIN BIOTECH, V16, P19, DOI 10.1016/j.copbio.2004.12.002; Yonekawa Y, 1998, J CELL BIOL, V141, P431, DOI 10.1083/jcb.141.2.431	45	50	50	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2573	+		10.1096/fj.06-6679fje	http://dx.doi.org/10.1096/fj.06-6679fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17068110				2022-12-28	WOS:000242490700028
J	von Degenfeld, G; Banfi, A; Springer, ML; Wagner, RA; Jacobi, J; Ozawa, CR; Merchant, MJ; Cooke, JP; Blau, HM				von Degenfeld, Georges; Banfi, Andrea; Springer, Matthew L.; Wagner, Roger A.; Jacobi, Johannes; Ozawa, Clare R.; Merchant, Milton J.; Cooke, John P.; Blau, Helen M.			Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia	FASEB JOURNAL			English	Article						angiogenesis; gene therapy; cell transplantation	REGIONAL BLOOD-FLOW; GENE DELIVERY; STIMULATES ANGIOGENESIS; VASCULATURE; THERAPY; MUSCLE; MODEL; LIMB; OVEREXPRESSION; ANGIOPOIETIN-1	The critical role of vascular endothelial growth factor (VEGF) expression levels in developmental angiogenesis is well established. Nonetheless, the effects of different local (microenvironmental) VEGF concentrations in ischemia have not been studied in the adult organism, and VEGF delivery to patients has been disappointing. Here, we demonstrate the existence of both lower and upper threshold levels of microenvironmental VEGF concentrations for the induction of therapeutic vessel growth in ischemia. In the ischemic hind limb, implantation of myoblasts transduced to express VEGF(164) at different levels per cell increased blood flow only moderately, and vascular leakage and aberrant preangiomatous vessels were always induced. When the same total dose was uniformly distributed by implanting a monoclonal population derived from a single VEGF-expressing myoblast, blood flow was fully restored to nonischemic levels, collateral growth was induced, and ischemic damage was prevented. Hemangiomas were avoided and only normal, pericyte-covered vessels were induced persisting over 15 mo. Surprisingly, clones uniformly expressing either lower or higher VEGF levels failed to provide any functional benefit. A biphasic effect of VEGF dose on vessel number and diameter was found. Blood flow was only improved if vessels were increased both in size and in number. Microenvironmental VEGF concentrations determine efficacy and safety in a therapeutic setting.	Stanford Univ, Sch Med, Baxter Lab Genet Pharmacol, Dept Mol Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Baxter Lab Genet Pharmacol, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA; Bayer Healthcare, Cardiovasc Res, Wuppertal, Germany; Univ Basel Hosp, Inst Surg Res & Hosp Management, Dept Res, CH-4031 Basel, Switzerland; Univ Basel Hosp, Dept Surg, CH-4031 Basel, Switzerland; Univ Calif San Francisco, Div Cardiol, San Francisco, CA 94143 USA	Stanford University; Stanford University; Stanford University; Bayer AG; Bayer Healthcare Pharmaceuticals; University of Basel; University of Basel; University of California System; University of California San Francisco	Blau, HM (corresponding author), Stanford Univ, Sch Med, Baxter Lab Genet Pharmacol, Dept Mol Pharmacol, Stanford, CA 94305 USA.	hblau@stanford.edu	Banfi, Andrea/B-8720-2008	Banfi, Andrea/0000-0001-5737-8811; Cooke, John/0000-0003-0033-9138	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020961, R01AG009521, R01AG024987, R37AG009521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL065572] Funding Source: Medline; NIA NIH HHS [AG020961, AG024987, AG009521] Funding Source: Medline; NICHD NIH HHS [HD018179] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baffour R, 2000, J SURG RES, V93, P219, DOI 10.1006/jsre.2000.5980; Banfi A, 2002, METHOD ENZYMOL, V346, P145; Banfi Andrea, 2005, Curr Atheroscler Rep, V7, P227, DOI 10.1007/s11883-005-0011-7; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHIEN GL, 1995, CARDIOVASC RES, V30, P405, DOI 10.1016/0008-6363(95)00060-7; Deindl E, 2001, CIRC RES, V89, P779, DOI 10.1161/hh2101.098613; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gounis MJ, 2005, GENE THER, V12, P762, DOI 10.1038/sj.gt.3302481; Grinberg OY, 2004, PHYSIOL MEAS, V25, P659, DOI 10.1088/0967-3334/25/3/006; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Hershey JC, 2003, HEART VESSELS, V18, P142, DOI 10.1007/s00380-003-0694-z; Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7; Jacobi J, 2005, CIRCULATION, V111, P1431, DOI 10.1161/01.CIR.0000158487.80483.09; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Masaki I, 2002, CIRC RES, V90, P966, DOI 10.1161/01.RES.0000019540.41697.60; Miquerol L, 2000, DEVELOPMENT, V127, P3941; Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; Ozawa CR, 2004, J CLIN INVEST, V113, P516, DOI 10.1172/JCI200418420; Paek R, 2002, J VASC SURG, V36, P172, DOI 10.1067/mva.2002.124361; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Rissanen TT, 2005, CIRCULATION, V112, P3937, DOI 10.1161/CIRCULATIONAHA.105.543124; Rissanen TT, 2002, FASEB J, V16, P100, DOI 10.1096/fj.02-0377fje; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Schaper W, 2003, ARTERIOSCL THROM VAS, V23, P1143, DOI 10.1161/01.ATV.0000069625.11230.96; Scholz D, 2002, J MOL CELL CARDIOL, V34, P775, DOI 10.1006/jmcc.2002.2013; Schwarz ER, 2000, J AM COLL CARDIOL, V35, P1323, DOI 10.1016/S0735-1097(00)00522-2; Simons M, 2005, CIRCULATION, V111, P1556, DOI 10.1161/01.CIR.0000159345.00591.8F; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Thein E, 2002, EUR SURG RES, V34, P215, DOI 10.1159/000063392; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Vajanto I, 2002, J GENE MED, V4, P371, DOI 10.1002/jgm.287; von Degenfeld G, 2003, J AM COLL CARDIOL, V42, P1120, DOI 10.1016/S0735-1097(03)00915-X; Zhou YF, 2004, J AM COLL CARDIOL, V44, P897, DOI 10.1016/j.jacc.2004.05.046	37	107	107	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2657	+		10.1096/fj.06-6568fje	http://dx.doi.org/10.1096/fj.06-6568fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17095533				2022-12-28	WOS:000242490700056
J	Fontaine, JM; Sun, XK; Hoppe, AD; Simon, S; Vicart, P; Welsh, MJ; Benndorf, R				Fontaine, Jean-Marc; Sun, Xiankui; Hoppe, Adam D.; Simon, Stephanie; Vicart, Patrick; Welsh, Michael J.; Benndorf, Rainer			Abnormal small heat shock protein interactions involving neuropathy-associated HSP22 (HSPB8) mutants	FASEB JOURNAL			English	Article						distal hereditary motor neuropathy; Charcot-Marie-Tooth disease; fluorescence resonance energy transfer	ALPHA-B-CRYSTALLIN; MARIE-TOOTH-DISEASE; HEREDITARY MOTOR; MUTATION; DYNAMICS; TISSUES	Two mutations (K141E, K141N) in the small heat shock protein ( sHSP) HSP22 (HSPB8) are associated with the inherited peripheral motor neuron disorders distal hereditary motor neuropathy type II and axonal Charcot-Marie-Tooth disease type 2L. HSP22 is known to form homodimers, heterodimers with other sHSPs, and larger oligomers. In an effort to elucidate the cellular basis for these diseases, we have determined the ability of mutant HSP22 to interact with itself, with wild-type HSP22, and with other sHSPs that are abundant in neurons. Using the yeast two-hybrid method, quantitative fluorescence resonance energy transfer in live cells, and cross-linking, we found aberrantly increased interactions of mutant HSP22 forms with themselves, with wild-type HSP22, and with the other sHSPs, alpha B-crystallin, and HSP27. Interaction with HSP20 was not affected by the mutations. The data suggest that each mutant form of HSP22 has a characteristic pattern of abnormal interaction properties. A mutation (S135F) in HSP27 that is also associated with these disorders showed increased interaction with wild-type HSP22 also, suggesting linkage of these two etiologic factors, HSP22 and HSP27, into one common pathway. Increased interactions involving mutant sHSPs may be the molecular basis for their increased tendency to form cytoplasmic protein aggregates, and for the occurrence of the associated neuropathies.	Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Paris 07, UFR Biochim, Paris, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; UDICE-French Research Universities; Universite Paris Cite	Benndorf, R (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	rbenndo@umich.edu	Stephanie, Simon/A-3845-2013; Welsh, Michael/B-1968-2008; Hoppe, Adam/U-8563-2019	Hoppe, Adam/0000-0003-4180-0840	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011188] Funding Source: NIH RePORTER; NIEHS NIH HHS [P01ES11188] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ackerley S, 2006, HUM MOL GENET, V15, P347, DOI 10.1093/hmg/ddi452; Benndorf R, 2004, NAT GENET, V36, P547, DOI 10.1038/ng0604-547; Dierick I, 2005, ANN MED, V37, P413, DOI 10.1080/07853890500296410; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354; Fontaine JM, 2005, BIOCHEM BIOPH RES CO, V337, P1006, DOI 10.1016/j.bbrc.2005.09.148; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; HARDING AE, 1980, BRAIN, V103, P259, DOI 10.1093/brain/103.2.259; Hoppe A, 2002, BIOPHYS J, V83, P3652, DOI 10.1016/S0006-3495(02)75365-4; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Inagaki N, 2006, BIOCHEM BIOPH RES CO, V342, P379, DOI 10.1016/j.bbrc.2006.01.154; INAGUMA Y, 1995, J BIOCHEM-TOKYO, V117, P1238, DOI 10.1093/oxfordjournals.jbchem.a124850; Irobi J, 2004, NAT GENET, V36, P597, DOI 10.1038/ng1328; Irobi J, 2004, HUM MOL GENET, V13, pR195, DOI 10.1093/hmg/ddh226; Kijima K, 2005, J HUM GENET, V50, P473, DOI 10.1007/s10038-005-0280-6; Lelj-Garolla B, 2005, J MOL BIOL, V345, P631, DOI 10.1016/j.jmb.2004.10.056; Liu CH, 1999, BIOCHEM BIOPH RES CO, V255, P256, DOI 10.1006/bbrc.1999.0174; Liu Xiao-min, 2005, Zhonghua Yixue Yichuanxue Zazhi, V22, P510; Lowe J, 2001, ADV EXP MED BIOL, V487, P169; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Sanbe A, 2004, P NATL ACAD SCI USA, V101, P10132, DOI 10.1073/pnas.0401900101; Selcen D, 2003, ANN NEUROL, V54, P804, DOI 10.1002/ana.10767; Shy ME, 2004, CURR OPIN NEUROL, V17, P579, DOI 10.1097/00019052-200410000-00008; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Sun XK, 2006, CELL STRESS CHAPERON, V11, P61, DOI 10.1379/CSC-149R.1; Sun XK, 2004, J BIOL CHEM, V279, P2394, DOI 10.1074/jbc.M311324200; Tang BS, 2005, HUM GENET, V116, P222, DOI 10.1007/s00439-004-1218-3; Verschuure P, 2003, EUR J CELL BIOL, V82, P523, DOI 10.1078/0171-9335-00337; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wigley WC, 1999, J CELL BIOL, V145, P481; Zobel ATC, 2003, HUM MOL GENET, V12, P1609, DOI 10.1093/hmg/ddg173	33	70	75	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2168	+		10.1096/fj.06-5911fje	http://dx.doi.org/10.1096/fj.06-5911fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935933	Green Submitted			2022-12-28	WOS:000241156900057
J	Scamuffa, N; Calvo, F; Chretien, M; Seidah, NG; Khatib, AM				Scamuffa, Nathalie; Calvo, Fabien; Chretien, Michel; Seidah, Nabil G.; Khatib, Abdel-Majid			Proprotein convertases: lessons from knockouts	FASEB JOURNAL			English	Review						abnormal embryonic development; hormonal disorder; cellular proliferation; infertility; dyslipidemias; human patients	PROHORMONE CONVERTASES; SITE-1 PROTEASE; BETA-SECRETASE; LDL RECEPTOR; FURIN; MICE; EXPRESSION; GROWTH; PRECURSOR; CLEAVAGE	The physiological role of the subtilisin/kexin-like proprotein convertases (PCs) in rodents has been examined through the use of knockout mice. This review will summarize the major in vivo defects that result from the disruption of the expression of their genes. This includes abnormal embryonic development, hormonal disorder, infertility, and/or modified lipid/sterol metabolism. Members of the PC family play a central role in the processing of various protein precursors ranging from hormones and growth factors to bacterial toxins and viral glycoproteins. Proteolysis occurring at basic residues is mediated by the basic amino acid-specific proprotein convertases, namely: PC1/3, PC2, furin, PACE4, PC4, PC5/6, and PC7. In contrast, proteolysis at nonbasic residues is performed by the subtilisin/kexin-like isozyme-1 (SKI-1/S1P) and the newly identified neural apoptosis-regulated convertase-1 (PCSK9/NARC-1). In addition to their requirement for many physiological processes, these enzymes are also involved in various pathologies such as cancer, obesity, diabetes, lipid disorders, infectious diseases, atherosclerosis and neurodegenerative diseases.	Inst Genet Mol, CNRS, Lab Pharmacol Expt & Clin, INSERM U716,Equipe AVENIR, F-75010 Paris, France; Univ Paris 07, Paris, France; Univ Ottawa, Ottawa Hosp, Dis Aging Program, Ottawa Hlth Res Inst, Ottawa, ON, Canada; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Ottawa; Ottawa Hospital Research Institute; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Khatib, AM (corresponding author), Inst Genet Mol, CNRS, Lab Pharmacol Expt & Clin, INSERM U716,Equipe AVENIR, 27 Rue Juliette Dodu, F-75010 Paris, France.	majid.khatib@stlouis.inserm.fr	Seidah, Nabil/I-3596-2013; KHATIB, Abdel-Majid/A-9948-2015	Seidah, Nabil/0000-0001-6503-9342; KHATIB, Abdel-Majid/0000-0001-6957-0384; calvo, fabien/0000-0002-0298-7633				Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Allen RG, 2001, J NEUROSCI, V21, P5864, DOI 10.1523/JNEUROSCI.21-16-05864.2001; Attie AD, 2005, CELL METAB, V1, P290, DOI 10.1016/j.cmet.2005.04.006; Basak A, 2002, FEBS LETT, V514, P333, DOI 10.1016/S0014-5793(02)02394-3; Basak A, 2001, J BIOL CHEM, V276, P32720, DOI 10.1074/jbc.M104064200; Basak A, 2001, BIOCHEM J, V353, P537, DOI 10.1042/0264-6021:3530537; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bergeron E, 2005, BIOCHEM BIOPH RES CO, V326, P554, DOI 10.1016/j.bbrc.2004.11.063; Bergeron E, 2003, BIOCHEM J, V373, P475, DOI 10.1042/BJ20021630; Berman Y, 2000, J NEUROCHEM, V75, P1763, DOI 10.1046/j.1471-4159.2000.0751763.x; Bisgrove BW, 1999, DEVELOPMENT, V126, P3253; Breyer PR, 1996, ENDOCRINOLOGY, V137, P2159, DOI 10.1210/en.137.5.2159; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; Constam DB, 2000, GENE DEV, V14, P1146; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Cross JC, 2003, ANN NY ACAD SCI, V995, P84, DOI 10.1111/j.1749-6632.2003.tb03212.x; DICKSON MC, 1993, DEVELOPMENT, V117, P625; Dubois CM, 2001, AM J PATHOL, V158, P305, DOI 10.1016/S0002-9440(10)63970-3; Dunker N, 2000, EUR J BIOCHEM, V267, P6982, DOI 10.1046/j.1432-1327.2000.01825.x; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Essalmani R, 2006, MOL CELL BIOL, V26, P354, DOI 10.1128/MCB.26.1.354-361.2006; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Gaylinn BD, 1999, ENDOCRINOLOGY, V140, P5066, DOI 10.1210/en.140.11.5066; GORDON VM, 1995, INFECT IMMUN, V63, P82, DOI 10.1128/IAI.63.1.82-87.1995; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; HANNIBAL J, 1995, REGUL PEPTIDES, V55, P111, DOI 10.1016/0167-0115(94)00110-J; Jackson RS, 2003, J CLIN INVEST, V112, P1550, DOI 10.1172/JCI18784; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; KEW D, 1990, P NATL ACAD SCI USA, V87, P9143, DOI 10.1073/pnas.87.23.9143; Khatib AM, 2005, J MOL MED, V83, P856, DOI 10.1007/s00109-005-0692-y; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; Kibler KV, 2004, J BIOL CHEM, V279, P49055, DOI 10.1074/jbc.M403394200; Laurent V, 2002, P NATL ACAD SCI USA, V99, P3087, DOI 10.1073/pnas.261715099; Lenz O, 2001, P NATL ACAD SCI USA, V98, P12701, DOI 10.1073/pnas.221447598; Li M, 2000, ENDOCRINOLOGY, V141, P3723, DOI 10.1210/en.141.10.3723; Mbikay M, 1997, P NATL ACAD SCI USA, V94, P6842, DOI 10.1073/pnas.94.13.6842; Mbikay M, 2001, BIOCHEM J, V357, P329, DOI 10.1042/0264-6021:3570329; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Mouchantaf R, 2004, REGUL PEPTIDES, V120, P133, DOI 10.1016/j.regpep.2004.02.022; Moulard M, 1999, VIRUS RES, V60, P55, DOI 10.1016/S0168-1702(99)00002-7; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nour N, 2005, MOL BIOL CELL, V16, P5215, DOI 10.1091/mbc.E05-06-0504; PERRY ACF, 1995, BIOCHEM J, V307, P843, DOI 10.1042/bj3070843; Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102; Rehfeld JF, 2002, J NEUROCHEM, V83, P1329, DOI 10.1046/j.1471-4159.2002.01244.x; Roebroek AJM, 2004, J BIOL CHEM, V279, P53442, DOI 10.1074/jbc.M407152200; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Schlombs K, 2003, P NATL ACAD SCI USA, V100, P14024, DOI 10.1073/pnas.2331794100; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; Siegfried G, 2005, ONCOGENE, V24, P6925, DOI 10.1038/sj.onc.1208838; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Siegfried G, 2003, CANCER RES, V63, P1458; Suarez SS, 2003, REPROD DOMEST ANIM, V38, P119, DOI 10.1046/j.1439-0531.2003.00397.x; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Vickers MH, 1999, GROWTH HORM IGF RES, V9, P236, DOI 10.1054/ghir.1999.0114; Villeneuve P, 2002, J NEUROCHEM, V82, P783, DOI 10.1046/j.1471-4159.2002.00988.x; Wagener A, 2000, ANIM REPROD SCI, V64, P65, DOI 10.1016/S0378-4320(00)00191-3; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; YANG JT, 1995, DEVELOPMENT, V121, P549; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; ZHENG M, 1994, J NEUROSCI, V14, P4656; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10299, DOI 10.1073/pnas.162352799; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	78	173	180	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					1954	1963		10.1096/fj.05-5491rev	http://dx.doi.org/10.1096/fj.05-5491rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012247				2022-12-28	WOS:000241156900003
J	Dragusin, M; Wehner, S; Kelly, S; Wang, E; Merrill, AH; Kalff, JC; van Echten-Deckert, G				Dragusin, Mihaela; Wehner, Sven; Kelly, Samuel; Wang, Elaine; Merrill, Alfred H., Jr.; Kalff, Joerg C.; van Echten-Deckert, Gerhild			Effects of sphingosine-1-phosphate and ceramide-1-phosphate on rat intestinal smooth muscle cells: implications for postoperative ileus	FASEB JOURNAL			English	Article						sphingolipids; inflammation; COX-2; PGE(2)	SPHINGOSINE 1-PHOSPHATE; GENE-EXPRESSION; INFLAMMATION; CYCLOOXYGENASE-2; SPHINGOLIPIDS; MANIPULATION; METABOLISM; RECEPTORS; PATHWAYS; CERAMIDE	Postoperative ileus, a major cause of morbidity after abdominal surgery, is characterized by intestinal dysmotility and inflammation. The aim was to investigate the involvement of sphingolipids in postoperative intestinal inflammation using a standardized rat model of intestinal surgical manipulation. Sphingolipid analysis (ESI-MS) of intestinal muscularis after manipulation revealed a time-dependent increase of sphingosine 1-phosphate (S1P) and of ceramide 1-phosphate (C1P). We therefore established a culture system of primary rat intestinal smooth muscle cells and examined the potential role of these sphingolipids in intestinal inflammation. Incubation of cells with either of the two sphingolipid-phosphates resulted in an elevated production of PGE2. Further analysis revealed that S1P enhances cyclooxygenase 2 (COX-2) expression whereas C1P increases release of arachidonic acid, indicating an enhanced phospholipase A(2) activity. S1P-induced COX-2 expression was pertussis toxin sensitive, suggesting the involvement of Gi/o protein-coupled S1P receptors. Further downstream mediators of S1P induced COX-2 expression appear to be extracellular regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK). Collectively, our results demonstrate that intestinal smooth muscle cells represent a major target for both C1P and S1P activity. Thus, the sustained elevated concentration of the two bioactive sphingolipids in this tissue could at least in part explain postoperative intestinal dysmotility.	Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Univ Bonn, Dept Surg, D-53121 Bonn, Germany; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA	University of Bonn; University of Bonn; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	van Echten-Deckert, G (corresponding author), Univ Bonn, Kekule Inst Organ Chem & Biochem, Gerhard Domagk Str 1, D-53121 Bonn, Germany.	g.echten.deckert@uni-bonn.de	Wehner, Sven/X-6326-2019; Kalff, Joerg C/U-8580-2017	Merrill, Alfred/0000-0002-6673-968X; Wehner, Sven/0000-0002-8632-7631	NIGMS NIH HHS [GM069338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BALLOU LR, 1990, J IMMUNOL, V145, P4245; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637; Damirin A, 2005, MOL PHARMACOL, V67, P1177, DOI 10.1124/mol.104.004317; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Donati C, 2004, FASEB J, V18, P449, DOI 10.1096/fj.04-1780fje; Eskandari MK, 1997, AM J PHYSIOL-GASTR L, V273, pG727, DOI 10.1152/ajpgi.1997.273.3.G727; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kalff JC, 1998, ANN SURG, V228, P652, DOI 10.1097/00000658-199811000-00004; Kalff JC, 1999, SURGERY, V126, P498, DOI 10.1016/S0039-6060(99)70091-7; KHAN I, 1995, GASTROENTEROLOGY, V108, P1720, DOI 10.1016/0016-5085(95)90133-7; Kim JI, 2003, J BIOL CHEM, V278, P31731, DOI 10.1074/jbc.M300625200; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; Luckey A, 2003, ARCH SURG-CHICAGO, V138, P206, DOI 10.1001/archsurg.138.2.206; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pettus BJ, 2005, MOL PHARMACOL, V68, P330, DOI 10.1124/mol.104.008722; Pettus BJ, 2004, CURR MOL MED, V4, P405, DOI 10.2174/1566524043360573; Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Salinthone S, 2004, AM J PHYSIOL-GASTR L, V287, pG627, DOI 10.1152/ajpgi.00462.2003; Schwarz NT, 2001, GASTROENTEROLOGY, V121, P1354, DOI 10.1053/gast.2001.29605; Spiegel S, 2003, BIOCHEM SOC T, V31, P1216; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Wehner S, 2005, SURGERY, V137, P436, DOI 10.1016/j.surg.2004.11.003	30	24	24	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1930	+		10.1096/fj.05-5518fje	http://dx.doi.org/10.1096/fj.05-5518fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877527				2022-12-28	WOS:000240267000034
J	Liao, XD; Liu, JM; Du, L; Tang, AH; Shang, YL; Wang, SQ; Chen, LY; Chen, Q				Liao, Xudong; Liu, Jun-Ming; Du, Lei; Tang, Aihui; Shang, Yingli; Wang, Shi Qiang; Chen, Lan-Ying; Chen, Quan			Nitric oxide signaling in stretch-induced apoptosis of neonatal rat cardiomyocytes	FASEB JOURNAL			English	Article						hypertension; Ca2+; eNOS; iNOS; signal transduction	HEART-FAILURE; MECHANICAL STRETCH; CARDIAC MYOCYTES; ANGIOTENSIN-II; CELL-DEATH; SYNTHASE; INOS; HYPERTENSION; HYPERTROPHY; FIBROBLASTS	Pressure overload associated with hypertension is an important pathological factor leading to heart remodeling and ultimately heart failure partially due to cardiomyocyte apoptosis. Here we show that endogenous NO signaling plays a critical role in mechanical stretch-induced cardiomyocyte apoptosis. Mechanical stretch induced elevated expression of both eNOS and inducible NO synthase (iNOS) and increased synthesis of NO. A sustained increase in iNOS expression was also found in hearts of hypertensive rats in vivo. Blockade of NO signaling by inhibitors of NOS (L-NAME and AMT) or downstream guanylyl cyclase (ODQ) strongly inhibited stretch-induced apoptosis, mitochondria depolarization, and cytochrome c release, suggesting that NO is required in stretch-induced cardiomyocyte apoptosis. The expression of iNOS, but not eNOS, was blocked by L-NAME and ODQ, indicating that the iNOS induction is NO dependent. The initial elevation of NO is likely due to Ca2+-dependent activation of eNOS because elimination of intracellular calcium by EGTA-AM inhibited both iNOS induction and NO elevation. Other calcium signaling inhibitors (nifedipine, ryanodine, thapsigargin, and ionic gadolinium) also attenuated the initial NO elevation. These data indicate that mechanical signals initiate Ca2+-dependent NO synthesis, which is further amplified by activation of NO-induced iNOS expression, to regulate cardiomyocyte apoptosis.-Liao, X., Liu, J-M., Du, Lei, Tang, A., Shang, Y., Wang, S. Q., Chen, L-Y, Chen, Q. Nitric oxide signaling in stretch-induced apoptosis of neonatal rat cardiomyocytes.	Chinese Acad Sci, State Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, Beijing 100080, Peoples R China; Cardiovasc Inst, Beijing, Peoples R China; Fu Wai Hosp, Peking Union Med Coll, Beijing, Peoples R China; Chinese Acad Med Sci, Beijing 100037, Peoples R China; Peking Univ, Coll Life Sci, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100871, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking University	Chen, Q (corresponding author), Chinese Acad Sci, State Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, 25 Beisihuanxi Rd, Beijing 100080, Peoples R China.	lanyingchen@hotmail.com; chenq@ioz.ac.cn	Tang, Ai-Hui/D-4311-2009	Tang, Ai-Hui/0000-0003-3715-6714; Chen, Quan/0000-0001-7539-8728; Wang, Shi-Qiang/0000-0001-7784-4461				Aizawa T, 2000, HYPERTENSION, V35, P800, DOI 10.1161/01.HYP.35.3.800; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Arstall MA, 1999, CORONARY ARTERY DIS, V10, P301, DOI 10.1097/00019501-199907000-00005; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Bishopric Nanette H., 2001, Current Opinion in Pharmacology, V1, P141, DOI 10.1016/S1471-4892(01)00032-7; Fortuno MA, 2001, HYPERTENSION, V38, P1406, DOI 10.1161/hy1201.099615; Gill C, 2002, FASEB J, V16, P135, DOI 10.1096/fj.01-0629com; Hare JM, 2003, J MOL CELL CARDIOL, V35, P719, DOI 10.1016/S0022-2828(03)00143-3; Ing DJ, 1999, CIRC RES, V84, P21; Jones WK, 1999, J MOL CELL CARDIOL, V31, P1469, DOI 10.1006/jmcc.1999.0983; Kang PM, 2003, TRENDS MOL MED, V9, P177, DOI 10.1016/S1471-4914(03)00025-X; Khadour FH, 1997, AM J PHYSIOL-HEART C, V273, pH1223, DOI 10.1152/ajpheart.1997.273.3.H1223; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Lee AA, 1996, AM J PHYSIOL-CELL PH, V271, pC1400, DOI 10.1152/ajpcell.1996.271.4.C1400; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; Liao XD, 2005, LIFE SCI, V77, P160, DOI 10.1016/j.lfs.2004.11.029; Liao XD, 2004, CELL RES, V14, P16, DOI 10.1038/sj.cr.7290198; Liao XD, 2003, BIOCHEM BIOPH RES CO, V310, P405, DOI 10.1016/j.bbrc.2003.09.023; Linke A, 2003, HEART FAIL REV, V8, P87, DOI 10.1023/A:1022151106019; Meghji P, 1997, J MOL CELL CARDIOL, V29, P3147, DOI 10.1006/jmcc.1997.0545; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Mungrue IN, 2002, J CLIN INVEST, V109, P735, DOI 10.1172/JCI200213265; Narula J, 2000, CURR OPIN CARDIOL, V15, P183, DOI 10.1097/00001573-200005000-00011; Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001-867; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Pinsky DJ, 1999, AM J PHYSIOL-HEART C, V277, pH1189, DOI 10.1152/ajpheart.1999.277.3.H1189; Razavi HM, 2005, PHARMACOL THERAPEUT, V106, P147, DOI 10.1016/j.pharmthera.2004.11.006; Schonhoff CM, 2003, J BIOL CHEM, V278, P18265, DOI 10.1074/jbc.M212459200; Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008-6363(99)00395-8; Sun Y, 2005, HYPERTENSION, V46, P1355, DOI 10.1161/01.HYP.0000192651.06674.3f; SWYNGHEDAUW B, 1982, PATHOBIOL ANN, V12, P137; Szabolcs M, 1996, CIRCULATION, V94, P1665, DOI 10.1161/01.CIR.94.7.1665; Valenti L, 2003, CELL IMMUNOL, V221, P50, DOI 10.1016/S0008-8749(03)00064-9; van Kesteren CAM, 1999, CARDIOVASC RES, V43, P148, DOI 10.1016/S0008-6363(99)00057-7; Wu B, 2002, FREE RADICAL BIO MED, V33, P649, DOI 10.1016/S0891-5849(02)00917-6; Xu L, 2004, J HYPERTENS, V22, P1579, DOI 10.1097/01.hjh.0000133717.48334.cf; Yamamoto K, 1998, J BIOL CHEM, V273, P11862, DOI 10.1074/jbc.273.19.11862; Yoshioka Y, 2003, BRIT J PHARMACOL, V139, P28, DOI 10.1038/sj.bjp.0705206	38	31	33	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1883	+		10.1096/fj.06-5717fje	http://dx.doi.org/10.1096/fj.06-5717fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877524				2022-12-28	WOS:000240267000018
J	Miyoshi, T; Hirohata, S; Ogawa, H; Doi, M; Obika, M; Yonezawa, T; Sado, Y; Kusachi, S; Kyo, S; Kondo, S; Shiratori, Y; Hudson, BG; Ninomiya, Y				Miyoshi, Toru; Hirohata, Satoshi; Ogawa, Hiroko; Doi, Masayuki; Obika, Masanari; Yonezawa, Tomoko; Sado, Yoshikazu; Kusachi, Shozo; Kyo, Satoru; Kondo, Seiji; Shiratori, Yasushi; Hudson, Billy G.; Ninomiya, Yoshifumi			Tumor-specific expression of the RGD-alpha 3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice	FASEB JOURNAL			English	Article						adenovirus; angiogenesis; basement membrane; cancer dormancy; hTERT	TELOMERASE REVERSE-TRANSCRIPTASE; DISTINCT ANTITUMOR PROPERTIES; CATALYTIC SUBUNIT HTERT; MALIGNANT GLIOMA-CELLS; HUMAN BONE-MARROW; IV COLLAGEN; BASEMENT-MEMBRANE; MYOCARDIAL-INFARCTION; GENE-TRANSFER; NC1 DOMAIN	Angiogenesis plays an essential role in tumor growth. This study investigated expression of the noncollagenous domain of alpha 3(IV) collagen (alpha 3(IV) NC1) transduced into tumors and its inhibition of tumor growth. We hypothesized that if a human telomerase reverse transcriptase (hTERT) promoter-driven RGD motif containing alpha 3(IV) NC1 (hTERT/ RGD-alpha 3(IV) NC1) were expressed in telomerase-expressing tumor cells, it would inhibit tumor growth by its anti-angiogenic property. Adenoviral transduction of hTERT/ RGD-alpha 3(IV) NC1 expressed RGD-alpha 3(IV) NC1 in hTERT-positive tumor cell lines. However, hTERT/ RGD-alpha 3(IV) NC1 did not express RGD-alpha 3(IV) NC1 in hTERT-negative cells such as keratinocytes and fibroblasts. The secreted RGD-alpha 3(IV) NC1 in the conditioned medium from tumor cells inhibited cell proliferation as well as tube formation in cultured endothelial cells, but had no effect on other types of cells. In an in vivo model, adenoviral hTERT/ RGD-alpha 3(IV) NC1 gene therapy showed limited expression of RGD-alpha 3(IV) NC1 in tumors and resulted in a significant decrease of vessel density in tumors. The growth of subcutaneous (s. c.) tumors in nude mice was significantly suppressed by treatment with hTERT/ RGD-alpha 3(IV) NC1. In addition, long-term inhibition of tumor growth was achieved by intermittent administration of hTERT/ RGD-alpha 3(IV) NC1. In conclusion, our findings demonstrate that tumor-specific antiangiogenic gene therapy utilizing RGD-alpha 3(IV) NC1 under the hTERT promoter inhibited angiogenesis in tumors, resulting in an antitumor effect.	Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol & Biochem, Okayama 7008558, Japan; Okayama Univ, Dept Med & Med Sci, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008558, Japan; Shigei Med Res Inst, Div Immunol, Okayama, Japan; Okayama Univ, Sch Med, Fac Hlth Sci, Dept Med Technol, Okayama 700, Japan; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA	Okayama University; Okayama University; Okayama University; Kanazawa University; University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University	Ninomiya, Y (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol & Biochem, 2-5-1,Shikatacho, Okayama 7008558, Japan.	yoshinin@cc.okayama-u.ac.jp	Kusachi, Shozo/B-1779-2011	Hudson, Billy/0000-0002-5420-4100; YONEZAWA, Tomoko/0000-0002-3380-8298	NIDDK NIH HHS [DK 18381] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, R01DK018381] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; De Bouard S, 2003, HUM GENE THER, V14, P883, DOI 10.1089/104303403765701178; Demircan K, 2005, ARTHRITIS RHEUM-US, V52, P1451, DOI 10.1002/art.21010; Eskens FALM, 2004, BRIT J CANCER, V90, P1, DOI 10.1038/sj.bjc.6601401; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fujisaki H, 2002, EXP CELL RES, V280, P255, DOI 10.1006/excr.2002.5639; Furumatsu T, 2002, J BIOCHEM, V131, P619, DOI 10.1093/oxfordjournals.jbchem.a003142; Gu J, 2000, CANCER RES, V60, P5359; Hirohata S, 2002, J BIOL CHEM, V277, P12182, DOI 10.1074/jbc.M109665200; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Hopfer H, 2003, FASEB J, V17, P860, DOI 10.1096/fj.02-0746com; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; Indraccolo S, 2002, GENE THER, V9, P867, DOI 10.1038/sj.gt.3301703; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Kim KS, 2004, CANCER GENE THER, V11, P441, DOI 10.1038/sj.cgt.7700716; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Komata T, 2002, HUM GENE THER, V13, P1015, DOI 10.1089/104303402753812421; Kuroiwa M, 2003, J PEDIATR SURG, V38, P1499, DOI 10.1016/S0022-3468(03)00503-7; Kyo S, 2003, AM J PATHOL, V163, P859, DOI 10.1016/S0002-9440(10)63446-3; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura K, 2004, J BIOCHEM, V136, P439, DOI 10.1093/jb/mvh138; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Ogawa H, 2004, MATRIX BIOL, V23, P287, DOI 10.1016/j.matbio.2004.07.001; Pasco S, 2004, EXP CELL RES, V301, P251, DOI 10.1016/j.yexcr.2004.07.036; Pedchenko V, 2004, J BIOL CHEM, V279, P2772, DOI 10.1074/jbc.M311901200; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; SADO Y, 1995, HISTOCHEM CELL BIOL, V104, P267, DOI 10.1007/BF01464322; SAUS J, 1988, J BIOL CHEM, V263, P13374; Sezaki S, 2005, EXP BIOL MED, V230, P621; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sudhakar A, 2005, J CLIN INVEST, V115, P2801, DOI 10.1172/JCI24813; Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100; Takakura M, 1999, CANCER RES, V59, P551; Toeda K, 2005, MOL CELL BIOCHEM, V280, P47, DOI 10.1007/s11010-005-8051-4; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Watanabe T, 1996, BLOOD, V87, P5032, DOI 10.1182/blood.V87.12.5032.bloodjournal87125032; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Won J, 2004, P NATL ACAD SCI USA, V101, P11328, DOI 10.1073/pnas.0401801101; Wright WE, 1996, DEV GENET, V18, P173; Yao B, 2005, HUM GENE THER, V16, P1075, DOI 10.1089/hum.2005.16.1075; ZHANG XM, 1994, DEV BIOL, V164, P10, DOI 10.1006/dbio.1994.1176	53	35	39	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1904	+		10.1096/fj.05-5565fje	http://dx.doi.org/10.1096/fj.05-5565fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877525	Green Submitted			2022-12-28	WOS:000240267000025
J	Tenhunen, O; Soini, Y; Ilves, M; Rysa, J; Tuukkanen, J; Serpi, R; Pennanen, H; Ruskoaho, H; Leskinen, H				Tenhunen, Olli; Soini, Ylermi; Ilves, Mika; Rysa, Jaana; Tuukkanen, Juha; Serpi, Raisa; Pennanen, Harri; Ruskoaho, Heikki; Leskinen, Hanna			p38 kinase rescues failing myocardium after myocardial infarction: evidence for angiogenic and antiapoptotic mechanisms	FASEB JOURNAL			English	Article						remodeling; signal transduction; gene therapy	ACTIVATED PROTEIN-KINASE; IMPROVES CARDIAC-FUNCTION; MAP KINASE; CARDIOMYOCYTE APOPTOSIS; HEART-FAILURE; GENE-TRANSFER; INHIBITION; GROWTH; ISCHEMIA; DYSFUNCTION	As a leading cause of heart failure, postinfarction left ventricular remodeling represents an important target for therapeutic interventions. Mitogen-activated protein kinases regulate critical cellular processes including stress response and survival, but their role in left ventricular remodeling is unknown. In the present study, rats were subjected to myocardial infarction by ligating the left anterior descending coronary artery. Western blot and kinase assay analysis revealed an inactivation of p38 kinase after myocardial infarction. Local adenovirus-mediated cotransfection of wild-type (WT) p38 kinase and constitutively active MKK3b reduced infarct size (26 +/- 3% vs. 47 +/- 4%, P < 0.05 vs. LacZ-treated control) associated with improved ejection fraction (66.9 +/- 5.5% vs. 44.4 +/- 4.0%, P < 0.001), fractional shortening (30.2 +/- 2.1% vs. 19.7 +/- 2.2%, P < 0.001), and decreased left ventricular diastolic diameter (8.5 +/- 0.4 mm vs. 9.5 +/- 0.2 mm, P < 0.01). p38 kinase gene transfer increased capillary density (2423 +/- 107/ mm(2) vs. 1934 +/- 86/mm(2), P < 0.001) and resulted in microvessel enlargement in the ischemic border zone. Apoptosis (35 +/- 7 vs. 69 +/- 13 cells, P < 0.01) and fibrosis (16 +/- 3% vs. 34 +/- 8%, P < 0.05) were reduced, while the number of c-kit positive cardiac stem-like cells remained unchanged. These results indicate that reduced p38 signaling predisposes to adverse postinfarction remodeling. The rescue of failing myocardium with p38 kinase may be a potential new therapy for heart failure after myocardial infarction.	Univ Oulu, Dept Pharmacol & Toxicol, Fac Med, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Pathol, FIN-90014 Oulu, Finland; Univ Oulu, Dept Physiol, FIN-90014 Oulu, Finland; Univ Oulu, Dept Anat & Cell Biol, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu; University of Oulu; University of Oulu	Ruskoaho, H (corresponding author), Univ Oulu, Dept Pharmacol & Toxicol, Fac Med, Bioctr Oulu, POB 5000, FIN-90014 Oulu, Finland.	heikki.ruskoaho@oulu.fi	Tuukkanen, Juha/R-3728-2018	Tuukkanen, Juha/0000-0002-1723-6461; Rysa, Jaana/0000-0003-2205-6323; Serpi, Raisa/0000-0002-8207-4673				Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Anversa P, 2002, NATURE, V415, P240, DOI 10.1038/415240a; Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295; Gheorghiade M, 1998, CIRCULATION, V97, P282, DOI 10.1161/01.CIR.97.3.282; Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje; Jackson JR, 1998, J PHARMACOL EXP THER, V284, P687; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Lemke LE, 2001, J MOL CELL CARDIOL, V33, P1527, DOI 10.1006/jmcc.2001.1415; Li YW, 2003, CIRCULATION, V107, P2499, DOI 10.1161/01.CIR.0000065579.19126.B8; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Liu CL, 2005, PATTERN RECOGN, V38, P11, DOI 10.1016/j.patcog.2004.05.013; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Majalahti-Palviainen T, 2000, ENDOCRINOLOGY, V141, P731, DOI 10.1210/en.141.2.731; Martindale JJ, 2005, J BIOL CHEM, V280, P669, DOI 10.1074/jbc.M406690200; Nishida K, 2004, MOL CELL BIOL, V24, P10611, DOI 10.1128/MCB.24.24.10611-10620.2004; Pfeffer MA, 1979, CIRC RES, V13, P293; Ravingerova T, 2003, MOL CELL BIOCHEM, V247, P127, DOI 10.1023/A:1024119224033; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Rutanen J, 2004, CIRCULATION, V109, P1029, DOI 10.1161/01.CIR.0000115519.03688.A2; See F, 2004, J AM COLL CARDIOL, V44, P1679, DOI 10.1016/j.jacc.2004.07.038; Soini Y, 1996, BRIT J CANCER, V73, P1025, DOI 10.1038/bjc.1996.199; Sutton MGS, 2000, CIRCULATION, V101, P2981, DOI 10.1161/01.CIR.101.25.2981; Szatkowski ML, 2001, J CLIN INVEST, V107, P191, DOI 10.1172/JCI9862; Tenhunen O, 2004, J BIOL CHEM, V279, P24852, DOI 10.1074/jbc.M314317200; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; West JB, 2001, HIGH ALT MED BIOL, V2, P1, DOI 10.1089/152702901750067846; Widder J, 2004, CARDIOVASC RES, V63, P161, DOI 10.1016/j.cardiores.2004.03.008; Wilson JM, 1996, NEW ENGL J MED, V334, P1185, DOI 10.1056/NEJM199605023341809; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694	32	51	53	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1907	+		10.1096/fj.05-5618fje	http://dx.doi.org/10.1096/fj.05-5618fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16849392				2022-12-28	WOS:000240267000026
J	Bondjers, C; He, LQ; Takemoto, M; Norlin, J; Asker, N; Mats, HRM; Lindahl, P; Betsholtz, C				Bondjers, Cecilia; He, Liqun; Takemoto, Minoru; Norlin, Jenny; Asker, Noomi; Mats, Hellstro R. M.; Lindahl, Per; Betsholtz, Christer			Microarray analysis of blood microvessels from PDGF-RB and PDGF-R beta mutant mice identifies novel markers for brain pericytes	FASEB JOURNAL			English	Article						vascular stability; Kir6.1; SUR2; DLK1; RGS5	SMOOTH-MUSCLE-CELLS; RETINAL VASCULAR PATTERNS; GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; GENE-EXPRESSION; CORONARY-ARTERIES; MURAL CELLS; ANGIOGENESIS; TUMORS; RECEPTOR	Normal blood microvessels are lined by pericytes, which contribute to microvessel development and stability through mechanisms that are poorly understood. Pericyte deficiency has been implicated in the pathogenesis of microvascular abnormalities associated with diabetes and tumors. However, the unambiguous identification of pericytes is still a problem because of cellular heterogeneity and few available molecular markers. Here we describe an approach to identify pericyte markers based on transcription profiling of pericyte-deficient brain microvessels isolated from platelet-derived growth factor (PDGF-B)-/- and PDGF beta receptor (PDGFR beta)-/- mouse mutants. The approach was validated by the identification of known pericyte markers among the most down-regulated genes in PDGF-B-/- and PDGFR beta-/- microvessels. Of candidates for novel pericyte markers, we selected ATP-sensitive potassium-channel Kir6.1 (also known as Kcnj8) and sulfonylurea receptor 2, (SUR2, also known as Abcc9), both part of the same channel complex, as well as delta homologue 1 (DLK1) for in situ hybridization, which demonstrated their specific expression in brain pericytes of mouse embryos. We also show that Kir6.1 is highly expressed in pericytes in brain but undetectable in pericytes in skin and heart. The three new brain pericyte markers are signaling molecules implicated in ion transport and intercellular signaling, potentially opening new windows on pericyte function in brain microvessels.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, SE-17177 Stockholm, Sweden; Gothenburg Univ, Sahlgrenska Acad, Dept Med Biochem, S-41124 Gothenburg, Sweden	Karolinska Institutet; University of Gothenburg	Betsholtz, C (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, SE-17177 Stockholm, Sweden.	christer.betsholtz@ki.se		Hellstrom, Mats/0000-0002-7088-9533; He, Liqun/0000-0003-2127-7597				Abramsson A, 2002, CIRCULATION, V105, P112, DOI 10.1161/hc0102.101437; Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549; Adams LD, 2000, CIRC RES, V87, P623, DOI 10.1161/01.RES.87.7.623; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Alliot F, 1999, J NEUROSCI RES, V58, P367; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; Apte SS, 1997, J BIOL CHEM, V272, P25511, DOI 10.1074/jbc.272.41.25511; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; ARTAVANISTSAKON.S, 1995, SCIENCE, V268, P1127; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger M, 2005, BLOOD, V105, P1094, DOI 10.1182/blood-2004-06-2315; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bondjers C, 2003, AM J PATHOL, V162, P721, DOI 10.1016/S0002-9440(10)63868-0; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cho H, 2003, FASEB J, V17, P440, DOI 10.1096/fj.02-0340fje; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; CUEVAS P, 1984, ANAT EMBRYOL, V170, P155, DOI 10.1007/BF00319000; Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015; DAUT J, 1990, SCIENCE, V247, P1341, DOI 10.1126/science.2107575; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Fisher SA, 1995, BIOCHEM BIOPH RES CO, V217, P696, DOI 10.1006/bbrc.1995.2829; FRID MG, 1992, DEV BIOL, V153, P185, DOI 10.1016/0012-1606(92)90104-O; FUNK JL, 2002, BIOCHEM BIOPH RES CO, V297, P980; Furuhashi M, 2004, CANCER RES, V64, P2725, DOI 10.1158/0008-5472.CAN-03-1489; Gee MS, 2003, AM J PATHOL, V162, P183, DOI 10.1016/S0002-9440(10)63809-6; Gerhardt H, 2000, DEV DYNAM, V218, P472, DOI 10.1002/1097-0177(200007)218:3<472::AID-DVDY1008>3.0.CO;2-#; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107; Heldin CH, 2002, ARCH BIOCHEM BIOPHYS, V398, P284, DOI 10.1006/abbi.2001.2707; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; HELMAN LJ, 1990, NUCLEIC ACIDS RES, V18, P685; Hirschi KK, 2003, CIRC RES, V93, P429, DOI 10.1161/01.RES.0000091259.84556.D5; Hogan B, 1994, MANIPULATING MOUSE E; Ikedo H, 2003, INT J MOL MED, V11, P645; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Jensen CH, 2001, NEUROREPORT, V12, P3959, DOI 10.1097/00001756-200112210-00021; Kale S, 2004, FASEB J, V18, P270, DOI 10.1096/fj.04-1604fje; KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013; Laborda J, 2000, HISTOL HISTOPATHOL, V15, P119, DOI 10.14670/HH-15.119; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li X, 2001, AM J PHYSIOL-HEART C, V281, pH1890, DOI 10.1152/ajpheart.2001.281.5.H1890; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu Q, 1997, BRIT J PHARMACOL, V120, P728, DOI 10.1038/sj.bjp.0700939; Mazurais D, 2002, J HISTOCHEM CYTOCHEM, V50, P661, DOI 10.1177/002215540205000507; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; NEHLS V, 1991, J CELL BIOL, V113, P147, DOI 10.1083/jcb.113.1.147; Nelander S, 2003, GENOME RES, V13, P1838, DOI 10.1101/gr.1197303; Okamoto M, 1997, STEROIDS, V62, P73, DOI 10.1016/S0039-128X(96)00162-6; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Reinmuth N, 2001, FASEB J, V15, P1239, DOI 10.1096/fj.00-0693fje; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; Scheidl SJ, 2002, AM J PATHOL, V160, P801, DOI 10.1016/S0002-9440(10)64903-6; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393; SCHLINGEMANN RO, 1991, AM J PATHOL, V138, P1335; Seino S, 2003, PROG BIOPHYS MOL BIO, V81, P133, DOI 10.1016/S0079-6107(02)00053-6; Shaheen RM, 2001, CANCER RES, V61, P1464; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288; Song WW, 2005, INVEST OPHTH VIS SCI, V46, P2974, DOI 10.1167/iovs.04-1505; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Sundberg C, 2002, LAB INVEST, V82, P387, DOI 10.1038/labinvest.3780433; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takemoto M, 2006, EMBO J, V25, P1160, DOI 10.1038/sj.emboj.7601014; Tidhar A, 2001, DEV DYNAM, V220, P60, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1089>3.0.CO;2-X; Uemura A, 2002, J CLIN INVEST, V110, P1619, DOI 10.1172/JCI200215621; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963	78	139	139	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1703	+		10.1096/fj.05-4944fje	http://dx.doi.org/10.1096/fj.05-4944fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807374				2022-12-28	WOS:000240266600021
J	Pan, GJ; Li, J; Zhou, YL; Zheng, H; Pei, DQ				Pan, Guangjin; Li, Jun; Zhou, Yali; Zheng, Hui; Pei, Duanqing			A negative feedback loop of transcription factors that controls stem cell pluripotency and self-renewal	FASEB JOURNAL			English	Article						embryonic stem cells	SUSTAINING FACTOR; GENE-EXPRESSION; FACTOR NANOG; FACTOR OCT4; ES CELLS; IDENTIFICATION; EMBRYO	Embryonic stem (ES) cells possess the ability to renew themselves while maintaining the capacity to differentiate into virtually all cell types of the body. Current evidence suggests that ES cells maintain their pluripotent state by expressing a battery of transcription factors including Oct4 and Nanog. However, little is known about how ES cells maintain the expression of these pluripotent factors in ES cells. Here we present evidence that Oct4, Nanog, and FoxD3 form a negative feedback loop to maintain their expression in pluripotent ES cells. First, Oct4 maintains Nanog activity by directly activating its promoter at sub-steady-state concentration but repressing it at or above steady-state levels. On the other hand, FoxD3 behaves as a positive activator of Nanog to counter the repressive effect of Oct4. The expression of Oct4 is activated by FoxD3 and Nanog but repressed by Oct4 itself, thus, exerting an important negative feedback loop to limit its own activity. Indeed, overexpression of either FoxD3 or Nanog in ES cells failed to increase the concentration of Oct4 beyond the steady-state concentration, whereas knocking down either FoxD3 or Nanog reduces the expression of Oct4 in ES cells. Finally, overexpression of Oct4 or Nanog failed to compensate the loss of Nanog or Oct4, respectively, suggesting that both are required for ES self-renewal and pluripotency. Our results suggest the FoxD3-Nanog-Oct4 loop anchors an interdependent network of transcription factors that regulate stem cell pluripotency.	Tsinghua Univ, Sch Med, Inst Pharmacol,Inst Biomed, Dept Biol Sci & Biotechnol,State Key Lab Biomembr, Beijing 100084, Peoples R China	Tsinghua University	Pei, DQ (corresponding author), Chinese Acad Sci, GIBH, Guangzhou 510663, Guangdong, Peoples R China.	pei-duanqing@gibh.ac.cn	zhou, xingru/G-4442-2012	Pan, Guangjin/0000-0002-2378-7198; Zheng, Hui/0000-0001-6801-0529				Audet J, 2004, EXPERT OPIN BIOL TH, V4, P631, DOI 10.1517/eobt.4.5.631.31058; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Constantinescu S, 2003, J CELL MOL MED, V7, P103, DOI 10.1111/j.1582-4934.2003.tb00209.x; Guo JH, 2002, ASIAN J ANDROL, V4, P3; Hanna LA, 2002, GENE DEV, V16, P2650, DOI 10.1101/gad.1020502; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Pan GJ, 2005, J BIOL CHEM, V280, P1401, DOI 10.1074/jbc.M407847200; Pan GJ, 2003, CELL RES, V13, P499, DOI 10.1038/sj.cr.7290193; Pan GJ, 2004, J BIOL CHEM, V279, P37013, DOI 10.1074/jbc.M405117200; Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134; Pesce M, 2000, MOL REPROD DEV, V55, P452, DOI 10.1002/(SICI)1098-2795(200004)55:4&lt;452::AID-MRD14&gt;3.0.CO;2-S; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145	22	167	200	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1730	+		10.1096/fj.05-5543fje	http://dx.doi.org/10.1096/fj.05-5543fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790525				2022-12-28	WOS:000240266600030
J	Boutte, AM; Woltjer, RL; Zimmerman, LJ; Stamer, SL; Montine, KS; Manno, MV; Cimino, PJ; Liebler, DC; Montine, TJ				Boutte, Angela M.; Woltjer, Randall L.; Zimmerman, Lisa J.; Stamer, Sheryl L.; Montine, Kathleen S.; Manno, Michael V.; Cimino, Patrick J.; Liebler, Daniel C.; Montine, Thomas J.			Selectively increased oxidative modifications mapped to detergent-insoluble forms of A beta and beta-III tubulin in Alzheimer's disease	FASEB JOURNAL			English	Article						PTMs; gene expression; paired helical filament; dendrites	AMYLOID-BETA; TAU-PROTEIN; PROTEOMIC IDENTIFICATION; LIPID-PEROXIDATION; METHIONINE; BRAIN; MICROTUBULES; BINDING; GLYCOXIDATION; PATHOGENESIS	Deleterious post-translational modifications (PTMs)to the neuronal cytoskeleton are a proposed mechanistic link between accumulation of amyloid (A) beta peptides and subsequent abnormalities of tau and neurodegeneration in Alzheimer's disease (AD). Here we tested the hypothesis that PTMs on neuronal tubulins selectively accumulate in a pathological protein fraction in AD. We used new software, P-MOD, to identify comprehensively and map PTMs using mass spectral data from soluble (normal) and detergent-insoluble (pathological) protein fractions from AD, as well as total extracts from controls, for selected proteins: A beta, tau, apolipoprotein (apo) E, glial fibrillary acidic protein (GFAP), alpha-III tubulin, and beta-III tubulin. Our results confirmed direct observations of others by identifying methionine (M) sulfoxides at A beta position 35 and numerous sites of tau phosphorylation in detergent-insoluble protein from AD, while no PTMs were enriched on primarily astrocyte-derived apoE or GFAP in this fraction. P-MOD mapped several abundant M sulfoxides to neuron-enriched alpha-III tubulin but not its heterodimeric partner, neuron-enriched alpha-III tubulin, a result confirmed by selective suppression of CNBr-mediated cleavage of alpha-III tubulin. These findings are the first comprehensive assessment of PTMs in AD and point to oxidative modification of beta-III tubulin as a potential contributor to the neuronal cytoskeletal disruption that is characteristic of AD.	Univ Washington, Harborview Med Ctr, Dept Pathol, Seattle, WA 98104 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN USA; Vanderbilt Univ, Dept Biochem, Nashville, TN USA; Vanderbilt Univ, Mass Spectrometry Res Ctr, Nashville, TN USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Washington; University of Washington Seattle	Montine, TJ (corresponding author), Univ Washington, Harborview Med Ctr, Dept Pathol, Box 359791, Seattle, WA 98104 USA.	tmontine@u.washington.edu		Liebler, Daniel/0000-0002-7873-3031; Montine, Kathleen/0000-0003-2110-8363; Cimino, P.J./0000-0003-0441-4502	NATIONAL INSTITUTE ON AGING [P50AG005136, F31AG023483, K01AG022040, R01AG024011] Funding Source: NIH RePORTER; NIA NIH HHS [AG24011, AG05136, AG023483, AG022040] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ali FE, 2005, J PEPT SCI, V11, P353, DOI 10.1002/psc.626; Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; Barnham KJ, 2003, J BIOL CHEM, V278, P42959, DOI 10.1074/jbc.M305494200; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Buee Luc, 2002, Journal de la Societe de Biologie, V196, P103; Butterfield DA, 2005, BBA-PROTEINS PROTEOM, V1703, P149, DOI 10.1016/j.bbapap.2004.10.014; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Christie RH, 1996, J NEUROPATH EXP NEUR, V55, P491, DOI 10.1097/00005072-199604000-00012; dePereda JM, 1996, BIOCHEMISTRY-US, V35, P14184, DOI 10.1021/bi961356j; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Gong CX, 2005, J NEURAL TRANSM, V112, P813, DOI 10.1007/s00702-004-0221-0; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hansen BT, 2005, J PROTEOME RES, V4, P358, DOI 10.1021/pr0498234; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Hollemeyer K, 2002, PROTEOMICS, V2, P1524, DOI 10.1002/1615-9861(200211)2:11<1524::AID-PROT1524>3.0.CO;2-7; Ichihashi K, 2001, J BIOL CHEM, V276, P23903, DOI 10.1074/jbc.M101947200; Iqbal Khalid, 1993, Acta Neurobiologiae Experimentalis (Warsaw), V53, P325; Jing Z, 2005, NEUROBIOL AGING, V26, P207, DOI 10.1016/j.neurobiolaging.2004.03.012; Kaiser R, 1999, ANAL BIOCHEM, V266, P1, DOI 10.1006/abio.1998.2945; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; McLaughlin L, 1997, BRAIN RES BULL, V43, P501, DOI 10.1016/S0361-9230(97)80003-2; Mirra SS, 1997, NEUROBIOL AGING, V18, pS91, DOI 10.1016/S0197-4580(97)00058-4; Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Neely MD, 2005, BRAIN RES, V1037, P90, DOI 10.1016/j.brainres.2004.12.027; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1999, CELL MOL LIFE SCI, V56, P133, DOI 10.1007/s000180050012; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200; Perez M, 2001, BIOCHEMISTRY-US, V40, P5983, DOI 10.1021/bi002961w; Praprotnik D, 1996, ACTA NEUROPATHOL, V91, P226, DOI 10.1007/s004010050420; SCHEFF SW, 1990, NEUROBIOL AGING, V11, P29, DOI 10.1016/0197-4580(90)90059-9; Schiewe AJ, 2004, PHARM RES-DORDR, V21, P1094, DOI 10.1023/B:PHAM.0000032994.36343.02; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; SHECHTER Y, 1975, BIOCHEMISTRY-US, V14, P4497, DOI 10.1021/bi00691a025; Shibata N, 2001, BRAIN RES, V917, P97, DOI 10.1016/S0006-8993(01)02926-2; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Vanacore RM, 2005, J BIOL CHEM, V280, P29300, DOI 10.1074/jbc.M502752200; Wang Q, 2005, FASEB J, V19, P869, DOI 10.1096/fj.04-3210fje; Woltjer RL, 2005, FASEB J, V19, P1923, DOI 10.1096/fj.05-4263fje; Zhou Y, 2004, J BIOL CHEM, V279, P39155, DOI 10.1074/jbc.M405456200	47	26	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1473	1483		10.1096/fj.06-5920com	http://dx.doi.org/10.1096/fj.06-5920com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816122				2022-12-28	WOS:000240266000024
J	Mathews, CK				Mathews, Christopher K.			DNA precursor metabolism and genomic stability	FASEB JOURNAL			English	Review						mutagenesis; deoxyribonucleotides; nucleotide pools; ribonucleotide reductase; mitochondria; oxidative DNA damage	THYMIDINE PHOSPHORYLASE-DEFICIENCY; REDUCTASE SMALL-SUBUNIT; STATE KINETIC-ANALYSIS; HUMAN MUTT HOMOLOG; RIBONUCLEOTIDE REDUCTASE; MITOCHONDRIAL-DNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; REPLICATION FIDELITY; IN-VITRO	Intracellular concentrations of the four deoxyribonucleoside triphosphates (dNTPs) are closely regulated, and imbalances in the four dNTP pools have genotoxic consequences. Replication errors leading to mutations can occur, for example, if one dNTP in excess drives formation of a non-Watson-Crick base pair or if it forces replicative DNA chain elongation past a mismatch before DNA polymerase can correct the error by 3' exonuclease proofreading. This review focuses on developments since 1994, when the field was last reviewed comprehensively. Emphasis is placed on the following topics: 1) novel aspects of dNTP pool regulation, 2) dNTP pool asymmetries as mutagenic determinants, 3) dNTP metabolism and hypermutagenesis of retroviral genomes, 4) dNTP metabolism and mutagenesis in the mitochondrial genome, 5) chemical modification of nucleotides as a premutagenic event, 6) relationships between dNTP metabolism, genome stability, aging, and cancer.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 Agr & Life Sci Bldg, Corvallis, OR 97331 USA.	mathewsc@onid.orst.edu						Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; Bishop KN, 2004, SCIENCE, V305, P645, DOI 10.1126/science.1100658; Bouzon M, 1997, CR ACAD SCI III-VIE, V320, P427, DOI 10.1016/S0764-4469(97)81969-5; Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200; Bradshaw JS, 2003, MOL MICROBIOL, V48, P1711, DOI 10.1046/j.1365-2958.2003.03540.x; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes AL, 2004, J BIOL CHEM, V279, P10796, DOI 10.1074/jbc.M312482200; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chen RX, 2002, J GEN VIROL, V83, P2339, DOI 10.1099/0022-1317-83-10-2339; Chimploy K, 2001, J BIOL CHEM, V276, P7093, DOI 10.1074/jbc.M006232200; Clayton DA, 2000, EXP CELL RES, V255, P4, DOI 10.1006/excr.1999.4763; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; DARE E, 1995, J MOL BIOL, V252, P514, DOI 10.1006/jmbi.1995.0516; Diaz M, 2003, MOL IMMUNOL, V40, P261, DOI 10.1016/S0161-5890(03)00113-5; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; Einolf HJ, 2001, J BIOL CHEM, V276, P3764, DOI 10.1074/jbc.M006696200; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; Fish J, 2004, SCIENCE, V306, P2098, DOI 10.1126/science.1102077; FOWLER RG, 1994, J BACTERIOL, V176, P7727, DOI 10.1128/JB.176.24.7727-7729.1994; Fujikawa K, 1999, J BIOL CHEM, V274, P18201, DOI 10.1074/jbc.274.26.18201; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Henderson JP, 2001, P NATL ACAD SCI USA, V98, P1631, DOI 10.1073/pnas.041146998; Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279; Ito R, 2005, BIOCHEMISTRY-US, V44, P6670, DOI 10.1021/bi047550k; Jiang Q, 2003, J BIOL CHEM, V278, P32834, DOI 10.1074/jbc.M304021200; Kamiya H, 2000, NUCLEIC ACIDS RES, V28, P1640, DOI 10.1093/nar/28.7.1640; Kamiya H, 2003, NUCLEIC ACIDS RES, V31, P517, DOI 10.1093/nar/gkg137; Kamiya H, 2001, BIOCHEM BIOPH RES CO, V288, P499, DOI 10.1006/bbrc.2001.5781; Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Ke PY, 2005, GENE DEV, V19, P1920, DOI 10.1101/gad.1322905; Koc A, 2003, J BIOL CHEM, V278, P9345, DOI 10.1074/jbc.M213013200; Kouzminova EA, 2004, P NATL ACAD SCI USA, V101, P16262, DOI 10.1073/pnas.0405943101; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Lee H, 2003, BIOCHEMISTRY-US, V42, P14711, DOI 10.1021/bi035596s; Li ZQ, 2004, GENE DEV, V18, P1, DOI 10.1101/gad.1161904; Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4; Lin SR, 2001, J BIOL CHEM, V276, P18695, DOI 10.1074/jbc.M011084200; Liu XY, 2005, BIOCHEM PHARMACOL, V70, P1288, DOI 10.1016/j.bcp.2005.08.005; LU Q, 1995, J MOL BIOL, V254, P337, DOI 10.1006/jmbi.1995.0620; Macpherson P, 2005, NUCLEIC ACIDS RES, V33, P5094, DOI 10.1093/nar/gki813; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; MARABOU CMT, 2006, BIOCHEM J, V393, P441; Marcelino LA, 1999, MUTAT RES-DNA REPAIR, V434, P177, DOI 10.1016/S0921-8777(99)00028-2; Marti R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8; MARTINEZ MA, 1994, P NATL ACAD SCI USA, V91, P11787, DOI 10.1073/pnas.91.25.11787; Martomo SA, 2002, MUTAT RES-FUND MOL M, V499, P197, DOI 10.1016/S0027-5107(01)00283-4; Mason PA, 2003, FEBS LETT, V554, P6, DOI 10.1016/S0014-5793(03)01169-4; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; Mazzon C, 2003, BIOCHEM PHARMACOL, V66, P471, DOI 10.1016/S0006-2952(03)00290-9; MEUTH M, 1983, MUTAT RES, V110, P383, DOI 10.1016/0027-5107(83)90154-9; MICHAEL ML, 1992, J BACTERIOL, V174, P115; Miller JH, 2002, GENETICS, V162, P5; Miller JH, 2005, CRIT REV BIOCHEM MOL, V40, P155, DOI 10.1080/10409230590954153; Nakabeppu Y, 2001, MUTAT RES-FUND MOL M, V477, P59, DOI 10.1016/S0027-5107(01)00096-3; Neuberger MS, 2005, NAT REV IMMUNOL, V5, P171, DOI 10.1038/nri1553; Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Outten CE, 2003, EMBO J, V22, P2015, DOI 10.1093/emboj/cdg211; OZAWA T, 2004, ANN NY ACAD SCI, V124, P128; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; Perlstein DL, 2005, BIOCHEMISTRY-US, V44, P15366, DOI 10.1021/bi051616+; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Pham P, 2005, BIOCHEMISTRY-US, V44, P2703, DOI 10.1021/bi047481+; Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948; Russo MT, 2004, MOL CELL BIOL, V24, P465, DOI 10.1128/MCB.24.1.465-474.2004; Song S., 2005, THESIS OREGON STATE; Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102; Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200; Stoler DL, 1999, P NATL ACAD SCI USA, V96, P15121, DOI 10.1073/pnas.96.26.15121; Strand MK, 2003, EUKARYOT CELL, V2, P809, DOI 10.1128/EC.2.4.809-820.2003; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tassotto ML, 2002, J BIOL CHEM, V277, P15807, DOI 10.1074/jbc.M200965200; Taylor SD, 2005, MOL BIOL CELL, V16, P3010, DOI 10.1091/mbc.E05-01-0053; TOPAL MD, 1982, P NATL ACAD SCI-BIOL, V79, P2211, DOI 10.1073/pnas.79.7.2211; Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tsuzuki T, 2001, P NATL ACAD SCI USA, V98, P11456, DOI 10.1073/pnas.191086798; Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; Venkatesan RN, 2006, DNA REPAIR, V5, P294, DOI 10.1016/j.dnarep.2005.10.012; Vozza A, 2004, J BIOL CHEM, V279, P20850, DOI 10.1074/jbc.M313610200; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5; Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200; Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447; Wheeler LJ, 2005, DNA REPAIR, V4, P1450, DOI 10.1016/j.dnarep.2005.09.003; YANG DL, 2006, GENE DEV, V20, P334; Yao RJ, 2003, P NATL ACAD SCI USA, V100, P6628, DOI 10.1073/pnas.1131932100; YOUNG P, 1994, BIOCHEM BIOPH RES CO, V203, P46, DOI 10.1006/bbrc.1994.2146; ZEVIANI M, 2003, CURR OPIN GENE DEV, V13, P1; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; ZHANG XL, 1995, J BIOL CHEM, V270, P8401, DOI 10.1074/jbc.270.15.8401; Zhang Z, 2006, P NATL ACAD SCI USA, V103, P1422, DOI 10.1073/pnas.0510516103; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	118	213	221	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1300	1314		10.1096/fj.06-5730rev	http://dx.doi.org/10.1096/fj.06-5730rev			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816105				2022-12-28	WOS:000240266000007
J	Ding, QX; Dimayuga, E; Markesbery, WR; Keller, JN				Ding, Qunxing; Dimayuga, Edgardo; Markesbery, William R.; Keller, Jeffrey N.			Proteasome inhibition induces reversible impairments in protein synthesis	FASEB JOURNAL			English	Article						aging; Alzheimer's disease; neurodegeneration; Parkinson's disease; protein aggregation	OXIDATIVE STRESS; GENE-EXPRESSION; DYSFUNCTION; APOPTOSIS; BRAIN; DEATH; CELLS; INCLUSIONS; INDUCTION; TOXICITY	Proteasome inhibition occurs during normal aging and in a variety of age-related diseases, with inhibition of proteasome function sufficient to induce physiological and pathological alterations observed in each of these conditions. It is presumed that proteasome inhibition induces cellular alterations by promoting rapid protein accumulation, as the direct result of impairments in protein removal, which assumes protein synthesis remains relatively unchanged during proteasome inhibition. We conducted experimentation using established proteasome inhibitors and primary rat neuron cultures in order to elucidate whether proteasome inhibition had any effect on neuronal protein synthesis. Proteasome inhibition impaired neuronal protein synthesis, with concentrations of inhibitor necessary to significantly inhibit protein synthesis similar to the concentrations necessary to induce subsequent neuron death. The inhibition of protein synthesis was reversible during the first 6 h of treatment, with the neurotoxicity of proteasome inhibition reversible during the first 12 h of treatment. These studies are the first to demonstrate a potentially important interplay between the proteasome and protein synthesis in neurons, and the first to identify that some effects of proteasome inhibition are reversible in neurons. Together these findings have important implications for understanding proteasome inhibition as a potential contributor to aging and age-related disease.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol & Neuropathol, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Keller, JN (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 205 Sanders Brown,800 S Limestone, Lexington, KY 40536 USA.	jnkell0@uky.edu	Keller, Jeffrey N/N-1975-2017	keller, jeffrey/0000-0002-9892-7423	NIA NIH HHS [AG018437, 5P01 AG05114] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018437] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALONI R, 1992, MOL CELL BIOL, V12, P2203, DOI 10.1128/MCB.12.5.2203; Chondrogianni N, 2005, EXP GERONTOL, V40, P931, DOI 10.1016/j.exger.2005.09.004; Chondrogianni N, 2003, J BIOL CHEM, V278, P28026, DOI 10.1074/jbc.M301048200; COSGROVE JW, 1986, NEUROCHEM RES, V11, P1289, DOI 10.1007/BF00966123; Diaz-Hernandez M, 2003, J NEUROSCI, V23, P11653; Dietrich P, 2003, MOL CELL NEUROSCI, V24, P430, DOI 10.1016/S1044-7431(03)00201-X; Ding QX, 2005, J NEUROSCI, V25, P9171, DOI 10.1523/JNEUROSCI.3040-05.2005; Ding QX, 2004, J NEUROCHEM, V91, P1211, DOI 10.1111/j.1471-4159.2004.02802.x; Ding QX, 2004, FREE RADICAL BIO MED, V36, P445, DOI 10.1016/j.freeradbiomed.2003.10.025; Ding QX, 2003, FEBS LETT, V546, P228, DOI 10.1016/S0014-5793(03)00582-9; Ding QX, 2002, J BIOL CHEM, V277, P13935, DOI 10.1074/jbc.M107706200; Ding QX, 2001, J NEUROCHEM, V77, P1010, DOI 10.1046/j.1471-4159.2001.00302.x; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Halliwell B, 2002, ANN NY ACAD SCI, V962, P182, DOI 10.1111/j.1749-6632.2002.tb04067.x; Hanna J, 2003, MOL CELL BIOL, V23, P9251, DOI 10.1128/MCB.23.24.9251-9261.2003; Hyun DH, 2003, J NEUROCHEM, V86, P363, DOI 10.1046/j.1471-4159.2003.01841.x; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; Keller JN, 1999, J NEUROSCI RES, V58, P823, DOI 10.1002/(SICI)1097-4547(19991215)58:6<823::AID-JNR9>3.0.CO;2-T; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Keller JN, 2002, AGEING RES REV, V1, P279, DOI 10.1016/S1568-1637(01)00006-X; Keller JN, 1999, J NEUROCHEM, V72, P2601, DOI 10.1046/j.1471-4159.1999.0722601.x; KIM TS, 2005, IN PRESS MOL BIOL CE; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Lang-Rollin I, 2005, APOPTOSIS, V10, P809, DOI 10.1007/s10495-005-0378-5; Lang-Rollin I, 2004, J NEUROCHEM, V90, P1511, DOI 10.1111/j.1471-4159.2004.02684.x; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; McNaught KSP, 2004, INT REV NEUROBIOL, V62, P95, DOI 10.1016/S0074-7742(04)62003-4; Othumpangat S, 2005, J BIOL CHEM, V280, P25162, DOI 10.1074/jbc.M414303200; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Rattan SIS, 1996, EXP GERONTOL, V31, P33, DOI 10.1016/0531-5565(95)02022-5; Rattan SIS, 1996, BIOCHEM SOC T, V24, P1043, DOI 10.1042/bst0241043; Rideout HJ, 2003, J NEUROSCI, V23, P1237, DOI 10.1523/JNEUROSCI.23-04-01237.2003; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Robertson JD, 1999, BIOCHEM J, V344, P477, DOI 10.1042/0264-6021:3440477; Seo H, 2004, ANN NEUROL, V56, P319, DOI 10.1002/ana.20207; Shringarpure R, 2002, FREE RADICAL BIO MED, V32, P1084, DOI 10.1016/S0891-5849(02)00824-9; Stolzing A, 2001, CLIN EXP DERMATOL, V26, P566, DOI 10.1046/j.1365-2230.2001.00867.x; Sullivan PG, 2004, J BIOL CHEM, V279, P20699, DOI 10.1074/jbc.M313579200; Yew EHJ, 2005, J NEUROCHEM, V94, P943, DOI 10.1111/j.1471-4159.2005.03220.x	39	81	92	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1055	1063		10.1096/fj.05-5495com	http://dx.doi.org/10.1096/fj.05-5495com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770004				2022-12-28	WOS:000240210300005
J	Kilic, E; Kilic, U; Wang, YM; Bassetti, CL; Marti, HH; Hermann, DM				Kilic, Ertugrul; Kilic, Ulkan; Wang, Yaoming; Bassetti, Claudio L.; Marti, Hugo H.; Hermann, Dirk M.			The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia	FASEB JOURNAL			English	Article							ENDOTHELIAL GROWTH-FACTOR; EXPRESSION; ANGIOGENESIS; ACTIVATION; LEAKAGE; INJURY	Based on its trophic influence on neurons and vascular cells, vascular endothelial growth factor (VEGF) is a promising candidate for stroke treatment. VEGF's survival-promoting effects are purchased at the expense of an increased blood brain barrier permeability, which potentially compromises tissue survival. The mechanisms via which VEGF protects the brain against ischemia remained unknown. We examined signaling pathways underlying VEGF's neuroprotective activity in our transgenic mouse line, which expresses human VEGF165 under a neuron-specific enolase (NSE) promoter. We show that VEGF receptor-2 (Flk-1) is expressed on ischemic neurons and astrocytes and is activated by VEGF. Following 90-min episodes of middle cerebral artery occlusion, VEGF increased phosphorylated ( but not total) Akt and ERK1/-2 and reduced phosphorylated mitogen activated protein kinase/p38 and c-Jun NH2-terminal kinase (JNK)-1/-2 levels, at the same time decreasing inducible NO synthase expression in ischemic neurons. Inhibition of Akt with Wortmannin reversed VEGF's neuroprotective properties, diminished brain swelling, and restored the vascular permeability induced by VEGF to below levels in WT animals. The aggravation of brain injury by Wortmannin was associated with the restitution of p38, but not of JNK-1/-2, ERK-1/-2, or inducible NOS ( iNOS). Our data demonstrate that VEGF mediates both neuroprotection and blood brain barrier permeability via the phosphatidylinositol-3 kinase (PI3K)/Akt pathway. Based on our observation that VEGF neuroprotection and vascular leakage depend on PI3K/Akt, which is putatively regulated by VEGF receptor-2, we predict that it may not easily be possible to make use of VEGF's neuroprotective function without accepting its unfavorable consequence, the increased vascular permeability.	Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; Heidelberg Univ, Inst Physiol & Pathophysiol, Heidelberg, Germany	University of Zurich; University Zurich Hospital; Ruprecht Karls University Heidelberg	Kilic, E (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklinstr 26, CH-8091 Zurich, Switzerland.	ertugrul.kilic@usz.ch	Kilic, Ertugrul/W-4563-2018; Hermann, Dirk M./AAT-3652-2021; Hermann, Dirk M/AAP-5538-2020; Hermann, Dirk/GZB-9350-2022	Kilic, Ertugrul/0000-0001-6494-8923; Hermann, Dirk M./0000-0003-0198-3152; Marti, Hugo/0000-0002-8456-334X; Bassetti, Claudio/0000-0002-4535-0245				DALKARA T, 1994, BRAIN PATHOL, V4, P49; Fischer S, 2004, J CELL PHYSIOL, V198, P359, DOI 10.1002/jcp.10417; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hermann DM, 1998, NEUROREPORT, V9, P1917, DOI 10.1097/00001756-199806010-00046; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Issbrucker K, 2002, FASEB J, V16, P262, DOI 10.1096/fj.02-0329fje; Jin K, 2001, NEUROSCIENCE, V108, P351, DOI 10.1016/S0306-4522(01)00154-3; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kaya D, 2005, J CEREBR BLOOD F MET, V25, P1111, DOI 10.1038/sj.jcbfm.9600109; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865; Marti HH, 1998, P NATL ACAD SCI USA, V95, P15809, DOI 10.1073/pnas.95.26.15809; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Matsuzaki H, 2001, FASEB J, V15, P1218, DOI 10.1096/fj.00-0495fje; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200; Schoch HJ, 2002, BRAIN, V125, P2549, DOI 10.1093/brain/awf257; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Vogel J, 2004, J CEREBR BLOOD F MET, V24, P849, DOI 10.1097/01.WCB.0000126564.89011.11; Wang YM, 2005, BRAIN, V128, P52, DOI 10.1093/brain/awh325; Wick A, 2002, J NEUROSCI, V22, P6401; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	24	184	196	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1185	+		10.1096/fj.05-4829fje	http://dx.doi.org/10.1096/fj.05-4829fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16641198				2022-12-28	WOS:000240210300020
J	von Gunten, S; Simon, HU				von Gunten, Stephan; Simon, Hans-Uwe			Sialic acid binding immunoglobulin-like lectins may regulate innate immune responses by modulating the life span of granulocytes	FASEB JOURNAL			English	Article						apoptosis; caspases; eosinophils; inflammation; neutrophils; non-apoptotic cell death; Siglecs	APOPTOTIC PATHWAYS; FAS LIGAND; DEATH; EXPRESSION; SIGLECS; CD22; NEUTROPHILS; ACTIVATION; MECHANISM; AUTOPHAGY	The regulation of cell death is a key element in building up and maintaining both innate and adaptive immunity. A critical role in this process plays the tumor necrosis factor (TNF)/nerve growth factor (NGF) receptor family of death receptors. Recent work suggests that sialic acid binding immunoglobulin (Ig) -like lectins (Siglecs) are also empowered to transmit death signals, at least into myeloid cells. Strikingly, death induction by Siglecs is enhanced when cells are exposed to proinflammatory survival cytokines. Based on these recent insights, we hypothesize that at least some members of the Siglec family regulate immune responses via the activation of caspase-dependent and caspase-independent cell death pathways. von Gunten, S., Simon, H.-U. Sialic acid binding immunoglobulinlike lectins ( Siglecs) may regulate innate immune responses by modulating the life span of granulocytes.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland	University of Bern	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736; von Gunten, Stephan/0000-0002-2753-8738				Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com; Baumann R, 2004, EUR J IMMUNOL, V34, P2268, DOI 10.1002/eji.200424863; Blixt O, 2003, J BIOL CHEM, V278, P31007, DOI 10.1074/jbc.M304331200; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; Bruno A, 2005, J IMMUNOL, V174, P8090, DOI 10.4049/jimmunol.174.12.8090; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Erickson LD, 1996, INT IMMUNOL, V8, P1121, DOI 10.1093/intimm/8.7.1121; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104; Hayakawa T, 2005, SCIENCE, V309, P1693, DOI 10.1126/science.1114321; Hoeberichts FA, 2003, BIOESSAYS, V25, P47, DOI 10.1002/bies.10175; Irie A, 1998, J BIOL CHEM, V273, P15866, DOI 10.1074/jbc.273.25.15866; Kavurma MM, 2003, CELL DEATH DIFFER, V10, P36, DOI 10.1038/sj.cdd.4401179; MEDAWAR PB, 1945, J ANAT, V79, P157; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nitschke L, 2004, TRENDS IMMUNOL, V25, P543, DOI 10.1016/j.it.2004.08.002; Nutku E, 2005, BIOCHEM BIOPH RES CO, V336, P918, DOI 10.1016/j.bbrc.2005.08.202; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Rapoport E, 2003, BIOORG MED CHEM LETT, V13, P675, DOI 10.1016/S0960-894X(02)00998-8; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Streilein JW, 2000, J LEUKOCYTE BIOL, V67, P479, DOI 10.1002/jlb.67.4.479; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vitale C, 2001, P NATL ACAD SCI USA, V98, P5764, DOI 10.1073/pnas.091097198; von Gunten S, 2005, BLOOD, V106, P1423, DOI 10.1182/blood-2004-10-4112; Yousefi S, 2003, CELL DEATH DIFFER, V10, P861, DOI 10.1038/sj.cdd.4401262; Yousefi S, 2003, SEMIN IMMUNOL, V15, P195, DOI 10.1016/S1044-5323(03)00033-2; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200	42	32	37	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					601	605		10.1096/fj.05-5401hyp	http://dx.doi.org/10.1096/fj.05-5401hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581967				2022-12-28	WOS:000240130900005
J	Shureiqi, I; Zuo, XS; Broaddus, R; Wu, Y; Guan, BX; Morris, JS; Lippman, SM				Shureiqi, Imad; Zuo, Xiangsheng; Broaddus, Russell; Wu, Yuanqing; Guan, Baoxiang; Morris, Jeffrey S.; Lippman, Scott M.			The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer	FASEB JOURNAL			English	Article						transcriptional regulation; apoptosis	CARCINOMA CELL-LINE; 15-LIPOXYGENASE-1 EXPRESSION; INDUCED APOPTOSIS; DIFFERENTIATION; ACTIVATION; INHIBITOR; CELECOXIB; CACO-2; GENES	Transcriptional suppression of 15-lipoxygenase (LOX)-1 (15-LOX-1) helps enable human colorectal cancer cells escape apoptosis, a critical mechanism for colonic tumorigenesis. GATA-6 is strongly expressed in vitro in cancer cells; its down-regulation by pharmaceuticals is associated with reversal of 15-LOX-1 transcriptional suppression. The mechanistic contribution of GATA-6 overexpression to colonic tumorigenesis, especially concerning 15-LOX-1 transcriptional suppression, remains unknown. We tested whether GATA-6 is differentially overexpressed in human colorectal cancers and whether reversing GATA-6 overexpression in colon cancer cells is sufficient to restore 15-LOX-1 expression and influence cell proliferation or apoptosis. The expression of GATA-6 RNA and protein was measured in paired human colorectal cancer and normal tissues from two separate patient groups. We used GATA-6 small interfering RNA transfection to down-regulate GATA-6 expression and examine the effects of this down-regulation on 15-LOX-1 expression, cell proliferation, and apoptosis in Caco-2 and HCT-116 colon cancer cells with and without the nonsteroidal antiinflammatory drug NS-398 or the histone deacetylase inhibitor sodium butyrate. GATA-6 mRNA and protein expressions were higher in cancer than normal epithelia of the colon. GATA-6 knockdown was insufficient by itself but contributed significantly to restoring 15-LOX-1 expression and inducing apoptosis by NS-398 or sodium butyrate. Maintaining 15-LOX-1 transcriptional silencing in cancer cells is a multifactorial process involving GATA-6 overexpression and other regulatory events.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Shureiqi, I (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, 1515 Holocombe Blvd, Houston, TX 77030 USA.	ishureiqi@mdanderson.org	Shureiqi, imad/T-6214-2019	Shureiqi, Imad/0000-0003-2019-938X; Zuo, Xiangsheng/0000-0002-8593-1132	NATIONAL CANCER INSTITUTE [R01CA106577] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Al-azzeh ED, 2000, BBA-GENE STRUCT EXPR, V1490, P324, DOI 10.1016/S0167-4781(00)00013-0; Conrad DJ, 2000, AM J RESP CELL MOL, V22, P226, DOI 10.1165/ajrcmb.22.2.3786; Deguchi A, 2005, CANCER RES, V65, P8442, DOI 10.1158/0008-5472.CAN-05-1109; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Grullich C, 2001, FEBS LETT, V489, P51, DOI 10.1016/S0014-5793(01)02080-4; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; Hawk ET, 2005, J CLIN ONCOL, V23, P378, DOI 10.1200/JCO.2005.08.097; Heslin MJ, 2005, ANN SURG, V241, P941, DOI 10.1097/01.sla.0000164177.95620.c1; Hill EM, 1998, AM J RESP CELL MOL, V18, P662, DOI 10.1165/ajrcmb.18.5.2985; Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Kamitani H, 2000, FEBS LETT, V467, P341, DOI 10.1016/S0014-5793(00)01155-8; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morrison B, 1998, SWINE HEALTH PROD, V6, P4; Nixon JB, 2004, PROSTAG LEUKOTR ESS, V70, P7, DOI 10.1016/j.plefa.2003.06.001; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PINTO M, 1983, BIOL CELL, V47, P323; RAMITANI H, 2001, CARCINOGENESIS, V22, P187; Shankaranarayanan P, 2001, J BIOL CHEM, V276, P42753, DOI 10.1074/jbc.M102626200; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985; Shureiqi I, 2005, CANCER RES, V65, P11486, DOI 10.1158/0008-5472.CAN-05-2180; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2002, CANCER RES, V62, P1178; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Yu JS, 2003, CANCER RES, V63, P6170; Zuo X, 2006, ONCOGENE, V25, P1225, DOI 10.1038/sj.onc.1209160	32	49	51	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					743	753		10.1096/fj.06-6830com	http://dx.doi.org/10.1096/fj.06-6830com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17167069	Green Accepted			2022-12-28	WOS:000244686400013
J	Clough, RL; Stefanis, L				Clough, R. Lee; Stefanis, Leonidas			A novel pathway for transcriptional regulation of alpha-synuclein	FASEB JOURNAL			English	Article						Parkinson's disease; PC12 cells; ERK; PI3 kinase; NGF	NERVE GROWTH-FACTOR; FAMILIAL PARKINSONS-DISEASE; PC12 CELLS; GENE-EXPRESSION; NEURONAL DIFFERENTIATION; DOPAMINERGIC-NEURONS; UP-REGULATION; SUSCEPTIBILITY; POLYMORPHISM; NACP-REP1	alpha-Synuclein is an abundant neuronal protein that has been linked to both normal synaptic function and neurodegeneration-in particular, Parkinson's disease (PD). Uncovering mechanisms that control alpha-synuclein transcription is therefore critical for PD pathogenesis and synaptic function. We previously reported that in PC12 cells and primary neurons, alpha-synuclein is transcriptionally up-regulated after application of growth factors. In the current work we have characterized the pathway involved in this regulation in PC12 cells. The MAP/ERK pathway, and in particular Ras, is both sufficient and necessary for the NGF and basic fibroblast growth factor (bFGF) -mediated response. Significantly, response elements for this pathway, including a putative occult promoter, lie within intron 1, a hitherto unappreciated regulatory region of the gene that may be utilized in this or other settings. The PI3 kinase pathway is also involved in alpha-synuclein regulation, but response elements for this pathway appear to lie primarily outside of intron 1. These findings indicate that NGF- and bFGF-mediated signal transduction via the MAP/ERK and PI3 kinase pathways, and in part via regulatory regions within intron 1, may be involved in alpha-synuclein transcriptional regulation. Targeting of these pathways may serve to modulate alpha-synuclein so that it achieves desirable levels within neuronal cells.	Acad Athens, Fdn Biomed Res, IIBEAA, Div Basic Neurosci, GR-11527 Athens, Greece	Academy of Athens	Stefanis, L (corresponding author), Acad Athens, Fdn Biomed Res, IIBEAA, Div Basic Neurosci, GR-11527 Athens, Greece.	lstefanis@bioacademy.gr	Stefanis, Leonidas/AAD-7192-2019					Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Baptista MJ, 2003, J NEUROCHEM, V85, P957, DOI 10.1046/j.1471-4159.2003.01742.x; Chiba-Falek O, 2001, HUM MOL GENET, V10, P3101, DOI 10.1093/hmg/10.26.3101; Chong YH, 2006, J BIOL CHEM, V281, P20315, DOI 10.1074/jbc.M601016200; Conlon TM, 2006, EUR J IMMUNOL, V36, P139, DOI 10.1002/eji.200535219; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Gomez-Santos C, 2005, BRAIN RES BULL, V65, P87, DOI 10.1016/j.brainresbull.2004.11.008; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Izumi Y, 2001, NEUROSCI LETT, V300, P125, DOI 10.1016/S0304-3940(01)01557-9; Kawamata T, 2003, NEUROCHEM RES, V28, P1221, DOI 10.1023/A:1024284529945; Khan N, 2001, ANN NEUROL, V49, P665; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Kruger R, 1999, ANN NEUROL, V45, P611, DOI 10.1002/1531-8249(199905)45:5<611::AID-ANA9>3.0.CO;2-X; Li WX, 2004, J NEUROSCI, V24, P7400, DOI 10.1523/JNEUROSCI.1370-04.2004; Madziar B, 2005, J NEUROCHEM, V92, P767, DOI 10.1111/j.1471-4159.2004.02908.x; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; Marek L, 2004, J CELL PHYSIOL, V201, P459, DOI 10.1002/jcp.20087; Mash DC, 2003, J NEUROSCI, V23, P2564; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Mellick GD, 2005, NEUROSCI LETT, V375, P112, DOI 10.1016/j.neulet.2004.10.078; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Mueller JC, 2005, ANN NEUROL, V57, P535, DOI 10.1002/ana.20438; Pals P, 2004, ANN NEUROL, V56, P591, DOI 10.1002/ana.20268; Parsian A, 1998, NEUROLOGY, V51, P1757, DOI 10.1212/WNL.51.6.1757; Pereira PS, 2006, DEV DYNAM, V235, P225, DOI 10.1002/dvdy.20606; Petersen K, 1999, NEUROSCIENCE, V91, P651, DOI 10.1016/S0306-4522(98)00596-X; Rideout HJ, 2003, J NEUROCHEM, V84, P803, DOI 10.1046/j.1471-4159.2003.01574.x; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; Schonhoff CM, 2001, J NEUROCHEM, V78, P631, DOI 10.1046/j.1471-4159.2001.00432.x; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spadafora P, 2003, NEUROSCI LETT, V351, P75, DOI 10.1016/S0304-3940(03)00859-0; Stefanis L, 2001, J NEUROCHEM, V76, P1165, DOI 10.1046/j.1471-4159.2001.00114.x; Subramaniam S, 2006, NEUROSCIENCE, V138, P1055, DOI 10.1016/j.neuroscience.2005.12.013; Tan EK, 2004, NEUROLOGY, V62, P128, DOI 10.1212/01.WNL.0000101721.25345.DC; Tan EK, 2003, NEUROSCI LETT, V336, P70, DOI 10.1016/S0304-3940(02)01178-3; Vekrellis K, 2004, MOL NEUROBIOL, V30, P1, DOI 10.1385/MN:30:1:001; Vila M, 2000, J NEUROCHEM, V74, P721, DOI 10.1046/j.1471-4159.2000.740721.x; Waetzig V, 2003, MOL CELL NEUROSCI, V24, P238, DOI 10.1016/S1044-7431(03)00126-X; Waetzig V, 2003, J BIOL CHEM, V278, P567, DOI 10.1074/jbc.M207391200; Xia Y, 1996, ANN NEUROL, V40, P207, DOI 10.1002/ana.410400212; Xia Y, 2001, J ALZHEIMERS DIS, V3, P485, DOI 10.3233/JAD-2001-3508	46	42	44	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					596	607		10.1096/fj.06-7111com	http://dx.doi.org/10.1096/fj.06-7111com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17167067				2022-12-28	WOS:000244686300032
J	Kappert, K; Paulsson, J; Sparwel, J; Leppanen, O; Hellberg, C; Ostman, A; Micke, P				Kappert, Kai; Paulsson, Janna; Sparwel, Jan; Leppanen, Olli; Hellberg, Carina; Ostman, Arne; Micke, Patrick			Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation	FASEB JOURNAL			English	Article						tissue remodeling; laser capture microdissection; vascular smooth muscle cell; protein tyrosine phosphalase	PROTEIN-TYROSINE PHOSPHATASES; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; BETA-RECEPTOR; PROLIFERATION; IDENTIFICATION; INSULIN; INJURY	Growth factor-dependent tissue remodeling, such as restenosis, is believed to be predominantly regulated by changes in expression of receptor-tyrosine-kinases (RTKs) and their ligands. As endogenous antagonists of RTKs, protein-tyrosine-phosphatases (PTPs) are additional candidate regulators of these processes. Using laser-capture-microdissection and quantitative RT-polymerase chain reaction (qRT-PCR), we investigated the layer-specific expression of the four platelet-derived growth factor (PDGF) isoforms, the PDGF-alpha and beta receptors, and five PTPs implied in control of PDGF-receptor signaling 8 and 14 days after balloon injury of the rat carotid. Results were correlated with analyses of PDGF-beta receptor phosphorylation and vascular smooth muscle cell (VSMC) proliferation in vivo. The expression levels of all components, as well as receptor activation and VSMC proliferation, showed specific changes, which varied between media and neointima. Interestingly, PTP expression-particularly, DEP-1 levels-appeared to be the dominating factor determining receptor-phosphorylation and VSMC proliferation. In support of these findings, cultured DEP-1(-/-) cells displayed increased PDGF-dependent cell signaling. Hyperactivation of PDGF-induced signaling was also observed after siRNA-down-regulation of DEP-1 in VSMCs. The results indicate a previously unrecognized role of PDGF-receptor-targeting PTPs in controlling neointima formation. In more general terms, the observations indicate transcriptional regulation of PTPs as an important mechanism for controlling onset and termination of RTK-dependent tissue remodeling.	Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden; Univ Uppsala Hosp, Div Vasc Surg, Uppsala, Sweden; Uppsala Univ, Ludwig Inst Canc Res, Uppsala, Sweden	Karolinska Institutet; Uppsala University; Uppsala University Hospital; Ludwig Institute for Cancer Research; Uppsala University	Ostman, A (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden.	arne.ostman@ki.se	Kappert, Kai/H-4116-2017	Kappert, Kai/0000-0001-6976-0428				Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Berset TA, 2005, GENE DEV, V19, P1328, DOI 10.1101/gad.333505; Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006; Borges LG, 1996, CIRC RES, V79, P570, DOI 10.1161/01.RES.79.3.570; Chang YZ, 2006, ARTERIOSCL THROM VAS, V26, P501, DOI 10.1161/01.ATV.0000201070.71787.b8; Chang YZ, 2004, AM J PHYSIOL-HEART C, V287, pH2201, DOI 10.1152/ajpheart.00520.2004; Chen JZ, 2005, BIOCHEM BIOPH RES CO, V329, P976, DOI 10.1016/j.bbrc.2005.02.062; CLOWES AW, 1983, LAB INVEST, V49, P327; Fukada T, 2003, EMBO J, V22, P479, DOI 10.1093/emboj/cdg067; Galic S, 2005, MOL CELL BIOL, V25, P819, DOI 10.1128/MCB.25.2.819-829.2005; Giese NA, 1999, ARTERIOSCL THROM VAS, V19, P900, DOI 10.1161/01.ATV.19.4.900; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Heldin CH, 2002, ARCH BIOCHEM BIOPHYS, V398, P284, DOI 10.1006/abbi.2001.2707; Jandt E, 2003, ONCOGENE, V22, P4175, DOI 10.1038/sj.onc.1206652; Kappert K, 2006, AM J PHYSIOL-HEART C, V290, pH538, DOI 10.1152/ajpheart.00240.2005; Kappert K, 2005, CARDIOVASC RES, V65, P587, DOI 10.1016/j.cardiores.2004.08.016; Kokel M, 1998, GENE DEV, V12, P1425, DOI 10.1101/gad.12.10.1425; Levitzki A, 2004, CYTOKINE GROWTH F R, V15, P229, DOI 10.1016/j.cytogfr.2004.03.010; Lin J, 2004, J IMMUNOL, V173, P2324, DOI 10.4049/jimmunol.173.4.2324; Markova B, 2003, BIOCHEMISTRY-US, V42, P2691, DOI 10.1021/bi0265574; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Persson C, 2004, MOL CELL BIOL, V24, P2190, DOI 10.1128/MCB.24.5.2190-2201.2004; Persson C, 2002, FEBS LETT, V517, P27, DOI 10.1016/S0014-5793(02)02570-X; Ponten A, 2005, CIRC RES, V97, P1036, DOI 10.1161/01.RES.0000190590.31545.d4; Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; VACARESSE N, 2005, EMBO C FEBS WORKSH E	27	39	40	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					523	534		10.1096/fj.06-6219com	http://dx.doi.org/10.1096/fj.06-6219com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158785				2022-12-28	WOS:000244686300025
J	Sugimoto, H; Yang, CQ; LeBleu, VS; Soubasakos, MA; Giraldo, M; Zeisberg, M; Kalluri, R				Sugimoto, Hikaru; Yang, Changqing; LeBleu, Valerie S.; Soubasakos, Mary A.; Giraldo, Mauricio; Zeisberg, Michael; Kalluri, Raghu			BMP-7 functions as a novel hormone to facilitate liver regeneration	FASEB JOURNAL			English	Article						transforming growth factor beta; hepatocytes	VASCULAR CALCIFICATION; OSTEOGENIC PROTEIN; RENAL FIBROSIS; HEPATOCYTES; FAMILY; KIDNEY; CELLS; MODEL; OP-1	Bone morphogenic protein-7 (BMP-7) is a key protein involved in liver organogenesis and development. The physiological circulating concentration of BMP-7 is between 100 and 300 pg/ml. BMP-7 expression is absent in the liver, but the receptors for BMP-7 are present on adult hepatocytes. Therefore, we hypothesized that BMP-7 might function as an endogenous regulator of adult hepatocyte proliferation and liver homeostasis. Here, we demonstrate that neutralization of circulating endogenous BMP-7 results in significantly impaired regeneration of the liver after partial hepatectomy. Therapeutic administration of recombinant human BMP-7 (rhBMP-7) significantly enhances liver regeneration associated with accelerated improvement of liver function. Collectively, our results argue for the role of BMP-7 as a kidney- and bone-produced endogenous regulator of hepatocyte health.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Matrix Biol,Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02215 USA; Harvard Mit Div Hlth Sci & Technol, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University	Kalluri, R (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Matrix Biol,Dept Med, Dana 514,330 Brookline Ave, Boston, MA 02215 USA.	rkalluri@bidmc.harvard.edu	LeBleu, Valerie/E-2991-2015; Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI053194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK074558, R01DK061688] Funding Source: NIH RePORTER; NIAID NIH HHS [AI53194] Funding Source: Medline; NIDDK NIH HHS [DK55001, 1K08DK074558-01, DK61688] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Davies MR, 2005, J AM SOC NEPHROL, V16, P917, DOI 10.1681/ASN.2004100835; Davies MR, 2003, J AM SOC NEPHROL, V14, P1559, DOI 10.1097/01.ASN.0000068404.57780.DD; Fausto N, 2001, LIVER TRANSPLANT, V7, P835, DOI 10.1053/jlts.2001.27865; Gill RQ, 2001, J CLIN GASTROENTEROL, V33, P191, DOI 10.1097/00004836-200109000-00005; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hruska KA, 2000, AM J PHYSIOL-RENAL, V279, pF130, DOI 10.1152/ajprenal.2000.279.1.F130; Kaibori M, 2002, BIOCHEM BIOPH RES CO, V290, P475, DOI 10.1006/bbrc.2001.6170; Kalluri R, 2003, HISTOL HISTOPATHOL, V18, P217, DOI 10.14670/HH-18.217; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Okuno Y, 2002, BLOOD, V100, P4420, DOI 10.1182/blood-2002-03-0788; OZKAYNAK E, 1991, BIOCHEM BIOPH RES CO, V179, P116, DOI 10.1016/0006-291X(91)91342-A; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; RABES HM, 1976, CELL TISSUE KINET, V9, P517; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Thorgeirsson SS, 1996, FASEB J, V10, P1249, DOI 10.1096/fasebj.10.11.8836038; VUKICEVIC S, 1994, BIOCHEM BIOPH RES CO, V198, P693, DOI 10.1006/bbrc.1994.1100; Wozney JM, 1998, EUR J ORAL SCI, V106, P160, DOI 10.1111/j.1600-0722.1998.tb02170.x; Wrana J, 1997, NATURE, V388, P28, DOI 10.1038/40290; Yang CQ, 2003, GASTROENTEROLOGY, V124, P147, DOI 10.1053/gast.2003.50012; Zaret KS, 2002, NAT REV GENET, V3, P499, DOI 10.1038/nrg837; Zeisberg M, 2006, MOL CELL BIOCHEM, V283, P181, DOI 10.1007/s11010-006-2677-8; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7	26	89	107	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2007	21	1					256	264		10.1096/fj.06-6837com	http://dx.doi.org/10.1096/fj.06-6837com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17116741				2022-12-28	WOS:000243130200028
J	Vila-Carriles, WH; Zhao, GL; Bryan, J				Vila-Carriles, Wanda H.; Zhao, Guiling; Bryan, Joseph			Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels	FASEB JOURNAL			English	Article						ATP-binding cassette proteins; potassium inward rectifier; glibenclamide; hypoglycemia	GLUCOSE LOWERING SULFONAMIDES; INSULIN-SECRETING CELLS; ASYMMETRIC CARBON-ATOMS; MULTIDRUG-RESISTANCE PROTEIN; MODULATED K+ CHANNEL; HIGH-AFFINITY; GLIBENCLAMIDE BINDING; GLYBURIDE ANALOG; ABC TRANSPORTER; N-TERMINUS	Sulfonylurea receptors SUR1 and SUR2 are the regulatory subunits of K-ATP channels. Their differential affinity for hypoglycemic sulfonylureas provides a basis for the selectivity of these compounds for different K-ATP channel isoforms. Sulfonylureas have a 100- to 1000- fold greater affinity for SUR1 vs. SUR2. Structure-activity studies suggested a bipartite binding pocket. Chimeric SUR1 similar to SUR2 receptors have shown TMD2, the third bundle of transmembrane helices, to be part of an "A" site that confers SUR1 selectivity for sulfonylureas. The purpose of this study is to determine the position of the "B" site. Previous photoaffinity labeling studies have placed the B site on the amino-terminal third of SUR and colabeled the associated K-IR. In our study, deletion of TMD0, the first bundle of transmembrane helices, did not compromise labeling. Further deletions into the cytoplasmic linker, L0, eliminated binding and labeling. Alanine substitutions in L0 identified a limited number of conserved residues, Y230 and W232, important for affinity labeling. A fragment of K(IR)6.2, missing M2 and the entire carboxyl terminal, assembles with SUR1 and is affinity labeled, while deletion of 10 or more amino-terminal residues compromises labeling. These studies indicate that the B site involves L0 and the KIR amino terminus, elements that are critical for control of channel gating.	Baylor Coll Med, Dept Physiol & Mol Biophys, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Vila-Carriles, WH (corresponding author), Univ Alabama, Dept Physiol & Biophys, 1918 Univ Blvd,MCLM 705, Birmingham, AL 35294 USA.	carriles@uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM066478, R25GM056929] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44311] Funding Source: Medline; NIGMS NIH HHS [R25 GM056929, GM66478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Babenko AP, 2003, J BIOL CHEM, V278, P41577, DOI 10.1074/jbc.C300363200; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Babenko AP, 2002, J BIOL CHEM, V277, P43997, DOI 10.1074/jbc.M208085200; Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; Bakos E, 2000, J CELL SCI, V113, P4451; BIERE H, 1974, J MED CHEM, V17, P716, DOI 10.1021/jm00253a011; BROWN GR, 1984, J MED CHEM, V27, P79, DOI 10.1021/jm00367a016; Bryan J, 2005, CURR PHARM DESIGN, V11, P2699, DOI 10.2174/1381612054546879; Bryan J, 2004, DIABETES, V53, pS104, DOI 10.2337/diabetes.53.suppl_3.S104; BRYAN J, 2004, CURR PHARMA DESIGN, V112, P12; Chachin M, 2003, J PHARMACOL EXP THER, V304, P1025, DOI 10.1124/jpet.102.044917; Chan KW, 2003, EMBO J, V22, P3833, DOI 10.1093/emboj/cdg376; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHUDZIAK F, 1994, J LABELLED COMPD RAD, V34, P675, DOI 10.1002/jlcr.2580340713; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Crane A, 2004, J BIOL CHEM, V279, P9080, DOI 10.1074/jbc.M311079200; Dean M, 2001, J BIOENERG BIOMEMBR, V33, P475, DOI 10.1023/A:1012823120935; Densmore CL, 2000, MOL THER, V1, P180, DOI 10.1006/mthe.1999.0021; DUHAULT J, 1991, DIABETES RES CLIN PR, V14, pS9, DOI 10.1016/0168-8227(91)90003-V; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Grell W, 1998, J MED CHEM, V41, P5219, DOI 10.1021/jm9810349; Gribble FM, 2003, J DIABETES COMPLICAT, V17, P11, DOI 10.1016/S1056-8727(02)00272-6; GUTSCHE K, 1974, ARZNEIMITTEL-FORSCH, V24, P1028; Hambrock A, 2002, BRIT J PHARMACOL, V136, P995, DOI 10.1038/sj.bjp.0704801; Hambrock A, 2001, MOL PHARMACOL, V60, P190, DOI 10.1124/mol.60.1.190; Hansen AMK, 2002, DIABETES, V51, P2789, DOI 10.2337/diabetes.51.9.2789; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loubatieres A, 1969, Acta Diabetol Lat, V6 Suppl 1, P20; Mikhailov MV, 2001, FEBS LETT, V499, P154, DOI 10.1016/S0014-5793(01)02538-8; NELSON DA, 1992, J BIOL CHEM, V267, P14928; Reimann F, 1999, J PHYSIOL-LONDON, V518, P325, DOI 10.1111/j.1469-7793.1999.0325p.x; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; RUFER C, 1979, J MED CHEM, V22, P750, DOI 10.1021/jm00192a028; RUFER C, 1974, J MED CHEM, V17, P708, DOI 10.1021/jm00253a010; SCHMIDANTOMARCHI H, 1987, J BIOL CHEM, V262, P15840; SCHMIDANTOMARCHI H, 1987, BIOCHEM BIOPH RES CO, V146, P21, DOI 10.1016/0006-291X(87)90684-X; SCHWANSTECHER M, 1994, J BIOL CHEM, V269, P17768; SCHWANSTECHER M, 1994, J NEUROCHEM, V63, P698; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655	46	54	57	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					18	25		10.1096/fj.06-6730hyp	http://dx.doi.org/10.1096/fj.06-6730hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17110465				2022-12-28	WOS:000243130200003
J	Chade, AR; Zhu, XY; Mushin, OP; Napoli, C; Lerman, A; Lerman, LO				Chade, Alejandro R.; Zhu, Xiangyang; Mushin, Oren P.; Napoli, Claudio; Lerman, Amir; Lerman, Lilach O.			Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia	FASEB JOURNAL			English	Article						kidney; ischemia; simvastatin; angiogenesis; microvessels; remodeling	EXPERIMENTAL RENOVASCULAR DISEASE; INCREASED OXIDATIVE STRESS; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; EXPERIMENTAL HYPERCHOLESTEROLEMIA; ARTERY STENOSIS; MYOCARDIAL NEOVASCULARIZATION; TISSUE TRANSGLUTAMINASE; STENOTIC KIDNEY; RAT MODEL	We tested the hypothesis that statins would decrease renal injury in renal artery stenosis (RAS) by restoring angiogenesis and attenuating intrarenal microvascular (IMV) remodeling. Single-kidney hemodynamics and function were quantified using electronbeam- computed tomography (CT) in normocholesterolemic pigs after 12 wk of experimental RAS, RAS supplemented with simvastatin (RAS+simvastatin), and normal controls. Renal circulation was also studied in vivo using angiography and ex vivo using a unique 3D micro-CT imaging technique. Angiogenic and remodeling pathways were subsequently explored in renal tissue. Blood pressure and the degree of stenosis were similarly increased in RAS groups. Simvastatin in RAS enhanced both intrarenal angiogenesis and peri-steno-sis arteriogenesis and increased the expression of angiogenic growth factors and hypoxia-inducible factor-1 alpha . Furthermore, simvastatin decreased tissue-transglutaminase expression and IMV inward remodeling, restored IMV endothelial function, decreased fibrogenic activity, and improved renal function. Chronic simvastatin supplementation promoted angiogenesis in vivo, decreased ischemia-induced IMV remodeling, and improved IMV function in the stenotic kidney, independent of lipid lowering. These novel renoprotective effects suggest a role for simvastatin in preserving the ischemic kidney in chronic RAS.	Mayo Clin, Coll Med, Div Nephrol & Hypertens, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Univ Naples Federico 2, Res Ctr Excellence Cardiovasc Dis, I-80138 Naples, Italy; Univ Naples Federico 2, Dept Gen Pathol, I-80138 Naples, Italy; Univ Naples Federico 2, Dept Med, I-80138 Naples, Italy; Boston Univ, Evans Dept Med, Boston, MA 02215 USA; Boston Univ, Whitaker Cardiovasc Inst, Boston, MA 02215 USA	Mayo Clinic; Mayo Clinic; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Boston University; Boston University	Lerman, LO (corresponding author), Mayo Clin, Coll Med, Div Nephrol & Hypertens, Dept Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	lerman.lilach@mayo.edu	Lerman, Lilach/M-4962-2017	Napoli, Claudio/0000-0002-5455-555X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073608] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-77131] Funding Source: Medline; NIBIB NIH HHS [EB 000305] Funding Source: Medline; NIDDK NIH HHS [DK-73608] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakker ENTP, 2005, CIRC RES, V96, P119, DOI 10.1161/01.RES.0000151333.56089.66; Bentley MD, 2002, KIDNEY INT, V61, P1056, DOI 10.1046/j.1523-1755.2002.00211.x; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; Carey GB, 1997, MED SCI SPORT EXER, V29, P1437, DOI 10.1097/00005768-199711000-00008; Chade AR, 2003, HYPERTENSION, V42, P605, DOI 10.1161/01.HYP.0000089880.32275.7C; Chade AR, 2004, J AM SOC NEPHROL, V15, P1816, DOI 10.1097/01.ASN.0000130428.85603.6B; Chade AR, 2004, AM J PHYSIOL-RENAL, V286, pF1079, DOI 10.1152/ajprenal.00385.2003; Chade AR, 2004, J AM SOC NEPHROL, V15, P958, DOI 10.1097/01.ASN.0000117774.83396.E9; Chade AR, 2003, ARTERIOSCL THROM VAS, V23, P1295, DOI 10.1161/01.ATV.0000077477.40824.52; Chade AR, 2002, CIRCULATION, V106, P1165, DOI 10.1161/01.CIR.0000027105.02327.48; Chen CH, 2000, CIRCULATION, V101, P171, DOI 10.1161/01.CIR.101.2.171; Cheng JF, 2002, EXP BIOL MED, V227, P943, DOI 10.1177/153537020222701102; Edwards MS, 2005, ARCH INTERN MED, V165, P207, DOI 10.1001/archinte.165.2.207; Eickelberg O, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022008.30175.5B; ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7; Gueler F, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000026609.45827.3D; HaslerRapacz J, 1996, ARTERIOSCL THROM VAS, V16, P137, DOI 10.1161/01.ATV.16.1.137; Hodivala-Dilke KM, 2003, CELL TISSUE RES, V314, P131, DOI 10.1007/s00441-003-0774-5; Imanishi T, 2003, CLIN EXP PHARMACOL P, V30, P665, DOI 10.1046/j.1440-1681.2003.03894.x; Inman SR, 2003, AM J MED SCI, V326, P117, DOI 10.1097/00000441-200309000-00002; Johnson TS, 2003, J AM SOC NEPHROL, V14, P2052, DOI 10.1097/01.ASN.0000079614.63463.DD; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Krier JD, 2001, AM J PHYSIOL-RENAL, V281, pF630, DOI 10.1152/ajprenal.2001.281.4.F630; Landmesser U, 2004, CIRCULATION, V110, P1933, DOI 10.1161/01.CIR.0000143232.67642.7A; Langille BL, 2005, CIRC RES, V96, P9, DOI 10.1161/01.RES.0000153883.55971.81; Lerman L, 2001, UROL CLIN N AM, V28, P793, DOI 10.1016/S0094-0143(01)80034-3; Lerman LO, 1999, J AM SOC NEPHROL, V10, P1455; Lerman LO, 2001, HYPERTENSION, V37, P541, DOI 10.1161/01.HYP.37.2.541; Levy AP, 1999, CORONARY ARTERY DIS, V10, P427, DOI 10.1097/00019501-199909000-00013; Manotham K, 2005, KIDNEY INT, V67, P1428, DOI 10.1111/j.1523-1755.2005.00220.x; Moriyama T, 2001, KIDNEY INT, V59, P2095, DOI 10.1046/j.1523-1755.2001.0590062095.x; Nakagawa T, 2004, KIDNEY INT, V66, P605, DOI 10.1111/j.1523-1755.2004.00780.x; Pourati I, 2003, AM HEART J, V146, P876, DOI 10.1016/S0002-8703(03)00413-7; RENTROP KP, 1985, J AM COLL CARDIOL, V5, P587; Rizzoni D, 2003, CIRCULATION, V108, P2230, DOI 10.1161/01.CIR.0000095031.51492.C5; Safian RD, 2001, NEW ENGL J MED, V344, P431, DOI 10.1056/NEJM200102083440607; Sata M, 2004, HYPERTENSION, V43, P1214, DOI 10.1161/01.HYP.0000126186.29571.41; Simons M, 2005, CIRCULATION, V111, P1556, DOI 10.1161/01.CIR.0000159345.00591.8F; Smith RS, 2002, ARTERIOSCL THROM VAS, V22, P1279, DOI 10.1161/01.ATV.0000026613.18742.67; Sottile J, 2004, BBA-REV CANCER, V1654, P13, DOI 10.1016/j.bbcan.2003.07.002; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Urbich C, 2002, CIRC RES, V90, P737, DOI 10.1161/01.RES.0000014081.30867.F8; Usui H, 2003, NEPHROL DIAL TRANSPL, V18, P265, DOI 10.1093/ndt/18.2.265; Vaughan CJ, 2004, CIRCULATION, V110, P886, DOI 10.1161/01.CIR.0000139312.10076.BA; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Wilson SH, 2002, CIRCULATION, V105, P415, DOI 10.1161/hc0402.104119; Wilson SH, 2003, NEPHROL DIAL TRANSPL, V18, P703, DOI 10.1093/ndt/gfg143; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200; Zhu XY, 2004, ARTERIOSCL THROM VAS, V24, P1854, DOI 10.1161/01.ATV.0000142443.52606.81; Zhu XY, 2004, CIRCULATION, V109, P2109, DOI 10.1161/01.CIR.0000125742.65841.8B	50	104	107	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1706	+		10.1096/fj.05-5680fje	http://dx.doi.org/10.1096/fj.05-5680fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790524				2022-12-28	WOS:000240266600022
J	Cella, N; Contreras, A; Latha, K; Rosen, JM; Zhang, M				Cella, Nathalie; Contreras, Alejandro; Latha, Khatri; Rosen, Jeffrey M.; Zhang, Ming			Maspin is physically associated with beta 1 integrin regulating cell adhesion in mammary epithelial cells	FASEB JOURNAL			English	Article						maspin; cell adhesion; beta 1 integrin; RSL; ECM	TUMOR-SUPPRESSOR MASPIN; EXTRACELLULAR-MATRIX; PLASMINOGEN-ACTIVATOR; CRYSTAL-STRUCTURE; CYTOSKELETON; MEMBRANE; INHIBITION; EXPRESSION; APOPTOSIS; GROWTH	Maspin is a tumor-suppressor serpin (serine protease inhibitor), which inhibits cell invasion and migration. Here, we analyzed maspin function in cell adhesion in nontransformed mammary epithelial cells and investigated the underlying mechanism involved in this process. We report that maspin acts in the early steps in the cell adhesion process. Addition of recombinant maspin rapidly increased MCF-10A cell adhesion to the endogenously deposited matrix, and conversely both an antimaspin antibody (Ab) and maspin knockdown by RNA interference resulted in decreased cell adhesion. Mutation analyses revealed that a region of 86 amino acids located between aa 139 and aa 225 was responsible for maspin effect on adhesion. In addition, we show that maspin is associated with detergent-insoluble cortical cytoskeleton elements. Collectively, these results suggest that maspin is part of the supramolecular structure of the adhesion plaque and it modulates cell adhesion via a beta 1 integrin-dependent mechanism.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhang, M (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, ALKEK Bldg,Rm N630,1 Baylor Plaza, Houston, TX 77030 USA.	mzhang@bcm.tmc.edu	Cella, Nathalie/A-3542-2012; Cella, Nathalie/AAX-5494-2021	Cella, Nathalie/0000-0001-6060-1076; Cella, Nathalie/0000-0001-6060-1076	NATIONAL CANCER INSTITUTE [R01CA079736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM056929] Funding Source: NIH RePORTER; NCI NIH HHS [CA79736] Funding Source: Medline; NIGMS NIH HHS [R25 GM056929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham S, 2003, J UROLOGY, V169, P1157, DOI 10.1097/01.ju.0000040245.70349.37; Al-Ayyoubi M, 2004, J BIOL CHEM, V279, P55540, DOI 10.1074/jbc.M409957200; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; BENZEEV A, 1979, CELL, V17, P859, DOI 10.1016/0092-8674(79)90326-X; Biliran H, 2001, CANCER RES, V61, P8676; Bissell MJ, 2003, BREAST CANCER RES, V5, P117, DOI 10.1186/bcr579; BLACQUE OE, 2002, J BIOL CHEM; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DELCOMMENNE M, 1995, J BIOL CHEM, V270, P26794, DOI 10.1074/jbc.270.45.26794; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Gao F, 2004, DEVELOPMENT, V131, P1479, DOI 10.1242/dev.01048; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; GONEN A, 1979, BIOCHIM BIOPHYS ACTA, V552, P307, DOI 10.1016/0005-2736(79)90285-2; Hikita C, 2000, J CELL BIOL, V151, P1235, DOI 10.1083/jcb.151.6.1235; LANGHOFER M, 1993, J CELL SCI, V105, P753; Latha K, 2005, MOL CELL BIOL, V25, P1737, DOI 10.1128/MCB.25.5.1737-1748.2005; Law RHP, 2005, J BIOL CHEM, V280, P22356, DOI 10.1074/jbc.M412043200; Li N, 2005, EMBO J, V24, P1942, DOI 10.1038/sj.emboj.7600674; Liu T, 1999, J BIOL CHEM, V274, P29628, DOI 10.1074/jbc.274.42.29628; MANDERS EMM, 1992, J CELL SCI, V103, P857; MAUTNER V, 1977, J CELL BIOL, V75, P743, DOI 10.1083/jcb.75.3.743; McGowen R, 2000, CANCER RES, V60, P4771; NGAMKITIDECHAKU.C, 2003, J BIOL CHEM; Ngamkitidechakul C, 2001, INVEST OPHTH VIS SCI, V42, P3135; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; Plopper GE, 1998, BREAST CANCER RES TR, V51, P57, DOI 10.1023/A:1006086218174; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi HY, 2001, CANCER RES, V61, P6945; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1999, DEV BIOL, V215, P278, DOI 10.1006/dbio.1999.9442; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	47	52	57	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1510	+		10.1096/fj.05-5500fje	http://dx.doi.org/10.1096/fj.05-5500fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720730				2022-12-28	WOS:000240266000034
J	Pignatelli, P; Di Santo, S; Buchetti, B; Sanguigni, V; Brunelli, A; Violi, F				Pignatelli, P.; Di Santo, S.; Buchetti, B.; Sanguigni, V.; Brunelli, A.; Violi, F.			Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment	FASEB JOURNAL			English	Article						oxidative stress; polyphenols; platelet recruitment	CORONARY-HEART-DISEASE; FLAVONOID INTAKE; RISK; WINE; PHOSPHORYLATION; AGGREGATION; EXPRESSION; THROMBOSIS; QUERCETIN; JUICE	Several studies demonstrated an inverse association between polyphenol intake and cardiovascular events. Platelet recruitment is an important phase of platelet activation at the site of vascular injury, but it has never been investigated whether polyphenols influence platelet recruitment. The aim of the study was to analyze in vitro whether two polyphenols, quercetin and catechin, were able to affect platelet recruitment. Platelet recruitment was reduced by NO donors and by NADPH oxidase inhibitors and was enhanced by L-NAME, an inhibitor of NO synthase. Quercetin and catechin, but not single polyphenol, significantly inhibited platelet recruitment in a concentration- dependent fashion. The formation of superoxide anion was significantly inhibited in platelets incubated with quercetin and catechin but was unaffected by a single polyphenol. Incubation of platelets with quercetin and catechin resulted in inhibition of PKC and NADPH oxidase activation. Treatment of platelets with quercetin and catechin resulted in an increase of NO and also down-regulated the expression of GpIIb/IIIa glycoprotein. This study shows that the polyphenols quercetin and catechin synergistically act in reducing platelet recruitment via inhibition of PKC-dependent NADPH oxidase activation. This effect, resulting in NO-mediated platelet glycoprotein GpIIb/IIIa down-regulation, could provide a novel mechanism through which polyphenols reduce cardiovascular disease.	Univ Roma La Sapienza, Div Clin Med 4, Dipartimento Med Sperimentale & Patol, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Med Interna, I-00173 Rome, Italy	Sapienza University Rome; University of Rome Tor Vergata	Violi, F (corresponding author), Univ Roma La Sapienza, Div Clin Med 4, Dipartimento Med Sperimentale & Patol, Policlin Umberto 1, I-00185 Rome, Italy.	francesco.violi@uniroma1.it	Sanguigni, Valerio/AAH-2515-2020; Violi, Francesco/K-1509-2016; pignatelli, pasquale/K-2116-2016	Violi, Francesco/0000-0002-6610-7068; pignatelli, pasquale/0000-0002-2265-7455				Al-Awwadi NA, 2005, J AGR FOOD CHEM, V53, P151, DOI 10.1021/jf048919f; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; BEGONIA AJ, 2005, BLOOD, V15, P2757; Burns J, 2000, J AGR FOOD CHEM, V48, P220, DOI 10.1021/jf9909757; Casani L, 2004, CIRCULATION, V110, P460, DOI 10.1161/01.CIR.0000136027.98303.4D; Cathcart MK, 2004, ARTERIOSCL THROM VAS, V24, P23, DOI 10.1161/01.ATV.0000097769.47306.12; DEMROW HS, 1995, CIRCULATION, V91, P1182, DOI 10.1161/01.CIR.91.4.1182; Fichtlscherer S, 2004, CURR OPIN PHARMACOL, V4, P124, DOI 10.1016/j.coph.2004.01.002; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Freedman JE, 1997, J CLIN INVEST, V100, P350, DOI 10.1172/JCI119540; Freedman JE, 2001, CIRCULATION, V103, P2792, DOI 10.1161/01.CIR.103.23.2792; HAUT MJ, 1974, AM J MED, V56, P22, DOI 10.1016/0002-9343(74)90747-5; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Hertog MGL, 1997, AM J CLIN NUTR, V65, P1489, DOI 10.1093/ajcn/65.5.1489; Janssen PLTMK, 1998, AM J CLIN NUTR, V67, P255, DOI 10.1093/ajcn/67.2.255; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; Krotz F, 2002, BLOOD, V100, P917, DOI 10.1182/blood.V100.3.917; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Miura T, 2003, FOOD CHEM TOXICOL, V41, P759, DOI 10.1016/S0278-6915(03)00005-X; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Oelze M, 2000, CIRC RES, V87, P999, DOI 10.1161/01.RES.87.11.999; Pignatelli P, 2000, AM J CLIN NUTR, V72, P1150; Pignatelli P, 2004, CIRCULATION, V110, P1326, DOI 10.1161/01.CIR.0000134963.77201.55; Pignatelli P, 2003, AM J PHYSIOL-HEART C, V284, pH41, DOI 10.1152/ajpheart.00249.2002; Poolman TM, 2005, FREE RADICAL BIO MED, V39, P118, DOI 10.1016/j.freeradbiomed.2005.02.036; Rimm EB, 1996, ANN INTERN MED, V125, P384, DOI 10.7326/0003-4819-125-5-199609010-00005; Stocker R, 2004, AM J CLIN NUTR, V79, P123; Violi F, 2002, CIRCULATION, V105, pE53; Watala C, 2003, THROMB RES, V109, P299, DOI 10.1016/S0049-3848(03)00238-X; Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.230S, 10.1093/ajcn/81.1.243S]; WOLLNY T, 1999, BRIT J PHARMACOL, V127, P147; Woodman OL, 2004, CLIN EXP PHARMACOL P, V31, P786, DOI 10.1111/j.1440-1681.2004.04072.x; Xu JW, 2005, LIFE SCI, V76, P2861, DOI 10.1016/j.lfs.2004.11.015	35	103	108	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1082	1089		10.1096/fj.05-5269com	http://dx.doi.org/10.1096/fj.05-5269com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770007				2022-12-28	WOS:000240210300008
J	Yamada, M; Ikeda, Y; Yano, M; Yoshimura, K; Nishino, S; Aoyama, H; Wang, LL; Aoki, H; Matsuzaki, M				Yamada, Michio; Ikeda, Yasuhiro; Yano, Masafumi; Yoshimura, Koichi; Nishino, Shizuka; Aoyama, Hidekazu; Wang, Lili; Aoki, Hiroki; Matsuzaki, Masunori			Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy	FASEB JOURNAL			English	Article						gene transfer; protein kinase A; phosphorylation; phospholamban	CHANNEL RYANODINE RECEPTOR; DELTA-SARCOGLYCAN GENE; N-TERMINAL KINASE; DILATED CARDIOMYOPATHY; CARDIAC-FUNCTION; SARCOPLASMIC-RETICULUM; PROTEIN PHOSPHATASE-1; DEFECTIVE REGULATION; MEMBRANE-PROTEINS; FAILING HEARTS	The type 1 protein phosphatase (PP1) has been reported to be overactivated in the failing heart, leading to a depression in cardiac function. We investigated whether in vivo PP1 inhibition by myocardial gene transfer of inhibitor-2 (INH-2), an endogenous PP1 inhibitor, alleviates heart failure (HF) progression in the cardiomyopathic (CM) hamster, a well-established HF model. Adenoviral INH-2 gene delivery improved % fractional shortening of the left ventricle (LV) accompanied by reduced chamber size at 1 wk. In vivo myocardial INH-2 gene delivery induced an increase in cytosolic PP1 catalytic subunit alpha (PP1C alpha) without inducing the corresponding increase in cytosolic PP1 activity. On the other hand, INH-2 delivery induced a decrease in microsomal PP1C alpha, resulting in a preferential decrease in microsomal PP1 activity, thereby increasing in phospholamban phosphorylation at Ser16. INH-2 gene transfer alleviated brain natriuretic peptide expression, presumably reflecting improved cardiac function. Moreover, adeno-associated virus-mediated INH-2 gene delivery significantly extended the survival time for 3 mo. These results indicate that increased PP1 activity is an exacerbating factor during progression of genetic cardiomyopathy and modulation of PP1 activity by INH-2 provides a potential new treatment for HF without activating protein kinase A signaling in cardiomyocytes.	Yamaguchi Univ, Sch Med, Dept Mol Cardiovasc Biol, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Grad Sch Med, Div Cardiol, Dept Med & Clin Sci, Ube, Yamaguchi 7558505, Japan; Univ Penn, Dept Med, Div Med Genet, Philadelphia, PA 19104 USA	Yamaguchi University; Yamaguchi University; University of Pennsylvania	Ikeda, Y (corresponding author), Yamaguchi Univ, Sch Med, Dept Mol Cardiovasc Biol, 1-1-1 Minamikogushi, Ube, Yamaguchi 7558505, Japan.	ysikeda@yamaguchi-u.ac.jp		Wang, Lili/0000-0001-9347-3939				Antos CL, 2001, CIRC RES, V89, P997, DOI 10.1161/hh2301.100003; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bartel S, 1996, MOL CELL BIOCHEM, V157, P171; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bisognano JD, 2000, J MOL CELL CARDIOL, V32, P817, DOI 10.1006/jmcc.2000.1123; BOHM M, 1994, CARDIOVASC RES, V28, P1713, DOI 10.1093/cvr/28.11.1713; Boknik P, 2000, N-S ARCH PHARMACOL, V362, P222, DOI 10.1007/s002100000283; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Cohen PTW, 2002, J CELL SCI, V115, P241; Cohn JN, 1997, CIRCULATION, V95, P766; CRUICKSHANK JM, 1993, CARDIOVASC DRUG THER, V7, P655, DOI 10.1007/BF00877818; Dodge-Kafka KL, 2005, NATURE, V437, P574, DOI 10.1038/nature03966; El-Armouche A, 2003, FASEB J, V17, P437, DOI 10.1096/fj.02-0057fje; Freeman K, 2001, J CLIN INVEST, V107, P967, DOI 10.1172/JCI12083; Gupta RC, 2003, AM J PHYSIOL-HEART C, V285, pH2373, DOI 10.1152/ajpheart.00442.2003; Hoshijima M, 2002, NAT MED, V8, P864, DOI 10.1038/nm739; Huang BY, 1999, CIRC RES, V85, P848, DOI 10.1161/01.RES.85.9.848; Ikeda Y, 2000, AM J PHYSIOL-HEART C, V278, pH1362, DOI 10.1152/ajpheart.2000.278.4.H1362; Ikeda Y, 2002, CIRCULATION, V105, P502, DOI 10.1161/hc0402.102953; Iwanaga Y, 2004, J CLIN INVEST, V113, P727, DOI 10.1172/JCI200418716; Karkkainen S, 2003, J MOL MED-JMM, V81, P795, DOI 10.1007/s00109-003-0480-5; Kirchhefer U, 2005, CARDIOVASC RES, V68, P98, DOI 10.1016/j.cardiores.2005.05.019; MACKINTOSH K, 1993, PROTEIN PHOSPHORYLAR, P167; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; NEUMANN J, 1993, AM J PHYSIOL, V265, pH257, DOI 10.1152/ajpheart.1993.265.1.H257; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; Okuda S, 2004, CIRCULATION, V109, P911, DOI 10.1161/01.CIR.0000115526.92541.D2; Pathak A, 2005, CIRC RES, V96, P756, DOI 10.1161/01.RES.0000161256.85833.fa; Reiken S, 2003, CIRCULATION, V107, P2459, DOI 10.1161/01.CIR.0000068316.53218.49; Reiken S, 2003, J CELL BIOL, V160, P919, DOI 10.1083/jcb.200211012; Sande JB, 2002, CARDIOVASC RES, V53, P382, DOI 10.1016/S0008-6363(01)00489-8; Sato Y, 2001, J BIOL CHEM, V276, P9392, DOI 10.1074/jbc.M006889200; SCHWINGER RHG, 1995, CIRCULATION, V92, P3220, DOI 10.1161/01.CIR.92.11.3220; Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224; Wehrens XHT, 2004, SCIENCE, V304, P292, DOI 10.1126/science.1094301; Wehrens XHT, 2004, NAT REV DRUG DISCOV, V3, P565, DOI 10.1038/nrd1440; Xiao BL, 2005, CIRC RES, V96, P847, DOI 10.1161/01.RES.0000163276.26083.e8; Yano M, 2000, CIRCULATION, V102, P2131, DOI 10.1161/01.CIR.102.17.2131; Yoshimura K, 2005, NAT MED, V11, P1330, DOI 10.1038/nm1335	41	60	62	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1197	+		10.1096/fj.05-5299fje	http://dx.doi.org/10.1096/fj.05-5299fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16627625				2022-12-28	WOS:000240210300024
J	Schwarz, J; Schwarz, SC; Dorigo, O; Stutzer, A; Wegner, F; Labarca, C; Deshpande, P; Gil, JS; Berk, AJ; Lester, HA				Schwarz, Johannes; Schwarz, Sigrid C.; Dorigo, Oliver; Stuetzer, Alexandra; Wegner, Florian; Labarca, Cesar; Deshpande, Purnima; Gil, Jose S.; Berk, Arnold J.; Lester, Henry A.			Enhanced expression of hypersensitive alpha 4*nAChR in adult mice increases the loss of midbrain dopaminergic neurons	FASEB JOURNAL			English	Article						nicotinic receptor; substantia nigra; cholinergic excitotoxicity; knock-in mouse; helper-dependent adenovirus; Parkinson's disease	CAPACITY ADENOVIRAL VECTORS; ALPHA-4 NICOTINIC RECEPTORS; VIRAL CODING SEQUENCES; RAT SUBSTANTIA-NIGRA; GENE-TRANSFER; PARKINSONS-DISEASE; INFLAMMATORY RESPONSE; EXTENDED EXPRESSION; BETA-GALACTOSIDASE; IMMUNE-RESPONSES	We describe an inducible genetic model for degeneration of midbrain dopaminergic neurons in adults. In previous studies, knock-in mice expressing hypersensitive M2 domain Leu9'Ser (L9'S) alpha 4 nicotinic receptors ( nAChR) at near-normal levels displayed dominant neonatal lethality and dopaminergic deficits in embryonic midbrain, because the hypersensitive nAChR is excitotoxic. However, heterozygous L9'S mice that retain the neomycin resistance cassette (neo) in a neighboring intron express low levels of the mutant allele (similar to 25% of normal levels), and these neo-intact mice are therefore viable and fertile. The neo cassette is flanked by loxP sites. In adult animals, we locally injected helper-dependent adenovirus (HDA) expressing cre recombinase. Local excision of the neo cassette, via cre-mediated recombination, was verified by genomic analysis. In L9'S HDA-cre injected animals, locomotion was reduced both under baseline conditions and after amphetamine application. There was no effect in L9'S HDA-control treated animals or in wild-type ( WT) littermates injected with either virus. Immunocytochemical analyses revealed marked losses (> 70%) of dopaminergic neurons in L9'S HDA-cre injected mice compared to controls. At 20-33 days postinjection in control animals, the coexpressed marker gene, yellow fluorescent protein (YFP), was expressed in many neurons and few glial cells near the injection, emphasizing the neurotropic utility of the HDA. Thus, HDA-mediated gene transfer into adult midbrain induced sufficient functional expression of cre in dopaminergic neurons to allow for postnatal deletion of neo. This produced increased L9'S mutant nAChR expression, which in turn led to nicotinic cholinergic excitotoxicity in dopaminergic neurons.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Leipzig, Dept Neurol, D-7010 Leipzig, Germany; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90024 USA	California Institute of Technology; Leipzig University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lester, HA (corresponding author), CALTECH, Div Biol, 156-26, Pasadena, CA 91125 USA.	lester@caltech.edu	BERK, ARNOLD/AAF-7052-2020		NIGMS NIH HHS [GM07185] Funding Source: Medline; NIMH NIH HHS [MH-49176] Funding Source: Medline; NINDS NIH HHS [NS-11756] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH049176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011756] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN JK, 1992, HUM GENE THER, V3, P487, DOI 10.1089/hum.1992.3.5-487; Arroyo-Jimenez MD, 1999, J NEUROSCI, V19, P6475; Breit S, 2001, EUR J NEUROSCI, V14, P1833, DOI 10.1046/j.0953-816x.2001.01800.x; Breyer Benjamin, 2001, Current Gene Therapy, V1, P149, DOI 10.2174/1566523013348689; Cartmell T, 1999, J NEUROSCI, V19, P1517; DOBSON AT, 1990, NEURON, V5, P353, DOI 10.1016/0896-6273(90)90171-B; Dorigo O, 2004, J VIROL, V78, P6556, DOI 10.1128/JVI.78.12.6556-6566.2004; Ehrengruber MU, 2002, MOL NEUROBIOL, V26, P183, DOI 10.1385/MN:26:2-3:183; Fonck C, 2003, J NEUROSCI, V23, P2582; FUNG YK, 1989, PHARMACOL BIOCHEM BE, V32, P221, DOI 10.1016/0091-3057(89)90237-2; FUTAMI T, 1995, NEUROSCI RES, V21, P331, DOI 10.1016/0168-0102(94)00869-H; Hsich G, 2002, HUM GENE THER, V13, P579, DOI 10.1089/10430340252837198; Ideguchi M, 2000, NEUROSCIENCE, V95, P217; Iribe Y, 1999, J NEUROPHYSIOL, V82, P925, DOI 10.1152/jn.1999.82.2.925; Kirik D, 2003, P NATL ACAD SCI USA, V100, P2884, DOI 10.1073/pnas.0536383100; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Klein RL, 2002, HUM GENE THER, V13, P605, DOI 10.1089/10430340252837206; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; Kochanek S, 2001, CURR OPIN MOL THER, V3, P454; KOVOOR A, 2005, IN PRESS J NEUROSCI; Labarca C, 2001, P NATL ACAD SCI USA, V98, P2786, DOI 10.1073/pnas.041582598; Lo Bianco C, 2002, P NATL ACAD SCI USA, V99, P10813, DOI 10.1073/pnas.152339799; Lowenstein PR, 2003, GENE THER, V10, P946, DOI 10.1038/sj.gt.3302048; Lowenstein PR, 2002, METHOD ENZYMOL, V346, P292; Luo SQ, 1998, J NEUROSCI, V18, P8571; Marazziti D, 2004, P NATL ACAD SCI USA, V101, P10189, DOI 10.1073/pnas.0403661101; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Millecamps S, 1999, NAT BIOTECHNOL, V17, P865, DOI 10.1038/12849; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Morsy MA, 1999, MOL MED TODAY, V5, P18, DOI 10.1016/S1357-4310(98)01376-8; Nabel GJ, 1999, P NATL ACAD SCI USA, V96, P324, DOI 10.1073/pnas.96.2.324; Navarro V, 1999, GENE THER, V6, P1884, DOI 10.1038/sj.gt.3301008; Nisell M, 1996, SYNAPSE, V22, P369, DOI 10.1002/(SICI)1098-2396(199604)22:4<369::AID-SYN8>3.0.CO;2-9; Orb S, 2004, PHYSIOL GENOMICS, V18, P299, DOI 10.1152/physiolgenomics.00012.2004; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; Peltekian E, 2002, MOL THER, V5, P25, DOI 10.1006/mthe.2001.0517; Pidoplichko VI, 1997, NATURE, V390, P401, DOI 10.1038/37120; Post Leonard E, 2002, Curr Opin Investig Drugs, V3, P1768; Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016; Sapolsky RM, 2003, NAT REV NEUROSCI, V4, P61, DOI 10.1038/nrn1006; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; Schiedner G, 2002, J VIROL, V76, P1600, DOI 10.1128/JVI.76.4.1600-1609.2002; Soudais C, 2003, FASEB J, V17, P391, DOI 10.1096/fj.03-0438fje; STORCH A, 1995, EUR J PHARM-MOLEC PH, V290, P207, DOI 10.1016/0922-4106(95)00080-1; Takada M, 2000, EUR J NEUROSCI, V12, P1771, DOI 10.1046/j.1460-9568.2000.00062.x; Takaki T, 1995, Nihon Shinkei Seishin Yakurigaku Zasshi, V15, P335; Tapper AR, 2004, SCIENCE, V306, P1029, DOI 10.1126/science.1099420; TRIARHOU LC, 1988, EXP BRAIN RES, V70, P256; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Warren Robert S, 2002, Surg Oncol Clin N Am, V11, P571, DOI 10.1016/S1055-3207(02)00043-1; Worgall S, 1997, HUM GENE THER, V8, P1675, DOI 10.1089/hum.1997.8.14-1675	52	11	11	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					935	946		10.1096/fj.05-5497com	http://dx.doi.org/10.1096/fj.05-5497com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675851				2022-12-28	WOS:000240157700016
J	Thakrar, RR; Patel, VP; Hamilton, G; Fuller, BJ; Seifalian, AM				Thakrar, Raj R.; Patel, Vishal P.; Hamilton, George; Fuller, Barry J.; Seifalian, Alexander M.			Vitreous cryopreservation maintains the viscoelastic property of human vascular grafts	FASEB JOURNAL			English	Article						vessel wall; vitrification; vascular grafting; allograft	FRESH	Assess the effects of cryopreservation ( cryo) and vitrification ( vitro) on the viscoelastic properties of blood vessels. Human external Iliac artery vessels were harvested from liver organ donors (n = 8). In each case the vessel was segmented into 3 equal parts, which were randomly placed in one of 3 categories: Fresh ( stored in 4 degrees C UW for 6 h), Cryo ( Placed in 10% Dulbecco's modified Eagle medium ( DMEM) and slowly frozen to -196 degrees C), or Vitro ( Placed in 40% DMEM and rapidly cooled to -196 degrees C). A pulsatile flow circuit was used to perfuse arterial segments at physiological pulse pressure and flow. Intraluminal pressure was measured using a Millar Mikro-tip catheter transducer, and vessel wall motion was determined with duplex ultrasonography coupled with a novel echo-locked vessel wall tracking system. Diametrical compliance ( DC), Petersons elastic modulus (Ep), and stiffness index (beta) were then calculated for each of the three groups over 3 mean pressure ranging from 40 to 80 mmHg. The change in the viscous component of arterial wall (lag phase angle, theta) was calculated from hysteresis plots. No significant changes were observed in the elastic properties of fresh and vitrified vessels (P > 0.05 for each of DC, Ep, and beta). Similarly, variation in the wall viscosity between fresh and vitrified vessels appeared to be nonsignificant (theta = 12.60 +/- 4.04 vs. 17.60 +/- 1.14, respectively). In contrast, statistical analysis of results obtained for cryopreserved vessels to the fresh vessels showed significant reduction in elastic parameter values. There was also a significant increase in the phase angle theta of the cryopreserved vessels (theta = 24.30 +/- 6.32; P < 0.001) compared with fresh vessel. Results suggest that vitrification maintains both elastic and viscous components of the mechanical properties of vascular grafts, which is positively correlated with their functional patency. In contrast, damage caused during cryopreservation significantly affects the overall tensile strength and elasticity of the vessel (i.e., Ep and beta), the dynamic properties (DC), and appears to significantly affect the viscous component of the vessel wall (theta), which is likely reduce the patency of the graft for transplantation purposes.	UCL, Biomat & Tissue Engn Ctr, Acad Div Surg & Intervent Sci, London SW3 2PF, England; Royal Free Hampstead NHS Trust, Vasc Biol Unit, London, England	University of London; University College London; University of London; University College London	Seifalian, AM (corresponding author), UCL, Biomat & Tissue Engn Ctr, Acad Div Surg & Intervent Sci, Rowland Hill St, London SW3 2PF, England.	a.seifalian@medsch.ucl.ac.uk	Seifalian, Alexander M/I-6028-2013; hamilton, george/K-4764-2013	Seifalian, Alexander M/0000-0002-1180-3322; seifalian, Alexander/0000-0002-8334-9376				Baguneid M, 2004, BIOTECHNOL APPL BIOC, V39, P151, DOI 10.1042/BA20030148; BOUTRON P, 1986, CRYOBIOLOGY, V23, P453, DOI 10.1016/0011-2240(86)90031-3; Bujan J, 2000, EUR J VASC ENDOVASC, V20, P13, DOI 10.1053/ejvs.2000.1090; CHENG K, 2002, EUR J VASC ENDOVASC, V24, P7; Cheng KS, 2003, J VASC SURG, V37, P403, DOI 10.1067/mva.2003.52; FAHY GM, 1984, CRYOBIOLOGY, V21, P407, DOI 10.1016/0011-2240(84)90079-8; Fuller B.J., 1991, CLIN APPL CRYOBIOLOG; Gamero LG, 2001, EXP PHYSIOL, V86, P519, DOI 10.1113/eph8602172; Giudiceandrea A, 2000, J ARTIF ORGANS, V3, P16; GLUCK T, 1898, BERL KLIN, V70, P1; Harris L, 2001, J VASC SURG, V33, P528, DOI 10.1067/mva.2001.111729; JAMIESON NV, 1988, TRANSPLANTATION, V46, P512, DOI 10.1097/00007890-198810000-00009; Jiang ZH, 2004, AM J PHYSIOL-HEART C, V286, pH240, DOI 10.1152/ajpheart.00760.2003; Kannan RY, 2005, J BIOMED MATER RES B, V74B, P570, DOI 10.1002/jbm.b.30247; Kannan RY, 2005, BIOMATERIALS, V26, P1857, DOI 10.1016/j.biomaterials.2004.07.006; Lakhani K, 2002, CIRCULATION, V106, P81, DOI 10.1161/01.CIR.0000020681.19400.8A; LIN TT, 1989, CRYOBIOLOGY, V26, P453, DOI 10.1016/0011-2240(89)90070-9; McVeigh GE, 2002, CLIN SCI, V102, P51, DOI 10.1042/CS20010191; Mingoli A, 1996, J SURG RES, V62, P95, DOI 10.1006/jsre.1996.0180; Nichols WW, 1990, MCDONALDS BLOOD FLOW; Pascual G, 2002, EUR J VASC ENDOVASC, V24, P23, DOI 10.1053/ejvs.2002.1663; Pegg D.E., 1987, BIOPHYSICS ORGAN CRY, P117; Pegg DE, 1997, CRYOBIOLOGY, V34, P183, DOI 10.1006/cryo.1996.1997; Pukacki F, 2000, EUR J VASC ENDOVASC, V20, P21, DOI 10.1053/ejvs.2000.1120; RALL WF, 1980, NATURE, V286, P511, DOI 10.1038/286511a0; Rashid ST, 2004, CELL PROLIFERAT, V37, P351, DOI 10.1111/j.1365-2184.2004.00318.x; Sales KM, 2005, TRENDS BIOTECHNOL, V23, P461, DOI 10.1016/j.tibtech.2005.06.006; Shadwick RE, 1999, J EXP BIOL, V202, P3305; SHWOODSMITH MJ, 1988, HUM REPROD, V3, P795; Song YC, 2000, J INVEST SURG, V13, P279; Song YC, 2000, NAT BIOTECHNOL, V18, P296, DOI 10.1038/73737; Spurr EE, 2002, CRYOBIOLOGY, V44, P210, DOI 10.1016/S0011-2240(02)00027-5; Tai NR, 2000, BRIT J SURG, V87, P1516, DOI 10.1046/j.1365-2168.2000.01566.x; Taylor MJ, 2004, LIFE IN THE FROZEN STATE, P603, DOI 10.1201/9780203647073.ch22; Tiwari A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0826com; Wusteman M, 2004, LIFE IN THE FROZEN STATE, P541, DOI 10.1201/9780203647073.ch19; Wusteman M. C., 2000, Cell and Tissue Banking, V1, P295, DOI 10.1023/A:1010167604609	37	32	36	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					874	881		10.1096/fj.05-5304com	http://dx.doi.org/10.1096/fj.05-5304com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675845				2022-12-28	WOS:000240157700010
J	Andriamampandry, C; Taleb, O; Kemmel, V; Humbert, JP; Aunis, D; Maitre, M				Andriamampandry, Christian; Taleb, Omar; Kemmel, Veronique; Humbert, Jean-Paul; Aunis, Dominique; Maitre, Michel			Cloning and functional characterization of a gamma-hydroxybutyrate receptor identified in the human brain	FASEB JOURNAL			English	Article						G-protein coupled receptors; electrophysiological characterization; functional expression; GHB	RAT-BRAIN; HIPPOCAMPAL-NEURONS; GABA(B) RECEPTORS; BINDING-SITES; ACID; DESENSITIZATION; CELLS; PIG	Two parent clones of a gamma-hydroxybutyrate (GHB) receptor, C12K32 and GHBh1, were isolated from a human frontal cortex cDNA library. The two clones differ by a deleted cytosine in C12K32. CHO cells transfected with either C12K32 or GHBh1 responded positively to submicromolar GHB stimulation. However, unlike C12K32, GHBh1 desensitizes rapidly on application of low concentrations of GHB. GHB receptor properties were then studied on C I 2K32 expressed in CHO cells. C12K32 bound GHB with a K-d of 114 nM and has no affinity for GABA or glutamate. GHB and NCS-382 displaced [H-3]GHB with an IC50 of 53 +/- 8 and 120 +/- 18 nM, respectively. In patch-clamp experiments, GHB induced a dose-dependent response with an EC50 of 130 nM. This response was antagonized by NCS-382, was not reproduced by GABA, and was sensitive to the addition of GTP-gamma-S in the recording pipette. CHO cells transfected with C12K32 exhibited GTP gamma-S-35 binding with an EC50 of 462 nM for GHB and an IC50 of 2.9 mu M for NCS-382. The present data led to the conclusion that both C12K32 and GHBh1 are two closely related isoforms of a human GHB receptor, GHBh1, that is described in the databank as the GPCR 172A.	Fac Med, INSERM, U575, F-67085 Strasbourg, France; INSERM, Inst Chim Biol, F-67085 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Maitre, M (corresponding author), Fac Med, INSERM, U575, 11 Rue Humann, F-67085 Strasbourg, France.	maitre@neurochem.u-strasbg.fr	Kemmel, Véronique/V-2590-2019; Taleb, Omar/K-1457-2016; Dominique, Aunis/W-1419-2019; Kemmel, Veronique/O-9018-2015; Maitre, Michel/J-9974-2016	Kemmel, Véronique/0000-0003-4680-4293; Taleb, Omar/0000-0003-2407-0380; Kemmel, Veronique/0000-0003-4680-4293; Maitre, Michel/0000-0003-1478-4806				Andriamampandry C, 2003, FASEB J, V17, P1691, DOI 10.1096/fj.02-0846fje; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BENAVIDES J, 1982, LIFE SCI, V30, P953, DOI 10.1016/0024-3205(82)90624-5; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Castelli MP, 2000, MOL BRAIN RES, V78, P91, DOI 10.1016/S0169-328X(00)00078-4; Castelli MP, 2004, CNS DRUG REV, V10, P243; DOHERTY JD, 1978, J PHARMACOL EXP THER, V207, P130; Ericsson TA, 2003, P NATL ACAD SCI USA, V100, P6759, DOI 10.1073/pnas.1138025100; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; GALLIMBERTI L, 1989, LANCET, V2, P787; Gould GG, 2003, BRAIN RES, V979, P51, DOI 10.1016/S0006-8993(03)02865-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kam PCA, 1998, ANAESTHESIA, V53, P1195, DOI 10.1046/j.1365-2044.1998.00603.x; Kaupmann K, 2003, EUR J NEUROSCI, V18, P2722, DOI 10.1111/j.1460-9568.2003.03013.x; LABORIT H, 1964, INT J NEUROPHARMACOL, V3, P433; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Letunic I, 2006, NUCLEIC ACIDS RES, V34, pD257, DOI 10.1093/nar/gkj079; Lingenhoehl K, 1999, NEUROPHARMACOLOGY, V38, P1667, DOI 10.1016/S0028-3908(99)00131-8; Lorente P, 2000, P NATL ACAD SCI USA, V97, P8664, DOI 10.1073/pnas.97.15.8664; MAITRE M, 1990, J PHARMACOL EXP THER, V255, P657; Maitre M, 1997, PROG NEUROBIOL, V51, P337, DOI 10.1016/S0301-0082(96)00064-0; MAMELAK M, 1986, SLEEP, V9, P285, DOI 10.1093/sleep/9.1.285; Muller C, 2002, J NEUROCHEM, V80, P899, DOI 10.1046/j.0022-3042.2002.00780.x; NELSON T, 1981, J NEUROCHEM, V37, P1345, DOI 10.1111/j.1471-4159.1981.tb04689.x; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schweitzer P, 2004, J PHARMACOL EXP THER, V311, P172, DOI 10.1124/jpet.104.069534; WILLIAMS SR, 1995, NEUROSCIENCE, V66, P133, DOI 10.1016/0306-4522(94)00604-4; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; XIE XM, 1992, EUR J PHARMACOL, V212, P291, DOI 10.1016/0014-2999(92)90347-7	30	59	61	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					885	895		10.1096/fj.06-6509com	http://dx.doi.org/10.1096/fj.06-6509com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197387				2022-12-28	WOS:000244686400025
J	Goossens, S; Janssens, B; Vanpoucke, G; De Rycke, R; van Hengel, J; van Roy, F				Goossens, Steven; Janssens, Barbara; Vanpoucke, Griet; De Rycke, Riet; van Hengel, Jolanda; van Roy, Frans			Truncated isoform of mouse alpha T-catenin is testis-restricted in expression and function	FASEB JOURNAL			English	Article						afadin; testis; spermatogenesis	CELL-CELL ADHESION; CADHERIN-ASSOCIATED PROTEIN; COLON-CANCER CELLS; BETA-CATENIN; INTERCELLULAR-ADHESION; ADHERENS JUNCTIONS; BINDING; COMPLEX; NECTIN; AFADIN	alpha T-Catenin is a recently identified member of the alpha-catenin family of cell-cell adhesion molecules. For decades it was thought that ot-catenins mediate solid cell-cell adhesion by linking the cadherin-mediated cell-cell adhesion complex with the actin cytoskeleton. However, the roles of (alpha-catenins in this classical adhesion model have been questioned recently. (alpha T-Catenin has a restricted expression pattern, in contrast to the ubiquitously expressed (alpha E-catenin. High levels of off-catenin were detected in heart and testis. Northern and Western blot experiments indicated that besides the standard full-length alpha T-catenin transcript, smaller alternative transcripts are expressed in testis. We report the cloning of two alternative transcripts of the mouse alpha T-catenin gene (transcript-B and -X), both of which are expressed in a testisrestricted manner from two putative alternative promoters. Alternative transcript-X encodes a smaller protein, isoform-X, which lacks the amino-terminal beta-catenin binding domain of the standard mouse alpha T-catenin protein, and is therefore unable to restore cell-cell adhesion in an alpha-catenin-negative colon carcinoma cell line. Immunohistochemical analysis showed specific localization of the alpha T-catenin isoform-X in the differentiating germ cells. In contrast to the standard full-length alpha T-catenin protein, this shortened isoform-X can bind to I-afadin, an important component of the nectin/afadin/ponsin adhesion complex that reportedly is essential for spermatogenesis.	Univ Ghent VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium; Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	van Roy, F (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Technol Pk 927, B-9052 Ghent, Belgium.	f.vanroy@dmbr.ugent.be	van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039; Goossens, Steven/0000-0002-5693-8570				Asada M, 2003, J BIOL CHEM, V278, P4103, DOI 10.1074/jbc.M209832200; Busby V, 2004, NEUROMOL MED, V5, P133, DOI 10.1385/NMM:5:2:133; CLAVERIE JM, 1993, GENOMICS, V15, P13, DOI 10.1006/geno.1993.1004; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goossens S, 2005, FRONT BIOSCI-LANDMRK, V10, P398, DOI 10.2741/1537; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; Janssens B, 2003, HUM GENET, V112, P227, DOI 10.1007/s00439-002-0857-5; Janssens B, 2001, J CELL SCI, V114, P3177; Kierszenbaum AL, 2004, ARCH HISTOL CYTOL, V67, P271, DOI 10.1679/aohc.67.271; Kobielak A, 2004, NAT REV MOL CELL BIO, V5, P614, DOI 10.1038/nrm1433; Kobielak A, 2006, P NATL ACAD SCI USA, V103, P2322, DOI 10.1073/pnas.0510422103; Kobielak A, 2004, NAT CELL BIOL, V6, P21, DOI 10.1038/ncb1075; Kotaja N, 2004, NAT METHODS, V1, P249, DOI 10.1038/nmeth1204-249; Mueller S, 2003, BIOL REPROD, V69, P1330, DOI 10.1095/biolreprod.102.014670; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; Pokutta S, 2002, J BIOL CHEM, V277, P18868, DOI 10.1074/jbc.M201463200; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vermeulen SJ, 1999, ONCOGENE, V18, P905, DOI 10.1038/sj.onc.1202348; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Zhang JY, 2005, ENDOCRINOLOGY, V146, P1268, DOI 10.1210/en.2004-1194	27	20	20	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					647	655		10.1096/fj.06-6066com	http://dx.doi.org/10.1096/fj.06-6066com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17185752				2022-12-28	WOS:000244686400004
J	Kwon, O; Eck, P; Chen, SL; Corpe, CP; Lee, JH; Kruhlak, M; Levine, M				Kwon, Oran; Eck, Peter; Chen, Shenglin; Corpe, Christopher P.; Lee, Je-Hyuk; Kruhlak, Michael; Levine, Mark			Inhibition of the intestinal glucose transporter GLUT2 by flavonoids	FASEB JOURNAL			English	Article						intestinal sugar transporter; polyphenols; intraluminal flavonoids; Xenopus laevis	BRUSH-BORDER-MEMBRANE; DIFFUSIVE COMPONENT; DIETARY FLAVONOIDS; FRUCTOSE TRANSPORT; ABSORPTION; QUERCETIN; RAT; POLYPHENOLS; CACO-2; COTRANSPORTER	We tested whether the dominant intestinal sugar transporter GLUT2 was inhibited by intestinal luminal compounds that are inefficiently absorbed and naturally present in foods. Because of their abundance in fruits and vegetables, flavonoids were selected as model compounds. Robust inhibition of glucose and fructose transport by GLUT2 expressed in Xenopus laevis oocytes was produced by the flavonols myricetin, fisetin, the widely consumed flavonoid quercetin, and its glucoside precursor isoquercetrin. IC(50)s for quercetin, myricetin, and isoquercetirin were similar to 200- to 1000-fold less than glucose or fructose concentrations, and noncompetitive inhibition was observed. The two other major intestinal sugar transporters, GLUT5 and SGLT1, were unaffected by flavonoids. Sugar transport by GLUT2 overexpressed in pituitary cells and naturally present in Caco-2E intestinal cells was similarly inhibited by quercetin. GLUT2 was detected on the apical side of Caco-2E cells, indicating that GLUT2 was in the correct orientation to be inhibited by luminal compounds. Quercetin itself was not transported by the three major intestinal glucose transporters. Because the flavonoid quercetin, a food component with an excellent pharmacology safety profile, might act as a potent luminal inhibitor of sugar absorption independent of its own transport, flavonols show promise as new pharmacologic agents in the obesity epidemic.	NIDDKD, NIH, Mol & Clin Nutr Sect, Digest Dis Branch,Intramural Res Program, Bethesda, MD 20892 USA; NCI, Expt Immunol Branch, Intramural Res Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Levine, M (corresponding author), NIDDKD, NIH, Mol & Clin Nutr Sect, Digest Dis Branch,Intramural Res Program, Bethesda, MD 20892 USA.	markl@mail.nih.gov	Chen, Shenglin/B-4049-2010	Eck, Peter/0000-0003-2371-9774; corpe, christopher/0000-0003-1994-8312; Levine, Michael/0000-0003-0036-7809	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK053214, Z01DK053214] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ANSHIMA H, 2005, J AGR FOOD CHEM, V53, P1955; Beecher GR, 2003, J NUTR, V133, p3248S; Bissonnette P, 1996, AM J PHYSIOL-GASTR L, V270, pG833, DOI 10.1152/ajpgi.1996.270.5.G833; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; Cermak R, 2004, BRIT J NUTR, V91, P849, DOI 10.1079/BJN20041128; CHANTRET I, 1994, J CELL SCI, V107, P213; CHANTRET I, 1988, CANCER RES, V48, P1936; Corpe CP, 1996, PFLUG ARCH EUR J PHY, V432, P192, DOI 10.1007/s004240050124; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; Dandona P, 2005, CIRCULATION, V111, P1448, DOI 10.1161/01.CIR.0000158483.13093.9D; DEBNAM ES, 1975, J PHYSIOL-LONDON, V246, P181, DOI 10.1113/jphysiol.1975.sp010885; DELEZAY O, 1995, J CELL PHYSIOL, V163, P120, DOI 10.1002/jcp.1041630114; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Grundy SM, 2005, AM J CARDIOL, V96, p47D, DOI 10.1016/j.amjcard.2005.03.020; Helliwell PA, 2000, BIOCHEM J, V350, P149, DOI 10.1042/0264-6021:3500149; Helliwell PA, 2002, J PHYSIOL-LONDON, V544, P579, DOI 10.1113/jphysiol.2002.028209; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; Hossain SJ, 2002, J AGR FOOD CHEM, V50, P5215, DOI 10.1021/jf020252e; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; Johnston K, 2005, FEBS LETT, V579, P1653, DOI 10.1016/j.febslet.2004.12.099; Kellett GL, 2000, BIOCHEM J, V350, P155, DOI 10.1042/0264-6021:3500155; Kellett GL, 2005, DIABETES, V54, P3056, DOI 10.2337/diabetes.54.10.3056; Kobayashi Y, 2000, J AGR FOOD CHEM, V48, P5618, DOI 10.1021/jf0006832; Kroon PA, 2004, AM J CLIN NUTR, V80, P15; MAHRAOUI L, 1992, AM J PHYSIOL, V263, pG312, DOI 10.1152/ajpgi.1992.263.3.G312; McGovern SL, 2003, J MED CHEM, V46, P1478, DOI 10.1021/jm020427b; Murota K, 2003, ARCH BIOCHEM BIOPHYS, V417, P12, DOI 10.1016/S0003-9861(03)00284-4; Okamoto T, 2005, INT J MOL MED, V16, P275; OLEFSKY JM, 1978, BIOCHEM J, V172, P137, DOI 10.1042/bj1720137; Park JB, 2000, J NUTR, V130, P1297, DOI 10.1093/jn/130.5.1297; Plat J, 2005, AM J CARDIOL, V96, p15D, DOI 10.1016/j.amjcard.2005.03.015; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Scalbert A, 2005, AM J CLIN NUTR, V81, p215S, DOI 10.1093/ajcn/81.1.215S; Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S; Scheepers A, 2004, JPEN-PARENTER ENTER, V28, P364, DOI 10.1177/0148607104028005364; Song J, 2002, J BIOL CHEM, V277, P15252, DOI 10.1074/jbc.M110496200; Strobel P, 2005, BIOCHEM J, V386, P471, DOI 10.1042/BJ20040703; THORENS B, 1990, AM J PHYSIOL, V259, P279; Uldry M, 2004, PFLUG ARCH EUR J PHY, V447, P480, DOI 10.1007/s00424-003-1085-0; van de Laar FA, 2005, DIABETES CARE, V28, P154, DOI 10.2337/diacare.28.1.154; Vera JC, 2001, BIOCHEMISTRY-US, V40, P777, DOI 10.1021/bi001660j; Walgren RA, 2000, J PHARMACOL EXP THER, V294, P837; Walle T, 2004, FREE RADICAL BIO MED, V36, P829, DOI 10.1016/j.freeradbiomed.2004.01.002; Walle T, 2003, DRUG METAB DISPOS, V31, P1288, DOI 10.1124/dmd.31.11.1288; Williams RJ, 2004, FREE RADICAL BIO MED, V36, P838, DOI 10.1016/j.freeradbiomed.2004.01.001; Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.230S, 10.1093/ajcn/81.1.243S]; Wolffram S, 2002, J NUTR, V132, P630, DOI 10.1093/jn/132.4.630; Wright EM, 2003, BEST PRACT RES CL GA, V17, P943, DOI 10.1016/S1521-6918(03)00107-0; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586	51	292	306	4	74	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					366	377		10.1096/fj.06-6620com	http://dx.doi.org/10.1096/fj.06-6620com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17172639				2022-12-28	WOS:000244686300010
J	Llorens, JV; Navarro, JA; Martinez-Sebastian, MJ; Baylies, MR; Schneuwly, S; Botella, JA; Molto, MD				Llorens, Jose V.; Navarro, Juan A.; Martinez-Sebastian, Maria J.; Baylies, Mary R.; Schneuwly, S.; Botella, Jose A.; Molto, Maria D.			Causative role of oxidative stress in a Drosophila model of Friedreich ataxia	FASEB JOURNAL			English	Article						frataxin; aconitase; mitochondrial respiration; hyperoxia; RNAi	CITRIC-ACID CYCLE; YEAST FRATAXIN; MITOCHONDRIAL ACONITASE; ELECTRON-TRANSPORT; IRON HOMEOSTASIS; GENE-EXPRESSION; IN-VITRO; PROTEIN; MELANOGASTER; HOMOLOG	Friedreich ataxia (FA), the most common form of hereditary ataxia, is caused by a deficit in the mitochondrial protein frataxin. While several hypotheses have been suggested, frataxin function is not well understood. Oxidative stress has been suggested to play a role in the pathophysiology of FA, but this view has been recently questioned, and its link to frataxin is unclear. Here, we report the use of RNA interference (RNAi) to suppress the Drosophila frataxin gene (fh) expression. This model system parallels the situation in FA patients, namely a moderate systemic reduction of frataxin levels compatible with normal embryonic development. Under these conditions, fh-RNAi flies showed a shortened life span, reduced climbing abilities, and enhanced sensitivity to oxidative stress. Under hyperoxia, fh-RNAi flies also showed a dramatic reduction of aconitase activity that seriously impairs the mitochondrial respiration while the activities of succinate dehydrogenase, respiratory complex I and II, and indirectly complex III and IV are normal. Remarkably, frataxin overexpression also induced the oxidative-mediated inactivation of mitochondrial aconitase. This work demonstrates, for the first time, the essential function of frataxin in protecting aconitase from oxidative stress-dependent inactivation in a multicellular organism. Moreover our data support an important role of oxidative stress in the progression of FA and suggest a tissue-dependent sensitivity to frataxin imbalance. We propose that in FA, the oxidative mediated inactivation of aconitase, which occurs normally during the aging process, is enhanced due to the lack of frataxin.	Univ Valencia, Dept Genet, Fac Ciencias Biol, E-46100 Valencia, Spain; Univ Regensburg, Inst Zool, D-8400 Regensburg, Germany; Mem Sloan Kettering Canc Ctr, Dev Biol Program, New York, NY 10021 USA	University of Valencia; University of Regensburg; Memorial Sloan Kettering Cancer Center	Molto, MD (corresponding author), Univ Valencia, Dept Genet, Fac Ciencias Biol, Carrer Doctor Moliner 50, E-46100 Valencia, Spain.	dmolto@uv.es	Langa, Juan Antonio Navarro/AAA-8013-2020	Langa, Juan Antonio Navarro/0000-0003-2266-728X; Schneuwly, Stephan/0000-0001-7711-8902; Llorens, Jose V./0000-0001-9823-6246; Martinez-Sebastian, Maria-Jose/0000-0001-5549-7921; Molto, Maria Dolores/0000-0001-5219-2022				Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Anderson PR, 2005, HUM MOL GENET, V14, P3397, DOI 10.1093/hmg/ddi367; Botella JA, 2004, CURR BIOL, V14, P782, DOI 10.1016/j.cub.2004.04.036; Bradley JL, 2004, NEUROCHEM RES, V29, P561, DOI 10.1023/B:NERE.0000014826.00881.c3; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brazzolotto X, 1999, J BIOL CHEM, V274, P21625, DOI 10.1074/jbc.274.31.21625; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Canizares J, 2000, GENE, V256, P35, DOI 10.1016/S0378-1119(00)00343-7; Chantrel-Groussard K, 2001, HUM MOL GENET, V10, P2061, DOI 10.1093/hmg/10.19.2061; Chen OS, 2002, P NATL ACAD SCI USA, V99, P16922, DOI 10.1073/pnas.232392299; Coppola G, 2006, NEUROBIOL DIS, V22, P302, DOI 10.1016/j.nbd.2005.11.014; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Cripps RM, 2002, DEV BIOL, V246, P14, DOI 10.1006/dbio.2002.0666; Das N, 2001, BIOCHEM J, V360, P209, DOI 10.1042/0264-6021:3600209; Delatycki MB, 2000, J MED GENET, V37, P1, DOI 10.1136/jmg.37.1.1; Delaval E, 2004, EUR J BIOCHEM, V271, P4559, DOI 10.1111/j.1432-1033.2004.04422.x; Drysdale RA, 2005, NUCLEIC ACIDS RES, V33, pD390, DOI 10.1093/nar/gki046; Emond M, 2000, NEUROLOGY, V55, P1752, DOI 10.1212/WNL.55.11.1752; Ferguson M, 2005, BIOCHEM J, V390, P501, DOI 10.1042/BJ20042130; Gakh O, 2006, HUM MOL GENET, V15, P467, DOI 10.1093/hmg/ddi461; Gakh O, 2002, BIOCHEMISTRY-US, V41, P6798, DOI 10.1021/bi025566+; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gibson TJ, 1996, TRENDS NEUROSCI, V19, P465, DOI 10.1016/S0166-2236(96)20054-2; Gonzalez-Cabo P, 2005, HUM MOL GENET, V14, P2091, DOI 10.1093/hmg/ddi214; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; HARDING AE, 1993, ADV NEUROL, V61, P1; HARDING AE, 1983, Q J MED, V52, P489; IAZUSTA V, 2006, J BIOL CHEM, V281, P12227; Janero DR, 1996, AM J PHYSIOL-CELL PH, V270, pC1735, DOI 10.1152/ajpcell.1996.270.6.C1735; Kaplan J, 1999, P NATL ACAD SCI USA, V96, P10948, DOI 10.1073/pnas.96.20.10948; Kimbrell DA, 2002, GENESIS, V34, P23, DOI 10.1002/gene.10134; Kirby K, 2002, P NATL ACAD SCI USA, V99, P16162, DOI 10.1073/pnas.252342899; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492; Mockett RJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P260, DOI 10.1006/abbi.1999.1460; Mockett RJ, 2001, EXP GERONTOL, V36, P441, DOI 10.1016/S0531-5565(00)00258-8; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; MUNUJOS P, 1993, ANAL BIOCHEM, V212, P506, DOI 10.1006/abio.1993.1360; Nie GJ, 2005, BLOOD, V105, P2161, DOI 10.1182/blood-2004-07-2722; Park S, 2003, J BIOL CHEM, V278, P31340, DOI 10.1074/jbc.M303158200; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; Pianese L, 2004, J NEUROL NEUROSUR PS, V75, P1061, DOI 10.1136/jnnp.2003.028605; Pianese L, 2002, HUM MOL GENET, V11, P2989, DOI 10.1093/hmg/11.23.2989; Piccin A, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.12.e55; Piemonte F, 2001, EUR J CLIN INVEST, V31, P1007, DOI 10.1046/j.1365-2362.2001.00922.x; PRABHU HR, 1993, INDIAN J BIOCHEM BIO, V30, P289; Puccio H, 2002, CURR OPIN GENET DEV, V12, P272, DOI 10.1016/S0959-437X(02)00298-8; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Ristow M, 2000, P NATL ACAD SCI USA, V97, P12239, DOI 10.1073/pnas.220403797; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Schulz JB, 2000, NEUROLOGY, V55, P1719, DOI 10.1212/WNL.55.11.1719; Seznec H, 2005, HUM MOL GENET, V14, P463, DOI 10.1093/hmg/ddi042; Shoichet SA, 2002, HUM MOL GENET, V11, P815, DOI 10.1093/hmg/11.7.815; Tan GL, 2003, HUM MOL GENET, V12, P1699, DOI 10.1093/hmg/ddg187; Vazquez-Manrique RP, 2005, FASEB J, V19, P172, DOI 10.1096/fj.05-4212fje; Vorgerd M, 2000, NEUROMUSCULAR DISORD, V10, P430, DOI 10.1016/S0960-8966(00)00108-5; Williamson D. H., 1974, METHODS ENZYMATIC AN, P2266, DOI [10.1016/B978-0-12-091304-6.50093-8, DOI 10.1016/B978-0-12-091304-6.50093-8]; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; Yarian CS, 2006, MECH AGEING DEV, V127, P79, DOI 10.1016/j.mad.2005.09.028; Yarian CS, 2005, J BIOENERG BIOMEMBR, V37, P91, DOI 10.1007/s10863-005-4132-z; Yoon T, 2004, J BIOL CHEM, V279, P25943, DOI 10.1074/jbc.C400107200; Zahavi M., 1965, Journal of Insect Physiology, V11, P811, DOI 10.1016/0022-1910(65)90160-5	68	99	99	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					333	344		10.1096/fj.05-5709com	http://dx.doi.org/10.1096/fj.05-5709com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17167074				2022-12-28	WOS:000244686300007
J	Berndt, S; d'Hauterive, SP; Blacher, S; Pequeux, C; Lorquet, S; Munaut, C; Applanat, M; Herve, MA; Lamande, N; Corvol, P; van den Brule, F; Frankenne, F; Poutanen, M; Huhtaniemi, I; Geenen, V; Noel, A; Foidart, JM				Berndt, Sarah; d'Hauterive, Sophie Perrier; Blacher, Silvia; Pequeux, Christel; Lorquet, Sophie; Munaut, Carine; Applanat, Martine; Herve, Marie Astrid; Lamande, Noel; Corvol, Pierre; van den Brule, Frederic; Frankenne, Francis; Poutanen, Matti; Huhtaniemi, Ilpo; Geenen, Vincent; Noel, Agnes; Foidart, Jean-Michel			Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium	FASEB JOURNAL			English	Article						angiogenesis; hCG	HUMAN CORPUS-LUTEUM; OVARIAN HYPERSTIMULATION SYNDROME; SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE-C; EARLY-PREGNANCY; GROWTH-FACTOR; GRANULOSA-CELLS; MESSENGER-RNA; IN-VITRO; EXPRESSION	Successful embryo development requires an extensive endometrial angiogenesis in proximity of implantation site. The glycoprotein hCG is produced even before implantation by trophoblast in normal pregnancy. In this manuscript, we demonstrate an angiogenic effect of hCG in several in vivo (chick chorioallantoic membrane, matrigel plug assay, aortic ring assay) and in vitro experimental models. In contrast, human placental lactogen (hPL) did not display angiogenic properties. LH/hCG receptor was detected in endothelial cells by reverse-transcriptase polymerase chain reaction (RT-PCR) and by Western blotting. In mice aortic ring assay, angiostimulation by hCG was abrogated by deletion of LH/hCG receptor (LuRKO mice). Use of recombinant hCG and anti-hCG antibody (Ab) further confirmed the specificity of this angiogenic activity. By using dibutyryl cAMP, adenylate cyclase, or protein kinase A inhibitors, we demonstrate that hCG-mediated angiogenesis involves adenylyl-cyclase-protein kinase A activation. Addition of hCG to endometrial epithelial epithelial cells, but not to cultured endothelial cells, stimulated vascular endothelial growth factor (VEGF). VEGF and hCG also displayed additive activities. Altogether, these data demonstrate that peritrophoblastic angiostimulation may result from a paracrine dialogue between trophoblast, epithelial, and endothelial cells through hCG and VEGF.	Univ Liege, Lab Tumor Biol & Dev, Inst Pathol, CRCE, B-4000 Liege, Belgium; Univ Liege, Ctr Immunol, Liege, Belgium; CHR Citadelle, Dept Gynecol & Obstet, Liege, Belgium; INSERM, U135, Paris, France; Coll France, INSERM, U36, F-75231 Paris, France; Imperial Coll London, Fac Med, Inst Reprod & Dev Biol, London, England; Univ Turku, Dept Physiol, Turku, Finland	University of Liege; University of Liege; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Imperial College London; University of Turku	Foidart, JM (corresponding author), Univ Liege, Lab Tumor Biol & Dev, Inst Pathol, CRCE, CHU-B23, B-4000 Liege, Belgium.	jmfoidart@ulg.ac.be	Munaut, Carine/K-8138-2019; Poutanen, Matti/I-1700-2018	Poutanen, Matti/0000-0002-8953-1734; Pequeux, Christel/0000-0001-8275-1489; Noel, Agnes/0000-0002-7670-6179; Geenen, Vincent/0000-0002-8733-7284				Artini PG, 2002, EUR J OBSTET GYN R B, V101, P169, DOI 10.1016/S0301-2115(01)00568-1; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; Bausero P, 1998, Angiogenesis, V2, P167, DOI 10.1023/A:1009292506879; Blacher S., 2005, IMAGE ANAL STEREOL, V24, P169, DOI [10.5566/ias.v24.p169-180, DOI 10.5566/IAS.V24.P169-180]; Blacher Silvia, 2001, Angiogenesis, V4, P133, DOI 10.1023/A:1012251229631; Butler SA, 2003, CLIN CANCER RES, V9, P4666; Cameo Paula, 2004, Reprod Biol Endocrinol, V2, P50, DOI 10.1186/1477-7827-2-50; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; DAVIS CM, 1993, J CELL BIOCHEM, V51, P206, DOI 10.1002/jcb.240510213; Drabkin DL, 1932, J BIOL CHEM, V98, P719; Duncan WC, 2000, REV REPROD, V5, P12, DOI 10.1530/revreprod/5.1.12; Fazleabas AT, 1999, SEMIN REPROD ENDOCR, V17, P257, DOI 10.1055/s-2007-1016233; Filicori M, 2005, FERTIL STERIL, V84, P275, DOI 10.1016/j.fertnstert.2005.02.033; Gallo RC, 1998, NAT BIOTECHNOL, V16, P218, DOI 10.1038/nbt0398-218a; Hermsteiner M, 1999, PFLUG ARCH EUR J PHY, V439, P186, DOI 10.1007/s004240051143; Herve MA, 2005, EXP CELL RES, V309, P24, DOI 10.1016/j.yexcr.2005.05.022; Ilan N, 1998, J CELL SCI, V111, P3621; Islami D, 2003, MOL HUM REPROD, V9, P395, DOI 10.1093/molehr/gag053; Islami D, 2001, SEMIN REPROD MED, V19, P49, DOI 10.1055/s-2001-13910; Jones CJP, 2001, HUM REPROD, V16, P2680, DOI 10.1093/humrep/16.12.2680; Kelly RW, 2001, REPRODUCTION, V121, P3, DOI 10.1530/rep.0.1210003; Kruger EA, 1999, INVAS METAST, V18, P209, DOI 10.1159/000024514; Kunzi-Rapp K, 2001, J UROLOGY, V166, P1502, DOI 10.1016/S0022-5347(05)65820-X; LAIRD SM, 1993, HUM REPROD, V8, P793, DOI 10.1093/oxfordjournals.humrep.a138144; Leemhuis J, 2002, J PHARMACOL EXP THER, V300, P1000, DOI 10.1124/jpet.300.3.1000; LEI ZM, 1992, J CLIN ENDOCR METAB, V75, P651, DOI 10.1210/jc.75.2.651; Licht P, 2003, FERTIL STERIL, V79, P718, DOI 10.1016/S0015-0282(02)04822-7; Licht P, 2001, SEMIN REPROD MED, V19, P37, DOI 10.1055/s-2001-13909; Lovely LP, 2005, J CLIN ENDOCR METAB, V90, P2351, DOI 10.1210/jc.2004-2130; Masson Veronique, 2002, Biological Procedures Online, V4, P24, DOI 10.1251/bpo30; Neulen J, 1998, MOL HUM REPROD, V4, P203, DOI 10.1093/molehr/4.3.203; Noyes R W, 1975, Am J Obstet Gynecol, V122, P262; Ohba T, 2003, MOL CELL ENDOCRINOL, V202, P47, DOI 10.1016/S0303-7207(03)00061-3; Pabon JE, 1996, J CLIN ENDOCR METAB, V81, P2738, DOI 10.1210/jc.81.7.2738; PASSANITI A, 1992, LAB INVEST, V67, P519; Pellicer A, 1999, FERTIL STERIL, V71, P482, DOI 10.1016/S0015-0282(98)00484-1; Perrier d'Hauterive S, 2004, HUM REPROD, V19, P2633, DOI 10.1093/humrep/deh450; RAO CV, 2004, J BIOL CHEM; Rao SC, 2003, NEUROSCI LETT, V336, P135, DOI 10.1016/s0304-3940(02)01157-6; REYNOLDS LP, 1992, FASEB J, V6, P886, DOI 10.1096/fasebj.6.3.1371260; Robert C, 2003, REPRODUCTION, V125, P437, DOI 10.1530/rep.0.1250437; Srisuparp S, 2003, BIOL REPROD, V68, P457, DOI 10.1095/biolreprod.102.007625; Srisuparp S, 2001, ARCH MED RES, V32, P627, DOI 10.1016/S0188-4409(01)00330-7; Strakova Z, 2005, ENDOCRINOLOGY, V146, P4097, DOI 10.1210/en.2005-0380; Sugino N, 2000, J CLIN ENDOCR METAB, V85, P4379, DOI 10.1210/jc.85.11.4379; Tao YX, 1997, LIFE SCI, V60, P1297, DOI 10.1016/S0024-3205(97)00073-8; Thompson DA, 1998, LIFE SCI, V63, P1057, DOI 10.1016/S0024-3205(98)00367-1; TOTH P, 1994, J CLIN ENDOCR METAB, V79, P307, DOI 10.1210/jc.79.1.307; Wulff C, 2001, HUM REPROD, V16, P2515, DOI 10.1093/humrep/16.12.2515; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Zhang FP, 2001, MOL ENDOCRINOL, V15, P172, DOI 10.1210/me.15.1.172; Zygmunt M, 2002, J CLIN ENDOCR METAB, V87, P5290, DOI 10.1210/jc.2002-020642	52	115	121	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2630	+		10.1096/fj.06-5885fje	http://dx.doi.org/10.1096/fj.06-5885fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065221				2022-12-28	WOS:000242490700047
J	Fernando, MR; Lechner, JM; Lofgren, S; Gladyshev, VN; Lou, MF				Fernando, M. Rohan; Lechner, Joel M.; Lofgren, Stefan; Gladyshev, Vadim N.; Lou, Marjorie F.			Mitochondrial thioltransferase (glutaredoxin 2) has GSH-dependent and thioredoxin reductase-dependent peroxidase activities in vitro and in lens epithelial cells	FASEB JOURNAL			English	Article						peroxiredoxins; oxidative stress; antioxidant enzymes; peroxide removal	APOPTOSIS; OXIDATION; DAMAGE; YEAST	Thioltransferase (or Grx) belongs to the oxidoreductase family and is known to regulate redox homeostasis in cells. Mitochondrial Grx2 is a recent discovery, but its function is largely unknown. In this study we investigate Grx2 function by examining its potential peroxidase activity using lens epithelial cells (LEC). cDNA for human and mouse Grx2 was cloned into pET21d(+) vector and used to produce respective recombinant Grx2 for kinetic studies. cDNA for human Grx2 was transfected into human LEC and used for in vivo studies. Both human and mouse Grx2 showed glutathione (GSH)-dependent and thioredoxin reductase (TR)-dependent peroxidase activity. The catalytic efficiency of human and mouse Grx2 was lower than that of glutathione peroxidases (2.5 and 0.8 x 104 s(-1)M(-1), respectively), but comparable with TR-dependent peroxiredoxins (16.5 and 2.7 x 10(4) s(-1)M(-1), respectively). TR-dependent peroxidase activity increased 2-fold in the transfected cells and was completely abolished by addition of anti-Grx2 antibody (Ab). Flow cytometry (FACS) analysis and confocal microscopy revealed that cells preloaded with pure Grx2 detoxified peroxides more efficiently. Grx2 over-expression protected cells against H2O2-mediated disruption of mitochondrial transmembrane potential. These results suggest that Grx2 has a novel function as a peroxidase, accepting electrons both from GSH and TR. This unique property may play a role in protecting the mitochondria from oxidative damage.	Univ Nebraska, Dept Vet & Biomed Sci, Lincoln, NE 68583 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68583 USA; Univ Nebraska, Ctr Redox Biol, Lincoln, NE 68583 USA; Univ Nebraska Med Ctr, Dept Ophthalmol, Omaha, NE USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Medical Center	Lou, MF (corresponding author), Univ Nebraska, Dept Vet & Biomed Sci, Lincoln, NE 68583 USA.	mlou1@unl.edu	Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013	Lofgren, Stefan/0000-0002-9869-085X; Gladyshev, Vadim/0000-0002-0372-7016	NEI NIH HHS [R01 EY-10590] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BASS DA, 1983, J IMMUNOL, V130, P1910; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V2, P579, DOI DOI 10.1016/B978-0-12-091302-2.50011-6; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Chen KCW, 2004, EXP EYE RES, V78, P1057, DOI 10.1016/j.exer.2004.02.004; Collinson EJ, 2002, J BIOL CHEM, V277, P16712, DOI 10.1074/jbc.M111686200; Enoksson M, 2005, BIOCHEM BIOPH RES CO, V327, P774, DOI 10.1016/j.bbrc.2004.12.067; FORMAN HJ, 1982, FREE RADICALS BIOL, V5; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Johansson CC, 2003, J BIOL CHEM, V278, P17573, DOI 10.1074/jbc.M300311200; Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lai J C, 1979, Methods Enzymol, V55, P51; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Lillig CH, 2004, P NATL ACAD SCI USA, V101, P13227, DOI 10.1073/pnas.0401896101; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MACKLER B, 1962, J BIOL CHEM, V237, P2968; MATSUDA NH, 2004, J BIOL CHEM, V280, P840; Moon S, 2005, INVEST OPHTH VIS SCI, V46, P3783, DOI 10.1167/iovs.05-0237; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514	23	48	54	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2645	+		10.1096/fj.06-5919fje	http://dx.doi.org/10.1096/fj.06-5919fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065220				2022-12-28	WOS:000242490700052
J	Wang, GY; Qi, X; Wei, W; Englander, EW; Greeley, GH				Wang, Guiyun; Qi, Xiang; Wei, Wei; Englander, Ella W.; Greeley, George H., Jr.			Characterization of the 5 '-regulatory regions of the rat and human apelin genes and regulation of breast apelin by USF	FASEB JOURNAL			English	Article						hormone; transcription; ChIP assay; in vivo peptide	UPSTREAM STIMULATORY FACTORS; TRANSCRIPTION FACTOR USF; FOOD-INTAKE; PEPTIDE-YY; APJ RECEPTOR; EXPRESSION; PROMOTER; LIGAND; LOCALIZATION; CLONING	Apelin, a peptide widely expressed in the body, is the endogenous ligand for the APJ receptor. To investigate how the apelin gene is regulated transcriptionally, we cloned and characterized similar to 3000 and similar to 4000 bp 5'-upstream fragments of the rat and human apelin genes. Putative CAAT-like box, but not TATA-box sites were identified. The rat (-207/-1 bp) and human (-100/+74 bp) core promoter sequences contain putative binding sites for upstream stimulatory factor (USF)-1/-2. Mutagenesis and overexpression assays showed that USF up-regulates basal and inducible apelin transcription. EMSA and supershift experiments indicated binding of USF-1/-2 to the rat (-114/-109 bp) and human (-84/-79 bp) apelin promoters. ChIP experiments show that USF is recruited to the putative USF binding site in the human apelin promoter in cultured breast cells. In concert with increased breast apelin expression during pregnancy and lactation in rats, EMSAs demonstrate an elevated binding of pregnant and lactating rat breast nuclear proteins to a consensus USF oligonucleotide. In vivo ChIP assays verified increased USF binding to the apelin promoter in breast of lactating rats. Together, our findings show that USF exerts a stimulatory role in regulation of breast apelin expression during pregnancy and lactation.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Greeley, GH (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	ggreeley@utmb.edu			NIDDK NIH HHS [P01 DK35608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035608] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Corre S, 2006, M S-MED SCI, V22, P62, DOI 10.1051/medsci/200622162; COX CM, 2006, DEV BIOL; DAVIAUD D, 2006, FASEB J; deGraffenried LA, 2004, BREAST CANCER RES TR, V85, P111, DOI 10.1023/B:BREA.0000025398.93829.78; Devic E, 1996, MECH DEVELOP, V59, P129, DOI 10.1016/0925-4773(96)00585-0; Devic E, 1999, PATHOL BIOL, V47, P330; EVERS BM, 1995, MOL CELL BIOL, V15, P3870; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Golubovskaya V, 2004, BBA-GENE STRUCT EXPR, V1678, P111, DOI 10.1016/j.bbaexp.2004.03.002; GOMEZ G, 1995, AM J PHYSIOL-GASTR L, V268, pG71, DOI 10.1152/ajpgi.1995.268.1.G71; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Griffin MJ, 2004, IUBMB LIFE, V56, P595, DOI 10.1080/15216540400022474; Grindstaff KK, 1996, J BIOL CHEM, V271, P23211, DOI 10.1074/jbc.271.38.23211; Gualillo O, 2001, ENDOCRINOLOGY, V142, P788, DOI 10.1210/en.142.2.788; Habata Y, 1999, BBA-MOL CELL RES, V1452, P25, DOI 10.1016/S0167-4889(99)00114-7; Hadsell DL, 2003, MOL ENDOCRINOL, V17, P2251, DOI 10.1210/me.2002-0031; Hasegawa J, 1999, J BIOL CHEM, V274, P1100, DOI 10.1074/jbc.274.2.1100; Hocker M, 1997, AM J PHYSIOL-GASTR L, V272, pG822, DOI 10.1152/ajpgi.1997.272.4.G822; Ishida J, 2004, J BIOL CHEM, V279, P26274, DOI 10.1074/jbc.M404149200; ITO R, 1984, P NATL ACAD SCI-BIOL, V81, P4662, DOI 10.1073/pnas.81.15.4662; Jiang B, 2005, MOL CELL BIOL, V25, P8824, DOI 10.1128/MCB.25.20.8824-8833.2005; Jiang QP, 2000, AM J PHYSIOL-REG I, V278, pR425, DOI 10.1152/ajpregu.2000.278.2.R425; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Kleinz MJ, 2004, REGUL PEPTIDES, V118, P119, DOI 10.1016/j.regpep.2003.11.002; KOHRI K, 1993, BIOCHIM BIOPHYS ACTA, V1173, P345, DOI 10.1016/0167-4781(93)90136-2; KRASINSKI SD, 1991, MOL ENDOCRINOL, V5, P433, DOI 10.1210/mend-5-3-433; Lambrecht NWG, 2006, PHYSIOL GENOMICS, V25, P153, DOI 10.1152/physiolgenomics.00271.2005; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Lee HM, 2004, J NEUROCHEM, V88, P394, DOI 10.1046/j.1471-4159.2003.02164.x; Lee JM, 2005, MACROMOL RES, V13, P236, DOI 10.1007/BF03219058; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386; Martinez-Fuentes AJ, 2004, MOL ENDOCRINOL, V18, P1808, DOI 10.1210/me.2003-0321; MASRI B, 2006, J BIOL CHEM; Matsukawa T, 2001, ENDOCRINOLOGY, V142, P4643, DOI 10.1210/en.142.11.4643; Medhurst AD, 2003, J NEUROCHEM, V84, P1162, DOI 10.1046/j.1471-4159.2003.01587.x; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; O'Carroll AM, 2000, BBA-GENE STRUCT EXPR, V1492, P72, DOI 10.1016/S0167-4781(00)00072-5; O'Shea M, 2003, NUTR NEUROSCI, V6, P163, DOI 10.1080/1028415031000111273; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Petersenn S, 2002, ENDOCRINOLOGY, V143, P2626, DOI 10.1210/en.143.7.2626; Reaux A, 2001, J NEUROCHEM, V77, P1085, DOI 10.1046/j.1471-4159.2001.00320.x; Ross S, 2002, J BIOL CHEM, V277, P4455, DOI 10.1074/jbc.M110771200; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Segal ED, 1996, P NATL ACAD SCI USA, V93, P1259, DOI 10.1073/pnas.93.3.1259; Sellak H, 2005, J BIOL CHEM, V280, P18425, DOI 10.1074/jbc.M500775200; Sharma SK, 2005, BIOCHEM J, V389, P831, DOI 10.1042/BJ20050334; Shoulders CC, 2004, TRENDS MOL MED, V10, P362, DOI 10.1016/j.molmed.2004.06.011; Sirito Mario, 1992, Gene Expression, V2, P231; Sunter D, 2003, NEUROSCI LETT, V353, P1, DOI 10.1016/S0304-3940(03)00351-3; Suttner DM, 1999, AM J PHYSIOL-LUNG C, V276, pL443, DOI 10.1152/ajplung.1999.276.3.L443; Szentirmay MN, 2003, J BIOL CHEM, V278, P37231, DOI 10.1074/jbc.M305791200; Taheri S, 2002, BIOCHEM BIOPH RES CO, V291, P1208, DOI 10.1006/bbrc.2002.6575; Takahashi Y, 2001, DRUG METAB REV, V33, P37, DOI 10.1081/DMR-100000139; TAKAHASHI Y, 1986, GENE, V50, P353; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang GY, 2004, ENDOCRINOLOGY, V145, P1342, DOI 10.1210/en.2003-1116; Wei W, 2005, ENDOCRINOLOGY, V146, P1611, DOI 10.1210/en.2004-1306; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030	60	27	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2639	+		10.1096/fj.06-6315fje	http://dx.doi.org/10.1096/fj.06-6315fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17060400				2022-12-28	WOS:000242490700050
J	Yaddanapudi, K; Palacios, G; Towner, JS; Chen, I; Sariol, CA; Nichol, ST; Lipkin, WI				Yaddanapudi, Kavitha; Palacios, Gustavo; Towner, Jonathan S.; Chen, Ivy; Sariol, Carlos A.; Nichol, Stuart T.; Lipkin, W. Ian			Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses	FASEB JOURNAL			English	Article						filovirus; immunosuppression; lymphocyte depletion; apoptosis; cytokine	BLOOD MONONUCLEAR-CELLS; PROTEIN-KINASE-C; DENDRITIC CELLS; T-CELLS; LYMPHOCYTE-PROLIFERATION; STIMULATORY FACTOR; HEMORRHAGIC-FEVER; ENVELOPE PROTEINS; INFECTED PATIENTS; UP-REGULATION	Ebola and Marburg viruses can cause hemorrhagic fever (HF) outbreaks with high mortality in primates. Whereas Marburg (MARV), Ebola Zaire (ZEBOV), and Ebola Sudan (SEBOV) viruses are pathogenic in humans, apes, and monkeys, Ebola Reston (REBOV) is pathogenic only in monkeys (1-3). Early immunosuppression may contribute to pathogenesis by facilitating viral replication (4-6). Lymphocyte depletion, intravascular apoptosis, and cytokine dysregulation are prominent in fatal cases (7). Here we functionally characterize a 17 amino acid domain in filoviral glycoproteins that resembles an immunosuppressive motif in retroviral envelope proteins (8, 9). Activated human or rhesus peripheral blood mononuclear cells (PBMC) were exposed to inactivated ZEBOV or a panel of 17mer peptides representing all sequenced strains of filoviruses, then analyzed for CD4+ and CD8+ T cell activation, apoptosis, and cytokine expression. Exposure of human and rhesus PBMC to ZEBOV, SEBOV, or MARV peptides or inactivated ZEBOV resulted in decreased expression of activation markers on CD4 and CD8 cells; CD4 and CD8 cell apoptosis as early as 12 h postexposure; inhibition of CD4 and CD8 cell cycle progression; decreased interleukin (IL)-2, IFN-gamma, and IL12-p40 expression; and increased IL-10 expression. In contrast, only rhesus T cells were sensitive to REBOV peptides. These findings are consistent with the observation that REBOV is not pathogenic in humans and have implications for understanding the pathogenesis of filoviral HF.-Yaddanapudi, K., Palacios, G., Towner, J. S., Chen, I., Sariol, C. A., Nichol, S. T., Lipkin, W. I. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses.	Columbia Univ, Mailman Sch Publ Hlth, Jerome L & Dawn Greene Infect Dis Lab, New York, NY 10032 USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Special Pathogens Branch, Atlanta, GA USA; Univ Puerto Rico, Mayaguez, PR USA	Columbia University; Centers for Disease Control & Prevention - USA; University of Puerto Rico; University of Puerto Rico Mayaguez	Lipkin, WI (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Jerome L & Dawn Greene Infect Dis Lab, 722 W 168th St,Rm 1801, New York, NY 10032 USA.	wil2001@columbia.edu	Towner, Jonathan/ABC-3780-2020; Palacios, Gustavo/I-7773-2015; Sariol, Carlos A./W-6360-2019; Lipkin, W. Ian/ABE-6216-2020	Palacios, Gustavo/0000-0001-5062-1938; Sariol, Carlos A./0000-0001-7535-4303; Lipkin, W. Ian/0000-0002-8768-9386	NIAID NIH HHS [AI51292, AI056118, AI55466, U54-AI057158] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051292, R21AI055466, U54AI057158, R21AI056118] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baize S, 1999, NAT MED, V5, P423, DOI 10.1038/7422; Baize S, 2002, CLIN EXP IMMUNOL, V128, P163, DOI 10.1046/j.1365-2249.2002.01800.x; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003; Bosio CM, 2003, J INFECT DIS, V188, P1630, DOI 10.1086/379199; BUKREYEV AA, 1993, FEBS LETT, V323, P183, DOI 10.1016/0014-5793(93)81476-G; CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DENNER J, 1994, AIDS, V8, P1063, DOI 10.1097/00002030-199408000-00005; DING L, 1993, J IMMUNOL, V151, P1224; Feldmann H, 2001, J GEN VIROL, V82, P2839, DOI 10.1099/0022-1317-82-12-2839; Feldmann H, 1996, ADV VIRUS RES, V47, P1, DOI 10.1016/S0065-3527(08)60733-2; Geisbert TW, 2000, LAB INVEST, V80, P171, DOI 10.1038/labinvest.3780021; Geisbert TW, 2003, AM J PATHOL, V163, P2347, DOI 10.1016/S0002-9440(10)63591-2; GOTTLIEB RA, 1990, J IMMUNOL, V145, P2566; Gupta M, 2001, VIROLOGY, V284, P20, DOI 10.1006/viro.2001.0836; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; HARAGUCHI S, 1995, P NATL ACAD SCI USA, V92, P3611, DOI 10.1073/pnas.92.8.3611; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; HARAGUCHI S, 1995, P NATL ACAD SCI USA, V92, P5568, DOI 10.1073/pnas.92.12.5568; Harcourt BH, 1998, VIROLOGY, V252, P179, DOI 10.1006/viro.1998.9446; Hartman AL, 2004, VIROLOGY, V328, P177, DOI 10.1016/j.virol.2004.07.006; Hensley LE, 2002, IMMUNOL LETT, V80, P169, DOI 10.1016/S0165-2478(01)00327-3; JACOBSEN CN, 1993, VET IMMUNOL IMMUNOP, V39, P461, DOI 10.1016/0165-2427(93)90075-F; JAHRLING PB, 1996, ARCH VIROL         S, V11, P115; KADOTA J, 1991, MICROBIOL IMMUNOL, V35, P443, DOI 10.1111/j.1348-0421.1991.tb01575.x; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Mahanty S, 2003, J IMMUNOL, V170, P2797, DOI 10.4049/jimmunol.170.6.2797; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Peters CJ, 1999, J INFECT DIS, V179, pIX; REID SLL, 2006, J VIROL, V80, P1; Sanchez A, 2004, J VIROL, V78, P10370, DOI 10.1128/JVI.78.19.10370-10377.2004; SANCHO J, 1992, J BIOL CHEM, V267, P7871; Sopper S, 1997, CYTOMETRY, V29, P351; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; Villinger F, 1999, J INFECT DIS, V179, pS188, DOI 10.1086/514283; VOLCHKOV VE, 1992, FEBS LETT, V305, P181, DOI 10.1016/0014-5793(92)80662-Z; Volchkov VE, 2001, SCIENCE, V291, P1965, DOI 10.1126/science.1057269; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WOLF SF, 1991, J IMMUNOL, V146, P3074; Yang ZY, 2000, NAT MED, V6, P886, DOI 10.1038/78654	42	60	69	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2519	2530		10.1096/fj.06-6151com	http://dx.doi.org/10.1096/fj.06-6151com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17023517	Green Submitted			2022-12-28	WOS:000242490700012
J	Fox, MS; Klawansky, S				Fox, Maurice S.; Klawansky, Sidney			Interruption of cell transformation and cancer formation	FASEB JOURNAL			English	Article						epigenetics; carcinogenesis; hypermutability; genetic regulation; prevention	C3H 10T1/2 CELLS; MALIGNANT TRANSFORMATION; RADIATION TRANSFORMATION; CHROMOSOMAL INSTABILITY; GAMMA-RADIATION; MUTATIONS; INVITRO; CARCINOGENESIS; IRRADIATION; MECHANISM	A review of the results of X-ray and chemical carcinogen induction of transformation of mouse cells supports a two-step epigenetic model of transformation. According to this model, exposure induces an epigenetic regulatory alteration that makes the cells hypermutable so that when the cell population inheriting this alteration becomes sufficiently large, the second step, a mutation to the transformant phenotype, becomes increasingly likely. The epigenetic alteration in X-ray-exposed mouse cells has been demonstrated to be reversible by brief exposure to certain protease inhibitors. If the rodent cell experiments constitute a valid system for studying human cancer, then this two-step model may herald rich opportunities for preventing and perhaps even treating cancer in humans.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard T.H. Chan School of Public Health	Fox, MS (corresponding author), MIT, Dept Biol, Rm 68-577A, Cambridge, MA 02139 USA.	msfox@mit.edu						Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Drake JW, 2005, P NATL ACAD SCI USA, V102, P12849, DOI 10.1073/pnas.0503009102; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; FERNANDEZ A, 1980, P NATL ACAD SCI-BIOL, V77, P7272, DOI 10.1073/pnas.77.12.7272; Gowans ID, 2005, CANCER RES, V65, P3527, DOI 10.1158/0008-5472.CAN-04-4242; KAMIYA K, 1995, P NATL ACAD SCI USA, V92, P1332, DOI 10.1073/pnas.92.5.1332; KENNEDY AR, 1984, RADIAT RES, V99, P228, DOI 10.2307/3576368; KENNEDY AR, 1984, NATURE, V307, P85, DOI 10.1038/307085a0; KENNEDY AR, 1978, NATURE, V276, P825, DOI 10.1038/276825a0; KENNEDY AR, 1980, CARCINOGENESIS, V1, P1039, DOI 10.1093/carcin/1.12.1039; KENNEDY AR, 1982, CARCINOGENESIS, V3, P1093, DOI 10.1093/carcin/3.9.1093; KENNEDY AR, 1994, CANCER RES, V54, pS1999; KENNEDY AR, 1980, P NATL ACAD SCI-BIOL, V77, P7262, DOI 10.1073/pnas.77.12.7262; KENNEDY D, 1980, RES L SOC, V3, P10; KLAWANSKY S, 1984, J THEOR BIOL, V111, P531, DOI 10.1016/S0022-5193(84)80238-6; Little JB, 1997, RADIAT RES, V148, P299, DOI 10.2307/3579514; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Luria SE, 1943, GENETICS, V28, P491; MONDAL S, 1970, P NATL ACAD SCI USA, V65, P219, DOI 10.1073/pnas.65.1.219; O'Reilly S, 1998, RADIAT RES, V150, P577, DOI 10.2307/3579875; REZNIKOFF CA, 1973, CANCER RES, V33, P3239; TERZAGHI M, 1976, CANCER RES, V36, P1367; Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f	26	3	3	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2209	2213		10.1096/fj.06-6455hyp	http://dx.doi.org/10.1096/fj.06-6455hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077297				2022-12-28	WOS:000241702600005
J	Perotti, MA; Clarke, HK; Turner, BD; Braig, HR				Perotti, M. Alejandra; Clarke, Heather K.; Turner, Bryan D.; Braig, Henk R.			Rickettsia as obligate and mycetomic bacteria	FASEB JOURNAL			English	Article						evolution; development; Liposcelis bostrychophila; Cerobasis guestfalica; Psocoptera	APHID ACYRTHOSIPHON-PISUM; PHYLOGENETIC ANALYSIS; CHROMOSOME-NUMBERS; MULTIPLE ORIGINS; TICK-BORNE; WOLBACHIA; INSECT; ENDOSYMBIONTS; HOST; SYMBIONTS	Rickettsiae are well known as intracellular pathogens of animals, humans, and plants and facultative and unorganized symbionts of invertebrates. No close relative of mitochondria has yet been associated with nutritional or developmental dependency of its host cell or organism. We have found a mycetomic Rickettsia that is a strict obligatory symbiont of the parthenogenetic booklouse Liposcelis bostrychophila (Psocoptera). These rickettsiae show an evolutionary transition from a solitary to a primary mycetomic bacterium adapted to the development of its host. These intracellular and intranuclear bacteria reside in specialized cells in several tissues. Their distribution changes markedly with the development of their host. The most advanced phenotype is a paired mycetome in the abdomen, described for the first time for Rickettsia and this host order. The mycetomic rickettsiae of two parthenogenetic book lice species are in the spotted fever group and in the basal limoniae group. While mycetomic bacteria are well known for their metabolic or light-emitting functions, these rickettsiae have an essential role in the early development of the oocyte. Removal of the Rickettsia stops egg production and reproduction in the book louse. In two phylogenetically distant psocopteran species, Rickettsia are shown to be associated with four transitional stages from free bacteria, infected cells, through single mycetocytes to organ-forming mycetomes.	Univ Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; Kings Coll London, Dept Life Sci, London WC2R 2LS, England	Bangor University; University of London; King's College London	Braig, HR (corresponding author), Univ Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales.	bss40c@bangor.ac.uk	Braig, Henk/I-5477-2013	Braig, Henk/0000-0001-9592-1141				AKSOY S, 1995, INT J SYST BACTERIOL, V45, P848, DOI 10.1099/00207713-45-4-848; Andersson SGE, 2004, INT J MED MICROBIOL, V293, P463, DOI 10.1078/1438-4221-00304; BADONNEL ANDRE, 1934, BULL BIOL FRANCE ET BELGIQUE SUPPL, V18, P1; Batut J, 2004, NAT REV MICROBIOL, V2, P933, DOI 10.1038/nrmicro1044; BAUMANN P, 2000, PROKARYOTES EVOLVING; Bourtzis K, 2003, CONT T ENT, P217; Braendle C, 2003, PLOS BIOL, V1, P70, DOI 10.1371/journal.pbio.0000021; Braig HR, 1998, J BACTERIOL, V180, P2373, DOI 10.1128/JB.180.9.2373-2378.1998; Buchner P., 1965, ENDOSYMBIOSIS ANIMAL; Chapman GB, 2003, INVERTEBR BIOL, V122, P52, DOI 10.1111/j.1744-7410.2003.tb00072.x; Chen DQ, 1996, CURR MICROBIOL, V33, P123, DOI 10.1007/s002849900086; Corsaro D, 1999, CRIT REV MICROBIOL, V25, P39, DOI 10.1080/10408419991299167; Cowdry EV, 1923, J EXP MED, V37, P431, DOI 10.1084/jem.37.4.431; Davis MJ, 1998, CURR MICROBIOL, V36, P80, DOI 10.1007/s002849900283; Dobson SL, 1999, INSECT BIOCHEM MOLEC, V29, P153, DOI 10.1016/S0965-1748(98)00119-2; DOUGLAS AE, 1989, BIOL REV, V64, P409, DOI 10.1111/j.1469-185X.1989.tb00682.x; Dykova I, 2003, FOLIA PARASIT, V50, P161, DOI 10.14411/fp.2003.030; FINLAYSON LH, 1949, P ZOOL SOC LOND, V119, P301; Fukatsu T, 1999, APPL ENTOMOL ZOOL, V34, P391, DOI 10.1303/aez.34.391; Gil R, 2004, ENVIRON MICROBIOL, V6, P1109, DOI 10.1111/j.1462-2920.2004.00691.x; Goebel W, 2001, TRENDS MICROBIOL, V9, P267, DOI 10.1016/S0966-842X(01)02040-6; Gomez-Valero L, 2004, J BACTERIOL, V186, P6626, DOI 10.1128/JB.186.19.6626-6633.2004; GOSS RICHARD J., 1954, ANN ENT SOC AMER, V47, P190; GOSS RJ, 1953, J MORPHOL, V92, P157, DOI 10.1002/jmor.1050920106; GOSS RJ, 1952, J MORPHOL, V91, P135, DOI 10.1002/jmor.1050910107; GOSTEVA VV, 1991, ACTA VIROL, V35, P174; Gottlieb Y, 2006, APPL ENVIRON MICROB, V72, P3646, DOI 10.1128/AEM.72.5.3646-3652.2006; Grandi G, 1997, J SUBMICR CYTOL PATH, V29, P281; Hagimori T, 2006, CURR MICROBIOL, V52, P97, DOI 10.1007/s00284-005-0092-0; Heddi A, 2005, CELL MICROBIOL, V7, P293, DOI 10.1111/j.1462-5822.2004.00461.x; Heddi A, 1999, P NATL ACAD SCI USA, V96, P6814, DOI 10.1073/pnas.96.12.6814; Heinzen RA, 1999, INFECT IMMUN, V67, P4201, DOI 10.1128/IAI.67.8.4201-4207.1999; Hertig M, 1924, J MED RES, V44, P329; Hoy MA, 2005, BIOL CONTROL, V32, P427, DOI 10.1016/j.biocontrol.2004.12.012; Iturbe-Ormaetxe I, 2005, J BACTERIOL, V187, P5136, DOI 10.1128/JB.187.15.5136-5145.2005; Johnson KP, 2004, P ROY SOC B-BIOL SCI, V271, P1771, DOI 10.1098/rspb.2004.2798; JOSTES RF, 1975, CYTOLOGIA, V40, P553; Kikuchi Y, 2005, MICROBIAL ECOL, V49, P265, DOI 10.1007/s00248-004-0140-5; Koivisto RKK, 2003, BIOL J LINN SOC, V79, P43, DOI 10.1046/j.1095-8312.2003.00185.x; Lawson ET, 2001, HEREDITY, V86, P497, DOI 10.1046/j.1365-2540.2001.00848.x; LYAL CHC, 1985, SYST ENTOMOL, V10, P145; Majerus MEN, 1997, ENTOMOPHAGA, V42, P13, DOI 10.1007/BF02769875; Marchesi JR, 1998, APPL ENVIRON MICROB, V64, P795; Montllor CB, 2002, ECOL ENTOMOL, V27, P189, DOI 10.1046/j.1365-2311.2002.00393.x; Moran NA, 2005, APPL ENVIRON MICROB, V71, P3302, DOI 10.1128/AEM.71.6.3302-3310.2005; Moran NA, 1998, BIOSCIENCE, V48, P295, DOI 10.2307/1313356; MUNGOMBA LM, 1989, PARASITOL RES, V75, P167, DOI 10.1007/BF00931269; Murrell A, 2005, PARASITOL RES, V97, P274, DOI 10.1007/s00436-005-1413-8; Niebylski ML, 1999, APPL ENVIRON MICROB, V65, P773; Noda H, 1997, APPL ENVIRON MICROB, V63, P3926, DOI 10.1128/AEM.63.10.3926-3932.1997; Noland R. C., 1924, Transactions of the Wisconsin Academy of Sciences Arts and Letters, V21, P195; Ogata H, 2005, PLOS BIOL, V3, P1391, DOI 10.1371/journal.pbio.0030248; Ogata H, 2006, PLOS GENET, V2, P733, DOI 10.1371/journal.pgen.0020076; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2699, DOI 10.1073/pnas.89.7.2699; Parola P, 2005, VET RES, V36, P469, DOI 10.1051/vetres:2005004; Perotti MA, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-10; Perotti Maria Alejandra, 2005, Phytophaga - Palermo, V14, P457; Pongponratn E, 1998, TROP MED INT HEALTH, V3, P242, DOI 10.1046/j.1365-3156.1998.00231.x; Ries E., 1931, Zeitschrift fuer Morphologie und Oekologie der Tiere Berlin, V20, P233, DOI 10.1007/BF00444101; Rigaud T, 1997, INFLUENTIAL PASSENGERS, P81; Sakurai M, 2005, APPL ENVIRON MICROB, V71, P4069, DOI 10.1128/AEM.71.7.4069-4075.2005; Seeger W, 1979, STUTTGARTER BEITRA A, V329, P1; SIKORA H., 1920, Archiv fur Schiffs- und Tropenhygiene, V24, P347; Simser JA, 2002, APPL ENVIRON MICROB, V68, P4559, DOI 10.1128/AEM.68.9.4559-4566.2002; SUTAKOVA G, 1986, MYCOPLASMA MYCOPLASM, V22, P43; Tamas I, 2001, FEBS LETT, V498, P135, DOI 10.1016/S0014-5793(01)02459-0; Veneti Z, 2005, SCIENCE, V307, P1461, DOI 10.1126/science.1107182; WERREN JH, 1994, J BACTERIOL, V176, P388, DOI 10.1128/JB.176.2.388-394.1994; WEYDA F, 1991, ACTA ENTOMOL BOHEMOS, V88, P95; Whiting MF, 1997, SYST BIOL, V46, P1, DOI 10.1093/sysbio/46.1.1; Whitworth T, 2003, ANN NY ACAD SCI, V990, P67, DOI 10.1111/j.1749-6632.2003.tb07339.x; WONG S K, 1970, New Zealand Entomologist, V4, P66; WONG SK, 1966, NATURE, V211, P214, DOI 10.1038/211214a0; Yano Y, 2004, MICROBIOL IMMUNOL, V48, P535, DOI 10.1111/j.1348-0421.2004.tb03549.x; Yoshizawa K, 2003, MOL PHYLOGENET EVOL, V29, P102, DOI 10.1016/S1055-7903(03)00073-3; YU XJ, 2003, PROKARYOTES EVOLVING; Yusuf M, 2004, J STORED PROD RES, V40, P207, DOI 10.1016/S0022-474X(02)00098-X; Yusuf M, 2000, J STORED PROD RES, V36, P169, DOI 10.1016/S0022-474X(99)00037-5; Zchori-Fein E, 2001, P NATL ACAD SCI USA, V98, P12555, DOI 10.1073/pnas.221467498; Zientz E, 2004, MICROBIOL MOL BIOL R, V68, P745, DOI 10.1128/MMBR.68.4.745-770.2004	80	84	86	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2372	+		10.1096/fj.06-5870fje	http://dx.doi.org/10.1096/fj.06-5870fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17012243				2022-12-28	WOS:000241702600024
J	Wang, J; Ho, L; Zhao, Z; Seror, I; Humala, N; Dickstein, DL; Thiyagarajan, M; Percival, SS; Talcott, ST; Pasinetti, GM				Wang, Jun; Ho, Lap; Zhao, Zhong; Seror, Ilana; Humala, Nelson; Dickstein, Dara L.; Thiyagarajan, Meenakshisundaram; Percival, Susan S.; Talcott, Stephen T.; Pasinetti, Giulio Maria			Moderate consumption of Cabernet Sauvignon attenuates A beta neuropathology in a mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						APP; nonamyloidogenic; polyphenols; AD dementia	AMYLOID PRECURSOR PROTEIN; COGNITIVE IMPAIRMENT; TRANSGENIC MICE; SENILE PLAQUES; DEMENTIA; WINE; ALCOHOL; ASSOCIATION; DEPOSITION; CLEAVAGE	Recent studies suggest that moderate red wine consumption reduces the incidence of Alzheimer's disease (AD) clinical dementia. Using Tg2576 mice, which model AD-type amyloid beta-protein (A beta) neuropathology, we tested whether moderate consumption of the red wine Cabernet Sauvignon modulates AD-type neuropathology and cognitive deterioration. The wine used in the study was generated using Cabernet Sauvignon grapes from Fresno, California, and was delivered to Tg2576 in a final concentration of similar to 6% ethanol. We found that Cabernet Sauvignon significantly attenuated AD-type deterioration of spatial memory function and A beta neuropathology in Tg2576 mice relative to control Tg2576 mice that were treated with either a comparable amount of ethanol or water alone. Chemical analysis showed the Cabernet Sauvignon used in this study contains a very low content of resveratrol (0.2 mg/L), 10-fold lower than the minimal effective concentration shown to promote A beta clearance in vitro. Our studies suggest Cabernet Sauvignon exerts a beneficial effect by promoting nonamyloidogenic processing of amyloid precursor protein, which ultimately prevents the generation of A beta peptides. This study supports epidemiological evidence indicating that moderate wine consumption, within the range recommended by the FDA dietary guidelines of one drink per day for women and two for men, may help reduce the relative risk for AD clinical dementia.	CUNY Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; James J Peters VA Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY USA; Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; State University System of Florida; University of Florida	Pasinetti, GM (corresponding author), CUNY Mt Sinai Sch Med, Dept Neurosci, 1 Gustave L Levy Pl, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu	Dickstein, Dara/F-3036-2013; Dickstein, Dara/AAH-6603-2020	Pasinetti, Giulio/0000-0002-1524-5196				BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Booyse FM, 2001, THROMB HAEMOSTASIS, V86, P517; Bussiere T, 2002, NEUROSCIENCE, V112, P75, DOI 10.1016/S0306-4522(02)00056-8; CUMMINGS BJ, 1995, LANCET, V346, P1524, DOI 10.1016/S0140-6736(95)92053-6; Curin Y, 2005, PHARMACOL REP, V57, P97; DARTIGUES JF, 1993, THERAPIE, V48, P185; Dorozynski A, 1997, BRIT MED J, V314, P997; Hampl JS, 2002, J AM DIET ASSOC, V102, P1680, DOI 10.1016/S0002-8223(02)90359-7; HO L, 2004, FASEB J; Karsten SL, 2005, CELL, V120, P572, DOI 10.1016/j.cell.2005.02.027; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lau FC, 2005, NEUROBIOL AGING, V26, pS128, DOI 10.1016/j.neurobiolaging.2005.08.007; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Luchsinger JA, 2004, J AM GERIATR SOC, V52, P540, DOI 10.1111/j.1532-5415.2004.52159.x; Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nimchinsky EA, 2000, J COMP NEUROL, V416, P112, DOI 10.1002/(SICI)1096-9861(20000103)416:1<112::AID-CNE9>3.0.CO;2-K; Ono K, 2004, BBA-MOL BASIS DIS, V1690, P193, DOI 10.1016/j.bbadis.2004.06.008; Orgogozo JM, 1997, REV NEUROL-FRANCE, V153, P185; Patel NV, 2005, NEUROBIOL AGING, V26, P995, DOI 10.1016/j.neurobiolaging.2004.09.014; Percival SS, 2000, J NUTR, V130, P1091, DOI 10.1093/jn/130.5.1091; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; Pompl PN, 1999, J NEUROSCI METH, V87, P87, DOI 10.1016/S0165-0270(98)00169-1; Qin WP, 2003, J BIOL CHEM, V278, P50970, DOI 10.1074/jbc.M307699200; Reid M Carrington, 2002, Subst Abus, V23, P149; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Stecher G, 2001, FRESEN J ANAL CHEM, V371, P73, DOI 10.1007/s002160100898; Talcott ST, 2002, J AGR FOOD CHEM, V50, P3186, DOI 10.1021/jf011500u; Truelsen T, 2002, ANN NEUROL, V52, pS31; VALLET PG, 1992, ACTA NEUROPATHOL, V83, P170, DOI 10.1007/BF00308476; WANG J, 2005, FASEB J; Zenebe W, 2002, Bratisl Lek Listy, V103, P159; ZOECKLIN B, 1990, PRODUCTION WINE ANAL	34	213	226	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2313	2320		10.1096/fj.06-6281com	http://dx.doi.org/10.1096/fj.06-6281com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077308				2022-12-28	WOS:000241702600016
J	Kontrogianni-Konstantopoulos, A; Catino, DH; Strong, JC; Sutter, S; Borisov, AB; Pumplin, DW; Russell, MW; Bloch, RJ				Kontrogianni-Konstantopoulos, Aikaterini; Catino, Dawn H.; Strong, John C.; Sutter, Sarah; Borisov, Andrei B.; Pumplin, David W.; Russell, Mark W.; Bloch, Robert J.			Obscurin modulates the assembly and organization of sarcomeres and the sarcoplasmic reticulum	FASEB JOURNAL			English	Article						obscurin; myosin; myomesin; titin; small ankyrin 1; A-band; M-band	M-LINE; PROTEIN; TITIN; MYOFIBRILLOGENESIS; EXPRESSION; MYOSIN; GIANT; DIFFERENTIATION; MLCK; IDENTIFICATION	Obscurin (similar to 800 kDa) in striated muscle closely surrounds sarcomeres at the level of the M-band and Z-disk where, we hypothesize, it participates in the assembly of the contractile apparatus and membrane systems required for Ca2+ homeostasis. In this study, we used small inhibitory RNA (siRNA) technology to reduce the levels of obscurin in primary cultures of skeletal myotubes to study its role in myofibrillogenesis and the organization of the sarcoplasmic reticulum (SR). siRNA-treated myotubes showed a specific and dramatic reduction in the similar to 800 kDa form of obscurin by reverse transcription-polymerase chain reaction, immunoblotting, and immunofluorescence. M-bands and A-bands, but not Z-disks or I-bands, were disrupted when the synthesis of obscurin was inhibited. Small ankyrin 1, an integral protein of the network SR that binds to obscurin, also failed to align around developing sarcomeres in treated myotubes. Myosin and myomesin levels were significantly reduced in treated myotubes but alpha-actinin was not, suggesting that down-regulation of obscurin destabilizes proteins of the M-band and A-band but not of the Z-disk. Our findings suggest that obscurin is required for the assembly of the M-band and A-band and for the regular alignment of the network SR around the contractile apparatus.	Univ Maryland, Dept Physiol, Sch Med, Baltimore, MD 21201 USA; Univ Maryland, Dept Anat & Neurobiol, Sch Med, Baltimore, MD 21201 USA; Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Michigan System; University of Michigan	Kontrogianni-Konstantopoulos, A (corresponding author), Univ Maryland, Dept Physiol, Sch Med, Baltimore, MD 21201 USA.	akons001@umaryland.edu			NHLBI NIH HHS [R01 HL 075093-01, R01 HL 64304] Funding Source: Medline; NIAMS NIH HHS [R01 AR52768-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064304, R01HL075093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052768] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarkova I, 2003, J MUSCLE RES CELL M, V24, P191, DOI 10.1023/A:1026094924677; Auerbach D, 1997, CELL STRUCT FUNCT, V22, P139, DOI 10.1247/csf.22.139; Bagnato P, 2003, J CELL BIOL, V160, P245, DOI 10.1083/jcb.200208109; Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; Barral JM, 1999, BIOESSAYS, V21, P813, DOI 10.1002/(SICI)1521-1878(199910)21:10<813::AID-BIES3>3.0.CO;2-0; Benian GM, 1996, J CELL BIOL, V132, P835, DOI 10.1083/jcb.132.5.835; Borisov AB, 2006, HISTOCHEM CELL BIOL, V125, P227, DOI 10.1007/s00418-005-0069-x; Borisov AB, 2004, J HISTOCHEM CYTOCHEM, V52, P1117, DOI 10.1369/jhc.3A6183.2004; Borisov AB, 2003, BIOCHEM BIOPH RES CO, V310, P910, DOI 10.1016/j.bbrc.2003.09.035; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Dabiri GA, 1997, P NATL ACAD SCI USA, V94, P9493, DOI 10.1073/pnas.94.17.9493; De Deyne PG, 1998, J CELL SCI, V111, P2729; Du AP, 2003, DEV BIOL, V257, P382, DOI 10.1016/S0012-1606(03)00104-0; Ehler E, 1999, J CELL SCI, V112, P1529; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; Furst DO, 1999, REV PHYSIOL BIOCH P, V138, P163, DOI 10.1007/BF02346663; Gautel M, 1999, REV PHYSIOL BIOCH P, V138, P97, DOI 10.1007/BF02346661; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; Kontrogianni-Konstantopoulos A, 2006, AM J PHYSIOL-CELL PH, V290, pC626, DOI 10.1152/ajpcell.00442.2005; Kontrogianni-Konstantopoulos A, 2004, AM J PHYSIOL-CELL PH, V287, pC209, DOI 10.1152/ajpcell.00497.2003; Kontrogianni-Konstantopoulos A, 2003, MOL BIOL CELL, V14, P1138, DOI 10.1091/mbc.E02-07-0411; KONTROGIANNIKON.A, 2005, IN PRESS J MUSCLE RE; Labeit S, 1997, CIRC RES, V80, P290, DOI 10.1161/01.RES.80.2.290; Mason P, 1999, BIOCHEM BIOPH RES CO, V257, P699, DOI 10.1006/bbrc.1999.0531; McElhinny AS, 2003, TRENDS CARDIOVAS MED, V13, P195, DOI 10.1016/S1050-1738(03)00076-8; Miller G, 2003, J CELL SCI, V116, P4811, DOI 10.1242/jcs.00768; Ojima K, 1999, J CELL SCI, V112, P4101; RHEE D, 1994, CELL MOTIL CYTOSKEL, V28, P1, DOI 10.1002/cm.970280102; Russell MW, 2002, GENE, V282, P237, DOI 10.1016/S0378-1119(01)00795-8; Sanger JW, 2002, CLIN ORTHOP RELAT R, pS153, DOI 10.1097/01.blo.0000031973.69509.21; SCHULTHEISS T, 1990, J CELL BIOL, V110, P1159, DOI 10.1083/jcb.110.4.1159; Small TM, 2004, J MOL BIOL, V342, P91, DOI 10.1016/j.jmb.2004.07.006; TAKEKURA H, 1993, J MUSCLE RES CELL M, V14, P633, DOI 10.1007/BF00141560; Takekura H, 2001, DEV BIOL, V239, P204, DOI 10.1006/dbio.2001.0437; Van der Ven PFM, 1998, J MUSCLE RES CELL M, V19, P767, DOI 10.1023/A:1005443203238; Van der Ven PFM, 1999, J MUSCLE RES CELL M, V20, P569, DOI 10.1023/A:1005569225773; Wang SM, 1998, J CELL BIOCHEM, V71, P82, DOI 10.1002/(SICI)1097-4644(19981001)71:1<82::AID-JCB9>3.0.CO;2-Y; Wright C, 1997, J APPL PHYSIOL, V83, P1389, DOI 10.1152/jappl.1997.83.4.1389; WRIGHT J, 1993, J MUSCLE RES CELL M, V14, P476, DOI 10.1007/BF00297210; Yang YG, 2000, CELL STRUCT FUNCT, V25, P177, DOI 10.1247/csf.25.177; Young P, 2001, J CELL BIOL, V154, P123, DOI 10.1083/jcb.200102110; Zhou DX, 1997, J CELL BIOL, V136, P621, DOI 10.1083/jcb.136.3.621	43	81	81	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2102	2111		10.1096/fj.06-5761com	http://dx.doi.org/10.1096/fj.06-5761com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012262	Green Submitted			2022-12-28	WOS:000241156900018
J	Wang, JG; Barsky, LW; Davicioni, E; Weinberg, KI; Triche, TJ; Zhang, XK; Wu, LT				Wang, Jian-guang; Barsky, Lora W.; Davicioni, Elai; Weinberg, Kenneth I.; Triche, Timothy J.; Zhang, Xiao-kun; Wu, Lingtao			Retinoic acid induces leukemia cell G(1) arrest and transition into differentiation by inhibiting cyclin-dependent kinase-activating kinase binding and phosphorylation of PML/RAR alpha	FASEB JOURNAL			English	Article						MAT1 degradation; cell cycle; proliferation/differentiation transition	TRANSCRIPTION FACTOR TFIIH; UBIQUITIN PROTEIN LIGASE; RAR-ALPHA; NUCLEAR RECEPTORS; T(15-17) TRANSLOCATION; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; ASSEMBLY FACTOR; CAK ACTIVITY; S-PHASE	Acute promyelocytic leukemia (APL) cells express promyelocytic leukemia/retinoic acid receptor alpha (PML/RAR alpha) fusion protein, which leads to the blocking of APL cell differentiation. Treatment of APL with all-trans-retinoic acid ( ATRA) induces disease remission by in vivo differentiation of APL cells. Differentiation requires cell cycle exit; yet how ATRA couples cell cycle exit to differentiation of APL remains largely unknown. We previously found that ATRA-induced cell differentiation accompanies ubiquitination-proteolysis of menage a trois 1 ( MAT1), an assembly factor and targeting subunit of cyclin-dependent kinase (CDK)-activating kinase (CAK) that regulates G(1) exit. We report here that CAK binds to and phosphorylates PML/RAR alpha in actively proliferating APL cells. In response to ATRA, PML/RAR alpha is dissociated from CAK, leading to MAT1 degradation, G(1) arrest, and decreased CAK phosphorylation of PML/RAR alpha. CAK phosphorylation of PML/RAR alpha is inhibited when MAT1 levels are reduced. Both MAT1 degradation and PML/RAR alpha hypophosphorylation occur in ATRA-induced G(1)-arresting cells undergoing differentiation but not in the synchronized G(1) cells that do not differentiate. These findings reveal a novel ATRA signaling on APL cell differentiation, in which ATRA coordinates G(1) arrest and transition into differentiation by inducing MAT1 degradation and PML/RAR alpha hypophosphorylation through disrupting PML/RAR alpha binding and phosphorylation by CAK.	Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Dept Pathol,Saban Res Inst, Los Angeles, CA 90027 USA; Burnham Inst, Ctr Canc, La Jolla, CA 92037 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA USA; Childrens Hosp Los Angeles, Saban Res Inst, Div Res Immunol BMT, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; Sanford Burnham Prebys Medical Discovery Institute; University of Southern California; Children's Hospital Los Angeles	Wu, LT (corresponding author), Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Dept Pathol,Saban Res Inst, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	lingtaow@usc.edu		Davicioni, Elai/0000-0001-9136-099X				Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Crowe David L, 2002, Cancer Cell Int, V2, P15, DOI 10.1186/1475-2867-2-15; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Egea PF, 2001, J MOL BIOL, V307, P557, DOI 10.1006/jmbi.2000.4409; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Glass CK, 2000, GENE DEV, V14, P121; He QJ, 2004, FASEB J, V18, P1734, DOI 10.1096/fj.04-2182fje; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Nouzova M, 2004, J PHARMACOL EXP THER, V311, P968, DOI 10.1124/jpet.104.072488; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slack JL, 2000, ANN HEMATOL, V79, P227, DOI 10.1007/s002770050585; Slack JL, 1999, CANC TREAT, V99, P75; Studzinski GP, 1999, INT REV CYTOL, V189, P1, DOI 10.1016/S0074-7696(08)61384-4; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang JW, 2002, J BIOL CHEM, V277, P43369, DOI 10.1074/jbc.M206792200; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu LT, 2001, MOL CELL BIOL, V21, P260, DOI 10.1128/MCB.21.1.260-270.2001; Wu LT, 1999, J BIOL CHEM, V274, P5564, DOI 10.1074/jbc.274.9.5564; WU LT, 1994, ONCOGENE, V9, P2089; WU LT, 1993, INT J ONCOL, V3, P859; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yee A, 1996, J BIOL CHEM, V271, P471, DOI 10.1074/jbc.271.1.471; YEE A, 1995, CANCER RES, V55, P6058; Zhang SN, 2004, CANCER RES, V64, P2977, DOI 10.1158/0008-5472.CAN-03-4018; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	69	30	36	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2142	+		10.1096/fj.06-5900fje	http://dx.doi.org/10.1096/fj.06-5900fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935935				2022-12-28	WOS:000241156900039
J	Sironi, M; Pozzoli, U; Comi, GP; Riva, S; Bordoni, A; Bresolin, N; Nag, DK				Sironi, Manuela; Pozzoli, Uberto; Comi, Giacomo P.; Riva, Stefania; Bordoni, Andreina; Bresolin, Nereo; Nag, Dilip K.			A region in the dystrophin gene major hot spot harbors a cluster of deletion breakpoints and generates double-strand breaks in yeast	FASEB JOURNAL			English	Article						DMD/BMD; yeast meiosis	MEIOTIC RECOMBINATION; SACCHAROMYCES-CEREVISIAE; MUSCULAR-DYSTROPHY; CHROMOSOMAL TRANSLOCATIONS; HISTOCOMPATIBILITY COMPLEX; DMD GENE; DNA; SEQUENCE; MEIOSIS; IDENTIFICATION	Deletions within the dystrophin gene (DMD) account for > 70% of mutations leading to Duchenne and Becker muscular dystrophies (DMD and BMD). Deletion breakpoints were reported to be scattered within regions that also represent meiotic recombination hot spots. Recent studies indicates that deletion junctions arise from nonhomologous end joining (NHEJ), a major pathway for repairing DNA double-strand breaks (DSBs) in mammals. Here we show that a region in intron 47 (i. e., a major deletion hot spot in the DMD gene) generates DSBs during meiosis in yeast and harbors a cluster of previously sequenced deletion breaks. Mapping of breakpoints in 26 BMD/ DMD patients indicated that the frequency of breakpoint occurrence around this region is 3-fold higher than expected by chance. These findings suggest that DSBs mediate deletion formation in intron 47 and possibly account for the high frequency of meiotic recombination in the region. Statistical analysis indicated the presence of at least one other breakpoint cluster in intron 47. Taken together, these results suggest that the primary events in deletion formation occur within discrete regions and that the scattered breakpoint distribution reflects both a variable degree of DSB end processing and the availability of a small (compared to the huge regions involved) deletion junction sample.	IRCCS E Medea, Inst Sci, I-23842 Bosisio Parini, LC, Italy; Wadsworth Ctr, Ctr Med Sci, Mol Genet Program, Albany, NY USA; Univ Milan, Dino Ferrari Ctr, Dept Neurol Sci,Mangiagalli & Regina Elena Fdn, IRCCS,Osped Maggiore Policlin, Milan, Italy; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12222 USA	IRCCS Eugenio Medea; Wadsworth Center; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Sironi, M (corresponding author), IRCCS E Medea, Inst Sci, Via Don L Monza 20, I-23842 Bosisio Parini, LC, Italy.	msironi@bp.lnf.it	Sironi, manuela/K-5633-2016; Comi, Giacomo P/K-5702-2016; Pozzoli, Uberto/AAH-5492-2019; Pozzoli, Uberto/K-6587-2016	Sironi, manuela/0000-0002-2267-5266; Comi, Giacomo P/0000-0002-1383-5248; Pozzoli, Uberto/0000-0003-0670-7106; Pozzoli, Uberto/0000-0003-0670-7106; Bresolin, Nereo/0000-0001-6694-3595	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056266] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56266] Funding Source: Medline; Telethon [GTF02008] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon)		AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; Bacolla A, 2004, P NATL ACAD SCI USA, V101, P14162, DOI 10.1073/pnas.0405974101; BEGGS AH, 1990, HUM GENET, V86, P45; Blumental-Perry A, 2000, EMBO REP, V1, P232, DOI 10.1093/embo-reports/kvd047; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; Cullen M, 2002, AM J HUM GENET, V71, P759, DOI 10.1086/342973; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; Espinas ML, 1996, J BIOL CHEM, V271, P31807, DOI 10.1074/jbc.271.50.31807; Fan QQ, 1996, MOL CELL BIOL, V16, P2037; Gusev VD, 1999, BIOINFORMATICS, V15, P994; Jankowski C, 2000, P NATL ACAD SCI USA, V97, P2134, DOI 10.1073/pnas.040460297; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; Kelmenson PM, 2005, GENETICS, V169, P833, DOI 10.1534/genetics.104.035063; Klein S, 1996, NAT GENET, V13, P481, DOI 10.1038/ng0896-481; KOENIG M, 1989, AM J HUM GENET, V45, P498; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lemoine FJ, 2005, CELL, V120, P587, DOI 10.1016/j.cell.2004.12.039; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lobachev KS, 1998, GENETICS, V148, P1507; LOVE DR, 1991, GENOMICS, V10, P57, DOI 10.1016/0888-7543(91)90484-V; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; McNaughton JC, 1998, GENE, V222, P41, DOI 10.1016/S0378-1119(98)00466-1; Nag DK, 1997, GENETICS, V146, P835; NAG DK, 1989, NATURE, V340, P318, DOI 10.1038/340318a0; NISHIO H, 1994, J CLIN INVEST, V94, P1037, DOI 10.1172/JCI117417; Nobile C, 2002, HUM GENET, V110, P418, DOI 10.1007/s00439-002-0721-7; OHTA K, 1994, EMBO J, V13, P5754, DOI 10.1002/j.1460-2075.1994.tb06913.x; OUDET C, 1992, HUM MOL GENET, V1, P599, DOI 10.1093/hmg/1.8.599; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pecina A, 2002, CELL, V111, P173, DOI 10.1016/S0092-8674(02)01002-4; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; ROONEY SM, 1995, P NATL ACAD SCI USA, V92, P2141, DOI 10.1073/pnas.92.6.2141; Rose MD., 1990, METHODS YEAST GENETI; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Schneider KU, 2005, AM J HUM GENET, V77, P89, DOI 10.1086/431655; SIKORSKI RS, 1989, GENETICS, V122, P19; Sironi M, 2003, HUM GENET, V112, P272, DOI 10.1007/s00439-002-0881-5; Toffolatti L, 2002, GENOMICS, V80, P523, DOI 10.1006/geno.2002.6861; TRECO D, 1986, MOL CELL BIOL, V6, P3934, DOI 10.1128/MCB.6.11.3934; Visser R, 2005, AM J HUM GENET, V76, P52, DOI 10.1086/426950; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x	44	12	12	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1910	+		10.1096/fj.05-5635fje	http://dx.doi.org/10.1096/fj.05-5635fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16891620				2022-12-28	WOS:000240267000027
J	Nyborg, AC; Ladd, TB; Jansen, K; Kukar, T; Golde, TE				Nyborg, Andrew C.; Ladd, Thomas B.; Jansen, Karen; Kukar, Thomas; Golde, Todd E.			Intramembrane proteolytic cleavage by human signal peptide peptidase like 3 and malaria signal peptide peptidase	FASEB JOURNAL			English	Article						gamma-secretase; aspartyl protease; hepatitis C virus; MHC class I; Plasmodium falciparum	GAMMA-SECRETASE ACTIVITY; RETICULUM STRESS-RESPONSE; PLASMODIUM-FALCIPARUM; PRESENILIN HOMOLOGS; TRANSCRIPTIONAL INDUCTION; PROTEASE INHIBITORS; ASPARTIC PROTEASES; POTENT INHIBITORS; PLASMEPSIN-II; BETA-APP	Signal peptide peptidase (SPP) is an intramembrane cleaving protease (I-CLiP) identified by its cleavage of several type II membrane signal peptides. To date, only human SPP has been directly shown to have proteolytic activity. Here we demonstrate that the most closely related human homologue of SPP, signal peptide peptidase like 3 (SPPL3), cleaves a SPP substrate, but a more distantly related homologue, signal peptide peptidase like 2b (SPPL2b), does not. These data provide strong evidence that the SPP and SPPL3 have conserved active sites and suggest that the active sites SPPL2b is distinct. We have also synthesized a cDNA designed to express the single SPP gene present in Plasmodium falciparum and cloned this into a mammalian expression vector. When the malaria SPP protein is expressed in mammalian cells it cleaves a SPP substrate. Notably, several human SPP inhibitors block the proteolytic activity of malarial SPP (mSPP). Studies from several model organisms that express multiple SPP homologs demonstrate that the silencing of a single SPP homologue is lethal. Based on these data, we hypothesize that mSPP is a potential a novel therapeutic target for malaria.	Mayo Clin, Coll Med, Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic	Golde, TE (corresponding author), Mayo Clin, Coll Med, Mayo Clin Jacksonville, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	tgolde@mayo.edu	Kukar, Thomas/AAW-2612-2021	Kukar, Thomas/0000-0002-3750-6262	NINDS NIH HHS [NS44734, NS39072] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS044734, R01NS039072] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrews KT, 2006, ANTIMICROB AGENTS CH, V50, P639, DOI 10.1128/AAC.50.2.639-648.2006; Beher D, 2005, EXPERT OPIN INV DRUG, V14, P1385, DOI 10.1517/13543784.14.11.1385; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Casso DJ, 2005, GENETICS, V170, P139, DOI 10.1534/genetics.104.039933; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Friedmann E, 2004, J BIOL CHEM, V279, P50790, DOI 10.1074/jbc.M407898200; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gelb MH, 2002, SCIENCE, V297, P343, DOI 10.1126/science.1073126; GOLDE TE, 2003, SCI STKE, pRE4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grigorenko AP, 2004, P NATL ACAD SCI USA, V101, P14955, DOI 10.1073/pnas.0406462101; Grigorenko AP, 2002, BIOCHEMISTRY-MOSCOW+, V67, P826, DOI 10.1023/A:1016365227942; Johansson PO, 2005, J MED CHEM, V48, P4400, DOI 10.1021/jm040884n; Johansson PO, 2004, J MED CHEM, V47, P3353, DOI 10.1021/jm031106i; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Krawitz P, 2005, J BIOL CHEM, V280, P39515, DOI 10.1074/jbc.M501645200; Lanz TA, 2004, J PHARMACOL EXP THER, V309, P49, DOI 10.1124/jpet.103.060715; Lemberg MK, 2004, FEBS LETT, V564, P213, DOI 10.1016/S0014-5793(04)00192-9; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; Marlow L, 2003, BIOCHEM BIOPH RES CO, V305, P502, DOI 10.1016/S0006-291X(03)00797-6; Martoglio B, 2003, BIOCHEM SOC T, V31, P1243; Martoglio B, 2003, HUM MOL GENET, V12, pR201, DOI 10.1093/hmg/ddg303; Moliaka YK, 2004, FEBS LETT, V557, P185, DOI 10.1016/S0014-5793(03)01489-3; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Nomura T, 2001, J INFECT DIS, V183, P1653, DOI 10.1086/320707; Nyborg AC, 2004, J BIOL CHEM, V279, P43148, DOI 10.1074/jbc.M405879200; Nyborg AC, 2004, J BIOL CHEM, V279, P15153, DOI 10.1074/jbc.M309305200; Okamoto K, 2004, J VIROL, V78, P6370, DOI 10.1128/JVI.78.12.6370-6380.2004; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Rosenthal PJ, 1996, ANTIMICROB AGENTS CH, V40, P1600, DOI 10.1128/AAC.40.7.1600; Sibley CH, 2001, IUBMB LIFE, V52, P285, DOI 10.1080/152165401317291138; Sibley CH, 2001, TRENDS PARASITOL, V17, P582, DOI 10.1016/S1471-4922(01)02085-2; Siemers E, 2005, CLIN NEUROPHARMACOL, V28, P126, DOI 10.1097/01.wnf.0000167360.27670.29; Sun LQ, 2005, CELL CYCLE, V4, P3, DOI 10.4161/cc.4.1.1341; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wang J, 2006, J NEUROCHEM, V96, P218, DOI 10.1111/j.1471-4159.2005.03548.x; Wang J, 2004, NEUROBIOL DIS, V15, P654, DOI 10.1016/j.nbd.2003.12.008; Wang Y, 2000, J BIOL CHEM, V275, P27013; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	52	37	42	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1671	1679		10.1096/fj.06-5762com	http://dx.doi.org/10.1096/fj.06-5762com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873890				2022-12-28	WOS:000240266600012
J	Nakayama, S; Ito, Y; Sato, S; Kamijo, A; Liu, HN; Kajioka, S				Nakayama, Shinsuke; Ito, Yasushi; Sato, Shinji; Kamijo, Atsushi; Liu, Hong-Nian; Kajioka, Shunichi			Tyrosine kinase inhibitors and ATP modulate the conversion of smooth muscle L-type Ca2+ channels toward a second open state	FASEB JOURNAL			English	Article						persistent Ca2+ channel current; genistein; genistin	BETA-ADRENERGIC STIMULATION; MULTIPLE OPEN STATES; C-SRC; GENISTEIN; CELLS; INACTIVATION; CURRENTS; MECHANISM; PHOSPHORYLATION; MYOCYTES	Properties of smooth and cardiac L-type Ca2+ channels differ prominently in several physiological aspects, including sympathetic modulation. To assess the possible underlying mechanisms, we applied the whole cell patch-clamp technique to guinea pig detrusor smooth muscle cells, in which only L-type Ca2+ channel currents are observed in practice. During depolarization to large positive potentials, the conformation of the majority of L-type Ca2+ channels is converted from the normal (O-1) to a second open state (O-2), which undergoes little inactivation during depolarization. Extracellular application of genistein, a known tyrosine kinase inhibitor, significantly attenuated the voltage-dependent conversion of Ca2+ channels to O-2, accompanied by reduction of availability, whereas genistin, an inactive analog, had little effect. In the absence of ATP in the patch pipette, intracellular application of either genistein or tyrphostin-47 suppressed the conversion to O-2. Computer calculation revealed that the acceleration of the O-1 to an inactivated state qualitatively reconstructs the unique effects of PTK inhibitors antagonized by ATP. We concluded that under normal conditions smooth muscle L-type Ca2+ channels are already modulated by tyrosine-kinase and ATP-related mechanism(s) and thereby easily achieve the second conversion, which yields voltage-dependent modulation of L-type Ca2+ current analogous to that in cardiac myocytes during beta-adrenoceptor stimulation.	Nagoya Univ, Grad Sch Med, Dept Cell Physiol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi, Japan	Nagoya University; Nagoya University	Nakayama, S (corresponding author), Nagoya Univ, Grad Sch Med, Dept Cell Physiol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.	h44673a@nucc.cc.nagoya-u.ac.jp						AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Aoyama M, 2003, BIOPHYS J, V84, P709, DOI 10.1016/S0006-3495(03)74890-5; Beech D. J., 1996, P39; Belevych AE, 2002, MOL PHARMACOL, V62, P554, DOI 10.1124/mol.62.3.554; BULBRING E, 1981, SMOOTH MUSCLE ASSESS, P219; CAVALIE A, 1991, PFLUG ARCH EUR J PHY, V419, P433, DOI 10.1007/BF00370785; Chow KY, 2003, NEUROUROL URODYNAM, V22, P77, DOI 10.1002/nau.10081; Du XL, 2004, J GEN PHYSIOL, V123, P427, DOI 10.1085/jgp.200409013; Findlay I, 2004, J PHYSIOL-LONDON, V554, P275, DOI 10.1113/jphysiol.2003.047902; Findlay I, 2002, J PHYSIOL-LONDON, V541, P741, DOI 10.1113/jphysiol.2002.019737; Flatman PW, 1996, AM J PHYSIOL-CELL PH, V271, pC255, DOI 10.1152/ajpcell.1996.271.1.C255; Fry C H, 1998, Int Urogynecol J Pelvic Floor Dysfunct, V9, P291, DOI 10.1007/BF01901509; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Hu XQ, 1998, J BIOL CHEM, V273, P5337, DOI 10.1074/jbc.273.9.5337; IMAIZUMI Y, 1991, METHODS NEUROSCI, V4, P44; Jin XC, 2002, GASTROENTEROLOGY, V123, P827, DOI 10.1053/gast.2002.35388; KAMEYAMA M, 1985, PFLUG ARCH EUR J PHY, V405, P285, DOI 10.1007/BF00582573; Karni R, 2003, FEBS LETT, V537, P47, DOI 10.1016/S0014-5793(03)00069-3; KLOCKNER U, 1992, PFLUG ARCH EUR J PHY, V420, P413, DOI 10.1007/BF00374479; Liu HY, 1997, CAN J PHYSIOL PHARM, V75, P1058, DOI 10.1139/cjpp-75-9-1058; MARKS TN, 1992, J GEN PHYSIOL, V99, P367, DOI 10.1085/jgp.99.3.367; Mitarai S, 2000, AM J PHYSIOL-CELL PH, V279, pC603, DOI 10.1152/ajpcell.2000.279.3.C603; Murakami M, 2003, MOL CELL BIOCHEM, V254, P217, DOI 10.1023/A:1027316017156; Murakami M, 2003, J BIOL CHEM, V278, P43261, DOI 10.1074/jbc.M211380200; NAKAYAMA S, 1995, AM J PHYSIOL-CELL PH, V269, pC48, DOI 10.1152/ajpcell.1995.269.1.C48; Nakayama S, 1995, J GEN PHYSIOL, V106, P1211, DOI 10.1085/jgp.106.6.1211; Nakayama S., 1996, P13; NAKAYAMA S, 1993, J PHYSIOL-LONDON, V471, P107, DOI 10.1113/jphysiol.1993.sp019893; NAKAYAMA S, 1993, J PHYSIOL-LONDON, V471, P87, DOI 10.1113/jphysiol.1993.sp019892; Nakayama S, 2000, J PHYSIOL-LONDON, V526, P47, DOI 10.1111/j.1469-7793.2000.00047.x; OCHI R, 1993, JPN J PHYSIOL, V43, P571, DOI 10.2170/jjphysiol.43.571; Ogura T, 1999, AM J PHYSIOL-HEART C, V276, pH1724, DOI 10.1152/ajpheart.1999.276.5.H1724; Rothberg BS, 2001, BIOPHYS J, V80, P3025, DOI 10.1016/S0006-3495(01)76268-6; Schafer M, 2000, AM J PHYSIOL-CELL PH, V279, pC495, DOI 10.1152/ajpcell.2000.279.2.C495; Sears CL, 1995, AM J PHYSIOL-GASTR L, V269, pG874, DOI 10.1152/ajpgi.1995.269.6.G874; Seki T, 1999, PFLUG ARCH EUR J PHY, V437, P317, DOI 10.1007/s004240050785; Smith LM, 1999, EUR J PHARMACOL, V370, P187, DOI 10.1016/S0014-2999(99)00119-3; Tsang F, 2002, BIOCHEM BIOPH RES CO, V293, P72, DOI 10.1016/S0006-291X(02)00170-5; Wang YG, 1998, AM J PHYSIOL-HEART C, V275, pH204, DOI 10.1152/ajpheart.1998.275.1.H204; Wijetunge S, 1995, BIOCHEM BIOPH RES CO, V217, P1039, DOI 10.1006/bbrc.1995.2874; Wijetunge S, 2000, BRIT J PHARMACOL, V129, P1347, DOI 10.1038/sj.bjp.0703186; Yamamoto K, 2003, AUTOIMMUN REV, V2, P13, DOI 10.1016/S1568-9972(02)00121-0; Yazawa K, 1997, PFLUG ARCH EUR J PHY, V433, P557, DOI 10.1007/s004240050314; YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753	44	12	13	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1492	+		10.1096/fj.05-5049fje	http://dx.doi.org/10.1096/fj.05-5049fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16738256				2022-12-28	WOS:000240266000028
J	Su, YC; Cui, ZQ; Li, ZZ; Block, ER				Su, Yunchao; Cui, Zhaoqiang; Li, Zhaozhong; Block, Edward R.			Calpain-2 regulation of VEGF-mediated angiogenesis	FASEB JOURNAL			English	Article						calpains; actin; calpastatin	ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; IN-VITRO; CELL-MIGRATION; FAMILY-MEMBERS; ACTIVATION; CALPASTATIN; INVOLVEMENT; TRANSFORMATION; ORGANIZATION	Angiogenesis is a complex process involving endothelial cell migration, proliferation, and differentiation as well as tube formation. These processes are stimulated by a variety of growth factors such as vascular endothelial growth factor (VEGF). VEGF-induced cytoskeletal reorganization plays a crucial role in the angiogenic processes. In the present study, we evaluated the role of calpain in VEGF-induced angiogenesis in vitro and in vivo. Human pulmonary microvascular endothelial cells (PMEC) were incubated with VEGF (10-60 ng/ml) for 2-24 h, after which we measured calpain activities, protein contents of the calpain subunits and of calpastatin, endothelial monolayer wound repair, tube formation, and actin cytoskeleton changes. Incubation of PMEC with VEGF resulted in dose- and time-dependent increases in calpain activity and protein content of calpain-2. VEGF did not change the protein contents of calpain-1 and the small subunit or of calpastatin. Incubation of PMEC with a VEGF receptor blocker prevented the VEGF-induced increase in calpain activity. Inhibition of calpain activity by siRNA directed against calpain-2 and by overexpression of calpastatin prevented VEGF-induced increases in actin stress fibers in endothelial cells and angiogenesis. Overexpression of calpastatin also inhibits vessel formation in subcutaneous (s.c.) matrigel plugs in mice. These results indicate that calpain mediates VEGF-induced angiogenic effects by modulating actin cytoskeletal organization.	Univ Florida, Dept Med, Coll Med, Gainesville, FL 32610 USA; Malcom Randall Vet Affairs Med Ctr, Res Serv, Gainesville, FL USA	State University System of Florida; University of Florida	Su, YC (corresponding author), Univ Florida, Dept Med, Coll Med, MSB M452,Box 100225,1600 SW Archer Rd, Gainesville, FL 32610 USA.	ysu@ufl.edu			NHLBI NIH HHS [HL52136, HL67951] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067951, R01HL052136, R37HL052136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88; Boussat S, 2000, AM J PHYSIOL-LUNG C, V279, pL371, DOI 10.1152/ajplung.2000.279.2.L371; Carragher NO, 2002, INT J BIOCHEM CELL B, V34, P1539, DOI 10.1016/S1357-2725(02)00069-9; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Cui ZQ, 2005, AM J RESP CELL MOL, V33, P513, DOI 10.1165/rcmb.2005-0046OC; Dedieu S, 2004, EXP CELL RES, V292, P187, DOI 10.1016/j.yexcr.2003.08.014; Deroanne CF, 2001, CARDIOVASC RES, V49, P647, DOI 10.1016/S0008-6363(00)00233-9; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Ferrara N, 2001, ACTA HAEMATOL-BASEL, V106, P148, DOI 10.1159/000046610; Forsberg NE, 2000, METH MOL B, V144, P319; Fox JEB, 1999, THROMB HAEMOSTASIS, V82, P385; Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Frelin C, 2000, ANN ENDOCRINOL-PARIS, V61, P70; Fujitani K, 1997, J CELL BIOCHEM, V66, P197, DOI 10.1002/(SICI)1097-4644(19970801)66:2<197::AID-JCB7>3.0.CO;2-L; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Khorchid A, 2002, NAT STRUCT BIOL, V9, P239, DOI 10.1038/nsb0402-239; Kliche S, 2001, IUBMB LIFE, V52, P61, DOI 10.1080/15216540252774784; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; Lee PC, 2000, MICROVASC RES, V60, P269, DOI 10.1006/mvre.2000.2265; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Linz-McGillem LA, 2004, STEM CELLS DEV, V13, P496, DOI 10.1089/1547328042417282; Min JK, 2004, CANCER RES, V64, P644, DOI 10.1158/0008-5472.CAN-03-3250; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Newcomb JK, 2000, METH MOL B, V144, P219; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Su YC, 2004, AM J PHYSIOL-LUNG C, V287, pL794, DOI 10.1152/ajplung.00079.2004; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; SUZUKI K, 2004, DIABETES, V53, P12; Tamada Y, 2000, J OCUL PHARMACOL TH, V16, P271, DOI 10.1089/jop.2000.16.271; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; Wendt A, 2004, BIOL CHEM, V385, P465, DOI 10.1515/BC.2004.054; Xu Y, 2002, J BIOL CHEM, V277, P21474, DOI 10.1074/jbc.M111689200; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	43	62	65	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1443	1451		10.1096/fj.05-5354com	http://dx.doi.org/10.1096/fj.05-5354com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816119				2022-12-28	WOS:000240266000021
J	Woodruff, TM; Crane, JW; Proctor, LM; Buller, KM; Shek, AB; de Vos, K; Pollitt, S; Williams, HM; Shiels, IA; Monk, PN; Taylor, SM				Woodruff, Trent M.; Crane, James W.; Proctor, Lavinia M.; Buller, Kathryn M.; Shek, Annie B.; de Vos, Kurt; Pollitt, Sandra; Williams, Hua M.; Shiels, Ian A.; Monk, Peter N.; Taylor, Stephen M.			Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration	FASEB JOURNAL			English	Article						complement system; inflammation; 3-nitropropionic acid	TOXIN 3-NITROPROPIONIC ACID; INFLAMMATORY-BOWEL-DISEASE; CENTRAL-NERVOUS-SYSTEM; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; COMPLEMENT-SYSTEM; ANAPHYLATOXIN C5A; STRIATAL LESIONS; HUMAN LEUKOCYTES; EXPRESSION	The complement system is thought to be involved in the pathogenesis of numerous neurological diseases, although its precise role remains controversial. In this study we used orally active C5a receptor antagonists (PMX53 and PMX205) developed in our laboratories in a rat model of 3-nitropropionic acid (3-NP) -induced Huntington's disease. Administration of the C5a antagonists (10 mg/kg/day, oral) either 48 h pre- or 48 h post-toxin significantly reduced body weight loss, anorexia, and behavioral and motor deficits associated with 3-NP intoxication. Striatal lesion size, apoptosis, neutrophil infiltration, and hemorrhage were also significantly reduced in C5a antagonist-treated rats. Immunohistochemical analysis demonstrated marked deposition of C3 and C9, and upregulation of C5a receptors on neuronal cells at the time of lesion formation. Inhibition of prostaglandins or TNF-alpha with ibuprofen or infliximab had no effect in this model. The C5a antagonists did not affect 3-NP-induced cell death when added directly to rat striatal neuronal cultures, indicating a secondary mechanism of action in vivo. Our findings demonstrate for the first time that complement activation in the brain, particularly C5a, is a key event in the pathogenesis of this disease model, and suggest a future role for inhibitors of C5a in the treatment of neurodegenerative diseases.	Univ Queensland, Promics Ltd, Brisbane, Qld 4072, Australia; Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Sheffield, Sch Med, Dept Neurol, Sheffield, S Yorkshire, England	University of Queensland; University of Queensland; University of Queensland; University of Sheffield	Woodruff, TM (corresponding author), Univ Queensland, Promics Ltd, Brisbane, Qld 4072, Australia.	trent.woodruff@promics.com	De Vos, Kurt/D-8380-2011; Monk, Peter/C-6155-2008; Woodruff, Trent M/B-4861-2009; Buller, Kathryn/F-1227-2010; Woodruff, Trent/AAS-4629-2020; Shiels, Ian/C-8046-2009	De Vos, Kurt/0000-0003-2161-6309; Monk, Peter/0000-0003-4637-3059; Woodruff, Trent M/0000-0003-1382-911X; Woodruff, Trent/0000-0003-1382-911X; Crane, James/0000-0002-4601-0189	Wellcome Trust [072231] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arumugam TV, 2004, SHOCK, V21, P401, DOI 10.1097/00024382-200405000-00002; Barnum SR, 2002, IMMUNOL RES, V26, P7, DOI 10.1385/IR:26:1-3:007; Benard M, 2004, J BIOL CHEM, V279, P43487, DOI 10.1074/jbc.M404124200; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Farkas I, 2003, J IMMUNOL, V170, P5764, DOI 10.4049/jimmunol.170.11.5764; Garcia M, 2002, J NEUROSCI, V22, P2174, DOI 10.1523/JNEUROSCI.22-06-02174.2002; Gasque P, 2002, MOL NEUROBIOL, V25, P1, DOI 10.1385/MN:25:1:001; Gavrilyuk V, 2005, J NEUROCHEM, V92, P1140, DOI 10.1111/j.1471-4159.2004.02942.x; Girardi G, 2003, J CLIN INVEST, V112, P1644, DOI 10.1172/JCI200318817; GOLDSTEIN I, 1973, P NATL ACAD SCI USA, V70, P2916, DOI 10.1073/pnas.70.10.2916; GOLDSTEIN IM, 1975, J CLIN INVEST, V56, P1155, DOI 10.1172/JCI108191; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Guyot MC, 1997, NEUROSCIENCE, V79, P45, DOI 10.1016/S0306-4522(96)00602-1; Harkin DW, 2004, J VASC SURG, V39, P196, DOI 10.1016/j.jvs.2003.07.001; Hillebrandt S, 2005, NAT GENET, V37, P835, DOI 10.1038/ng1599; Hosokawa M, 2003, GLIA, V42, P417, DOI 10.1002/glia.10234; Hua Y, 2000, J NEUROSURG, V92, P1016, DOI 10.3171/jns.2000.92.6.1016; Huber-Lang M, 2005, J IMMUNOL, V174, P1104, DOI 10.4049/jimmunol.174.2.1104; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; Klegeris Andis, 2005, Current Alzheimer Research, V2, P355, DOI 10.2174/1567205054367883; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; Kulkarni AP, 2004, ANN NY ACAD SCI, V1035, P147, DOI 10.1196/annals.1332.010; Lan Min-Yu, 2005, Chang Gung Med J, V28, P77; Leventhal L, 2000, J COMP NEUROL, V425, P471, DOI 10.1002/1096-9861(20001002)425:4<471::AID-CNE1>3.0.CO;2-U; March DR, 2004, MOL PHARMACOL, V65, P868, DOI 10.1124/mol.65.4.868; Mittoux V, 2002, J NEUROSCI, V22, P4478, DOI 10.1523/JNEUROSCI.22-11-04478.2002; Mukherjee P, 2000, J NEUROIMMUNOL, V105, P124, DOI 10.1016/S0165-5728(99)00261-1; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; NISHINO H, 1995, NEUROSCI LETT, V186, P161, DOI 10.1016/0304-3940(95)11311-J; Osaka H, 1999, NEUROSCIENCE, V88, P1073, DOI 10.1016/S0306-4522(98)00372-8; Osaka H, 1999, J CELL BIOCHEM, V73, P303, DOI 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.0.CO;2-2; Ouary S, 2000, NEUROSCIENCE, V97, P521, DOI 10.1016/S0306-4522(00)00020-8; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Singhrao SK, 1999, EXP NEUROL, V159, P362, DOI 10.1006/exnr.1999.7170; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Van Beek J, 2000, EXP NEUROL, V161, P373, DOI 10.1006/exnr.1999.7273; Vis JC, 2001, NEUROPATH APPL NEURO, V27, P68, DOI 10.1046/j.0305-1846.2001.00305.x; Woodruff TM, 2005, J PHARMACOL EXP THER, V314, P811, DOI 10.1124/jpet.105.086835; Woodruff TM, 2003, J IMMUNOL, V171, P5514, DOI 10.4049/jimmunol.171.10.5514; Woodruff TM, 2002, ARTHRITIS RHEUM-US, V46, P2476, DOI 10.1002/art.10449; Yasojima K, 1999, AM J PATHOL, V154, P927, DOI 10.1016/S0002-9440(10)65340-0	44	114	118	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1407	1417		10.1096/fj.05-5814com	http://dx.doi.org/10.1096/fj.05-5814com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816116				2022-12-28	WOS:000240266000018
J	Muhlhausler, BS; Adam, CL; Findlay, PA; Duffield, JA; McMillen, IC				Muhlhausler, B. S.; Adam, C. L.; Findlay, P. A.; Duffield, J. A.; McMillen, I. C.			Increased maternal nutrition alters development of the appetite-regulating network in the brain	FASEB JOURNAL			English	Article						nutrition; programming; energy balance; obesity	HYPOTHALAMIC GENE-EXPRESSION; BROWN ADIPOSE-TISSUE; NEUROPEPTIDE-Y; LEPTIN RECEPTOR; MESSENGER-RNA; NEURONS; SHEEP; RESPONSES; INSULIN; OVINE	Individuals exposed to an increased nutrient supply before birth have a high risk of becoming obese children and adults. It has been proposed that exposure of the fetus to high maternal nutrient intake results in permanent changes within the central appetite regulatory network. No studies, however, have investigated the impact of increased maternal nutrition on the appetite regulatory network in species in which this network develops before birth, as in the human. In the present study, pregnant ewes were fed a diet which provided 100% (control, n = 8) or similar to 160% (well-fed, n=8) of metabolizable energy requirements. Ewes were allowed to lamb spontaneously, and lambs were sacrificed at 30 days of postnatal age. All fat depots were dissected and weighed, and expression of the appetite-regulating neuropeptides and the leptin receptor ( OBRb) were determined by in situ hybridization. Lambs of well-fed ewes had higher glucose (Glc) concentrations during early postnatal life (F=5.93, P < 0.01) and a higher relative subcutaneous (s.c.) fat mass at 30 days of age (34.9 +/- 4.7 g/ kg vs. 22.8 +/- 3.3 g/ kg; P < 0.05). The hypothalamic expression of proopiomelanocortin was higher in lambs of well-fed ewes (0.48 +/- 0.09 vs. 0.28 +/- 0.04, P < 0.05). In lambs of over-nourished mothers, but not in controls, the expression of OBRb was inversely related to total relative fat mass (r(2)=0.50, P=0.05, n=8), and the direct relationship between the expression of the central appetite inhibitor CART and fat mass was lost. The expression of neuropeptide Y and AGRP was inversely related to total relative fat mass (NPY, r(2)=0.28, P < 0.05; agouti-related peptide, r(2)=0.39, P < 0.01). These findings suggest that exposure to increased nutrition before birth alters the responses of the central appetite regulatory system to signals of increased adiposity after birth.-Muhlhausler, B. S., Adam, C. L., Findlay, P. A., Duffield, J. A., and McMillen, I. C. Increased maternal nutrition alters development of the appetite-regulating network in the brain.	Univ Adelaide, Res Ctr Early Origins Adult Hlth, Sch Mol & Biomed Sci, Adelaide, SA, Australia; Rowett Res Inst, Obes & Metab Div, Aberdeen, Scotland	University of Adelaide; University of Aberdeen	McMillen, IC (corresponding author), Univ S Adelaide, Sansom Res Inst, Adelaide, SA 5005, Australia.	caroline.mcmillen@unisa.edu.au	McMillen, Isabella Caroline/N-5540-2019	Muhlhausler, Beverly/0000-0002-9021-6790				Adam CL, 1997, J ENDOCRINOL, V152, P329, DOI 10.1677/joe.0.1520329; Adam CL, 2002, NEUROENDOCRINOLOGY, V75, P250, DOI 10.1159/000054716; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; ALDERMANN GA, 1975, MINISTRY AGR FISHERI, V33; Barrett P, 2001, J NEUROENDOCRINOL, V13, P347, DOI 10.1046/j.1365-2826.2001.00634.x; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; Budge H, 2000, PEDIATR RES, V47, P781, DOI 10.1203/00006450-200006000-00017; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Catalano PM, 2003, AM J OBSTET GYNECOL, V189, P1698, DOI 10.1016/S0002-9378(03)00828-7; Cone RD, 2001, INT J OBESITY, V25, pS63, DOI 10.1038/sj.ijo.0801913; Davidowa H, 2003, EUR J NEUROSCI, V18, P613, DOI 10.1046/j.1460-9568.2003.02789.x; Davidowa H, 2000, NEUROSCI LETT, V293, P21, DOI 10.1016/S0304-3940(00)01475-0; Davidowa H, 2000, NEUROREPORT, V11, P2795, DOI 10.1097/00001756-200008210-00037; Davidowa H, 2001, NEUROREPORT, V12, P3201, DOI 10.1097/00001756-200110290-00012; Dunn-Meynell AA, 2002, DIABETES, V51, P2056, DOI 10.2337/diabetes.51.7.2056; FOWDEN AL, 1995, FETUS NEONATE PHYSL, V3, P31; Grove KL, 2003, PHYSIOL BEHAV, V79, P47, DOI 10.1016/S0031-9384(03)00104-5; HIGUCHI H, 1988, J BIOL CHEM, V263, P6288; HINCH GN, 1989, APPL ANIM BEHAV SCI, V22, P39, DOI 10.1016/0168-1591(89)90078-6; Ibrahim N, 2003, ENDOCRINOLOGY, V144, P1331, DOI 10.1210/en.2002-221033; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kauter K, 2000, J ENDOCRINOL, V166, P127, DOI 10.1677/joe.0.1660127; Koutcherov Y, 2003, J CHEM NEUROANAT, V26, P253, DOI 10.1016/j.jchemneu.2003.07.002; Martin RJ, 1998, P SOC EXP BIOL MED, V219, P200; Mercer JG, 1998, REGUL PEPTIDES, V75-6, P271, DOI 10.1016/S0167-0115(98)00078-0; MERCER JG, 1995, AM J PHYSIOL-REG I, V269, pR1099, DOI 10.1152/ajpregu.1995.269.5.R1099; Mercer JG, 2000, AM J PHYSIOL-REG I, V278, pR271, DOI 10.1152/ajpregu.2000.278.1.R271; Muhlhausler BS, 2004, J NEUROENDOCRINOL, V16, P502, DOI 10.1111/j.1365-2826.2004.01197.x; Muhlhausler BS, 2005, J PHYSIOL-LONDON, V565, P185, DOI 10.1113/jphysiol.2004.079079; Muhlhausler BS, 2002, BIOL REPROD, V67, P493, DOI 10.1095/biolreprod67.2.493; PETTITT DJ, 1987, DIABETES CARE, V10, P76, DOI 10.2337/diacare.10.1.76; Picciano MF, 2003, J NUTR, V133, p1997S, DOI 10.1093/jn/133.6.1997S; Plagemann A, 1997, INT J OBESITY, V21, P451, DOI 10.1038/sj.ijo.0800429; Plagemann A, 1999, J NEUROENDOCRINOL, V11, P541; RUSSEL AJF, 1981, J AGR SCI, V97, P723, DOI 10.1017/S0021859600037096; Silverman BL, 1998, DIABETES CARE, V21, pB142; SILVERMAN BL, 1991, DIABETES, V40, P121, DOI 10.2337/diab.40.2.S121; Warnes KE, 1998, J NEUROENDOCRINOL, V10, P51, DOI 10.1046/j.1365-2826.1998.00172.x; Williams G, 2001, PHYSIOL BEHAV, V74, P683, DOI 10.1016/S0031-9384(01)00612-6; Williams LM, 1999, J NEUROENDOCRINOL, V11, P165	40	175	177	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1257	+		10.1096/fj.05-5241fje	http://dx.doi.org/10.1096/fj.05-5241fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16684802				2022-12-28	WOS:000240210300044
J	Xu, Y; Williams, SJ; O'Brien, D; Davidge, ST				Xu, Yi; Williams, Sarah J.; O'Brien, Darryl; Davidge, Sandra T.			Hypoxia or nutrient restriction during pregnancy in rats leads to progressive cardiac remodeling and impairs postischemic recovery in adult male offspring	FASEB JOURNAL			English	Article						cardiac development; ischemia; reperfusion	INTRAUTERINE GROWTH RESTRICTION; FOR-GESTATIONAL-AGE; CARDIOVASCULAR-DISEASE; FIBRILLAR COLLAGEN; MATERNAL HYPOXIA; GENE-EXPRESSION; FETAL-GROWTH; RETARDATION; CARDIOPROTECTION; HYPERTENSION	Intrauterine growth restriction ( IUGR) increases the risk of developing adult-onset cardiovascular disease. We hypothesized that IUGR resulting from maternal hypoxia or nutrient restriction during late gestation will produce cardiac remodeling and impair cardiac recovery after ischemia/reperfusion (I/R) in adult male offspring aged 4 or 7 mo. Sprague-Dawley rats were randomized on day 15 of pregnancy to hypoxia (IUGR-H, 12% oxygen), nutrient restriction (IUGR-NR, 40% of control diet) or control ( room air) groups. In 4-mo IUGR-H offspring, left ventricular wt/body wt ratio (LVW/BW) and right ventricular wt/BW ratio (RVW/BW) increased, in association with increased collagen I and III expression, beta and alpha myosin heavy chain (beta/alpha MHC) ratio, and decreased matrix metalloproteinase (MMP)-2 activity compared to the other groups. Left ventricular end diastolic pressure was higher in perfused hearts. Functional recovery after I/R was remarkably reduced (10 +/- 3%) compared to both control (39 +/- 5%) and IUGR-NR rats (32 +/- 4%). At 7 mo, both IUGR-H and IUGR-NR offspring had increased LVW/BW, collagen I and III, beta/alpha MHC ratio, and decreased cardiac recovery and MMP-2 activity compared to control. These findings suggest that hypoxia or undernutrition during development leads to pathological cardiac remodeling, diastolic dysfunction, and increased sensitivity to ischemic injury during adult life.-Xu, Y., Williams, S. J. O'Brien, D., and Davidge, S. T. Hypoxia or nutrient restriction during pregnancy in rats leads to progressive cardiac remodeling and impairs postischemic recovery in adult male offspring.	Univ Alberta, Perinatal Res Ctr, Dept Obstet Gynecol & Physiol, Edmonton, AB T6G 2S2, Canada; Univ Adelaide, Dept Physiol, Ctr Early Origins Adult Hlth, Sch Mol & Biomed Sci, Adelaide, SA, Australia	University of Alberta; University of Adelaide	Davidge, ST (corresponding author), Univ Alberta, Perinatal Res Ctr, Dept Obstet Gynecol & Physiol, 232 HMRC, Edmonton, AB T6G 2S2, Canada.	sandra.davidge@ualberta.ca		Davidge, Sandra/0000-0002-5559-4905				ALPERT NR, 1982, FED PROC, V41, P192; ALPERT NR, 1979, AM J CARDIOL, V44, P947, DOI 10.1016/0002-9149(79)90227-3; Barker DJP, 2002, TRENDS ENDOCRIN MET, V13, P364, DOI 10.1016/S1043-2760(02)00689-6; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; Battista MC, 2005, J PHYSIOL-LONDON, V565, P197, DOI 10.1113/jphysiol.2004.078139; BERSOHN MM, 1977, CIRC RES, V40, P510, DOI 10.1161/01.RES.40.5.510; Briscoe TA, 2004, AM J OBSTET GYNECOL, V191, P847, DOI 10.1016/j.ajog.2004.01.050; BUTTRICK P, 1991, CIRC RES, V68, P645, DOI 10.1161/01.RES.68.3.645; Corstius HB, 2005, PEDIATR RES, V57, P796, DOI 10.1203/01.PDR.0000157726.65492.CD; de Onis M, 1998, EUR J CLIN NUTR, V52, pS5; DEGRAUW TJ, 1986, BIOL NEONATE, V49, P85, DOI 10.1159/000242515; EGHBALI M, 1988, J MOL CELL CARDIOL, V20, P267, DOI 10.1016/S0022-2828(88)80059-2; EGHBALI M, 1990, MOL CELL BIOCHEM, V96, P1; GLEED RD, 1991, J APPL PHYSIOL, V70, P1146, DOI 10.1152/jappl.1991.70.3.1146; Godfrey KM, 2000, AM J CLIN NUTR, V71, p1344S, DOI 10.1093/ajcn/71.5.1344s; Han HC, 2004, J PHYSIOL-LONDON, V558, P111, DOI 10.1113/jphysiol.2004.061697; Harada K, 1998, EARLY HUM DEV, V51, P197, DOI 10.1016/S0378-3782(97)00122-9; Hemmings DG, 2005, AM J PHYSIOL-HEART C, V289, pH674, DOI 10.1152/ajpheart.00191.2005; Kamitomo M, 2002, J SOC GYNECOL INVEST, V9, P335, DOI 10.1016/S1071-5576(02)00180-6; Kumaran K, 2000, HEART, V83, P272, DOI 10.1136/heart.83.3.272; Leipala JA, 2003, PEDIATR RES, V53, P989, DOI 10.1203/01.PDR.0000061564.86797.78; Li GH, 2003, J SOC GYNECOL INVEST, V10, P265, DOI 10.1016/S1071-5576(03)00074-1; McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Ostadalova I, 2002, PEDIATR RES, V52, P561, DOI 10.1203/01.PDR.0000030879.20888.5B; POPE B, 1980, FEBS LETT, V118, P205, DOI 10.1016/0014-5793(80)80219-5; Reiser PJ, 2001, AM J PHYSIOL-HEART C, V280, pH1814, DOI 10.1152/ajpheart.2001.280.4.H1814; Robert V, 1997, LAB INVEST, V76, P729; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; TAKAHASHI T, 1992, J CLIN INVEST, V89, P939, DOI 10.1172/JCI115675; Tsyvian P, 2002, ULTRASOUND OBST GYN, V20, P35, DOI 10.1046/j.1469-0705.2002.00734.x; VANGEIJN HP, 1980, AM J OBSTET GYNECOL, V137, P43, DOI 10.1016/0002-9378(80)90384-1; VEILLE JC, 1993, AM J PERINAT, V10, P275, DOI 10.1055/s-2007-994739; WEBER KT, 1988, AM HEART J, V116, P1641, DOI 10.1016/0002-8703(88)90763-6; WEBER KT, 1990, CIRCULATION, V82, P1387, DOI 10.1161/01.CIR.82.4.1387; WEBER KT, 1989, J AM COLL CARDIOL, V13, P1637, DOI 10.1016/0735-1097(89)90360-4; Williams SJ, 2005, J PHYSIOL-LONDON, V565, P125, DOI 10.1113/jphysiol.2005.084889; Williams SJ, 2005, AM J PHYSIOL-REG I, V288, pR360, DOI 10.1152/ajpregu.00178.2004; Xi L, 1999, LIFE SCI, V65, P935, DOI 10.1016/S0024-3205(99)00323-9; Xiao DL, 2000, J SOC GYNECOL INVEST, V7, P279, DOI 10.1016/S1071-5576(00)00066-6; Xu Y, 2000, HYPERTENSION, V36, P506, DOI 10.1161/01.HYP.36.4.506; Xu Y, 2004, AM J PHYSIOL-HEART C, V287, pH165, DOI 10.1152/ajpheart.00037.2004; Xu Y, 2003, CARDIOVASC RES, V57, P388, DOI 10.1016/S0008-6363(02)00705-8; Xu Y, 2002, AM J PHYSIOL-HEART C, V282, pH1206, DOI 10.1152/ajpheart.00839.2000	45	142	148	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1251	+		10.1096/fj.05-4917fje	http://dx.doi.org/10.1096/fj.05-4917fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16632594				2022-12-28	WOS:000240210300042
J	Zhao, Y; Patzer, A; Herdegen, T; Gohlke, P; Culman, J				Zhao, Yi; Patzer, Andreas; Herdegen, Thomas; Gohlke, Peter; Culman, Juraj			Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats	FASEB JOURNAL			English	Article						cerebral ischemia; PPAR gamma; pioglitazone; cyclooxygenase-2; cyclooxygenase-1; rat	CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; PPAR-GAMMA; CELL-DEATH; CORTICAL-NEURONS; GENE-EXPRESSION; BRAIN ISCHEMIA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); GLOBAL-ISCHEMIA; ACID-RECEPTORS	Up-regulation of cyclooxygenase (COX)-2 exacerbates neuronal injury after cerebral ischemia and contributes to neuronal cell death. The present study clarifies the function of cerebral peroxisome-proliferator-activated receptor(s) gamma (PPAR gamma) in the expression of COX-2 in neurons of the rat brain after middle cerebral artery occlusion (MCAO) with reperfusion by immunohistochemistry, Western blot, and immunofluorescence staining. In peri-infarct cortical areas the PPAR gamma was located in both microglia and neurons, whereas COX-2 was almost exclusively expressed in neurons. PPAR gamma immunolabeling reached the peak 12 h after MCAO, whereas the number of COX-2 immunostained cells gradually rose and reached its peak at 48 h. Intracerebroventricular infusion of pioglitazone, an agonist of the PPAR gamma, over a 5-day period before and 2 days after MCAO, reduced the infarct size, the expression of tumor necrosis factor alpha (TNF-alpha), COX-2, and the number of cells positively stained for COX-1 and COX-2 in the peri-infarct cortical regions. COX-2 induction was also attenuated in the ipsilateral but not in the contralateral hippocampus. In primary cortical neurons expressing the PPAR gamma, pioglitazone suppressed COX-2 expression in response to oxidative stress. This protective effect was reversed after cotreatment with GW 9662, a selective antagonist of the PPAR gamma, clearly demonstrating a PPAR gamma-dependent mechanism. Our data provide evidence that activation of neuronal PPAR gamma considerably contributes to neuroprotection by prevention of COX-2 up-regulation in vitro and in peri-infarct brain areas.	Univ Hosp Schleswig Holstein, Inst Pharmacol, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Culman, J (corresponding author), Univ Hosp Schleswig Holstein, Inst Pharmacol, Campus Kiel Hosp Str 4, D-24105 Kiel, Germany.	juraj.culman@pharmakologie.uni-kiel.de	Zhao, Yi/A-8806-2010; herdegen, thomas/E-5135-2010					Araki E, 2001, STROKE, V32, P2370, DOI 10.1161/hs1001.096057; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Candelario-Jalil E, 2003, J NEUROCHEM, V86, P545, DOI 10.1046/j.1471-4159.2003.01812.x; Candelario-Jalil E, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-3; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Cimini A, 2005, NEUROSCIENCE, V130, P325, DOI 10.1016/j.neuroscience.2004.09.043; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; Cristiano L, 2001, J NEUROCYTOL, V30, P671, DOI 10.1023/A:1016525716209; Cullingford TE, 1998, J NEUROCHEM, V70, P1366; Dai WJ, 1999, STROKE, V30, P2391, DOI 10.1161/01.STR.30.11.2391; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dobrian AD, 2004, HYPERTENSION, V43, P48, DOI 10.1161/01.HYP.0000103629.01745.59; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; Drew PD, 2005, BRAIN RES REV, V48, P322, DOI 10.1016/j.brainresrev.2004.12.020; Graham SH, 2003, ARCH NEUROL-CHICAGO, V60, P628, DOI 10.1001/archneur.60.4.628; Han SW, 2003, CLIN CANCER RES, V9, P4627; Heneka MT, 2000, J NEUROSCI, V20, P6862, DOI 10.1523/JNEUROSCI.20-18-06862.2000; Heneka MT, 1999, J NEUROIMMUNOL, V100, P156, DOI 10.1016/S0165-5728(99)00192-7; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086; Iadecola C, 2001, J CEREBR BLOOD F MET, V21, P1436, DOI 10.1097/00004647-200112000-00008; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kielian T, 2003, J NEUROSCI RES, V71, P315, DOI 10.1002/jnr.10501; Kim EJ, 2002, BRAIN RES, V941, P1, DOI 10.1016/S0006-8993(02)02480-0; Koistinaho J, 1999, STROKE, V30, P1900, DOI 10.1161/01.STR.30.9.1900; Koizumi J., 1986, JPN J STROKE, V8, P1, DOI DOI 10.3995/JSTROKE.8.1; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; Lin BJ, 2003, J MICROLITH MICROFAB, V2, P5, DOI 10.1117/1.1536623; Lou M, 2004, J CEREBR BLOOD F MET, V24, P536, DOI 10.1097/00004647-200405000-00008; Luna-Medina R, 2005, J BIOL CHEM, V280, P21453, DOI 10.1074/jbc.M414390200; Mendez M, 2003, HYPERTENSION, V42, P844, DOI 10.1161/01.HYP.0000085332.69777.D1; Miettinen S, 1997, P NATL ACAD SCI USA, V94, P6500, DOI 10.1073/pnas.94.12.6500; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Niwa K, 2001, CIRC RES, V88, P600, DOI 10.1161/01.RES.88.6.600; Nogawa S, 1997, J NEUROSCI, V17, P2746; Pepicelli O, 2002, J NEUROCHEM, V81, P1028, DOI 10.1046/j.1471-4159.2002.00897.x; Phillis John W., 2003, Critical Reviews in Neurobiology, V15, P61, DOI 10.1615/CritRevNeurobiol.v15.i1.30; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sasaki T, 2004, J CEREBR BLOOD F MET, V24, P107, DOI 10.1097/01.WCB.0000100065.36077.4A; Schmid-Elsaesser R, 1998, STROKE, V29, P2162, DOI 10.1161/01.STR.29.10.2162; Schwab JM, 2003, ARCH NEUROL-CHICAGO, V60, P630, DOI 10.1001/archneur.60.4.630; SHIRAZ T, 2005, STROKE, V36, P353; Smith SA, 2003, J NEUROSCI RES, V72, P747, DOI 10.1002/jnr.10613; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Sundararajan S, 2005, NEUROSCIENCE, V130, P685, DOI 10.1016/j.neuroscience.2004.10.021; Sundararajan S, 2004, DRUG NEWS PERSPECT, V17, P229, DOI 10.1358/dnp.2004.17.4.829049; Tomimoto H, 2002, ACTA NEUROPATHOL, V104, P601, DOI 10.1007/s00401-002-0590-0; Vasudevan Abu R, 2004, Diabetes Technol Ther, V6, P850, DOI 10.1089/dia.2004.6.850; Xu JH, 2003, STROKE, V34, P1287, DOI 10.1161/01.STR.0000066308.25088.64; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yokota C, 2004, NEUROSCI LETT, V357, P219, DOI 10.1016/j.neulet.2003.12.109; Zhao Y, 2005, J NEUROCHEM, V94, P1395, DOI 10.1111/j.1471-4159.2005.03275.x; Zhao Y, 2005, EUR J NEUROSCI, V22, P278, DOI 10.1111/j.1460-9568.2005.04200.x	60	162	171	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1162	1175		10.1096/fj.05-5007com	http://dx.doi.org/10.1096/fj.05-5007com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770015				2022-12-28	WOS:000240210300016
J	Bilsland, LG; Dick, JRT; Pryce, G; Petrosino, S; Di Marzo, V; Baker, D; Greensmith, L				Bilsland, Lynsey G.; Dick, James R. T.; Pryce, Gareth; Petrosino, Stefania; Di Marzo, Vincenzo; Baker, David; Greensmith, Linda			Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice	FASEB JOURNAL			English	Article						motoneuron; WIN55,212-2; endocannabinoids; neurodegeneration; transgenic mice	AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MOUSE MODEL; MOTOR-NEURON DEGENERATION; RECEPTOR KNOCKOUT MICE; RAT MICROGLIAL CELLS; MULTIPLE-SCLEROSIS; PROLONGS SURVIVAL; FAMILIAL ALS; SPINAL-CORD; TNF-ALPHA	Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the selective loss of motoneurons in the spinal cord, brain stem, and motor cortex. However, despite intensive research, an effective treatment for this disease remains elusive. In this study we show that treatment of postsymptomatic, 90-day-old SOD1(G93A) mice with a synthetic cannabinoid, WIN55,212-2, significantly delays disease progression. Furthermore, genetic ablation of the Faah enzyme, which results in raised levels of the endocannabinoid anandamide, prevented the appearance of disease signs in 90-day-old SOD1(G93A) mice. Surprisingly, elevation of cannabinoid levels with either WIN55,212-2 or Faah ablation had no effect on life span. Ablation of the CB(1) receptor, in contrast, had no effect on disease onset in SOD1(G93A) mice but significantly extended life span. Together these results show that cannabinoids have significant neuroprotective effects in this model of ALS and suggest that these beneficial effects may be mediated by non-CB(1) receptor mechanisms.	UCL, Sobell Dept Motor Neurosci & Movement Disorders, Inst Neurol, London WC1N 3BG, England; UCL, Dept Neuroinflammat, Inst Neurol, London WC1N 3BG, England; CNR, Ist Chim Biomol, Endocannabinoid Res Grp, I-80125 Naples, Italy	University of London; University College London; University of London; University College London; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR)	Greensmith, L (corresponding author), UCL, Sobell Dept Motor Neurosci & Movement Disorders, Inst Neurol, Queen Sq, London WC1N 3BG, England.	l.greensmith@ion.ucl.ac.uk	Di Marzo, Vincenzo/AAD-7742-2019	Di Marzo, Vincenzo/0000-0002-1490-3070	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abood ME, 2001, NEUROSCI LETT, V309, P197, DOI 10.1016/S0304-3940(01)02065-1; Alexianu ME, 2001, NEUROLOGY, V57, P1282, DOI 10.1212/WNL.57.7.1282; Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Baker D, 2001, FASEB J, V15, P300, DOI 10.1096/fj.00-0399fje; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Cadas H, 1996, J NEUROSCI, V16, P3934; Canton T, 2001, J PHARMACOL EXP THER, V299, P314; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; CUDKOWICZ M, 2004, CONSORTIUM NEALS S2, V5; Culling CFA, 1963, HDB HISTOPATHOLOGICA, V2nd, P362; Di Marzo V, 2000, J NEUROCHEM, V75, P2434, DOI 10.1046/j.1471-4159.2000.0752434.x; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Drachman DB, 2002, ANN NEUROL, V52, P771, DOI 10.1002/ana.10374; Facchinetti F, 2003, GLIA, V41, P161, DOI 10.1002/glia.10177; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hajos N, 2001, NEUROSCIENCE, V106, P1, DOI 10.1016/S0306-4522(01)00287-1; Hall ED, 1998, GLIA, V23, P249, DOI 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hampson AJ, 1998, J NEUROCHEM, V70, P671; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HH, 2002, J NEUROCHEM, V82, P154, DOI 10.1046/j.1471-4159.2002.00961.x; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Kieran D, 2004, NAT MED, V10, P402, DOI 10.1038/nm1021; Kieran D, 2004, NEUROSCIENCE, V125, P427, DOI 10.1016/j.neuroscience.2004.01.046; Klegeris A, 2003, BRIT J PHARMACOL, V139, P775, DOI 10.1038/sj.bjp.0705304; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Maihofner C, 2003, EUR J NEUROSCI, V18, P1527, DOI 10.1046/j.1460-9568.2003.02879.x; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Marsicano G, 2002, J NEUROCHEM, V80, P448, DOI 10.1046/j.0022-3042.2001.00716.x; Massa F, 2004, J CLIN INVEST, V113, P1202, DOI 10.1172/JCI200419465; McGeer PL, 2002, MUSCLE NERVE, V26, P459, DOI 10.1002/mus.10191; Molina-Holgado F, 2003, J NEUROSCI, V23, P6470; MolinaHolgado F, 1997, NEUROREPORT, V8, P1929, DOI 10.1097/00001756-199705260-00027; Nagayama T, 1999, J NEUROSCI, V19, P2987; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pompl PN, 2003, FASEB J, V17, P725, DOI 10.1096/fj.02-0876fje; Pryce G, 2003, BRAIN, V126, P2191, DOI 10.1093/brain/awg224; Puffenbarger RA, 2000, GLIA, V29, P58, DOI 10.1002/(SICI)1098-1136(20000101)29:1<58::AID-GLIA6>3.3.CO;2-N; Raman C, 2004, AMYOTROPH LATERAL SC, V5, P33, DOI 10.1080/14660820310016813; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sharp PS, 2005, NEUROSCIENCE, V130, P897, DOI 10.1016/j.neuroscience.2004.09.069; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; Sugiura T, 2000, BIOCHEM BIOPH RES CO, V271, P654, DOI 10.1006/bbrc.2000.2686; Tikka TM, 2002, BRAIN, V125, P722, DOI 10.1093/brain/awf068; Van Damme P, 2003, NEUROSCI LETT, V343, P81, DOI 10.1016/S0304-3940(03)00314-8; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667; WEYDT P, 2003, 2003 ABSTRACT VIEWER; Witting A, 2004, J NEUROCHEM, V89, P1555, DOI 10.1111/j.1471-4159.2004.02544.x; Yasojima K, 2001, NEUROLOGY, V57, P952, DOI 10.1212/WNL.57.6.952; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	53	104	109	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					1003	+		10.1096/fj.05-4743fje	http://dx.doi.org/10.1096/fj.05-4743fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571781				2022-12-28	WOS:000240157700036
J	Robert, JS				Robert, Jason Scott			The science and ethics of making part-human animals in stem cell biology	FASEB JOURNAL			English	Article						chimeras; ethics; history; policy; stem cells	CHIMERAS; ISSUES; MODEL; SHEEP; DIFFERENTIATION; TRANSPLANTATION; ORGANISM; DEFENSE; DIGNITY; PATENTS	The National Academy of Sciences recently issued voluntary guidelines to govern human embryonic stem cell research. Among other restrictions, these guidelines prohibit certain kinds of combinations of human and nonhuman animal cells, and call for ethics review and oversight of any protocol involving the transfer of human embryonic stem cells into nonhuman animals. In this essay, I discuss the history of and scientific rationales for combining human cells with cells of nonhuman animals, and critically assess the most recent attempts to limit such research on moral grounds-and find them lacking. Nonetheless, as I show, this research remains scientifically and morally contested. I then explore whether and how the NAS's recommended Embryonic Stem Cell Research and Oversight committees will allow for scientifically well-informed moral assessment of this controversial, but possibly important, research.	Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Robert, JS (corresponding author), Arizona State Univ, Sch Life Sci, POB 874501, Tempe, AZ 85287 USA.	jason.robert@asu.edu		Robert, Jason/0000-0002-5346-0575				Almeida-Porada G, 2005, BRIT J HAEMATOL, V130, P276, DOI 10.1111/j.1365-2141.2005.05588.x; Almeida-Porada G, 2004, YONSEI MED J, V45, P7; Almeida-Porada G, 2004, BLOOD, V104, P2582, DOI 10.1182/blood-2004-01-0259; Bostrom N, 2005, BIOETHICS, V19, P202, DOI 10.1111/j.1467-8519.2005.00437.x; Brivanlou AH, 2003, SCIENCE, V300, P913, DOI 10.1126/science.1082940; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Caulfield T, 2005, PLOS MED, V2, P736, DOI 10.1371/journal.pmed.0020244; Check E, 2004, NATURE, V431, P885, DOI 10.1038/431885a; Chen Y, 2003, CELL RES, V13, P251, DOI 10.1038/sj.cr.7290170; Dawson L, 2003, FERTIL STERIL, V80, P1077, DOI 10.1016/S0015-0282(03)02218-0; DeWitt N, 2002, NATURE, V420, P255, DOI 10.1038/420255a; Dick JE, 2001, ANN NY ACAD SCI, V938, P184; DICK JE, 1991, CANCER CELL-MON REV, V3, P39; DOWIE M, 2004, MOTHER JONES     JAN, P48; DOWIE M, 2004, MOTHER JONES     JAN, P84; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; FEHILLY CB, 1984, NATURE, V307, P634, DOI 10.1038/307634a0; Fukuyama Francis, 2002, OUR POSTHUMAN FUTURE; Goldstein RS, 2002, DEV DYNAM, V225, P80, DOI 10.1002/dvdy.10108; Greene M, 2005, SCIENCE, V309, P385, DOI 10.1126/science.1112207; HARRISON RG, 1969, ORG DEV EMBRYO, P215; Institute of Medicine and National Research Council, 2007, GUID HUM EMBR STEM C, DOI [10.17226/11870, DOI 10.17226/11153]; Karpowicz P, 2005, KENNEDY INST ETHIC J, V15, P107, DOI 10.1353/ken.2005.0015; Karpowicz P, 2003, AM J BIOETHICS, V3, pW17; Karpowicz P, 2004, NAT MED, V10, P331, DOI 10.1038/nm0404-331; KRIEGER LM, 2002, MERCURY NEWS    1209; Laubichler MD, 2000, PHILOS SCI, V67, pS256, DOI 10.1086/392823; Laubichler MD, 2000, PHILOS SCI, V67, pS289, DOI 10.1086/392826; Le Douarin N., 1969, Bulletin Biologique de la France et de la Belgique, V103, P435; Le Douarin NM, 2004, MECH DEVELOP, V121, P1089, DOI 10.1016/j.mod.2004.06.003; Macklin R, 2003, BRIT MED J, V327, P1419, DOI 10.1136/bmj.327.7429.1419; Maienschein Jane., 2003, WHOSE VIEW LIFE EMBR, DOI [10.4159/9780674040434, DOI 10.4159/9780674040434]; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; McLaren A., 1976, MAMMALIAN CHIMAERAS; MEINECKETILLMANN S, 1984, NATURE, V307, P637, DOI 10.1038/307637a0; MORENO JD, 2005, NTA BIOTECHNOL, V23, P723; MOSIER DE, 1996, SEMIN IMMUNOL, V8, P185; MOTT M, 2005, NATL GEOGRAPHIC 0125; NEWMAN SA, 2002, LAHEY CLIN MED ETHIC, V9, P4; NEWMAN SA, 2002, LAHEY CLIN MED ETHIC, V9, P7; Ourednik V, 2001, SCIENCE, V293, P1820, DOI 10.1126/science.1060580; Resnik DB, 2003, AM J BIOETHICS, V3, P35, DOI 10.1162/15265160360706534; Resnik DB, 2001, J LAW MED ETHICS, V29, P152, DOI 10.1111/j.1748-720X.2001.tb00335.x; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Robert JS, 2004, BIOESSAYS, V26, P1005, DOI 10.1002/bies.20100; ROSSANT J, 1980, SCIENCE, V208, P419, DOI 10.1126/science.7367871; Solter D, 2003, NAT BIOTECHNOL, V21, P1154, DOI 10.1038/nbt1003-1154; Tam PPL, 2003, DEVELOPMENT, V130, P6155, DOI 10.1242/dev.00893; TARKOWSKI AK, 1961, NATURE, V190, P857, DOI 10.1038/190857a0; WEISS R, 2005, WASHINGTON POST 0213	50	33	33	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					838	845		10.1096/fj.05-4286lsf	http://dx.doi.org/10.1096/fj.05-4286lsf			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675841				2022-12-28	WOS:000240157700006
J	Servillo, L; Balestrieri, C; Giovane, A; Pari, P; Palma, D; Giannattasio, G; Triggiani, M; Balestrieri, ML				Servillo, Luigi; Balestrieri, Ciro; Giovane, Alfonso; Pari, Paola; Palma, Davide; Giannattasio, Giorgio; Triggiani, Massimo; Balestrieri, Maria Luisa			Lysophospholipid transacetylase in the regulation of PAF levels in human monocytes and macrophages	FASEB JOURNAL			English	Article						PAF; inflammation	PLATELET-ACTIVATING-FACTOR; FACTOR (PAF)-DEPENDENT TRANSACETYLASE; COLONY-STIMULATING FACTOR; FACTOR-ACETYLHYDROLASE; ENDOTHELIAL-CELLS; PROTEIN-KINASE; ALVEOLAR MACROPHAGES; OXIDATIVE STRESS; ACYL ANALOGS; BIOSYNTHESIS	The transacetylase (TA), reported to be identical to platelet-activating factor (PAF) acetylhydrolase (II), is a multifunctional enzyme with three catalytic activities: lysophospholipid transacetylase (TAL), sphingosine transacetylase (TAS), and acetylhydrolase (AH). We report that TAL activity participates in the control of PAF levels in monocytes and macrophages and that its regulation differs in these two types of cells. In monocytes, LPS or granulocyte-macrophage colony-stimulating factor (GM-CSF) specifically increased the TAL activity. Western blot analysis and enzyme assays on immunoprecipitates revealed that the increased activity can be ascribed to PAF-AH (II) and that both translocation from cytosol to membranes and p38/ ERKs-mediated phosphorylation regulate the enzyme activation. Instead, in macrophages differentiated in vitro from monocytes by incubation with FCS, an increase of both TAL and AH activities was observed. Moreover, activation of ERKs and p38 MAP kinase was not required for the up-regulation of PAF-AH (II) in differentiated macrophages. The differences observed in macrophages as compared to monocytes can be explained by 1) p38/ ERKs-independent phosphorylation of PAF-AH (II) and 2) appearance of plasma PAF-AH in the course of macrophage differentiation.	Univ Naples 2, Dept Biochem & Biophys, I-80138 Naples, Italy; Univ Naples Federico II, Div Allergy & Clin Immunol, Naples, Italy	Universita della Campania Vanvitelli; University of Naples Federico II	Balestrieri, C (corresponding author), Univ Naples 2, Dept Biochem & Biophys, Via Le Crecchio 7, I-80138 Naples, Italy.	mluisa.balestrieri@unina2.it	Triggiani, Massimo/K-8271-2016	Triggiani, Massimo/0000-0001-7318-2093; Balestrieri, Maria Luisa/0000-0001-6001-1789; Giovane, Alfonso/0000-0002-2508-2597				AKOH CC, 1990, LIPIDS, V25, P613, DOI 10.1007/BF02536011; ALBERT DH, 1983, J BIOL CHEM, V258, P97; Arai H, 2002, PROSTAG OTH LIPID M, V68-9, P83, DOI 10.1016/S0090-6980(02)00023-0; Aronoff DM, 2004, J IMMUNOL, V173, P559, DOI 10.4049/jimmunol.173.1.559; Bae KA, 2000, J BIOL CHEM, V275, P26704; Baker PRS, 2002, BBA-MOL CELL RES, V1592, P175, DOI 10.1016/S0167-4889(02)00314-2; Balestrieri ML, 2004, FREE RADICAL BIO MED, V36, P1058, DOI 10.1016/j.freeradbiomed.2004.01.014; Balestrieri ML, 2003, J LIPID RES, V44, P380, DOI 10.1194/jlr.M200292-JLR200; Balestrieri ML, 2000, FEBS LETT, V479, P63, DOI 10.1016/S0014-5793(00)01870-6; Balestrieri ML, 1997, J BIOL CHEM, V272, P17431, DOI 10.1074/jbc.272.28.17431; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bussolati B, 1997, IMMUNOLOGY, V90, P440, DOI 10.1111/j.1365-2567.1997.00440.x; CAMUSSI G, 1983, INT ARCH ALLER A IMM, V70, P245, DOI 10.1159/000233331; Dupuis F, 1996, BBA-MOL CELL RES, V1311, P27, DOI 10.1016/0167-4889(95)00193-X; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; Gaposchkin DP, 1999, J LIPID RES, V40, P495; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; HENSON PM, 1989, AM J RESP CELL MOL, V1, P263, DOI 10.1165/ajrcmb/1.4.263; Jacob SS, 2002, MOL CELL BIOCHEM, V233, P9, DOI 10.1023/A:1015593232347; Karasawa K, 2003, PROG LIPID RES, V42, P93, DOI 10.1016/S0163-7827(02)00049-8; Karasawa K, 1999, J BIOL CHEM, V274, P8655, DOI 10.1074/jbc.274.13.8655; Koch A, 2004, AM J RESP CELL MOL, V30, P342, DOI 10.1165/rcmb.2003-0122OC; Lee TC, 2001, ARCH BIOCHEM BIOPHYS, V387, P41, DOI 10.1006/abbi.2000.2226; LEE TC, 1992, J BIOL CHEM, V267, P19992; LEE TC, 1987, PLATELET ACTIVATING; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; MCMANUS LM, 1993, LAB INVEST, V69, P639; Meja KK, 2000, BRIT J PHARMACOL, V131, P1143, DOI 10.1038/sj.bjp.0703684; Min JH, 2001, BIOCHEMISTRY-US, V40, P4539, DOI 10.1021/bi002600g; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; NAKAGAWA Y, 1992, BIOCHIM BIOPHYS ACTA, V1126, P277, DOI 10.1016/0005-2760(92)90241-M; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Nixon AB, 1999, J BIOL CHEM, V274, P5469, DOI 10.1074/jbc.274.9.5469; Pearson LL, 2001, INT IMMUNOL, V13, P273, DOI 10.1093/intimm/13.3.273; Shindou H, 2005, J IMMUNOL, V175, P1177, DOI 10.4049/jimmunol.175.2.1177; Sodhi A, 2002, J INTERF CYTOK RES, V22, P517, DOI 10.1089/10799900252981990; Tjoelker LW, 2000, BBA-MOL CELL BIOL L, V1488, P102, DOI 10.1016/S1388-1981(00)00114-1; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; Triggiani M, 2000, J IMMUNOL, V164, P4908, DOI 10.4049/jimmunol.164.9.4908; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; Winkler JD, 1997, BBA-LIPID LIPID MET, V1346, P173, DOI 10.1016/S0005-2760(97)00032-5; Wittmann M, 2002, J IMMUNOL, V168, P3793, DOI 10.4049/jimmunol.168.8.3793; Wu XQ, 2004, J BIOL CHEM, V279, P36158, DOI 10.1074/jbc.M402454200	46	9	9	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					1015	+		10.1096/fj.05-5059fje	http://dx.doi.org/10.1096/fj.05-5059fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571775				2022-12-28	WOS:000240157700040
J	Beattie, JR; Maguire, C; Gilchrist, S; Barrett, LJ; Cross, CE; Possmayer, F; Ennis, M; Elborn, JS; Curry, WJ; McGarvey, JJ; Schock, BC				Beattie, J. Renwick; Maguire, Ciaran; Gilchrist, Sarah; Barrett, Lindsay J.; Cross, Carroll E.; Possmayer, Fred; Ennis, Madeleine; Elborn, J. Stuart; Curry, W. James; McGarvey, John J.; Schock, Bettina C.			The use of Raman microscopy to determine and localize vitamin E in biological samples	FASEB JOURNAL			English	Article						alpha-tocopherol; tissue distribution; lung tissue; Raman mapping	RAC-ALPHA-TOCOPHEROL; LIPID-PEROXIDATION; MASS-SPECTROMETRY; TRANSFER PROTEIN; II CELLS; LUNG; SPECTROSCOPY; ANTIOXIDANT; PLASMA; CHROMATOGRAPHY	Alpha-tocopherol (aT), the predominant form of vitamin E in mammals, is thought to prevent oxidation of polyunsaturated fatty acids. In the lung, aT is perceived to be accumulated in alveolar type 11 cells and secreted together with surfactant into the epithelial lining fluid. Conventionally, determination of aT and related compounds requires extraction with organic solvents. This study describes a new method to determine and image the distribution of aT and related compounds within cells and tissue sections using the light-scattering technique of Raman microscopy to enable high spatial as well as spectral resolution. This study compared the nondestructive analysis by Raman microscopy of vitamin E, in particular aT, in biological samples with data obtained using conventional HPLC analysis. Raman spectra were acquired at spatial resolutions of 2-0.8 mu m. Multivariate analysis techniques were used for analyses and construction of corresponding maps showing the distribution of aT, alpha-tocopherol quinone (aTQ), and other constituents (hemes, proteins, DNA, and surfactant lipids). A combination of images enabled identification of colocalized constituents (heme/aTQ and aT/surfactant lipids). Our data demonstrate the ability of Raman microscopy to discriminate between different tocopherols and oxidation products in biological specimens without sample destruction. By enabling the visualization of lipid-protein interactions, Raman microscopy offers a novel method of investigating biological characterization of lipid-soluble compounds, including those that may be embedded in biological membranes such as aT.	Queens Univ Belfast, Sch Chem & Chem Engn, Dept Med, Resp Res Grp, Belfast BT12 6BJ, Antrim, North Ireland; Queens Univ Belfast, Sch Med & Dent, Belfast BT12 6BJ, Antrim, North Ireland; Queens Univ Belfast, Sch Biomed Sci, Belfast BT12 6BJ, Antrim, North Ireland; Univ Calif Davis, Davis, CA 95616 USA; Univ Western Ontario, Dept Ob Gyn & Biochem, London, ON N6A 3K7, Canada	Queens University Belfast; Queens University Belfast; Queens University Belfast; University of California System; University of California Davis; Western University (University of Western Ontario)	Schock, BC (corresponding author), Queens Univ Belfast, Sch Chem & Chem Engn, Dept Med, Resp Res Grp, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.	b.schock@qub.ac.uk	Beattie, Renwick/B-7810-2008; Ennis, Madeleine/GZG-4070-2022; Beattie, James Renwick/I-4506-2015	Beattie, James Renwick/0000-0002-0205-717X; elborn, joseph/0000-0002-2323-442X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011985] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES011985] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atkinson JK, 2004, ANN NY ACAD SCI, V1031, P324, DOI 10.1196/annals.1331.032; Azzi A, 2002, FEBS LETT, V519, P8, DOI 10.1016/S0014-5793(02)02706-0; Barbas C, 1997, J CHROMATOGR A, V778, P415, DOI 10.1016/S0021-9673(97)00416-0; Beattie JR, 2006, LIPIDS, V41, P287, DOI 10.1007/s11745-006-5099-1; Beattie JR, 2005, MOL VIS, V11, P825; Beattie JR, 2004, LIPIDS, V39, P897, DOI 10.1007/s11745-004-1312-5; Beattie JR, 2004, LIPIDS, V39, P407, DOI 10.1007/s11745-004-1245-z; Blatt DH, 2001, NUTRITION, V17, P799, DOI 10.1016/S0899-9007(01)00637-2; Bouhafs RKL, 1999, LUNG, V177, P101, DOI 10.1007/PL00007629; Bouhafs RKL, 1999, PEDIATR PULM, V27, P322, DOI 10.1002/(SICI)1099-0496(199905)27:5<322::AID-PPUL5>3.3.CO;2-5; Bruno Richard S, 2006, Pathophysiology, V13, P143, DOI 10.1016/j.pathophys.2006.05.003; Celedon A, 2002, FOOD SCI TECHNOL INT, V8, P101, DOI 10.1106/108201302024208; CROSS CE, 1994, ENVIRON HEALTH PERSP, V102, P185, DOI 10.2307/3432237; Everall NJ, 2000, APPL SPECTROSC, V54, P1515, DOI 10.1366/0003702001948439; Galli F, 2002, FREE RADICAL BIO MED, V32, P333, DOI 10.1016/S0891-5849(01)00800-0; Gille L, 2004, ANN NY ACAD SCI, V1031, P341, DOI 10.1196/annals.1331.039; Haka AS, 2006, CANCER RES, V66, P3317, DOI 10.1158/0008-5472.CAn-05-2815; IKENOYA S, 1979, CHEM PHARM BULL, V27, P1237; INGOLD KU, 1987, ARCH BIOCHEM BIOPHYS, V259, P224, DOI 10.1016/0003-9861(87)90489-9; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; ITO Y, 1990, CLIN CHIM ACTA, V194, P131, DOI 10.1016/0009-8981(90)90128-F; Kolleck I, 2002, AM J RESP CRIT CARE, V166, pS62, DOI 10.1164/rccm.2206019; Kolleck I, 2002, AM J RESP CELL MOL, V27, P57, DOI 10.1165/ajrcmb.27.1.4774; Kraemer K, 2004, ANN NY ACAD SCI, V1031, P435, DOI 10.1196/annals.1331.066; LANG JK, 1986, ANAL BIOCHEM, V157, P106, DOI 10.1016/0003-2697(86)90203-4; Leonard SW, 2003, FREE RADICAL BIO MED, V35, P1560, DOI 10.1016/j.freeradbiomed.2003.09.010; LEVIN IW, 1988, BIOPHYS J, V53, pA244; MacNee W, 2000, CHEST, V117, p303S, DOI 10.1378/chest.117.5_suppl_1.303S-a; Min YK, 2005, J RAMAN SPECTROSC, V36, P73, DOI 10.1002/jrs.1280; Muller PY, 2005, J PLANT PHYSIOL, V162, P811, DOI 10.1016/j.jplph.2005.04.015; Nardini M, 2002, TOXICOLOGY, V170, P173, DOI 10.1016/S0300-483X(01)00540-6; PACHT ER, 1986, J CLIN INVEST, V77, P789, DOI 10.1172/JCI112376; Panin L E, 1998, Membr Cell Biol, V11, P631; Podda M, 1996, J LIPID RES, V37, P893; PRYOR WA, 1991, AM J CLIN NUTR, V53, P702, DOI 10.1093/ajcn/53.3.702; PUPPELS GJ, 1990, NATURE, V347, P301, DOI 10.1038/347301a0; Qian J, 2004, ANN NY ACAD SCI, V1031, P330, DOI 10.1196/annals.1331.034; Qian JH, 2005, J LIPID RES, V46, P2072, DOI 10.1194/jlr.M500143-JLR200; Romieu I, 2001, EPIDEMIOL REV, V23, P268, DOI 10.1093/oxfordjournals.epirev.a000806; RUSTOW B, 1993, AM J PHYSIOL, V265, pL133, DOI 10.1152/ajplung.1993.265.2.L133; Saito Y, 2004, ANN NY ACAD SCI, V1031, P368, DOI 10.1196/annals.1331.047; Schock BC, 2004, ARCH BIOCHEM BIOPHYS, V423, P162, DOI 10.1016/j.abb.2003.12.009; Sijtsema NM, 2000, BIOPHYS J, V78, P2606, DOI 10.1016/S0006-3495(00)76805-6; Singh U, 2005, ANNU REV NUTR, V25, P151, DOI 10.1146/annurev.nutr.24.012003.132446; Sinha P, 2002, BBA-MOL CELL BIOL L, V1583, P91, DOI 10.1016/S1388-1981(02)00189-0; Smit HA, 1999, P NUTR SOC, V58, P309, DOI 10.1017/S0029665199000427; Song LMWK, 2002, GASTROENTEROLOGY, V122, pA288; SPIRO TG, 1986, BIOL APPL RAMAN SPEC, V1; Tabak C, 1999, THORAX, V54, P1021, DOI 10.1136/thx.54.11.1021; Tang Wei, 2005, Genomics Proteomics & Bioinformatics, V3, P169; Tolle A, 2005, FREE RADICAL BIO MED, V38, P1401, DOI 10.1016/j.freeradbiomed.2005.02.001; Touboul D, 2005, J LIPID RES, V46, P1388, DOI 10.1194/jlr.M500058-JLR200; TRABER MG, 2005, MODERN NUTR HLTH DIS, P396; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401, DOI 10.1164/ajrccm.151.5.7735592; Tu A.T., 1982, RAMAN SPECTROSCOPY B; Yang H, 2002, J PHARM PHARMACOL, V54, P1247, DOI 10.1211/002235702320402099	56	33	33	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					766	776		10.1096/fj.06-7028com	http://dx.doi.org/10.1096/fj.06-7028com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17209128				2022-12-28	WOS:000244686400015
J	Shraga-Heled, N; Kessler, O; Prahst, C; Kroll, J; Augustin, H; Neufeld, G				Shraga-Heled, Niva; Kessler, Ofra; Prahst, Claudia; Kroll, Jens; Augustin, Hellmut; Neufeld, Gera			Neuropilin-1 and neuropilin-2 enhance VEGF(121) stimulated signal transduction by the VEGFR-2 receptor	FASEB JOURNAL			English	Article						angiogenesis; semaphorin; endothelial cells; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE; TUMOR ANGIOGENESIS; BINDING; CELLS; MICE; FORM; ISOFORM; KDR; VASCULOGENESIS	The neuropilin-1 (np1) receptor binds the 165 amino-acid form of vascular endothelial growth factor(165) (VEGF(165)) and functions as an enhancer that potentiates VEGF(165) signaling via the VEGFR-2 tyrosine-kinase receptor. To study the mechanism by which neuropilins potentiate VEGF activity we produced a VEGF(165) mutant (VEGF(165KF)) that binds to neuropilins but displays a much lower affinity toward VEGFR-1 and VEGFR-2. VEGF(165KF) failed to induce VEGFR-2 phosphorylation in cells lacking neuropilins. However, in the presence of np1, VEGF(165KF) bound weakly to VEGFR-2, induced VEGFR-2 phosphorylation, and activated ERK1/2. Interestingly, VEGF(165KF) did not promote formation of VEGFR-2/np1 complexes nor did high concentrations of VEGF(165KF) inhibit VEGF165 induced formation of such complexes, suggesting that VEGF(165) does not stabilize VEGFR-2/np1 complexes by forming bridges spanning VEGFR-2 and np1. VEGF(121) is a VEGF form that does not bind to neuropilins. Surprisingly, both np1 and neuropilin-2 (np2) enhanced VEGF(121)-induced phosphorylation of VEGFR-2 and VEGF121-induced proliferation of endothelial cells. The enhancement of VEGF(121) activity by np1 was accompanied by a 10-fold increase in binding affinity. to, VEGFR-2 and was not associated with the formation of new VEGFR-2/np1 complexes. These observations suggest that neuropilins enhance the activity of VEGF forms that do not bind to neuropilins, indicate that np2 is a functional VEGF receptor, and imply that spontaneously formed VEGFR-2/np1 complexes suffice for efficient neuropilin mediated enhancement of VEGF activity.	Technion Israel Inst Technol, Rappaport Res Inst Med Sci, Canc & Vasc Biol Res Ctr, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; Tumor Biol Ctr, Dept Vasc Biol & Angiogenesis Res, Freiburg, Germany	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Neufeld, G (corresponding author), Technion Israel Inst Technol, Rappaport Res Inst Med Sci, Canc & Vasc Biol Res Ctr, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel.	gera@tx.technion.ac.il	Augustin, Hellmut/AAA-5246-2020; Neufeld, Gera/F-1524-2019	Augustin, Hellmut/0000-0002-7173-4242; 				COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Gluzman-Poltorak Z, 2001, J BIOL CHEM, V276, P18688, DOI 10.1074/jbc.M006909200; Hiratsuka S, 2005, MOL CELL BIOL, V25, P346, DOI 10.1128/MCB.25.1.346-354.2005; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kessler O, 2004, CANCER RES, V64, P1008, DOI 10.1158/0008-5472.CAN-03-3090; Korff T, 2001, FASEB J, V15, P447, DOI 10.1096/fj.00-0139com; Korff T, 1999, J CELL SCI, V112, P3249; Lange T, 2003, J BIOL CHEM, V278, P17164, DOI 10.1074/jbc.M212224200; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Liu WB, 2005, CYTOKINE, V32, P206, DOI 10.1016/j.cyto.2005.09.009; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Prewett M, 1999, CANCER RES, V59, P5209; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen JK, 2004, MOL MED, V10, P12, DOI 10.2119/2004-00017.Campochiaro; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; West DC, 2005, J BIOL CHEM, V280, P13457, DOI 10.1074/jbc.M410924200; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Yuan L, 2002, DEVELOPMENT, V129, P4797	36	55	57	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					915	926		10.1096/fj.06-6277com	http://dx.doi.org/10.1096/fj.06-6277com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17185751				2022-12-28	WOS:000244686400028
J	Michaelis, M; Michaelis, R; Suhan, T; Schmidt, H; Mohamed, A; Doerr, HW; Cinatl, J				Michaelis, Martin; Michaelis, Ruth; Suhan, Tatyana; Schmidt, Helmut; Mohamed, Annisuddin; Doerr, Hans Wilhelm; Cinatl, Jindrich, Jr.			Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion	FASEB JOURNAL			English	Article						endothelial cell; hepatitis C; inosine monophospate dehydrogenase; NO	CHRONIC HEPATITIS-C; NITRIC-OXIDE SYNTHASE; VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; PEGYLATED INTERFERON; ANTIVIRAL TREATMENT; ENDOTHELIAL-CELLS; LIVER; PHARMACOKINETICS; DEHYDROGENASE	Ribavirin is a broad-spectrum antiviral drug that is used to treat hepatitis C virus ( HCV)infected patients. The virological response after ribavirin treatment appears to be insufficient to fully explain ribavirin-induced beneficial effects. Angiogenesis plays a pathogenic role in HCV-induced liver damage. Here, we investigated the influence of therapeutic ribavirin concentrations on angiogenesis. Ribavirin inhibited endothelial cell tube formation in vitro and vessel formation in the chick chorioallantoic membrane assay in vivo. Ribavirin inhibits inosine monophosphate dehydrogenase, which causes depletion of cellular GTP and in turn reduction of cellular tetrahydrobiopterin levels. The availability of tetrahydrobiopterin limits NO production by endothelial NO synthase. Ribavirin reduced levels of tetrahydrobiopterin ( as revealed by HPLC), NO ( as revealed by electron spin resonance spectroscopy), and cGMP ( as revealed by RIA) in endothelial cells. Addition of tetrahydrobiopterin or NO prevented ribavirin-induced tube formation inhibition. In conclusion, angiogenesis inhibition by ribavirin has not been described before. This inhibition may contribute to ribavirin-induced pharmacological effects including adverse events.	Univ Frankfurt Klinikum, Inst Med Virol, D-60596 Frankfurt, Germany; Univ Frankfurt Klinikum, Inst Kardiovask Physiol, D-6000 Frankfurt, Germany; Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, Inst Klin Pharmakol, D-6000 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Cinatl, J (corresponding author), Univ Frankfurt Klinikum, Inst Med Virol, Paul Ehrlich Str 40, D-60596 Frankfurt, Germany.	cinatl@em.uni-frankfurt.de		Michaelis, Martin/0000-0002-5710-5888				Alp NJ, 2004, ARTERIOSCL THROM VAS, V24, P413, DOI 10.1161/01.ATV.0000110785.96039.f6; Arase Y, 2005, INTERVIROLOGY, V48, P138, DOI 10.1159/000081741; BALZARINI J, 1993, J BIOL CHEM, V268, P24591; Bartlett JB, 2004, NAT REV CANCER, V4, P314, DOI 10.1038/nrc1323; Brok J, 2006, AM J GASTROENTEROL, V101, P842, DOI 10.1111/j.1572-0241.2006.00505.x; Caseiro Marcos Montani, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P109, DOI 10.1590/S0036-46652006000200011; Chong CR, 2006, J MED CHEM, V49, P2677, DOI 10.1021/jm051225t; Corpechot C, 2002, HEPATOLOGY, V35, P1010, DOI 10.1053/jhep.2002.32524; DECLERCQ E, 1991, ANTIMICROB AGENTS CH, V35, P679, DOI 10.1128/AAC.35.4.679; Deli G, 2005, WORLD J GASTROENTERO, V11, P960, DOI 10.3748/wjg.v11.i7.960; Fleming I, 2003, THROMB HAEMOSTASIS, V90, P863, DOI 10.1160/TH03-04-0228; Fontaine H, 2004, TRANSPLANTATION, V78, P853, DOI 10.1097/01.TP.0000128911.87538.AA; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GARCIAMONZON C, 1995, GASTROENTEROLOGY, V108, P231, DOI 10.1016/0016-5085(95)90029-2; Graci JD, 2006, REV MED VIROL, V16, P37, DOI 10.1002/rmv.483; HATAKEYAMA K, 1992, J BIOL CHEM, V267, P20734; Huang YF, 2005, INT IMMUNOPHARMACOL, V5, P1029, DOI 10.1016/j.intimp.2005.01.015; Hugle T, 2003, REV MED VIROL, V13, P361, DOI 10.1002/rmv.397; Jain A, 2005, TRANSPL P, V37, P3190, DOI 10.1016/j.transproceed.2005.07.057; Kast RE, 2003, NEOPLASIA, V5, P3; Lau JYN, 2002, HEPATOLOGY, V35, P1002, DOI 10.1053/jhep.2002.32672; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Lin CC, 2004, ANTIMICROB AGENTS CH, V48, P1872, DOI 10.1128/AAC.48.5.1872-1875.2004; Lin CC, 2004, J CLIN PHARMACOL, V44, P265, DOI 10.1177/0091270004262974; Lin CC, 2003, J ANTIMICROB CHEMOTH, V51, P93, DOI 10.1093/jac/dkg046; Lin Chin-chung, 2003, Antiviral Chemistry & Chemotherapy, V14, P145; Marinos RS, 2001, AM J PHYSIOL-HEART C, V281, pH482, DOI 10.1152/ajpheart.2001.281.2.H482; Mazzanti R, 1997, HEPATOLOGY, V25, P229, DOI 10.1002/hep.510250142; Medina J, 2003, J HEPATOL, V38, P660, DOI 10.1016/S0168-8278(03)00053-9; Messerini L, 2004, J CLIN PATHOL, V57, P867, DOI 10.1136/jcp.2003.015784; Michaelis M, 2006, CELL DEATH DIFFER, V13, P446, DOI 10.1038/sj.cdd.4401759; Michaelis M, 2004, MOL PHARMACOL, V65, P520, DOI 10.1124/mol.65.3.520; Milazzo L, 2006, AM J GASTROENTEROL, V101, P399, DOI 10.1111/j.1572-0241.2006.00350.x; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Pawlotsky JM, 2004, GASTROENTEROLOGY, V126, P703, DOI 10.1053/j.gastro.2003.12.002; Pawlotsky JM, 2003, ANTIVIR RES, V59, P1, DOI 10.1016/S0166-3542(03)00088-3; Salcedo X, 2005, HEPATOLOGY, V42, P696, DOI 10.1002/hep.20828; Schlossmann J, 2003, ANN MED, V35, P21, DOI 10.1080/07853890310004093; Sun HC, 2004, J CANCER RES CLIN, V130, P307, DOI 10.1007/s00432-003-0530-y; Tsubota A, 2003, BRIT J CLIN PHARMACO, V55, P360, DOI 10.1046/j.1365-2125.2003.01780.x; Vogten JM, 2004, INT J COLORECTAL DIS, V19, P387, DOI 10.1007/s00384-003-0562-4; Ward RP, 2005, AM FAM PHYSICIAN, V72, P655; Wu JZ, 2003, ANTIMICROB AGENTS CH, V47, P426, DOI 10.1128/AAC.47.1.426-431.2003	43	26	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2007	21	1					81	87		10.1096/fj.06-6779com	http://dx.doi.org/10.1096/fj.06-6779com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135367				2022-12-28	WOS:000243130200010
J	He, DY; Ron, D				He, Dao-Yao; Ron, Dorit			Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine	FASEB JOURNAL			English	Article						growth factor; SHSY5Y; gene expression	NUCLEUS-ACCUMBENS; PURKINJE-CELLS; GDNF; MORPHINE; RATS; DEGENERATION; ATTENUATION; ACQUISITION; WITHDRAWAL; MELATONIN	We recently showed that the up-regulation of the glial cell line-derived neurotrophic factor (GDNF) pathway in the midbrain, is the molecular mechanism by which the putative anti-addiction drug Ibogaine mediates its desirable action of reducing alcohol consumption (1). Human reports and studies in rodents have shown that a single administration of Ibogaine results in a long-lasting reduction of drug craving (humans) and drug and alcohol intake ( rodents). Here we determine whether, and how, Ibogaine exerts its long-lasting actions on GDNF expression and signaling. Using the dopaminergic-like SHSY5Y cell line as a culture model, we observed that short-term Ibogaine exposure results in a sustained increase in GDNF expression that is mediated via the induction of a long-lasting autoregulatory cycle by which GDNF positively regulates its own expression. We show that the initial exposure of cells to Ibogaine or GDNF results in an increase in GDNF mRNA, leading to protein expression and to the corresponding activation of the GDNF signaling pathway. This, in turn, leads to a further increase in the mRNA level of the growth factor. The identification of a GDNF-mediated, autoregulatory long-lasting feedback loop could have important implications for GDNF's potential value as a treatment for addiction and neurodegenerative diseases.	Univ Calif San Francisco, Ernest Gallo Res Ctr, Emeryville, CA USA; Univ Calif San Francisco, Dept Neurol, Emeryville, CA USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco	Ron, D (corresponding author), 5858 Horton St,Ste 200, Emeryville, CA 94608 USA.	dorit.ron@ucsf.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA014366] Funding Source: NIH RePORTER; NIAAA NIH HHS [5 R01 AA014366-02] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Alper KR, 1999, AM J ADDICTION, V8, P234; Armstrong KJ, 2002, NEUROREPORT, V13, P473, DOI 10.1097/00001756-200203250-00023; Baecker PA, 1999, MOL BRAIN RES, V69, P209, DOI 10.1016/S0169-328X(99)00106-0; Beck KD, 1996, NEURON, V16, P665, DOI 10.1016/S0896-6273(00)80085-9; Bourque MJ, 2000, EUR J NEUROSCI, V12, P3172, DOI 10.1046/j.1460-9568.2000.00219.x; Canossa M, 1997, P NATL ACAD SCI USA, V94, P13279, DOI 10.1073/pnas.94.24.13279; CAPPENDIJK SLT, 1993, EUR J PHARMACOL, V241, P261, DOI 10.1016/0014-2999(93)90212-Z; Castro LMR, 2005, J NEUROCHEM, V95, P1227, DOI 10.1111/j.1471-4159.2005.03457.x; Gerlai R, 2001, EUR J NEUROSCI, V14, P1153, DOI 10.1046/j.0953-816x.2001.01724.x; GLICK SD, 1992, NEUROPHARMACOLOGY, V31, P497, DOI 10.1016/0028-3908(92)90089-8; GLICK SD, 1994, BRAIN RES, V657, P14, DOI 10.1016/0006-8993(94)90948-2; GLICK SD, 1991, EUR J PHARMACOL, V195, P341, DOI 10.1016/0014-2999(91)90474-5; Glick SD, 2000, ANN NY ACAD SCI, V909, P88; Green-Sadan T, 2005, EXP NEUROL, V194, P97, DOI 10.1016/j.expneurol.2005.01.020; Green-Sadan T, 2003, EUR J NEUROSCI, V18, P2093, DOI 10.1046/j.1460-9568.2003.02943.x; He DY, 2005, J NEUROSCI, V25, P619, DOI 10.1523/JNEUROSCI.3959-04.2005; Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1; Kobori N, 2004, J BIOL CHEM, V279, P2182, DOI 10.1074/jbc.M310734200; Mash DC, 1998, ANN NY ACAD SCI, V844, P274, DOI 10.1111/j.1749-6632.1998.tb08242.x; Mash DC, 2000, ANN NY ACAD SCI, V914, P394, DOI 10.1111/j.1749-6632.2000.tb05213.x; Messer CJ, 2000, NEURON, V26, P247, DOI 10.1016/S0896-6273(00)81154-X; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; OHearn E, 1997, J NEUROSCI, V17, P8828; OHEARN E, 1993, NEUROSCIENCE, V55, P303, DOI 10.1016/0306-4522(93)90500-F; REZVANI AH, 1995, PHARMACOL BIOCHEM BE, V52, P615, DOI 10.1016/0091-3057(95)00152-M; Rezvani AH, 1997, PHARMACOL BIOCHEM BE, V58, P615, DOI 10.1016/S0091-3057(97)10003-X; Righi M, 2000, J NEUROSCI, V20, P3165, DOI 10.1523/JNEUROSCI.20-09-03165.2000; SHEPPARD SG, 1994, J SUBST ABUSE TREAT, V11, P379, DOI 10.1016/0740-5472(94)90049-3; Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346; Verity AN, 1999, J NEUROSCI RES, V55, P187, DOI 10.1002/(SICI)1097-4547(19990115)55:2<187::AID-JNR6>3.0.CO;2-T; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2; Xiong H, 2002, NEUROPHARMACOLOGY, V42, P903, DOI 10.1016/S0028-3908(02)00043-6; Yang F, 2001, NAT NEUROSCI, V4, P1071, DOI 10.1038/nn734	35	41	58	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2420	+		10.1096/fj.06-6394fje	http://dx.doi.org/10.1096/fj.06-6394fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023388				2022-12-28	WOS:000241702600040
J	Weller, K; Foitzik, K; Paus, R; Syska, W; Maurer, M				Weller, Karsten; Foitzik, Kerstin; Paus, Ralf; Syska, Wolfgang; Maurer, Marcus			Mast cells are required for normal healing of skin wounds in mice	FASEB JOURNAL			English	Article						inflammation; neutrophil	TUMOR-NECROSIS-FACTOR; TNF-ALPHA; EXOGENOUS HISTAMINE; LATE-PHASE; PROLIFERATION; DEFICIENT; MEDIATORS; MOUSE; INFLAMMATION; ANGIOGENESIS	Mast cells (MCs) have recently been reported to play a pivotal role in the elicitation of inflammatory reactions that are beneficial to the host, e. g., during innate immune responses to bacteria. To explore whether MCs also contribute to wound repair, we studied experimentally induced skin wounds in MC-deficient Kit(W)/Kit(W-v) mice, normal Kit+/+ mice, and MC-reconstituted Kit(W)/Kit(W-v) mice. Wound closure was significantly impaired in the absence of MCs during the first 6 days of wound healing and histomorphometric analyses of MC degranulation at the wound edges revealed distance-dependent MC activation, i.e., MC degranulation was most prominent directly adjacent to the wound. In addition, Kit(W)/Kit(W-v) mice showed impaired extravasation and recruitment of neutrophils to the wounded areas. Notably, wound closure, extravasation, and neutrophil recruitment were found to be normal in MC-reconstituted Kit(W)/Kit(W-v) mice. Therefore, we examined whether MCs promote wound healing by releasing histamine or TNF-alpha. Interestingly, wound closure was reduced in mice treated with an H-1-receptor antagonist but not after treatment with an H-2-receptor antagonist or in the absence of TNF-alpha. Taken together, our findings indicate that MC activation and histamine release are required for normal cutaneous wound healing.	Univ Med Berlin, Dept Dermatol & Allergy, Charite, Allergie Ctr, D-10117 Berlin, Germany; Univ Hosp Wurzburg, Dept Dermatol, Wurzburg, Germany; Univ Hosp Hamburg Eppendorf, Dept Dermatol, Hamburg, Germany; Univ Hosp Lubeck, Dept Dermatol, Lubeck, Germany; Univ Hosp Mainz, Dept Dermatol, Mainz, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck; University Hospital Mainz	Maurer, M (corresponding author), Univ Med Berlin, Dept Dermatol & Allergy, Charite, Allergie Ctr, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de	Maurer, Marcus/ABG-2174-2020; Paus, Ralf/F-6243-2011	Maurer, Marcus/0000-0002-4121-481X; Weller, Karsten/0000-0003-4437-0313				Abraham SN, 1997, INFECT IMMUN, V65, P3501, DOI 10.1128/IAI.65.9.3501-3508.1997; Artuc M, 1999, EXP DERMATOL, V8, P1, DOI 10.1111/j.1600-0625.1999.tb00342.x; BAIRY K L, 1991, Indian Journal of Physiology and Pharmacology, V35, P180; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Biro T, 2005, EXP DERMATOL, V14, P225, DOI 10.1111/j.0906-6705.2005.0321a.x; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cregar L, 1999, ARCH BIOCHEM BIOPHYS, V366, P125, DOI 10.1006/abbi.1999.1220; DABROWSKI R, 1975, AGENTS ACTIONS, V5, P311, DOI 10.1007/BF02205236; Deiters U, 2004, EXP DERMATOL, V13, P731, DOI 10.1111/j.0906-6705.2004.00233.x; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Egozi EI, 2003, WOUND REPAIR REGEN, V11, P46, DOI 10.1046/j.1524-475X.2003.11108.x; Gailit J, 2001, J INVEST DERMATOL, V117, P1113, DOI 10.1046/j.1523-1747.2001.15211.x; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GRABBE J, 1994, HAUTARZT, V45, P55; GRUBER BL, 1995, BLOOD, V86, P2488; HEBDA PA, 1993, DERMATOL CLIN, V11, P685, DOI 10.1016/S0733-8635(18)30221-3; Iba Y, 2004, INT IMMUNOPHARMACOL, V4, P1873, DOI 10.1016/j.intimp.2004.08.009; Kanbe N, 1999, EUR J IMMUNOL, V29, P2645; KATAYAMA I, 1992, INT ARCH ALLERGY IMM, V98, P410, DOI 10.1159/000236218; Kauhanen P, 1998, THROMB HAEMOSTASIS, V79, P843, DOI 10.1055/s-0037-1615075; LEVISCHAFFER F, 1990, EXP CELL RES, V188, P42, DOI 10.1016/0014-4827(90)90275-F; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; LI L, 1994, J IMMUNOL, V153, P3967; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Maurer M, 1997, J DERMATOL SCI, V16, P79, DOI 10.1016/S0923-1811(97)00043-1; Maurer M, 2005, EXP DERMATOL, V14, P923, DOI 10.1111/j.1600-0625.2005.00369.x; Maurer M, 1998, J EXP MED, V188, P2343, DOI 10.1084/jem.188.12.2343; Maurer M, 1997, LAB INVEST, V77, P319; Maurer M, 2003, EXP DERMATOL, V12, P886, DOI 10.1111/j.0906-6705.2003.0109a.x; MOLLER A, 1993, J IMMUNOL, V151, P3261; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; Noli C, 2001, VET DERMATOL, V12, P303, DOI 10.1046/j.0959-4493.2001.00272.x; NORRBY K, 1986, VIRCHOWS ARCH B, V52, P195, DOI 10.1007/BF02889963; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PAUS R, 1994, DEV BIOL, V163, P230, DOI 10.1006/dbio.1994.1139; Peters EMJ, 2003, J INVEST DERMATOL, V121, P976, DOI 10.1046/j.1523-1747.2003.12478.x; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; RAMOS BF, 1992, J PHARMACOL EXP THER, V262, P559; Singh LK, 1999, J PHARMACOL EXP THER, V288, P1349; Takanami I, 2000, CANCER, V88, P2686, DOI 10.1002/1097-0142(20000615)88:12<2686::AID-CNCR6>3.0.CO;2-6; TRABUCCHI E, 1988, INT J TISSUE REACT, V10, P367; Trautmann A, 2000, J PATHOL, V190, P100, DOI 10.1002/(SICI)1096-9896(200001)190:1<100::AID-PATH496>3.0.CO;2-Q; ULOGOL A, 1996, YONSEI MED J, V37, P97; von Stebut E, 2003, BLOOD, V101, P210, DOI 10.1182/blood-2002-03-0921; WEBER A, 2003, BRIT J DERMATOL, V148, P625; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WERSHIL BK, 1988, J IMMUNOL, V140, P2356; YAMATODANI A, 1982, BIOCHEM PHARMACOL, V31, P305; YOSHIDA S, 1989, P SOC EXP BIOL MED, V191, P90; ZHANG Y, 1992, IMMUNOLOGY, V77, P422	55	209	220	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2366	+		10.1096/fj.06-5837fje	http://dx.doi.org/10.1096/fj.06-5837fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	16966487				2022-12-28	WOS:000241702600022
J	Massiello, A; Roesser, JR; Chalfant, CE				Massiello, Autumn; Roesser, James R.; Chalfant, Charles E.			SAP155 binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5 ' splice site selection of Bcl-x pre-mRNA	FASEB JOURNAL			English	Article						Bcl-x; alternative splicing; A549 cells; daunorubicin; chemotherapy	PROTEIN PHOSPHATASE-1; CELL-DIFFERENTIATION; SPHINGOMYELIN TURNOVER; IDENTIFICATION; DEPENDENCE; COMPLEXES; DEATH; CYCLE; SITE	Two splice variants are derived from the BCL-x gene, proapoptotic Bcl-x(s) and antiapoptotic Bcl-x(L), via alternative 5' splice site selection. In previous studies, our laboratory identified an RNA cis-element within exon 2 of Bcl-x pre-mRNA that is a ceramide responsive termed CRCE 1. In this study, mass spectrometric analysis identified the splicing factor SAP155, as an RNA trans-acting factor binding to the purine-rich CRCE 1. The interaction of SAP155 with CRCE 1 was confirmed by the addition of an anti-SAP155 antibody (Ab) to EMSA decreasing the mobility of a protein: CRCE 1 complex (SuperShift). Furthermore, the down-regulation of SAP155 in A549 cells by RNA interference (RNAi) technology resulted in the loss of a 155 kDa protein complexed with CRCE 1. Moreover, this down-regulation of SAP155 induced an increase in the Bcl-x(s) with a concomitant decrease in the Bcl-x(L) splice variants and immunoreactive protein levels, thereby decreasing the Bcl-x(L)/Bcl-x(s) ratio. Specific down-regulation of SAP155 also inhibited the ability of exogenous ceramide treatment to further induce the activation of the Bcl-x(s) 5' splice site. Additionally, the specific downregulation of SAP155 sensitized cells to undergo apoptosis in response to daunorubicin in a manner similar to ceramide. Therefore, we have identified SAP155 as an RNA trans-acting factor that binds to CRCE 1, functions to regulate the alternative 5' splice site selection of Bcl-x pre-mRNA, and is required for ceramide to induce the activation of the Bcl-x(s) 5' splice site. Furthermore, we have demonstrated that activation of the Bcl-x(s) 5' splice site can increase the effectiveness of chemotherapeutic drug treatment, thus establishing a role for the alternative splicing mechanism of Bcl-x in chemotherapeutic sensitivity.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Hunter Holmes McGuire Vet Adm Med Ctr, Richmond, VA USA	Virginia Commonwealth University; Hunter Holmes McGuire Veterinary Affairs Medical Center	Chalfant, CE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Rm 2-016,Sanger Hall,1101 E Marshall St,POB 98061, Richmond, VA 23298 USA.	cechalfant@vcu.edu	, Proteomics Core UNC/AFQ-7201-2022		NCRR NIH HHS [1C06-RR-17393] Funding Source: Medline; NHLBI NIH HHS [R01-HL-072925] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR017393] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072925] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Das BK, 1999, MOL CELL BIOL, V19, P6796; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gozani O, 1998, MOL CELL BIOL, V18, P4752, DOI 10.1128/MCB.18.8.4752; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Huppi K, 2005, MOL CELL, V17, P1, DOI 10.1016/j.molcel.2004.12.017; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KIM MY, 1991, J BIOL CHEM, V266, P484; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; Massiello A, 2004, J BIOL CHEM, V279, P15799, DOI 10.1074/jbc.M313950200; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Parker Carol E., 2005, V301, P117; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Tran HT, 2004, MOL CELL PROTEOMICS, V3, P257, DOI 10.1074/mcp.M300115-MCP200	23	66	69	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1680	+		10.1096/fj.05-5021fje	http://dx.doi.org/10.1096/fj.05-5021fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790528				2022-12-28	WOS:000240266600013
J	Broome, CS; Kayani, AC; Palomero, J; Dillmann, WH; Mestril, R; Jackson, MJ; McArdle, A				Broome, Caroline S.; Kayani, Anna C.; Palomero, Jesus; Dillmann, Wolfgang H.; Mestril, Ruben; Jackson, Malcolm J.; McArdle, Anne			Effect of lifelong overexpression of HSP70 in skeletal muscle on age-related oxidative stress and adaptation after nondamaging contractile activity	FASEB JOURNAL			English	Article						aging; exercise	REACTIVE OXYGEN; CALORIC RESTRICTION; SUPEROXIDE-DISMUTASE; DIETARY RESTRICTION; KAPPA-B; RAT; INCREASES; PROTEIN; ANTIOXIDANTS; GENERATION	Skeletal muscle aging is characterized by atrophy, a deficit in specific force generation, increased susceptibility to injury, and incomplete recovery after severe injury. The ability of muscles of old mice to produce heat shock proteins (HSPs) in response to stress is severely diminished. Studies in our laboratory using HSP70 overexpressor mice demonstrated that lifelong overexpression of HSP70 in skeletal muscle provided protection against damage and facilitated successful recovery after damage in muscles of old mice. The mechanisms by which HSP70 provides this protection are unclear. Aging is associated with the accumulation of oxidation products, and it has been proposed that this may play a major role in age-related muscle dysfunction. Muscles of old wild-type (WT) mice demonstrated increased lipid peroxidation, decreased glutathione content, increased catalase and superoxide dismutase (SOD) activities, and an inability to activate nuclear factor (NF)-kappa B after contractions in comparison with adult WT mice. In contrast, levels of lipid peroxidation, glutathione content, and the activities of catalase and SOD in muscles of old HSP70 overexpressor mice were similar to adult mice and these muscles also maintained the ability to activate NF-kappa B after contractions. These data provide an explanation for the preservation of muscle function in old HSP70 overexpressor mice.	Univ Liverpool, Sch Clin Sci, Div Metab & Cellular Med, Liverpool L69 3GA, Merseyside, England; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Loyola Univ, Dept Physiol, Chicago, IL 60611 USA	University of Liverpool; University of California System; University of California San Diego; Loyola University Chicago	McArdle, A (corresponding author), Univ Liverpool, Sch Clin Sci, Div Metab & Cellular Med, Liverpool L69 3GA, Merseyside, England.	mdcr02@liv.ac.uk	Palomero, Jesus/L-4783-2014	Palomero, Jesus/0000-0002-1013-9992; Mestril, Ruben/0000-0003-3631-2236; Jackson, Malcolm/0000-0003-3683-8297	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061339, R37HL049434, R01HL067971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG020591] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37HL-049434, HL-61339, HL-67971] Funding Source: Medline; NIA NIH HHS [AG20591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BROOKS SV, 1990, AM J PHYSIOL, V258, pC436, DOI 10.1152/ajpcell.1990.258.3.C436; BROOKS SV, 1988, J PHYSIOL-LONDON, V404, P71, DOI 10.1113/jphysiol.1988.sp017279; CHIRICO S, 1994, METHOD ENZYMOL, V233, P314; Claiborne A, 1985, CRC HDB METHODS OXYG, P283; Cotto JJ, 1999, BIOCHEM SOC SYMP, P105; Crapo J D, 1978, Methods Enzymol, V53, P382; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P334, DOI 10.1016/0003-9861(84)90206-6; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Grune T, 2001, J GERONTOL A-BIOL, V56, pB459, DOI 10.1093/gerona/56.11.B459; HADLEY EC, 1993, J GERONTOL, V48, pR7, DOI 10.1093/geronj/48.Special_Issue.vii; Hollander JM, 2003, FREE RADICAL BIO MED, V35, P742, DOI 10.1016/S0891-5849(03)00400-3; Jackson MJ, 2002, MOL ASPECTS MED, V23, P209, DOI 10.1016/S0098-2997(02)00018-3; JACKSON MJ, 1985, BIOCHIM BIOPHYS ACTA, V847, P185, DOI 10.1016/0167-4889(85)90019-9; JI LL, 1990, AM J PHYSIOL, V258, pR918, DOI 10.1152/ajpregu.1990.258.4.R918; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; LEEUWENBURGH C, 1994, AM J PHYSIOL, V267, pR439, DOI 10.1152/ajpregu.1994.267.2.R439; LUHTALA TA, 1994, J GERONTOL, V49, pB231, DOI 10.1093/geronj/49.5.B231; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; McArdle A, 2001, AM J PHYSIOL-CELL PH, V280, pC621, DOI 10.1152/ajpcell.2001.280.3.C621; McArdle A, 2003, FASEB J, V17, P355, DOI 10.1096/fj.03-0395fje; McArdle A, 2004, AM J PHYSIOL-CELL PH, V286, pC1152, DOI 10.1152/ajpcell.00322.2003; Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Porter M. M., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P129; Radak Z, 2002, EXP GERONTOL, V37, P1423, DOI 10.1016/S0531-5565(02)00116-X; Reid MB, 2002, ANN NY ACAD SCI, V959, P108, DOI 10.1111/j.1749-6632.2002.tb02087.x; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9; Selsby JT, 2005, EXP GERONTOL, V40, P37, DOI 10.1016/j.exger.2004.08.012; SOHAL RS, 1992, ANN NY ACAD SCI, V663, P74, DOI 10.1111/j.1749-6632.1992.tb38651.x; Vasilaki A, 2003, BIOCHEM SOC T, V31, P455, DOI 10.1042/BST0310455; Vasilaki A, 2002, MUSCLE NERVE, V25, P902, DOI 10.1002/mus.10094; WARNER HR, 1994, FREE RADICAL BIO MED, V17, P249, DOI 10.1016/0891-5849(94)90080-9; ZERBA E, 1990, AM J PHYSIOL, V258, pC429, DOI 10.1152/ajpcell.1990.258.3.C429; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5	39	131	136	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1549	+		10.1096/fj.05-4935fje	http://dx.doi.org/10.1096/fj.05-4935fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723383				2022-12-28	WOS:000240266000047
J	Jernas, M; Palming, J; Sjoholm, K; Jennische, E; Svensson, PA; Gabrielsson, BG; Levin, M; Sjogren, A; Rudemo, M; Lystig, TC; Carlsson, B; Carlsson, LMS; Lonn, M				Jernas, Margareta; Palming, Jenny; Sjoholm, Kajsa; Jennische, Eva; Svensson, Per-Arne; Gabrielsson, Britt G.; Levin, Max; Sjogren, Anders; Rudemo, Mats; Lystig, Theodore C.; Carlsson, Bjorn; Carlsson, Lena M. S.; Lonn, Malin			Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression	FASEB JOURNAL			English	Article						cell size; serum amyloid A; transmembrane 4 L six family member 1; leptin; insulin resistance	SERUM-AMYLOID-A; MESSENGER-RNA EXPRESSION; CORONARY-ARTERY-DISEASE; VISCERAL ADIPOSE-TISSUE; GLUCOSE-METABOLISM; PROTEIN; OBESITY; INSULIN; INFLAMMATION; RECEPTOR	Enlarged adipocytes are associated with insulin resistance and are an independent predictor of type 2 diabetes. To understand the molecular link between these diseases and adipocyte hypertrophy, we developed a technique to separate human adipocytes from an adipose tissue sample into populations of small cells (mean 57.6 +/- 3.54 mu m) and large cells (mean 100.1 +/- 3.94 mu m). Microarray analysis of the cell populations separated from adipose tissue from three subjects identified 14 genes, of which five immune-related, with more than fourfold higher expression in large cells than small cells. Two of these genes were serum amyloid A (SAA) and transmembrane 4 L six family member 1 (TM4SF1). Real-time RT-PCR analysis of SAA and TM4SF1 expression in adipocytes from seven subjects revealed 19-fold and 22-fold higher expression in the large cells, respectively, and a correlation between adipocyte size and both SAA and TM4SF1 expression. The results were verified using immunohistochemistry. In comparison with 17 other human tissues and cell types by microarray, large adipocytes displayed by far the highest SAA and TM4SF1 expression. Thus, we have identified genes with markedly higher expression in large, compared with small, human adipocytes. These genes may link hypertrophic obesity to insulin resistance/type 2 diabetes.	RCEM, Dept Internal Med, Div Body Composit & Metab, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Inst Anat & Cell Biol, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Cardiovasc Inst, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Wallenberg Lab, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Inst Anat & Cell Biol, SE-41345 Gothenburg, Sweden; Chalmers Univ Technol, Dept Math Sci, S-41296 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg; Chalmers University of Technology	Lonn, M (corresponding author), RCEM, Dept Internal Med, Div Body Composit & Metab, Vita Straket 15, SE-41345 Gothenburg, Sweden.	malin.lonn@medic.gu.se	Gabrielsson, Britt/B-9870-2011; Carlsson, Lena/F-7570-2018; Gabrielsson, Britt/A-9304-2008; Svensson, Per-Arne/R-4626-2019; Lystig, Theodore/E-4149-2015	Gabrielsson, Britt/0000-0003-4318-8704; Carlsson, Lena/0000-0003-4145-6242; Lystig, Theodore/0000-0002-4523-0761; Svensson, Per-Arne/0000-0002-6731-806X; Sjoholm, Kajsa/0000-0003-0146-8193				Arroyo-Espliguero R, 2004, EUR HEART J, V25, P401, DOI 10.1016/j.ehj.2003.12.017; Artl A, 2000, ARTERIOSCL THROM VAS, V20, P763, DOI 10.1161/01.ATV.20.3.763; Bjornheden T, 2004, OBES RES, V12, P95, DOI 10.1038/oby.2004.13; BJORNTORP P, 1972, EUR J CLIN INVEST, V2, P78, DOI 10.1111/j.1365-2362.1972.tb00573.x; Boisvert WA, 2004, TRENDS CARDIOVAS MED, V14, P161, DOI 10.1016/j.tcm.2004.02.006; Cai L, 2005, J BIOL CHEM, V280, P2954, DOI 10.1074/jbc.M411555200; Chait A, 2005, J LIPID RES, V46, P389, DOI 10.1194/jlr.R400017-JLR200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cortes-Canteli M, 2004, J BIOL CHEM, V279, P14409, DOI 10.1074/jbc.M313253200; DRAPER NR, 1998, APPL REGRESSION ANAL, P570; Farnier C, 2003, INT J OBESITY, V27, P1178, DOI 10.1038/sj.ijo.0802399; FISHER LD, 1993, BIOSTATISTICS METHOD, P319; Fyfe AI, 1997, CIRCULATION, V96, P2914, DOI 10.1161/01.CIR.96.9.2914; Gabrielsson BG, 2005, OBES RES, V13, P649, DOI 10.1038/oby.2005.72; Gabrielsson BG, 2003, OBES RES, V11, P699, DOI 10.1038/oby.2003.100; Guo KY, 2004, AM J PHYSIOL-REG I, V287, pR112, DOI 10.1152/ajpregu.00028.2004; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Johnson BD, 2004, CIRCULATION, V109, P726, DOI 10.1161/01.CIR.0000115516.54550.B1; Karlsson HKR, 2004, DIABETES, V53, P1424, DOI 10.2337/diabetes.53.6.1424; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Krishnamurthy V, 2005, IEEE T NANOBIOSCI, V4, P1, DOI 10.1109/TNB.2005.845391; Le Lay S, 2001, J BIOL CHEM, V276, P16904, DOI 10.1074/jbc.M010955200; Lee YH, 2005, DIABETOLOGIA, V48, P1776, DOI 10.1007/s00125-005-1867-3; Leinonen E, 2003, ATHEROSCLEROSIS, V166, P387, DOI 10.1016/S0021-9150(02)00371-4; Lelliott C, 2004, INT J OBESITY, V28, pS22, DOI 10.1038/sj.ijo.0802854; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Pickup JC, 2004, DIABETES CARE, V27, P813, DOI 10.2337/diacare.27.3.813; Poitou C, 2005, DIABETOLOGIA, V48, P519, DOI 10.1007/s00125-004-1654-6; Pratley RE, 1998, J CLIN INVEST, V101, P1757, DOI 10.1172/JCI1850; SALANS LB, 1968, J CLIN INVEST, V47, P153, DOI 10.1172/JCI105705; SALANS LB, 1971, J CLIN INVEST, V50, P1399, DOI 10.1172/JCI106623; Sjoholm K, 2005, J CLIN ENDOCR METAB, V90, P2233, DOI 10.1210/jc.2004-1830; SMITH U, 1972, ANAT REC, V172, P597, DOI 10.1002/ar.1091720401; SMITH U, 1972, J LIPID RES, V13, P822; Sopasakis VR, 2004, OBES RES, V12, P454, DOI 10.1038/oby.2004.51; Stonik JA, 2004, BIOCHEM BIOPH RES CO, V321, P936, DOI 10.1016/j.bbrc.2004.07.052; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Tataranni PA, 2005, DIABETES, V54, P917, DOI 10.2337/diabetes.54.4.917; Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213; van der Westhuyzen DR, 2005, J BIOL CHEM, V280, P35890, DOI 10.1074/jbc.M505685200; Van Harmelen V, 1998, DIABETES, V47, P913, DOI 10.2337/diabetes.47.6.913; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Weyer C, 2000, DIABETOLOGIA, V43, P1498, DOI 10.1007/s001250051560; Winkler G, 2003, EUR J ENDOCRINOL, V149, P129, DOI 10.1530/eje.0.1490129; Wright MD, 2000, PROTEIN SCI, V9, P1594, DOI 10.1110/ps.9.8.1594; Wu XD, 2002, AM J HUM GENET, V70, P1247, DOI 10.1086/340362; Yudkin JS, 2003, INT J OBESITY, V27, pS25, DOI 10.1038/sj.ijo.0802496; Zhang YY, 2002, AM J PHYSIOL-REG I, V282, pR226, DOI 10.1152/ajpregu.00392.2001	51	327	336	4	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1540	+		10.1096/fj.05-5678fje	http://dx.doi.org/10.1096/fj.05-5678fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16754744				2022-12-28	WOS:000240266000044
J	Maurelli, R; Zambruno, G; Guerra, L; Abbruzzese, C; Dimri, G; Gellini, M; Bondanza, S; Dellambra, E				Maurelli, Riccardo; Zambruno, Giovanna; Guerra, Liliana; Abbruzzese, Claudia; Dimri, Goberdhan; Gellini, Mara; Bondanza, Sergio; Dellambra, Elena			Inactivation of p16(INK4a) (inhibitor of cyclin-dependent kinase 4A) immortalizes primary human keratinocytes by maintaining cells in the stem cell compartment	FASEB JOURNAL			English	Article						Bmi-; telomerase; keratinocyte clonal evolution; keratinocyte senescence	TELOMERASE ACTIVITY; LIFE-SPAN; REPLICATIVE SENESCENCE; TRANSCRIPTIONAL SUPPRESSION; TUMOR SUPPRESSION; HAIR-FOLLICLES; BASAL LAYER; EXPRESSION; SKIN; INK4A	Replicative senescence of human keratinocytes is determined by a progressive decline of clonogenic and dividing cells, and its timing is controlled by clonal evolution (i.e., the transition from stem cells to transient amplifying and postmitotic cells). Progressive increase of p16(INK4a) (inhibitor of cyclin-dependent kinase 4A) expression has been shown to correlate with keratinocyte clonal evolution. Thus, the aim of our study is to understand whether p16(INK4a) accumulation is a triggering mechanism of epidermal clonal evolution or a secondary event. We show that inactivation of p16(INK4a), by an antisense strategy, allows primary human keratinocytes to escape replicative senescence. Specifically, p16(INK4a) inactivation alone blocks clonal evolution and maintains keratinocytes in the stem cell compartment. Antisense excision is followed by keratinocyte senescence, confirming that persistent p16(INK4a) inactivation is required for maintenance of clonal evolution block. Immortalization is accompanied by resumption of B-Cell Specific Moloney murine leukemia virus site 1 (Bmi-1) expression and telomerase activity, hallmarks of tissue regenerative capacity. In turn, Bmi-1 expression is necessary to maintain the impairment of clonal evolution induced by p16(INK4a) inactivation. Finally, p16(INK4a) down-regulation in transient amplifying keratinocytes does not affect clonal evolution, and cells undergo senescence. Thus, p16(INK4a) inactivation appears to selectively prevent clonal conversion in cells endowed with a high proliferative potential. These data indicate that p16(INK4a) regulates keratinocyte clonal evolution and that inactivation of p16(INK4a) in epidermal stem cells is necessary for maintaining stemness.	IDI, Lab Tissue Engn & Cutaneous Physiopathol, IRCCS, I-00040 Pomezia, Roma, Italy; IDI, Lab Mol & Cell Biol, IRCCS, I-00040 Pomezia, Roma, Italy; Dept Med, Div Canc Biol, Evanston, IL USA	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Dellambra, E (corresponding author), IDI, Lab Tissue Engn & Cutaneous Physiopathol, IRCCS, Via Castelli Romani 83-85, I-00040 Pomezia, Roma, Italy.	e.dellambra@idi.it	Dellambra, Elena/A-4005-2014; Guerra, Liliana/G-8849-2016; Maurelli, Riccardo/AAA-7723-2020; Zambruno, Giavanna/K-2933-2018; Abbruzzese, Claudia/U-7576-2017; Dimri, Goberdhan/AAO-4210-2021; GELLINI, MARA/D-7954-2016	Dellambra, Elena/0000-0002-4329-3312; Abbruzzese, Claudia/0000-0003-3301-9421; GELLINI, MARA/0000-0002-6243-7836; Guerra, Liliana/0000-0001-6274-6607; Zambruno, Giovanna/0000-0002-1295-056X				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Barrandon Y., 1993, SEMIN DEV BIOL, V4, P209, DOI [DOI 10.1006/SEDB.1993.1025, 10.1006/sedb.1993.1025]; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Berghella L, 1999, HUM GENE THER, V10, P1607, DOI 10.1089/10430349950017617; Bernerd F, 2001, P NATL ACAD SCI USA, V98, P7817, DOI 10.1073/pnas.141221998; Bickenbach JR, 1998, J INVEST DERMATOL, V111, P1045, DOI 10.1046/j.1523-1747.1998.00420.x; Bitoun E, 2003, HUM MOL GENET, V12, P2417, DOI 10.1093/hmg/ddg247; Bond JA, 1999, MOL CELL BIOL, V19, P3103; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Campisi J, 1998, J Investig Dermatol Symp Proc, V3, P1; Claudinot S, 2005, P NATL ACAD SCI USA, V102, P14677, DOI 10.1073/pnas.0507250102; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Dimri GP, 2002, CANCER RES, V62, P4736; Duan JM, 2001, J BIOL CHEM, V276, P48325, DOI 10.1074/jbc.M104814200; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gunes C, 2000, CANCER RES, V60, P2116; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; Harada H, 2003, MOL CANCER RES, V1, P729; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Huschtscha LI, 1999, CARCINOGENESIS, V20, P921, DOI 10.1093/carcin/20.6.921; JONES P, 1996, CELL, V73, P713; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; LAJTHA LG, 1979, DIFFERENTIATION, V14, P23, DOI 10.1111/j.1432-0436.1979.tb01007.x; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Mathor MB, 1996, P NATL ACAD SCI USA, V93, P10371, DOI 10.1073/pnas.93.19.10371; Munro J, 1999, CANCER RES, V59, P2516; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Opitz OG, 2001, J CLIN INVEST, V108, P725, DOI 10.1172/JCI11909; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Pellegrini G, 2004, EUR J CELL BIOL, V83, P691, DOI 10.1078/0171-9335-00424; QUELLE DE, 1995, CELL, V83, P993; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reddel RR, 2001, J CLIN INVEST, V108, P665, DOI 10.1172/JCI200113818; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; ROOP DR, 1988, CANCER RES, V48, P3245; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Saito M, 2004, INT J ONCOL, V24, P1213; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Watt FM, 2001, CURR OPIN GENET DEV, V11, P410, DOI 10.1016/S0959-437X(00)00211-2	67	42	44	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1516	+		10.1096/fj.05-4480fje	http://dx.doi.org/10.1096/fj.05-4480fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16754749				2022-12-28	WOS:000240266000036
J	Patel, VI; Daniel, S; Longo, CR; Shrikhande, GV; Scali, ST; Czismadia, E; Groft, CM; Shukri, T; Motley-Dore, C; Ramsey, HE; Fisher, MD; Grey, ST; Arvelo, MB; Ferran, C				Patel, Virendra I.; Daniel, Soizic; Longo, Christopher R.; Shrikhande, Gautam V.; Scali, Salvatore T.; Czismadia, Eva; Groft, Caroline M.; Shukri, Tala; Motley-Dore, Christina; Ramsey, Haley E.; Fisher, Mark D.; Grey, Shane T.; Arvelo, Maria B.; Ferran, Christiane			A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia	FASEB JOURNAL			English	Article						NO; cell cycle; intimal hyperplasia	NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; IN-VITRO; HUMAN ATHEROSCLEROSIS; MEDIATED APOPTOSIS; ENDOTHELIAL INJURY; DEFICIENT MICE; VESSEL WALL; ACTIVATION	A20 is a NF-kappa B-dependent gene that has dual anti-inflammatory and antiapoptotic functions in endothelial cells (EC). The function of A20 in smooth muscle cells (SMC) is unknown. We demonstrate that A20 is induced in SMC in response to inflammatory stimuli and serves an anti-inflammatory function via blockade of NF-kappa B and NF-kappa B-dependent proteins ICAM-1 and MCP-1. A20 inhibits SMC proliferation via increased expression of cyclin-dependent kinase inhibitors p21(waf1) and p27(kip1). Surprisingly, A20 sensitizes SMC to cytokine- and Fas-mediated apoptosis through a novel NO-dependent mechanism. In vivo, adenoviral delivery of A20 to medial rat carotid artery SMC after balloon angioplasty prevents neointimal hyperplasia by blocking SMC proliferation and accelerating re-endothelialization, without causing apoptosis. However, expression of A20 in established neointimal lesions leads to their regression through increased apoptosis. This is the first demonstration that A20 exerts two levels of control of vascular remodeling and healing. A20 prevents neointimal hyperplasia through combined anti-inflammatory and antiproliferative functions in medial SMC. If SMC evade this first barrier and neointima is formed, A20 has a therapeutic potential by uniquely sensitizing neointimal SMC to apoptosis. A20-based therapies hold promise for the prevention and treatment of neointimal disease.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Vasc Surg, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Transplant Ctr,Dept Surg, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Nephrol,Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ferran, C (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Res N Rm 370F,99 Brookline Ave, Boston, MA 02215 USA.	cferran@caregroup.harvard.edu	Grey, Shane T/B-3020-2008	Grey, Shane T/0000-0003-2160-1625	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021796, T32HL007734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063275] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07734, R01 HL08013, R01 HL021796] Funding Source: Medline; NIDDK NIH HHS [R01 DK063275] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abid MR, 2005, J BIOL CHEM, V280, P29864, DOI 10.1074/jbc.M502149200; Beck KF, 1996, FEBS LETT, V394, P263, DOI 10.1016/0014-5793(96)00966-0; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; BLANCBRUDE OP, 2002, NAT MED, V9, P987; Bornfeldt KE, 2003, CIRC RES, V92, P345, DOI 10.1161/01.RES.0000061765.06145.10; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Chan SW, 2000, CIRC RES, V86, P1038, DOI 10.1161/01.RES.86.10.1038; Chen LH, 2000, CIRC RES, V86, P520, DOI 10.1161/01.RES.86.5.520; Cimbrone A, 1995, AM J CARDIOL, V75, P67, DOI 10.1016/0002-9149(95)80016-L; CLOWES AW, 1983, LAB INVEST, V49, P208; Collins RG, 2000, J EXP MED, V191, P189, DOI 10.1084/jem.191.1.189; Cooke JP, 2003, ATHEROSCLEROSIS SUPP, V4, P53, DOI 10.1016/S1567-5688(03)00034-5; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; Daniel S, 2004, BLOOD, V104, P2376, DOI 10.1182/blood-2003-02-0635; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; Fukumoto Y, 1997, CIRCULATION, V96, P3104, DOI 10.1161/01.CIR.96.9.3104; Fukuo K, 1996, HYPERTENSION, V27, P823, DOI 10.1161/01.HYP.27.3.823; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; Gomes D, 2001, J VASC SURG, V34, P707, DOI 10.1067/mva.2001.116802; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; HANSSON GK, 1994, J EXP MED, V180, P733, DOI 10.1084/jem.180.2.733; HARIRI RJ, 1986, J EXP MED, V164, P1171, DOI 10.1084/jem.164.4.1171; Hsieh JK, 2000, ARTERIOSCL THROM VAS, V20, P973, DOI 10.1161/01.ATV.20.4.973; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Iwashina M, 1998, CIRCULATION, V98, P1212, DOI 10.1161/01.CIR.98.12.1212; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kunter U, 2003, TRANSPLANTATION, V75, P3, DOI 10.1097/00007890-200301150-00002; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; Longo CR, 2003, CIRCULATION, V108, P1113, DOI 10.1161/01.CIR.0000083718.76889.D0; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Moussa I, 2004, CIRCULATION, V109, P2273, DOI 10.1161/01.CIR.0000129767.45513.71; Ni WH, 2001, CIRCULATION, V103, P2096; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Rembold C, 1996, PERSPECT BIOL MED, V39, P405; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736; Storz P, 2005, BIOCHEM J, V387, P47, DOI 10.1042/BJ20041443; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; Wang BY, 1999, CIRCULATION, V99, P1236, DOI 10.1161/01.CIR.99.9.1236; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xu QB, 2003, CIRC RES, V93, pE76, DOI 10.1161/01.RES.0000097864.24725.60; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Yu ZY, 2004, J BIOL CHEM, V279, P46954, DOI 10.1074/jbc.M407192200	52	69	72	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1418	1430		10.1096/fj.05-4981com	http://dx.doi.org/10.1096/fj.05-4981com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816117	Green Submitted			2022-12-28	WOS:000240266000019
J	Simon, DM; Arikan, MC; Srisuma, S; Bhattacharya, S; Tsai, LW; Ingenito, EP; Gonzalez, F; Shapiro, SD; Mariani, TJ				Simon, Dawn M.; Arikan, Meltem C.; Srisuma, Sorachai; Bhattacharya, Soumyaroop; Tsai, Larry W.; Ingenito, Edward P.; Gonzalez, Frank; Shapiro, Steven D.; Mariani, Thomas J.			Epithelial cell PPAR gamma contributes to normal lung maturation	FASEB JOURNAL			English	Article						Cre recombinase; Clara cell; lung development; airspace enlargement	ACTIVATED-RECEPTOR-GAMMA; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; ADIPOSE-TISSUE; MOUSE MODEL; INFLAMMATION; APOPTOSIS; INDUCTION; LIGANDS	Peroxisome proliferator-activated receptor (PPAR)-gamma is a member of the nuclear hormone receptor superfamily that can promote cellular differentiation and organ development. PPAR gamma expression has been reported in a number of pulmonary cell types, including inflammatory, mesenchymal, and epithelial cells. We find that PPAR gamma is prominently expressed in the airway epithelium in the mouse lung. In an effort to define the physiological role of PPAR gamma within the lung, we have ablated PPAR gamma using a novel line of mice capable of specifically targeting the airway epithelium. Airway epithelial cell PPAR gamma-targeted mice display enlarged airspaces resulting from insufficient postnatal lung maturation. The increase in airspace size is accompanied by alterations in lung physiology, including increased lung volumes and decreased tissue resistance. Genome-wide expression profiling reveals a reduction in structural extracellular matrix (ECM) gene expression in conditionally targeted mice, suggesting a disruption in epithelial-mesenchymal interactions necessary for the establishment of normal lung structure. Expression profiling of airway epithelial cells isolated from conditionally targeted mice indicates PPAR gamma regulates genes encoding known PPAR gamma targets, additional lipid metabolism enzymes, and markers of cellular differentiation. These data reveal airway epithelial cell PPAR gamma is necessary for normal lung structure and function.	Harvard Univ, Div Pulm & Crit Care Med, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Resp Dis, Boston, MA 02115 USA; Mahidol Univ, Siriraj Hosp, Fac Med, Dept Physiol, Bangkok 10700, Thailand; Natl Canc Inst, Lab Metab, Bethesda, MD USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Mahidol University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mariani, TJ (corresponding author), Harvard Univ, Div Pulm & Crit Care Med, Brigham & Womens Hosp, Sch Med, 75 Francis St,Thorn 908, Boston, MA 02115 USA.	tmariani@rics.bwh.harvard.edu	Bhattacharya, Soumyaroop/E-7669-2010	Bhattacharya, Soumyaroop/0000-0003-1140-7845	NHLBI NIH HHS [HL70321, HL071885] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070321, R01HL071885] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Arikan MC, 2005, J CELL PHYSIOL, V204, P139, DOI 10.1002/jcp.20271; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487, DOI 10.1164/ajrccm.164.8.2101070; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Birrell MA, 2004, EUR RESPIR J, V24, P18, DOI 10.1183/09031936.04.00098303; Bren-Mattison Y, 2005, ONCOGENE, V24, P1412, DOI 10.1038/sj.onc.1208333; Buhling F, 2002, DEV DYNAM, V225, P14, DOI 10.1002/dvdy.10134; Cabrero A, 2003, METABOLISM, V52, P652, DOI 10.1053/meta.2003.50100; Chang TH, 2000, CANCER RES, V60, P1129; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Drori S, 2005, GENE DEV, V19, P362, DOI 10.1101/gad.1240705; Genovese T, 2005, EUR RESPIR J, V25, P225, DOI 10.1183/09031936.05.00049704; Gosset P, 2001, EUR J IMMUNOL, V31, P2857, DOI 10.1002/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO;2-X; Hammad H, 2004, AM J PATHOL, V164, P263, DOI 10.1016/S0002-9440(10)63116-1; Honda K, 2004, J ALLERGY CLIN IMMUN, V113, P882, DOI 10.1016/j.jaci.2004.02.036; Hoyle GW, 1998, AM J RESP CELL MOL, V18, P149, DOI 10.1165/ajrcmb.18.2.2803m; Ito S, 2005, J APPL PHYSIOL, V98, P503, DOI 10.1152/japplphysiol.00590.2004; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Lian XM, 2005, AM J PATHOL, V167, P813, DOI 10.1016/S0002-9440(10)62053-6; Lian XM, 2004, AM J PHYSIOL-LUNG C, V286, pL801, DOI 10.1152/ajplung.00335.2003; Mariani TJ, 2002, AM J RESP CELL MOL, V26, P541, DOI 10.1165/ajrcmb.26.5.2001-00080c; Mariani TJ, 1998, MOL BIOL CELL, V9, P1411, DOI 10.1091/mbc.9.6.1411; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Padilla J, 2000, ANN NY ACAD SCI, V905, P97; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roth-Kleiner M, 2003, BIOL NEONATE, V84, P83, DOI 10.1159/000071009; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Shankaranarayanan P, 2003, J IMMUNOL, V170, P887, DOI 10.4049/jimmunol.170.2.887; Shannon JM, 2004, ANNU REV PHYSIOL, V66, P625, DOI 10.1146/annurev.physiol.66.032102.135749; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tokunou M, 2000, LAB INVEST, V80, P1643, DOI 10.1038/labinvest.3780174; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Wang ACC, 2001, AM J RESP CELL MOL, V24, P688, DOI 10.1165/ajrcmb.24.6.4376; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; Yang L, 2003, J BIOL CHEM, V278, P36841, DOI 10.1074/jbc.M304156200; You YJ, 2002, AM J PHYSIOL-LUNG C, V283, pL1315, DOI 10.1152/ajplung.00169.2002; Yue LL, 2004, J BIOL CHEM, V279, P47626, DOI 10.1074/jbc.M408461200; Zhang JF, 2004, P NATL ACAD SCI USA, V101, P10703, DOI 10.1073/pnas.0403652101	41	81	82	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1507	+		10.1096/fj.05-5410fje	http://dx.doi.org/10.1096/fj.05-5410fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720732				2022-12-28	WOS:000240266000033
J	Wang, X; Hockerman, GH; Green, HW; Babbs, CF; Mohammad, SI; Gerrard, D; Latour, MA; London, B; Hannon, KM; Pond, AL				Wang, Xun; Hockerman, Gregory H.; Green, Henry W., III; Babbs, Charles F.; Mohammad, Sulma I.; Gerrard, David; Latour, Mickey A.; London, Barry; Hannon, Kevin M.; Pond, Amber L.			Merg1a K+ channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway	FASEB JOURNAL			English	Article						ectopic gene expression; hindlimb suspension; astemizole	SIGNALING PATHWAYS; I-KR; MOUSE; EXPRESSION; HYPERTROPHY; HEART; RAT; PROTEOLYSIS; COMPONENT; PROTEINS	Skeletal muscle atrophy results from an imbalance in protein degradation and protein synthesis and occurs in response to injury, various disease states, disuse, and normal aging. Current treatments for this debilitating condition are inadequate. More information about mechanisms involved in the onset and progression of muscle atrophy is necessary for development of more effective therapies. Here we show that expression of the mouse ether-a-go-go related gene (Merg1a) K+ channel is up-regulated in skeletal muscle of mice experiencing atrophy as a result of both malignant tumor expression and disuse. Further, ectopic expression of Merg1a in vivo induces atrophy in healthy wt-bearing mice, while expression of a dysfunctional Merg1a mutant suppresses atrophy in hindlimb-suspended mice. Treatment of hindlimb-suspended mice with astemizole, a known Merg1a channel blocker, inhibits atrophy in these animals. Importantly, in vivo expression of Merg1a in mouse skeletal muscle activates the ubiquitin proteasome pathway that is responsible for the majority of protein degradation that causes muscle atrophy, yet expression of a dysfunctional Merg1a mutant decreases levels of ubiquitin-proteasome proteolysis. Thus, expression of Merg1a likely initiates atrophy by activating ubiquitin-proteasome proteolysis. This gene and its product are potential targets for prevention and treatment of muscle atrophy.	Purdue Univ, Sch Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Coll Pharm, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Purdue Univ, Sch Vet Med, Dept Vet Clin Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Vet Pathobiol, W Lafayette, IN 47907 USA; Purdue Univ, Ctr Canc, W Lafayette, IN 47907 USA; Purdue Univ, Coll Agr, Dept Anim Sci, W Lafayette, IN 47907 USA; Univ Pittsburgh, Cardiovasc Inst, Pittsburgh, PA USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pond, AL (corresponding author), Purdue Univ, Sch Vet Med, Dept Basic Med Sci, 625 Harrison St, W Lafayette, IN 47907 USA.	pond@purdue.edu	gerrard, david/AAG-7507-2019	gerrard, david/0000-0002-3482-1400; Pond, Amber/0000-0002-2836-889X; London, Barry/0000-0003-1506-3947				Alzghoul MB, 2004, FASEB J, V18, P221, DOI 10.1096/fj.03-0293fje; BIAN JS, 2004, AJP HEART, V287, P2154; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Franch HA, 2005, CURR OPIN CLIN NUTR, V8, P271, DOI 10.1097/01.mco.0000165005.01331.45; Fraysse B, 2003, FASEB J, V17, P1916, DOI 10.1096/fj.02-1012fje; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Haddad F, 2003, J APPL PHYSIOL, V95, P791, DOI 10.1152/japplphysiol.01113.2002; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; Jones EMC, 2004, J BIOL CHEM, V279, P44690, DOI 10.1074/jbc.M408344200; Kirchhoff S, 1998, CURR BIOL, V8, P299, DOI 10.1016/S0960-9822(98)70114-9; LeesMiller JP, 1997, CIRC RES, V81, P719; London B, 1997, CIRC RES, V81, P870; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Matsushita S, 1999, CANCER RES, V59, P1911; McArdle A, 2003, FASEB J, V17, P355, DOI 10.1096/fj.03-0395fje; Miranda P, 2005, J PHYSIOL-LONDON, V566, P717, DOI 10.1113/jphysiol.2005.085803; Mitchell GF, 1998, AM J PHYSIOL-HEART C, V274, pH747, DOI 10.1152/ajpheart.1998.274.3.H747; Pette D, 2001, HISTOCHEM CELL BIOL, V115, P359, DOI 10.1007/s004180100268; Polvani S, 2003, GENE EXPR PATTERNS, V3, P767, DOI 10.1016/S1567-133X(03)00124-8; Pond AL, 2000, J BIOL CHEM, V275, P5997, DOI 10.1074/jbc.275.8.5997; Razeghi P, 2003, CIRCULATION, V108, P2536, DOI 10.1161/01.CIR.0000096481.45105.13; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rosati B, 2000, FASEB J, V14, P2601, DOI 10.1096/fj.00-0077com; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; Selyanko AA, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-05-j0001.2002; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; Taylor J, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-11; Thomas D, 2004, BASIC RES CARDIOL, V99, P279, DOI 10.1007/s00395-004-0474-7; Zhou ZF, 1999, J CARDIOVASC ELECTR, V10, P836, DOI 10.1111/j.1540-8167.1999.tb00264.x	32	21	23	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1531	+		10.1096/fj.05-5350fje	http://dx.doi.org/10.1096/fj.05-5350fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723379				2022-12-28	WOS:000240266000041
J	Zhang, YJ; Xu, YF; Liu, YH; Yin, J; Li, HL; Wang, Q; Wang, JZ				Zhang, Yong-Jie; Xu, Ya-Fei; Liu, Ying-Hua; Yin, Jun; Li, Hong-Lian; Wang, Qun; Wang, Jian-Zhi			Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms	FASEB JOURNAL			English	Article						tau; glycogen synthase kinase-3 beta; p38 MAPKs; proteasome	NITRIC-OXIDE SYNTHASE; BETA-AMYLOID STIMULATION; PAIRED HELICAL FILAMENTS; OXIDATIVE STRESS; GROWTH-FACTOR; PROTEIN-TAU; URIC-ACID; TYROSINE NITRATION; PHOSPHORYLATES TAU; ENDOTHELIAL-CELLS	To investigate the upstream effector that led to tau hyperphosphorylation, nitration, and accumulation as seen in Alzheimer's disease brain, and the underlying mechanisms, we bilaterally injected SIN-1, a recognized peroxynitrite donor, into the hippocampus of rat brain. We observed that the level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h after drug administration, and these alterations were prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. Concomitantly, we detected a significant activation in glycogen synthase kinase-3 beta (GSK-3 beta) and p38 MAPKs, including p38 alpha, p38 beta, and p38 delta, but no obvious change was measured in the activity of p38 gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, in which the activity of 20S proteasome was significantly arrested in SIN-1-injected rats. Further studies demonstrated that the hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis. These results provide the first in vivo evidence showing that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3 beta, p38 beta, p38 delta, p38 delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation. Our findings reveal a common upstream stimulator and a potential therapeutic target for Alzheimer-like neurodegeneration.	Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Pathophysiol, Key Lab Neurol Dis Hubei Prov, Wuhan 430030, Peoples R China	Huazhong University of Science & Technology	Wang, JZ (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Pathophysiol, Key Lab Neurol Dis Hubei Prov, Wuhan 430030, Peoples R China.	wangjz@mails.tjmu.edu.cn	Zhang, Yong-Jie/G-3378-2011; liu, ying/GXF-4294-2022; LIU, YING/GZL-7252-2022					Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; Bapat S, 2001, FEBS LETT, V499, P21, DOI 10.1016/S0014-5793(01)02511-X; Cardozo C, 2002, ARCH BIOCHEM BIOPHYS, V408, P103, DOI 10.1016/S0003-9861(02)00493-9; Castegna A, 2003, J NEUROCHEM, V85, P1394, DOI 10.1046/j.1471-4159.2003.01786.x; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Combs CK, 2001, J NEUROSCI, V21, P1179; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; El-Remessy AB, 2005, J CELL SCI, V118, P243, DOI 10.1242/jcs.01612; El-Remessy AB, 2003, AM J PATHOL, V162, P1995, DOI 10.1016/S0002-9440(10)64332-5; Feijoo C, 2005, J CELL SCI, V118, P397, DOI 10.1242/jcs.01655; Freels JL, 2002, J IMMUNOL, V169, P4568, DOI 10.4049/jimmunol.169.8.4568; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goldbaum O, 2003, J NEUROSCI, V23, P8872; Good PF, 1996, AM J PATHOL, V149, P21; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Hellberg CB, 1998, BIOCHEM BIOPH RES CO, V252, P313, DOI 10.1006/bbrc.1998.9581; Hensley K, 1998, J NEUROSCI, V18, P8126; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Hickman-Davis J, 1999, P NATL ACAD SCI USA, V96, P4953, DOI 10.1073/pnas.96.9.4953; Hodara R, 2004, J BIOL CHEM, V279, P47746, DOI 10.1074/jbc.M408906200; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; Hyun DH, 2003, J NEUROCHEM, V86, P363, DOI 10.1046/j.1471-4159.2003.01841.x; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Koppal T, 1999, J NEUROCHEM, V72, P310, DOI 10.1046/j.1471-4159.1999.0720310.x; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lee HG, 2005, TRENDS MOL MED, V11, P164, DOI 10.1016/j.molmed.2005.02.008; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 2004, TRENDS NEUROSCI, V27, P129, DOI 10.1016/j.tins.2004.01.007; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Liu SJ, 2004, J BIOL CHEM, V279, P50078, DOI 10.1074/jbc.M406109200; Liu SJ, 2002, ACTA PHARMACOL SIN, V23, P183; Luth HJ, 2002, BRAIN RES, V953, P135, DOI 10.1016/S0006-8993(02)03280-8; McDonald DR, 1997, J NEUROSCI, V17, P2284; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Morsch R, 1999, J NEUROPATH EXP NEUR, V58, P188, DOI 10.1097/00005072-199902000-00008; Muyderman H, 2004, J NEUROSCI, V24, P8019, DOI 10.1523/JNEUROSCI.1103-04.2004; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Oh-Hashi K, 2001, FREE RADICAL BIO MED, V30, P213, DOI 10.1016/S0891-5849(00)00461-5; Osna NA, 2004, HEPATOLOGY, V40, P574, DOI 10.1002/hep.20352; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Pesse B, 2005, J MOL CELL CARDIOL, V38, P765, DOI 10.1016/j.yjmcc.2005.02.020; Possel H, 2002, GLIA, V38, P339, DOI 10.1002/glia.10066; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Reynolds CH, 1997, J NEUROCHEM, V69, P191; Reynolds MR, 2005, BIOCHEMISTRY-US, V44, P1690, DOI 10.1021/bi047982v; Salon ML, 2000, J NEUROSCI RES, V62, P302, DOI 10.1002/1097-4547(20001015)62:2<302::AID-JNR15>3.0.CO;2-L; Schildknecht S, 2005, FASEB J, V19, P1169, DOI 10.1096/fj.04-3465fje; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; Shringarpure R, 2001, CELL MOL LIFE SCI, V58, P1442, DOI 10.1007/PL00000787; Smith MA, 1997, J NEUROSCI, V17, P2653; Spear N, 1997, J NEUROCHEM, V69, P53; Sun AY, 2003, EXP NEUROL, V183, P394, DOI 10.1016/S0014-4886(03)00180-8; Tohgi H, 1999, NEUROSCI LETT, V269, P52, DOI 10.1016/S0304-3940(99)00406-1; Tran MH, 2001, FASEB J, V15, P1407, DOI 10.1096/fj.00-0719fje; Tsujio I, 2000, FEBS LETT, V469, P111, DOI 10.1016/S0014-5793(00)01234-5; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; Wang JZ, 1998, FEBS LETT, V436, P28, DOI 10.1016/S0014-5793(98)01090-4; Wang QW, 2004, J NEUROSCI, V24, P6049, DOI 10.1523/JNEUROSCI.0233-04.2004; Whiteman M, 2004, FASEB J, V18, P1395, DOI 10.1096/fj.03-1096fje; Zhang P, 2000, J BIOL CHEM, V275, P22479, DOI 10.1074/jbc.M910425199; Zhang YJ, 2005, FEBS LETT, V579, P2421, DOI 10.1016/j.febslet.2005.03.041; Zhu XW, 2000, J NEUROPATH EXP NEUR, V59, P880, DOI 10.1093/jnen/59.10.880; Zhu XW, 2001, J NEUROCHEM, V79, P311, DOI 10.1046/j.1471-4159.2001.00597.x; Zouki C, 2001, FASEB J, V15, P25	74	65	70	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1431	1442		10.1096/fj.05-5223com	http://dx.doi.org/10.1096/fj.05-5223com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816118				2022-12-28	WOS:000240266000020
J	Sohn, H; Kim, YS; Kim, HT; Kim, CH; Cho, EW; Kang, HY; Kim, NS; Kim, CH; Ryu, SE; Lee, JH; Ko, JH				Sohn, Hosung; Kim, Yong-Sam; Kim, Hyun-Taek; Kim, Cheol-Hee; Cho, Eun-Wie; Kang, Hye-Yeon; Kim, Nam-Soon; Kim, Cheorl-Ho; Ryu, Seong Eon; Lee, Jeong-Hwa; Ko, Jeong Heon			Ganglioside GM3 is involved in neuronal cell death	FASEB JOURNAL			English	Article						GM3; 12-lipoxygenase; glycosphingolipid-enriched microdomains; ROS; neuronal cell death	GD3 GANGLIOSIDE; ARACHIDONIC-ACID; OXIDATIVE STRESS; RAT CEREBELLUM; APOPTOSIS; ASSOCIATION; ACTIVATION; GLUTAMATE; 12-LIPOXYGENASE; EXPRESSION	Gangliosides abundant in the nervous system have been implicated in a broad range of biological functions, including the regulation of cell proliferation and death. Glutamate-induced cell death, which is accompanied by an accumulation of reactive oxygen species (ROS), is a major contributor to pathological cell death within the nervous system. However, the mechanism underlying this neuronal cell death has not been fully elucidated. In this study, we report that ganglioside GM3 is involved in neuronal cell death. GM3 was up-regulated in the mouse hippocampal cell line HT22 death caused by glutamate. Increment in GM3 levels by both the exogenous addition of GM3 and the overexpression of the GM3 synthase gene induced neuronal cell death. Overexpression of GM3 synthase by microinjecting mRNA into zebrafish embryos resulted in neuronal cell death in the central nervous system (CNS). Conversely, RNA interference-mediated silencing of GM3 synthase rescued glutamate-induced neuronal death, as evidenced by the inhibition of massive ROS production and intracellular calcium ion influx. 12-lipoxygenase (12-lipoxygenase) (12-LOX) was recruited to glycosphingolipid-enriched microdomains (GEM) in a GM3-dependent manner during oxidative glutamate toxicity. Our findings suggest that GM3 acts as not only a mediator of oxidative HT22 death by glutamate but also a modulator of in vivo neuronal cell death.-Sohn, H., Kim, Y.-S., Kim, H.-T., Kim, C.-H., Cho, E.-W., Kang, H.-y., Kim, N.-S., Kim, C.-H., Ryu, S. E., Lee, J.-H., Ko, J.H. Ganglioside GM3 is involved in neuronal cell death.	Korea Res Inst Biosci & Biotechnol, Proteom Res Ctr, Taejon 305333, South Korea; Korea Res Inst Biosci & Biotechnol, Ctr Funct Anal Human Genome, Taejon 305333, South Korea; Chungnam Natl Univ, Taejon, South Korea; Sungkyunkwan Univ, Dept Biol Sci, Suwon, South Korea; Catholic Univ Korea, Coll Med, Dept Biochem, Seoul, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University; Sungkyunkwan University (SKKU); Catholic University of Korea	Ko, JH (corresponding author), Korea Res Inst Biosci & Biotechnol, Proteom Res Ctr, 52 Eoeun Dong, Taejon 305333, South Korea.	jhko@kribb.re.kr	Kim, Cheorl-Ho/T-6753-2019	Kim, Cheorl-Ho/0000-0002-6323-0714; Kim, Cheol-Hee/0000-0002-3019-0699				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Blader P, 2000, HUM MOL GENET, V9, P945, DOI 10.1093/hmg/9.6.945; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Brosamle C, 2002, GLIA, V39, P47, DOI 10.1002/glia.10088; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Coffey MJ, 2004, FEBS LETT, V576, P165, DOI 10.1016/j.febslet.2004.09.007; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; FREDMAN P, 1994, PROG BRAIN RES, V101, P225; Fujimoto Y, 2005, J NEURO-ONCOL, V71, P99, DOI 10.1007/s11060-004-9602-3; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garofalo T, 2003, J BIOL CHEM, V278, P8309, DOI 10.1074/jbc.M207618200; Garofalo T, 2002, J BIOL CHEM, V277, P11233, DOI 10.1074/jbc.M109601200; Giammarioli AM, 2001, FEBS LETT, V506, P45, DOI 10.1016/S0014-5793(01)02776-4; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; KAWAI K, 1994, NEUROSCI LETT, V174, P225, DOI 10.1016/0304-3940(94)90027-2; KIGUCHI K, 1990, J BIOCHEM-TOKYO, V107, P8, DOI 10.1093/oxfordjournals.jbchem.a123016; Kwon KJ, 2005, J NEUROSCI RES, V81, P73, DOI 10.1002/jnr.20520; Lebeau A, 2004, CELL DEATH DIFFER, V11, P875, DOI 10.1038/sj.cdd.4401395; LEDEEN RW, 1978, J SUPRAMOL STR CELL, V8, P1, DOI 10.1002/jss.400080102; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Li YH, 1997, J CELL BIOL, V139, P1317, DOI 10.1083/jcb.139.5.1317; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Molander M, 2000, J NEUROSCI RES, V60, P531, DOI 10.1002/(SICI)1097-4547(20000515)60:4<531::AID-JNR12>3.0.CO;2-6; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; NAKAMURA M, 1991, CANCER RES, V51, P1940; Nakatsuji Y, 2001, EXP NEUROL, V168, P290, DOI 10.1006/exnr.2000.7602; Nojiri H, 2002, CANCER DETECT PREV, V26, P114, DOI 10.1016/S0361-090X(02)00033-8; Noll ENE, 2001, EXP NEUROL, V168, P300, DOI 10.1006/exnr.2000.7603; Ono M, 1999, CANCER RES, V59, P2335; Ozeki Y, 1999, BRIT J PHARMACOL, V128, P1699, DOI 10.1038/sj.bjp.0702976; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SAQR HE, 1993, J NEUROCHEM, V61, P395; SENN HJ, 1989, EUR J BIOCHEM, V181, P657, DOI 10.1111/j.1432-1033.1989.tb14773.x; Sioud M, 2004, TRENDS PHARMACOL SCI, V25, P22, DOI 10.1016/j.tips.2003.11.006; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Tagami S, 2002, J BIOL CHEM, V277, P3085, DOI 10.1074/jbc.M103705200; Tan S, 2001, J CELL BIOL, V152, P997, DOI 10.1083/jcb.152.5.997; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; Tan SL, 1998, J NEUROCHEM, V71, P95; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; THISSE C, 1993, DEVELOPMENT, V119, P1203; Watanabe R, 2002, CANCER RES, V62, P3850; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; WOLSWIJK G, 1995, GLIA, V13, P13, DOI 10.1002/glia.440130103; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Yamashita T, 2005, P NATL ACAD SCI USA, V102, P2725, DOI 10.1073/pnas.0407785102; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	57	57	60	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1248	+		10.1096/fj.05-4911fje	http://dx.doi.org/10.1096/fj.05-4911fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636105				2022-12-28	WOS:000240210300041
J	Greenberg, RS; Bernstein, AM; Benezra, M; Gelman, IH; Taliana, L; Masur, SK				Greenberg, Roseanne S.; Bernstein, Audrey M.; Benezra, Miriam; Gelman, Irwin H.; Taliana, Lavinia; Masur, Sandra K.			FAK-dependent regulation of myofibroblast differentiation	FASEB JOURNAL			English	Article						FGF; TGF beta; fibrosis	FIBROBLAST-GROWTH-FACTOR; FOCAL ADHESION KINASE; SMOOTH MUSCLE ACTIN; ENDOTHELIAL-CELL GROWTH; FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; TYROSINE PHOSPHORYLATION; NEUTRALIZING ANTIBODY; GRANULATION-TISSUE; CYCLIN D1	Fibroblasts and myofibroblasts both participate in wound healing. Transforming growth factor beta (TGF beta) induces fibroblasts to differentiate into myofibroblasts, whereas fibroblast growth factor and heparin (FGF/ h) induce myofibroblasts to "de-differentiate" into fibroblasts. TGF beta induces expression of smooth muscle alpha actin (SM alpha A) and incorporation into in stress fibers, a phenotype of differentiated myofibroblasts. Additionally, TGF beta induces the expression of fibronectin and fibronectin integrins. Fibronectin-generated signals contribute to the TGF beta-mediated myofibroblast differentiation. Because fibronectin signals are transmitted through focal adhesion kinase (FAK), it was predicted that FAK would be essential to TGF beta-mediated myofibroblast differentiation. To determine whether the FAK signaling pathway is required for myofibroblast differentiation, we used two approaches to decrease FAK in mouse embryo fibroblasts (MEFs): 1) FAK+/+ MEFs, in which FAK protein expression was greatly decreased by short hairpin RNA (shRNA), and 2) FAK-/-MEFs, which lack FAK. In both cases, the majority of cells were myofibroblasts, expressing SM alpha A in stress fibers even after treatment with FGF/ h. Furthermore, both the surface expression of FGFRs and FGF signaling were greatly reduced in FAK-/-MEFs. We conclude that FAK does not contribute to TGF beta-dependent myofibroblast differentiation. Instead, FAK was necessary for FGF/ h signaling in down-regulating expression of SM alpha A, which is synonymous with myofibroblast differentiation. FAK activation could contribute to regulating myofibroblast differentiation, thereby ameliorating fibrosis.	Mt Sinai Sch Med, Dept Ophthalmol, New York, NY 10029 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Icahn School of Medicine at Mount Sinai; Roswell Park Cancer Institute	Greenberg, RS (corresponding author), Mt Sinai Sch Med, Dept Ophthalmol, Box 1183,1 Gustave Levey Pl, New York, NY 10029 USA.	roseanne.greenberg@mssm.edu		Bernstein, Audrey/0000-0002-2537-2594	NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY017030, P30EY001867, R01EY009414, F32EY007049] Funding Source: NIH RePORTER; NCI NIH HHS [1-R24-CA095823] Funding Source: Medline; NEI NIH HHS [R01 EY09414, R01 EY009414, R01 EY017030, F32 EY07049, P30 EY001867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Armulik A, 2004, MOL BIOL CELL, V15, P2558, DOI 10.1091/mbc.E03-09-0700; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Bochaton-Piallat ML, 2000, INVEST OPHTH VIS SCI, V41, P2336; BORSI L, 1990, FEBS LETT, V261, P175, DOI 10.1016/0014-5793(90)80664-5; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLARK RAF, 1996, WOUND REPAIR OVERVIE; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; DARBY I, 1990, LAB INVEST, V63, P21; DAVID T, 1995, CORNEA, V14, P227, DOI 10.1097/00003226-199505000-00001; Denton CP, 2005, J BIOL CHEM, V280, P16053, DOI 10.1074/jbc.M413134200; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Ding Q, 2005, J BIOL CHEM, V280, P6802, DOI 10.1074/jbc.M409180200; Dugina V, 2001, J CELL SCI, V114, P3285; GARANA RMR, 1992, INVEST OPHTH VIS SCI, V33, P3271; George J, 2000, AM J PATHOL, V156, P115, DOI 10.1016/S0002-9440(10)64711-6; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GRESSNER AM, 1990, SEMIN LIVER DIS, V10, P30, DOI 10.1055/s-2008-1040455; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Hinz B, 2003, THROMB HAEMOSTASIS, V90, P993, DOI 10.1160/TH03-05-0328; Hinz B, 2003, MOL BIOL CELL, V14, P2508, DOI 10.1091/mbc.E02-11-0729; Hinz B, 2002, J CELL BIOL, V157, P657, DOI 10.1083/jcb.200201049; Hinz B, 2001, AM J PATHOL, V159, P1009, DOI 10.1016/S0002-9440(10)61776-2; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; HOPPENREIJS VPT, 1994, INVEST OPHTH VIS SCI, V35, P931; Hsia DA, 2005, MOL CELL BIOL, V25, P9700, DOI 10.1128/MCB.25.21.9700-9712.2005; Ilic D, 2004, J CELL SCI, V117, P177, DOI 10.1242/jcs.00845; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Jester JV, 1996, CORNEA, V15, P505; Jester JV, 1997, CORNEA, V16, P177; Jester JV, 1999, INVEST OPHTH VIS SCI, V40, P1959; JESTER JV, 1995, INVEST OPHTH VIS SCI, V36, P809; Jester JV, 2003, EXP EYE RES, V77, P581, DOI 10.1016/S0014-4835(03)00188-X; Jester JV, 1999, PROG RETIN EYE RES, V18, P311, DOI 10.1016/S1350-9462(98)00021-4; Kawai-Kowase K, 2004, ARTERIOSCL THROM VAS, V24, P1384, DOI 10.1161/01.ATV.0000136548.17816.07; Kilkenny DM, 2003, J BIOL CHEM, V278, P17448, DOI 10.1074/jbc.M209698200; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Masur SK, 1999, INVEST OPHTH VIS SCI, V40, P904; Masur SK, 1996, P NATL ACAD SCI USA, V93, P4219, DOI 10.1073/pnas.93.9.4219; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Moissoglu K, 2005, BIOCHEM BIOPH RES CO, V330, P673, DOI 10.1016/j.bbrc.2005.03.025; Moller-Pedersen T, 1998, CURR EYE RES, V17, P736, DOI 10.1076/ceyr.17.7.736.5163; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Petridou S, 2000, INVEST OPHTH VIS SCI, V41, P89; Petroll WM, 1998, INVEST OPHTH VIS SCI, V39, P2018; RICH LF, 1992, CURR EYE RES, V11, P719, DOI 10.3109/02713689209000746; RIECK P, 1992, EXP EYE RES, V54, P987, DOI 10.1016/0014-4835(92)90163-M; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; Roy SG, 2001, INT J BIOCHEM CELL B, V33, P723, DOI 10.1016/S1357-2725(01)00041-3; SAPPINO AP, 1990, AM J PATHOL, V137, P585; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; SHAH M, 1994, J CELL SCI, V107, P1137; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; SINGER II, 1984, J CELL BIOL, V98, P2091, DOI 10.1083/jcb.98.6.2091; SKALLI OGG, 1996, BIOL MYOFIBROBLAST R; Tashiro E, 2003, ONCOGENE, V22, P5630, DOI 10.1038/sj.onc.1206636; Tashiro E, 2003, CANCER RES, V63, P424; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Tseng SCG, 1999, J CELL PHYSIOL, V179, P325, DOI 10.1002/(SICI)1097-4652(199906)179:3<325::AID-JCP10>3.0.CO;2-X; TSUBOI R, 1990, J EXP MED, V172, P245, DOI 10.1084/jem.172.1.245; Uchio K, 1999, J VET MED SCI, V61, P769, DOI 10.1292/jvms.61.769; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Watanabe E, 1998, BASIC RES CARDIOL, V93, P30, DOI 10.1007/s003950050059; Yamauchi K, 2004, J BIOL CHEM, V279, P55104, DOI 10.1074/jbc.M407423200; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P1401, DOI 10.1126/science.1382313; Young GD, 2004, J BIOL CHEM, V279, P38032, DOI 10.1074/jbc.M405658200; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	79	68	71	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					1006	+		10.1096/fj.05-4838fje	http://dx.doi.org/10.1096/fj.05-4838fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585062				2022-12-28	WOS:000240157700037
J	Gnecchi, M; He, HM; Noiseux, N; Liang, OD; Zhang, LM; Morello, F; Mu, H; Melo, LG; Pratt, RE; Ingwall, JS; Dzau, VJ				Gnecchi, Massimiliano; He, Huamei; Noiseux, Nicolas; Liang, Olin D.; Zhang, Lunan; Morello, Fulvio; Mu, Hui; Melo, Luis G.; Pratt, Richard E.; Ingwall, Joanne S.; Dzau, Victor J.			Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement	FASEB JOURNAL			English	Article						cell therapy; cytoprotection; inotropism; myocardial infarction; secreted factors	MARROW STROMAL CELLS; HUMAN BONE-MARROW; GROWTH-FACTOR-I; MYOCARDIAL REGENERATION; CARDIOMYOCYTE APOPTOSIS; ISCHEMIC-MYOCARDIUM; HEART FUNCTION; REPAIR; RAT; DIFFERENTIATE	We previously reported that intramyocardial injection of bone marrow-derived mesenchymal stem cells overexpressing Akt (Akt-MSCs) inhibits ventricular remodeling and restores cardiac function measured 2 wk after myocardial infarction. Here, we report that the functional improvement occurs in (c) 72 h. This early remarkable effect cannot be readily attributed to myocardial regeneration from the donor cells. Thus, we hypothesized that paracrine actions exerted by the cells through the release of soluble factors might be important mechanisms of tissue repair and functional improvement after injection of the Akt-MSCs. Indeed, in the current study we demonstrate that conditioned medium from hypoxic Akt-MSCs markedly inhibits hypoxia-induced apoptosis and triggers vigorous spontaneous contraction of adult rat cardiomyocytes in vitro. When injected into infarcted hearts, the Akt-MSC conditioned medium significantly limits infarct size and improves ventricular function relative to controls. Support to the paracrine hypothesis is provided by data showing that several genes, coding for factors ( VEGF, FGF-2, HGF, IGF-I, and TB4) that are potential mediators of the effects exerted by the Akt-MSC conditioned medium, are significantly up-regulated in the Akt-MSCs, particularly in response to hypoxia. Taken together, our data support Akt-MSC-mediated paracrine mechanisms of myocardial protection and functional improvement. -Gnecchi, M., He, H., Noiseux, N., Liang, O. D., Zhang, L., Morello, F., Mu, H., Melo, L. G., Pratt, R. E., Ingwall, J. S., Dzau, V. J. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Boston, MA USA	Duke University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Dzau, VJ (corresponding author), Duke Univ, Med Ctr, Dept Med, DUMC 3701, Durham, NC 27710 USA.	victor.dzau@duke.edu	Gnecchi, Massimiliano/J-8609-2018; Morello, Fulvio/G-8519-2011; Gnecchi, Massimiliano/X-7095-2019	Gnecchi, Massimiliano/0000-0001-7435-4328; Morello, Fulvio/0000-0002-7833-9632; Gnecchi, Massimiliano/0000-0001-7435-4328	NHLBI NIH HHS [HL 35610, HL73219, HL 72010, HL 63985, HL 58516, HL 5320] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005320, R01HL063985, R01HL035610, R01HL058516, R01HL073219, R01HL072010, R37HL035610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anversa P, 2002, NATURE, V415, P240, DOI 10.1038/415240a; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Cittadini A, 1996, CIRCULATION, V93, P800, DOI 10.1161/01.CIR.93.4.800; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Couzin J, 2004, SCIENCE, V304, P192, DOI 10.1126/science.304.5668.192; Davani S, 2003, CIRCULATION, V108, P253, DOI 10.1161/01.cir.0000089186.09692.fa; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; Freestone NS, 1996, MOL CELL BIOCHEM, V164, P223, DOI 10.1007/BF00408662; FRIEDRICH J, 1995, CIRCULATION, V92, P3527, DOI 10.1161/01.CIR.92.12.3527; Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Kawada H, 2004, BLOOD, V104, P3581, DOI 10.1182/blood-2004-04-1488; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Mathur A, 2004, LANCET, V364, P183, DOI 10.1016/S0140-6736(04)16632-4; Melo LG, 2004, CIRCULATION, V109, P2386, DOI 10.1161/01.CIR.0000128597.37025.00; Min JY, 2002, ANN THORAC SURG, V74, P1568, DOI 10.1016/S0003-4975(02)03952-8; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f; Pochampally RR, 2004, P NATL ACAD SCI USA, V101, P9282, DOI 10.1073/pnas.0401558101; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Shake JG, 2002, ANN THORAC SURG, V73, P1919, DOI 10.1016/S0003-4975(02)03517-8; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Tomita S, 2002, J THORAC CARDIOV SUR, V123, P1132, DOI 10.1067/mtc.2002.120716; Wang JS, 2001, J THORAC CARDIOV SUR, V122, P699, DOI 10.1067/mtc.2001.116317	31	917	1004	1	79	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					661	669		10.1096/fj.05-5211com	http://dx.doi.org/10.1096/fj.05-5211com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581974				2022-12-28	WOS:000240130900012
J	Kimber, MJ; McKinney, S; McMaster, S; Day, TA; Fleming, CC; Maule, AG				Kimber, Michael J.; McKinney, Susan; McMaster, Steven; Day, Tim A.; Fleming, Colin C.; Maule, Aaron G.			flp gene disruption in a parasitic nematode reveals motor dysfunction and unusual neuronal sensitivity to RNA interference	FASEB JOURNAL			English	Article						FMRFamide-like peptide; neuropeptide; nervous system; locomotion; helminth parasite	DOUBLE-STRANDED-RNA; FUNCTIONAL GENOMIC ANALYSIS; FMRFAMIDE-RELATED PEPTIDES; FREE-LIVING NEMATODE; CAENORHABDITIS-ELEGANS; NEUROPEPTIDE GENE; GLOBODERA-ROSTOCHIENSIS; KSAYMRFAMIDE PF3/AF8; EXPRESSION; MUSCLE	The potato cyst nematode Globodera pallida is a serious pest of potato crops. Nematode FMRFamide-like peptides (FLPs) are one of the most diverse neuropeptide families known, and modulate sensory and motor functions. As neuromuscular function is a well-established target for parasite control, parasitic nematode FLP signaling has significant potential in novel control strategies. In the absence of transgenic parasitic nematodes and the reported ineffectiveness of neuronal gene RNAi in Caenorhabditis elegans, nothing is known about flp function in nematode parasites. In attempts to evaluate flp function in G. pallida, we have discovered that, unlike in C. elegans, these genes are readily susceptible to RNAi. Silencing any of the five characterized G. pallida flp genes (Gp-flp-1, -6, -12, -14, or -18) incurred distinct aberrant behavioral phenotypes consistent with key roles in motor function. Further delineation of these effects revealed that double-stranded RNA exposure time (>= 18 h) and concentration (>= 0.1 mu g/ml) were critical to the observed effects, which were reversible. G. pallida flp genes are essential to coordinated locomotory activities, do not display redundancy, and are susceptible to RNAi, paving the way for the investigation of RNAi-mediated flp gene silencing as a novel plant parasite control strategy.	Queens Univ Belfast, Sch Biol Sci, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland; Iowa State Univ, Dept Biomed Sci, Ames, IA USA; Agri Food & Biosci Inst, Belfast, Antrim, North Ireland	Queens University Belfast; Iowa State University; Agri-Food & Biosciences Institute	Maule, AG (corresponding author), Queens Univ Belfast, Sch Biol Sci, Ctr Med Biol, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	a.maule@qub.ac.uk		Day, Tim/0000-0002-9037-6540; Maule, Aaron/0000-0003-0862-2667				Aboobaker AA, 2003, MOL BIOCHEM PARASIT, V129, P41, DOI 10.1016/S0166-6851(03)00092-6; Asikainen S, 2005, NEUROREPORT, V16, P1995, DOI 10.1097/00001756-200512190-00005; ATKINSON HJ, 1988, J ZOOL, V216, P663, DOI 10.1111/j.1469-7998.1988.tb02464.x; Bakhetia M, 2005, TRENDS PLANT SCI, V10, P362, DOI 10.1016/j.tplants.2005.06.007; Bakhetia M, 2005, MOL PLANT MICROBE IN, V18, P1099, DOI 10.1094/MPMI-18-1099; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Briese Michael, 2006, Invertebrate Neuroscience, V6, P5, DOI 10.1007/s10158-005-0011-x; Chen Q, 2005, MOL PLANT MICROBE IN, V18, P621, DOI 10.1094/MPMI-18-0621; Chitwood DJ, 2003, PEST MANAG SCI, V59, P748, DOI 10.1002/ps.684; COWDEN C, 1995, PEPTIDES, V16, P491, DOI 10.1016/0196-9781(94)00211-N; Day TA, 1999, PEPTIDES, V20, P999, DOI 10.1016/S0196-9781(99)00093-5; Fanelli E, 2005, GENE, V349, P87, DOI 10.1016/j.gene.2004.11.045; Feinberg EH, 2003, SCIENCE, V301, P1545, DOI 10.1126/science.1087117; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; GEARY TG, 1999, ANN NY ACAD SCI, V897, P213; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Greenwood K, 2005, PARASITOLOGY, V131, pS169, DOI 10.1017/S003118200500819X; Grishok A, 2005, FEBS LETT, V579, P5932, DOI 10.1016/j.febslet.2005.08.001; Hussein AS, 2002, MOL BIOCHEM PARASIT, V122, P91, DOI 10.1016/S0166-6851(02)00068-3; Husson S. J., 2005, Communications in Agricultural and Applied Biological Sciences, V70, P153; Issa Z, 2005, INT J PARASITOL, V35, P935, DOI 10.1016/j.ijpara.2005.06.001; Jiang GL, 2005, J BIOL CHEM, V280, P2065, DOI 10.1074/jbc.M408470200; Johnson NA, 2005, GENE, V359, P26, DOI 10.1016/j.gene.2005.05.034; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Kim K, 2004, J COMP NEUROL, V475, P540, DOI 10.1002/cne.20189; Kimber MJ, 2002, INT J PARASITOL, V32, P1095, DOI 10.1016/S0020-7519(02)00084-X; Kimber MJ, 2001, MOL BIOCHEM PARASIT, V116, P199, DOI 10.1016/S0166-6851(01)00323-1; Kotze AC, 2006, MOL BIOCHEM PARASIT, V145, P101, DOI 10.1016/j.molbiopara.2005.09.012; Li C, 1999, BRAIN RES, V848, P26, DOI 10.1016/S0006-8993(99)01972-1; Li C, 2005, PARASITOLOGY, V131, pS109, DOI 10.1017/S0031182005009376; Lilley CJ, 2005, INT J PARASITOL, V35, P1577, DOI 10.1016/j.ijpara.2005.07.017; Lustigmana S, 2004, MOL BIOCHEM PARASIT, V138, P165, DOI 10.1016/j.molbiopara.2004.08.003; Marks NJ, 1998, BIOCHEM BIOPH RES CO, V248, P422, DOI 10.1006/bbrc.1998.8982; Marks NJ, 1999, MOL BIOCHEM PARASIT, V100, P185, DOI 10.1016/S0166-6851(99)00057-2; Maule AG, 1995, INVERTEBR NEUROSCI, V1, P255, DOI 10.1007/BF02211027; Maule Aaron G., 2002, Current Topics in Medicinal Chemistry, V2, P733, DOI 10.2174/1568026023393697; MAULE AG, 1994, BIOCHEM BIOPH RES CO, V200, P973, DOI 10.1006/bbrc.1994.1545; McVeigh P, 2005, INT J PARASITOL, V35, P1043, DOI 10.1016/j.ijpara.2005.05.010; McVeigh P, 2006, TRENDS PARASITOL, V22, P385, DOI 10.1016/j.pt.2006.06.010; Mousley A, 2004, TRENDS PARASITOL, V20, P482, DOI 10.1016/j.pt.2004.07.011; Nathoo AN, 2001, P NATL ACAD SCI USA, V98, P14000, DOI 10.1073/pnas.241231298; Nelson LS, 1998, SCIENCE, V281, P1686, DOI 10.1126/science.281.5383.1686; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Rosso MN, 2005, MOL PLANT MICROBE IN, V18, P615, DOI 10.1094/MPMI-18-0615; Saleh MC, 2006, NAT CELL BIOL, V8, P793, DOI 10.1038/ncb1439; Sasser J. N., 1987, Vistas on Nematology: A Commemoration of the Twenty-fifth Anniversary of the Society of Nematologists, P7; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; TURNER SJ, 1981, NEMATOLOGICA, V27, P315, DOI 10.1163/187529281X00548; Urwin PE, 2002, MOL PLANT MICROBE IN, V15, P747, DOI 10.1094/MPMI.2002.15.8.747; van Roessel P, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-208; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Yadav BC, 2006, MOL BIOCHEM PARASIT, V148, P219, DOI 10.1016/j.molbiopara.2006.03.013; Yang D, 2000, CURR BIOL, V10, P1191, DOI 10.1016/S0960-9822(00)00732-6	57	97	115	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1233	1243		10.1096/fj.06-7343com	http://dx.doi.org/10.1096/fj.06-7343com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17200420				2022-12-28	WOS:000245650400027
J	Haddy, FJ				Haddy, Francis J.			NASA - Has its biological groundwork for a trip to Mars improved?	FASEB JOURNAL			English	Article						life sciences; mission; planet earth; US Space Program; deep space	RADIATION; HUMANS	In a 1991 editorial in The FASEB journal, Robert W. Krauss commented on a recent report of the Presidential Advisory Committee on the Future of the U.S. Space Program (Augustine report). He concluded that, although a maimed mission to Mars with life sciences as the priority was endorsed by the Committee, it failed to deal realistically with one huge gap; biological sciences have never been given high priority. According to Krauss, this left a void that will cripple, perhaps fatally, any early effort to ensure long-term survival on any mission of extended duration. The gap included insufficient flight time for fundamental biological space research and insufficient funds. Krauss expressed his opinions 15 years ago. Have we better knowledge of space biology now? This question becomes more acute now that President George W. Bush recently proposed a manned return to the moon by 2015 or 2020, with the moon to become our staging post for manned missions to Mars. Will we be ready so soon? A review of the progress in the last 15 years suggests that we will not. Because of the Columbia disaster, flight opportunities for biological sciences in shuttle spacelabs and in Space Station laboratories compete with time for engineering problems and construction. Thus, research on gravity, radiation, and isolation loses out to problems deemed to be of higher priority. Radiation in deep space and graded gravity in space with on board centrifuges are areas that must be studied before we undertake prolonged space voyages. Very recent budgetary changes within National Aeronautics and Space Administration threaten to greatly reduce the fundamental space biology funds. Are we ready for a trip to Mars? Like Krauss 15 years ago, I drink not for some time.	Mayo Coll Med, Mayo Grad Fac, Dept Physiol & Biomed Engn, Rochester, MN USA	Mayo Clinic	Haddy, FJ (corresponding author), 211 2nd St NW,1607, Rochester, MN 55901 USA.	tbhaddy@aol.com						*COMM SPAC BIOL ME, 1987, STRAT SPAC BIOL MED; KRAUSS RW, 1991, FASEB J, V5, P251, DOI 10.1096/fasebj.5.3.2001785; LONG ME, 2001, NATL GEOGR MAG, V199, P2; MAZZASCHI A, 1990, FASEB J, V4, P3; MOORE FD, 1992, FASEB J, V6, P2871; MOORE FD, 1992, FASEB J, V6, P2338, DOI 10.1096/fasebj.6.6.1544543; *NASA ADV COUNC, 1988, EXPL LIV U STRAT SPA; REYNOLDS RD, 1992, FASEB J, V6, P2870, DOI 10.1096/fasebj.6.10.1634053	8	5	5	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					643	646		10.1096/fj.06-7262LSF	http://dx.doi.org/10.1096/fj.06-7262LSF			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17200421				2022-12-28	WOS:000244686400003
J	Yang, YZ; Goldstein, BG; Nakagawa, H; Katz, JP				Yang, Yizeng; Goldstein, Bree G.; Nakagawa, Hiroshi; Katz, Jonathan P.			Kruppel-like factor 5 activates MEK/ERK signaling via EGFR in primary squamous epithelial cells	FASEB JOURNAL			English	Article						keratinocytes; proliferation	KRUPPEL-LIKE FACTOR-5; EPIDERMAL-GROWTH-FACTOR; KLF5 TRANSCRIPTION FACTOR; ESOPHAGEAL KERATINOCYTES; STEM-CELLS; RECEPTOR; EXPRESSION; CANCER; PROLIFERATION; REGULATOR	Rapid cell proliferation is a hallmark of transit amplifying cells, but the mechanisms of this localized proliferation are not well understood. The Kruppel-like factor family member Klf5 (IKLF; BTEB2) promotes cell proliferation and is highly expressed in squamous epithelia, in regions of active proliferation. Here, using mouse primary esophageal keratinocytes as a model, we identify a critical role for Klf5 in regulating squamous epithelial proliferation via the epidermal growth factor receptor (EGFR), which, like Klf5, is localized to basal cells in squamous epithelia. We show that Klf5 increases proliferation, transcriptionally upregulates EGFR, and activates MEK/ERK signaling, as indicated by increased phosphorylation of MEK and ERK. By chromatin immunoprecipitation, we demonstrate that Klf5 binds directly to the 5' regulatory region of EGFR. In addition, we show that regulation of proliferation by Klf5 is dependent on EGFR and MEK/ ERK signaling, as the proliferative response to Klf5 is blocked by pharmacologic inhibition of EGFR or MEK. Inhibition of EGFR or MEK also decreases Klf5 expression. Thus, Klf5 regulates MEK/ERK signaling via EGFR and is also downstream of MAPK signaling, providing a novel mechanism for signal amplification or suppression and control of proliferation in basal cells.	Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA	University of Pennsylvania	Katz, JP (corresponding author), Univ Penn, Sch Med, Dept Med, Div Gastroenterol, 600 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	jpkatz@mail.med.upenn.edu			NCI NIH HHS [P01-CA098101] Funding Source: Medline; NIDDK NIH HHS [P30 DK050306, R21 DK073888] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA098101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK073888, P30DK050306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALYASSIN TM, 1977, J ANAT, V123, P705; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Calabro A, 1997, HISTOCHEM J, V29, P745, DOI 10.1023/A:1026469219190; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CH, 2006, INT J CANCER, V118, P1346, DOI 10.1002/ijc.21533; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Fujiwara Y, 2002, ALIMENT PHARM THERAP, V16, P52, DOI 10.1046/j.1365-2036.16.s2.29.x; Goessel G, 2005, P NATL ACAD SCI USA, V102, P15599, DOI 10.1073/pnas.0409730102; Harada H, 2003, MOL CANCER RES, V1, P729; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Karam Sherif M., 1999, Frontiers in Bioscience, V4, pD286, DOI 10.2741/Karam; Katz JP, 2002, GASTROENTEROL CLIN N, V31, P379, DOI 10.1016/S0889-8553(02)00006-7; Mandard AM, 2000, MUTAT RES-REV MUTAT, V462, P335, DOI 10.1016/S1383-5742(00)00019-3; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nandan MO, 2005, FEBS LETT, V579, P4757, DOI 10.1016/j.febslet.2005.07.053; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Ohlstein B, 2004, CURR OPIN CELL BIOL, V16, P693, DOI 10.1016/j.ceb.2004.09.003; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Pandey PK, 2005, MOL CELL BIOL, V25, P10695, DOI 10.1128/MCB.25.24.10695-10710.2005; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seery JP, 2002, J CELL SCI, V115, P1783; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Takaoka M, 2004, CANCER RES, V64, P7711, DOI 10.1158/0008-5472.CAN-04-0715; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Usui S, 2004, J BIOL CHEM, V279, P12300, DOI 10.1074/jbc.M305025200; Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090	40	66	69	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					543	550		10.1096/fj.06-6694com	http://dx.doi.org/10.1096/fj.06-6694com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158781				2022-12-28	WOS:000244686300027
J	Zerr-Fouineau, M; Chataigneau, M; Blot, C; Schini-Kerth, VB				Zerr-Fouineau, Murielle; Chataigneau, Marta; Blot, Christian; Schini-Kerth, Valerie B.			Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors	FASEB JOURNAL			English	Article						thrombosis; hormone replacement; therapy; contraception	HORMONE REPLACEMENT THERAPY; NITRIC-OXIDE SYNTHASE; 17 BETA-ESTRADIOL; VENOUS THROMBOEMBOLISM; ORAL-CONTRACEPTIVES; MEDROXYPROGESTERONE ACETATE; RISK; EXPRESSION; ADHESION; USERS	Hormone replacement therapy with estroprogestin preparations is associated with an increased risk of venous and arterial thromboembolic events in postmenopausal women. This study examined whether progestins affect the formation of NO in endothelial cells, and, if so, to determine the underlying mechanism. Experiments were performed with human umbilical vein endothelial cells. Endothelial nitric oxide synthase ( eNOS) expression was assessed by real-time polymerase chain reaction (PCR) and Western blot analysis, NO formation by electron spin resonance spectroscopy, nuclear translocation of the glucocorticoid receptor by immunofluorescence microscopy, and platelet aggregation by an aggregometer. Medroxyprogesterone acetate (MPA) and progesterone markedly decreased the eNOS mRNA and protein levels, whereas levonorgestrel and nomegestrol acetate had only small effects. This effect was associated with a decreased NO formation leading to a reduced ability of endothelial cells to prevent platelet aggregation and was prevented by knockdown of the glucocorticoid receptor using siRNA. MPA and progesterone, but not levonorgestrel and nomegestrol acetate, caused nuclear translocation of the glucocorticoid receptor. The present findings indicate that certain progestins, including MPA, reduce the antiaggregatory effect of endothelial cells by decreasing the expression of eNOS and the formation of NO in endothelial cells, an effect that is mediated via activation of glucocorticoid receptors.	Univ Strasbourg 1, UMR 7151 LC1, Dept Pharmacol & Physicochim, F-67401 Illkirch Graffenstaden, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Schini-Kerth, VB (corresponding author), Univ Strasbourg 1, UMR CNRS 7151 LC1, Fac Pharm, 74 Route Rhin,BP 60024, F-67401 Illkirch Graffenstaden, France.	valerie.schini-kerth@pharma.u-strasbg.fr						AZUMA H, 1986, BRIT J PHARMACOL, V88, P411, DOI 10.1111/j.1476-5381.1986.tb10218.x; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; Bourassa PAK, 1996, P NATL ACAD SCI USA, V93, P10022, DOI 10.1073/pnas.93.19.10022; CaulinGlaser T, 1996, J CLIN INVEST, V98, P36, DOI 10.1172/JCI118774; Cazenave Jean-Pierre, 2004, Methods Mol Biol, V272, P13; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DEGRAAF JC, 1992, CIRCULATION, V85, P2284, DOI 10.1161/01.CIR.85.6.2284; FARLEY TMM, 1995, LANCET, V346, P1582; Freedman JE, 1997, J CLIN INVEST, V100, P350, DOI 10.1172/JCI119540; FURLONG B, 1987, BRIT J PHARMACOL, V90, P687, DOI 10.1111/j.1476-5381.1987.tb11221.x; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Hamada AL, 2003, GYNECOL ENDOCRINOL, V17, P247, DOI 10.1080/713603254; Herkert O, 2001, CIRCULATION, V104, P2826, DOI 10.1161/hc4801.099737; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Iuchi T, 2003, CIRC RES, V92, P81, DOI 10.1161/01.RES.0000050588.35034.3C; Jick H, 2000, BMJ-BRIT MED J, V321, P1190, DOI 10.1136/bmj.321.7270.1190; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; KLEINSOYER C, 1986, THROMB HAEMOSTASIS, V56, P232; Kleschyov AL, 2002, METHOD ENZYMOL, V359, P42; Krasinski K, 1997, CIRCULATION, V95, P1768; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Node K, 1997, CIRCULATION, V96, P1953, DOI 10.1161/01.CIR.96.6.1953; Pervin S, 1998, ARTERIOSCL THROM VAS, V18, P1575, DOI 10.1161/01.ATV.18.10.1575; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; Rosendaal FR, 2001, THROMB HAEMOSTASIS, V86, P112; Rosenfeld CR, 1996, J CLIN INVEST, V98, P2158, DOI 10.1172/JCI119022; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schindler AE, 2003, MATURITAS, V46, pS7, DOI 10.1016/j.maturitas.2003.09.014; SJOBERG HE, 1976, ACTA MED SCAND, V199, P95; SNEDDON JM, 1988, P NATL ACAD SCI USA, V85, P2800, DOI 10.1073/pnas.85.8.2800; Sorensen MB, 2002, CIRCULATION, V106, P1646, DOI 10.1161/01.CIR.0000030940.73167.4E; SVENSSON LO, 1994, MATURITAS, V18, P229, DOI 10.1016/0378-5122(94)90129-5; VANBUREN GA, 1992, AM J OBSTET GYNECOL, V167, P828, DOI 10.1016/S0002-9378(11)91597-X; Vanin AF, 1999, METHOD ENZYMOL, V301, P269; Wallerath T, 1999, P NATL ACAD SCI USA, V96, P13357, DOI 10.1073/pnas.96.23.13357; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Wiegratz I, 2004, TRENDS ENDOCRIN MET, V15, P277, DOI 10.1016/j.tem.2004.06.006; Yang Y, 2000, CIRCULATION, V101, P2144, DOI 10.1161/01.CIR.101.18.2144	41	26	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					265	273		10.1096/fj.06-6840com	http://dx.doi.org/10.1096/fj.06-6840com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17116740				2022-12-28	WOS:000243130200029
J	Gueorguieva, D; Li, SH; Walsh, N; Mukerji, A; Tanha, J; Pandey, S				Gueorguieva, Deyzi; Li, Shenghua; Walsh, Nicole; Mukerji, Amit; Tanha, Jamshid; Pandey, Siyaram			Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis	FASEB JOURNAL			English	Article						VHH; phage display library; mitochondria; neurodegenerative diseases	INTRACELLULAR ANTIBODY; PHAGE DISPLAY; CYTOCHROME-C; SELECTION; PROTEIN; ANTIGEN; MITOCHONDRIA; PEROXIDATION; TECHNOLOGY; HUNTINGTIN	Bax is a proapoptotic protein implicated in cell death involved in several neurodegenerative diseases. Intracellularly expressed antibody (Ab) fragments (intrabodies) inhibiting Bax function would have potential for developing therapeutics for the aforementioned diseases and can serve as research tools. We report identification, cloning, and functional characterization of several Bax-specific single-domain antibodies (sdAbs). These minimal size Ab fragments, which were isolated from a llama VHH phage display library by panning, inhibited Bax function in in vitro assays. Importantly, as intrabodies, these sdAbs, which were stably expressed in mammalian cells, were nontoxic to their host cells and rendered them highly resistant to oxidative-stress-induced apoptosis. The intrabodies prevented mitochondrial membrane potential collapse and apoptosis after oxidative stress in the host cells. These anti-Bax V(H)Hs could be used as tools for studying the role of Bax in oxidative-stress-induced apoptosis and for developing novel therapeutics for the degenerative diseases involving oxidative stress.	Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON, Canada	University of Windsor; National Research Council Canada	Pandey, S (corresponding author), Univ Windsor, Dept Chem & Biochem, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	spandey@uwindsor.ca	Pandey, Siyaram/AAI-5491-2020; Mukerji, Amit/AAS-5922-2021	Mukerji, Amit/0000-0003-2609-9240				Adachi M, 2004, AM J PHYSIOL-GASTR L, V287, pG695, DOI 10.1152/ajpgi.00415.2003; ADHIHETTY PJ, 2003, BASIC APPL MYOL, V13, P171; Battistutta R, 2000, PROTEINS, V41, P429, DOI 10.1002/1097-0134(20001201)41:4<429::AID-PROT10>3.0.CO;2-D; Cherubini A, 2005, FREE RADICAL BIO MED, V39, P841, DOI 10.1016/j.freeradbiomed.2005.06.025; Colby DW, 2004, J MOL BIOL, V342, P901, DOI 10.1016/j.jmb.2004.07.054; Colby DW, 2004, P NATL ACAD SCI USA, V101, P17616, DOI 10.1073/pnas.0408134101; Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1; da Silva FA, 2004, J MOL BIOL, V340, P525, DOI 10.1016/j.jmb.2004.04.062; Dekker S, 2003, J VIROL, V77, P12132, DOI 10.1128/JVI.77.22.12132-12139.2003; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Jespers L, 2004, NAT BIOTECHNOL, V22, P1161, DOI 10.1038/nbt1000; Jobling SA, 2003, NAT BIOTECHNOL, V21, P77, DOI 10.1038/nbt772; Kabat EA, 1991, SEQUENCES PROTEINS I; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Miller TW, 2005, MOL THER, V12, P394, DOI 10.1016/j.ymthe.2005.04.003; Nguyen VK, 2001, ADV IMMUNOL, V79, P261, DOI 10.1016/S0065-2776(01)79006-2; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Rajpal A, 2001, J BIOL CHEM, V276, P33139, DOI 10.1074/jbc.M101332200; Somayajulu M, 2005, NEUROBIOL DIS, V18, P618, DOI 10.1016/j.nbd.2004.10.021; SUNDERMAN FW, 1985, ANN CLIN LAB SCI, V15, P229; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tanaka T, 2003, J MOL BIOL, V331, P1109, DOI 10.1016/S0022-2836(03)00836-2; Tanha J, 2002, J IMMUNOL METHODS, V263, P97, DOI 10.1016/S0022-1759(02)00027-3; Tanha Jamshid, 2003, Methods Mol Med, V89, P435; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; Warner HR, 1999, ANTICANCER RES, V19, P2837; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795; Yau KYF, 2005, J IMMUNOL METHODS, V297, P213, DOI 10.1016/j.jim.2004.12.005; Yau KYF, 2003, J IMMUNOL METHODS, V281, P161, DOI 10.1016/j.jim.2003.07.011; Zhu QA, 1999, J IMMUNOL METHODS, V231, P207, DOI 10.1016/S0022-1759(99)00158-1	33	43	52	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2636	+		10.1096/fj.06-6306fje	http://dx.doi.org/10.1096/fj.06-6306fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17060401				2022-12-28	WOS:000242490700049
J	Liu, H; Liu, L; Fletcher, BS; Visner, GA				Liu, Hanzhong; Liu, Li; Fletcher, Bradley S.; Visner, Gary A.			Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis	FASEB JOURNAL			English	Article						lung transplantation; nonviral gene therapy	BRONCHIOLITIS OBLITERANS SYNDROME; GROWTH-FACTOR-BETA; TRANSPLANT RECIPIENTS; PHENOTYPIC CORRECTION; ACTIVE GENES; LAVAGE FLUID; TRYPTOPHAN; RISK; INTEGRATION; TRANSPOSON	Sleeping Beauty (SB) transposon is a natural nonviral gene transfer system that can mediate long-term transgene expression. Its potential utility in treating organ transplantation-associated long-term complications has not yet been explored. In the present study we generated an improved SB transposon encoding the human gene indoleamine-2,3-dioxygenase (hIDO), an enzyme that possesses both T cell-suppressive and antioxidant properties and selectively delivered the SB transposon in combination with a hyperactive transposase plasmid to donor lung using the cationic polymer polyethylenimine (PEI) as transfection reagent. This nonviral gene therapeutic approach led to persistent and uniform transgene expression in the rat lung tissue without noticeable toxicity and inflammation. Importantly, IDO activity produced by hIDO transgene showed a remarkable therapeutic response, as evident by near normal pulmonary function ( peak airway pressure and oxygenation), histological appearance, and reduced collagen content in lung allografts. In addition, we established a hIDO-overexpressing type II cell line using the SB-based gene transfer system and found that hIDO-overexpressing lung cells effectively inhibited transforming growth factor-beta-stimulated fibroblast proliferation in vitro. In summary, the SB-based gene therapy with hIDO represents a new strategy for treating lung transplantation-associated chronic complications, e.g., obliterative bronchiolitis.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA USA; Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL USA; Dept Vet Affairs Med Ctr, Med Res Serv, Gainesville, FL USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; State University System of Florida; University of Florida	Visner, GA (corresponding author), Childrens Hosp Philadelphia, Div Pulm Med, 34th & Civic Ctr Blvd,Abramson Res Bldg,916D, Philadelphia, PA 19104 USA.	visner@email.chop.edu	Marzocchi, Warner/J-9299-2012	Marzocchi, Warner/0000-0002-9114-1516				Baus J, 2005, MOL THER, V12, P1148, DOI 10.1016/j.ymthe.2005.06.484; de Lima MCP, 2003, CURR MED CHEM, V10, P1221, DOI 10.2174/0929867033457430; de Perrot M, 2003, AM J RESP CELL MOL, V28, P616, DOI 10.1165/rcmb.2002-0109OC; DiGiovine B, 1996, J IMMUNOL, V157, P4194; El-Gamel A, 1999, J HEART LUNG TRANSPL, V18, P828, DOI 10.1016/S1053-2498(99)00047-9; Elssner A, 2000, TRANSPLANTATION, V70, P362, DOI 10.1097/00007890-200007270-00022; Estenne M, 2002, AM J RESP CRIT CARE, V166, P440, DOI 10.1164/rccm.200201-003PP; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Hirsch J, 1999, AM J RESP CRIT CARE, V160, P1640, DOI 10.1164/ajrccm.160.5.9902012; Hopkins PM, 2004, AM J RESP CRIT CARE, V170, P1022, DOI 10.1164/rccm.200302-165oc; Husain AN, 1999, AM J RESP CRIT CARE, V159, P829, DOI 10.1164/ajrccm.159.3.9607099; Izsvak Z, 2004, MOL THER, V9, P147, DOI 10.1016/j.ymthe.2003.11.009; Jia SF, 2003, CLIN CANCER RES, V9, P3462; Khalifah AP, 2004, AM J RESP CRIT CARE, V170, P181, DOI 10.1164/rccm.200310-1359OC; Khalifah AP, 2005, AM J TRANSPLANT, V5, P2022, DOI 10.1111/j.1600-6143.2005.00953.x; Koshkina NV, 2003, MOL THER, V8, P249, DOI 10.1016/S1525-0016(03)00177-1; Leuchte HH, 2004, AM J RESP CRIT CARE, V170, P360, DOI 10.1164/rccm.200308-1142OC; Liu HZ, 2006, AM J RESP CRIT CARE, V173, P566, DOI 10.1164/rccm.200509-1413OC; Liu HZ, 2005, AM J TRANSPLANT, V5, P1256, DOI 10.1111/j.1600-6143.2005.00876.x; Liu L, 2004, MOL THER, V10, P97, DOI 10.1016/j.ymthe.2004.04.006; Liu L, 2006, MOL THER, V13, P1006, DOI 10.1016/j.ymthe.2005.11.021; Maddox L, 2002, ANNU REV MED, V53, P477, DOI 10.1146/annurev.med.53.082901.103921; Moffett JR, 2003, IMMUNOL CELL BIOL, V81, P247, DOI 10.1046/j.1440-1711.2003.t01-1-01177.x; Nakai H, 2003, NAT GENET, V34, P297, DOI 10.1038/ng1179; Neurohr C, 2005, AM J TRANSPLANT, V5, P2982, DOI 10.1111/j.1600-6143.2005.01103.x; Ohlfest JR, 2005, BLOOD, V105, P2691, DOI 10.1182/blood-2004-09-3496; Platten M, 2005, SCIENCE, V310, P850, DOI 10.1126/science.1117634; Riise GC, 1998, EUR RESPIR J, V12, P82, DOI 10.1183/09031936.98.12010082; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Shoji F, 2003, GENE THER, V10, P213, DOI 10.1038/sj.gt.3301847; Swanson KA, 2004, AM J RESP CELL MOL, V30, P311, DOI 10.1165/rcmb.2003-0268OC; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Wilkes DS, 2005, AM J RESP CRIT CARE, V172, P944, DOI 10.1164/rccm.200501-098WS; Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005; YASUI H, 1986, P NATL ACAD SCI USA, V83, P6622, DOI 10.1073/pnas.83.17.6622; Zhu YX, 2003, P NATL ACAD SCI USA, V100, P5891, DOI 10.1073/pnas.1036705100	37	67	70	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2384	+		10.1096/fj.06-6228fje	http://dx.doi.org/10.1096/fj.06-6228fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17015408				2022-12-28	WOS:000241702600028
J	Bublil, EM; Yeger-Azuz, S; Gershoni, JM				Bublil, Erez M.; Yeger-Azuz, Sharon; Gershoni, Jonathan M.			Computational prediction of the cross-reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV-1 gp120	FASEB JOURNAL			English	Article						mapitope algorithm; combinatorial phage display peptide library; epitope mapping; vaccine design	HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 BINDING-SITE; BORRELIA-BURGDORFERI; CRYSTAL-STRUCTURE; FAB FRAGMENTS; TYPE-1; IDENTIFICATION; PEPTIDE; VACCINE; IMMUNOGENICITY	Backtracking from antibodies to their corresponding epitopes is a rational approach for vaccine design. Here we apply such a reverse immunological strategy for mapping the cross-reactive neutralizing epitope corresponding to the monoclonal antibody (mAb) b12 specific for HIV-1 gp120. b12 was used to screen a combinatorial phage display random peptide library and nineteen 12mer cysteine-looped peptides were affinity purified. These were used as input for analysis with the predictive algorithm Mapitope. Based on the input panel of peptides and the antigen's atomic structure, Mapitope predicts candidate epitopes on the surface of the antigen. Two major clusters were predicted as candidate b12 epitopes. These could be discriminated by a series of experiments, which included point mutagenesis of selected residues and binding assays. Moreover, the prediction of the b12 epitope was further strengthened by comparison with additional predictions for two competing antibodies, b6 and m14. Finally, support of our prediction was obtained in view of the fact that b12, m14, and b6 were found to compete against mAb 17b binding to gp120. The b12 epitope is predicted to consist of four peptide segments of gp120 (residues V254-T257, D368-F376, E381-Y384, and I420-I424), which lie at the periphery of the CD4 binding site. - Bublil, E. M., Yeger-Azuz, S., Gershoni, J. M. Computational prediction of the cross-reactive neutralizing epitope corresponding to monoclonal antibody b12 specific for HIV-1 gp120.	Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gershoni, JM (corresponding author), Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.	gershoni@tauex.tau.ac.il						Alaedini A, 2005, J NEUROIMMUNOL, V159, P192, DOI 10.1016/j.jneuroim.2004.10.014; Andre FE, 2003, VACCINE, V21, P593, DOI 10.1016/S0264-410X(02)00702-8; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9339, DOI 10.1073/pnas.89.19.9339; Barquet N, 1997, ANN INTERN MED, V127, P635, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00010; Berthet-Colominas C, 1999, EMBO J, V18, P1124, DOI 10.1093/emboj/18.5.1124; Bolz DD, 2004, AUTOIMMUNITY, V37, P387, DOI 10.1080/08916930410001713098; Bonnycastle LLC, 1996, J MOL BIOL, V258, P747, DOI 10.1006/jmbi.1996.0284; Boots LJ, 1997, AIDS RES HUM RETROV, V13, P1549, DOI 10.1089/aid.1997.13.1549; Burton DR, 2005, P NATL ACAD SCI USA, V102, P14943, DOI 10.1073/pnas.0505126102; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; CONLEY AJ, 1994, J VIROL, V68, P6994, DOI 10.1128/JVI.68.11.6994-7000.1994; Donnelly JJ, 2005, J IMMUNOL, V175, P633, DOI 10.4049/jimmunol.175.2.633; Douek DC, 2006, CELL, V124, P677, DOI 10.1016/j.cell.2006.02.005; Enshell-Seijffers D, 2003, J MOL BIOL, V334, P87, DOI 10.1016/j.jmb.2003.09.002; Enshell-Seijffers D, 2001, Nucleic Acids Res, V29, pE50, DOI 10.1093/nar/29.10.e50; ENSHELLSEIFFERS D, 2002, CURRENT PROTOCOLS IM, V2; GERSHONI JM, 1993, FASEB J, V7, P1185, DOI 10.1096/fasebj.7.12.7690724; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; GORNY MK, 1992, J VIROL, V66, P7538, DOI 10.1128/JVI.66.12.7538-7542.1992; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; JAMES JS, 2003, AIDS TREAT NEWS, V6; KELLER PM, 1993, VIROLOGY, V193, P709, DOI 10.1006/viro.1993.1179; Khurana S, 2005, J VIROL, V79, P6791, DOI 10.1128/JVI.79.11.6791-6800.2005; Kwong PD, 2004, STRUCTURE, V12, P173, DOI 10.1016/j.str.2004.01.018; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lehner T, 2003, VACCINE, V21, pS68, DOI 10.1016/S0264-410X(03)00204-4; Lehner T, 2002, AIDS, V16, pS125, DOI 10.1097/00002030-200216004-00017; Mascola JR, 2003, CURR MOL MED, V3, P209, DOI 10.2174/1566524033479799; Mascola JR, 1997, J VIROL, V71, P7198, DOI 10.1128/JVI.71.10.7198-7206.1997; Meissner HC, 2004, PEDIATRICS, V114, P1065, DOI 10.1542/peds.2004-0440; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Pantophlet R, 2003, J VIROL, V77, P642, DOI 10.1128/JVI.77.1.642-658.2003; PANTOPHLET R, 2006, ANN REV IMMUNOL; Raveche ES, 2005, J CLIN MICROBIOL, V43, P850, DOI 10.1128/JCM.43.2.850-856.2005; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; Ruf BR, 2004, INFECTION, V32, P191, DOI 10.1007/s15010-004-3204-z; Ruprecht RM, 2003, VACCINE, V21, P3370, DOI 10.1016/S0264-410X(03)00335-9; Rustgi VK, 1995, VACCINE, V13, P1665, DOI 10.1016/0264-410X(95)00118-K; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9; Stern B, 1997, FASEB J, V11, P147, DOI 10.1096/fasebj.11.2.9039957; STEWARD MW, 1995, J VIROL, V69, P7668, DOI 10.1128/JVI.69.12.7668-7673.1995; Tarnovitski N, 2006, J MOL BIOL, V359, P190, DOI 10.1016/j.jmb.2006.03.008; *UNAIDS WHO, 2005, AIDS EP UPD; Vidor E, 2004, EUR J CLIN MICROBIOL, V23, P300, DOI 10.1007/s10096-003-1094-0; Villard S, 2003, BLOOD, V102, P949, DOI 10.1182/blood-2002-06-1886; Willett TA, 2004, P NATL ACAD SCI USA, V101, P1303, DOI 10.1073/pnas.0305680101; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Zhang MY, 2004, J VIROL, V78, P9233, DOI 10.1128/JVI.78.17.9233-9242.2004; Zhang YJ, 1997, J INFECT DIS, V176, P1180, DOI 10.1086/514111; Zolla-Pazner S, 2004, NAT REV IMMUNOL, V4, P199, DOI 10.1038/nri1307; Zwick MB, 2001, J VIROL, V75, P6692, DOI 10.1128/JVI.75.14.6692-6699.2001; 2003, AIDS ALERT, V41, P43	58	28	30	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1762	1774		10.1096/fj.05-5509rev	http://dx.doi.org/10.1096/fj.05-5509rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940148				2022-12-28	WOS:000240267000004
J	Launay, JM; Schneider, B; Loric, S; Da Prada, M; Kellermann, O				Launay, Jean-Marie; Schneider, Benoit; Loric, Sylvain; Da Prada, Mose; Kellermann, Odile			Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells	FASEB JOURNAL			English	Article						SERT; neuronal differentiation; transporter(s)	BINDING-SITES; NITRIC-OXIDE; PHOSPHORYLATION; BRAIN; DEPRESSION; EXPRESSION; PLATELETS; CLONING; 5-HYDROXYTRYPTAMINE; PURIFICATION	The plasma membrane 5-HT transporter (SERT) is the major protagonist in regulating extracellular 5-HT concentration and constitutes the target of drugs used to treat a host of metabolic and psychiatric disorders. The exact mechanisms sustaining SERT function still remain elusive. The present work exploits the properties of the 1C11 neuroectodermal progenitor, which acquires, upon 4 days of differentiation, a functional SERT within an integrated serotonergic phenotype to investigate regulatory mechanisms involved in SERT onset and functions. We show that poly(A) addition precedes SERT mRNA translation on day 2 of the serotonergic program. The newly translated transporter molecules immediately bind cocaine. Day 4 must be awaited to monitor antidepressant recognition and 5-HT uptake. Because external 5-HT reduces both 5-HT transport and SERT antidepressant binding, we identify 5-HT2B receptors as key players in controlling the overall 5-HT transport system. In the absence of external 5-HT, 5-HT2B receptor coupling to NO production ensures SERT phosphorylation to basal level and maximal 5-HT uptake. In the presence of 5-HT, the 5-HT2B receptor-PKC coupling promotes additional phosphorylations of both SERT and Na+, K+-ATPase alpha-subunit, impairing the electrochemical gradient necessary to 5-HT uptake. SERT hyperphosphorylation also affects antidepressant recognition. Finally, such 5-HT2B receptor-mediated control of SERT activity operates in primary neurons from raphe nuclei. Altogether, our data shed new light on the 5-HT-driven post-translational modifications involved in the control of SERT activity. - Launay, J-M., Schneider, B., Loric, S., Da Prada, M., Kellermann, O. Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells.	Hop Lariboisiere, Serv Biochim, IFR 139, F-75475 Paris 10, France; Univ Paris 05, Biol Cellulaire Lab, EA3621, Fac Pharm, Paris, France; CNRS, UPR 1983, Inst Andre Lwoff, Villejuif, France; Inst Pasteur, Dept Biol Cellulaire & Infect, Paris, France; Hoffmann La Roche Ag, Pharma Res Dept, CH-4002 Basel, Switzerland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Roche Holding	Launay, JM (corresponding author), Hop Lariboisiere, Serv Biochim, IFR 139, F-75475 Paris 10, France.	jean-marie.launay@lrb.aphp.fr	loric, sylvain/F-7224-2011; Schneider, Benoit/AAF-3850-2019					AGREZ MV, 1984, BIOGENIC AMINES, V1, P223; AKUNNE HC, 1992, NEUROCHEM RES, V17, P1275, DOI 10.1007/BF00968412; Audia JE, 1996, J MED CHEM, V39, P2773, DOI 10.1021/jm960062t; BECK O, 1993, BIOCHEM BIOPH RES CO, V196, P260, DOI 10.1006/bbrc.1993.2243; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Bonaventure P, 2002, BRAIN RES, V943, P38, DOI 10.1016/S0006-8993(02)02504-0; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; BRILEY MS, 1980, SCIENCE, V209, P303, DOI 10.1126/science.7384806; BUCCARON MH, 1990, P NATL ACAD SCI USA, V87, P1922, DOI 10.1073/pnas.87.5.1922; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; CATTERALL W, 2001, LOCAL ANESTHETICS; CELSI G, 1991, AM J PHYSIOL, V260, pF192, DOI 10.1152/ajprenal.1991.260.2.F192; DAPRADA M, 1988, EXPERIENTIA, V44, P115; DOUCET A, 1979, AM J PHYSIOL, V237, pF105, DOI 10.1152/ajprenal.1979.237.2.F105; Gaspar P, 2003, NAT REV NEUROSCI, V4, P1002, DOI 10.1038/nrn1256; GRAY EG, 1962, J ANAT, V96, P79; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; Jacobs B. L., 1998, SOC NEUR ABSTR, V24, P1992; Kellermann O, 1996, BRIT J PHARMACOL, V118, P1161, DOI 10.1111/j.1476-5381.1996.tb15519.x; Lauder J M, 1983, Monogr Neural Sci, V9, P3; LAUNAY JM, 1994, AM J PHYSIOL, V266, pR526, DOI 10.1152/ajpregu.1994.266.2.R526; LAUNAY JM, 1992, J BIOL CHEM, V267, P11344; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Lieberman JA, 1998, BIOL PSYCHIAT, V44, P1099, DOI 10.1016/S0006-3223(98)00187-5; Logvinenko NS, 1996, P NATL ACAD SCI USA, V93, P9132, DOI 10.1073/pnas.93.17.9132; LORIC S, 1995, MOL PHARMACOL, V47, P458; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Manivet P, 2000, J BIOL CHEM, V275, P9324, DOI 10.1074/jbc.275.13.9324; MARCUSSON JO, 1990, PSYCHOPHARMACOLOGY, V102, P145, DOI 10.1007/BF02245915; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Mouillet-Richard S, 2000, J BIOL CHEM, V275, P9186, DOI 10.1074/jbc.275.13.9186; Nelson N, 1998, J NEUROCHEM, V71, P1785; OREILLY CA, 1988, J BIOL CHEM, V263, P6115; OWENS MJ, 1994, CLIN CHEM, V40, P288; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; POLIARD A, 1993, J CELL SCI, V106, P503; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Read RL, 2002, J CELL BIOCHEM, V87, P258, DOI 10.1002/jcb.10300; Rotondo A, 1996, NEUROCHEM INT, V28, P299, DOI 10.1016/0197-0186(95)00080-1; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; SARRIAS MJ, 1990, J NEUROCHEM, V54, P783, DOI 10.1111/j.1471-4159.1990.tb02319.x; SCHLOSS P, 1995, BIOCHEMISTRY-US, V34, P12590, DOI 10.1021/bi00039a014; SHUEY DL, 1992, TERATOLOGY, V46, P367, DOI 10.1002/tera.1420460407; Svenningsson P, 2006, SCIENCE, V311, P77, DOI 10.1126/science.1117571; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; TUOMISTO J, 1976, NATURE, V262, P596, DOI 10.1038/262596a0; VANDENBERGH DJ, 1991, DEV BIOL, V148, P10, DOI 10.1016/0012-1606(91)90313-R; Vaughan RA, 2004, J PHARMACOL EXP THER, V310, P1, DOI 10.1124/jpet.103.052423; WALKER RF, 1983, LIFE SCI, V33, P1915, DOI 10.1016/0024-3205(83)90676-8; White KJ, 2005, AAPS J, V7; Wong ML, 2001, NAT REV NEUROSCI, V2, P343, DOI 10.1038/35072566; Zhang YW, 2005, NEUROPHARMACOLOGY, V49, P791, DOI 10.1016/j.neuropharm.2005.06.019; Zhu CB, 2004, MOL PHARMACOL, V65, P1462, DOI 10.1124/mol.65.6.1462	62	80	82	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1843	1854		10.1096/fj.06-5724com	http://dx.doi.org/10.1096/fj.06-5724com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940156				2022-12-28	WOS:000240267000012
J	Maragathavally, KJ; Kaminski, JM; Coates, CJ				Maragathavally, K. J.; Kaminski, J. M.; Coates, C. J.			Chimeric Mos1 and piggyBac transposases result in site-directed integration	FASEB JOURNAL			English	Article						mariner; Gal4-UAS; transposition assay	TARGETED GENE-EXPRESSION; DROSOPHILA-MELANOGASTER; DNA-BINDING; GERMLINE TRANSFORMATION; GENOME MODIFICATION; BACULOVIRUS GENOME; SILENT CHROMATIN; PRECISE EXCISION; ELEMENT MARINER; AEDES-AEGYPTI	Genetic transformation systems based on Mos1 and piggyBac transposable elements are used to achieve stable chromosomal integration. However, integration sites are randomly distributed in the genome and transgene expression can be influenced by position effects. We developed a novel technology that utilizes chimeric transposases to direct integration into specific sites on a target DNA molecule. The Gal4 DNA binding domain was fused to the NH2 terminus of the Mos1 and piggyBac transposases and a target plasmid was created that contained upstream activating sequences (UAS), to which the Gal4 DBD binds with high affinity. The transpositional activity of the Gal4-Mos1 transposase was 12.7-fold higher compared to controls where the Gal4-UAS interaction was absent and 96% of the recovered transposition products were identical, with integration occurring at the same TA site. In a parallel experiment, a Gal4-piggyBac transposase resulted in an 11.6-fold increase in transpositional activity compared to controls, with 67% of the integrations occurring at a single TTAA site. This technology has the potential to minimize nonspecific integration events that may result in insertional mutagenesis and reduced fitness. Site-directed integration will be advantageous to the manipulation of genomes, study of gene function, and for the development of gene therapy techniques.-Maragathavally, K. J., Kaminski, J. M., Coates, C. J. Chimeric Mos1 and piggyBac transposases result in site-directed integration.	Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA; Med Coll Georgia, Dept Radiol, Augusta, GA 30912 USA	Texas A&M University System; Texas A&M University College Station; University System of Georgia; Augusta University	Coates, CJ (corresponding author), Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA.	ccoates@tamu.edu	Kaminski, Joseph/AAB-6493-2020; Wilson, Matthew H/K-3193-2013	Kaminski, Joseph/0000-0002-7518-4962	NIAID NIH HHS [AI047303] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047303] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akopian A, 2003, P NATL ACAD SCI USA, V100, P8688, DOI 10.1073/pnas.1533177100; Atkinson PW, 2001, ANNU REV ENTOMOL, V46, P317, DOI 10.1146/annurev.ento.46.1.317; AUGEGOUILLOU C, 1995, FEBS LETT, V368, P541, DOI 10.1016/0014-5793(95)00735-R; Boisnard-Lorig C, 2001, PLANT CELL, V13, P495, DOI 10.1105/tpc.13.3.495; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown SE, 2001, GENETICS, V157, P1299; Carlson CM, 2003, GENETICS, V165, P243; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; Coates CJ, 2005, TRENDS BIOTECHNOL, V23, P407, DOI 10.1016/j.tibtech.2005.06.009; Coates CJ, 1997, MOL GEN GENET, V253, P728, DOI 10.1007/s004380050377; Coates CJ, 1999, GENE, V226, P317, DOI 10.1016/S0378-1119(98)00557-5; COATES CJ, 1995, MOL GEN GENET, V249, P246, DOI 10.1007/BF00290372; Ding S, 2005, CELL, V122, P473, DOI 10.1016/j.cell.2005.07.013; Dupuy AJ, 2002, P NATL ACAD SCI USA, V99, P4495, DOI 10.1073/pnas.062630599; FRASER MJ, 1995, VIROLOGY, V211, P397, DOI 10.1006/viro.1995.1422; Fraser MJ, 1996, INSECT MOL BIOL, V5, P141, DOI 10.1111/j.1365-2583.1996.tb00048.x; Frisch M, 2002, GENOME RES, V12, P349, DOI 10.1101/gr.206602.ArticlepublishedonlinebeforeprintinJanuary2002; GARCIAFERNANDEZ J, 1995, MOL BIOL EVOL, V12, P421; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Groth AC, 2004, GENETICS, V166, P1775, DOI 10.1534/genetics.166.4.1775; Handler AM, 2002, INSECT BIOCHEM MOLEC, V32, P1211, DOI 10.1016/S0965-1748(02)00084-X; Hartley KO, 2002, P NATL ACAD SCI USA, V99, P1377, DOI 10.1073/pnas.022646899; Hartung M, 1998, J BIOL CHEM, V273, P22884, DOI 10.1074/jbc.273.36.22884; Henikoff S, 1992, CURR OPIN GENET DEV, V2, P907, DOI 10.1016/S0959-437X(05)80114-5; Horn C, 2005, P NATL ACAD SCI USA, V102, P12483, DOI 10.1073/pnas.0504305102; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Jarvik T, 1998, GENETICS, V149, P1569; Kaminski JM, 2002, FASEB J, V16, DOI 10.1096/fj.02-0127hyp; Kawakami K, 2004, DEV CELL, V7, P133, DOI 10.1016/j.devcel.2004.06.005; Kolb AF, 2005, TRENDS BIOTECHNOL, V23, P399, DOI 10.1016/j.tibtech.2005.06.005; Konev AY, 2003, GENETICS, V165, P2039; Li X, 2001, INSECT MOL BIOL, V10, P447, DOI 10.1046/j.0962-1075.2001.00283.x; LIDHOLM DA, 1993, GENETICS, V134, P859; Lobo N, 1999, MOL GEN GENET, V261, P803, DOI 10.1007/s004380050024; Malla S, 2005, NUCLEIC ACIDS RES, V33, P6101, DOI 10.1093/nar/gki922; MORGAN GT, 1995, J MOL BIOL, V254, P1, DOI 10.1006/jmbi.1995.0593; O'Brochta DA, 2004, METH MOL B, V260, P227, DOI 10.1385/1-59259-755-6:227; O'Brochta DA, 2003, J EXP BIOL, V206, P3823, DOI 10.1242/jeb.00638; Oberstein A, 2005, NAT METHODS, V2, P583, DOI 10.1038/NMETH775; OBrochta DA, 1996, INSECT BIOCHEM MOLEC, V26, P739, DOI 10.1016/S0965-1748(96)00022-7; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; Phelps CB, 1998, METHODS, V14, P367, DOI 10.1006/meth.1998.0592; PIRROTTA V, 1994, BIOESSAYS, V16, P549, DOI 10.1002/bies.950160808; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; Ringrose L, 1998, J MOL BIOL, V284, P363, DOI 10.1006/jmbi.1998.2149; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTSON HM, 1995, J INSECT PHYSIOL, V41, P99, DOI 10.1016/0022-1910(94)00082-R; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; Rowan KH, 2004, INSECT BIOCHEM MOLEC, V34, P695, DOI 10.1016/j.ibmb.2004.03.022; Sarkar A, 1997, INSECT BIOCHEM MOLEC, V27, P359, DOI 10.1016/S0965-1748(97)00018-0; Scheer N, 1999, MECH DEVELOP, V80, P153, DOI 10.1016/S0925-4773(98)00209-3; Schotta G, 2003, SEMIN CELL DEV BIOL, V14, P67, DOI 10.1016/S1084-9521(02)00138-6; SEDENSKY MM, 1994, NUCLEIC ACIDS RES, V22, P1719, DOI 10.1093/nar/22.9.1719; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; Sumitani M, 2003, INSECT BIOCHEM MOLEC, V33, P449, DOI 10.1016/S0965-1748(03)00009-2; Szuts D, 2000, P NATL ACAD SCI USA, V97, P5351, DOI 10.1073/pnas.97.10.5351; Thibault ST, 1999, INSECT MOL BIOL, V8, P119, DOI 10.1046/j.1365-2583.1999.810119.x; Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001; Thyagarajan B, 2000, GENE, V244, P47, DOI 10.1016/S0378-1119(00)00008-1; Wang AB, 2003, EXP CELL RES, V290, P1, DOI 10.1016/S0014-4827(03)00313-6; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; Wilson MH, 2005, FEBS LETT, V579, P6205, DOI 10.1016/j.febslet.2005.10.004; Wilson R, 2003, INSECT BIOCHEM MOLEC, V33, P853, DOI 10.1016/S0965-1748(03)00044-4; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Xie WW, 2001, MOL CELL BIOL, V21, P6606, DOI 10.1128/MCB.21.19.6606-6614.2001; Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Yusa K, 2004, MOL CELL BIOL, V24, P4004, DOI 10.1128/MCB.24.9.4004-4018.2004; Zhu YX, 2003, P NATL ACAD SCI USA, V100, P5891, DOI 10.1073/pnas.1036705100; Zou S, 1997, P NATL ACAD SCI USA, V94, P7412, DOI 10.1073/pnas.94.14.7412	72	50	63	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1880	+		10.1096/fj.05-5485fje	http://dx.doi.org/10.1096/fj.05-5485fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877528				2022-12-28	WOS:000240267000017
J	Wu, YH; Fischer, DF; Kalsbeek, A; Garidou-Boof, ML; van der Vliet, J; van Heijningen, C; Liu, RY; Zhou, JN; Swaab, DF				Wu, Ying-Hui; Fischer, David F.; Kalsbeek, Andries; Garidou-Boof, Marie-Laure; van der Vliet, Jan; van Heijningen, Caroline; Liu, Rong-Yu; Zhou, Jiang-Ning; Swaab, Dick F.			Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock"	FASEB JOURNAL			English	Article						circadian system; clock gene; vasopressin mRNA; superchiasmatic nucleus	ARYLALKYLAMINE N-ACETYLTRANSFERASE; HUMAN SUPRACHIASMATIC NUCLEUS; MAMMALIAN CIRCADIAN CLOCK; MESSENGER-RNA LEVELS; RAT PINEAL; MELATONIN SYNTHESIS; PARAVENTRICULAR NUCLEUS; EXPRESSION; GLAND; RHYTHM	The suprachiasmatic nucleus (SCN) is the "master clock" of the mammalian brain. It coordinates the peripheral clocks in the body, including the pineal clock that receives SCN input via a multisynaptic noradrenergic pathway. Rhythmic pineal melatonin production is disrupted in Alzheimer's disease (AD). Here we show that the clock genes hBmal1, hCry1, and hPer1 were rhythmically expressed in the pineal of controls (Braak 0). Moreover, hPer1 and h beta 1-adrenergic receptor (h beta 1-ADR) mRNA were positively correlated and showed a similar daily pattern. In contrast, in both preclinical (Braak I-II) and clinical AD patients (Braak V-VI), the rhythmic expression of clock genes was lost as well as the correlation between hPer1 and h beta 1-ADR mRNA. Intriguingly, hCry1 mRNA was increased in clinical AD. These changes are probably due to a disruption of the SCN control, as they were mirrored in the rat pineal deprived of SCN control. Indeed, a functional disruption of the SCN was observed from the earliest AD stages onward, as shown by decreased vasopressin mRNA, a clock- controlled major output of the SCN. Thus, a functional disconnection between the SCN and the pineal from the earliest AD stage onward could account for the pineal clock gene changes and underlie the circadian rhythm disturbances in AD. Wu, Y-H., Fischer, D. F., Kalsbeek, A., Garidou-Boof, M-L., van der Vliet, J., van Heijningen, C., Liu, R-Y., Zhou, J-N., Swaab, D. F. Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock."	Netherlands Inst Neurosci, NL-1105 BA Amsterdam, Netherlands; Anhui Med Univ, Affiliated Hosp 1, Anhui Geriatr Inst, Hefei, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Dept Neurobiol, Hefei, Peoples R China	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Anhui Medical University; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Swaab, DF (corresponding author), Netherlands Inst Neurosci, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.	d.f.swaab@nin.knaw.nl	Zhou, JiangNing/N-3374-2013; Kalsbeek, Andries/H-3076-2019	Kalsbeek, Andries/0000-0001-9606-8453; Swaab, Dick/0000-0002-9665-7845; Fischer, David/0000-0002-6690-0197				Abe M, 2002, J NEUROSCI, V22, P350, DOI 10.1523/JNEUROSCI.22-01-00350.2002; ARENDT J, 1985, J CLIN ENDOCR METAB, V60, P1166, DOI 10.1210/jcem-60-6-1166; BARTON AJL, 1993, J NEUROCHEM, V61, P1, DOI 10.1111/j.1471-4159.1993.tb03532.x; Bell-Pedersen D, 2005, NAT REV GENET, V6, P544, DOI 10.1038/nrg1633; BERLIN I, 1995, LIFE SCI, V56, pPL325; Bjarnason GA, 2002, CHRONOBIOL INT, V19, P129, DOI 10.1081/CBI-120002595; Boivin DB, 2003, BLOOD, V102, P4143, DOI 10.1182/blood-2003-03-0779; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Buijs RM, 2001, NAT REV NEUROSCI, V2, P521, DOI 10.1038/35081582; BURKE WJ, 1991, MOL BRAIN RES, V11, P37, DOI 10.1016/0169-328X(91)90018-S; CARTER DA, 1993, ENDOCRINOLOGY, V133, P2263, DOI 10.1210/en.133.5.2263; CARTER DA, 1992, MOL BRAIN RES, V12, P315, DOI 10.1016/0169-328X(92)90133-V; CASSONE VM, 1986, PHYSIOL BEHAV, V36, P1111, DOI 10.1016/0031-9384(86)90488-9; Coon SL, 2002, J CLIN ENDOCR METAB, V87, P4699, DOI 10.1210/jc.2002-020683; Coon SL, 2001, J BIOL CHEM, V276, P24097, DOI 10.1074/jbc.M011298200; Engel L, 2005, EUR J NEUROSCI, V21, P2297, DOI 10.1111/j.1460-9568.2005.04040.x; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Friedland R P, 1990, Int Psychogeriatr, V2, P36; Fukuhara C, 2005, J NEUROCHEM, V93, P156, DOI 10.1111/j.1471-4159.2004.03008.x; Fukuhara C, 2004, J NEUROSCI, V24, P1803, DOI 10.1523/JNEUROSCI.4988-03.2004; Fukuhara C, 2000, NEUROSCI LETT, V286, P167, DOI 10.1016/S0304-3940(00)01129-0; Garidou ML, 2001, NEUROSCIENCE, V105, P721, DOI 10.1016/S0306-4522(01)00197-X; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Grady CL, 2001, BRAIN, V124, P739, DOI 10.1093/brain/124.4.739; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Hida A, 2000, GENOMICS, V65, P224, DOI 10.1006/geno.2000.6166; HOFMAN MA, 1994, BRAIN RES, V651, P134, DOI 10.1016/0006-8993(94)90689-0; Ingram CD, 1998, PROG BRAIN RES, V119, P351; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Johnston JD, 2004, NEUROSCIENCE, V124, P789, DOI 10.1016/j.neuroscience.2004.01.011; Kalsbeek A, 2000, EUR J NEUROSCI, V12, P3146, DOI 10.1046/j.1460-9568.2000.00202.x; Kalsbeek A, 1996, J NEUROSCI, V16, P5555, DOI 10.1523/jneurosci.16-17-05555.1996; Klein D. C., 1997, RECENT PROG HORM RES, V52, p[307, 357]; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1985, CIBA F SYMP, V117, P38; Liu RY, 2000, J NEUROPATH EXP NEUR, V59, P314, DOI 10.1093/jnen/59.4.314; Liu RY, 1999, J CLIN ENDOCR METAB, V84, P323, DOI 10.1210/jc.84.1.323; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; PARDO CA, 1990, ACTA NEUROPATHOL, V80, P535, DOI 10.1007/BF00294615; Perreau-Lenz S, 2004, EUR J NEUROSCI, V19, P318, DOI 10.1111/j.0953-816X.2003.03132.x; Perreau-Lenz S, 2003, EUR J NEUROSCI, V17, P221, DOI 10.1046/j.1460-9568.2003.02442.x; Pfeffer M, 1998, EUR J NEUROSCI, V10, P2896, DOI 10.1111/j.1460-9568.1998.00309.x; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; RAVID R, 1992, PROG BRAIN RES, V93, P83; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; SCHWARTZ WJ, 1987, BRAIN RES, V424, P249, DOI 10.1016/0006-8993(87)91468-5; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; Simonneaux V, 2004, MOL BRAIN RES, V120, P164, DOI 10.1016/j.molbrainres.2003.10.019; SKENE DJ, 1990, BRAIN RES, V528, P170, DOI 10.1016/0006-8993(90)90214-V; Steeves TDL, 1999, GENOMICS, V57, P189, DOI 10.1006/geno.1998.5675; Stopa EG, 1999, J NEUROPATH EXP NEUR, V58, P29, DOI 10.1097/00005072-199901000-00004; SWAAB DF, 1985, BRAIN RES, V342, P27; Takekida S, 2000, EUR J NEUROSCI, V12, P4557, DOI 10.1046/j.0953-816X.2000.01324.x; Tousson E, 2004, J NEUROSCI, V24, P2983, DOI 10.1523/JNEUROSCI.5044-03.2004; Travnickova-Bendova Z, 2002, P NATL ACAD SCI USA, V99, P7728, DOI 10.1073/pnas.102075599; vanSomeren EJW, 1996, BIOL PSYCHIAT, V40, P259, DOI 10.1016/0006-3223(95)00370-3; VAUGHAN GM, 1976, J CLIN ENDOCR METAB, V42, P752, DOI 10.1210/jcem-42-4-752; von Gall C, 2001, J NEUROENDOCRINOL, V13, P313, DOI 10.1046/j.1365-2826.2001.00643.x; Wu YH, 2003, J CLIN ENDOCR METAB, V88, P5898, DOI 10.1210/jc.2003-030833; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Zanello SB, 2000, J INVEST DERMATOL, V115, P757, DOI 10.1046/j.1523-1747.2000.00121.x	65	126	135	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1874	+		10.1096/fj.05-4446fje	http://dx.doi.org/10.1096/fj.05-4446fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16818472				2022-12-28	WOS:000240267000015
J	Daviaud, D; Boucher, J; Gesta, S; Dray, C; Guigne, C; Quilliot, D; Ayav, A; Ziegler, O; Carpene, C; Saulnier-Blache, JS; Valet, P; Castan-Laurell, I				Daviaud, Daniele; Boucher, Jeremie; Gesta, Stephane; Dray, Cedric; Guigne, Charlotte; Quilliot, Didier; Ayav, Ahmet; Ziegler, Olivier; Carpene, Christian; Saulnier-Blache, Jean-Sebastien; Valet, Philippe; Castan-Laurell, Isabelle			TNF alpha up-regulates apelin expression in human and mouse adipose tissue	FASEB JOURNAL			English	Article						obesity; adipocyte; adipokine	NECROSIS-FACTOR-ALPHA; PLASMINOGEN-ACTIVATOR INHIBITOR-1; INSULIN-RESISTANCE; PEPTIDE APELIN; RECEPTOR; APJ; LIGAND; OBESITY; ADIPOCYTES; CLONING	We have recently identified apelin as a novel adipokine up-regulated by insulin and obesity. Since obesity and insulin resistance are associated with chronically elevated levels of both insulin and TNF alpha, the present study was performed to investigate a putative regulation of apelin expression in adipocytes by TNF alpha. Herein, we report a tight correlation between apelin and TNF alpha expression in adipose tissue of lean and obese humans. Apelin regulation by TNF alpha was further studied in cultured explants of human adipose tissue. The endogenous expression of TNF alpha in adipocytes isolated from the explants was accompanied by a 6-9 h subsequent increase of apelin expression in adipocytes. This increase was reversed by inhibiting TNF alpha expression with 100 mu M isobutylmethylxanthine. In different mouse models of obesity, expression of both TNF alpha and apelin was also significantly increased in adipocytes of obese mice. Furthermore, short-term exposure to an i.p. injection of TNF alpha in C57B16/J mice induced an increase of apelin expression in adipose tissue as well as apelin plasma levels. Finally, a direct positive effect of TNF alpha has been shown in differentiated 3T3F442A adipocytes on apelin expression and secretion. The signaling pathways of TNF alpha for the induction of apelin were dependent of PI3-kinase, c-Jun NH2-terminal kinase (JNK), and MAPK but not PKC activation. All together, these findings suggest that apelin might be a candidate to better understand potential links between obesity and associated disorders such as inflammation and insulin resistance.	Univ Toulouse 3, Inst Louis Bugnard, FIR 31, U586,INSERM,IFR31,Unite Rech Obesites, F-31432 Toulouse 4, France; CHU Nancy, Hop J DArc, Serv Diabetol Malad Metab & Nutr, Nancy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Nancy	Castan-Laurell, I (corresponding author), Univ Toulouse 3, Inst Louis Bugnard, FIR 31, U586,INSERM,IFR31,Unite Rech Obesites, BP 84 225, F-31432 Toulouse 4, France.	isabelle.castan@toulouse.inserm.fr	Carpéné, Christian/S-3279-2019; Valet, Philippe/N-7472-2017; Quillot, Didier/ABB-5326-2021; Saulnier-Blache, Jean Sebastien/X-7729-2018; Boucher, Jeremie/G-6602-2015; dray, cedric/N-7440-2017	Valet, Philippe/0000-0001-6520-7393; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723; Castan-Laurell, Isabelle/0000-0002-0488-9789; DRAY, Cedric/0000-0002-4712-791X				Ashley EA, 2005, CARDIOVASC RES, V65, P73, DOI 10.1016/j.cardiores.2004.08.018; Boucher J, 2005, ENDOCRINOLOGY, V146, P1764, DOI 10.1210/en.2004-1427; Boucher J, 2005, HORM METAB RES, V37, P761, DOI 10.1055/s-2005-921098; Brailoiu GC, 2002, NEUROSCI LETT, V327, P193, DOI 10.1016/S0304-3940(02)00411-1; Coppack SW, 2001, P NUTR SOC, V60, P349, DOI 10.1079/PNS2001110; De Mota N, 2000, NEUROENDOCRINOLOGY, V72, P400, DOI 10.1159/000054609; De Mota N, 2004, P NATL ACAD SCI USA, V101, P10464, DOI 10.1073/pnas.0403518101; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; Foldes G, 2003, BIOCHEM BIOPH RES CO, V308, P480, DOI 10.1016/S0006-291X(03)01424-4; Gesta S, 2003, HORM METAB RES, V35, P158, DOI 10.1055/s-2003-39070; Gronning LM, 2002, MOL ENDOCRINOL, V16, P873, DOI 10.1210/me.16.4.873; Heinonen MV, 2005, REGUL PEPTIDES, V130, P7, DOI 10.1016/j.regpep.2005.05.003; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Ishida J, 2004, J BIOL CHEM, V279, P26274, DOI 10.1074/jbc.M404149200; Jain RG, 1999, J CELL PHYSIOL, V179, P58, DOI 10.1002/(SICI)1097-4652(199904)179:1<58::AID-JCP8>3.0.CO;2-1; Kasai A, 2004, BIOCHEM BIOPH RES CO, V325, P395, DOI 10.1016/j.bbrc.2004.10.042; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kleinz MJ, 2004, REGUL PEPTIDES, V118, P119, DOI 10.1016/j.regpep.2003.11.002; Kleinz MJ, 2005, PHARMACOL THERAPEUT, V107, P198, DOI 10.1016/j.pharmthera.2005.04.001; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Masri B, 2005, CELL SIGNAL, V17, P415, DOI 10.1016/j.cellsig.2004.09.018; Pandey M, 2005, FASEB J, V19, P1317, DOI 10.1096/fj.04-3459fje; Ruan H, 2003, CYTOKINE GROWTH F R, V14, P447, DOI 10.1016/S1359-6101(03)00052-2; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Taheri S, 2002, BIOCHEM BIOPH RES CO, V291, P1208, DOI 10.1006/bbrc.2002.6575; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Valet P, 2000, J BIOL CHEM, V275, P34797, DOI 10.1074/jbc.M005210200; Winzell MS, 2005, REGUL PEPTIDES, V131, P12, DOI 10.1016/j.regpep.2005.05.004; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	29	166	182	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1528	+		10.1096/fj.05-5243fje	http://dx.doi.org/10.1096/fj.05-5243fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723381				2022-12-28	WOS:000240266000040
J	Ghoumari, AM; Piochon, C; Tomkiewicz, C; Eychenne, B; Levenes, C; Dusart, I; Schumacher, M; Baulieu, EE				Ghoumari, A. M.; Piochon, C.; Tomkiewicz, C.; Eychenne, B.; Levenes, C.; Dusart, I.; Schumacher, M.; Baulieu, E. E.			Neuroprotective effect of mifepristone involves neuron depolarization	FASEB JOURNAL			English	Article						Purkinje cells; Na+/K+-ATPase; rat cerebella	CEREBELLAR GRANULE CELLS; VESICULAR GLUTAMATE TRANSPORTERS; ELECTRO-PHYSIOLOGICAL PROPERTIES; POSTNATAL MOUSE CEREBELLUM; DEVELOPING RAT CEREBELLUM; PURKINJE-CELL; IN-VITRO; MULTIPLE INNERVATION; SYNAPTIC POTENTIALS; AXONAL REGENERATION	In several regions of the developing nervous system, neurons undergo programmed cell death. In the rat cerebellum, Purkinje cell apoptosis is exacerbated when cerebellar slices are cultured during the first postnatal week. To understand the mechanism of this developmental apoptosis, we took advantage of its inhibition by the steroid analog mifepristone. This effect did not involve the classical steroid nuclear receptors. Microarray analysis revealed that mifepristone down-regulated mRNA levels of the Na+/K+-ATPase alpha 3 subunit more than three times. Consistent with the down-regulation of the Na+/K+-ATPase, mifepristone caused Purkinje cell membrane depolarization. Depolarizing agents like ouabain (1 mu M), tetraethylammonium (2 mM), and veratridine (2 mu M) protected Purkinje cells from apoptosis. These results suggest a role of excitatory inputs in Purkinje cell survival during early postnatal development. Indeed, coculturing cerebellar slices with glutamatergic inferior olivary neuron preparations allowed rescue of Purkinje cells. These findings reveal a new neuroprotective mechanism of mifepristone and support a pivotal role for excitatory inputs in the survival of Purkinje neurons. Mifepristone may be a useful lead compound in the development of novel therapeutic approaches for maintaining the resting potential of neurons at values favorable for their survival under neuropathological conditions.	Univ Paris 11, Le Kremlin Bicetre, France; INSERM UMR 788, Le Kremlin Bicetre, France; Univ Paris 06, CNRS, UMR7102, Paris, France; INSERM, U490, Paris, France	UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Ghoumari, AM (corresponding author), INSERM, U488, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	ghoumari@kb.inserm.fr	Schumacher, Michael/G-3581-2013	Schumacher, Michael/0000-0001-6117-5371; Dusart, Isabelle/0000-0002-3211-4323; Levenes, Carole/0000-0002-1345-180X				ARMENGOL JA, 1991, DEV BRAIN RES, V64, P95, DOI 10.1016/0165-3806(91)90213-3; AUDINAT E, 1992, NEUROSCIENCE, V49, P903, DOI 10.1016/0306-4522(92)90366-A; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; Behl C, 1997, EUR J NEUROSCI, V9, P912, DOI 10.1111/j.1460-9568.1997.tb01442.x; Biser PS, 2000, DEV BRAIN RES, V123, P165, DOI 10.1016/S0165-3806(00)00084-5; COUSIN MA, 1995, J NEUROCHEM, V64, P2097; CREPEL F, 1978, BRAIN RES, V155, P176, DOI 10.1016/0006-8993(78)90321-9; CREPEL F, 1971, BRAIN RES, V35, P272, DOI 10.1016/0006-8993(71)90617-2; CREPEL F, 1976, J NEUROBIOL, V7, P567, DOI 10.1002/neu.480070609; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; De Angelis C, 1998, AM J PHYSIOL-RENAL, V274, pF182, DOI 10.1152/ajprenal.1998.274.1.F182; Dusart I, 1997, J NEUROSCI, V17, P3710; GALLO V, 1987, J NEUROSCI, V7, P2203; Gardette R, 1985, Brain Res, V352, P97; Genet S, 1997, PFLUG ARCH EUR J PHY, V434, P559, DOI 10.1007/s004240050436; Ghoumari AM, 2000, EUR J NEUROSCI, V12, P2935, DOI 10.1046/j.1460-9568.2000.00186.x; Ghoumari AM, 2003, P NATL ACAD SCI USA, V100, P7953, DOI 10.1073/pnas.1332667100; Ghoumari AM, 2002, J NEUROSCI, V22, P3531; Gonzalez S, 1996, NEUROREPORT, V7, P1041, DOI 10.1097/00001756-199604100-00017; Hioki H, 2003, NEUROSCIENCE, V117, P1, DOI 10.1016/S0306-4522(02)00943-0; Isaev NK, 2000, NEUROSCI LETT, V283, P41, DOI 10.1016/S0304-3940(00)00903-4; ITO M, 1984, JPN J PHYSIOL, V34, P781, DOI 10.2170/jjphysiol.34.781; KANEKO T, 1989, NEUROSCIENCE, V32, P79, DOI 10.1016/0306-4522(89)90109-7; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; MARIANI J, 1981, J NEUROSCI, V1, P696, DOI 10.1523/JNEUROSCI.01-07-00696.1981; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; MASON CA, 1990, J COMP NEUROL, V297, P77, DOI 10.1002/cne.902970106; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McKay BE, 2005, J PHYSIOL-LONDON, V567, P829, DOI 10.1113/jphysiol.2005.089383; Miyazaki T, 2003, EUR J NEUROSCI, V17, P2563, DOI 10.1046/j.1460-9568.2003.02698.x; MURPHY TH, 1988, BRAIN RES, V460, P155, DOI 10.1016/0006-8993(88)91216-4; MUSZBEK L, 1977, ANAL BIOCHEM, V77, P286, DOI 10.1016/0003-2697(77)90315-3; Orlov SN, 2004, PFLUG ARCH EUR J PHY, V448, P335, DOI 10.1007/s00424-004-1262-9; Orlov SN, 1999, J BIOL CHEM, V274, P16545, DOI 10.1074/jbc.274.23.16545; Orlov SN, 2001, J HYPERTENS, V19, P1559, DOI 10.1097/00004872-200109000-00007; Peng L, 1997, J NEUROSCI, V17, P3488; Salthun-Lassalle B, 2004, J NEUROSCI, V24, P5922, DOI 10.1523/JNEUROSCI.5668-03.2004; Scelfo B, 2005, EUR J NEUROSCI, V21, P971, DOI 10.1111/j.1460-9568.2005.03933.x; SCOTT BS, 1970, EXP NEUROL, V27, P16, DOI 10.1016/0014-4886(70)90197-4; SHIMONO T, 1976, BRAIN RES, V108, P279, DOI 10.1016/0006-8993(76)90186-4; TANAKA S, 1995, DEV BIOL, V168, P166, DOI 10.1006/dbio.1995.1069; Yu SP, 2003, BIOCHEM PHARMACOL, V66, P1601, DOI 10.1016/S0006-2952(03)00531-8; Zhou XM, 2001, BIOCHEM BIOPH RES CO, V285, P46, DOI 10.1006/bbrc.2001.5126	45	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1377	1386		10.1096/fj.05-5832com	http://dx.doi.org/10.1096/fj.05-5832com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816113				2022-12-28	WOS:000240266000015
J	Hasenbrink, G; Sievernich, A; Wildt, L; Ludwig, J; Lichtenberg-Frate, H				Hasenbrink, Guido; Sievernich, Andre; Wildt, Ludwig; Ludwig, Jost; Lichtenberg-Frate, Hella			Estrogenic effects of natural and synthetic compounds including tibolone assessed in Saccharomyces cerevisiae expressing the human estrogen alpha and beta receptors	FASEB JOURNAL			English	Article						S. cerevisiae in vitro assay; hER alpha; hER beta	GREEN FLUORESCENT PROTEIN; POTASSIUM-TRANSPORT; YEAST; ACTIVATION; SCREEN; ASSAY; PHYTOESTROGENS; METABOLISM; MECHANISM; MUTANTS	The human estrogen receptors (hER)alpha and hER beta, differentially expressed and localized in various tissues and cell types, mediate transcriptional activation of target genes. These encode a variety of physiological reproductive and nonreproductive functions involved in energy metabolism, salt balance, immune system, development, and differentiation. As a step toward developing a screening assay for the use in applications where significant numbers of compounds or complex matrices need to be tested for (anti) estrogenic bioactivity, hER alpha and hER beta were expressed in a genetically modified Saccharomyces cerevisiae strain, devoid of three endogenous xenobiotic transporters (PDR5, SNQ2, and YOR1). By using receptor-mediated transcriptional activation of the green fluorescent protein optimized for expression in yeast (yEGFP) as reporter 17 natural, comprising estrogens and phytoestrogens or synthetic compounds among which tibolone with its metabolites, gestagens, and antiestrogens were investigated. The reporter assay deployed a simple and robust protocol for the rapid detection of estrogenic effects within a 96-well microplate format. Results were expressed as effective concentrations (EC50) and correlated to other yeast based and cell line assays. Tibolone and its metabolites exerted clear estrogenic effects, though considerably less potent than all other natural and synthetic compounds. For the blood serum of two volunteers, considerable higher total estrogenic bioactivity than single estradiol concentrations as determined by immunoassay was found. Visualization of a hER alpha/GFP fusion protein in yeast revealed a sub cellular cytosolic localization. This study demonstrates the versatility of (anti) estrogenic bioactivity determination using sensitized S. cerevisiae cells to assess estrogenic exposure and effects.	Univ Bonn, IZMB, AG Mol Bioenerget, D-53115 Bonn, Germany; Univ Innsbruck, Klin Gynakol Endokrinol & Sterilitat, A-6020 Innsbruck, Austria	University of Bonn; University of Innsbruck	Lichtenberg-Frate, H (corresponding author), Univ Bonn, IZMB, AG Mol Bioenerget, Kirschallee 1, D-53115 Bonn, Germany.	h.lichtenberg@uni-bonn.de	Ludwig, Jost/K-3446-2017					Agradi E, 2001, PLANTA MED, V67, P553, DOI 10.1055/s-2001-16485; Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; Arnold SF, 1996, ENVIRON HEALTH PERSP, V104, P544, DOI 10.2307/3432996; Bertl A, 2003, MOL MICROBIOL, V47, P767, DOI 10.1046/j.1365-2958.2003.03335.x; Bovee TFH, 2004, J STEROID BIOCHEM, V91, P99, DOI 10.1016/j.jsbmb.2004.03.118; Bovee TFH, 2004, GENE, V325, P187, DOI 10.1016/j.gene.2003.10.015; Caplan AJ, 1997, TRENDS ENDOCRIN MET, V8, P271, DOI 10.1016/S1043-2760(97)00079-9; Chen CW, 1997, BIOCHEM PHARMACOL, V53, P1161; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; De Boever P, 2001, ENVIRON HEALTH PERSP, V109, P691, DOI 10.2307/3454785; de Gooyer ME, 2003, STEROIDS, V68, P21, DOI 10.1016/S0039-128X(02)00112-5; DeFranco Donald B., 1999, Cell Biochemistry and Biophysics, V30, P1, DOI 10.1007/BF02737882; Graumann K, 1996, J STEROID BIOCHEM, V57, P293, DOI 10.1016/0960-0760(95)00274-X; Graumann K, 1999, SCI TOTAL ENVIRON, V225, P69; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Gustafsson JA, 1999, J ENDOCRINOL, V163, P379, DOI 10.1677/joe.0.1630379; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; Hobe G, 2002, STEROIDS, V67, P883, DOI 10.1016/S0039-128X(02)00058-2; Jungbauer A, 2002, J CHROMATOGR B, V777, P167, DOI 10.1016/S1570-0232(02)00083-1; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; Kloosterboer HJ, 2004, MATURITAS, V49, pS5, DOI 10.1016/j.maturitas.2004.06.022; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; McEwan IJ, 1999, FEMS MICROBIOL LETT, V176, P1; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Payne J, 2000, ENVIRON HEALTH PERSP, V108, P983, DOI 10.1289/ehp.00108983; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING; Schultis T, 2004, CHEMOSPHERE, V57, P1649, DOI 10.1016/j.chemosphere.2004.06.027; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Shiau SP, 1996, GENE, V179, P205, DOI 10.1016/S0378-1119(96)00345-9; Sievernich A, 2004, J STEROID BIOCHEM, V92, P455, DOI 10.1016/j.jsbmb.2004.09.004; Vico P, 2002, YEAST, V19, P873, DOI 10.1002/yea.882; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Witters HE, 2001, WATER SCI TECHNOL, V43, P117, DOI 10.2166/wst.2001.0080; WRENN CK, 1993, J BIOL CHEM, V268, P24089	39	24	24	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1552	+		10.1096/fj.05-5413fje	http://dx.doi.org/10.1096/fj.05-5413fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720731				2022-12-28	WOS:000240266000048
J	Petermann, I; Mayer, C; Stypmann, J; Biniossek, ML; Tobin, DJ; Engelen, MA; Dandekar, T; Grune, T; Schild, L; Peters, C; Reinheckel, T				Petermann, Ivonne; Mayer, Christian; Stypmann, Joerg; Biniossek, Martin L.; Tobin, Desmond J.; Engelen, Markus A.; Dandekar, Thomas; Grune, Tilman; Schild, Lorenz; Peters, Christoph; Reinheckel, Thomas			Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice	FASEB JOURNAL			English	Article						protease; cardiomyopathy; lysosome; proteome	DILATED CARDIOMYOPATHY; OXIDATIVE STRESS; HEART-FAILURE; POLYACRYLAMIDE-GELS; PROTEINS; PEPTIDE; PROLIFERATION; KERATINOCYTE; DEGRADATION; DISRUPTION	Although lysosomal proteases are expressed in the heart at considerable levels, their specific functions in this organ remain elusive. Mice deficient for the lysosomal cysteine protease cathepsin L (CTSL) develop a late onset dilated cardiomyopathy (DCM) that is characterized by cardiac chamber dilation, fibrosis, and impaired cardiac contraction at 12 month of age. Investigation of the pathogenic sequence of DCM in ctsl(-/-) mice revealed numerous dysmorphic lysosome-like structures in heart muscle as early as 3 days after birth, whereas skeletal muscle was not affected. Labeling of the acidic cell compartment of neonatal cardiomyocytes and detection of lysosomal markers after subcellular fractionation confirmed increased lysosome content in CTSL deficient myocardium; however, specific storage materials were not detected. The myocardium of ctsl(-/-) and ctsl(-/-) mice revealed no differences in incidence of cell death, proliferation, and capillary density during DCM progression. However, an observed increase in mRNA expression of natriuretic peptides in young adult mice indicates the activation of the adaptive "fetal" gene program, while proteome analysis revealed decreased levels of the sarcomere-associated proteins alpha-tropomyosin, desmin, and calsarcin 1, as well as considerable changes of metabolic enzymes. Bioinformatic pathway analysis suggested a switch to anaerobic catabolism and impairment of mitochondrial respiration. This interpretation was supported by a 50% reduction in resting state oxygen consumption and impaired respiration capacity in ctsl(-/-) myocardial homogenates. In summary, the data indicate an essential role of CTSL in maintaining the structure of the endosomal/lysosomal compartment in cardiomyocytes. Lysosomal impairment in ctsl(-/-) hearts results in metabolic and sarcomeric alterations that promote DCM development. Petermann, I., Mayer, C., Stypmann, J., Biniossek, M. L., Tobin, D. J., Engelen, M. A., Dandekar, T., Grune, T., Schild, L., Peters, C., Reinheckel, T. Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice.	Univ Freiburg, Inst Mol Med & Zellforsch, D-79104 Freiburg, Germany; Univ Munster, Univ Klinikum,Zentrum Klin Forsch Munster, Med Klin & Poliklin Kardiol & Angiol C, Zent Projektgrp Kleintierdiagnost Interdisziplina, Munster, Germany; Univ Bradford, Sch Life Sci, Bradford BD7 1DP, W Yorkshire, England; Biozentrum, Lehrstuhl Bioinformat, Wurzburg, Germany; Univ Dusseldorf, Environm Med Res Inst, D-4000 Dusseldorf, Germany; Otto Von Guericke Univ, Inst Klin Chem & Pathol Biochem, Bereich Pathol Biochem, Fak Med, Magdeburg, Germany	University of Freiburg; University of Munster; University of Bradford; University of Wurzburg; Heinrich Heine University Dusseldorf; Otto von Guericke University	Peters, C (corresponding author), Univ Freiburg, Inst Mol Med & Zellforsch, D-79104 Freiburg, Germany.	christoph.peters@mol-med.uni.freiburg-de	Reinheckel, Thomas/AAL-9761-2021; Engelen, Markus/AAV-8632-2020; Dandekar, Thomas/A-4431-2017; Tobin, Desmond/A-5228-2009	Reinheckel, Thomas/0000-0001-9866-9105; Dandekar, Thomas/0000-0003-1886-7625; Grune, Tilman/0000-0003-4775-9973; Tobin, Desmond/0000-0003-4566-9392				Ahn SG, 2003, GENE DEV, V17, P516, DOI 10.1101/gad.1044503; Bednarski E, 1997, J NEUROSCI, V17, P4006; Bromme D, 2002, CURR PHARM DESIGN, V8, P1639, DOI 10.2174/1381612023394179; Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4; Chevallet M, 2003, J BIOL CHEM, V278, P37146, DOI 10.1074/jbc.M305161200; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Foo RSY, 2005, J CLIN INVEST, V115, P565, DOI 10.1172/JCI200524569; Francis Gary S., 2001, American Journal of Medicine, V110, p37S; Frey N, 2004, NAT MED, V10, P1336, DOI 10.1038/nm1132; Garnier A, 2003, J PHYSIOL-LONDON, V551, P491, DOI 10.1113/jphysiol.2003.045104; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100; Huss JM, 2005, J CLIN INVEST, V115, P547, DOI 10.1172/JCI200524405; Ide T, 2001, CIRC RES, V88, P529, DOI 10.1161/01.RES.88.5.529; Kussmann M, 1997, J MASS SPECTROM, V32, P593; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Li H, 2000, P NATL ACAD SCI USA, V97, P3467, DOI 10.1073/pnas.97.7.3467; MAISCH B, 1996, CARDIOLOGY S1, V81, P2; Marin-Garcia J, 2001, CARDIOVASC RES, V52, P103, DOI 10.1016/S0008-6363(01)00368-6; Mason JW, 2003, CARDIOVASC RES, V60, P5, DOI 10.1016/S0008-6363(03)00437-1; MCMANUS JFA, 1948, STAIN TECHNOL, V23, P99, DOI 10.3109/10520294809106232; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Morita H, 2005, J CLIN INVEST, V115, P518, DOI 10.1172/JCI200524351; MOWRY RW, 1958, LAB INVEST, V7, P566; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Nian M, 2004, CIRC RES, V94, P1543, DOI 10.1161/01.RES.0000130526.20854.fa; Nishimune H, 2000, NAT CELL BIOL, V2, P906, DOI 10.1038/35046558; Nohl H, 2003, BIOCHEM SOC T, V31, P1308; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Perriard JC, 2003, TRENDS CARDIOVAS MED, V13, P30, DOI 10.1016/S1050-1738(02)00209-8; PERTOFT H, 1978, ANAL BIOCHEM, V88, P271, DOI 10.1016/0003-2697(78)90419-0; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Rawlings ND, 2000, NUCLEIC ACIDS RES, V28, P323, DOI 10.1093/nar/28.1.323; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; Somme L., 1993, Arctic Insect News, P2; Strauch OF, 2003, PEDIATR RES, V54, P701, DOI 10.1203/01.PDR.0000084085.65972.3F; Stypmann J, 2002, P NATL ACAD SCI USA, V99, P6234, DOI 10.1073/pnas.092637699; Suttner Stefan W, 2004, Curr Opin Crit Care, V10, P336, DOI 10.1097/01.ccx.0000135513.26376.4f; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Tobin DJ, 2002, AM J PATHOL, V160, P1807, DOI 10.1016/S0002-9440(10)61127-3; Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182; WONG SHY, 1987, CLIN CHEM, V33, P214; Yasothornsrikul S, 2003, P NATL ACAD SCI USA, V100, P9590, DOI 10.1073/pnas.1531542100	52	58	60	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1266	+		10.1096/fj.05-5517fje	http://dx.doi.org/10.1096/fj.05-5517fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636100				2022-12-28	WOS:000240210300047
J	Pscherer, A; Schliwka, J; Wildenberger, K; Mincheva, A; Schwaenen, C; Dohner, H; Stilgenbauer, S; Lichter, P				Pscherer, Armin; Schliwka, Julia; Wildenberger, Kathrin; Mincheva, Antoaneta; Schwaenen, Carsten; Dohner, Hartmun; Stilgenbauer, Stephan; Lichter, Peter			Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: application in mantle cell lymphoma	FASEB JOURNAL			English	Article						functional genomics; RNA; transgenes oncogenomics; genomic complementation; genetics of disease	CHRONIC LYMPHOCYTIC-LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; SHORT-INTERFERING RNAS; NON-HODGKINS-LYMPHOMAS; CYCLIN D1; BLASTOID VARIANTS; EXPRESSION; MICE; IMBALANCES; APOPTOSIS	A broad range of malignant diseases, such as mantle cell lymphoma (MCL), is associated with complex genomic alterations, demanding multimodal functional testing of candidate genes. To assess such candidate disease genes, we have developed a bidirectional targeted transgenesis tool, which allows well-controlled modulation of individual gene activities within a cellular MCL system. The engineered versatile transgenesis system permits functional analysis of virtually any candidate gene: for tumor suppressor genes by complementation via integration of respective genomic DNA or for oncogenes by inactivation via integrated shRNA coding plasmids. Complementation by genomic DNA ensures wild-type (WT) regulated gene expression, whereas genomic integration of shRNA coding inserts by an advanced RNAi-strategy mediates specific knock-down of gene expression. Site-specific genomic integration of an unmodified BAC, which contains the CDKN2A/B genes absent in the MCL model system, restored CDKN2A/B expression resulting in the inhibition of cell proliferation. CCND1, strongly overexpressed in the model system, was down-regulated via shRNA expression, again inhibiting proliferation. Notably, the presented site-specific shRNA-strategy circumvents interference by IFN-response induced when using other RNAi gene knock-down methods. In conclusion, we here demonstrate that adequate restoration of a range of different gene activities yields in a desired antiproliferative effect in MCL-derived cells. By antagonizing inactivated tumor suppressor genes or activated oncogenes, the presented approach can be readily used for the functional analysis of a broad range of disease-related genetic defects.	Deutsch Krebsforschungszentrum, Abt Mol Genet B060, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Mol Genet, D-6900 Heidelberg, Germany; Med Sch Ulm, Dept Internal Med 3, Ulm, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ulm University	Lichter, P (corresponding author), Deutsch Krebsforschungszentrum, Abt Mol Genet B060, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.macleod@dkfz.de	Stilgenbauer, Stephan/ABE-6609-2020					Amin HM, 2003, ARCH PATHOL LAB MED, V127, P424; Baer A, 2001, CURR OPIN BIOTECH, V12, P473, DOI 10.1016/S0958-1669(00)00248-2; Battistini A, 2002, J INTERF CYTOK RES, V22, P27, DOI 10.1089/107999002753452638; Bea S, 1999, BLOOD, V93, P4365; Bea S, 2001, CANCER RES, V61, P2409; Bentz M, 2000, GENE CHROMOSOME CANC, V27, P285, DOI 10.1002/(SICI)1098-2264(200003)27:3<285::AID-GCC9>3.3.CO;2-D; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campo E, 1999, SEMIN HEMATOL, V36, P115; D'Amico M, 2004, CANCER RES, V64, P4122, DOI 10.1158/0008-5472.CAN-03-2519; Dreyling MH, 1997, CANCER RES, V57, P4608; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gandini D, 1996, CANCER GENET CYTOGEN, V86, P120, DOI 10.1016/0165-4608(95)00173-5; Hernandez L, 1999, LEUKEMIA, V13, P2087, DOI 10.1038/sj.leu.2401599; Jadayel DM, 1997, LEUKEMIA, V11, P64, DOI 10.1038/sj.leu.2400555; Kittler R, 2005, P NATL ACAD SCI USA, V102, P2396, DOI 10.1073/pnas.0409861102; Korz C, 2002, BLOOD, V99, P4554, DOI 10.1182/blood.V99.12.4554; Lauth M, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf114; LICHTER P, 1995, METHOD ENZYMOL, V254, P334; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Osoegawa K, 2001, GENOME RES, V11, P483, DOI 10.1101/gr.169601; Ott G, 1997, BLOOD, V89, P1421, DOI 10.1182/blood.V89.4.1421; Plumas J, 1998, BLOOD, V91, P2875, DOI 10.1182/blood.V91.8.2875.2875_2875_2885; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; ROSENBERG SA, 1991, BIOL THER CANCER UPD, V1, P1; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Schiedner G, 1998, NAT GENET, V18, P180, DOI 10.1038/ng0298-180; Seibler J, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni065; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Stilgenbauer S, 1998, ONCOGENE, V16, P1891, DOI 10.1038/sj.onc.1201764	33	18	18	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1188	+		10.1096/fj.05-4854fje	http://dx.doi.org/10.1096/fj.05-4854fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636107				2022-12-28	WOS:000240210300021
J	Kauser, S; Slominski, A; Wei, ET; Tobin, DJ				Kauser, Sobia; Slominski, Andrzej; Wei, Edward T.; Tobin, Desmond J.			Modulation of the human hair follicle pigmentary unit by corticotropin-releasing hormone and urocortin peptides	FASEB JOURNAL			English	Article						hair follicle melanocytes; melanogenesis; corticotropin-releasing hormone; CRH receptors; hair growth	NORMAL HUMAN MELANOCYTES; HUMAN SKIN; CUTANEOUS EXPRESSION; CYTOKINETIC DYNAMICS; BETA-ENDORPHIN; MELANOMA-CELLS; MAMMALIAN SKIN; GROWTH-CONTROL; CRH-RECEPTOR; DNA-DAMAGE	Human skin is a local source of cortico-tropin-releasing hormone (CRH) and expresses CRH and CRH receptors (CRH-R) at mRNA and protein levels. Epidermal melanocytes respond to CRH by induction of cAMP with up-regulation of pro-opiomelanocortin gene expression and subsequent production of adrenocorticotropin hormone. However, the role of CRH/CRH-R in melanocyte biology is complicated by the significant heterogeneity of cutaneous melanocyte subpopulations, from continuously active and UV-responsive melanocytes in epidermis to UV nonresponsive, hair growth cycle-coupled melanogenesis in hair follicles. In the present study we report that normal human scalp hair follicle melanocytes express CRH at the mRNA level. Furthermore, CRH, urocortin and CRH-R 1 and 2 were differentially expressed in follicular melanocytes, fibroblasts, and keratinocytes depending on anatomic location and differentiation status in situ and in vitro. Stimulation of follicular melanocytes with CRH and CRH peptides, modified for selectivity for CRH-R1 and/or CRH-R2, variably induced cell melanogenesis, dendricity, and proliferation. CRH-peptides also stimulated the expression and activity of Tyrosinase, and expression of Tyrosinase-related protein-1 and-2. However, a modified urocortin peptide highly selective for CRH-R2 down-regulated melanocyte differentiation phenotype. This study indicates that CRH peptides can differentially influence hair follicle melanocyte behavior not only via CRH-R1 signaling but also by complex cross-talk between CRH-R1 and CRH-R2.	Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England; Univ Tennessee, Dept Pathol & Lab Med, HSC, Memphis, TN 38163 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of Bradford; University of Tennessee System; University of Tennessee Health Science Center; University of California System; University of California Berkeley	Tobin, DJ (corresponding author), Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England.	dtobin@bradford.ac.uk	; Tobin, Desmond/A-5228-2009	Slominski, Andrzej/0000-0001-8963-3995; Tobin, Desmond/0000-0003-4566-9392	NIAMS NIH HHS [R01 AR047079-01A2, 1R01-AR047079, R01 AR047079, R01 AR047079-02] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047079] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aguilera G, 2001, PEPTIDES, V22, P769, DOI 10.1016/S0196-9781(01)00390-4; Bittencourt JC, 1999, J COMP NEUROL, V415, P285; Bohm M, 2005, J BIOL CHEM, V280, P5795, DOI 10.1074/jbc.M406334200; Botchkarev VA, 2003, AM J PATHOL, V162, P709, DOI 10.1016/S0002-9440(10)63866-7; Carlson KW, 2001, ANTICANCER RES, V21, P1173; CASTROL MG, 1995, MOL CELL ENDOCRINOL, V107, P17, DOI 10.1016/0303-7207(94)03416-Q; EKMAN R, 1993, J NEUROIMMUNOL, V44, P7, DOI 10.1016/0165-5728(93)90262-W; Fazal N, 1998, FEBS LETT, V435, P187, DOI 10.1016/S0014-5793(98)01067-9; Funasaka Y, 1999, J INVEST DERM SYMP P, V4, P105, DOI 10.1038/sj.jidsp.5640192; Gillbro JM, 2004, J INVEST DERMATOL, V123, P346, DOI 10.1111/j.0022-202X.2004.23210.x; Grammatopoulos DK, 2002, TRENDS ENDOCRIN MET, V13, P436, DOI 10.1016/S1043-2760(02)00670-7; HALABAN R, 1984, IN VITRO CELL DEV B, V20, P447; Hearing VJ, 1999, J INVEST DERM SYMP P, V4, P24, DOI 10.1038/sj.jidsp.5640176; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Ito N, 2004, J INVEST DERMATOL, V122, P235, DOI 10.1046/j.1523-1747.2003.22145.x; Kadekaro AL, 2005, CANCER RES, V65, P4292, DOI 10.1158/0008-5472.CAN-04-4535; Kauser S, 2005, ENDOCRINOLOGY, V146, P532, DOI 10.1210/en.2004-1145; Kauser S, 2004, J INVEST DERMATOL, V123, P184, DOI 10.1111/j.0022-202X.2004.22724.x; Kauser S, 2003, J INVEST DERMATOL, V120, P1073, DOI 10.1046/j.1523-1747.2003.12242.x; Kishimoto T, 2000, NAT GENET, V24, P415, DOI 10.1038/74271; Magerl M, 2002, EXP DERMATOL, V11, P381, DOI 10.1034/j.1600-0625.2002.110414.x; Miki F, 2004, J PHARMACOL SCI, V96, P170, DOI 10.1254/jphs.FP0040364; Morrison Ewan, 1993, Biochemical Society Transactions, V21, p318S; Nordlund JJ, 1998, PIGMENTARY SYSTEM PH, P475; ORTH DN, 1992, ENDOCR REV, V13, P164, DOI 10.1210/er.13.2.164; Pedersen WA, 2002, J NEUROSCI, V22, P404, DOI 10.1523/JNEUROSCI.22-02-00404.2002; Peters EMJ, 2000, J INVEST DERMATOL, V114, P430, DOI 10.1046/j.1523-1747.2000.00913.x; Quevedo ME, 2001, IN VITRO CELL DEV-AN, V37, P50; Rees JL, 2003, ANNU REV GENET, V37, P67, DOI 10.1146/annurev.genet.37.110801.143233; RomeroGraillet C, 1996, J BIOL CHEM, V271, P28052, DOI 10.1074/jbc.271.45.28052; SAPHIER PW, 1992, J ENDOCRINOL, V133, P487, DOI 10.1677/joe.0.1330487; Slominski A, 2000, J CLIN ENDOCR METAB, V85, P815, DOI 10.1210/jc.85.2.815; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2005, AM J PHYSIOL-ENDOC M, V288, pE701, DOI 10.1152/ajpendo.00519.2004; Slominski A, 2005, ENDOCRINOLOGY, V146, P1245, DOI 10.1210/en.2004-0733; Slominski A, 2004, EUR J BIOCHEM, V271, P4178, DOI 10.1111/j.1432-1033.2004.04356.x; Slominski A, 1998, J CLIN ENDOCR METAB, V83, P1020, DOI 10.1210/jc.83.3.1020; Slominski A, 1996, INT J DERMATOL, V35, P849, DOI 10.1111/j.1365-4362.1996.tb05049.x; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2005, J INVEST DERMATOL, V124, P13, DOI 10.1111/j.0022-202X.2004.23528.x; SLOMINSKI A, 1995, FEBS LETT, V374, P113, DOI 10.1016/0014-5793(95)01090-2; Slominski A, 2002, J INVEST DERMATOL, V119, P1449, DOI 10.1046/j.1523-1747.2002.19617.x; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2004, ENDOCRINOLOGY, V145, P941, DOI 10.1210/en.2003-0851; Slominski A, 2005, J NEUROIMMUNOL, V162, P97, DOI 10.1016/j.jneuroim.2005.01.014; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; Slominski A, 2006, J CELL PHYSIOL, V206, P780, DOI 10.1002/jcp.20530; SLOMINSKI A, 2005, IN PRESS DERMATOLOGY; Slominski AT, 2000, IN VITRO CELL DEV-AN, V36, P211; Slominski AT, 1999, ANN NY ACAD SCI, V885, P287; Tobin DJ, 2001, EXP GERONTOL, V36, P29, DOI 10.1016/S0531-5565(00)00210-2; TOBIN DJ, 1995, J INVEST DERMATOL, V104, P86, DOI 10.1111/1523-1747.ep12613573; Tobin DJ, 1996, PIGM CELL RES, V9, P304, DOI 10.1111/j.1600-0749.1996.tb00122.x; Tobin DJ, 2003, J INVEST DERMATOL, V120, P895, DOI 10.1046/j.1523-1747.2003.12237.x; Tobin DJ, 2003, J INVEST DERM SYMP P, V8, P80, DOI 10.1046/j.1523-1747.2003.12177.x; TOBIN DJ, 2004, HAIR NAIL SKIN, P319; VENNEGOOR C, 1988, AM J PATHOL, V130, P179; Wei ET, 1998, PEPTIDES, V19, P1183, DOI 10.1016/S0196-9781(98)00085-0; Wiesner B, 2003, J CELL SCI, V116, P1261, DOI 10.1242/jcs.00301; Wille S, 1999, J NEUROCHEM, V72, P388, DOI 10.1046/j.1471-4159.1999.0720388.x; Zbytek B, 2005, BRIT J DERMATOL, V152, P474, DOI 10.1111/J.1365-2133.2005.06217.X; Zbytek B, 2005, J CELL PHYSIOL, V203, P118, DOI 10.1002/jcp.20209; Zouboulis CC, 2002, P NATL ACAD SCI USA, V99, P7148, DOI 10.1073/pnas.102180999	65	39	44	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					882	895		10.1096/fj.05-5257com	http://dx.doi.org/10.1096/fj.05-5257com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675846	Green Accepted			2022-12-28	WOS:000240157700011
J	Bloch, I; Quintana, FJ; Gerber, D; Cohen, T; Cohen, IR; Shai, Y				Bloch, Itai; Quintana, Francisco J.; Gerber, Doron; Cohen, Tomer; Cohen, Irun R.; Shai, Yechiel			T-Cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif	FASEB JOURNAL			English	Article						membrane proteins; protein-membrane interaction; peptide-membrane interaction; transmembrane domain; recognition within membranes	TERMINAL HEPTAD REPEAT; TRANSFORM INFRARED-SPECTROSCOPY; FUSION PEPTIDE; MEMBRANE-FUSION; DC-SIGN; UNILAMELLAR VESICLES; RECEPTOR-CD3 COMPLEX; ADJUVANT ARTHRITIS; HELIX INTERACTIONS; ENVELOPE PROTEIN	Fusion peptide (FP) of the HIV gp41 molecule inserts into the T cell membrane during virus-cell fusion. FP also blocks the TCR/CD3 interaction needed for antigen-triggered T cell activation. Here we used in vitro (fluorescence and immunoprecipitation), in vivo (T cell mediated autoinumme disease adjuvant arthritis), and in silico methods to identify the FP-TCR novel interaction motif: the alpha-helical transmembrane domain (TMD) of the TCR alpha chain, and the beta-sheet 5-13 region of the 16 N-terminal aa of FP (FP1-16). Deciphering the molecular mechanism of the immunosuppressive activity of FP provides a new potential target to overcome the immunosuppressant activity of HIV, and in addition a tool for down-regulating immune mediated inflammation.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	yechiel.shai@weizmann.ac.il	Quintana, Francisco Javier/AAB-6915-2020; Cohen, Irun R/B-3542-2009; Cohen, Tomer/HIR-6215-2022					Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; Agirre A, 2000, BBA-BIOMEMBRANES, V1467, P153, DOI 10.1016/S0005-2736(00)00214-5; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Call ME, 2004, EMBO J, V23, P2348, DOI 10.1038/sj.emboj.7600245; Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Chang DK, 1997, J VIROL, V71, P6593, DOI 10.1128/JVI.71.9.6593-6602.1997; Chang DK, 1997, EUR J BIOCHEM, V247, P896, DOI 10.1111/j.1432-1033.1997.00896.x; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Epand RM, 2003, BBA-BIOMEMBRANES, V1614, P116, DOI 10.1016/S0005-2736(03)00169-X; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; Garcia E, 2005, TRAFFIC, V6, P488, DOI 10.1111/j.1600-0854.2005.00293.x; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Gerber D, 2005, FASEB J, V19, P1190, DOI 10.1096/fj.04-3498fje; Gordon LM, 2002, BBA-BIOMEMBRANES, V1559, P96, DOI 10.1016/S0005-2736(01)00443-6; Gordon LM, 2004, PROTEIN SCI, V13, P1012, DOI 10.1110/ps.03407704; GORDON SM, 1992, J EXPO ANAL ENV EP S, V1, P41; Gorfe AA, 2004, J AM CHEM SOC, V126, P15277, DOI 10.1021/ja046607n; HAYNES BF, 1993, J EXP MED, V177, P717, DOI 10.1084/jem.177.3.717; Johnson WE, 2002, ANNU REV MED, V53, P499, DOI 10.1146/annurev.med.53.082901.104053; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; Kliger Y, 2000, J MOL BIOL, V301, P905, DOI 10.1006/jmbi.2000.4004; Kucerka N, 2005, BIOPHYS J, V88, P2626, DOI 10.1529/biophysj.104.056606; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Manolios N, 1997, NAT MED, V3, P84, DOI 10.1038/nm0197-84; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; Mobley PW, 1999, BBA-BIOMEMBRANES, V1418, P1, DOI 10.1016/S0005-2736(99)00014-0; Nagle JF, 2000, CURR OPIN STRUC BIOL, V10, P474, DOI 10.1016/S0959-440X(00)00117-2; Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2; Peisajovich SG, 2000, BIOCHEMISTRY-US, V39, P1826, DOI 10.1021/bi991887i; Peisajovich SG, 2002, TRENDS BIOCHEM SCI, V27, P183, DOI 10.1016/S0968-0004(01)02050-3; Peisajovich SG, 2003, BBA-BIOMEMBRANES, V1614, P122, DOI 10.1016/S0005-2736(03)00170-6; Petrache HI, 1998, CHEM PHYS LIPIDS, V95, P83, DOI 10.1016/S0009-3084(98)00068-1; Petrache HI, 2000, BIOPHYS J, V79, P3172, DOI 10.1016/S0006-3495(00)76551-9; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Quintana FJ, 2005, J CLIN INVEST, V115, P2149, DOI 10.1172/JCI23956; Quintana FJ, 2003, J IMMUNOL, V171, P3533, DOI 10.4049/jimmunol.171.7.3533; Quintana FJ, 2002, J IMMUNOL, V169, P3422, DOI 10.4049/jimmunol.169.6.3422; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; Sackett K, 2002, BIOCHEMISTRY-US, V41, P4678, DOI 10.1021/bi0255322; Sackett K, 2005, J MOL BIOL, V350, P790, DOI 10.1016/j.jmb.2005.05.030; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; SLEPUSHKIN VA, 1992, AIDS RES HUM RETROV, V8, P9, DOI 10.1089/aid.1992.8.9; Sugaya M, 2004, J IMMUNOL, V172, P2219, DOI 10.4049/jimmunol.172.4.2219; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; Wexler-Cohen Y, 2005, BIOCHEMISTRY-US, V44, P5853, DOI 10.1021/bi047666g; Woods TC, 1997, BLOOD, V89, P1635, DOI 10.1182/blood.V89.5.1635.1635_1635_1641; Yang J, 2001, BIOCHEMISTRY-US, V40, P8126, DOI 10.1021/bi0100283; Yang J, 2001, J MOL GRAPH MODEL, V19, P129, DOI 10.1016/S1093-3263(00)00128-5	53	35	41	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					393	401		10.1096/fj.06-7061com	http://dx.doi.org/10.1096/fj.06-7061com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17185749				2022-12-28	WOS:000244686300013
J	Knauer, SK; Kramer, OH; Knosel, T; Engels, K; Rodel, F; Kovacs, AF; Dietmaier, W; Klein-Hitpass, L; Habtemichael, N; Schweitzer, A; Brieger, J; Rodel, C; Mann, W; Petersen, I; Heinzel, T; Stauber, RH				Knauer, Shirley K.; Kraemer, Oliver H.; Knoesel, Thomas; Engels, Knut; Roedel, Franz; Kovacs, Adorjan F.; Dietmaier, Wolfgang; Klein-Hitpass, Ludger; Habtemichael, Negusse; Schweitzer, Andrea; Brieger, Juergen; Roedel, Claus; Mann, Wolf; Petersen, Iver; Heinzel, Thorsten; Stauber, Roland H.			Nuclear export is essential for the tumor-promoting activity of survivin	FASEB JOURNAL			English	Article						nucleocytoplasmic transport; apoptosis; Crm1; head and neck cancer; colorectal cancer; cancer therapy; LMB; cisplatin; valproic acid; HDAC	NUCLEOCYTOPLASMIC TRANSPORT; CYTOPLASMIC EXPRESSION; CANCER; APOPTOSIS; LOCALIZATION; PROTEINS; PHOSPHORYLATION; INDUCTION; PATHWAYS; BINDING	Survivin appears to function as an apoptosis inhibitor and a regulator of cell division during development and tumorigenesis. Here we report the molecular characterization of the nucleocytoplasmic transport of survivin and its potential implications for tumorigenesis. We identified an evolutionary conserved Crm1-dependent nuclear export signal (NES) in survivin. In dividing cells, the NES is essential for tethering survivin and the survivin/Aurora-B kinase complex to the mitotic machinery, which in turn appears to be essential for proper cell division. In addition, export seems to be required for the cytoprotective activity of survivin, as export-deficient survivin fails to protect tumor cells against chemo- and radiotherapy-induced apoptosis. These findings appear to be clinically relevant since preferential nuclear localization of survivin correlated with enhanced survival in colorectal cancer patients. Targeting survivin's nuclear export by the application of NES-specific antibodies promoted its nuclear accumulation and inhibited its cytoprotective function. We demonstrate that nuclear export is essential for the biological activity of survivin and promote the identification of molecular decoys to specifically interfere with survivin's nuclear export as potential anticancer therapeutics.	Georg Speyer Haus Inst Biomed Res, D-60596 Frankfurt, Germany; Univ Jena, Inst Biochem & Biophys, D-6900 Jena, Germany; Humboldt Univ, Charite CCM, Fac Med, Inst Pathol, D-1086 Berlin, Germany; Univ Hosp Frankfurt, Dept Pathol, Frankfurt, Germany; Univ Erlangen Nurnberg, Dept Radiat Oncol, D-8520 Erlangen, Germany; Univ Regensburg, Inst Pathol, D-8400 Regensburg, Germany; Univ Hosp Essen, Inst Cell Biol, Essen, Germany; Univ Hosp Mainz, Dept Otorhinolaryngol, Mainz, Germany	Friedrich Schiller University of Jena; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Erlangen Nuremberg; University of Regensburg; University of Duisburg Essen; University Hospital Mainz	Stauber, RH (corresponding author), Georg Speyer Haus Inst Biomed Res, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	stauber@em.uni-frankfurt.de	Krämer, Oliver H/L-9266-2015; Heinzel, Thorsten/B-1013-2015; Knauer, Shirley K/E-7931-2012	Krämer, Oliver H/0000-0003-3973-045X; Knauer, Shirley K/0000-0003-4321-0924; Stauber, Roland/0000-0002-1341-4523				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Arnaoutov A, 2005, NAT CELL BIOL, V7, P626, DOI 10.1038/ncb1263; Blanc-Brude OP, 2003, CLIN CANCER RES, V9, P2683; Bug G, 2005, CANCER, V104, P2717, DOI 10.1002/cncr.21589; Chakravarti A, 2004, ONCOGENE, V23, P7494, DOI 10.1038/sj.onc.1208049; Dalken B, 2006, CELL DEATH DIFFER, V13, P576, DOI 10.1038/sj.cdd.4401773; Dohi T, 2005, CELL CYCLE, V4, P21, DOI 10.4161/cc.4.1.1367; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Ferrandina G, 2005, BRIT J CANCER, V92, P271, DOI 10.1038/sj.bjc.6602332; Ferrando-May E, 2005, CELL DEATH DIFFER, V12, P1263, DOI 10.1038/sj.cdd.4401626; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Grabowski P, 2005, NEUROENDOCRINOLOGY, V81, P1, DOI 10.1159/000084892; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heger P, 2001, TRAFFIC, V2, P544, DOI 10.1034/j.1600-0854.2001.20804.x; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Kennedy SM, 2003, BRIT J CANCER, V88, P1077, DOI 10.1038/sj.bjc.6600776; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Knauer SK, 2005, TRAFFIC, V6, P594, DOI 10.1111/j.1600-0854.2005.00298.x; Knauer SK, 2005, MOL CELL BIOL, V25, P2573, DOI 10.1128/MCB.25.7.2573-2582.2005; Knosel T, 2004, DIS COLON RECTUM, V47, P70, DOI 10.1007/s10350-003-0008-7; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Li F, 2005, BRIT J CANCER, V92, P212, DOI 10.1038/sj.bjc.6602340; Li FZ, 2005, INT J CANCER, V114, P509, DOI 10.1002/ijc.20768; Maiato H, 2004, J CELL SCI, V117, P5461, DOI 10.1242/jcs.01536; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Rodel F, 2005, CANCER RES, V65, P4881, DOI 10.1158/0008-5472.CAN-04-3028; Rodriguez JA, 2002, EXP CELL RES, V275, P44, DOI 10.1006/excr.2002.5492; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schlingemann J, 2005, LAB INVEST, V85, P1024, DOI 10.1038/labinvest.3700293; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Shinohara ET, 2005, CANCER-AM CANCER SOC, V103, P1685, DOI 10.1002/cncr.20951; Stauber RH, 1998, VIROLOGY, V251, P38, DOI 10.1006/viro.1998.9295; Sun CH, 2005, BIOCHEMISTRY-US, V44, P11, DOI 10.1021/bi0485171; Tonini G, 2005, BRIT J CANCER, V92, P2225, DOI 10.1038/sj.bjc.6602632; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Vischioni B, 2004, ANN ONCOL, V15, P1654, DOI 10.1093/annonc/mdh436; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wheatley SP, 2004, J BIOL CHEM, V279, P5655, DOI 10.1074/jbc.M311299200; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331	42	110	114	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					207	216		10.1096/fj.06-5741com	http://dx.doi.org/10.1096/fj.06-5741com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17099069				2022-12-28	WOS:000243130200022
J	Landi, S; Sale, A; Berardi, N; Viegi, A; Maffei, L; Cenni, MC				Landi, S.; Sale, A.; Berardi, N.; Viegi, A.; Maffei, L.; Cenni, M. C.			Retinal functional development is sensitive to environmental enrichment: a role for BDNF	FASEB JOURNAL			English	Article						retina; visual acuity; pattern electroretinogram; brain derived neurotrophic factor	NEUROTROPHIC FACTOR; GANGLION-CELLS; VISUAL EXPERIENCE; AMACRINE CELLS; POSTNATAL-DEVELOPMENT; RECEPTOR TRKB; INNER RETINA; SECTION; SYSTEM; OLIGONUCLEOTIDES	Retina has long been considered less plastic than cortex or hippocampus, the very sites of experience-dependent plasticity. Now, we show that retinal development is responsive to the experience provided by an enriched environment ( EE): the maturation of retinal acuity, which is a sensitive index of retinal circuitry development, is strongly accelerated in EE rats. This effect is present also in rats exposed to EE up to P10, that is before eye opening, suggesting that factors sufficient to trigger retinal acuity development are affected by EE during the first days of life. Brain derived neurotrophic factor ( BDNF) is precociously expressed in the ganglion cell layer of EE with respect to non-EE rats and reduction of BDNF expression in EE animals counteracts EE effects on retinal acuity. Thus, EE controls the development of retinal circuitry, and this action depends on retinal BDNF expression.	CNR, Ist Neurosci, Scuola Normale Super Pisa, I-56100 Pisa, Italy; Scuola Normale Super Pisa, Neurobiol Lab, Pisa, Italy; Univ Florence, Dipartimento Psicol, Florence, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR); Scuola Normale Superiore di Pisa; Scuola Normale Superiore di Pisa; University of Florence	Landi, S (corresponding author), CNR, Ist Neurosci, Scuola Normale Super Pisa, Via G Moruzzi 1, I-56100 Pisa, Italy.	landi@in.cnr.it	Landi, Silvia/P-9418-2018; Sale, Alessandro/K-7760-2016	Landi, Silvia/0000-0001-7999-3452; Sale, Alessandro/0000-0001-7608-4456				Alter J, 2006, NAT MED, V12, P175, DOI 10.1038/nm1345; BARO JA, 1990, INVEST OPHTH VIS SCI, V31, P1405; Bartoletti A, 2004, NAT NEUROSCI, V7, P215, DOI 10.1038/nn1201; BERARDI N, 1990, EXP BRAIN RES, V79, P539; Cancedda L, 2004, J NEUROSCI, V24, P4840, DOI 10.1523/JNEUROSCI.0845-04.2004; Cellerino A, 1999, EUR J NEUROSCI, V11, P2824, DOI 10.1046/j.1460-9568.1999.00690.x; Cellerino A, 2003, J COMP NEUROL, V467, P97, DOI 10.1002/cne.10908; Cellerino A, 1998, J NEUROSCI, V18, P3351; Cellerino A, 1997, J COMP NEUROL, V386, P149; Cohen-Cory S, 2004, INT J DEV BIOL, V48, P947, DOI 10.1387/ijdb.041883sc; Contini M, 2003, P NATL ACAD SCI USA, V100, P1358, DOI 10.1073/pnas.0337681100; Cook PB, 1998, J NEUROPHYSIOL, V79, P197, DOI 10.1152/jn.1998.79.1.197; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Di Cristo G, 2001, SCIENCE, V292, P2337, DOI 10.1126/science.1059075; Di Polo A, 2000, INVEST OPHTH VIS SCI, V41, P4014; DOMENICI L, 1991, EXP BRAIN RES, V86, P579; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; Fine I, 2003, NAT NEUROSCI, V6, P915, DOI 10.1038/nn1102; Flores-Herr N, 2001, J NEUROSCI, V21, P4852, DOI 10.1523/JNEUROSCI.21-13-04852.2001; Galli-Resta L, 2002, DEVELOPMENT, V129, P3803; Garrett KL, 2001, J GENE MED, V3, P373, DOI 10.1002/jgm.197; Gianfranceschi L, 2003, P NATL ACAD SCI USA, V100, P12486, DOI 10.1073/pnas.1934836100; Gomez-Pinilla F, 2002, J NEUROPHYSIOL, V88, P2187, DOI 10.1152/jn.00152.2002; Haverkamp S, 2000, J COMP NEUROL, V424, P1; Hu B, 2005, DEVELOPMENT, V132, P4285, DOI 10.1242/dev.02017; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; JENSEN RJ, 1986, NEUROSCIENCE, V17, P837, DOI 10.1016/0306-4522(86)90049-7; Ladewig T, 2004, NEUROREPORT, V15, P2495, DOI 10.1097/00001756-200411150-00013; Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702; Lom B, 2002, J NEUROSCI, V22, P7639; Lom B, 1999, J NEUROSCI, V19, P9928; Ma YT, 1998, J NEUROSCI, V18, P2097; MAFFEI L, 1981, SCIENCE, V211, P953, DOI 10.1126/science.7466368; Mandolesi G, 2005, CURR BIOL, V15, P2119, DOI 10.1016/j.cub.2005.10.045; Masland RH, 2005, TRENDS NEUROSCI, V28, P395, DOI 10.1016/j.tins.2005.06.002; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; Menna E, 2003, MOL CELL NEUROSCI, V24, P972, DOI 10.1016/S1044-7431(03)00258-6; Munakata Y, 2004, TRENDS COGN SCI, V8, P122, DOI 10.1016/j.tics.2004.01.005; OKOJE G, 2003, J NEUROSCI, V23, P4164; OMALLEY DM, 1992, J NEUROSCI, V12, P1394; PAXINOS G, 1986, RAT STEREOTAXIC BRAI; Pham TM, 2002, PHARMACOL BIOCHEM BE, V73, P167, DOI 10.1016/S0091-3057(02)00783-9; Pollock GS, 2001, J NEUROSCI, V21, P3923, DOI 10.1523/JNEUROSCI.21-11-03923.2001; PURVES D, 1988, NATURE, V336, P123, DOI 10.1038/336123a0; Rohrer B, 1999, J NEUROSCI, V19, P8919, DOI 10.1523/JNEUROSCI.19-20-08919.1999; Rossi FM, 2001, P NATL ACAD SCI USA, V98, P6453, DOI 10.1073/pnas.101120998; Rothe T, 1999, J NEUROBIOL, V40, P407, DOI 10.1002/(SICI)1097-4695(19990905)40:3<407::AID-NEU12>3.0.CO;2-T; RUSOFF AC, 1978, INVEST OPHTH VIS SCI, V17, P819; Sale A, 2004, NEUROPHARMACOLOGY, V47, P649, DOI 10.1016/j.neuropharm.2004.07.008; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; Seki M, 2003, INVEST OPHTH VIS SCI, V44, P3211, DOI 10.1167/iovs.02-1089; Sernagor E, 2001, J ANAT, V199, P375, DOI 10.1046/j.1469-7580.2001.19940375.x; Sinclair JR, 2004, J NEUROSCI, V24, P1459, DOI 10.1523/JNEUROSCI.3959-03.2004; Taylor WR, 1999, VISUAL NEUROSCI, V16, P285, DOI 10.1017/S0952523899162096; Thaler S, 2006, MOL VIS, V12, P100; Tian N, 2003, NEURON, V39, P85, DOI 10.1016/S0896-6273(03)00389-1; Tian N, 2001, NEURON, V32, P439, DOI 10.1016/S0896-6273(01)00470-6; Vecino E, 2002, VISION RES, V42, P151, DOI 10.1016/S0042-6989(01)00251-6; Vistamehr S, 2004, VISUAL NEUROSCI, V21, P23, DOI 10.1017/S0952523804041033; Vorwerk CK, 2000, INVEST OPHTH VIS SCI, V41, P3615; Witkovsky P, 2004, DOC OPHTHALMOL, V108, P17, DOI 10.1023/B:DOOP.0000019487.88486.0a; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000	62	73	75	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					130	139		10.1096/fj.06-6083com	http://dx.doi.org/10.1096/fj.06-6083com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135370				2022-12-28	WOS:000243130200015
J	Chen, ZL; Deddish, PA; Minshall, RD; Becker, RP; Erdos, EG; Tan, FL				Chen, Zhenlong; Deddish, Peter A.; Minshall, Richard D.; Becker, Robert P.; Erdos, Ervin G.; Tan, Fulong			Human ACE and bradykinin B-2 receptors form a complex at the plasma membrane	FASEB JOURNAL			English	Article						oligomer; FRET; converting enzyme; peptide receptors; kinins	ANGIOTENSIN-CONVERTING-ENZYME; CARDIOVASCULAR EVENTS; INHIBITORS; POTENTIATION; RESENSITIZATION; TRAFFICKING; CONTRIBUTES; HYDROLYSIS; ACTIVATION; KININASE	To investigate how angiotensin I-converting enzyme ( ACE) inhibitors enhance the actions of bradykinin (BK) on B-2 receptors independent of blocking BK inactivation, we expressed human somatic ACE and B-2 receptors in CHO cells. Bradykinin and its ACE-resistant analog were the receptor agonists. B-2 fused with green fluorescent protein (GFP) and ACE were coprecipitated with antisera to GFP or ACE shown in Western blots. Immunohistochemistry of fixed cells localized ACE by red color and B-2-GFP by green. Yellow on plasma membranes of coexpressing cells also indicated enzyme-receptor complex formation. Using ACE-fused cyan fluorescent protein donor and B-2-fused yellow fluorescent protein (YFP) acceptor, we registered fluorescence resonance energy transfer (FRET) by the enhanced fluorescence of donor on acceptor photobleaching, establishing close (within 10 nm) positions of B-2 receptors and ACE. Bradykinin stimulation cointernalized ACE and B-2 receptors. We expressed ACE fused to N terminus of B-2 receptors, anchoring only receptors to plasma membranes. Here, in contrast to cells, where both ACE and B-2 receptors are separately anchored, ACE inhibitors neither enhance activation of chimeric B-2 nor resensitize desensitized B-2 receptors. Heterodimer formation between ACE and B-2 receptors can be a mechanism for ACE inhibitors to augment kinin activity at cellular level.	Univ Illinois, Coll Med, Dept Pharmacol, Lab Peptide Res, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Anat & Cell Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Erdos, EG (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, Lab Peptide Res, MC 868,835 S Wolcott Rm E403, Chicago, IL 60612 USA.	egerdos@uic.edu	Chen, Zhenlong/AAQ-9578-2021		NHLBI NIH HHS [R01 HL036473, HL68580, R01 HL068580, HL36473] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068580, R37HL036473, R01HL036473] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUCHSCHWELK W, 1993, CARDIOVASC RES, V27, P312, DOI 10.1093/cvr/27.2.312; Barbe F, 1996, AM J PHYSIOL-HEART C, V270, pH1985, DOI 10.1152/ajpheart.1996.270.6.H1985; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; BERALDO WT, 1997, KININ SYSTEM, P1; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bosch J, 2005, CIRCULATION, V112, P1339, DOI 10.1161/CIRCULATIONAHA.105.548461; Changeux JP, 2005, SCIENCE, V308, P1424, DOI 10.1126/science.1108595; Chen ZL, 2005, HYPERTENSION, V46, P1368, DOI 10.1161/01.HYP.0000188905.20884.63; Corvol P., 2004, HDB PROTEOLYTIC ENZY, V1, P332, DOI DOI 10.1016/B978-0-12-079611-3.50090-2; Couture R, 2004, EUR J PHARMACOL, V500, P467, DOI 10.1016/j.ejphar.2004.07.045; Cruden NLM, 2004, ARTERIOSCL THROM VAS, V24, P1043, DOI 10.1161/01.ATV.0000129331.21092.1d; Deddish PA, 1997, BIOCHEM PHARMACOL, V53, P1459, DOI 10.1016/S0006-2952(97)00087-7; Deddish PA, 2002, HYPERTENSION, V39, P619, DOI 10.1161/hy0202.103298; ERDOS EG, 1983, CLIN EXP HYPERTENS A, V5, P1251, DOI 10.3109/10641968309048855; Erdos EG, 1999, TRENDS ENDOCRIN MET, V10, P223, DOI 10.1016/S1043-2760(99)00156-3; Erdos EG, 1997, KININ SYSTEM, P111; Ferreira S.H., 1966, HYPOTENSIVE PEPTIDES, P356; Frohlich ED, 2006, LOCAL CARDIAC RENIN, P1; GAVRAS H, 1978, CIRCULATION, V58, P770, DOI 10.1161/01.CIR.58.5.770; Herrick-Davis K, 2004, BIOCHEMISTRY-US, V43, P13963, DOI 10.1021/bi048398p; Hornig B, 1997, CIRCULATION, V95, P1115; Ignjatovic T, 2004, MOL PHARMACOL, V66, P1310, DOI 10.1124/mol.104.001990; Ignjatovic T, 2002, J BIOL CHEM, V277, P16847, DOI 10.1074/jbc.M200355200; JASPARD E, 1993, J BIOL CHEM, V268, P9496; Kohlstedt K, 2005, HYPERTENSION, V45, P126, DOI 10.1161/01.HYP.0000150159.48992.11; Marcic B, 2000, J BIOL CHEM, V275, P16110, DOI 10.1074/jbc.M909490199; Marcic B, 1999, HYPERTENSION, V33, P835, DOI 10.1161/01.HYP.33.3.835; Marcic BM, 2000, J PHARMACOL EXP THER, V294, P605; Marianayagam NJ, 2004, TRENDS BIOCHEM SCI, V29, P618, DOI 10.1016/j.tibs.2004.09.006; Minshall RD, 1997, CIRC RES, V81, P848; Mueller S, 2005, PEPTIDES, V26, P1235, DOI 10.1016/j.peptides.2005.03.046; PAGE IH, 1998, HYPERTENSION RES MEM, P1; Peng HM, 2005, CIRCULATION, V112, P2436, DOI 10.1161/CIRCULATIONAHA.104.528695; PFEFFER M, 2001, ANGIOTENSIN CONVERTI, P219; Pfeiffer M, 2003, J BIOL CHEM, V278, P51630, DOI 10.1074/jbc.M307095200; RUBIN B, 1978, J PHARMACOL EXP THER, V204, P271; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; SIEGEL RM, 2000, SCI STKE, pPL1; Skidgel R.A., 1993, RENIN ANGIOTENSIN SY, V1, DOI DOI 10.1-10.10; Solomon SD, 2005, AM HEART J, V150, P257, DOI 10.1016/j.ahj.2004.09.056; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; Stanisavljevic S, 2006, J PHARMACOL EXP THER, V316, P1153, DOI 10.1124/jpet.105.093849; Tschope C, 2002, J CARDIOVASC PHARM, V39, P478, DOI 10.1097/00005344-200204000-00003; Valentin G, 2005, NAT METHODS, V2, P801, DOI 10.1038/nmeth1105-801; VOGEL R, 1970, Z KLIN CHEM KLIN BIO, V8, P177; WEBSTER ME, 1970, HDB EXPERIMENTAL PHA, V25, P131; Werle E., 1970, HDB EXPT PHARM, V25, P1; Witherow FN, 2001, CIRCULATION, V104, P2177, DOI 10.1161/hc4301.098252; YANG HYT, 1967, NATURE, V215, P1402, DOI 10.1038/2151402a0; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6; Yusuf S, 2000, NEW ENGL J MED, V342, P145	51	35	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2261	2270		10.1096/fj.06-6113com	http://dx.doi.org/10.1096/fj.06-6113com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077303	Green Accepted			2022-12-28	WOS:000241702600011
J	Kane, GC; Lam, CF; O'Cochlain, F; Hodgson, DM; Reyes, S; Liu, XK; Miki, T; Seino, S; Katusic, ZS; Terzic, A				Kane, Garvan C.; Lam, Chen-Fuh; O'Cochlain, Fearghas; Hodgson, Denice M.; Reyes, Santiago; Liu, Xiao-Ke; Miki, Takashi; Seino, Susumu; Katusic, Zvonimir S.; Terzic, Andre			Gene knockout of the KCNJ8-encoded Kir6.1 K-ATP channel imparts fatal susceptibility to endotoxemia	FASEB JOURNAL			English	Article						ATP-sensitive K+ channel; Kir6.1; metabolism; sepsis; septic shock; vasodilation	HEART-FAILURE; POTASSIUM CHANNELS; ENERGETIC SIGNALS; BLOOD-FLOW; ADENOSINE; SEPSIS; STRESS; CARDIOMYOPATHY; HYPOTENSION; ADAPTATION	Sepsis, the systemic inflammatory response to infection, imposes a high demand for bodily adaptation, with the cardiovascular response a key determinant of outcome. The homeostatic elements that secure cardiac tolerance in the setting of the sepsis syndrome are poorly understood. Here, in a model of acute septic shock induced by endotoxin challenge with Escherichia coli lipopolysaccharide (LPS), knockout of the KCNJ8 gene encoding the vascular Kir6.1 KATP channel pore predisposed to an early and profound survival disadvantage. The exaggerated susceptibility provoked by disruption of this stress- responsive sensor of cellular metabolism was linked to progressive deterioration in cardiac activity, ischemic myocardial damage, and contractile dysfunction. Deletion of KCNJ8 blunted the responsiveness of coronary vessels to cytokine- or metabolic-mediated vasodilation necessary to support myocardial perfusion in the wild-type (WT), creating a deficit in adaptive response in the Kir6.1 knockout. Application of a KATP channel opener drug improved survival in the endotoxic WT but had no effect in the Kir6.1 knockout. Restoration of the dilatory capacity of coronary vessels was required to rescue the Kir6.1 knockout phenotype and reverse survival disadvantage in lethal endotoxemia. Thus, the Kir6.1-containing KATP channel, by coupling vasoreactivity with metabolic demand, provides a vital feedback element for cardiovascular tolerance in endotoxic shock.	Mayo Clin & Mayo Fdn, Coll Med, Dept Med, Div Cardiovasc Dis,Marriott Heart Dis Res Program, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Anesthesiol, Rochester, MN 55905 USA; Kobe Univ, Grad Sch Med, Div Cellular & Mol Med, Kobe, Hyogo 657, Japan	Mayo Clinic; Mayo Clinic; Mayo Clinic; Kobe University	Terzic, A (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Med, Div Cardiovasc Dis,Marriott Heart Dis Res Program, 200 1st St SW, Rochester, MN 55905 USA.	terzic.andre@mayo.edu	MIKI, Takashi/ABD-3995-2020	MIKI, Takashi/0000-0001-5741-1626; Liu, Xiaoke/0000-0003-4782-0957				Abraham MR, 2002, J BIOL CHEM, V277, P24427, DOI 10.1074/jbc.M201777200; Alekseev AE, 2005, J MOL CELL CARDIOL, V38, P895, DOI 10.1016/j.yjmcc.2005.02.022; Ammann P, 2003, J AM COLL CARDIOL, V41, P2004, DOI 10.1016/S0735-1097(03)00421-2; Ashcroft FM, 2005, J CLIN INVEST, V115, P2047, DOI 10.1172/JCI25495; AVONTUUR JAM, 1995, CIRC RES, V76, P418, DOI 10.1161/01.RES.76.3.418; Bell J, 2004, NATURE, V429, P453, DOI 10.1038/nature02624; BERNE RM, 1964, PHYSIOL REV, V44, P1, DOI 10.1152/physrev.1964.44.1.1; Bienengraeber M, 2004, NAT GENET, V36, P382, DOI 10.1038/ng1329; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; Chutkow WA, 2002, J CLIN INVEST, V110, P203, DOI 10.1172/JCI200215672; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; CUNNION RE, 1986, CIRCULATION, V73, P637, DOI 10.1161/01.CIR.73.4.637; d'Uscio LV, 2001, ARTERIOSCL THROM VAS, V21, P1017, DOI 10.1161/01.ATV.21.6.1017; DAUT J, 1990, SCIENCE, V247, P1341, DOI 10.1126/science.2107575; Grandel U, 2001, CRIT CARE MED, V29, P1, DOI 10.1097/00003246-200101000-00001; GROENEVELD ABJ, 1991, CARDIOVASC RES, V25, P80, DOI 10.1093/cvr/25.1.80; Gumina RJ, 2003, AM J PHYSIOL-HEART C, V284, pH2106, DOI 10.1152/ajpheart.00057.2003; Hodgson DM, 2003, EMBO J, V22, P1732, DOI 10.1093/emboj/cdg192; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Ismail JA, 1998, AM J PHYSIOL-HEART C, V275, pH8, DOI 10.1152/ajpheart.1998.275.1.H8; Jahangir A, 2005, J MOL CELL CARDIOL, V39, P99, DOI 10.1016/j.yjmcc.2005.04.006; Kane GC, 2006, HUM MOL GENET, V15, P2285, DOI 10.1093/hmg/ddl154; Kane GC, 2005, J MOL CELL CARDIOL, V38, P937, DOI 10.1016/j.yjmcc.2005.02.026; KANE GC, 2004, DIABETES, V53, pS168; Landry DW, 2001, NEW ENGL J MED, V345, P588, DOI 10.1056/NEJMra002709; LANDRY DW, 1992, J CLIN INVEST, V89, P2071, DOI 10.1172/JCI115820; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mann DL, 2003, ANNU REV PHYSIOL, V65, P81, DOI 10.1146/annurev.physiol.65.092101.142249; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x; Miki T, 2002, NAT MED, V8, P466, DOI 10.1038/nm0502-466; Miki T, 2005, J MOL CELL CARDIOL, V38, P917, DOI 10.1016/j.yjmcc.2004.11.019; Motew SJ, 1997, SHOCK, V7, P439, DOI 10.1097/00024382-199706000-00009; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; Nichols CG, 2006, NATURE, V440, P470, DOI 10.1038/nature04711; O'Cochlain DF, 2004, HUM MOL GENET, V13, P2505, DOI 10.1093/hmg/ddh266; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Repunte VP, 1999, EMBO J, V18, P3317, DOI 10.1093/emboj/18.12.3317; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Selivanov VA, 2004, MOL CELL BIOCHEM, V256, P243, DOI 10.1023/B:MCBI.0000009872.35940.7d; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Suzuki M, 2001, CIRC RES, V88, P570, DOI 10.1161/01.RES.88.6.570; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; Vincent JL, 2003, INTENS CARE MED, V29, pS74; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963; Zager RA, 2006, AM J PHYSIOL-RENAL, V290, pF1453, DOI 10.1152/ajprenal.00485.2005; Zingman LV, 2003, MOL PSYCHIATR, V8, P253, DOI 10.1038/sj.mp.4001323; Zingman LV, 2002, P NATL ACAD SCI USA, V99, P13278, DOI 10.1073/pnas.212315199; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	53	65	69	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2271	2280		10.1096/fj.06-6349com	http://dx.doi.org/10.1096/fj.06-6349com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077304				2022-12-28	WOS:000241702600012
J	Armstrong, MT; Theg, SM; Braun, N; Wainwright, N; Pardy, RL; Armstrong, PB				Armstrong, Margaret T.; Theg, Steven M.; Braun, Nikolai; Wainwright, Norman; Pardy, R. L.; Armstrong, Peter B.			Histochemical evidence for lipid A (endotoxin) in eukaryote chloroplasts	FASEB JOURNAL			English	Article						lipopolysaccaride; E. coli; LALF; prokaryote	CRYSTAL-STRUCTURE; POLYMYXIN-B; BINDING; LIPOPOLYSACCHARIDE	Lipopolysaccharide (LPS) (a. k. a., endotoxin) is an essential component of the outer leaflet of the outer membrane of Gram-negative bacteria and is a potent activator of the innate immune system of animals. Lipid A, the glycolipid core of LPS, is the agent responsible for disease and death from Gram-negative sepsis, an important cause of human mortality and morbidity. Although it is generally accepted that lipid A is restricted to the prokaryotes, recent efforts to purify molecules from green algae with structural features unique to lipid A have met with success. Furthermore, the vascular plant Arabidopsis thaliana has been found to contain genes that encode all of the enzymes of the biosynthetic pathway for lipid A. It is not known whether vascular plants synthesize lipid A or where lipid A might be located in the tissues. For the present study, we used affinity reagents for lipid A to probe green alga and tissues of the garden pea for a light microscopic localization of lipid A in these eukaryote cells. We find staining for lipid A in free-living and endosymbiotic green algae and in the chloroplasts of vascular plants, indicating that this molecule is not restricted to prokaryotes, but is found also in select eukaryotes.	Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Plant Biol, Davis, CA 95616 USA; Marine Biol Lab, Woods Hole, MA 02543 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE USA	University of California System; University of California Davis; University of California System; University of California Davis; Marine Biological Laboratory - Woods Hole; University of Nebraska System; University of Nebraska Lincoln	Armstrong, PB (corresponding author), Univ Calif Davis, Dept Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	pbarmstrong@ucdavis.edu		Armstrong, Peter/0000-0001-5197-1999				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ARMSTRONG PB, 1982, EXP CELL RES, V140, P15, DOI 10.1016/0014-4827(82)90150-1; Bedick JC, 2001, NATURWISSENSCHAFTEN, V88, P482, DOI 10.1007/s00114-001-0269-8; Bedick JC, 2000, J INSECT PHYSIOL, V46, P1481, DOI 10.1016/S0022-1910(00)00073-1; BOGGS JM, 1985, BIOCHIM BIOPHYS ACTA, V816, P221, DOI 10.1016/0005-2736(85)90489-4; CLINE K, 1985, J BIOL CHEM, V260, P3691; Diks SH, 2004, CURR TOP MED CHEM, V4, P1115, DOI 10.2174/1568026043388141; Hoess A, 1995, Prog Clin Biol Res, V392, P327; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; KUBESCH P, 1987, BIOCHEMISTRY-US, V26, P2139, DOI 10.1021/bi00382a012; LEVIN J, 1988, HORSESHOE CRAB MODEL, P3; Margulis Lynn, 1970, ORIGIN EUKARYOTE CEL; MIKHEYSKAYA LV, 1977, J BACTERIOL, V130, P1; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; PETERSON AA, 1985, J BACTERIOL, V164, P1256, DOI 10.1128/JB.164.3.1256-1261.1985; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RICKLES FR, 1979, J LAB CLIN MED, V93, P128; RICKLES FR, 1977, J LAB CLIN MED, V89, P792; Ried C, 1996, J BIOL CHEM, V271, P28120, DOI 10.1074/jbc.271.45.28120; ROTH RI, 1993, TRANSFUSION, V33, P919, DOI 10.1046/j.1537-2995.1993.331194082383.x; Royce CL, 1996, J ENDOTOXIN RES, V3, P437, DOI 10.1177/096805199600300601; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; Seydel U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P195; WARREN HS, 1992, INFECT IMMUN, V60, P2506, DOI 10.1128/IAI.60.6.2506-2513.1992	26	22	22	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2145	+		10.1096/fj.05-5484fje	http://dx.doi.org/10.1096/fj.05-5484fje			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935939				2022-12-28	WOS:000241156900041
J	Cisterna, B; Necchi, D; Prosperi, E; Biggiogera, M				Cisterna, Barbara; Necchi, Daniela; Prosperi, Ennio; Biggiogera, Marco			Small ribosomal subunits associate with nuclear myosin and actin in transit to the nuclear pores	FASEB JOURNAL			English	Article						ribosomal protein S6; ultrastructural immunocytochemistry; ribosome movement; nucleocytoplasmic transport; ribosome biogenesis	RNA; TRANSCRIPTION; NUCLEOLUS; VISUALIZATION; COMPONENT; BODIES; EXPORT; SITES; CELLS; BODY	We have followed at high resolution the ribosomal protein S6 entering the nucleus of HeLa cells, stopping in some (not all) interchromatin granules clusters and reaching, via Cajal bodies, the nucleolus. There, S6 is assembled with other proteins and rRNA into small ribosomal subunit (SSU), released in the nucleoplasm, and exported through the nuclear pores. We show for the first time the spatial association of nuclear myosin I (NMI) and actin with the SSU already at the nucleolar periphery to the nuclear pore. A blockade of NMI or actin induces an upstream accumulation of the S6 protein en route to the nucleolus, and a temperature lower than normal influences RNA export. Our data strongly suggest a functional relationship of SSU with NMI and actin. In our hypothesis, an active, myosin-driven movement of the small ribosomal subunit can be responsible for the export of similar to 10% of SSUs. This hypothesis is supported by ultrastructural, immunofluorescence, and biochemical analyses. The currently accepted model for the subunit release suggests a diffusive, temperature-independent mechanism. However, the advantage of the double mechanism would assure that the movement of a part of the subunits could be modulated, increased, or decreased according to the needs of the cell at a specific moment in the cell cycle.	Univ Pavia, Dipartimento Biol Anim, Lab Biol Cellulare & Neurobiol, I-27100 Pavia, Italy; Univ Pavia, Ist Genet Mol, CNR, Sez Istochim & Citometria, I-27100 Pavia, Italy	University of Pavia; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Pavia	Biggiogera, M (corresponding author), Univ Pavia, Dipartimento Biol Anim, Lab Biol Cellulare & Neurobiol, Piazza Botta 10, I-27100 Pavia, Italy.	marcobig@unipv.it	Prosperi, Ennio/A-3439-2014; Biggiogera, Marco/AAH-3543-2019	Prosperi, Ennio/0000-0001-5391-5157; 				BERNHARD W, 1969, J ULTRA MOL STRUCT R, V27, P250, DOI 10.1016/S0022-5320(69)80016-X; BIGGIOGERA M, 1990, MOL REPROD DEV, V26, P150, DOI 10.1002/mrd.1080260209; Biggiogera M, 2001, J CELL SCI, V114, P3199; Biggiogera M, 1998, J HISTOCHEM CYTOCHEM, V46, P389, DOI 10.1177/002215549804600313; CLEVENGER CV, 1984, EXP CELL RES, V151, P194, DOI 10.1016/0014-4827(84)90368-9; Fakan S, 2004, EUR J HISTOCHEM, V48, P5; Gleizes PE, 2001, J CELL BIOL, V155, P923, DOI 10.1083/jcb.200108142; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; JEFFERIS HBJ, 1996, TRANSLATIONAL CONTRO; JIMENEZGARCIA LF, 1994, MOL BIOL CELL, V5, P955, DOI 10.1091/mbc.5.9.955; Johnson AW, 2002, TRENDS BIOCHEM SCI, V27, P580, DOI 10.1016/S0968-0004(02)02208-9; Nowak G, 1997, J BIOL CHEM, V272, P17176, DOI 10.1074/jbc.272.27.17176; Olson MOJ, 2002, INT REV CYTOL, V219, P199; Osheim YN, 2004, MOL CELL, V16, P943, DOI 10.1016/j.molcel.2004.11.031; Pestic-Dragovich L, 2000, SCIENCE, V290, P337, DOI 10.1126/science.290.5490.337; Philimonenko VV, 2004, NAT CELL BIOL, V6, P1165, DOI 10.1038/ncb1190; Platani M, 2002, NAT CELL BIOL, V4, P502, DOI 10.1038/ncb809; Politz JC, 1999, CURR BIOL, V9, P285, DOI 10.1016/S0960-9822(99)80136-5; Politz JCR, 2003, MOL BIOL CELL, V14, P4805, DOI 10.1091/mbc.E03-06-0395; PUVIONDUTILLEUL F, 1995, J CELL SCI, V108, P1143; Raska I, 2004, BIOL CELL, V96, P579, DOI 10.1016/j.biolcel.2004.04.015; Riva F, 2004, EXP CELL RES, V293, P357, DOI 10.1016/j.yexcr.2003.10.025; Saitoh N, 2004, MOL BIOL CELL, V15, P3876, DOI 10.1091/mbc.E04-03-0253; SHEA TB, 1991, BIOTECHNIQUES, V10, P288; THIRY M, 1996, NUCLEOLUS CELL CYCLE; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Tseng Y, 2004, J CELL SCI, V117, P2159, DOI 10.1242/jcs.01073; UDEM SA, 1973, J BIOL CHEM, V248, P1412	28	41	42	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1901	+		10.1096/fj.05-5278fje	http://dx.doi.org/10.1096/fj.05-5278fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877530				2022-12-28	WOS:000240267000024
J	Karpanen, T; Heckman, CA; Keskitalo, S; Jeltsch, M; Ollila, H; Neufeld, G; Tamagnone, L; Alitalo, K				Karpanen, Terhi; Heckman, Caroline A.; Keskitalo, Salla; Jeltsch, Michael; Ollila, Hanna; Neufeld, Gera; Tamagnone, Luca; Alitalo, Kari			Functional interaction of VEGF-C and VEGF-D with neuropilin receptors	FASEB JOURNAL			English	Article						lymphatic endothelial cell; VEGFR-3; NP2	ENDOTHELIAL GROWTH-FACTOR; TUMOR-CELLS; BINDING; LYMPHANGIOGENESIS; SPECIFICITY; FACTOR-2; SIGNALS; MORPHOGENESIS; INHIBITION; ANTIBODIES	Lymphatic vascular development is regulated by vascular endothelial growth factor receptor-3 (VEGFR-3), which is activated by its ligands VEGF-C and VEGF-D. Neuropilin-2 (NP2), known to be involved in neuronal development, has also been implicated to play a role in lymphangiogenesis. We aimed to elucidate the mechanism by which NP2 is involved in lymphatic endothelial cell signaling. By in vitro binding studies we found that both VEGF-C and VEGF-D interact with NP2, VEGF-C in a heparin-independent and VEGF-D in a heparin-dependent manner. We also mapped the domains of VEGF-C and NP2 required for their binding. The functional importance of the interaction of NP2 with the lymphangiogenic growth factors was demonstrated by cointernalization of NP2 along with VEGFR-3 in endocytic vesicles of lymphatic endothelial cells upon stimulation with VEGF-C or VEGF-D. NP2 also interacted with VEGFR-3 in coprecipitation studies. Our results show that NP2 is directly involved in an active signaling complex with the key regulators of lymphangiogenesis and thus suggest a mechanism by which NP2 functions in the development of the lymphatic vasculature.	Univ Helsinki, Biomedicum Helsinki, Lab Mol Canc Biol, Haartman Inst, FI-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Biomedicum Helsinki, Haartman Inst, FI-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FI-00014 Helsinki, Finland; Technion Israel Inst Technol, Dept Cell Biol & Anat, Rappaport Family Inst Res Med Sci, Haifa, Israel; Univ Turin, Sch Med, IRCC, Inst Canc Res & Treatment, Turin, Italy	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Alitalo, K (corresponding author), Univ Helsinki, Biomedicum Helsinki, Lab Mol Canc Biol, Haartman Inst, POB 63, FI-00014 Helsinki, Finland.	kari.alitalo@helsinki.fi	Tamagnone, Luca/J-8948-2018; Neufeld, Gera/F-1524-2019; Alitalo, Kari K/J-5013-2014; Ollila, Hanna M/I-8552-2017; Ollila, Hanna M/GQA-6308-2022; Jeltsch, Michael/I-5340-2012	Tamagnone, Luca/0000-0002-2884-7946; Alitalo, Kari K/0000-0002-7331-0902; Ollila, Hanna M/0000-0002-5302-6429; Ollila, Hanna M/0000-0002-5302-6429; Jeltsch, Michael/0000-0003-2890-7790; Karpanen, Terhi/0000-0002-2803-083X; Keskitalo, Salla/0000-0001-5555-1975; Heckman, Caroline/0000-0002-4324-8706	NHLBI NIH HHS [5 R01 HL075183-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075183] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Chen H, 2000, NEURON, V25, P43, DOI 10.1016/S0896-6273(00)80870-3; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Feiner L, 2001, DEVELOPMENT, V128, P3061; Fuh G, 2000, J BIOL CHEM, V275, P26690; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Giger RJ, 2000, NEURON, V25, P29, DOI 10.1016/S0896-6273(00)80869-7; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Herzog Y, 2001, MECH DEVELOP, V109, P115, DOI 10.1016/S0925-4773(01)00518-4; Jekely G, 2005, DEV CELL, V9, P197, DOI 10.1016/j.devcel.2005.06.004; Jeltsch M, 2006, J BIOL CHEM, V281, P12187, DOI 10.1074/jbc.M511593200; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Jussila L, 1998, CANCER RES, V58, P1599; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Karpanen T, 2001, CANCER RES, V61, P1786; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kessler O, 2004, CANCER RES, V64, P1008, DOI 10.1158/0008-5472.CAN-03-3090; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Moyon D, 2001, DEVELOPMENT, V128, P3359; Ober EA, 2004, EMBO REP, V5, P78, DOI 10.1038/sj.embor.7400047; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; Robinson CJ, 2001, J CELL SCI, V114, P853; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Shen JK, 2004, MOL MED, V10, P12, DOI 10.2119/2004-00017.Campochiaro; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Uutela M, 2004, BLOOD, V104, P3198, DOI 10.1182/blood-2004-04-1485; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang L, 2003, J BIOL CHEM, V278, P48848, DOI 10.1074/jbc.M310047200; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yuan L, 2002, DEVELOPMENT, V129, P4797; Zhu Z, 2003, LEUKEMIA, V17, P604, DOI 10.1038/sj.leu.2402831	53	223	241	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1462	1472		10.1096/fj.05-5646com	http://dx.doi.org/10.1096/fj.05-5646com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816121				2022-12-28	WOS:000240266000023
J	Yamaguchi, Y; Takahashi, K; Zmudzka, BZ; Kornhauser, A; Miller, SA; Tadokoro, T; Berens, W; Beer, JZ; Hearing, VJ				Yamaguchi, Yuji; Takahashi, Kaoruko; Zmudzka, Barbara Z.; Kornhauser, Andrija; Miller, Sharon A.; Tadokoro, Taketsugu; Berens, Werner; Beer, Janusz Z.; Hearing, Vincent J.			Human skin responses to UV radiation: pigment in the upper epidermis protects against DNA damage in the lower epidermis and facilitates apoptosis	FASEB JOURNAL			English	Article						pigmentation; melanocyte; melanosome; photoprotection	ULTRAVIOLET-RADIATION; MELANIN; P53; SUNBURN; PHOTOPRODUCTS; EXPRESSION; MUTATIONS; CANCER; DIMERS; REPAIR	Melanin plays an important role in protecting the skin against UV radiation, and melanomas and basal/squamous cell carcinomas occur more frequently in individuals with fair/light skin. We previously reported that levels of melanin correlate inversely with amounts of DNA damage induced by UV in normal human skin of different racial/ethnic groups. We have now separately examined DNA damage in the upper and lower epidermal layers in various types of skin before and after exposure to UV and have measured subsequent apoptosis and phosphorylation of p53. The results show that two major mechanisms underlie the increased photocarcinogenesis in fair/light skin. First, UV-induced DNA damage in the lower epidermis (including keratinocyte stem cells and melanocytes) is more effectively prevented in darker skin, suggesting that the pigmented epidermis is an efficient UV filter. Second, UV-induced apoptosis is significantly greater in darker skin, which suggests that UV-damaged cells may be removed more efficiently in pigmented epidermis. The combination of decreased DNA damage and more efficient removal of UV-damaged cells may play a critical role in the decreased photocarcinogenesis seen in individuals with darker skin.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA; US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 2132, Bethesda, MD 20892 USA.	hearingv@nih.gov	Yamaguchi, Yuji/B-9312-2008; Yamaguchi, Yuji/X-6681-2019	Yamaguchi, Yuji/0000-0003-4338-2662	Intramural NIH HHS Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; Bykov VJ, 2000, J INVEST DERMATOL, V114, P40, DOI 10.1046/j.1523-1747.2000.00821.x; Cario-Andre M, 2000, J INVEST DERMATOL, V115, P193, DOI 10.1046/j.1523-1747.2000.00007.x; English DR, 1997, CANCER CAUSE CONTROL, V8, P271, DOI 10.1023/A:1018440801577; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; HALDER RM, 1995, CANCER, V75, P667, DOI 10.1002/1097-0142(19950115)75:2+<667::AID-CNCR2820751409>3.0.CO;2-I; HALL PA, 1993, ONCOGENE, V8, P203; Hemminki K, 2002, CARCINOGENESIS, V23, P605, DOI 10.1093/carcin/23.4.605; Iyoda T, 2005, J IMMUNOL, V175, P3475, DOI 10.4049/jimmunol.175.6.3475; JOHNSON BE, 1972, NATURE-NEW BIOL, V235, P147, DOI 10.1038/newbio235147a0; Kadekaro AL, 2003, PIGM CELL RES, V16, P434, DOI 10.1034/j.1600-0749.2003.00088.x; KAIDBEY KH, 1979, J AM ACAD DERMATOL, V1, P249, DOI 10.1016/S0190-9622(79)70018-1; Kobayashi N, 1998, J INVEST DERMATOL, V110, P806, DOI 10.1046/j.1523-1747.1998.00178.x; McKay BC, 2004, P NATL ACAD SCI USA, V101, P6582, DOI 10.1073/pnas.0308181101; Moan J, 1999, PHOTOCHEM PHOTOBIOL, V70, P243, DOI 10.1111/j.1751-1097.1999.tb07995.x; Murphy G, 2001, EXP DERMATOL, V10, P155, DOI 10.1034/j.1600-0625.2001.010003155.x; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; OLSON RL, 1974, J CUTAN PATHOL, V1, P120, DOI 10.1111/j.1600-0560.1974.tb00203.x; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Ortonne JP, 2002, BRIT J DERMATOL, V146, P7, DOI 10.1046/j.1365-2133.146.s61.3.x; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; Setlow RB, 1999, J INVEST DERM SYMP P, V4, P46, DOI 10.1038/sj.jidsp.5640180; Sheehan JM, 2002, J INVEST DERMATOL, V118, P825, DOI 10.1046/j.1523-1747.2002.01681.x; SZABO G, 1969, NATURE, V222, P1082, DOI 10.1038/2221081a0; Tadokoro T, 2005, J INVEST DERMATOL, V124, P1326, DOI 10.1111/j.0022-202X.2005.23760.x; Tadokoro T, 2003, FASEB J, V17, P1177, DOI 10.1096/fj.02-0865fje; Takeuchi S, 2004, P NATL ACAD SCI USA, V101, P15076, DOI 10.1073/pnas.0403994101; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Virador VM, 2001, FASEB J, V15, P105, DOI 10.1096/fj.01-0518fje; Wagner JK, 2002, PIGM CELL RES, V15, P385, DOI 10.1034/j.1600-0749.2002.02046.x; Weber JD, 2003, CELL DEATH DIFFER, V10, P409, DOI 10.1038/sj.cdd.4401226; Wikonkal NM, 1999, J INVEST DERM SYMP P, V4, P6, DOI 10.1038/sj.jidsp.5640173; Yamaguchi Y, 2004, J CELL BIOL, V165, P275, DOI 10.1083/jcb.200311122; Yoon TJ, 2003, ANAL BIOCHEM, V318, P260, DOI 10.1016/S0003-2697(03)00172-6; Young AR, 1996, J INVEST DERMATOL, V106, P1307, DOI 10.1111/1523-1747.ep12349031; ZEISE L, 1995, MELANIN ITS ROLE HUM; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	42	140	144	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1486	+		10.1096/fj.06-5725fje	http://dx.doi.org/10.1096/fj.06-5725fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16793869				2022-12-28	WOS:000240266000026
J	Guha, M; Kumar, S; Choubey, V; Maity, P; Bandyopadhyay, U				Guha, Mithu; Kumar, Sanjay; Choubey, Vinay; Maity, Pallab; Bandyopadhyay, Uday			Apoptosis in liver during malaria: role of oxidative stress and implication of mitochondrial pathway	FASEB JOURNAL			English	Article						malaria; Plasmodium yoelii; apoptosis; oxidative stress	CYTOCHROME-C; HEPATOCYTE APOPTOSIS; PERIPHERAL-BLOOD; HEME OXYGENASE; CELL; ANTIOXIDANT; ACTIVATION; MECHANISMS; PROOXIDANT; INVOLVEMENT	Hepatic dysfunction is a common clinical complication in malaria, although its pathogenesis remains largely unknown. Using a variety of in vivo and ex vivo approaches, we have shown for the first time that malarial infection induces hepatic apoptosis through augmentation of oxidative stress. Apoptosis in hepatocyte has been confirmed by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin-nick-end labeling assay (TUNEL) and caspase-3 activation. Gene expression analysis using RT-PCR indicates the significant down-regulation of Bcl-2 and up-regulation of Bax expression in liver of malaria infected mice suggesting the involvement of mitochondrial pathway of apoptosis. The levels of Fas expression and caspase-8 activity in infected liver were same as that of uninfected control mice indicating death receptor ( Fas) pathway did not contribute to liver apoptosis during malarial infection. Moreover, evidence has been presented by confocal microscopy to show the translocation of Bax from cytosol to mitochondria in apoptotic hepatocyte, resulting in opening of permeability transition pores, which in turn decreases mitochondrial membrane potential and induces cytochrome c release into cytosol. Malarial infection induces the generation of hydroxyl radical (.OH) in liver, which may be responsible for the induction of oxidative stress and apoptosis as administration of .OH specific antioxidant as well as spin trap, alpha-phenyl-tert-butyl-nitrone in malaria-infected mice significantly inhibits the development of oxidative stress as well as induction of apoptosis. Thus, results suggest the implication of oxidative stress induced-mitochondrial pathway of apoptosis in the pathophysiology of hepatic dysfunction in malaria.-Guha, M., Kumar, S., Choubey, V., Maity, P., Bandyopadhyay, U. Apoptosis in liver during malaria: Role of oxidative stress and implication of mitochondrial pathway.	Cent Drug Res Inst, Div Drug Target Discovery & Dev, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Bandyopadhyay, U (corresponding author), Cent Drug Res Inst, Div Drug Target Discovery & Dev, Chatter Manzil Palace,Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India.	ubandyo_1964@yahoo.com	Maity, Pallab/L-3896-2017; Choubey, Vinay/H-3170-2015	Maity, Pallab/0000-0001-9769-3533; Choubey, Vinay/0000-0002-1953-5692; kumar, sanjay/0000-0002-2678-3387				ABDALLA SH, 1988, ANN TROP PAEDIATR, V8, P250, DOI 10.1080/02724936.1988.11748582; Agarwala Sanjiv S, 2002, Curr Treat Options Oncol, V3, P205, DOI 10.1007/s11864-002-0010-7; [Anonymous], 1998, MALARIA PARASITE BIO; Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023; BABBS CF, 1990, METHOD ENZYMOL, V186, P137; Bandyopadhyay D, 2000, J PINEAL RES, V29, P143, DOI 10.1034/j.1600-079X.2000.290303.x; Bandyopadhyay U, 2002, LIFE SCI, V71, P2845, DOI 10.1016/S0024-3205(02)02143-4; Bandyopadhyay U, 1997, BIOCHEM PHARMACOL, V54, P241, DOI 10.1016/S0006-2952(97)00156-1; Bhattacharjee M, 2002, FREE RADICAL BIO MED, V32, P731, DOI 10.1016/S0891-5849(02)00757-8; Biswas K, 2003, J BIOL CHEM, V278, P10993, DOI 10.1074/jbc.M210328200; Brand VB, 2003, CELL PHYSIOL BIOCHEM, V13, P347, DOI 10.1159/000075122; Buege J A, 1978, Methods Enzymol, V52, P302; BURKITT MJ, 1991, P NATL ACAD SCI USA, V88, P8440, DOI 10.1073/pnas.88.19.8440; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; CLARK IA, 1989, FREE RADICAL BIO MED, V6, P315, DOI 10.1016/0891-5849(89)90058-0; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; COSSON P, 1993, RACHIS, V5, P5; Czaja MJ, 2002, ANTIOXID REDOX SIGN, V4, P759, DOI 10.1089/152308602760598909; Das D, 1997, FREE RADICAL BIO MED, V23, P8, DOI 10.1016/S0891-5849(96)00547-3; EISENSTEIN RS, 1990, ENZYME, V44, P42, DOI 10.1159/000468746; Erel O, 1997, CLIN BIOCHEM, V30, P631, DOI 10.1016/S0009-9120(97)00119-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gulbins E, 2003, EXP PHYSIOL, V88, P85, DOI 10.1113/eph8802503; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Helmby H, 2000, INFECT IMMUN, V68, P1485, DOI 10.1128/IAI.68.3.1485-1490.2000; Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088; Kumar KA, 2002, NEUROSCI LETT, V329, P319, DOI 10.1016/S0304-3940(02)00470-6; Kumar S, 2005, TOXICOL LETT, V157, P175, DOI 10.1016/j.toxlet.2005.03.004; Lang F, 2004, PFLUG ARCH EUR J PHY, V448, P319, DOI 10.1007/s00424-004-1254-9; Lang KS, 2005, CELL PHYSIOL BIOCHEM, V15, P195, DOI 10.1159/000086406; Leiriao P, 2005, J INFECT DIS, V191, P1576, DOI 10.1086/429635; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Mak S, 2001, CHEST, V120, P2035, DOI 10.1378/chest.120.6.2035; Matsumoto J, 2000, INFECT IMMUN, V68, P1183, DOI 10.1128/IAI.68.3.1183-1188.2000; Minana JB, 2002, HEPATOLOGY, V35, P1205, DOI 10.1053/jhep.2002.32969; Najera J. A., 2001, Parassitologia (Rome), V43, P1; Oliveira MF, 2002, FEBS LETT, V512, P139, DOI 10.1016/S0014-5793(02)02243-3; Omodeo-Sale F, 2001, BIOCHEM PHARMACOL, V61, P999, DOI 10.1016/S0006-2952(01)00558-5; Pabon A, 2003, CLIN BIOCHEM, V36, P71, DOI 10.1016/S0009-9120(02)00423-X; Pandey AV, 1997, MOL BIOCHEM PARASIT, V90, P281, DOI 10.1016/S0166-6851(97)00161-8; PERRIN LH, 1982, SEMIN HEMATOL, V19, P70; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Quaresma JAS, 2005, ACTA TROP, V94, P116, DOI 10.1016/j.actatropica.2005.03.003; Rodriguez-Acosta A, 1998, J SUBMICR CYTOL PATH, V30, P299; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Sanchez-Torres L, 2001, PARASITE IMMUNOL, V23, P617, DOI 10.1046/j.1365-3024.2001.00422.x; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shiff C, 2002, CLIN MICROBIOL REV, V15, P278, DOI 10.1128/CMR.15.2.278-293.2002; Siddiqi NJ, 1999, MOL CELL BIOCHEM, V196, P169, DOI 10.1023/A:1006944313291; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Srivastava A, 1996, Trop Gastroenterol, V17, P172; ToureBalde A, 1996, INFECT IMMUN, V64, P744, DOI 10.1128/IAI.64.3.744-750.1996; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; van de Sand C, 2005, MOL MICROBIOL, V58, P731, DOI 10.1111/j.1365-2958.2005.04888.x; Wissing D, 1998, FREE RADICAL BIO MED, V25, P57, DOI 10.1016/S0891-5849(98)00043-4; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	65	116	125	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1224	+		10.1096/fj.05-5338fje	http://dx.doi.org/10.1096/fj.05-5338fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16603602				2022-12-28	WOS:000240210300033
J	Valaperta, R; Chigorno, V; Basso, L; Prinetti, A; Bresciani, R; Preti, A; Miyagi, T; Sonnino, S				Valaperta, Rea; Chigorno, Vanna; Basso, Luisa; Prinetti, Alessandro; Bresciani, Roberto; Preti, Augusto; Miyagi, Taeko; Sonnino, Sandro			Plasma membrane production of ceramide from ganglioside GM3 in human fibroblasts	FASEB JOURNAL			English	Article						plasma membrane-associated sialidase; Neu3; GM3 synthase; glycosylhydrolases; apoptosis	HUMAN NEUROBLASTOMA-CELLS; HUMAN SKIN FIBROBLASTS; SPHINGOLIPID METABOLISM; PROTEIN-KINASE; GROWTH-CONTROL; SIALIDASE; DIFFERENTIATION; INTERNALIZATION; SPHINGOSINE; GLYCOLIPIDS	Ceramide is a key lipid molecule necessary to regulate some cellular processes, including apoptosis and cell differentiation. In this context, its production has been shown to occur via sphingomyelin hydrolysis or sphingosine acylation. Here, we show that in human fibroblasts, plasma membrane ceramide is also produced from ganglioside GM3 by detachment of sugar units. Membrane-bound glycosylhydrolases have a role in this process. In fact, the production of ceramide from GM3 has been observed even under experimental conditions able to block endocytosis or lysosomal activity, and the overexpression of the plasma membrane ganglioside sialidase Neu3 corresponded to a higher production of ceramide in the plasma membrane. The increased activity of Neu3 was paralleled by an increase of GM3 synthase mRNA and GM3 synthase activity. Neu3-overexpressing fibroblasts were characterized by a reduced proliferation rate and higher basal number of apoptotic cells in comparison with wild-type cells. A similar behavior was observed when normal fibroblasts were treated with exogenous C-2-ceramide.-Valaperta, R., Chigorno, V., Basso, L., Prinetti, A., Bresciani, R., Preti, A., Miyagi, T., and Sonnino, S. Plasma membrane production of ceramide from ganglioside GM3 in human fibroblasts.	Univ Milan, Dept Med Chem Biochem & Biotechnol, I-20090 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20090 Milan, Italy; Univ Brescia, Dept Biomed Sci & Biotechnol, Brescia, Italy; Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi, Japan	University of Milan; University of Milan; University of Brescia	Sonnino, S (corresponding author), Univ Milan, Dept Med Chem Biochem & Biotechnol, Via Fratelli Cervi 93, I-20090 Milan, Italy.	sandro.sonnino@unimi.it	Bresciani, Roberto/AAA-9728-2020; Sonnino, Sandro/R-4154-2017; Prinetti, Alessandro/R-4206-2017	Bresciani, Roberto/0000-0002-7881-7550; Sonnino, Sandro/0000-0001-8180-5908; Prinetti, Alessandro/0000-0003-0252-2593				Alessenko A V, 2000, Membr Cell Biol, V13, P303; Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CARTER HE, 1961, J LIPID RES, V2, P228; Chester MA, 1997, PURE APPL CHEM, V69, P2475, DOI 10.1351/pac199769122475; Chigorno V, 1997, EUR J BIOCHEM, V250, P661, DOI 10.1111/j.1432-1033.1997.00661.x; CHIGORNO V, 1986, ANAL BIOCHEM, V153, P283, DOI 10.1016/0003-2697(86)90094-1; Chigorno V, 1985, GLYCOCONJUGATE J, VV2, P279; Cordero OJ, 2001, EUR J BIOCHEM, V268, P3321, DOI 10.1046/j.1432-1327.2001.02237.x; Cornish-Bowden A, 1998, CARBOHYD RES, V312, P167; DAWSON G, 1972, J BIOL CHEM, V247, P5944; Fang DY, 2004, P NATL ACAD SCI USA, V101, P14782, DOI 10.1073/pnas.0404445101; FURLANETTO RW, 1988, ENDOCRINOLOGY, V122, P2044, DOI 10.1210/endo-122-5-2044; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; ITO M, 1986, J BIOL CHEM, V261, P14278; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; Koh YH, 2005, J BIOL CHEM, V280, P32499, DOI 10.1074/jbc.M506199200; Kopitz J, 1997, EUR J CELL BIOL, V73, P1; KOPITZ J, 1994, BIOCHEM BIOPH RES CO, V199, P1188, DOI 10.1006/bbrc.1994.1356; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; LEON A, 1981, J NEUROCHEM, V37, P350, DOI 10.1111/j.1471-4159.1981.tb00462.x; LEROY JG, 1972, PEDIATR RES, V6, P752, DOI 10.1203/00006450-197210000-00002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Marks DL, 2005, METHODS, V36, P186, DOI 10.1016/j.ymeth.2004.12.001; Marques C, 2004, FASEB J, V18, P1424, DOI 10.1096/fj.04-1743fje; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Mauri L, 1999, GLYCOCONJUGATE J, V16, P197, DOI 10.1023/A:1007072203345; Mencarelli S, 2005, FEBS LETT, V579, P5501, DOI 10.1016/j.febslet.2005.08.081; MIYAGI T, 1990, J BIOCHEM-TOKYO, V107, P787, DOI 10.1093/oxfordjournals.jbchem.a123126; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Papini N, 2004, J BIOL CHEM, V279, P16989, DOI 10.1074/jbc.M400881200; PARTINGTON CR, 1979, MOL PHARMACOL, V15, P484; Prinetti A, 2003, J BIOL CHEM, V278, P5574, DOI 10.1074/jbc.M207269200; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; RADSAK K, 1982, H-S Z PHYSIOL CHEM, V363, P263, DOI 10.1515/bchm2.1982.363.1.263; SCHEEL G, 1982, EUR J BIOCHEM, V127, P245, DOI 10.1111/j.1432-1033.1982.tb06862.x; SCHWARZMANN G, 1983, BIOCHEMISTRY-US, V22, P5041, DOI 10.1021/bi00290a025; Sonnino S, 2000, METHOD ENZYMOL, V311, P639; SONNINO S, 1978, J NEUROCHEM, V31, P947, DOI 10.1111/j.1471-4159.1978.tb00132.x; TETTAMANTI G, 1977, Biochemistry and Experimental Biology, V13, P45; TOYOKUNI T, 1991, J LABELLED COMPD RAD, V29, P567, DOI 10.1002/jlcr.2580290508; YATES AJ, 1989, J NEUROCHEM, V53, P162, DOI 10.1111/j.1471-4159.1989.tb07308.x	49	95	96	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1227	+		10.1096/fj.05-5077fje	http://dx.doi.org/10.1096/fj.05-5077fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16645048				2022-12-28	WOS:000240210300034
J	Beck, A; Kolisek, M; Bagley, LA; Fleig, A; Penner, R				Beck, Andreas; Kolisek, Martin; Bagley, Leigh Anne; Fleig, Andrea; Penner, Reinhold			Nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose regulate TRPM2 channels in T lymphocytes	FASEB JOURNAL			English	Article						TRPM2; cADPR; NAADP	HYDROGEN-PEROXIDE; CALCIUM-RELEASE; CATION CHANNELS; CA2+ RELEASE; NAADP; ACTIVATION; INFLUX; 2ND-MESSENGER; MESSENGERS; RECEPTORS	TRPM2 (previously designated TRPC7 or LTRPC2) is a Ca(2+)-permeable nonselective cation channel that contains a C-terminal enzymatic domain with pyrophosphatase activity, which specifically binds ADP-ribose. Cyclic ADP-ribose ( cADPR) and hydrogen peroxide (H(2)O(2)) can facilitate ADPR-mediated activation of heterologously expressed TRPM2. Here, we show that the two Ca(2+)-mobilizing second messengers cyclic ADP-ribose ( cADPR) and nicotinic acid adenine dinucleotide phosphate ( NAADP) strongly activate natively expressed TRPM2 channels in Jurkat T cells. TRPM2 activation by both agonists can be partially suppressed by the ADPR antagonist adenosine monophosphate ( AMP), which suggests that cADPR and NAADP lead to mobilization of endogenous ADPR presumably via metabolic conversion. The remaining channel activity is due to direct gating of TRPM2 by the two agonists and can be completely suppressed by 8-Br-cADPR, which suggests that cADPR and NAADP share a common binding site on TRPM2 that can regulate TRPM2 activity in synergy with ADPR. We conclude that cADPR and NAADP, in combination with ADPR, represent physiological co-activators of TRPM2 that contribute to Ca(2+)-influx in T lymphocytes and presumably other cell types that express this channel.	Queens Med Ctr, Ctr Biomed Res, Lab Cell & Mol Signaling, Honolulu, HI 96813 USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA	The Queen's Medical Center; University of Hawaii System	Penner, R (corresponding author), Queens Med Ctr, Ctr Biomed Res, Lab Cell & Mol Signaling, 1301 Punchbowl St UHT 8, Honolulu, HI 96813 USA.	rpenner@hawaii.edu		Fleig, Andrea/0000-0001-8396-7249; Penner, Reinhold/0000-0002-5366-1537	NIAID NIH HHS [R01-AI50200] Funding Source: Medline; NIGMS NIH HHS [R01-GM 063954, R01-GM 65360] Funding Source: Medline; NINDS NIH HHS [R01-NS40927] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063954, R01GM065360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040927] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Billington RA, 2002, J PHYSIOL-LONDON, V544, P107, DOI 10.1113/jphysiol.2002.030098; Dousa TP, 1996, AM J PHYSIOL-CELL PH, V271, pC1007, DOI 10.1152/ajpcell.1996.271.4.C1007; Galione A, 2005, MOL INTERV, V5, P73, DOI 10.1124/mi.5.2.4; Galione A, 2000, Sci STKE, V2000, ppe1; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Guse Andreas H., 2002, Current Molecular Medicine (Hilversum), V2, P273, DOI 10.2174/1566524024605707; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Heiner I, 2003, CELL CALCIUM, V33, P533, DOI 10.1016/S0143-4160(03)00058-7; Inamura K, 2003, J MEMBRANE BIOL, V191, P201, DOI 10.1007/s00232-002-1057-x; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; Kuhn FJP, 2004, J BIOL CHEM, V279, P46431, DOI 10.1074/jbc.M407263200; Langhorst MF, 2004, CELL SIGNAL, V16, P1283, DOI 10.1016/j.cellsig.2004.03.013; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; Lee HC, 1999, MOL CELL BIOCHEM, V193, P89; LEE S, 2000, JPL OPTICAL COMMUNIC, V2000, P1; Lund FE, 1998, IMMUNOL REV, V161, P79, DOI 10.1111/j.1600-065X.1998.tb01573.x; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Perraud AL, 2005, J BIOL CHEM, V280, P6138, DOI 10.1074/jbc.M411446200; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Santella L, 2005, MOL INTERV, V5, P70, DOI 10.1124/mi.5.2.3; Turner H, 2003, BIOCHEM J, V371, P341, DOI 10.1042/BJ20021381; Wilding M, 1998, AM J PHYSIOL-CELL PH, V275, pC1277, DOI 10.1152/ajpcell.1998.275.5.C1277; Yamasaki M, 2005, CURR BIOL, V15, P874, DOI 10.1016/j.cub.2005.04.033	30	148	151	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					962	+		10.1096/fj.05-5538fje	http://dx.doi.org/10.1096/fj.05-5538fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585058				2022-12-28	WOS:000240157700022
J	Kang, BN; Tirumurugaan, KG; Deshpande, DA; Amrani, Y; Panettieri, RA; Walseth, TF; Kannano, MS				Kang, Bit-Na; Tirumurugaan, K. G.; Deshpande, Deepak A.; Amrani, Yassine; Panettieri, Reynold A.; Walseth, Timothy F.; Kannano, Mathur S.			Transcriptional regulation of CD38 expression by tumor necrosis factor-alpha in human airway smooth muscle cells: role of NF-kappa B and sensitivity to glucocorticoids	FASEB JOURNAL			English	Article						cytokines; transcription factors; smooth muscle; airway; glucocorticoid	RIBOSE HYDROLASE ACTIVITIES; NUCLEAR EXPORT SIGNAL; GENE-EXPRESSION; DNA-BINDING; AP-1 ACTIVITY; C-JUN; RECEPTOR; INHIBITION; CYTOKINES; PATHWAY	The transmembrane glycoprotein CD38 catalyzes the synthesis of the calcium mobilizing molecule cyclic ADP-ribose from NAD. In human airway smooth muscle (HASM) cells, the expression and function of CD38 are augmented by the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha), leading to increased intracellular calcium response to agonists. A glucocorticoid response element in the CD38 gene has been computationally described, providing evidence for transcriptional regulation of its expression. In the present study, we investigated the effects of dexamethasone, a glucocorticoid, on CD38 expression and ADP-ribosyl cyclase activity in HASM cells stimulated with TNF-alpha. In HASM cells, TNF-alpha augmented CD38 expression and ADP-ribosyl cyclase activity, which were attenuated by dexamethasone. TNF-alpha increased NF-kappa B expression and its activation, and dexamethasone partially reversed these effects. TNF-alpha increased the expression of I kappa B alpha, and dexamethasone increased it further. An inhibitor of NF-kappa B activation or transfection of cells with I kappa B mutants decreased TNF-alpha-induced CD38 expression. The results indicate that TNF-alpha-induced CD38 expression involves NF-kappa B expression and its activation and dexamethasone inhibits CD38 expression through NF-kappa B-dependent and -independent mechanisms.	Univ Minnesota, Coll Vet Med, Dept Vet & Biomed Sci, St Paul, MN 55108 USA; Univ Minnesota, Dept Pharmacol, St Paul, MN 55108 USA; Univ Minnesota, Dept Pediat, St Paul, MN 55108 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania	Kannano, MS (corresponding author), Univ Minnesota, Coll Vet Med, Dept Vet & Biomed Sci, 1971 Commonwealth Ave, St Paul, MN 55108 USA.	kanna001@umn.edu	Amrani, Yassine/Q-6323-2019; Amrani, Yassine/A-1826-2013; panettieri, reynold/AAG-9485-2019; Walseth, Timothy F/F-9518-2010	Amrani, Yassine/0000-0002-7042-6926; Walseth, Timothy F/0000-0003-2558-7859	NHLBI NIH HHS [R01 HL055301, HL55301, HL057498, R01 HL057498] Funding Source: Medline; NIDA NIH HHS [DA11806, P50 DA011806] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057498, R01HL055301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ammit AJ, 2002, AM J RESP CELL MOL, V26, P465, DOI 10.1165/ajrcmb.26.4.4681; Amrani Y, 2000, Respir Res, V1, P49, DOI 10.1186/rr12; Amrani Y, 2001, MOL PHARMACOL, V60, P646; Amrani Y, 1999, J IMMUNOL, V163, P2128; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Barata H, 2004, ENDOCRINOLOGY, V145, P881, DOI 10.1210/en.2003-0774; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Chikanza IC, 2003, J ENDOCRINOL, V179, P301, DOI 10.1677/joe.0.1790301; Deshpande DA, 2005, AM J PHYSIOL-LUNG C, V288, pL773, DOI 10.1152/ajplung.00217.2004; Deshpande DA, 2005, AM J RESP CELL MOL, V32, P149, DOI 10.1165/rcmb.2004-0243OC; Deshpande DA, 2004, AM J RESP CELL MOL, V31, P36, DOI 10.1165/rcmb.2003-0313OC; Deshpande DA, 2003, FASEB J, V17, P452, DOI 10.1096/fj.02-0450fje; Dogan S, 2002, BIOL REPROD, V66, P596, DOI 10.1095/biolreprod66.3.596; dos Santos CC, 2004, PHYSIOL GENOMICS, V19, P331, DOI 10.1152/physiolgenomics.00153.2004; Doucas V, 2000, P NATL ACAD SCI USA, V97, P11893, DOI 10.1073/pnas.220413297; Ferrero E, 2000, CHEM IMMUNOL, V75, P1; Hakonarson H, 2001, AM J RESP CELL MOL, V25, P761, DOI 10.1165/ajrcmb.25.6.4628; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Jiang X, 2004, J BIOL CHEM, V279, P38480, DOI 10.1074/jbc.M403948200; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Mehta K, 2000, CHEM IMMUNOL, V75, P20; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Riffo-Vasquez Y, 2000, INT J BIOCHEM CELL B, V32, P833, DOI 10.1016/S1357-2725(00)00029-7; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SCHEINMAN RI, 1995, SCIENCE, V270, P286; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Shore SA, 2002, CLIN EXP PHARMACOL P, V29, P859, DOI 10.1046/j.1440-1681.2002.03756.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Tliba O, 2004, MOL PHARMACOL, V66, P322, DOI 10.1124/mol.104.001040; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; White TA, 2000, BBA-MOL CELL RES, V1498, P64, DOI 10.1016/S0167-4889(00)00077-X; Wyszomierski SL, 1999, MOL ENDOCRINOL, V13, P330, DOI 10.1210/me.13.2.330; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	47	51	54	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					1000	+		10.1096/fj.05-4585fje	http://dx.doi.org/10.1096/fj.05-4585fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571778				2022-12-28	WOS:000240157700035
J	Drenkard, D; Becke, FM; Langstein, J; Spruss, T; Kunz-Schughart, LA; Tan, TE; Lim, YC; Schwarz, H				Drenkard, Daniela; Becke, Florian M.; Langstein, Joachim; Spruss, Thilo; Kunz-Schughart, Leoni A.; Tan, Teng Ee; Lim, Yaw Chyn; Schwarz, Herbert			CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity	FASEB JOURNAL			English	Article						extravasation; vascular biology	FACTOR-RECEPTOR FAMILY; DENDRITIC CELLS; 4-1BB LIGAND; LYMPHOCYTE-ACTIVATION; IN-VIVO; PROLIFERATION; SELECTINS; SURVIVAL; ADHESION; MEMBER	The cytokine receptor CD137 is a member of the TNF receptor family and a potent T cell costimulatory molecule. Its ligand is expressed on antigen presenting cells as a transmembrane protein and it too can deliver signals into the cells it is expressed on (reverse signaling). In monocytes, immobilized CD137 protein induces activation, prolongation of survival and proliferation. Here we show that recombinant immobilized CD137 protein enhances migration of monocytes in vitro. Further, CD137 expression on spheroids leads to a significantly enhanced infiltration by monocytes. The migration-inducing activity of CD137 could be confirmed in vivo. Matrigel, which was coated with recombinant CD137 protein and was inserted into the flanks of mice attracted large numbers of monocytes and was heavily infiltrated by these cells. In vivo, expression of CD137 by blood vessel walls at sites of inflammation was detectable by immunohistochemistry. CD 137 expression is inducible by proinflammatory cytokines in endothelial cells, suggesting that a physiological function of CD 137 may be the facilitation of monocyte extravasation in inflammatory tissues.	Natl Univ Singapore, Dept Physiol, Immunol Program, Singapore 117597, Singapore; Natl Univ Singapore, Dept Pathol, Singapore 117597, Singapore; Univ Regensburg, Dept Pathol, D-8400 Regensburg, Germany; Univ Regensburg, Vet Serv, D-8400 Regensburg, Germany	National University of Singapore; National University of Singapore; University of Regensburg; University of Regensburg	Schwarz, H (corresponding author), Natl Univ Singapore, Dept Physiol, Immunol Program, 2 Med Dr,MD 9, Singapore 117597, Singapore.	phssh@nus.edu.sg		Kunz-Schughart, Leoni/0000-0003-3912-6594				ANDREESEN R, 1990, J LEUKOCYTE BIOL, V47, P490, DOI 10.1002/jlb.47.6.490; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Duffield JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240; Futagawa T, 2002, INT IMMUNOL, V14, P275, DOI 10.1093/intimm/14.3.275; Gonzalez-Amaro R, 1999, CRIT REV IMMUNOL, V19, P389; Guinn B, 1999, J IMMUNOL, V162, P5003; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; Kim YJ, 2002, J HEMATOTH STEM CELL, V11, P895, DOI 10.1089/152581602321080556; Laderach D, 2003, CELL IMMUNOL, V226, P37, DOI 10.1016/j.cellimm.2003.11.003; Langstein J, 2000, BIOCHEM BIOPH RES CO, V273, P117, DOI 10.1006/bbrc.2000.2889; Langstein J, 1999, BLOOD, V94, P3161, DOI 10.1182/blood.V94.9.3161.421k31_3161_3168; Langstein J, 1999, J LEUKOCYTE BIOL, V65, P829, DOI 10.1002/jlb.65.6.829; Langstein J, 1998, J IMMUNOL, V160, P2488; Lotz M, 1996, J LEUKOCYTE BIOL, V60, P1; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Melero I, 1998, EUR J IMMUNOL, V28, P1116, DOI 10.1002/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A; Michel J, 1999, IMMUNOLOGY, V98, P42; Mittler RS, 2004, IMMUNOL RES, V29, P197, DOI 10.1385/IR:29:1-3:197; Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0; Pauly S, 2002, J LEUKOCYTE BIOL, V72, P35; ROMEIS B, 1989, MIKROSKOPISCHE TECHN, P497; Rossiter H, 1997, MOL MED TODAY, V3, P214, DOI 10.1016/S1357-4310(97)01040-X; Schwarz H, 2005, J LEUKOCYTE BIOL, V77, P281, DOI 10.1189/jlb.0904558; Schwarz H, 1996, BLOOD, V87, P2839, DOI 10.1182/blood.V87.7.2839.bloodjournal8772839; SCHWARZ H, 1993, GENE, V134, P295, DOI 10.1016/0378-1119(93)90110-O; SCHWARZ H, 1995, BLOOD, V85, P1043, DOI 10.1182/blood.V85.4.1043.bloodjournal8541043; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; Sica G, 2000, ADV EXP MED BIOL, V465, P355; Tohka S, 2001, FASEB J, V15, P373, DOI 10.1096/fj.00-0240com; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Vestweber D, 2002, CURR OPIN CELL BIOL, V14, P587, DOI 10.1016/S0955-0674(02)00372-1	31	84	90	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					456	463		10.1096/fj.05-4739com	http://dx.doi.org/10.1096/fj.05-4739com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17167064				2022-12-28	WOS:000244686300019
J	Sacheck, JM; Hyatt, JPK; Raffaello, A; Jagoe, RT; Roy, RR; Edgerton, VR; Lecker, SH; Goldberg, AL				Sacheck, Jennifer M.; Hyatt, Jon-Philippe K.; Raffaello, Anna; Jagoe, R. Thomas; Roy, Roland R.; Edgerton, V. Reggie; Lecker, Stewart H.; Goldberg, Alfred L.			Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases	FASEB JOURNAL			English	Article						atrogene; PGC-1; ubiquitin; proteasome; muscle wasting; inactivity; muscle disease	UBIQUITIN-PROTEASOME PATHWAY; RAT SKELETAL-MUSCLE; NF-KAPPA-B; GENE-EXPRESSION; MESSENGER-RNA; PROTEOLYTIC PATHWAY; CELL-PROLIFERATION; ENCODING PROTEINS; ACTIVATION; INCREASE	We previously identified a common set of genes, termed atrogenes, whose expression is coordinately induced or suppressed in muscle during systemic wasting states ( fasting, cancer cachexia, renal failure, diabetes). To determine whether this transcriptional program also functions during atrophy resulting from loss of contractile activity and whether atrogene expression correlates with the rate of muscle weight loss, we used cDNA microarrays and RT-polymerase chain reaction to analyze changes in mRNA from rat gastrocnemius during disuse atrophy induced by denervation or spinal cord isolation. Three days after Den or SI, the rate of muscle weight loss was greatest, and 78% of the atrogenes identified during systemic catabolic states were induced or repressed. Of particular interest were the large inductions of key ubiquitin ligases, atrogin-1 ( 35- to 44-fold) and MuRF1 ( 12- to 22-fold), and the suppression of PGC-1 alpha and PGC-1 beta coactivators ( 15-fold). When atrophy slowed ( day 14), the expression of 92% of these atrogenes returned toward basal levels. At 28 days, the atrophy-inducing transcription factor, FoxO1, was still induced and may be important in maintaining the "atrophied" state. Thus, 1) the atrophy associated with systemic catabolic states and following disuse involves similar transcriptional adaptations; and 2) disuse atrophy proceeds through multiple phases corresponding to rapidly atrophying and atrophied muscles that involve distinct transcriptional patterns.	Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Georgetown Univ, Dept Human Sci, Sch Nursing & Hlth Studies, Washington, DC USA; Aintree Univ Hosp NHS Fdn Trust, Dept Med, Pulm & Rehabil Res Grp, Liverpool, Merseyside, England; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Georgetown University; Aintree University Hospitals NHS Foundation Trust; University of Liverpool; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lecker, SH (corresponding author), Beth Israel Deaconess Med Ctr, Renal Unit, 330 Brookline Ave, Boston, MA 02215 USA.	slecker@bidmc.harvard.edu; alfred_goldberg@hms.harvard.edu	Raffaello, Anna/K-7052-2016	RAFFAELLO, ANNA/0000-0002-8344-6459; Jagoe, R. Thomas/0000-0001-7069-0519	NIAMS NIH HHS [R01 AR055255-02, F32 AR048517, R01 AR055255] Funding Source: Medline; NIDDK NIH HHS [DK6230701] Funding Source: Medline; NINDS NIH HHS [NS16333] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR055255, F32AR048517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016333] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams GR, 1996, J APPL PHYSIOL, V81, P2509, DOI 10.1152/jappl.1996.81.6.2509; ADAMS L, 1995, J CELL BIOL, V131, P1341, DOI 10.1083/jcb.131.5.1341; Atherton PJ, 2005, FASEB J, V19, P786, DOI 10.1096/fj.04-2179fje; Attaix D, 2005, INT J BIOCHEM CELL B, V37, P1962, DOI 10.1016/j.biocel.2005.04.009; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; Bey L, 2003, PHYSIOL GENOMICS, V13, P157, DOI 10.1152/physiolgenomics.00001.2002; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; CHEN FOK, 2003, BIOCHEM J, V15, P257; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DUBOIS DC, 1981, MUSCLE NERVE, V4, P370, DOI 10.1002/mus.880040504; Fischer D, 2000, BIOCHEM BIOPH RES CO, V267, P504, DOI 10.1006/bbrc.1999.1987; FURUNO K, 1990, J BIOL CHEM, V265, P8550; GARDINER PF, 1980, PFLUG ARCH EUR J PHY, V385, P147, DOI 10.1007/BF00588695; Giresi PG, 2005, PHYSIOL GENOMICS, V21, P253, DOI 10.1152/physiolgenomics.00249.2004; GOLDBERG AL, 1969, J BIOL CHEM, V244, P3223; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Grossman EJ, 1998, MUSCLE NERVE, V21, P375, DOI 10.1002/(SICI)1097-4598(199803)21:3<375::AID-MUS12>3.3.CO;2-Y; Haddad F, 2003, J APPL PHYSIOL, V95, P791, DOI 10.1152/japplphysiol.01113.2002; Haddad F, 2003, J APPL PHYSIOL, V95, P781, DOI 10.1152/japplphysiol.00317.2003; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hasselgren P O, 1999, Curr Opin Clin Nutr Metab Care, V2, P201, DOI 10.1097/00075197-199905000-00002; Hasselgren PO, 2005, INT J BIOCHEM CELL B, V37, P2156, DOI 10.1016/j.biocel.2005.01.017; Huey KA, 2001, MUSCLE NERVE, V24, P517, DOI 10.1002/mus.1035; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Hunter RB, 2002, FASEB J, V16, P529, DOI 10.1096/fj.01-0866com; Hyatt JPK, 2003, AM J PHYSIOL-CELL PH, V285, pC1161, DOI 10.1152/ajpcell.00128.2003; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; JASPERS SR, 1986, MUSCLE NERVE, V9, P554, DOI 10.1002/mus.880090613; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; KONDO H, 1992, AM J PHYSIOL, V262, pE583, DOI 10.1152/ajpendo.1992.262.5.E583; Ladner KJ, 2003, J BIOL CHEM, V278, P2294, DOI 10.1074/jbc.M207129200; Latres E, 2005, J BIOL CHEM, V280, P2737, DOI 10.1074/jbc.M407517200; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lecker SH, 1999, J CLIN INVEST, V104, P1411, DOI 10.1172/JCI7300; LI JB, 1976, AM J PHYSIOL, V231, P441, DOI 10.1152/ajplegacy.1976.231.2.441; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Macallan DC, 1996, INT J BIOCHEM CELL B, V28, P511, DOI 10.1016/1357-2725(95)00170-0; MAGNUSSON C, 2002, EUR J NEUROSCI, V21, P557; Marino JH, 2003, J IMMUNOL METHODS, V283, P291, DOI 10.1016/S0022-1759(03)00103-0; Marszalek JR, 1999, J CELL BIOL, V145, P469, DOI 10.1083/jcb.145.3.469; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; MERLIE JP, 1984, J CELL BIOL, V99, P332, DOI 10.1083/jcb.99.1.332; Mitch WE, 1999, AM J PHYSIOL-CELL PH, V276, pC1132, DOI 10.1152/ajpcell.1999.276.5.C1132; MURRAY MA, 1982, NEUROSCIENCE, V7, P1823, DOI 10.1016/0306-4522(82)90040-9; Norrbom J, 2004, J APPL PHYSIOL, V96, P189, DOI 10.1152/japplphysiol.00765.2003; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Pan DS, 2002, J CLIN INVEST, V110, P1349, DOI 10.1172/JCI200215614; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phan J, 2004, J BIOL CHEM, V279, P29558, DOI 10.1074/jbc.M403506200; Powers SK, 2005, AM J PHYSIOL-REG I, V288, pR337, DOI 10.1152/ajpregu.00469.2004; Price SR, 1996, MINER ELECTROL METAB, V22, P72; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; Raffaello A, 2006, PHYSIOL GENOMICS, V25, P60, DOI 10.1152/physiolgenomics.00051.2005; Reid MB, 2001, RESP RES, V2, P269, DOI 10.1186/rr67; Roy RL, 2000, MUSCLE NERVE, V23, P735, DOI 10.1002/(SICI)1097-4598(200005)23:5<735::AID-MUS11>3.0.CO;2-T; Roy RR, 2002, MUSCLE NERVE, V26, P404, DOI 10.1002/mus.10219; Russell AP, 2003, DIABETES, V52, P2874, DOI 10.2337/diabetes.52.12.2874; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Schulze PC, 2005, CIRC RES, V97, P418, DOI 10.1161/01.RES.0000179580.72375.c2; Simpkins CO, 2000, CELL MOL BIOL, V46, P465; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; Stevenson EJ, 2003, J PHYSIOL-LONDON, V551, P33, DOI 10.1113/jphysiol.2003.044701; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; THOMASON DB, 1989, AM J PHYSIOL, V257, pR300, DOI 10.1152/ajpregu.1989.257.2.R300; THOMASON DB, 1990, J APPL PHYSIOL, V68, P1, DOI 10.1152/jappl.1990.68.1.1; TISCHLER ME, 1990, METABOLISM, V39, P756, DOI 10.1016/0026-0495(90)90113-Q; Tower SS, 1937, J COMP NEUROL, V67, P109, DOI 10.1002/cne.900670107; Tupling AR, 2002, J BIOL CHEM, V277, P44740, DOI 10.1074/jbc.M206171200; WING SS, 1995, BIOCHEM J, V307, P639, DOI 10.1042/bj3070639; Wray CJ, 2003, INT J BIOCHEM CELL B, V35, P698, DOI 10.1016/S1357-2725(02)00341-2; Yakar S, 2001, DIABETES, V50, P1110, DOI 10.2337/diabetes.50.5.1110	78	418	440	0	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					140	155		10.1096/fj.06-6604com	http://dx.doi.org/10.1096/fj.06-6604com			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17116744				2022-12-28	WOS:000243130200016
J	Spitzner, M; Ousingsawat, J; Scheidt, K; Kunzelmann, K; Schreiber, R				Spitzner, Melanie; Ousingsawat, Jiraporn; Scheidt, Kerstin; Kunzelmann, Karl; Schreiber, Rainer			Voltage-gated K+ channels support proliferation of colonic carcinoma cells	FASEB JOURNAL			English	Article						Eag; T-84; intracellular Ca2+; growth; Ussing chamber; patch clamp; intracellular pH; ion channels cancer	POTASSIUM-ION CHANNELS; RNA INTERFERENCE; INTRACELLULAR PH; PROSTATE-CANCER; MESSENGER-RNA; CA2+ INFLUX; HT29 CELLS; EXPRESSION; PROGRESSION; PROTEIN	Plasma membrane potassium ( K+) channels are required for cell proliferation. Evidence is growing that K+ channels play a central role in the development and growth of human cancer. Here we examine the contribution and the mechanism by which K+ channels control proliferation of T-84 human colonic carcinoma cells. Numerous K+ channels are expressed in T-84 cells, but only voltage-gated K+ ( Kv) channels influenced proliferation. A number of Kv channel inhibitors reduced DNA synthesis and cell number, without exerting apoptotic or toxic effects. Expression of several Kv channels, such as EagI, Kv 3.4 and Kv 1.5, was detected in patch clamp experiments and in fluorescence-based assays using a voltage sensitive dye. The contribution of EagI channels to proliferation was confirmed by siRNA, which abolished EagI activity and inhibited cell growth. Inhibition of Kv channels did not interfere with the ability of T-84 cells to regulate their cell vol, but it restricted intracellular pH regulation. In addition, inhibitors of Kv channels, as well as siRNA for EagI, attenuated intracellular Ca2+ signaling. The data suggest that Kv channels control proliferation of colonic cancer cells by affecting intracellular pH and Ca2+ signaling.	Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany	University of Regensburg	Kunzelmann, K (corresponding author), Univ Regensburg, Inst Physiol, Univ Str 31, D-93053 Regensburg, Germany.	uqkkunze@mailbox.uq.edu		Spitzner, Melanie/0000-0002-3673-0625; Kunzelmann, Karl/0000-0002-4583-7037				Abdul M, 2002, ONCOL REP, V9, P961; Abdul M, 2002, CANCER LETT, V186, P99, DOI 10.1016/S0304-3835(02)00348-8; Abdul M, 2002, ANTICANCER RES, V22, P1727; Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; Baxter DF, 2002, J BIOMOL SCREEN, V7, P79, DOI 10.1177/108705710200700110; Cao YJ, 2002, EUR J PHARMACOL, V449, P47, DOI 10.1016/S0014-2999(02)01987-8; Chang KW, 2003, J ORAL PATHOL MED, V32, P606, DOI 10.1034/j.1600-0714.2003.00197.x; Conti DJ, 2004, AM J TRANSPLANT, V4, P166; Czarnecki A, 2003, AM J PHYSIOL-CELL PH, V284, pC1054, DOI 10.1152/ajpcell.00446.2002; Diochot S, 1998, J BIOL CHEM, V273, P6744, DOI 10.1074/jbc.273.12.6744; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elso CM, 2004, HUM MOL GENET, V13, P2813, DOI 10.1093/hmg/ddh307; Farias LMB, 2004, CANCER RES, V64, P6996, DOI 10.1158/0008-5472.CAN-04-1204; Fischer KG, 1996, PFLUG ARCH EUR J PHY, V432, P735, DOI 10.1007/s004240050192; GARCIAFERREIRO RE, 2004, J GEN PHYSL; Grace AA, 1998, NEW ENGL J MED, V338, P35, DOI 10.1056/NEJM199801013380107; Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008; Kazerounian S, 2005, J PHARMACOL EXP THER, V314, P1013, DOI 10.1124/jpet.105.089052; Klimatcheva E, 1999, J MEMBRANE BIOL, V171, P35, DOI 10.1007/s002329900556; Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232-005-0781-4; Lal A, 1999, CANCER RES, V59, P5403; Lang F, 2004, J MOL RECOGNIT, V17, P473, DOI 10.1002/jmr.705; Lastraioli E, 2004, CANCER RES, V64, P606, DOI 10.1158/0008-5472.CAN-03-2360; Mu D, 2003, CANCER CELL, V3, P297, DOI 10.1016/S1535-6108(03)00054-0; Nitschke R, 1996, PFLUG ARCH EUR J PHY, V433, P98, DOI 10.1007/s004240050254; O'Grady SM, 2005, INT J BIOCHEM CELL B, V37, P1578, DOI 10.1016/j.biocel.2005.04.002; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pardo LA, 2004, PHYSIOLOGY, V19, P285, DOI 10.1152/physiol.00011.2004; Patel AJ, 2000, J BIOL CHEM, V275, P28722, DOI 10.1074/jbc.M003755200; Patel AJ, 2004, PFLUG ARCH EUR J PHY, V448, P261, DOI 10.1007/s00424-004-1255-8; Patt S, 2004, NEUROSCI LETT, V368, P249, DOI 10.1016/j.neulet.2004.07.001; Pei L, 2003, P NATL ACAD SCI USA, V100, P7803, DOI 10.1073/pnas.1232448100; PERES A, 1988, FEBS LETT, V241, P164, DOI 10.1016/0014-5793(88)81052-4; RUTILI G, 1977, ACTA PHYSIOL SCAND, V99, P1, DOI 10.1111/j.1748-1716.1977.tb10345.x; Schonherr R, 2005, J MEMBRANE BIOL, V205, P175, DOI 10.1007/s00232-005-0782-3; Schreiber R, 2005, J MEMBRANE BIOL, V205, P129, DOI 10.1007/s00232-005-0778-z; Suzuki T, 2004, INT J ONCOL, V25, P153; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Wang XT, 2000, AM J PATHOL, V157, P1549, DOI 10.1016/S0002-9440(10)64792-X; Wang ZG, 2004, PFLUG ARCH EUR J PHY, V448, P274, DOI 10.1007/s00424-004-1258-5; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; Yao XQ, 1999, LIFE SCI, V65, P55, DOI 10.1016/S0024-3205(99)00218-0	43	81	86	2	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					35	44		10.1096/fj.06-6200com	http://dx.doi.org/10.1096/fj.06-6200com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135369				2022-12-28	WOS:000243130200005
J	D'Argenio, G; Calvani, M; Casamassimi, A; Petillo, O; Margarucci, S; Rienzo, M; Peluso, I; Calvani, R; Ciccodicola, A; Caporaso, N; Peluso, G				D'Argenio, Giuseppe; Calvani, Menotti; Casamassimi, Amelia; Petillo, Orsolina; Margarucci, Sabrina; Rienzo, Monica; Peluso, Ivana; Calvani, Riccardo; Ciccodicola, Alfredo; Caporaso, Nicola; Peluso, Gianfranco			Experimental colitis: decreased Octn2 and Atb0+expression in rat colonocytes induces carnitine depletion that is reversible by carnitine-loaded liposomes	FASEB JOURNAL			English	Article						butyrate; acetyl-CoA; mitochondria	CHAIN FATTY-ACID; SKELETAL-MUSCLE; TRANSPORTER; METABOLISM; EXPRESSION; CELLS; BUTYRATE; PROFILE; COLON	Carnitine transporters have recently been implicated in susceptibility to inflammatory bowel disease (IBD). Because carnitine is required for beta-oxidation, it was suggested that decreased carnitine transporters, and hence reduced carnitine uptake, could lead to impaired fatty acid oxidation in intestinal epithelial cells, and to cell injury. We investigated this issue by examining the expression of the carnitine transporters OCTN2 and ATB0+, and butyrate metabolism in colonocytes in a rat model of IBD induced by trinitrobenzene sulfonic acid (TNBS). We found that Octn2 and Atb0+ expression was decreased in inflammatory samples at translational and functional level. Butyrate oxidation, evaluated based on CO2 production and acetyl-coenzyme A synthesis, was deranged in colonocytes from TNBS-treated rats. Treatment with carnitine-loaded liposomes corrected the butyrate metabolic alterations in vitro and reduced the severity of colitis in vivo. These results suggest that carnitine depletion in colonocytes is associated with the inability of mitochondria to maintain normal butyrate beta-oxidation. Our data indicate that carnitine is a rate-limiting factor for the maintenance of physiological butyrate oxidation in colonic cells. This hypothesis could also explain the contradictory therapeutic efficacy of butyrate supplementation observed in clinical trials of IBD.-D'Argenio, G., Calvani, M., Casamassimi, A., Petillo, O., Margarucci, S., Rienzo, M., Peluso, I., Calvani, R., Ciccodicola, A., Caporaso, N., and Peluso, G. Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes induces carnitine depletion that is reversible by carnitine-loaded liposomes.	Univ Naples Federico II, Dept Clin & Expt Med, Gastroenterol Unit, Naples, Italy; Sigma Tau Pharmaceut Co, Dept Sci, Rome, Italy; CNR, IGB, Inst Genet & Biophys A Buzzati Traverso, I-80125 Naples, Italy; CNR, IBP, Inst Prot Biochem, I-80125 Naples, Italy; Telethon Inst Genet & Med, Naples, Italy	University of Naples Federico II; Italfarmaco; Leadiant Biosciences; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM)	Peluso, G (corresponding author), CNR, IBP, Inst Prot Biochem, Via P Castellino 111, I-80125 Naples, Italy.	g.peluso@ibp.cnr.it	Casamassimi, Amelia/AAD-2816-2020; Calvani, Riccardo/K-2011-2018	Casamassimi, Amelia/0000-0002-6010-4261; Calvani, Riccardo/0000-0001-5472-2365; Rienzo, Monica/0000-0002-4496-4894; MARGARUCCI, SABRINA/0000-0001-5361-1241; Ciccodicola, Alfredo/0000-0002-9924-1482	Telethon [TGM06S01, TGM03Z04] Funding Source: Medline	Telethon(Fondazione Telethon)		Bene J, 2006, WORLD J GASTROENTERO, V12, P110, DOI 10.3748/wjg.v12.i1.110; Boren J, 2003, J BIOL CHEM, V278, P28395, DOI 10.1074/jbc.M302932200; BREMER J, 1977, TRENDS BIOCHEM SCI, V2, P207; CARTER AL, 1995, J CHILD NEUROL, V10, pS2; D'Argenio G, 1999, ADV EXP MED BIOL, V472, P149; DARGENIO G, 1994, GASTROENTEROLOGY, V106, P399, DOI 10.1016/0016-5085(94)90598-3; Domazou AS, 2002, J LIPOSOME RES, V12, P205, DOI 10.1081/LPR-120014758; Evans AM, 2003, CLIN PHARMACOKINET, V42, P941, DOI 10.2165/00003088-200342110-00002; FLEMING SE, 1994, CAN J PHYSIOL PHARM, V72, P266, DOI 10.1139/y94-041; Foster DW, 2004, ANN NY ACAD SCI, V1033, P1, DOI 10.1196/annals.1320.001; HARIG JM, 1989, NEW ENGL J MED, V320, P23, DOI 10.1056/NEJM198901053200105; Jorgensen JR, 1997, GUT, V40, P400, DOI 10.1136/gut.40.3.400; Kerner J, 1998, ANNU REV NUTR, V18, P179, DOI 10.1146/annurev.nutr.18.1.179; Lahjouji K, 2001, MOL GENET METAB, V73, P287, DOI 10.1006/mgme.2001.3207; Loguercio C, 1996, DIGEST DIS SCI, V41, P1204, DOI 10.1007/BF02088238; Matern D, 2001, J NUTR, V131, p1615S, DOI 10.1093/jn/131.5.1615S; Matsuda K, 1998, BIOL PHARM BULL, V21, P752, DOI 10.1248/bpb.21.752; Michno A, 2005, CLIN CHEM, V51, P1673, DOI 10.1373/clinchem.2005.050328; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9; Nakanishi T, 2001, J PHYSIOL-LONDON, V532, P297, DOI 10.1111/j.1469-7793.2001.0297f.x; Newman B, 2005, GASTROENTEROLOGY, V128, P260, DOI 10.1053/j.gastro.2004.11.056; Ohashi R, 2001, MOL PHARMACOL, V59, P358, DOI 10.1124/mol.59.2.358; Ohashi R, 1999, J PHARMACOL EXP THER, V291, P778; Peluso G, 2005, J CELL PHYSIOL, V203, P439, DOI 10.1002/jcp.20239; Peluso G, 2002, FRONT BIOSCI, V7, pA109, DOI 10.2741/peluso; Peluso G, 2000, J CELL PHYSIOL, V182, P339, DOI 10.1002/(SICI)1097-4652(200003)182:3<339::AID-JCP4>3.3.CO;2-2; Pizarro TT, 2003, TRENDS MOL MED, V9, P218, DOI 10.1016/S1471-4914(03)00052-2; REBOUCHE CJ, 1992, FASEB J, V6, P3379, DOI 10.1096/fasebj.6.15.1464372; Rebouche CJ, 1998, ANNU REV NUTR, V18, P39, DOI 10.1146/annurev.nutr.18.1.39; ROEDIGER WEW, 1979, GUT, V20, P484, DOI 10.1136/gut.20.6.484; ROEDIGER WEW, 1988, DIS COLON RECTUM, V31, P482, DOI 10.1007/BF02552623; ROEDIGER WEW, 1980, LANCET, V2, P712; Rytting E, 2005, J PHARMACOL EXP THER, V312, P192, DOI 10.1124/jpet.104.072363; Sekine T, 1998, BIOCHEM BIOPH RES CO, V251, P586, DOI 10.1006/bbrc.1998.9521; Sloan JL, 2003, AM J PHYSIOL-LUNG C, V284, pL39, DOI 10.1152/ajplung.00164.2002; Spinozzi F, 1998, FASEB J, V12, P1747, DOI 10.1096/fasebj.12.15.1747; Stano P, 2004, J LIPOSOME RES, V14, P87, DOI 10.1081/LPR-120039794; SZUTOWICZ A, 1987, ANAL BIOCHEM, V164, P292, DOI 10.1016/0003-2697(87)90495-7; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Waller S, 2006, GUT, V55, P809, DOI 10.1136/gut.2005.084574; WILEMAN T, 1984, BIOCHEM J, V198, P665; WU GY, 1988, BIOCHEM J, V255, P139, DOI 10.1042/bj2550139; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482	43	37	38	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2544	+		10.1096/fj.06-5950fje	http://dx.doi.org/10.1096/fj.06-5950fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065219				2022-12-28	WOS:000242490700018
J	Kwakkenbos, MJ; Matmati, M; Madsen, O; Pouwels, W; Wang, YY; Bontrop, RE; Heidt, PJ; Hoek, RM; Hamann, J				Kwakkenbos, Mark J.; Matmati, Mourad; Madsen, Ole; Pouwels, Walter; Wang, YongYi; Bontrop, Ronald E.; Heidt, Peter J.; Hoek, Robert M.; Hamann, Jorg			An unusual mode of concerted evolution of the EGF-TM7 receptor chimera EMR2	FASEB JOURNAL			English	Article						adhesion class; gene conversion; ligand specificity; mammals	CHONDROITIN SULFATE; CELLULAR LIGAND; FAMILY; CD97; EXPRESSION; MOLECULE; MEMBER; GENE; 7-TRANSMEMBRANE; MACROPHAGES	The epidermal growth factor (EGF)-TM7 receptors CD97, EMR1, EMR2, EMR3, and EMR4 form a group of adhesion class heptahelical molecules predominantly expressed by cells of the immune system. These receptors bind cellular ligands through EGF-like domains, localized N-terminal to a large extracellular region. Remarkably, EMR2 possesses a chimeric structure with a seven-span transmembrane (TM7) region most related to EMR3 and an EGF domain region nearly identical to CD97. By comparing EGF-TM7 receptors in primates and dogs, we identified an intriguing pattern of concerted evolution, apparently mediated by gene conversion, among EMR2 and the oppositely orientated and physically adjacent genes CD97 and EMR3. This concerted evolution has continuously maintained the chimeric structure of EMR2 since early mammal radiation. Most highly conserved between EMR2 and CD97 is the fourth EGF domain, which mediates binding to chondroitin sulfate, a ligand specificity shared by both receptors. Another ligand, CD55, is bound effectively only by CD97. We show that different molecular mechanisms (mutations vs. alternative splicing) prevent CD55 binding by EMR2 in hominoids. Our findings illustrate how various and partially opposing evolutionary events have shaped the structure and ligand specificity of a modern mammalian gene family.	Univ Amsterdam, Dept Expt Immunol, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands; Radboud Univ Nijmegen, Dept Biochem, Nijmegen, Netherlands; Biomed Primate Res Ctr, Dept Comparat Genet & Refinement, Rijswijk, Netherlands; Biomed Primate Res Ctr, Dept Anim Sci, Rijswijk, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen	Hamann, J (corresponding author), Univ Amsterdam, Dept Expt Immunol, Acad Med Ctr, K1-144,POB 22700, NL-1100 DE Amsterdam, Netherlands.	j.hamann@amc.uva.nl	Bontrop, Ronald E./D-4844-2011; Madsen, Ole/E-3730-2012; Heidt, Peter/GQQ-8459-2022; Bontrop, Ronald E/J-3628-2012	Madsen, Ole/0000-0001-8082-7881; Bontrop, Ronald E/0000-0003-0874-6467; Kwakkenbos, Mark/0000-0003-0340-5655; Hamann, Jorg/0000-0002-9448-1727				BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Benedict MQ, 1996, INSECT MOL BIOL, V5, P73, DOI 10.1111/j.1365-2583.1996.tb00042.x; Bjarnadottir TK, 2004, GENOMICS, V84, P23, DOI 10.1016/j.ygeno.2003.12.004; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Eichler EE, 2001, TRENDS GENET, V17, P661, DOI 10.1016/S0168-9525(01)02492-1; Eichler W, 2000, J LEUKOCYTE BIOL, V68, P561; ESKO JD, 1987, J BIOL CHEM, V262, P12189; Gagneux P, 2001, MOL PHYLOGENET EVOL, V18, P2, DOI 10.1006/mpev.2000.0799; Gray JX, 1996, J IMMUNOL, V157, P5438; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hamann J, 1998, EUR J IMMUNOL, V28, P1701, DOI 10.1002/(SICI)1521-4141(199805)28:05<1701::AID-IMMU1701>3.0.CO;2-2; Hamann J, 2004, IMMUNOGENETICS, V56, P679, DOI 10.1007/s00251-004-0729-3; Hamann J, 2003, EUR J IMMUNOL, V33, P1365, DOI 10.1002/eji.200323881; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; Hamann J, 2000, INT IMMUNOL, V12, P439, DOI 10.1093/intimm/12.4.439; Hayakawa T, 2005, SCIENCE, V309, P1693, DOI 10.1126/science.1114321; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; Kop EN, 2005, ARTHRITIS RHEUM-US, V52, P442, DOI 10.1002/art.20788; Kwakkenbos MJ, 2005, J LEUKOCYTE BIOL, V77, P112, DOI 10.1189/jlb.0704402; Kwakkenbos MJ, 2004, IMMUNOGENETICS, V55, P655, DOI 10.1007/s00251-003-0625-2; Kwakkenbos MJ, 2002, J LEUKOCYTE BIOL, V71, P854; Kwakkenbos MJ, 2001, LEUCOCYTE TYPING, P381; Leemans JC, 2004, J IMMUNOL, V172, P1125, DOI 10.4049/jimmunol.172.2.1125; Li W. H, 1997, MOL EVOLUTION; Liao DQ, 1999, AM J HUM GENET, V64, P24, DOI 10.1086/302221; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lin HH, 2004, J BIOL CHEM, V279, P31823, DOI 10.1074/jbc.M402974200; Lin HH, 2005, J EXP MED, V201, P1615, DOI 10.1084/jem.20042307; Lin HH, 2001, J BIOL CHEM, V276, P24160, DOI 10.1074/jbc.M101770200; Lin HH, 2000, GENOMICS, V67, P188, DOI 10.1006/geno.2000.6238; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; O'Brien SJ, 1999, SCIENCE, V286, P458, DOI 10.1126/science.286.5439.458; Olson MV, 2003, NAT REV GENET, V4, P20, DOI 10.1038/nrg981; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Schimenti JC, 1999, AM J HUM GENET, V64, P40, DOI 10.1086/302220; Shimodaira H, 1999, MOL BIOL EVOL, V16, P1114, DOI 10.1093/oxfordjournals.molbev.a026201; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Stacey M, 2003, BLOOD, V102, P2916, DOI 10.1182/blood-2002-11-3540; Stacey M, 2002, J BIOL CHEM, V277, P29283, DOI 10.1074/jbc.M204306200; Stacey M, 2001, J BIOL CHEM, V276, P18863, DOI 10.1074/jbc.M101147200; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Swofford D. L., 2003, PAUP PHYLOGENTIC ANA; Thornton JW, 2000, ANNU REV GENOM HUM G, V1, P41, DOI 10.1146/annurev.genom.1.1.41; Wang T, 2005, BLOOD, V105, P2836, DOI 10.1182/blood-2004-07-2878	44	38	38	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2582	+		10.1096/fj.06-6500fje	http://dx.doi.org/10.1096/fj.06-6500fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17068111				2022-12-28	WOS:000242490700031
J	Maurer, M; Kostka, SL; Siebenhaar, F; Moelle, K; Metz, M; Knop, J; von Stebut, E				Maurer, Marcus; Kostka, Susanna Lopez; Siebenhaar, Frank; Moelle, Katharina; Metz, Martin; Knop, Juergen; von Stebut, Esther			Skin mast cells control T cell-dependent host defense in Leishmania major infections	FASEB JOURNAL			English	Article						leishmaniasis; Th1/Th2; dendritic cell; cytokine release	DENDRITIC CELLS; SUSCEPTIBLE MICE; LANGERHANS CELLS; DEFICIENT W/WV; IMMUNITY; INNATE; ACTIVATION; INDUCTION; MODEL; IL-12	Mast cells (MCs) initiate protective immunity against bacteria. Here we demonstrate that MCs also contribute to the control of parasitic skin infections by Leishmania major. L. major-infected MC-deficient Kit(W)/Kit(W-v) v mice developed markedly larger skin lesions than did normal Kit+/+ mice (> 2-fold), and cutaneous reconstitution with MCs resulted in normalization of lesion development. Kit(W)/Kit(W-v) lesions contained significantly more parasites, and infections resulted in enhanced spreading of parasites to the spleens as compared to controls. In addition, recruitment of proinflammatory neutrophils, macrophages, and dendritic cells (DCs) in infected mice was MC dependent. In the absence of MCs, reduced numbers of lesional DCs were associated with decreased production of Th1-promoting interleukin (IL)-12. Antigen-specific T cell priming was delayed in Kit(W)/Kit(W-v) mice and cytokine responses were skewed towards Th2. Notably, local skin MC reconstitution at sites of infection was sufficient for the induction of systemic protection. Thus, MC-mediated control of L. major infections is not limited to the induction of local inflammation. Instead, MCs contribute significantly to local DC recruitment, which mediates protective immunity. These findings extend the view of MCs as salient sentinels of innate immunity to complex host defense reactions against intracellular pathogens.	Univ Hosp Mainz, Dept Dermatol, Mainz, Germany; Univ Med Berlin, Charite, Allergie Ctr Charite, Dept Dermatol & Allergy, Berlin, Germany	University Hospital Mainz; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	von Stebut, E (corresponding author), Johannes Gutenberg Univ Mainz, Dept Dermatol, Langenbeckstr 1, D-55131 Mainz, Germany.	vonstebu@mail.uni-mainz.de	Maurer, Marcus/ABG-2174-2020; Metz, Martin/M-5237-2013; Metz, Martin/B-8799-2009	Maurer, Marcus/0000-0002-4121-481X; Metz, Martin/0000-0002-4070-9976; Metz, Martin/0000-0002-4070-9976; Siebenhaar, Frank/0000-0003-4532-1644				Adkins B, 2003, J IMMUNOL, V170, P4548, DOI 10.4049/jimmunol.170.9.4548; Ahuja SS, 1999, J IMMUNOL, V163, P3890; Artis D, 2004, J IMMUNOL, V173, P5626, DOI 10.4049/jimmunol.173.9.5626; Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969; Belkaid Y, 1998, EUR J IMMUNOL, V28, P1389, DOI 10.1002/(SICI)1521-4141(199804)28:04&lt;1389::AID-IMMU1389&gt;3.0.CO;2-1; Belkaid Y, 2002, J IMMUNOL, V168, P3992, DOI 10.4049/jimmunol.168.8.3992; Bidri M, 1997, PARASITE IMMUNOL, V19, P475, DOI 10.1046/j.1365-3024.1997.d01-153.x; Carrera L, 1996, J EXP MED, V183, P515, DOI 10.1084/jem.183.2.515; Chen JC, 2003, J IMMUNOL METHODS, V279, P123, DOI 10.1016/S0022-1759(03)00236-9; de Oliveira MP, 2005, EXP PARASITOL, V109, P72, DOI 10.1016/j.exppara.2004.11.011; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Finkelman FD, 2004, IMMUNOL REV, V201, P139, DOI 10.1111/j.0105-2896.2004.00192.x; Flohe SB, 1998, EUR J IMMUNOL, V28, P3800, DOI 10.1002/(SICI)1521-4141(199811)28:11&lt;3800::AID-IMMU3800&gt;3.0.CO;2-0; GALLI SJ, 1987, AM J PATHOL, V127, P191; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; GRIMALDI G, 1984, PARASITE IMMUNOL, V6, P397, DOI 10.1111/j.1365-3024.1984.tb00811.x; Henz BM, 2001, EXP DERMATOL, V10, P1, DOI 10.1034/j.1600-0625.2001.100101.x; KATAKURA K, 1993, INFECT IMMUN, V61, P2242, DOI 10.1128/IAI.61.5.2242-2244.1993; Knight PA, 2004, INFECT IMMUN, V72, P6076, DOI 10.1128/IAI.72.10.6076-6086.2004; Li EQ, 2004, INFECT IMMUN, V72, P6642, DOI 10.1128/IAI.72.11.6642-6649.2004; Maurer M, 1998, J EXP MED, V188, P2343, DOI 10.1084/jem.188.12.2343; Nakae S, 2005, P NATL ACAD SCI USA, V102, P6467, DOI 10.1073/pnas.0501912102; Onah Denis Nnabuike, 2004, J Vet Sci, V5, P221; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Ritter U, 2004, EUR J IMMUNOL, V34, P1542, DOI 10.1002/eji.200324586; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Saha B, 2004, CLIN EXP IMMUNOL, V137, P19, DOI 10.1111/j.1365-2249.2004.02505.x; Tacchini-Cottier F, 2000, J IMMUNOL, V165, P2628, DOI 10.4049/jimmunol.165.5.2628; von Stebut E, 2003, J EXP MED, V198, P191, DOI 10.1084/jem.20030159; von Stebut E, 2003, BLOOD, V101, P210, DOI 10.1182/blood-2002-03-0921; von Stebut E, 1998, J EXP MED, V188, P1547, DOI 10.1084/jem.188.8.1547; von Stebut E, 2000, EUR J IMMUNOL, V30, P3498, DOI 10.1002/1521-4141(2000012)30:12&lt;3498::AID-IMMU3498&gt;3.0.CO;2-6; Weber A, 2003, BRIT J DERMATOL, V148, P224, DOI 10.1046/j.1365-2133.2003.05090.x; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; WERSHIL BK, 1994, J IMMUNOL, V152, P4563; WERSHIL BK, 1988, J IMMUNOL, V140, P2356	37	107	109	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2460	2467		10.1096/fj.06-5860com	http://dx.doi.org/10.1096/fj.06-5860com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17142795				2022-12-28	WOS:000242490700006
J	Nahmias, Y; Kramvis, Y; Barbe, L; Casali, M; Berthiaume, F; Yarmush, ML				Nahmias, Yaakov; Kramvis, Yiannos; Barbe, Laurent; Casali, Monica; Berthiaume, Francois; Yarmush, Martin L.			A novel formulation of oxygen-carrying matrix enhances liver-specific function of cultured hepatocytes	FASEB JOURNAL			English	Article						cytochrome P450; fluorocarbon	LONG-TERM CULTURE; BLOOD SUBSTITUTES; RAT HEPATOCYTES; IN-VITRO; PERFLUOROCARBON; HEMOGLOBIN; GRADIENTS; GROWTH; CELLS; PERFLUOROCHEMICALS	Oxygen is an important component of the cellular microenvironment, mediating cell survival, differentiation, and function. Oxygen supply is a limiting factor during culture of highly metabolic cells such as hepatocytes. Here we present a simple formulation of a fluorocarbon-based oxygen carrier embedded in collagen gel that increases oxygen concentration in culture 6-fold. Rat hepatocytes cultured on oxygen carrier-collagen showed a significant increase in viability and function. Cytochrome P450IA1 activity was increased by 140% in serum-free cultures and by 820% in serum-containing cultures. The significantly higher hepatocellular function on oxygen carrier-collagen matrix persisted and increased during long-term culture. Long-term albumin secretion was increased by 350% in serum-free cultures and by 166% in serum-containing culture. Long-term urea secretion was increased by 79% in serum-free cultures and by 76% in serum-containing cultures. We conclude that oxygen supply may limit hepatocyte function in vitro. This limitation can be overcome by addition of an oxygen carrier to the extracellular matrix. Culture of hepatocytes on oxygen-carrying matrix mimics the oxygen-rich environment of the liver and provides a simple method for enhanced long-term function.-Nahmias, Y., Kramvis, Y., Barbe, L., Casali, M., Berthiaume, F., Yarmush, M. L. A novel formulation of oxygen-carrying matrix enhances liver-specific function of cultured hepatocytes.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Burns Hosp,Dept Surg,Ctr Engn Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Yarmush, ML (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Burns Hosp,Dept Surg,Ctr Engn Med, Boston, MA 02114 USA.	ireis@sbi.org	Barbe, Laurent/G-3676-2019; Berthiaume, Francois/ABD-2139-2020; Nahmias, Yaakov/AAM-3872-2020; Nahmias, Yaakov/H-4725-2013	Barbe, Laurent/0000-0003-4475-6478; Nahmias, Yaakov/0000-0002-6051-616X; Nahmias, Yaakov/0000-0002-6051-616X; Yarmush, Martin/0000-0003-4986-8444				Alayash AI, 2004, NAT REV DRUG DISCOV, V3, P152, DOI 10.1038/nrd1307; Alayash AI, 1999, NAT BIOTECHNOL, V17, P545, DOI 10.1038/9849; Allen JW, 2003, BIOTECHNOL BIOENG, V82, P253, DOI 10.1002/bit.10569; Arendt E, 2005, CELL PROLIFERAT, V38, P287, DOI 10.1111/j.1365-2184.2005.00350.x; Balis UJ, 1999, METAB ENG, V1, P49, DOI 10.1006/mben.1998.0105; Behnia K, 2000, TISSUE ENG, V6, P467, DOI 10.1089/107632700750022125; Bertilla SM, 2004, LANGMUIR, V20, P3920, DOI 10.1021/la036381m; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; BURKE MD, 1994, BIOCHEM PHARMACOL, V48, P923, DOI 10.1016/0006-2952(94)90363-8; Cain K, 2001, TOXICOL LETT, V120, P307, DOI 10.1016/S0378-4274(01)00283-1; Dieryck W, 1997, NATURE, V386, P29, DOI 10.1038/386029b0; DROCHMANS P, 1975, J CELL BIOL, V66, P1, DOI 10.1083/jcb.66.1.1; Dudich E, 1998, TUMOR BIOL, V19, P30, DOI 10.1159/000029972; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; Eguchi H, 1987, Alcohol Alcohol Suppl, V1, P519; FARISS MW, 1990, FREE RADICAL BIO MED, V9, P333, DOI 10.1016/0891-5849(90)90008-7; FOY BD, 1994, CELL TRANSPLANT, V3, P515, DOI 10.1177/096368979400300609; GIAEVER I, 1983, P NATL ACAD SCI-BIOL, V80, P219, DOI 10.1073/pnas.80.1.219; KEESE CR, 1983, SCIENCE, V219, P1448, DOI 10.1126/science.6828872; KING AT, 1989, BIO-TECHNOL, V7, P1037; Krafft MP, 1998, BIOCHIMIE, V80, P489, DOI 10.1016/S0300-9084(00)80016-4; LEMASTERS JJ, 1981, SCIENCE, V213, P661, DOI 10.1126/science.7256265; Lemasters JJ., 2001, LIVER BIOL PATHOBIOL, P257; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; Lowe KC, 2003, TISSUE ENG, V9, P389, DOI 10.1089/107632703322066570; Lowe KC, 1998, TRENDS BIOTECHNOL, V16, P272, DOI 10.1016/S0167-7799(98)01205-0; MAGDASSI S, 1992, INT J PHARMACEUT, V88, P171, DOI 10.1016/0378-5173(92)90314-R; Martin H, 2002, CELL BIOL TOXICOL, V18, P73, DOI 10.1023/A:1015379815897; Matsumoto S, 2002, TRANSPLANTATION, V74, P1804, DOI 10.1097/01.TP.0000038315.74633.DE; McCuskey RS, 2003, ANAT REC PART A, V275A, P1019, DOI 10.1002/ar.a.10117; NI Y, 1994, ARTIF CELL BLOOD SUB, V22, P1307, DOI 10.3109/10731199409138831; Radisic M, 2006, BIOTECHNOL BIOENG, V93, P332, DOI 10.1002/bit.20722; Rappaport C, 2002, BIOTECHNIQUES, V32, P142, DOI 10.2144/02321rr03; Riess JG, 2005, ARTIF CELL BLOOD SUB, V33, P47, DOI 10.1081/BIO-200046659; Riess JG, 2001, CHEM REV, V101, P2797, DOI 10.1021/cr970143c; Riess JG, 1998, BIOMATERIALS, V19, P1529, DOI 10.1016/S0142-9612(98)00071-4; ROTEM A, 1994, BIOTECHNOL BIOENG, V43, P654, DOI 10.1002/bit.260430715; STEVENS KM, 1965, NATURE, V206, P199, DOI 10.1038/206199a0; Strain AJ, 2002, SCIENCE, V295, P1005, DOI 10.1126/science.1068660; Tilles AW, 2001, BIOTECHNOL BIOENG, V73, P379, DOI 10.1002/bit.1071; Wang WJ, 2005, J ENDOCRINOL, V185, P445, DOI 10.1677/joe.1.06092; Wu FJ, 1999, CELL TRANSPLANT, V8, P233, DOI 10.1177/096368979900800304; YARMUSH ML, 1992, ANN NY ACAD SCI, V665, P238, DOI 10.1111/j.1749-6632.1992.tb42588.x; ZHANG JX, 1994, AM J PHYSIOL, V266, pG624, DOI 10.1152/ajpgi.1994.266.4.G624	45	68	72	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2531	+		10.1096/fj.06-6192fje	http://dx.doi.org/10.1096/fj.06-6192fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077286				2022-12-28	WOS:000242490700013
J	Porto, A; Palumbo, R; Pieroni, M; Aprigliano, G; Chiesa, R; Sanvito, F; Maseri, A; Bianchi, ME				Porto, Annalisa; Palumbo, Roberta; Pieroni, Maurizio; Aprigliano, Gianfranco; Chiesa, Roberto; Sanvito, Francesca; Maseri, Attilio; Bianchi, Marco E.			Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein	FASEB JOURNAL			English	Article						atherosclerosis; cholesterol; cytokine; inflammation	CHROMATIN PROTEIN; DOWN-REGULATION; HMGB1; INFLAMMATION; EXPRESSION; MEDIATOR; HMG-1; MONOCYTES; MIGRATION; LESIONS	High mobility group box 1 protein (HMGB1) is a chromatin component leaked out by necrotic cells and actively secreted by activated myeloid cells. The extracellular protein is a potent mediator of tissue remodeling. We show here that human atherosclerotic plaques, but not normal arteries, produce extracellular HMGB1. Secreted HMGB1 originates from endothelial cells, by neointimal foam cells, and also smooth muscle cells (SMCs). SMCs are an unexpected source for secreted HMGB1, since they normally express much lower amounts of HMGB1 than other cells types, and they do not secrete it. However, cultured SMCs actively secrete HMGB1 after cholesterol loading. In turn, in response to HMGB1, SMCs proliferate, migrate, and secrete more HMGB1. Thus, SMCs are both a source and a target of HMGB1; blocking HMGB1 secretion by SMCs can be an important strategy for treatment of atherosclerotic disease and in particular restenosis.-Porto, A., Palumbo, R., Pieroni, M., Aprigliano, G., Chiesa, R., Sanvito, F., Maseri, A., Bianchi, M. E. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility protein box 1.	San Raffaele Univ, I-20132 Milan, Italy; San Raffaele Sci Inst, I-20132 Milan, Italy; Catholic Univ, Inst Cardiol, Rome, Italy	Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Bianchi, ME (corresponding author), San Raffaele Univ, Via Olgettina 58, I-20132 Milan, Italy.	bianchi.marco@hsr.it	Roberto, Chiesa/AAV-6476-2021; Bianchi, Marco Emilio/K-3417-2018; Pieroni, Maurizio/K-8488-2019	Bianchi, Marco Emilio/0000-0002-5329-6445; Pieroni, Maurizio/0000-0002-6830-4292				Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; Agresti A, 2003, CURR OPIN GENET DEV, V13, P170, DOI 10.1016/S0959-437X(03)00023-6; Andersson U, 2004, J INTERN MED, V255, P344, DOI 10.1111/j.1365-2796.2003.01303.x; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Bianchi ME, 2004, BBA-GENE STRUCT EXPR, V1677, P181, DOI 10.1016/j.bbaexp.2003.10.017; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Brunelli S, 2004, CIRC RES, V94, P1571, DOI 10.1161/01.RES.0000132747.12860.10; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197; Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009; Duran MC, 2003, PROTEOMICS, V3, P973, DOI 10.1002/pmic.200300389; Fiuza C, 2002, BLOOD, V27, P2652; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; JAULMES A, 2006, IN PRESS FASEB J; Kalinina N, 2004, ARTERIOSCL THROM VAS, V24, P2320, DOI 10.1161/01.ATV.0000145573.36113.8a; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Muller S, 2004, J INTERN MED, V255, P332, DOI 10.1111/j.1365-2796.2003.01296.x; Palumbo R, 2004, J CELL BIOL, V164, P441, DOI 10.1083/jcb.200304135; Palumbo R, 2000, CIRCULATION, V102, P225, DOI 10.1161/01.CIR.102.2.225; Rong JX, 2003, P NATL ACAD SCI USA, V100, P13531, DOI 10.1073/pnas.1735526100; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sappington PL, 2002, GASTROENTEROLOGY, V123, P790, DOI 10.1053/gast.2002.35391; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schwartz S M, 2000, Curr Atheroscler Rep, V2, P422, DOI 10.1007/s11883-000-0081-5; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Ulfgren AK, 2004, ARTHRITIS RHEUM, V50, P1586, DOI 10.1002/art.20220; Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262; Wang H, 2004, J INTERN MED, V255, P320, DOI 10.1111/j.1365-2796.2003.01302.x; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yan SF, 2003, CIRC RES, V93, P1159, DOI 10.1161/01.RES.0000103862.26506.3D	32	148	159	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2565	+		10.1096/fj.06-5867fje	http://dx.doi.org/10.1096/fj.06-5867fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17060403				2022-12-28	WOS:000242490700025
J	Zangarelli, A; Chanseaume, E; Morio, B; Brugere, C; Mosoni, L; Rousset, P; Giraudet, C; Patrac, V; Gachon, P; Boirie, Y; Walrand, S				Zangarelli, Aude; Chanseaume, Emilie; Morio, Beatrice; Brugere, Corinne; Mosoni, Laurent; Rousset, Paulette; Giraudet, Christophe; Patrac, Veronique; Gachon, Pierre; Boirie, Yves; Walrand, Stephane			Synergistic effects of caloric restriction with maintained protein intake on skeletal muscle performance in 21-month-old rats: a mitochondria-mediated pathway	FASEB JOURNAL			English	Article						age; skeletal muscle; mitochondria; caloric restriction; protein intake	LOWERS OXIDATIVE DAMAGE; DNA DELETION MUTATIONS; MYOSIN HEAVY-CHAIN; DIETARY RESTRICTION; RADICAL GENERATION; CONTRACTILE TYPE; PROTON LEAK; SHORT-TERM; COMPLEX-I; AGE	Caloric restriction (CR) delays the onset of age-related mitochondrial abnormalities but does not prevent the decline in ATP production needed to sustain muscle protein fractional synthesis rate (FSR) and contractile activity. We hypothesized that improving mitochondrial activity and FSR using a CR diet with maintained protein intakes could enhance myofibrillar protein FSR and consequently improve muscle strength in aging rats. Wistar rats (21 months old) were fed either an ad libitum (AL), 40% protein-energy restricted (PER) or 40% AL-isonitrogenous energy restricted (ER) diet for 5 months. ATP production, electron transport chain activity, reactive oxygen species (ROS) generation, protein carbonyl content and FSR were determined in both tibialis anterior (TA) and soleus muscle mitochondria. Myosin and actin FSR and grip force were also investigated. The ER diet led to improved mitochondrial activity and ATP production in the TA and soleus muscles in comparison with PER. Furthermore, mitochondrial FSR in the TA was enhanced under the ER diet but diminished under the PER. Mitochondrial protein carbonyl content was decreased by both the ER and PER diets. The ER diet was able to improve myosin and actin FSR and grip force. Therefore, the synergistic effects of CR with maintained protein intake may help to limit the progression of sarcopenia by optimizing the turnover rates and functions of major proteins in skeletal muscle. -Zangarelli, A., Chanseaume, E., Morio, B., Brugere, C., Mosoni, L., Rousset, P., Giraudet, C., Patrac, V., Gachon, P., Boirie, Y., Walrand, S. Synergistic effects of caloric restriction with maintained protein intake on skeletal muscle performance in 21-month-old rats: a mitochondriamediated pathway.	UNH, UMR1019, INRA, Clermont Ferrand, France; Univ Clemont 1, UFR Med, Clermont Ferrand, France; UMR1019, Clermont Ferrand, France; CRNH Auvergne, Clermont Ferrand, France; CHU Clermont Ferrand, Hop Gabriel Montpied, Clermont Ferrand, France	INRAE; CHU Clermont Ferrand	Zangarelli, A (corresponding author), Univ Auvergne, CHU Clermont Ferrand, INRA, Ctr Rech Nutr Humaine,Unite Nutr Humaine, Clermont Ferrand, France.	boirie@sancy.clermont.inra.fr	Morio, Béatrice/G-3571-2018; Malpuech-Brugère, Corinne/D-6848-2017	Morio, Béatrice/0000-0002-2418-1438; Malpuech-Brugère, Corinne/0000-0001-9286-4647; Walrand, Stephane/0000-0002-4349-3664; Mosoni, Laurent/0000-0002-5409-6760				AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; Anderson J, 2003, CONTEMP THEATRE REV, V13, P47, DOI 10.1080/10267160302725; Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Bach-Rojecky Lidija, 2005, Acta Pharmaceutica (Zagreb), V55, P115; BAUMANN PQ, 1994, AM J PHYSIOL, V267, pE203, DOI 10.1152/ajpendo.1994.267.2.E203; Bevilacqua L, 2004, AM J PHYSIOL-ENDOC M, V286, pE852, DOI 10.1152/ajpendo.00367.2003; Boirie Y, 2001, DIABETES, V50, P2652, DOI 10.2337/diabetes.50.12.2652; BOTTINELLI R, 1994, J MUSCLE RES CELL M, V15, P413, DOI 10.1007/BF00122115; Bua EA, 2004, FASEB J, V18, P582, DOI 10.1096/fj.03-0668fje; Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001; Caldefie-Chezet F, 2002, CLIN CHIM ACTA, V319, P9, DOI 10.1016/S0009-8981(02)00015-3; Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502; Castaneda C, 2000, J Nutr Health Aging, V4, P85; CASTANEDA C, 1995, AM J CLIN NUTR, V62, P30, DOI 10.1093/ajcn/62.1.30; Clark BD, 2004, J ORTHOP SPORT PHYS, V34, P244, DOI 10.2519/jospt.2004.34.5.244; Conley KE, 2000, J PHYSIOL-LONDON, V526, P211, DOI 10.1111/j.1469-7793.2000.00211.x; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Fecho K, 2005, PHYSIOL BEHAV, V85, P177, DOI 10.1016/j.physbeh.2005.03.018; Gredilla R, 2004, ANN NY ACAD SCI, V1019, P333, DOI 10.1196/annals.1297.057; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; Gueguen N, 2005, MOL CELL BIOCHEM, V276, P15, DOI 10.1007/s11010-005-2464-y; Gueguen N, 2005, COMP BIOCHEM PHYS B, V140, P287, DOI 10.1016/j.cbpc.2004.10.014; Guillet C, 2004, FASEB J, V18, P1586, DOI 10.1096/fj.03-1341fje; Guillet C, 2004, EXP GERONTOL, V39, P745, DOI 10.1016/j.exger.2004.02.011; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; Judge S, 2005, FASEB J, V19, P419, DOI 10.1096/fj.04-2622fje; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; Kehl LJ, 2000, PAIN, V85, P333, DOI 10.1016/S0304-3959(99)00282-1; Lal SB, 2001, J GERONTOL A-BIOL, V56, pB116, DOI 10.1093/gerona/56.3.B116; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Mayhew M, 1998, BIOCHEM BIOPH RES CO, V251, P95, DOI 10.1006/bbrc.1998.9438; Minet-Quinard R, 2000, JPEN-PARENTER ENTER, V24, P30, DOI 10.1177/014860710002400130; Minet-Quinard R, 1999, AM J PHYSIOL-ENDOC M, V276, pE558, DOI 10.1152/ajpendo.1999.276.3.E558; Miro O, 2000, CARDIOVASC RES, V47, P624, DOI 10.1016/S0008-6363(00)00122-X; MOSONI L, 1995, AM J PHYSIOL-ENDOC M, V268, pE328, DOI 10.1152/ajpendo.1995.268.2.E328; Nagai M, 2000, BIOGERONTOLOGY, V1, P321, DOI 10.1023/A:1026590819033; Ouhabi R, 1998, ANAL BIOCHEM, V263, P169, DOI 10.1006/abio.1998.2776; Payne AM, 2003, J APPL PHYSIOL, V95, P2554, DOI 10.1152/japplphysiol.00758.2003; Pette D, 2001, INT J SPORT NUTR EXE, V11, pS3, DOI 10.1123/ijsnem.11.s1.s3; Pugh TD, 1999, NEUROBIOL AGING, V20, P157, DOI 10.1016/S0197-4580(99)00043-3; Raha S, 2002, FREE RADICAL BIO MED, V32, P421, DOI 10.1016/S0891-5849(01)00816-4; Ramamurthy B, 2001, FASEB J, V15, P2415, DOI 10.1096/fj.01-0183com; Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2; Reid MB, 2001, ACTA PHYSIOL SCAND, V171, P225, DOI 10.1046/j.1365-201x.2001.00824.x; Rooyackers OE, 1996, P NATL ACAD SCI USA, V93, P15364, DOI 10.1073/pnas.93.26.15364; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; Sanz A, 2004, J BIOENERG BIOMEMBR, V36, P545, DOI 10.1007/s10863-004-9001-7; Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; WALRAND S, 2003, AMINO METABOLISM THE, P389; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; Yarovaya NO, 2002, BIOGERONTOLOGY, V3, P25, DOI 10.1023/A:1015295011131; YOUNGMAN LD, 1992, P NATL ACAD SCI USA, V89, P9112, DOI 10.1073/pnas.89.19.9112; Zainal TA, 2000, FASEB J, V14, P1825, DOI 10.1096/fj.99-0881com; Zangarelli A, 2004, ANAL BIOCHEM, V327, P55, DOI 10.1016/j.ab.2003.11.024	60	53	53	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2439	2450		10.1096/fj.05-4544com	http://dx.doi.org/10.1096/fj.05-4544com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17142793				2022-12-28	WOS:000242490700004
J	Quaranta, MG; Mattioli, B; Giordani, L; Viora, M				Quaranta, Maria Giovanna; Mattioli, Benedetta; Giordani, Luciana; Viora, Marina			The immunoregulatory effects of HIV-1 Nef on dendritic cells and the pathogenesis of AIDS	FASEB JOURNAL			English	Review						antigen presenting cells; viral spreading; immune evasion	HUMAN-IMMUNODEFICIENCY-VIRUS; NATURAL-KILLER-CELLS; COMPLEX CLASS-II; CD4(+) T-CELLS; TYPE-1 NEF; DOWN-REGULATION; DC-SIGN; INFECTED-CELLS; UP-REGULATION; PRODUCTIVE INFECTION	Dendritic cells (DC) play a crucial role in the generation and regulation of immunity, and their interaction with HIV is relevant in the pathogenesis of AIDS favoring both the initial establishment and spread of the infection and the development of antiviral immunity. HIV-1 Nef is an essential factor for efficient viral replication and pathogenesis, and several studies have been addressed to assess the possible influence of endogenous or exogenous Nef on DC biology. Our findings and other reported data described in this review demonstrate that Nef subverts DC biology interfering with phenotypical, morphological, and functional DC developmental programs, thus representing a viral tool underlying AIDS pathogenesis. This review provides an overview on the mechanism by which Nef, hijacking DC functional activity, may favor both the replication of HIV-1 and the escape from immune surveillance. Overall, the findings described here may contribute to the understanding of Nef function, mechanism of action, and cellular partners. Further elucidation of genes induced through Nef signaling in DC could reveal pathways used by DC to drive HIV spread and will be critical to identify therapeutic strategies to bias the DC system toward activation of antiviral immunity instead of facilitating virus dissemination.	Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Viora, M (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	viora@iss.it		Quaranta, Maria Giovanna/0000-0002-1077-1488				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Al-Alwan MM, 2001, J IMMUNOL, V166, P1452, DOI 10.4049/jimmunol.166.3.1452; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Alcami A, 2000, TRENDS MICROBIOL, V8, P410, DOI 10.1016/S0966-842X(00)01830-8; Alessandrini L, 2000, J GEN VIROL, V81, P2905, DOI 10.1099/0022-1317-81-12-2905; Andrieu M, 2001, AIDS RES HUM RETROV, V17, P1365, DOI 10.1089/08892220152596623; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Briggs SD, 2001, J BIOL CHEM, V276, P25605, DOI 10.1074/jbc.M103244200; Burleigh L, 2006, J VIROL, V80, P2949, DOI 10.1128/JVI.80.6.2949-2957.2006; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Caldwell RL, 2000, J IMMUNOL, V165, P7035, DOI 10.4049/jimmunol.165.12.7035; Cambi A, 2004, J CELL BIOL, V164, P145, DOI 10.1083/jcb.200306112; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chassin D, 1999, EUR J IMMUNOL, V29, P196, DOI 10.1002/(SICI)1521-4141(199901)29:01<196::AID-IMMU196>3.3.CO;2-W; Chaudhry A, 2005, J IMMUNOL, V175, P4566, DOI 10.4049/jimmunol.175.7.4566; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Collins KL, 1999, IMMUNOL REV, V168, P65, DOI 10.1111/j.1600-065X.1999.tb01283.x; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Cramer LA, 2001, J ACQ IMMUN DEF SYND, V27, P417; Das SR, 2005, INDIAN J MED RES, V121, P315; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; Donaghy H, 2003, BLOOD, V101, P4505, DOI 10.1182/blood-2002-10-3189; Engering A, 2002, TRENDS IMMUNOL, V23, P480, DOI 10.1016/S1471-4906(02)02296-2; Engering A, 2002, BLOOD, V100, P1780, DOI 10.1182/blood-2001-12-0179; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Fackler OT, 1997, EUR J BIOCHEM, V247, P843, DOI 10.1111/j.1432-1033.1997.00843.x; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Fantuzzi L, 2004, J VIROL, V78, P9763, DOI 10.1128/JVI.78.18.9763-9772.2004; Federico M, 2001, BLOOD, V98, P2752, DOI 10.1182/blood.V98.9.2752; Fortis C, 2005, IMMUNOL RES, V33, P1, DOI 10.1385/IR:33:1:001; Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Giordani L, 2000, CLIN EXP IMMUNOL, V122, P358, DOI 10.1046/j.1365-2249.2000.01388.x; Granelli-Piperno A, 2006, J IMMUNOL, V176, P991, DOI 10.4049/jimmunol.176.2.991; Granelli-Piperno A, 2004, P NATL ACAD SCI USA, V101, P7669, DOI 10.1073/pnas.0402431101; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Gratton S, 2000, P NATL ACAD SCI USA, V97, P14566, DOI 10.1073/pnas.97.26.14566; Greenway AL, 2003, J BIOSCIENCES, V28, P323, DOI 10.1007/BF02970151; Holm GH, 2004, J VIROL, V78, P4541, DOI 10.1128/JVI.78.9.4541-4551.2004; HUSSAIN LA, 1995, IMMUNOLOGY, V85, P475; James CO, 2004, J VIROL, V78, P3099, DOI 10.1128/JVI.78.6.3099-3109.2004; Jameson B, 2002, J VIROL, V76, P1866, DOI 10.1128/JVI.76.4.1866-1875.2002; Janvier K, 2003, J BIOL CHEM, V278, P8725, DOI 10.1074/jbc.M210115200; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Knight SC, 1997, ANNU REV IMMUNOL, V15, P593, DOI 10.1146/annurev.immunol.15.1.593; Kohleisen B, 2001, J NEUROVIROL, V7, P52; Krautkramer E, 2004, J VIROL, V78, P4085, DOI 10.1128/JVI.78.8.4085-4097.2004; LEWIS DE, 1994, J IMMUNOL, V153, P412; Maccormac LP, 2004, VACCINE, V22, P528, DOI 10.1016/j.vaccine.2003.07.009; Mann J, 2005, J IMMUNOL, V175, P6560, DOI 10.4049/jimmunol.175.10.6560; Manninen A, 2002, J EXP MED, V195, P1023, DOI 10.1084/jem.20012039; Martin JC, 1999, J ACQ IMMUN DEF SYND, V22, P413; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; Messmer D, 2000, J VIROL, V74, P2406, DOI 10.1128/JVI.74.5.2406-2413.2000; Messmer D, 2002, J IMMUNOL, V169, P4172, DOI 10.4049/jimmunol.169.8.4172; Messmer D, 2002, AIDS RES HUM RETROV, V18, P1043, DOI 10.1089/08892220260235407; Michel N, 2005, CURR BIOL, V15, P714, DOI 10.1016/j.cub.2005.02.058; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Mueller YM, 2001, IMMUNITY, V15, P871, DOI 10.1016/S1074-7613(01)00246-1; Nguyen DG, 2003, EUR J IMMUNOL, V33, P483, DOI 10.1002/immu.200310024; Olivetta E, 2006, EXP CELL RES, V312, P890, DOI 10.1016/j.yexcr.2005.12.003; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998; Petit C, 2001, VIROLOGY, V286, P225, DOI 10.1006/viro.2001.0984; Piguet V, 2000, NAT CELL BIOL, V2, P163, DOI 10.1038/35004038; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Poudrier J, 2001, IMMUNITY, V15, P173, DOI 10.1016/S1074-7613(01)00177-7; Pulkkinen K, 2004, J VIROL, V78, P12773, DOI 10.1128/JVI.78.23.12773-12780.2004; Qiao XG, 2006, NAT IMMUNOL, V7, P302, DOI 10.1038/ni1302; Quaranta MG, 1999, EXP CELL RES, V250, P112, DOI 10.1006/excr.1999.4494; Quaranta MG, 2004, FASEB J, V18, P1459, DOI 10.1096/fj.04-1633fje; Quaranta MG, 2003, FASEB J, V17, P2025, DOI 10.1096/fj.03-0272com; Quaranta MG, 2002, EXP CELL RES, V275, P243, DOI 10.1006/excr.2002.5497; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Sawai ET, 1996, CURR BIOL, V6, P1519, DOI 10.1016/S0960-9822(96)00757-9; Schacker T, 2001, J INFECT DIS, V183, P555, DOI 10.1086/318524; Schindler M, 2003, J VIROL, V77, P10548, DOI 10.1128/JVI.77.19.10548-10556.2003; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Shinya E, 2004, VIROLOGY, V326, P79, DOI 10.1016/j.virol.2004.06.004; Shutt DC, 2000, CELL MOTIL CYTOSKEL, V46, P200, DOI 10.1002/1097-0169(200007)46:3<200::AID-CM5>3.0.CO;2-M; Sims TN, 2002, IMMUNOL REV, V186, P100, DOI 10.1034/j.1600-065X.2002.18610.x; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; STEINMAN RM, 1999, DENDRITIC CELLS BIOL, P421; Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853; Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498; Stumptner-Cuvelette P, 2003, MOL BIOL CELL, V14, P4857, DOI 10.1091/mbc.E03-04-0211; Swigut T, 2001, EMBO J, V20, P1593, DOI 10.1093/emboj/20.7.1593; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; Tobiume M, 2002, AIDS RES HUM RETROV, V18, P461, DOI 10.1089/088922202753614227; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Trimble LA, 1998, BLOOD, V91, P585, DOI 10.1182/blood.V91.2.585.585_585_594; Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841; Verhasselt B, 1999, BLOOD, V94, P2809, DOI 10.1182/blood.V94.8.2809.420k11_2809_2818; Vigerust DJ, 2005, J LEUKOCYTE BIOL, V77, P522, DOI 10.1189/jlb.0804454; Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240; Xu XN, 1999, J EXP MED, V189, P1489, DOI 10.1084/jem.189.9.1489; Zhang R, 2006, BLOOD, V107, P1989, DOI 10.1182/blood-2005-07-2731	112	29	30	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2198	2208		10.1096/fj.06-6260rev	http://dx.doi.org/10.1096/fj.06-6260rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077296				2022-12-28	WOS:000241702600004
J	Weiss, TW; Samson, AL; Niego, B; Daniel, PB; Medcalf, RL				Weiss, Thomas W.; Samson, Andre L.; Niego, Be'eri; Daniel, Philip B.; Medcalf, Robert L.			Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo	FASEB JOURNAL			English	Article						inflammation; glycoprotein 130; glutamate; stroke	NMDA RECEPTOR; PLASMINOGEN-ACTIVATOR; CEREBRAL INFARCT; GROWTH-FACTOR; EXPRESSION; GLUTAMATE; INTERLEUKIN-6; CELLS; NEUROTOXICITY; NEURODEGENERATION	Oncostatin M (OsM) is a member of the interleukin (IL)-6 family of cytokines and is well known for its role in inflammation, cell proliferation, and hematopoiesis. OsM, together with its glycoprotein 130 containing receptor complex, is expressed and regulated in most cells of the central nervous system (CNS), yet the function of OsM within this compartment is poorly understood. Here we have investigated the effect of OsM using in vitro and in vivo models of excitotoxic injury. Using primary cultures of mouse cortical neurons, OsM was shown to reduce N-methyl-D- aspartate (NMDA) - induced neuronal death by 50% when added simultaneously with NMDA while pretreatment of neurons with OsM fully prevented NMDA toxicity indicating a profound protective effect of this cytokine. OsM was also shown to inhibit NMDA-mediated increase in levels of free intracellular calcium and to selectively reduce neuronal expression of the NR2C subunit of the NMDA receptor. Finally, using an in vivo model of excitotoxic injury, OsM significantly reduced the NMDA-induced lesion volume when coinjected with NMDA into the mouse striatum. Taken together, these results identify OsM as a powerful neuroprotective cytokine and provide a rational foundation to explore the therapeutic potential for OsM in diseases of the CNS.	Monash Univ, Australian Ctr Blood Dis, Prahran, Vic 3181, Australia	Monash University	Medcalf, RL (corresponding author), Monash Univ, Australian Ctr Blood Dis, 89 Commercial Rd,Alfred Med Res & Educ Precinct, Prahran, Vic 3181, Australia.	robert.medcalf@med.monash.edu.au	Medcalf, Robert L/E-9632-2011; Niego, Beeri/AAG-5534-2019; Samson, Andre L/I-3432-2012	Niego, Beeri/0000-0001-6714-9131; Samson, Andre L/0000-0003-4825-1645; Samson, Andre/0000-0002-0637-2716				Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Brandoli C, 1998, J NEUROSCI, V18, P7953; Cacquevel M, 2004, CURR DRUG TARGETS, V5, P529, DOI 10.2174/1389450043345308; Callaway JK, 2000, J NEUROSCI METH, V102, P53, DOI 10.1016/S0165-0270(00)00278-8; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chen SH, 2006, GLIA, V53, P191, DOI 10.1002/glia.20264; Chen SH, 2004, CYTOKINE GROWTH F R, V15, P379, DOI 10.1016/j.cytogfr.2004.06.002; Choi JS, 2003, GLIA, V41, P237, DOI 10.1002/glia.10186; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; D'Arcangelo G, 2000, EUR J NEUROSCI, V12, P1241, DOI 10.1046/j.1460-9568.2000.00011.x; Ensoli F, 1999, J IMMUNOL, V162, P6268; Fernandez-Monreal M, 2004, MOL CELL NEUROSCI, V25, P594, DOI 10.1016/j.mcn.2003.11.002; Gomez-Lechon MJ, 1999, LIFE SCI, V65, P2019, DOI 10.1016/S0024-3205(99)00296-9; Igaz P, 2006, ENDOCRINOLOGY, V147, P1037, DOI 10.1210/en.2005-0729; Jankowsky JL, 1999, EXP NEUROL, V159, P333, DOI 10.1006/exnr.1999.7137; Jensen JB, 1999, J NEUROSCI RES, V55, P208, DOI 10.1002/(SICI)1097-4547(19990115)55:2<208::AID-JNR8>3.0.CO;2-P; Kadotani H, 1998, NEUROREPORT, V9, P471, DOI 10.1097/00001756-199802160-00021; Kasza A, 2002, J NEUROCHEM, V83, P696, DOI 10.1046/j.1471-4159.2002.01163.x; Leuchtmann EA, 2003, NEUROBIOL DIS, V14, P336, DOI 10.1016/j.nbd.2003.07.004; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Petzold GC, 2005, BRAIN RES, V1063, P9, DOI 10.1016/j.brainres.2005.09.048; Pizzi M, 1999, EUR J NEUROSCI, V11, P2489, DOI 10.1046/j.1460-9568.1999.00669.x; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; Qiu ZH, 1998, J NEUROSCI, V18, P10445; Reddrop C, 2005, STROKE, V36, P1241, DOI 10.1161/01.STR.0000166050.84056.48; ROMANO C, 1995, J NEUROCHEM, V65, P59; Rosenberg PA, 2003, J NEUROSCI RES, V71, P237, DOI 10.1002/jnr.10472; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Ruprecht K, 2001, J NEUROPATH EXP NEUR, V60, P1087, DOI 10.1093/jnen/60.11.1087; Stroemer RP, 1998, J CEREBR BLOOD F MET, V18, P833, DOI 10.1097/00004647-199808000-00003; Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254-003-0013-1; Tanaka M, 2003, BLOOD, V102, P3154, DOI 10.1182/blood-2003-02-0367; Tong L, 2004, CELL SIGNAL, V16, P1123, DOI 10.1016/j.cellsig.2004.03.003; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Wallace PM, 1999, J IMMUNOL, V162, P5547; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; Weiss TW, 2005, J MOL CELL CARDIOL, V39, P545, DOI 10.1016/j.yjmcc.2005.03.015; Weiss TW, 2003, CARDIOVASC RES, V59, P628, DOI 10.1016/S0008-6363(03)00463-2; Yepes M, 2000, BLOOD, V96, P569	41	37	39	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2369	+		10.1096/fj.06-5850fje	http://dx.doi.org/10.1096/fj.06-5850fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023520				2022-12-28	WOS:000241702600023
J	Lei, XB; Chen, YY; Du, GH; Yu, WY; Wang, XH; Qu, H; Xia, B; He, HP; Mao, JH; Zong, WX; Liao, XD; Mehrpour, M; Hao, XJ; Chen, Q				Lei, Xiaobo; Chen, Yingyu; Du, Guanhua; Yu, Wenyu; Wang, Xiaohui; Qu, Hong; Xia, Bin; He, Hongping; Mao, Jianhua; Zong, Weixing; Liao, Xudong; Mehrpour, Maryam; Hao, Xiaojiang; Chen, Quan			Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2	FASEB JOURNAL			English	Article						mitochondria; Bcl-2 inhibitors; drug screening	PERMEABILITY TRANSITION PORE; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; CASPASE ACTIVATION; FAMILY PROTEINS; CANCER-CELLS; X-L; BAX; AUTOPHAGY; ABSENCE	Cells without Bak and Bax are largely resistant to apoptosis (1; 2), despite the presence of other key components of the apoptotic machinery. We screened 7,800 natural compounds and found several that could specifically induce caspase activation and the release of cytochrome c (cyto c) in the bak(-/-)/bax(-/-) cells. One of these was gossypol, a polyphenolic compound naturally found in cottonseed that has been used in antifertility trials. We found that gossypol, but not other Bcl-2-interacting molecules, induced cyto c release and loss of mitochondrial membrane potential (Delta Psi m) independently of mPTP and Bak/Bax activation. Furthermore, we found that gossypol induced an allosteric change in Bcl-2 in both bak(-/-)/bax(-/-) cells and Bcl-2 overexpressing cells. This change in Bcl-2 conformation led to the release of cyto c in the presence of Bcl-2 and Bcl-xL in reconstituted proteoliposomes. We also observed that gossypol substantially reduced the growth of tumor xenografts from Bcl- 2 overexpressing cells in nude mice. We conclude that gossypol converts the antiapoptotic molecule Bcl-2 into a proapoptotic molecule that can mediate the release of cyto c and induce apoptosis	Chinese Acad Sci, Lab Apoptosis & Canc Biol, State Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, Beijing 100080, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; Peking Univ, Ctr Human Dis Genom, Beijing 100871, Peoples R China; Acad Med Sci, Inst Mat Med, Beijing, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Chinese Acad Sci, State Key Lab Phytochem & Plant Resources W China, Kunming Inst Bot, Beijing, Peoples R China; Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; Inst Gustave Roussy PR1, INSERM, U 487, Lab Cytokines & Immunol Tumeurs Humaines, Villejuif, France	Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Materia Medica - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking University; Chinese Academy of Sciences; Kunming Institute of Botany, CAS; University of Pennsylvania; Pennsylvania Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Chen, Q (corresponding author), Chinese Acad Sci, Lab Apoptosis & Canc Biol, State Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, Bei Si Huan Xi Rd 25, Beijing 100080, Peoples R China.	chenq@ioz.ac.cn	Xia, Bin/O-1160-2016; Mehrpour, Maryam/D-8640-2017; Mao, Jianhua/GOK-2713-2022; lei, xiaobo/GLN-4194-2022; chen, ying/HHS-8254-2022	Xia, Bin/0000-0002-2197-6403; Chen, Quan/0000-0001-7539-8728				Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; BERNARDI P, 1984, BIOCHIM BIOPHYS ACTA, V766, P277, DOI 10.1016/0005-2728(84)90242-1; Castelli M, 2004, CELL DEATH DIFFER, V11, P906, DOI 10.1038/sj.cdd.4401433; Chanan-Khan A, 2005, BLOOD REV, V19, P213, DOI 10.1016/j.blre.2004.11.002; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Claveria C, 2004, J BIOL CHEM, V279, P1368, DOI 10.1074/jbc.M309819200; Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Kim YK, 2004, INT J CONTROL AUTOM, V2, P523; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; LIU G-Z, 1981, Reproduccion, V5, P189; Lugovskoy AA, 2002, J AM CHEM SOC, V124, P1234, DOI 10.1021/ja011239y; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Mohammad RM, 2005, MOL CANCER THER, V4, P13; Oliver CL, 2005, MOL CANCER THER, V4, P23; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Paglin S, 2001, CANCER RES, V61, P439; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Rashmi R, 2005, CARCINOGENESIS, V26, P713, DOI 10.1093/carcin/bgi025; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; SHEPU X, 1980, SCI SINICA, V232, P642; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xia T, 2002, FEBS LETT, V510, P62, DOI 10.1016/S0014-5793(01)03228-8; Xu L, 2005, MOL CANCER THER, V4, P197; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Zhang MC, 2003, BIOCHEM PHARMACOL, V66, P93, DOI 10.1016/S0006-2952(03)00248-X; Zheng YH, 2005, ONCOGENE, V24, P3339, DOI 10.1038/sj.onc.1208484; Zheng YH, 2004, ONCOGENE, V23, P1239, DOI 10.1038/sj.onc.1207205; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	39	97	102	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2147	+		10.1096/fj.05-5665fje	http://dx.doi.org/10.1096/fj.05-5665fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935937				2022-12-28	WOS:000241156900043
J	Roy, H; Bhardwaj, S; Babu, M; Kokina, I; Uotila, S; Ahtialansaari, T; Laitinen, T; Hakumaki, J; Laakso, M; Herzig, KH; Yla-Herttuala, S				Roy, Himadri; Bhardwaj, Shalini; Babu, Mohan; Kokina, Ilze; Uotila, Sanna; Ahtialansaari, Tiia; Laitinen, Teemu; Hakumaki, Juhana; Laakso, Markku; Herzig, Karl-Heinz; Yla-Herttuala, Seppo			VEGF-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, NF-kappa B, and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits	FASEB JOURNAL			English	Article						diabetes; dyslipidemia; atherosclerosis; vascular endothelial growth factor; plaque angiogenesis	INSULIN-RESISTANCE; METABOLIC SYNDROME; SKELETAL-MUSCLE; IN-VIVO; EXPRESSION; PATHOPHYSIOLOGY; ABNORMALITIES; CONSEQUENCES; ANGIOGENESIS; PROGRESSION	Plaque angiogenesis may be associated with the development of unstable and vulnerable plaques. Vascular endothelial growth factors (VEGFs) are potent angiogenic factors that can affect plaque neovascularization. Our objective was to determine the effect of diabetes on atherosclerosis and on the expression of angiogenesis-related genes in atherosclerotic lesions. Alloxan was used to induce diabetes in male Watanabe heritable hyperlipidemic (WHHL) rabbits that were sacrificed 2 and 6 months after the induction of diabetes. Nondiabetic WHHL rabbits served as controls. Blood glucose (Glc), serum-free fatty acids (FFA), and serum triglyceride levels were significantly higher in diabetic rabbits. Accelerated atherogenesis was observed in the diabetic WHHL rabbits together with increased intramyocellular lipids (IMCL), as determined by 1H-NMR spectroscopy. Atherosclerotic lesions in the diabetic rabbits had an increased content of macrophages and showed significant increases in immunostainings for vascular endothelial growth factor (VEGF)-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, RAGE, and NF-kappa B. VEGF-A(165) and VEGFR-2 mRNA levels were significantly increased in aortas of the diabetic rabbits, where a trend toward increased plaque vascularization was also observed. These results suggest that diabetes accelerates atherogenesis, up-regulates VEGF-A, VEGF-D, and VEGF receptor-2 expression, and increases NF-kappa B, RAGE, and inflammatory responses in atherosclerotic lesions in WHHL rabbits.	Univ Kuopio, Dept Biotechnol & Mol Med, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Med, SF-70210 Kuopio, Finland; Kuopio Univ Hosp, Gene Therapy Unit, SF-70210 Kuopio, Finland; Univ Kuopio, Dept Biomed NMR, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland	University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland	Yla-Herttuala, S (corresponding author), Univ Kuopio, Dept Mol Med, AI Virtanen Inst, POB 1627, FIN-70211 Kuopio, Finland.	seppo.ylaherttuala@uku.fi	Mohan, Babu P./I-7362-2019; Bhardwaj, Shalini/AAE-6796-2021; Babu, Mohan/I-7416-2012; Hakumäki, Juhana/AAH-1058-2021	Babu, Mohan/0000-0001-5482-2622; Yla-Herttuala, Seppo/0000-0001-7593-2708; Hakumaki, Juhana/0000-0001-7341-5440				Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Bhardwaj S, 2005, EUR J CLIN INVEST, V35, P669, DOI 10.1111/j.1365-2362.2005.01555.x; Brasen JH, 2003, ATHEROSCLEROSIS, V166, P13, DOI 10.1016/S0021-9150(02)00130-2; Brey EM, 2003, J HISTOCHEM CYTOCHEM, V51, P575, DOI 10.1177/002215540305100503; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Cipollone F, 2003, CIRCULATION, V108, P1070, DOI 10.1161/01.CIR.0000086014.80477.0D; Creager MA, 2003, CIRCULATION, V108, P1527, DOI 10.1161/01.CIR.0000091257.27563.32; Ezzahiri R, 2002, CARDIOVASC RES, V56, P269, DOI 10.1016/S0008-6363(02)00544-8; Garwood M, 2001, J MAGN RESON, V153, P155, DOI 10.1006/jmre.2001.2340; Hayden MR, 2004, CARDIOVASC DIABETOL, V3, DOI 10.1186/1475-2840-3-1; Hayden MR, 2002, CARDIOVASC DIABETOL, V1, DOI 10.1186/1475-2840-1-3; Hofstaetter JG, 2004, BIOCHEM BIOPH RES CO, V324, P667, DOI 10.1016/j.bbrc.2004.09.103; Ishida A, 2001, J CELL PHYSIOL, V188, P359, DOI 10.1002/jcp.1121; Jacob S, 1999, DIABETES, V48, P1113, DOI 10.2337/diabetes.48.5.1113; Kuhlmann J, 2003, DIABETES, V52, P138, DOI 10.2337/diabetes.52.1.138; Laakso M, 1999, DIABETES, V48, P937, DOI 10.2337/diabetes.48.5.937; Moreno PR, 2004, CIRCULATION, V110, P2032, DOI 10.1161/01.CIR.0000143233.87854.23; Naka Y, 2004, ARTERIOSCL THROM VAS, V24, P1342, DOI 10.1161/01.ATV.0000133191.71196.90; Niemeijer-Kanters SDJM, 2001, NETH J MED, V58, P214, DOI 10.1016/S0300-2977(01)00105-X; Okamoto T, 2002, FASEB J, V16, P1928, DOI 10.1096/fj.02-0030fje; Renard CB, 2004, J CLIN INVEST, V114, P659, DOI 10.1172/JCI200417867; Rutanen J, 2003, CARDIOVASC RES, V59, P971, DOI 10.1016/S0008-6363(03)00518-2; SCHICK F, 1993, MAGN RESON MED, V29, P158, DOI 10.1007/BF01769418; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Sinha R, 2002, DIABETES, V51, P1022, DOI 10.2337/diabetes.51.4.1022; Taskinen MR, 2003, DIABETES RES CLIN PR, V61, pS19, DOI 10.1016/S0168-8227(03)00126-8; Verges BL, 1999, DIABETES METAB, V25, P32; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971; ZHANG B, 1991, ATHEROSCLEROSIS, V91, P277, DOI 10.1016/0021-9150(91)90175-3	31	30	32	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2159	+		10.1096/fj.05-5029fje	http://dx.doi.org/10.1096/fj.05-5029fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935942				2022-12-28	WOS:000241156900051
J	da Costa, KA; Kozyreva, OG; Song, JN; Galanko, JA; Fischer, LM; Zeisel, SH				da Costa, Kerry-Ann; Kozyreva, Olga G.; Song, Jiannan; Galanko, Joseph A.; Fischer, Leslie M.; Zeisel, Steven H.			Common genetic polymorphisms affect the human requirement for the nutrient choline	FASEB JOURNAL			English	Article						choline deficiency; phosphatidylethanolamine; N-methyltransferase; PEMT; choline dehydrogenase; CHDH; betaine : homocysteine methyltransferase; BHMT; genetic polymorphism	PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; DENSITY LIPOPROTEIN SECRETION; BETAINE-HOMOCYSTEINE; PARENTERAL-NUTRITION; DEFICIENCY; SUPPLEMENTATION; AVAILABILITY; PHOSPHATIDYLCHOLINE; APOPTOSIS; FOLATE	Humans eating diets deficient in the essential nutrient choline can develop organ dysfunction. We hypothesized that common single nucleotide polymorphisms (SNPs) in genes involved in choline metabolism influence the dietary requirement of this nutrient. Fifty-seven humans were fed a low choline diet until they developed organ dysfunction or for up to 42 days. We tested DNA SNPs for allelic association with susceptibility to developing organ dysfunction associated with choline deficiency. We identified an SNP in the promoter region of the phosphatidylethanolamine N-methyltransferase gene (PEMT; -744 G -> C; rs12325817) for which 18 of 23 carriers of the C allele (78%) developed organ dysfunction when fed a low choline diet (odds ratio 25, P = 0.002). The first of two SNPs in the coding region of the choline dehydrogenase gene (CHDH; +318 A -> C; rs9001) had a protective effect on susceptibility to choline deficiency, while a second CHDH variant (+432 G -> T; rs12676) was associated with increased susceptibility to choline deficiency. A SNP in the PEMT coding region (+5465 G -> A; rs7946) and a betaine: homocysteine methyltransferase (BHMT) SNP (+742 G -> A; rs3733890) were not associated with susceptibility to choline deficiency. Identification of common polymorphisms that affect dietary requirements for choline could enable us to identify individuals for whom we need to assure adequate dietary choline intake.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7461, Chapel Hill, NC 27599 USA.	steven_zeisel@unc.edu			NCRR NIH HHS [M01 RR000046, RR00046] Funding Source: Medline; NIA NIH HHS [AG09525, P01 AG009525] Funding Source: Medline; NIDDK NIH HHS [R01 DK055865, DK55865, DK56350, P30 DK056350] Funding Source: Medline; NIEHS NIH HHS [R21 ES012997, P30 ES010126, ES012997, ES10126] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865, P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, R21ES012997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 2005, CELL PHYSIOL BIOCHEM, V15, P59, DOI 10.1159/000083653; Albright CD, 1996, FASEB J, V10, P510, DOI 10.1096/fasebj.10.4.8647350; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; BREMER J, 1961, BIOCHIM BIOPHYS ACTA, V46, P205, DOI 10.1016/0006-3002(61)90745-4; BUCHMAN AL, 1995, HEPATOLOGY, V22, P1399, DOI 10.1002/hep.1840220510; Buchman AL, 2001, JPEN-PARENTER ENTER, V25, P260, DOI 10.1177/0148607101025005260; Busby MG, 2004, J AM DIET ASSOC, V104, P1836, DOI 10.1016/j.jada.2004.09.027; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Cui Z, 1996, J BIOL CHEM, V271, P2839, DOI 10.1074/jbc.271.5.2839; da Costa KA, 2005, AM J CLIN NUTR, V81, P440; da Costa KA, 2004, AM J CLIN NUTR, V80, P163; DROUVA SV, 1986, ENDOCRINOLOGY, V119, P2611, DOI 10.1210/endo-119-6-2611; Fishbein MH, 1997, MAGN RESON IMAGING, V15, P287, DOI 10.1016/S0730-725X(96)00224-X; Fotino M, 1971, Ann Clin Lab Sci, V1, P131; Institute of Medicine, 1998, DIET REF INT THIAM R, P390, DOI [DOI 10.17226/6015, 10.17226/6015]; Istrail S, 2004, P NATL ACAD SCI USA, V101, P1916, DOI 10.1073/pnas.0307971100; Johnson PI, 1998, NEUROCHEM RES, V23, P583, DOI 10.1023/A:1022470301550; Jones JP, 1999, DEV BRAIN RES, V118, P159, DOI 10.1016/S0165-3806(99)00103-0; Koc H, 2002, ANAL CHEM, V74, P4734, DOI 10.1021/ac025624x; Kohlmeier M, 2005, P NATL ACAD SCI USA, V102, P16025, DOI 10.1073/pnas.0504285102; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; Meck WH, 1997, NEUROREPORT, V8, P2831, DOI 10.1097/00001756-199709080-00005; Meck WH, 2003, NEUROSCI BIOBEHAV R, V27, P385, DOI 10.1016/S0149-7634(03)00069-1; Meyer K, 2004, CLIN CHEM, V50, P391, DOI 10.1373/clinchem.2003.026799; Montoya DAC, 2000, DEV BRAIN RES, V123, P25, DOI 10.1016/S0165-3806(00)00075-4; Morin I, 2003, AM J MED GENET A, V119A, P172, DOI 10.1002/ajmg.a.20115; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; Saito S, 2001, J HUM GENET, V46, P529, DOI 10.1007/s100380170035; Shaw GM, 2004, AM J EPIDEMIOL, V160, P102, DOI 10.1093/aje/kwh187; Shelnutt KP, 2003, J NUTR, V133, P4107, DOI 10.1093/jn/133.12.4107; Shields DJ, 2001, BBA-MOL CELL BIOL L, V1532, P105, DOI 10.1016/S1388-1981(01)00122-6; Song JN, 2005, FASEB J, V19, P1266, DOI 10.1096/fj.04-3580com; TING A, 1971, VOX SANG, V20, P561, DOI 10.1111/j.1423-0410.1971.tb00469.x; Waite KA, 2002, J NUTR, V132, P68, DOI 10.1093/jn/132.1.68; Weisberg IS, 2003, ATHEROSCLEROSIS, V167, P205, DOI 10.1016/S0021-9150(03)00010-8; Williams CL, 1998, BRAIN RES, V794, P225, DOI 10.1016/S0006-8993(98)00229-7; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; Zeisel SH, 2003, J NUTR, V133, P1302; ZEISEL SH, 1995, J NUTR, V125, P3049; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	47	145	149	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1336	1344		10.1096/fj.06-5734com	http://dx.doi.org/10.1096/fj.06-5734com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816108	Green Accepted, Green Submitted			2022-12-28	WOS:000240266000010
J	Guo, Z; Shao, LF; Du, Q; Park, KS; Geller, DA				Guo, Zhong; Shao, Lifang; Du, Qiang; Park, Kyung Soo; Geller, David A.			Identification of a classic cytokine-induced enhancer upstream in the human iNOS promoter	FASEB JOURNAL			English	Article						NO; ChIP	NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; GENE-TRANSCRIPTION; MOLECULAR-CLONING; MOUSE MACROPHAGES; CELL-LINE; CHROMATIN STRUCTURE; HUMAN HEPATOCYTES; INTERFERON-GAMMA; RESPONSE ELEMENT	The human inducible NOS (iNOS) promoter transcriptionally regulated by 5' flanking region extending 16 kb upstream that contains cytokine-responsive DNA motifs. In this study, we further identified a classic inducible enhancer located between -5 and -6 kb in the hiNOS upstream promoter. This 1 kb promoter sequence functions as a cytokine-inducible enhancer in an orientation- and position-independent manner in human lung A549 and liver AKN1 cells. This DNA enhancer also confers cytokine inducibility to the heterologous thymidine kinase (TK) promoter. Chromatin immunoprecipitation (ChIP) analysis was applied, and confirmed cytokine-inducible in vivo DNA-protein interactions within this enhancer region. In vivo functional binding of both NF-kappa B (p65/p50) and Stat-1 alpha at the -5.8 kb human iNOS promoter site was significantly increased in A549 cells after cytokine stimulation, while only Stat-1 alpha bound at the -5.2 kb site. These results identify the -5 to -6 kb promoter region as a classic transcriptional enhancer for the human iNOS gene and provide definitive in vivo evidence of specific NF-kappa B and Stat-1 nuclear protein binding that mediates transcription of the hiNOS gene under cytokine stimulation.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Geller, DA (corresponding author), Univ Pittsburgh, Dept Surg, Kaufmann Med Bldg,Ste 300,3471 5th Ave, Pittsburgh, PA 15213 USA.	gellerda@upmc.edu			NIDDK NIH HHS [R01-DK62313] Funding Source: Medline; NIGMS NIH HHS [R01-GM52021] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052021] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Burgess-Beusse B, 2002, P NATL ACAD SCI USA, V99, P16433, DOI 10.1073/pnas.162342499; Chan GC, 2005, J IMMUNOL, V175, P3846, DOI 10.4049/jimmunol.175.6.3846; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; Chu SC, 1998, BIOCHEM BIOPH RES CO, V248, P871, DOI 10.1006/bbrc.1998.9062; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Du QA, 2006, CANCER RES, V66, P7024, DOI 10.1158/0008-5472.CAN-05-4110; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Feng XS, 2002, P NATL ACAD SCI USA, V99, P14212, DOI 10.1073/pnas.212306199; Ganster R. W., 2000, NITRIC OXIDE; Ganster RW, 2005, J INTERF CYTOK RES, V25, P707, DOI 10.1089/jir.2005.25.707; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GELLER DA, 1995, J IMMUNOL, V155, P4890; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Guo Z, 2003, FASEB J, V17, P1718, DOI 10.1096/fj.02-1172fje; Hausding M, 2000, BRIT J PHARMACOL, V131, P553, DOI 10.1038/sj.bjp.0703607; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Linn SC, 1997, AM J PHYSIOL-GASTR L, V272, pG1499, DOI 10.1152/ajpgi.1997.272.6.G1499; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Mellott JK, 2001, AM J PHYSIOL-LUNG C, V280, pL390, DOI 10.1152/ajplung.2001.280.3.L390; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Nussler AK, 1999, IN VITRO CELL DEV-AN, V35, P190, DOI 10.1007/s11626-999-0026-4; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Suschek CV, 2004, CURR MOL MED, V4, P763, DOI 10.2174/1566524043359908; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Taylor BS, 2000, SHOCK, V13, P413, DOI 10.1097/00024382-200006000-00001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	37	52	56	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					535	542		10.1096/fj.06-6739com	http://dx.doi.org/10.1096/fj.06-6739com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158780				2022-12-28	WOS:000244686300026
J	Vandebrouck, A; Sabourin, J; Rivet, J; Balghi, H; Sebille, S; Kitzis, A; Raymond, G; Cognard, C; Bourmeyster, N; Constantin, B				Vandebrouck, Aurelie; Sabourin, Jessica; Rivet, Jerome; Balghi, Haouria; Sebille, Stephane; Kitzis, Alain; Raymond, Guy; Cognard, Christian; Bourmeyster, Nicolas; Constantin, Bruno			Regulation of capacitative calcium entries by alpha 1-syntrophin: association of TRPC1 with dystrophin complex and the PDZ domain of alpha 1-syntrophin	FASEB JOURNAL			English	Article						dystrophic muscle; store-operated calcium entries; TRP channels; scaffolding proteins	ALPHA-SYNTROPHIN; CATION CHANNEL; MUSCLE-FIBERS; PROTEIN; MDX; BINDING; INFLUX; CA2+; DYSTROBREVIN; EXPRESSION	Calcium mishandling in Duchenne dystrophic muscle suggested that dystrophin, a membrane-associated cytoskeleton protein, might regulate calcium signaling cascade such as calcium influx pathway. It was previously shown that abnormal calcium entries involve uncontrolled stretch-activated currents and store-operated Ca2+ currents supported by TRPC1 channels. Moreover, our recent work demonstrated that reintroduction of minidystrophin in dystrophic myotubes restores normal capacitative calcium entries (CCEs). However, until now, no molecular link between the dystrophin complex and calcium entry channels has been described. This study is the first to show by coimmunoprecipitation assays the molecular association of TRPC1 with dystrophin and alpha 1-syntrophin in muscle cells. TRPC1 was also associated with alpha 1-syntrophin in dystrophic muscle cells independently of dystrophin. Furthermore, glutathione S-transferase (GST) pull-down assays showed that TRPC1 binds to the alpha 1-syntrophin PDZ domain. Transfected recombinant alpha 1-syntrophin formed a complex with TRPC1 channels and restored normal CCEs in dystrophic muscle cells. We suggest that normal regulation of CCEs in skeletal muscle depends on the association between TRPC1 channels and alpha 1-syntrophin that may anchor the store-operated channels to the dystrophin-associated protein complex (DAPC). The loss of this molecular association could participate in the calcium alterations observed in dystrophic muscle cells. This study provides a new model for the regulation of calcium influx by interaction with the scaffold of the DAPC in muscle cells.	Univ Poitiers, CNRS, UMR6187, Inst Physiol & Biol Cellulaires, F-86022 Poitiers, France; CHU Poitiers, LGCM, Poitiers, France	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; CHU Poitiers; Universite de Poitiers	Constantin, B (corresponding author), Univ Poitiers, CNRS, UMR6187, Inst Physiol & Biol Cellulaires, F-86022 Poitiers, France.	bruno.constantin@univ-poitiers.fr	Sebille, Stéphane/P-7959-2016; Constantin, Bruno/AAH-6463-2021; COGNARD, Christian/P-5305-2016	Constantin, Bruno/0000-0003-1668-581X; Bourmeyster, Nicolas/0000-0002-9563-5142; Sabourin, Jessica/0000-0002-2980-8455				Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; Albrecht DE, 2002, NEUROSIGNALS, V11, P123, DOI 10.1159/000065053; Alderton JM, 2000, J BIOL CHEM, V275, P9452, DOI 10.1074/jbc.275.13.9452; Balghi H, 2006, J GEN PHYSIOL, V127, P171, DOI 10.1085/jgp.200509456; Compton AG, 2005, J NEUROPATH EXP NEUR, V64, P350, DOI 10.1093/jnen/64.4.350; Connors NC, 2004, J BIOL CHEM, V279, P28387, DOI 10.1074/jbc.M402604200; Crawford GE, 2000, J CELL BIOL, V150, P1399, DOI 10.1083/jcb.150.6.1399; Ducret T, 2006, J PHYSIOL-LONDON, V575, P913, DOI 10.1113/jphysiol.2006.115154; Engelke M, 2002, FEBS LETT, V523, P193, DOI 10.1016/S0014-5793(02)02971-X; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; Froehner SC, 1997, SOC GEN PHY, V52, P197; Gee SH, 1998, J NEUROSCI, V18, P128; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hopf FW, 1996, J BIOL CHEM, V271, P22358, DOI 10.1074/jbc.271.37.22358; IMBERT N, 1995, CELL CALCIUM, V18, P177, DOI 10.1016/0143-4160(95)90062-4; Iwata Y, 2004, EUR J CELL BIOL, V83, P555, DOI 10.1078/0171-9335-00415; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Mallouk N, 2000, P NATL ACAD SCI USA, V97, P4950, DOI 10.1073/pnas.97.9.4950; Marchand E, 2004, EXP CELL RES, V297, P363, DOI 10.1016/j.yexcr.2004.02.032; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; Obukhov AG, 2004, J CELL PHYSIOL, V201, P227, DOI 10.1002/jcp.20057; Ou YJ, 2003, J BIOL CHEM, V278, P1915, DOI 10.1074/jbc.M209938200; Pan Z, 2002, NAT CELL BIOL, V4, P379, DOI 10.1038/ncb788; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; Tutdibi O, 1999, J PHYSIOL-LONDON, V515, P859, DOI 10.1111/j.1469-7793.1999.859ab.x; Vandebrouck A, 2005, FASEB J, V19, P136, DOI 10.1096/fj.04-3633fje; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Vandebrouck C, 2001, NEUROMUSCULAR DISORD, V11, P72, DOI 10.1016/S0960-8966(00)00153-X; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; Yeung EW, 2005, J PHYSIOL-LONDON, V562, P367, DOI 10.1113/jphysiol.2004.075275; Zhou YW, 2005, AM J PHYSIOL-CELL PH, V288, pC377, DOI 10.1152/ajpcell.00279.2004	40	90	93	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					608	617		10.1096/fj.06-6683com	http://dx.doi.org/10.1096/fj.06-6683com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17202249				2022-12-28	WOS:000244686300033
J	Theiss, AL; Idell, RD; Srinivasan, S; Klapproth, JM; Jones, DP; Merlin, D; Sitaraman, SV				Theiss, Arianne L.; Idell, Richard D.; Srinivasan, Shanthi; Klapproth, Jan-Michael; Jones, Dean P.; Merlin, Didier; Sitaraman, Shanthi V.			Prohibitin protects against oxidative stress in intestinal epithelial cells	FASEB JOURNAL			English	Article						epithelial permeability; inflammatory bowel diseases; glutathione	INFLAMMATORY-BOWEL-DISEASE; REACTIVE OXYGEN METABOLITES; EXPERIMENTAL COLITIS; BREAST-CANCER; MICROTUBULE CYTOSKELETON; INDUCED DISRUPTION; DNA-DAMAGE; GLUTATHIONE; MICE; EXPRESSION	Prohibitin (PHB) is an evolutionarily conserved and ubiquitously expressed protein whose expression or function in intestinal diseases is not known. In this study, we examined the expression and role of PHB in oxidative stress associated with inflammatory bowel disease. Our results show that PHB primarily localizes to the mitochondria in intestinal epithelial cells. Its expression is down-regulated during active human Crohn's disease, experimental colitis in vivo, and oxidative stress in vitro. PHB overexpression increases the expression of glutathione-S-transferase pi and protects from oxidant-induced depletion of glutathione. Finally, PHB overexpression decreases accumulation of reactive oxygen metabolites, as well as increased permeability induced by oxidative stress in intestinal epithelial cells. Together, these results suggest that PHB constitutes a previously unrecognized cellular defense against oxidant injury. Thus, strategies to modulate PHB levels may constitute a novel therapeutic approach for intestinal inflammatory diseases, wherein oxidative stress plays a critical role in tissue injury and inflammation.	Emory Univ, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Dept Med, Div Pulm Med, Atlanta, GA 30322 USA	Emory University; Emory University	Theiss, AL (corresponding author), Emory Univ, Div Digest Dis, 615 Michael St,Whitehead Biomed Res Bldg 265, Atlanta, GA 30322 USA.	atheiss@emory.edu	Srinivasan, Shanthi/A-6133-2013	Theiss, Arianne/0000-0003-2862-0933	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399] Funding Source: NIH RePORTER; NIDDK NIH HHS [R24-DK-064399] Funding Source: Medline; PHS HHS [R01-DKO 6411] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Araki Y, 2006, INT J MOL MED, V17, P331; Banan A, 2003, J PHARMACOL EXP THER, V306, P13, DOI 10.1124/jpet.103.047415; Banan A, 2000, FREE RADICAL BIO MED, V28, P727, DOI 10.1016/S0891-5849(00)00160-X; Berg DJ, 2002, GASTROENTEROLOGY, V123, P1527, DOI 10.1053/gast.2002.1231527; Bourges I, 2004, BIOCHEM J, V383, P491, DOI 10.1042/BJ20040256; BUFFINTON GD, 1995, FREE RADICAL BIO MED, V19, P911, DOI 10.1016/0891-5849(95)94362-H; Campbell IG, 2003, CANCER EPIDEM BIOMAR, V12, P1273; CARRIER JC, 2005, INT J COLORECTAL DIS, P1; Castaneda FE, 2005, GASTROENTEROLOGY, V129, P1991, DOI 10.1053/j.gastro.2005.09.017; Chen JC, 2005, PLANT J, V44, P16, DOI 10.1111/j.1365-313X.2005.02505.x; Coles BF, 2002, ARCH BIOCHEM BIOPHYS, V403, P270, DOI 10.1016/S0003-9861(02)00226-6; D'Odorico A, 2001, SCAND J GASTROENTERO, V36, P1289, DOI 10.1080/003655201317097146; DellOrco RT, 1996, EXP GERONTOL, V31, P245, DOI 10.1016/0531-5565(95)02009-8; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; He QY, 2004, PROTEOMICS, V4, P3276, DOI 10.1002/pmic.200300916; Henschke P, 2006, PROTEOMICS, V6, P1957, DOI 10.1002/pmic.200500245; HERTERVIG E, 1994, SCAND J GASTROENTERO, V29, P729, DOI 10.3109/00365529409092501; Kamada K, 2004, FREE RADICAL BIO MED, V37, P1875, DOI 10.1016/j.freeradbiomed.2004.09.002; KESHAVARZIAN A, 1992, GASTROENTEROLOGY, V103, P177, DOI 10.1016/0016-5085(92)91111-G; KESHAVARZIAN A, 1990, GUT, V31, P786, DOI 10.1136/gut.31.7.786; Kolsch H, 2004, NEUROLOGY, V63, P2255, DOI 10.1212/01.WNL.0000147294.29309.47; Koutroubakis IE, 2004, DIGEST DIS SCI, V49, P1433, DOI 10.1023/B:DDAS.0000042242.22898.d9; Kruidenier L, 2003, J PATHOL, V201, P17, DOI 10.1002/path.1408; Kruidenier L, 2003, J PATHOL, V201, P28, DOI 10.1002/path.1409; Kruidenier L, 2003, FREE RADICAL BIO MED, V34, P753, DOI 10.1016/S0891-5849(02)01426-0; LEGGETT B, 1995, BRIT J CANCER, V71, P1070, DOI 10.1038/bjc.1995.206; Manjeshwar S, 2004, J MOL HISTOL, V35, P639; Manjeshwar S, 2003, CANCER RES, V63, P5251; Mielenz D, 2005, J IMMUNOL, V174, P3508, DOI 10.4049/jimmunol.174.6.3508; Miralles-Barrachina O, 1999, CLIN NUTR, V18, P313, DOI 10.1016/S0261-5614(98)80030-7; Mishra S, 2005, TRENDS MOL MED, V11, P192, DOI 10.1016/j.molmed.2005.02.004; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Narushima S, 2003, FREE RADICAL BIO MED, V34, P1153, DOI 10.1016/S0891-5849(03)00065-0; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; Oz HS, 2005, J NUTR BIOCHEM, V16, P297, DOI 10.1016/j.jnutbio.2004.09.007; PETERS WHM, 1991, GUT, V32, P408, DOI 10.1136/gut.32.4.408; Piper PW, 2002, AGING CELL, V1, P149, DOI 10.1046/j.1474-9728.2002.00018.x; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; Rastogi S, 2006, J BIOL CHEM, V281, P2951, DOI 10.1074/jbc.M508669200; ROSKAMS AJI, 1993, J CELL PHYSIOL, V157, P289, DOI 10.1002/jcp.1041570211; Ryu JW, 2003, J KOREAN MED SCI, V18, P505, DOI 10.3346/jkms.2003.18.4.505; Sanz MA, 2003, J BIOL CHEM, V278, P32091, DOI 10.1074/jbc.M304877200; SATO T, 1992, MRS BULL, V17, P52; Schreiber S, 2000, GASTROENTEROLOGY, V119, P1461, DOI 10.1053/gast.2000.20196; Segui J, 2005, INFLAMM BOWEL DIS, V11, P872, DOI 10.1097/01.MIB.0000183420.25186.7a; Sharma A, 2004, P NATL ACAD SCI USA, V101, P17492, DOI 10.1073/pnas.0407536101; Sheth P, 2003, J BIOL CHEM, V278, P49239, DOI 10.1074/jbc.M305654200; Sitaraman SV, 2002, J BIOL CHEM, V277, P33188, DOI 10.1074/jbc.M202522200; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tardieu D, 1998, CANCER LETT, V134, P1, DOI 10.1016/S0304-3835(98)00228-6; Tatsuta T, 2005, MOL BIOL CELL, V16, P248, DOI 10.1091/mbc.e04-09-0807; Tsai HW, 2006, HUM PATHOL, V37, P198, DOI 10.1016/j.humpath.2005.10.012; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944	58	124	130	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					197	206		10.1096/fj.06-6801com	http://dx.doi.org/10.1096/fj.06-6801com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135366				2022-12-28	WOS:000243130200021
J	Jiang, ZL; Clemens, PR				Jiang, Zhilong; Clemens, Paula R.			Cellular caspase-8-like inhibitory protein (cFLIP) prevents inhibition of muscle cell differentiation induced by cancer cells	FASEB JOURNAL			English	Article						cachexia; NF-kappa B; apoptosis	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; MYOGENIC DIFFERENTIATION; INDUCED APOPTOSIS; MESSENGER-RNA; FACTOR-ALPHA; ACTIVATION; DEATH; EXPRESSION; CACHEXIA	Cachexia is a frequent complication of cancer or other chronic diseases. To investigate the pathophysiology of cancer cachexia and pursue treatment options, we developed an in vitro assay of the effects of cancer cell-produced cytokines on primary muscle cells derived from murine skeletal muscle. These studies led to the novel observation that factors secreted by cell lines from prostate cancer and melanoma significantly inhibit differentiation of primary mouse muscle cells. The expression of interleukin (IL) -1 beta, TNF-alpha, and proteolysis-inducing factor (PIF) by cancer cells used in this study suggested their role in preventing myogenic differentiation. Both NF-kappa B binding and transcriptional activity were enhanced in muscle cells treated with conditioned media from cancer cells or with proinflammatory cytokines. Stable expression of IKBSR, a known repressor of NF-kappa B activation, and cellular caspase-8-like inhibitory protein (cFLIP) inhibited activation of NF-kappa B in cancer cell media-treated muscle cells with an accompanying enhancement of myogenic protein expression and differentiation. In contrast, overexpression of antiapoptotic protein Bcl-xL did not protect myoblast cells exposed to the same treatment. Instead, we observed enhanced activation of NF-kappa B in Bcl-xL overexpressing cells. These studies show that the in vitro system recapitulates some of the molecular events causing muscle cachexia and provides the basis for new treatment approaches.-Jiang, Z., Clemens, P. R. Cellular caspase-8-like inhibitory protein (cFLIP) prevents inhibition of muscle cell differentiation induced by cancer cells.	Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15213 USA; Dept Vet Affairs Med Ctr, Neurol Serv, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Clemens, PR (corresponding author), Univ Pittsburgh, Dept Neurol, Sch Med, Biomed Sci Tower,S Wing,Rm 250,203 Lothrop St, Pittsburgh, PA 15213 USA.	pclemens@pitt.edu						Anker SD, 1999, CURR OPIN CARDIOL, V14, P211, DOI 10.1097/00001573-199905000-00004; Bannerman DD, 2004, AM J PATHOL, V165, P1423, DOI 10.1016/S0002-9440(10)63400-1; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chen GG, 2004, APOPTOSIS, V9, P619, DOI 10.1023/B:APPT.0000038041.57782.84; Crawford MJ, 2001, BIOCHEM BIOPH RES CO, V281, P1304, DOI 10.1006/bbrc.2001.4501; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; ESPAT NJ, 1994, SURG ONCOL, V3, P255, DOI 10.1016/0960-7404(94)90027-2; FONG Y, 1989, AM J PHYSIOL, V256, pR659, DOI 10.1152/ajpregu.1989.256.3.R659; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Huang YT, 1999, CANCER RES, V59, P1599; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jeong CW, 2003, CLIN EXP ALLERGY, V33, P1717, DOI 10.1111/j.1365-2222.2003.01782.x; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; NAKASHIMA J, 1995, CANCER RES, V55, P4881; Okano H, 2003, LAB INVEST, V83, P1033, DOI 10.1097/01.LAB.0000079328.76631.28; Pfitzenmaier J, 2003, CANCER, V97, P1211, DOI 10.1002/cncr.11178; Qin ZH, 2000, MOL BRAIN RES, V80, P111, DOI 10.1016/S0169-328X(00)00147-9; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Song YS, 2004, NEUROSCI RES, V49, P69, DOI 10.1016/j.neures.2004.01.010; Tisdale MJ, 2002, NAT REV CANCER, V2, P862, DOI 10.1038/nrc927; Tisdale MJ, 1997, J NATL CANCER I, V89, P1763, DOI 10.1093/jnci/89.23.1763; Todorov PT, 1996, CANCER RES, V56, P1256; VREUGDENHIL G, 1992, EUR J CLIN INVEST, V22, P488, DOI 10.1111/j.1365-2362.1992.tb01495.x; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wang ZJ, 2003, INT J CANCER, V105, P123, DOI 10.1002/ijc.11035; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	34	15	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2570	+		10.1096/fj.06-6347fje	http://dx.doi.org/10.1096/fj.06-6347fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17060399				2022-12-28	WOS:000242490700027
J	Reijerkerk, A; Kooij, G; van der Pol, SMA; Khazen, S; Dijkstra, CD; de Vries, HE				Reijerkerk, Arie; Kooij, Gijs; van der Pol, Susanne M. A.; Khazen, Shadi; Dijkstra, Christine D.; de Vries, Helga E.			Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells	FASEB JOURNAL			English	Article						tight junction; occludin; blood-brain barrier; matrix metalloproteinase; diapedesis	TIGHT JUNCTION PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MATRIX-METALLOPROTEINASE EXPRESSION; INTEGRAL MEMBRANE-PROTEIN; BLOOD-BRAIN; LEUKOCYTE TRANSMIGRATION; BARRIER PERMEABILITY; ZONULA OCCLUDENS-1; CADHERIN COMPLEX; WHITE-MATTER	The blood-brain barrier (BBB), a selective barrier formed by endothelial cells and dependent on the presence of tight junctions, is compromised during neuroinflammation. A detailed study of tight junction dynamics during transendothelial migration of leukocytes has been lacking. Therefore, we retrovirally expressed green fluorescent protein (GFP) fused to the N-terminus of the tight junction protein occludin in the rat brain endothelial cell line GP8/3.9. Confocal microscopy analyses revealed that GFP-occludin colocalized with the intracellular tight junction protein, ZO-1, localized at intercellular connections, and was absent at cell borders lacking apposing cells. Using live cell imaging we found that monocytes scroll over the brain endothelial cell surface toward cell-cell contacts, induce gap formation, which is associated with local disappearance of GFP-occludin, and subsequently traverse the endothelium paracellularly. Immunoblot analyses indicated that loss of occludin was due to protein degradation. The broad spectrum matrix metalloproteinase (MMP) inhibitor BB-3103 significantly inhibited endothelial gap formation, occludin loss, and the ability of monocytes to pass the endothelium. Our results provide a novel insight into the mechanism by which leukocytes traverse the BBB and illustrate that therapeutics aimed at the stabilization of the tight junction may be beneficial to resist a neuroinflammatory attack.-Reijerkerk, A., Kooij, G., van der Pol, S. M. A., Khazen, S., Dijkstra, C. D., de Vries, H. E. Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells.	Vrije Univ Amsterdam, Med Ctr, Neuroimmunol Res Grp, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Reijerkerk, A (corresponding author), Vrije Univ Amsterdam, Med Ctr, Neuroimmunol Res Grp, POB 7057, NL-1007 MB Amsterdam, Netherlands.	a.reijerkerk@vumc.nl	Kooij, Gijs/AAA-4268-2020	Kooij, Gijs/0000-0002-9488-2918; de Vries, Helga/0000-0001-7904-7124				Allport JR, 1997, J EXP MED, V186, P517, DOI 10.1084/jem.186.4.517; Allport JR, 2000, J CELL BIOL, V148, P203, DOI 10.1083/jcb.148.1.203; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Balda MS, 2000, J CELL BIOCHEM, V78, P85, DOI 10.1002/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.3.CO;2-6; Basuroy S, 2006, BIOCHEM J, V393, P69, DOI 10.1042/BJ20050959; Behzadian MA, 2001, INVEST OPHTH VIS SCI, V42, P853; Bojarski C, 2004, J CELL SCI, V117, P2097, DOI 10.1242/jcs.01071; Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X; Boven LA, 2000, NEUROPATH APPL NEURO, V26, P356, DOI 10.1046/j.1365-2990.2000.00255.x; Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129; Caron A, 2005, EXP CELL RES, V310, P105, DOI 10.1016/j.yexcr.2005.07.004; Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3; de Vries HE, 2002, J IMMUNOL, V168, P5832, DOI 10.4049/jimmunol.168.11.5832; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903; Floris S, 2004, BRAIN, V127, P616, DOI 10.1093/brain/awh068; Floris S, 2002, J NEUROIMMUNOL, V127, P69, DOI 10.1016/S0165-5728(02)00098-X; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1996, J CELL SCI, V109, P429; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251; Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0; Harkness KA, 2000, BRAIN, V123, P698, DOI 10.1093/brain/123.4.698; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hirase T, 1997, J CELL SCI, V110, P1603; Huber JD, 2002, AM J PHYSIOL-HEART C, V283, pH1531, DOI 10.1152/ajpheart.00027.2002; Huber JD, 2001, AM J PHYSIOL-HEART C, V280, pH1241, DOI 10.1152/ajpheart.2001.280.3.H1241; Kago T, 2006, BIOCHEM BIOPH RES CO, V339, P1197, DOI 10.1016/j.bbrc.2005.11.133; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kirk J, 2003, J PATHOL, V201, P319, DOI 10.1002/path.1434; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lohmann C, 2004, BRAIN RES, V995, P184, DOI 10.1016/j.brainres.2003.10.002; Mark KS, 2002, AM J PHYSIOL-HEART C, V282, pH1485, DOI 10.1152/ajpheart.00645.2001; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Moll T, 1998, J CELL BIOL, V140, P403, DOI 10.1083/jcb.140.2.403; Pflugfelder SC, 2005, AM J PATHOL, V166, P61, DOI 10.1016/S0002-9440(10)62232-8; Plumb J, 2002, BRAIN PATHOL, V12, P154; Polette M, 2005, CANCER RES, V65, P7691, DOI 10.1158/0008-5472.CAN-04-4230; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; SCHNEEBERGER EE, 1976, CIRC RES, V38, P404, DOI 10.1161/01.RES.38.5.404; Seguin R, 2003, J NEUROPATH EXP NEUR, V62, P412, DOI 10.1093/jnen/62.4.412; Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323; Sheth P, 2003, J BIOL CHEM, V278, P49239, DOI 10.1074/jbc.M305654200; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; van der Goes A, 2001, FASEB J, V15, P1852, DOI 10.1096/fj.00-0881fje; VanItallie CM, 1997, J CELL SCI, V110, P1113; Wachtel M, 1999, J CELL SCI, V112, P4347; Wolburg H, 2003, ACTA NEUROPATHOL, V105, P586, DOI 10.1007/s00401-003-0688-z; Wolburg H, 2005, ACTA NEUROPATHOL, V109, P181, DOI 10.1007/s00401-004-0928-x; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859, DOI 10.1152/ajpcell.1997.273.6.C1859; Xu HP, 2005, INVEST OPHTH VIS SCI, V46, P2487, DOI 10.1167/iovs.04-1333; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	59	103	107	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2550	+		10.1096/fj.06-6099fje	http://dx.doi.org/10.1096/fj.06-6099fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065217				2022-12-28	WOS:000242490700020
J	Vengeliene, V; Leonardi-Essmann, F; Perreau-Lenz, S; Gebicke-Haerter, P; Drescher, K; Gross, G; Spanagel, R				Vengeliene, Valentina; Leonardi-Essmann, Fernando; Perreau-Lenz, Stephanie; Gebicke-Haerter, Peter; Drescher, Karla; Gross, Gerhard; Spanagel, Rainer			The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse	FASEB JOURNAL			English	Article						gene expression profiling; alcohol deprivation effect; cue-induced reinstatement of ethanol-seeking behavior	CONDITIONED PLACE PREFERENCE; D-3 RECEPTOR; COCAINE-SEEKING; DORSAL STRIATUM; PARTIAL AGONIST; DRUG-ADDICTION; ANTAGONIST; EXPRESSION; BEHAVIOR; ETHANOL	Our study aimed to identify new candidate genes, which might be involved in alcohol craving and relapse. To find changes in gene expression after long-term alcohol consumption, we studied gene expression profiles in the striatal dopamine system by using DNA microarrays of two different alcohol-preferring rat lines (HAD and P). Our data revealed an up-regulation of the dopamine D3 receptor (D3R) after 1 yr of voluntary alcohol consumption in the striatum of alcohol preferring rats that was confirmed by qRT-polymerase chain reaction. This finding was further supported by the finding of up-regulated striatal D3R mRNA in nonselected Wistar rats after long-term alcohol consumption when compared with age-matched control animals. We further examined the role of the D3R in mediating alcohol relapse behavior using the alcohol deprivation effect (ADE) model in long-term alcohol drinking Wistar rats and the model of cue-induced reinstatement of alcohol-seeking behavior using the selective D3R antagonist SB-277011-A ( 0, 1, 3, and 10 mg/kg) and the partial agonist BP 897 (0, 0.1, 1, and 3 mg/kg). Both treatments caused a dose-dependent reduction of relapse-like drinking in the ADE model as well as a decrease in cue-induced ethanol-seeking behavior. We conclude that long-term alcohol consumption leads to an up-regulation of the dopamine D3R that may contribute to alcohol-seeking and relapse. We therefore suggest that selective antagonists of this pharmacological target provide a specific treatment approach to reduce alcohol craving and relapse behavior.	Heidelberg Univ, Dept Psychopharmacol, CIMH, D-68159 Mannheim, Germany; Abbott, Neurosci Discovery Res, Ludwigshafen, Germany	Central Institute of Mental Health; Ruprecht Karls University Heidelberg	Vengeliene, V (corresponding author), Heidelberg Univ, Dept Psychopharmacol, CIMH, J5, D-68159 Mannheim, Germany.	valentinavengeliene@zi-mannheim.de	Perreau-Lenz, Stephanie/D-2309-2014	Perreau-Lenz, Stephanie/0000-0001-9529-6403				Andreoli M, 2003, NEUROPSYCHOPHARMACOL, V28, P1272, DOI 10.1038/sj.npp.1300183; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ashby CR, 2003, SYNAPSE, V48, P154, DOI 10.1002/syn.10188; Aujla H, 2002, NEUROREPORT, V13, P173, DOI 10.1097/00001756-200201210-00039; Cervo L, 2003, NEUROPSYCHOPHARMACOL, V28, P1150, DOI 10.1038/sj.npp.1300169; Di Ciano P, 2003, NEUROPSYCHOPHARMACOL, V28, P329, DOI 10.1038/sj.npp.1300148; Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016; Duarte C, 2003, NEUROPSYCHOPHARMACOL, V28, P1903, DOI 10.1038/sj.npp.1300276; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Gal K, 2006, DRUG ALCOHOL DEPEN, V81, P63, DOI 10.1016/j.drugalcdep.2005.05.011; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gerdeman GL, 2003, TRENDS NEUROSCI, V26, P184, DOI 10.1016/S0166-2236(03)00065-1; Gonzales RA, 2004, PHARMACOL THERAPEUT, V103, P121, DOI 10.1016/j.pharmthera.2004.06.002; Heidbreder CA, 2004, DRUG TODAY, V40, P355, DOI 10.1358/dot.2004.40.4.820081; IRIZARRY R, 2005, AFFY METHODS AFFYMET; Ito R, 2002, J NEUROSCI, V22, P6247; Jeanblanc J, 2006, J NEUROSCI, V26, P1457, DOI 10.1523/JNEUROSCI.3786-05.2006; Le Foll B, 2003, MOL PSYCHIATR, V8, P225, DOI 10.1038/sj.mp.4001202; Le Foll B, 2005, NEUROREPORT, V16, P175, DOI 10.1097/00001756-200502080-00022; Le Foll B, 2003, SYNAPSE, V47, P176, DOI 10.1002/syn.10170; LI TK, 1993, BEHAV GENET, V23, P163, DOI 10.1007/BF01067421; McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40; McBride WJ, 1997, ALCOHOL, V14, P603, DOI 10.1016/S0741-8329(97)00072-4; Melis M, 2005, INT REV NEUROBIOL, V63, P101, DOI 10.1016/S0074-7742(05)63005-X; Neisewander JL, 2004, NEUROPSYCHOPHARMACOL, V29, P1479, DOI 10.1038/sj.npp.1300456; Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944; *R DEV COR TEAM, 2005, R LANG ENV STAT COMP; Reavill C, 2000, J PHARMACOL EXP THER, V294, P1154; Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x; Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x; Spanagel R, 2005, ADDICTION, V100, P1813, DOI 10.1111/j.1360-0443.2005.01260.x; Spanagel R, 1997, TRENDS PHARMACOL SCI, V18, P54, DOI 10.1016/S0165-6147(97)89800-8; Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2; Staley JK, 1996, J NEUROSCI, V16, P6100; Thanos PK, 2005, PHARMACOL BIOCHEM BE, V81, P190, DOI 10.1016/j.pbb.2005.03.013; Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005; Vengeliene V, 2005, NEUROPHARMACOLOGY, V48, P822, DOI 10.1016/j.neuropharm.2005.01.002; Vengeliene V, 2003, ALCOHOL CLIN EXP RES, V27, P1048, DOI 10.1097/01.ALC.0000075829.81211.0C; Vorel SR, 2002, J NEUROSCI, V22, P9595; Weiss F, 2005, MIL DRUG TH, P135; Wicke K, 2001, EUR J PHARMACOL, V424, P85, DOI 10.1016/S0014-2999(01)01054-8; Wiesbeck GA, 2005, MIL DRUG TH, P155	42	89	96	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2223	2233		10.1096/fj.06-6110com	http://dx.doi.org/10.1096/fj.06-6110com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077299				2022-12-28	WOS:000241702600007
J	Fu, Q; McKnight, RA; Yu, X; Callaway, CW; Lane, RH				Fu, Qi; McKnight, Robert A.; Yu, Xing; Callaway, Christopher W.; Lane, Robert H.			Growth retardation alters the epigenetic characteristics of hepatic dual specificity phosphatase 5	FASEB JOURNAL			English	Article						DNA methylation; chromatin; insulin receptor substrate	INSULIN-RECEPTOR SUBSTRATE-1; COACTIVATOR-1 GENE-EXPRESSION; UTEROPLACENTAL INSUFFICIENCY; DNA METHYLATION; RETARDED FETAL; TYROSINE PHOSPHORYLATION; HISTONE ACETYLATION; GLUCOSE-TOLERANCE; RAT; LIVER	Uteroplacental insufficiency leads to intrauterine growth retardation ( IUGR) and adult onset insulin resistance in both humans and rats. IUGR rat liver is characterized by persistent changes in histone 3 lysine 9 and lysine 14 acetylation, which may induce postnatal changes in gene expression. We hypothesized that it would be possible to identify hepatic genes whose epigenetic characteristics and mRNA levels are altered due to IUGR using chromatin immunoprecipitation (ChIP) coupled with random primed differential display polymerase chain reaction (PCR). One of the isolated sequences identified contained exon 2 of the dual specificity phosphatase-5 gene (DUSP5). IUGR affected hepatic DUSP5 mRNA levels and exon 2 DNA methylation into adulthood in the rat. DUSP5 dephosphorylates Erk1 and Erk2 within the MAPK signaling cascade, which in turn affects serine 612 phosphorylation of insulin receptor substrate - 1 (p612 IRS-1). In adult rat liver, IUGR increased Erk1/Erk2 phosphorylation and p612 IRS-1 phosphorylation. Increased serine phosphorylation of hepatic IRS-1 may contribute to the insulin resistance that characterizes these animals. We conclude that intrauterine growth retardation induced by uteroplacental insufficiency 1) affects the hepatic epigenetic characteristics and mRNA of the DUSP-5 and 2) increases hepatic insulin receptor substrate-1 phosphorylation at serine 612 in adult rats.	Univ Utah, Sch Med, Dept Pediat, Div Neonatol, Salt Lake City, UT 84158 USA	Utah System of Higher Education; University of Utah	Lane, RH (corresponding author), Univ Utah, Sch Med, Dept Pediat, Div Neonatol, POB 581289, Salt Lake City, UT 84158 USA.	robert.lane@hsc.utah.edu		Callaway, Christopher/0000-0003-2072-0972	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041075] Funding Source: NIH RePORTER; NICHD NIH HHS [HD41075] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bard-Chapeau EA, 2005, NAT MED, V11, P567, DOI 10.1038/nm1227; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1995, BRIT MED J, V310, P703, DOI 10.1136/bmj.310.6981.703; Baserga M, 2005, AM J PHYSIOL-REG I, V289, pR1348, DOI 10.1152/ajpregu.00211.2005; Baserga M, 2004, EARLY HUM DEV, V79, P93, DOI 10.1016/j.earlhumdev.2004.04.015; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Burke JP, 2004, DIABETES CARE, V27, P2512, DOI 10.2337/diacare.27.10.2512; BUSSEY ME, 1985, PEDIATR RES, V19, P363, DOI 10.1203/00006450-198519040-00010; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Clark JA, 2005, AM J PHYSIOL-GASTR L, V288, pG755, DOI 10.1152/ajpgi.00172.2004; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Fayyad AM, 2005, EARLY HUM DEV, V81, P865, DOI 10.1016/j.earlhumdev.2005.09.005; Fu Q, 2004, PHYSIOL GENOMICS, V20, P108, DOI 10.1152/physiolgenomics.00175.2004; Gual P, 2003, DIABETOLOGIA, V46, P1532, DOI 10.1007/s00125-003-1223-4; HA DEB, 2006, AUST NZJ OBSTET GYNA, V46, P4; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hevroni D, 1998, J MOL NEUROSCI, V10, P75, DOI 10.1007/BF02737120; Houdijk ECAM, 2000, J ENDOCRINOL, V166, P599, DOI 10.1677/joe.0.1660599; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; Kang S, 2003, EUR J ENDOCRINOL, V148, P147, DOI 10.1530/eje.0.1480147; Ke X, 2006, PHYSIOL GENOMICS, V25, P16, DOI 10.1152/physiolgenomics.00093.2005; Ke XR, 2005, AM J PHYSIOL-REG I, V288, pR1038, DOI 10.1152/ajpregu.00701.2004; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Lane RH, 2003, PEDIATR RES, V53, P994, DOI 10.1203/01.PDR.0000064583.40495.51; Lane RH, 2002, ENDOCRINOLOGY, V143, P2486, DOI 10.1210/en.143.7.2486; Lane RH, 1998, PEDIATR RES, V43, P563, DOI 10.1203/00006450-199805000-00001; Lane RH, 2001, BRAIN RES, V895, P186, DOI 10.1016/S0006-8993(01)02074-1; Lane RH, 2001, AM J PHYSIOL-REG I, V280, pR183, DOI 10.1152/ajpregu.2001.280.1.R183; Lane RH, 2001, PEDIATR RES, V50, P83, DOI 10.1203/00006450-200107000-00016; Lane RH, 1999, AM J PHYSIOL-ENDOC M, V276, pE135, DOI 10.1152/ajpendo.1999.276.1.E135; Lane RH, 1996, BIOCHEM MOL MED, V59, P192, DOI 10.1006/bmme.1996.0087; Lane RH, 1996, PEDIATR RES, V39, P390, DOI 10.1203/00006450-199603000-00003; Lane RH, 2000, PEDIATR RES, V47, P792, DOI 10.1203/00006450-200006000-00019; LANE RH, 2003, PEDIAT RES, V535; Liu L, 2003, MECH AGEING DEV, V124, P989, DOI 10.1016/j.mad.2003.08.001; Lopez-Jaramillo P, 2005, J HYPERTENS, V23, P1121, DOI 10.1097/01.hjh.0000170371.49010.4a; MacLennan NK, 2004, PHYSIOL GENOMICS, V18, P43, DOI 10.1152/physiolgenomics.00042.2004; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; McNairn AJ, 2003, BIOESSAYS, V25, P647, DOI 10.1002/bies.10305; Morino K, 2005, J CLIN INVEST, V115, P3587, DOI 10.1172/JCI25151; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; OGATA ES, 1986, METABOLISM, V35, P970, DOI 10.1016/0026-0495(86)90064-8; OGATA ES, 1985, PEDIATR RES, V19, P32, DOI 10.1203/00006450-198501000-00010; OGATA ES, 1990, PEDIATR RES, V27, P56, DOI 10.1203/00006450-199001000-00017; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Pham TD, 2003, AM J PHYSIOL-REG I, V285, pR962, DOI 10.1152/ajpregu.00201.2003; Roberts CL, 2005, MED J AUSTRALIA, V182, P332, DOI 10.5694/j.1326-5377.2005.tb06730.x; Rosseland CM, 2005, HEPATOLOGY, V42, P200, DOI 10.1002/hep.20762; Sadiq HF, 1999, BRAIN RES, V823, P96, DOI 10.1016/S0006-8993(99)01145-2; Simmons RA, 2001, DIABETES, V50, P2279, DOI 10.2337/diabetes.50.10.2279; Singh R, 2004, PEDIATR DIABETES, V5, P154, DOI 10.1111/j.1399-543X.2004.00060.x; Smith R A, 2005, Minerva Ginecol, V57, P379; Taniguchi CM, 2005, J CLIN INVEST, V115, P718, DOI 10.1172/JCI200523187; Torii S, 2004, J BIOCHEM, V136, P557, DOI 10.1093/jb/mvh159; Tsirka AE, 2001, J ENDOCRINOL, V169, P373, DOI 10.1677/joe.0.1690373; Vilatoba M, 2005, TRANSPL P, V37, P399, DOI 10.1016/j.transproceed.2004.12.053; World Medical Association, 2002, AM J PHYSIOL-REG I, V283, pR281, DOI DOI 10.1152/AJPREGU.00279.2002	65	55	58	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2127	+		10.1096/fj.06-6179fje	http://dx.doi.org/10.1096/fj.06-6179fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16940436				2022-12-28	WOS:000241156900029
J	Yamasaki, K; Schauber, J; Coda, A; Lin, H; Dorschner, RA; Schechter, NM; Bonnart, C; Descargues, P; Hovnanian, A; Gallo, RL				Yamasaki, Kenshi; Schauber, Jurgen; Coda, Alvin; Lin, Henry; Dorschner, Robert A.; Schechter, Norman M.; Bonnart, Chrystelle; Descargues, Pascal; Hovnanian, Alain; Gallo, Richard L.			Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin	FASEB JOURNAL			English	Article						antimicrobial peptide; stratum corneum tryptic enzyme; stratum corneum chymotryptic protease; lympho-epithelial Kazal-type related inhibitor; SELDI-TOF-MS	ANTIBACTERIAL PEPTIDE LL-37; CORNEUM CHYMOTRYPTIC ENZYME; SERINE-PROTEASE INHIBITOR; NETHERTON-SYNDROME; INNATE IMMUNITY; CUTTING EDGE; EXPRESSION; GENE; MUTATIONS; DEFENSE	The presence of cathelicidin antimicrobial peptides provides an important mechanism for prevention of infection against a wide variety of microbial pathogens. The activity of cathelicidin is controlled by enzymatic processing of the proform (hCAP18 in humans) to a mature peptide (LL-37 in human neutrophils). In this study, elements important to the processing of cathelicidin in the skin were examined. Unique cathelicidin peptides distinct from LL-37 were identified in normal skin. Through the use of selective inhibitors, SELDI-TOF-MS, Western blot, and siRNA, the serine proteases stratum corneum tryptic enzyme (SCTE, kallikrein 5) and stratum corneum chymotryptic protease (SCCE, kallikrein 7) were shown to control activation of the human cathelicidin precursor protein hCAP18 and also influence further processing to smaller peptides with alternate biological activity. The importance of this serine protease activity to antimicrobial activity in vivo was illustrated in SPINK5-deficent mice that lack the serine protease inhibitor LEKTI. Epidermal extracts of these animals show a significant increase in antimicrobial activity compared with controls, and immunoabsorption of cathelicidin diminished antimicrobial activity. These observations demonstrate that the balance of proteolytic activity at an epithelial interface will control innate immune defense.	Univ Calif San Diego, Div Dermatol, San Diego, CA 92103 USA; VA San Diego Hlth Care Syst, San Diego, CA USA; Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA; Inserm U563, F-31300 Toulouse, France; Univ Toulouse 3, F-31062 Toulouse, France; CHU Purpan, Dept Genet, Toulouse, France	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of Pennsylvania; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Gallo, RL (corresponding author), MC 9111B,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	rgallo@ucsd.edu	Yamasaki, Kenshi/C-8905-2018; BONNART, Chrystelle/A-1309-2011; Hovnanian, Alain/I-4711-2017; Gallo, Richard L/A-8931-2009	Yamasaki, Kenshi/0000-0002-5495-4956; Hovnanian, Alain/0000-0003-3412-7512; Gallo, Richard L/0000-0002-1401-7861	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052453, R37AI052453, R21AI048176, N01AI040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045676] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57345] Funding Source: Medline; NIAID NIH HHS [N01-AI-40029, R01-AI052453, AI48176] Funding Source: Medline; NIAMS NIH HHS [R01-AR45676] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALKEMADE JAC, 1994, J CELL SCI, V107, P2335; Bitoun E, 2002, J INVEST DERMATOL, V118, P352, DOI 10.1046/j.1523-1747.2002.01603.x; Braff MH, 2005, J INVEST DERMATOL, V125, P9, DOI 10.1111/j.0022-202X.2004.23587.x; Braff MH, 2005, J INVEST DERMATOL, V124, P394, DOI 10.1111/j.0022-202X.2004.23443.x; Braff MH, 2005, J IMMUNOL, V174, P4271, DOI 10.4049/jimmunol.174.7.4271; Chang CI, 2005, INFECT IMMUN, V73, P5053, DOI 10.1128/IAI.73.8.5053-5064.2005; Chao SC, 2005, BRIT J DERMATOL, V152, P159, DOI 10.1111/J.1365-2133.2005.06337.X; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; Ekholm IE, 2000, J INVEST DERMATOL, V114, P56, DOI 10.1046/j.1523-1747.2000.00820.x; Franzke CW, 1996, J BIOL CHEM, V271, P21886, DOI 10.1074/jbc.271.36.21886; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gallo RL, 1997, J BIOL CHEM, V272, P13088, DOI 10.1074/jbc.272.20.13088; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; HANSSON L, 1994, J BIOL CHEM, V269, P19420; Hase K, 2002, INFECT IMMUN, V70, P953, DOI 10.1128/IAI.70.2.953-963.2002; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; Iimura M, 2005, J IMMUNOL, V174, P4901, DOI 10.4049/jimmunol.174.8.4901; Ishida-Yamamoto A, 2005, J INVEST DERMATOL, V124, P360, DOI 10.1111/j.0022-202X.2004.23583.x; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Komatsu N, 2003, J INVEST DERMATOL, V121, P542, DOI 10.1046/j.1523-1747.2003.12363.x; Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102; Magert HJ, 1999, J BIOL CHEM, V274, P21499, DOI 10.1074/jbc.274.31.21499; Michael IP, 2005, J BIOL CHEM, V280, P14628, DOI 10.1074/jbc.M408132200; Murakami M, 2002, J INVEST DERMATOL, V119, P1090, DOI 10.1046/j.1523-1747.2002.19507.x; Murakami M, 2004, J IMMUNOL, V172, P3070, DOI 10.4049/jimmunol.172.5.3070; Niyonsaba F, 2002, IMMUNOLOGY, V106, P20, DOI 10.1046/j.1365-2567.2002.01398.x; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oppenheim JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/j.coi.2005.06.002; Peyssonnaux C, 2005, J CLIN INVEST, V115, P1806, DOI 10.1172/JCI23865; Putsep K, 2002, LANCET, V360, P1144, DOI 10.1016/S0140-6736(02)11201-3; Raghunath M, 2004, J INVEST DERMATOL, V123, P474, DOI 10.1111/j.0022-202X.2004.23220.x; Rosenberger CM, 2004, P NATL ACAD SCI USA, V101, P2422, DOI 10.1073/pnas.0304455101; Sayama K, 2005, EUR J IMMUNOL, V35, P1886, DOI 10.1002/eji.200425827; Schechter NM, 2005, BIOL CHEM, V386, P1173, DOI 10.1515/BC.2005.134; Sorensen OE, 2003, J BIOL CHEM, V278, P28540, DOI 10.1074/jbc.M301608200; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; Strub MP, 2003, STRUCTURE, V11, P1359, DOI 10.1016/j.str.2003.09.014; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; van Dijk A, 2005, VET IMMUNOL IMMUNOP, V106, P321, DOI 10.1016/j.vetimm.2005.03.003; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; WIEDOW O, 1991, BIOCHEM BIOPH RES CO, V174, P6, DOI 10.1016/0006-291X(91)90476-N; Wu H, 2000, INFECT IMMUN, V68, P5552, DOI 10.1128/IAI.68.10.5552-5558.2000; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zaiou M, 2002, J MOL MED, V80, P549, DOI 10.1007/s00109-002-0350-6; Zanetti M, 2005, CURR ISSUES MOL BIOL, V7, P179, DOI 10.21775/cimb.007.179; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147	51	343	361	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2068	2080		10.1096/fj.06-6075com	http://dx.doi.org/10.1096/fj.06-6075com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012259				2022-12-28	WOS:000241156900015
J	Mancek-Keber, M; Jerala, R				Mancek-Keber, Mateja; Jerala, Roman			Structural similarity between the hydrophobic fluorescent probe and lipid A as a ligand of MD-2	FASEB JOURNAL			English	Article						bacteria; Toll-like receptor; LPS	CRYSTAL-STRUCTURE; LIPOPOLYSACCHARIDE; BINDING; ENDOTOXIN; CONFERS; PROTEIN; RESPONSIVENESS; ANTAGONIST; ALLERGEN; COMPLEX	Toll-like receptors (TLRs) belong to the family of pattern recognition receptors, as they recognize molecules sharing a broad structural pattern rather than a single defined structure. Bacterial LPS is recognized by MD-2, which is associated with the extracellular domain of TLR4. Understanding the molecular recognition pattern of MD-2 could lead to efficient inhibitors of the excessive LPS signaling needed for early treatment of sepsis. The effect of the acyl chain variability of lipid A on its biological activity indicates that in addition to electrostatic interactions, the recognition must also involve hydrophobic interactions. We show that the fluorescent hydrophobic probe bis-ANS binds to MD-2 with a dissociation constant in the 10 nanomolar range, both to glycosylated and to nonglycosylated MD-2, and requires its native conformation. The binding site of bis-ANS overlaps with the binding site of LPS and is in the proximity of the single tryptophan residue. Furthermore, photoincorporation of bis-ANS by UV light inhibits the ability of MD-2 to confer the LPS responsiveness to the TLR4-transfected HEK293 cell line. Our results show that the structural pattern recognized by MD-2 is defined by the hydrophobic patch and a pair of separated negative charges. Mancek-Keber, M., Jerala, R. Structural similarity between the hydrophobic fluorescent probe and lipid A as a ligand of MD-2.	Natl Inst Chem, Biotechnol Lab, Ljubljana 1000, Slovenia	National Institute of Chemistry - Slovenia	Jerala, R (corresponding author), Natl Inst Chem, Biotechnol Lab, Hajdrihova 19, Ljubljana 1000, Slovenia.	roman.jerala@ki.si	Jerala, Roman/H-9850-2015	Jerala, Roman/0000-0002-6337-5251				Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Bothra A, 1998, J BIOMOL STRUCT DYN, V15, P959, DOI 10.1080/07391102.1998.10508216; Collini M, 2003, PROTEIN SCI, V12, P1596, DOI 10.1110/ps.0304403; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.1016/S0022-2836(02)00027-X; Friedland N, 2003, P NATL ACAD SCI USA, V100, P2512, DOI 10.1073/pnas.0437840100; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Hawkins LD, 2004, CURR TOP MED CHEM, V4, P1147, DOI 10.2174/1568026043388123; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; Keber MM, 2005, J ENDOTOXIN RES, V11, P186, DOI 10.1179/096805105X35206; Lee HJ, 2003, EUR J BIOCHEM, V270, P3988, DOI 10.1046/j.1432-1033.2003.03787.x; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Mogensen JE, 2002, J BIOL CHEM, V277, P23684, DOI 10.1074/jbc.M202065200; Mueller M, 2005, J ENDOTOXIN RES, V11, P299, DOI 10.1179/096805105X46574; Mueller M, 2004, J BIOL CHEM, V279, P26307, DOI 10.1074/jbc.M401231200; Mullen GED, 2003, P NATL ACAD SCI USA, V100, P3919, DOI 10.1073/pnas.0630495100; Muller M, 2003, J ENDOTOXIN RES, V9, P181, DOI 10.1179/096805103125001595; Muroi M, 2006, J BIOL CHEM, V281, P5484, DOI 10.1074/jbc.M509193200; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohnishi T, 2003, CLIN DIAGN LAB IMMUN, V10, P405, DOI 10.1128/CDLI.10.3.405-410.2003; Pastukhov AV, 2003, PROTEINS, V53, P607, DOI 10.1002/prot.10401; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Re F, 2003, J IMMUNOL, V171, P5272, DOI 10.4049/jimmunol.171.10.5272; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Saitoh S, 2004, INT IMMUNOL, V16, P961, DOI 10.1093/intimm/dxh097; Seale JW, 1998, METHOD ENZYMOL, V290, P318, DOI 10.1016/S0076-6879(98)90028-3; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Stevens A, 1997, EUR J BIOCHEM, V243, P792, DOI 10.1111/j.1432-1033.1997.00792.x; Triantafilou M, 2004, BIOCHEM J, V381, P527, DOI 10.1042/BJ20040172; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2005, J IMMUNOL, V175, P6465, DOI 10.4049/jimmunol.175.10.6465; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Wright CS, 2003, J MOL BIOL, V331, P951, DOI 10.1016/S0022-2836(03)00794-0; Wright CS, 2004, J MOL BIOL, V342, P585, DOI 10.1016/j.jmb.2004.07.063; Wright CS, 2000, J MOL BIOL, V304, P411, DOI 10.1006/jmbi.2000.4225	40	43	44	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1836	1842		10.1096/fj.06-5862com	http://dx.doi.org/10.1096/fj.06-5862com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940155				2022-12-28	WOS:000240267000011
J	Movafagh, S; Hobson, JP; Spiegel, S; Kleinman, HK; Zukowska, Z				Movafagh, Sharareh; Hobson, John P.; Spiegel, Sarah; Kleinman, Hynda K.; Zukowska, Zofia			Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors	FASEB JOURNAL			English	Article						bimodal dose-response curve; chemotaxis; mitogenesis; oligomerization; GPCRs	SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; THERAPEUTIC IMPLICATIONS; ISCHEMIC ANGIOGENESIS; MOLECULAR-MECHANISMS; NPY; SUBTYPES; HORMONE; NEURONS; NEOVASCULARIZATION	sPreviously we discovered that NPY induces ischemic angiogenesis by activating Y2 and Y5 receptors. The receptors that mediate specific steps of the complex process of angiogenesis are unknown. Here, we studied in vitro NPY receptors subtypes involved in migration, proliferation, and differentiation of human endothelial cells. In cells that expressed Y1, Y2, and Y5 receptors, NPY bimodally stimulated migration and proliferation with a 2-fold increase at 10(-12) M and 10(-8) M (high- and low-affinity peaks, respectively). Preincubation of cells with NPY up-regulated the Y5 receptor and markedly enhanced endothelial cell migration and proliferation. NPY-induced endothelial cell migration was mimicked by agonists and fully blocked by antagonists for any specific NPY receptors (Y1, Y2, or Y5), while proliferation was blocked by any two antagonists (Y1 + Y2, Y1 + Y5, or Y2 + Y5), and capillary tube formation on Matrigel was blocked by all three (Y1 + Y2 + Y5). Thus, NPY-induced angiogenesis requires participation of Y1, Y2, and Y5 receptor subtypes, with the Y5 receptor acting as an enhancer. We propose that these receptors form heteromeric complexes, and the Y1/ Y2/ Y5 receptor oligomer may be the uncloned Y3 receptor.	Georgetown Univ, Med Ctr, Dept Physiol & Biophys, Washington, DC 20057 USA; Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA USA; Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA	Georgetown University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Zukowska, Z (corresponding author), Georgetown Univ, Med Ctr, Dept Physiol & Biophys, Washington, DC 20057 USA.	zzukow01@georgetown.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000230] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL0553, HL67357] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agnati LF, 2003, PHARMACOL REV, V55, P509, DOI 10.1124/pr.55.3.2; ALLEN JM, 1983, J AUTONOM NERV SYST, V9, P559, DOI 10.1016/0165-1838(83)90013-9; Anderson RL, 2001, J COMP NEUROL, V429, P419, DOI 10.1002/1096-9861(20010115)429:3<419::AID-CNE5>3.0.CO;2-D; BALASUBRAMANIAM A, 1990, PEPTIDES, V11, P545, DOI 10.1016/0196-9781(90)90057-C; Berglund MM, 2003, EXP BIOL MED, V228, P217, DOI 10.1177/153537020322800301; BOUALI SM, 1995, BRAIN RES BULL, V36, P131, DOI 10.1016/0361-9230(94)00177-3; Bouis Diane, 2001, Angiogenesis, V4, P91, DOI 10.1023/A:1012259529167; Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cavadas C, 2001, J CLIN ENDOCR METAB, V86, P5956, DOI 10.1210/jc.86.12.5956; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; DESAI KS, 1973, J LIPID RES, V14, P647; Duhault J, 2000, CAN J PHYSIOL PHARM, V78, P173, DOI 10.1139/cjpp-78-2-173; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Folkman J, 1974, Symp Soc Dev Biol, V30, P43; GEROZISSIS K, 1987, BRAIN RES, V416, P54, DOI 10.1016/0006-8993(87)91495-8; Ghersi G, 2001, PEPTIDES, V22, P453, DOI 10.1016/S0196-9781(01)00340-0; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; Grigor'ev E I, 2003, Radiats Biol Radioecol, V43, P358; GRUNDEMAR L, 1991, J PHARMACOL EXP THER, V258, P633; Gupta SK, 2001, IMMUNOL LETT, V78, P29, DOI 10.1016/S0165-2478(01)00228-0; Herzog H, 1997, GENOMICS, V41, P315, DOI 10.1006/geno.1997.4684; Husum H, 2002, NEUROPEPTIDES, V36, P363, DOI 10.1016/S0143-4179(02)00086-0; JIH Y, 2002, ANGIOGENESIS, V4, P313; Jinde S, 2002, NEUROSCIENCE, V115, P1035, DOI 10.1016/S0306-4522(02)00545-6; Kim J, 1998, REGUL PEPTIDES, V75-6, P201, DOI 10.1016/S0167-0115(98)00069-X; Kitlinska J, 2005, CANCER RES, V65, P1719, DOI 10.1158/0008-5472.CAN-04-2192; Kitlinska J, 2002, PEPTIDES, V23, P71, DOI 10.1016/S0196-9781(01)00581-2; Klagsbrun M, 1992, Semin Cancer Biol, V3, P81; Koulu M, 2004, ANN MED, V36, P232, DOI 10.1080/07853890410031236; Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929; Lee EW, 2003, PEPTIDES, V24, P99, DOI 10.1016/S0196-9781(02)00281-4; Li LJ, 2003, ARTERIOSCL THROM VAS, V23, P1204, DOI 10.1161/01.ATV.0000071349.30914.25; LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V116, P477, DOI 10.1111/j.1748-1716.1982.tb07171.x; Mannon PJ, 1998, BIOCHEM BIOPH RES CO, V246, P91, DOI 10.1006/bbrc.1998.8577; MORL K, 2004, 7 INT NPY M COIMBR; Nakamura J, 2003, NUCLEIC ACIDS RES, V31, P1790, DOI 10.1093/nar/gkg263; NAN YS, 2003, AM J PHYSIOL, V286, pH1027; OH-ISHI T, 1981, Hokkaido Journal of Medical Science, V56, P421; PALMER JM, 1989, MOL CELL ENDOCRINOL, V63, P167, DOI 10.1016/0303-7207(89)90093-2; PATZ A, 1978, NEW ENGL J MED, V298, P1451, DOI 10.1056/NEJM197806292982605; Phillips JK, 1998, BRIT J PHARMACOL, V124, P1403, DOI 10.1038/sj.bjp.0701976; Pons J, 2003, CAN J PHYSIOL PHARM, V81, P177, DOI 10.1139/Y02-166; Price ML, 2001, J NEUROSCI, V21, P2833, DOI 10.1523/JNEUROSCI.21-08-02833.2001; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rosen Lee S, 2002, Cancer Control, V9, P36; SCHOBER DS, 2004, 7 INT NPY M COIMBR; SCHWEIGERER L, 1989, Z KARDIOL, V78, P12; Smialowska M, 1997, POL J PHARMACOL, V49, P357; Vezzani A, 2000, EPILEPSIA, V41, pS115, DOI 10.1111/j.1528-1157.2000.tb01569.x; Zukowska Z, 2003, TRENDS CARDIOVAS MED, V13, P86, DOI 10.1016/S1050-1738(02)00232-3; Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187; ZUKOWSKAGROJEC Z, 1988, LIFE SCI, V42, P1615, DOI 10.1016/0024-3205(88)90440-7; ZUKOWSKAGROJEC Z, 1993, PEPTIDES, V14, P263, DOI 10.1016/0196-9781(93)90040-N	55	100	109	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1924	+		10.1096/fj.05-4770fje	http://dx.doi.org/10.1096/fj.05-4770fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16891622				2022-12-28	WOS:000240267000032
J	Kong, KC; Billington, CK; Gandhi, U; Panettieri, RA; Penn, RB				Kong, Kok Choi; Billington, Charlotte K.; Gandhi, Uma; Panettieri, Reynold A., Jr.; Penn, Raymond B.			Cooperative mitogenic signaling by G protein-coupled receptors and growth factors is dependent on G(q/11)	FASEB JOURNAL			English	Article						airway remodeling; airway smooth muscle; asthma; p70S6 kinase; phosphoinositide 3 '-kinase	AIRWAY SMOOTH-MUSCLE; G-BETA-GAMMA; BRONCHOALVEOLAR LAVAGE FLUID; TYROSINE KINASES; ACTIVATION; SRC; STIMULATION; ASTHMA; PHOSPHORYLATION; PROLIFERATION	Previously we reported that the G protein-coupled receptor (GPCR) agonist thrombin potentiated the mitogenic effect of epidermal growth factor (EGF) on human airway smooth muscle (ASM) by promoting sustained late-phase activation of PI3K and p70S6K via a pathway dependent on G beta gamma subunits of heterotrimeric G proteins. Here, we provide additional mechanistic insight and reveal the robustness of this phenomenon by demonstrating that H1 histamine and thromboxane receptors utilize the same mechanism to augment ASM growth via specific activation of the heterotrimeric G protein G(q/11). Thrombin, histamine, and U46619 all enhanced EGF-stimulated [H-3]-thymidine incorporation as well as late-phase Akt and p70S6K phosphorylation in ASM cultures. Heterologous expression of G beta gamma sequestrants (GRK2CT-GFP or G alpha(i)G203A), as well as GRK2NT-GFP (an RGS protein for G(q/11)) but neither p115RhoGEFRGS-GFP (an RGS for G(12/13)) nor pertussis toxin pretreatment (inactivating G(i/o)), attenuated the effects on both signaling and growth. Inhibition of Rho, Rho kinase, or Src, or modulation of arrestin expression did not significantly affect the cooperative signaling by EGF and any of the GPCR agonists. Thus, G(q/11)-coupled receptors are the principal GPCR subfamily mediating cooperative mitogenic signaling in ASM, acting through G beta gamma-dependent, and Src/arrestin-independent activation of PI3K and p70S6K.	Wake Forest Univ, Hlth Sci Ctr, Ctr Human Genom, Winston Salem, NC 27157 USA; Wake Forest Univ, Hlth Sci Ctr, Dept Internal Med, Winston Salem, NC 27157 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	Wake Forest University; Wake Forest University; University of Pennsylvania	Penn, RB (corresponding author), Wake Forest Univ, Hlth Sci Ctr, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rpenn@wfubmc.edu	Billington, Charlotte/A-2304-2011; Gandhi, Uma/ABB-3802-2021; panettieri, reynold/AAG-9485-2019		NHLBI NIH HHS [R01 HL065338, HL58506, P01 HL067663, P50 HL067663, HL67663, R29 HL058506, HL65338] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058506, R29HL058506, P01HL067663, P50HL067663, R01HL065338] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN V, 1995, J ALLERGY CLIN IMMUN, V96, P618, DOI 10.1016/S0091-6749(95)70260-1; Bhattacharyya R, 2003, BIOCHEM J, V371, P709, DOI 10.1042/BJ20021897; Billington CK, 2005, BIOCHEMISTRY-US, V44, P14595, DOI 10.1021/bi0510734; Billington CK, 2003, RESP RES, V4; Carman CV, 2000, J BIOL CHEM, V275, P10443, DOI 10.1074/jbc.275.14.10443; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Ediger TL, 2000, J PHARMACOL EXP THER, V294, P1076; Ediger TL, 2003, EUR RESPIR J, V21, P759, DOI 10.1183/09031936.03.00075702; Goel R, 2004, J BIOL CHEM, V279, P6701, DOI 10.1074/jbc.M308753200; Goel R, 2002, J BIOL CHEM, V277, P18640, DOI 10.1074/jbc.M108995200; Gosens R, 2003, AM J RESP CELL MOL, V28, P257, DOI 10.1165/rcmb.2002-0128OC; Hauck RW, 1999, AM J PHYSIOL-LUNG C, V277, pL22, DOI 10.1152/ajplung.1999.277.1.L22; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Hirshman CA, 1999, AM J PHYSIOL-LUNG C, V277, pL653, DOI 10.1152/ajplung.1999.277.3.L653; Krymskaya VP, 2004, FASEB J, V18, P428, DOI 10.1096/fj.04-2869fje; Krymskaya VP, 2000, AM J RESP CELL MOL, V23, P546, DOI 10.1165/ajrcmb.23.4.4115; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Lutz S, 2005, J BIOL CHEM, V280, P11134, DOI 10.1074/jbc.M411322200; MURRAY RK, 1993, AM J PHYSIOL, V264, pC485, DOI 10.1152/ajpcell.1993.264.2.C485; Panettieri Jr RA, 1994, AIRWAYS SMOOTH MUSCL, P41; PANETTIERI RA, 1995, AM J RESP CELL MOL, V13, P205, DOI 10.1165/ajrcmb.13.2.7626288; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; PENN RB, 1998, HDB PHYSL, P125; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; SOFIA M, 1993, RESPIRATION, V60, P89; UEDA N, 1994, J BIOL CHEM, V269, P4388; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; ZEHR BB, 1989, CHEST, V95, P1059, DOI 10.1378/chest.95.5.1059	40	36	36	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1558	+		10.1096/fj.05-5622fje	http://dx.doi.org/10.1096/fj.05-5622fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723377				2022-12-28	WOS:000240266000050
J	Chen, F; Eckman, EA; Eckman, CB				Chen, Feng; Eckman, Elizabeth A.; Eckman, Christopher B.			Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides	FASEB JOURNAL			English	Article						ginseng; Rg1; Rg3; RE; Tg2576	GAMMA-SECRETASE INHIBITOR; EVENT-RELATED POTENTIALS; FREE TG2576 MICE; COGNITIVE PERFORMANCE; GINKGO-BILOBA; CEREBROSPINAL-FLUID; PROTEIN-PRECURSOR; MEMORY DEFICITS; PANAX-GINSENG; ANIMAL-MODEL	For millennia, ginseng and some of its components have been used to treat a wide variety of medical conditions, including age-related memory impairment. Because of its purported effects and apparently low rate of side effects, ginseng remains one of the top selling natural product remedies in the United States. Given its potential role for improving age-related memory impairments and its common use in China for the treatment of Alzheimer's disease-like symptoms, we analyzed the effects of commercially available preparations of ginseng on the accumulation of the Alzheimer's amyloid beta peptide (A beta) in a cell-based model system. In this model system, ginseng treatment resulted in a significant reduction in the levels of A beta in the conditioned medium. We next examined the effects of several compounds isolated from ginseng and found that certain ginsenosides lowered A beta concentration in a dose-dependent manner with ginsenoside Rg3 having an approximate IC50 of under 25 mu M against A beta 42. Furthermore, we found that three of these isolated components, ginsenoside Rg1, Rg3, and RE, resulted in significant reductions in the amount of A beta detected in the brains of animals after single oral doses of these agents. The results indicate that ginseng itself, or purified ginsenosides, may have similarly useful effects in human disease. Chen, F., Eckman, E. A., Eckman, C. B. Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides.	Mayo Clin, Coll Med, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Eckman, CB (corresponding author), Mayo Clin, Coll Med, Dept Pharmacol, Birdsall Bldg Rm 327,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	Eckman@mayo.edu	Eckman, Elizabeth/AAL-7316-2021	Eckman, Elizabeth/0000-0002-5391-4960				Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9; Bao HY, 2005, ARCH PHARM RES, V28, P335, DOI 10.1007/BF02977802; Barnes Patricia M, 2004, Adv Data, P1; Best JD, 2005, J PHARMACOL EXP THER, V313, P902, DOI 10.1124/jpet.104.081174; Bour A, 2004, NEUROBIOL LEARN MEM, V81, P27, DOI 10.1016/S1074-7427(03)00071-6; DANGELO L, 1986, J ETHNOPHARMACOL, V16, P15, DOI 10.1016/0378-8741(86)90063-2; Dergal JM, 2002, DRUG AGING, V19, P879, DOI 10.2165/00002512-200219110-00005; Dominguez DI, 2002, TRENDS PHARMACOL SCI, V23, P324, DOI 10.1016/S0165-6147(02)02038-2; GARCIA RR, 1988, PRENSA MED ARGENT, V75, P134; Gold JL, 2001, CURR OPIN CLIN NUTR, V4, P29, DOI 10.1097/00075197-200101000-00006; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harnack LJ, 2001, MAYO CLIN PROC, V76, P688, DOI 10.4065/76.7.688; Haugabook SJ, 2001, J NEUROSCI METH, V108, P171, DOI 10.1016/S0165-0270(01)00388-0; Haugabook SJ, 2001, FASEB J, V15, P16; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Huang KC, 1999, PHARM CHINESE HERBS; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Katada E, 2003, J GERIATR PSYCH NEUR, V16, P39, DOI 10.1177/0891988702250561; Katada E, 2004, CURR ALZHEIMER RES, V1, P63, DOI 10.2174/1567205043480609; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Kennedy DO, 2004, PHARMACOL BIOCHEM BE, V79, P401, DOI 10.1016/j.pbb.2004.07.014; Kennedy DO, 2003, PHARMACOL BIOCHEM BE, V75, P687, DOI 10.1016/S0091-3057(03)00126-6; Kennedy DO, 2003, PHARMACOL BIOCHEM BE, V75, P701, DOI 10.1016/S0091-3057(03)00120-5; Kennedy DO, 2002, PHYSIOL BEHAV, V75, P739, DOI 10.1016/S0031-9384(02)00665-0; Kennedy DO, 2001, NUTR NEUROSCI, V4, P295, DOI 10.1080/1028415X.2001.11747370; Kim YC, 1998, J NEUROSCI RES, V53, P426, DOI 10.1002/(SICI)1097-4547(19980815)53:4<426::AID-JNR4>3.3.CO;2-K; Koo BS, 2004, PHYTOTHER RES, V18, P488, DOI 10.1002/ptr.1457; Lanz TA, 2005, J PHARMACOL EXP THER, V312, P399, DOI 10.1124/jpet.104.073965; Lanz TA, 2004, J PHARMACOL EXP THER, V309, P49, DOI 10.1124/jpet.103.060715; Lian XY, 2005, ANN NEUROL, V57, P642, DOI 10.1002/ana.20450; Liu ZQ, 2003, J AGR FOOD CHEM, V51, P2555, DOI 10.1021/jf026228i; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Nishijo H, 2004, J PHARMACOL SCI, V95, P145, DOI 10.1254/jphs.FMJ04001X3; Oishi M, 1998, ALZ DIS ASSOC DIS, V12, P247, DOI 10.1097/00002093-199809000-00019; Petkov VD, 2003, AM J CHINESE MED, V31, P841, DOI 10.1142/S0192415X03001533; Polich John, 2005, Current Alzheimer Research, V2, P515, DOI 10.2174/156720505774932214; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; Scarpini E, 2003, LANCET NEUROL, V2, P539, DOI 10.1016/S1474-4422(03)00502-7; Sorensen H, 1996, CURR THER RES CLIN E, V57, P959, DOI 10.1016/S0011-393X(96)80114-7; Spinella M., 2001, PSYCHOPHARMACOLOGY H; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tohda C, 2005, NEUROSIGNALS, V14, P34, DOI 10.1159/000085384; Tohda C, 2004, NEUROPSYCHOPHARMACOL, V29, P860, DOI 10.1038/sj.npp.1300388; Vogler BK, 1999, EUR J CLIN PHARMACOL, V55, P567, DOI 10.1007/s002280050674; Winther K., 1997, Journal of the Neurological Sciences, V150, pS90, DOI 10.1016/S0022-510X(97)85276-8	49	119	126	2	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1269	+		10.1096/fj.05-5530fje	http://dx.doi.org/10.1096/fj.05-5530fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636099				2022-12-28	WOS:000240210300048
J	Chaudhry, UI; Katz, SC; Kingham, TP; Pillarisetty, VG; Raab, JR; Shah, AB; DeMatteo, RP				Chaudhry, Umer I.; Katz, Steven C.; Kingham, T. Peter; Pillarisetty, Venu G.; Raab, Jesse R.; Shah, Alaap B.; DeMatteo, Ronald P.			In vivo overexpression of Flt3 ligand expands and activates murine spleen natural killer dendritic cells	FASEB JOURNAL			English	Article						antigen presentation/processing; cell proliferation; cytotoxicity	IFN-GAMMA-PRODUCTION; TOLL-LIKE RECEPTORS; HUMAN NK CELLS; CROSS-PRESENTATION; T-CELLS; INTERFERON-GAMMA; APOPTOTIC CELLS; ANTIGEN; CD8(+); ALPHA	Natural killer dendritic cells ( NKDC) are a unique class of murine immune cells that possess the characteristics of both natural killer ( NK) cells and dendritic cells ( DC). Because NKDC are able to secrete IFN-gamma, directly lyse tumor cells, and present antigen to naive T cells, they have immunotherapeutic potential. The relative paucity of NKDC, however, impedes their detailed study. We have found that in vivo, overexpression of the hematopoietic cytokine Flt3 ligand ( Flt3L) expands NKDC in various organs from 2-18 fold. Flt3L expanded splenic NKDC retain the ability to lyse tumor cells and become considerably more potent at activating naive allogeneic and antigen-specific T cells. Compared to normal splenic NKDC, Flt3L-expanded splenic NKDC have a more mature phenotype, a slightly increased ability to capture and process antigen, and a similar cytokine profile. In vivo, we found that Flt3L-expanded splenic NKDC are more effective than normal splenic NKDC in stimulating antigen-specific CD8 T cells. Additionally, we show that NKDC are able to cross-present antigen in vivo. The ability to expand NKDC in vivo using Flt3L will facilitate further analysis of their unique biology. Moreover, Flt3L-expanded NKDC may have enhanced immunotherapeutic potential, given their increased ability to stimulate T cells.	Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	DeMatteo, RP (corresponding author), Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, Box 203,1275 York Ave, New York, NY 10021 USA.	dematter@mskcc.org	Pillarisetty, Venu/AAF-4425-2020	Pillarisetty, Venu/0000-0002-1162-9643; Raab, Jesse/0000-0001-6387-8994; Chaudhry, Umer/0000-0002-9080-9131; Kingham, T Peter/0000-0002-3359-3186	NIDDK NIH HHS [R01 DK068346, DK-068346] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068346] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Belz GT, 2002, CRIT REV IMMUNOL, V22, P439; CARBONE FR, 1992, INT IMMUNOL, V4, P861, DOI 10.1093/intimm/4.8.861; Chakravarty PK, 1999, CANCER RES, V59, P6028; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Esche C, 1998, CANCER RES, V58, P380; Eto M, 2002, J IMMUNOL, V169, P2390, DOI 10.4049/jimmunol.169.5.2390; Frucht DM, 2001, TRENDS IMMUNOL, V22, P556, DOI 10.1016/S1471-4906(01)02005-1; Fukao T, 2000, J IMMUNOL, V164, P64, DOI 10.4049/jimmunol.164.1.64; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Granucci F, 2004, J EXP MED, V200, P287, DOI 10.1084/jem.20040370; Hanada K, 1996, J LEUKOCYTE BIOL, V60, P181, DOI 10.1002/jlb.60.2.181; Hanna J, 2004, J CLIN INVEST, V114, P1612, DOI 10.1172/JCI200422787; Heath WR, 2004, IMMUNOL REV, V199, P9, DOI 10.1111/j.0105-2896.2004.00142.x; Heath WR, 2001, NAT REV IMMUNOL, V1, P126, DOI 10.1038/35100512; Hochrein H, 2001, J IMMUNOL, V166, P5448, DOI 10.4049/jimmunol.166.9.5448; Homann D, 2002, IMMUNITY, V16, P403, DOI 10.1016/S1074-7613(02)00290-X; Iyoda T, 2002, J EXP MED, V195, P1289, DOI 10.1084/jem.20020161; Josien R, 1997, J EXP MED, V186, P467, DOI 10.1084/jem.186.3.467; Kaisho T, 2003, CURR MOL MED, V3, P759, DOI 10.2174/1566524033479366; Kaisho T, 2001, ACTA ODONTOL SCAND, V59, P124, DOI 10.1080/000163501750266701; Kamath AT, 2005, J IMMUNOL, V174, P767, DOI 10.4049/jimmunol.174.2.767; Lian ZX, 2003, J IMMUNOL, V170, P2323, DOI 10.4049/jimmunol.170.5.2323; Lynch DH, 1997, NAT MED, V3, P625, DOI 10.1038/nm0697-625; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; Marquez C, 1998, BLOOD, V91, P2760, DOI 10.1182/blood.V91.8.2760.2760_2760_2771; Melief CJM, 2003, EUR J IMMUNOL, V33, P2645, DOI 10.1002/eji.200324341; Miller G, 2003, J IMMUNOL, V170, P3554, DOI 10.4049/jimmunol.170.7.3554; Miller G, 2002, J IMMUNOL, V169, P2875, DOI 10.4049/jimmunol.169.6.2875; Miller JS, 1999, BLOOD, V93, P96, DOI 10.1182/blood.V93.1.96.401k13_96_106; Munder M, 1998, J EXP MED, V187, P2103, DOI 10.1084/jem.187.12.2103; Ohteki T, 1999, J EXP MED, V189, P1981, DOI 10.1084/jem.189.12.1981; Peron JM, 1998, J IMMUNOL, V161, P6164; Pillarisetty VG, 2005, J IMMUNOL, V174, P2612, DOI 10.4049/jimmunol.174.5.2612; Pillarisetty VG, 2003, HEPATOLOGY, V37, P641, DOI 10.1053/jhep.2003.50074; Pillarisetty VG, 2004, J IMMUNOL, V172, P1009, DOI 10.4049/jimmunol.172.2.1009; Pooley JL, 2001, J IMMUNOL, V166, P5327, DOI 10.4049/jimmunol.166.9.5327; Puddu P, 1997, J IMMUNOL, V159, P3490; Schindler H, 2001, J IMMUNOL, V166, P3075, DOI 10.4049/jimmunol.166.5.3075; Schleicher U, 2005, BLOOD, V105, P1319, DOI 10.1182/blood-2004-05-1749; Shaw SG, 1998, J IMMUNOL, V161, P2817; Shen HQ, 2003, J IMMUNOL, V171, P3401, DOI 10.4049/jimmunol.171.7.3401; Shurin MR, 1997, CELL IMMUNOL, V179, P174, DOI 10.1006/cimm.1997.1152; Sivori S, 2004, P NATL ACAD SCI USA, V101, P10116, DOI 10.1073/pnas.0403744101; Stober D, 2001, J IMMUNOL, V167, P957, DOI 10.4049/jimmunol.167.2.957; Trinite B, 2000, J IMMUNOL, V165, P4202, DOI 10.4049/jimmunol.165.8.4202; Viney JL, 1998, J IMMUNOL, V160, P5815; Wilson JL, 1999, J IMMUNOL, V163, P6365; Wilson NS, 2005, ADV IMMUNOL, V86, P241, DOI 10.1016/S0065-2776(04)86007-3	51	31	32	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					982	+		10.1096/fj.05-5411fje	http://dx.doi.org/10.1096/fj.05-5411fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571772				2022-12-28	WOS:000240157700029
J	Koschinski, A; Repp, H; Unver, B; Dreyer, F; Brockmeier, D; Valeva, A; Bhakdi, S; Walev, I				Koschinski, Andreas; Repp, Holger; Uenver, Baris; Dreyer, Florian; Brockmeier, Dierk; Valeva, Angela; Bhakdi, Sucharit; Walev, Iwan			Why Escherichia coli alpha-hemolysin induces calcium oscillations in mammalian cells - the pore is on its own	FASEB JOURNAL			English	Article						pore-forming toxins; RTX toxins; gram-negative bacteria; membrane lesions	MEMBRANE; TOXIN; PROTEINS; CHANNELS; RECEPTOR	Escherichia coli alpha-hemolysin ( HlyA), archetype of a bacterial pore-forming toxin, has been reported to deregulate physiological Ca2+ channels, thus inducing periodic low-frequency Ca2+ oscillations that trigger transcriptional processes in mammalian cells. The present study was undertaken to delineate the mechanisms underlying the Ca2+ oscillations. Patch-clamp experiments were combined with single cell measurements of intracellular Ca2+ and with flow-cytometric analyses. Application of HlyA at subcytocidal concentrations provoked Ca2+ oscillations in human renal and endothelial cells. However, contrary to the previous report, the phenomenon could not be inhibited by the Ca2+ channel blocker nifedipine and Ca2+ oscillations showed no constant periodicity at all. Ca2+ oscillations were dependent on the pore-forming activity of HlyA: application of a nonhemolytic but bindable toxin had no effect. Washout experiments revealed that Ca2+ oscillations could not be maintained in the absence of toxin in the medium. Analogously, propidium iodide flux into cells occurred in the presence of HlyA, but cells rapidly became impermeable toward the dye after toxin washout, indicating resealing or removal of the membrane lesions. Finally, patchclamp experiments revealed temporal congruence between pore formation and Ca2+ influx. We conclude that the nonperiodic Ca2+ oscillations induced by HlyA are not due to deregulation of physiological Ca2+ channels but derive from pulsed influxes of Ca2+ as a consequence of formation and rapid closure of HlyA pores in mammalian cell membranes.	Univ Giessen, Rudolf Buchheim Inst Pharmacol, D-35392 Giessen, Germany; Johannes Gutenberg Univ Mainz, Inst Med Microbiol & Hyg, D-6500 Mainz, Germany	Justus Liebig University Giessen; Johannes Gutenberg University of Mainz	Repp, H (corresponding author), Univ Giessen, Rudolf Buchheim Inst Pharmacol, Frankfurter Str 107, D-35392 Giessen, Germany.	Holger.Repp@pharma.med.uni-giessen.de; walev@mail.uni-mainz.de						BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; Berjukow S, 1996, BRIT J PHARMACOL, V118, P748, DOI 10.1111/j.1476-5381.1996.tb15463.x; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bhakdi S, 1996, CURR TOP MICROBIOL, V216, P101; Cortajarena AL, 2001, J BIOL CHEM, V276, P12513, DOI 10.1074/jbc.M006792200; de Vries H, 1998, J PHOTOCH PHOTOBIO B, V43, P217, DOI 10.1016/S1011-1344(98)00111-0; Dragneva Y, 2001, INFECT IMMUN, V69, P2630, DOI 10.1128/IAI.69.4.2630-2635.2001; Frick M, 2001, BIOCHEM PHARMACOL, V61, P1161, DOI 10.1016/S0006-2952(01)00582-2; Hyland C, 2001, J BACTERIOL, V183, P5364, DOI 10.1128/JB.183.18.5364-5370.2001; Koschinski A, 2003, J GEN VIROL, V84, P1711, DOI 10.1099/vir.0.19062-0; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; Lewis RS, 2003, BIOCHEM SOC T, V31, P925; Menestrina G, 1996, J MEMBRANE BIOL, V149, P113, DOI 10.1007/s002329900012; MENESTRINA G, 1987, BIOCHIM BIOPHYS ACTA, V905, P109, DOI 10.1016/0005-2736(87)90014-9; Randall AD, 1998, J MEMBRANE BIOL, V161, P207, DOI 10.1007/s002329900327; Repp H, 2002, CELL MICROBIOL, V4, P483, DOI 10.1046/j.1462-5822.2002.00207.x; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; Savigni DL, 2003, BIOCHEM PHARMACOL, V65, P1215, DOI 10.1016/S0006-2952(03)00045-5; Schindel C, 2001, EUR J BIOCHEM, V268, P800, DOI 10.1046/j.1432-1327.2001.01937.x; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; Valeva A, 2000, MOL MICROBIOL, V36, P467, DOI 10.1046/j.1365-2958.2000.01865.x; Walev I, 2001, P NATL ACAD SCI USA, V98, P3185, DOI 10.1073/pnas.051429498; WALEV I, 2002, FASEB J, V216, P237; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85	25	39	40	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					973	+		10.1096/fj.05-4561fje	http://dx.doi.org/10.1096/fj.05-4561fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16597673				2022-12-28	WOS:000240157700026
J	Prosperi, E				Prosperi, Ennio			The fellowship of the rings: distinct pools of proliferating cell nuclear antigen trimer at work	FASEB JOURNAL			English	Article						proliferating cell nuclear antigen; DNA replication; DNA repair; CDK2; chromatin-modifying enzymes	DNA-POLYMERASE-DELTA; REPLICATION SITES; STRUCTURAL BASIS; PCNA-BINDING; TERMINAL DEOXYNUCLEOTIDYLTRANSFERASE; POLY(ADP-RIBOSE) POLYMERASE-1; FLAP ENDONUCLEASE-1; SUBUNIT; PROTEIN; REPAIR	The proliferating cell nuclear antigen ( PCNA) is a homotrimeric ring-shaped protein that, by encircling DNA, may function as a sliding platform for proteins participating in various DNA transactions. PCNA plays a fundamental role in DNA replication and repair, but also in postreplicative events, like DNA methylation, chromatin assembly and remodeling, sister chromatid cohesion, and coordinates these activities with cell cycle control. However, relevant aspects of PCNA function are still not well understood, like the role of PCNA in the association with partner proteins, and how multiple protein interactions are orchestrated. Based on emerging evidence, I suggest that 1) PCNA interacting proteins may be reclassified in three major categories, namely, a) cell cycle control; b) DNA replication/repair; c) chromatin regulation/transcription. 2) PCNA is a negative regulator, rather than a processivity/recruitment factor, of chromatin-modifying enzymes. 3) At DNA replication sites, PCNA function may be envisaged with a model of "dynamic hand-off" of interacting partners that rapidly and transiently exchange in a mutually exclusive manner, while cyclin-dependent kinase ( Cdk) 2 ( CDK2) is stably bound to PCNA. The partner exchange might occur through a conformational change of the PCNA/protein/DNA complex allowing CDK2 to phosphorylate the partner protein, thereby enabling its hand-off from PCNA.	Univ Pavia, CNR, Ist Genet Mol, Sez Istochim & Citometria,Dept Biol Anim, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Pavia	Prosperi, E (corresponding author), Univ Pavia, CNR, Ist Genet Mol, Sez Istochim & Citometria,Dept Biol Anim, Piazza Botta 10, I-27100 Pavia, Italy.	prosperi@igm.cnr.it		Prosperi, Ennio/0000-0001-5391-5157				Bruning JB, 2004, STRUCTURE, V12, P2209, DOI 10.1016/j.str.2004.09.018; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Cazzalini O, 2003, CELL CYCLE, V2, P596, DOI 10.4161/cc.2.6.502; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DARLYMPLE BP, 2001, P NATL ACAD SCI USA, V98, P11627; Dionne I, 2003, MOL CELL, V11, P275, DOI 10.1016/S1097-2765(02)00824-9; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Frouin I, 2003, J BIOL CHEM, V278, P39265, DOI 10.1074/jbc.C300098200; Fujita K, 2003, GENES CELLS, V8, P559, DOI 10.1046/j.1365-2443.2003.00656.x; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hasan S, 2002, J MOL MED, V80, P463, DOI 10.1007/s00109-002-0341-7; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; Henderson DS, 2000, GENETICS, V154, P1721; HENNECKE G, 2003, EMBO REP, V4, P1; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hong R, 2003, J BIOL CHEM, V278, P44505, DOI 10.1074/jbc.M303138200; Ibe S, 2001, GENES CELLS, V6, P815, DOI 10.1046/j.1365-2443.2001.00460.x; Ise T, 1999, CANCER RES, V59, P342; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Martin PJ, 2005, NUCLEIC ACIDS RES, V33, P4311, DOI 10.1093/nar/gki745; Milutinovic S, 2002, J BIOL CHEM, V277, P20974, DOI 10.1074/jbc.M202504200; Naryzhny SN, 2005, J BIOL CHEM, V280, P13888, DOI 10.1074/jbc.M500304200; Oyama M, 2004, BIOCHEM BIOPH RES CO, V321, P183, DOI 10.1016/j.bbrc.2004.06.136; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Pohler JRG, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-17; Poot RA, 2004, NAT CELL BIOL, V6, P1236, DOI 10.1038/ncb1196; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Riva F, 2004, EXP CELL RES, V293, P357, DOI 10.1016/j.yexcr.2003.10.025; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Sakurai S, 2005, EMBO J, V24, P683, DOI 10.1038/sj.emboj.7600519; Solovjeva L, 2005, MOL BIOL CELL, V16, P2518, DOI 10.1091/mbc.e04-12-1066; Sporbert A, 2005, NUCLEIC ACIDS RES, V33, P3521, DOI 10.1093/nar/gki665; Sporbert A, 2002, MOL CELL, V10, P1355, DOI 10.1016/S1097-2765(02)00729-3; Stauffer ME, 2004, J BIOL CHEM, V279, P30915, DOI 10.1074/jbc.R400015200; Sukhanova MV, 2005, NUCLEIC ACIDS RES, V33, P1222, DOI 10.1093/nar/gki266; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Vivona JB, 2003, FEBS LETT, V546, P167, DOI 10.1016/S0014-5793(03)00622-7; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Xia LQ, 2005, J MOL BIOL, V346, P1259, DOI 10.1016/j.jmb.2005.01.014; Xin HW, 2004, J BIOL CHEM, V279, P9539, DOI 10.1074/jbc.M311587200; Xu H, 2001, BIOCHEMISTRY-US, V40, P4512, DOI 10.1021/bi010103+; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189	49	38	40	2	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					833	837		10.1096/fj.05-5469hyp	http://dx.doi.org/10.1096/fj.05-5469hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675840				2022-12-28	WOS:000240157700005
J	Vacher, H; Mohapatra, DP; Misonou, H; Trimmer, JS				Vacher, Helene; Mohapatra, Durga P.; Misonou, Hiroaki; Trimmer, Jaimes S.			Regulation of Kv1 channel trafficking by the mamba snake neurotoxin dendrotoxin K	FASEB JOURNAL			English	Article						potassium channel; neuron; endoplasmic reticulum	BETA-SUBUNIT POLYPEPTIDES; POTASSIUM CHANNEL; SURFACE EXPRESSION; CELL-SURFACE; MOLECULAR-PROPERTIES; MAMMALIAN BRAIN; ALPHA-SUBUNIT; ION CHANNELS; AMINO-ACIDS; IDENTIFICATION	Modulation of voltage-gated potassium (Kv) channel surface expression can profoundly affect neuronal excitability. Some, but not all, mammalian Shaker or Kv1 alpha subunits contain a dominant endoplasmic reticulum (ER) retention signal in their pore region, preventing surface expression of Kv1.1 homotetrameric channels and of heteromeric Kv1 channels containing more than one Kv1.1 subunit. The critical amino acid residues within this ER pore-region retention signal are also critical for high-affinity binding of snake dendrotoxins (DTX). This suggests that ER retention may be mediated by an ER protein with a domain structurally similar to that of DTX. One facet of such a model is that expression of soluble DTX in the ER lumen should compete for binding to the retention protein and allow for surface expression of retained Kv1.1. Here, we show that luminal DTX expression dramatically increased both the level of cell surface Kv1.1 immunofluorescence staining and the proportion of Kv1.1 with processed N-linked oligosaccharides. Electrophysiological analyses showed that luminal DTX expression led to significant increases in Kv1.1 currents. Together, these data showed that luminal DTX expression increases surface expression of functional Kv1.1 homotetrameric channels and support a model whereby a DTX-like ER protein regulates abundance of cell surface Kv1 channels.	Univ Calif Davis, Sch Med, Dept Pharmacol, Davis, CA 95616 USA	University of California System; University of California Davis	Trimmer, JS (corresponding author), Univ Calif Davis, Sch Med, Dept Pharmacol, 3502 GBSF,451 W Hlth Sci Dr,1 Shields Ave, Davis, CA 95616 USA.	jtrimmer@ucdavis.edu	Durga, Mohapatra/B-3620-2008; Mohapatra, Durga/M-2133-2017	Mohapatra, Durga/0000-0001-5016-1281; Misono, Hiroaki/0000-0001-5892-1804	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034383, R01NS034383] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS034383, R37 NS034383, NS34383, R37 NS034383-12] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BekeleArcuri Z, 1996, NEUROPHARMACOLOGY, V35, P851, DOI 10.1016/0028-3908(96)00128-1; Campomanes CR, 2002, J BIOL CHEM, V277, P8298, DOI 10.1074/jbc.M110276200; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Dolly JO, 1996, J BIOENERG BIOMEMBR, V28, P231, DOI 10.1007/BF02110698; Fu W, 2002, BIOPHYS J, V83, P2370, DOI 10.1016/S0006-3495(02)75251-X; Harvey AL, 2001, TOXICON, V39, P15, DOI 10.1016/S0041-0101(00)00162-8; Hille B., 2001, IONIC CHANNELS EXCIT, P814; HURST RS, 1991, MOL PHARMACOL, V40, P572; Imredy JP, 2000, J MOL BIOL, V296, P1283, DOI 10.1006/jmbi.2000.3522; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Lopantsev V, 2003, EPILEPSIA, V44, P1506, DOI 10.1111/j.0013-9580.2003.44602.x; Manganas LN, 2001, P NATL ACAD SCI USA, V98, P14055, DOI 10.1073/pnas.241403898; Manganas LN, 2001, J BIOL CHEM, V276, P49427, DOI 10.1074/jbc.M109325200; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; Misonou H, 2005, J NEUROSCI METH, V144, P165, DOI 10.1016/j.jneumeth.2004.11.007; Miwa JM, 1999, NEURON, V23, P105, DOI 10.1016/S0896-6273(00)80757-6; Mohapatra DP, 2006, J NEUROSCI, V26, P685, DOI 10.1523/JNEUROSCI.4620-05.2006; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RHODES KJ, 1995, J NEUROSCI, V15, P5360; Robertson GA, 2006, HANDB EXP PHARMACOL, V171, P349; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Smart SL, 1998, NEURON, V20, P809, DOI 10.1016/S0896-6273(00)81018-1; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; SMITH LA, 1993, BIOCHEMISTRY-US, V32, P5692, DOI 10.1021/bi00072a026; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Trimmer JS, 2004, ANNU REV PHYSIOL, V66, P477, DOI 10.1146/annurev.physiol.66.032102.113328; TYTGAT J, 1995, J BIOL CHEM, V270, P24776, DOI 10.1074/jbc.270.42.24776; Wang FC, 1999, EUR J BIOCHEM, V263, P222, DOI 10.1046/j.1432-1327.1999.00494.x; Zhu J, 2005, BIOCHEM J, V388, P355, DOI 10.1042/BJ20041447; Zhu J, 2003, J BIOL CHEM, V278, P25558, DOI 10.1074/jbc.M207984200; Zhu J, 2001, J BIOL CHEM, V276, P39419, DOI 10.1074/jbc.M107399200	35	27	27	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					906	914		10.1096/fj.06-7229com	http://dx.doi.org/10.1096/fj.06-7229com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17185748	Green Accepted			2022-12-28	WOS:000244686400027
J	Bezaire, V; Seifert, EL; Harper, ME				Bezaire, Veronic; Seifert, Erin L.; Harper, Mary Ellen			Uncoupling protein-3: clues in an ongoing mitochondrial mystery	FASEB JOURNAL			English	Review						proton leak; skeletal muscle; thermogenesis; ROS; fatty acid metabolism	MESSENGER-RNA EXPRESSION; BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE MITOCHONDRIA; BASAL PROTON CONDUCTANCE; FATTY-ACID OXIDATION; UCP3 GENE; INSULIN-RESISTANCE; UP-REGULATION; HYDROGEN-PEROXIDE; THYROID-HORMONE	Uncoupling protein (UCP) 3 (UCP3) is a mitochondrial anion carrier protein with highly selective expression in skeletal muscle. Despite a great deal of interest, to date neither its molecular mechanism nor its biochemical and physiological functions are well understood. Based on its high degree of homology to the original UCP (UCP I), early studies examined a role for UCP3 in thermogenesis. However, evidence for such a function is lacking. Recent studies have focused on two distinct, but not mutually exclusive, hypotheses: 1) UCP3 mitigates reactive oxygen species (ROS) production, and 2) UCP3 is somehow involved in fatty acid (FA) translocation. While supportive evidence exists for both hypotheses, the interpretation of the corresponding evidence has created some controversy. Mechanistic studies examining mitigated ROS production have been largely conducted in vitro, and the physiological significance of the findings is questioned. Conversely, while physiological evidence exists for FA translocation hypotheses, the evidence is largely correlative, leaving causal relationships unexplored. This review critically assesses evidence for the hypotheses and attempts to link the outcomes from mechanistic studies to physiological implications. Important directions for future studies, using current and novel approaches, are discussed.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Fac Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Harper, ME (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, Fac Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	maryellen.harper@uottawa.ca		Harper, Mary-Ellen/0000-0003-3864-5886				Acin A, 1999, BIOCHEM BIOPH RES CO, V258, P278, DOI 10.1006/bbrc.1999.0530; Alonso A, 2005, ANN NUTR METAB, V49, P183, DOI 10.1159/000086883; Andrews ZB, 2005, NAT REV NEUROSCI, V6, P829, DOI 10.1038/nrn1767; Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; Berentzen T, 2005, INT J OBESITY, V29, P93, DOI 10.1038/sj.ijo.0802841; Bezaire V, 2005, FASEB J, V19, P977, DOI 10.1096/fj.04-2765fje; Bezaire V, 2001, AM J PHYSIOL-ENDOC M, V281, pE975, DOI 10.1152/ajpendo.2001.281.5.E975; Boss O, 1998, FASEB J, V12, P335, DOI 10.1096/fasebj.12.3.335; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brand MD, 2005, BIOCHEM J, V392, P353, DOI 10.1042/BJ20050890; Brand MD, 2002, BIOCHEM J, V368, P597, DOI 10.1042/BJ20021077; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; Brown AM, 1999, FEBS LETT, V464, P189, DOI 10.1016/S0014-5793(99)01708-1; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Cadenas S, 2002, J BIOL CHEM, V277, P2773, DOI 10.1074/jbc.M109736200; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cassell PG, 2000, DIABETOLOGIA, V43, P1558, DOI 10.1007/s001250051569; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chung WK, 1999, DIABETES, V48, P1890, DOI 10.2337/diabetes.48.9.1890; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Costford SR, 2006, AM J PHYSIOL-ENDOC M, V290, pE1304, DOI 10.1152/ajpendo.00401.2005; Dalgaard LT, 2001, DIABETOLOGIA, V44, P1065; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Flandin P, 2005, FEBS LETT, V579, P3411, DOI 10.1016/j.febslet.2005.04.084; Gable DR, 2006, DIABETES, V55, P1504, DOI 10.2337/db05-1645; Garcia-Martinez C, 2001, FASEB J, V15, P2033, DOI 10.1096/fj.00-0828fje; Gerber LK, 2006, AM J PHYSIOL-CELL PH, V291, pC1198, DOI 10.1152/ajpcell.00246.2006; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Hagen T, 1999, FEBS LETT, V454, P201, DOI 10.1016/S0014-5793(99)00811-X; Halsall DJ, 2001, INT J OBESITY, V25, P472, DOI 10.1038/sj.ijo.0801584; Haluzik M, 2004, ENDOCRINOLOGY, V145, P3258, DOI 10.1210/en.2004-0219; Hamilton JA, 1999, PROSTAG LEUKOTR ESS, V60, P291, DOI 10.1016/S0952-3278(99)80002-7; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Harper JA, 2002, BIOCHEM J, V361, P49, DOI 10.1042/0264-6021:3610049; Harper ME, 2004, ACTA PHYSIOL SCAND, V182, P321, DOI 10.1111/j.1365-201X.2004.01370.x; Harper ME, 2002, DIABETES, V51, P2459, DOI 10.2337/diabetes.51.8.2459; Herrmann SM, 2003, J MOL MED, V81, P327, DOI 10.1007/s00109-003-0431-1; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Hoeks J, 2006, FEBS LETT, V580, P1371, DOI 10.1016/j.febslet.2006.01.059; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Huppertz C, 2001, J BIOL CHEM, V276, P12520, DOI 10.1074/jbc.M011708200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; JANSKY L, 1995, PHYSIOL REV, V75, P237, DOI 10.1152/physrev.1995.75.2.237; Jezek P, 2000, IUBMB LIFE, V49, P63; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kiens B, 2006, PHYSIOL REV, V86, P205, DOI 10.1152/physrev.00023.2004; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Koves TR, 2005, J BIOL CHEM, V280, P33588, DOI 10.1074/jbc.M507621200; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Liebig M, 2004, PHYSIOL BIOCHEM ZOOL, V77, P116, DOI 10.1086/381464; Liu YJ, 2005, PHYSIOL GENOMICS, V22, P197, DOI 10.1152/physiolgenomics.00031.2005; MacLellan JD, 2005, DIABETES, V54, P2343, DOI 10.2337/diabetes.54.8.2343; Matsuda J, 1997, FEBS LETT, V418, P200, DOI 10.1016/S0014-5793(97)01381-1; McLeod CJ, 2005, J BIOL CHEM, V280, P33470, DOI 10.1074/jbc.M505258200; Meirhaeghe A, 2000, DIABETOLOGIA, V43, P1424, DOI 10.1007/s001250051549; Merry BJ, 2004, AGING CELL, V3, P7, DOI 10.1046/j.1474-9728.2003.00074.x; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Mills EM, 2004, J MOL MED, V82, P787, DOI 10.1007/s00109-004-0591-7; Mills EM, 2003, NATURE, V426, P403, DOI 10.1038/426403a; Mingrone G, 2003, OBES RES, V11, P632, DOI 10.1038/oby.2003.91; Mingrone G, 1997, DIABETOLOGIA, V40, P599, DOI 10.1007/s001250050721; Mozo J, 2006, BIOCHEM J, V393, P431, DOI 10.1042/BJ20050494; Nagase I, 1999, FEBS LETT, V461, P319, DOI 10.1016/S0014-5793(99)01477-5; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Nicholls DG, 2006, BBA-BIOENERGETICS, V1757, P459, DOI 10.1016/j.bbabio.2006.02.005; Otabe S, 1999, DIABETES, V48, P206; Paradis E, 2003, TRENDS MOL MED, V9, P522, DOI 10.1016/j.molmed.2003.10.009; Pedraza N, 2006, ENDOCRINOLOGY, V147, P4695, DOI 10.1210/en.2006-0226; Powers SK, 1999, P NUTR SOC, V58, P1025, DOI 10.1017/S0029665199001342; Rossmeisl M, 2003, DIABETES, V52, P1958, DOI 10.2337/diabetes.52.8.1958; Russell AP, 2003, PFLUG ARCH EUR J PHY, V445, P563, DOI 10.1007/s00424-002-0943-5; Rusyniak DE, 2005, J PHARMACOL EXP THER, V313, P629, DOI 10.1124/jpet.104.079236; Samec S, 2002, PFLUG ARCH EUR J PHY, V445, P80, DOI 10.1007/s00424-002-0879-9; Samec S, 1998, DIABETES, V47, P1693, DOI 10.2337/diabetes.47.11.1693; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Schrauwen P, 1999, INT J OBESITY, V23, P1242, DOI 10.1038/sj.ijo.0801057; Schrauwen P, 2004, INT J OBESITY, V28, P824, DOI 10.1038/sj.ijo.0802629; Schrauwen P, 2001, FASEB J, V15, P2497, DOI 10.1096/fj.01-0400hyp; Schreibman L., 2000, J POSIT BEHAV INTERV, V2, P3, DOI [10.1177/109830070000200102, DOI 10.1177/109830070000200102]; Schreyer M, 2001, SOLID STATE SCI, V3, P25, DOI 10.1016/S1293-2558(00)01128-6; Schroder J, 2003, LECT NOTES CONTR INF, V282, P1; Silva JP, 2005, EMBO J, V24, P4061, DOI 10.1038/sj.emboj.7600866; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Son C, 2004, DIABETOLOGIA, V47, P47, DOI 10.1007/s00125-003-1272-8; Surwit RS, 1997, DIABETES, V46, P1516, DOI 10.2337/diabetes.46.9.1516; Talbot DA, 2005, BBA-BIOENERGETICS, V1709, P150, DOI 10.1016/j.bbabio.2005.07.001; Talbot DA, 2004, FEBS LETT, V556, P111, DOI 10.1016/S0014-5793(03)01386-3; Tsuboyama-Kasaoka N, 1998, BIOCHEM BIOPH RES CO, V247, P498, DOI 10.1006/bbrc.1998.8818; Vesce S, 2005, J BIOL CHEM, V280, P38720, DOI 10.1074/jbc.M506575200; Vidal-Puig A, 1999, OBES RES, V7, P133, DOI 10.1002/j.1550-8528.1999.tb00694.x; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Wang EJ, 2003, BMC PSYCHIATRY, V3, DOI 10.1186/1471-244X-3-5; Yu BP, 2006, MECH AGEING DEV, V127, P436, DOI 10.1016/j.mad.2006.01.023; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	107	111	117	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					312	324		10.1096/fj.06-6966rev	http://dx.doi.org/10.1096/fj.06-6966rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17202247				2022-12-28	WOS:000244686300005
J	Wulczyn, FG; Smirnova, L; Rybak, A; Brandt, C; Kwidzinski, E; Ninnemann, O; Strehle, M; Sefler, A; Schumacher, S; Nitsch, R				Wulczyn, F. Gregory; Smirnova, Lena; Rybak, Agnieszka; Brandt, Christine; Kwidzinski, Erik; Ninnemann, Olaf; Strehle, Michael; Sefler, Andrea; Schumacher, Stefan; Nitsch, Robert			RETRACTED: Post-transcriptional regulation of the let-7 microRNA during neural cell specification (Retracted article. See vol. 35, 2021)	FASEB JOURNAL			English	Article; Retracted Publication						embryonic stem cells; neurogenesis; fragile X mental retardation protein; miRISC; P/GW bodies	GENE-EXPRESSION; MESSENGER-RNA; DICER; PROTEIN; BODIES; IDENTIFICATION; MORPHOGENESIS; TRANSCRIPTION; BIOGENESIS; INTERACTS	The let-7 miRNA regulates developmental timing in C. elegans and is an important paradigm for investigations of miRNA functions in mammalian development. We have examined the role of miRNA precursor processing in the temporal control and lineage specificity of the let-7 miRNA. In situ hybridization (ISH) in E9.5 mouse embryos revealed early induction of let-7 in the developing central nervous system. The expression pattern of three let-7 family members closely resembled that of the brain-enriched miRNAs mir-124, mir-125 and mir-128. Comparison of primary, precursor, and mature let-7 RNA levels during both embryonic brain development and neural differentiation of embryonic stem cells and embryocarcinoma (EC) cells suggest post-transcriptional regulation of let-7 accumulation. Reflecting these results, let-7 sensor constructs were strongly down-regulated during neural differentiation of EC cells and displayed lineage specificity in primary cells. Neural differentiation of EC cells was accompanied by an increase in let-7 precursor processing activity in vitro. Furthermore, undifferentiated and differentiated cells contained distinct precursor RNA binding complexes. A neuron-enhanced binding complex was shown by antibody challenge to contain the miRNA pathway proteins Argonaute1 and FMRP. Developmental regulation of the processing pathway correlates with differential localization of the proteins Argonaute, FMRP, MOV10, and TNRC6B in self-renewing stem cells and neurons.	Charite Univ Med Berlin, Ctr Anat, Inst Cell Biol & Neurobiol, D-10098 Berlin, Germany; Fed Inst Risk Assessment, Natl Ctr Documentat & Evaluat Alternat Methods An, Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin Buch, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Federal Institute for Risk Assessment; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Wulczyn, FG (corresponding author), Charite Univ Med Berlin, Ctr Anat, Inst Cell Biol & Neurobiol, Schumannstr 20-21, D-10098 Berlin, Germany.	gregory.wulczyn@charite.de	Nitsch, Robert/AAI-9129-2021	Rybak-Wolf, Agnieszka/0000-0002-1192-5290				Abbott AL, 2005, DEV CELL, V9, P403, DOI 10.1016/j.devcel.2005.07.009; Abrahante JE, 2003, DEV CELL, V4, P625, DOI 10.1016/S1534-5807(03)00127-8; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Ashraf SI, 2006, CELL, V124, P191, DOI 10.1016/j.cell.2005.12.017; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Biemar F, 2005, P NATL ACAD SCI USA, V102, P15907, DOI 10.1073/pnas.0507817102; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Cao XW, 2006, ANNU REV NEUROSCI, V29, P77, DOI 10.1146/annurev.neuro.29.051605.112839; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Ding L, 2005, MOL CELL, V19, P437, DOI 10.1016/j.molcel.2005.07.013; Erdtmann-Vourliotis M, 1999, BRAIN RES PROTOC, V4, P82, DOI 10.1016/S1385-299X(99)00006-9; Filipowicz W, 2005, CELL, V122, P17, DOI 10.1016/j.cell.2005.06.023; Filipowicz W, 2005, CURR OPIN STRUC BIOL, V15, P331, DOI 10.1016/j.sbi.2005.05.006; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Haase AD, 2005, EMBO REP, V6, P961, DOI 10.1038/sj.embor.7400509; Hammond SM, 2005, FEBS LETT, V579, P5822, DOI 10.1016/j.febslet.2005.08.079; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Jiang F, 2005, GENE DEV, V19, P1674, DOI 10.1101/gad.1334005; Jin P, 2004, NAT CELL BIOL, V6, P1048, DOI 10.1038/ncb1104-1048; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Johnston RJ, 2005, DEVELOPMENT, V132, P5451, DOI 10.1242/dev.02163; Kataoka Y, 2001, GENES CELLS, V6, P313, DOI 10.1046/j.1365-2443.2001.00427.x; Kaytor MD, 2001, CELL, V107, P555, DOI 10.1016/S0092-8674(01)00590-6; Klein ME, 2005, CURR OPIN NEUROBIOL, V15, P507, DOI 10.1016/j.conb.2005.08.011; Kloosterman WP, 2004, NUCLEIC ACIDS RES, V32, P6284, DOI 10.1093/nar/gkh968; Kloosterman WP, 2006, NAT METHODS, V3, P27, DOI 10.1038/NMETH843; Kosik KS, 2005, NEURON, V47, P779, DOI 10.1016/j.neuron.2005.08.019; Kotaja N, 2006, P NATL ACAD SCI USA, V103, P2647, DOI 10.1073/pnas.0509333103; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Leaman D, 2005, CELL, V121, P1097, DOI 10.1016/j.cell.2005.04.016; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Li M, 2005, DEV CELL, V9, P415, DOI 10.1016/j.devcel.2005.08.002; Lin SY, 2003, DEV CELL, V4, P639, DOI 10.1016/S1534-5807(03)00124-2; Liu JD, 2005, NAT CELL BIOL, V7, P1261, DOI 10.1038/ncb1333; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Maniataki E, 2005, GENE DEV, V19, P2979, DOI 10.1101/gad.1384005; Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421; Mazroui R, 2002, HUM MOL GENET, V11, P3007, DOI 10.1093/hmg/11.24.3007; Meister G, 2005, CURR BIOL, V15, P2149, DOI 10.1016/j.cub.2005.10.048; Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68; Pasquinelli AE, 2002, ANNU REV CELL DEV BI, V18, P495, DOI 10.1146/annurev.cellbio.18.012502.105832; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Reinscheid RK, 2000, PEPTIDES, V21, P901, DOI 10.1016/S0196-9781(00)00226-6; Saito K, 2005, PLOS BIOL, V3, P1202, DOI 10.1371/journal.pbio.0030235; Sandoval J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh091; SEMERE LF, 2004, GENOME BIOL, V5, pR13; Sen GL, 2005, NAT CELL BIOL, V7, P633, DOI 10.1038/ncb1265; Sernpere LF, 2003, DEV BIOL, V259, P9, DOI 10.1016/S0012-1606(03)00208-2; Smirnova L, 2005, EUR J NEUROSCI, V21, P1469, DOI 10.1111/j.1460-9568.2005.03978.x; Sokol NS, 2005, GENE DEV, V19, P2343, DOI 10.1101/gad.1356105; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; Yang Z, 2004, J CELL SCI, V117, P5567, DOI 10.1242/jcs.01477	58	268	282	0	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					415	426		10.1096/fj.06-6130com	http://dx.doi.org/10.1096/fj.06-6130com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17167072				2022-12-28	WOS:000244686300015
J	Cyr, M; Sotnikova, TD; Gainetdinov, RR; Caron, MG				Cyr, Michel; Sotnikova, Tatyana D.; Gainetdinov, Raul R.; Caron, Marc G.			Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin	FASEB JOURNAL			English	Article						polyglutamine disease; basal ganglia; chorea; hyperkinetic disorders; Huntington's disease; medium spiny neurons	NEURONAL INTRANUCLEAR INCLUSIONS; HD TRANSGENIC MICE; STRIATAL NEURONS; MOUSE MODEL; BEHAVIORAL ABNORMALITIES; TETRABENAZINE TREATMENT; DIFFERENTIAL REGULATION; MORPHOLOGICAL-CHANGES; FUNCTIONAL-ANATOMY; MUTANT HUNTINGTIN	An expansion in the CAG repeat of the IT15 ( huntingtin) gene underlies the development of Huntington's disease (HD), but the basis for the specific vulnerability of dopamine-receptive striatal neurons remains unclear. To examine the potential role of the dopamine system in the emergence of pathological conditions in HD, we generated a double mutant mouse strain with both enhanced dopamine transmission and endogenous expression of a mutant huntingtin gene. This strain was generated by crossing the dopamine transporter knock-out mouse, which exhibits a 5-fold elevation in extracellular dopamine levels in the striatum and locomotor hyperactivity, to a knock-in mouse model of HD containing 92 CAG repeats. These double mutant mice exhibited an increased stereotypic activity at 6 months of age, followed by a progressive decline of their locomotor hyperactivity. Expression of the mutated huntingtin did not alter dopamine or its metabolite levels in normal or dopamine transporter knock-out mice. However, the mutant huntingtin protein aggregated much earlier and to a greater extent in the striatum and other dopaminergic brain regions in the hyperdopaminergic mouse model of HD. Furthermore, the formation of neuropil aggregates in the striatum and other regions of hyperdopaminergic HD mice was observed at 4 months of age, well before similar events occurred in normal HD mice ( 12 months). These findings indicate that dopamine contributes to the deleterious effects of mutated huntingtin on striatal function, and this is accompanied by enhanced formation of huntingtin aggregates.-Cyr, M., Sotnikova, T. D., Gainetdinov, R. R., Caron, M. G. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.	Duke Univ, Ctr Models Human Dis, Dept Cell Biol, IGSP, Durham, NC 27710 USA; Univ Quebec Trois Rivieres, Neurosci Res Grp, Trois Rivieres, PQ GA9 5H7, Canada	Duke University; University of Quebec; University of Quebec Trois Rivieres	Caron, MG (corresponding author), Duke Univ, Ctr Models Human Dis, Dept Cell Biol, IGSP, Box 3287, Durham, NC 27710 USA.	cyrmi@uqtr.ca	Sotnikova, Tatyana D/T-9992-2017; Gainetdinov, Raul R/G-5875-2011	Gainetdinov, Raul R/0000-0003-2951-6038	NINDS NIH HHS [NS19576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALBIN RL, 1990, ANN NEUROL, V27, P357, DOI 10.1002/ana.410270403; Andrews TC, 1999, BRAIN, V122, P2353, DOI 10.1093/brain/122.12.2353; Antonini A, 1996, BRAIN, V119, P2085, DOI 10.1093/brain/119.6.2085; Ariano MA, 2002, J NEUROSCI RES, V68, P716, DOI 10.1002/jnr.10272; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Cepeda C, 2001, J NEUROSCI RES, V66, P525, DOI 10.1002/jnr.1244; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; Charvin D, 2005, P NATL ACAD SCI USA, V102, P12218, DOI 10.1073/pnas.0502698102; Cyr M, 2005, NEUROIMAGE, V26, P83, DOI 10.1016/j.neuroimage.2005.01.039; Cyr M, 2003, P NATL ACAD SCI USA, V100, P11035, DOI 10.1073/pnas.1831768100; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Fauchey V, 2000, EUR J NEUROSCI, V12, P19, DOI 10.1046/j.1460-9568.2000.00876.x; FEIGIN A, 1995, MOVEMENT DISORD, V10, P211, DOI 10.1002/mds.870100213; Fernagut PO, 2003, NEUROSCIENCE, V116, P1123, DOI 10.1016/S0306-4522(02)00778-9; Fernagut PO, 2002, EUR J NEUROSCI, V15, P2053, DOI 10.1046/j.1460-9568.2002.02047.x; FERRANTE RJ, 1987, BRAIN RES, V411, P162, DOI 10.1016/0006-8993(87)90694-9; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; Folstein S.E., 1989, HUNTINGTONS DIS DISO; Fumagalli F, 1998, J NEUROSCI, V18, P4861; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; GERFEN CR, 1992, ANNU REV NEUROSCI, V15, P285, DOI 10.1146/annurev.neuro.15.1.285; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Harper PS, 1991, HUNTINGTONS DIS; Hayden MR., 1981, HUNTINGTONS CHOREA, P45; Hersch SM, 2003, CURR OPIN NEUROL, V16, P501, DOI 10.1097/01.wco.0000084229.82329.03; Higgins Donald S Jr, 2006, Curr Treat Options Neurol, V8, P236, DOI 10.1007/s11940-006-0014-x; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Jaber M, 1999, EUR J NEUROSCI, V11, P3499, DOI 10.1046/j.1460-9568.1999.00764.x; Jakel RJ, 2000, TRENDS NEUROSCI, V23, P239, DOI 10.1016/S0166-2236(00)01568-X; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Kennedy L, 2005, BRAIN RES, V1039, P14, DOI 10.1016/j.brainres.2005.01.029; Kenney Christopher, 2006, Expert Rev Neurother, V6, P7, DOI 10.1586/14737175.6.1.7; Klapstein GJ, 2001, J NEUROPHYSIOL, V86, P2667, DOI 10.1152/jn.2001.86.6.2667; KLAWANS HC, 1970, LANCET, V2, P1185; Laforet GA, 2001, J NEUROSCI, V21, P9112, DOI 10.1523/JNEUROSCI.21-23-09112.2001; Levine MS, 1999, J NEUROSCI RES, V58, P515, DOI 10.1002/(SICI)1097-4547(19991115)58:4<515::AID-JNR5>3.0.CO;2-F; Levine MS, 2004, TRENDS NEUROSCI, V27, P691, DOI 10.1016/j.tins.2004.08.008; Li H, 2001, J NEUROSCI, V21, P8473, DOI 10.1523/JNEUROSCI.21-21-08473.2001; Lindvall O, 1978, Adv Biochem Psychopharmacol, V19, P1; Luesse HG, 2001, BEHAV BRAIN RES, V126, P185, DOI 10.1016/S0166-4328(01)00261-3; Luo SQ, 2005, J CELL BIOL, V169, P647, DOI 10.1083/jcb.200412071; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Marshall FJ, 2006, NEUROLOGY, V66, P366, DOI 10.1212/01.wnl.0000198586.85250.13; MCCORMACK MK, 1982, NEW ENGL J MED, V307, P1406; Menalled LB, 2003, J COMP NEUROL, V465, P11, DOI 10.1002/cne.10776; Menalled LB, 2002, J NEUROSCI, V22, P8266; MYERS RH, 1991, ARCH NEUROL-CHICAGO, V48, P800, DOI 10.1001/archneur.1991.00530200036015; Ondo WG, 2002, CLIN NEUROPHARMACOL, V25, P300, DOI 10.1097/00002826-200211000-00003; Paleacu D, 2004, CLIN NEUROPHARMACOL, V27, P230, DOI 10.1097/01.wnf.0000136892.24629.96; Paulsen JS, 2001, J NEUROL NEUROSUR PS, V71, P310, DOI 10.1136/jnnp.71.3.310; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; Reddy PH, 1998, NAT GENET, V20, P198, DOI 10.1038/2510; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; RICHFIELD EK, 1995, ANN NEUROL, V37, P335, DOI 10.1002/ana.410370309; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; SAPP E, 1995, NEUROSCIENCE, V64, P397, DOI 10.1016/0306-4522(94)00427-7; Slow EJ, 2005, P NATL ACAD SCI USA, V102, P11402, DOI 10.1073/pnas.0503634102; Slow EJ, 2003, HUM MOL GENET, V12, P1555, DOI 10.1093/hmg/ddg169; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; Sotnikova TD, 2005, PLOS BIOL, V3, P1488, DOI 10.1371/journal.pbio.0030271; Spektor BS, 2002, MOL BRAIN RES, V102, P118, DOI 10.1016/S0169-328X(02)00216-4; Stevanin G, 1996, HUM MOL GENET, V5, P1887, DOI 10.1093/hmg/5.12.1887; Tallaksen-Greene SJ, 2005, NEUROSCIENCE, V131, P843, DOI 10.1016/j.neuroscience.2004.10.037; Tang TS, 2005, P NATL ACAD SCI USA, V102, P2602, DOI 10.1073/pnas.0409402102; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P1; von Horsten S, 2003, HUM MOL GENET, V12, P617, DOI 10.1093/hmg/ddg075; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5; Warby SC, 2005, HUM MOL GENET, V14, P1569, DOI 10.1093/hmg/ddi165; Weeks RA, 1996, ANN NEUROL, V40, P49, DOI 10.1002/ana.410400110; Wexler NS, 2004, P NATL ACAD SCI USA, V101, P3498, DOI 10.1073/pnas.0308479101; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503	80	52	52	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2541	+		10.1096/fj.06-6533fje	http://dx.doi.org/10.1096/fj.06-6533fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065224				2022-12-28	WOS:000242490700017
J	McDonnell, DP				McDonnell, Donald P.			Mechanism-based discovery as an approach to identify the next generation of estrogen receptor modulators	FASEB JOURNAL			English	Editorial Material									Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	McDonnell, DP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, 6259 LSRC,Box 3813, Durham, NC 27710 USA.	donald.mcdonnel@duke.edu						Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; HARPER MJK, 1966, NATURE, V212, P87, DOI 10.1038/212087a0; JENSEN EV, 1962, RECENT PROG HORM RES, V18, P387; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MEANS AR, 1972, P NATL ACAD SCI USA, V69, P1146, DOI 10.1073/pnas.69.5.1146; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999	8	7	7	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2432	2434		10.1096/fj.06-1202ufm	http://dx.doi.org/10.1096/fj.06-1202ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17142791				2022-12-28	WOS:000242490700002
J	Moghimi, SM; Hamad, I; Andresen, TL; Jorgensen, K; Szebeni, J				Moghimi, S. Moein; Hamad, Islam; Andresen, Thomas L.; Jorgensen, Kent; Szebeni, Janos			Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production	FASEB JOURNAL			English	Article						stealth liposomes; anaphylactic reactions; complement system; steric stabilization; SC5b-9; C3a-desarg	ENCAPSULATED HEMOGLOBIN; SURFACE-CHARGE; POLY(ETHYLENE GLYCOL); GLOBULAR HEAD; IN-VITRO; BINDING; PATHWAY; DOXORUBICIN; C1Q; PHARMACOKINETICS	Methoxy(polyethylene glycol), mPEG, -grafted liposomes are known to exhibit prolonged circulation time in the blood, but their infusion into a substantial percentage of human subjects triggers immediate non-IgE-mediated hypersensitivity reactions. These reactions are strongly believed to arise from anaphylatoxin production through complement activation. Despite the general view that vesicle surface camouflaging with mPEG should dramatically suppress complement activation, here we show that bilayer enrichment of noncomplement activating liposomes [di-palmitoylphosphatidylcholine (DPPC) vesicles] with phospholipid-mPEG conjugate induces complement activation resulting in vesicle recognition by macrophage complement receptors. The extent of vesicle uptake, however, is dependent on surface mPEG density. We have delineated the likely structural features of phospholipid-mPEG conjugate responsible for PEGylated liposome-induced complement activation in normal as well as C1q-deficient human sera, using DPPC vesicles bearing the classical as well as newly synthesized lipid-mPEG conjugates. With PEGylated DPPC vesicles, the net anionic charge on the phosphate moiety of phospholipid-mPEG conjugate played a key role in activation of both classical and alternative pathways of complement and anaphylatoxin production (reflected in significant rises in SC5b-9, C4d, and C3a-desarg levels in normal human sera as well as SC5b-9 in EGTA-chelated/Mg2+ supplemented serum), since methylation of the phosphate oxygen of phospholipid-mPEG conjugate, and hence the removal of the negative charge, totally prevented complement activation. To further corroborate on the role of the negative charge in complement activation, vesicles bearing anionic phospholipid-mPEG conjugates, but not the methylated phospholipid-mPEG, were shown to significantly decrease serum hemolytic activity and increase plasma thromboxane B2 levels in rats. In contrast to liposomes, phospholipid-mPEG micelles had no effect on complement activation, thus suggesting a possible role for vesicular zwitterionic phospholipid head-groups as an additional factor contributing to PEGylated liposome-mediated complement activation. Our findings provide a rational conceptual basis for development of safer vesicles for site-specific drug delivery and controlled release at pathological sites.	Univ Brighton, Sch Pharm, Mol Targeting & Polymer Toxicol Grp, Brighton BN2 4GJ, E Sussex, England; Tech Univ Denmark, LiPlasome Pharm AS, DK-2800 Lyngby, Denmark; Hungarian Acad Sci, Nephrol Res Grp, Budapest, Hungary; Semmelweis Univ, Inst Pathophysiol, Budapest, Hungary	University of Brighton; Technical University of Denmark; Hungarian Academy of Sciences; Semmelweis University	Moghimi, SM (corresponding author), Univ Brighton, Sch Pharm, Mol Targeting & Polymer Toxicol Grp, Cockcroft Bldg,Lewes Rd, Brighton BN2 4GJ, E Sussex, England.	s.m.moghimi@brighton.ac.uk	Hamad, Islam/AAY-2540-2020; Andresen, Thomas L/B-5324-2012	Moghimi, Seyed Moein/0000-0003-0836-926X; Andresen, Thomas Lars/0000-0002-1048-127X				Alberts DS, 1997, DRUGS, V54, P30, DOI 10.2165/00003495-199700544-00007; Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; ALVING CR, 1991, CRIT REV IMMUNOL, V10, P441; Andresen Thomas L., 2005, Current Drug Delivery, V2, P353, DOI 10.2174/156720105774370203; Andresen TL, 2004, J MED CHEM, V47, P1694, DOI 10.1021/jm031029r; Andresen TL, 2005, PROG LIPID RES, V44, P68, DOI 10.1016/j.plipres.2004.12.001; Bradley AJ, 1999, BBA-BIOMEMBRANES, V1418, P19, DOI 10.1016/S0005-2736(99)00013-9; Bradley AJ, 1998, ARCH BIOCHEM BIOPHYS, V357, P185, DOI 10.1006/abbi.1998.0798; Bradley AJ, 1999, BIOCHEMISTRY-US, V38, P8112, DOI 10.1021/bi990480a; Chanan-Khan A, 2003, ANN ONCOL, V14, P1430, DOI 10.1093/annonc/mdg374; Chiu GNC, 2001, BBA-BIOMEMBRANES, V1510, P56, DOI 10.1016/S0005-2736(00)00335-7; CHONN A, 1991, J IMMUNOL, V146, P4234; DEVINE DV, 1994, BBA-BIOMEMBRANES, V1191, P43, DOI 10.1016/0005-2736(94)90231-3; FRIES LF, 1984, J EXP MED, V160, P1640, DOI 10.1084/jem.160.6.1640; Gaboriaud C, 2004, TRENDS IMMUNOL, V25, P368, DOI 10.1016/j.it.2004.04.008; Gaboriaud C, 2003, J BIOL CHEM, V278, P46974, DOI 10.1074/jbc.M307764200; Garbuzenko O, 2005, LANGMUIR, V21, P2560, DOI 10.1021/la0479105; Gbadamosi JK, 2002, FEBS LETT, V532, P338, DOI 10.1016/S0014-5793(02)03710-9; Gulati S, 2002, J IMMUNOL, V168, P4078, DOI 10.4049/jimmunol.168.8.4078; KENWORTHY AK, 1995, BIOPHYS J, V68, P1921, DOI 10.1016/S0006-3495(95)80369-3; Kishore U, 2003, J IMMUNOL, V171, P812, DOI 10.4049/jimmunol.171.2.812; Klint C, 2000, SCAND J IMMUNOL, V52, P103; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; Moghimi SM, 2006, BIOMATERIALS, V27, P136, DOI 10.1016/j.biomaterials.2005.05.082; Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Moghimi SM, 2002, J CONTROL RELEASE, V78, P55, DOI 10.1016/S0168-3659(01)00481-3; Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev; Moghimi SM, 2001, PHARM RES-DORDR, V18, P1, DOI 10.1023/A:1011054123304; MOORE FD, 1982, J IMMUNOL, V128, P1302; Price ME, 2001, BBA-BIOMEMBRANES, V1512, P191, DOI 10.1016/S0005-2736(01)00330-3; SAVAY S, 2002, BIOCHIM BIOPHYS ACTA, V1559, P29; Sohn JH, 2003, NAT MED, V9, P206, DOI 10.1038/nm814; SZEBENI J, 1994, BIOCHEM BIOPH RES CO, V205, P255, DOI 10.1006/bbrc.1994.2658; Szebeni J, 2006, AM J PHYSIOL-HEART C, V290, pH1050, DOI 10.1152/ajpheart.00622.2005; Szebeni J, 2002, J LIPOSOME RES, V12, P165, DOI 10.1081/LPR-120004790; Szebeni J, 1996, BBA-BIOMEMBRANES, V1285, P127, DOI 10.1016/S0005-2736(96)00201-5; Szebeni J, 2000, J LIPOSOME RES, V10, P467, DOI 10.3109/08982100009031112; Szebeni J, 1997, TRANSFUSION, V37, P150, DOI 10.1046/j.1537-2995.1997.37297203517.x; Szebeni J, 2000, AM J PHYSIOL-HEART C, V279, pH1319, DOI 10.1152/ajpheart.2000.279.3.H1319; Szebeni J, 2003, METHOD ENZYMOL, V373, P136; Tirosh O, 1998, BIOPHYS J, V74, P1371, DOI 10.1016/S0006-3495(98)77849-X; UZIELY B, 1995, J CLIN ONCOL, V13, P1777, DOI 10.1200/JCO.1995.13.7.1777; Webb MS, 1998, BBA-BIOMEMBRANES, V1372, P272, DOI 10.1016/S0005-2736(98)00077-7; Zalipsky S., 2004, PCT Patent Application, Patent No. [WO 2004/078121, 2004078121]	45	156	161	1	47	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2591	+		10.1096/fj.06-6186fje	http://dx.doi.org/10.1096/fj.06-6186fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065229				2022-12-28	WOS:000242490700034
J	Chang, WC; Nelson, C; Parekh, AB				Chang, Wei-Chiao; Nelson, Charmaine; Parekh, Anant B.			Ca2+ influx through CRAC channels activates cytosolic phospholipase A(2), leukotriene C-4 secretion, and expression of c-fos through ERK-dependent and -independent pathways in mast cells	FASEB JOURNAL			English	Article						store-operated influx; 5-lipoxygenase; protein kinase	PROTEIN-KINASE-C; ARACHIDONIC-ACID RELEASE; BASOPHILIC LEUKEMIA-CELLS; SIGNAL-REGULATED KINASES; CURRENT I-CRAC; PHOSPHORYLATION SITES; MAP KINASE; HUMAN EOSINOPHILS; CALCIUM-RELEASE; HUMAN PLATELETS	Cytosolic phospholipase A(2) (cPLA(2)) is a Ca2+-dependent enzyme that mediates agonist-dependent arachidonic acid release in most cell types. Arachidonic acid can then be metabolized by the 5-lipoxygenase enzyme to generate the proinflammatory signal leukotriene C-4 (LTC4). Here we report that Ca2+ entry through store-operated CRAC (Ca2+ release-activated Ca2+) channels activates the extracellular signal-regulated kinases (ERKs), members of the mitogen-activated protein kinase family, within minutes and this is necessary for stimulation of cPLA(2). Ca2+ entry activates ERK indirectly, via recruitment of Ca2+-dependent protein kinase C alpha and beta I. Ca2+ influx also promotes translocation of cytosolic 5-lipoxygenase to the nuclear membrane, a key step in the activation of this enzyme. Translocation is dependent on ERK activation. A role for gene activation is shown by the finding that CRAC channel opening results in increased transcription and translation of c-fos. Inhibition of ERK activation failed to prevent c-fos expression. Our results show that CRAC channel activation elicits short-term effects through the co-coordinated regulation of two metabolic pathways (cPLA(2) and 5-lipoxygenase), which results in the generation of both intra- and intercellular messengers within minutes, as well as longer term changes involving gene activation. These short-term effects are mediated via ERK, whereas, paradoxically, c-fos expression is not. Ca2+ influx through CRAC channels can therefore activate different signaling pathways at the same time, culminating in a range of temporally diverse responses.	Univ Oxford, Dept Physiol, Oxford OX1 3PT, England	University of Oxford	Parekh, AB (corresponding author), Univ Oxford, Dept Physiol, Parks Rd, Oxford OX1 3PT, England.	anant.parekh@physiol.ox.ac.uk		Chang, Wei-Chiao/0000-0002-8573-5924	Medical Research Council [G0200218] Funding Source: Medline; MRC [G0200218] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahamed J, 2002, J BIOL CHEM, V277, P22685, DOI 10.1074/jbc.M110210200; AMBS P, 1995, BIOCHEM J, V311, P189, DOI 10.1042/bj3110189; Atherfold PA, 1999, MOL IMMUNOL, V36, P543, DOI 10.1016/S0161-5890(99)00076-0; Bates ME, 2000, J BIOL CHEM, V275, P10968, DOI 10.1074/jbc.275.15.10968; Boden SE, 2000, INT J BIOCHEM CELL B, V32, P1069, DOI 10.1016/S1357-2725(00)00049-2; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; BUERKERT E, 2002, BIOCHEM BIOPH RES CO, P985; Chang WC, 2004, J BIOL CHEM, V279, P29994, DOI 10.1074/jbc.M403969200; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Das S, 2003, J BIOL CHEM, V278, P41431, DOI 10.1074/jbc.M304897200; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Dellis O, 2002, J BIOL CHEM, V277, P6044, DOI 10.1074/jbc.M111831200; Denys A, 2004, FEBS LETT, V564, P177, DOI 10.1016/S0014-5793(04)00361-8; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fierro AF, 2004, J BIOL CHEM, V279, P25646, DOI 10.1074/jbc.M400296200; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hanaka H, 2002, BIOCHEM J, V361, P505, DOI 10.1042/0264-6021:3610505; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Lepley RA, 1996, ARCH BIOCHEM BIOPHYS, V331, P141, DOI 10.1006/abbi.1996.0292; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McCoy CE, 2005, BIOCHEM J, V387, P507, DOI 10.1042/BJ20041501; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Oliver D, 2004, SCIENCE, V304, P265, DOI 10.1126/science.1094113; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1994, J BIOL CHEM, V269, P19480; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Rosado JA, 2001, J BIOL CHEM, V276, P15659, DOI 10.1074/jbc.M009218200; Schliess F, 1996, BIOCHEM J, V320, P167, DOI 10.1042/bj3200167; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shuttleworth TJ, 2004, PHYSIOLOGY, V19, P355, DOI 10.1152/physiol.00018.2004; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1141; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; TAYLOR GW, 1989, LANCET, V1, P584; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje; Zhu XD, 2001, J IMMUNOL, V167, P461, DOI 10.4049/jimmunol.167.1.461	66	77	79	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2381	+		10.1096/fj.06-6016fje	http://dx.doi.org/10.1096/fj.06-6016fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023391				2022-12-28	WOS:000241702600027
J	Gonzalez, D; Gomez-Hernandez, JM; Barrio, LC				Gonzalez, Daniel; Gomez-Hernandez, Juan M.; Barrio, Luis C.			Species specificity of mammalian connexin-26 to form open voltage-gated hemichannels	FASEB JOURNAL			English	Article						GJB2; hearing; skin; deafness; genodermatosis	GAP-JUNCTION HEMICHANNELS; SUPPORTING CELLS; PLASMA-MEMBRANE; EXPRESSION; MECHANISM; COMMUNICATION; MUTATIONS; PROTEIN; LOCALIZATION; PERMEABILITY	Mutations of connexin-26 (Cx26) cause nonsyndromic hearing loss and other syndromes affecting ectoderm-derived tissues. While the exact mechanisms underlying these diseases remain elusive, Cx's are generally considered to mediate cell-to-cell communication by forming gap junction channels. We show here that unlike rat Cx26, human and sheep Cx26 form voltage-gated hemichannels when expressed in oocytes and Neuro2A cells. A single evolutionary amino acidic change at position 159 of the rodent protein, the replacement of aspartic acid with asparagine in the human and sheep proteins, accounts for this species specificity. At the resting potential and in normal millimolar extracellular calcium, open human Cx26 hemichannels can be detected both electrophysiologically and by dye uptake, although they did not affect cell viability. These hemichannels opened at similar to - 50 mV and their activation increased by depolarization until they inactivate at positive membrane potentials. Single-channel analysis revealed that activation and inactivation involved two distinct voltage gating mechanisms and that the fully open hemichannel displays a conductance twice that of the intercellular channel. The existence of a hemichannel that opens under physiological control of the membrane potential may have important implications for the normal and pathological activity of Cx26 in humans, particularly with respect to hearing and the epidermis.	Hosp Ramon & Cajal, Dept Invest, Unidad Neurol Expt, E-28034 Madrid, Spain	Hospital Universitario Ramon y Cajal	Barrio, LC (corresponding author), Hosp Ramon & Cajal, Dept Invest, Unidad Neurol Expt, Carretera Colmenar Km 9, E-28034 Madrid, Spain.	luis.c.barrio@hrc.es		GONZALEZ NIETO, DANIEL/0000-0003-2972-729X				Al-Ubaidi MR, 2000, J NEUROSCI RES, V59, P813, DOI 10.1002/(SICI)1097-4547(20000315)59:6<813::AID-JNR14>3.3.CO;2-R; Arita K, 2002, J HISTOCHEM CYTOCHEM, V50, P1493, DOI 10.1177/002215540205001109; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Beahm DL, 2002, BIOPHYS J, V82, P2016, DOI 10.1016/S0006-3495(02)75550-1; Beltramello M, 2005, NAT CELL BIOL, V7, P63, DOI 10.1038/ncb1205; Beltramello M, 2003, BIOCHEM BIOPH RES CO, V305, P1024, DOI 10.1016/S0006-291X(03)00868-4; Bruzzone R, 2003, FEBS LETT, V533, P79, DOI 10.1016/S0014-5793(02)03755-9; Bruzzone S, 2001, FASEB J, V15, P10; Chen YY, 2005, FASEB J, V19, P1516, DOI 10.1096/fj.04-3491fje; Cherian PP, 2005, MOL BIOL CELL, V16, P3100, DOI 10.1091/mbc.E04-10-0912; Cohen-Salmon M, 2002, CURR BIOL, V12, P1106, DOI 10.1016/S0960-9822(02)00904-1; Common JEA, 2004, J MED GENET, V41, P573, DOI 10.1136/jmg.2003.017632; Contreras JE, 2004, BRAIN RES REV, V47, P290, DOI 10.1016/j.brainresrev.2004.08.002; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Eastman SD, 2006, GENOMICS, V87, P265, DOI 10.1016/j.ygeno.2005.10.005; Gale JE, 2004, CURR BIOL, V14, P526, DOI 10.1016/j.cub.2004.03.002; GOLIGER JA, 1994, DEV DYNAM, V200, P1, DOI 10.1002/aja.1002000102; Gomez-Hernandez JM, 2003, P NATL ACAD SCI USA, V100, P16030, DOI 10.1073/pnas.2530348100; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Janssen-Bienhold U, 2001, VISUAL NEUROSCI, V18, P169, DOI 10.1017/S0952523801182015; Kamermans M, 2001, SCIENCE, V292, P1178, DOI 10.1126/science.1060101; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kelsell DP, 2001, AM J HUM GENET, V68, P559, DOI 10.1086/318803; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; Kojima T, 1999, CELL STRUCT FUNCT, V24, P435, DOI 10.1247/csf.24.435; Lauf U, 2002, P NATL ACAD SCI USA, V99, P10446, DOI 10.1073/pnas.162055899; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; Lucke T, 1999, J INVEST DERMATOL, V112, P354, DOI 10.1046/j.1523-1747.1999.00512.x; Montgomery JR, 2004, J AM ACAD DERMATOL, V51, P377, DOI 10.1016/j.jaad.2003.12.042; OESTERLE EC, 1990, J NEUROPHYSIOL, V64, P617, DOI 10.1152/jn.1990.64.2.617; Oh S, 1999, J GEN PHYSIOL, V114, P339, DOI 10.1085/jgp.114.3.339; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; Pottek M, 2003, J COMP NEUROL, V466, P468, DOI 10.1002/cne.10897; Richard G, 2003, CLIN EXP DERMATOL, V28, P397, DOI 10.1046/j.1365-2230.2003.01312.x; Ripps H, 2004, CELL MOL NEUROBIOL, V24, P647, DOI 10.1023/B:CEMN.0000036403.43484.3d; Saez JC, 2005, BBA-BIOMEMBRANES, V1711, P215, DOI 10.1016/j.bbamem.2005.01.014; SALOMON D, 1994, J INVEST DERMATOL, V103, P240, DOI 10.1111/1523-1747.ep12393218; SANTOS-SACCHI J, 1991, HEARING RES, V52, P89, DOI 10.1016/0378-5955(91)90190-K; Segretain D, 2004, BBA-BIOMEMBRANES, V1662, P3, DOI 10.1016/j.bbamem.2004.01.007; Spicer SS, 1998, HEARING RES, V118, P1, DOI 10.1016/S0378-5955(98)00006-9; Srinivas M, 2005, BIOPHYS J, V88, P1725, DOI 10.1529/biophysj.104.054023; Suchyna TM, 1999, BIOPHYS J, V77, P2968, DOI 10.1016/S0006-3495(99)77129-8; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; Valiunas V, 2000, PFLUG ARCH EUR J PHY, V440, P366, DOI 10.1007/s004240000294; Van Nhieu GT, 2003, NAT CELL BIOL, V5, P720, DOI 10.1038/ncb1021; VERSELIS VK, 1994, NATURE, V368, P348, DOI 10.1038/368348a0; White TW, 1999, EUR J NEUROSCI, V11, P1883, DOI 10.1046/j.1460-9568.1999.00607.x; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; Zhang YP, 2005, P NATL ACAD SCI USA, V102, P15201, DOI 10.1073/pnas.0501859102; Zhao HB, 2005, P NATL ACAD SCI USA, V102, P18724, DOI 10.1073/pnas.0506481102	51	56	57	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2329	2338		10.1096/fj.06-5828com	http://dx.doi.org/10.1096/fj.06-5828com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077310				2022-12-28	WOS:000241702600018
J	Li, W; Ostblom, M; Xu, LH; Hellsten, A; Leanderson, P; Liedberg, B; Brunk, UT; Eaton, JW; Yuan, XM				Li, Wei; Ostblom, Mattias; Xu, Li-Hua; Hellsten, Anna; Leanderson, Per; Liedberg, Bo; Brunk, Ulf T.; Eaton, John W.; Yuan, Xi-Ming			Cytocidal effects of atheromatous plaque components: the death zone revisited	FASEB JOURNAL			English	Article						atherosclerosis; apoferritin; apoptosis; carbonyls; ceroid; iron; macrophages	ATHEROSCLEROTIC LESIONS; INFLAMMATORY CELLS; IRON; MACROPHAGES; APOPTOSIS; CALCIUM; INJURY; OXIDATION; FERRITIN; CHELATOR	Objective: Earlier we suggested that atheroma lesions constitute a "death zone" containing toxic materials that may cause dysfunction and demise of invading macrophages to prevent the removal of plaque materials. Here we have assessed the cytotoxic effects of nonfractionated gruel and insoluble (ceroidlike) material derived from advanced human atheroma. Methods and Results: The insoluble material within advanced atherosclerotic plaque was isolated following protease K digestion and extensive extraction with aqueous and organic solvents. FTIR, Raman, and atomic absorption spectroscopy suggested that, despite its fluorescent nature, this material closely resembled hydroxyapatite and dentin, but also contained a significant amount of iron and calcium. When added to J774 cells and human macrophages in culture, this insoluble substance was phagocytosed, and progressive cell death followed. However, an even more cytotoxic activity was found in the atheromatous "gruel" that contains abundant carbonyls/aldehydes. Cell death caused by both crude gruel and ceroid could be blocked by preincubating cells with the lipophilic iron chelator salicylaldehyde isonicotinoyl hydrazone, apoferritin, BAPTA/AM, or sodium borohydride, indicating that cellular iron, calcium, and reactive aldehyde(s) are responsible for the observed cytotoxicity. Conclusions: Toxic materials within atheromatous lesions include both ceroid and even more cytotoxic lipidaceous materials. The cytotoxic effects of these plaque components may help explain the persistence of atherosclerotic lesions.	Linkoping Univ, Fac Hlth Sci, Div Expt Pathol, SE-58185 Linkoping, Sweden; Linkoping Univ, Fac Hlth Sci, Div Sensor Sci & Mol Phys, SE-58185 Linkoping, Sweden; Linkoping Univ, Fac Hlth Sci, Div Environm & Occupat Med, SE-58185 Linkoping, Sweden; Linkoping Univ, Fac Hlth Sci, Div Pharmacol, SE-58185 Linkoping, Sweden; Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA	Linkoping University; Linkoping University; Linkoping University; Linkoping University; University of Louisville	Yuan, XM (corresponding author), Linkoping Univ, Fac Hlth Sci, Div Expt Pathol, SE-58185 Linkoping, Sweden.	yuan.ximing@inr.liu.se	Liedberg, Bo/N-6093-2014	Yuan, Ximing/0000-0001-9328-7140; Leanderson, Per/0000-0001-6724-7305				Arai H, 2005, P NATL ACAD SCI USA, V102, P10472, DOI 10.1073/pnas.0504685102; Bjorkerud S, 1996, AM J PATHOL, V149, P367; Britigan BE, 1998, BIOCHEM PHARMACOL, V55, P287, DOI 10.1016/S0006-2952(97)00463-2; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Buschman HP, 2001, CARDIOVASC PATHOL, V10, P69, DOI 10.1016/S1054-8807(01)00064-3; Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4; CARLSTROM D, 1953, LAB INVEST, V2, P325; Cusco R, 1998, J EUR CERAM SOC, V18, P1301, DOI 10.1016/S0955-2219(98)00057-0; DAVIES MJ, 1993, BRIT HEART J, V69, P377; Ferry-Dumazet H, 2002, LEUKEMIA, V16, P708, DOI 10.1038/sj.leu.2402404; FOWLER BO, 1974, INORG CHEM, V13, P194, DOI 10.1021/ic50131a039; Garner B, 1997, FREE RADICAL RES, V27, P487, DOI 10.3109/10715769709065788; Iskra M, 1997, J TRACE ELEM MED BIO, V11, P248, DOI 10.1016/S0946-672X(97)80020-X; Kolodgie FD, 2000, AM J PATHOL, V157, P1259, DOI 10.1016/S0002-9440(10)64641-X; Kolodgie FD, 2003, NEW ENGL J MED, V349, P2316, DOI 10.1056/NEJMoa035655; Lee FY, 1998, ATHEROSCLEROSIS, V138, P281, DOI 10.1016/S0021-9150(98)00033-1; Li W, 2005, FREE RADICAL BIO MED, V39, P864, DOI 10.1016/j.freeradbiomed.2005.05.006; Li W, 2004, J MOL CELL CARDIOL, V37, P969, DOI 10.1016/j.yjmcc.2004.07.009; Li W, 1998, FREE RADICAL RES, V29, P389, DOI 10.1080/10715769800300431; Li W, 2001, ARTERIOSCL THROM VAS, V21, P1124, DOI 10.1161/hq0701.092145; MITCHINSON MJ, 1990, BIOCHEM SOC T, V18, P1066, DOI 10.1042/bst0181066; Nishi K, 2002, ATHEROSCLEROSIS, V160, P289, DOI 10.1016/S0021-9150(01)00583-4; Simunek T, 2005, J MOL CELL CARDIOL, V39, P345, DOI 10.1016/j.yjmcc.2005.05.008; SOHAL RS, 1989, ADV EXP MED BIOL, V266, P17; van de Poll SWE, 2002, J RAMAN SPECTROSC, V33, P544, DOI 10.1002/jrs.865; WEISSMANN G, 1960, J CLIN INVEST, V39, P1657, DOI 10.1172/JCI104189; Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YUAN XM, 1995, ARTERIOSCL THROM VAS, V15, P1345, DOI 10.1161/01.ATV.15.9.1345; Yuan XM, 1996, REDOX REP, V2, P9, DOI 10.1080/13510002.1996.11747021; Yuan XM, 1996, ATHEROSCLEROSIS, V124, P61, DOI 10.1016/0021-9150(96)05817-0	31	43	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2281	2290		10.1096/fj.06-6114com	http://dx.doi.org/10.1096/fj.06-6114com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077305				2022-12-28	WOS:000241702600013
J	Endeward, V; Musa-Aziz, R; Cooper, GJ; Chen, LM; Pelletier, MF; Virkki, LV; Supuran, CT; King, LS; Boron, WF; Gros, G				Endeward, V.; Musa-Aziz, R.; Cooper, G. J.; Chen, L. -M.; Pelletier, M. F.; Virkki, L. V.; Supuran, C. T.; King, L. S.; Boron, W. F.; Gros, G.			Evidence that aquaporin 1 is a major pathway for CO2 transport across the human erythrocyte membrane	FASEB JOURNAL			English	Article						human red cell membrane; CO2 permeability; pCMBS; DIDS	CARBON-DIOXIDE PERMEABILITY; RED-BLOOD-CELLS; INTRACELLULAR PH; WATER CHANNEL; INHIBITORS; DIFFUSION; ANHYDRASE; EXCHANGE; PCMBS; CHIP	We report here the application of a previously described method to directly determine the CO2 permeability (P-CO2) of the cell membranes of normal human red blood cells (RBCs) vs. those deficient in aquaporin 1 (AQP1), as well as AQP1-expressing Xenopus laevis oocytes. This method measures the exchange of O-18 between CO2, HCO3-, and H2O in cell suspensions. In addition, we measure the alkaline surface pH (pH(S)) transients caused by the dominant effect of entry of CO2 vs. HCO3- into oocytes exposed to step increases in [CO2]. We report that 1) AQP1 constitutes the major pathway for molecular CO2 in human RBCs; lack of AQP1 reduces P-CO2 from the normal value of 0.15 +/- 0.08 (SD; n = 85) cm/s by 60% to 0.06 cm/s. Expression of AQP1 in oocytes increases P-CO2 2-fold and doubles the alkaline pHS gradient. 2) pCMBS, an inhibitor of the AQP1 water channel, reduces P-CO2 of RBCs solely by action on AQP1 as it has no effect in AQP1-deficient RBCs. 3) P-CO2 determinations of RBCs and pH(S) measurements of oocytes indicate that DIDS inhibits the CO2 pathway of AQP1 by half. 4) RBCs have at least one other DIDS-sensitive pathway for CO2. We conclude that AQP1 is responsible for 60% of the high P-CO2 of red cells and that another, so far unidentified, CO2 pathway is present in this membrane that may account for at least 30% of total P-CO2.	Hannover Med Sch, Zentrum Physiol, Abt Vegetat Physiol, D-30625 Hannover, Germany; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Univ Florence, Dipartimento Chim, Chim Bioorgan Lab, Florence, Italy; Johns Hopkins Univ, Dept Med, Baltimore, MD USA	Hannover Medical School; Yale University; University of Florence; Johns Hopkins University	Gros, G (corresponding author), Hannover Med Sch, Zentrum Physiol, Abt Vegetat Physiol, D-30625 Hannover, Germany.	gros.gerolf@mh-hannover.de	Supuran, Claudiu T/A-5151-2008; Musa-Aziz, Raif/F-3434-2013; Gros, Gerolf/K-8421-2012; Chen, Li-Ming/AAU-2363-2021; Boron, Walter/ABI-1564-2020	Musa-Aziz, Raif/0000-0002-0386-4248; Chen, Li-Ming/0000-0002-8129-9563; Boron, Walter/0000-0003-4741-7287; Supuran, Claudiu/0000-0003-4262-0323				BENGA G, 1992, EUR J CELL BIOL, V59, P219; BENGA G, 1983, J MEMBRANE BIOL, V76, P129, DOI 10.1007/BF02000613; Blank ME, 2003, J PHYSIOL-LONDON, V550, P419, DOI 10.1113/jphysiol.2003.040113; Casey JR, 2004, J MED CHEM, V47, P2337, DOI 10.1021/jm031079w; CHESLER M, 1986, J PHYSIOL-LONDON, V381, P241, DOI 10.1113/jphysiol.1986.sp016325; Cooper GJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1481, DOI 10.1152/ajpcell.1998.275.6.C1481; DEHEMPTINNE A, 1984, J PHYSIOL-LONDON, V347, P581, DOI 10.1113/jphysiol.1984.sp015084; EDSALL JT, 1966, CO2 CHEM BIOCH PHYSL; Endeward V, 2005, J PHYSIOL-LONDON, V567, P253, DOI 10.1113/jphysiol.2005.085761; Forster RE, 1998, P NATL ACAD SCI USA, V95, P15815, DOI 10.1073/pnas.95.26.15815; Forster RE, 1964, HDB PHYSIOLOGY     3, V1, P827; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GROS G, 1971, PFLUG ARCH EUR J PHY, V324, P249, DOI 10.1007/BF00586422; GROS G, 1979, Pfluegers Archiv European Journal of Physiology, V382, pR21; GUTKNECHT J, 1977, J GEN PHYSIOL, V69, P779; ITADA N, 1977, J BIOL CHEM, V252, P3881; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; Moore W. J., 1962, PHYS CHEM; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Prasad Ramjee, 1998, IEEE Communications Surveys & Tutorials, V1, P2, DOI 10.1109/COMST.1998.5340404; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; Ren G, 2001, P NATL ACAD SCI USA, V98, P1398, DOI 10.1073/pnas.041489198; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; THEWS G, 1960, PFLUG ARCH GES PHYS, V271, P227, DOI 10.1007/BF00363006; TSAI ST, 1991, BIOCHEMISTRY-US, V30, P2087, DOI 10.1021/bi00222a013; Uehlein N, 2003, NATURE, V425, P734, DOI 10.1038/nature02027; Virkki LV, 2002, J BIOL CHEM, V277, P40610, DOI 10.1074/jbc.M206157200; WAISBREN SJ, 1994, NATURE, V368, P332, DOI 10.1038/368332a0; Weast R. C., 1977, CRC HDB CHEM PHYS; Wunder M, 1998, ISOT ENVIRON HEALT S, V34, P197, DOI 10.1080/10256019808036371; Wunder MA, 1998, ISOT ENVIRON HEALT S, V34, P303, DOI 10.1080/10256019808234064; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686; Yool AJ, 2002, NEWS PHYSIOL SCI, V17, P68, DOI 10.1152/nips.01372.2001; ZHANG ZH, 1992, BIOCHIM BIOPHYS ACTA, V1106, P31, DOI 10.1016/0005-2736(92)90218-B	37	160	168	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					1974	1981		10.1096/fj.04-3300com	http://dx.doi.org/10.1096/fj.04-3300com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012249				2022-12-28	WOS:000241156900005
J	Pey, AL; Martinez, A; Charubala, R; Maitland, DJ; Teigen, K; Calvo, A; Pfleiderer, W; Wood, JM; Schallreuter, KU				Pey, Angel L.; Martinez, Aurora; Charubala, Ramamurthy; Maitland, Derek J.; Teigen, Knut; Calvo, Ana; Pfleiderer, Wolfgang; Wood, John M.; Schallreuter, Karin U.			Specific interaction of the diastereomers 7(R)- and 7(S)-tetrahydrobiopterin with phenylalanine hydroxylase: implications for understanding primapterinuria and vitiligo	FASEB JOURNAL			English	Article						pterin 4a-carbinolamine dehydratase; NMR; isothermal titration calorimetry	PTERIN-4A-CARBINOLAMINE DEHYDRATASE DEFICIENCY; AMINO-ACID HYDROXYLASES; 7-SUBSTITUTED PTERINS; TYROSINE-HYDROXYLASE; PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; ACTIVE-SITE; TETRAHYDROBIOPTERIN; COFACTOR	Pterin-4a-carbinolamine dehydratase (PCD) is an essential component of the phenylalanine hydroxylase (PAH) system, catalyzing the regeneration of the essential cofactor 6(R)-L-erythro-5,6,7,8-tetrahydrobiopterin [6(R)BH4]. Mutations in PCD or its deactivation by hydrogen peroxide result in the generation of 7( R, S) BH4, which is a potent inhibitor of PAH that has been implicated in primapterinuria, a variant form of phenylketonuria, and in the skin depigmentation disorder vitiligo. We have synthesized and separated the 7( R) and 7( S) diastereomers confirming their structure by NMR. Both 7(R)- and 7(S)BH4 function as poor cofactors for PAH, whereas only 7( S) BH4 acts as a potent competitive inhibitor vs. 6 R)BH4 (K-i = 2.3 - 4.9 mu M). Kinetic and binding studies, as well as characterization of the pterin-enzyme complexes by fluorescence spectroscopy, revealed that the inhibitory effects of 7( R, S) BH4 on PAH are in fact specifically based on 7( S) BH4 binding. The molecular dynamics simulated structures of the pterin-PAH complexes indicate that 7( S) BH4 inhibition is due to its interaction with the polar region at the pterin binding site close to Ser-251, whereas its low efficiency as cofactor is related to a suboptimal positioning toward the catalytic iron. 7( S) BH4 is not an inhibitor for tyrosine hydroxylase (TH) in the physiological range, presumably due to the replacement of Ser-251 by the corresponding Ala297. Taken together, our results identified structural determinants for the specific regulation of PAH and TH by 7(S) BH4, which in turn aid in the understanding of primapterinuria and acute vitiligo.	Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England; Univ Bergen, Dept Biomed, Bergen, Norway; Univ Konstanz, Fachbereich Chem, D-7750 Constance, Germany; Univ Bradford, Dept Chem Sci, Bradford BD7 1DP, W Yorkshire, England; Univ Bradford, Dept Forens Sci, Bradford BD7 1DP, W Yorkshire, England	University of Bradford; University of Bergen; University of Konstanz; University of Bradford; University of Bradford	Schallreuter, KU (corresponding author), Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England.	k.schallreuter@bradford.ac.uk	Teigen, Knut/K-3934-2012; Martinez, Aurora/M-3088-2019	Teigen, Knut/0000-0002-7031-9215; Martinez, Aurora/0000-0003-1643-6506; Pey, Angel Luis/0000-0001-7706-3243				ADLER C, 1992, J INHERIT METAB DIS, V15, P405, DOI 10.1007/BF02435989; ADLER C, 1992, EUR J BIOCHEM, V208, P139, DOI 10.1111/j.1432-1033.1992.tb17167.x; Andersen OA, 2002, J MOL BIOL, V320, P1095, DOI 10.1016/S0022-2836(02)00560-0; BAILEY SW, 1978, J BIOL CHEM, V253, P1598; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; Bjorgo E, 1998, EUR J BIOCHEM, V257, P1, DOI 10.1046/j.1432-1327.1998.2570001.x; BLAU N, 1989, J INHERIT METAB DIS, V12, P335, DOI 10.1007/BF03335415; Blau N., 2001, METABOLIC MOL BASIS, P1725; CITRON BA, 1993, AM J HUM GENET, V53, P768; CURTIUS HC, 1988, BIOCHEM BIOPH RES CO, V153, P715, DOI 10.1016/S0006-291X(88)81153-7; CURTIUS HC, 1990, BIOCHEM BIOPH RES CO, V172, P1060, DOI 10.1016/0006-291X(90)91554-6; DAVIS MD, 1992, P NATL ACAD SCI USA, V89, P10109, DOI 10.1073/pnas.89.21.10109; DAVIS MD, 1991, FEBS LETT, V285, P17, DOI 10.1016/0014-5793(91)80714-E; DAVIS MD, 1991, P NATL ACAD SCI USA, V88, P385, DOI 10.1073/pnas.88.2.385; Depaepe V, 2000, MOL BRAIN RES, V75, P76, DOI 10.1016/S0169-328X(99)00297-1; DOSKELAND AP, 1984, J BIOL CHEM, V259, P1242; Erlandsen H, 2000, BIOCHEMISTRY-US, V39, P2208, DOI 10.1021/bi992531+; Erlandsen H, 2004, P NATL ACAD SCI USA, V101, P16903, DOI 10.1073/pnas.0407256101; Flatmark T, 1999, EUR J BIOCHEM, V262, P840, DOI 10.1046/j.1432-1327.1999.00445.x; Flatmark T, 1999, CHEM REV, V99, P2137, DOI 10.1021/cr980450y; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; HAAVIK J, 1986, EUR J BIOCHEM, V160, P1, DOI 10.1111/j.1432-1033.1986.tb09932.x; HAAVIK J, 1991, EUR J BIOCHEM, V199, P371, DOI 10.1111/j.1432-1033.1991.tb16133.x; Haavik J, 1997, J NEUROCHEM, V68, P328; Hevel JM, 2006, MOL GENET METAB, V88, P38, DOI 10.1016/j.ymgme.2005.11.014; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; KNAPPSKOG PM, 1995, BIOCHEMISTRY-US, V34, P11790, DOI 10.1021/bi00037a017; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; Luque I, 2002, PROTEINS, V49, P181, DOI 10.1002/prot.10208; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; Matulis D, 2005, BIOCHEMISTRY-US, V44, P5258, DOI 10.1021/bi048135v; Olafsdottir S, 1999, J BIOL CHEM, V274, P6280, DOI 10.1074/jbc.274.10.6280; Pey AL, 2004, J AM CHEM SOC, V126, P13670, DOI 10.1021/ja047713s; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P3836, DOI 10.1021/bi00312a007; REINHARD S, 1986, PUBLIC HEALTH NURS, V3, P3, DOI 10.1111/j.1525-1446.1986.tb00461.x; Resibois A, 1999, HISTOCHEM CELL BIOL, V111, P381, DOI 10.1007/s004180050371; Schallreuter KU, 1998, BIOCHEM BIOPH RES CO, V243, P395, DOI 10.1006/bbrc.1997.8107; Schallreuter KU, 2005, MOL GENET METAB, V86, pS27, DOI 10.1016/j.ymgme.2005.07.023; SCHALLREUTER KU, 1994, SCIENCE, V263, P1444, DOI 10.1126/science.8128228; Schallreuter KU, 2001, J INVEST DERMATOL, V116, P167, DOI 10.1046/j.1523-1747.2001.00220.x; SCRIVER CR, 2001, METABOLIC MOL BASES, P1667; Solstad T, 2003, EUR J BIOCHEM, V270, P981, DOI 10.1046/j.1432-1033.2003.03471.x; Spencer JD, 2005, J ENDOCRINOL, V187, P293, DOI 10.1677/joe.1.06275; Teigen K, 1999, J MOL BIOL, V294, P807, DOI 10.1006/jmbi.1999.3288; Teigen K, 2004, J MED CHEM, V47, P5962, DOI 10.1021/jm0497646; Teigen K, 2003, J BIOMOL STRUCT DYN, V20, P733, DOI 10.1080/07391102.2003.10506889; Thony B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001; Thony B, 1998, HUM GENET, V103, P162, DOI 10.1007/s004390050800; Thorolfsson M, 2003, BIOCHEMISTRY-US, V42, P3419, DOI 10.1021/bi034021s; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; WOOD JM, 2005, PTERIDINES, V16, P93	52	28	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2130	+		10.1096/fj.06-5835fje	http://dx.doi.org/10.1096/fj.06-5835fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935936				2022-12-28	WOS:000241156900031
J	Boulter, E; Grall, D; Cagnol, S; Van Obberghen-Schilling, E				Boulter, Etienne; Grall, Dominique; Cagnol, Sebastien; Van Obberghen-Schilling, Ellen			Regulation of cell-matrix adhesion dynamics and Rac-1 by integrin linked kinase	FASEB JOURNAL			English	Article						Rho family GTPase; integrin signaling; cell spreading; RNA interference	BINDING PROTEIN; FOCAL ADHESIONS; ALPHA-PIX; ILK; PAXILLIN; ACTIN; COMPLEX; GROWTH; PAK; SITES	Extracellular matrix (ECM) receptors of the integrin family initiate changes in cell shape and motility by recruiting signaling components that coordinate these events. Integrin-linked kinase (ILK) is one such partner of beta 1 integrins that participates in dynamic rearrangement of cell-matrix adhesions and cell spreading by mechanisms that are not well understood. To further elucidate the role of ILK in these events, we engineered a chimeric molecule comprising ILK fused to a membrane-targeted green fluorescent protein (ILK-GFP-F). ILK-GFP-F is highly enriched in cell-matrix adhesions, and its expression in fibroblasts leads to an accumulation of focal adhesions (2-5 mu m) and elongated adhesions (> 5 mu m). ILK-GFP-F enhances cell spreading on fibronectin and induces a constitutive increase in the levels of GTP-bound Rac-1. Conversely, ILK knock-down by siRNA transfection decreases active Rac-1. Endogenous ILK was found to associate with PKL (paxillin kinase linker) and the Rac/Cdc42 guanine nucleotide exchange factor beta PIX. Further, expression of a dominant negative beta PIX mutant reversed the increase in active Rac-1 levels of ILK-GFP-F-expressing cells, thus placing beta PIX in the pathway leading from ILK to Rac-1 activation. However, expression of constitutively active Rac only partially restores the spreading defects of ILK-depleted cells, suggesting that an additional ILK-dependent signal is required for cell spreading.	CNRS, Inst Signaling Dev Biol & Canc Res, UMR6543, Ctr Antoine Lacassagne, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Centre Antoine Lacassagne	Van Obberghen-Schilling, E (corresponding author), CNRS, Inst Signaling Dev Biol & Canc Res, UMR6543, Ctr Antoine Lacassagne, 33 Ave Valombrose, F-06189 Nice, France.	vanobber@unice.fr	Van Obberghen-Schilling, Ellen/Q-4372-2019; Van Obberghen-Schilling, Ellen/O-1581-2016; Boulter, Etienne/R-1737-2016	Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Boulter, Etienne/0000-0001-6597-9086				Adams JC, 2001, CELL MOL LIFE SCI, V58, P371, DOI 10.1007/PL00000864; Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Grashoff C, 2004, CURR OPIN CELL BIOL, V16, P565, DOI 10.1016/j.ceb.2004.07.004; Guo LD, 2001, AM J PATHOL, V159, P1735, DOI 10.1016/S0002-9440(10)63020-9; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Katz BZ, 2003, J BIOL CHEM, V278, P29115, DOI 10.1074/jbc.M212396200; KHYRUL WA, 2004, J BIOL CHEM; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Lamorte L, 2003, MOL BIOL CELL, V14, P2818, DOI 10.1091/mbc.E02-08-0497; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Liu SC, 2000, J CELL SCI, V113, P3563; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Mishima W, 2004, GENES CELLS, V9, P193, DOI 10.1111/j.1356-9597.2004.00717.x; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Torgler CN, 2004, DEV CELL, V6, P357, DOI 10.1016/S1534-5807(04)00055-3; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vouret-Craviari V, 2004, J CELL SCI, V117, P4559, DOI 10.1242/jcs.01331; Vouret-Craviari V, 2002, J CELL SCI, V115, P2475; Wu CY, 2004, BBA-MOL CELL RES, V1692, P55, DOI 10.1016/j.bbamcr.2004.01.006; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Zamir E, 2001, J CELL SCI, V114, P3577; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	50	43	44	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1489	+		10.1096/fj.05-4579fje	http://dx.doi.org/10.1096/fj.05-4579fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723384				2022-12-28	WOS:000240266000027
J	Gigante, B; Morlino, G; Gentile, MT; Persico, MG; De Falco, S				Gigante, Bruna; Morlino, Giulia; Gentile, Maria Teresa; Persico, Maria Graziella; De Falco, Sandro			Plgf(-/-) eNos(-/-) mice show defective angiogenesis associated with increased oxidative stress in response to tissue ischemia	FASEB JOURNAL			English	Article						hindlimb ischemia; macrophage infiltration; nitric oxide	ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; IN-VIVO; GENE; EXPRESSION; RECEPTOR; DISEASE; BINDING; LACKING; VEGF	Neo-angiogenesis is a complex phenomenon modulated by the concerted action of several molecular factors. We have generated a congenic line of knockout mice carrying null mutations of both placental growth factor ( PlGF) and endothelial nitric oxide synthase ( eNOS), two genes that play a pivotal role in the regulation of pathological angiogenesis. In the present study, we describe the phenotype of this new experimental animal model after surgically induced hind-limb ischemia. Plgf(-/-), eNos(-/-), Plgf(-/-) eNos(-/-), and wild-type C57BL/6J mice were studied. Plgf(-/-) eNos(-/-) mice showed the most severe phenotype: self-amputation, and death occurred in up to 47% of the animals studied; in ischemic legs, capillary density was severely reduced; macrophage infiltration and oxidative stress increased as compared to the other groups of animals. These changes were associated with an up-regulation of both inducible NOS ( iNOS) expression and vascular endothelial growth factor ( VEGF) protein levels in ischemic limbs, and to an increased extent of protein nitration. Our results demonstrate that the deletion of these two genes, Plgf, which acts in synergism with VEGF, and eNos, a downstream mediator of VEGF, determines a significant change in the vascular response to an ischemic stimulus and that oxidative stress within the ischemic tissue represents a crucial factor to maintain tissue homeostasis.	CNR, Inst Genet & Biophys Adriano Buzzati Traverso, I-80131 Naples, Italy; Ist Ric & Cura Caratere Sci Neuromed, Pozzilli, IS, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); IRCCS Neuromed	De Falco, S (corresponding author), CNR, Inst Genet & Biophys Adriano Buzzati Traverso, Via P Castellino 111, I-80131 Naples, Italy.	defalco@igb.cnr.it	De Falco, Sandro/P-6724-2015; Gigante, Bruna/I-9252-2012	De Falco, Sandro/0000-0002-6501-1697; GENTILE, Maria Teresa/0000-0003-4239-5330; Gigante, Bruna/0000-0003-4508-7990				Amano K, 2003, HYPERTENSION, V41, P156, DOI 10.1161/01.HYP.0000053552.86367.12; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Bonthu S, 1997, ARTERIOSCL THROM VAS, V17, P2333, DOI 10.1161/01.ATV.17.11.2333; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; De Falco S, 2002, TRENDS CARDIOVAS MED, V12, P241, DOI 10.1016/S1050-1738(02)00168-8; Epstein SE, 2001, CIRCULATION, V104, P115, DOI 10.1161/01.CIR.104.1.115; Errico M, 2004, J BIOL CHEM, V279, P43929, DOI 10.1074/jbc.M401418200; Ferdinandy P, 2003, BRIT J PHARMACOL, V138, P532, DOI 10.1038/sj.bjp.0705080; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Gigante Bruna, 2004, Angiogenesis, V7, P277, DOI 10.1007/s10456-004-4179-1; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Hiratsuka S, 2005, MOL CELL BIOL, V25, P346, DOI 10.1128/MCB.25.1.346-354.2005; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Khatri JJ, 2004, CIRCULATION, V109, P520, DOI 10.1161/01.CIR.0000109698.70638.2B; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; MONCADA S, 1991, PHARMACOL REV, V43, P109; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Namba T, 2003, CIRCULATION, V108, P2250, DOI 10.1161/01.CIR.0000093190.53478.78; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; PARK JE, 1994, J BIOL CHEM, V269, P25646; Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72; Poon BY, 2003, CIRCULATION, V108, P1107, DOI 10.1161/01.CIR.0000086321.04702.AC; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Ramanathan MD, 2003, EXP BIOL MED, V228, P697, DOI 10.1177/153537020322800608; Richard DE, 2000, J BIOL CHEM, V275, P26765; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Simons M, 2003, NAT REV DRUG DISCOV, V2, P863, DOI 10.1038/nrd1226; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; Su YR, 2002, J LIPID RES, V43, P2180, DOI 10.1194/jlr.D200020-JLR200; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; Westenfeld R, 2002, KIDNEY INT, V61, P834, DOI 10.1046/j.1523-1755.2002.00229.x; Williams SM, 2004, BIOESSAYS, V26, P170, DOI 10.1002/bies.10401; Zhu XY, 2004, CIRCULATION, V109, P2109, DOI 10.1161/01.CIR.0000125742.65841.8B; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	39	48	52	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					970	+		10.1096/fj.05-4481fje	http://dx.doi.org/10.1096/fj.05-4481fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16608872				2022-12-28	WOS:000240157700025
J	Mentaverri, R; Yano, S; Chattopadhyay, N; Petit, L; Kifor, O; Kamel, S; Terwilliger, EF; Brazier, M; Brown, EM				Mentaverri, R.; Yano, S.; Chattopadhyay, N.; Petit, L.; Kifor, O.; Kamel, S.; Terwilliger, E. F.; Brazier, M.; Brown, E. M.			The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis	FASEB JOURNAL			English	Article						phospholipase C; NF-kappa B; caspases	HIGH EXTRACELLULAR CALCIUM; FACTOR-KAPPA-B; OSTEOPROTEGERIN LIGAND; CHICKEN OSTEOCLASTS; MATURE OSTEOCLASTS; BONE-RESORPTION; NITRIC-OXIDE; IN-VITRO; CA2+; ACTIVATION	Intracellular transduction pathways that are dependent on activation of the CaR by Ca-o(2+) have been studied extensively in parathyroid and other cell types, and include cytosolic calcium, phospholipases C, A(2), and D, protein kinase C isoforms and the cAMP/protein kinase A system. In this study, using bone marrow cells isolated from CaR-/- mice as well as DN-CaR-transfected RAW 264.7 cells, we provide evidence that expression of the CaR plays an important role in osteoclast differentiation. We also establish that activation of the CaR and resultant stimulation of PLC are involved in high Ca-o(2+)-induced apoptosis of mature rabbit osteoclasts. Similar to RANKL, Ca-o(2+) (20 mM) appeared to trigger rapid and significant nuclear translocation of NF-kappa B in a CaR- and PLC-dependent manner. In summary, our data suggest that stimulation of the CaR may play a pivotal role in the control of both osteoclast differentiation and apoptosis in the systems studied here through a signaling pathway involving activation of the CaR, phospholipase C, and NF-kappa B. Mentaverri, R., Yano, S., Chattopadhyay, N., Petit, L., Kifor, O., Kamel, S., Terwilliger, E. F., Brazier, M., Brown, E. M. The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis.	Univ Picardie, Unite Rech Mecan Resorpt Osseuse, F-80037 Amiens, France; Harvard Univ, Sch Med, Div Endocrinol Diabet & Hypertens, Brigham & Womens Hosp, Boston, MA 02115 USA; INSERM, ERI12, Amiens, France; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Picardie Universites; Universite de Picardie Jules Verne (UPJV); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); Harvard University; Beth Israel Deaconess Medical Center	Mentaverri, R (corresponding author), Univ Picardie, Unite Rech Mecan Resorpt Osseuse, ERI-12,1 Rue Louvels, F-80037 Amiens, France.	romuald.mentaverri@sa.u-picardie.fr	Chattopadhyay, Naibedya/AAF-2058-2019; Kamel, Said/HGA-7781-2022; Chattopadhyay, Naibedya/AAQ-3213-2021	Chattopadhyay, Naibedya/0000-0003-2473-0246				Anderson HC, 1997, J CLIN INVEST, V99, P2059, DOI 10.1172/JCI119375; Anderson JJB, 1998, BAILLIERE CLIN ENDOC, V12, P543, DOI 10.1016/S0950-351X(98)80003-7; Bennett BD, 2001, ENDOCRINOLOGY, V142, P1968, DOI 10.1210/en.142.5.1968; Boyce BF, 2003, KIDNEY INT, V63, pS2, DOI 10.1046/j.1523-1755.63.s85.2.x; Bruce JIE, 1999, J BIOL CHEM, V274, P20561, DOI 10.1074/jbc.274.29.20561; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chattopadhyay N, 2004, ENDOCRINOLOGY, V145, P3451, DOI 10.1210/en.2003-1127; Chattopadhyay N, 1998, AM J PHYSIOL-GASTR L, V274, pG122, DOI 10.1152/ajpgi.1998.274.1.G122; Chen XF, 2003, CANCER RES, V63, P1059; Collin-Osdoby P, 2003, METH MOLEC MED, V80, P65; Foged NT, 1996, J BONE MINER RES, V11, P226; Garner SC, 2001, ENDOCRINOLOGY, V142, P3996, DOI 10.1210/en.142.9.3996; Goldsmith PK, 1997, J BONE MINER RES, V12, P1780, DOI 10.1359/jbmr.1997.12.11.1780; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; Hofer AM, 2005, J CELL SCI, V118, P855, DOI 10.1242/jcs.01705; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; KAMEDA T, 1995, BIOCHEM BIOPH RES CO, V207, P753, DOI 10.1006/bbrc.1995.1251; Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448; Kanaoka K, 2000, ENDOCRINOLOGY, V141, P2995, DOI 10.1210/en.141.8.2995; Kanatani N, 1999, BIOCHEM BIOPH RES CO, V261, P144, DOI 10.1006/bbrc.1999.0932; Kifor O, 2003, J BIOL CHEM, V278, P31167, DOI 10.1074/jbc.M303377200; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; LA RF, 1994, MOL CELL BIOL, V14, P1039; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Lorget F, 2000, BIOCHEM BIOPH RES CO, V268, P899, DOI 10.1006/bbrc.2000.2229; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; Mentaverri R, 2003, J CELL BIOCHEM, V88, P1145, DOI 10.1002/jcb.10463; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; Pi M, 2005, J BIOL CHEM, V280, P40201, DOI 10.1074/jbc.M505186200; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Saunders R, 1998, NEUROPHARMACOLOGY, V37, P273, DOI 10.1016/S0028-3908(98)00027-6; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Spurr NK, 2003, CURR OPIN PHARMACOL, V3, P291, DOI 10.1016/S1471-4892(03)00034-1; Takayashiki T, 2002, HEPATO-GASTROENTEROL, V49, P109; Tfelt-Hansen J, 2003, AM J PHYSIOL-ENDOC M, V285, pE329, DOI 10.1152/ajpendo.00489.2002; WU HY, 1994, J BIOL CHEM, V269, P20067; Xu JK, 2005, J CELL PHYSIOL, V202, P554, DOI 10.1002/jcp.20159; Yamaguchi T, 1998, BIOCHEM BIOPH RES CO, V243, P753, DOI 10.1006/bbrc.1998.8178; Yano S, 2005, ENDOCRINOLOGY, V146, P2324, DOI 10.1210/en.2005-0065; Zaidi M, 1999, J BONE MINER RES, V14, P669, DOI 10.1359/jbmr.1999.14.5.669; Zaidi M, 1999, P ASSOC AM PHYSICIAN, V111, P319, DOI 10.1046/j.1525-1381.1999.99233.x; ZAIDI M, 1995, J CLIN INVEST, V96, P1582, DOI 10.1172/JCI118197; Ziegelstein RC, 2006, BIOCHEM BIOPH RES CO, V342, P153, DOI 10.1016/j.bbrc.2006.01.135	50	151	157	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2562	+		10.1096/fj.06-6304fje	http://dx.doi.org/10.1096/fj.06-6304fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077282				2022-12-28	WOS:000242490700024
J	Duka, T; Rusnak, M; Drolet, RE; Duka, V; Wersinger, C; Goudreau, JL; Sidhu, A				Duka, Tetyana; Rusnak, Milan; Drolet, Robert E.; Duka, Valeriy; Wersinger, Christophe; Goudreau, John L.; Sidhu, Anita			Alpha-Synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism	FASEB JOURNAL			English	Article						PD; Alzheimer's disease; mesencephalic neurons; alpha-synuclein knock-out mice; neurodegeneration	HELICAL FILAMENT-TAU; ALZHEIMERS-DISEASE; LEWY BODIES; DOPAMINERGIC-NEURONS; SUBSTANTIA-NIGRA; NEURODEGENERATIVE DISORDERS; MICROTUBULE-BINDING; GENE-EXPRESSION; P301L TAU; PHOSPHORYLATION	Many neurodegenerative diseases associated with functional Tau dysregulation, including Alzheimer's disease (AD) and other tauopathies, also show alpha-synuclein (alpha-Syn) pathology, a protein associated with Parkinson's disease (PD) pathology. Here we show that treatment of primary mesencephalic neurons (48 h) or subchronic treatment of wild-type (WT) mice with the Parkinsonism-inducing neurotoxin MPP+/MPTP, results in selective dose-dependent hyperphosphorylation of Tau at Ser396/404 (PHF-1-reactive Tau, p-Tau), with no changes in pSer202 but with nonspecific increases in pSer262 levels. The presence of alpha-Syn was absolutely mandatory to observe MPP+/MPTP-induced increases in p-Tau levels, since no alterations in p-Tau were seen in transfected cells not expressing alpha-Syn or in alpha-Syn-/- mice. MPP+/MPTP also induced a significant accumulation of alpha-Syn in both mesencephalic neurons and in WT mice striatum. MPTP/MPP+ lead to differential alterations in p-Tau and alpha-Syn levels in a cytoskeleton-bound, vs. a soluble, cytoskeleton-free fraction, inducing their coimmunoprecipitation in the cytoskeleton-free fraction and neuronal soma. Subchronic MPTP exposure increased sarkosyl-insoluble p-Tau in striatum of WT but not alpha-Syn-/- mice. These studies describe a novel mechanism for MPTP neurotoxicity, namely a MPTP-inducible, strictly alpha-Syn-dependent, increased formation of PHF-1-reactive Tau, suggesting convergent overlapping pathways in the genesis of clinically divergent diseases such as AD and PD.	Georgetown Univ, Dept Biochem Mol & Cellular Biol, Lab Mol Neurochem, Washington, DC 20007 USA; Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA	Georgetown University; Michigan State University	Sidhu, A (corresponding author), Georgetown Univ, Dept Biochem Mol & Cellular Biol, Lab Mol Neurochem, Res Bldg,Rm W222,3970 Reservoir Rd NW, Washington, DC 20007 USA.	sidhua@georgetown.edu			NINDS NIH HHS [NS-34914, NS-41555, NS-45326] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045326, R01NS034914, R01NS041555] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraha A, 2000, J CELL SCI, V113, P3737; Alim MA, 2004, J ALZHEIMERS DIS, V6, P435; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Arima K, 1999, BRAIN RES, V843, P53, DOI 10.1016/S0006-8993(99)01848-X; Benussi L, 2005, EXP CELL RES, V308, P78, DOI 10.1016/j.yexcr.2005.04.021; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Drolet RE, 2004, NEUROTOXICOLOGY, V25, P761, DOI 10.1016/j.neuro.2004.05.002; Du HN, 2003, BIOCHEMISTRY-US, V42, P8870, DOI 10.1021/bi034028+; Fornai F, 2005, P NATL ACAD SCI USA, V102, P3413, DOI 10.1073/pnas.0409713102; Frasier M, 2005, EXP NEUROL, V192, P274, DOI 10.1016/j.expneurol.2004.07.016; Friedhoff P, 2000, BBA-MOL BASIS DIS, V1502, P122, DOI 10.1016/S0925-4439(00)00038-7; Giasson BI, 2003, SCIENCE, V300, P636, DOI 10.1126/science.1082324; Goedert M, 1998, MOL PSYCHIATR, V3, P462, DOI 10.1038/sj.mp.4000458; Gomez-Santos C, 2002, BRAIN RES, V935, P32, DOI 10.1016/S0006-8993(02)02422-8; Hanger DP, 1998, J NEUROCHEM, V71, P2465; Ikura Y, 1998, NEUROREPORT, V9, P2375, DOI 10.1097/00001756-199807130-00041; Iqbal K, 2005, ACTA NEUROPATHOL, V109, P25, DOI 10.1007/s00401-004-0951-y; Iseki E, 1999, NEUROSCI LETT, V265, P9, DOI 10.1016/S0304-3940(99)00178-0; Ishizawa T, 2003, J NEUROPATH EXP NEUR, V62, P389, DOI 10.1093/jnen/62.4.389; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Kotzbauer PT, 2004, EXP NEUROL, V187, P279, DOI 10.1016/j.expneurol.2004.01.007; Kotzbauer PT, 2001, J MOL NEUROSCI, V17, P225, DOI 10.1385/JMN:17:2:225; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kuhn K, 2003, EUR J NEUROSCI, V17, P1, DOI 10.1046/j.1460-9568.2003.02408.x; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; LINDLEY SE, 1990, NEUROENDOCRINOLOGY, V52, P46, DOI 10.1159/000125537; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; Loo DT, 1998, METHOD CELL BIOL, V57, P251; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Mandel S, 2004, J MOL NEUROSCI, V24, P401, DOI 10.1385/JMN:24:3:401; Meredith GE, 2002, BRAIN RES, V956, P156, DOI 10.1016/S0006-8993(02)03514-X; Michaelis ML, 2002, J MOL NEUROSCI, V19, P289, DOI 10.1385/JMN:19:3:289; Morishima-Kawashima M, 2002, J NEUROSCI RES, V70, P392, DOI 10.1002/jnr.10355; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Morris HR, 2005, ANN MED, V37, P86, DOI 10.1080/07853890510007269; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; PALKOVITS M, 1973, BRAIN RES, V59, P449, DOI 10.1016/0006-8993(73)90290-4; Pandey N, 2006, EXP NEUROL, V197, P515, DOI 10.1016/j.expneurol.2005.10.019; Payton JE, 2001, MOL BRAIN RES, V95, P138, DOI 10.1016/S0169-328X(01)00257-1; Perez RG, 2004, J NEUROCHEM, V89, P1318, DOI 10.1111/j.1471-4159.2004.02423.x; Purisai MG, 2005, NEUROBIOL DIS, V20, P898, DOI 10.1016/j.nbd.2005.05.028; Sahara N, 2002, J NEUROCHEM, V83, P1498, DOI 10.1046/j.1471-4159.2002.01241.x; Schluter OM, 2003, NEUROSCIENCE, V118, P985, DOI 10.1016/S0306-4522(03)00036-8; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Sidhu A, 2004, FASEB J, V18, P637, DOI 10.1096/fj.03-1112rev; Sidhu A, 2004, FEBS LETT, V565, P1, DOI 10.1016/j.febslet.2004.03.063; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Vila M, 2000, J NEUROCHEM, V74, P721, DOI 10.1046/j.1471-4159.2000.740721.x; Wersinger C, 2005, BIOCHEMISTRY-US, V44, P13612, DOI 10.1021/bi050402p; Wersinger C, 2003, FASEB J, V17, P2151, DOI 10.1096/fj.03-0152fje; Xu Z, 2005, SYNAPSE, V55, P45, DOI 10.1002/syn.20089	61	84	86	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2302	2312		10.1096/fj.06-6092com	http://dx.doi.org/10.1096/fj.06-6092com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077307				2022-12-28	WOS:000241702600015
J	Kong, TQ; Westerman, KA; Faigle, M; Eltzschig, HK; Colgan, SP				Kong, Tianqing; Westerman, Karen A.; Faigle, Marion; Eltzschig, Holger K.; Colgan, Sean P.			HIF-dependent induction of adenosine A2B receptor in hypoxia	FASEB JOURNAL			English	Article						hypoxia-inducible factor; endothelium; chromatin; angiogenesis	INDUCIBLE FACTOR 1-ALPHA; BARRIER FUNCTION; A(2B) RECEPTOR; FACTOR-I; CELLS; ANGIOGENESIS; EXPRESSION; AGONISTS; TARGET; OVEREXPRESSION	Adenosine has been widely associated with hypoxia of many origins, including those associated with inflammation and tumorogenesis. A number of recent studies have implicated metabolic control of adenosine generation at sites of tissue hypoxia. Here, we examine adenosine receptor control and amplification of signaling through transcriptional regulation of endothelial and epithelial adenosine receptors. Initial studies confirmed previous findings indicating selective induction of human adenosine A2B receptor (A2BR) by hypoxia. Analysis of the cloned human A2BR promoter identified a functional hypoxia-responsive region, including a functional binding site for hypoxia-inducible factor (HIF) within the A2BR promoter. Further studies examining HIF-1 alpha DNA binding and HIF-1 alpha gain and loss of function confirmed strong dependence of A2BR induction by HIF-1 alpha in vitro and in vivo mouse models. Additional studies in endothelia overexpressing full-length A2BR revealed functional phenotypes of increased barrier function and enhanced angiogenesis. Taken together, these results demonstrate transcriptional coordination of A2BR by HIF-1 alpha and amplified adenosine signaling during hypoxia. These findings may provide an important link between hypoxia and metabolic conditions associated with inflammation and angiogenesis.	Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, Denver, CO 80262 USA; Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, Tubingen, Germany; Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Expt Therapeut, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol, Boston, MA 02115 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Colgan, SP (corresponding author), Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, BRB702, Denver, CO 80262 USA.	sean.colgan@uchsc.edu	Colgan, Sean P./B-4573-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050189, R01DK050189, R29DK050189] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60569] Funding Source: Medline; NIDCR NIH HHS [DE016191] Funding Source: Medline; NIDDK NIH HHS [DK50189] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Decking UKM, 1997, CIRC RES, V81, P154, DOI 10.1161/01.RES.81.2.154; Desai A, 2005, MOL PHARMACOL, V67, P1406, DOI 10.1124/mol.104.007807; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Feoktistov I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14; Feoktistov I, 2004, HYPERTENSION, V44, P649, DOI 10.1161/01.HYP.0000144800.21037.a5; Fishman P, 2002, ANTI-CANCER DRUG, V13, P437, DOI 10.1097/00001813-200206000-00001; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Giatromanolaki A, 2003, J CLIN PATHOL, V56, P209, DOI 10.1136/jcp.56.3.209; Holgate ST, 2005, BRIT J PHARMACOL, V145, P1009, DOI 10.1038/sj.bjp.0706272; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ji XD, 2001, BIOCHEM PHARMACOL, V61, P657, DOI 10.1016/S0006-2952(01)00531-7; Karhausen J, 2005, CELL CYCLE, V4, P256; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Kong TQ, 2004, P NATL ACAD SCI USA, V101, P10440, DOI 10.1073/pnas.0401339101; Leibovich SJ, 2002, AM J PATHOL, V160, P2231, DOI 10.1016/S0002-9440(10)61170-4; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; Li SY, 2005, INT J ONCOL, V27, P1329; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; LOUIS NA, 2005, IN PRESS FASEB J, P2287; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Merighi S, 2003, PHARMACOL THERAPEUT, V100, P31, DOI 10.1016/S0163-7258(03)00084-6; Montesinos MC, 2004, AM J PATHOL, V164, P1887, DOI 10.1016/S0002-9440(10)63749-2; Montesinos MC, 2002, AM J PATHOL, V160, P2009, DOI 10.1016/S0002-9440(10)61151-0; Montesinos MC, 1997, J EXP MED, V186, P1615, DOI 10.1084/jem.186.9.1615; Odashima M, 2005, GASTROENTEROLOGY, V129, P26, DOI 10.1053/j.gastro.2005.05.032; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Pawliuk R, 2001, SCIENCE, V294, P2368, DOI 10.1126/science.1065806; Pinhal-Enfield G, 2003, AM J PATHOL, V163, P711, DOI 10.1016/S0002-9440(10)63698-X; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; STROHMEIER GR, 1995, J BIOL CHEM, V270, P2387, DOI 10.1074/jbc.270.5.2387; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Tang CM, 2005, PHARMACOGENET GENOM, V15, P321, DOI 10.1097/01213011-200505000-00007; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Weissmuller Thomas, 2005, Purinergic Signal, V1, P229, DOI 10.1007/s11302-005-6323-9; Yamashita R, 2006, NUCLEIC ACIDS RES, V34, pD86, DOI 10.1093/nar/gkj129; ZHONG H, 2005, AM J RESP CELL MOL B, V32	42	267	274	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2242	2250		10.1096/fj.06-6419com	http://dx.doi.org/10.1096/fj.06-6419com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077301				2022-12-28	WOS:000241702600009
J	Klegeris, A; Giasson, BI; Zhang, H; Maguire, J; Pelech, S; McGeer, PL				Klegeris, Andis; Giasson, Benoit I.; Zhang, Hong; Maguire, John; Pelech, Steven; McGeer, Patrick L.			Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells	FASEB JOURNAL			English	Article						c-Jun N-terminal kinase; MAPK/ERK kinase; neuroinflammation; p38 mitogen-activated protein kinase; Parkinson disease	PARKINSONS-DISEASE; WILD-TYPE; DEGENERATION PROCESS; NEUROBLASTOMA-CELLS; OXIDATIVE STRESS; LEWY BODIES; KINASE; EXPRESSION; SYSTEM; ACTIVATION	Autosomal dominant Parkinson disease (PD) is caused by duplication or triplication of the alpha-synuclein gene as well as by the A30P, E46K, and A53T mutations. The mechanisms are unknown. Reactive astrocytes in the substantia nigra of PD and MPTP-treated monkeys display high levels of the inflammatory mediator intercellular adhesion molecule-1 (ICAM-1), indicating that chronic inflammation contributes to the degeneration. Here we report that alpha-synuclein strongly stimulates human astrocytes as well as human U-373 MG astrocytoma cells to up-regulate both interleukin (IL)-6 and ICAM-1 (ED50 = 5 mu g ml(-1)). The mutated forms are more potent stimulators than wild-type (WT) alpha-synuclein in these assays. We demonstrate by immunoblotting analysis that this up-regulation is associated with activation of the major mitogen-activated protein kinase (MAPK) pathways. It is also attenuated by PD 98059, an inhibitor of the MAPK/extracellular-regulated kinase kinase MEK1/2, SP 600125, an inhibitor of c-Jun N-terminal kinase (JNK), and SB 202190, an inhibitor of p38 MAPK. The inhibitory effects on human astrocytes have IC50 values of 2, 5, and 1.5 mu M respectively. We hypothesize that the neuroinflammation stimulated by release of an excess of normal alpha-synuclein or by release of its mutated forms can be involved in the pathobiology of PD.	Univ British Columbia, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Kinexus Bioinformat Corp, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of Pennsylvania	Klegeris, A (corresponding author), Univ British Columbia, Kinsmen Lab Neurol Res, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	aklegeri@interchange.ubc.ca						AKIYAMA H, 1993, ACTA NEUROPATHOL, V85, P628, DOI 10.1007/BF00334673; Betarbet R, 2005, EXP NEUROL, V191, pS17, DOI 10.1016/j.expneurol.2004.08.021; Borghi R, 2000, NEUROSCI LETT, V287, P65, DOI 10.1016/S0304-3940(00)01153-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Croisier E, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-14; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; De Groot CJA, 2000, BRAIN RES PROTOC, V5, P85, DOI 10.1016/S1385-299X(99)00059-8; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Ferrer I, 2001, J NEURAL TRANSM, V108, P1383, DOI 10.1007/s007020100015; Frasier M, 2005, EXP NEUROL, V192, P274, DOI 10.1016/j.expneurol.2004.07.016; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gasser T, 2005, CURR OPIN NEUROL, V18, P363, DOI 10.1097/01.wco.0000170951.08924.3d; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Greenbaum EA, 2005, J BIOL CHEM, V280, P7800, DOI 10.1074/jbc.M411638200; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Hosokawa M, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-17; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; Iseki E, 2000, NEUROSCI LETT, V286, P69, DOI 10.1016/S0304-3940(00)01090-9; Ishizawa K, 2004, J NEUROPATH EXP NEUR, V63, P43, DOI 10.1093/jnen/63.1.43; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; Klegeris A, 2000, BIOCHEM PHARMACOL, V59, P1305, DOI 10.1016/S0006-2952(00)00252-5; Klegeris A, 2003, BRIT J PHARMACOL, V139, P775, DOI 10.1038/sj.bjp.0705304; Klegeris A, 2001, NEUROSCI LETT, V313, P41, DOI 10.1016/S0304-3940(01)02251-0; Lee HJ, 2005, J NEUROSCI, V25, P6016, DOI 10.1523/JNEUROSCI.0692-05.2005; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lee SJ, 1999, J NEUROIMMUNOL, V98, P77, DOI 10.1016/S0165-5728(99)00084-3; Martin FL, 2003, J NEUROCHEM, V87, P620, DOI 10.1046/j.1471-4159.2003.02013.x; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; Miklossy J, 2006, EXP NEUROL, V197, P275, DOI 10.1016/j.expneurol.2005.10.034; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nishioka K, 2006, ANN NEUROL, V59, P298, DOI 10.1002/ana.20753; Norris EH, 2004, CURR TOP DEV BIOL, V60, P17; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Stefanova N, 2005, AM J PATHOL, V166, P869, DOI 10.1016/S0002-9440(10)62307-3; Suh HS, 2005, J IMMUNOL, V174, P2712, DOI 10.4049/jimmunol.174.5.2712; Sung JY, 2005, J BIOL CHEM, V280, P25216, DOI 10.1074/jbc.M503341200; Tanji K, 2001, NEUROREPORT, V12, P1909, DOI 10.1097/00001756-200107030-00028; Togo T, 2001, J NEUROL SCI, V184, P71, DOI 10.1016/S0022-510X(00)00498-6; von Bohlen und Halbach O, 2004, CELL TISSUE RES, V318, P163, DOI 10.1007/s00441-004-0921-7; Wakabayashi K, 2000, ACTA NEUROPATHOL, V99, P14, DOI 10.1007/PL00007400; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang J, 2002, CURR TOP MICROBIOL, V265, P23; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com; Zhu JH, 2003, BRAIN PATHOL, V13, P473; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	56	106	110	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2000	2008		10.1096/fj.06-6183com	http://dx.doi.org/10.1096/fj.06-6183com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012252				2022-12-28	WOS:000241156900008
J	Dommange, F; Cartron, G; Espanel, C; Gallay, N; Domenech, J; Benboubker, L; Ohresser, M; Colombat, P; Binet, C; Watier, H; Herault, O				Dommange, Florence; Cartron, Guillaume; Espanel, Claire; Gallay, Nathalie; Domenech, Jorge; Benboubker, Lotfi; Ohresser, Marc; Colombat, Philippe; Binet, Chistian; Watier, Herve; Herault, Olivier		GOELAMS Study Group	CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia	FASEB JOURNAL			English	Article						SDF-1; CXCR4; blast cells; microenvironment	BREAST-CANCER METASTASIS; CHEMOKINE RECEPTOR CXCR4; FACTOR-I; STROMAL CELLS; TUMOR-CELLS; STEM-CELLS; EXPRESSION; BONE; GENE; MIGRATION	Stromal cell-derived factor 1 (SDF-1), a chemokine abundantly produced by the bone marrow microenvironment, and its receptor CXCR4 have crucial roles in malignant cell trafficking. In acute myeloid leukemia (AML), blasts invade the bloodstream and may localize in extramedullar sites, with variations from one patient to another. We hypothesized that a polymorphism in the SDF-1 coding gene (CXCL12 G801A) could influence blast dissemination and tissue infiltration in AML. CXCL12 G801A polymorphism was determined in 86 adult patients and 100 healthy volunteers. The allelic status and CXCR4 expression on bone marrow blasts were analyzed in relation to peripheral blood blast (PBB) counts and frequency of extramedullar tumor sites. 801A carrier status (801G/A, 801A/A) was found to be associated with a higher PBB count compared with 801G/G homozygous patients (P = 0.031) and higher frequency of extramedullar tumor sites (odds ratio 2.92, 95% confidence interval 1.18 -7.21, P = 0.018). Moreover, the PBB count was correlated with CXCR4 expression (correlation coefficient 0.546, P = 0.001) when considering 801A carriers. In conclusion, a polymorphism in the SDF-1 gene is shown for the first time to be associated with the clinical presentation of a malignant hematological disease and more generally with the risk of distant tissue infiltration by tumor cells.	CHRU, Labs Hematol & Immunol, F-37044 Tours, France; CHRU, Serv Hematol & Therapie Cellulaire, F-37044 Tours, France; Univ Tours, Equipe EA 3853, Tours, France; Univ Tours, Equipe EA 3855, Tours, France; INSERM, Equipe ESPRI Microenvironm Hematopoiese & Cellule, Tours, France	CHU Tours; CHU Tours; Universite de Tours; Universite de Tours; Institut National de la Sante et de la Recherche Medicale (Inserm)	Herault, O (corresponding author), CHRU, Hop Bretonneau, Hematol Lab, Equipe Inserm ESPRI EA3855, 2 Bd Tonnelle, F-37044 Tours, France.	olivier.herault@med.univ-tours.fr		, Nathalie GALLAY/0000-0002-4236-4780; Cartron, Guillaume/0000-0003-0659-9635; Herault, Olivier/0000-0002-7419-1124				Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Arai J, 2000, EUR J HAEMATOL, V64, P323, DOI 10.1034/j.1600-0609.2000.90147.x; Benboubker L, 2001, BRIT J HAEMATOL, V113, P247, DOI 10.1046/j.1365-2141.2001.02717.x; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Howell WM, 2002, GENES IMMUN, V3, P229, DOI 10.1038/sj.gene.6363851; Kimura R, 2005, HUM MOL GENET, V14, P1579, DOI 10.1093/hmg/ddi166; Koshiba T, 2000, CLIN CANCER RES, V6, P3530; Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342; Lacombe F, 1997, LEUKEMIA, V11, P1878, DOI 10.1038/sj.leu.2400847; Liang ZX, 2005, CANCER RES, V65, P967; Magierowska M, 1998, IMMUNOGENETICS, V48, P417, DOI 10.1007/s002510050454; Mohle R, 2000, BRIT J HAEMATOL, V110, P563, DOI 10.1046/j.1365-2141.2000.02157.x; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Poulain S, 2003, BLOOD, V102, p669A; Russell HV, 2004, J PEDIATR SURG, V39, P1506, DOI 10.1016/j.jpedsurg.2004.06.019; Scotton CJ, 2002, CANCER RES, V62, P5930; Soriano A, 2002, J INFECT DIS, V186, P922, DOI 10.1086/343741; Taichman RS, 2002, CANCER RES, V62, P1832; Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008-5472.CAN-03-3693; Voermans C, 2002, LEUKEMIA, V16, P650, DOI 10.1038/sj.leu.2402431; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389	26	50	53	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1913	+		10.1096/fj.05-5667fje	http://dx.doi.org/10.1096/fj.05-5667fje			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16818471				2022-12-28	WOS:000240267000028
J	Aquilano, K; Vigilanza, P; Rotilio, G; Ciriolo, MR				Aquilano, Katia; Vigilanza, Paola; Rotilio, Giuseppe; Ciriolo, Maria Rosa			Mitochondrial damage due to SOD1 deficiency in SH-SY5Y neuroblastoma cells: a rationale for the redundancy of SOD1	FASEB JOURNAL			English	Article						oxidative stress; aging; Bcl-2; neurodegeneration	AMYOTROPHIC-LATERAL-SCLEROSIS; CU,ZN SUPEROXIDE-DISMUTASE; NITRIC-OXIDE; OXIDATIVE STRESS; MOTOR-NEURONS; CU,ZN-SUPEROXIDE DISMUTASE; INTERMEMBRANE SPACE; SPORADIC ALS; FAMILIAL ALS; LIFE-SPAN	Superoxide dismutases (SODs) represent the first line of defense against oxidative stress, which is considered an essential factor in several neurodegenerative diseases and aging. We investigated the role of the copper, zinc superoxide dismutase (SOD1) in the maintenance of intracellular redox homeostasis by analyzing the early effects of SOD1 down-regulation in SH-SY5Y neuroblastoma cells. Through the use of small interference RNA, SOD1 was efficiently downregulated at 48 h after transfection without any significant effect on cell viability. The steady-state concentration of superoxide was significantly increased after 12 h, when SOD1 was only slightly decreased, and progressively returned to values close to those observed in control cells. The superoxide increase was buffered by the enhanced levels of antioxidant glutathione (GSH); however, GSH increase was not sufficient to avoid damage to proteins in terms of carbonyls. GSH-depleting agents, such as BSO or diamide, further increased protein damage and committed SOD1 deficient cells to death, confirming the pivotal role played by this antioxidant. Although SOD1 declined mostly in the cytosolic compartment, mitochondria were significantly affected with impairment of the mitochondrial transmembrane potential and a decrease in ATP production. Together with these effects carbonylation of mitochondrial proteins was detected and in particular a consistent carbonylation and decrease of the antiapoptotic protein Bcl-2. These conditions induced a high susceptibility of SOD1-depleted cells to treatment with the mitochondrial reactive oxygen species producing agent rotenone. Overall, the results demonstrate that loss of SOD1 leads to severe damage of mitochondria, suggesting an important biological role for this enzyme in the preservation of mitochondrial homeostasis.	Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00133 Rome, Italy	University of Rome Tor Vergata	Ciriolo, MR (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00133 Rome, Italy.	ciriolo@bio.uniroma2.it	Ciriolo, Maria Rosa/K-6572-2016; AQUILANO, KATIA/K-8888-2016	AQUILANO, KATIA/0000-0002-5905-9870; Ciriolo, Maria Rosa/0000-0002-7863-9029				Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624; Blander G, 2003, J BIOL CHEM, V278, P38966, DOI 10.1074/jbc.M307146200; Busuttil RA, 2005, CANCER RES, V65, P11271, DOI 10.1158/0008-5472.CAN-05-2980; Cahuana GM, 2004, EXP CELL RES, V293, P22, DOI 10.1016/j.yexcr.2003.10.004; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; Ciriolo MR, 2001, J NEUROCHEM, V77, P1433, DOI 10.1046/j.1471-4159.2001.00383.x; Cova E, 2006, NEUROSCI LETT, V399, P186, DOI 10.1016/j.neulet.2006.01.057; Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207; Filomeni G, 2005, ANTIOXID REDOX SIGN, V7, P446, DOI 10.1089/ars.2005.7.446; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gupta S, 2005, J CELL MOL MED, V9, P51, DOI 10.1111/j.1582-4934.2005.tb00336.x; Huang TT, 2000, J GERONTOL A-BIOL, V55, pB5; Inarrea P, 2005, BIOCHEM J, V387, P203, DOI 10.1042/BJ20041683; Kato S, 2005, ACTA NEUROPATHOL, V110, P101, DOI 10.1007/s00401-005-1019-3; Kira Y, 2002, ARCH BIOCHEM BIOPHYS, V399, P96, DOI 10.1006/abbi.2001.2738; Kong JM, 1998, J NEUROSCI, V18, P3241; Landis GN, 2005, MECH AGEING DEV, V126, P365, DOI 10.1016/j.mad.2004.08.012; Lee M, 2001, J NEUROCHEM, V78, P209, DOI 10.1046/j.1471-4159.2001.00417.x; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manfredi G, 2005, MITOCHONDRION, V5, P77, DOI 10.1016/j.mito.2005.01.002; Matzuk MM, 1998, ENDOCRINOLOGY, V139, P4008, DOI 10.1210/en.139.9.4008; Multhaup G, 1997, BIOCHEM PHARMACOL, V54, P533, DOI 10.1016/S0006-2952(97)00062-2; Noor Rana, 2002, Med Sci Monit, V8, pRA210; O'Brien KM, 2004, J BIOL CHEM, V279, P51817, DOI 10.1074/jbc.M405958200; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Parker JD, 2004, P NATL ACAD SCI USA, V101, P3486, DOI 10.1073/pnas.0400222101; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Rizzardini M, 2005, J NEUROL SCI, V232, P95, DOI 10.1016/j.jns.2005.02.004; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN JD, 1994, P NATL ACAD SCI USA, V91, P4155, DOI 10.1073/pnas.91.10.4155; Rotilio G, 2003, IUBMB LIFE, V55, P629, DOI 10.1080/15216540310001628717; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Sentman ML, 2006, J BIOL CHEM, V281, P6904, DOI 10.1074/jbc.M510764200; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Troy CM, 1996, J NEUROSCI, V16, P253; Vijayvergiya C, 2005, J NEUROSCI, V25, P2463, DOI 10.1523/JNEUROSCI.4385-04.2005; Wallace MA, 2004, J BIOL CHEM, V279, P32055, DOI 10.1074/jbc.M403590200; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793	46	48	49	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1683	+		10.1096/fj.05-5225fje	http://dx.doi.org/10.1096/fj.05-5225fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790527				2022-12-28	WOS:000240266600014
J	Mallawaarachchi, CM; Weissberg, PL; Siow, RCM				Mallawaarachchi, Chandike M.; Weissberg, Peter L.; Siow, Richard C. M.			Antagonism of platelet-derived growth factor by perivascular gene transfer attenuates adventitial cell migration after vascular injury: new tricks for old dogs?	FASEB JOURNAL			English	Article						restenosis; vascular remodeling; balloon angioplasty; PDGF	SMOOTH-MUSCLE-CELLS; FACTOR-B-CHAIN; MATRIX METALLOPROTEINASES; PROGENITOR CELLS; BALLOON INJURY; PDGF; KINASE; INHIBITION; PROLIFERATION; ANGIOPLASTY	Migration of adventitial fibroblasts contributes to vascular remodeling after angioplasty. This study has used perivascular gene transfer of a truncated platelet-derived growth factor PDGF receptor (PDGFXR) to investigate whether antagonism of PDGF signaling alters adventitial cell migration after balloon injury in rat carotid arteries. Adenoviruses coordinating expression of beta-galactosidase (LacZ) and PDGFXR or LacZ and green fluorescent protein (GFP) were applied to the perivascular surface of arteries and balloon injury performed 4 days later. Vessels were excised at 3, 7, and 14 days to determine morphology and gene expression. Uninjured arteries only expressed LacZ positive cells in the adventitial compartment; however, after injury in LacZ and GFP transfected arteries, LacZ positive cells contributed to the population of cells within the media and neointima at 7-14 days. Overexpression of PDGFXR and LacZ resulted in a significant reduction in the number of LacZ labeled cells in the neointima after vascular injury, concomitant with reduced remodeling, collagen content, expression of matrix metalloproteinase-2, and increased levels of tissue inhibitors of metalloproteinase-1 and -2. We provide evidence that perivascular antagonism of PDGF attenuates remodeling and contribution of adventitial fibroblasts to neointima formation after balloon angioplasty. Perivascular gene transfer may represent a therapeutic strategy to reduce the incidence of restenosis.	Kings Coll London, Sch Biomed & Hlth Sci, Div Cardiovasc, London SE1 1UL, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Div Cardiovasc Med, Cambridge, England	University of London; King's College London; Addenbrooke's Hospital; University of Cambridge	Siow, RCM (corresponding author), Kings Coll London, Sch Biomed & Hlth Sci, Div Cardiovasc, Guys Hosp Campus, London SE1 1UL, England.	richard.siow@kcl.ac.uk						Buetow BS, 2003, AM J PATHOL, V163, P979, DOI 10.1016/S0002-9440(10)63457-8; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; Deguchi J, 1999, GENE THER, V6, P956, DOI 10.1038/sj.gt.3300918; Dourron HM, 2005, AM J PHYSIOL-HEART C, V288, pH946, DOI 10.1152/ajpheart.00413.2004; DUAN DSR, 1991, J BIOL CHEM, V266, P413; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Hu YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628; Kreuzer J, 2002, FASEB J, V16, P38, DOI 10.1096/fj.01-1036fje; Lambiase PD, 2004, CIRCULATION, V109, P2986, DOI 10.1161/01.CIR.0000130639.97284.EC; Lau HKF, 1999, CARDIOVASC RES, V43, P1049, DOI 10.1016/S0008-6363(99)00136-4; Levitzki A, 2005, CARDIOVASC RES, V65, P581, DOI 10.1016/j.cardiores.2004.08.008; LINDNER V, 1995, CIRC RES, V76, P951, DOI 10.1161/01.RES.76.6.951; Mallawaarachchi CM, 2005, ARTERIOSCL THROM VAS, V25, P1383, DOI 10.1161/01.ATV.0000168415.33812.51; Miyata T, 2005, J CELL PHYSIOL, V204, P948, DOI 10.1002/jcp.20362; Myllarniemi M, 1997, FASEB J, V11, P1119, DOI 10.1096/fasebj.11.13.9367346; Newby AC, 2005, PHYSIOL REV, V85, P1, DOI 10.1152/physrev.00048.2003; Ohashi N, 2000, ARTERIOSCL THROM VAS, V20, P2521, DOI 10.1161/01.ATV.20.12.2521; Peppel K, 2005, CARDIOVASC RES, V65, P674, DOI 10.1016/j.cardiores.2004.10.031; Pires NMM, 2005, BIOMATERIALS, V26, P5386, DOI 10.1016/j.biomaterials.2005.01.063; Rey FE, 2002, ARTERIOSCL THROM VAS, V22, P1962, DOI 10.1161/01.ATV.0000043452.30772.18; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rutherford C, 1997, ATHEROSCLEROSIS, V130, P45, DOI 10.1016/S0021-9150(96)06042-X; Sartore S, 2001, CIRC RES, V89, P1111, DOI 10.1161/hh2401.100844; SCHWARTZ SM, 1995, THROMB HAEMOSTASIS, V74, P541; Schwartz SM, 1997, J CLIN INVEST, V100, pS87; Shi Y, 1999, ARTERIOSCL THROM VAS, V19, P1150, DOI 10.1161/01.ATV.19.5.1150; Siow RCM, 2003, CARDIOVASC RES, V59, P212, DOI 10.1016/S0008-6363(03)00292-X; Torsney E, 2005, TRENDS CARDIOVAS MED, V15, P64, DOI 10.1016/j.tcm.2005.02.003; Yamasaki Y, 2001, CIRC RES, V88, P630, DOI 10.1161/01.RES.88.6.630	30	18	19	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1686	+		10.1096/fj.05-5435fje	http://dx.doi.org/10.1096/fj.05-5435fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790526				2022-12-28	WOS:000240266600015
J	Dang, PMC; Elbim, C; Marie, JC; Chiandotto, M; Gougerot-Pocidalo, MA; El-Benna, J				Dang, Pham My-Chan; Elbim, Carole; Marie, Jean-Claude; Chiandotto, Melanie; Gougerot-Pocidalo, Marie-Anne; El-Benna, Jamel			Anti-inflammatory effect of interleukin-10 on human neutrophil respiratory burst involves inhibition of GM-CSF-induced p47(PHOX) phosphorylation through a decrease in ERK1/2 activity	FASEB JOURNAL			English	Article						IL-10; NADPH oxidase; inflammation; ROS	COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; IL-1 RECEPTOR ANTAGONIST; PROTEIN-KINASE-C; NADPH OXIDASE; TNF-ALPHA; ACTIVATION; EXPRESSION; CYTOKINE	Interleukin-10 (IL-10) exerts its anti-inflammatory properties by down-regulating polymorphonuclear neutrophil (PMN) functions such as reactive oxygen species (ROS) production via NADPH oxidase. The molecular mechanisms underlying this process are unclear. Partial phosphorylation of the NADPH oxidase cytosolic component p47(PHOX) induced by proinflammatory cytokines, such as granulocyte-macrophage colony stimulating factor (GM-CSF) and tumor necrosis factor (TNF)-alpha, is essential for priming ROS production by PMN. The aim of this study was to determine whether IL-10 inhibits GM-CSF- and TNF alpha-induced p47PHOX phosphorylation and to investigate the molecular mechanisms involved in this effect. We found that IL-10 selectively inhibited GM-CSF- but not TNF alpha-induced p47PHOX phosphorylation in a concentration-dependent manner. As GM-CSF-induced p47(PHOX) phosphorylation is mediated by extracellular signal-regulated kinase 1/2 (ERK1/2), we tested the effect of IL-10 on this pathway. We found that IL-10 inhibited GM-CSF-induced ERK1/2 activity in an immunocomplex kinase assay. This inhibitory effect was confirmed by analyzing the phosphorylation status of the endogenous substrate of ERK1/2, p90RSK, in intact PMN. Furthermore, IL-10 decreased ROS production by adherent GM-CSF-treated PMN in keeping with the higher ROS production observed in whole blood from IL-10 knockout mice compared to their wild-type counterparts. Together, these results suggest that IL-10 inhibits GM-CSF-induced priming of ROS production by inhibiting p47PHOX phosphorylation through a decrease in ERK1/2 activity. This IL-10 effect could contribute to the tight regulation of NADPH oxidase activity at the inflammatory site.	CHU Xavier Bichat, INSERM, U773, Fac Med, F-75018 Paris, France; Univ Paris Denis Diderot 7, Paris, France; AP HP, CIB, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP)	Dang, PMC (corresponding author), CHU Xavier Bichat, INSERM, U773, Fac Med, 16 Rue Henri Huchard, F-75018 Paris, France.	dang@bichat.inserm.fr						Al-Shami A, 1998, J BIOL CHEM, V273, P1058, DOI 10.1074/jbc.273.2.1058; BABIOR BM, 1984, BLOOD, V64, P959; BENGISGARBER C, 1995, CELL SIGNAL, V7, P721, DOI 10.1016/0898-6568(95)00040-V; BERKOW RL, 1987, J IMMUNOL, V139, P3783; Bovolenta C, 1998, J IMMUNOL, V160, P911; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; Bussolati B, 1997, IMMUNOLOGY, V90, P440, DOI 10.1111/j.1365-2567.1997.00440.x; Capsoni F, 1997, SCAND J IMMUNOL, V45, P269, DOI 10.1046/j.1365-3083.1997.d01-393.x; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; Cassatella MA, 1998, INT J CLIN LAB RES, V28, P148, DOI 10.1007/s005990050036; Chaves MM, 1996, INFLAMM RES, V45, P313, DOI 10.1007/BF02252942; Crepaldi L, 2002, INT IMMUNOL, V14, P1145, DOI 10.1093/intimm/dxf079; Crepaldi L, 2001, J IMMUNOL, V167, P2312, DOI 10.4049/jimmunol.167.4.2312; DANG PM, 2006, IN PRESS J CLIN INVE; Dang PMC, 1999, J BIOL CHEM, V274, P20704, DOI 10.1074/jbc.274.29.20704; Dang PMC, 2002, P NATL ACAD SCI USA, V99, P4262, DOI 10.1073/pnas.072345299; DeLeo FR, 1999, J IMMUNOL, V163, P6732; Dewas C, 2003, J IMMUNOL, V171, P4392, DOI 10.4049/jimmunol.171.8.4392; DOWNEY GP, 1995, SEMIN CELL BIOL, V6, P345, DOI 10.1016/S1043-4682(05)80005-4; El Benna J, 2002, INFLAMMATION, V26, P273; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ELBIM C, 1993, BLOOD, V82, P633; Elbim C, 2001, J IMMUNOL, V166, P5201, DOI 10.4049/jimmunol.166.8.5201; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Gallova L, 2004, PHYSIOL RES, V53, P199; Gasperini S, 1999, J IMMUNOL, V162, P4928; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Grutz G, 2005, J LEUKOCYTE BIOL, V77, P3, DOI 10.1189/jlb.0904484; HALLETT MB, 1995, IMMUNOL TODAY, V16, P264, DOI 10.1016/0167-5699(95)80178-2; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; Inoue Y, 2004, J IMMUNOL, V172, P2147, DOI 10.4049/jimmunol.172.4.2147; Joseph DE, 1996, J BIOL CHEM, V271, P13088, DOI 10.1074/jbc.271.22.13088; KASAMA T, 1994, J IMMUNOL, V152, P3559; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laichalk LL, 1996, FEMS IMMUNOL MED MIC, V15, P181, DOI 10.1016/0928-8244(96)00048-X; LIU Y, 1994, J IMMUNOL, V152, P1821; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; MULLER T, 1989, J BIOLUM CHEMILUM, V3, P105, DOI 10.1002/bio.1170030304; Niiro H, 1997, BLOOD, V89, P1621, DOI 10.1182/blood.V89.5.1621.1621_1621_1628; Nijhuis E, 2002, J LEUKOCYTE BIOL, V71, P115; OKUDA K, 1992, BLOOD, V79, P2880; Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162; Ricevuti G, 1997, ANN NY ACAD SCI, V832, P426, DOI 10.1111/j.1749-6632.1997.tb46269.x; Roos D, 1996, BLOOD, V87, P1663; Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571; SULLIVAN GW, 1993, BLOOD, V81, P1863; Sur R, 2005, BIOCHEM J, V387, P315, DOI 10.1042/BJ20041713; Suzuki K, 1999, BLOOD, V93, P341, DOI 10.1182/blood.V93.1.341.401k09_341_349; Thivierge M, 1999, J IMMUNOL, V162, P3590; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Williams LM, 2004, IMMUNOLOGY, V113, P281, DOI 10.1111/j.1365-2567.2004.01988.x; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; Zacharowski P, 2005, EUR J PHARMACOL, V508, P7, DOI 10.1016/j.ejphar.2004.11.064	62	53	55	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1504	+		10.1096/fj.05-5395fje	http://dx.doi.org/10.1096/fj.05-5395fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720733				2022-12-28	WOS:000240266000032
J	Wang, T; Allie, R; Conant, K; Haughey, N; Turchan-Chelowo, J; Hahn, K; Rosen, A; Steiner, J; Keswani, S; Jones, M; Calabresi, PA; Nath, A				Wang, Tongguang; Allie, Rameeza; Conant, Katherine; Haughey, Norman; Turchan-Chelowo, Jadwiga; Hahn, Katrin; Rosen, Antony; Steiner, Joseph; Keswani, Sanjay; Jones, Melina; Calabresi, Peter A.; Nath, Avindra			Granzyme B mediates neurotoxicity through a G-protein-coupled receptor	FASEB JOURNAL			English	Article						T cell; multiple sclerosis; pertussis toxin; cAMP; caspase-3; immune reconstitution syndrome	REMITTING MULTIPLE-SCLEROSIS; CYTOTOXIC T-LYMPHOCYTES; LONG-TERM-MEMORY; BRAIN ATROPHY; CELL-DEATH; VENTRICULAR ENLARGEMENT; RASMUSSENS ENCEPHALITIS; CEREBRAL ATROPHY; AXONAL DAMAGE; LATE-PHASE	Neuroinflammatory diseases such as multiple sclerosis ( MS) are characterized by focal regions of demyelination and axonal loss associated with infiltrating T cells. However, the role of activated T cells in causing neuronal injury remains unclear. CD4 and CD8 T cells were isolated from normal donors and polyclonally activated using plate-bound anti-CD3 and soluble anti-CD28. The conditioned T cell supernatants caused toxicity to cultured human fetal neurons, which could be blocked by immunodepleting the supernatants of granzyme B (GrB). Recombinant GrB also caused toxicity in neurons by caspase-dependent pathways but no toxicity was seen in astrocytes. The neurotoxicity was independent of perforin and could not be blocked by mannose-6-phosphate. However, GrB-induced neurotoxicity was sensitive to pertussis toxin, implicating the stimulation of Gi alpha protein-coupled receptors. GrB caused a decrease in cAMP levels but only modest increases in intracellular calcium. The effect on intracellular calcium could be markedly potentiated by stromal-derived factor 1 alpha. GrB-induced neurotoxicity could also be blocked by vitamin E and a neuroimmunophilin ligand. In conclusion, GrB may be an important mediator of neuronal injury in T cell-mediated neuroinflammatory disorders.	Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Internal Med, Baltimore, MD USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Johns Hopkins University; Johns Hopkins University; University of Kentucky	Nath, A (corresponding author), Johns Hopkins Univ, Dept Neurol, Pathol Bldg Rm 509,600 N Wolfe St, Baltimore, MD 21287 USA.	anath1@jhmi.edu	Calabresi, Peter A./AAF-2288-2019	Hahn, Katrin/0000-0002-6013-0072	NIMH NIH HHS [P01MH070056] Funding Source: Medline; NINDS NIH HHS [R01NS043990, R01NS039253] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH070056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039253, R01NS043990] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Adrain C, 2005, J BIOL CHEM, V280, P4663, DOI 10.1074/jbc.M410915200; Bauer J, 2002, CURR OPIN NEUROL, V15, P197, DOI 10.1097/00019052-200204000-00012; Bien CG, 2002, ANN NEUROL, V51, P311, DOI 10.1002/ana.10100; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Bjartmar C, 2001, NEUROLOGY, V57, P1248, DOI 10.1212/WNL.57.7.1248; Brex PA, 2000, NEUROLOGY, V54, P1689, DOI 10.1212/WNL.54.8.1689; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Comi G, 2002, NEUROLOGIA, V17, P244; Dalton CM, 2004, J NEUROL, V251, P407, DOI 10.1007/s00415-004-0332-4; Dalton CM, 2002, J NEUROL NEUROSUR PS, V73, P141, DOI 10.1136/jnnp.73.2.141; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Fox NC, 2000, NEUROLOGY, V54, P807, DOI 10.1212/WNL.54.4.807; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Giuliani F, 2003, J IMMUNOL, V171, P368, DOI 10.4049/jimmunol.171.1.368; Hardmeier M, 2003, ARCH NEUROL-CHICAGO, V60, P1736, DOI 10.1001/archneur.60.12.1736; Haughey NJ, 1999, J NEUROCHEM, V73, P1363, DOI 10.1046/j.1471-4159.1999.0731363.x; Hoftberger R, 2004, BRAIN PATHOL, V14, P43; Kalkers NF, 2002, ARCH NEUROL-CHICAGO, V59, P1572, DOI 10.1001/archneur.59.10.1572; Kalman B, 2003, NEUROMOL MED, V3, P147, DOI 10.1385/NMM:3:3:147; Kuhlmann T, 2002, BRAIN, V125, P2202, DOI 10.1093/brain/awf235; Kurschus FC, 2005, BLOOD, V105, P2049, DOI 10.1182/blood-2004-06-2180; Lazarini F, 2000, EUR J NEUROSCI, V12, P117, DOI 10.1046/j.1460-9568.2000.00894.x; Leist TP, 2001, ARCH NEUROL-CHICAGO, V58, P57, DOI 10.1001/archneur.58.1.57; LovettRacke AE, 1997, J NEUROIMMUNOL, V78, P162, DOI 10.1016/S0165-5728(97)00097-0; Lu FM, 2000, J NEUROL SCI, V177, P95, DOI 10.1016/S0022-510X(00)00343-9; MAGNAN A, 1995, ENFANCE, V1, P37; Martens PB, 1997, ARTHRITIS RHEUM, V40, P1106, DOI 10.1002/art.1780400615; Medana I, 2001, AM J PATHOL, V159, P809, DOI 10.1016/S0002-9440(10)61755-5; Miller RF, 2004, ACTA NEUROPATHOL, V108, P17, DOI 10.1007/s00401-004-0852-0; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Neumann H, 2002, TRENDS NEUROSCI, V25, P313, DOI 10.1016/S0166-2236(02)02154-9; Pashenkov M, 2003, J NEUROIMMUNOL, V135, P154, DOI 10.1016/S0165-5728(02)00441-1; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Pinkoski MJ, 2001, J BIOL CHEM, V276, P12060, DOI 10.1074/jbc.M009038200; Raja SM, 2003, CURR OPIN IMMUNOL, V15, P528, DOI 10.1016/S0952-7915(03)00111-0; Redmond IT, 2000, ACTA NEUROL SCAND, V102, P99, DOI 10.1034/j.1600-0404.2000.102002099.x; Scholz C, 1998, J IMMUNOL, V160, P1532; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; Tepe NM, 2000, J RECEPT SIGNAL TR R, V20, P75, DOI 10.3109/10799890009150038; Trapani JA, 2003, J CELL BIOL, V160, P223, DOI 10.1083/jcb.200210150; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; Trapani JA, 2001, GENOME BIOL, V2; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; van Leeuwen EMM, 2004, J IMMUNOL, V173, P1834, DOI 10.4049/jimmunol.173.3.1834; Vanhoose AM, 2004, NEUROSCI LETT, V370, P80, DOI 10.1016/j.neulet.2004.07.093; Wong ST, 1999, NEURON, V23, P787, DOI 10.1016/S0896-6273(01)80036-2; Wulff H, 2003, J CLIN INVEST, V111, P1703, DOI 10.1172/JCI200316921; Zivadinov R, 2004, J NEUROL SCI, V223, P185, DOI 10.1016/j.jns.2004.05.010; Zivadinov R, 2001, J NEUROL NEUROSUR PS, V70, P773, DOI 10.1136/jnnp.70.6.773; Zivadinov R, 2001, NEUROLOGY, V57, P1239, DOI 10.1212/WNL.57.7.1239	52	51	53	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1209	+		10.1096/fj.05-5022fje	http://dx.doi.org/10.1096/fj.05-5022fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636104				2022-12-28	WOS:000240210300028
J	Ishikawa, F; Shimazu, H; Shultz, LD; Fukata, M; Nakamura, R; Lyons, B; Shimoda, K; Shimoda, S; Kanemaru, T; Nakamura, KI; Ito, H; Kaji, Y; Perry, ACF; Harada, M				Ishikawa, Fumihiko; Shimazu, Hideki; Shultz, Leonard D.; Fukata, Mitsuhiro; Nakamura, Ryu; Lyons, Bonnie; Shimoda, Kazuya; Shimoda, Shinji; Kanemaru, Takaaki; Nakamura, Kei-ichiro; Ito, Hiroyuki; Kaji, Yoshikazu; Perry, Anthony C. F.; Harada, Mine			Purified human hematopoietic stem cells contribute to the generation of cardiomyocytes through cell fusion	FASEB JOURNAL			English	Article							ADULT BONE-MARROW; MYOCARDIAL INFARCTS; PROGENITOR CELLS; OVAL CELLS; MICE; DIFFERENTIATE; HEPATOCYTES; LIVER; PLASTICITY; BLOOD	To obtain insights into the cardiomyogenic potential of hematopoietic tissue, we intravenously (i.v.) injected purified hematopoietic stem/progenitor cells into newborn recipients that may fully potentiate the developmental plasticity of stem cells. Transplantation of mouse bone marrow ( BM) lineage antigen-negative (Lin(-)) cells resulted in the generation of the cells that displayed cardiomyocyte- specific antigenic profiles and contractile function when transplanted into syngeneic newborn recipients. To clarify the mechanism underlying the cardiomyogenic potential, green fluorescent protein (GFP)-labeled BM Lin(-)ScaI(+) hematopoietic progenitors were transplanted into neonatal mice constitutively expressing cyan fluorescence protein ( CFP). Lambda image acquisition and linear unmixing analysis using confocal microscopy successfully separated GFP and CFP, and revealed that odonor GFP(+) cardiomyocytes coexpressed host-derived CFP. We further reconstituted human hemopoietic- and immune systems in mice by injecting human cord blood (CB)-derived Lin(-)CD34(+)CD38(-) hematopoietic stem cells (HSCs) into neonatal T cell(-)B cell(-)NK cell(-) immune-deficient NOD/SCID/IL2r gamma(null) mice. Fluoroescence in situ hybridization analysis of recipient cardiac tissues demonstrated that human and murine chromosomes were colocalized in the same cardiomyocytes, indicating that cell fusion occurred between human hematopoietic progeny and mouse cardiomyocytes. These syngeneic- and xenogeneic neonatal transplantations provide compelling evidence that hematopoietic stem/progenitor cells contribute to the postnatal generation of cardiomyocytes through cell fusion, not through transdifferentiation.	Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosystem Sci, Higashi Ku, Fukuoka 8128582, Japan; Kurume Univ, Sch Med, Dept Anat 2, Kurume, Fukuoka 830, Japan; Zeiss Japan, Tokyo, Japan; RIKEN, Ctr Dev Biol, Lab Mammalian Mol Embryol, Kobe, Hyogo, Japan; Jackson Lab, Bar Harbor, ME 04609 USA; RIKEN, Ctr Allergy & Immunol, Res Unit Human Dis Model, Yokohama, Kanagawa, Japan	Kyushu University; Kurume University; RIKEN; Jackson Laboratory; RIKEN	Ishikawa, F (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosystem Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	f_ishika@intmed1.med.kyushu-u.ac.jp	石川, 文彦/L-4488-2014	Perry, Tony/0000-0003-3136-5355	NHLBI NIH HHS [HL077642] Funding Source: Medline; PHS HHS [A130389] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077642] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Dickinson ME, 2001, BIOTECHNIQUES, V31, P1272, DOI 10.2144/01316bt01; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Ishikawa F, 2002, EXP HEMATOL, V30, P488, DOI 10.1016/S0301-472X(02)00784-1; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Jang YY, 2004, NAT CELL BIOL, V6, P532, DOI 10.1038/ncb1132; Kajstura J, 2005, CIRC RES, V96, P127, DOI 10.1161/01.RES.0000151843.79801.60; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Matsuura K, 2004, J BIOL CHEM, V279, P11384, DOI 10.1074/jbc.M310822200; Matsuura K, 2004, J CELL BIOL, V167, P351, DOI 10.1083/jcb.200312111; Misteli T, 1997, NAT BIOTECHNOL, V15, P961, DOI 10.1038/nbt1097-961; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Orlic D, 2001, ANN NY ACAD SCI, V938, P221; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Prockop DJ, 2004, NEW ENGL J MED, V350, P2302, DOI 10.1056/NEJMcibr040806; Reinecke H, 2004, CIRC RES, V94, pE56, DOI 10.1161/01.RES.0000125294.04612.81; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wang X, 2003, P NATL ACAD SCI USA, V100, P11881, DOI 10.1073/pnas.1734199100; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	36	61	68	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					950	+		10.1096/fj.05-4863fje	http://dx.doi.org/10.1096/fj.05-4863fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585061				2022-12-28	WOS:000240157700018
J	Rastaldi, MP; Armelloni, S; Berra, S; Calvaresi, N; Corbelli, A; Giardino, LA; Li, M; Wang, GQ; Fornasieri, A; Villa, A; Heikkila, E; Soliymani, R; Boucherot, A; Cohen, CD; Kretzler, M; Nitsche, A; Ripamonti, M; Malgaroli, A; Pesaresi, M; Forloni, GL; Schlondoff, D; Holthofer, H; D'Amico, G				Rastaldi, Maria Pia; Armelloni, Silvia; Berra, Silvia; Calvaresi, Novella; Corbelli, Alessandro; Giardino, Laura Anna; Li, Min; Wang, Guo Quin; Fornasieri, Alessandro; Villa, Antonello; Heikkila, Eija; Soliymani, Rabah; Boucherot, Anissa; Cohen, Clemens David; Kretzler, Matthias; Nitsche, Almut; Ripamonti, Maddalena; Malgaroli, Antonio; Pesaresi, Marzia; Forloni, Gian Luigi; Schloendoff, Detlef; Holthofer, Harry; D'Amico, Giuseppe			Glomerular podocytes contain neuron-like functional synaptic vesicles	FASEB JOURNAL			English	Article						synaptic communication; exocytosis; endocytosis; visceral epithelial cells; renal glomerulus	DEPENDENT GLUTAMATE RELEASE; LONG-TERM POTENTIATION; SLIT DIAPHRAGM; PROTEIN; EXPRESSION; MOUSE; RAT; DIFFERENTIATION; ASTROCYTES; RECEPTORS	Although patients with chronic renal failure are increasing worldwide, many aspects of kidney biology remain to be elucidated. Recent research has uncovered several molecular properties of the glomerular filtration barrier, in which podocytes, highly differentiated, ramified cells that enwrap the glomerular basement membrane, have been reported to be mainly responsible for filter's selectivity. We previously described that podocytes express Rab3A, a GTPase restricted to cell types that are capable of highly regulated exocytosis, such as neuronal cells. Here, we first demonstrate by a proteomic study that Rab3A in podocytes coimmmunoprecipitates with molecules once thought to be synapse specific. We then show that podocytes possess structures resembling synaptic vesicles, which contain glutamate, coexpress Rab3A and synaptotagmin 1, and undergo spontaneous and stimulated exocytosis and recycling, with glutamate release. Finally, from the results of a cDNA microarray study, we describe the presence of a series of neuron- and synapse-specific molecules in normal human glomeruli and confirm the glomerular protein expression of both metabotropic and ionotropic glutamate receptors. These data point toward a synaptic-like mechanism of communication among glomerular cells, which perfectly fits with the molecular composition of the glomerular filter and puts in perspective several previous observations, proposing a different working hypothesis for understanding glomerular signaling dynamics.	San Carlos Borromeo Hosp, Renal Immunopathol Lab, Associaz Nuova Nefrol & Fdn Amico Ric Malattie Re, Dept Nephrol & Immunol, I-20153 Milan, Italy; Univ Milan, Microscopy & Image Anal Consortium, Dept Neurosci & Biomed Techol, Monza, Italy; Biomedicum, Helsinki, Finland; Biomedicum, Prot Chem Unit, Helsinki, Finland; Univ Munich, Med Policlin, Munich, Germany; Univ Vita Salute S Raffaele, Neurobiol Learning Unit, Segrate, Italy; Sanofi Aventis, Frankfurt, Germany; Mario Negri Inst Pharmacol Res, Biol Neurodegenerat Dis Lab, I-20157 Milan, Italy	San Carlo Borromeo Hospital; University of Milan; University of Helsinki; University of Helsinki; University of Munich; Sanofi-Aventis; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Rastaldi, MP (corresponding author), San Carlos Borromeo Hosp, Renal Immunopathol Lab, Associaz Nuova Nefrol & Fdn Amico Ric Malattie Re, Dept Nephrol & Immunol, Via Pio 2,3, I-20153 Milan, Italy.	mp.rastaldi@fastwebnet.it	Corbelli, Alessandro/ABG-3900-2020; Villa, Antonello/B-4781-2012; Berra, Silvia/E-2863-2015; Forloni, Gianluigi/AAB-2115-2020; Malgaroli, Antonio/I-5090-2013; Li, Min/AAL-7828-2021; Ripamonti, Maddalena/AAN-2430-2020; Li, Min/AFJ-8435-2022; Armelloni, Silvia/AAP-8617-2021; Li, Min/AAF-5252-2022	Corbelli, Alessandro/0000-0001-8545-8050; Berra, Silvia/0000-0003-1151-7040; Forloni, Gianluigi/0000-0001-5374-3914; Malgaroli, Antonio/0000-0003-3758-7477; Li, Min/0000-0003-1350-9909; Ripamonti, Maddalena/0000-0002-2664-8898; Armelloni, Silvia/0000-0001-6431-2642; Villa, Antonello/0000-0002-3820-8072				Ahola H, 2003, J AM SOC NEPHROL, V14, P1731, DOI 10.1097/01.ASN.0000075553.33781.9F; APVENSTADT H, 2003, PHYSIOL REV, V83, P253; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Bek M, 1999, NEPHROL DIAL TRANSPL, V14, P581, DOI 10.1093/ndt/14.3.581; Beltran PJ, 2003, J COMP NEUROL, V456, P384, DOI 10.1002/cne.10532; Benson DL, 2001, NAT REV NEUROSCI, V2, P899, DOI 10.1038/35104078; Benzing T, 2004, J AM SOC NEPHROL, V15, P1382, DOI 10.1097/01.ASN.0000130167.30769.55; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Cohen CD, 2005, J AM SOC NEPHROL, V16, P1958, DOI 10.1681/ASN.2005020204; Cohen CD, 2002, KIDNEY INT, V61, P133, DOI 10.1046/j.1523-1755.2002.00113.x; Cousin MA, 1999, J NEUROCHEM, V73, P2227, DOI 10.1046/j.1471-4159.1999.0732227.x; Gloy J, 2000, AM J PHYSIOL-RENAL, V278, pF999, DOI 10.1152/ajprenal.2000.278.6.F999; Hinoi E, 2004, EUR J BIOCHEM, V271, P1, DOI 10.1046/j.1432-1033.2003.03907.x; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; Kobayashi Naoto, 2004, Anatomical Science International, V79, P1, DOI 10.1111/j.1447-073x.2004.00066.x; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Miner JH, 2005, J AM SOC NEPHROL, V16, P857, DOI 10.1681/ASN.2004121139; MUNDEL P, 1991, J HISTOCHEM CYTOCHEM, V39, P1047, DOI 10.1177/39.8.1856454; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Nitschke R, 2001, J AM SOC NEPHROL, V12, P678, DOI 10.1681/ASN.V124678; OConnell KL, 1997, ELECTROPHORESIS, V18, P349, DOI 10.1002/elps.1150180309; Peitsch WK, 2003, J AM SOC NEPHROL, V14, P1452, DOI 10.1097/01.ASN.0000069222.63700.DE; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Raats CJI, 2000, AM J PATHOL, V156, P1749, DOI 10.1016/S0002-9440(10)65046-8; Rastaldi MP, 2003, AM J PATHOL, V163, P889, DOI 10.1016/S0002-9440(10)63449-9; REEVES W, 1978, LAB INVEST, V39, P90; RODEWALD R, 1974, J CELL BIOL, V60, P423, DOI 10.1083/jcb.60.2.423; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schluter OM, 2004, J NEUROSCI, V24, P6629, DOI 10.1523/JNEUROSCI.1610-04.2004; Shen K, 2003, CELL, V112, P619, DOI 10.1016/S0092-8674(03)00113-2; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Yamagata M, 2003, CURR OPIN CELL BIOL, V15, P621, DOI 10.1016/S0955-0674(03)00107-8	34	81	88	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					976	+		10.1096/fj.05-4962fje	http://dx.doi.org/10.1096/fj.05-4962fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585060				2022-12-28	WOS:000240157700027
J	Cheon, SS; Wei, QX; Gurung, A; Youn, A; Bright, T; Poon, R; Whetstone, H; Guha, A; Alman, BA				Cheon, Sophia S.; Wei, Qingxia; Gurung, Ananta; Youn, Andrew; Bright, Tamara; Poon, Raymond; Whetstone, Heather; Guha, Abhijit; Alman, Benjamin A.			Beta-catenin regulates wound size and mediates the effect of TGF-beta in cutaneous healing	FASEB JOURNAL			English	Article						beta-catenin; wound healing; transgenic mice	GROWTH-FACTOR-BETA; DEPENDENT TRANSCRIPTIONAL ACTIVATION; MARROW-DERIVED CELLS; MICE LACKING SMAD3; AGGRESSIVE FIBROMATOSIS; WNT; DIFFERENTIATION; EXPRESSION; PROLIFERATION; GENE	After cutaneous injury, a variety of cell types are activated to reconstitute the epithelial and dermal components of the skin. beta-Catenin plays disparate roles in keratinocytes and fibroblasts, inhibiting keratinocyte migration and activating fibroblast proliferation, suggesting that beta-catenin could either inhibit or enhance the healing process. How beta-catenin functions in concert with other signaling pathways important in the healing process is unknown. Wound size was examined in mice expressing conditional null or conditional stabilized alleles of beta-catenin, regulated by an adenovirus expressing cre-recombinase. The size of the wounds in the mice correlated with the protein level of beta-catenin. Using mice expressing these conditional alleles, we found that the wound phenotype imparted by Smad3 deficiency and by the injection of TGF beta before wounding is mediated in part by beta-catenin. TGF beta was not able to regulate proliferation in beta-catenin null fibroblasts, whereas keratinocyte proliferation rate was independent of beta-catenin. When mice are treated with lithium, beta-catenin-mediated signaling was activated in cutaneous wounds, which healed with a larger size. These results demonstrate a crucial role for beta-catenin in regulating cutaneous wound size. Furthermore, these data implicate mesenchymal cells as playing a critical role regulating wound size.-Cheon, S. S., Wei, Q., Gurung, A., Youn, A., Bright, T., Poon, R., Whetstone, H., Guha, A., Alman, B. A. Beta-catenin regulates wound size and mediates the effect of TGF-beta in cutaneous healing.	Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; Hosp Sick Children, Program Canc Res, Arthur & Sonia Labatts Brain Tumor Ctr, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Alman, BA (corresponding author), 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	benjamin.alman@sickkids.ca						Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Badiavas EV, 2003, J CELL PHYSIOL, V196, P245, DOI 10.1002/jcp.10260; Behrens J, 2000, J CELL SCI, V113, P911; Brault V, 2001, DEVELOPMENT, V128, P1253; Cheon S, 2005, LAB INVEST, V85, P416, DOI 10.1038/labinvest.3700237; Cheon SS, 2004, EXP CELL RES, V293, P267, DOI 10.1016/j.yexcr.2003.09.029; Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016; De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753; Dehpour AR, 2002, PHARMACOL TOXICOL, V90, P89, DOI 10.1034/j.1600-0773.2002.900206.x; Denys H, 2004, BRIT J CANCER, V90, P1443, DOI 10.1038/sj.bjc.6601661; Derfoul A, 2004, DIFFERENTIATION, V72, P209, DOI 10.1111/j.1432-0436.2004.07205003.x; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Falanga V, 2004, WOUND REPAIR REGEN, V12, P320, DOI 10.1111/j.1067-1927.2004.012316.x; Fathke C, 2004, STEM CELLS, V22, P812, DOI 10.1634/stemcells.22-5-812; Flanders KC, 2002, AM J PATHOL, V160, P1057, DOI 10.1016/S0002-9440(10)64926-7; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Harada N, 2002, CANCER RES, V62, P1971; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Kong Y, 2004, CANCER RES, V64, P5795, DOI 10.1158/0008-5472.CAN-03-3112; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; McClain SA, 1996, AM J PATHOL, V149, P1257; MIESCHER GC, 1989, IMMUNOL LETT, V23, P113, DOI 10.1016/0165-2478(89)90122-3; MONTAGNA W, 1987, AM J DERMATOPATH, V9, P26, DOI 10.1097/00000372-198702000-00006; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Philipp K, 2005, INT J MOL MED, V15, P299; Poon R, 2001, ONCOGENE, V20, P451, DOI 10.1038/sj.onc.1204107; Posthaus H, 2002, J CELL SCI, V115, P4587, DOI 10.1242/jcs.00141; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Scheid A, 2000, EXP PHYSIOL, V85, P687, DOI 10.1017/S0958067000021035; Schiller M, 2004, J DERMATOL SCI, V35, P83, DOI 10.1016/j.jdermsci.2003.12.006; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stojadinovic O, 2005, AM J PATHOL, V167, P59, DOI 10.1016/S0002-9440(10)62953-7; Sylvester KG, 2000, WOUND REPAIR REGEN, V8, P36, DOI 10.1046/j.1524-475x.2000.00036.x; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	49	169	184	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					692	701		10.1096/fj.05-4759com	http://dx.doi.org/10.1096/fj.05-4759com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581977				2022-12-28	WOS:000240130900015
J	Budas, GR; Sukhodub, A; Alessi, DR; Jovanovic, A				Budas, Grant R.; Sukhodub, Andrey; Alessi, Dario R.; Jovanovic, Aleksandar			3 ' phosphoinositide-dependent kinase-1 is essential for ischemic preconditioning of the myocardium	FASEB JOURNAL			English	Article						GSK-3; hypoxia; ischemia; mitochondria; cardioprotection	K-ATP CHANNELS; GLYCOGEN-SYNTHASE KINASE-3-BETA; SIGNALING PATHWAYS; INSULIN; PDK1; ACTIVATION; PHOSPHORYLATION; PHYSIOLOGY; MECHANISM; RABBIT	Brief periods of ischemia and reperfusion that precede sustained ischemia lead to a reduction in myocardial infarct size. This phenomenon, known as ischemic preconditioning, is mediated by signaling pathway(s) that are yet to be fully defined. 3'-phosphoinositide- dependent kinase-1 (PDK1) has been implicated in numerous cellular processes. However, the involvement of PDK1 in preconditioning has yet to be elucidated. Studying PDK1 is not as straightforward as it is for the majority of kinases, due to the lack of a specific inhibitor of PDK1. Therefore, we have taken advantage of PDK1 hypomorphic mutant mice with reduced expression of PDK1 to study the role of PDK1 in preconditioning. Whole heart and single cell models of preconditioning demonstrated that the hearts and cardiac cells from PDK1 hypomorphic mice could not be preconditioned. The cardioprotective effect of PDK1 was not related to the effect that preconditioning has on sarcolemmal membrane action potential as revealed by di-8-ANEPPS, a sarcolemmalpotential sensitive dye, and laser confocal microscopy. In contrast, experiments with JC-1, a mitochondrial membrane potential-sensitive dye, has demonstrated that intact PDK1 levels were required for preconditioningmediated regulation of mitochondrial membrane potential. Western blotting combined with functional experiments have shown that intact PDK1 levels were required for preconditioning-induced phosphorylation of protein kinase B (PKB), glycogen synthase kinase-3 beta (GSK-3 beta), and cardioprotection. We conclude that PDK1 mediates preconditioning in the heart by regulating activating PKB-GSK-3 beta to regulate mitochondrial but not sarcolemmal membrane potential. 3'phosphoinositidedependent kinase-1 (PDK1) is essential for ischemic preconditioning of the myocardium.-Budas, G. R., Sukhodub, A., Alessi, D. R., Jovanovic, A. 3'phosphoinositidedependent kinase-1 is essential for ischemic preconditioning of the myocardium.	Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ Dundee, MRC, Prot Phosphorylat Unit, Sch Life Sci, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Jovanovic, A (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.	a.jovanovic@dundee.ac.uk	Jovanovic, Aleksandar/A-4482-2008	Jovanovic, Aleksandar/0000-0002-1214-9318; Alessi, Dario/0000-0002-2140-9185	MRC [G0400608, MC_U127015387] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [S18744] Funding Source: Medline; British Heart Foundation [PG/04/096/17627, PG/02/117/14488, PG/04/086/17410] Funding Source: Medline; Medical Research Council [MC_U127015387, G0400608(71317), G0400608] Funding Source: Medline; Wellcome Trust [059528/Z/99/Z/JMW/CP/JF] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; BILLMAN GE, 1994, CARDIOVASC RES, V28, P762, DOI 10.1093/cvr/28.6.762; Budas GR, 2004, FASEB J, V18, P1046, DOI 10.1096/fj.04-1602fje; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Du QY, 2006, FASEB J, V20, P1131, DOI 10.1096/fj.05-5483com; Farese RV, 2005, EXP BIOL MED, V230, P593; Gross GJ, 2003, AM J PHYSIOL-HEART C, V285, pH921, DOI 10.1152/ajpheart.00421.2003; Halestrap AP, 2004, CARDIOVASC RES, V61, P372, DOI 10.1016/S0008-6363(03)00533-9; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hanley PJ, 2005, J MOL CELL CARDIOL, V39, P17, DOI 10.1016/j.yjmcc.2005.04.002; Hausenloy DJ, 2002, CARDIOVASC RES, V55, P534, DOI 10.1016/S0008-6363(02)00455-8; Javadov SA, 2003, J PHYSIOL-LONDON, V549, P513, DOI 10.1113/jphysiol.2003.034231; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Kane GC, 2005, J MOL CELL CARDIOL, V38, P937, DOI 10.1016/j.yjmcc.2005.02.026; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; LIU YG, 1994, J MOL CELL CARDIOL, V26, P661, DOI 10.1006/jmcc.1994.1078; Minners J, 2001, CIRC RES, V89, P787, DOI 10.1161/hh2101.098372; Mirshamsi S, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-54; Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; O'Rourke B, 2005, PHYSIOLOGY, V20, P303, DOI 10.1152/physiol.00020.2005; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SPEECHLYDICK ME, 1994, CIRC RES, V75, P586, DOI 10.1161/01.RES.75.3.586; Sugden PH, 2001, ANN MED, V33, P611; SUKHODUB A, 2006, IN PRESS J CELL PHYS; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Tong HY, 2000, CIRC RES, V87, P309, DOI 10.1161/01.RES.87.4.309; Tong HY, 2002, CIRC RES, V90, P377, DOI 10.1161/01.RES.0000012567.95445.55; Uchiyama T, 2004, CIRCULATION, V109, P3042, DOI 10.1161/01.CIR.0000130647.29030.90; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Verkerk AO, 1996, J MOL CELL CARDIOL, V28, P2443, DOI 10.1006/jmcc.1996.0237; Weiss JN, 2003, CIRC RES, V93, P292, DOI 10.1161/01.RES.0000087542.26971.D4; Wick MJ, 2003, J BIOL CHEM, V278, P42913, DOI 10.1074/jbc.M304172200; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003; Zhuo ML, 2005, INT J BIOCHEM CELL B, V37, P751, DOI 10.1016/j.biocel.2004.10.008	41	38	38	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2556	+		10.1096/fj.06-6252fje	http://dx.doi.org/10.1096/fj.06-6252fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077284	Green Accepted			2022-12-28	WOS:000242490700022
J	Browne, CD; Hindmarsh, EJ; Smith, JW				Browne, Cecille D.; Hindmarsh, Elizabeth J.; Smith, Jeffrey W.			Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor	FASEB JOURNAL			English	Article						VEGF; KDR; neovascularization	GROWTH-FACTOR; ANTITUMOR-ACTIVITY; FAS EXPRESSION; CANCER; OVEREXPRESSION; ARCHITECTURE; SYNTHETASE; APOPTOSIS; COMPLEX; MODEL	Orlistat, an antiobesity drug, is cytostatic and cytotoxic to tumor cells (1). The antitumor activity of orlistat can be attributed to its ability to inhibit the thioesterase domain of fatty acid synthase (FAS). The objective of the present study was to test the effect of orlistat on endothelial cell proliferation and angiogenesis. Orlistat inhibits endothelial cell FAS, blocks the synthesis of fatty acids, and prevents endothelial cell proliferation. More significantly, orlistat inhibits human neovascularization in an ex vivo assay, which suggests that it may be useful as an antiangiogenic drug. The mechanism of these effects can be traced to the fact that orlistat prevents the display of the vascular endothelial growth factor (VEGF) receptor (VEGFR2/KDR/Flk1) on the endothelial cell surface. Thus, orlistat is an antiangiogenic agent with a novel mechanism of action.	Burke Med Res Inst, Canc Res Ctr, La Jolla, CA 92037 USA		Smith, JW (corresponding author), Burke Med Res Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	liesa.hindmarsh@anu.edu.au; jsmith@burnham.org			NCI NIH HHS [P01 CA82713-06, R01 CA106582-02] Funding Source: Medline; NCRR NIH HHS [U54 RR020843-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106582, P01CA082713] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Bandyopadhyay S, 2005, ONCOGENE, V24, P5389, DOI 10.1038/sj.onc.1208555; Brown KJ, 1996, LAB INVEST, V75, P539; Chirala SS, 2001, P NATL ACAD SCI USA, V98, P3104, DOI 10.1073/pnas.051635998; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DEMETRI GDV, 2005, 2005 ASCO ANN M ORL; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Furuya Y, 1997, ANTICANCER RES, V17, P4589; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Heiligtag SJ, 2002, CELL DEATH DIFFER, V9, P1017, DOI 10.1038/sj.cdd.4401055; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.can-03-3645; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Li JN, 2001, CANCER RES, V61, P1493; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; MATTICK JS, 1983, J BIOL CHEM, V258, P5300; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Menendez JA, 2005, MED HYPOTHESES, V64, P997, DOI 10.1016/j.mehy.2004.09.027; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; MOTZER RJB, 2005, 2005 ASCO ANN M ORL; Nakamura I, 1999, INT J MOL MED, V4, P381; Patricelli MP, 2001, PROTEOMICS, V1, P1067, DOI 10.1002/1615-9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; Rangan VS, 2001, BIOCHEMISTRY-US, V40, P10792, DOI 10.1021/bi015535z; Rossi S, 2003, MOL CANCER RES, V1, P707; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; TSUKAMOTO Y, 1983, J BIOL CHEM, V258, P5312; *USFDA, 2004, FDA NEWS; Wang Y, 2001, CANCER LETT, V167, P99, DOI 10.1016/S0304-3835(01)00464-5; WITTE K, 1998, HLTH RISK COMMUNICAT, V2, P1; Zeng HY, 2003, J BIOL CHEM, V278, P20738, DOI 10.1074/jbc.M209712200	36	76	85	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2027	2035		10.1096/fj.05-5404com	http://dx.doi.org/10.1096/fj.05-5404com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012255				2022-12-28	WOS:000241156900011
J	Falagas, ME; Zarkadoulia, EA; Bliziotis, IA; Samonis, G				Falagas, Matthew E.; Zarkadoulia, Efstathia A.; Bliziotis, Ioannis A.; Samonis, George			Science in Greece: from the age of Hippocrates to the age of the genome	FASEB JOURNAL			English	Article									Alfa Inst Biomed Sci, Athens, Greece; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Univ Crete, Sch Med, Dept Med, Iraklion, Crete, Greece	Alfa Institute Of Biomedical Sciences; Tufts University; University of Crete	Falagas, ME (corresponding author), Alfa Inst Biomed Sci, 9 Neapoleos St, Maroursi 15123, Greece.	m.falagas@aibs.gr	Bliziotis, Ioannis/C-3801-2011	Bliziotis, Ioannis/0000-0002-3825-4167				Angeletti L R, 1991, Forum (Genova), V1, P1; Bliziotis IA, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-16; Cheng TO, 2001, INT J CARDIOL, V81, P219, DOI 10.1016/S0167-5273(01)00571-X; Cheng TO, 2001, AM HEART J, V141, P173, DOI 10.1067/mhj.2001.112490; EKNOYAN G, 1988, AM J NEPHROL, V8, P498, DOI 10.1159/000167669; GAHHOS F, 1984, HEAD NECK SURG, V6, P1007, DOI 10.1002/hed.2890060605; LASCARATOS J, 1988, DOC OPHTHALMOL, V68, P35; Luce JV, 2001, IRISH J MED SCI, V170, P200, DOI 10.1007/BF03173893; Manolidis LS, 2002, ORL J OTO-RHINO-LARY, V64, P152, DOI 10.1159/000057796; Marketos SG, 1999, SPINE, V24, P1381, DOI 10.1097/00007632-199907010-00018; Soteriades ES, 2006, FASEB J, V20, P29, DOI 10.1096/fj.05-4711lsf	11	14	16	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					1946	1950		10.1096/fj.06-1002ufm	http://dx.doi.org/10.1096/fj.06-1002ufm			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012246				2022-12-28	WOS:000241156900002
J	Morris, GE; Parker, LC; Ward, JR; Jones, EC; Whyte, MKB; Brightling, CE; Bradding, P; Dower, SK; Sabroe, I				Morris, Gavin E.; Parker, Lisa C.; Ward, Jon R.; Jones, Elizabeth C.; Whyte, Moira K. B.; Brightling, Christopher E.; Bradding, Peter; Dower, Steven K.; Sabroe, Ian			Cooperative molecular and cellular networks regulate Toll-like receptor-dependent inflammatory responses	FASEB JOURNAL			English	Article						airway smooth muscle; TLR; asthma	DOUBLE-STRANDED-RNA; AIRWAY SMOOTH-MUSCLE; HOUSE-DUST ENDOTOXIN; MAST-CELLS; DIFFERENTIAL EXPRESSION; CHEMOKINE RECEPTORS; HUMAN LUNG; T-CELLS; RECOGNITION; ACTIVATION	Viral and bacterial pathogens cause inflammation via Toll-like receptor (TLR) signaling. We have shown that effective responses to LPS may depend on cooperative interactions between TLR-expressing leukocytes and TLR-negative tissue cells. The aim of this work was to determine the roles of such networks in response to agonists of TLRs associated with antiviral and autoimmune responses. The TLR3 agonist poly( I: C) activated epithelial cells, primary endothelial cells, and two types of primary human smooth muscle cells ( airway [ASMC] and vascular) directly, while the TLR7/8 agonist R848 required the presence of leukocytes to activate ASMC. In keeping with these data, ASMC expressed TLR3 but not TLR7 or TLR8. Activation of ASMC by poly( I: C) induced a specific cytokine repertoire characterized by induction of CXCL10 generation and the potential to recruit mast cells. We subsequently explored the ability of TLR agonists to cooperate in the induction of inflammation. Dual stimulation with LPS and poly( I: C) caused enhanced cytokine generation from epithelial and smooth muscle cells when in the presence of leukocytes. Thus, inflammatory responses to pathogens are regulated by networks in which patterns of TLR expression and colocalization of tissue cells and leukocytes are critical.	Univ Sheffield, Acad Unit Resp Med, Div Genom Med, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Acad Unit Cell Biol, Div Genom Med, Sheffield S10 2JF, S Yorkshire, England; Leicester Warwick Med Sch, Inst Lung Hlth, Dept Infect Inflammat & Immun, Leicester, Leics, England; Univ Hosp Leicester, Leicester, Leics, England	University of Sheffield; University of Sheffield; University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester	Sabroe, I (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Acad Unit Resp Med, Div Genom Med, M Floor, Sheffield S10 2JF, S Yorkshire, England.	i.sabroe@sheffield.ac.uk	Sabroe, Ian/AAE-5858-2019; Sabroe, Ian/I-5981-2013; Whyte, Moira/E-6210-2010	Sabroe, Ian/0000-0001-9750-8975; brightling, chris/0000-0002-9345-4903; Bradding, Peter/0000-0001-8403-0319; Morris, Gavin/0000-0003-4054-6959; dower, steve/0000-0002-4675-4225	Medical Research Council [G116/170] Funding Source: Medline; MRC [G116/170] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Applequist SE, 2002, INT IMMUNOL, V14, P1065, DOI 10.1093/intimm/dxf069; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brightling CE, 2005, AM J RESP CRIT CARE, V171, P1103, DOI 10.1164/rccm.200409-1220OC; Brightling CE, 2005, J LEUKOCYTE BIOL, V77, P759, DOI 10.1189/jlb.0904511; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Campbell JJ, 2001, J IMMUNOL, V166, P2842, DOI 10.4049/jimmunol.166.4.2842; de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Doyle SE, 2003, J IMMUNOL, V170, P3565, DOI 10.4049/jimmunol.170.7.3565; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Hakonarson H, 1998, J CLIN INVEST, V102, P1732, DOI 10.1172/JCI4141; Harii N, 2005, MOL ENDOCRINOL, V19, P1231, DOI 10.1210/me.2004-0100; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hochrein H, 2004, P NATL ACAD SCI USA, V101, P11416, DOI 10.1073/pnas.0403555101; Hollingsworth JW, 2005, AM J RESP CRIT CARE, V171, P806, DOI 10.1164/rccm.200407-953OC; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lee HK, 2006, IMMUNITY, V24, P153, DOI 10.1016/j.immuni.2005.12.012; Li K, 2005, J BIOL CHEM, V280, P16739, DOI 10.1074/jbc.M414139200; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Matsushima H, 2004, J IMMUNOL, V173, P531, DOI 10.4049/jimmunol.173.1.531; Morris GE, 2005, AM J RESP CRIT CARE, V171, P814, DOI 10.1164/rccm.200403-406OC; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Orinska Z, 2005, BLOOD, V106, P978, DOI 10.1182/blood-2004-07-2656; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Parker LC, 2004, J IMMUNOL, V172, P4977, DOI 10.4049/jimmunol.172.8.4977; Patole PS, 2005, J AM SOC NEPHROL, V16, P1326, DOI 10.1681/ASN.2004100820; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Rudd BD, 2005, J VIROL, V79, P3350, DOI 10.1128/JVI.79.6.3350-3357.2005; Sabroe I, 2003, J IMMUNOL, V171, P1630, DOI 10.4049/jimmunol.171.4.1630; Sabroe I, 2002, J IMMUNOL, V168, P4701, DOI 10.4049/jimmunol.168.9.4701; Schilling D, 2002, J IMMUNOL, V169, P5874, DOI 10.4049/jimmunol.169.10.5874; Schreiner B, 2005, FASEB J, V19, P118, DOI 10.1096/fj.05-4342fje; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305, DOI 10.1164/ajrccm.163.2.ed2000a; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Tissari J, 2005, J IMMUNOL, V174, P4289, DOI 10.4049/jimmunol.174.7.4289; Triantafilou K, 2005, CELL MICROBIOL, V7, P1117, DOI 10.1111/j.1462-5822.2005.00537.x; Vijay-Kumar M, 2005, J IMMUNOL, V174, P6322, DOI 10.4049/jimmunol.174.10.6322; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249	54	70	74	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2153	+		10.1096/fj.06-5910fje	http://dx.doi.org/10.1096/fj.06-5910fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935934				2022-12-28	WOS:000241156900047
J	Richardson, JR; Caudle, WM; Wang, MZ; Dean, ED; Pennell, KD; Miller, GW				Richardson, Jason R.; Caudle, W. Michael; Wang, Minzheng; Dean, E. Danielle; Pennell, Kurt D.; Miller, Gary W.			Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease	FASEB JOURNAL			English	Article						PD; pesticides; MPTP; alpha-synuclein; dopamine transporter; vesicular monoamine transporter 2	SUBSTANTIA-NIGRA; MPTP NEUROTOXICITY; MONOAMINE NEURONS; GENE-EXPRESSION; MOUSE STRIATUM; RISK-FACTORS; EARLY-LIFE; IN-VITRO; TRANSPORTER; MIDBRAIN	Exposure to pesticides has been suggested to increase the risk of Parkinson's disease (PD), but the mechanisms responsible for this association are not clear. Here, we report that perinatal exposure of mice during gestation and lactation to low levels of dieldrin (0.3, 1, or 3 mg/ kg every 3 days) alters dopaminergic neurochemistry in their offspring and exacerbates MPTP toxicity. At 12 wk of age, protein and mRNA levels of the dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) were increased by perinatal dieldrin exposure in a dose-related manner. We then administered MPTP (2 x 10 mg/ kg s. c) at 12 wk of age and observed a greater reduction of striatal dopamine in dieldrin-exposed offspring, which was associated with a greater DAT: VMAT2 ratio. Additionally, dieldrin exposure during development potentiated the increase in GFAP and alpha-synuclein levels induced by MPTP, indicating increased neurotoxicity. In all cases there were greater effects observed in the male offspring than the female, similar to that observed in human cases of PD. These data suggest that developmental exposure to dieldrin leads to persistent alterations of the developing dopaminergic system and that these alterations induce a "silent" state of dopamine dysfunction, thereby rendering dopamine neurons more vulnerable later in life.	Emory Univ, Ctr Neurodegenerat Dis, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; Emory Univ, Dept Environm & Occupat Hlth, Atlanta, GA 30322 USA; Georgia Inst Technol, Sch Civil & Environm Engn, Atlanta, GA 30332 USA	Emory University; Rollins School Public Health; Emory University; University System of Georgia; Georgia Institute of Technology	Miller, GW (corresponding author), Emory Univ, Ctr Neurodegenerat Dis, Rollins Sch Publ Hlth, Whitehead Biomd Res,Bldg,Rm 505,615 Michael St, Atlanta, GA 30322 USA.	jricha3@eohsi.rutgers.edu; gary.miller@emory.edu	Richardson, Jason/AAG-5281-2019; Pennell, Kurt/ABD-8337-2020; Pennell, Kurt D/F-6862-2010	Richardson, Jason/0000-0001-6521-610X; Pennell, Kurt D/0000-0002-5788-6397	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES012870, U54ES012068, F32ES013457, R21ES012315, R21ES013828] Funding Source: NIH RePORTER; NIEHS NIH HHS [F32ES013457, T32 ES012870, R21 ES012315, R21ES013828, U54 ES012068] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baldereschi M, 2003, ACTA NEUROL SCAND, V108, P239, DOI 10.1034/j.1600-0404.2003.00128.x; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Barlow BK, 2004, DEV NEUROSCI-BASEL, V26, P11, DOI 10.1159/000080707; Brosenitsch TA, 2001, J NEUROSCI, V21, P2571, DOI 10.1523/JNEUROSCI.21-08-02571.2001; Caudle WM, 2005, NEUROTOXICOLOGY, V26, P721, DOI 10.1016/j.neuro.2004.09.003; Corrigan FM, 1998, EXP NEUROL, V150, P339, DOI 10.1006/exnr.1998.6776; Corrigan FM, 2000, J TOXICOL ENV HEAL A, V59, P229, DOI 10.1080/009841000156907; Crispino M, 1998, MOL BRAIN RES, V59, P178, DOI 10.1016/S0169-328X(98)00143-0; Crofton KM, 2000, TOXICOL SCI, V57, P131, DOI 10.1093/toxsci/57.1.131; Donovan DM, 1999, MOL BRAIN RES, V73, P37, DOI 10.1016/S0169-328X(99)00235-1; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; FEKETE MIK, 1980, EUR J PHARMACOL, V64, P231, DOI 10.1016/0014-2999(80)90230-7; FLEMING L, 1994, ANN NEUROL, V36, P100, DOI 10.1002/ana.410360119; FORNSTEDT B, 1989, J NEURAL TRANSM, V76, P155, DOI 10.1007/BF01578755; Fumagalli F, 1999, J NEUROSCI, V19, P2424; Gainetdinov RR, 1997, J NEUROCHEM, V69, P1322; Gainetdinov RR, 1998, J NEUROCHEM, V70, P1973; GIOVANNI A, 1991, J PHARMACOL EXP THER, V257, P691; Hermanson E, 2003, EXP CELL RES, V288, P324, DOI 10.1016/S0014-4827(03)00216-7; Jorgenson JL, 2001, ENVIRON HEALTH PERSP, V109, P113, DOI 10.2307/3434852; Kanthasamy AG, 2005, NEUROTOXICOLOGY, V26, P701, DOI 10.1016/j.neuro.2004.07.010; Lauder JM, 1998, PERSPECT DEV NEUROBI, V5, P247; Le Couteur DG, 1999, BIOMED PHARMACOTHER, V53, P122, DOI 10.1016/S0753-3322(99)80077-8; Ling ZD, 2002, MOVEMENT DISORD, V17, P116, DOI 10.1002/mds.10078; Liu JP, 1997, J NEUROSCI, V17, P2420; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Logroscino G, 2005, ENVIRON HEALTH PERSP, V113, P1234, DOI 10.1289/ehp.7573; Marek K, 2001, NEUROLOGY, V57, P2089, DOI 10.1212/WNL.57.11.2089; MARTYN CN, 1995, J NEUROL SCI, V132, P201, DOI 10.1016/0022-510X(95)00148-U; Miller DB, 1998, ANN NY ACAD SCI, V844, P153, DOI 10.1111/j.1749-6632.1998.tb08230.x; Miller GW, 1999, NEUROTOXICOLOGY, V20, P631; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Narahashi T, 1995, TOXICOL LETT, V82-3, P239, DOI 10.1016/0378-4274(95)03482-X; Narahashi T, 1996, PHARMACOL TOXICOL, V79, P1, DOI 10.1111/j.1600-0773.1996.tb00234.x; Okada H, 2004, J NEUROCHEM, V89, P7, DOI 10.1111/j.1471-4159.2004.02271.x; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Paladini CA, 1999, SYNAPSE, V32, P165, DOI 10.1002/(SICI)1098-2396(19990601)32:3<165::AID-SYN3>3.0.CO;2-N; Park M, 2005, NEUROLOGY, V64, P1047, DOI 10.1212/01.WNL.0000154532.98495.BF; Pohl HR, 2000, TOXICOL IND HEALTH, V16, P65, DOI 10.1191/074823300678827672; POLISHUK ZW, 1977, PESTIC MONIT J, V10, P121; Priyadarshi A, 2000, NEUROTOXICOLOGY, V21, P435; Purkerson-Parker S, 2001, TOXICOL SCI, V64, P216, DOI 10.1093/toxsci/64.2.216; Rabinovic AD, 2000, NEUROSCIENCE, V101, P67, DOI 10.1016/S0306-4522(00)00293-1; REINHARD JF, 1988, NEUROSCI LETT, V95, P246, DOI 10.1016/0304-3940(88)90665-9; Richardson JR, 2004, TOXICOL LETT, V148, P29, DOI 10.1016/j.toxlet.2003.12.006; ROGAN WJ, 1994, ENVIRON HEALTH PERSP, V102, P89, DOI 10.1289/ehp.94102s1189; SAVAGE EP, 1981, AM J EPIDEMIOL, V113, P413, DOI 10.1093/oxfordjournals.aje.a113109; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328, DOI 10.1212/WNL.42.7.1328; Shim JW, 2004, J NEUROSCI, V24, P843, DOI 10.1523/JNEUROSCI.3977-03.2004; Sim M, 1998, ARCH ENVIRON HEALTH, V53, P114, DOI 10.1080/00039896.1998.10545972; Smits SM, 2003, EUR J NEUROSCI, V18, P1731, DOI 10.1046/j.1460-9568.2003.02885.x; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Spencer JPE, 2002, J NEUROCHEM, V81, P122, DOI 10.1046/j.1471-4159.2002.00808.x; Tanner CM, 1996, NEUROL CLIN, V14, P317, DOI 10.1016/S0733-8619(05)70259-0; TANNER CM, 1990, NEUROLOGY, V40, P17; Tillerson JL, 2002, EXP NEUROL, V178, P80, DOI 10.1006/exnr.2002.8021; Uhl GR, 1998, ANN NEUROL, V43, P555, DOI 10.1002/ana.410430503; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; Vila M, 2000, J NEUROCHEM, V74, P721, DOI 10.1046/j.1471-4159.2000.740721.x	59	152	153	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1695	+		10.1096/fj.06-5864fje	http://dx.doi.org/10.1096/fj.06-5864fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16809432				2022-12-28	WOS:000240266600018
J	Rothe, A; Hosse, RJ; Power, BE				Rothe, Achim; Hosse, Ralf J.; Power, Barbara E.			In vitro display technologies reveal novel biopharmaceutics	FASEB JOURNAL			English	Review						Ab engineering; scaffold; high affinity	MESSENGER-RNA DISPLAY; RIBOSOME DISPLAY; DIRECTED EVOLUTION; PHAGE-DISPLAY; ANTIBODY FRAGMENTS; DOMAIN ANTIBODIES; BINDING-PROTEINS; COMBINATORIAL LIBRARIES; AFFINITY MATURATION; MONOCLONAL-ANTIBODY	Display technologies are fundamental to the isolation of specific high-affinity binding proteins for diagnostic and therapeutic applications in cancer, neurodegenerative, and infectious diseases as well as autoimmune and inflammatory disorders. Applications extend into the broad field of antibody (Ab) engineering, synthetic enzymes, proteomics, and cell-free protein synthesis. Recently, in vitro display technologies have come to prominence due to the isolation of high-affinity human antibodies by phage display, the development of novel scaffolds for ribosome display, and the discovery of novel protein-protein interactions. In vitro display represents an emerging and innovative technology for the rapid isolation and evolution of high-affinity peptides and proteins. So far, only one clinical drug candidate produced by in vitro display technology has been approved by the FDA for use in humans, but several are in clinical or preclinical testing. This review highlights recent advances in various engineered biopharmaceutical products isolated by in vitro display with a focus on the commercial developments.	CSIRO Mol & Hlth Technol, Prot Design Diagnost, Parkville, Vic 3052, Australia; Prevent Hlth Natl Res Flagship, Parkville, Vic, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Power, BE (corresponding author), CSIRO Mol & Hlth Technol, Prot Design Diagnost, 343 Royal Parade, Parkville, Vic 3052, Australia.	barbara.power@csiro.au		Power, Barbara/0000-0002-4182-3375				Adams GP, 2004, CANCER RES, V64, P6200, DOI 10.1158/0008-5472.CAN-03-2382; Aharoni A, 2005, CURR OPIN CHEM BIOL, V9, P210, DOI 10.1016/j.cbpa.2005.02.002; Amstutz P, 2005, J BIOL CHEM, V280, P24715, DOI 10.1074/jbc.M501746200; Baggio R, 2002, J MOL RECOGNIT, V15, P126, DOI 10.1002/jmr.567; Baker KP, 2003, ARTHRITIS RHEUM-US, V48, P3253, DOI 10.1002/art.11299; Baker M, 2005, NAT BIOTECHNOL, V23, P1065, DOI 10.1038/nbt0905-1065; Barrick JE, 2003, BIOCHEMISTRY-US, V42, P12998, DOI 10.1021/bi035163p; Bernath K, 2005, J MOL BIOL, V345, P1015, DOI 10.1016/j.jmb.2004.11.017; Bertschinger J, 2004, PROTEIN ENG DES SEL, V17, P699, DOI 10.1093/protein/gzh082; Beste G, 1999, P NATL ACAD SCI USA, V96, P1898, DOI 10.1073/pnas.96.5.1898; Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Blanchard C, 2005, CLIN EXP ALLERGY, V35, P1096, DOI 10.1111/j.1365-2222.2005.02299.x; Bradbury A, 2003, TRENDS BIOTECHNOL, V21, P312, DOI 10.1016/S0167-7799(03)00117-3; Bradbury ARM, 2004, J IMMUNOL METHODS, V290, P29, DOI 10.1016/j.jim.2004.04.007; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935; Cujec TP, 2002, CHEM BIOL, V9, P253, DOI 10.1016/S1074-5521(02)00098-4; De Pascalis R, 2003, CLIN CANCER RES, V9, P5521; DESOUZA M, 2004, PRECLINICA, V2, P114; Dower WJ, 2002, CURR OPIN CHEM BIOL, V6, P390, DOI 10.1016/S1367-5931(02)00332-0; Fernandez-Gacio A, 2003, TRENDS BIOTECHNOL, V21, P408, DOI 10.1016/S0167-7799(03)00194-X; Flego M, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-73; Frankel A, 2003, CURR OPIN STRUC BIOL, V13, P506, DOI 10.1016/S0959-440X(03)00110-6; Georgakis GV, 2005, BRIT J HAEMATOL, V130, P501, DOI 10.1111/j.1365-2141.2005.05656.x; Ghadessy FJ, 2004, NAT BIOTECHNOL, V22, P755, DOI 10.1038/nbt974; Griffiths AD, 2000, CURR OPIN BIOTECH, V11, P338, DOI 10.1016/S0958-1669(00)00109-9; Groves MAT, 2005, EXPERT OPIN BIOL TH, V5, P125, DOI 10.1517/14712598.5.1.125; Gunneriusson E, 1999, PROTEIN ENG, V12, P873, DOI 10.1093/protein/12.10.873; Hanes J, 1999, FEBS LETT, V450, P105, DOI 10.1016/S0014-5793(99)00475-5; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; He MY, 2005, EXPERT REV PROTEOMIC, V2, P421, DOI 10.1586/14789450.2.3.421; He MY, 2005, J IMMUNOL METHODS, V297, P73, DOI 10.1016/j.jim.2004.11.022; Hey T, 2005, TRENDS BIOTECHNOL, V23, P514, DOI 10.1016/j.tibtech.2005.07.007; Heyd B, 2003, BIOCHEMISTRY-US, V42, P5674, DOI 10.1021/bi0273664; Ho M, 2005, J BIOL CHEM, V280, P607, DOI 10.1074/jbc.M409783200; Hoet RM, 2005, NAT BIOTECHNOL, V23, P344, DOI 10.1038/nbt1067; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Holt LJ, 2003, TRENDS BIOTECHNOL, V21, P484, DOI 10.1016/j.tibtech.2003.08.007; Hoogenboom Hennie R, 2002, Methods Mol Biol, V178, P1; Hoogenboom HR, 2005, NAT BIOTECHNOL, V23, P1105, DOI 10.1038/nbt1126; Horisawa K, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh167; Hosse RJ, 2006, PROTEIN SCI, V15, P14, DOI 10.1110/ps.051817606; Hulstein JJJ, 2005, BLOOD, V106, P3035, DOI 10.1182/blood-2005-03-1153; Ja WW, 2004, BIOCHEMISTRY-US, V43, P9265, DOI 10.1021/bi0498398; Jermutus L, 2001, P NATL ACAD SCI USA, V98, P75, DOI 10.1073/pnas.011311398; Jespers L, 2004, NAT BIOTECHNOL, V22, P1161, DOI 10.1038/nbt1000; Keefe AD, 2001, NATURE, V410, P715, DOI 10.1038/35070613; Ladner RC, 2004, DRUG DISCOV TODAY, V9, P525, DOI 10.1016/S1359-6446(04)03104-6; Lamla T, 2004, PROTEIN EXPRES PURIF, V33, P39, DOI 10.1016/j.pep.2003.08.014; Lamla T, 2003, J MOL BIOL, V329, P381, DOI 10.1016/S0022-2836(03)00432-7; Li SW, 2003, CHEM BIOL, V10, P233, DOI 10.1016/S1074-5521(03)00047-4; Li Y, 2005, NAT BIOTECHNOL, V23, P349, DOI 10.1038/nbt1070; Lipovsek D, 2004, J IMMUNOL METHODS, V290, P51, DOI 10.1016/j.jim.2004.04.008; Marks James D, 2004, Methods Mol Biol, V248, P327; MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; McPherson M, 2002, CHEM BIOL, V9, P691, DOI 10.1016/S1074-5521(02)00148-5; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Nellis DF, 2005, BIOTECHNOL PROGR, V21, P205, DOI 10.1021/bp049840y; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Nicaise M, 2004, PROTEIN SCI, V13, P1882, DOI 10.1110/ps.03540504; Noble CO, 2004, EXPERT OPIN THER TAR, V8, P335, DOI 10.1517/14728222.8.4.335; Nord K, 1997, NAT BIOTECHNOL, V15, P772, DOI 10.1038/nbt0897-772; Odegrip R, 2004, P NATL ACAD SCI USA, V101, P2806, DOI 10.1073/pnas.0400219101; Osbourn J, 2005, METHODS, V36, P61, DOI 10.1016/j.ymeth.2005.01.006; Power Barbara E, 2003, Methods Mol Biol, V207, P335; Raffler NA, 2003, CHEM BIOL, V10, P69, DOI 10.1016/S1074-5521(02)00309-5; Reichert JM, 2005, NAT BIOTECHNOL, V23, P1073, DOI 10.1038/nbt0905-1073; Reiersen H, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni010; Renberg B, 2005, ANAL BIOCHEM, V341, P334, DOI 10.1016/j.ab.2005.03.039; Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297; Romanov VI, 2003, CURR CANCER DRUG TAR, V3, P119, DOI 10.2174/1568009033482010; Rothe A, 2006, EXPERT OPIN BIOL TH, V6, P177, DOI 10.1517/14712598.6.2.177; Sawata SY, 2004, PROTEIN ENG DES SEL, V17, P501, DOI 10.1093/protein/gzh060; Schimmele B, 2005, J MOL BIOL, V352, P229, DOI 10.1016/j.jmb.2005.06.073; Schimmele B, 2005, PROTEIN ENG DES SEL, V18, P285, DOI 10.1093/protein/gzi030; Schlehuber S, 2000, J MOL BIOL, V297, P1105, DOI 10.1006/jmbi.2000.3646; Shen XC, 2005, P NATL ACAD SCI USA, V102, P5969, DOI 10.1073/pnas.0407928102; Silverman J, 2005, NAT BIOTECHNOL, V23, P1556, DOI 10.1038/nbt1166; Smith G P, 1991, Curr Opin Biotechnol, V2, P668, DOI 10.1016/0958-1669(91)90032-Z; Spirin AS, 2004, TRENDS BIOTECHNOL, V22, P538, DOI 10.1016/j.tibtech.2004.08.012; Steffen AC, 2005, CANCER BIOTHER RADIO, V20, P239, DOI 10.1089/cbr.2005.20.239; Streltsov VA, 2004, P NATL ACAD SCI USA, V101, P12444, DOI 10.1073/pnas.0403509101; Takahashi TT, 2003, TRENDS BIOCHEM SCI, V28, P159, DOI 10.1016/S0968-0004(03)00036-7; Tawfik DS, 1998, NAT BIOTECHNOL, V16, P652, DOI 10.1038/nbt0798-652; Valjakka J, 2002, J BIOL CHEM, V277, P44021, DOI 10.1074/jbc.M208392200; van Beijnum JR, 2002, INT J CANCER, V101, P118, DOI 10.1002/ijc.10584; Van de Wiele C, 2004, Q J NUCL MED MOL IM, V48, P317; Vogt M, 2004, CHEMBIOCHEM, V5, P191, DOI 10.1002/cbic.200300703; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; Weiner LM, 2005, NAT BIOTECHNOL, V23, P556, DOI 10.1038/nbt0505-556; Wikman M, 2004, PROTEIN ENG DES SEL, V17, P455, DOI 10.1093/protein/gzh053; Williams A, 2003, TRANSFUS APHER SCI, V29, P255, DOI 10.1016/S1473-0502(03)00170-8; Wilson DS, 2001, P NATL ACAD SCI USA, V98, P3750, DOI 10.1073/pnas.061028198; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141; Xu LH, 2002, CHEM BIOL, V9, P933, DOI 10.1016/S1074-5521(02)00187-4; Yonezawa M, 2004, J BIOCHEM, V135, P285, DOI 10.1093/jb/mvh034; Zahnd C, 2004, J BIOL CHEM, V279, P18870, DOI 10.1074/jbc.M309169200	99	89	108	2	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1599	1610		10.1096/fj.05-5650rev	http://dx.doi.org/10.1096/fj.05-5650rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873883				2022-12-28	WOS:000240266600005
J	Yang, BH; Oo, TN; Rizzo, V				Yang, Baohua; Oo, Tin N.; Rizzo, Victor			Lipid rafts mediate H2O2 prosurvival effects in cultured endothelial cells	FASEB JOURNAL			English	Article						caveolae; apoptosis; reactive oxygen species; endothelium	NITRIC-OXIDE SYNTHASE; N-TERMINAL KINASE; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; SIGNALING PATHWAYS; CELLULAR-RESPONSE; ACTIVATION; PHOSPHORYLATION; APOPTOSIS; RECEPTOR	Reactive oxygen species (ROS) generated during pathological events, such as inflammation and ischemia-reperfusion, activates both proapoptotic and antiapoptotic signaling programs in endothelial cells. Because cholesterol-rich, plasma membrane rafts serve as platforms for organizing and integrating signaling transduction processes, we asked whether these membrane regions play a mechanistic role in H2O2-induced responses. Bovine aortic endothelial cell cultures exposed to a 500-mu M bolus of H2O2 showed progressive activation of caspase 3 and an increase in the number of TUNEL-positive cells. Pretreatment with either wortmannin or PD 098059 heightened these apoptotic responses, demonstrating that both PI3 kinase/Akt and ERK1/2 serve as signaling mediators to alleviate H2O2 cytotoxic effects. To investigate the role of lipid rafts in these signaling processes, endothelial cells were pretreated with methyl-beta-cyclodextrin (CD) or filipin to ablate raft structures. H2O2-induced phosphorylation of Akt and ERK 1/2 was attenuated, while caspase 3 and the number of TUNEL positive cells was enhanced in CD-pretreated cells exposed to H2O2. Reconstitution of raft domains restored H2O2-induced Akt and ERK1/ 2 phosphorylation, which was concomitant with reduction of caspase 3 activation and DNA fragmentation. Taken together, our findings suggest that plasma membrane compartments rich in cholesterol participate in signal transduction pathways activated by oxidative stress.	Temple Univ, Sch Med, Cardiovasc Res Ctr, Dept Anat & Cell Biol, Philadelphia, PA 19140 USA; Albany Med Coll, Cardiovasc Res Ctr, Albany, NY 12208 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Albany Medical College	Rizzo, V (corresponding author), Temple Univ, Sch Med, Cardiovasc Res Ctr, Dept Anat & Cell Biol, 3420 N Broad St,MRB826, Philadelphia, PA 19140 USA.	rizzov@temple.edu			NHLBI NIH HHS [HL66301-VR] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066301] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Cai H, 2003, MOL PHARMACOL, V63, P325, DOI 10.1124/mol.63.2.325; Chambaut-Guerin AM, 2005, BIOL CELL, V97, P339, DOI 10.1042/BC200400062; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; D'Alessio A, 2005, AM J PATHOL, V166, P1273, DOI 10.1016/S0002-9440(10)62346-2; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Ferraro JT, 2004, AM J PHYSIOL-CELL PH, V286, pC831, DOI 10.1152/ajpcell.00224.2003; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Ko YG, 1999, J IMMUNOL, V162, P7217; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Nguyen A, 2004, FEBS LETT, V572, P307, DOI 10.1016/j.febslet.2004.06.061; Niwa K, 2003, ANTIOXID REDOX SIGN, V5, P713, DOI 10.1089/152308603770380016; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Oxhorn BC, 2003, CELL SIGNAL, V15, P489, DOI 10.1016/S0898-6568(02)00149-3; Ramachandran A, 2002, BIOL CHEM, V383, P693, DOI 10.1515/BC.2002.071; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Sudoh N, 2001, CIRCULATION, V103, P724; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zmijewski JW, 2005, BIOCHEM SOC T, V33, P1385, DOI 10.1042/BST0331385	34	100	102	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1501	+		10.1096/fj.05-5359fje	http://dx.doi.org/10.1096/fj.05-5359fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16754746				2022-12-28	WOS:000240266000031
J	Kues, WA; Schwinzer, R; Wirth, D; Verhoeyen, E; Lemme, E; Herrmann, D; Barg-Kues, B; Hauser, H; Wonigeit, K; Niemann, H				Kues, Wilfried A.; Schwinzer, Reinhard; Wirth, Dagmar; Verhoeyen, Els; Lemme, Erika; Herrmann, Doris; Barg-Kues, Brigitte; Hauser, Hansjorg; Wonigeit, Kurt; Niemann, Heiner			Epigenetic silencing and tissue independent expression of a novel tetracycline inducible system in double-transgenic pigs	FASEB JOURNAL			English	Article						autoregulative cassette; bicistronic; transgenic livestock; tissue independent expression; DNA methylation	GENE-EXPRESSION; AUTOREGULATORY LOOP; PROMOTER; CELLS; VECTORS; BRAIN; INTEGRATION; REPRESSION; DELIVERY; MURINE	The applicability of tightly regulated transgenesis in domesticated animals is severely hampered by the present lack of knowledge of regulatory mechanisms and the long generation intervals. To capitalize on the tightly controlled expression of mammalian genes made possible by using prokaryotic control elements, we have used a single-step transduction to introduce an autoregulative tetracycline-responsive bicistronic expression cassette (NTA) into transgenic pigs. Transgenic pigs carrying one NTA cassette showed a mosaic transgene expression restricted to single muscle fibers. In contrast, crossbred animals carrying two NTA cassettes with different transgenes, revealed a broad tissue-independent and tightly regulated expression of one cassette, but not of the other one. The expression pattern correlated inversely with the methylation status of the NTA transcription start sites indicating epigenetic silencing of one NTA cassette. This first approach on tetracycline regulated transgene expression in farm animals will be valuable for developing precisely controlled expression systems for transgenes in large animals relevant for biomedical and agricultural biotechnology.	Hannover Med Sch, Klin Viszeral & Transplantat Clin, D-30623 Hannover, Germany; Hannover Med Sch, Viszeral & Transplantat Chirurg Klin, D-30623 Hannover, Germany; Inst Anim Breeding, Dept Biotechnol, Mariensee, Germany; Gesell Biotechnol Forsch mbH, D-3300 Braunschweig, Germany	Hannover Medical School; Hannover Medical School; Gesellschaft fur Biotechnologische Forschung mbH	Niemann, H (corresponding author), Hannover Med Sch, Klin Viszeral & Transplantat Clin, Carl Neuberg Str 1, D-30623 Hannover, Germany.	niemann@tzv.fal.de	Kues, Wilfried/AAX-2466-2020; Kues, Wilfried/D-9232-2011; Verhoeyen, Els/AAW-4853-2021; Verhoeyen, Els/H-6360-2016	Kues, Wilfried/0000-0002-0850-8103; Verhoeyen, Els/0000-0001-9224-5491; 				Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Boger H, 1999, MECH DEVELOP, V83, P141, DOI 10.1016/S0925-4773(99)00042-8; Corbel SY, 2002, CURR OPIN BIOTECH, V13, P448, DOI 10.1016/S0958-1669(02)00361-0; DIRKS W, 1994, GENE, V149, P387, DOI 10.1016/0378-1119(94)90186-4; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Hajkova Petra, 2002, Methods Mol Biol, V200, P143; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Kringstein AM, 1998, P NATL ACAD SCI USA, V95, P13670, DOI 10.1073/pnas.95.23.13670; Kues WA, 2004, TRENDS BIOTECHNOL, V22, P286, DOI 10.1016/j.tibtech.2004.04.003; Kues WA, 2005, BIOL REPROD, V72, P1020, DOI 10.1095/biolreprod.104.031229; KUES WA, 1995, J CELL BIOL, V130, P949, DOI 10.1083/jcb.130.4.949; Kuhnel F, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh034; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Lindeberg J, 2002, J NEUROSCI RES, V68, P248, DOI 10.1002/jnr.10213; Markusic D, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni062; May T, 2004, NUCLEIC ACIDS RES, V32, P5529, DOI 10.1093/nar/gkh887; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MILLER KF, 1989, J ENDOCRINOL, V120, P481, DOI 10.1677/joe.0.1200481; Niemann H, 2003, ANIM REPROD SCI, V79, P291, DOI 10.1016/S0378-4320(03)00169-6; Niemann H, 2001, TRANSPLANTATION, V72, P1898, DOI 10.1097/00007890-200112270-00006; PURSEL VG, 1989, SCIENCE, V244, P1281, DOI 10.1126/science.2499927; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Robertson A, 2002, GENE, V282, P65, DOI 10.1016/S0378-1119(01)00793-4; ROBERTSON KD, 1995, MOL CELL BIOL, V15, P6150; Sakai N, 2002, MOL PHARMACOL, V61, P1453, DOI 10.1124/mol.61.6.1453; Schoberlein L., 1976, Monatshefte fur Veterinarmedizin, V31, P457; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Smith-Arica JR, 2000, MOL THER, V2, P579, DOI 10.1006/mthe.2000.0215; Spitzer D, 1999, HUM GENE THER, V10, P1893, DOI 10.1089/10430349950017572; Stepensky D, 2003, CLIN PHARMACOKINET, V42, P863, DOI 10.2165/00003088-200342100-00001; Unsinger J, 2004, BIOCHEM BIOPH RES CO, V319, P879, DOI 10.1016/j.bbrc.2004.05.067; Unsinger J, 2001, MOL THER, V4, P484, DOI 10.1006/mthe.2001.0480; White D, 1996, TRENDS BIOTECHNOL, V14, P3, DOI 10.1016/0167-7799(96)80906-1; Yew NS, 2002, MOL THER, V5, P731, DOI 10.1006/mthe.2002.0598; Zhu Z, 2001, J BIOL CHEM, V276, P25222, DOI 10.1074/jbc.M101512200	45	62	62	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1200	+		10.1096/fj.05-5415fje	http://dx.doi.org/10.1096/fj.05-5415fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16684801				2022-12-28	WOS:000240210300025
J	Sotiropoulos, KB; Clermont, A; Yasuda, Y; Rask-Madsen, C; Mastumoto, M; Takahashi, J; Della Vecchia, K; Kondo, T; Aiello, LP; King, GL				Sotiropoulos, Konstantinos B.; Clermont, Allen; Yasuda, Yutaka; Rask-Madsen, Christian; Mastumoto, Motonobu; Takahashi, Junichi; Della Vecchia, Kim; Kondo, Tatsuya; Aiello, Lloyd P.; King, George L.			Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPAR gamma agonist's effects on edema and weight gain	FASEB JOURNAL			English	Article						Zucker diabetic fatty rat; ruboxistaurin; vascular endothelial growth factor; insulin receptor knockout mice; thiazolidinedione	ENDOTHELIAL GROWTH-FACTOR; TIGHT JUNCTION PERMEABILITY; INSULIN-RESISTANCE; GENE-EXPRESSION; SKELETAL-MUSCLE; DIABETIC-RATS; THIAZOLIDINEDIONE; BETA; ISOFORM; OVEREXPRESSION	PPAR gamma agonists, thiazolidinediones, cause fluid retention and edema due to unknown mechanisms. We characterized the effect of rosiglitazone (RSG), a thiazolidinedione, to induce vascular permeability, vascular endothelial growth factor (VEGF) expression, and protein kinase C (PKC) activation with edema and wt gain. In lean, fatty and diabetic Zucker rats, and endothelial insulin receptor knockout mice, RSG increased wt and vascular permeability, selectively in fat and retina, but not in heart or skeletal muscle. H2O content and wt of epididymal fat were increased by RSG and correlated to increases in capillary permeability in fat and body wt. RSG induced VEGF mRNA expression and PKC activation in fat and retina up to 2.5-fold. Ruboxistaurin, a PKC beta isoform inhibitor, in the latter 2 wk of a 4-wk study, normalized vascular permeability in fat and decreased total wt gain, H2O content, and wt of fat vs. RSG alone but did not decrease VEGF expression, basal permeability, or food intake. Finally, RSG did not increase wt or vascular permeability in PKC beta knockout vs. control mice. Thus, thiazolidinedione's effects on edema and wt are partially due to an adipose tissue-selective activation of PKC and vascular permeability that may be prevented by PKC beta inhibition.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	King, GL (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	george.king@joslin.harvard.edu		Kondo, Tatsuya/0000-0003-4830-8955; Rask-Madsen, Christian/0000-0002-8548-466X	NEI NIH HHS [EY05110] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abiko T, 2003, DIABETES, V52, P829, DOI 10.2337/diabetes.52.3.829; Acarregui MJ, 2003, AM J PHYSIOL-LUNG C, V284, pL395, DOI 10.1152/ajplung.00202.2002; Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; Chou E, 2002, CIRCULATION, V105, P373, DOI 10.1161/hc0302.102143; Claesson-Welsh L, 2003, BIOCHEM SOC T, V31, P20, DOI 10.1042/bst0310020; Clarke H, 2000, J CELL SCI, V113, P3187; Etgen GJ, 2002, DIABETES, V51, P1083, DOI 10.2337/diabetes.51.4.1083; Hollenberg NK, 2003, AM J MED, V115, P111, DOI 10.1016/j.amjmed.2003.09.018; Idris I, 2003, DIABETOLOGIA, V46, P288, DOI 10.1007/s00125-002-1008-1; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Isshiki K, 2000, DIABETES, V49, P1022, DOI 10.2337/diabetes.49.6.1022; Jiang GQ, 2002, DIABETES, V51, P2412, DOI 10.2337/diabetes.51.8.2412; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; Knudsen ST, 2002, DIABETES CARE, V25, P2328, DOI 10.2337/diacare.25.12.2328; Kondo T, 2003, J CLIN INVEST, V111, P1835, DOI 10.1172/JCI200317455; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Kruszynska YT, 1998, J CLIN INVEST, V101, P543, DOI 10.1172/JCI1076; Lebovitz HE, 2002, DIABETES-METAB RES, V18, pS23, DOI 10.1002/dmrr.252; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Mullin JM, 1998, AM J PHYSIOL-CELL PH, V275, pC544, DOI 10.1152/ajpcell.1998.275.2.C544; Murata T, 2001, ARCH OPHTHALMOL-CHIC, V119, P709, DOI 10.1001/archopht.119.5.709; Nagpala PG, 1996, J CELL PHYSIOL, V166, P249, DOI 10.1002/(SICI)1097-4652(199602)166:2<249::AID-JCP2>3.0.CO;2-P; Nesto RW, 2003, CIRCULATION, V108, P2941, DOI 10.1161/01.CIR.0000103683.99399.7E; Newton Alexandra C, 2003, Methods Mol Biol, V233, P3; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Raskin P, 2001, DIABETES CARE, V24, P1226, DOI 10.2337/diacare.24.7.1226; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SPENCE CA, 1978, BRIT J NUTR, V39, P647, DOI 10.1079/BJN19780080; STASEK JE, 1992, J CELL PHYSIOL, V153, P62, DOI 10.1002/jcp.1041530110; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x; Werner AL, 2001, PHARMACOTHERAPY, V21, P1082, DOI 10.1592/phco.21.13.1082.34615; Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789; Yamakawa K, 2000, BIOCHEM BIOPH RES CO, V271, P571, DOI 10.1006/bbrc.2000.2665; Yang BC, 2003, J CARDIOVASC PHARM, V42, P436, DOI 10.1097/00005344-200309000-00016; Zanchi A, 2004, J CLIN ENDOCR METAB, V89, P1140, DOI 10.1210/jc.2003-031526; Zhang H, 2005, P NATL ACAD SCI USA, V102, P9406, DOI 10.1073/pnas.0501744102; Zierath JR, 1998, ENDOCRINOLOGY, V139, P5034, DOI 10.1210/en.139.12.5034	46	73	78	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1203	+		10.1096/fj.05-4617fje	http://dx.doi.org/10.1096/fj.05-4617fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16672634				2022-12-28	WOS:000240210300026
J	Dawson, NS; Zawieja, DC; Wu, MH; Granger, HJ				Dawson, Nancy S.; Zawieja, David C.; Wu, Mack H.; Granger, Harris J.			Signaling pathways mediating VEGF(165)-induced calcium transients and membrane depolarization in human endothelial cells	FASEB JOURNAL			English	Article						endothelium; membrane potential; intracellular calcium; signal transduction	CAPACITATIVE CA2+ ENTRY; ACTIVATED CL-CURRENTS; GROWTH-FACTOR; NITRIC-OXIDE; VASCULAR-PERMEABILITY; TYROSINE KINASE; MICROVASCULAR PERMEABILITY; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; CYTOSOLIC CALCIUM	Cytosolic calcium and membrane potential were monitored simultaneously in quiescent human umbilical vein endothelial cells (HUVEC) exposed to vascular endothelial growth factor (VEGF)(165) using the fluorescent indicators indo-1 AM and DiSBAC(2)(3), respectively. Application of VEGF(165) to cells elicits a rapid rise in cytosolic calcium followed by a slower decline toward control values. Peak calcium is associated with a slight membrane hyperpolarization; however, as calcium falls toward control, a strong depolarization develops and is sustained throughout a 10-min period of VEGF(165) stimulation. Both the VEGF(165)-mediated rise in cytosolic calcium and membrane depolarization are eliminated by inhibitors of VEGFR-2, tyrosine kinase, src kinase and inositol-1,4,5 triphosphate-operated calcium channels. Calcium entry, which is initially facilitated by transient hyperpolarization, is restricted by a substantial, sustained depolarization that developed during the downstroke of the calcium spike. Inhibition of plasmalemmal calcium channels diminished the magnitude and duration of the calcium spike, suggesting that extracellular calcium influx, secondary to stores release, is a significant component of the calcium transient. Inhibition of chloride channels substantially reduced membrane depolarization. In addition, the depolarization is modulated by PI3 kinase in a ras-independent manner. In summary, intracellular calcium and membrane potential are influenced by several key signaling cascades of VEGFR-2 activation in HUVEC.	Texas A&M Univ Sys, Lymphat Biol Div, Cardiovasc Res Inst, Hlth Sci Ct,Coll Med, College Stn, TX 77843 USA; Texas A&M Univ Sys, Dept Med Physiol, Coll Med, Hlth Sci Ctr, College Stn, TX 77843 USA; Univ Calif Davis, Med Ctr, Dept Surg, MIND Inst, Sacramento, CA 95817 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of California System; University of California Davis	Granger, HJ (corresponding author), Texas A&M Univ Sys, Lymphat Biol Div, Cardiovasc Res Inst, Hlth Sci Ct,Coll Med, College Stn, TX 77843 USA.	dcz@tamu.edu	Wu, Mack/I-6536-2012	Zawieja, David/0000-0002-2644-6524	NHLBI NIH HHS [HL-058062, HL-075199] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058062, R01HL075199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Bates DO, 1996, AM J PHYSIOL-HEART C, V271, pH2520, DOI 10.1152/ajpheart.1996.271.6.H2520; Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687; BROCK TA, 1991, AM J PATHOL, V138, P213; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; Cunningham SA, 1999, AM J PHYSIOL-CELL PH, V276, pC176, DOI 10.1152/ajpcell.1999.276.1.C176; Dedkova EN, 2002, J PHYSIOL-LONDON, V539, P77, DOI 10.1113/jphysiol.2001.013258; Diver JM, 2001, CELL CALCIUM, V30, P323, DOI 10.1054/ceca.2001.0239; Doanes AM, 1999, BIOCHEM BIOPH RES CO, V255, P545, DOI 10.1006/bbrc.1999.0227; Faehling M, 2002, FASEB J, V16, P1805, DOI 10.1096/fj.01-0938fje; Faehling M, 2001, INT J BIOCHEM CELL B, V33, P337, DOI 10.1016/S1357-2725(01)00021-8; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Fong TAT, 1999, CANCER RES, V59, P99; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GERICKE M, 1994, EUR J PHARM-MOLEC PH, V269, P381, DOI 10.1016/0922-4106(94)90046-9; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HE P, 1994, J APPL PHYSIOL, V76, P2288, DOI 10.1152/jappl.1994.76.6.2288; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; Kawaji J., 2003, Transactions of the Magnetics Society of Japan, V3, P1, DOI 10.3379/tmjpn2001.3.1; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; LUCKHOFF A, 1990, N-S ARCH PHARMACOL, V342, P94; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Nilius B, 1997, J PHYSIOL-LONDON, V498, P381, DOI 10.1113/jphysiol.1997.sp021865; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; NILIUS B, 1994, BRIT J PHARMACOL, V112, P1049, DOI 10.1111/j.1476-5381.1994.tb13189.x; Otun H, 1996, CELL CALCIUM, V19, P315, DOI 10.1016/S0143-4160(96)90072-X; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Pocock TM, 2000, AM J PHYSIOL-HEART C, V279, pH1625, DOI 10.1152/ajpheart.2000.279.4.H1625; SCHILLING WP, 1989, AM J PHYSIOL, V257, pH778, DOI 10.1152/ajpheart.1989.257.3.H778; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Shi CJ, 2002, INVEST OPHTH VIS SCI, V43, P1525; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Tilly BC, 1996, MOL BIOL CELL, V7, P1419, DOI 10.1091/mbc.7.9.1419; VACA L, 1995, AM J PHYSIOL-CELL PH, V269, pC733, DOI 10.1152/ajpcell.1995.269.3.C733; VOETS T, 1995, PFLUG ARCH EUR J PHY, V431, P132, DOI 10.1007/BF00374387; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Whittles CE, 2002, MICROCIRCULATION, V9, P513, DOI 10.1038/sj.mn.7800164; Wu HM, 1999, AM J PHYSIOL-HEART C, V276, pH535, DOI 10.1152/ajpheart.1999.276.2.H535; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735; Wu MH, 2005, J PHYSIOL-LONDON, V563, P95, DOI 10.1113/jphysiol.2004.076075; Wu SW, 2000, J BIOL CHEM, V275, P18887, DOI 10.1074/jbc.M002795200; ZICHE M, 1993, AM J PHYSIOL, V265, pH569, DOI 10.1152/ajpheart.1993.265.2.H569	50	32	32	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					991	+		10.1096/fj.05-3923fje	http://dx.doi.org/10.1096/fj.05-3923fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16581961				2022-12-28	WOS:000240157700032
J	Mahmoodzadeh, S; Eder, S; Nordmeyer, J; Ehler, E; Huber, O; Martus, P; Weiske, J; Pregla, R; Hetzer, R; Regitz-Zagrosek, V				Mahmoodzadeh, Shokoufeh; Eder, Sarah; Nordmeyer, Johannes; Ehler, Elisabeth; Huber, Otmar; Martus, Peter; Weiske, Joerg; Pregla, Reinhard; Hetzer, Roland; Regitz-Zagrosek, Vera			Estrogen receptor alpha up-regulation and redistribution in human heart failure	FASEB JOURNAL			English	Article						estrogen receptors; dilated cardiomyopathy; intercalated disc	RAT CARDIOMYOCYTES; IN-VITRO; MEMBRANE; ACTIVATION; EXPRESSION; CONNEXIN43; JUNCTIONS; CATENIN; SEX	Clinical and animal studies suggest that estrogen receptors are involved in the development of myocardial hypertrophy and heart failure. In this study, we investigated whether human myocardial estrogen receptor alpha (ER alpha) expression, localization, and association with structural proteins was altered in end stage-failing hearts. We found a 1.8-fold increase in ER alpha mRNA and protein in end-stage human dilated cardiomyopathy ( DCM, n = 41), as compared with controls (n = 25). ER alpha was visualized by confocal immunofluorescence microscopy and localized to the cytoplasm, sarcolemma, intercalated discs and nuclei of cardiomyocytes. Immunofluorescence studies demonstrated colocalization of ER alpha with beta-catenin at the intercalated disc in control hearts and immunoprecipitation studies confirmed complex formation of both proteins. Interestingly, the ER alpha/beta-catenin colocalization was lost at the intercalated disc in DCM hearts. Thus, the ER alpha/beta-catenin colocalization in the intercalated disc may be of functional relevance and a loss of this association may play a role in the progression of heart failure. The increase of total ER alpha expression may represent a compensatory process to contribute to the stability of cardiac intercalated discs.	Deutsch Herzzentrum Berlin, D-13353 Berlin, Germany; Charite, Cardiovasc Res Ctr, Berlin, Germany; DHZB, Klin Herz Gefass & Thoraxchirurg, Berlin, Germany; DHZB Berlin, Klin Herz Gefass & Thoraxchirurg, Berlin, Germany; Kings Coll London, Randall Div Cell & Mol Biophys, London WC2R 2LS, England; Kings Coll London, Div Cardiovasc, London WC2R 2LS, England; Inst Clin Chem & Pathobiochem, Berlin, Germany; Inst Med Stat & Clin Epidemiol, Berlin, Germany	German Heart Center Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Heart Center Berlin; German Heart Center Berlin; University of London; King's College London; University of London; King's College London	Regitz-Zagrosek, V (corresponding author), Deutsch Herzzentrum Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany.	vrz@dhzb.de	Huber, Otmar/AAA-4548-2021	Huber, Otmar/0000-0003-4359-1747; Regitz-Zagrosek, Vera/0000-0002-3566-3467; Ehler, Elisabeth/0000-0001-5646-5964; Mahmoodzadeh, Shokoufeh/0000-0002-3094-7874				Arnold SF, 1997, MOL ENDOCRINOL, V11, P48, DOI 10.1210/me.11.1.48; Babiker FA, 2004, CIRCULATION, V109, P269, DOI 10.1161/01.CIR.0000105682.85732.BD; Beardslee MA, 2000, CIRC RES, V87, P656, DOI 10.1161/01.RES.87.8.656; Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Cardona-Gomez P, 2004, MOL CELL NEUROSCI, V25, P363, DOI 10.1016/j.mcn.2003.10.008; CARROLL JD, 1992, CIRCULATION, V86, P1099, DOI 10.1161/01.CIR.86.4.1099; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chung TH, 2004, J MOL CELL CARDIOL, V37, P1013, DOI 10.1016/j.yjmcc.2004.08.003; Du XJ, 2004, CARDIOVASC RES, V63, P510, DOI 10.1016/j.cardiores.2004.03.027; Ehler E, 2001, J CELL BIOL, V153, P763, DOI 10.1083/jcb.153.4.763; Fielitz J, 2001, J AM COLL CARDIOL, V37, P1443, DOI 10.1016/S0735-1097(01)01170-6; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; Grohe C, 1998, J ENDOCRINOL, V156, pR1, DOI 10.1677/joe.0.156R001; Groten T, 2005, FASEB J, V19, P1368, DOI 10.1096/fj.04-2558fje; Guerra S, 1999, CIRC RES, V85, P856, DOI 10.1161/01.RES.85.9.856; Hertig CM, 1996, J CELL SCI, V109, P1; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Lechat P, 1999, LANCET, V353, P9; Leinwand LA, 2003, J CLIN INVEST, V112, P302, DOI 10.1172/JCI200319429; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Nadal A, 2001, NEWS PHYSIOL SCI, V16, P251; Nordmeyer J, 2004, CIRCULATION, V110, P3270, DOI 10.1161/01.CIR.0000147610.41984.E8; Nuedling S, 1999, CARDIOVASC RES, V43, P666, DOI 10.1016/S0008-6363(99)00093-0; Patten RD, 2004, CIRC RES, V95, P692, DOI 10.1161/01.RES.0000144126.57786.89; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; Perriard JC, 2003, TRENDS CARDIOVAS MED, V13, P30, DOI 10.1016/S1050-1738(02)00209-8; Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101; Razandi M, 2004, MOL ENDOCRINOL, V18, P2854, DOI 10.1210/me.2004-0115; Weiske J, 2001, J BIOL CHEM, V276, P41175, DOI 10.1074/jbc.M105769200; Wu JC, 2003, J CELL BIOCHEM, V88, P823, DOI 10.1002/jcb.10390; Zhang ZG, 2002, BIOCHEM BIOPH RES CO, V294, P926, DOI 10.1016/S0006-291X(02)00348-0	32	104	109	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					926	934		10.1096/fj.05-5148com	http://dx.doi.org/10.1096/fj.05-5148com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675850				2022-12-28	WOS:000240157700015
J	Rauter, I; Krauth, MT; Flicker, S; Gieras, A; Westritschnig, K; Vrtala, S; Balic, N; Spitzauer, S; Huss-Marp, J; Brockow, K; Darsow, U; Ring, J; Behrendt, H; Semper, H; Valent, P; Valenta, R				Rauter, Ingrid; Krauth, Maria-Theresa; Flicker, Sabine; Gieras, Anna; Westritschnig, Kerstin; Vrtala, Susanne; Balic, Nadja; Spitzauer, Susanne; Huss-Marp, Johannes; Brockow, Knut; Darsow, Ulf; Ring, Johannes; Behrendt, Heidrun; Semper, Hans; Valent, Peter; Valenta, Rudolf			Allergen cleavage by effector cell-derived proteases regulates allergic inflammation	FASEB JOURNAL			English	Article						allergy; mast cells; tryptase; allergen	GRASS-POLLEN ALLERGEN; PHLEUM-PRATENSE POLLEN; MAST-CELL; MAJOR ALLERGEN; STRUCTURAL-CHARACTERIZATION; SECRETORY GRANULES; GENE FRAGMENTATION; IGE-RECOGNITION; MOLECULAR-BASIS; P-V	The key event of allergic inflammation, allergen-induced crosslinking of mast cell-bound IgE antibodies, is accompanied by release of inflammatory mediators, cytokines, and proteases, in particular beta-tryptase. We provide evidence that protease-mediated cleavage of allergens represents a mechanism that regulates allergen-induced mast cell activation. When used in molar ratios as they occur in vivo, purified beta-tryptase cleaved major grass and birch pollen allergens, resulting in defined peptide fragments as mapped by mass spectrometry. Tryptase-cleaved allergens showed reduced IgE reactivity and allergenic activity. The biological relevance is demonstrated by the fact that lysates from activated human mast cells containing tryptase levels as they occur in vivo cleaved allergens. Additionally, protamine, an inhibitor of heparin-dependent effector cell proteases, augmented allergen-induced release of mediators from effector cells. Protease-mediated allergen cleavage may represent an important mechanism for terminating allergen-induced effector cell activation.	Med Univ Vienna, Div Immunopathol, Dept Pathophysiol, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria; Med Univ Vienna, Med & Chem Lab Diagnost, Vienna, Austria; Tech Univ Munich, ZAUM Ctr Allergy & Environm, Div Environm Dermatol & Allergy GSF, Dept Dermatol & Allergy, D-8000 Munich, Germany	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Technical University of Munich	Valenta, R (corresponding author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol, Ctr Physiol & Pathophysiol, 3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Test, Test/Y-7921-2019; Ring, Johannes/GLN-4341-2022; Gieras, Anna/S-8345-2019; Gamperl, Susi/V-2715-2019; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016	Ring, Johannes/0000-0001-8236-3152; Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Vrtala, Susanne/0000-0003-4250-8243; Gieras, Anna/0000-0002-5147-2281; Valenta, Rudolf/0000-0001-5944-3365; Flicker, Sabine/0000-0003-4768-8693				Ball T, 1999, FASEB J, V13, P1277, DOI 10.1096/fasebj.13.11.1277; Ball T, 2005, FEBS J, V272, P217, DOI 10.1111/j.1432-1033.2004.04403.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Brockow K, 2002, J ALLERGY CLIN IMMUN, V109, P82, DOI 10.1067/mai.2002.120524; Bufe A, 1998, AM J RESP CRIT CARE, V157, P1269, DOI 10.1164/ajrccm.157.4.9709040; De Marino S, 1999, STRUCT FOLD DES, V7, P943; ECCLESTON E, 1973, NATURE-NEW BIOL, V244, P73, DOI 10.1038/newbio244073b0; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Flicker S, 2002, EUR J IMMUNOL, V32, P2156, DOI 10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO;2-A; Flicker S, 2000, J IMMUNOL, V165, P3849, DOI 10.4049/jimmunol.165.7.3849; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Hoffmann A, 1997, J ALLERGY CLIN IMMUN, V99, P227, DOI 10.1016/S0091-6749(97)70101-5; IRANI AMA, 1992, BLOOD, V80, P3009; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P88, DOI 10.1016/0091-6749(94)90075-2; MACGLASHAM DW, 2002, IGE ANTIIGE THERAPY; Maglio O, 2002, PROTEIN ENG, V15, P635, DOI 10.1093/protein/15.8.635; Mellon MB, 2002, J IMMUNOL, V168, P290, DOI 10.4049/jimmunol.168.1.290; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; ONG EK, 1995, MOL IMMUNOL, V32, P295, DOI 10.1016/0161-5890(94)00127-M; Pejler G, 1996, FEBS LETT, V383, P170, DOI 10.1016/0014-5793(96)00239-6; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; PETERSEN A, 1994, CLIN EXP ALLERGY, V24, P250, DOI 10.1111/j.1365-2222.1994.tb00227.x; Saito H, 1996, J IMMUNOL, V157, P343; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1987, AM REV RESPIR DIS, V135, P1186; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; Suphioglu C, 1998, MOL IMMUNOL, V35, P293, DOI 10.1016/S0161-5890(98)00050-9; Tkaczyk C, 2004, INT ARCH ALLERGY IMM, V133, P305, DOI 10.1159/000077213; TOBIN MC, 1986, MOL IMMUNOL, V23, P245, DOI 10.1016/0161-5890(86)90050-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENT P, 1991, Progress in Growth Factor Research, V3, P27, DOI 10.1016/0955-2235(91)90011-R; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 2004, ADV IMMUNOL, V82, P105, DOI 10.1016/S0065-2776(04)82003-0; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Vrtala S, 1999, J IMMUNOL, V163, P5489; Xu K, 1998, J CELL SCI, V111, P2385; Zhao XY, 2004, ANALYST, V129, P817, DOI 10.1039/b407322c	47	23	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					967	+		10.1096/fj.05-3999fje	http://dx.doi.org/10.1096/fj.05-3999fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585063				2022-12-28	WOS:000240157700024
J	Tsang, VL; Chen, AA; Cho, LM; Jadin, KD; Sah, RL; DeLong, S; West, JL; Bhatia, SN				Tsang, Valerie Liu; Chen, Alice A.; Cho, Lisa M.; Jadin, Kyle D.; Sah, Robert L.; DeLong, Solitaire; West, Jennifer L.; Bhatia, Sangeeta N.			Fabrication of 3D hepatic tissues by additive photopatterning of cellular hydrogels	FASEB JOURNAL			English	Article						tissue engineering; liver; hepatic; PEG; microscale	POLY(VINYL ALCOHOL) HYDROGELS; SOLID FREEFORM FABRICATION; IN-VITRO CULTURE; EXTRACELLULAR-MATRIX; RAT HEPATOCYTES; ADHESION PEPTIDES; SANDWICH CONFIGURATION; BIODEGRADABLE POLYMERS; INTEGRIN EXPRESSION; GLYCOL) HYDROGELS	We have fabricated a hepatic tissue construct using a multilayer photopatteming platform for embedding cells in hydrogels of complex architecture. We first explored the potential of established hepatocyte culture models to stabilize isolated hepatocytes for photoencapsulation (e.g., double gel, Matrigel, cocultivation with nonparenchymal cells). Using photopolymerizable PEG hydrogels, we then tailored both the chemistry and architecture of the hydrogels to further support hepatocyte survival and liver-specific function. Specifically, we incorporated adhesive peptides to ligate key integrins on these adhesion-dependent cells. To identify the appropriate peptides for incorporation, the integrin expression of cultured hepatocytes was monitored by flow cytometry and their functional role in cell adhesion was assessed on full-length extracellular matrix (ECM) molecules and their adhesive peptide domains. In addition, we modified the hydrogel architecture to minimize barriers to nutrient transport for these highly metabolic cells. Viability of encapsulated cells was improved in photopatterned hydrogels with structural features of 500 mu m in width over unpatterned, bulk hydrogels. Based on these findings, we fabricated a multilayer photopatterned PEG hydrogel structure containing the adhesive RGD peptide sequence to ligate the 01501 integrin of cocultured hepatocytes. Three-dimensional photopatterned constructs were visualized by digital volumetric imaging and cultured in a continuous flow bioreactor for 12 d where they performed favorably in comparison to unpatterned, unperfused constructs. These studies will have impact in the field of liver biology as well as provide enabling tools for tissue engineering of other organs.	MIT, Cambridge, MA 02139 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Harvard Mit Div Hlth Sci & Technol, Brigham & Womens Hosp, Div Hlth Sci & Technol, Boston, MA USA; Brigham & Womens Hosp, Dept Elect Engn & Comp Sci, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Med, Boston, MA 02115 USA; Rice Univ, Dept Bioengn, Houston, TX 77251 USA	Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Rice University	Bhatia, SN (corresponding author), MIT, E19-502D,77 Massachusetts Ave, Cambridge, MA 02139 USA.	sbhatia@mit.edu	West, Jennifer L/A-4582-2008	West, Jennifer L/0000-0001-8550-2875				Albrecht DR, 2005, LAB CHIP, V5, P111, DOI 10.1039/b406953f; Albrecht DR, 2006, NAT METHODS, V3, P369, DOI 10.1038/NMETH873; Alhadlaq A, 2005, TISSUE ENG, V11, P556, DOI 10.1089/ten.2005.11.556; Allen JW, 2003, BIOTECHNOL BIOENG, V82, P253, DOI 10.1002/bit.10569; Alsberg E, 2002, P NATL ACAD SCI USA, V99, P12025, DOI 10.1073/pnas.192291499; Aucoin L, 2002, J BIOMAT SCI-POLYM E, V13, P447, DOI 10.1163/156856202320253956; Balis UJ, 1999, METAB ENG, V1, P49, DOI 10.1006/mben.1998.0105; Behravesh E, 2003, J BIOMED MATER RES A, V65A, P260, DOI 10.1002/jbm.a.10461; Bhadriraju K, 2000, BIOMATERIALS, V21, P267, DOI 10.1016/S0142-9612(99)00175-1; Bhatia SN, 1998, J BIOMAT SCI-POLYM E, V9, P1137, DOI 10.1163/156856298X00695; Boland T, 2003, ANAT REC PART A, V272A, P497, DOI 10.1002/ar.a.10059; Brown LA, 2003, IN VITRO CELL DEV-AN, V39, P13; Bryant SJ, 2002, J BIOMED MATER RES, V59, P63, DOI 10.1002/jbm.1217; Bryant SJ, 2003, J BIOMED MATER RES A, V64A, P70, DOI 10.1002/jbm.a.10319; Carlisle ES, 2000, TISSUE ENG, V6, P45, DOI 10.1089/107632700320883; Catapano G, 1996, INT J ARTIF ORGANS, V19, P61, DOI 10.1177/039139889601900110; Cooke MN, 2003, J BIOMED MATER RES B, V64B, P65, DOI 10.1002/jbm.b.10485; Cruise GM, 1998, BIOMATERIALS, V19, P1287, DOI 10.1016/S0142-9612(98)00025-8; Cutler SM, 2003, BIOMATERIALS, V24, P1759, DOI 10.1016/S0142-9612(02)00570-7; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; Davis MW, 1996, BIOMATERIALS, V17, P365, DOI 10.1016/0142-9612(96)85575-X; DEMETRIOU AA, 1986, SCIENCE, V233, P1190, DOI 10.1126/science.2426782; DIXIT V, 1990, HEPATOLOGY, V12, P1342, DOI 10.1002/hep.1840120615; DUNKELMAN NS, 1995, BIOTECHNOL BIOENG, V46, P299, DOI 10.1002/bit.260460402; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; DUNN JCY, 1989, FASEB J, V3, P1873; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; Dvir-Ginzberg M, 2003, TISSUE ENG, V9, P757, DOI 10.1089/107632703768247430; Elisseeff J, 2000, J BIOMED MATER RES, V51, P164, DOI 10.1002/(SICI)1097-4636(200008)51:2<164::AID-JBM4>3.0.CO;2-W; Ewald AJ, 2002, DEV DYNAM, V225, P369, DOI 10.1002/dvdy.10169; Garcia AJ, 2002, BIOCHEMISTRY-US, V41, P9063, DOI 10.1021/bi025752f; Gobin AS, 2002, FASEB J, V16, P751, DOI 10.1096/fj.01-0759fje; Gobin AS, 2003, BIOTECHNOL PROGR, V19, P1781, DOI 10.1021/bp0341390; Griffith LG, 2002, ANN NY ACAD SCI, V961, P83, DOI 10.1111/j.1749-6632.2002.tb03056.x; Halstenberg S, 2002, BIOMACROMOLECULES, V3, P710, DOI 10.1021/bm015629o; Hamazaki K, 2002, HEPATO-GASTROENTEROL, V49, P1514; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; Hasirci V, 2001, TISSUE ENG, V7, P385, DOI 10.1089/10763270152436445; Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B; Houseman BT, 2001, BIOMATERIALS, V22, P943, DOI 10.1016/S0142-9612(00)00259-3; Hutmacher DW, 2001, J BIOMAT SCI-POLYM E, V12, P107, DOI 10.1163/156856201744489; Hwang NS, 2006, STEM CELLS, V24, P284, DOI 10.1634/stemcells.2005-0024; Itle LJ, 2005, BIOTECHNOL PROGR, V21, P926, DOI 10.1021/bp049681i; Jakab K, 2004, P NATL ACAD SCI USA, V101, P2864, DOI 10.1073/pnas.0400164101; Kaihara S, 2000, J PEDIATR SURG, V35, P1287, DOI 10.1053/jpsu.2000.9298; Kaihara S, 2000, TISSUE ENG, V6, P105, DOI 10.1089/107632700320739; Kantlehner M, 2000, CHEMBIOCHEM, V1, P107, DOI 10.1002/1439-7633(20000818)1:2<107::AID-CBIC107>3.0.CO;2-4; Kao WYJ, 1998, BIOTECHNOL BIOENG, V59, P2, DOI 10.1002/(SICI)1097-0290(19980705)59:1<2::AID-BIT2>3.3.CO;2-N; Kato M, 2004, BIOCHEMISTRY-US, V43, P2699, DOI 10.1021/bi0352670; Kim SH, 2003, J BIOMED MATER RES A, V67A, P1351, DOI 10.1002/jbm.a.10166; Kim SS, 2000, TISSUE ENG, V6, P39, DOI 10.1089/107632700320874; Klein TJ, 2003, OSTEOARTHR CARTILAGE, V11, P595, DOI 10.1016/S1063-4584(03)00090-6; Kong HJ, 2005, P NATL ACAD SCI USA, V102, P4300, DOI 10.1073/pnas.0405873102; Koo LY, 2002, J CELL SCI, V115, P1423; Lee H, 2002, TRANSPLANTATION, V73, P1589, DOI 10.1097/00007890-200205270-00011; Leong KF, 2003, BIOMATERIALS, V24, P2363, DOI 10.1016/S0142-9612(03)00030-9; Li Q, 2004, J BIOMED MATER RES A, V68A, P28, DOI 10.1002/jbm.a.20007; Liu VA, 2002, BIOMED MICRODEVICES, V4, P257, DOI 10.1023/A:1020932105236; Lutolf MP, 2003, P NATL ACAD SCI USA, V100, P5413, DOI 10.1073/pnas.0737381100; Mahoney MJ, 2006, BIOMATERIALS, V27, P2265, DOI 10.1016/j.biomaterials.2005.11.007; Mann BK, 2001, BIOMATERIALS, V22, P3045, DOI 10.1016/S0142-9612(01)00051-5; Mann BK, 2001, BIOMATERIALS, V22, P439, DOI 10.1016/S0142-9612(00)00196-4; Mann BK, 1999, BIOMATERIALS, V20, P2281, DOI 10.1016/S0142-9612(99)00158-1; Merzkirch C, 2001, ANAT RECORD, V263, P379, DOI 10.1002/ar.1118; MIYAZAKI M, 1988, ACTA MED OKAYAMA, V42, P351; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; MOONEY DJ, 1995, J CELL SCI, V108, P2311; Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C; Nejjari M, 1999, INT J CANCER, V83, P518, DOI 10.1002/(SICI)1097-0215(19991112)83:4<518::AID-IJC14>3.3.CO;2-H; Nishimura I, 2003, TISSUE ENG, V9, pS77; Nuttelman CR, 2002, BIOMATERIALS, V23, P3617, DOI 10.1016/S0142-9612(02)00093-5; Nuttelman CR, 2001, J BIOMED MATER RES, V57, P217, DOI 10.1002/1097-4636(200111)57:2<217::AID-JBM1161>3.0.CO;2-I; Park KH, 2005, BIOTECHNOL LETT, V27, P1081, DOI 10.1007/s10529-005-8453-0; Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4; PIERSCHBACHER M, 1983, P NATL ACAD SCI-BIOL, V80, P1224, DOI 10.1073/pnas.80.5.1224; Raeber GP, 2005, BIOPHYS J, V89, P1374, DOI 10.1529/biophysj.104.050682; Sachlos E, 2003, BIOMATERIALS, V24, P1487, DOI 10.1016/S0142-9612(02)00528-8; SAWHNEY AS, 1994, J BIOMED MATER RES, V28, P831, DOI 10.1002/jbm.820280710; Schmedlen KH, 2002, BIOMATERIALS, V23, P4325, DOI 10.1016/S0142-9612(02)00177-1; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shu XZ, 2004, BIOMATERIALS, V25, P1339, DOI 10.1016/j.biomaterials.2003.08.014; Sodian R, 2002, ASAIO J, V48, P12, DOI 10.1097/00002480-200201000-00004; Sun W, 2002, COMPUT METH PROG BIO, V67, P85, DOI 10.1016/S0169-2607(01)00116-X; Taboas JM, 2003, BIOMATERIALS, V24, P181, DOI 10.1016/S0142-9612(02)00276-4; Takezawa T, 2000, TISSUE ENG, V6, P641, DOI 10.1089/10763270050199587; ter Brugge PJ, 2002, TISSUE ENG, V8, P615, DOI 10.1089/107632702760240535; Uyama S, 2001, TRANSPLANTATION, V71, P1226, DOI 10.1097/00007890-200105150-00008; VACANTI JP, 1988, J PEDIATR SURG, V23, P3, DOI 10.1016/S0022-3468(88)80529-3; WEIGEL PH, 1980, J CELL BIOL, V87, P855, DOI 10.1083/jcb.87.3.855; Yoon JJ, 2002, BIOTECHNOL BIOENG, V78, P1, DOI 10.1002/bit.10239; Zajaczkowski MB, 2003, TISSUE ENG, V9, P525, DOI 10.1089/107632703322066705; Zein I, 2002, BIOMATERIALS, V23, P1169, DOI 10.1016/S0142-9612(01)00232-0	93	333	360	2	121	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					790	801		10.1096/fj.06-7117com	http://dx.doi.org/10.1096/fj.06-7117com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197384				2022-12-28	WOS:000244686400017
J	Koncarevic, A; Jackman, RW; Kandarian, SC				Koncarevic, Alan; Jackman, Robert W.; Kandarian, Susan C.			The ubiquitin-protein ligase Nedd4 targets Notch1 in skeletal muscle and distinguishes the subset of atrophies caused by reduced muscle tension	FASEB JOURNAL			English	Article						hind limb unloading; denervation; starvation; diabetes; ubiquitination	DIRECT GENE-TRANSFER; END RULE PATHWAY; DENERVATION ATROPHY; CELL-ACTIVATION; WW DOMAINS; DEGRADATION; EXPRESSION; GROWTH; PROTEOLYSIS; INVIVO	Ubiquitination-dependent proteolysis is a fundamental process underlying skeletal muscle atrophy. Thus, the role of ubiquitin ligases is of great interest. There are no focused studies in muscle on the ubiquitin ligase Nedd4. We first confirmed increased mRNA expression in rat soleus muscles due to 1-14 days of hind limb unloading. Nedd4 protein localized to the sarcolemmal region of muscle fibers. Hind limb unloading, sciatic nerve denervation, starvation, and diabetes led to atrophy of soleus, plantaris, and gastrocnemius muscles, but only unloaded and denervated muscles showed a marked increase in Nedd4 protein expression. This increase was strongly correlated with decreased Notch1 expression, a known target of Nedd4 in other cell types. Overexpression of dominant negative Nedd4 in soleus muscles completely reversed the unloading-induced decrease of Notch1 expression, indicating that Nedd4 is required for Notch1 inactivation. Overexpression of wild-type Nedd4 in soleus muscles of weight bearing rats caused a decrease in Notch1 protein, indicating that Nedd4 is sufficient for Notch1 down-regulation. To further show that Notch1 is a Nedd4 substrate in muscle, conditional overexpression of Nedd4 in C2C12 myotubes induced ubiquitination of Notch1. This is the first finding of a Nedd4 substrate in muscle and of an ubiquitin ligase, the activity of which distinguishes disuse from cachexia atrophy.	Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA	Boston University	Kandarian, SC (corresponding author), Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA.	skandar@bu.edu			NIAMS NIH HHS [R01 AR41705] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041705] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACSADI G, 1991, NEW BIOL, V3, P71; Anan T, 1998, GENES CELLS, V3, P751, DOI 10.1046/j.1365-2443.1998.00227.x; Ardley HC, 2005, ESSAYS BIOCHEM, V41, P15, DOI 10.1042/EB0410015; Batt J, 2005, FASEB J, V19, P115, DOI 10.1096/fj.04-3640fje; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Boppart MD, 2006, AM J PHYSIOL-CELL PH, V290, pC1660, DOI 10.1152/ajpcell.00317.2005; Cao PR, 2005, INT J BIOCHEM CELL B, V37, P2088, DOI 10.1016/j.biocel.2004.11.010; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Costelli P, 2003, CURR OPIN CLIN NUTR, V6, P407, DOI 10.1097/01.mco.0000078984.18774.02; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; DARR KC, 1989, J APPL PHYSIOL, V67, P1827, DOI 10.1152/jappl.1989.67.5.1827; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Dupont-Versteegden EE, 2006, J APPL PHYSIOL, V101, P202, DOI 10.1152/japplphysiol.01540.2005; Flores SY, 2003, PFLUG ARCH EUR J PHY, V446, P334, DOI 10.1007/s00424-003-1027-x; FURUNO K, 1990, J BIOL CHEM, V265, P8550; GOLDSPINK DF, 1983, BIOCHEM J, V210, P89, DOI 10.1042/bj2100089; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Hansson EM, 2004, SEMIN CANCER BIOL, V14, P320, DOI 10.1016/j.semcancer.2004.04.011; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Heissmeyer V, 2004, NAT IMMUNOL, V5, P255, DOI 10.1038/ni1047; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; JASPERS SR, 1984, J APPL PHYSIOL, V57, P1472, DOI 10.1152/jappl.1984.57.5.1472; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kandarian SC, 2006, MUSCLE NERVE, V33, P155, DOI 10.1002/mus.20442; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Kwon YT, 2001, MOL CELL BIOL, V21, P8007, DOI 10.1128/MCB.21.23.8007-8021.2001; Lange S, 2005, SCIENCE, V308, P1599, DOI 10.1126/science.1110463; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Li HH, 2004, J CLIN INVEST, V114, P1058, DOI 10.1172/JCl200422220; MEDINA R, 1991, BIOMED BIOCHIM ACTA, V50, P347; Mitchell-Felton H, 1999, AM J PHYSIOL-CELL PH, V277, pC1269, DOI 10.1152/ajpcell.1999.277.6.C1269; Morris CA, 2005, J APPL PHYSIOL, V99, P1719, DOI 10.1152/japplphysiol.01419.2004; Murdaca J, 2004, J BIOL CHEM, V279, P26754, DOI 10.1074/jbc.M311802200; Peters DG, 1999, AM J PHYSIOL-CELL PH, V276, pC1218, DOI 10.1152/ajpcell.1999.276.5.C1218; Pham N, 2001, J BIOL CHEM, V276, P46995, DOI 10.1074/jbc.M108373200; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Price S R, 1998, Curr Opin Clin Nutr Metab Care, V1, P79, DOI 10.1097/00075197-199801000-00013; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; Radtke F, 2005, EMBO REP, V6, P1120, DOI 10.1038/sj.embor.7400585; Sakata T, 2004, CURR BIOL, V14, P2228, DOI 10.1016/j.cub.2004.12.028; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Scharschmidt E, 2004, MOL CELL BIOL, V24, P3860, DOI 10.1128/MCB.24.9.3860-3873.2004; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, AM J PHYSIOL-CELL PH, V272, pC1871, DOI 10.1152/ajpcell.1997.272.6.C1871; Stevenson EJ, 2003, J PHYSIOL-LONDON, V551, P33, DOI 10.1113/jphysiol.2003.044701; STPIERRE BA, 1994, AM J PATHOL, V145, P1463; Tidball JG, 2002, J PHYSIOL-LONDON, V545, P819, DOI 10.1113/jphysiol.2002.024935; TIDBALL JG, 1995, MED SCI SPORT EXER, V27, P1022, DOI 10.1249/00005768-199507000-00011; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Wilkin MB, 2004, CURR BIOL, V14, P2237, DOI 10.1016/j.cub.2004.11.030; Witt SH, 2005, J MOL BIOL, V350, P713, DOI 10.1016/j.jmb.2005.05.021; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	62	64	66	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					427	437		10.1096/fj.06-6665com	http://dx.doi.org/10.1096/fj.06-6665com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17172638				2022-12-28	WOS:000244686300016
J	El-Andaloussi, N; Valovka, T; Toueille, M; Hassa, PO; Gehrig, P; Covic, M; Huebscher, U; Hottiger, MO				El-Andaloussi, Nazim; Valovka, Taras; Toueille, Magali; Hassa, Paul O.; Gehrig, Peter; Covic, Marcela; Huebscher, Ulrich; Hottiger, Michael O.			Methylation of DNA polymerase beta by protein arginine methyltransferase 1 regulates its binding to proliferating cell nuclear antigen	FASEB JOURNAL			English	Article						posttranslational modification; DNA repair; protein interactions	BASE-EXCISION-REPAIR; N-METHYLTRANSFERASE; MAMMALIAN-CELLS; IN-VIVO; PRMT1; REQUIREMENT; MECHANISM; TRANSCRIPTION; SUBSTRATE; PATHWAYS	DNA polymerase beta ( pol beta) is a key player in DNA base excision repair ( BER). Here, we describe the complex formation of pol beta with the protein arginine methyltransferase 1 ( PRMT1). PRMT1 specifically methylated pol beta in vitro and in vivo. Arginine 137 was identified in pol beta as an important target for methylation by PRMT1. Neither the polymerase nor the dRP-lyase activities of pol beta were affected by PRMT1 methylation. However, this modification abolished the interaction of pol beta with proliferating cell nuclear antigen ( PCNA). Together, our results provide evidence that PRMT1 methylation of pol beta might play a regulatory role in BER by preventing the involvement of pol beta in PCNA-dependent DNA metabolic events.	Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland; Funct Genom Ctr Zurich, Zurich, Switzerland	University of Zurich	Hottiger, MO (corresponding author), Univ Zurich, Inst Vet Biochem & Mol Biol, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	hottiger@vetbio.unizh.ch	Hottiger, Michael O./J-7747-2013	Hottiger, Michael O./0000-0002-7323-2270				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Boisvert FM, 2005, GENE DEV, V19, P671, DOI 10.1101/gad.1279805; Boisvert FM, 2005, CELL CYCLE, V4, P1834, DOI 10.4161/cc.4.12.2250; Boisvert FM, 2004, MOL CELL, V15, P492, DOI 10.1016/j.molcel.2004.08.011; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; DAVIS GM, 1994, NAUTILUS, V108, P3; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; El-Andaloussi N, 2006, MOL CELL, V22, P51, DOI 10.1016/j.molcel.2006.02.013; Fan JS, 2005, FREE RADICAL BIO MED, V38, P1121, DOI 10.1016/j.freeradbiomed.2005.01.012; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Hasan S, 2002, MOL CELL, V10, P1213, DOI 10.1016/S1097-2765(02)00745-1; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; Herrmann F, 2004, J BIOL CHEM, V279, P48774, DOI 10.1074/jbc.M407332200; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Huang SM, 2005, GENE DEV, V19, P1885, DOI 10.1101/gad.1333905; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Idriss HT, 2002, INT J BIOCHEM CELL B, V34, P321, DOI 10.1016/S1357-2725(01)00131-5; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; TOKUI T, 1991, J BIOL CHEM, V266, P10820; Wysocka J, 2006, FRONT BIOSCI-LANDMRK, V11, P344, DOI 10.2741/1802	52	48	48	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					26	34		10.1096/fj.06-6194com	http://dx.doi.org/10.1096/fj.06-6194com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17116746				2022-12-28	WOS:000243130200004
J	Reilly, SJ; O'Shea, EM; Andersson, U; O'Byrne, J; Alexson, SEH; Hunt, MC				Reilly, Sarah-Jayne; O'Shea, Ethna M.; Andersson, Ulla; O'Byrne, James; Alexson, Stefan E. H.; Hunt, Mary C.			A peroxisomal acyltransferase in mouse identifies a novel pathway for taurine conjugation of fatty acids	FASEB JOURNAL			English	Article						acyl-coenzyme A; fatty acid amide hydrolase; N-acyltaurine	ACYL-COA THIOESTERASE; GLYCINE N-ACYLTRANSFERASE; ACTIVATED RECEPTORS ALPHA; MOLECULAR-CLONING; SPECIES-DIFFERENCES; BETA-OXIDATION; CLOFIBRIC ACID; RAT-LIVER; EXPRESSION; PURIFICATION	A wide variety of endogenous carboxylic acids and xenobiotics are conjugated with amino acids, before excretion in urine or bile. The conjugation of carboxylic acids and bile acids with taurine and glycine has been widely characterized, and de novo synthesized bile acids are conjugated to either glycine or taurine in peroxisomes. Peroxisomes are also involved in the oxidation of several other lipid molecules, such as very long chain acyl-CoAs, branched chain acyl-CoAs, and prostaglandins. In this study, we have now identified a novel peroxisomal enzyme called acyl-coenzyme A: amino acid N-acyltransferase ( ACNAT1). Recombinantly expressed ACNAT1 acts as an acyltransferase that efficiently conjugates very long-chain and long-chain fatty acids to taurine. The enzyme shows no conjugating activity with glycine, showing that it is a specific taurine conjugator. Acnat1 is mainly expressed in liver and kidney, and the gene is localized in a gene cluster, together with two further acyltransferases, one of which conjugates bile acids to glycine and taurine. In conclusion, these data describe ACNAT1 as a new acyltransferase, involved in taurine conjugation of fatty acids in peroxisomes, identifying a novel pathway for production of N-acyltaurines as signaling molecules or for excretion of fatty acids.	Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Div Clin Chem, SE-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Hunt, MC (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Div Clin Chem, C1-74, SE-14186 Stockholm, Sweden.	mary.hunt@ki.se	O'Byrne, James/AAE-8182-2021	Hunt, Mary/0000-0001-6415-2992				ASAOKA K, 1991, INT J BIOCHEM, V23, P429, DOI 10.1016/0020-711X(91)90170-R; Cox KB, 2001, HUM MOL GENET, V10, P2069, DOI 10.1093/hmg/10.19.2069; DICZFALUSY U, 1991, J CLIN INVEST, V88, P978, DOI 10.1172/JCI115401; EMUDIANUGHE TS, 1983, DRUG METAB DISPOS, V11, P97; FALANY CN, 1994, J BIOL CHEM, V269, P19375; Falany CN, 1997, J LIPID RES, V38, P1139; FARRELL SO, 1984, J BIOL CHEM, V259, P3089; Ferdinandusse S, 1999, BIOCHEM BIOPH RES CO, V263, P213, DOI 10.1006/bbrc.1999.1340; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HALPIN RA, 1993, DRUG METAB DISPOS, V21, P1003; Hankin JA, 1997, ARCH BIOCHEM BIOPHYS, V340, P317, DOI 10.1006/abbi.1997.9921; He DN, 2003, J LIPID RES, V44, P2242, DOI 10.1194/jlr.M300128-JLR200; Hostetler HA, 2005, J BIOL CHEM, V280, P18667, DOI 10.1074/jbc.M412062200; Huang SM, 2001, J BIOL CHEM, V276, P42639, DOI 10.1074/jbc.M107351200; Huhtinen K, 2002, J BIOL CHEM, V277, P3424, DOI 10.1074/jbc.M109040200; Hunt MC, 2006, FASEB J, V20, P1855, DOI 10.1096/fj.06-6042com; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Keller W, 1842, LIEBIGS ANN CHEM, V43, P108; KELLEY M, 1993, J BIOCHEM TOXICOL, V8, P63, DOI 10.1002/jbt.2570080203; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Knights KM, 1998, CLIN EXP PHARMACOL P, V25, P776, DOI 10.1111/j.1440-1681.1998.tb02152.x; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MAWAL YR, 1994, BIOCHEM BIOPH RES CO, V205, P1373, DOI 10.1006/bbrc.1994.2817; Mihalik SJ, 2002, J BIOL CHEM, V277, P24771, DOI 10.1074/jbc.M203295200; NANDI DL, 1979, J BIOL CHEM, V254, P7230; O'Byrne J, 2003, J BIOL CHEM, V278, P34237, DOI 10.1074/jbc.M300987200; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Saghatelian A, 2005, LIFE SCI, V77, P1759, DOI 10.1016/j.lfs.2005.05.019; Saghatelian A, 2004, BIOCHEMISTRY-US, V43, P14332, DOI 10.1021/bi0480335; Sfakianos MK, 2002, J BIOL CHEM, V277, P47270, DOI 10.1074/jbc.M207463200; Spiekerkoetter U, 2004, EUR J CLIN INVEST, V34, P191, DOI 10.1111/j.1365-2362.2004.01308.x; Suga Tetsuya, 2003, Drug Metab Pharmacokinet, V18, P155, DOI 10.2133/dmpk.18.155; Van Veldhoven PP, 1999, ADV EXP MED BIOL, V466, P261; Vessey D. A., 1997, COMPREHENSIVE TOXICO, P455; Wanders RJA, 2004, MOL GENET METAB, V83, P16, DOI 10.1016/j.ymgme.2004.08.016; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Westin MAK, 2005, J BIOL CHEM, V280, P38125, DOI 10.1074/jbc.M508479200; Westin MAK, 2004, J BIOL CHEM, V279, P21841, DOI 10.1074/jbc.M313863200; Wilcox BJ, 1999, BIOCHEMISTRY-US, V38, P3235, DOI 10.1021/bi982255j; YAMADA J, 1994, ARCH BIOCHEM BIOPHYS, V308, P118, DOI 10.1006/abbi.1994.1017	46	31	33	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					99	107		10.1096/fj.06-6919com	http://dx.doi.org/10.1096/fj.06-6919com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17116739	Green Submitted			2022-12-28	WOS:000243130200012
J	Dedja, A; Zaglia, T; Dall'Olmo, L; Chioato, T; Thiene, G; Fabris, L; Ancona, E; Schiaffino, S; Ausoni, S; Cozzi, E				Dedja, Arben; Zaglia, Tania; Dall'Olmo, Luigi; Chioato, Tatiana; Thiene, Gaetano; Fabris, Luca; Ancona, Ermanno; Schiaffino, Stefano; Ausoni, Simonetta; Cozzi, Emanuele			Hybrid cardiomyocytes derived by cell fusion in heterotopic cardiac xenografts	FASEB JOURNAL			English	Article						stem cells; transgenic animals; cardiac transplantation	HEMATOPOIETIC STEM-CELLS; SKELETAL-MUSCLE; TRANSPLANTATION; EXPRESSION; CHIMERISM; MYOCYTES; HEART; XENOTRANSPLANTATION; REGENERATION; MYOCARDIUM	Cardiomyocytes expressing host markers, such as the Y chromosome in sex-mismatched transplants, have been described in human allografts, suggesting that circulating cells can contribute to cardiac regeneration. It has not been established, however, whether host-derived cardiomyocytes result from transdifferentiation of stem cells or cell fusion. To address this issue, we used heterotopic heart xenografts and looked for markers of donor and recipient cells. Golden Syrian hamsters or transgenic mice expressing nuclear beta-galactosidase under the control of the cardiac troponin I promoter served as organ donors, while GFP(+) transgenic rats were used as recipients. GFP(+) cells, including abundant CD-45(+) inflammatory cells and rare undifferentiated cells expressing early cardiac markers (GATA-4 or MEF2C), were found in xenografts harvested two weeks after surgery. In addition, rare GFP(+) mature cardiomyocytes were found in 7 of 8 hamster xenografts and 6 of 6 mouse xenografts. The proportion of these cells was very low (0.0001% to 0.0344% in hamster xenografts) but similar to the one observed in control rat heart allografts. Without exception, all GFP(+) cardiomyocytes also expressed donor markers, i.e., hamster membrane antigens or lacZ, so they must derive from cell fusion, not transdifferentiation. Dedja, A., Zaglia T., Dall'Olmo, L., Chioato, T., Thiene, G., Fabris, L., Ancona, E., Schiaffino, S., Ausoni, S., Cozzi, E. Hybrid cardiomyocytes derived by cell fusion in heterotopic cardiac xenografts.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Dept Med & Surg Sci, I-35121 Padua, Italy; CORIT, Padua, Italy; CNR, Inst Neurosci, Padua, Italy; Univ Padua, Inst Pathol Anat, I-35100 Padua, Italy; Padova Gen Hosp, Clin Chirurg 3, Padua, Italy; Venetian Inst Mol Med, Padua, Italy; Direz Sanitaria, Padua, Italy	University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; Azienda Ospedaliera - Universita di Padova; Veneto Institute Molecular Medicine	Schiaffino, S (corresponding author), Univ Padua, Dept Biomed Sci, Via G Colombo 3, I-35121 Padua, Italy.	stefano.schiaffino@unipd.it; ausoni@bio.unipd.it; emanuele.cozzi@unipd.it	Dedja, Arben/J-2138-2018; Fabris, Luca/J-7565-2018	Dedja, Arben/0000-0003-3535-598X; Fabris, Luca/0000-0001-8538-6317; Cadamuro, Massimiliano/0000-0002-0899-7613; Schiaffino, Stefano/0000-0002-5607-6421; dall'olmo, luigi/0000-0003-1564-2594; Cozzi, Emanuele/0000-0001-7855-5055				Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Anversa P, 2002, CIRCULATION, V106, pE129, DOI 10.1161/01.CIR.0000035926.40150.D0; Ausoni S, 2005, CARDIOVASC RES, V68, P394, DOI 10.1016/j.cardiores.2005.06.014; Bayes-Genis A, 2002, CARDIOVASC RES, V56, P404, DOI 10.1016/S0008-6363(02)00597-7; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Dedja A, 2005, MICROSURG, V25, P227, DOI 10.1002/micr.20101; Di Lisi R, 1998, J BIOL CHEM, V273, P25371, DOI 10.1074/jbc.273.39.25371; Fogt F, 2003, J HEART LUNG TRANSPL, V22, P1314, DOI 10.1016/S1053-2498(03)00035-4; Glaser R, 2002, CIRCULATION, V106, P17, DOI 10.1161/01.CIR.0000021923.58307.8F; Ishikawa F, 2006, FASEB J, V20, P950, DOI 10.1096/fj.05-4863fje; Koopmans M, 2005, AM J TRANSPLANT, V5, P1495, DOI 10.1111/j.1600-6143.2005.00858.x; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lapidos KA, 2004, J CLIN INVEST, V114, P1577, DOI 10.1172/JCI200423071; Matsuura K, 2004, J CELL BIOL, V167, P351, DOI 10.1083/jcb.200312111; Muller P, 2002, CIRCULATION, V106, P31, DOI 10.1161/01.CIR.0000022405.68464.CA; Musaro A, 2004, P NATL ACAD SCI USA, V101, P1206, DOI 10.1073/pnas.0303792101; Niimi M, 2001, J HEART LUNG TRANSPL, V20, P1123, DOI 10.1016/S1053-2498(01)00309-6; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; Pomerantz J, 2004, NAT CELL BIOL, V6, P810, DOI 10.1038/ncb0904-810; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Reinecke H, 2004, CIRC RES, V94, pE56, DOI 10.1161/01.RES.0000125294.04612.81; Rubart M, 2004, J CLIN INVEST, V114, P775, DOI 10.1172/JCI200421589; Sacco A, 2005, J CELL BIOL, V171, P483, DOI 10.1083/jcb.200506123; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; SARTORE S, 1981, J CELL BIOL, V88, P226, DOI 10.1083/jcb.88.1.226; Takayama J, 2001, TRANSPLANT P, V33, P749, DOI 10.1016/S0041-1345(00)02236-3; Taylor DA, 2002, CIRCULATION, V106, P2, DOI 10.1161/01.CIR.0000024386.99599.4A; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wu GD, 2001, XENOTRANSPLANTATION, V8, P291, DOI 10.1034/j.1399-3089.2001.00136.x; Yoon YS, 2005, J CLIN INVEST, V115, P326, DOI 10.1172/JCI200522326; Zhang S, 2004, CIRCULATION, V110, P3803, DOI 10.1161/01.CIR.0000150796.18473.8E	39	14	14	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2534	+		10.1096/fj.06-6586fje	http://dx.doi.org/10.1096/fj.06-6586fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077278				2022-12-28	WOS:000242490700014
J	Nishikawa, K; Watanabe, M; Kita, E; Igai, K; Omata, K; Yaffe, MB; Natori, Y				Nishikawa, Kiyotaka; Watanabe, Miho; Kita, Eiji; Igai, Katsura; Omata, Kazumi; Yaffe, Michael B.; Natori, Yasuhiro			A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin	FASEB JOURNAL			English	Article						multivalent interaction; retrograde transport; globotriaosylceramide; Shiga toxin-producing E. coli infection; therapeutic agent	HEMOLYTIC-UREMIC SYNDROME; ESCHERICHIA-COLI; INFECTIONS; AGENT	Infection with Shiga toxin (Stx)-producing Escherichia coli O157:H7 causes bloody diarrhea and hemorrhagic colitis in humans, sometimes resulting in fatal systemic complications. Among the known Stx family members, Stx2 is responsible for the most severe forms of disease. Stx2 binds to target cells via multivalent interactions between its B-subunit pentamer and globotriaosyl ceramide. After binding, it is first retrogradely transported to the Golgi and then to the endoplasmic reticulum (ER). Using a multivalent peptide library approach, we identified a tetravalent peptide that exhibits a high affinity for the Stx2 B-subunit pentamer (K-D = 0.13 mu M) and markedly inhibits Stx2 cytotoxicity. The tetravalent peptide exerted its inhibitory effects by inducing aberrant cellular transport of Stx2. Although the tetravalent peptide/Stx2 complex was incorporated into cells and translocated to the Golgi, this process was followed by the effective degradation of Stx2 in an acidic compartment rather than by its transfer to the ER. This peptide thoroughly protected mice from a fatal dose of E. coli O157:H7 even when administered after an established infection. Thus, the multivalent peptide library approach enabled the identification of a peptide-based Stx2 inhibitor that has remarkable therapeutic potency and appears to function by inducing aberrant cellular transport and degradation of Stx2.	Int Med Ctr Japan, Dept Clin Pharmacol, Res Inst, Shinjuku Ku, Tokyo 1628655, Japan; Nara Med Univ, Dept Bacteriol, Kashihara, Nara 634, Japan; Int Med Ctr Japan, Dept Med Ecol & Informat, Res Inst, Tokyo, Japan; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	National Center for Global Health & Medicine - Japan; Nara Medical University; National Center for Global Health & Medicine - Japan; Massachusetts Institute of Technology (MIT)	Nishikawa, K (corresponding author), Int Med Ctr Japan, Dept Clin Pharmacol, Res Inst, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	knishika@ri.imcj.go.jp						BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Fraser ME, 2004, J BIOL CHEM, V279, P27511, DOI 10.1074/jbc.M401939200; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KARMALI MA, 1983, LANCET, V1, P619, DOI 10.1016/s0140-6736(83)91795-6; Kita E, 2000, INFECT IMMUN, V68, P1207, DOI 10.1128/IAI.68.3.1207-1214.2000; Kitov PI, 2000, NATURE, V403, P669, DOI 10.1038/35001095; Kurioka T, 1998, INFECT IMMUN, V66, P1726, DOI 10.1128/IAI.66.4.1726-1734.1998; Ling H, 1998, BIOCHEMISTRY-US, V37, P1777, DOI 10.1021/bi971806n; Matsuoka K, 1999, TETRAHEDRON LETT, V40, P7839, DOI 10.1016/S0040-4039(99)01632-9; Melton-Chelsa A.R., 1998, ESCHERICHIA COLI O15, P121; Miyagawa A, 2004, CARBOHYD POLYM, V57, P441, DOI 10.1016/j.carbpol.2004.06.001; Mulvey GL, 2003, J INFECT DIS, V187, P640, DOI 10.1086/373996; Nishikawa K, 2000, MOL CELL, V6, P969, DOI 10.1016/S1097-2765(05)00085-7; Nishikawa K, 2005, J INFECT DIS, V191, P2097, DOI 10.1086/430388; Nishikawa K, 2002, P NATL ACAD SCI USA, V99, P7669, DOI 10.1073/pnas.112058999; OBRIEN AD, 1987, MICROBIOL REV, V51, P206, DOI 10.1128/MMBR.51.2.206-220.1987; Paton AW, 2000, NAT MED, V6, P265, DOI 10.1038/73111; Paton AW, 2006, NAT REV MICROBIOL, V4, P193, DOI 10.1038/nrmicro1349; Paton JC, 1998, CLIN MICROBIOL REV, V11, P450, DOI 10.1128/CMR.11.3.450; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Watanabe M, 2004, J INFECT DIS, V189, P360, DOI 10.1086/381124; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	27	51	53	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2597	+		10.1096/fj.06-6572fje	http://dx.doi.org/10.1096/fj.06-6572fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065223				2022-12-28	WOS:000242490700036
J	Lee, J; Kosaras, B; Aleyasin, H; Han, JA; Park, DS; Ratan, RR; Kowall, NW; Ferrante, RJ; Lee, SW; Ryu, H				Lee, Junghee; Kosaras, Bela; Aleyasin, Hossein; Han, Jeong A.; Park, David S.; Ratan, Rajiv R.; Kowall, Neil W.; Ferrante, Robert J.; Lee, Sam W.; Ryu, Hoon			Role of cyclooxygenase-2 induction by transcription factor Sp1 and Sp3 in neuronal oxidative and DNA damage response	FASEB JOURNAL			English	Article						oxidative stress; neuronal survival	MESSENGER-RNA; LATE-PHASE; CORTICAL-NEURONS; BINDING PROTEIN; C/EBP-BETA; RAT-BRAIN; EXPRESSION; COX-2; ISCHEMIA; INJURY	Cyclooxygenase-2 (COX-2) has been implicated in neuronal survival and death. However, the precise regulatory mechanisms involved in COX-2 function are unclear. In the present study we found that COX-2 is induced in response to glutathione depletion-induced oxidative stress in primary cortical neurons. Two proximal specific Sp1 and Sp3 binding sites are responsible for the COX-2 promoter activity under normal as well as oxidative stress conditions through enhanced Sp1 and Sp3 DNA binding activity. Site-directed mutagenesis confirmed that -268/-267 positions serve as specific Sp1 and Sp3 recognition sites under oxidative stress. Enforced expression of Sp1 and Sp3 using HSV vectors increased the promoter activity, transcription, and protein level of COX-2 in cortical neurons. The dominant negative form of Sp1 abrogated the oxidative stress-induced promoter activity and expression of COX-2. We also demonstrated that adenovirus-mediated COX-2 gene delivery protected neurons from DNA damage induced by oxidative, genotoxic, and excitotoxic stresses and by ischemic injury. Moreover, COX-2(-/-) cortical neurons were more susceptible to DNA damage-induced cell death. These results indicate that in primary neurons Sp1 and Sp3 play an essential role in the modulation of COX-2 transcription, which mediates neuronal homeostasis and survival by preventing DNA damage in response to neuronal stress.	VA Med Ctr, GRECC, Bedford, MA 01730 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; Univ Ottawa, Ottawa Hlth Res Inst, Neurosci Res Program, Ottawa, ON, Canada; Harvard Univ, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA; Harvard Univ, Sch Med, Charlestown, MA USA; Cornell Univ, Weill Med Coll, Dept Neurol, White Plains, NY USA; Burke Cornell Med Res Inst, White Plains, NY USA	Geriatric Research Education & Clinical Center; Boston University; Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; University of Ottawa; Ottawa Hospital Research Institute; Harvard University; Massachusetts General Hospital; Harvard University; Cornell University	Ryu, H (corresponding author), VA Med Ctr, GRECC, 200 Springs Rd,Unit 182B, Bedford, MA 01730 USA.	hoonryu@bu.edu	Kowall, Neil/M-5378-2019	Kowall, Neil/0000-0002-6624-0213; Aleyasin, Hossein/0000-0002-0021-2586; Park, David/0000-0002-4490-3784; Ryu, Hoon/0000-0001-6544-3732	NATIONAL CANCER INSTITUTE [R01CA085214, R01CA097216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS045806, R01NS052724, P01NS045242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013846] Funding Source: NIH RePORTER; NCI NIH HHS [CA097216, CA8521406] Funding Source: Medline; NIA NIH HHS [P30 AG13846] Funding Source: Medline; NINDS NIH HHS [NS045242, NS045806, NS52724-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Anderson I, 2001, BIOCHEM SOC SYMP, V67, P141, DOI 10.1042/bss0670141; Baik EJ, 1999, BRAIN RES, V843, P118, DOI 10.1016/S0006-8993(99)01797-7; Bolli R, 2002, CARDIOVASC RES, V55, P506, DOI 10.1016/S0008-6363(02)00414-5; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Camilleri M, 2001, Rev Gastroenterol Disord, V1, P2; Chang JW, 1996, NEUROBIOL AGING, V17, P801; Dowd NP, 2001, J CLIN INVEST, V108, P585, DOI 10.1172/JCI11334; FENG JF, 1995, NEURAL PROCESS LETT, V2, P9, DOI 10.1007/BF02309009; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Ho L, 1999, J NEUROSCI RES, V57, P295; Hoozemans JJM, 2001, ACTA NEUROPATHOL, V101, P2, DOI 10.1007/s004010000251; Hoozemans JJM, 2001, EXP GERONTOL, V36, P559, DOI 10.1016/S0531-5565(00)00226-6; Iadecola C, 1997, ANN NY ACAD SCI, V835, P203, DOI 10.1111/j.1749-6632.1997.tb48631.x; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Lukiw WJ, 1997, J NEUROSCI RES, V50, P937, DOI 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E; MATTAMMAL MB, 1995, J NEUROCHEM, V64, P1645; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; Miettinen S, 1997, P NATL ACAD SCI USA, V94, P6500, DOI 10.1073/pnas.94.12.6500; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Mukutmoni M, 2001, PROSTAG LEUKOTR ESS, V65, P123, DOI 10.1054/plef.2001.0300; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Ohtsuki T, 1996, BRAIN RES, V736, P353, DOI 10.1016/S0006-8993(96)00948-1; Planas AM, 1999, NEUROSCI LETT, V275, P141, DOI 10.1016/S0304-3940(99)00756-9; Reuter BK, 1996, J CLIN INVEST, V98, P2076, DOI 10.1172/JCI119013; Rocha JL, 2001, LANCET, V357, P1946, DOI 10.1016/S0140-6736(00)05083-2; Rudnick DA, 2001, P NATL ACAD SCI USA, V98, P8885, DOI 10.1073/pnas.151217998; Ryu H, 2003, J NEUROSCI, V23, P3597; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Shinmura K, 2000, P NATL ACAD SCI USA, V97, P10197, DOI 10.1073/pnas.97.18.10197; Shinmura K, 2002, CIRC RES, V90, P602, DOI 10.1161/01.RES.0000012202.52809.40; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; Tocco G, 1997, EXP NEUROL, V144, P339, DOI 10.1006/exnr.1997.6429; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yermakova A, 2000, CURR PHARM DESIGN, V6, P1755, DOI 10.2174/1381612003398672	44	46	53	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2375	+		10.1096/fj.06-5957fje	http://dx.doi.org/10.1096/fj.06-5957fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17012241				2022-12-28	WOS:000241702600025
J	Novak, J; Parry, LJ; Matthews, JE; Kerchner, LJ; Indovina, K; Hanley-Yanez, K; Doty, KD; Debrah, DO; Shroff, SG; Conrad, KP				Novak, Jacqueline; Parry, Laura J.; Matthews, Julianna E.; Kerchner, Laurie J.; Indovina, Kimberly; Hanley-Yanez, Karen; Doty, Ketah D.; Debrah, Dan O.; Shroff, Sanjeev G.; Conrad, Kirk P.			Evidence for local relaxin ligand-receptor expression and function in arteries	FASEB JOURNAL			English	Article						vascular biology; relaxin knockout mouse; vasodilation; myogenic reactivity; passive compliance	LGR7 EXPRESSION; TAMMAR WALLABY; BINDING CELLS; GENE; IDENTIFICATION; PROTEIN; RELAXIN-3/INSL7; PREGNANCY; GPCR142; PEPTIDE	Relaxin is a 6 kDa protein hormone produced by the corpus luteum and secreted into the blood during pregnancy in rodents and humans. Growing evidence indicates that circulating relaxin causes vasodilatation and increases in arterial compliance, which may be among its most important actions during pregnancy. Here we investigated whether there is local expression and function of relaxin and relaxin receptor in arteries of nonpregnant females and males. Relaxin-1 and its major receptor, Lgr7, mRNA are expressed in thoracic aortas, small renal and mesenteric arteries from mice and rats of both sexes, as well as in small renal arteries from female tammar wallabies (an Australian marsupial). Using available antibodies for rat and mouse Lgr7 receptor and rat relaxin, we also identified protein expression in arteries. Small renal arteries isolated from relaxin-1 gene-deficient mice demonstrate enhanced myogenic reactivity and decreased passive compliance relative to wild-type (WT) and heterozygous mice. Taken together, these findings reveal an arterial-derived, relaxin ligand-receptor system that acts locally to regulate arterial function.	Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; Magee Womens Res Inst, Pittsburgh, PA USA; Univ Melbourne, Dept Zool, Parkville, Vic 3052, Australia; Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Physiol & Cell Biol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; University of Melbourne; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Conrad, KP (corresponding author), Univ Florida, Coll Med, Dept Physiol & Funct Genom, 1600 SW Archer Rd,M552,POB 100274, Gainesville, FL 32610 USA.	kpconrad@ufl.edu	Indovina, Kimberly/AAU-7236-2020	Parry, Laura/0000-0002-6883-3418	NHLBI NIH HHS [F31 HL79882, R01 HL67937] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F31HL079882, R01HL067937] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; Bogatcheva NV, 2003, MOL ENDOCRINOL, V17, P2639, DOI 10.1210/me.2003-0096; Bond CP, 2004, J CLIN ENDOCR METAB, V89, P3477, DOI 10.1210/jc.2003-030798; Burazin TCD, 2002, J NEUROCHEM, V82, P1553, DOI 10.1046/j.1471-4159.2002.01114.x; Chen JC, 2005, J PHARMACOL EXP THER, V312, P83, DOI 10.1124/jpet.104.073486; Cholley BP, 2001, J APPL PHYSIOL, V90, P2427, DOI 10.1152/jappl.2001.90.6.2427; Conrad KP, 2004, AM J PHYSIOL-REG I, V287, pR250, DOI 10.1152/ajpregu.00672.2003; Conrad KP, 2004, ENDOCRINOLOGY, V145, P3289, DOI 10.1210/en.2003-1612; DEBRAH DO, 2006, IN PRESS ENDOCRINOLO; Dschietzig T, 2001, FASEB J, V15, P2187, DOI 10.1096/fj.01-0070com; Feng S, 2006, ENDOCRINOLOGY, V147, P407, DOI 10.1210/en.2005-0626; GUICOLAMM ML, 1988, ENDOCRINOLOGY, V123, P2472, DOI 10.1210/endo-123-5-2472; GUNNERSEN JM, 1995, MOL CELL ENDOCRINOL, V110, P55, DOI 10.1016/0303-7207(95)03516-A; Gwyther J, 2005, ANN NY ACAD SCI, V1041, P118, DOI 10.1196/annals.1282.016; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Hsu SYT, 2003, TRENDS ENDOCRIN MET, V14, P303, DOI 10.1016/S1043-2760(03)00106-1; Ivell R, 2003, MOL HUM REPROD, V9, P175, DOI 10.1093/molehr/gag025; Jacob MP, 2003, BIOMED PHARMACOTHER, V57, P195, DOI 10.1016/S0753-3322(03)00065-9; Jeyabalan A, 2003, CIRC RES, V93, P1249, DOI 10.1161/01.RES.0000104086.43830.6C; Jeyabalan A, 2006, J APPL PHYSIOL, V100, P1955, DOI 10.1152/japplphysiol.01330.2005; Kohsaka T, 1998, BIOL REPROD, V59, P991, DOI 10.1095/biolreprod59.4.991; Krajnc-Franken MAM, 2004, MOL CELL BIOL, V24, P687, DOI 10.1128/MCB.24.2.687-696.2004; Kubota Y, 2002, MOL HUM REPROD, V8, P900, DOI 10.1093/molehr/8.10.900; Liu CL, 2005, MOL PHARMACOL, V67, P231, DOI 10.1124/mol.104.006700; Liu CL, 2003, J BIOL CHEM, V278, P50754, DOI 10.1074/jbc.M308995200; LOWNDES K, 2005, IN PRESS PLACENTA; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; Min G, 1996, BIOL REPROD, V55, P1243, DOI 10.1095/biolreprod55.6.1243; Novak J, 2001, J CLIN INVEST, V107, P1469, DOI 10.1172/JCI11975; Novak J, 2002, AM J PHYSIOL-REG I, V283, pR349, DOI 10.1152/ajpregu.00635.2001; Parry LJ, 2005, J SOC GYNECOL INVEST, V12, p231A; Parry LJ, 1997, BIOL REPROD, V57, P119, DOI 10.1095/biolreprod57.1.119; Ratkowsky D.A., 1983, NONLINEAR REGRESSION, P135; Sherwood O. David, 1994, P861; Siebel AL, 2003, ENDOCRINOLOGY, V144, P4272, DOI 10.1210/en.2003-0548; Smith MC, 2006, FERTIL STERIL, V86, P253, DOI 10.1016/j.fertnstert.2005.11.070; SMITH MC, 2005, IN PRESS J AM SOC NE; SOLOFF MS, 1992, ENDOCRINOLOGY, V130, P1844, DOI 10.1210/en.130.4.1844; Tan YY, 1998, BRIT J PHARMACOL, V123, P762, DOI 10.1038/sj.bjp.0701659; VODSTRCIL LA, 2004, THESIS U MELBOURNE A; Zhao L, 1999, ENDOCRINOLOGY, V140, P445, DOI 10.1210/en.140.1.445	41	87	87	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2352	2362		10.1096/fj.06-6263com	http://dx.doi.org/10.1096/fj.06-6263com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077312				2022-12-28	WOS:000241702600020
J	Sajjan, US; Jia, Y; Newcomb, DC; Bentley, JK; Lukacs, NW; LiPuma, JJ; Hershenson, MB				Sajjan, Umadevi S.; Jia, Yue; Newcomb, Dawn C.; Bentley, J. Kelley; Lukacs, Nicholas W.; LiPuma, John J.; Hershenson, Marc B.			H-influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression	FASEB JOURNAL			English	Article						chronic obstructive pulmonary disease; IL-8; epithelial-derived neutrophil attractant-78; growth-related oncogene-alpha; chemokine	NF-KAPPA-B; DOUBLE-STRANDED-RNA; OBSTRUCTIVE PULMONARY-DISEASE; LOWER RESPIRATORY-TRACT; TOLL-LIKE RECEPTOR-3; INFLAMMATORY MARKERS; BRONCHIAL INFLAMMATION; ACUTE EXACERBATIONS; ADHESION MOLECULES; CYSTIC-FIBROSIS	Rhinovirus (RV) is an important trigger of chronic obstructive pulmonary disease (COPD) exacerbations. In addition, respiratory viruses are more likely to be isolated in patients with a history of frequent exacerbations, suggesting that these patients are more susceptible to viral infection. To examine potential mechanisms for cooperative effects between bacterial and viral infection in COPD, we studied the responses of cultured human airway epithelial cells to nontypeable Hemophilus influenzae and RV. In both 16HBE14o- and primary mucociliary-differentiated cells, preincubation with H. influenzae enhanced RV serotype 39-induced protein expression of interleukin (IL)-8, epithelial-derived neutrophil attractant-78, and growth-related oncogene-alpha. H. influenzae infection also increased the binding of RV39 to cultured cells, as well as expression of intercellular adhesion molecule (ICAM)-1 and Toll-like receptor (TLR)-3, receptors for RV and dsRNA, respectively. Neutralizing antibody against tumor necrosis factor-alpha inhibited IL-8 expression induced by H. influenzae and RV39. Finally, siRNA against TLR3 attenuated RV-induced IL-8 expression. We conclude that H. influenzae infection increases airway epithelial cell ICAM-1 and TLR3 expression, leading to enhanced binding of RV and a potentiation of RV-induced chemokine release. These data provide a cellular mechanism by which H. influenzae infection may increase the susceptibility of COPD patients to RV-induced exacerbations.	Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hershenson, MB (corresponding author), Univ Michigan, Dept Pediat & Communicable Dis, 1150 W Med Ctr Dr,Rm 3570,MSRBII,Box 0688, Ann Arbor, MI 48109 USA.	mhershen@umich.edu	Lukacs, Nicholas W/ABH-5583-2020	Bentley, John Kelley/0000-0001-8865-7979	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081420, R01HL082550, P50HL056399] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56399, HL82550, HL81420] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaron SD, 2001, AM J RESP CRIT CARE, V163, P349, DOI 10.1164/ajrccm.163.2.2003122; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bandi V, 2001, AM J RESP CRIT CARE, V164, P2114, DOI 10.1164/ajrccm.164.11.2104093; Bayer N, 2001, J BIOL CHEM, V276, P3952, DOI 10.1074/jbc.M004722200; BeckSchimmer B, 1997, AM J RESP CELL MOL, V17, P344, DOI 10.1165/ajrcmb.17.3.2861; Bhowmik A, 2000, THORAX, V55, P114, DOI 10.1136/thorax.55.2.114; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; Casola A, 2002, VIROLOGY, V298, P8, DOI 10.1006/viro.2002.1475; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x; DISTEFANO A, 1994, AM J RESP CRIT CARE, V149, P803, DOI 10.1164/ajrccm.149.3.7509705; Duits LA, 2003, FEMS IMMUNOL MED MIC, V38, P59, DOI 10.1016/S0928-8244(03)00106-8; Eller J, 1998, CHEST, V113, P1542, DOI 10.1378/chest.113.6.1542; Frick AG, 2000, J IMMUNOL, V164, P4185, DOI 10.4049/jimmunol.164.8.4185; Furrie E, 2005, IMMUNOLOGY, V115, P565, DOI 10.1111/j.1365-2567.2005.02200.x; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gern JE, 2003, AM J RESP CELL MOL, V28, P731, DOI 10.1165/rcmb.2002-0055OC; Gompertz S, 2001, EUR RESPIR J, V17, P1112, DOI 10.1183/09031936.01.99114901; Greenberg SB, 2000, AM J RESP CRIT CARE, V162, P167, DOI 10.1164/ajrccm.162.1.9911019; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; HALPERIN SA, 1983, AM REV RESPIR DIS, V128, P806; Hewson CA, 2005, J VIROL, V79, P12273, DOI 10.1128/JVI.79.19.12273-12279.2005; Isogawa M, 2005, J VIROL, V79, P7269, DOI 10.1128/JVI.79.11.7269-7272.2005; Johnston SL., 1997, DIAGNOSTIC PROCEDURE, P553; Kim J, 2000, J IMMUNOL, V165, P3384, DOI 10.4049/jimmunol.165.6.3384; Lopez-Souza N, 2004, AM J PHYSIOL-LUNG C, V286, pL373, DOI 10.1152/ajplung.00300.2003; MONSO E, 1995, AM J RESP CRIT CARE, V152, P1316, DOI 10.1164/ajrccm.152.4.7551388; Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC; Murphy TF, 2004, AM J RESP CRIT CARE, V170, P266, DOI 10.1164/rccm.200403-354OC; Newcomb DC, 2005, J BIOL CHEM, V280, P36952, DOI 10.1074/jbc.M502449200; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Qiu YS, 2003, AM J RESP CRIT CARE, V168, P968, DOI 10.1164/rccm.200208-794OC; Ritter Mirko, 2005, J Inflamm (Lond), V2, P16, DOI 10.1186/1476-9255-2-16; Rohde G, 2003, THORAX, V58, P37, DOI 10.1136/thorax.58.1.37; Rudd BD, 2005, J VIROL, V79, P3350, DOI 10.1128/JVI.79.6.3350-3357.2005; Sajjan U, 2004, INFECT IMMUN, V72, P4188, DOI 10.1128/IAI.72.7.4188-4199.2004; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; Seemungal TAR, 2000, EUR RESPIR J, V16, P677, DOI 10.1034/j.1399-3003.2000.16d19.x; Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561; Sethi Sanjay, 2004, Proc Am Thorac Soc, V1, P109, DOI 10.1513/pats.2306029; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; Soler N, 1999, EUR RESPIR J, V14, P1015, DOI 10.1183/09031936.99.14510159; Suzuki T, 2002, AM J RESP CRIT CARE, V165, P1113, DOI 10.1164/ajrccm.165.8.2103094; Wedzicha Jadwiga A, 2004, Proc Am Thorac Soc, V1, P115, DOI 10.1513/pats.2306030; Winter LE, 2003, INFECT IMMUN, V71, P6884, DOI 10.1128/IAI.71.12.6884-6891.2003	47	102	108	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2121	+		10.1096/fj.06-5806fje	http://dx.doi.org/10.1096/fj.06-5806fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16914605	Green Submitted			2022-12-28	WOS:000241156900025
J	Jaulmes, A; Thierry, S; Janvier, B; Raymondjean, M; Marechal, V				Jaulmes, Amandine; Thierry, Sylvain; Janvier, Brigitte; Raymondjean, Michel; Marechal, Vincent			Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1 beta	FASEB JOURNAL			English	Article						inflammation; atherosclerosis; VSMCs; sPLA2-IIA	GLYCATION END-PRODUCTS; FACTOR-KAPPA-B; TOLL-LIKE RECEPTOR-2; HUMAN ATHEROSCLEROTIC LESIONS; PROSTAGLANDIN-E SYNTHASE; PHOSPHOLIPASE A(2) GENE; GROUP BOX-1 PROTEIN; TRANSCRIPTIONAL REGULATION; NEURITE OUTGROWTH; HMGB1	Lipid mediators such as prostaglandin E2 (PGE2) play a central role during atherogenesis as a consequence of inflammation. PGE2 is produced from phospholipids by a cascade of enzymatic reactions involving phospholipase A2 (PLA2), cyclooxygenase ( COX), and prostaglandin E synthase (PGES). It is released by several cell types, including vascular smooth muscle cells (VSMCs). Recent work has shown that the secretory PLA2-IIA (sPLA2-IIA), the most abundant isoform of secreted PLA2 in VSMCs, acts as a potent cytokine and activates VSMCs through a positive feedback loop. High mobility group protein 1 (HMGB1), also known as amphoterin, is a ubiquitous protein that plays various roles in the nucleus. HMGB1 is released by necrotic cells and by immune cells in response to various inflammatory mediators and acts as a potent proinflammatory cytokine. The present study investigates the role of HMGB1 in the activation of sPLA2-IIA expression and PGE2 production in VSMCs. Recombinant HMGB1 slightly activated the sPLA2-IIA, COX-2, and mPGES-1 genes but dramatically stimulated these genes in VSMCs that had been incubated with the proinflammatory cytokine IL-1 beta for 24 h. This effect was accompanied by significantly increased PGE2 release. Induction of the three known receptors of HMGB1, namely RAGE, TLR-2, and TLR-4, by IL-1 beta suggests that proinflammatory cytokines sensitize VSMCs to HMGB1. This provides new insights into the role of HMGB1 in VSMCs, suggesting it may be essential for the progression of atherosclerosis.	Ctr Rech Biomed Cordeliers, F-75270 Paris 06, France; Univ Paris 06, CNRS, UMR Physiol & Physiopathol, F-75005 Paris, France	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Marechal, V (corresponding author), Ctr Rech Biomed Cordeliers, 15 Rue Ecole Med, F-75270 Paris 06, France.	vincent.marechal@snv.jussieu.fr	marechal, vincent/P-7719-2017					Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Andreani M, 2000, BBA-MOL CELL BIOL L, V1488, P149, DOI 10.1016/S1388-1981(00)00117-7; Antonio V, 2002, BIOCHEM J, V368, P415, DOI 10.1042/BJ20020658; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Burke AP, 2004, ARTERIOSCL THROM VAS, V24, P1266, DOI 10.1161/01.ATV.0000131783.74034.97; Cipollone F, 2003, CIRCULATION, V108, P1070, DOI 10.1161/01.CIR.0000086014.80477.0D; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; Couturier C, 1999, J BIOL CHEM, V274, P23085, DOI 10.1074/jbc.274.33.23085; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300; Fuentes L, 2002, FEBS LETT, V531, P7, DOI 10.1016/S0014-5793(02)03401-4; Gaillard Claire, 2000, BMC Biochemistry, V1, P1; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; HAJJAR DP, 1992, FASEB J, V6, P2933, DOI 10.1096/fasebj.6.11.1644257; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Higashi T, 1997, DIABETES, V46, P463, DOI 10.2337/diabetes.46.3.463; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Jaulmes A, 2005, ARTERIOSCL THROM VAS, V25, P1161, DOI 10.1161/01.ATV.0000164310.67356.a9; Jiang BB, 2002, ARTERIOSCL THROM VAS, V22, P1811, DOI 10.1161/01.ATV.0000037679.60584.3F; Jimenez R, 2005, P NATL ACAD SCI USA, V102, P4637, DOI 10.1073/pnas.0407655101; Kalinina N, 2004, ARTERIOSCL THROM VAS, V24, P2320, DOI 10.1161/01.ATV.0000145573.36113.8a; Li JH, 2004, J IMMUNOL METHODS, V289, P211, DOI 10.1016/j.jim.2004.04.019; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Matsumoto H, 1997, BIOCHEM BIOPH RES CO, V230, P110, DOI 10.1006/bbrc.1996.5894; Morris GE, 2005, AM J RESP CRIT CARE, V171, P814, DOI 10.1164/rccm.200403-406OC; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; RITTHALER U, 1995, AM J PATHOL, V146, P688; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; Seki N, 2003, METABOLISM, V52, P1558, DOI 10.1016/j.metabol.2003.07.010; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Stros M, 2004, BIOCHEMISTRY-US, V43, P7215, DOI 10.1021/bi049928k; Sunden-Cullberg J, 2005, CRIT CARE MED, V33, P564, DOI [10.1097/01.CCM.0000155991.88802.4D, 10.1097/01.ccm.0000155991.88802.4D]; Ueno H, 2004, AM J RESP CRIT CARE, V170, P1310, DOI 10.1164/rccm.200402-188OC; Wautier J L, 1998, Vasc Med, V3, P131, DOI 10.1191/135886398672565440; Zimmermann K, 2004, INFLAMMATION, V28, P221, DOI 10.1023/B:IFLA.0000049047.61014.e3	46	55	58	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1727	+		10.1096/fj.05-5514fje	http://dx.doi.org/10.1096/fj.05-5514fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807371				2022-12-28	WOS:000240266600029
J	Russo, J; Fernandez, SV; Russo, PA; Fernbaugh, R; Sheriff, FS; Lareef, HM; Garber, J; Russo, IH				Russo, Jose; Fernandez, Sandra V.; Russo, Patricia A.; Fernbaugh, Rachael; Sheriff, Fathima S.; Lareef, Hasan M.; Garber, James; Russo, Irma H.			17-beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells	FASEB JOURNAL			English	Article						estrogen; invasiveness; CGH; breast cancer	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; CHROMOSOMAL IMBALANCES; ENDOGENOUS HORMONES; CANCER; ESTROGEN; RECEPTOR; ESTRADIOL; DNA; REGIONS	Breast cancer is a malignancy whose dependence on estrogen exposure has long been recognized even though the mechanisms whereby estrogens cause cancer are not clearly understood. This work was performed to determine whether 17 beta-estradiol (E-2), the predominant circulating ovarian steroid, is carcinogenic in human breast epithelial cells and whether nonreceptor mechanisms are involved in the initiation of breast cancer. For this purpose, the effect of four 24 h alternate periods of 70 nM E-2 treatment of the estrogen receptor alpha (ER-alpha) negative MCF-10F cell line on the in vitro expression of neoplastic transformation was evaluated. E-2 treatment induced the expression of anchorage-independent growth, loss of ductulogenesis in collagen, invasiveness in Matrigel, and loss of 9p11-13. Only invasive cells that exhibited a 4p15.3-16 deletion were tumorigenic. Tumors were poorly differentiated ER-alpha and progesterone receptornegative adenocarcinomas that expressed keratins, EMA, and E-cadherin. Tumors and tumor-derived cell lines exhibited loss of chromosome 4, deletions in chromosomes 3p12.3-13, 8p11.1-21, 9p21-qter, and 18q, and gains in 1p, and 5q15-qter. The induction of complete transformation of MCF-10F cells in vitro confirms the carcinogenicity of E-2, supporting the concept that this hormone could act as an initiator of breast cancer in women. This model provides a unique system for understanding the genomic changes that intervene for leading normal cells to tumorigenesis and for testing the functional role of specific genomic events taking place during neoplastic transformation.	Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Russo, J (corresponding author), Fox Chase Canc Ctr, Breast Canc Res Lab, 333 Cottman Ave, Philadelphia, PA 19111 USA.	j_russo@fccc.edu						Achuthan R, 2001, CANCER GENET CYTOGEN, V130, P166, DOI 10.1016/S0165-4608(01)00475-7; Adam Z, 2000, CLIN EXP METASTAS, V18, P295, DOI 10.1023/A:1011043412634; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; Berrino F, 1996, JNCI-J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; Bieche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2; Bieche I, 1998, ONCOL REP, V5, P267; BLOCK GE, 1958, SURGERY, V43, P415; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; Boyd S, 1900, BRIT MED J, V1900, P1161; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; CALAF G, 1995, INT J ONCOL, V6, P5; Cauley JA, 1999, ANN INTERN MED, V130, P270, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00004; Cavalieri E, 2004, METHOD ENZYMOL, V382, P293; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; Cavalieri EL, 2001, CHEM RES TOXICOL, V14, P1041, DOI 10.1021/tx010042g; Chakravarti D, 2001, ONCOGENE, V20, P7945, DOI 10.1038/sj.onc.1204969; Cuendet M, 2004, MUTAT RES-FUND MOL M, V550, P109, DOI 10.1016/j.mrfmmm.2004.02.005; Dallol A, 2002, CANCER RES, V62, P5874; Dellas A, 2002, CLIN CANCER RES, V8, P1210; Dorgan JF, 1997, CANCER EPIDEM BIOMAR, V6, P177; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533; Fernandez SV, 2006, INT J CANCER, V118, P1862, DOI 10.1002/ijc.21590; Fernandez SV, 2005, INT J ONCOL, V26, P691; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Forozan F, 2000, CANCER RES, V60, P4519; GARLAND CF, 1992, AM J EPIDEMIOL, V135, P1220, DOI 10.1093/oxfordjournals.aje.a116228; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; HELZLSOUER KJ, 1994, CANCER DETECT PREV, V18, P79; HENDERSON BE, 1988, CANCER RES, V48, P246; Hopman AHN, 2002, AM J PATHOL, V161, P1119, DOI 10.1016/S0002-9440(10)64388-X; Jakob J, 2005, GENE CHROMOSOME CANC, V42, P372, DOI 10.1002/gcc.20142; Johannsdottir HK, 2004, ANTICANCER RES, V24, P2681; Kabuto M, 2000, CANCER EPIDEM BIOMAR, V9, P575; Kaneko Mayumi, 2002, J Exp Ther Oncol, V2, P9, DOI 10.1046/j.1359-4117.2002.01001.x; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; Lareef MH, 2005, INT J ONCOL, V26, P423; LI JJ, 1995, CANCER RES, V55, P4347; LI JJ, 1983, CANCER RES, V43, P5200; LI JJ, 1987, FED PROC, V46, P1858; LIEHR JG, 1986, J STEROID BIOCHEM, V24, P353, DOI 10.1016/0022-4731(86)90080-4; Liu Suling, 2004, Breast J, V10, P514, DOI 10.1111/j.1075-122X.2004.21410.x; Loveday RL, 2000, INT J CANCER, V86, P494, DOI 10.1002/(SICI)1097-0215(20000515)86:4<494::AID-IJC8>3.3.CO;2-F; Marsit CJ, 2005, MOL CARCINOGEN, V44, P146, DOI 10.1002/mc.20125; MEITES J, 1972, J NATL CANCER I, V48, P1217; Melcher R, 2000, CYTOGENET CELL GENET, V88, P145, DOI 10.1159/000015508; MILLER W R, 1987, Steroids, V50, P537, DOI 10.1016/0039-128X(87)90037-7; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Nessling M, 2005, CANCER RES, V65, P439; Newbold RR, 2000, CANCER RES, V60, P235; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Richard F, 2000, INT J CANCER, V89, P305; Rogan EG, 2003, CARCINOGENESIS, V24, P697, DOI 10.1093/carcin/bgg004; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; RUSSO IH, 2005, MOL BASIS BREAST CAN, P89; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Russo J, 2002, J STEROID BIOCHEM, V80, P149, DOI 10.1016/S0960-0760(01)00183-2; Russo J, 2001, APMIS, V109, P39, DOI 10.1111/j.1600-0463.2001.tb00013.x; Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X; RUSSO J, 2000, ENDOCRINE DISRUPTERS, P1; Russo Jose, 2005, Proceedings of the American Association for Cancer Research Annual Meeting, V46, P1464; Sarkar S, 2002, J BIOL CHEM, V277, P36585, DOI 10.1074/jbc.M204244200; Shivapurkar N, 1999, CANCER RES, V59, P3576; Simons A, 2000, CANCER GENET CYTOGEN, V118, P89, DOI 10.1016/S0165-4608(99)00178-8; Tahara H, 1996, J CLIN ENDOCR METAB, V81, P3663, DOI 10.1210/jc.81.10.3663; Thomas HV, 1997, BRIT J CANCER, V76, P401, DOI 10.1038/bjc.1997.398; TOFT D, 1967, P NATL ACAD SCI USA, V57, P1740, DOI 10.1073/pnas.57.6.1740; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; Tsao SW, 2001, CANCER GENET CYTOGEN, V130, P141, DOI 10.1016/S0165-4608(01)00473-3; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Verdorfer I, 1999, CANCER GENET CYTOGEN, V111, P61, DOI 10.1016/S0165-4608(98)00217-9; Weber-Mangal S, 2003, INT J CANCER, V107, P583, DOI 10.1002/ijc.11460; Yager J D, 2000, J Natl Cancer Inst Monogr, P67; Yokota T, 1997, JPN J CANCER RES, V88, P959, DOI 10.1111/j.1349-7006.1997.tb00315.x; Zettl A, 2004, AM J PATHOL, V164, P1837, DOI 10.1016/S0002-9440(10)63742-X; Zhang LH, 2003, J CANCER RES CLIN, V129, P279, DOI 10.1007/s00432-002-0407-5; Zinn-Justin A, 2001, GENET EPIDEMIOL, V21, P40, DOI 10.1002/gepi.1017	82	117	121	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1622	1634		10.1096/fj.05-5399com	http://dx.doi.org/10.1096/fj.05-5399com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873885				2022-12-28	WOS:000240266600007
J	Kivela, R; Silvennoinen, M; Touvra, AM; Lehti, TM; Kainulainen, H; Vihko, V				Kivela, Riikka; Silvennoinen, Mika; Touvra, Anna-Maria; Lehti, T. Maarit; Kainulainen, Heikki; Vihko, Veikko			Effects of experimental type 1 diabetes and exercise training on angiogenic gene expression and capillarization in skeletal muscle	FASEB JOURNAL			English	Article						angiogenesis; hyperglycemia; growth factor; VEGF	ENDOTHELIAL GROWTH-FACTOR; ANIMAL-MODELS; TEACH US; INSULIN; IMPAIRMENT; METABOLISM; RESPONSES; THERAPY; DENSITY; DISEASE	Diabetes alters microvascular structure and function and is a major risk factor for cardiovascular diseases. In diabetic skeletal muscle, impaired angiogenesis and reduced VEGF-A expression have been observed, whereas in healthy muscle exercise is known to have opposite effects. We studied the effects of type 1 diabetes and combined exercise training on angiogenic mRNA expression and capillarization in mouse skeletal muscle. Microarray and real-time PCR analyses showed that diabetes altered the expression of several genes involved in angiogenesis. For example, levels of proangiogenic VEGF-A, VEGF-B, neuropilin-1, VEGFR-1, and VEGFR-2 were reduced and the levels of antiangiogenic thrombospondin-1 and retinoblastoma like-2 were increased. Exercise training alleviated some of these changes, but could not completely restore them. VEGF-A protein content was also reduced in diabetic muscles. In line with the reduced levels of VEGF-A and other angiogenic factors, and increased levels of angiogenesis inhibitors, capillary-to-muscle fiber ratio was lower in diabetic mice compared to healthy controls. Exercise training could not restore capillarization in diabetic mice. In conclusion, these data illustrate that type 1 diabetes is associated with reduced skeletal muscle capillarization and the dysregulation of complex angiogenesis pathways.	LIKES Res Ctr Sport & Hlth Sci, FIN-40740 Jyvaskyla, Finland; Univ Jyvaskyla, Dept Biol Phys Activ, Neuromuscular Res Ctr, SF-40351 Jyvaskyla, Finland	University of Jyvaskyla	Kivela, R (corresponding author), LIKES Res Ctr Sport & Hlth Sci, Rautpohjankatu 8A, FIN-40740 Jyvaskyla, Finland.	riikka.kivela@likes.fi	Kivelä, Riikka/AAD-9636-2020; Lehti, Maarit/T-3824-2019; Kivelä, Riikka/I-2859-2016	Kivelä, Riikka/0000-0002-2686-8890; Kivelä, Riikka/0000-0002-2686-8890; Kainulainen, Heikki/0000-0001-5102-4350; Silvennoinen, Mika/0000-0002-5389-8251; Lehti, Maarit/0000-0002-9063-6541				Abaci A, 1999, CIRCULATION, V99, P2239, DOI 10.1161/01.CIR.99.17.2239; Ameln H, 2005, FASEB J, V19, P1009, DOI 10.1096/fj.04-2304fje; Breen EC, 1996, J APPL PHYSIOL, V81, P355, DOI 10.1152/jappl.1996.81.1.355; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chou E, 2002, CIRCULATION, V105, P373, DOI 10.1161/hc0302.102143; Claudio PP, 2001, CANCER RES, V61, P462; Emanueli C, 2004, DIABETES, V53, P1096, DOI 10.2337/diabetes.53.4.1096; Gavin TP, 2001, J APPL PHYSIOL, V90, P1219, DOI 10.1152/jappl.2001.90.4.1219; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Gonzalez C, 2003, DIABETOLOGIA, V46, P1291, DOI 10.1007/s00125-003-1168-7; Gustafsson T, 1999, AM J PHYSIOL-HEART C, V276, pH679, DOI 10.1152/ajpheart.1999.276.2.H679; Gustafsson T, 2002, PFLUG ARCH EUR J PHY, V444, P752, DOI 10.1007/s00424-002-0845-6; HENRIKSSON J, 1992, DIABETES CARE, V15, P1701, DOI 10.2337/diacare.15.11.1701; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585; HUDLICKA O, 1991, J PHYSIOL-LONDON, V444, P1; HUDLICKA O, 1992, PHYSIOL REV, V71, P541; Jemiolo B, 2004, BIOCHEM BIOPH RES CO, V320, P1043, DOI 10.1016/j.bbrc.2004.05.223; Jiang ZY, 2003, J BIOL CHEM, V278, P31964, DOI 10.1074/jbc.M303314200; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KAINULAINEN H, 1984, BASIC RES CARDIOL, V79, P110, DOI 10.1007/BF01935813; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; Kindig CA, 1998, RESP PHYSIOL, V111, P163, DOI 10.1016/S0034-5687(97)00122-9; Laakso M, 1997, DIABETES REV, V5, P294; Larger E, 2004, DIABETES, V53, P752, DOI 10.2337/diabetes.53.3.752; LASH JM, 1989, DIABETES, V38, P854, DOI 10.2337/diabetes.38.7.854; LEINONEN H, 1982, DIABETOLOGIA, V22, P158; Leiter EH, 2004, DIABETOLOGIA, V47, P1657, DOI 10.1007/s00125-004-1518-0; Lerman OZ, 2003, AM J PATHOL, V162, P303, DOI 10.1016/S0002-9440(10)63821-7; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; Magnusson C, 2005, EUR J NEUROSCI, V21, P577, DOI 10.1111/j.1460-9568.2005.03855.x; Mora S, 2002, CIRCULATION, V106, P601; Olefsky JM, 2001, JAMA-J AM MED ASSOC, V285, P628, DOI 10.1001/jama.285.5.628; Penkowa M, 2005, EXP PHYSIOL, V90, P477, DOI 10.1113/expphysiol.2004.029371; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Rees DA, 2005, DIABETIC MED, V22, P359, DOI 10.1111/j.1464-5491.2005.01499.x; Richardson RS, 2000, AM J PHYSIOL-HEART C, V279, pH772, DOI 10.1152/ajpheart.2000.279.2.H772; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Rissanen TT, 2002, AM J PATHOL, V160, P1393, DOI 10.1016/S0002-9440(10)62566-7; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Roep BO, 2004, DIABETOLOGIA, V47, P1650, DOI 10.1007/s00125-004-1517-1; Sage EH, 2003, J BIOL CHEM, V278, P37849, DOI 10.1074/jbc.M302946200; Sasso FC, 2005, J AM COLL CARDIOL, V46, P827, DOI 10.1016/j.jacc.2005.06.007; Schiekofer S, 2005, ARTERIOSCL THROM VAS, V25, P1603, DOI 10.1161/01.ATV.0000171994.89106.ca; SEXTON WL, 1994, AM J PHYSIOL, V266, pH1502, DOI 10.1152/ajpheart.1994.266.4.H1502; Sreenivasulu K., 2002, Gene Expression Patterns, V2, P51, DOI 10.1016/S0925-4773(02)00357-X; Stenina OI, 2003, CIRCULATION, V107, P3209, DOI 10.1161/01.CIR.0000074223.56882.97; Tamarat R, 2003, P NATL ACAD SCI USA, V100, P8555, DOI 10.1073/pnas.1236929100; Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002; *TIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977; van Weel V, 2004, CIRC RES, V95, P58, DOI 10.1161/01.RES.0000133247.69803.c3; WALLBERGHENRIKSSON H, 1984, DIABETES, V33, P851, DOI 10.2337/diabetes.33.9.851; Williams RS, 2004, CIRC RES, V95, P7, DOI 10.1161/01.RES.0000136345.81719.37; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999	55	93	96	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1570	+		10.1096/fj.05-4780fje	http://dx.doi.org/10.1096/fj.05-4780fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816123				2022-12-28	WOS:000240266000054
J	Murashov, AK; Chintalgattu, V; Islamov, RR; Lever, TE; Pak, ES; Sierpinski, PL; Katwa, LC; Van Scott, MR				Murashov, Alexander K.; Chintalgattu, Vishnu; Islamov, Rustem R.; Lever, Teresa E.; Pak, Elena S.; Sierpinski, Paulina L.; Katwa, Laxmansa C.; Van Scott, Michael R.			RNAi pathway is functional in peripheral nerve axons	FASEB JOURNAL			English	Article						RNA interference; axonal protein synthesis; SiRNA; sciatic nerve; DRG	SPINAL MOTOR-NEURONS; FRAGILE-X-SYNDROME; MESSENGER-RNA; PROTEIN-SYNTHESIS; SCIATIC-NERVE; SYMPATHETIC NEURONS; LOCAL TRANSLATION; MAMMALIAN NEURONS; INTERFERING RNAS; SENSORY NEURONS	Recent observations demonstrated that translation of mRNAs may occur in axonal processes at sites that are long distances away from the neuronal perikaria. While axonal protein synthesis has been documented in several studies, the mechanism of its regulation remains unclear. The aim of this study was to investigate whether RNA interference (RNAi) may be one of the pathways that control local protein synthesis in axons. Here we show that sciatic nerve contains Argonaute2 nuclease, fragile X mental retardation protein, p100 nuclease, and Gemin3 helicase-components of the RNA-induced silencing complex (RISC). Application of short-interfering RNAs against neuronal beta-tubulin to the sciatic nerve initiated RISC formation, causing a decrease in levels of neuronal P-tubulin III mRNA and corresponding protein, as well as a significant reduction in retrograde labeling of lumbar motor neurons. Our observations indicate that RNAi is functional in peripheral mammalian axons and is independent from the neuronal cell body or Schwann cells. We introduce a concept of local regulation of axonal translation via RNAi.	E Carolina Univ, Brody Sch Med, Dept Physiol, Greenville, NC 27834 USA; E Carolina Univ, Brody Sch Med, Dept Commun Sci & Disorders, Greenville, NC 27834 USA; Kazan VI Lenin State Univ, Dept Histol, Kazan 420008, Russia	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; Kazan Federal University	Murashov, AK (corresponding author), E Carolina Univ, Brody Sch Med, Dept Physiol, 600 Moye Blvd, Greenville, NC 27834 USA.	murashoval@ecu.edu	Islamov, Rustem R/H-8722-2015; Islamov, Rustem R/A-3581-2019; Katwa, Laxmansa C/AID-0012-2022; Murashov, Alexander K/F-2241-2011	Islamov, Rustem R/0000-0002-6632-4636; Katwa, Laxmansa C/0000-0001-7479-4630; Murashov, Alexander K/0000-0002-8912-5891; Van Scott, Michael/0000-0003-1782-1334				Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brittis PA, 2002, CELL, V110, P223, DOI 10.1016/S0092-8674(02)00813-9; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; Cerutti H, 2003, TRENDS GENET, V19, P39, DOI 10.1016/S0168-9525(02)00010-0; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Chintalgattu V, 2003, J MOL CELL CARDIOL, V35, P277, DOI 10.1016/S0022-2828(03)00006-3; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dorn G, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh044; Dostie J, 2003, RNA, V9, P180, DOI 10.1261/rna.2141503; Eberwine J, 2002, NEUROCHEM RES, V27, P1065, DOI 10.1023/A:1020956805307; GAUDY AA, 2002, GENE DEV, V16, P2491; Ginty DD, 2002, CURR OPIN NEUROBIOL, V12, P268, DOI 10.1016/S0959-4388(02)00326-4; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; Giuditta A, 2002, TRENDS NEUROSCI, V25, P400, DOI 10.1016/S0166-2236(02)02188-4; Gubitz AK, 2002, J BIOL CHEM, V277, P5631, DOI 10.1074/jbc.M109448200; Guo SC, 2005, HUM GENE THER, V16, P1097, DOI 10.1089/hum.2005.16.1097; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hengst U, 2006, J NEUROSCI, V26, P5727, DOI 10.1523/JNEUROSCI.5229-05.2006; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Islamov RR, 2004, NEUROREPORT, V15, P2117, DOI 10.1097/00001756-200409150-00024; Islamov RR, 2003, MOL BRAIN RES, V116, P163, DOI 10.1016/S0169-328X(03)00258-4; Keenan TW, 2000, BBA-GEN SUBJECTS, V1523, P84, DOI 10.1016/S0304-4165(00)00106-9; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Kuruvilla R, 2000, NEURON, V27, P499, DOI 10.1016/S0896-6273(00)00061-1; Lee SK, 2003, J CELL SCI, V116, P4467, DOI 10.1242/jcs.00745; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Mader K, 2004, J NEUROTRAUM, V21, P956, DOI 10.1089/0897715041526113; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; McMurray R, 2003, BRAIN RES, V980, P140, DOI 10.1016/S0006-8993(03)02984-6; Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Murashov AK, 2004, AM J PHYSIOL-CELL PH, V287, pC320, DOI 10.1152/ajpcell.00542.2003; Murashov AK, 1996, MOL BRAIN RES, V37, P85, DOI 10.1016/0169-328X(95)00288-4; Murashov AK, 1998, MOL BRAIN RES, V63, P14, DOI 10.1016/S0169-328X(98)00258-7; Murashov AK, 2001, MOL BRAIN RES, V93, P199, DOI 10.1016/S0169-328X(01)00212-1; Nelson PT, 2004, RNA, V10, P387, DOI 10.1261/rna.5181104; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Reinscheid RK, 2000, PEPTIDES, V21, P901, DOI 10.1016/S0196-9781(00)00226-6; Scherr M, 2004, CURR OPIN MOL THER, V6, P129; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Sharifi N, 2002, ENDOCRINOLOGY, V143, P2503, DOI 10.1210/en.143.7.2503; Sharp PA, 2000, SCIENCE, V287, P2431, DOI 10.1126/science.287.5462.2431; Shen YP, 2002, J NEUROSCI, V22, P239, DOI 10.1523/JNEUROSCI.22-01-00239.2002; Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Tijsterman M, 2004, CELL, V117, P1, DOI 10.1016/S0092-8674(04)00293-4; Wagey R, 2001, NEUROSCIENCE, V103, P257, DOI 10.1016/S0306-4522(00)00551-0; Wienholds E, 2003, NAT GENET, V35, P217, DOI 10.1038/ng1251; Willis D, 2005, J NEUROSCI, V25, P778, DOI 10.1523/JNEUROSCI.4235-04.2005; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076; Ye HH, 2003, NEURON, V39, P57, DOI 10.1016/S0896-6273(03)00266-6; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zhang Y, 2004, CLIN CANCER RES, V10, P3667, DOI 10.1158/1078-0432.CCR-03-0740; Zheng JQ, 2001, J NEUROSCI, V21, P9291, DOI 10.1523/JNEUROSCI.21-23-09291.2001	69	77	81	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					656	670		10.1096/fj.06-6155com	http://dx.doi.org/10.1096/fj.06-6155com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17209129				2022-12-28	WOS:000244686400005
J	Hafezi-Moghadam, A; Noda, K; Almulki, L; Ilmaki, EF; Poulaki, V; Thomas, KL; Nakazawa, T; Hisatomi, T; Miller, JW; Gragoudas, ES				Hafezi-Moghadam, A.; Noda, K.; Almulki, L.; Ilmaki, E. F.; Poulaki, V.; Thomas, K. L.; Nakazawa, T.; Hisatomi, T.; Miller, J. W.; Gragoudas, E. S.			VLA-4 blockade suppresses endotoxin-induced uveitis: in vivo evidence for functional integrin up-regulation	FASEB JOURNAL			English	Article						EIU; VCAM-1; autoperfused microflow chamber; leukocyle-endothelial interaction	EXPERIMENTAL AUTOIMMUNE UVEITIS; ADHESION MOLECULES; CELL-ADHESION; MONOCLONAL-ANTIBODIES; P-SELECTIN; LEUKOCYTE; INFLAMMATION; DISEASE; NEUTROPHIL; ICAM-1	Leukocyte adhesion to the vascular wall is a critical early step in the pathogenesis of inflammatory diseases and is mediated in part by the leukocyte integrin, VLA-4, which binds to endothelial vascular cell adhesion molecule (VCAM) -1. Here, we investigate VLA-4's role in endotoxin-induced uveitis (EIU). At various time points (6-48 h) after EIU induction, the severity of the inflammation was evaluated by quantifying cell and protein content in the aqueous fluid, firm leukocyte adhesion in the retinal vessels, and the number of extravasated leukocytes into the vitreous. Functional activation of VLA-4 in vivo was investigated in our previously introduced autoperfused micro flow chamber assay. Firm adhesion of EIU leukocytes to immobilized VCAM-1 under physiological blood flow conditions was significantly increased compared with normal controls (P < 0.05), suggesting an important role for VLA-4 in EIU. VLA-4 blockade in vivo significantly suppressed all uveitis-related inflammatory parameters studied, decreasing the clinical score by 45% (P < 0.01), protein content in the aqueous fluid by 21% (P < 0.01), retinal leukostasis by 68% (P < 0.01), and leukocyte accumulation in the vitreous by 75% (P < 0.01). Our data provide novel evidence for functional up-regulation of VLA-4 during EIU and suggest VLA-4 blockade as a promising therapeutic strategy for treatment of acute inflammatory eye diseases.	Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School	Hafezi-Moghadam, A (corresponding author), Angiogenesis Lab, 325 Cambridge St,3rd Floor, Boston, MA 02114 USA.	ahm@meei.harvard.edu		Miller, Joan/0000-0003-2046-3996; Hisatomi, Toshio/0000-0003-2552-9595; Hafezi-Moghadam, Ali/0000-0002-5336-0697	NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER; NEI NIH HHS [EY14104] Funding Source: Medline; NIAID NIH HHS [AI050775] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adamus G, 2006, INVEST OPHTH VIS SCI, V47, P2555, DOI 10.1167/iovs.05-1242; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Avunduk MC, 2004, EXP EYE RES, V79, P357, DOI 10.1016/j.exer.2004.06.001; Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153; Becker MD, 2001, INVEST OPHTH VIS SCI, V42, P2563; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chaney E, 2005, INC, V27, P50; Ciardella Antonio P, 2004, Curr Opin Ophthalmol, V15, P519; CROSS AS, 1991, J CLIN INVEST, V88, P2067, DOI 10.1172/JCI115536; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dunn James P, 2004, Curr Opin Ophthalmol, V15, P293, DOI 10.1097/00055735-200408000-00003; Durrani OM, 2004, OPHTHALMOLOGICA, V218, P223, DOI 10.1159/000078612; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FORRESTER JV, 1991, LANCET, V338, P1498, DOI 10.1016/0140-6736(91)92309-P; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; Hafezi-Moghadam A, 2004, AM J PHYSIOL-CELL PH, V286, pC876, DOI 10.1152/ajpcell.00500.2003; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; Holt PG, 1999, NATURE, V402, pB12; Honjo M, 2003, P NATL ACAD SCI USA, V100, P1274, DOI 10.1073/pnas.0337528100; Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807; Issekutz AC, 1996, IMMUNOLOGY, V88, P569, DOI 10.1046/j.1365-2567.1996.d01-695.x; Issekutz TB, 1996, J EXP MED, V183, P2175, DOI 10.1084/jem.183.5.2175; Kiely JM, 1999, METH MOL B, V96, P131; La Heij E, 1998, BRIT J OPHTHALMOL, V82, P432; Leger Olivier J. P., 1997, Human Antibodies, V8, P3; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lightman S, 1997, EYE, V11, P222, DOI 10.1038/eye.1997.56; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; LUSCINSKAS FW, 1992, J IMMUNOL, V149, P2163; Martin AP, 2005, INVEST OPHTH VIS SCI, V46, P2056, DOI 10.1167/iovs.04-0418; MARX JL, 1982, SCIENCE, V215, P1380, DOI 10.1126/science.6278589; MCMENAMIN PG, 1995, INVEST OPHTH VIS SCI, V36, P1949; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Moorthy RS, 1997, SURV OPHTHALMOL, V41, P361, DOI 10.1016/S0039-6257(97)00006-4; Planck SR, 1998, CURR EYE RES, V17, P941, DOI 10.1076/ceyr.17.9.941.5139; ROSENBAUM JT, 1993, CURR EYE RES, V12, P827, DOI 10.3109/02713689309020387; ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0; Salas A, 2002, J BIOL CHEM, V277, P50255, DOI 10.1074/jbc.M209822200; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Suzuma K, 1997, INVEST OPHTH VIS SCI, V38, P1610; WHITCUP SM, 1993, CLIN IMMUNOL IMMUNOP, V67, P143, DOI 10.1006/clin.1993.1057; WHITCUP SM, 1995, EXP EYE RES, V60, P597, DOI 10.1016/S0014-4835(05)80001-6; WHITCUP SM, 1993, INVEST OPHTH VIS SCI, V34, P673; WHITCUP SM, 1992, ARCH OPHTHALMOL-CHIC, V110, P662, DOI 10.1001/archopht.1992.01080170084029; Whitcup SM, 1997, CLIN IMMUNOL IMMUNOP, V83, P45, DOI 10.1006/clin.1996.4324; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	49	26	30	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					464	474		10.1096/fj.06-6390com	http://dx.doi.org/10.1096/fj.06-6390com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17202250				2022-12-28	WOS:000244686300020
J	Kim, HR; Chae, HJ; Thomas, M; Miyazaki, T; Monosov, A; Monosov, E; Krajewska, M; Krajewski, S; Reed, JC				Kim, Hyung-Ryong; Chae, Han-Jung; Thomas, Michael; Miyazaki, Tadaaki; Monosov, Anna; Monosov, Edward; Krajewska, Maryla; Krajewski, Stan; Reed, John C.			Mammalian dap3 is an essential gene required for mitochondrial homeostasis in vivo and contributing to the extrinsic pathway for apoptosis	FASEB JOURNAL			English	Article						mitochondrial respiration; DAP3 protein; genotypic analysis; beta-actin; GTP binding protein	SERINE-PROTEASE; IDENTIFICATION; STAUROSPORINE; DEGRADATION; EXPRESSION; FAMILY; ALPHA; BCL-2	Death-associated protein-3 ( DAP3) is a GTP binding protein previously implicated in both intramitochondrial protein synthesis and apoptosis. To explore the in vivo roles of DAP3, we generated and characterized DAP3-deficient mice. Homozygous dap3-/- embryos died at similar to day 9.5 in utero. The dap3-/- embryos and placentas were markedly shrunken. Embryos had arrested development, displaying severe growth restriction and lack of axial turning. Transmission electron microscopy analysis revealed abnormal, shrunken mitochondria with swollen crystae in dap3(-/-) embryos. Levels of cytochrome c oxidase-I, a protein encoded in the mitochondrial genome, were reduced in dap3(-/-) embryos, consistent with a role for DAP3 in intramitochondrial protein synthesis. A requirement for DAP3 in mitochondrial respiration was also revealed by oxygen consumption measurements using cultured cells treated with DAP3-specific small interfering RNA ( siRNA). Studies of cultured cells from dap3(-/-) embryos confirmed a role in apoptosis induced by stimuli that trigger the extrinsic (TNF alpha, TRAIL, anti-Fas antibody) but not intrinsic ( mitochondrial) cell death pathway. Thus, DAP3 joins a growing list of bifunctional proteins that play roles in normal mitochondrial physiology and in apoptosis.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org	Miyazaki, Tadaaki/D-9368-2012	Chae, Han-Jung/0000-0003-4190-9889	NIGMS NIH HHS [GM 60554, GM-61694] Funding Source: Medline; NINDS NIH HHS [NS036821] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061694, R01GM060554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036821] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Berg RW, 2002, CURR DRUG TARGETS, V3, P297, DOI 10.2174/1389450023347605; Berger T, 2000, J CELL SCI, V113, P3603; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Gan X, 2002, EUR J BIOCHEM, V269, P5203, DOI 10.1046/j.1432-1033.2002.03226.x; GRAHAM RC, 1965, J HISTOCHEM CYTOCHEM, V13, P604, DOI 10.1177/13.7.604; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Jacques C, 2006, EXP CELL RES, V312, P737, DOI 10.1016/j.yexcr.2005.11.027; KISS A, 1995, SUPPORT CARE CANCER, V3, P270; Kissil JL, 1999, EMBO J, V18, P353, DOI 10.1093/emboj/18.2.353; Maianski NA, 2003, BLOOD, V101, P1987, DOI 10.1182/blood-2002-02-0522; Marriott JB, 2003, CANCER RES, V63, P593; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Miyazaki T, 2004, J BIOL CHEM, V279, P44667, DOI 10.1074/jbc.M408101200; Miyazaki T, 2002, NAT IMMUNOL, V3, P4, DOI 10.1038/ni0102-4; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; Morgan CJ, 2001, BIOCHEM BIOPH RES CO, V280, P177, DOI 10.1006/bbrc.2000.4119; Mukamel Z, 2004, J BIOL CHEM, V279, P36732, DOI 10.1074/jbc.M400041200; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Saveanu C, 2001, J BIOL CHEM, V276, P15861, DOI 10.1074/jbc.M010864200; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Stupack DG, 2004, NAT CELL BIOL, V6, P388, DOI 10.1038/ncb0504-388; Tizon B, 1999, YEAST, V15, P145, DOI 10.1002/(SICI)1097-0061(19990130)15:2<145::AID-YEA346>3.0.CO;2-J; van Hoof A, 2002, SCIENCE, V295, P2262, DOI 10.1126/science.1067272; Vasudevan S, 2002, BIOESSAYS, V24, P785, DOI 10.1002/bies.10153; Zhang XD, 2004, MOL CANCER THER, V3, P187	33	43	43	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					188	196		10.1096/fj.06-6283com	http://dx.doi.org/10.1096/fj.06-6283com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135360				2022-12-28	WOS:000243130200020
J	Tahara, EB; Barros, MH; Oliveira, GA; Netto, LES; Kowaltowski, AJ				Tahara, Erich B.; Barros, Mario H.; Oliveira, Graciele A.; Netto, Luis E. S.; Kowaltowski, Alicia J.			Dihydrolipoyl dehydrogenase as a source of reactive oxygen species inhibited by caloric restriction and involved in Saccharomyces cerevisiae aging	FASEB JOURNAL			English	Article						free radicals; yeast; senescence; alpha-ketoglutarate dehydrogenase	LIFE-SPAN EXTENSION; ALPHA-KETOGLUTARATE DEHYDROGENASE; OXIDATIVE STRESS; HISTONE DEACETYLASE; DIETARY RESTRICTION; RAT-BRAIN; COMPLEX-I; YEAST; DAMAGE; MITOCHONDRIA	Replicative life span in Saccharomyces cerevisiae is increased by glucose (G1c) limitation [ calorie restriction (CR)] and by augmented NAD(+). Increased survival promoted by CR was attributed previously to the NAD(+)-dependent histone deacetylase activity of sirtuin family protein Sir2p but not to changes in redox state. Here we show that strains defective in NAD(+) synthesis and salvage pathways (pnc1 Delta, npt1 Delta, and bna6 Delta) exhibit decreased oxygen consumption and increased mitochondrial H2O2 release, reversed over time by CR. These null mutant strains also present decreased chronological longevity in a manner rescued by CR. Furthermore, we observed that changes in mitochondrial H2O2 release alter cellular redox state, as attested by measurements of total, oxidized, and reduced glutathione. Surprisingly, our results indicate that matrix-soluble dihydrolipoyl-dehydrogenases are an important source of CR-preventable mitochondrial reactive oxygen species (ROS). Indeed, deletion of the LPD1 gene prevented oxidative stress in npt1 Delta and bna6 Delta mutants. Furthermore, pyruvate and alpha-ketoglutarate, substrates for dihydrolipoyl dehydrogenase-containing enzymes, promoted pronounced reactive oxygen release in permeabilized wild-type mitochondria. Altogether, these results substantiate the concept that mitochondrial ROS can be limited by caloric restriction and play an important role in S. cerevisiae senescence. Furthermore, these findings uncover dihydrolipoyl dehydrogenase as an important and novel source of ROS leading to life span limitation.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil; Univ Estadual Paulista, Inst Biociencias, Dept Genet, Botucatu, SP, Brazil; Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Inst Biociencias, Dept Biol, BR-05508900 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade Estadual Paulista; Universidade de Sao Paulo; Universidade de Sao Paulo	Kowaltowski, AJ (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, 748, BR-05508900 Sao Paulo, Brazil.	alicia@iq.usp.br	Kowaltowski, Alicia J/H-8698-2012; Almeida de Oliveira, Graciele/E-9509-2010; Barros, Mario/Q-6358-2019; Netto, Luis/A-3783-2008; Barros, Mario H/B-8118-2012	Almeida de Oliveira, Graciele/0000-0002-9722-3096; Barros, Mario/0000-0003-2977-9815; Netto, Luis/0000-0002-4250-9177; 				Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005; Barros MH, 2004, J BIOL CHEM, V279, P49883, DOI 10.1074/jbc.M408918200; Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002; Brookes PS, 2005, FREE RADICAL BIO MED, V38, P12, DOI 10.1016/j.freeradbiomed.2004.10.016; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; DICKINSON JR, 1986, MOL GEN GENET, V204, P103; Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; Fabrizio P, 2003, AGING CELL, V2, P73, DOI 10.1046/j.1474-9728.2003.00033.x; Fabrizio P, 2003, GENETICS, V163, P35; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Harman D, 2003, ANTIOXID REDOX SIGN, V5, P557, DOI 10.1089/152308603770310202; Harris N, 2003, FREE RADICAL BIO MED, V34, P1599, DOI 10.1016/S0891-5849(03)00210-7; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Jazwinski SM, 2005, MECH AGEING DEV, V126, P243, DOI 10.1016/j.mad.2004.08.016; Jiang JC, 2000, FASEB J, V14, P2135; Jiang JC, 2002, EXP GERONTOL, V37, P1023, DOI 10.1016/S0531-5565(02)00064-5; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kim S, 1999, MOL BIOL CELL, V10, P3125, DOI 10.1091/mbc.10.10.3125; Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027; Kowaltowski AJ, 2000, FEBS LETT, V473, P177, DOI 10.1016/S0014-5793(00)01526-X; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Lambert AJ, 2004, AM J PHYSIOL-REG I, V286, pR71, DOI 10.1152/ajpregu.00341.2003; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Merry BJ, 2004, AGING CELL, V3, P7, DOI 10.1046/j.1474-9728.2003.00074.x; Millard PJ, 1997, APPL ENVIRON MICROB, V63, P2897, DOI 10.1128/AEM.63.7.2897-2905.1997; Monteiro G, 2004, ARCH BIOCHEM BIOPHYS, V425, P14, DOI 10.1016/j.abb.2004.03.005; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; Panozzo C, 2002, FEBS LETT, V517, P97, DOI 10.1016/S0014-5793(02)02585-1; Radak Z, 1998, LIFE SCI, V62, P1317, DOI 10.1016/S0024-3205(98)00065-4; Reverter-Branchat G, 2004, J BIOL CHEM, V279, P31983, DOI 10.1074/jbc.M404849200; Sanz A, 2005, J BIOENERG BIOMEMBR, V37, P83, DOI 10.1007/s10863-005-4131-0; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Skulachev VP, 2004, AGING CELL, V3, P17, DOI 10.1111/j.1474-9728.2003.00076.x; Skulachev VP, 1997, BIOSCIENCE REP, V17, P347, DOI 10.1023/A:1027344914565; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stadtman ER, 2004, CURR MED CHEM, V11, P1105, DOI 10.2174/0929867043365341; Starkov AA, 1997, BIOSCIENCE REP, V17, P273, DOI 10.1023/A:1027380527769; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Tretter L, 2004, J NEUROSCI, V24, P7771, DOI 10.1523/JNEUROSCI.1842-04.2004; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; WALFORD RL, 1987, J NUTR, V117, P1650, DOI 10.1093/jn/117.10.1650	50	89	94	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2007	21	1					274	283		10.1096/fj.06-6686com	http://dx.doi.org/10.1096/fj.06-6686com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17110466				2022-12-28	WOS:000243130200030
J	Contin, MA; Verra, DM; Guido, ME				Contin, Maria Ana; Verra, Daniela M.; Guido, Mario E.			An invertebrate-like phototransduction cascade mediates light detection in the chicken retinal ganglion cells	FASEB JOURNAL			English	Article						RGCs; rhabdomeric photoreceptors; melatonin; phosphoinositide cascade	PINEAL-GLAND; NON-CONE; NON-ROD; DIFFERENTIAL REGULATION; N-ACETYLTRANSFERASE; CYCLIC-AMP; EXPRESSION; MELATONIN; PHOTORECEPTORS; LOCALIZATION	Prebilaterian animals perceived ambient light through nonvisual rhabdomeric photoreceptors (RPs), which evolved as support of the chordate visual system. In vertebrates, the identity of nonvisual photoreceptors and the phototransduction cascade involved in nonimage forming tasks remain uncertain. We investigated whether chicken retinal ganglion cells (RGCs) could be nonvisual photoreceptors and the nature of the photocascade involved. We found that primary cultures of chicken embryonic RGCs express such RP markers as transcription factors Pax6 and Brn3, photopigment melanopsin, and G-protein q but not markers for ciliary photoreceptors (alpha-transducin and Crx). To investigate the photoreceptive capability of RGCs, we assessed the direct effect of light on H-3-melatonin synthesis in RGC cultures synchronized to 12: 12 h light-dark cycles. In constant dark, RGCs displayed a daily variation in 3H-melatonin levels peaking at subjective day, which was significantly inhibited by light. This light effect was further increased by the chromophore all-trans-retinal and suppressed by specific inhibitors of the invertebrate photocascade involving phosphoinositide hydrolysis (100 mu M neomycin; 5 mu M U73122) and Ca2+ mobilization (10 mM BAPTA; 1 mM lanthanum). The results demonstrate that chicken RGCs are intrinsically photosensitive RPs operating via an invertebrate-like phototransduction cascade, which may be responsible for early detection of light before vision occurs.	Univ Nacl Cordoba, CIQUIBIC, Dept Quim Biol, Fac Ciencias Quim,CONICET, RA-5000 Cordoba, Argentina	National University of Cordoba	Guido, ME (corresponding author), Univ Nacl Cordoba, CIQUIBIC, Dept Quim Biol, Fac Ciencias Quim,CONICET, Ciudad Univ, RA-5000 Cordoba, Argentina.	mguido@mail.fcq.unc.edu.ar						Arendt D, 2003, INT J DEV BIOL, V47, P563; Babity J M, 1997, Methods Mol Biol, V85, P285; Bailey MJ, 2004, INVEST OPHTH VIS SCI, V45, P769, DOI 10.1167/iovs.03-1125; Bailey MJ, 2002, FEBS LETT, V513, P169, DOI 10.1016/S0014-5793(02)02276-7; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Berson DM, 2003, TRENDS NEUROSCI, V26, P314, DOI 10.1016/S0166-2236(03)00130-9; Bradford RL, 2005, DEV BIOL, V286, P31, DOI 10.1016/j.ydbio.2005.07.002; Brewer GJ, 2003, J NEUROSURG, V98, P1291, DOI 10.3171/jns.2003.98.6.1291; Brewer GJ, 2001, J NEUROSCI METH, V107, P15, DOI 10.1016/S0165-0270(01)00342-9; Brocco M, 2003, J NEUROSCI RES, V74, P744, DOI 10.1002/jnr.10781; Brocco MA, 1999, DEV BRAIN RES, V118, P23, DOI 10.1016/S0165-3806(99)00120-0; CAHILL GM, 1989, P NATL ACAD SCI USA, V86, P1098, DOI 10.1073/pnas.86.3.1098; Chaurasia SS, 2005, J NEUROCHEM, V92, P158, DOI 10.1111/j.1471-4159.2004.02874.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crousillac S, 2003, VISUAL NEUROSCI, V20, P453, DOI 10.1017/S0952523803204107; David-Gray ZK, 1998, NAT NEUROSCI, V1, P655, DOI 10.1038/3656; Dunlap J.C., 2004, CHRONOBIOLOGY BIOL T; Erkman L, 2000, NEURON, V28, P779, DOI 10.1016/S0896-6273(00)00153-7; FAILLACE MP, 1994, J NEUROCHEM, V62, P1995; Foster RG, 2002, PROG RETIN EYE RES, V21, P507, DOI 10.1016/S1350-9462(02)00036-8; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; Fu YB, 2005, P NATL ACAD SCI USA, V102, P10339, DOI 10.1073/pnas.0501866102; Garbarino-Pico E, 2004, J BIOL CHEM, V279, P51172, DOI 10.1074/jbc.M309248200; Garbarino-Pico E, 2004, J NEUROSCI RES, V76, P642, DOI 10.1002/jnr.20126; Guido ME, 2002, NEUROCHEM RES, V27, P1473, DOI 10.1023/A:1021696321391; Guido ME, 2001, J NEUROCHEM, V76, P835, DOI 10.1046/j.1471-4159.2001.00081.x; Hardie RC, 2001, NATURE, V413, P186, DOI 10.1038/35093002; Holthues H, 2004, BRAIN RES, V999, P175, DOI 10.1016/j.brainres.2003.11.059; Isoldi MC, 2005, P NATL ACAD SCI USA, V102, P1217, DOI 10.1073/pnas.0409252102; Iuvone PM, 2005, PROG RETIN EYE RES, V24, P433, DOI 10.1016/j.preteyeres.2005.01.003; Klein DC, 2004, J BIOL RHYTHM, V19, P264, DOI 10.1177/0748730404267340; KLEIN DC, 1969, ANAL BIOCHEM, V31, P480, DOI 10.1016/0003-2697(69)90290-5; Liu W, 2000, DEVELOPMENT, V127, P3237; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Melyan Z, 2005, NATURE, V433, P741, DOI 10.1038/nature03344; Mey J, 2000, BRAIN RES REV, V32, P343, DOI 10.1016/S0165-0173(99)00022-3; Morin F, 2001, J NEUROCHEM, V78, P88, DOI 10.1046/j.1471-4159.2001.00407.x; Panda S, 2005, SCIENCE, V307, P600, DOI 10.1126/science.1105121; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Qiu XD, 2005, NATURE, V433, P745, DOI 10.1038/nature03345; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Selby CP, 2000, P NATL ACAD SCI USA, V97, P14697, DOI 10.1073/pnas.260498597; Sernagor E, 2005, CURR BIOL, V15, pR556, DOI 10.1016/j.cub.2005.07.004; TESSIERLAVIGNE M, 1991, PRINCIPLES NEURAL SC, P400; UKHANOV K, 1995, CELL CALCIUM, V18, P301, DOI 10.1016/0143-4160(95)90026-8; Wang X, 2000, Chin J Dent Res, V3, P16; Wang Y, 2002, CELL CALCIUM, V32, P209, DOI 10.1016/S0143416002001562; Zatz M, 2000, J NEUROCHEM, V74, P2315, DOI 10.1046/j.1471-4159.2000.0742315.x	48	54	55	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2648	+		10.1096/fj.06-6133fje	http://dx.doi.org/10.1096/fj.06-6133fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077288				2022-12-28	WOS:000242490700053
J	Cuellar, H; Kim, JA; Unguez, GA				Cuellar, Heriberto; Kim, Jung A.; Unguez, Graciela A.			Evidence of post-transcriptional regulation in the maintenance of a partial muscle phenotype by electrogenic cells of S-macrurus	FASEB JOURNAL			English	Article						electric fish; electric organ; muscle proteins; muscle gene regulation	GYMNOTIFORM ELECTRIC FISH; CREATINE-KINASE; SKELETAL-MUSCLE; COMMUNICATION SIGNALS; MESSENGER-RNA; TROPONIN-T; EXPRESSION; ORGAN; PROTEINS; PROMOTER	Electrocytes, the current-producing cells of electric organs (EOs) in electric fish, are unique in that they derive from striated muscle and they possess biochemical characteristics of both muscle and non-muscle cells. In the freshwater teleost Sternopygus macrurus, electrocytes are multinucleated cells that do not contract yet retain expression of some proteins common to skeletal muscle cells. Given the role that transcriptional regulation plays in the activation of the myogenic program in vertebrates, we examined the expression patterns of several genes associated with multiple functions of skeletal muscle in mature electrocytes of S. macrurus. Our expression analyses detected transcripts for alpha-actin, alpha-acetylcholine (ACh) receptor (alpha-AChR), desmin, muscle creatine kinase (MCK), myosin heavy chain (MHC) isoforms, titin, tropomyosin, and troponin-T genes in the EO. However, immunolabeling studies revealed that electrocytes do not contain MCK, MHCs, or tropomyosin or troponin-T proteins. These results underscore the contribution of gene regulatory mechanisms in the maintenance of the muscle-like phenotype of EO that may be transcriptional-independent. We also report the classification and frequency of distinct transcripts from a random selection of 420 clones from an EO cDNA library. This is the first characterization of expressed genes in an EO, and it is an important step toward identifying mechanisms that affect different muscle protein systems for the evolution of highly specialized noncontractile tissues. Evidence of post-transcriptional regulation in the maintenance of a partial muscle phenotype by electrogenic cells of S. macrurus.-Cuellar, H., Jung, K. A., and Unguez, G. A. Evidence of post-transcriptional regulation in the maintenance of a partial muscle phenotype by electrogenic cells of S. macrurus.	New Mexico State Univ, Dept Biol, Las Cruces, NM 88003 USA	New Mexico State University	Unguez, GA (corresponding author), New Mexico State Univ, Dept Biol, Foster Hall, Las Cruces, NM 88003 USA.	gunguez@nmsu.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM061222] Funding Source: NIH RePORTER; NCRR NIH HHS [RR16480-01] Funding Source: Medline; NIGMS NIH HHS [GM061222-05] Funding Source: Medline; PHS HHS [S06-GMO8136-27] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABE H, 1986, DEV BIOL, V118, P42, DOI 10.1016/0012-1606(86)90071-0; Arnegard ME, 2005, P ROY SOC B-BIOL SCI, V272, P1305, DOI 10.1098/rspb.2005.3101; Bass A.H., 1986, P13; Bastian J, 2004, NEURON, V41, P767, DOI 10.1016/S0896-6273(04)00071-6; Basyuk E, 2000, Nucleic Acids Res, V28, pE46, DOI 10.1093/nar/28.10.e46; BENNET MVL, 1971, ANN NY ACAD SCI, V54, P458; Berkes CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI 10.1016/j.semcdb.2005.07.006; Brand-Saberi B, 2005, ANN ANAT, V187, P199, DOI 10.1016/j.aanat.2004.12.018; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; Chakkalakal JV, 2003, BIOESSAYS, V25, P25, DOI 10.1002/bies.10205; Deschenes-Furry J, 2005, J BIOL CHEM, V280, P25361, DOI 10.1074/jbc.M410929200; EILERTSEN KJ, 1992, J CELL BIOL, V119, P549, DOI 10.1083/jcb.119.3.549; EKSTROM TJ, 1993, DNA CELL BIOL, V12, P63, DOI 10.1089/dna.1993.12.63; FABBRIZIO E, 1993, NEUROSCI LETT, V155, P51, DOI 10.1016/0304-3940(93)90671-7; Fortune ES, 2000, J NEUROSCI, V20, P7122, DOI 10.1523/JNEUROSCI.20-18-07122.2000; FOX GQ, 1978, J COMP NEUROL, V179, P677, DOI 10.1002/cne.901790313; Furlong EE, 2004, CURR OPIN GENET DEV, V14, P343, DOI 10.1016/j.gde.2004.06.011; HAGEDORN M, 1992, J NEUROBIOL, V23, P1446, DOI 10.1002/neu.480231007; Hoover F, 2002, MOL CELL NEUROSCI, V19, P125, DOI 10.1006/mcne.2001.1053; Keller TCS, 2000, ADV EXP MED BIOL, V481, P265; Kim JA, 2004, DEV GENES EVOL, V214, P380, DOI 10.1007/s00427-004-0421-5; Kiri A, 2002, J MUSCLE RES CELL M, V23, P119, DOI 10.1023/A:1020211729728; KIRSCHBAUM F, 1977, NATURWISSENSCHAFTEN, V64, P387, DOI 10.1007/BF00368748; Lange S, 2006, TRENDS CELL BIOL, V16, P11, DOI 10.1016/j.tcb.2005.11.007; LI H, 1993, NUCLEIC ACIDS RES, V21, P335, DOI 10.1093/nar/21.2.335; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MOSS JB, 1994, J BIOL CHEM, V269, P12731; Nikcevic G, 2000, J MUSCLE RES CELL M, V21, P599, DOI 10.1023/A:1026507727700; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; Patterson JM, 1997, DEV BIOL, V186, P115, DOI 10.1006/dbio.1997.8580; Patterson JM, 1996, J COMP NEUROL, V370, P367, DOI 10.1002/(SICI)1096-9861(19960701)370:3<367::AID-CNE7>3.0.CO;2-2; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; Qi M, 1997, AM J PHYSIOL-CELL PH, V273, pC394, DOI 10.1152/ajpcell.1997.273.2.C394; QUEST AFG, 1990, FEBS LETT, V269, P457, DOI 10.1016/0014-5793(90)81215-A; Rome LC, 1996, P NATL ACAD SCI USA, V93, P8095, DOI 10.1073/pnas.93.15.8095; ROME LC, 1992, J EXP BIOL, V163, P259; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sisneros JA, 2000, J NEUROSCI, V20, P8586, DOI 10.1523/JNEUROSCI.20-22-08586.2000; Stoddard PK, 2003, J EXP BIOL, V206, P1353, DOI 10.1242/jeb.00252; SUGIURA T, 1990, BIOMED RES-TOKYO, V11, P87, DOI 10.2220/biomedres.11.87; Swoap SJ, 1998, AM J PHYSIOL-CELL PH, V274, pC681, DOI 10.1152/ajpcell.1998.274.3.C681; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; Unguez GA, 1998, J COMP NEUROL, V399, P20; Unguez GA, 1998, J NEUROSCI, V18, P9924; VISCHER HA, 1989, J COMP NEUROL, V290, P16, DOI 10.1002/cne.902900103; Vracar-Grabar M, 2004, J MUSCLE RES CELL M, V25, P397, DOI 10.1007/s10974-004-1141-1; WALLIMANN T, 1990, PROG CLIN BIOL RES, V344, P877; WHITING PJ, 1987, J NEUROSCI, V7, P4005; WILKINSON JM, 1984, EUR J BIOCHEM, V143, P47, DOI 10.1111/j.1432-1033.1984.tb08337.x; Zakon HH, 1999, BRAIN BEHAV EVOLUT, V54, P61, DOI 10.1159/000006612; Zakon HH, 1996, DEV NEUROSCI-BASEL, V18, P115, DOI 10.1159/000111399; ZAKON HH, 1991, J COMP PHYSIOL A, V169, P493	54	13	13	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2540	+		10.1096/fj.06-6474fje	http://dx.doi.org/10.1096/fj.06-6474fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077280				2022-12-28	WOS:000242490700016
J	Jiang, H; Olson, MV; Medrano, DR; Lee, OH; Xu, J; Piao, Y; Alonso, MM; Gomez-Manzano, C; Hung, MC; Yung, WKA; Fueyo, J				Jiang, Hong; Olson, Melissa V.; Medrano, Diana R.; Lee, Ok-Hee; Xu, Jing; Piao, Yuji; Alonso, Marta M.; Gomez-Manzano, Candelaria; Hung, Mien-Chie; Yung, W. K. Alfred; Fueyo, Juan			A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation	FASEB JOURNAL			English	Article						leptomycin B; NES; NLS	HISTONE H1 PHOSPHORYLATION; LOCALIZATION SIGNAL; EXPRESSION; ONCOPROTEIN; TRANSPORT; PROMOTER; XENOPUS; TYPE-5; KINASE; REGION	Adenoviral E1A is a versatile protein that can reprogram host cells for efficient viral replication. The nuclear import of E1A is mediated by a nuclear localization signal; however, whether E1A can be actively exported from the nucleus is unknown. We first reported a CRM1-dependent nuclear export signal (NES) in E1A that is conserved in the group C adeno-viruses. We showed that CRM1 and E1A coimmunoprecipitated and that blockage of CRM1 function by leptomycin B or small interfering RNA resulted in the nuclear localization of E1A. Through mutational analyses, we identified an active canonical NES element within the E1A protein spanning amino acids 70-80. We further demonstrated that phosphorylation of adjacent serine (S) 89 resulted in the cytoplasmic accumulation of E1A. Interestingly, coincident with the accumulation of cells in the S/G(2)/M phase and histone H1 phosphorylation, E1A was relocated to the cytoplasm at the late stage of the viral cycle, which was blocked by the CDC2/CDK2 inhibitor roscovitine. Importantly, titration of the progenies of the viruses in infected cells showed that the replication efficiency of the NES mutant adenovirus was up to 500-fold lower than that of the wild-type adenovirus. Collectively, our data demonstrate the existence of a NES in E1A that is modulated by the phosphorylation of the S89 residue and the NES plays a role for an efficient viral replication in the host cells.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Brain Tumor Ctr, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Jiang, H (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Brain Tumor Ctr, 1515 Holcombe Blvd,Unit 1002, Houston, TX 77030 USA.	hjiang@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021; Alonso, Marta M/AAI-9457-2020	Hung, Mien-Chie/0000-0003-4317-4740; Alonso, Marta M/0000-0002-7520-7351; Fueyo, Juan/0000-0001-6941-2335; Gomez-Manzano, Candelaria/0000-0002-1259-2133				Alexandrow MG, 2005, J CELL BIOL, V168, P875, DOI 10.1083/jcb.200409055; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Doree M, 2002, J CELL SCI, V115, P2461; DUMONT DJ, 1993, J GEN VIROL, V74, P583, DOI 10.1099/0022-1317-74-4-583; DUMONT DJ, 1992, VIROLOGY, V189, P111, DOI 10.1016/0042-6822(92)90686-J; Fax P, 2001, VIROLOGY, V285, P30, DOI 10.1006/viro.2001.0926; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fontoura BMA, 2005, IUBMB LIFE, V57, P65, DOI 10.1080/15216540500078608; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Halmer L, 1996, NUCLEIC ACIDS RES, V24, P1420, DOI 10.1093/nar/24.8.1420; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jiang H, 2005, NEOPLASIA, V7, P723, DOI 10.1593/neo.04793; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; JONES N, 1978, CELL, V13, P181, DOI 10.1016/0092-8674(78)90148-4; Kohler M, 2001, VIROLOGY, V289, P186, DOI 10.1006/viro.2001.1151; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; Madison DL, 2002, J BIOL CHEM, V277, P38755, DOI 10.1074/jbc.M207512200; Mal A, 1996, J VIROL, V70, P2911, DOI 10.1128/JVI.70.5.2911-2921.1996; Mangel WF, 2003, CELL MOL LIFE SCI, V60, P2347, DOI 10.1007/s00018-003-2318-2; Padmanabhan R, 2003, CURR TOP MICROBIOL, V272, P365; RICHTER JD, 1985, P NATL ACAD SCI USA, V82, P8434, DOI 10.1073/pnas.82.24.8434; Sang NL, 2002, FRONT BIOSCI, V7, pD407, DOI 10.2741/sang; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Shimada A, 1998, BIOL CELL, V90, P519, DOI 10.1016/S0248-4900(99)80010-0; STANDIFORD DM, 1992, J CELL BIOL, V118, P991, DOI 10.1083/jcb.118.5.991; TREMBLAY ML, 1989, VIROLOGY, V169, P397, DOI 10.1016/0042-6822(89)90165-7; Vertegaal ACO, 2003, J BIOL CHEM, V278, P139, DOI 10.1074/jbc.M206267200; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Whalen SG, 1996, J VIROL, V70, P5373, DOI 10.1128/JVI.70.8.5373-5383.1996; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; Wolff R, 1997, GENOME ANAL, V1, P1; Zhang ZY, 2001, MOL BIOL CELL, V12, P699, DOI 10.1091/mbc.12.3.699	39	10	10	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2603	+		10.1096/fj.06-6433fje	http://dx.doi.org/10.1096/fj.06-6433fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065226				2022-12-28	WOS:000242490700038
J	Kang, JM; Iovine, NM; Blaser, MJ				Kang, Josephine M.; Iovine, Nicole M.; Blaser, Martin J.			A paradigm for direct stress-induced mutation in prokaryotes	FASEB JOURNAL			English	Article						adaptation; repetitive DNA; reactive nitrogen species; ROS	PATHOGEN HELICOBACTER-PYLORI; ESCHERICHIA-COLI; NITRIC-OXIDE; NATURAL TRANSFORMATION; INDUCED MUTAGENESIS; GENETIC DIVERSITY; ERROR-PRONE; DNA-DAMAGE; HUMAN HOST; BACTERIA	Environmental stresses may lead to selection for hypermutator bacterial cells, which have an increased chance of generating beneficial variants. With stress removal, cost of mutation exceeds the fitness advantage, selecting against hypermutators. Hypermutators arise through several mechanisms, including inactivation of mismatch repair genes (MMR) or induction of error-prone polymerases. Helicobacter pylori may provide an alternative mechanism of stress-induced mutagenesis, since it lacks the MMR genes and error-prone polymerases found in other bacterial species, and possesses an endogenously high mutation frequency. In this study, we expose H. pylori strains to reactive oxygen species and reactive nitrogen species, stressors found in their natural environment. These exposures directly resulted in elevated rates of spontaneous point mutation, deletion between direct repeats, and intergenomic recombination. We demonstrate that these effects are transient and do not involve selection for hypermutator strains. That H. pylori possesses direct repeats in regions where potential gene rearrangements can occur suggests a mechanism for targeted mutation in response to stress that avoids the deleterious fitness costs of fixed hypermutation. These studies provide a new paradigm for adaptation under increased selective pressures that may be present in other prokaryotes.-Kang, J. M., Iovine, N. M., Blaser, M. J. A paradigm for direct stress-induced mutation in prokaryotes.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; VA Med Ctr, New York, NY USA	New York University; New York University	Kang, JM (corresponding author), NYU, Sch Med, Dept Med, 550 1St Ave, New York, NY 10016 USA.	kangm01@med.nyu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM62370, 5T32 GM07308] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akaike T, 2000, FASEB J, V14, P1447, DOI 10.1096/fj.14.10.1447; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Alm RA, 1999, J MOL MED, V77, P834, DOI 10.1007/s001099900067; Ando T, 1999, J BACTERIOL, V181, P5572, DOI 10.1128/JB.181.18.5572-5580.1999; Aras RA, 2003, P NATL ACAD SCI USA, V100, P13579, DOI 10.1073/pnas.1735481100; Aras RA, 2003, J EXP MED, V198, P1349, DOI 10.1084/jem.20030381; Aras RA, 2003, J INFECT DIS, V188, P486, DOI 10.1086/377098; Aras RA, 2001, MOL MICROBIOL, V42, P369, DOI 10.1046/j.1365-2958.2001.02637.x; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; Bagchi D, 2002, DIGEST DIS SCI, V47, P1405, DOI 10.1023/A:1015399204069; Bjedov I, 2003, SCIENCE, V300, P1404, DOI 10.1126/science.1082240; Bjorkholm B, 2001, P NATL ACAD SCI USA, V98, P14607, DOI 10.1073/pnas.241517298; Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI [10.1172/JCI200420925, 10.1172/JCI20925]; Blaser MJ, 1999, P NATL ACAD SCI USA, V96, P8359, DOI 10.1073/pnas.96.15.8359; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; Chang CS, 2004, WORLD J GASTROENTERO, V10, P2232; Chopra I, 2003, DRUG RESIST UPDATE, V6, P137, DOI 10.1016/S1368-7646(03)00041-4; Dawson KJ, 1999, THEOR POPUL BIOL, V55, P1, DOI 10.1006/tpbi.1998.1375; De Luca A, 2004, CANCER LETT, V213, P1, DOI 10.1016/j.canlet.2004.06.006; de Visser JAGM, 2002, MICROBIOL-SGM, V148, P1247, DOI 10.1099/00221287-148-5-1247; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; Feng G, 1996, J BACTERIOL, V178, P2388, DOI 10.1128/jb.178.8.2388-2396.1996; Giraud A, 2002, ANTIMICROB AGENTS CH, V46, P863, DOI 10.1128/AAC.46.3.863-865.2002; Heep M, 2000, ANTIMICROB AGENTS CH, V44, P1713, DOI 10.1128/AAC.44.6.1713-1715.2000; Hengge-Aronis R, 2002, MICROBIOL MOL BIOL R, V66, P373, DOI 10.1128/MMBR.66.3.373-395.2002; HUANG S, 2006, IN PRESS J BACTERIOL; Israel DA, 2000, FEMS MICROBIOL LETT, V186, P275, DOI 10.1016/S0378-1097(00)00156-7; Israel DA, 2001, P NATL ACAD SCI USA, V98, P14625, DOI 10.1073/pnas.251551698; Kang J, 2005, J BACTERIOL, V187, P3528, DOI 10.1128/JB.187.10.3528-3537.2005; Kang J, 2004, J BACTERIOL, V186, P7704, DOI 10.1128/JB.186.22.7704-7713.2004; KANG J, 2006, IN PRESS J BACTERIOL; Kuipers EJ, 2000, J INFECT DIS, V181, P273, DOI 10.1086/315173; Kuipers EJ, 1998, J BACTERIOL, V180, P2901, DOI 10.1128/JB.180.11.2901-2905.1998; Kurtz S, 1999, BIOINFORMATICS, V15, P426, DOI 10.1093/bioinformatics/15.5.426; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; Li BG, 2003, MICROBIOL-SGM, V149, P1323, DOI 10.1099/mic.0.26213-0; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; Moran AP, 2002, J BIOL CHEM, V277, P5785, DOI 10.1074/jbc.M108574200; Negri MC, 2002, ANTIMICROB AGENTS CH, V46, P528, DOI 10.1128/AAC.46.2.528-530.2002; Normark S, 2003, ADV CANCER RES, V90, P63, DOI 10.1016/S0065-230X(03)90002-9; Oliver A, 2000, SCIENCE, V288, P1251, DOI 10.1126/science.288.5469.1251; Ouchane S, 1997, EMBO J, V16, P4777, DOI 10.1093/emboj/16.15.4777; Pham P, 2001, P NATL ACAD SCI USA, V98, P8350, DOI 10.1073/pnas.111007198; Richardson AR, 2002, P NATL ACAD SCI USA, V99, P6103, DOI 10.1073/pnas.092568699; Robinson K, 2005, J INFECT DIS, V191, P579, DOI 10.1086/427657; Rocha EPC, 2002, NUCLEIC ACIDS RES, V30, P1886, DOI 10.1093/nar/30.9.1886; Rosche WA, 1999, P NATL ACAD SCI USA, V96, P6862, DOI 10.1073/pnas.96.12.6862; Solca NM, 2000, ANTIMICROB AGENTS CH, V44, P2207, DOI 10.1128/AAC.44.8.2207-2210.2000; SRIKHANTA YN, 2005, P NATL ACAD SCI US; Suerbaum S, 1998, P NATL ACAD SCI USA, V95, P12619, DOI 10.1073/pnas.95.21.12619; Tenaillon O, 2004, TRENDS MICROBIOL, V12, P264, DOI 10.1016/j.tim.2004.04.002; Tenaillon O, 1999, GENETICS, V152, P485; Tenaillon O, 2001, RES MICROBIOL, V152, P11, DOI 10.1016/S0923-2508(00)01163-3; Tippin B, 2004, TRENDS MICROBIOL, V12, P288, DOI 10.1016/j.tim.2004.04.004; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Yoshitake J, 2004, J VIROL, V78, P8709, DOI 10.1128/JVI.78.16.8709-8719.2004; Zahrt TC, 1997, P NATL ACAD SCI USA, V94, P9786, DOI 10.1073/pnas.94.18.9786	61	23	26	2	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2476	2485		10.1096/fj.06-6209com	http://dx.doi.org/10.1096/fj.06-6209com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17142797				2022-12-28	WOS:000242490700008
J	Mariggio, S; Sebastia, J; Filippi, BM; Iurisci, C; Volonte, C; Amadio, S; De Falco, V; Santoro, M; Corda, D				Mariggio, Stefania; Sebastia, Jordi; Filippi, Beatrice Maria; Iurisci, Cristiano; Volonte, Cinzia; Amadio, Susanna; De Falco, Valentina; Santoro, Massimo; Corda, Daniela			A novel pathway of cell growth regulation mediated by a PLA(2)alpha-derived phosphoinositide metabolite	FASEB JOURNAL			English	Article						glycerophosphoinositol; phosphatidylinositol; thyroid cells; phospholipases; cell signaling	CYTOSOLIC PHOSPHOLIPASE A(2); THYROID FRTL-5 CELLS; GLYCEROPHOSPHOINOSITOL 4-PHOSPHATE; SIGNALING PATHWAYS; ARACHIDONIC-ACID; EPITHELIAL-CELLS; IODIDE FLUXES; RAS; PROLIFERATION; RELEASE	The phosphoinositides have well-defined roles in the control of cellular functions, including cytoskeleton dynamics, membrane trafficking, and cell signaling. However, the interplay among the phosphoinositides and their diffusible derivatives that originate through phospholipase A(2) action (the lysophosphoinositides and glycerophosphoinositols) remains to be fully elucidated. Here we demonstrate that in PCCl3 rat thyroid cells, the intracellular levels of glycerophosphoinositol are finely modulated by ATP and norepinephrine through the P2Y metabotropic and alpha-adrenergic receptors, respectively. The enzyme involved here is phospholipase A(2) IV alpha (PLA(2)IV alpha), which in these cells specifically hydrolyzes phosphatidylinositol, forming lysophosphatidylinositol, glycerophosphoinositol, and arachidonic acid. This receptor-mediated activation of PLA(2)IV alpha leads to stimulation of PCCl3 cell growth. The involvement of a PLA2IV alpha-mediated pathway is demonstrated by inhibition of the increase in intracellular glycerophosphoinositol levels and cell proliferation by specific inhibitors, RNA interference, and overexpression of the dominant-negative PLA(2)IV alpha(1-522). Modulation of PCCl3 cell growth is not seen with inhibitors of arachidonic acid metabolism. In conclusion, these data characterize glycerophosphoinositol as a mediator of the purinergic and adrenergic regulation of PCCl3 cell proliferation, defining a novel regulatory cascade specifically involving this soluble phosphoinositide derivative and widening the involvement of the phosphoinositides in the regulation of cell function. Mariggio, S., Sebastia, J., Filippi, B. M., Iurisci, C., Volonte, C., Amadio, S., De Falco, V., Santoro, M., Corda, D. A Novel pathway of cell growth regulation mediated by a PLA(2)alpha-derived phosphoinositide metabolite.	Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Chieti, Italy; CNR, Santa Lucia Fdn, Rome, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy; CNR, Ist Endocrinol & Oncol Sperimentale, I-80125 Naples, Italy	Consorzio Mario Negri Sud; Consiglio Nazionale delle Ricerche (CNR); IRCCS Santa Lucia; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	Mariggio, S (corresponding author), Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Via Nazl 8, I-66030 Chieti, Italy.	mariggio@negrisud.it; corda@negrisud.it	Volonté, Cinzia/N-6474-2013; Amadio, Susanna/K-5580-2016; Mariggio', Stefania/H-5467-2015; Corda, Daniela/K-6385-2016; DE FALCO, VALENTINA/C-2061-2015	Volonté, Cinzia/0000-0001-7362-8307; Amadio, Susanna/0000-0002-9266-4597; Mariggio', Stefania/0000-0002-6397-3016; Corda, Daniela/0000-0002-3614-751X; DE FALCO, VALENTINA/0000-0002-8972-7921; Filippi, Beatrice Maria/0000-0002-8816-1559	Telethon [GGP030295] Funding Source: Medline	Telethon(Fondazione Telethon)		ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Berenbaum F, 2003, J BIOL CHEM, V278, P13680, DOI 10.1074/jbc.M211570200; Berrie CP, 2002, EUR J CANCER, V38, P2463, DOI 10.1016/S0959-8049(02)00485-9; Berrie CP, 1999, EUR J BIOCHEM, V266, P413, DOI 10.1046/j.1432-1327.1999.00870.x; Bjorklund S, 2005, MOL CELL ENDOCRINOL, V231, P65, DOI 10.1016/j.mce.2004.12.001; Botitsi E, 1998, J LIPID RES, V39, P1295; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Buccione R, 2005, EUR J CANCER, V41, P470, DOI 10.1016/j.ejca.2004.11.011; BURCH RM, 1986, J BIOL CHEM, V261, P1236; Carlton JG, 2005, TRENDS CELL BIOL, V15, P540, DOI 10.1016/j.tcb.2005.08.005; Choy PC, 1997, BBA-LIPID LIPID MET, V1348, P124, DOI 10.1016/S0005-2760(97)00114-8; CORDA D, 1986, BIOCHEM BIOPH RES CO, V141, P1000, DOI 10.1016/S0006-291X(86)80143-7; Corda D, 2002, BBA-MOL CELL BIOL L, V1582, P52, DOI 10.1016/S1388-1981(02)00137-3; Corda D, 1996, ANTICANCER RES, V16, P1341; Di Cerbo A, 1999, BIOCHIMIE, V81, P415, DOI 10.1016/S0300-9084(99)80090-X; DIGIROLAMO M, 1991, ACTA ENDOCRINOL-COP, V125, P192, DOI 10.1530/acta.0.1250192; Downes CP, 2005, TRENDS CELL BIOL, V15, P259, DOI 10.1016/j.tcb.2005.03.008; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; Falasca M, 1997, MOL BIOL CELL, V8, P443, DOI 10.1091/mbc.8.3.443; FALASCA M, 1995, ONCOGENE, V10, P2113; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Herbert SP, 2005, MOL BIOL CELL, V16, P3800, DOI 10.1091/mbc.E05-02-0164; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8; Klepeis VE, 2001, J CELL SCI, V114, P4185; Kohn L D, 1995, Vitam Horm, V50, P287, DOI 10.1016/S0083-6729(08)60658-5; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Leslie CC, 2004, BIOCHEM CELL BIOL, V82, P1, DOI 10.1139/o03-080; Mancini R, 2003, MOL BIOL CELL, V14, P503, DOI 10.1091/mbc.E02-04-0179; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; MONCADA S, 1988, ANN NY ACAD SCI, V522, P454; MORRIS AJ, 1995, MOL PHARMACOL, V48, P532; Ohto T, 2005, J BIOL CHEM, V280, P24576, DOI 10.1074/jbc.M413711200; Ono T, 2002, BIOCHEM J, V363, P727, DOI 10.1042/0264-6021:3630727; Patton-Vogt JL, 1998, GENETICS, V149, P1707; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Rotman-Pikielny P, 2002, HUM MOL GENET, V11, P2625, DOI 10.1093/hmg/11.21.2625; Snoek GT, 1999, J BIOL CHEM, V274, P35393, DOI 10.1074/jbc.274.50.35393; Tornquist K, 1996, J CELL PHYSIOL, V166, P241; TORNQUIST K, 1991, MOL CELL ENDOCRINOL, V79, P147, DOI 10.1016/0303-7207(91)90105-2; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; Zheng B, 2003, P NATL ACAD SCI USA, V100, P1745, DOI 10.1073/pnas.0337605100	46	29	29	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2567	+		10.1096/fj.05-5397fje	http://dx.doi.org/10.1096/fj.05-5397fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17060404				2022-12-28	WOS:000242490700026
J	Newell, FS; Su, H; Tornqvist, H; Whitehead, JP; Prins, JB; Hutley, LJ				Newell, Felicity S.; Su, Hua; Tornqvist, Hans; Whitehead, Jonathan P.; Prins, Johannes B.; Hutley, Louise J.			Characterization of the transcriptional and functional effects of fibroblast growth factor-1 on human preadipocyte differentiation	FASEB JOURNAL			English	Article						obesity; adipogenesis; mitosis	HUMAN ADIPOCYTE DIFFERENTIATION; MITOTIC CLONAL EXPANSION; ADIPOSE-TISSUE; HIGH-CAPACITY; C/EBP FAMILY; CELL; ADIPOGENESIS; GAMMA; GATA; ROSIGLITAZONE	We recently established that fibroblast growth factor (FGF)-1 promotes adipogenesis of primary human preadipocytes (phPA). In the current report, we have characterized the adipogenic effects of FGF-1 in phPA and also in a human PA strain derived from an individual with Simpson-Golabi-Behmel syndrome (SGBS PA), which exhibit an intrinsic capacity to differentiate with high efficiency. In further studies, we compared these models with the well-characterized murine 3T3-L1 preadipocyte cell line (3T3-L1 PA). FGF-1 up-regulated the adipogenic program in phPA, with increased expression of peroxisome proliferator-activated receptor-gamma in confluent PA prior to induction of differentiation and increased expression of adipocyte markers during differentiation. Moreover, phPA differentiated in the presence of FGF-1 were more insulin responsive and secreted increased levels of adiponectin. FGF-1 treatment of SGBS PA further enhanced differentiation. For the most part, the adipogenic program in phPA paralleled that observed in 3T3-L1 PA; however, we found no evidence of mitotic clonal expansion in the phPA. Finally, we investigated a role for extracellular regulated kinase 1/2 (ERK 1/2) in adipogenesis of phPA. FGF-1 induced robust phosphorylation of ERK1/2 in early differentiation and inhibition of ERK1/2 activity significantly reduced phPA differentiation. These data suggest that FGF-1 treated phPA represent a valuable in vitro model for the study of adipogenesis and insulin action and indicate that ERK1/2 activation is necessary for human adipogenesis in the absence of mitotic clonal expansion.	Univ Queensland, Princess Alexandra Hosp, Ctr Diabet & Endocrine Res, Brisbane, Qld, Australia; Novo Nordisk AS, Diabet Biol, R&D, Malov, Denmark; Lund Univ, Univ Hosp MAS, Dept Clin Sci Diabet & Endocrinol, Malmo, Sweden	University of Queensland; Novo Nordisk; Lund University; Skane University Hospital	Prins, JB (corresponding author), Princess Alexandra Hosp, Ctr Hlth Res, Level 2,Bldg 35,Ipswich rd, Woolloongabba, Qld 4102, Australia.	jprins@cder.soms.uq.edu.au	Prins, Johannes B/M-5884-2013; Prins, Johannes/I-3610-2019; Newell, Felicity/AAN-1253-2020	Prins, Johannes B/0000-0001-9497-927X; Prins, Johannes/0000-0001-9497-927X; Whitehead, Jonathan/0000-0003-3978-3148				Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; Aubin D, 2005, INT J OBESITY, V29, P1006, DOI 10.1038/sj.ijo.0802961; Bell A, 2000, OBES RES, V8, P249, DOI 10.1038/oby.2000.29; Bertrand V, 2003, CELL, V115, P615, DOI 10.1016/S0092-8674(03)00928-0; Bost F, 2005, DIABETES, V54, P402, DOI 10.2337/diabetes.54.2.402; Cho YC, 2004, J CELL BIOCHEM, V91, P336, DOI 10.1002/jcb.10743; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; Darimont C, 2003, BIOCHIMIE, V85, P1231, DOI 10.1016/j.biochi.2003.10.015; Entenmann G, 1996, AM J PHYSIOL-CELL PH, V270, pC1011, DOI 10.1152/ajpcell.1996.270.4.C1011; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fajas L, 2003, ANN MED, V35, P79, DOI 10.1080/07853890310009999; GREGOIRE F, 1990, BIOL CELL, V69, P215, DOI 10.1016/0248-4900(90)90348-7; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106; HARRISON RF, 1991, P INT JOINT C NEURAL, V1, P1; Hauner H, 1998, INT J OBESITY, V22, P448, DOI 10.1038/sj.ijo.0800606; Hidai C, 2003, J MOL CELL CARDIOL, V35, P421, DOI 10.1016/S0022-2828(03)00019-1; Hutley L, 2004, DIABETES, V53, P3097, DOI 10.2337/diabetes.53.12.3097; Hutley LJ, 2003, EUR J CLIN INVEST, V33, P574, DOI 10.1046/j.1365-2362.2003.01178.x; Hutley LJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE1037, DOI 10.1152/ajpendo.2001.281.5.E1037; HUTLEY LNF, 2001, ADIPOSE TISSUE PRIMA, P173; Kortum RL, 2005, MOL CELL BIOL, V25, P7592, DOI 10.1128/MCB.25.17.7592-7604.2005; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Neubauer M, 2004, FEBS LETT, V577, P277, DOI 10.1016/j.febslet.2004.10.020; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Patel NG, 2003, DIABETES, V52, P43, DOI 10.2337/diabetes.52.1.43; Perera RJ, 2006, GENE, V369, P90, DOI 10.1016/j.gene.2005.10.021; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; Tang QQ, 2005, P NATL ACAD SCI USA, V102, P9766, DOI 10.1073/pnas.0503891102; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; TOMIYAMA K, 1995, BIOCHEM BIOPH RES CO, V212, P263, DOI 10.1006/bbrc.1995.1965; Tong Q, 2005, MOL CELL BIOL, V25, P706, DOI 10.1128/MCB.25.2.706-715.2005; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Wabitsch M, 2000, INT J CANCER, V88, P889, DOI 10.1002/1097-0215(20001215)88:6<889::AID-IJC8>3.0.CO;2-N; Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520; Wolf G, 2003, NUTR REV, V61, P290, DOI 10.1301/nr.2003.aug.290-292; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	41	66	69	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2615	+		10.1096/fj.05-5710fje	http://dx.doi.org/10.1096/fj.05-5710fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17068114				2022-12-28	WOS:000242490700042
J	Ahmed, Z; Mazibrada, G; Seabright, RJ; Dent, RG; Berry, M; Logan, A				Ahmed, Zubair; Mazibrada, Gordon; Seabright, Ruth J.; Dent, Russell G.; Berry, Martin; Logan, Ann			TACE-induced cleavage of NgR and p75(NTR) in dorsal root ganglion cultures disinhibits outgrowth and promotes branching of neurites in the presence of inhibitory CNS myelin	FASEB JOURNAL			English	Article						ectodomain shedding; disinhibited DRGN neurite outgrowth; RIP of p75(NTR)	P75 NEUROTROPHIN RECEPTOR; NECROSIS-FACTOR-ALPHA; REGULATED INTRAMEMBRANE PROTEOLYSIS; CHONDROITIN SULFATE PROTEOGLYCANS; OPTIC-NERVE REGENERATION; HUMAN NOGO-66 RECEPTOR; SPINAL-CORD-INJURY; AXONAL REGENERATION; TNF RECEPTOR; PROTEIN 1B	After binding, central nervous system (CNS) myelin-derived axon growth inhibitory ligands, the Nogo-66 receptor (NgR), complexes with LINGO-1 and either the low-affinity neurotrophin receptor (p75(NTR)) or TROY to initiate growth cone collapse via a Rho-A inhibitory signaling pathway and/or Ca2+-dependent activation of epidermal growth factor receptor (EGFR) through an unknown signaling pathway. We have shown that axon growth through CNS myelin is disinhibited after neurotrophic factor administration by 1) initiating intramembranous proteolysis (RIP) of p75NTR, leading to cleavage of the extracellular (p75(ECD)) and intracellular domains (p75(ICD)) by alpha- and gamma-secretase, respectively, thereby paralyzing inhibitory signaling; 2) shedding of soluble NgR(ECD), which acts as a competitive antagonist to NgR for binding of inhibitory ligands; and 3) antagonizing NgR/p75(NTR) clustering by competitive p75(ECD)/NgR interaction. Here, we report that TNF-alpha converting enzyme (TACE) (a disintegrin and metalloproteinase 17, ADAM17) induces disinhibition of FGF2-stimulated neurite outgrowth of dorsal root ganglion neurons (DRGN) cultured in the presence of a predetermined concentration of inhibitory CNS myelin-derived ligands. After addition of TACE (which has alpha-secretase activity) to mitotically arrested adult rat mixed DRG cultures, we demonstrate 1) NgRECD shedding; 2) release of p75ECD and p75ICD by RIP of p75NTR; 3) blockade of Rho-A activation; 4) reduced EGFR phosphorylation; and 5) increased FGF2-stimulated DRGN neurite outgrowth and branching in the presence of CNS myelin-derived inhibitory ligands. Thus, TACE-induced cleavage of NgR and RIP of p75NTR abrogates axon growth inhibitory signaling, thereby disinhibiting CNS axon/neurite growth.	Univ Birmingham, Div Med Sci, Mol Neurosci Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Logan, A (corresponding author), Univ Birmingham, Div Med Sci, Mol Neurosci Grp, Birmingham B15 2TT, W Midlands, England.	a.logan@bham.ac.uk	Ahmed, Zubair/AAN-1869-2021	Logan, Ann/0000-0003-3215-5042	Wellcome Trust [065920] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed Z, 2005, MOL CELL NEUROSCI, V28, P509, DOI 10.1016/j.mcn.2004.11.002; Ahmed Z, 2005, MOL CELL NEUROSCI, V28, P64, DOI 10.1016/j.mcn.2004.08.013; Ahmed Z, 2006, BRAIN, V129, P1517, DOI 10.1093/brain/awl080; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Berry M, 1996, J NEUROCYTOL, V25, P147, DOI 10.1007/BF02284793; Berry M, 1999, J NEUROCYTOL, V28, P721, DOI 10.1023/A:1007086004022; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2004, NAT GENET, V36, P934, DOI 10.1038/ng0904-934; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Bouquet C, 2004, J NEUROSCI, V24, P7204, DOI 10.1523/JNEUROSCI.2254-04.2004; Chao MV, 2002, NEURON, V33, P9, DOI 10.1016/S0896-6273(01)00573-6; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; Dergham P, 2002, J NEUROSCI, V22, P6570; Domeniconi M, 2005, NEURON, V46, P849, DOI 10.1016/j.neuron.2005.05.029; Fischer D, 2004, J NEUROSCI, V24, P1646, DOI 10.1523/JNEUROSCI.5119-03.2004; Fournier AE, 2002, PROG BRAIN RES, V137, P361; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Galko MJ, 2000, SCIENCE, V289, P1365, DOI 10.1126/science.289.5483.1365; Goddard DR, 2001, GLIA, V34, P267, DOI 10.1002/glia.1060; Gonzalez-Billault C, 2002, BRAIN RES, V943, P56, DOI 10.1016/S0006-8993(02)02534-9; Hunt D, 2002, J NEUROCYTOL, V31, P93, DOI 10.1023/A:1023941421781; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Jiang H, 1999, J BIOL CHEM, V274, P26209, DOI 10.1074/jbc.274.37.26209; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kanning KC, 2003, J NEUROSCI, V23, P5425, DOI 10.1523/jneurosci.23-13-05425.2003; Karan D, 2003, INT J ONCOL, V23, P1365; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Landman N, 2004, CYTOKINE GROWTH F R, V15, P337, DOI 10.1016/j.cytogfr.2004.04.001; Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li SX, 2005, MOL CELL NEUROSCI, V29, P26, DOI 10.1016/j.mcn.2004.12.008; Logan A, 2006, BRAIN, V129, P490, DOI 10.1093/brain/awh706; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; Ma D, 2000, NEUROSCIENCE, V99, P157, DOI 10.1016/S0306-4522(00)00141-X; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; McKerracher L, 2002, NEURON, V36, P345, DOI 10.1016/S0896-6273(02)01018-8; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nothias F, 1997, EUR J NEUROSCI, V9, P1553, DOI 10.1111/j.1460-9568.1997.tb01513.x; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Russell JW, 2002, FASEB J, V16, P1738, DOI 10.1096/fj.01-1027com; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; Strittmatter SM, 2002, J MOL NEUROSCI, V19, P117, DOI 10.1007/s12031-002-0021-7; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Teng FYH, 2006, J NEUROCHEM, V96, P1501, DOI 10.1111/j.1471-4159.2006.03663.x; van Deventer SJH, 2002, GUT, V51, P5, DOI 10.1136/gut.51.1.5; Walmsley AR, 2005, BIOCHEM BIOPH RES CO, V327, P112, DOI 10.1016/j.bbrc.2004.12.001; Walmsley AR, 2004, J CELL SCI, V117, P4591, DOI 10.1242/jcs.01324; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	61	70	72	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1939	+		10.1096/fj.05-5339fje	http://dx.doi.org/10.1096/fj.05-5339fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16849393				2022-12-28	WOS:000240267000037
J	Bartfai, T				Bartfai, Tamas			From lab bench to Wall Street	FASEB JOURNAL			English	Editorial Material									Scripps Res Inst, Harold L Dorris Neurol Res Inst, Dept Mol & Integrated Neurosci, La Jolla, CA USA	Scripps Research Institute	Bartfai, T (corresponding author), Scripps Res Inst, Harold L Dorris Neurol Res Inst, Dept Mol & Integrated Neurosci, La Jolla, CA USA.	tbartfai@scripps.edu							0	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1578	1580		10.1096/fj.06-0802ufm	http://dx.doi.org/10.1096/fj.06-0802ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873880				2022-12-28	WOS:000240266600002
J	Craciunescu, CN; Wu, R; Zeisel, SH				Craciunescu, Corneliu N.; Wu, Renan; Zeisel, Steven H.			Diethanolamine alters neurogenesis and induces apoptosis in fetal mouse hippocampus	FASEB JOURNAL			English	Article						choline; pregnancy; brain development	CHOLINE AVAILABILITY ALTERS; EMBRYONIC-DEVELOPMENT ALTERS; METABOLISM; LOCALIZATION; MITOSIS; PHOSPHORYLATION; DEFICIENCY; INHIBITORS	Diethanolamine (DEA) is present in many consumer products such as shampoo. Dermal administration of DEA diminishes hepatic stores of the essential nutrient choline, and we previously reported that dietary choline deficiency during pregnancy reduces neurogenesis and increases apoptosis in the hippocampus of fetal rats and mice. Therefore, DEA could also alter brain development. Timed-pregnant C57BL/ 6 mice were dosed dermally from gestation day 7 through 17 with DEA at 0, 20, 80, 160, 320, and 640 mg/ kg body/ day. At doses of DEA > 80 mg/ kg body/ day, we observed decreased litter size. In fetuses (embryonic day 17) collected from dams treated dermally with 80 mg/ kg body/ day DEA, we observed decreased neural progenitor cell mitosis at the ventricular surface of the ventricular zone of the hippocampus [to 56 +/- 14% (SE) histone 3 (H3) phosphorylation as compared to controls; P < 0.01]. We also observed increased apoptosis in fetal hippocampus (to 170 +/- 10% of control measured using TUNEL and to 178 +/- 7% of control measured using activated caspase 3; P < 0.01). Thus, maternal exposure to DEA reduces the number of neural progenitor cells in hippocampus by two mechanisms, and this could permanently alter memory function in offspring of mothers exposed to this common ingredient of shampoos and soaps.	Univ N Carolina, Michael Hooker Res Ctr, Dept Nutr, Sch Publ Hlth & Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Zeisel, SH (corresponding author), Univ N Carolina, Michael Hooker Res Ctr, Dept Nutr, Sch Publ Hlth & Med, CB 7461,2115A, Chapel Hill, NC 27599 USA.	steven_zeisel@unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, R21ES012997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [AG09125, P01 AG009525] Funding Source: Medline; NIDDK NIH HHS [DK56350, P30 DK056350] Funding Source: Medline; NIEHS NIH HHS [ES012997, P30 ES010126, R21 ES012997, ES10126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 2005, DEV BRAIN RES, V159, P149, DOI 10.1016/j.devbrainres.2005.07.002; Albright CD, 2003, NUTR NEUROSCI, V6, P129, DOI 10.1080/1028415031000084418; Albright CD, 2001, DEV NEUROSCI-BASEL, V23, P100, DOI 10.1159/000048701; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; ALTMAN J, 1990, J COMP NEUROL, V301, P325, DOI 10.1002/cne.903010302; ANGEVINE JB, 1970, ANAT REC, V166, P257, DOI 10.1002/ar.1091660214; [Anonymous], 1983, J AM COLL TOXICOL, V2, P183; BARBEE SJ, 1979, TOXICOL APPL PHARM, V47, P421, DOI 10.1016/0041-008X(79)90511-8; Baschong W, 2001, J HISTOCHEM CYTOCHEM, V49, P1565, DOI 10.1177/002215540104901210; BROWNING E, 1987, ETHEL BROWNINGS TOXI, V4; *CIR, 1986, J AM COLL TOXICOL, V5, P415; Craciunescu CN, 2003, J NUTR, V133, P3614, DOI 10.1093/jn/133.11.3614; Fisher MC, 2002, FASEB J, V16, P619, DOI 10.1096/fj.01-0564fje; Fisher MC, 2001, TERATOLOGY, V64, P114, DOI 10.1002/tera.1053; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Hayashi SM, 2003, CHEM-BIOL INTERACT, V146, P251, DOI 10.1016/j.cbi.2003.07.001; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; IACONO JM, 2000, SOME IND CHEM, V77, P349; Institute of Medicine, 1998, DIET REF INT THIAM R, P390, DOI [DOI 10.17226/6015, 10.17226/6015]; Jacobowitz D.M, 1998, CHEMOARCHITECTONIC A; Knaak J B, 1997, Rev Environ Contam Toxicol, V149, P1; Koc H, 2002, ANAL CHEM, V74, P4734, DOI 10.1021/ac025624x; Lehman-McKeeman LD, 2002, TOXICOL SCI, V67, P38, DOI 10.1093/toxsci/67.1.38; Leung HW, 2005, REGUL TOXICOL PHARM, V43, P260, DOI 10.1016/j.yrtph.2005.08.001; MATHEWS JM, 1995, CHEM RES TOXICOL, V8, P625, DOI 10.1021/tx00047a001; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 2003, NEUROSCI BIOBEHAV R, V27, P385, DOI 10.1016/S0149-7634(03)00069-1; *NAT TOX PROGR, 1999, NATL TOXICOL PROG TE, V481; *NAT TOX PROGR, 1999, NATL TOXICOL PROG TE, V480, P1; National Toxicology Program, 1999, Natl Toxicol Program Tech Rep Ser, V478, P1; Niculescu MD, 2004, J NEUROCHEM, V89, P1252, DOI 10.1111/j.1471-4159.2004.02414.x; Romijn HJ, 1999, J HISTOCHEM CYTOCHEM, V47, P229, DOI 10.1177/002215549904700211; Stott WT, 2004, TOXICOL SCI, V79, P242, DOI 10.1093/toxsci/kfh115; Stott WT, 2000, TOXICOL LETT, V114, P67, DOI 10.1016/S0378-4274(99)00197-6; SUN JD, 1996, CUTANEOUS OCULAR TOX, V15, P131; *TECHN PLANN MAN C, 2002, N01ES85421 NAT TOX P, P229	37	12	13	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1635	1640		10.1096/fj.06-5978com	http://dx.doi.org/10.1096/fj.06-5978com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873886	Green Accepted, Green Submitted			2022-12-28	WOS:000240266600008
J	Moon, SK; Kang, SK; Kim, CH				Moon, Sung-Kwon; Kang, Sung-Koo; Kim, Cheorl-Ho			Reactive oxygen species mediates disialoganglioside GD3-induced inhibition of ERK1/2 and matrix metalloproteinase-9 expression in vascular smooth muscle cells	FASEB JOURNAL			English	Article						atherosclerosis; GD3 synthase gene; PDTC; NAC; cell cycle	MITOCHONDRIAL PERMEABILITY TRANSITION; SIGNALING TRANSDUCTION PATHWAY; NECROSIS-FACTOR-ALPHA; GD3 GANGLIOSIDE; DNA DAMAGE; ATHEROSCLEROSIS; APOPTOSIS; GROWTH; GLYCOSPHINGOLIPIDS; PROLIFERATION	Sialic acid containing glycosphingolipids (gangliosides) are thought to play important roles in the function of various biological phenomena such as atherosclerosis. We have previously shown that the overexpression of the disialoganglioside (GD3) synthase gene effectively suppresses cell proliferation, cell cycle progression, and MMP-9 expression in vascular smooth muscle cells (VSMC). However, the issue of how the overexpression of GD3 synthase gene results in the inhibition of cellular responses in VSMC remains unclear. The findings herein demonstrate that overexpression of the GD3 synthase gene suppresses VSMC responses through the generation of reactive oxygen species (ROS). Superoxide and hydrogen peroxide were generated at increased levels in GD3 synthase gene transfectants in comparison with empty vector (EV) -transfected VSMC. This phenomenon was blocked by antioxidants such as N-acetyl-L-cysteine (NAC) and pyrrolidine dithiocarbamate (PDTC). Increased ROS generation was associated with a decreased endogenous antioxidant activity, increased lipid peroxidation, and mitochondrial DNA damage. Further studies revealed that the blockade of ROS function with antioxidants reversed the effect of GD3 synthase gene overexpression on VSMC proliferation and cell cycle regulation in response to platelet-derived growth factor (PDGF). In addition, we found that treatment with antioxidants reversed the decreased matrix metalloproteinase-9 (MMP-9) expression in response to TNF-alpha as determined by zymography and immunoblot in GD3 synthase gene transfectants. This recovery effect was characterized by the up-regulation of MMP-9 promoter activity, which was transcriptionally regulated at NF-kappa B and activation protein-1 (activating protein (AP) -1) sites in the MMP-9 promoter. These findings suggest that ROS may play a role in GD3 synthase gene-mediated VSMC phenotypic changes that may contribute to plaque instability in atherosclerosis.	Sungkyunkwan Univ, Dept Sci Biol, Mol & Cellular Glycobiol Unit, Suwon 440746, South Korea	Sungkyunkwan University (SKKU)	Kim, CH (corresponding author), Sungkyunkwan Univ, Dept Sci Biol, Mol & Cellular Glycobiol Unit, Chunchun Dong 300, Suwon 440746, South Korea.	chkimbio@daum.net	Kim, Cheorl-Ho/T-6753-2019	Kim, Cheorl-Ho/0000-0002-6323-0714				Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; Akishita M, 1999, J CLIN INVEST, V103, P63, DOI 10.1172/JCI5182; Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; Bhunia AK, 2002, J BIOL CHEM, V277, P16396, DOI 10.1074/jbc.M200877200; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; Chatterjee SB, 1997, GLYCOBIOLOGY, V7, P57, DOI 10.1093/glycob/7.1.57; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Colell A, 2003, J BIOL CHEM, V278, P33928, DOI 10.1074/jbc.M210943200; Colell Anna, 2001, FASEB Journal, V15, P1068; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Fernandez-Checa JC, 2003, BIOCHEM BIOPH RES CO, V304, P471, DOI 10.1016/S0006-291X(03)00619-3; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; Galis ZS, 1998, CIRCULATION, V97, P2445, DOI 10.1161/01.CIR.97.24.2445; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gouni-Berthold L, 2001, HYPERTENSION, V38, P1030, DOI 10.1161/hy1101.093104; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HOLVOET P, 1995, J CLIN INVEST, V95, P2611, DOI 10.1172/JCI117963; Kawakami S, 2001, ANTICANCER RES, V21, P213; MCCORD JM, 1993, CLIN BIOCHEM, V26, P351, DOI 10.1016/0009-9120(93)90111-I; Moon SK, 2004, J BIOL CHEM, V279, P33063, DOI 10.1074/jbc.M313462200; Moon SK, 2003, BIOCHEM BIOPH RES CO, V301, P1069, DOI 10.1016/S0006-291X(03)00091-3; Moon SK, 2004, J CELL PHYSIOL, V198, P417, DOI 10.1002/jcp.10435; Moon SK, 2001, AM J PHYSIOL-HEART C, V280, pH2779, DOI 10.1152/ajpheart.2001.280.6.H2779; MUKHIN DN, 1995, ARTERIOSCL THROM VAS, V15, P1607, DOI 10.1161/01.ATV.15.10.1607; MULVANY MJ, 1990, PHYSIOL REV, V70, P921, DOI 10.1152/physrev.1990.70.4.921; Newby AC, 2000, J PATHOL, V190, P300, DOI 10.1002/(SICI)1096-9896(200002)190:3<300::AID-PATH596>3.0.CO;2-I; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sachinidis A, 1996, EUR J CELL BIOL, V71, P79; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SHAN XQ, 1993, CHEM RES TOXICOL, V6, P75, DOI 10.1021/tx00031a012; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIWIK DA, 2001, AM J PHYSIOL-CELL PH, V280, P53; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Wolin MS, 2000, ARTERIOSCL THROM VAS, V20, P1430, DOI 10.1161/01.ATV.20.6.1430; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514	50	22	24	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1387	1395		10.1096/fj.05-4618com	http://dx.doi.org/10.1096/fj.05-4618com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816114				2022-12-28	WOS:000240266000016
J	Solito, E; Christian, HC; Festa, M; Mulla, A; Tierney, T; Flower, RJ; Buckingham, JC				Solito, E.; Christian, H. C.; Festa, M.; Mulla, A.; Tierney, T.; Flower, R. J.; Buckingham, J. C.			Post-translational modification plays an essential role in the translocation of annexin A1 from the cytoplasm to the cell surface	FASEB JOURNAL			English	Article						phosphorylation; green fluorescence protein; lipidation; signaling	ANTERIOR-PITUITARY GLAND; N-TERMINAL DOMAIN; 1 EXPRESSION; PROTEIN; GLUCOCORTICOIDS; LIPOCORTIN-1; RAT; PHOSPHORYLATION; DEXAMETHASONE; INHIBITION	Annexin A1 (ANXA1) has an important role in cell-cell communication in the host defense and neuroendocrine systems. In both systems, its actions are exerted extracellularly via membrane-bound receptors on adjacent sites after translocation of the protein from the cytoplasm to the cell surface of adjacent cells. This study used molecular, microscopic, and pharmacological approaches to explore the mechanisms underlying the cellular exportation of ANXA1 in TtT/GF (pituitary folliculo-stellate) cells. LPS caused serine-phosphorylation of ANXA1 (ANXA1-S-27-PO4) and translocation of the phosphorylated protein to the cell membrane. The fundamental requirement of phosphorylation for membrane translocation was confirmed by immunofluorescence microscopy on cells transfected with wild-type or mutated (S-27/A) ANXA1 constructs tagged with enhanced green fluorescence protein. The trafficking of ANXA1-S-27-PO4 to the cell surface was dependent on PI3-kinase and MAP-kinase. It also required HMG-coenzyme A and myristoylation. The effects of HMG-coenzyme A blockade were overcome by mevalonic acid (the product of HMG-coenzyme A) and farnesyl-pyrophosphate but not by geranyl-geranylpyrophosphate or cholesterol. Together, these results suggest that serine-27 phosphorylation is essential for the translocation of ANXA1 across the cell membrane and also identify a role for isoprenyl lipids. Such lipids could target consensus sequences in ANXA1. Alternatively, they may target other proteins in the signal transduction cascade (e.g., transporters).	Univ London Imperial Coll Sci Technol & Med, Dept Cellular & Mol Neurosci, Div Neurosci & Mental Hlth, London W12 0NN, England; Univ Oxford, Dept Human Anat & Genet, Oxford, England; William Harvey Res Inst, Dept Biochem Pharmacol, London, England	Imperial College London; University of Oxford; University of London; Queen Mary University London	Solito, E (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Cellular & Mol Neurosci, Div Neurosci & Mental Hlth, Hammersmith Campus,Cane Rd, London W12 0NN, England.			Solito, Egle/0000-0001-5279-0049; Mulla, Abeda/0000-0002-0364-7972	Wellcome Trust [040269, N:069234/B/02/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; AMBROSE MP, 1990, AM J RESP CELL MOL, V3, P349, DOI 10.1165/ajrcmb/3.4.349; Beishuizen A, 2003, J ENDOTOXIN RES, V9, P3, DOI 10.1179/096805103125001298; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Chapman L, 2002, ENDOCRINOLOGY, V143, P4330, DOI 10.1210/en.2002-220529; Christian HC, 1997, ENDOCRINOLOGY, V138, P5341, DOI 10.1210/en.138.12.5341; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; de Coupade C, 2000, HEPATOLOGY, V31, P371, DOI 10.1002/hep.510310217; DECATERINA R, 1993, J APPL PHYSIOL, V75, P2368, DOI 10.1152/jappl.1993.75.6.2368; DelVillar K, 1996, BIOCHEM SOC T, V24, P709; Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Galbiati F, 1996, BIOCHEM J, V313, P717, DOI 10.1042/bj3130717; Gloddek J, 2001, EXP CLIN ENDOCR DIAB, V109, P410, DOI 10.1055/s-2001-18995; GOULDING NJ, 1992, ARTHRITIS RHEUM, V35, P1395, DOI 10.1002/art.1780351126; John C, 2002, ENDOCRINOLOGY, V143, P3060, DOI 10.1210/en.143.8.3060; John CD, 2004, TRENDS ENDOCRIN MET, V15, P103, DOI 10.1016/j.tem.2004.02.001; Kusumawati A, 2001, CELL BIOL INT, V25, P809, DOI 10.1006/cbir.2000.0704; Lohrer P, 2000, ENDOCRINOLOGY, V141, P4457, DOI 10.1210/en.141.12.4457; LOXLEY HD, 1993, NEUROENDOCRINOLOGY, V57, P801, DOI 10.1159/000126439; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Monick MM, 2003, J IMMUNOL, V171, P2625, DOI 10.4049/jimmunol.171.5.2625; Mulla A, 2004, CLIN ENDOCRINOL, V60, P107, DOI 10.1111/j.1365-2265.2004.01936.x; MUNCK A, 1994, ANN NY ACAD SCI, V746, P115, DOI 10.1111/j.1749-6632.1994.tb39221.x; PAYNE J, 2005, 24 JOINT M BRIT END, V9; PEPINSKY RB, 1986, J BIOL CHEM, V261, P4239; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Philip JG, 1998, REGUL PEPTIDES, V73, P133, DOI 10.1016/S0167-0115(97)01077-X; Rescher U, 2000, J CELL SCI, V113, P3931; Smith T., 1993, Molecular Neuropharmacology, V3, P45; SOLITO E, 1991, FEBS LETT, V291, P238, DOI 10.1016/0014-5793(91)81293-H; Solito E, 2003, ENDOCRINOLOGY, V144, P1164, DOI 10.1210/en.2002-220592; Solito E, 1998, CYTOKINE, V10, P514, DOI 10.1006/cyto.1997.0325; Solito E, 1998, CELL GROWTH DIFFER, V9, P327; Solito E, 1998, BRIT J PHARMACOL, V124, P1675, DOI 10.1038/sj.bjp.0701991; TAYLOR AD, 1993, NEUROENDOCRINOLOGY, V58, P430, DOI 10.1159/000126572; Taylor AD, 1997, ENDOCRINOLOGY, V138, P2909, DOI 10.1210/en.138.7.2909; Tierney T, 2003, J NEUROENDOCRINOL, V15, P1134, DOI 10.1111/j.1365-2826.2003.01111.x; Traverso V, 1999, ENDOCRINOLOGY, V140, P4311, DOI 10.1210/en.140.9.4311; YASUMURA Y, 1968, AM ZOOL, V8, P285	43	83	86	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1498	+		10.1096/fj.05-5319fje	http://dx.doi.org/10.1096/fj.05-5319fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720734	Green Accepted			2022-12-28	WOS:000240266000030
J	Converso, DP; Taille, C; Carreras, MC; Jaitovich, A; Poderoso, JJ; Boczkowski, J				Converso, Daniela P.; Taille, Camille; Carreras, Maria Cecilia; Jaitovich, Ariel; Poderoso, Juan Jose; Boczkowski, Jorge			HO-1 is located in liver mitochondria and modulates mitochondrial heme content and metabolism	FASEB JOURNAL			English	Article						cytochrome c oxidase; NOS; oxygen consumption	CYTOCHROME-C-OXIDASE; NITRIC-OXIDE; BILIVERDIN REDUCTASE; RAT-LIVER; SYNTHASE; OXYGENASE; PROTEIN; ACTIVATION; BILIRUBIN; LOCALIZATION	This study investigated whether inducible HO-1 is targeted to mitochondria and its putative effects on oxidative metabolism in rat liver. Western blot and immune-electron microscopy in whole purified and fractionated organelles showed basal expression of HO-1 protein in both microsomes and mitochondria (inner membrane), accompanied by a parallel HO activity. Inducers of HO-1 increased HO-1 targeting to the inner mitochondrial membrane, which also contained biliverdin reductase, supporting that both enzymes are in the same compartmentalization. Induction of mitochondrial HO-1 was associated with a decrease of mitochondrial heme content and selective reduction of protein expression of cytochrome oxidase ( COX) subunit I, which is coded by the mitochondrial genome and synthesized in the mitochondria depending on heme availability; these changes resulted in decreased COX spectrum and activity. Mitochondrial HO-1 induction was also associated with down-regulation of mitochondrial-targeted NO synthase expression and activity, resulting in a reduction of NO-dependent mitochondrial oxidant yield; inhibition of HO-1 activity reverted these effects. In conclusion, we demonstrated for the first time localization of HO-1 protein in mitochondria. It is surmised that mitochondrial HO-1 has important biological roles in regulating mitochondrial heme protein turnover and in protecting against conditions such as hypoxia, neurodegenerative diseases, or sepsis, in which substantially increased mitochondrial NO and oxidant production have been implicated. -Converso, D. P., Taille, C., Carreras, M. C., Jaitovich, A., Poderoso, J. J., Boczkowski, J. HO-1 is located in liver mitochondria and modulates mitochondrial heme content and metabolism.	Univ Paris 07, INSERM U700, Fac Xavier Bichat, F-75870 Paris 18, France; Univ Buenos Aires, Lab Oxygen Metab, Univ Hosp, Buenos Aires, DF, Argentina	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Buenos Aires	Boczkowski, J (corresponding author), Univ Paris 07, INSERM U700, Fac Xavier Bichat, BP416, F-75870 Paris 18, France.	jbb2@bichat.inserm.fr	Boczkowski, Jorge/S-7474-2018; Taille, Camille/J-3751-2017	Boczkowski, Jorge/0000-0001-6619-5785; 				Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; Almeida A, 1999, FEBS LETT, V452, P290, DOI 10.1016/S0014-5793(99)00628-6; Alonso M, 2004, J NEUROCHEM, V89, P248, DOI 10.1111/j.1471-4159.2004.02323.x; Atamna H, 2001, J BIOL CHEM, V276, P48410, DOI 10.1074/jbc.M108362200; BALLA G, 1992, J BIOL CHEM, V267, P18148; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Bender AT, 2000, J BIOL CHEM, V275, P26018, DOI 10.1074/jbc.275.34.26018; Boczkowski J, 1999, FASEB J, V13, P1637, DOI 10.1096/fasebj.13.12.1637; Boss V, 2005, BIOL NEONATE, V88, P313, DOI 10.1159/000087629; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Calabrese V, 2004, ANTIOXID REDOX SIGN, V6, P895, DOI 10.1089/1523086041798051; Carreras MC, 2004, HEPATOLOGY, V40, P157, DOI 10.1002/hep.20255; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466; Drysdale J, 2002, BLOOD CELL MOL DIS, V29, P376, DOI 10.1006/bcmd.2002.0577; Duchen Michael R., 2004, Molecular Aspects of Medicine, V25, P365, DOI 10.1016/j.mam.2004.03.001; Dzikaite V, 2003, BBA-GENE STRUCT EXPR, V1630, P19, DOI 10.1016/j.bbaexp.2003.08.012; ENYEDI P, 1993, CELL CALCIUM, V14, P485, DOI 10.1016/0143-4160(93)90007-S; Foresti R, 1999, FREE RADICAL RES, V31, P459, DOI 10.1080/10715769900301031; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; Iwata Y, 2004, EUR J CELL BIOL, V83, P555, DOI 10.1078/0171-9335-00415; Juckett M, 1998, J BIOL CHEM, V273, P23388, DOI 10.1074/jbc.273.36.23388; Kim HP, 2004, FASEB J, V18, P1080, DOI 10.1096/fj.03-1391com; Kim YS, 2005, FREE RADICAL BIO MED, V38, P85, DOI 10.1016/j.freeradbiomed.2004.09.031; Knowles RG, 1998, METH MOL B, V100, P67; Kone BC, 2003, AM J PHYSIOL-RENAL, V285, pF178, DOI 10.1152/ajprenal.00048.2003; KUTTY RK, 1987, BIOCHEM J, V246, P467, DOI 10.1042/bj2460467; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; LEMASTERS JJ, 2005, BIOCH BIOPHYS ACTA; Lisdero CL, 2004, METHOD ENZYMOL, V382, P67; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1975, J BIOL CHEM, V250, P2363; MAINES MD, 1974, P NATL ACAD SCI USA, V71, P4293, DOI 10.1073/pnas.71.11.4293; Maines MD, 2001, J PHARMACOL EXP THER, V296, P1091; MATUDA S, 1984, JPN J MED SCI BIOL, V37, P171, DOI 10.7883/yoken1952.37.171; MOTTERLINI R, 1995, AM J PHYSIOL-HEART C, V269, pH648, DOI 10.1152/ajpheart.1995.269.2.H648; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; NORSETH J, 1982, BIOCHIM BIOPHYS ACTA, V719, P569, DOI 10.1016/0304-4165(82)90247-1; Ockaili R, 2005, AM J PHYSIOL-HEART C, V289, pH542, DOI 10.1152/ajpheart.00089.2005; Piantadosi CA, 2002, ANTIOXID REDOX SIGN, V4, P259, DOI 10.1089/152308602753666316; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Ren SY, 2000, ARCH BIOCHEM BIOPHYS, V377, P195, DOI 10.1006/abbi.2000.1755; Richter OMH, 2003, REV PHYSIOL BIOCH P, V147, P47, DOI 10.1007/s10254-003-0006-0; Riobo NA, 2002, J BIOL CHEM, V277, P42447, DOI 10.1074/jbc.M204580200; Schulte U, 2001, J BIOENERG BIOMEMBR, V33, P205, DOI 10.1023/A:1010730919074; SHARMA RV, 1986, AM J PHYSIOL, V250, pC65, DOI 10.1152/ajpcell.1986.250.1.C65; Srivastava P, 1996, INT J BIOCHEM CELL B, V28, P1071, DOI 10.1016/1357-2725(96)00030-1; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Susa S, 2002, BLOOD, V100, P4678, DOI 10.1182/blood-2002-08-2621; Taanman JW, 2001, BIOCHEM SOC T, V29, P446, DOI 10.1042/BST0290446; Taille C, 2004, J BIOL CHEM, V279, P28681, DOI 10.1074/jbc.M310661200; Taille C, 2001, AM J RESP CRIT CARE, V163, P753, DOI 10.1164/ajrccm.163.3.2004202; VANNESTE WH, 1966, BIOCHIM BIOPHYS ACTA, V113, P175, DOI 10.1016/S0926-6593(66)80132-7; Vijayasarathy C, 1999, EUR J BIOCHEM, V266, P191, DOI 10.1046/j.1432-1327.1999.00843.x	60	122	126	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1236	+		10.1096/fj.05-4204fje	http://dx.doi.org/10.1096/fj.05-4204fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16672635				2022-12-28	WOS:000240210300037
J	Falagas, ME; Kavvadia, P				Falagas, Matthew E.; Kavvadia, Panorea			"Eigenlob": self-citation in biomedical journals	FASEB JOURNAL			English	Article							IMPACT; BIAS		Alfa Inst Biomed Sci, Maroussi 15123, Greece; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Alfa Institute Of Biomedical Sciences; Tufts University	Falagas, ME (corresponding author), Alfa Inst Biomed Sci, 9 Neapoleos St, Maroussi 15123, Greece.	m.falagas@aibs.gr						Bookstein A, 1999, SCIENTOMETRICS, V46, P337, DOI 10.1007/BF02464782; Callaham M, 2002, JAMA-J AM MED ASSOC, V287, P2847, DOI 10.1001/jama.287.21.2847; EPSTEIN RJ, 1993, BRIT MED J, V306, P765, DOI 10.1136/bmj.306.6880.765; Fassoulaki A, 2000, BRIT J ANAESTH, V84, P266, DOI 10.1093/oxfordjournals.bja.a013418; Gami AS, 2004, CAN MED ASSOC J, V170, P1925, DOI 10.1503/cmaj.1031879; Grange RI, 1999, BJU INT, V84, P601; Laband David N., 1994, JAMA (Journal of the American Medical Association), V272, P147, DOI 10.1001/jama.272.2.147; Ma LS, 2005, WORLD J GASTROENTERO, V11, P1; Miguel A, 2002, EUR RADIOL, V12, P248, DOI 10.1007/s003300100894; Montori VM, 2003, BMC MED, V1, DOI 10.1186/1741-7015-1-2; Motamed M, 2002, CLIN OTOLARYNGOL, V27, P318, DOI 10.1046/j.1365-2273.2002.00574.x; Rousseau R, 1999, SCIENTOMETRICS, V44, P521, DOI 10.1007/BF02458493; Snyder H, 1998, J INF SCI, V24, P431, DOI 10.1177/016555159802400606	13	37	38	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1039	1042		10.1096/fj.06-0603ufm	http://dx.doi.org/10.1096/fj.06-0603ufm			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770002				2022-12-28	WOS:000240210300003
J	Fasanaro, P; Magenta, A; Zaccagnini, G; Cicchillitti, L; Fucile, S; Eusebi, F; Biglioli, P; Capogrossi, MC; Martelli, F				Fasanaro, Pasquale; Magenta, Alessandra; Zaccagnini, Germana; Cicchillitti, Lucia; Fucile, Sergio; Eusebi, Fabrizio; Biglioli, Paolo; Capogrossi, Maurizio C.; Martelli, Fabio			Cyclin D1 degradation enhances endothelial cell survival upon oxidative stress	FASEB JOURNAL			English	Article						endothelium; ubiquitin-proteasome pathway; calcium signaling; apoptosis	HYDROGEN-PEROXIDE; CARDIOVASCULAR INJURY; CYCLE ARREST; D1; PHOSPHORYLATION; ACTIVATION; INHIBITION; APOPTOSIS; CALMODULIN; EXPRESSION	The understanding of endothelial cell responses to oxidative stress may provide insights into aging mechanisms and into the pathogenesis of numerous cardiovascular diseases. In this study, we examined the regulation and the functional role of cyclin D1, a crucial player in cell proliferation and survival. On H2O2 treatment, endothelial cells showed a rapid down-modulation of cyclin D1. Other D-cyclins were similarly regulated, and this decrease was also observed after exposure to other oxidative stress-inducing stimuli, namely 1,3-bis (2 chloroethyl)-1 nitrosourea treatment and ischemia. H2O2 treatment induced cyclin D1 ubiquitination followed by proteasome degradation. Phospholipase C inhibition prevented cyclin D1 degradation, and its activation triggered cyclin D1 down-modulation in the absence of oxidative stress. Activated phospholipase C generates inositol-1,4,5-trisphosphate (IP3) and Ca2+ release from internal stores. We found that both IP3-receptor inhibition and intracellular Ca2+ chelation prevented cyclin D1 degradation induced by oxidative stress. Furthermore, Ca2+ increase was transduced by Ca2+/calmodulin-dependent protein kinase (CaMK). In fact, H2O2 stimulated CaMK activity, CaMK inhibitors prevented H2O2-induced cyclin D1 downmodulation, and CaMK overexpression induced cyclin D1 degradation. Finally, overriding of cyclin D1 downmodulation via its forced overexpression or via CaMK inhibition increased cell sensitivity to H2O2-induced apoptotic cell death. Thus, cyclin D1 degradation enhances endothelial cell survival on oxidative stress. Fasanaro, P., Magenta, A., Zaccagnini, G., Cicchillitti, L., Fucile, S., Eusebi, F., Biglioli, P., Capogrossi, M. C., Martelli, F. Cyclin D1 degradation enhances endothelial cell survival upon oxidative stress.	IRCCS, Lab Patol Vasc, Ist Dermopat Immacolata, I-00167 Rome, Italy; IRCCS, Ctr Cardiol Monzino, Milan, Italy; Univ Roma La Sapienza, Dipartimento Fisiol Umana & Farmacol, Rome, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Centro Cardiologico Monzino; Sapienza University Rome	Martelli, F (corresponding author), IRCCS, Lab Patol Vasc, Ist Dermopat Immacolata, Via Monti di Creta 104, I-00167 Rome, Italy.	f.martelli@idi.it	Martelli, Fabio/AAL-3788-2020; magenta, alessandra/A-9473-2017; Fucile, Sergio/B-3934-2010; Zaccagnini, Germana/J-7722-2016	Martelli, Fabio/0000-0002-8624-7738; magenta, alessandra/0000-0002-9054-337X; Fucile, Sergio/0000-0003-0698-1148; Zaccagnini, Germana/0000-0002-9441-4735				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Bae YS, 2003, MOL PHARMACOL, V63, P1043, DOI 10.1124/mol.63.5.1043; Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582; Browder T, 2000, CANCER RES, V60, P1878; Cai H, 2001, ARTERIOSCL THROM VAS, V21, P1571, DOI 10.1161/hq1001.097028; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Fucile S, 2000, P NATL ACAD SCI USA, V97, P3643, DOI 10.1073/pnas.050582497; Fukami-Kobayashi J, 1999, EXP CELL RES, V246, P338, DOI 10.1006/excr.1998.4306; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Griendling KK, 2003, CIRCULATION, V108, P2034, DOI 10.1161/01.CIR.0000093661.90582.c4; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Howe CJ, 2004, J BIOL CHEM, V279, P44573, DOI 10.1074/jbc.M404175200; Hu QH, 1998, CIRCULATION, V97, P268, DOI 10.1161/01.CIR.97.3.268; Kahl CR, 2004, J BIOL CHEM, V279, P15411, DOI 10.1074/jbc.M312543200; Kahl CR, 2004, MOL BIOL CELL, V15, P1833, DOI 10.1091/mbc.e03-10-0730; Katayama K, 2001, FEBS LETT, V509, P382, DOI 10.1016/S0014-5793(01)03200-8; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; Leroy C, 2001, EMBO J, V20, P2896, DOI 10.1093/emboj/20.11.2896; Li DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; Martelli F, 1999, P NATL ACAD SCI USA, V96, P2858, DOI 10.1073/pnas.96.6.2858; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Noda T, 2001, FASEB J, V15, P2131, DOI 10.1096/fj.01-0131com; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Pirkmaier A, 2003, CLIN CANCER RES, V9, P1877; Pratt MAC, 2003, J BIOL CHEM, V278, P14219, DOI 10.1074/jbc.M209650200; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Schmitt JM, 2004, J BIOL CHEM, V279, P24064, DOI 10.1074/jbc.M401501200; Shao JH, 2002, BIOCHEM BIOPH RES CO, V290, P1101, DOI 10.1006/bbrc.2001.6314; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Zaccagnini G, 2004, CIRCULATION, V109, P2917, DOI 10.1161/01.CIR.0000129309.58874.0F; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	49	38	39	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1242	+		10.1096/fj.05-4695fje	http://dx.doi.org/10.1096/fj.05-4695fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16603604				2022-12-28	WOS:000240210300039
J	Almog, N; Henke, V; Flores, L; Hlatky, L; Kung, AL; Wright, RD; Berger, R; Hutchinson, L; Naumov, GN; Bender, E; Akslen, LA; Achilles, EG; Folkman, J				Almog, Nava; Henke, Vanessa; Flores, Ludmila; Hlatky, Lynn; Kung, Andrew L.; Wright, Renee D.; Berger, Raanan; Hutchinson, Lloyd; Naumov, George N.; Bender, Elise; Akslen, Lars A.; Achilles, Eike-Gert; Folkman, Judah			Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis	FASEB JOURNAL			English	Article							GROWTH-FACTOR; CANCER; THROMBOSPONDIN-1; EXPRESSION; MATRIX-METALLOPROTEINASE-9; DISEASE; SWITCH; CELLS	The disease state of cancer appears late in tumor development. Before being diagnosed, a tumor can remain for prolonged periods of time in a dormant state. Dormant human cancer is commonly defined as a microscopic tumor that does not expand in size and remains asymptomatic. Dormant tumors represent an early stage in tumor development and may therefore be a potential target for nontoxic, antiangiogenic therapy that could prevent tumor recurrence. Here, we characterize an experimental model that recapitulates the clinical dormancy of human tumors in mice. We demonstrate that these microscopic dormant cancers switch to the angiogenic phenotype at a predictable time. We further show that while angiogenic liposarcomas expand rapidly after inoculation of tumor cells in mice, nonangiogenic dormant liposarcomas remain microscopic up to one-third of the normal severe combined immune deficiency ( SCID) mouse life span, although they contain proliferating tumor cells. Nonangiogenic dormant tumors follow a similar growth pattern in subcutaneous (s.c.) and orthotopic environments. Throughout the dormancy period, development of intratumoral vessels is impaired. In nonangogenic dormant tumors, small clusters of endothelial cells without lumens are observed early after tumor cell inoculation, but the nonangiogenic tumor cannot sustain these vessels, and they disappear within weeks. There is a concomitant decrease in microvessel density, and the nonangiogenic dormant tumor remains harmless to the host. In contrast, microvessel density in tumors increases rapidly after the angiogenic switch and correlates with rapid expansion of tumor mass. Both tumor types cultured in vitro contain fully transformed cells, but only cells from the nonangiogenic human liposarcoma secrete relatively high levels of the angiogenesis inhibitors thrombospondin-1 and TIMP-1. This model suggests that as improved blood or urine molecular biomarkers are developed, the microscopic, nonangiogenic, dormant phase of human cancer may be vulnerable to antiangiogenic therapy years before symptoms, or before anatomical location of a tumor can be detected, by conventional methods.	Harvard Univ, Sch Med, Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Hamburg Hosp, Clin Hepatobiliary Surg & Visceral Transplantat, D-2000 Hamburg, Germany	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf	Folkman, J (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA.	judah.folkman@childrens.harvard.edu	Akslen, Lars A/C-1202-2017; Akslen, Lars A./AAG-6097-2021; Kung, Andrew/AAL-2384-2020; Kung, Andrew L/AEU-0826-2022	Akslen, Lars A/0000-0003-2710-9543; Akslen, Lars A./0000-0003-2710-9543; Kung, Andrew L/0000-0002-9091-488X; Henke, Vanessa Giselle/0000-0001-5579-3640	NCI NIH HHS [CA-64481, CA-78496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064481, R01CA078496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achilles EG, 2001, J NATL CANCER I, V93, P1075, DOI 10.1093/jnci/93.14.1075; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Armstrong SA, 2003, CANCER CELL, V3, P173, DOI 10.1016/S1535-6108(03)00003-5; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; Bode W, 1999, ANN NY ACAD SCI, V878, P73, DOI 10.1111/j.1749-6632.1999.tb07675.x; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Demicheli R, 2001, SEMIN CANCER BIOL, V11, P297, DOI 10.1006/scbi.2001.0385; Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a; FOLKMAN J, 2000, CANC MED, V5, P132; Govindarajan B, 2005, J BIOL CHEM, V280, P13936, DOI 10.1074/jbc.M500411200; Gupta K, 1999, Angiogenesis, V3, P147, DOI 10.1023/A:1009018702832; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; Hart IR, 1999, J PATHOL, V187, P91, DOI 10.1002/(SICI)1096-9896(199901)187:1<91::AID-PATH234>3.0.CO;2-J; Henson DE, 2001, PATHOLOGY INCIPIENT, P1; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Margosio B, 2003, BLOOD, V102, P4399, DOI 10.1182/blood-2003-03-0893; Naumov GN, 2006, JNCI-J NATL CANCER I, V98, P316, DOI 10.1093/jnci/djj068; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Uhr JW, 1997, NAT MED, V3, P505, DOI 10.1038/nm0597-505; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8	24	80	81	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					947	+		10.1096/fj.05-3946fje	http://dx.doi.org/10.1096/fj.05-3946fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16638967				2022-12-28	WOS:000240157700017
J	Deindl, E; Zaruba, MM; Brunner, S; Huber, B; Mehl, U; Assmann, G; Hoefer, IE; Mueller-Hoecker, J; Franz, WM				Deindl, Elisabeth; Zaruba, Marc-Michael; Brunner, Stefan; Huber, Bruno; Mehl, Ursula; Assmann, Gerald; Hoefer, Imo E.; Mueller-Hoecker, Josef; Franz, Wolfgang-Michael			G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis	FASEB JOURNAL			English	Article						granulocyte-colony stimulating factor; bone marrow derived cells; intercellular adhesion molecule-1	COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; GRANULOCYTE-COLONY; PROGENITOR CELLS; ENDOTHELIAL-CELLS; MOBILIZATION; REPAIR; TRANSPLANTATION; REGENERATION; MONOCYTES	Granulocyte-colony stimulating factor (G-CSF) has been shown to improve cardiac function after myocardial infarction (MI) by bone marrow cell mobilization and by protecting cardiomyocytes from apoptotic cell death. However, its role in collateral artery growth (arteriogenesis) has not been elucidated. Here, we investigated the effect of G-CSF on arteriolar growth and cardiac function in a murine MI model. Mice were treated with G-CSF (100 mu g/kg/day) directly after MI for 5 consecutive days. G-CSF application resulted in a significant increase of circulating mononuclear cells expressing stem cell markers. Arterioles in the border zone of infarcted myocardium showed an increased expression of ICAM-1 accompanied by an accumulation of bone marrow derived cells and a pronounced proliferation of endothelial and smooth muscle cells. Histology of G-CSF treated mice revealed a lower amount of granulation tissue (67.8 vs. 84.4%) associated with a subsequent reduction in free LV wall thinning and scar extension (23.1 vs. 30.8% of LV). Furthermore, G-CSF treated animals showed a significant improvement of post-MI survival (68.8 vs. 46.2%). Pressure-volume relations revealed a partially restored myocardial function at day 30 (EF: 32.5 vs. 17.2%). Our results demonstrate that G-CSF administration after MI stimulates arteriogenesis and attenuates ischemic cardiomyopathy after MI.	Univ Munich, Klinikum Grosshadern, Dept Med 1, D-81377 Munich, Germany; Univ Munich, Inst Pathol, D-8000 Munich, Germany; UMC, Dept Expt Cardiol, Utrecht, Netherlands	University of Munich; University of Munich	Franz, WM (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Med 1, Marchioninistr 15, D-81377 Munich, Germany.	wolfgang.franz@med.uni-muenchen.de	Deindl, Elisabeth/A-2511-2013; Zaruba, Marc-Michael/AAI-8571-2020	Zaruba, Marc-Michael/0000-0003-1074-5463				ARAI AE, 1992, CIRC RES, V70, P1137, DOI 10.1161/01.RES.70.6.1137; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; BRAUNWALD E, 1991, AM J CARDIOL, V68, pD1; Buschmann IR, 2001, ATHEROSCLEROSIS, V159, P343, DOI 10.1016/S0021-9150(01)00637-2; Buschmann IR, 2003, CIRCULATION, V108, P610, DOI 10.1161/01.CIR.0000074209.17561.99; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Carstanjen D, 2002, TRANSFUSION, V42, P588, DOI 10.1046/j.1537-2995.2002.00088.x; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; Deindl E, 2004, ARTERIOGENESIS, P115; Deindl E, 2003, FASEB J, V17, P1174, DOI 10.1096/fj.02-0800fje; Deten A, 2005, CARDIOVASC RES, V65, P52, DOI 10.1016/j.cardiores.2004.11.009; Fuste B, 2004, HAEMATOLOGICA, V89, P578; Georgakopoulos D, 1998, AM J PHYSIOL-HEART C, V274, pH1416, DOI 10.1152/ajpheart.1998.274.4.H1416; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; Heil M, 2002, AM J PHYSIOL-HEART C, V283, pH2411, DOI 10.1152/ajpheart.01098.2001; Herold J, 2004, HUM GENE THER, V15, P1, DOI 10.1089/10430340460732517; Hill JM, 2005, J AM COLL CARDIOL, V46, P1643, DOI 10.1016/j.jacc.2005.01.067; Hoefer IE, 2005, ATHEROSCLEROSIS, V181, P285, DOI 10.1016/j.atherosclerosis.2005.01.047; Hoefer IE, 2004, CIRC RES, V94, P1179, DOI 10.1161/01.RES.0000126922.18222.F0; Ince H, 2005, CIRCULATION, V112, P3097, DOI 10.1161/CIRCULATIONAHA.105.541433; JORGENSEN E, 2005, INT J CARDIOL; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kong DL, 2004, CIRCULATION, V110, P2039, DOI 10.1161/01.CIR.0000143161.01901.BD; Kuethe F, 2004, DEUT MED WOCHENSCHR, V129, P424, DOI 10.1055/s-2004-820062; Minatoguchi S, 2004, CIRCULATION, V109, P2572, DOI 10.1161/01.CIR.0000129770.93985.3E; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Norol F, 2003, BLOOD, V102, P4361, DOI 10.1182/blood-2003-03-0685; Ohtsuka M, 2004, FASEB J, V18, P851, DOI 10.1096/fj.03-0637fje; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Peter FW, 1999, BURNS, V25, P477, DOI 10.1016/S0305-4179(99)00036-4; Ryan TJ, 1999, J AM COLL CARDIOL, V34, P890, DOI 10.1016/S0735-1097(99)00351-4; Schneeloch E, 2004, P NATL ACAD SCI USA, V101, P12730, DOI 10.1073/pnas.0404880101; SCHWARZ F, 1982, AM J CARDIOL, V50, P933, DOI 10.1016/0002-9149(82)90398-8; Seiler C, 2001, CIRCULATION, V104, P2012, DOI 10.1161/hc4201.097835; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Sugano Y, 2005, CARDIOVASC RES, V65, P446, DOI 10.1016/j.cardiores.2004.10.008; Tanaka J, 2002, INT J HEMATOL, V75, P489, DOI 10.1007/BF02982111; Valgimigli M, 2005, EUR HEART J, V26, P1838, DOI 10.1093/eurheartj/ehi289; Vargel I, 2002, ANN PLAS SURG, V49, P646, DOI 10.1097/00000637-200212000-00015; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Yang F, 2002, EXP PHYSIOL, V87, P547, DOI 10.1113/eph8702385; Zbinden S, 2005, J AM COLL CARDIOL, V46, P1636, DOI 10.1016/j.jacc.2005.01.068; Ziegelhoeffer T, 2004, CIRC RES, V94, P230, DOI 10.1161/01.RES.0000110419.50982.1C	47	130	136	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					956	+		10.1096/fj.05-4763fje	http://dx.doi.org/10.1096/fj.05-4763fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571777				2022-12-28	WOS:000240157700020
J	Ingber, DE				Ingber, Donald E.			Cellular mechanotransduction: putting all the pieces together again	FASEB JOURNAL			English	Review						mechanical; mechanosensation; mechanochemical; prestress; tensegrity	FLUID SHEAR-STRESS; CAPILLARY ENDOTHELIAL-CELLS; FIBROBLAST GROWTH-FACTOR; SENSORY HAIR-CELLS; EXTRACELLULAR-MATRIX; CYTOSKELETAL TENSION; EPITHELIAL-CELLS; FOCAL ADHESIONS; LIVING CELLS; MECHANICAL FORCE	Analysis of cellular mechanotransduction, the mechanism by which cells convert mechanical signals into biochemical responses, has focused on identification of critical mechanosensitive molecules and cellular components. Stretch-activated ion channels, caveolae, integrins, cadherins, growth factor receptors, myosin motors, cytoskeletal filaments, nuclei, extracellular matrix, and numerous other structures and signaling molecules have all been shown to contribute to the mechanotransduction response. However, little is known about how these different molecules function within the structural context of living cells, tissues, and organs to produce the orchestrated cellular behaviors required for mechanosensation, embryogenesis, and physiological control. Recent work from a wide range of fields reveals that organ, tissue, and cell anatomy are as important for mechanotransduction as individual mechanosensitive proteins and that our bodies use structural hierarchies ( systems within systems) composed of interconnected networks that span from the macroscale to the nanoscale in order to focus stresses on specific mechanotransducer molecules. The presence of isometric tension ( prestress) at all levels of these multiscale networks ensures that various molecular scale mechanochemical transduction mechanisms proceed simultaneously and produce a concerted response. Future research in this area will therefore require analysis, understanding, and modeling of tensionally integrated (tensegrity) systems of mechanochemical control.	Childrens Hosp, Karp Family Res Labs 11 127, Vasc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Vasc Biol Program, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Vasc Biol Program, Dept Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ingber, DE (corresponding author), Childrens Hosp, Karp Family Res Labs 11 127, Vasc Biol Program, 300 Longwood Ave, Boston, MA 02115 USA.	donald.ingber@childrens.harvard.edu	Ingber, Donald E/AAC-5894-2019					Albrecht-Buehler G, 1991, ASGSB Bull, V4, P25; Alenghat FJ, 2004, EXP CELL RES, V301, P23, DOI 10.1016/j.yexcr.2004.08.003; Ali MH, 2004, AM J PHYSIOL-LUNG C, V287, pL486, DOI 10.1152/ajplung.00389.2003; Baneyx G, 2002, P NATL ACAD SCI USA, V99, P5139, DOI 10.1073/pnas.072650799; Bao L, 2004, AM J PHYSIOL-CELL PH, V287, pC1389, DOI 10.1152/ajpcell.00220.2004; Brewer KK, 2003, J APPL PHYSIOL, V95, P1926, DOI 10.1152/japplphysiol.00102.2003; Brock A, 2003, LANGMUIR, V19, P1611, DOI 10.1021/la026394k; Bursac P, 2000, J BIOMECH ENG-T ASME, V122, P347, DOI 10.1115/1.1286561; BUXBAUM RE, 1988, J THEOR BIOL, V134, P379, DOI 10.1016/S0022-5193(88)80068-7; Camalet S, 2000, P NATL ACAD SCI USA, V97, P3183, DOI 10.1073/pnas.97.7.3183; Carl P, 2001, P NATL ACAD SCI USA, V98, P1565, DOI 10.1073/pnas.031409698; Carrion-Vazquez M, 2003, NAT STRUCT BIOL, V10, P738, DOI 10.1038/nsb965; CASPAR DLD, 1980, BIOPHYS J, V32, P103, DOI 10.1016/S0006-3495(80)84929-0; Cattaruzza M, 2004, HYPERTENSION, V43, P726, DOI 10.1161/01.HYP.0000119189.82659.52; CHEN BM, 1995, SCIENCE, V269, P1578, DOI 10.1126/science.7667637; Chen CS, 2003, BIOCHEM BIOPH RES CO, V307, P355, DOI 10.1016/S0006-291X(03)01165-3; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; Connelly R, 1998, AM SCI, V86, P142, DOI 10.1511/1998.2.142; COREY DP, 2004, NATURE; Czarny M, 2004, AM J PHYSIOL-HEART C, V287, pH1344, DOI 10.1152/ajpheart.00222.2004; Davidson LA, 2002, CELL MOTIL CYTOSKEL, V53, P163, DOI 10.1002/cm.10070; DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Denk W, 1995, NEURON, V15, P1311, DOI 10.1016/0896-6273(95)90010-1; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; Dike LE, 1999, IN VITRO CELL DEV-AN, V35, P441; Eckes B, 1998, J CELL SCI, V111, P1897; Engler AJ, 2004, J CELL BIOL, V166, P877, DOI 10.1083/jcb.200405004; Evans E, 2004, P NATL ACAD SCI USA, V101, P11281, DOI 10.1073/pnas.0401870101; Farge E, 2003, CURR BIOL, V13, P1365, DOI 10.1016/S0960-9822(03)00576-1; Farrell HM, 2002, J DAIRY SCI, V85, P459, DOI 10.3168/jds.S0022-0302(02)74096-4; Ferraro JT, 2004, AM J PHYSIOL-CELL PH, V286, pC831, DOI 10.1152/ajpcell.00224.2003; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Fuller B., 1961, PORTFOLIO ARTNEWS AN, V4, P112; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Georges PC, 2005, J APPL PHYSIOL, V98, P1547, DOI 10.1152/japplphysiol.01121.2004; Gibson MC, 2005, SCIENCE, V307, P1785, DOI 10.1126/science.1104751; GIRARD PR, 1995, J CELL PHYSIOL, V163, P179, DOI 10.1002/jcp.1041630121; Griffin MA, 2004, J CELL SCI, V117, P5855, DOI 10.1242/jcs.01496; GRODZINSKY AJ, 1983, CRIT REV BIOMED ENG, V9, P133; Gudi SRP, 1998, AM J PHYSIOL-CELL PH, V274, pC1424, DOI 10.1152/ajpcell.1998.274.5.C1424; Guilak F, 1995, J BIOMECH, V28, P1529, DOI 10.1016/0021-9290(95)00100-X; Gupton SL, 2002, CURR BIOL, V12, P1891, DOI 10.1016/S0960-9822(02)01276-9; Haidekker MA, 2000, AM J PHYSIOL-HEART C, V278, pH1401, DOI 10.1152/ajpheart.2000.278.4.H1401; Han B, 2004, J BIOL CHEM, V279, P54793, DOI 10.1074/jbc.M406880200; Helmke BP, 2003, BIOPHYS J, V84, P2691, DOI 10.1016/S0006-3495(03)75074-7; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P5613, DOI 10.1073/pnas.78.9.5613; Howard J, 2004, CURR BIOL, V14, pR224, DOI 10.1016/j.cub.2004.02.050; Hu SH, 2005, BIOCHEM BIOPH RES CO, V329, P423, DOI 10.1016/j.bbrc.2005.02.026; Hu SH, 2004, AM J PHYSIOL-CELL PH, V287, pC1184, DOI 10.1152/ajpcell.00224.2004; Hu SH, 2004, FRONT BIOSCI-LANDMRK, V9, P2177, DOI 10.2741/1352; Hu SH, 2003, AM J PHYSIOL-CELL PH, V285, pC1082, DOI 10.1152/ajpcell.00159.2003; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Huijing PA, 2005, SCAND J MED SCI SPOR, V15, P349, DOI 10.1111/j.1600-0838.2005.00457.x; Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950; INGBER DE, 1993, CELL, V75, P1249, DOI 10.1016/0092-8674(93)90612-T; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359; INGBER DE, 1981, P NATL ACAD SCI-BIOL, V78, P3901, DOI 10.1073/pnas.78.6.3901; Ingber DE, 2000, BIOESSAYS, V22, P1160, DOI 10.1002/1521-1878(200012)22:12<1160::AID-BIES14>3.0.CO;2-5; Itano N, 2003, P NATL ACAD SCI USA, V100, P5181, DOI 10.1073/pnas.0531397100; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; Kaech S, 1996, NEURON, V17, P1189, DOI 10.1016/S0896-6273(00)80249-4; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Keller R, 2003, DIFFERENTIATION, V71, P171, DOI 10.1046/j.1432-0436.2003.710301.x; Khalsa PS, 1997, J BIOMECH, V30, P589, DOI 10.1016/S0021-9290(97)84508-3; Khan S, 1997, ANNU REV BIOCHEM, V66, P785, DOI 10.1146/annurev.biochem.66.1.785; KIEDROWSKI G, 2003, PURE APPL CHEM, V75, P609; Ko KS, 2001, J BIOL CHEM, V276, P35967, DOI 10.1074/jbc.M104106200; Komulainen J, 1998, PFLUG ARCH EUR J PHY, V436, P735, DOI 10.1007/s004240050696; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Kros CJ, 2002, NAT NEUROSCI, V5, P41, DOI 10.1038/nn784; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; KUMAR S, 2006, BIOPHYS J       0224; Kwei S, 2004, AM J PATHOL, V164, P81, DOI 10.1016/S0002-9440(10)63099-4; Laboureau J, 2004, EXP DERMATOL, V13, P70, DOI 10.1111/j.0906-6705.2004.00117.x; LAI WM, 1991, J BIOMECH ENG-T ASME, V113, P245, DOI 10.1115/1.2894880; Lammerding J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670; LEE EYH, 1984, J CELL BIOL, V98, P146, DOI 10.1083/jcb.98.1.146; Lele TP, 2006, J CELL PHYSIOL, V207, P187, DOI 10.1002/jcp.20550; Li HB, 2002, NATURE, V418, P998, DOI 10.1038/nature00938; Lin DC, 2004, J BIOMECH ENG-T ASME, V126, P104, DOI 10.1115/1.1645529; Lin T, 2003, CIRC RES, V92, P1296, DOI 10.1161/01.RES.0000078780.65824.8B; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Liu D, 2004, J AM CHEM SOC, V126, P2324, DOI 10.1021/ja031754r; Maniotis AJ, 1997, J CELL BIOCHEM, V65, P114; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; Matthews BD, 2006, J CELL SCI, V119, P508, DOI 10.1242/jcs.02760; Matthews BD, 2004, BIOCHEM BIOPH RES CO, V313, P758, DOI 10.1016/j.bbrc.2003.12.005; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; McMahon T.A., 1984, MUSCLES REFLEXES LOC; MCNEIL PL, 1989, GASTROENTEROLOGY, V96, P1238, DOI 10.1016/S0016-5085(89)80010-1; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; Miyake K, 2001, J CELL SCI, V114, P3487; MOONEY DJ, 1994, MOL BIOL CELL, V5, P1281, DOI 10.1091/mbc.5.12.1281; Moore KA, 2005, DEV DYNAM, V232, P268, DOI 10.1002/dvdy.20237; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nelson CM, 2004, MOL BIOL CELL, V15, P2943, DOI 10.1091/mbc.E03-10-0745; Nelson CM, 2005, P NATL ACAD SCI USA, V102, P11594, DOI 10.1073/pnas.0502575102; Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223-004-0213-y; Oberhauser AF, 2002, J MOL BIOL, V319, P433, DOI 10.1016/S0022-2836(02)00306-6; Paci E, 2000, P NATL ACAD SCI USA, V97, P6521, DOI 10.1073/pnas.100124597; Parker KK, 2002, FASEB J, V16, DOI 10.1096/fj.02-0038com; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Petroll WM, 2004, INVEST OPHTH VIS SCI, V45, P3466, DOI 10.1167/iovs.04-0361; PickettHeaps JD, 1997, CELL MOTIL CYTOSKEL, V37, P1, DOI 10.1002/(SICI)1097-0169(1997)37:1<1::AID-CM1>3.0.CO;2-D; PICKLES JO, 1992, TRENDS NEUROSCI, V15, P254, DOI 10.1016/0166-2236(92)90066-H; Polte TR, 2004, AM J PHYSIOL-CELL PH, V286, pC518, DOI 10.1152/ajpcell.00280.2003; Pommerenke H, 1996, EUR J CELL BIOL, V70, P157; Potard USB, 1997, AM J PHYSIOL-CELL PH, V272, pC1654, DOI 10.1152/ajpcell.1997.272.5.C1654; Praetorius HA, 2003, J MEMBRANE BIOL, V191, P193, DOI 10.1007/s00232-002-1055-z; Putnam AJ, 2003, AM J PHYSIOL-CELL PH, V284, pC627, DOI 10.1152/ajpcell.00137.2002; Putnam AJ, 2001, AM J PHYSIOL-CELL PH, V280, pC556, DOI 10.1152/ajpcell.2001.280.3.C556; Qin YX, 2003, J BIOMECH, V36, P1427, DOI 10.1016/S0021-9290(03)00127-1; Quinn TM, 2001, J BIOMECH, V34, P1483, DOI 10.1016/S0021-9290(01)00103-8; RADEL C, 2004, AM J PHYSIOL, V288, pH936; Ralphs JR, 2002, MATRIX BIOL, V21, P67, DOI 10.1016/S0945-053X(01)00179-2; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Saunders MM, 2001, AM J PHYSIOL-CELL PH, V281, pC1917, DOI 10.1152/ajpcell.2001.281.6.C1917; Schwarz US, 2004, P NATL ACAD SCI USA, V101, P6940, DOI 10.1073/pnas.0305822101; Seiler C, 2004, DEV BIOL, V272, P328, DOI 10.1016/j.ydbio.2004.05.004; Shakibael M, 2003, HISTOL HISTOPATHOL, V18, P343, DOI 10.14670/HH-18.343; Shefelbine SJ, 2004, J ORTHOPAED RES, V22, P346, DOI 10.1016/j.orthres.2003.08.004; Siemens J, 2004, NATURE, V428, P950, DOI 10.1038/nature02483; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; SITHARAM M, 2006, IN PRESS J COMPUT BI; Sollner C, 2004, NATURE, V428, P955, DOI 10.1038/nature02484; Spence HJ, 2002, BIOESSAYS, V24, P542, DOI 10.1002/bies.10098; Stamenovic D, 2000, J BIOMECH ENG-T ASME, V122, P39, DOI 10.1115/1.429631; STAMENOVIC D, 1990, PHYSIOL REV, V70, P1117, DOI 10.1152/physrev.1990.70.4.1117; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; SUKHAREV S, 2004, SCI STKE, pRE4; Suki B, 2005, J APPL PHYSIOL, V98, P1892, DOI 10.1152/japplphysiol.01087.2004; Sultan C, 2004, ANN BIOMED ENG, V32, P520, DOI 10.1023/B:ABME.0000019171.26711.37; Sun RJ, 2003, BIORHEOLOGY, V40, P31; Tan JL, 2003, P NATL ACAD SCI USA, V100, P1484, DOI 10.1073/pnas.0235407100; Toshima M, 2004, ARCH HISTOL CYTOL, V67, P31, DOI 10.1679/aohc.67.31; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; Tucker JB, 1999, J NEUROCYTOL, V28, P1017, DOI 10.1023/A:1007092105185; Tzima E, 2002, EMBO J, V21, P6791, DOI 10.1093/emboj/cdf688; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Vandenburgh H, 1996, HUM GENE THER, V7, P2195, DOI 10.1089/hum.1996.7.17-2195; Veigel C, 2003, NAT CELL BIOL, V5, P980, DOI 10.1038/ncb1060; Vera C, 2005, ANN BIOMED ENG, V33, P1387, DOI 10.1007/s10439-005-4698-y; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Wang N, 2005, BIOCHEM BIOPH RES CO, V328, P1133, DOI 10.1016/j.bbrc.2005.01.070; Wang N, 2001, P NATL ACAD SCI USA, V98, P7765, DOI 10.1073/pnas.141199598; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wang YX, 2005, NATURE, V434, P1040, DOI 10.1038/nature03469; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Wendling Sylvie, 2003, Computer Methods in Biomechanics and Biomedical Engineering, V6, P45, DOI 10.1080/1025584021000059413; WOLYNES PG, 2005, PHYS REV E, V72, P1927; Yamamoto K, 2005, AM J PHYSIOL-HEART C, V288, pH1915, DOI 10.1152/ajpheart.00956.2004; Yan L, 2000, J CELL SCI, V113, P3979; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445; Zanotti G, 2003, FEBS LETT, V534, P7, DOI 10.1016/S0014-5793(02)03853-X; Zhang Y, 2000, J PHYSIOL-LONDON, V523, P117, DOI 10.1111/j.1469-7793.2000.t01-1-00117.x	169	1120	1165	9	347	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					811	827		10.1096/fj.05-5424rev	http://dx.doi.org/10.1096/fj.05-5424rev			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675838				2022-12-28	WOS:000240157700003
J	Knoblauch, A; Will, C; Goncharenko, G; Ludwig, S; Wixler, V				Knoblauch, Alexander; Will, Carola; Goncharenko, Grigori; Ludwig, Stephan; Wixler, Viktor			The binding of Mss4 to alpha-integrin subunits regulates matrix metalloproteinase remodeling	FASEB JOURNAL			English	Article						integrin cytodomain; integrin-binding proteins; MT1-MMP; myoblast differentiation	MEMBRANE-PROXIMAL REGION; INSIDE-OUT ACTIVATION; PROTEIN TRANSDUCTION; NUCLEOTIDE EXCHANGE; CYTOPLASMIC DOMAINS; SKELETAL-MUSCLE; IN-VITRO; MT1-MMP; FIBRONECTIN; EXPRESSION	In four independent yeast two-hybrid screens with the integrin alpha-subunits alpha 3A, alpha 6A, alpha 7A, and alpha 7B, we identified the Mss4 protein, a nucleotide exchange factor for exocytic Rab GTPases, as a novel integrin interacting protein. We have previously shown that it binds to the conserved KXGFFKR region of integrin a-subunits located directly beneath the cell membrane. Here we show that the binding site for integrins on Mss4 is overlapping with those for Rab GTPases. Functional analysis of the Mss4/integrin interaction revealed its importance for activation of matrix metalloproteinases (MMPs) and remodeling of secreted extracellular matrix (ECM) proteins. The exocytosis of all the proteins analyzed, however, was unaffected. Furthermore, our data suggest that Mss4 drives the coordinated action of the MT1-MMP/integrin protein complex, thus regulating the presence and activation of MT1-MMP at newly formed filopodia and lamellipodia. This in turn facilitates the conversion of pro-MMPs to MMPs, resulting in cleavage and remodeling of ECM proteins. C2C12 myoblasts with stably down-regulated Mss4 showed a disturbed fibronectin remodeling during differentiation, resulting in malfunctioned myotube formation.	Munster Univ Hosp, Sch Med, Inst Mol Virol, D-48149 Munster, Germany; Univ Gomel, Dept Genet, Gomel, BELARUS	University of Munster; Francisk Skorina Gomel State University	Wixler, V (corresponding author), Munster Univ Hosp, Sch Med, Inst Mol Virol, Von Esmarch Str 56, D-48149 Munster, Germany.	vwixler@uni-muenster.de	Goncharenko, Grigori G./ABD-5708-2020	Goncharenko, Grigori G./0000-0003-1408-8843; Ludwig, Stephan/0000-0003-4490-3052				Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Briesewitz R, 1996, MOL BIOL CELL, V7, P1499, DOI 10.1091/mbc.7.10.1499; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Carmeli E, 2004, MUSCLE NERVE, V29, P191, DOI 10.1002/mus.10529; CHUNG CY, 1990, J CELL PHYSIOL, V142, P392, DOI 10.1002/jcp.1041420224; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; deMelker AA, 1997, BIOCHEM J, V328, P529, DOI 10.1042/bj3280529; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; El Mourabit H, 2002, MATRIX BIOL, V21, P207, DOI 10.1016/S0945-053X(01)00198-6; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Ginsberg MH, 2001, J BIOL CHEM, V276, P22514, DOI 10.1074/jbc.M101915200; Gullberg G, 1999, CELL MOL LIFE SCI, V56, P442, DOI 10.1007/PL00000616; Hintermann E, 2004, MATRIX BIOL, V23, P75, DOI 10.1016/j.matbio.2004.03.001; Ho A, 2001, CANCER RES, V61, P474; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Itzen A, 2006, EMBO J, V25, P1445, DOI 10.1038/sj.emboj.7601044; Jones CB, 2003, CARDIOVASC RES, V59, P812, DOI 10.1016/S0008-6363(03)00516-9; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Kherif S, 1999, DEV BIOL, V205, P158, DOI 10.1006/dbio.1998.9107; KUHL U, 1984, DIFFERENTIATION, V28, P164, DOI 10.1111/j.1432-0436.1984.tb00279.x; Leeman MF, 2003, J PATHOL, V201, P528, DOI 10.1002/path.1466; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Lluri G, 2005, MUSCLE NERVE, V32, P492, DOI 10.1002/mus.20383; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Ma YQ, 2006, BIOCHEMISTRY-US, V45, P6656, DOI 10.1021/bi060279h; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Remacle AG, 2005, J CELL SCI, V118, P4975, DOI 10.1242/jcs.02610; Samson T, 2004, J BIOL CHEM, V279, P28641, DOI 10.1074/jbc.M312894200; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Sato H, 2005, CANCER SCI, V96, P212, DOI 10.1111/j.1349-7006.2005.00039.x; SCHULER F, 1995, J CELL SCI, V108, P3795; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Strongin AY, 2006, CANCER METAST REV, V25, P87, DOI 10.1007/s10555-006-7892-y; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Takino T, 2006, EXP CELL RES, V312, P1381, DOI 10.1016/j.yexcr.2006.01.008; Thaw P, 2001, NAT STRUCT BIOL, V8, P701, DOI 10.1038/90415; Travis MA, 2003, TRENDS PHARMACOL SCI, V24, P192, DOI 10.1016/S0165-6147(03)00069-5; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9; Yamanouchi J, 2004, BIOCHEM J, V379, P317, DOI 10.1042/BJ20031753; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0; YU HT, 1995, BIOCHEMISTRY-US, V34, P9103, DOI 10.1021/bi00028a020; Zhu ZY, 2001, BIOCHEMISTRY-US, V40, P3027, DOI 10.1021/bi002680o	56	17	19	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					497	510		10.1096/fj.06-7022com	http://dx.doi.org/10.1096/fj.06-7022com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17172637				2022-12-28	WOS:000244686300023
J	Crawford, RM; Treharne, KJ; Arnaud-Dabernat, S; Daniel, JY; Foretz, M; Viollet, B; Mehta, A				Crawford, Russell M.; Treharne, Kate J.; Arnaud-Dabernat, Sandrine; Daniel, Jean-Yves; Foretz, Marc; Viollet, Benoit; Mehta, Anil			RETRACTED: Protein kinase CK2 acts as a signal molecule switching between the NDPK-A/AMPK alpha 1 complex and NDPK-B (Retracted Article. See vol 21, pg 3398, 2007)	FASEB JOURNAL			English	Article; Retracted Publication						substrate channeling; substrate steal; translocation; pleiotropic	NUCLEOSIDE-DIPHOSPHATE KINASE; BREAST-CARCINOMA CELLS; PHOSDUCIN-LIKE PROTEIN; IN-VITRO; BINDING; SITE; PHOSPHORYLATION; METASTASIS; EXPRESSION; NM23-H1	Previously we elucidated the molecular interaction between the nucleoside diphosphate kinase A ( NDPK-A)/AMP-activated protein kinase ( AMPK) alpha 1 complex, discovering a process we termed "substrate channeling." Here, we investigate the protein-protein interaction of the substrate channeling complex with the pleiotropic protein kinase, CK2 ( formerly casein kinase 2). We show that CK2 is part of the NDPK-A/AMPK alpha 1 complex under basal ( background AMPK activity) conditions, binding directly to each of the complex components independently. We report that when S122 on NDPK-A is phosphorylated by AMPK alpha 1 in vivo, ( i.e., stimulation of AMPK using either metformin or phenformin) initiating the substrate channeling mechanism, the catalytic subunit of CK2 ( CK2 alpha) is expelled from the complex and translocates to bind NDPK-B, a closely related but independent isoform of NDPK. Thus, we find that the AMPK-dependent phosphostatus of S122 on NDPK-A determines whether CK2 alpha swaps partners between NDPK-A and NDPK-B. This is the first reported linkage between NDPK-A and NDPK-B via a phosphorylation pathway and could explain the complex biology of NDPK. This study also offers an explanation as to how CK2 alpha exclusion mutations ( S120A or S122D of NDPK-A) on NDPK-A might have implications in cancer biology and general cellular energy metabolism.	Univ Dundee, Div Maternal & Child Hlth Sci, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ Victor Segalen Bordeaux 2, Lab Biol Differenciat & Dev, Bordeaux, France; Inst Cochin, INSERM, CNRS, U567,URM8104,Dept GDPM, Paris, France	University of Dundee; UDICE-French Research Universities; Universite de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mehta, A (corresponding author), Univ Dundee, Div Maternal & Child Hlth Sci, Dundee DD1 9SY, Scotland.	a.mehta@dundee.ac.uk	FORETZ, Marc/O-7334-2017	FORETZ, Marc/0000-0001-7017-9032	Wellcome Trust [075237/Z/04/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmad KA, 2005, ANTI-CANCER DRUG, V16, P1037, DOI 10.1097/00001813-200511000-00001; Almgren MAE, 2004, MOL CANCER RES, V2, P387; Arnaud-Dabernat S, 2003, J BIOENERG BIOMEMBR, V35, P19, DOI 10.1023/A:1023561821551; Biondi RM, 1996, FEBS LETT, V399, P183, DOI 10.1016/S0014-5793(96)01299-9; Bosnar MH, 2004, EXP CELL RES, V298, P275, DOI 10.1016/j.yexcr.2004.04.018; Cervoni L, 2006, J CELL BIOCHEM, V98, P421, DOI 10.1002/jcb.20808; Crawford RM, 2005, BIOCHEM J, V392, P201, DOI 10.1042/BJ20050269; Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje; Crawford RM, 2006, MOL CELL BIOL, V26, P5921, DOI 10.1128/MCB.00315-06; Russell M, 2006, CELL SIGNAL, V18, P1595, DOI 10.1016/j.cellsig.2006.01.001; Daval M, 2006, J PHYSIOL-LONDON, V574, P55, DOI 10.1113/jphysiol.2006.111484; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; HEIDBUCHEL H, 1992, CIRC RES, V71, P808, DOI 10.1161/01.RES.71.4.808; Leroy D, 1997, BIOCHEMISTRY-US, V36, P1242, DOI 10.1021/bi961949u; Litchfield DW, 2001, MOL CELL BIOCHEM, V227, P21, DOI 10.1023/A:1013188101465; Lukov GL, 2006, J BIOL CHEM, V281, P22261, DOI 10.1074/jbc.M601590200; Lukov GL, 2004, BIOCHEMISTRY-US, V43, P5651, DOI 10.1021/bi035903u; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; McKendrick L, 1999, MOL CELL BIOCHEM, V191, P187, DOI 10.1023/A:1006854109926; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Muimo R, 2000, J BIOL CHEM, V275, P36632, DOI 10.1074/jbc.M000829200; Nielsen JN, 2003, J APPL PHYSIOL, V94, P631, DOI 10.1152/japplphysiol.00642.2002; Olsten MEK, 2005, MOL CELL BIOCHEM, V274, P115, DOI 10.1007/s11010-005-3072-6; Pinna LA, 2003, ACCOUNTS CHEM RES, V36, P378, DOI 10.1021/ar020164f; Postel EH, 2000, J BIOENERG BIOMEMBR, V32, P277, DOI 10.1023/A:1005541114029; Ranki HJ, 2002, MECH AGEING DEV, V123, P695, DOI 10.1016/S0047-6374(01)00415-8; Roymans D, 2002, CLIN EXP METASTAS, V19, P465, DOI 10.1023/A:1020396722860; Salerno M, 2005, MOL CELL BIOL, V25, P1379, DOI 10.1128/MCB.25.4.1379-1388.2005; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Yang Zhan, 2003, Hua Xi Kou Qiang Yi Xue Za Zhi, V21, P263	37	4	5	2	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					88	98		10.1096/fj.06-6804com	http://dx.doi.org/10.1096/fj.06-6804com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135357				2022-12-28	WOS:000243130200011
J	Turmelle, YP; Shikapwashya, O; Tu, S; Hruz, PW; Yan, QY; Rudnick, DA				Turmelle, Yumirle P.; Shikapwashya, Olga; Tu, Shu; Hruz, Paul W.; Yan, Qingyun; Rudnick, David A.			Rosiglitazone inhibits mouse liver regeneration	FASEB JOURNAL			English	Article						partial hepatectomy; mouse model; cell cycle	ACTIVATED RECEPTOR-GAMMA; NECROSIS-FACTOR RECEPTOR; CELL-CYCLE ARREST; PPAR-GAMMA; PARTIAL-HEPATECTOMY; C/EBP-BETA; INTERLEUKIN-6-DEFICIENT MICE; HEPATOCYTE PROLIFERATION; SIGNAL-TRANSDUCTION; RAPID ACTIVATION	The remarkable regenerative potential of the liver is well known. Recent investigations have shown that this regenerative response is impaired in mouse models of fatty liver disease. Other studies demonstrate that mice engineered for liver-specific overexpression of the peroxisome proliferator activated receptor gamma (PPAR gamma) develop significant hepatic steatosis. These observations suggest that precise regulation of hepatic PPAR gamma activity may be essential for normal liver regeneration. To test this hypothesis, we analyzed the effects of PPAR gamma-activating thiazolidinediones on liver regeneration in the rodent partial hepatectomy model. Thiazolidinediones with different PPAR gamma-activating potencies were administered to mice, and those mice were subjected to partial hepatectomy and analyzed for resulting effects on hepatocellular proliferation and signaling pathways important during normal liver regeneration. The results showed that thiazolidinediones suppress liver regeneration with efficacies that correlate with their relative PPAR gamma-activating potencies. These studies provide the first evidence linking regulation of PPAR gamma activity and the hepatic regenerative response.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Rudnick, DA (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,Box 8208, St Louis, MO 63110 USA.	rudnick_d@kids.wustl.edu		Hruz, Paul/0000-0002-1478-3355	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068219, K08DK002900, P30DK052574] Funding Source: NIH RePORTER; NICHD NIH HHS [T32-HD07409] Funding Source: Medline; NIDDK NIH HHS [DK068219, P30 DK52574, DK02900] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Bedoucha M, 2001, J HEPATOL, V35, P17, DOI 10.1016/S0168-8278(01)00066-6; BONINI JA, 1995, AM J PHYSIOL-ENDOC M, V269, pE759, DOI 10.1152/ajpendo.1995.269.4.E759; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Campbell JS, 2006, J IMMUNOL, V176, P2522, DOI 10.4049/jimmunol.176.4.2522; Campbell JS, 2001, J CLIN INVEST, V107, P1285, DOI 10.1172/JCI11867; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DeAngelis RA, 2005, HEPATOLOGY, V42, P1148, DOI 10.1002/hep.20879; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DIEHL AM, 1999, SCHIFFS DIS LIVER, P39; Enomoto N, 2005, ALCOHOL CLIN EXP RES, V29, p216S, DOI 10.1097/01.alc.0000192394.26573.10; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Gale EAM, 2001, LANCET, V357, P1870, DOI 10.1016/S0140-6736(00)04960-6; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Hernandez R, 2004, DIABETOLOGIA, V47, P1615, DOI 10.1007/s00125-004-1503-7; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hupfeld CJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE207, DOI 10.1152/ajpendo.2001.281.2.E207; Im SS, 2005, EXP MOL MED, V37, P101, DOI 10.1038/emm.2005.14; Kitamura S, 2001, INT J CANCER, V94, P335, DOI 10.1002/ijc.1470; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Kohlroser J, 2000, AM J GASTROENTEROL, V95, P272; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Lazar MA, 2005, BIOCHIMIE, V87, P9, DOI 10.1016/j.biochi.2004.10.021; Lebovitz HE, 2002, DIABETES-METAB RES, V18, pS23, DOI 10.1002/dmrr.252; Leclercq IA, 2003, GASTROENTEROLOGY, V124, P1451, DOI 10.1016/S0016-5085(03)00270-1; Lee FYJ, 1999, HEPATOLOGY, V29, P677, DOI 10.1002/hep.510290320; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li W, 2002, J BIOL CHEM, V277, P28411, DOI 10.1074/jbc.M202807200; Liang CP, 2001, J BIOL CHEM, V276, P49066, DOI 10.1074/jbc.M107250200; Liao YJ, 2004, J BIOL CHEM, V279, P43107, DOI 10.1074/jbc.M407969200; Marcy TR, 2004, ANN PHARMACOTHER, V38, P1419, DOI 10.1345/aph.1E072; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Motomura W, 2004, INT J CANCER, V108, P41, DOI 10.1002/ijc.11561; Ohata M, 2004, ALCOHOL CLIN EXP RES, V28, p139S, DOI 10.1097/01.ALC.0000134412.38510.F7; Panigrahy D, 2003, EXPERT OPIN INV DRUG, V12, P1925, DOI 10.1517/13543784.12.12.1925; Rickheim DG, 2002, HEPATOLOGY, V36, P30, DOI 10.1053/jhep.2002.33996; Rudnick DA, 2005, HEPATOLOGY, V42, P1001, DOI 10.1002/hep.20931; Rudnick DA, 2001, P NATL ACAD SCI USA, V98, P8885, DOI 10.1073/pnas.151217998; Sakamoto T, 1999, HEPATOLOGY, V29, P403, DOI 10.1002/hep.510290244; Selzner M, 2000, HEPATOLOGY, V31, P35, DOI 10.1002/hep.510310108; Shao JY, 2002, CANCER RES, V62, P3282; Shteyer E, 2004, HEPATOLOGY, V40, P1322, DOI 10.1002/hep.20462; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Tolman KG, 2000, INT J CLIN PRACT, P29; Toyota M, 2002, LIFE SCI, V70, P1565, DOI 10.1016/S0024-3205(01)01524-7; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Yamada Y, 1998, HEPATOLOGY, V28, P959, DOI 10.1002/hep.510280410; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yamauchi H, 2003, EXP TOXICOL PATHOL, V54, P281, DOI 10.1078/0940-2993-00265; Yang SQ, 2001, HEPATOLOGY, V34, P694, DOI 10.1053/jhep.2001.28054; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zingarelli B, 2003, J IMMUNOL, V171, P6827, DOI 10.4049/jimmunol.171.12.6827; Zuo Y, 2006, J BIOL CHEM, V281, P7960, DOI 10.1074/jbc.M510682200	62	36	38	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2609	+		10.1096/fj.06-6511fje	http://dx.doi.org/10.1096/fj.06-6511fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077279				2022-12-28	WOS:000242490700040
J	Pederson, T				Pederson, Thoru			Reflections on the prize of prizes: Alfred Nobel	FASEB JOURNAL			English	Article									Univ Massachusetts, Sch Med, Program Cell Dynam, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA; Worcester Fdn Biomed Res, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; Worcester Foundation for Biomedical Research	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Program Cell Dynam, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu						CRICK F, 1988, WHAT MAD PRUSUIT PER; HENCH PS, 1951, P STAFF M MAYO CLIN, V26, P424; MADDOX B., 2002, R FRANKLIN DARK LADY; Pederson T, 2005, ASM NEWS, V71, P118; Pederson T., 2003, J STRUCT BIOL, V141, P5; Reichard P, 2002, J BIOL CHEM, V277, P13355, DOI 10.1074/jbc.R200002200; Ridley M., 2006, F CRICK; Weissmann G, 2005, FASEB J, V19, P1761, DOI 10.1096/fj.05-1101ufm; Weissmann G, 2006, J CLIN INVEST, V116, P1463, DOI 10.1172/JCI28895	9	5	5	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2186	2189		10.1096/fj.06-1102ufm	http://dx.doi.org/10.1096/fj.06-1102ufm			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077294				2022-12-28	WOS:000241702600002
J	Poupot, M; Griffe, L; Marchand, P; Maraval, A; Rolland, O; Martinet, L; L'Faqihi-Olive, FE; Turrin, CO; Caminade, AM; Fournie, JJ; Majoral, JP; Poupot, R				Poupot, Mary; Griffe, Laurent; Marchand, Patrice; Maraval, Alexandrine; Rolland, Olivier; Martinet, Ludovic; L'Faqihi-Olive, Fatima-Ezzahra; Turrin, Cedric-Olivier; Caminade, Anne-Marie; Fournie, Jean-Jacques; Majoral, Jean-Pierre; Poupot, Remy			Design of phosphorylated dendritic architectures to promote human monocyte activation	FASEB JOURNAL			English	Article						cellular immunotherapy; targeting; phosphorus dendrimers	CONTAINING DENDRIMERS; MACROPHAGE ACTIVATION; PROTEIN-KINASE; C-FOS; CELLS; RESPONSES	As first defensive line, monocytes are a pivotal cell population of innate immunity. Monocyte activation can be relevant to a range of immune conditions and responses. Here we present new insights into the activation of monocytes by a series of phosphonic acid-terminated, phosphorus-containing dendrimers. Various dendritic or subdendritic structures were synthesized and tested, revealing the basic structural requirements for monocyte activation. We showed that multivalent character and phosphonic acid capping of dendrimers are crucial for monocyte targeting and activation. Confocal videomicroscopy showed that a fluorescein-tagged dendrimer binds to isolated monocytes and gets internalized within a few seconds. We also found that dendrimers follow the phagolysosomial route during internalization by monocytes. Finally, we performed fluorescence resonance energy transfer (FRET) experiments between a specifically designed fluorescent dendrimer and phycoerythrin-coupled antibodies. We showed that the typical innate Toll-like receptor (TLR)-2 is clearly involved, but not alone, in the sensing of dendrimers by monocytes. In conclusion, phosphorus-containing dendrimers appear as precisely tunable nanobiotools able to target and activate human innate immunity and thus prove to be good candidates to develop new drugs for immunotherapies.	Hop Purpan, INSERM, Ctr Physiopathol Toulouse Purpan, U 563, F-31024 Toulouse 03, France; CNRS, Chim Coordinat Lab, F-31077 Toulouse, France; Univ Toulouse 3, F-31400 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Caminade, AM (corresponding author), Hop Purpan, INSERM, Ctr Physiopathol Toulouse Purpan, U 563, BP3028, F-31024 Toulouse 03, France.	caminade@lcc-toulouse.fr; majoral@lcc-toulouse.fr; remy.poupot@toulouse.inserm.fr	Caminade, Anne-Marie/E-2819-2015; Turrin, cedric-olivier/C-1746-2013; Fournie, Jean-Jacques/J-7805-2013; Marchand, Patrice/E-7156-2013; turrin, cedric-olivier/GQA-5382-2022; Martinet, ludovic/O-9693-2014; Poupot, Mary/F-8570-2013	Caminade, Anne-Marie/0000-0001-8487-3578; Turrin, cedric-olivier/0000-0001-7187-8070; Fournie, Jean-Jacques/0000-0001-6542-6908; Marchand, Patrice/0000-0001-5859-5324; turrin, cedric-olivier/0000-0001-7187-8070; Martinet, ludovic/0000-0002-0867-7724; Poupot, Mary/0000-0002-2688-1091				Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Asthana A, 2005, AAPS PHARMSCITECH, V6, DOI 10.1208/pt060367; Borges A. Rosa, 2005, Current Drug Targets - Infectious Disorders, V5, P247, DOI 10.2174/1568005054880127; Caminade AM, 2004, ACCOUNTS CHEM RES, V37, P341, DOI 10.1021/ar020077n; Cloninger MJ, 2002, CURR OPIN CHEM BIOL, V6, P742, DOI 10.1016/S1367-5931(02)00400-3; Crespo L, 2005, CHEM REV, V105, P1663, DOI 10.1021/cr030449l; Dillon S, 2004, J IMMUNOL, V172, P4733, DOI 10.4049/jimmunol.172.8.4733; Galliot C, 1997, SCIENCE, V277, P1981, DOI 10.1126/science.277.5334.1981; Gillies ER, 2005, DRUG DISCOV TODAY, V10, P35, DOI 10.1016/S1359-6446(04)03276-3; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Jotwani R, 2003, EUR J IMMUNOL, V33, P2980, DOI 10.1002/eji.200324392; LAUNAY N, 1994, ANGEW CHEM INT EDIT, V33, P1589, DOI 10.1002/anie.199415891; Launay N, 1997, J ORGANOMET CHEM, V529, P51, DOI 10.1016/S0022-328X(96)06293-6; Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171; Loup C, 1999, CHEM-EUR J, V5, P3644, DOI 10.1002/(SICI)1521-3765(19991203)5:12<3644::AID-CHEM3644>3.3.CO;2-9; Majoral JP, 1999, CHEM REV, V99, P845, DOI 10.1021/cr970414j; Maszewska M, 2003, OLIGONUCLEOTIDES, V13, P193, DOI 10.1089/154545703322460586; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Owais M., 2005, Current Drug Delivery, V2, P311, DOI 10.2174/156720105774370177; Poupot M, 2003, J IMMUNOL, V171, P2517, DOI 10.4049/jimmunol.171.5.2517; Sadler Kristen, 2002, J Biotechnol, V90, P195; Shaunak S, 2004, NAT BIOTECHNOL, V22, P977, DOI 10.1038/nbt995; Soler-Illia GJDA, 2000, ANGEW CHEM INT EDIT, V39, P4250; SOUCAILLE P, 1988, BIOCHIM BIOPHYS ACTA, V939, P289, DOI 10.1016/0005-2736(88)90073-9; Spaggiari GM, 2006, BLOOD, V107, P1484, DOI 10.1182/blood-2005-07-2775; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816	28	121	124	0	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2339	2351		10.1096/fj.06-5742com	http://dx.doi.org/10.1096/fj.06-5742com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077311				2022-12-28	WOS:000241702600019
J	Banu, N; Teichman, J; Dunlap-Brown, M; Villegas, G; Tufro, A				Banu, Nazifa; Teichman, Jason; Dunlap-Brown, Marya; Villegas, Guillermo; Tufro, Alda			Semaphorin 3C regulates endothelial cell function by increasing integrin activity	FASEB JOURNAL			English	Article						class 3 semaphorins; endothelial cell adhesion; migration; tube formation; VEGF(120) secretion	GROWTH-FACTOR; NEUROPILIN-1; RECEPTOR; GUIDANCE; PLEXIN; GENE; PHOSPHORYLATION; BIOAVAILABILITY; MORPHOGENESIS; EXPRESSION	Class 3 semaphorins ( sema 3) are secreted guidance proteins. Sema 3A expressed by endothelial cells controls vascular morphogenesis through integrin inhibition. Sema 3C is required for normal cardiovascular patterning. Here we examined the potential role of sema 3C as regulator of endothelial cell function in vitro using mouse glomerular endothelial cells (MGEC). We determined that MGEC express sema 3C mRNA and protein and its receptors mRNA. Recombinant sema 3C induced MGEC proliferation 18 +/- 2% above control, as assessed by bromodeoxyuridine ( BrdU) incorporation, and reduced starvation-induced apoptosis by 46 +/- 3%, as indicated by an in situ marker of activated caspase 3. Sema 3C increased MGEC adhesion to fibronectin 79 +/- 13% and to collagen 55 +/- 12% as compared with control. Sema 3C-induced MGEC adhesion was prevented by integrin blocking antibodies and involved beta(1) integrin serine phosphorylation. Sema 3C-induced MGEC adhesion and proliferation were similar to those induced by vascular endothelial growth factor (VEGF)-A. Sema 3C induced a 44 +/- 11% increase in MGEC directional migration and stimulated MGEC capillary-like network formation on collagen I gels. Collectively, our data indicate that sema 3C promotes glomerular endothelial cell proliferation, adhesion, directional migration, and tube formation in vitro by stimulating integrin phosphorylation and VEGF(120) secretion, functions that are similar to VEGF-A and opposite to sema 3A.	Albert Einstein Coll Med, Dept Pediat Nephrol, Dept Dev & Mol Biol, Div Nephrol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Nephrol, Dept Internal Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Nephrol, Dept Pediat, Bronx, NY 10461 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Virginia	Tufro, A (corresponding author), Albert Einstein Coll Med, Dept Pediat Nephrol, Dept Dev & Mol Biol, Div Nephrol, 1300 Morris Pk Ave,Forchheimer Bldg,Room 708, Bronx, NY 10461 USA.	atufro@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064187, P50DK064236, R01DK059333] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50-DK-064236, R01-DK-59333, R10-DK-64187] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Bagnard D, 2000, J NEUROSCI, V20, P1030, DOI 10.1523/JNEUROSCI.20-03-01030.2000; Barberis D, 2005, J CELL SCI, V118, P4689, DOI 10.1242/jcs.02590; Barberis D, 2004, FASEB J, V18, P592, DOI 10.1096/fj.03-0957fje; Basile JR, 2005, MOL CELL BIOL, V25, P6889, DOI 10.1128/MCB.25.16.6889-6898.2005; Bates D, 2003, DEV BIOL, V255, P77, DOI 10.1016/S0012-1606(02)00045-3; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Brown CB, 2001, DEVELOPMENT, V128, P3071; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Christensen CRL, 1998, CANCER RES, V58, P1238; Damon DH, 2006, AM J PHYSIOL-HEART C, V290, pH1220, DOI 10.1152/ajpheart.01232.2004; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; Eichmann A, 2005, CURR OPIN NEUROBIOL, V15, P108, DOI 10.1016/j.conb.2005.01.008; Fagerholm SC, 2004, TRENDS BIOCHEM SCI, V29, P504, DOI 10.1016/j.tibs.2004.07.005; Feiner L, 2001, DEVELOPMENT, V128, P3061; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Gitler AD, 2004, DEV CELL, V7, P107, DOI 10.1016/j.devcel.2004.06.002; Goshima Y, 2002, J CLIN INVEST, V109, P993, DOI 10.1172/JCI200215467; Guan F, 2006, KIDNEY INT, V69, P1564, DOI 10.1038/sj.ki.5000313; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Ito T, 2000, MECH DEVELOP, V97, P35, DOI 10.1016/S0925-4773(00)00401-9; Kagoshima M, 2001, GENES CELLS, V6, P559, DOI 10.1046/j.1365-2443.2001.00441.x; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Miller LE, 2004, ARTHRITIS RHEUM-US, V50, P1156, DOI 10.1002/art.20110; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; Moreno-Flores MT, 2003, J NEUROCHEM, V87, P879, DOI 10.1046/j.1471-4159.2003.02051.x; Mulrooney JP, 2001, J CELL SCI, V114, P2525; Neufeld G, 2005, FRONT BIOSCI-LANDMRK, V10, P751, DOI 10.2741/1569; NG YS, 2005, EXP CELL RES, V102, P18902; Pascual M, 2005, HIPPOCAMPUS, V15, P184, DOI 10.1002/hipo.20040; Renzi MJ, 1999, J NEUROSCI, V19, P7870; Risau W, 1998, KIDNEY INT, V54, pS3, DOI 10.1046/j.1523-1755.1998.06701.x; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Tamagnone L, 2004, EMBO REP, V5, P356, DOI 10.1038/sj.embor.7400114; Torres-Vazquez J, 2004, DEV CELL, V7, P117, DOI 10.1016/j.devcel.2004.06.008; Tufro A, 2000, DEV BIOL, V227, P558, DOI 10.1006/dbio.2000.9845; Villegas G, 2002, MECH DEVELOP, V119, pS149, DOI 10.1016/S0925-4773(03)00108-4; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Yamada T, 1997, P NATL ACAD SCI USA, V94, P14713, DOI 10.1073/pnas.94.26.14713	45	92	102	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2150	+		10.1096/fj.05-5698fje	http://dx.doi.org/10.1096/fj.05-5698fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16940438				2022-12-28	WOS:000241156900045
J	Hirakawa, M; Oike, M; Watanabe, M; Karashima, Y; Ito, Y				Hirakawa, Masakazu; Oike, Masahiro; Watanabe, Michi; Karashima, Yuji; Ito, Yushi			Pivotal role of integrin alpha 5 beta 1 in hypotonic stress-induced responses of human endothelium	FASEB JOURNAL			English	Article						ATP release; tyrosine kinase; RhoA; actin cytoskeleton	FOCAL ADHESION KINASE; INDUCED ATP RELEASE; SHEAR-STRESS; CELL-ADHESION; ACTIVATION; FLOW; RHO; REORGANIZATION; MECHANISM	We have previously reported that both hypotonic stress (HTS) and lysophosphatidic acid (LPA) induce ATP release and a transient reorganization of actin through sequential activation of RhoA/Rho-kinase and focal adhesion kinase F-actin (FAK)/paxillin in human umbilical cord vein endothelial cells (HUVECs). LPA is known to induce the activation of RhoA via its specific receptors, but the mechanisms by which HTS initiates these intracellular signals are not known. The present study aimed to identify the molecule(s) that are unique to the sensing and/or transducing the mechanical stress. Reverse transcriptase-polymerase chain reaction revealed the expression of several integrin subunits in HUVECs. Anti-integrin alpha 5 beta 1 antibody (Ab), but not anti-integrin alpha 2, alpha 6, alpha v, or beta 4 antibodies, inhibited HTS-induced RhoA translocation, tyrosine phosphorylation of FAK and paxillin, ATP release, and actin reorganization. However, the LPA-induced ATP release and actin reorganization were not inhibited by any of these anti-integrin antibodies, indicating that integrin alpha 5 beta 1 plays a pivotal role in the HTS-induced but not in the LPA-induced responses. It is therefore reasonable to assume that this particular subtype of integrin is involved in the initiation of the responses induced by mechanical stimuli in HUVECs.	Kyushu Univ, Grad Sch Med Sci, Dept Pharmacol, Fukuoka 8128582, Japan	Kyushu University	Oike, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Pharmacol, Fukuoka 8128582, Japan.	moike@pharmaco.med.kyushu-u.ac.jp	Karashima, Yuji/AGY-5391-2022	Karashima, Yuji/0000-0002-2866-8999				Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Ashida N, 2003, J BIOL CHEM, V278, P9327, DOI 10.1074/jbc.M212316200; Bodin P, 1998, INFLAMM RES, V47, P351, DOI 10.1007/s000110050341; BODIN P, 1991, BRIT J PHARMACOL, V103, P1203, DOI 10.1111/j.1476-5381.1991.tb12324.x; Buxton ILO, 2001, AM J PHYSIOL-HEART C, V281, pH1657, DOI 10.1152/ajpheart.2001.281.4.H1657; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Florian JA, 2003, CIRC RES, V93, pE136, DOI 10.1161/01.RES.0000101744.47866.D5; Guyot A, 2002, J PHYSIOL-LONDON, V545, P199, DOI 10.1113/jphysiol.2002.030148; HAMASAKI K, 1995, BIOCHEM BIOPH RES CO, V212, P544, DOI 10.1006/bbrc.1995.2004; HASSESSIAN H, 1993, BRIT J PHARMACOL, V109, P466, DOI 10.1111/j.1476-5381.1993.tb13592.x; Hirakawa M, 2004, J PHYSIOL-LONDON, V558, P479, DOI 10.1113/jphysiol.2004.065334; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; Jans D, 2002, J PHYSIOL-LONDON, V545, P543, DOI 10.1113/jphysiol.2002.026641; Kalinowski L, 2003, CIRCULATION, V107, P2747, DOI 10.1161/01.CIR.0000066912.58385.DE; Knight GE, 2002, AM J PHYSIOL-RENAL, V282, pF281, DOI 10.1152/ajprenal.00293.2000; Knudsen HL, 1997, AM J PHYSIOL-HEART C, V273, pH347, DOI 10.1152/ajpheart.1997.273.1.H347; Koyama T, 2001, J PHYSIOL-LONDON, V532, P759, DOI 10.1111/j.1469-7793.2001.0759e.x; Kranenburg O, 1997, J CELL SCI, V110, P2417; Li S, 1999, J CLIN INVEST, V103, P1141, DOI 10.1172/JCI5367; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Malek AM, 1996, J CELL SCI, V109, P713; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; Oike M, 2000, AM J PHYSIOL-HEART C, V279, pH630, DOI 10.1152/ajpheart.2000.279.2.H630; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Tzima E, 2002, EMBO J, V21, P6791, DOI 10.1093/emboj/cdf688; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Urbich C, 2002, ARTERIOSCL THROM VAS, V22, P69, DOI 10.1161/hq0102.101518; Wang YX, 2002, AM J PHYSIOL-CELL PH, V283, pC1540, DOI 10.1152/ajpcell.00222.2002	33	16	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					1992	1999		10.1096/fj.05-5580com	http://dx.doi.org/10.1096/fj.05-5580com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012251				2022-12-28	WOS:000241156900007
J	Cohen, L; Lipstein, N; Gordon, D				Cohen, Lior; Lipstein, Noa; Gordon, Dalia			Allosteric interactions between scorpion toxin receptor sites on voltage-gated Na channels imply a novel role for weakly active components in arthropod venom	FASEB JOURNAL			English	Article						ligand binding; toxicity to insects; gating modifiers; scorpion alpha toxin; beta-toxin	INSECT SODIUM-CHANNELS; LEIURUS-QUINQUESTRIATUS-HEBRAEUS; ALPHA-LIKE TOXINS; RAT-BRAIN; CURRENT INACTIVATION; DIFFERENTIALLY INTERACT; SELECTIVE NEUROTOXINS; MOLECULAR-MECHANISMS; DEPRESSANT TOXIN; DOMAIN-II	Scorpion beta and alpha-toxins modify the activation and inactivation of voltage-gated sodium channels. Although the two types of toxin bind at two distinct receptor sites on the same sodium channel, they exhibit synergic effects when coinjected into insects. To clarify the basis of this synergism we examined the mutual effects of alpha and beta toxin representatives in radio-ligand binding assays. We found positive allosteric interactions between receptor site-4 of the excitatory Bj-xtrIT and the depressant LqhIT2 beta toxins and receptor site-3 of the alpha toxin Lqh alpha IT, on locust neuronal membranes. Unexpectedly, a nontoxic mutant Bj-xtrIT-E15R, which binds with high affinity to receptor site-4, was able to enhance Lqh alpha IT binding and toxicity similarly to the unmodified Bj-xtrIT. This result indicates that mere binding of a nontoxic ligand to receptor site-4 ("silent binding") induces a conformational change that does not alter channel gating, but influences toxin binding at receptor site-3 leading to enhanced toxicity. This finding suggests a new functional role for weakly toxic polypeptides in that they enhance the effect of other active neurotoxins in the arthropod venom. Such silent binding may have also valuable implications in attempts to improve drug efficacy by combining potent drugs with nonactive allosteric enhancers.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gordon, D (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel.	dgordon@post.tau.ac.il		Lipstein, Noa/0000-0002-0755-5899				BABIN DR, 1974, ARCH BIOCHEM BIOPHYS, V164, P694, DOI 10.1016/0003-9861(74)90082-4; Benkhalifa R, 1997, LIFE SCI, V61, P819, DOI 10.1016/S0024-3205(97)00564-X; Benoit E, 2001, NEUROSCIENCE, V104, P551, DOI 10.1016/S0306-4522(01)00073-2; BLANC E, 1997, EUR J BIOCHEM, V247, P1181; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 1998, J NEUROCHEM, V70, P1217; Cestele S, 1999, EUR J NEUROSCI, V11, P975, DOI 10.1046/j.1460-9568.1999.00505.x; Cestele S, 2001, J GEN PHYSIOL, V118, P291, DOI 10.1085/jgp.118.3.291; CESTELE S, 1995, J BIOL CHEM, V270, P15153, DOI 10.1074/jbc.270.25.15153; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Chanda B, 2004, J GEN PHYSIOL, V123, P217, DOI 10.1085/jgp.200308971; Coronas FV, 2003, TOXICON, V41, P989, DOI 10.1016/S0041-0101(03)00071-0; Corzo G, 2001, PROTEIN PEPTIDE LETT, V8, P385, DOI 10.2174/0929866013409256; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; FAINZILBER M, 1995, J BIOL CHEM, V270, P1123, DOI 10.1074/jbc.270.3.1123; FONTECILLACAMPS JC, 1980, P NATL ACAD SCI-BIOL, V77, P6496, DOI 10.1073/pnas.77.11.6496; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; Gilles N, 2003, FEBS LETT, V540, P81, DOI 10.1016/S0014-5793(03)00226-6; Gilles N, 2000, J NEUROCHEM, V75, P1735, DOI 10.1046/j.1471-4159.2000.0751735.x; Gilles N, 2000, EUR J NEUROSCI, V12, P2823, DOI 10.1046/j.1460-9568.2000.00168.x; Gilles N, 1999, J NEUROSCI, V19, P8730, DOI 10.1523/JNEUROSCI.19-20-08730.1999; GORDON D, 1992, BIOCHEMISTRY-US, V31, P7622, DOI 10.1021/bi00148a025; Gordon D, 2003, EUR J BIOCHEM, V270, P2663, DOI 10.1046/j.1432-1033.2003.03643.x; Gordon D, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P215; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; GORDON D, 1984, BIOCHIM BIOPHYS ACTA, V778, P349, DOI 10.1016/0005-2736(84)90379-1; GORDON D, 1994, TOXINS SIGNAL TRANSD, P119; Gordon Dalia, 1997, Invertebrate Neuroscience, V3, P103, DOI 10.1007/BF02480365; Gurevitz M, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P239; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; Hamon A, 2002, EUR J BIOCHEM, V269, P3920, DOI 10.1046/j.1432-1033.2002.03065.x; HERRMANN R, 1995, TOXICON, V33, P1099, DOI 10.1016/0041-0101(95)98053-X; Karbat I, 2004, FASEB J, V18, P683, DOI 10.1096/fj.03-0733com; Lee D, 2000, J NEUROPHYSIOL, V83, P1181, DOI 10.1152/jn.2000.83.3.1181; LEIPOLD E, 2004, MOL PHARM, V65, P865; Mansuelle Pascal, 1992, Natural Toxins, V1, P61, DOI 10.1002/nt.2620010112; Marcotte P, 1997, CIRC RES, V80, P363, DOI 10.1161/01.RES.80.3.363; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; Moskowitz H, 1998, EUR J BIOCHEM, V254, P44, DOI 10.1046/j.1432-1327.1998.2540044.x; MOSKOWITZ H, 1994, INSECT BIOCHEM MOLEC, V24, P13, DOI 10.1016/0965-1748(94)90118-X; Oren DA, 1998, STRUCTURE, V6, P1095, DOI 10.1016/S0969-2126(98)00111-7; PELHATE M, 1982, J EXP BIOL, V97, P67; Pimenta AMC, 2001, RAPID COMMUN MASS SP, V15, P1562, DOI 10.1002/rcm.415; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Prikhod'ko GG, 1998, BIOL CONTROL, V12, P66, DOI 10.1006/bcon.1997.0605; ROCHAT H, 1977, ANAL BIOCHEM, V82, P532, DOI 10.1016/0003-2697(77)90192-0; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Sautiere P, 1998, TOXICON, V36, P1141, DOI 10.1016/S0041-0101(98)00080-4; SHARKEY RG, 1987, MOL PHARMACOL, V31, P273; Shichor I, 1996, J NEUROCHEM, V67, P2451; Shichor I, 2002, J NEUROSCI, V22, P4364, DOI 10.1523/JNEUROSCI.22-11-04364.2002; STANKIEWICZ M, 1996, PHYSL ECOTOXICOLOGY, V4, P93; Strugatsky D, 2005, BIOCHEMISTRY-US, V44, P9179, DOI 10.1021/bi050235t; Szeto TH, 2000, TOXICON, V38, P429, DOI 10.1016/S0041-0101(99)00174-9; Tedford HW, 2004, TOXICON, V43, P601, DOI 10.1016/j.toxicon.2004.02.010; Turkov M, 1997, PROTEIN EXPRES PURIF, V10, P123, DOI 10.1006/prep.1997.0724; ZLOTKIN E, 1991, BIOCHEMISTRY-US, V30, P4814, DOI 10.1021/bi00233a025; Zlotkin E., 1978, ARTHROPOD VENOMS, P317	62	28	29	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1933	+		10.1096/fj.05-5545fje	http://dx.doi.org/10.1096/fj.05-5545fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877526				2022-12-28	WOS:000240267000035
J	Pederson, T				Pederson, Thoru			New surprises in genetic coding and how an ingenious experiment was almost scooped, by evolution	FASEB JOURNAL			English	Editorial Material							SOLUBLE RIBONUCLEIC ACID; AMIDOTRANSFERASE	In 1962, one of the most creative and cogent experiments on the protein coding problem was published. Now it has been discovered that archaebacteria had been doing a related kind of "experiment" all along. Both involve a trick: changing an amino acid that is already attached to a "correct" transfer RNA.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Program Cell Dynam, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Program Cell Dynam, 377 Plantat St, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu						CHAPEVILLE F, 1962, P NATL ACAD SCI USA, V48, P1086, DOI 10.1073/pnas.48.6.1086; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; DEVLIN TM, 1992, TXB BIOCH CLIN CORRE, P504; HOAGLAND MB, 1958, J BIOL CHEM, V231, P241; Judson HF., 1979, 8 DAY CREATION; Kay L. E., 2000, WHO WROTE BOOK LIFE; O'Donoghue P, 2005, P NATL ACAD SCI USA, V102, P19003, DOI 10.1073/pnas.0509617102; Pederson T, 2005, FASEB J, V19, P1583, DOI 10.1096/fj.05-1002ufm; Sauerwald A, 2005, SCIENCE, V307, P1969, DOI 10.1126/science.1108329; Sethi A, 2005, P NATL ACAD SCI USA, V102, P4045, DOI 10.1073/pnas.0409715102; Tumbula D, 1999, GENETICS, V152, P1269	13	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1759	1760		10.1096/fj.06-0902ufm	http://dx.doi.org/10.1096/fj.06-0902ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940146				2022-12-28	WOS:000240267000002
J	Wada, K; Arita, M; Nakajima, A; Katayama, K; Kudo, C; Kamisaki, Y; Serhan, CN				Wada, Koichiro; Arita, Makoto; Nakajima, Atsushi; Katayama, Kazufumi; Kudo, Chiho; Kamisaki, Yoshinori; Serhan, Charles N.			Leukotriene B-4 and lipoxin A(4) are regulatory signals for neural stem cell proliferation and differentiation	FASEB JOURNAL			English	Article						inflammatory mediators; neural inflammation; BLT receptor; ALX receptors; neuron	ACUTE-INFLAMMATION; POTENT INHIBITORS; ACTIVATION; P27(KIP1); RECEPTOR	Leukotrienes (LTs) and lipoxins (LXs) are lipid mediators that play a key role in regulating acute inflammatory responses. Their roles in neural stem cell (NSC) functions are of interest. We showed here that LTB4 and LXA(4) regulated proliferation and differentiation of murine NSCs that were isolated from embryo brains. Proliferation of NSCs was stimulated by LTB4 (3 to 100 nM) and blocked by receptor antagonist (IC50 = 2.7 mu M). In contrast, LXA(4), and its aspirin-triggered-15-epi-LXA(4) stable analog attenuated growth of NSCs at as little as 1 nM. Both lipoxygenase (LOX) inhibitors and LTB4 receptor antagonists caused apoptosis and cell death. Gene chip analysis revealed that growth-related gene expressions such as epidermal growth factor (EGF) receptor, cyclin E, p27, and caspase 8 were tightly regulated by LTB4; LXA(4) gave the opposite gene expressions. In addition to proliferation, LTB4 induced differentiation of NSCs into neurons as monitored by neurite outgrowth and MAP2 expression. These results indicate for the first time that LTB4 and LXA(4) directly regulate proliferation and differentiation of NSCs, suggesting these new pathways may be useful in restoring stem cells. - Wada, K., Arita, M., Nakajima, A., Katayama, K., Kudo, C., Kamisaki, Y., Serhan, C. N. Leukotriene B-4 and lipoxin A(4) are regulatory signals for neural stem cell proliferation and differentiation.	Osaka Univ, Dept Pharmacol, Grad Sch Dent, Suita, Osaka 5650871, Japan; Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Yokohama City Univ, Sch Med, Dept Internal Med 3, Yokohama, Kanagawa 232, Japan	Osaka University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yokohama City University	Wada, K (corresponding author), Osaka Univ, Dept Pharmacol, Grad Sch Dent, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	kwada@dent.osaka-u.ac-jp		Arita, Makoto/0000-0001-9902-0463	NIGMS NIH HHS [4R37 GM038675] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Claria J, 1996, MOL MED, V2, P583, DOI 10.1007/BF03401642; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Fierro IM, 2002, J PHARMACOL EXP THER, V300, P385, DOI 10.1124/jpet.300.2.385; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; Goulet JL, 2000, J IMMUNOL, V164, P4899, DOI 10.4049/jimmunol.164.9.4899; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; Gritti A, 1996, J NEUROSCI, V16, P1091; Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Kudo C, 2004, J NEUROCHEM, V88, P1416, DOI 10.1046/j.1471-4159.2003.02270.x; Kudo C, 2003, BIOCHEM PHARMACOL, V66, P289, DOI 10.1016/S0006-2952(03)00235-1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Manev H, 2000, J NEUROCHEM, V74, pS64; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; Mitchell D, 2004, AM J PATHOL, V164, P937, DOI 10.1016/S0002-9440(10)63181-1; Reh TA, 2002, NAT NEUROSCI, V5, P392, DOI 10.1038/nn0502-392; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Torii MA, 1999, DEVELOPMENT, V126, P443; Vaughn MW, 2002, J IMMUNOL, V169, P3363, DOI 10.4049/jimmunol.169.6.3363; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhao L, 2004, TRENDS CARDIOVAS MED, V14, P191, DOI 10.1016/j.tcm.2004.04.003	29	113	116	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1785	1792		10.1096/fj.06-5809com	http://dx.doi.org/10.1096/fj.06-5809com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940150				2022-12-28	WOS:000240267000006
J	Li, HW; Gao, YX; Freire, CD; Raizada, MK; Toney, GM; Sumners, C				Li, Hongwei; Gao, Yongxin; Freire, Carlos Diez; Raizada, Mohan K.; Toney, Glenn M.; Sumners, Colin			Macrophage migration inhibitory factor in the PVN attenuates the central pressor and dipsogenic actions of angiotensin II	FASEB JOURNAL			English	Article						ANG II; blood pressure; paraventricular nucleus; thiol-protein oxidoreductase	ROSTRAL VENTROLATERAL MEDULLA; PARAVENTRICULAR NUCLEUS; SUBFORNICAL ORGAN; BLOOD-PRESSURE; RAT; DRINKING; NEURONS; BRAIN; MIF; ACTIVATION	Macrophage migration inhibitory factor (MIF) acts intracellularly to counteract the angiotensin (ANG) II type 1 receptor (AT1-R)-mediated chronotropic effect of ANG II in hypothalamic neurons, an effect mediated by the thiol-protein oxidoreductase (TPOR) activity of the MIF molecule. Here we determined the in vivo actions of MIF in regulating the physiological actions of ANG II that are mediated via the paraventricular nucleus (PVN), an area that serves as a relay point in the central nervous system (CNS)-mediated effects of ANG II on cardiovascular functions and water intake. Intracerebroventricular (icv) injection of ANG II into normotensive rats selectively increased MIF protein levels in the PVN and produced significant pressor and drinking responses that were inhibited by PVN administration of the AT1-R antagonist losartan. Overexpression of MIF in PVN neurons via Ad-Syn-MIF gene transfer attenuated the pressor and drinking responses produced by icv-injected ANG II. Consistently, intracellular application of MIF or MIF-(50-65) (which harbors the TPOR activity of MIF) into PVN sympathetic regulatory neurons, blunted the electrophysiological actions of ANG II at these cells. These observations establish for the first time that MIF within the PVN, acting via TPOR, is an intracellular regulator of the central cardiovascular and dipsogenic effects of ANG II.	Univ Florida, Coll Med, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System; University of Texas Health San Antonio	Sumners, C (corresponding author), Univ Florida, Coll Med, Dept Physiol & Funct Genom, Box 100274,1600 SW Archer Rd, Gainesville, FL 32610 USA.	csumners@phys.med.ufl.edu		Sumners, Colin/0000-0002-9689-2255	NHLBI NIH HHS [HL-071645, R01 HL071645, R01 HL076803, HL-076803] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071645, R01HL076803] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Bacher M, 1997, AM J PATHOL, V150, P235; Bacher M, 1998, MOL MED, V4, P217, DOI 10.1007/BF03401919; BAINS JS, 1992, BRAIN RES, V599, P223, DOI 10.1016/0006-8993(92)90395-P; Barnes KL, 2003, AM J PHYSIOL-REG I, V284, pR1340, DOI 10.1152/ajpregu.00505.2002; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Busche S, 2001, ENDOCRINOLOGY, V142, P4623, DOI 10.1210/en.142.11.4623; Cato MJ, 2005, J NEUROPHYSIOL, V93, P403, DOI 10.1152/jn.01055.2003; Chen QH, 2001, AM J PHYSIOL-REG I, V281, pR1844, DOI 10.1152/ajpregu.2001.281.6.R1844; Coote JH, 1995, BIOL SIGNAL, V4, P142; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; Dampney RAL, 2002, CLIN EXP PHARMACOL P, V29, P467, DOI 10.1046/j.1440-1681.2002.03658.x; Falcon BL, 2004, PHYSIOL GENOMICS, V19, P255, DOI 10.1152/physiolgenomics.00170.2004; Ferguson AV, 2001, EXP BIOL MED, V226, P85, DOI 10.1177/153537020122600205; Fingerle-Rowson GR, 2001, IMMUNOL CELL BIOL, V79, P368, DOI 10.1046/j.1440-1711.2001.01024.x; Fleegal MA, 2003, AM J PHYSIOL-REG I, V285, pR632, DOI 10.1152/ajpregu.00151.2003; Hardy SGP, 2001, BRAIN RES, V894, P233, DOI 10.1016/S0006-8993(01)02053-4; Iyer SN, 1996, P NATL ACAD SCI USA, V93, P9960, DOI 10.1073/pnas.93.18.9960; JENSEN LL, 1992, AM J PHYSIOL, V262, pF1068, DOI 10.1152/ajprenal.1992.262.6.F1068; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; Li DP, 2005, J PHARMACOL EXP THER, V313, P1035, DOI 10.1124/jpet.104.082495; Li HW, 2005, REGUL PEPTIDES, V126, P213, DOI 10.1016/j.regpep.2004.10.005; Li Y, 2003, NEUROSCIENCE, V118, P585, DOI 10.1016/S0306-4522(03)00042-3; LI ZH, 1993, AM J PHYSIOL, V265, pR302, DOI 10.1152/ajpregu.1993.265.2.R302; LIND RW, 1985, BRAIN RES BULL, V15, P79, DOI 10.1016/0361-9230(85)90064-4; McKinley MJ, 2003, INT J BIOCHEM CELL B, V35, P901, DOI 10.1016/S1357-2725(02)00306-0; Nguyen MT, 2003, J BIOL CHEM, V278, P33654, DOI 10.1074/jbc.M301735200; PAKHOMOV AG, IN PRESS J NEUROSCI; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Perez DM, 2005, PHARMACOL REV, V57, P147, DOI 10.1124/pr.57.2.2; Sumners C, 2002, CLIN EXP PHARMACOL P, V29, P483, DOI 10.1046/j.1440-1681.2002.03660.x; Sun CW, 2005, CIRC RES, V96, P659, DOI 10.1161/01.RES.0000161257.02571.4b; Sun CW, 2004, J NEUROSCI, V24, P9944, DOI 10.1523/JNEUROSCI.2856-04.2004; Tanaka J, 2001, BEHAV BRAIN RES, V118, P117, DOI 10.1016/S0166-4328(00)00320-X; Veerasingham SJ, 2004, PROG BIOPHYS MOL BIO, V84, P107, DOI 10.1016/j.pbiomolbio.2003.11.007; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; WRIGHT JW, 1987, BRAIN RES, V420, P289, DOI 10.1016/0006-8993(87)91249-2; WRIGHT JW, 1993, BRAIN RES BULL, V31, P649, DOI 10.1016/0361-9230(93)90136-Y; Zerrouk A, 1998, J CARDIOVASC PHARM, V31, P525, DOI 10.1097/00005344-199804000-00009; Zhu GQ, 2002, AM J PHYSIOL-HEART C, V282, pH2039, DOI 10.1152/ajpheart.00854.2001; Zimmerman MC, 2002, CIRC RES, V91, P1038, DOI 10.1161/01.RES.0000043501.47934.FA	42	21	21	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1748	+		10.1096/fj.06-5836fje	http://dx.doi.org/10.1096/fj.06-5836fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16809436				2022-12-28	WOS:000240266600036
J	Shen, HM; Pervaiz, S				Shen, Han-Ming; Pervaiz, Shazib			TNF receptor superfamily-induced cell death: redox-dependent execution	FASEB JOURNAL			English	Review						oxidative stress; reactive oxygen species; death receptor; TRAF	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; FAS-MEDIATED APOPTOSIS; MANGANOUS SUPEROXIDE-DISMUTASE; DRUG-INDUCED APOPTOSIS; OXYGEN SPECIES ROS; OXIDATIVE STRESS; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; INTRACELLULAR SUPEROXIDE	Tumor necrosis factor (TNF) superfamily is a group of cytokines with important functions in immunity, inflammation, differentiation, control of cell proliferation, and apoptosis. TNF alpha is the founding member of the 19 different proteins that have so far been identified within this family. TNF family members exert their biological effects through the TNF receptor (TNFR) superfamily of cell surface receptors that share a stretch of similar to 80 amino acids within their cytoplasmic region, the death domain (DD), critical for recruiting the death machinery. Work over the last decade has unraveled critical signaling networks involved in TNFR-induced cell death, specifically using the constitutively expressed TNFR1 as a prototype. Of particular interest is the intermediary role of intracellular reactive oxygen species (ROS) in signal transduction after ligation of the TNFR1. With the increasing understanding of the of death receptor signaling pathways, the exact role of ROS in TNF alpha-induced execution is now believed to be far more complicated than originally thought. Recently, some important discoveries have underscored the critical role of ROS in TNF alpha signaling, notably in TNF alpha-mediated activation of nuclear factor-kappa B (NF-kappa B) and c-Jun N-terminal kinase (c-Jun NH2-terminal kinase, JNK), as well as in cell death (apoptotic and necrotic) pathways. Here we attempt to review the existing knowledge on the involvement of ROS in death receptor signaling using TNF alpha-TNFR1 as the model system, specifically addressing the involvement of intracellular ROS in TNF alpha-induced cell death and in TNF alpha-induced activation of NF-kappa B and JNK and their crosstalk. Shen, H-M., Pervaiz, S. TNF receptor superfamily-induced cell death: redox-dependent execution.	Natl Univ Singapore, Dept Physiol, Yong Loo Lin Sch Med, Singapore 117597, Singapore; Natl Univ Singapore, Dept Community Occupat & Family Med, Yong Loo Lin Sch Med, Singapore 117597, Singapore; NUS, Grad Integrat Sci & Engn, Singapore, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Pervaiz, S (corresponding author), Natl Univ Singapore, Dept Physiol, Yong Loo Lin Sch Med, Bldg MD9,Level 3, Singapore 117597, Singapore.	phssp@nus.edu.sg	SHEN, Han-Ming/B-5942-2011; Pervaiz, Shazib/C-4188-2015	SHEN, Han-Ming/0000-0001-7369-5227; 				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Ahmad KA, 2004, CANCER RES, V64, P1452, DOI 10.1158/0008-5472.CAN-03-2414; Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Aronis A, 2003, CELL DEATH DIFFER, V10, P335, DOI 10.1038/sj.cdd.4401150; Banki K, 1999, J IMMUNOL, V162, P1466; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Borutaite V, 2001, FEBS LETT, V500, P114, DOI 10.1016/S0014-5793(01)02593-5; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Bubici C, 2004, CELL CYCLE, V3, P1524, DOI 10.4161/cc.3.12.1321; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Byun MS, 2002, EXP MOL MED, V34, P332, DOI 10.1038/emm.2002.47; Carmody RJ, 2001, REDOX REP, V6, P77, DOI 10.1179/135100001101536085; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; Chen F, 2003, CANCER RES, V63, P7689; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; Chovolou Y, 2003, J BIOL CHEM, V278, P29626, DOI 10.1074/jbc.M208665200; Clement MV, 2003, CELL DEATH DIFFER, V10, P1273, DOI 10.1038/sj.cdd.4401302; Clement MV, 2005, ANTIOXID REDOX SIGN, V7, P456, DOI 10.1089/ars.2005.7.456; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Clement MV, 2001, REDOX REP, V6, P211, DOI 10.1179/135100001101536346; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Denecker G, 2001, CELL MOL LIFE SCI, V58, P356, DOI 10.1007/PL00000863; Denning TL, 2002, FREE RADICAL BIO MED, V33, P1641, DOI 10.1016/S0891-5849(02)01141-3; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Devadas S, 2003, FREE RADICAL BIO MED, V35, P648, DOI 10.1016/S0891-5849(03)00391-5; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; Goossens V, 1999, ANTIOXID REDOX SIGN, V1, P285, DOI 10.1089/ars.1999.1.3-285; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; HALLIWELL B, 1994, ENVIRON HEALTH PERSP, V102, P5, DOI 10.2307/3432205; Hao JH, 2004, CANCER RES, V64, P3607, DOI 10.1158/0008-5472.CAN-03-3648; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Hirpara JL, 2001, J BIOL CHEM, V276, P514, DOI 10.1074/jbc.M004687200; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hughes G, 2005, BIOCHEM J, V389, P83, DOI 10.1042/bj20050078; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Izeradjene K, 2005, CANCER RES, V65, P7436, DOI 10.1158/0008-5472.CAN-04-2628; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Jayanthi S, 1999, MOL BRAIN RES, V72, P158, DOI 10.1016/S0169-328X(99)00216-8; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; JUNG EM, 2005, CARCINOGENESIS  0413; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kasahara Y, 1997, BLOOD, V89, P1748, DOI 10.1182/blood.V89.5.1748.1748_1748_1753; Kim H, 2005, ONCOGENE, V24, P1252, DOI 10.1038/sj.onc.1208282; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Le Bras M, 2005, HISTOL HISTOPATHOL, V20, P205, DOI 10.14670/HH-20.205; Lee MW, 2002, CANCER LETT, V182, P75; Lee MW, 2002, FEBS LETT, V512, P313, DOI 10.1016/S0014-5793(02)02225-1; Li JJ, 1997, CANCER RES, V57, P1991; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Liochev SI, 1997, FREE RADICAL BIO MED, V23, P668, DOI 10.1016/S0891-5849(97)00060-9; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Liu ZG, 2005, CELL RES, V15, P24, DOI 10.1038/sj.cr.7290259; Maianski NA, 2003, BLOOD, V101, P1987, DOI 10.1182/blood-2002-02-0522; Malassagne B, 2001, GASTROENTEROLOGY, V121, P1451, DOI 10.1053/gast.2001.29590; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; Medan D, 2005, J CELL PHYSIOL, V203, P78, DOI 10.1002/jcp.20201; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Meylan E, 2005, TRENDS BIOCHEM SCI, V30, P151, DOI 10.1016/j.tibs.2005.01.003; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Minana JB, 2002, HEPATOLOGY, V35, P1205, DOI 10.1053/jhep.2002.32969; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nakano H, 2004, TRENDS IMMUNOL, V25, P402, DOI 10.1016/j.it.2004.05.007; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; Panopoulos A, 2005, J BIOL CHEM, V280, P2912, DOI 10.1074/jbc.M409524200; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Papa S, 2005, CELL DEATH DIFFER, V12, P1259, DOI 10.1038/sj.cdd.4401694; Pervaiz S, 2002, BIOCHEM BIOPH RES CO, V290, P1145, DOI 10.1006/bbrc.2001.6274; Pervaiz S, 2004, CURR PHARM DESIGN, V10, P1969, DOI 10.2174/1381612043384411; Pervaiz S, 2001, ONCOGENE, V20, P6263, DOI 10.1038/sj.onc.1204840; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Piette J, 1997, BIOL CHEM, V378, P1237; Reinehr R, 2005, J BIOL CHEM, V280, P27179, DOI 10.1074/jbc.M414361200; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sasazuki T, 2004, MOL IMMUNOL, V41, P547, DOI 10.1016/j.molimm.2004.03.030; Sato T, 2004, J IMMUNOL, V173, P285, DOI 10.4049/jimmunol.173.1.285; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shakibaei M, 2005, ANTIOXID REDOX SIGN, V7, P482, DOI 10.1089/ars.2005.7.482; Shen HM, 2004, MOL CELL BIOL, V24, P5914, DOI 10.1128/MCB.24.13.5914-5922.2004; Siemankowski LM, 1999, FREE RADICAL BIO MED, V26, P919, DOI 10.1016/S0891-5849(98)00273-1; Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024; Suzuki Y, 1998, FEBS LETT, V425, P209, DOI 10.1016/S0014-5793(98)00228-2; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Temkin V, 2006, MOL CELL BIOL, V26, P2215, DOI 10.1128/MCB.26.6.2215-2225.2006; Tirosh O, 2003, BIOCHEM PHARMACOL, V66, P1331, DOI 10.1016/S0006-2952(03)00481-7; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Torres M, 2003, FRONT BIOSCI, V8, pD369, DOI 10.2741/999; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200; Xia SL, 2005, CANCER RES, V65, P5248, DOI 10.1158/0008-5472.CAN-04-4332; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yamagishi S, 2003, DRUG EXP CLIN RES, V29, P147; Yoon DY, 2004, CLIN CHEM LAB MED, V42, P499, DOI 10.1515/CCLM.2004.085; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhang YD, 2004, CANCER RES, V64, P1902, DOI 10.1158/0008-5472.CAN-03-3361; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644	139	234	249	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1589	1598		10.1096/fj.05-5603rev	http://dx.doi.org/10.1096/fj.05-5603rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873882				2022-12-28	WOS:000240266600004
J	Sen, GL; Blau, HM				Sen, George L.; Blau, Helen M.			A brief history of RNAi: the silence of the genes	FASEB JOURNAL			English	Review						Si RNA; shRNA; gene regulation; post-transitional gene silencing; dsRNA; mRNA degradation; mRNA decay centers; argonaute; p-bodies	DOUBLE-STRANDED-RNA; TARGETED MESSENGER-RNAS; C-ELEGANS; HUMAN-CELLS; ENDORIBONUCLEASE ACTIVITY; CAENORHABDITIS-ELEGANS; NEUROSPORA-CRASSA; MAMMALIAN-CELLS; INTERFERENCE; CLEAVAGE	The use of the RNA interference (RNAi) pathway to eliminate gene products has greatly facilitated the understanding of gene function. Behind this remarkable pathway is an intricate network of proteins that ensures the degradation of the target mRNA. In this review, we explore the history of RNAi as well as highlighting recent discoveries.	Stanford Univ, Sch Med, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Sen, GL (corresponding author), Stanford Univ, Sch Med, Baxter Lab Genet Pharmacol, 269 Campus Dr,CCSR 4225A, Stanford, CA 94305 USA.	gsen@stanford.edu; hblau@stanford.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024987, R37AG009521, R01AG020961, R01AG009521] Funding Source: NIH RePORTER; NIA NIH HHS [AG009521, AG024987, AG020961] Funding Source: Medline; NICHD NIH HHS [HD018179] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Bashkirov VI, 1997, J CELL BIOL, V136, P761, DOI 10.1083/jcb.136.4.761; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Coller J, 2005, CELL, V122, P875, DOI 10.1016/j.cell.2005.07.012; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fagard M, 2000, P NATL ACAD SCI USA, V97, P11650, DOI 10.1073/pnas.200217597; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gazzani S, 2004, SCIENCE, V306, P1046, DOI 10.1126/science.1101092; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Gu S, 2005, RNA, V11, P38, DOI 10.1261/rna.7158605; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; JAKYMIW A, 2005, NAT CELL BIOL, V7, P1167, DOI DOI 10.1038/ncb1334; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; LIU JD, 2005, NAT CELL BIOL, V7, P1161, DOI DOI 10.1038/ncb1333; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Orban TI, 2005, RNA, V11, P459, DOI 10.1261/rna.7231505; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020; ROMANO N, 1992, MOL MICROBIOL, V6, P3343, DOI 10.1111/j.1365-2958.1992.tb02202.x; Sen G, 2004, NAT GENET, V36, P183, DOI 10.1038/ng1288; Sen GL, 2005, NAT CELL BIOL, V7, P633, DOI 10.1038/ncb1265; Sen GL, 2005, DIFFERENTIATION, V73, P287, DOI 10.1111/j.1432-0436.2005.00029.x; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Shirane D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568; Souret FF, 2004, MOL CELL, V15, P173, DOI 10.1016/j.molcel.2004.06.006; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Unterholzner L, 2004, MOL CELL, V16, P587, DOI 10.1016/j.molcel.2004.10.013; Van Dijk EL, 1998, RNA, V4, P1623, DOI 10.1017/S1355838298981316; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; Wang ZR, 2000, EMBO J, V19, P295, DOI 10.1093/emboj/19.2.295; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	59	142	167	2	56	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1293	1299		10.1096/fj.06-6014rev	http://dx.doi.org/10.1096/fj.06-6014rev			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816104				2022-12-28	WOS:000240266000006
J	Erdos, EG				Erdos, Ervin G.			The ACE and I: how ACE inhibitors came to be	FASEB JOURNAL			English	Editorial Material							ANGIOTENSIN-CONVERTING-ENZYME; BRADYKININ; DISCOVERY; KIDNEY; KALLIKREINS; ACTIVATION; CAPTOPRIL; PEPTIDES; KININASE; VENOM		Univ Illinois, Chicago Lab Peptide Res, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Erdos, EG (corresponding author), Univ Illinois, Chicago Lab Peptide Res, Dept Pharmacol, MC 868,835 S Wolcott,Rm E403, Chicago, IL 60612 USA.	egerdos@uic.edu						BAKHLE YS, 1968, NATURE, V220, P919, DOI 10.1038/220919a0; BERALDO WT, 1997, KININ SYSTEM, P1; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bouchard C., 1884, CR HEBD ACAD SCI, V8, P665; Chen ZL, 2005, HYPERTENSION, V46, P1368, DOI 10.1161/01.HYP.0000188905.20884.63; Corvol P., 2004, HDB PROTEOLYTIC ENZY, V1, P332, DOI DOI 10.1016/B978-0-12-079611-3.50090-2; CUSHMAN DW, 1977, BIOCHEMISTRY-US, V16, P5484, DOI 10.1021/bi00644a014; ELLIOTT DF, 1970, HDB EXPT PHARM, V25, P7; Erdos E G, 1966, Adv Pharmacol, V4, P1, DOI 10.1016/S1054-3589(08)60097-6; ERDOS E. G., 1967, LIFE SCI, V6, P569, DOI 10.1016/0024-3205(67)90090-2; Erdos EG, 2004, FASEB J, V18, P226, DOI 10.1096/fj.03-0838lte; ERDOS EG, 1963, BIOCHEM PHARMACOL, V12, P1193, DOI 10.1016/0006-2952(63)90094-7; ERDOS EG, 1963, ANN NY ACAD SCI, V104, P222, DOI 10.1111/j.1749-6632.1963.tb17666.x; ERDOS EG, 2004, HIST BIOCH SELECTED, V8, P279; ERDOS EG, 1966, HYPOTENSIVE PEPTIDES, P235; ERDOS EG, 1962, METABOLIC FACTORS CO, P159; Erdos EG, 1997, KININ SYSTEM, P111; Ferrario CM, 2004, CELL MOL LIFE SCI, V61, P2720, DOI 10.1007/s00018-004-4243-4; Ferreira S.H., 1966, HYPOTENSIVE PEPTIDES, P356; FERREIRA SH, 1962, BIOCHEM PHARMACOL, V11, P1123, DOI 10.1016/0006-2952(62)90190-9; FERREIRA SH, 1970, BIOCHEMISTRY-US, V9, P2583, DOI 10.1021/bi00815a005; Frey EK, 1977, KALLIKREIN PADUTIN; GAFFORD JT, 1983, BIOCHEMISTRY-US, V22, P3265, DOI 10.1021/bi00282a035; GAVRAS H, 1974, NEW ENGL J MED, V291, P817, DOI 10.1056/NEJM197410172911603; GAVRAS H, 1978, CIRCULATION, V58, P770, DOI 10.1161/01.CIR.58.5.770; Gavras H, 2004, FASEB J, V18, P225, DOI 10.1096/fj.03-0837lte; GAVRAS H, 1978, NEW ENGL J MED, V298, P991, DOI 10.1056/NEJM197805042981803; Hemming ML, 2005, J BIOL CHEM, V280, P37644, DOI 10.1074/jbc.M508460200; Hooper NM, 2003, NAT STRUCT BIOL, V10, P155, DOI 10.1038/nsb0303-155; IGIC R, 1972, CIRC RES, V31, pII51; Igic R., 1972, PHARMACOLOGY FUTURE, V5, P307; Ignjatovic T, 2004, MOL PHARMACOL, V66, P1310, DOI 10.1124/mol.104.001990; Ignjatovic T, 2002, J BIOL CHEM, V277, P16847, DOI 10.1074/jbc.M200355200; JASPARD E, 1993, J BIOL CHEM, V268, P9496; KATO H, 1970, P JPN ACAD, V46, P176, DOI 10.2183/pjab1945.46.176; Kirschner MW, 2005, CELL, V121, P503, DOI 10.1016/j.cell.2005.05.005; Marcic B, 2000, J BIOL CHEM, V275, P16110, DOI 10.1074/jbc.M909490199; NG KKF, 1968, NATURE, V218, P144, DOI 10.1038/218144a0; ONDETTI MA, 1971, BIOCHEMISTRY-US, V10, P4033, DOI 10.1021/bi00798a004; OSHIMA G, 1974, BIOCHIM BIOPHYS ACTA, V350, P26, DOI 10.1016/0005-2744(74)90199-5; PAGE IH, 1988, HYPERTENSION RES MEM, P113; Patchett A A, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P1; Peng HM, 2005, CIRCULATION, V112, P2436, DOI 10.1161/CIRCULATIONAHA.104.528695; PFEFFER M, 2001, ANGIOTENSIN CONVERTI, P219; REGOLI D, 1980, PHARMACOL REV, V32, P1; RUBIN B, 1978, J PHARMACOL EXP THER, V204, P271; Skeggs LT, 2000, CLIN CHEM, V46, P1425; Skeggs LT., 1981, BIOCHEMICAL REGULATI, P3; Skidgel R.A., 1993, RENIN ANGIOTENSIN SY, V1, DOI DOI 10.1-10.10; Smith CG, 2004, FASEB J, V18, P935, DOI 10.1096/fj.04-1992lte; Smith CG, 2003, FASEB J, V17, P788, DOI 10.1096/fj.03-0093life; SOUBRIER F, 1993, J HYPERTENS, V11, P599, DOI 10.1097/00004872-199306000-00003; TAN F, 2004, J BIOL CHEM, V266, P1936; Tigerstedt R., 1898, SKAND ARCH PHYSIOL, V8, P223, DOI [10.1111/j.1748-1716.1898.tb00272.x, DOI 10.1111/J.1748-1716.1898.TB00272.X]; TURNER AJ, 2004, HDB PROTEOLYTIC ENZY, V1, P349; VANE JR, 1969, BRIT J PHARMACOL, V35, P209, DOI 10.1111/j.1476-5381.1969.tb07982.x; WEBSTER ME, 1963, ANN NY ACAD SCI, V104, P91, DOI 10.1111/j.1749-6632.1963.tb17655.x; WEBSTER ME, 1970, HDB EXPERIMENTAL PHA, V25, P131; WEI L, 1991, J BIOL CHEM, V266, P9002; Werle E., 1970, HDB EXPT PHARM, V25, P1; YANG HYT, 1967, NATURE, V215, P1402, DOI 10.1038/2151402a0; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6; YANG HYT, 1971, J PHARMACOL EXP THER, V177, P291	63	32	33	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1034	1038		10.1096/fj.06-0602ufm	http://dx.doi.org/10.1096/fj.06-0602ufm			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770001				2022-12-28	WOS:000240210300002
J	Stoldt, VR; Schnorr, O; Schulze-Osthoff, K; Scharf, RE				Stoldt, Volker R.; Schnorr, Oliver; Schulze-Osthoff, Klaus; Scharf, Rudiger E.			Transforming growth factor-beta 1 enhances the antifibrinolytic and prothrombotic state of growing endothelial cells in a cell cycle-specific manner	FASEB JOURNAL			English	Article						tissue repair; homeostasis; angiogenesis; plasminogen activator inhibitor; human umbilical vein endothelial cells	TRANSFORMING-GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR INHIBITOR-1; GENE DEFICIENT MICE; DIRECT BINDING; BETA; STIMULATION; MODULATION; EXPRESSION; THROMBOSIS; FIBROSIS	Cell cycle-dependent modulation of protein expression may influence the balance of antithrombotic and prothrombotic properties of endothelial cells. In the present study, we examined the regulation of prothrombotic and antithrombotic molecules by transforming growth factor-beta 1 (TGF-beta 1) during distinct phases of the cell cycle in human umbilical vein endothelial cells. In the absence of TGF-beta 1, the expression of thrombomodulin, the plasminogen activators u-PA and t-PA, and their inhibitor PAI-1 was significantly increased in the S/G2 compared to the G(1) phase. Treatment of endothelial cells with TGF-beta 1, however, resulted in elevated expression of PAI-1 specifically in the S/G2 phase, while t-PA and u-PA increased to the same extent in both the G1 and S/G2 phase. These findings demonstrate that the expression of a subset of hemostatically relevant proteins is regulated during endothelial cell cycle and that TGF-beta 1 can differentially modulate cell cycle-controlled protein expression.	Univ Dusseldorf, Dept Hemostasis & Transfus Med, Lab Vasc Biol, Med Ctr, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Ctr, Ctr Biol & Med Res, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Ctr, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Stoldt, VR (corresponding author), Univ Dusseldorf, Dept Hemostasis & Transfus Med, Lab Vasc Biol, Med Ctr, Bldg 12-49-00,Rm 9,Moorenstr 5, D-40225 Dusseldorf, Germany.	stoldt@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; Boehm JR, 1999, J CELL PHYSIOL, V181, P96, DOI 10.1002/(SICI)1097-4652(199910)181:1<96::AID-JCP10>3.0.CO;2-I; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Cines DB, 1998, BLOOD, V91, P3527; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; ERICKSON LA, 1990, NATURE, V346, P74, DOI 10.1038/346074a0; Fay WP, 1997, BLOOD, V90, P204; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Grainger DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/hmg/8.1.93; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; Hou BD, 2004, J BIOL CHEM, V279, P18127, DOI 10.1074/jbc.M310438200; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Le Breton M, 2005, BIOCHIMIE, V87, P805, DOI 10.1016/j.biochi.2005.04.014; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; OHJI T, 1995, THROMB HAEMOSTASIS, V73, P812; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V176, P633, DOI 10.1016/S0006-291X(05)80231-1; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; StaianoCoico L, 1996, EXP CELL RES, V227, P123, DOI 10.1006/excr.1996.0257; Tietze L, 1998, THROMB HAEMOSTASIS, V79, P362; Wu KK, 1996, ANNU REV MED, V47, P315	27	3	4	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					965	+		10.1096/fj.04-3032fje	http://dx.doi.org/10.1096/fj.04-3032fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571780				2022-12-28	WOS:000240157700023
J	Frosch, WA				Frosch, William A.			The sopranos: post-op virtuosi	FASEB JOURNAL			English	Editorial Material									Weill Cornell Med Coll, Dept Psychiat, New York, NY 10021 USA	Cornell University	Frosch, WA (corresponding author), Weill Cornell Med Coll, Dept Psychiat, 525 East 68th St, New York, NY 10021 USA.	wafrosc@med.cornell.edu						BARBIER, WORLD, P29; BARBIER, WORLD, P59; BARBIER, WORLD, P40; BARBIER P, 1992, WORLD CASTRATI, P9; BURNEY C, 1784, GEN HIST MUSIC, V4, P40; GILES, HIST TECHNIQUE, P396; GILES P, 1994, HIST TECHNIQUE COUNT, P391; KELLY M, 1826, REMINISCENCES M KELL, P121; MELICOW MM, 1977, NEW YORK STATE J MED, V77, P804; MILNER, SACRED CAPONS, P252; Milner Anthony, 1973, MUSIC TIMES, V114, P250; ROSELLI, CASTRATI, P160; ROSELLI, CASTRATI, P151; Roselli J, 1988, ACTA MUSICOLOGICA, V60, P143; ROSELLI J, 1992, NEW GROVE DICT OPERA, V1, P767; ROSELLI J, CASTRATI, P766; ROSELLI J, CASTRATI, P767; TOSI PF, 1943, OBSERVATIONS FLORID, P15; 1910, ENCY BRITTANNICA, V1, P94	19	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					595	597		10.1096/fj.06-0402ufm	http://dx.doi.org/10.1096/fj.06-0402ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581964				2022-12-28	WOS:000240130900003
J	Sriram, K; Matheson, JM; Benkovic, SA; Miller, DB; Luster, MI; O'Callaghan, JP				Sriram, Krishnan; Matheson, Joanna M.; Benkovic, Stanley A.; Miller, Diane B.; Luster, Michael I.; O'Callaghan, James P.			Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha	FASEB JOURNAL			English	Article						brain; neurodegeneration; neuroinflammation; neuroprotection; microglia	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; FIBRILLARY ACIDIC PROTEIN; DOPAMINERGIC NEUROTOXICITY; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; MICE LACKING; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; SUBSTANTIA-NIGRA; OXIDATIVE STRESS	Enhanced expression of tumor necrosis factor ( TNF)-alpha, is associated with the neuropathological effects underlying disease-, trauma- and chemically induced neurodegeneration. Previously, we have shown that deficiency of TNF receptors protects against MPTP-induced striatal dopaminergic neurotoxicity, findings suggestive of a role for TNF-alpha in neurodegeneration. Here, we demonstrate that deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP. MPTP-induced expression of microglia-derived factors, TNF-alpha, MCP-1, and IL-1 alpha, preceded the degeneration of striatal dopaminergic nerve terminals and astrogliosis, as assessed by loss of striatal dopamine and TH, and an increase in striatal GFAP. Pharmacological neuroprotection with the dopamine reuptake inhibitor, nomifensine, abolished striatal dopaminergic neurotoxicity and associated microglial activation. Similarly, in mice lacking TNF receptors, microglial activation was suppressed, findings consistent with a role for TNF-alpha in striatal MPTP neurotoxicity. In the hippocampus, however, TNF receptor-deficient mice showed exacerbated neuronal damage after MPTP, as evidenced by Fluoro Jade-B staining (to identify degenerating neurons) and decreased microtubule-associated protein-2 (MAP-2) immunoreactivity. These effects were not accompanied by microglial activation, but were associated with increased oxidative stress (nitrosylation of tyrosine residues). These findings suggest that TNF-alpha exerts a neurotrophic/ neuroprotective effect in hippocampus. The marked differences we observed in the regional density, distribution and/or activity of microglia and microgliaderived factors may influence the region-specific role for this cell type. Taken together, our results are indicative of a region-specific and dual role for TNF-alpha in the brain: a promoter of neurodegeneration in striatum and a protector against neurodegeneration in hippocampus. -Sriram, K., Matheson, J.M., Benkovic, S. A., Miller, D. B., Luster, M. I., O'Callaghan, J. P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP- induced neurotoxicity: role of TNF-alpha.	NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	O'Callaghan, JP (corresponding author), NIOSH, CDC, M-S L-3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.	jdo5@cdc.gov	O'Callaghan, James/O-2958-2013; Sriram, Krishnan/F-1039-2014	Sriram, Krishnan/0000-0001-7005-1872				Albensi BC, 2000, SYNAPSE, V35, P151; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; Benkovic SA, 2004, BRAIN RES, V1024, P59, DOI 10.1016/j.brainres.2004.07.021; Bezard E, 1997, EXP NEUROL, V148, P288, DOI 10.1006/exnr.1997.6648; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; BORIT A, 1975, BRAIN, V98, P101, DOI 10.1093/brain/98.1.101; Botchkina GI, 1999, MOL MED, V5, P372, DOI 10.1007/BF03402126; BRADBURY AJ, 1986, NEUROPHARMACOLOGY, V25, P939, DOI 10.1016/0028-3908(86)90025-0; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Calabresi P, 2000, TRENDS NEUROSCI, V23, pS57, DOI 10.1016/S1471-1931(00)00017-3; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Ferger B, 2004, J NEUROCHEM, V89, P822, DOI 10.1111/j.1471-4159.2004.02399.x; FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K; FRANCIS JW, 1995, NEUROTOXICOL TERATOL, V17, P7, DOI 10.1016/0892-0362(94)00048-I; Freyaldenhoven TE, 1997, BRAIN RES, V759, P9, DOI 10.1016/S0006-8993(97)00045-0; Galasso JM, 2000, NEUROREPORT, V11, P231, DOI 10.1097/00001756-200002070-00002; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; HEIKKILA RE, 1985, LIFE SCI, V36, P231, DOI 10.1016/0024-3205(85)90064-5; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; Hunot S, 2001, CLIN NEUROSCI RES, V1, P434, DOI 10.1016/S1566-2772(01)00022-6; ICHITANI Y, 1991, BRAIN RES, V549, P350, DOI 10.1016/0006-8993(91)90481-A; Imam SZ, 2001, J NEUROCHEM, V76, P745, DOI 10.1046/j.1471-4159.2001.00029.x; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; JONSSON G, 1985, N-S ARCH PHARMACOL, V331, P1, DOI 10.1007/BF00498844; Joseph SA, 1996, PEPTIDES, V17, P655, DOI 10.1016/0196-9781(96)00063-0; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; LEE SC, 1993, J IMMUNOL, V150, P2659; Leng A, 2005, NEUROSCI LETT, V375, P107, DOI 10.1016/j.neulet.2004.10.077; Little AR, 2002, NEUROSCIENCE, V115, P307, DOI 10.1016/S0306-4522(02)00359-7; MARTIN PM, 1995, J NEUROSCI METH, V58, P181, DOI 10.1016/0165-0270(94)00175-G; Masliah E., 2000, NEURODEGENERATIVE DE, P131; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; McGeer PL, 1998, ALZ DIS ASSOC DIS, V12, pS1; MERRILL JE, 1992, J IMMUNOTHER, V12, P167, DOI 10.1097/00002371-199210000-00004; Miller RG, 2001, AMYOTROPH LATERAL SC, V2, P3, DOI 10.1080/146608201300079355; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; O'Callaghan JP, 2004, J NEUROSCI METH, V135, P159, DOI 10.1016/j.jneumeth.2003.12.006; O'Callaghan JP, 1999, ANAL BIOCHEM, V274, P18, DOI 10.1006/abio.1999.4260; O'Callaghan JP, 1998, ANN NY ACAD SCI, V844, P40; OCALLAGHAN JP, 1990, BRAIN RES, V521, P73, DOI 10.1016/0006-8993(90)91526-M; OCALLAGHAN JP, 1995, NEUROCHEM INT, V26, P115, DOI 10.1016/0197-0186(94)00106-5; OCALLAGHAN JP, 1993, ANN NY ACAD SCI, V679, P195, DOI 10.1111/j.1749-6632.1993.tb18299.x; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; PERRY TL, 1985, NEUROSCI LETT, V58, P321, DOI 10.1016/0304-3940(85)90074-6; Raivich Gennadij, 1996, Keio Journal of Medicine, V45, P239; Ransohoff Richard M., 1996, Cytokine and Growth Factor Reviews, V7, P35, DOI 10.1016/1359-6101(96)00003-2; REINHARD JF, 1988, NEUROSCI LETT, V95, P246, DOI 10.1016/0304-3940(88)90665-9; Ren LQ, 1999, MOL BRAIN RES, V65, P198, DOI 10.1016/S0169-328X(99)00016-9; Rousselet E, 2002, EXP NEUROL, V177, P183, DOI 10.1006/exnr.2002.7960; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SCHNEIDER JS, 1988, J NEUROPATH EXP NEUR, V47, P452, DOI 10.1097/00005072-198807000-00006; Shen YQ, 2005, J NEUROIMMUNOL, V158, P14, DOI 10.1016/j.jneuroim.2004.06.011; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; Sriram K, 2006, J NEUROCHEM, V96, P706, DOI 10.1111/j.1471-4159.2005.03566.x; Sriram K, 2004, J BIOL CHEM, V279, P19936, DOI 10.1074/jbc.M309304200; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; Sriram K, 1997, BRAIN RES, V749, P44, DOI 10.1016/S0006-8993(96)01271-1; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; TAKADA M, 1993, NEUROSCI LETT, V150, P49, DOI 10.1016/0304-3940(93)90105-T; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Teismann P, 2001, NEUROREPORT, V12, P1049, DOI 10.1097/00001756-200104170-00037; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709	79	185	192	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					670	682		10.1096/fj.05-5106com	http://dx.doi.org/10.1096/fj.05-5106com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581975	Green Submitted			2022-12-28	WOS:000240130900013
J	Sausbier, M; Zhou, XB; Beier, C; Sausbier, U; Wolpers, D; Maget, S; Martin, C; Dietrich, A; Ressmeyer, AR; Renz, H; Schlossmann, J; Hofmann, F; Neuhuber, W; Gudermann, T; Uhlig, S; Korth, M; Ruth, P				Sausbier, Matthias; Zhou, Xiao-Bo; Beier, Caroline; Sausbier, Ulrike; Wolpers, Daniela; Maget, Syivi; Martin, Christian; Dietrich, Alexander; Ressmeyer, Anna-Rebekka; Renz, Harald; Schlossmann, Jens; Hofmann, Franz; Neuhuber, Winfried; Gudermann, Tbomas; Uhlig, Stefan; Korth, Michael; Ruth, Peter			Reduced rather than enhanced cholinergic airway constriction in mice with ablation of the large conductance Ca2+-activated K+ channel	FASEB JOURNAL			English	Article						knockout mice; BK channel; airway contractility; cyclic GMP/PKG signaling; cholinergic agonists	DEPENDENT PROTEIN-KINASE; TRACHEAL SMOOTH-MUSCLE; GUINEA-PIG TRACHEA; POTASSIUM CHANNELS; NITRIC-OXIDE; CALCIUM; CONTRACTION; RELAXATION; RECEPTOR; INHIBITION	The unique voltage- and Ca2+-dependent K+ (BK) channel, prominently expressed in airway smooth muscle cells, has been suggested as an important effector in controlling airway contractility. Its deletion in mice depolarized resting membrane potential of tracheal cells, suggesting an increased open-probability of voltage-gated Ca2+ channels. While carbachol concentration-dependently increased the tonic tension of wild-type (WT) trachea, mutant trachea showed a different response with rapid tension development followed by phasic contractions superimposed on a tonic component. Tonic contractions were substantially more dependent on 1-type Ca2+ current in mutant than in WT trachea, even though 1-type Ca2+ channels were not up-regulated. In the absence of 1-type Ca2+ current, half-maximal contraction of trachea was shifted from 0.51 to 1.7 mu M. In agreement, cholinergic bronchoconstriction was reduced in mutant lung slices, isolated-perfused lungs and, most impressively, in mutant mice analyzed by body plethysmography. Furthermore, isoprenaline-mediated airway relaxation was enhanced in mutants. In-depth analysis of cAMP and cGMP signaling revealed up-regulation of the cGMP pathway in mutant tracheal muscle. Inhibition of cGMP kinase reestablished normal sensitivity toward carbachol, indicating that up-regulation of cGMP signaling counterbalances for BK channel ablation, pointing to a predominant role of BK channel in regulation of airway tone.	Univ Hamburg, Klinikum Eppendorf, Inst Pharmacol & Pharmazeuten, D-20246 Hamburg, Germany; Univ Tubingen, Inst Pharmazeut, D-72074 Tubingen, Germany; Leibniz Zentrum Med & Biowissensch, Borstel, Germany; Univ Marburg, Inst Pharmacol & Toxicol, D-35032 Marburg, Germany; Univ Marburg, Inst Klin Chem & Mol Diagnost, D-35032 Marburg, Germany; Tech Univ Munich, Inst Pharmacol & Toxicol, D-8000 Munich, Germany; Univ Erlangen Nurnberg, Inst Anat, Erlangen, Germany; Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, D-5100 Aachen, Germany	University of Hamburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Philipps University Marburg; Philipps University Marburg; Technical University of Munich; University of Erlangen Nuremberg; RWTH Aachen University	Korth, M (corresponding author), Univ Hamburg, Klinikum Eppendorf, Inst Pharmacol & Pharmazeuten, Martinistr 52, D-20246 Hamburg, Germany.	korth@uke.uni-hamburg.de	Dietrich, Alexander/G-8619-2013; Schlossmann, Jens/I-7743-2016; Uhlig, Stefan/A-7290-2014	Dietrich, Alexander/0000-0002-1168-8707; Schlossmann, Jens/0000-0002-2550-6839; Uhlig, Stefan/0000-0003-2332-1280				AHMED F, 1985, BRIT J PHARMACOL, V84, P861, DOI 10.1111/j.1476-5381.1985.tb17380.x; Barnes PJ, 1998, AM J RESP CRIT CARE, V158, pS123, DOI 10.1164/ajrccm.158.supplement_2.13tac800; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BLACK JL, 1990, THORAX, V45, P213, DOI 10.1136/thx.45.3.213; Choi JW, 1998, J PHARMACOL EXP THER, V285, P588; Corompt E, 1998, N-S ARCH PHARMACOL, V357, P77; Dimitropoulou C, 2005, AM J RESP CELL MOL, V32, P239, DOI 10.1165/rcmb.2004-0331OC; Eglen RM, 1996, PHARMACOL REV, V48, P531; FLEISCHMANN BK, 1994, P NATL ACAD SCI USA, V91, P11914, DOI 10.1073/pnas.91.25.11914; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; Geiselhoringer A, 2004, EMBO J, V23, P4222, DOI 10.1038/sj.emboj.7600440; Glaab T, 2001, AM J PHYSIOL-LUNG C, V280, pL565, DOI 10.1152/ajplung.2001.280.3.L565; Held HD, 1999, BRIT J PHARMACOL, V126, P1191, DOI 10.1038/sj.bjp.0702394; HUANG JC, 1993, EUR J PHARMACOL, V235, P37, DOI 10.1016/0014-2999(93)90817-2; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V278, pC235, DOI 10.1152/ajpcell.2000.278.2.C235; Janssen LJ, 2002, AM J PHYSIOL-LUNG C, V282, pL1161, DOI 10.1152/ajplung.00452.2001; JANSSEN LJ, 1992, J PHYSIOL-LONDON, V453, P197, DOI 10.1113/jphysiol.1992.sp019224; JIANG H, 1992, J BIOL CHEM, V267, P1015; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110; JONES TR, 1993, J APPL PHYSIOL, V74, P1879, DOI 10.1152/jappl.1993.74.4.1879; JONES TR, 1990, J PHARMACOL EXP THER, V255, P697; KANNAN MS, 1995, LIFE SCI, V56, P2229, DOI 10.1016/0024-3205(95)00212-O; KIRKPATRICK CT, 1975, J PHYSIOL-LONDON, V244, P263, DOI 10.1113/jphysiol.1975.sp010796; KUME H, 1994, J CLIN INVEST, V93, P371, DOI 10.1172/JCI116969; Laporte R, 2004, PHARMACOL REV, V56, P439, DOI 10.1124/pr.56.4.1; Li L, 1998, EUR J PHARMACOL, V346, P255, DOI 10.1016/S0014-2999(98)00074-0; Lincoln T M, 1995, Adv Pharmacol, V34, P305; Madison JM, 2000, AM J RESP CELL MOL, V22, P513, DOI 10.1165/ajrcmb.22.5.f183; Martin C, 2004, AM J PHYSIOL-LUNG C, V287, pL250, DOI 10.1152/ajplung.00420.2003; Meredith AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200; MIURA M, 1992, AM REV RESPIR DIS, V146, P132, DOI 10.1164/ajrccm/146.1.132; MURRAY MA, 1991, BRIT J PHARMACOL, V103, P1814, DOI 10.1111/j.1476-5381.1991.tb09868.x; NADEL JA, 1984, ANNU REV MED, V35, P451, DOI 10.1146/annurev.med.35.1.451; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Oshiro T, 2000, AM J RESP CELL MOL, V22, P528, DOI 10.1165/ajrcmb.22.5.3837; Patel HJ, 1998, J PHARMACOL EXP THER, V286, P952; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Sausbier M, 2005, CIRCULATION, V112, P60, DOI 10.1161/01.CIR.0000156448.74296.FE; Sausbier M, 2004, P NATL ACAD SCI USA, V101, P9474, DOI 10.1073/pnas.0401702101; Sausbier U, 2006, HISTOCHEM CELL BIOL, V125, P725, DOI 10.1007/s00418-005-0124-7; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; SOMLYO AV, 1968, J PHARMACOL EXP THER, V159, P129; Stengel PW, 2002, AM J PHYSIOL-REG I, V282, pR1443, DOI 10.1152/ajpregu.00486.2001; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052; WERNER ME, 2005, J PHYSL, V267, P545; WORLEY JF, 1990, AM J PHYSIOL, V259, pL468, DOI 10.1152/ajplung.1990.259.6.L468; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760; ZhuGe R, 2002, J GEN PHYSIOL, V120, P15, DOI 10.1085/jgp.20028571; ZhuGe RH, 1998, J PHYSIOL-LONDON, V513, P711, DOI 10.1111/j.1469-7793.1998.711ba.x; Zimmerman JL, 2000, AM J RESP CRIT CARE, V162, P512, DOI 10.1164/ajrccm.162.2.9910105	52	27	28	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					812	822		10.1096/fj.06-7167com	http://dx.doi.org/10.1096/fj.06-7167com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197382				2022-12-28	WOS:000244686400019
J	Wotzlaw, C; Otto, T; Berchner-Pfannschmidt, U; Metzen, E; Acker, H; Fandrey, J				Wotzlaw, Christoph; Otto, Teresa; Berchner-Pfannschmidt, Utta; Metzen, Eric; Acker, Helmut; Fandrey, Joachim			Optical analysis of the HIF-1 complex in living cells by FRET and FRAP	FASEB JOURNAL			English	Article						fluorescence resonance energy transfer; fluorescence recoveiy after pholobleaching; hypoxia-inducible factor-1; oxygen sensing	HYPOXIA-INDUCIBLE-FACTOR; STRUCTURAL BASIS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; LIVE CELLS; ACTIVATION; FACTOR-1-ALPHA; HYDROXYLASES; PROTEIN; HETERODIMERIZATION	Hypoxia-inducible factor-1 (HIF-1) coordinates the cellular response to a lack of oxygen by controlling the expression of hypoxia-inducible genes that ensure an adequate energy supply. Assembly of the HIF-1 complex by its oxygen-regulated subunit HIF-1 alpha and its constitutive 0 subunit also known as ARNT is the key event of the cellular genetic response to hypoxia. By two-photon microscopy, we studied HIF-1 assembly in living cells and the mobility of fluorophore-labeled HIF-1 subunits by fluorescence recovery after photobleaching. We found a significantly slower nuclear migration of HIF-1 alpha than of HIF-1 beta, indicating that each subunit can move independently. We applied fluorescence resonance energy transfer to calculate the nanometer distance between alpha and beta subunits of the transcriptionally active HIF-1 complex bound to DNA. Both N terirnini of the fluorophore-labeled HIF-1 subunits were localized as close as 6.2 run, but even the N and C terminus of the HIF-1 complex were not further apart than 7.4 nm. Our data suggest a more compact 3-dimensional organization of the HIF complex than described so far by 2-dimensional models.	Univ Duisburg Gesamthsch, Inst Physiol, D-45122 Essen, Germany; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany	University of Duisburg Essen; University of Lubeck	Fandrey, J (corresponding author), Univ Duisburg Gesamthsch, Inst Physiol, Hufelandstr 55, D-45122 Essen, Germany.	joachim.fandrey@uni-due.de	Acker, Helmut/AAJ-8332-2020; Acker, Helmut Anton Josef/AAS-6841-2020; Fandrey, Joachim/AAA-3524-2021	Acker, Helmut Anton Josef/0000-0001-5589-5508; Fandrey, Joachim/0000-0001-9585-0531				Berchner-Pfannschmidt U, 2004, BIOL CHEM, V385, P231, DOI 10.1515/BC.2004.017; Berchner-Pfannschmidt U, 2004, J BIOL CHEM, V279, P44976, DOI 10.1074/jbc.M313995200; Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006-3495(03)75126-1; Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598; Bestvater F, 2002, J MICROSC-OXFORD, V208, P108, DOI 10.1046/j.1365-2818.2002.01074.x; Card PB, 2005, J MOL BIOL, V353, P664, DOI 10.1016/j.jmb.2005.08.043; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erbel PJA, 2003, P NATL ACAD SCI USA, V100, P15504, DOI 10.1073/pnas.2533374100; Fandrey J, 2006, CARDIOVASC RES, V71, P642, DOI 10.1016/j.cardiores.2006.05.005; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hopfl G, 2004, AM J PHYSIOL-REG I, V286, pR608, DOI 10.1152/ajpregu.00538.2003; Houtsmuller AB, 2001, HISTOCHEM CELL BIOL, V115, P13, DOI 10.1007/s004180000234; Kietzmann T, 2005, SEMIN CELL DEV BIOL, V16, P474, DOI 10.1016/j.semcdb.2005.03.010; Lee C, 2003, J BIOL CHEM, V278, P7558, DOI 10.1074/jbc.M210385200; Liu Q, 2004, P NATL ACAD SCI USA, V101, P4302, DOI 10.1073/pnas.0400265101; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Ruas JL, 2005, J CELL SCI, V118, P301, DOI 10.1242/jcs.01617; Rubart M, 2004, CIRC RES, V95, P1154, DOI 10.1161/01.RES.0000150593.30324.42; Schofield CJ, 2005, BIOCHEM BIOPH RES CO, V338, P617, DOI 10.1016/j.bbrc.2005.08.111; Semenza GL, 1997, KIDNEY INT, V51, P553, DOI 10.1038/ki.1997.77; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tramier M, 2002, BIOPHYS J, V83, P3570, DOI 10.1016/S0006-3495(02)75357-5; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	33	29	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					700	707		10.1096/fj.06-6280com	http://dx.doi.org/10.1096/fj.06-6280com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197389				2022-12-28	WOS:000244686400009
J	Hagerkvist, R; Sandler, S; Mokhtari, D; Welsh, N				Hagerkvist, Robert; Sandler, Stellan; Mokhtari, Dariush; Welsh, Nils			Amelioration of diabetes by imatinib mesylate (Gleevec (R)): role of beta-cell NF-kappa B activation and anti-apoptotic preconditioning	FASEB JOURNAL			English	Article						pancreatic islet; c-Abl; NO	ABL TYROSINE KINASE; RAT PANCREATIC-ISLETS; C-ABL; PROTEIN; INHIBITION; STRESS; TRANSCRIPTION; GENERATION; NECROSIS; DEATH	It was recently reported that tyrosine kinase inhibitor imatinib mesylate (Gleevec (R)) improves Type 2 diabetes, possibly by decreasing insulin resistance. However, as both Type 2 and Type I diabetes are characterized by beta-cell dysfunction and death, we investigated whether imatinib counteracts diabetes by maintaining beta-cell function. We observed that imatinib counteracted diabetes in two animal models, the streptozotocin-injected mouse and the nonobese diabetes mouse, and that this was paralleled by a partial preservation of the P-cell mass. In addition, imatinib decreased the death of human beta-cells in vitro when exposed to NO, cytokines, and streptozotocin. The imatinib effect was mimicked by siRNA-mediated knockdown of c-Ab1 mRNA. Imatinib enhanced beta-cell survival by promoting a state similar to ischemic preconditioning, as evidenced by NF-kappa B activation, increased NO and reactive oxygen species production, and depolarization of the inner mitochondrial membrane. Imatinib did not suppress islet cell death in the presence of an NF-kappa B inhibitor, suggesting that NF-kappa B activation is a necessary step in the antiapoptotic action of imatinib. We conclude that imatinib mediates P-cell survival and that this could contribute to the beneficial effects observed in diabetes.	Uppsala Univ, Biomedicum, Dept Med Cell Biol, SE-75123 Uppsala, Sweden	Uppsala University	Hagerkvist, R (corresponding author), Uppsala Univ, Biomedicum, Dept Med Cell Biol, POB 571, SE-75123 Uppsala, Sweden.	Nils.Welsh@medcellbiol.uu.se						Atkinson MA, 1999, NAT MED, V5, P601, DOI 10.1038/9442; Baines CP, 1999, J CARDIOVASC ELECTR, V10, P741, DOI 10.1111/j.1540-8167.1999.tb00251.x; Barbu A, 2002, MOL CELL ENDOCRINOL, V190, P75, DOI 10.1016/S0303-7207(02)00009-6; Breccia M, 2004, J CLIN ONCOL, V22, P4653, DOI 10.1200/JCO.2004.04.217; Buchdunger E, 1996, CANCER RES, V56, P100; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Ghosh S, 2000, CARDIOVASC RES, V45, P934, DOI 10.1016/S0008-6363(99)00407-1; Gottardi M, 2005, NEW ENGL J MED, V353, P2722, DOI 10.1056/NEJMc052500; Hagerkvist R, 2005, ANN NY ACAD SCI, V1040, P114, DOI 10.1196/annals.1327.014; HAGERKVIST R, 2006, IN PRESS CELL BIOL I; Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Kolb H, 2005, DIABETOLOGIA, V48, P1038, DOI 10.1007/s00125-005-1764-9; Kullin M, 2003, DIABETOLOGIA, V46, P80, DOI 10.1007/s00125-002-0997-0; Kumar S, 2003, MOL PHARMACOL, V63, P276, DOI 10.1124/mol.63.2.276; KUMAR S, 2001, MOL CELL BIOL, V21, P6233; KWON NS, 1994, FASEB J, V8, P529, DOI 10.1096/fasebj.8.8.8181671; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Raina D, 2002, MOL PHARMACOL, V61, P1489, DOI 10.1124/mol.61.6.1489; Raina D, 2005, J BIOL CHEM, V280, P11147, DOI 10.1074/jbc.M413787200; RAKIETEN N, 1963, CANCER CHEMOTH REP, P91; Riksen NP, 2004, NETH J MED, V62, P353; Saldeen J, 2000, ENDOCRINOLOGY, V141, P2003, DOI 10.1210/en.141.6.2003; SALDEEN J, 1994, BIOCHEM BIOPH RES CO, V203, P149, DOI 10.1006/bbrc.1994.2161; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; SVENNSON C, 1999, ENDOCRINOLOGY, V140, P3422; Tobe M, 2003, BIOORGAN MED CHEM, V11, P3869, DOI 10.1016/S0968-0896(03)00438-3; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Veneri D, 2005, NEW ENGL J MED, V352, P1049, DOI 10.1056/NEJM200503103521023; Wang JYJ, 2001, BIOCHEM SOC T, V29, P666, DOI 10.1042/0300-5127:0290666; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003	36	99	104	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					618	628		10.1096/fj.06-6910com	http://dx.doi.org/10.1096/fj.06-6910com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17135364				2022-12-28	WOS:000244686300034
J	Jones, A; Jonsson, AB; Aro, H				Jones, Allison; Jonsson, Ann-Beth; Aro, Helena			Neisseria gonorrhoeae infection causes a G1 arrest in human epithelial cells	FASEB JOURNAL			English	Article						gonococcal infection; cyclins; cell cycle; cell cycle arrest	HUMAN CYCLIN-A; CELLULAR PILUS RECEPTOR; PROGRESSION; PROTEIN; TRANSITION; G(1); CD46; PHOSPHORYLATION; ATTACHMENT; ADHERENCE	Pathogenic bacteria can modulate and interfere with human cell cycle progression. Here we study the human pathogen Neisseria gonorrhoeae and its ability to influence and affect the cell cycle in two human target cell lines. We found that bacteria adhere equally well to cells synchronized into the different cell cycle phases of G1, S, and G2, but were unable to adhere to cells in M phase or GO phase. In addition, using Western blot and/or flow cytometry analysis we demonstrate that bacterial infection for 24 h results in decreased levels of the cell cycle regulatory proteins cyclin B1, cyclin D1, and cyclin E. Further studies in N. gonorrhoeae-infected epithelial cells involving analysis of DNA content, bromodeoxyuridine (BrdU) incorporation, quantification of late mitotic cells and analysis of nuclear phenotype provide compelling evidence that a 24 h gonococcal infection arrests the cells in early G1 phase of the cell cycle. In summary, we present data showing that MS11 P+ strain of N. gonorrhoeae can down-regulate cyclins, important modulators of the cell cycle, and result in a G1 arrest.	Univ Uppsala, Dept Med Biochem & Microbiol, Uppsala Biomed Ctr, S-75123 Uppsala, Sweden	Uppsala University	Aro, H (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, Uppsala Biomed Ctr, Box 582, S-75123 Uppsala, Sweden.	helena.aro@imbim.uu.se						BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Chiou CC, 2003, SCAND J GASTROENTERO, V38, P147, DOI 10.1080/00365520310000627; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Edwards JL, 2005, CELL MICROBIOL, V7, P1197, DOI 10.1111/j.1462-5822.2005.00547.x; Edwards JL, 2002, CELL MICROBIOL, V4, P571, DOI 10.1046/j.1462-5822.2002.t01-1-00215.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Hu L, 1999, INFECT IMMUN, V67, P4171, DOI 10.1128/IAI.67.8.4171-4182.1999; Jacinto A, 2001, NAT CELL BIOL, V3, pE117, DOI 10.1038/35074643; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Johansson L, 2003, SCIENCE, V301, P373, DOI 10.1126/science.1086476; Kallstrom H, 1997, MOL MICROBIOL, V25, P639, DOI 10.1046/j.1365-2958.1997.4841857.x; Kallstrom H, 2001, CELL MICROBIOL, V3, P133, DOI 10.1046/j.1462-5822.2001.00095.x; KELLOGG DS, 1968, J BACTERIOL, V96, P596, DOI 10.1128/JB.96.3.596-605.1968; Koomey M, 2001, CURR OPIN MICROBIOL, V4, P53, DOI 10.1016/S1369-5274(00)00164-8; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; Marches O, 2003, MOL MICROBIOL, V50, P1553, DOI 10.1046/j.1365-2958.2003.03821.x; McCaw SE, 2003, MOL MICROBIOL, V49, P623, DOI 10.1046/j.1365-2958.2003.03591.x; Merz AJ, 1996, MOL MED, V2, P745, DOI 10.1007/BF03401658; Nougayrede JP, 2005, TRENDS MICROBIOL, V13, P103, DOI 10.1016/j.tim.2005.01.002; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Oswald E, 2005, CURR OPIN MICROBIOL, V8, P83, DOI 10.1016/j.mib.2004.12.011; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; SACCO RE, 1994, J IMMUNOL, V153, P1714; Scanlon M, 2000, J EUKARYOT MICROBIOL, V47, P525, DOI 10.1111/j.1550-7408.2000.tb00085.x; Shirin H, 1999, CANCER RES, V59, P2277; Sommi P, 2002, EXP CELL RES, V281, P128, DOI 10.1006/excr.2002.5629; SWANSON J, 1986, CELL, V47, P267, DOI 10.1016/0092-8674(86)90449-6; SWANSON J, 1973, J EXP MED, V137, P571, DOI 10.1084/jem.137.3.571; SWANSON J, 1987, ANTON LEEUW INT J G, V53, P44144; Wessler S, 2005, BIOL CHEM, V386, P481, DOI 10.1515/BC.2005.057	34	26	26	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					345	355		10.1096/fj.06-6675com	http://dx.doi.org/10.1096/fj.06-6675com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158783				2022-12-28	WOS:000244686300008
J	Auguste, KI; Jin, SW; Uchida, K; Yan, DH; Manley, GT; Papadopoulos, MC; Verkman, AS				Auguste, Kurtis I.; Jin, Songwan; Uchida, Kazunori; Yan, Donghong; Manley, Geoffrey T.; Papadopoulos, Marios C.; Verkman, A. S.			Greatly impaired migration of implanted aquaporin-4-deficient astroglial cells in mouse brain toward a site of injury	FASEB JOURNAL			English	Article						AQP4; astrocyte; chemotaxis; reactive gliosis; water channel	WATER CHANNELS; REACTIVE ASTROCYTES; RAT-BRAIN; MICE; AQUAPORIN-1; EXPRESSION; LACKING; TUMORS; ADULT; EDEMA	We reported previously that astroglia cultured from aquaporin-4-deficient ( AQP4(-/-)) mice migrate more slowly in vitro than those from wild-type ( AQP4(-/-)) mice ( J. Cell Sci. 2005; 118, 5691 - 5698). Here, we investigate the migration of fluorescently labeled AQP4(-/-) and AQP4(-/-) astroglia after implantation into mouse brains in which directional movement was stimulated by a planar stab wound 3 mm away from the axis of the injection needle. Two days after cell injection we determined the location, elongation ratio, and orientation of labeled cells. Migration of AQP4(+/+) but not AQP4(-/-) cells toward the stab was greater than away from the stab. AQP4(-/-) astroglia moved on average 1.5 mm toward the stab compared with 0.6 mm for AQP4(-/-) cells. More than 25% of the migrating AQP4(-/-) cells but < 3% of AQP4(-/-) cells appeared elongated ( axial ratio > 2.5). In transwell assays, AQP4(-/-) astroglia migrated faster than AQP4(-/-) cells in a manner dependent on pore size. At 8 h, similar to 50% of AQP4(-/-) cells migrated through 8-mu m diameter pores, whereas equivalent migration of AQP4(-/-) cells was found for 12-mu m diameter pores. These results provide in vivo evidence for AQP4-dependent astroglial migration and suggest that modulation of AQP4 expression or function might alter glial scarring.	Univ Calif San Francisco, Dept Physiol & Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; St Georges Univ London, Acad Neurosurg Unit, London, England	University of California System; University of California San Francisco; University of California System; University of California San Francisco; St Georges University London	Auguste, KI (corresponding author), Univ Calif San Francisco, Dept Physiol & Med, 1246 Hlth Sci E Tower,505 Parnassus Ave, San Francisco, CA 94143 USA.	alan.verkman@ucsf.edu		Papadopoulos, Marios/0000-0001-9174-4176	NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL73856, HL59198] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124, DK72517] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517, R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON C, 1993, INT J DEV NEUROSCI, V11, P555, DOI 10.1016/0736-5748(93)90045-F; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Binder DK, 2004, J NEUROSCI, V24, P8049, DOI 10.1523/JNEUROSCI.2294-04.2004; Binder DK, 2004, NEUROREPORT, V15, P259, DOI 10.1097/00001756-200402090-00009; Bloch O, 2005, J NEUROCHEM, V95, P254, DOI 10.1111/j.1471-4159.2005.03362.x; Brightman MW, 2002, J NEUROCYTOL, V31, P595, DOI 10.1023/A:1025783326667; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chu J, 1999, NEUROSURGERY, V45, P859, DOI 10.1097/00006123-199910000-00026; CONDEELIS J, 1990, DEV GENET, V11, P333, DOI 10.1002/dvg.1020110504; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Hara-Chikuma M, 2006, J AM SOC NEPHROL, V17, P39, DOI 10.1681/ASN.2005080846; Hoque MO, 2006, AM J PATHOL, V168, P1345, DOI 10.2353/ajpath.2006.050596; Hu J, 2006, FASEB J, V20, P1892, DOI 10.1096/fj.06-5930fje; King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; Levin MH, 2006, INVEST OPHTH VIS SCI, V47, P4365, DOI 10.1167/iovs.06-0335; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Moon C, 2003, ONCOGENE, V22, P6699, DOI 10.1038/sj.onc.1206762; Nielsen S, 1997, J NEUROSCI, V17, P171; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; OSTER GF, 1987, J CELL SCI, P35; Padmawar P, 2005, NAT METHODS, V2, P825, DOI 10.1038/NMETH801; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Rash JE, 2004, NEUROSCIENCE, V129, P915, DOI 10.1016/j.neuroscience.2004.06.076; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Saadoun S, 2002, BRIT J CANCER, V87, P621, DOI 10.1038/sj.bjc.6600512; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Schwab A, 2001, AM J PHYSIOL-RENAL, V280, pF739, DOI 10.1152/ajprenal.2001.280.5.F739; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Svitkina TM, 1999, TRENDS BIOCHEM SCI, V24, P432, DOI 10.1016/S0968-0004(99)01461-9; Verkman AS, 2005, REV PHYSIOL BIOCH P, V155, P31, DOI 10.1007/s10254-005-0040-1; Yang JH, 2006, GYNECOL ONCOL, V100, P294, DOI 10.1016/j.ygyno.2005.08.054; ZHOU HF, 1993, EXP NEUROL, V122, P155, DOI 10.1006/exnr.1993.1116	36	186	204	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					108	116		10.1096/fj.06-6848com	http://dx.doi.org/10.1096/fj.06-6848com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17135365				2022-12-28	WOS:000243130200013
J	Fishman, S; Muzumdar, RH; Atzmon, G; Ma, XH; Yang, XM; Einstein, FH; Barzilai, N				Fishman, Sigal; Muzumdar, Radhika H.; Atzmon, Gil; Ma, Xiaohui; Yang, Xiaoman; Einstein, Francine H.; Barzilai, Nir			Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo	FASEB JOURNAL			English	Article						hepatic insulin action; steatosis; metabolic syndrome	FATTY LIVER-DISEASE; DE-NOVO LIPOGENESIS; INSULIN-RESISTANCE; NONALCOHOLIC STEATOHEPATITIS; GLUCOSE-PRODUCTION; ADIPOSE-TISSUE; OB PROTEIN; OBESITY; ACIDS; MASS	Impairment of both insulin and leptin action has been implicated in the pathogenesis of nonalcoholic fatty liver disease. By assessing hepatic triglyceride ( TG) stores in response to modulation of leptin action ( by leptin infusion), we attempted to determine whether leptin has the major role in hepatic TG accumulation. TG were markedly decreased ( by 63%, P < 0.05) in young animals treated with leptin. However, this was also associated with improvement in hepatic insulin action ( 2-fold decrease in HGP during clamp, P < 0.05). These effects on hepatic TG stores and insulin action were abolished in old rats who demonstrate leptin resistance. Since these experiments could not discern the role of leptin from the role of hepatic insulin action on hepatic TG stores, we further examined the effect of improvement of hepatic insulin action by visceral fat removal ( VF-). Enhancement of hepatic insulin action in old VF- rats was associated with reduced hepatic TG stores ( by 64% P < 0.01). Because this manipulation may have induced an improvement in leptin action as well, we studied VF removal in a genetically leptin-resistant model ( Zucker Diabetic Fatty rats, ZDF). Only in this mode was exclusive improvement of hepatic insulin action by VF removal not associated with reduced hepatic TG stores, suggesting that improved hepatic insulin action is not necessary for modulation of hepatic TG stores. By dissociating action of leptin from that of insulin, we suggest that the failure of leptin action is the major physiological mechanism for hepatic steatosis.	Albert Einstein Coll Med, Inst Aging Res, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Pediat Endocrinol, Childrens Hosp Montefiore, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Montefiore Med Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Barzilai, N (corresponding author), Albert Einstein Coll Med, Inst Aging Res, Dept Med, Belfer Bldg 701,1300 Morris Pk Ave, Bronx, NY 10461 USA.	barzilai@aecom.yu.edu	Muzumdar, Radhika/D-9860-2014		NIA NIH HHS [P01-AG 21654, R01-AG 18381] Funding Source: Medline; NIDDK NIH HHS [DK 20541] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018381, P01AG021654] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Atzmon G, 2002, HORM METAB RES, V34, P622, DOI 10.1055/s-2002-38250; Barzilai N, 1996, DIABETES, V45, P1329, DOI 10.2337/diabetes.45.10.1329; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Barzilai N, 1999, DIABETES, V48, P94, DOI 10.2337/diabetes.48.1.94; Bugianesi E, 2005, HEPATOLOGY, V42, P987, DOI 10.1002/hep.20920; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CEFALU WT, 1995, METABOLISM, V44, P954, DOI 10.1016/0026-0495(95)90251-1; Charlton N, 2002, HEPATOLOGY, V35, P898, DOI 10.1053/jhep.2002.32527; Clark JM, 2002, GASTROENTEROLOGY, V122, P1649, DOI 10.1053/gast.2002.33573; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Cohen P, 2004, J NUTR, V134, p2455S, DOI 10.1093/jn/134.9.2455S; Deng QG, 2005, HEPATOLOGY, V42, P905, DOI 10.1002/hep.20877; Diraison F, 2003, DIABETES METAB, V29, P478, DOI 10.1016/S1262-3636(07)70061-7; Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI23621; Ferrannini E, 1997, HYPERTENSION, V30, P1144, DOI 10.1161/01.HYP.30.5.1144; Gabriely I, 2002, DIABETES, V51, P1016, DOI 10.2337/diabetes.51.4.1016; Gabriely I, 2002, DIABETES, V51, P2951, DOI 10.2337/diabetes.51.10.2951; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HUANG W, 2005, ENDOCRINOLOGY; Hughes DE, 2003, HEPATOLOGY, V37, P1414, DOI 10.1053/jhep.2003.50253; Javor ED, 2005, HEPATOLOGY, V41, P753, DOI 10.1002/hep.20672; Kusunoki M, 2002, METABOLISM, V51, P792, DOI 10.1053/meta.2002.32732; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Ma XH, 2002, J GERONTOL A-BIOL, V57, pB225, DOI 10.1093/gerona/57.6.B225; Medina J, 2004, DIABETES CARE, V27, P2057, DOI 10.2337/diacare.27.8.2057; Musso G, 2005, HEPATOLOGY, V42, P1175, DOI 10.1002/hep.20896; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; Schaffler A, 2005, NAT CLIN PRACT GASTR, V2, P273, DOI 10.1038/ncpgasthep0186; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; SHIMOKATA H, 1989, J GERONTOL, V44, pM66, DOI 10.1093/geronj/44.2.M66; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Sivitz WI, 1997, ENDOCRINOLOGY, V138, P3395, DOI 10.1210/en.138.8.3395; Stiles BL, 2006, MOL CELL BIOL, V26, P2772, DOI 10.1128/MCB.26.7.2772-2781.2006; Tamura S, 2005, J CLIN INVEST, V115, P1139, DOI 10.1172/JCI200524930; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Wang JL, 2001, DIABETES, V50, P2786, DOI 10.2337/diabetes.50.12.2786	39	51	53	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2007	21	1					53	60		10.1096/fj.06-6557com	http://dx.doi.org/10.1096/fj.06-6557com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17099068				2022-12-28	WOS:000243130200007
J	Lewis, BM; Pexa, A; Francis, K; Verma, V; McNicol, AM; Scanlon, M; Deussen, A; Evans, WH; Rees, DA; Ham, J				Lewis, B. Mary; Pexa, Annette; Francis, Karen; Verma, Vandana; McNicol, Anne M.; Scanlon, Maurice; Deussen, Andreas; Evans, W. Howard; Rees, D. Aled; Ham, Jack			Adenosine stimulates connexin 43 expression and gap junctional communication in pituitary folliculostellate cells	FASEB JOURNAL			English	Article						CD73; AMP; NECA; pituitary gland	ANTERIOR-PITUITARY; PROLACTIN-RELEASE; ALKALINE-PHOSPHATASE; GROWTH-FACTOR; ATP RELEASE; CYCLIC-AMP; IN-VITRO; RECEPTORS; INHIBITION; HEMICHANNELS	Adenosine is known to stimulate interleukin (IL)-6 and vascular endothelial growth factor (VEGF) secretion from pituitary TtT/GF folliculostellate sheath (FS) cells indicating that it is an important paracrine regulator of anterior pituitary function. This study demonstrates that rodent anterior pituitary cell lines produce extracellular adenosine that is able to increase intercellular gap junction communication in FS cells. Ecto-5'-nucleotidase (CD73), the enzyme that generates adenosine from AMP, was demonstrated by immunocytochemistry in similar to 20% of anterior pituitary cells, and some of these cells colocalized with prolactin and growth hormone. CD73 mRNA and protein were detected in GH3 and MMQ (somatotroph-lactotroph lineages) and TtT/GF cells, and enzyme activity was demonstrated by the conversion of exogenously added fluorescent ethenoAMP to ethenoadenosine. Adenosine production, as measured by HPLC, was detected in GH3 (1 mu M/h) and MMQ (3 mu M/h) but not in TtT/GF cells. Adenosine (EC50:0.5 mu M) and NECA (universal adenosine receptor agonist; EC50 0.1 mu M) stimulated connexin 43 (Cx43) mRNA and protein expression within 1-2 h in TtT/GF cells. Adenosine and NECA also stimulated gap junctional intercellular communication (as assessed by transmission of Alexa Fluor 488) by 6- to 8-fold in comparison with untreated TtT/GF cells. In cocultures of MMQ and TtT/GF cells, Cx43 expression in TtT/GF cells increased in proportion to the number of MMQ cells plated out. These data suggest that adenosine, formed locally in the anterior pituitary gland can stimulate gap junction communication in FS cells.	Univ Cardiff Wales, Ctr Endocrine & Diabet Sci, Sch Med, Cardiff CF14 4XN, Wales; Univ Cardiff Wales, Dept Med Biochem & Immunol, Sch Med, Cardiff CF14 4XN, Wales; Med Fak Carl Gustav Carus, Inst Physiol, Dresden, Germany; Royal Infirm, Dept Pathol, Glasgow G31 2ER, Lanark, Scotland	Cardiff University; Cardiff University; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Royal Infirmary of Edinburgh	Ham, J (corresponding author), Univ Cardiff Wales, Ctr Endocrine & Diabet Sci, Sch Med, Cardiff CF14 4XN, Wales.	wmdjh@cardiff.ac.uk						ANANDSRIVASTAVA MB, 1985, NEUROENDOCRINOLOGY, V41, P113, DOI 10.1159/000124163; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Dang XT, 2003, MOL CELL BIOCHEM, V242, P35, DOI 10.1023/A:1021152709313; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; DORFLINGER LJ, 1985, ENDOCRINOLOGY, V117, P2330, DOI 10.1210/endo-117-6-2330; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; Fauquier T, 2001, P NATL ACAD SCI USA, V98, P8891, DOI 10.1073/pnas.151339598; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Gramsch B, 2001, EXP CELL RES, V264, P397, DOI 10.1006/excr.2000.5145; Guerineau NC, 1998, J BIOL CHEM, V273, P10389, DOI 10.1074/jbc.273.17.10389; Haink G, 2003, J CHROMATOGR B, V784, P189, DOI 10.1016/S1570-0232(02)00752-3; HENTGES S, 2000, ENDOCRINOLOGY, V120, P75; HEURTAOCXAMPO I, 2005, ENDOCRINOLOGY, V146, P726; HILL MK, 1976, ENDOCRINOLOGY, V99, P1612, DOI 10.1210/endo-99-6-1612; Kabir N, 2005, ENDOCRINOLOGY, V146, P4054, DOI 10.1210/en.2005-0122; Kondo RP, 2000, J MOL CELL CARDIOL, V32, P1859, DOI 10.1006/jmcc.2000.1220; Kumari M, 1999, REGUL PEPTIDES, V79, P41, DOI 10.1016/S0167-0115(98)00143-8; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Latini S, 1999, BRIT J PHARMACOL, V127, P729, DOI 10.1038/sj.bjp.0702591; Leybaert L, 2003, CELL COMMUN ADHES, V10, P251, DOI 10.1080/15419060390262985; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; MADHUKAR BV, 1989, CARCINOGENESIS, V10, P13, DOI 10.1093/carcin/10.1.13; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; Meme W, 2004, NEUROSCIENCE, V126, P95, DOI 10.1016/j.neuroscience.2004.03.031; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; Ohkubo S, 2000, BRIT J PHARMACOL, V131, P1667, DOI 10.1038/sj.bjp.0703750; Park GH, 2002, EXP MOL MED, V34, P184, DOI 10.1038/emm.2002.27; PICANCODINIZ DLW, 1989, BRAZ J MED BIOL RES, V22, P783; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; PORTER JC, 1995, P NATL ACAD SCI USA, V92, P5351, DOI 10.1073/pnas.92.12.5351; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; Rees DA, 2003, BRIT J PHARMACOL, V140, P764, DOI 10.1038/sj.bjp.0705488; Rees DA, 2002, ENDOCRINOLOGY, V143, P2427, DOI 10.1210/en.143.6.2427; SCORZIELLO A, 1993, J MOL ENDOCRINOL, V11, P325, DOI 10.1677/jme.0.0110325; Spychala J, 2000, PHARMACOL THERAPEUT, V87, P161, DOI 10.1016/S0163-7258(00)00053-X; Suadicani SO, 2003, GLIA, V42, P160, DOI 10.1002/glia.10197; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Turner MS, 2004, CIRC RES, V95, P726, DOI 10.1161/01.RES.0000144805.11519.1e; VANBELLE H, 1987, AM J PHYSIOL, V252, pH886, DOI 10.1152/ajpheart.1987.252.5.H886; Vergara L, 2003, ACTA PHYSIOL SCAND, V179, P33, DOI 10.1046/j.1365-201X.2003.01198.x; Vitale ML, 2001, BIOL REPROD, V64, P625, DOI 10.1095/biolreprod64.2.625; Wynn J, 2002, ENDOCR RES, V28, P663, DOI 10.1081/ERC-120016983; YAMAMOTO T, 1993, HISTOCHEMISTRY, V100, P53, DOI 10.1007/BF00268878; YAMOMOTO T, 1993, HISTOCHEMISTRY, V100, P53; Yu WH, 1998, P NATL ACAD SCI USA, V95, P7795, DOI 10.1073/pnas.95.13.7795; ZIMMER AM, 1992, ANTIBODY IMMUNOCONJ, V5, P285	49	27	30	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2585	+		10.1096/fj.06-6121fje	http://dx.doi.org/10.1096/fj.06-6121fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065216				2022-12-28	WOS:000242490700032
J	Bultinck, J; Sips, P; Vakaet, L; Brouckaert, P; Cauwels, A				Bultinck, Jennyfer; Sips, Patrick; Vakaet, Luc; Brouckaert, Peter; Cauwels, Anje			Systemic NO production during (septic) shock depends on parenchymal and not on hematopoietic cells: in vivo iNOS expression pattern in (septic) shock	FASEB JOURNAL			English	Article						inflammation; inducible NOS; bone marrow transplantation	NITRIC-OXIDE SYNTHASE; ALPHA-DEFENSINS; ENDOTOXIC-SHOCK; MESSENGER-RNA; MICE LACKING; IFN-GAMMA; SEPSIS; MACROPHAGES; INHIBITION; INDUCTION	Septic shock is the leading cause of death in noncoronary intensive care units and the 10th leading cause of death overall. Several lines of evidence support an important role for the vasodilator NO in hypotension, a hallmark of septic shock. However, NO may also positively or negatively regulate inflammation, apoptosis, and oxidative stress. These dual effects of NO may relate to its isoform specific production but also to differences in cellular and/or temporal expression. Via bone marrow transplantations, we examined the contribution of hematopoietic cells to the dramatically elevated NO levels seen in (septic) shock. Surprisingly, hematopoietic cells are not responsible at all for the production of circulating NO after systemic tumor necrosis factor or lipopolysaccharide challenge and contribute only marginally in a bacteremic (Salmonella) model of septic shock. Immunohistochemistry identified the nonhematopoietic sources of NO as hepatocytes, paneth cells, and intestinal and renal epithelial cells. In contrast, during granulomatous Bacillus Calmette-Guerin inflammation, the hematopoietic cell population represents the sole source of systemic NO. These mouse data demonstrate that, in contrast to the general conjecture, the dramatically elevated levels of NO during (septic) shock are not produced by hematopoietic cells such as monocytes/macrophages but rather by parenchymal cells in liver, kidney and gut.	Univ Ghent VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium; Ghent Univ Hosp, Dept Radiotherapy, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Ghent University Hospital	Cauwels, A (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Technol Pk 927, B-9052 Ghent, Belgium.	anje.cauwels@dmbr.ugent.be	Sips, Patrick Y/O-9993-2017; Vakaet, Luc/A-6467-2010; Sips, Patrick/AAS-8985-2021	Sips, Patrick Y/0000-0001-9241-5980; Sips, Patrick/0000-0001-9241-5980				Alam MS, 2002, INFECT IMMUN, V70, P3130, DOI 10.1128/IAI.70.6.3130-3142.2002; Albina JE, 1995, J LEUKOCYTE BIOL, V58, P643, DOI 10.1002/jlb.58.6.643; Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Annane D, 2000, LANCET, V355, P1143, DOI 10.1016/S0140-6736(00)02063-8; Arias M, 1997, Allergol Immunopathol (Madr), V25, P280; Arkovitz MS, 1996, J PEDIATR SURG, V31, P1009, DOI 10.1016/S0022-3468(96)90075-5; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; Avontuur JAM, 1998, CRIT CARE MED, V26, P660, DOI 10.1097/00003246-199804000-00012; Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Bateman RM, 2003, CRIT CARE, V7, P359, DOI 10.1186/cc2353; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BUTTERY LDK, 1994, LAB INVEST, V71, P755; Cauwels A, 2005, CELL MOL LIFE SCI, V62, P1632, DOI 10.1007/s00018-005-5142-z; CAUWELS A, 1995, J IMMUNOL, V154, P2753; Cauwels A, 2000, IMMUNITY, V13, P223, DOI 10.1016/S1074-7613(00)00022-4; Ceppi ED, 1997, BIOCHEM SOC T, V25, P929, DOI 10.1042/bst0250929; Clark IA, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-6; Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1; Coleman JW, 2001, INT IMMUNOPHARMACOL, V1, P1397, DOI 10.1016/S1567-5769(01)00086-8; COOK HT, 1994, CLIN SCI, V87, P179, DOI 10.1042/cs0870179; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682, DOI 10.1002/jlb.55.5.682; Ehlers S, 1999, IMMUNOLOGY, V98, P313; EVANS T, 1993, CIRC SHOCK, V41, P77; Feihl F, 2001, PHARMACOL THERAPEUT, V91, P179, DOI 10.1016/S0163-7258(01)00155-3; GELLER DA, 1993, J SURG RES, V55, P427, DOI 10.1006/jsre.1993.1164; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hersch M, 2005, INTENS CARE MED, V31, P1132, DOI 10.1007/s00134-005-2680-7; Hickey MJ, 2002, FASEB J, V16, P1141, DOI 10.1096/fj.01-0764fje; Hoffman RA, 1997, AM J PHYSIOL-GASTR L, V272, pG383, DOI 10.1152/ajpgi.1997.272.2.G383; Johnson ML, 1998, WORLD J SURG, V22, P187, DOI 10.1007/s002689900368; Jungi TW, 1997, INFECT IMMUN, V65, P5279, DOI 10.1128/IAI.65.12.5279-5288.1997; Jungi TW, 1996, VET IMMUNOL IMMUNOP, V54, P323, DOI 10.1016/S0165-2427(96)05690-5; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Kilbourn R G, 1997, Dis Mon, V43, P277; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; Kobayashi A, 1998, CHEST, V113, P1632, DOI 10.1378/chest.113.6.1632; KOLLS J, 1994, P SOC EXP BIOL MED, V205, P220; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; Laubach VE, 1998, AM J PHYSIOL-HEART C, V275, pH2211, DOI 10.1152/ajpheart.1998.275.6.H2211; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237; MILES AM, 1995, J LEUKOCYTE BIOL, V58, P616, DOI 10.1002/jlb.58.5.616; NUSSLER AK, 1993, BIOCHEM BIOPH RES CO, V194, P826, DOI 10.1006/bbrc.1993.1896; Oliveira SHP, 1998, PARASITE IMMUNOL, V20, P405, DOI 10.1046/j.1365-3024.1998.00159.x; Parmely MJ, 2001, INFECT IMMUN, V69, P2621, DOI 10.1128/IAI.69.4.2621-2629.2001; Peschon JJ, 1998, J IMMUNOL, V160, P943; Poon BY, 2003, CIRCULATION, V108, P1107, DOI 10.1161/01.CIR.0000086321.04702.AC; Robertson DAF, 2004, MICROCIRCULATION, V11, P503, DOI 10.1080/10739680490476321; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; SATO K, 1995, J LEUKOCYTE BIOL, V57, P36, DOI 10.1002/jlb.57.1.36; Schluter D, 1997, AM J PATHOL, V150, P1021; Schon T, 2004, INT J TUBERC LUNG D, V8, P1134; STENGER S, 1994, J EXP MED, V180, P783, DOI 10.1084/jem.180.3.783; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stumm MM, 2002, LIVER, V22, P441, DOI 10.1034/j.1600-0676.2002.01653.x; Thiemermann C, 1997, GEN PHARMACOL-VASC S, V29, P159, DOI 10.1016/S0306-3623(96)00410-7; TRACEY WR, 1995, J PHARMACOL EXP THER, V272, P1011; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; Veihelmann A, 2002, RHEUMATOLOGY, V41, P509, DOI 10.1093/rheumatology/41.5.509; Victor VM, 2003, FREE RADICAL RES, V37, P919, DOI 10.1080/1071576031000148727; Vos TA, 1997, GASTROENTEROLOGY, V113, P1323, DOI 10.1053/gast.1997.v113.pm9322528; WEINBERG JB, 1995, BLOOD, V86, P1184; Wu F, 2001, MICROCIRCULATION, V8, P415; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635	71	61	63	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2363	+		10.1096/fj.06-5798fje	http://dx.doi.org/10.1096/fj.06-5798fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17020927				2022-12-28	WOS:000241702600021
J	Arredondo, J; Chernyavsky, AI; Jolkovsky, DL; Pinkerton, KE; Grando, SA				Arredondo, Juan; Chernyavsky, Alexander I.; Jolkovsky, David L.; Pinkerton, Kent E.; Grando, Sergei A.			Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha 7 nicotinic receptor in oral keratinocytes	FASEB JOURNAL			English	Article						nicotinic ACh receptors; gene expression; oral cancer; periodontal therapy	ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; CANCER CELL-LINES; ACETYLCHOLINE-RECEPTOR; GENE-EXPRESSION; KAPPA-B; SMOKE EXPOSURE; C-MYC; DIFFERENTIATION; SECRETION	The use of tobacco products is associated with an increased incidence of periodontal disease, poor response to periodontal therapy, and a high risk for developing head and neck cancer. Nicotine and tobacco-derived nitrosamines have been shown to exhibit their pathobiologic effects due in part to activation of the nicotinic acetylcholine (ACh) receptors (nAChRs), mainly alpha 7 nAChR, expressed by oral keratinocytes (KCs). This study was designed to gain mechanistic insight into alpha 7-mediated morbidity of tobacco products in the oral cavity. We investigated the signaling pathways downstream of alpha 7 nAChR in monolayers of oral KCs exposed for 24 h to aged and diluted sidestream cigarette smoke (ADSS) or an equivalent concentration of pure nicotine. By both real-time polymerase chain reaction (PCR) and In-cell Western, the KCs stimulated with ADSS or nicotine showed multifold increases of STAT-3. These effects could be completely blocked or significantly (P < 0.05) diminished if the cells were pretreated with the alpha 7 antagonist alpha-bungarotoxin (alpha BTX) or transfected with anti-alpha 7 small interfering RNA (siRNA-alpha 7). The use of pathway inhibitors revealed that signaling through the Ras/Raf-1/MEK1/ERK steps mediated alpha 7-dependent up-regulation of STAT-3. Targeted mutation of the alpha 7 gene prevented ERK1/2 activation by nicotine. Using the gel mobility shift assay, we demonstrated that an increased protein binding activity of STAT-3 caused by ADSS or pure nicotine was mediated by janus-activated kinase (JAK)-2. Activation of JAK-2/STAT-3 pathway could be prevented by alpha BTX or siRNA-alpha 7. Thus, nuclear transactivation of STAT-3 in KCs exposed to tobacco products is mediated via intracellular signaling downstream from alpha 7, which proceeds via two complementary pathways. The Ras/Raf-1/MEK1/ERK cascade culminates in up-regulated expression of the gene encoding STAT-3, whereas recruitment and activation of tyrosine kinase JAK-2 phosphorylates it. Elucidation of this novel mechanism of nicotine-dependent nuclear transactivation of STAT-3 identifies oral alpha 7 nAChR as a promising molecular target to prevent, reverse, or retard tobacco-related periodontal disease and progression of head and neck cancer by receptor inhibitors.	Univ Calif Davis, Dept Dermatol, Med Ctr, Sacramento, CA 95816 USA; Univ Calif Davis, Ctr Hlth & Environm, Sacramento, CA 95816 USA; Univ Calif Los Angeles, Sch Dent, Sect Periodont, Los Angeles, CA 90024 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Los Angeles	Grando, SA (corresponding author), Univ Calif Davis, Dept Dermatol, Med Ctr, 3301 C St,Ste 1400, Sacramento, CA 95816 USA.	sagrando@ucdavis.edu			NATIONAL CANCER INSTITUTE [R03CA117327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014173] Funding Source: NIH RePORTER; NCI NIH HHS [CA117327] Funding Source: Medline; NIDCR NIH HHS [DE14173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; Arredondo J, 2002, J CELL BIOL, V159, P325, DOI 10.1083/jcb.200206096; Arredondo J, 2005, J INVEST DERMATOL, V125, P1236, DOI 10.1111/j.0022-202X.2005.23973.x; Arredondo J, 2005, AM J PATHOL, V166, P597, DOI 10.1016/S0002-9440(10)62281-X; Arredondo J, 2003, LIFE SCI, V72, P2063, DOI 10.1016/S0024-3205(03)00084-5; Arredondo J, 2001, LAB INVEST, V81, P1653, DOI 10.1038/labinvest.3780379; Benowitz N L, 1997, Adv Dent Res, V11, P336; BERGSTROM J, 1989, COMMUNITY DENT ORAL, V17, P245, DOI 10.1111/j.1600-0528.1989.tb00626.x; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; Cattaneo MG, 1997, BIOCHEM J, V328, P499; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen BC, 2004, J IMMUNOL, V173, P5219, DOI 10.4049/jimmunol.173.8.5219; Chernyavsky AI, 2005, J BIOL CHEM, V280, P39220, DOI 10.1074/jbc.M504407200; Chernyavsky AI, 2004, J CELL SCI, V117, P5665, DOI 10.1242/jcs.01492; CODIGNOLA A, 1994, FEBS LETT, V342, P286, DOI 10.1016/0014-5793(94)80518-0; Conti-Fine BM, 2000, EUR J PHARMACOL, V393, P279, DOI 10.1016/S0014-2999(00)00036-4; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Cox ME, 1997, J NEUROCHEM, V69, P1119; Dajas-Bailador FA, 2002, J NEUROCHEM, V80, P520, DOI 10.1046/j.0022-3042.2001.00725.x; de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038/ni1229; Delbono O, 1997, J PHARMACOL EXP THER, V280, P428; Dunckley T, 2003, J BIOL CHEM, V278, P15633, DOI 10.1074/jbc.M210389200; Ehrhardt A, 2003, J CANCER RES CLIN, V129, P71, DOI 10.1007/s00432-002-0400-z; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Genersch E, 2000, J CELL SCI, V113, P4319; Grando SA, 2003, LIFE SCI, V72, P2009, DOI 10.1016/S0024-3205(03)00063-8; Gueorguiev VD, 2000, J NEUROCHEM, V75, P1997, DOI 10.1046/j.1471-4159.2000.0751997.x; Haber J, 1994, Compendium, V15, P1004; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; HOFFMANN D, 1981, CANCER RES, V41, P4305; JOAD JP, 1993, PEDIATR PULM, V16, P281, DOI 10.1002/ppul.1950160503; JOAD JP, 1995, TOXICOL APPL PHARM, V132, P63, DOI 10.1006/taap.1995.1087; Johnson Georgia K., 1993, Pediatric Dentistry, V15, P169; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Kwon OS, 1999, SKIN PHARMACOL APPL, V12, P227, DOI 10.1159/000066247; Lackey K, 2000, BIOORG MED CHEM LETT, V10, P223, DOI 10.1016/S0960-894X(99)00668-X; Lee YS, 1997, MOL CARCINOGEN, V18, P44, DOI 10.1002/(SICI)1098-2744(199701)18:1<44::AID-MC6>3.0.CO;2-R; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Li JM, 2004, ARTERIOSCL THROM VAS, V24, P80, DOI 10.1161/01.ATV.0000104007.17365.1c; LI LW, 1995, J CELL PHYSIOL, V163, P105, DOI 10.1002/jcp.1041630112; Li YX, 1999, BRAIN RES, V830, P218, DOI 10.1016/S0006-8993(99)01372-4; LINDELL G, 1993, SCAND J GASTROENTERO, V28, P487, DOI 10.3109/00365529309098254; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; MANDEL I, 1994, J AM DENT ASSOC, V125, P872, DOI 10.14219/jada.archive.1994.0192; MANECKJEE R, 1994, CELL GROWTH DIFFER, V5, P1033; Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492; Nguyen VT, 2000, AM J PATHOL, V157, P1377, DOI 10.1016/S0002-9440(10)64651-2; Nguyen VT, 2000, J DENT RES, V79, P939; Onoda N, 2001, HEAD NECK-J SCI SPEC, V23, P860, DOI 10.1002/hed.1125; OrrUrtreger A, 1997, J NEUROSCI, V17, P9165; Plummer HK, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-29; Quik M, 1997, MOL PHARMACOL, V51, P499; RUSSELL MAH, 1980, BMJ-BRIT MED J, V280, P972, DOI 10.1136/bmj.280.6219.972; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; SCHULLER HM, 1989, BIOCHEM PHARMACOL, V38, P3439, DOI 10.1016/0006-2952(89)90112-3; Schuller HM, 2000, EUR J PHARMACOL, V393, P265, DOI 10.1016/S0014-2999(00)00094-7; Schuller HM, 1998, BIOCHEM PHARMACOL, V55, P1377, DOI 10.1016/S0006-2952(97)00651-5; SEGUELA P, 1993, J NEUROSCI, V13, P596; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Shaw S, 2002, J BIOL CHEM, V277, P44920, DOI 10.1074/jbc.M204610200; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; Sugar Janos Iidiko Vereczkey, 1996, Journal of Environmental Pathology Toxicology and Oncology, V15, P195; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tang KC, 1998, MOL PHARMACOL, V54, P59, DOI 10.1124/mol.54.1.59; Taylor SC, 2000, J NEUROCHEM, V75, P1583, DOI 10.1046/j.1471-4159.2000.0751583.x; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; THEILIG C, 1994, SKIN PHARMACOL, V7, P307; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Wityak J, 2004, BIOORG MED CHEM LETT, V14, P1483, DOI 10.1016/j.bmcl.2004.01.012; Ye YN, 2004, J PHARMACOL EXP THER, V311, P123, DOI 10.1124/jpet.104.068031; Zhang SL, 2001, PHYSIOL GENOMICS, V5, P187, DOI 10.1152/physiolgenomics.2001.5.4.187; Zhang SL, 2001, ATHEROSCLEROSIS, V154, P277, DOI 10.1016/S0021-9150(00)00475-5; Zia S, 1997, RES COMMUN MOL PATH, V97, P243	77	161	166	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2093	2101		10.1096/fj.06-6191com	http://dx.doi.org/10.1096/fj.06-6191com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012261				2022-12-28	WOS:000241156900017
J	Borras, C; Gambini, J; Gomez-Cabrera, MC; Sastre, J; Pallardo, FV; Mann, GE; Vina, J				Borras, Consuelo; Gambini, Juan; Gomez-Cabrera, M. Carmen; Sastre, Juan; Pallardo, Federico V.; Mann, Giovanni E.; Vina, Jose			Genistein, a soy isoflavone, up-regulates expression of antioxidant genes: involvement of estrogen receptors, ERK1/2, and NF kappa B	FASEB JOURNAL			English	Article						phytoestrogens; aging; oxidative stress; redox signaling	PHYTOESTROGENS; WOMEN	We have previously reported that estrogens up-regulate longevity-associated genes. As recent evidence has shown that estrogen replacement therapy is associated with an increased risk of cardiovascular disease, we have studied the effects of genistein, a soy isoflavone with a similar structure to estradiol, on the expression of antioxidant, longevity-related genes. MCF-7 cells ( human mammary gland tumor cell line) were incubated for 48 h with 0.5 mu M genistein, a concentration found in the plasma of populations consuming diets rich in soy protein. Peroxide levels were determined by fluorimetry, activation of extracellular-signal regulated kinase (ERK1/2), and nuclear factor kappa B (NF kappa B)-signaling pathways by Western blot analysis and ELISA, respectively, and mRNA expression of antioxidant genes by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Inhibition of basal peroxide levels in MCF-7 cells by genistein was prevented by pretreatment of cells with the estrogen receptor antagonist tamoxifen. Phosphorylation of extracellular regulated kinase (ERK)1/2 led to an activation of NF kappa B, as indicated by increased p50 subunit expression in nuclear extracts, and increased mRNA levels of the antioxidant enzyme manganese-superoxide dismutase (MnSOD). Inhibition of ERK1/2 abrogated genistein-mediated NF kappa B activation and elevated expression of MnSOD. Our molecular studies may provide a basis to determine the effects of genistein and other soy protein-derived products on longevity in both animals and the human population.	Univ Valencia, Dept Physiol, Sch Med, Avda Blasco Ibanez 17, Valencia 46010, Spain; Catholic Univ Valencia, Valencia, Spain; Kings Coll London, Div Cardiovasc, London WC2R 2LS, England	University of Valencia; Universidad Catolica de Valencia San Vicente Martir; University of London; King's College London	Vina, J (corresponding author), Univ Valencia, Dept Physiol, Sch Med, Avda Blasco Ibanez 17, Valencia 46010, Spain.	jose.vina@uv.es	Gomez-Cabrera, Mari Carmen/O-3109-2019; Gomez-Cabrera, Maria Carmen/H-6911-2018; borras, consuelo/Y-3407-2019; Pallardo, Federico V./T-1156-2017; SASTRE, JUAN/AAB-2344-2019; Vina, Jose/AAB-3069-2021	Gomez-Cabrera, Mari Carmen/0000-0003-4000-1684; Gomez-Cabrera, Maria Carmen/0000-0003-4000-1684; borras, consuelo/0000-0003-4606-1792; Pallardo, Federico V./0000-0003-3715-1980; SASTRE, JUAN/0000-0002-4260-6604; Vina, Jose/0000-0001-9709-0089; Mann, Giovanni/0000-0001-7311-2044; Gambini, Juan/0000-0001-8979-2865					0	125	134	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2136	2138		10.1096/fj.05-5522fje	http://dx.doi.org/10.1096/fj.05-5522fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16966488				2022-12-28	WOS:000241156900035
J	Hershfield, JR; Madhavarao, CN; Moffett, JR; Benjamins, JA; Garbern, JY; Namboodiri, A				Hershfield, Jeremy R.; Madhavarao, Chikkathur N.; Moffett, John R.; Benjamins, Joyce A.; Garbern, James Y.; Namboodiri, Aryan			Aspartoacylase is a regulated nuclear-cytoplasmic enzyme	FASEB JOURNAL			English	Article						Canavan Disease; N-acetylaspartate; aminoacylase; kidney; oligodendrocytes; Tremor rat	ACETYL-L-ASPARTATE; MYELIN LIPID-SYNTHESIS; N-ACETYLASPARTATE; CANAVAN-DISEASE; IMMUNOHISTOCHEMICAL LOCALIZATION; GENE-TRANSFER; NUCLEOCYTOPLASMIC TRANSPORT; NERVOUS-SYSTEM; RAT; BRAIN	Mutations in the gene for aspartoacylase (ASPA), which catalyzes deacetylation of N-acetyl-L-aspartate in the central nervous system (CNS), result in Canavan Disease, a fatal dysmyelinating disease. Consistent with its role in supplying acetate for myelin lipid synthesis, ASPA is thought to be cytoplasmic. Here we describe the occurrence of ASPA within nuclei of rat brain and kidney, and in cultured rodent oligodendrocytes. Immunohistochemistry showed cytoplasmic and nuclear ASPA staining, the specificity of which was demonstrated by its absence from tissues of the Tremor rat, an ASPA-null mutant. Subcellular fractionation analysis revealed low enzyme activity against NAA in nuclear fractions from normal rats. Whereas two recent reports have indicated that ASPA exists as a dimer, size-exclusion chromatography of subcellular fractions showed ASPA is an active monomer in both subcellular fractions. Western blotting detected ASPA as a single 38 kD band. Because ASPA is small enough to passively diffuse into the nucleus, we constructed, expressed, and detected in COS-7 cells a green fluorescent protein-human ASPA (GFP-hASPA) fusion protein larger than the permissible size for the nuclear pore complex. GFP-hASPA was enzymatically active and showed mixed nuclear-cytoplasmic distribution. We conclude that ASPA is a regulated nuclear-cytoplasmic protein that may have distinct functional roles in the two cellular compartments.	Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI USA	Uniformed Services University of the Health Sciences - USA; Wayne State University; Wayne State University	Namboodiri, A (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	anamboodiri@usuhs.mil		Madhavarao, Chikkathur/0000-0003-3392-1159	NINDS NIH HHS [NS 39387] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039387, R56NS039387] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe A, 2000, BIOCHEM BIOPH RES CO, V268, P14, DOI 10.1006/bbrc.1999.2069; Armstrong RC, 1998, METHODS, V16, P282, DOI 10.1006/meth.1998.0685; Baslow MH, 1999, J MOL NEUROSCI, V13, P47, DOI 10.1385/JMN:13:1-2:47; Benjamins JA, 2003, NEUROCHEM RES, V28, P143, DOI 10.1023/A:1021612615554; BENUCK M, 1968, BIOCHIM BIOPHYS ACTA, V152, P611, DOI 10.1016/0005-2760(68)90101-X; Besley GTN, 1999, J INHERIT METAB DIS, V22, P263, DOI 10.1023/A:1005534105933; Bhakoo KK, 2001, J NEUROCHEM, V79, P211, DOI 10.1046/j.1471-4159.2001.00561.x; Bird CH, 2001, MOL CELL BIOL, V21, P5396, DOI 10.1128/MCB.21.16.5396-5407.2001; BIRNBAUM SM, 1952, J BIOL CHEM, V194, P455; BIRNBAUM SM, 1955, METHOD ENZYMOL, V2, P115, DOI 10.1016/S0076-6879(55)02176-9; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; Chakraborty G, 2001, J NEUROCHEM, V78, P736, DOI 10.1046/j.1471-4159.2001.00456.x; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; COOK RM, 1993, J BIOL CHEM, V268, P17010; DADAMO AF, 1966, J NEUROCHEM, V13, P961, DOI 10.1111/j.1471-4159.1966.tb10292.x; DADAMO AF, 1978, LIFE SCI, V23, P791, DOI 10.1016/0024-3205(78)90513-1; DADAMO AF, 1973, J NEUROCHEM, V20, P1275, DOI 10.1111/j.1471-4159.1973.tb00097.x; DADAMO AF, 1968, EXP BRAIN RES, V5, P267; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Elpeleg ON, 1999, J INHERIT METAB DIS, V22, P531, DOI 10.1023/A:1005512524957; FLEMING MC, 1966, J NEUROCHEM, V13, P779, DOI 10.1111/j.1471-4159.1966.tb05872.x; Foletti A, 2003, CELL MOL LIFE SCI, V60, P2254, DOI 10.1007/s00018-003-3258-6; Gill SK, 2003, J BIOL CHEM, V278, P20217, DOI 10.1074/jbc.M213153200; KAUL R, 1993, NAT GENET, V5, P118, DOI 10.1038/ng1093-118; KAUL R, 1994, AM J HUM GENET, V55, P34; KAUL R, 1991, J NEUROCHEM, V56, P129, DOI 10.1111/j.1471-4159.1991.tb02571.x; Kirmani BF, 2003, DEV BRAIN RES, V140, P105, DOI 10.1016/S0165-3806(02)00592-8; Kirmani BF, 2002, MOL BRAIN RES, V107, P176, DOI 10.1016/S0169-328X(02)00490-4; Kitada K, 2000, J NEUROCHEM, V74, P2512, DOI 10.1046/j.1471-4159.2000.0742512.x; Klugmann M, 2003, NEUROREPORT, V14, P1837, DOI 10.1097/00001756-200310060-00016; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Leone P, 1999, CURR OPIN MOL THER, V1, P487; Leone P, 2000, ANN NEUROL, V48, P27, DOI 10.1002/1531-8249(200007)48:1<27::AID-ANA6>3.0.CO;2-6; LINNINGTON C, 1984, J NEUROIMMUNOL, V6, P387, DOI 10.1016/0165-5728(84)90064-X; Ma ZL, 2004, ARCH BIOCHEM BIOPHYS, V422, P153, DOI 10.1016/j.abb.2003.11.024; Madhavarao CN, 2005, P NATL ACAD SCI USA, V102, P5221, DOI 10.1073/pnas.0409184102; Madhavarao CN, 2004, J COMP NEUROL, V472, P318, DOI 10.1002/cne.20080; Madhavarao CN, 2002, ANAL BIOCHEM, V308, P314, DOI 10.1016/S0003-2697(02)00225-7; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Matalon R, 2000, J GENE MED, V2, P165; MATALON R, 1988, AM J MED GENET, V29, P463, DOI 10.1002/ajmg.1320290234; Matalon R, 1999, NEUROCHEM RES, V24, P507, DOI 10.1023/A:1022531829100; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; MOFFETT JR, 1991, NEUROREPORT, V2, P131, DOI 10.1097/00001756-199103000-00005; Moore RA, 2003, ARCH BIOCHEM BIOPHYS, V413, P1, DOI 10.1016/S0003-9861(03)00055-9; Munster AK, 2002, J BIOL CHEM, V277, P19688, DOI 10.1074/jbc.M201093200; Namboodiri MAA, 2000, MOL BRAIN RES, V77, P285, DOI 10.1016/S0169-328X(00)00068-1; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; Pushkin A, 2004, AM J PHYSIOL-CELL PH, V286, pC848, DOI 10.1152/ajpcell.00192.2003; Resendes MC, 1999, J BIOL CHEM, V274, P19417, DOI 10.1074/jbc.274.27.19417; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P3961; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P1354; Sheng Z, 2004, J BIOL CHEM, V279, P40153, DOI 10.1074/jbc.M400123200; Uttamsingh V, 2000, DRUG METAB DISPOS, V28, P625; YAMADA J, 1985, EXP ANIM TOKYO, V34, P183, DOI 10.1538/expanim1978.34.2_183; Yamaki A, 2004, BIOCHEM BIOPH RES CO, V313, P482, DOI 10.1016/j.bbrc.2003.11.168; Yang YH, 2004, J BIOL CHEM, V279, P38820, DOI 10.1074/jbc.M401663200; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x	61	40	41	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2139	+		10.1096/fj.05-5358fje	http://dx.doi.org/10.1096/fj.05-5358fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935940				2022-12-28	WOS:000241156900037
J	Crean, JK; Furlong, F; Mitchell, D; McArdle, E; Godson, C; Martin, F				Crean, J. K.; Furlong, F.; Mitchell, D.; McArdle, E.; Godson, C.; Martin, F.			Connective tissue growth factor/CCN2 stimulates actin disassembly through Akt/protein kinase B-mediated phosphorylation and cytoplasmic translocation of p27(Kip-1)	FASEB JOURNAL			English	Article						CTGF; migration; actin cytoskeleton; p27(Kip-1); RhoA; PI-3 kinase; Akt/PKB; LIM kinase; cofilin; diabetic nephropathy	HUMAN MESANGIAL CELLS; DIABETIC-NEPHROPATHY; TGF-BETA; INTEGRIN ALPHA(V)BETA(3); SIGNALING PATHWAYS; FACTOR CTGF; P27; MIGRATION; EXPRESSION; PROTEINS	Connective tissue growth factor (CTGF/CCN2) is a 38-kDa secreted protein, a prototypic member of the CCN family, which is up-regulated in many diseases, including atherosclerosis, pulmonary fibrosis, and diabetic nephropathy. We previously showed that CTGF can cause actin disassembly with concurrent down-regulation of the small GTPase Rho A and proposed an integrated signaling network connecting focal adhesion dissolution and actin disassembly with cell polarization and migration. Here, we further delineate the role of CTGF in cell migration and actin disassembly in human mesangial cells, a primary target in the development of renal glomerulosclerosis. The functional response of mesangial cells to treatment with CTGF was associated with the phosphorylation of Akt/ protein kinase B (PKB) and resultant phosphorylation of a number of Akt/ PKB substrates. Two of these substrates were identified as FKHR and p27(Kip-1). CTGF stimulated the phosphorylation and cytoplasmic translocation of p27(Kip-1) on serine 10. Addition of the PI-3 kinase inhibitor LY294002 abrogated this response; moreover, addition of the Akt/ PKB inhibitor interleukin (IL)-6-hydroxymethyl-chiro-inositol-2(R)-2-methyl-3-O- octadecylcarbonate prevented p27(Kip-1) phosphorylation in response to CTGF. Immunocytochemistry revealed that serine 10 phosphorylated p27(Kip-1) colocalized with the ends of actin filaments in cells treated with CTGF. Further investigation of other Akt/ PKB sites on p27(Kip-1), revealed that phosphorylation on threonine 157 was necessary for CTGF mediated p27(Kip-1) cytoplasmic localization; mutation of the threonine 157 site prevented cytoplasmic localization, protected against actin disassembly and inhibited cell migration. CTGF also stimulated an increased association between Rho A and p27(Kip-1). Interestingly, this resulted in an increase in phosphorylation of LIM kinase and subsequent phosphorylation of cofilin, suggesting that CTGF mediated p27(Kip-1) activation results in uncoupling of the Rho A/LIM kinase/cofilin pathway. Confirming the central role of Akt/ PKB, CTGF-stimulated actin depolymerization only in wild-type mouse embryonic fibroblasts (MEFs) compared to Akt-1/3 (PKB alpha/gamma) knockout MEFs. These data reveal important mechanistic insights into how CTGF may contribute to mesangial cell dysfunction in the diabetic milieu and sheds new light on the proposed role of p27(Kip-1) as a mediator of actin rearrangement.	Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Sch Biomol & Biomed Sci, Dublin 4, Ireland; Univ Coll Dublin, Sch Med & Med Sci, Dublin 4, Ireland; Dublin Mol Med Ctr, Dublin, Ireland	University College Dublin; University College Dublin; Trinity College Dublin; University College Dublin	Crean, JK (corresponding author), Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Sch Biomol & Biomed Sci, Dublin 4, Ireland.	john.crean@ucd.ie		Godson, Catherine/0000-0003-0655-1041; Furlong, Fiona/0000-0002-9206-2297; /0000-0002-4337-6177				Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Awazu M, 2003, J AM SOC NEPHROL, V14, P699, DOI 10.1097/01.ASN.0000051726.41601.C0; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Blom IE, 2001, NEPHROL DIAL TRANSPL, V16, P1139, DOI 10.1093/ndt/16.6.1139; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Crean JK, 2004, FASEB J, V18, P1541, DOI 10.1096/fj.04-1546fje; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; Crean John KG, 2001, Expert Opin Ther Targets, V5, P519; DesMarais V, 2005, J CELL SCI, V118, P19, DOI 10.1242/jcs.01631; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Diviani D, 2004, EMBO J, V23, P2811, DOI 10.1038/sj.emboj.7600287; Fan WH, 2002, J BIOL CHEM, V277, P9800, DOI 10.1074/jbc.M111213200; Finlay D, 2000, CELL DEATH DIFFER, V7, P302, DOI 10.1038/sj.cdd.4400652; Gao RP, 2004, J BIOL CHEM, V279, P8848, DOI 10.1074/jbc.M313204200; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Grotendorst GR, 2004, FASEB J, V18, P469, DOI 10.1096/fj.03-0699com; Gubbay O, 2004, REPRODUCTION, V128, P607, DOI 10.1530/rep.1.00272; Huwiler A, 2002, BRIT J PHARMACOL, V136, P520, DOI 10.1038/sj.bjp.0704748; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; KANAMORI T, 1995, J BIOL CHEM, V270, P8061, DOI 10.1074/jbc.270.14.8061; Kotake Y, 2005, J BIOL CHEM, V280, P1095, DOI 10.1074/jbc.M406117200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365, DOI 10.1152/ajplung.1998.275.2.L365; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Mercurio S, 2004, DEVELOPMENT, V131, P2137, DOI 10.1242/dev.01045; MINATO M, J BIOCH TOKYO, V135, P347; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Oemar BS, 1997, CIRCULATION, V95, P831; Okada K, 1996, EXP CELL RES, V227, P116, DOI 10.1006/excr.1996.0256; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Twigg SM, 2004, DIABETOLOGIA, V47, P965, DOI 10.1007/s00125-004-1423-6; van Nieuwenhoven FA, 2005, NEPHROL DIAL TRANSPL, V20, P6, DOI 10.1093/ndt/gfh570; Wahab NA, 2005, J AM SOC NEPHROL, V16, P340, DOI 10.1681/ASN.2003100905; Wahab NA, 2002, J AM SOC NEPHROL, V13, P2437, DOI 10.1097/01.ASN.0000031828.58276.02; Wolf G, 2003, DIABETOLOGIA, V46, P1090, DOI 10.1007/s00125-003-1163-z; Wolf G, 2005, KIDNEY INT, V68, P1583, DOI 10.1111/j.1523-1755.2005.00570.x; Wolf G, 2003, J AM SOC NEPHROL, V14, P819, DOI 10.1097/01.ASN.0000057518.58420.E4; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005; Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x	54	32	33	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1712	+		10.1096/fj.05-5010fje	http://dx.doi.org/10.1096/fj.05-5010fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790529				2022-12-28	WOS:000240266600024
J	Parcellier, A; Brunet, M; Schmitt, E; Col, E; Didelot, C; Hammann, A; Nakayama, K; Nakayama, KI; Khochbin, S; Solary, E; Garrido, C				Parcellier, Arnaud; Brunet, Mathilde; Schmitt, Elise; Col, Edwige; Didelot, Celine; Hammann, Arlette; Nakayama, Keiko; Nakayama, Keiichi I.; Khochbin, Saadi; Solary, Eric; Garrido, Carmen			HSP27 favors ubiquitination and proteasomal degradation of p27(Kip1) and helps S-phase re-entry in stressed cells	FASEB JOURNAL			English	Article						stress proteins; proteasome; ubiquitin; cell death; cell proliferation	CDK INHIBITOR P27; HEAT-SHOCK PROTEINS; CYTOCHROME-C; DEPENDENT DEGRADATION; MEDIATED DEGRADATION; NUCLEAR EXPORT; IN-VITRO; PHOSPHORYLATION; CARCINOMA; PATHWAY	Stress-inducible HSP27 protects cells from death through various mechanisms. We have recently demonstrated that HSP27 can also enhance the degradation of some proteins through the proteasomal pathway. Here, we show that one of these proteins is the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1). The ubiquitination and degradation of this protein that favors progression through the cell cycle was previously shown to involve either a Skp2-dependent mechanism, i.e., at the S-/G(2)-transition, or a KPC (Kip1 ubiquitination-promoting complex)-dependent mechanism, i.e., at the G(0)/G(1) transition. In this work, we demonstrate that, in response to serum depletion, p27(Kip1) cellular content first increases then progressively decreases as cells begin to die. In this stressful condition, HSP27 favors p27(Kip1) ubiquitination and degradation by the proteasome. A similar observation was made in response to stress induced by the NO donor glyceryl trinitrate (GTN). HSP27-mediated ubiquitination of p27(Kip1) does not require its phosphorylation on Thr(187) or Ser-10, nor does it depend on the SCFSkp2 ubiquitin ligase E3 complex. It facilitates the G(1)/S transition, which suggests that, in stressful conditions, HSP27 might render quiescent cells competent to re-enter the cell cycle.	INSERM, Fac Med, U517, IFR100, F-21000 Dijon, France; INSERM, U309, La Tronche, France; Tohoku Univ, Ctr Translat & Adv Anim Res Human Dis, Sendai, Miyagi 980, Japan; Kyushu Univ, Med Inst Bioregulat, Div Cell Biol, Fukuoka 812, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Tohoku University; Kyushu University	Garrido, C (corresponding author), INSERM, Fac Med, U517, IFR100, 7 Blvd Jeanne DArc, F-21000 Dijon, France.	cgarrido@u-bourgogne.fr	Khochbin, Saadi/M-8090-2013; Garrido, carmen/G-1633-2018; Garrido, Carolina/GWM-5557-2022	Khochbin, Saadi/0000-0002-0455-0857; Garrido, carmen/0000-0003-1368-1493; Mirjolet Didelot, Celine/0000-0003-0047-9421; Solary, Eric/0000-0002-8629-1341				Aldrian S, 2002, CELL STRESS CHAPERON, V7, P177, DOI 10.1379/1466-1268(2002)007<0177:OOHATM>2.0.CO;2; Arrigo AP, 2000, PATHOL BIOL, V48, P280; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; den Engelsman J, 2003, J BIOL CHEM, V278, P4699, DOI 10.1074/jbc.M211403200; Duan HJ, 2001, MOL CARCINOGEN, V30, P37, DOI 10.1002/1098-2744(200101)30:1<37::AID-MC1011>3.0.CO;2-7; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Friant S, 2003, EMBO J, V22, P3783, DOI 10.1093/emboj/cdg375; GABAI VL, 1995, BIOCHEM MOL BIOL INT, V35, P95; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1996, EUR J BIOCHEM, V237, P653, DOI 10.1111/j.1432-1033.1996.0653p.x; Garrido C, 2003, CELL DEATH DIFFER, V10, P619, DOI 10.1038/sj.cdd.4401229; Garrido C, 2002, CELL DEATH DIFFER, V9, P483, DOI 10.1038/sj.cdd.4401005; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; Geisler JP, 1998, GYNECOL ONCOL, V69, P14, DOI 10.1006/gyno.1998.4961; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Ito Hidenori, 2003, Nihon Yakurigaku Zasshi, V121, P27; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; Mese H, 2002, ONCOL REP, V9, P341; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakano T, 1996, SYST COMPUT JPN, V27, P1, DOI 10.1002/scj.4690270601; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; OESTERREICH S, 1993, CANCER RES, V53, P4443; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Reidlinger J, 1997, J BIOL CHEM, V272, P24899, DOI 10.1074/jbc.272.40.24899; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Rosner M, 2004, J BIOL CHEM, V279, P48707, DOI 10.1074/jbc.M405528200; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334	56	92	98	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1179	+		10.1096/fj.05-4184fje	http://dx.doi.org/10.1096/fj.05-4184fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16641199				2022-12-28	WOS:000240210300018
J	Valderrama, B; Garcia-Arellano, H; Giansanti, S; Baratto, MC; Pogni, R; Vazquez-Duhalt, R				Valderrama, Brenda; Garcia-Arellano, Humberto; Giansanti, Stefania; Baratto, M. Camilla; Pogni, Rebecca; Vazquez-Duhalt, Rafael			Oxidative stabilization of iso-1-cytochrome c by redox-inspired protein engineering	FASEB JOURNAL			English	Article						hemeproteins; peroxidase; oxidative inactivation; protein engineering	ELECTRON-PARAMAGNETIC-RESONANCE; CYTOCHROME-C; HYDROGEN-PEROXIDE; YEAST ISO-1-CYTOCHROME-C; HORSERADISH-PEROXIDASE; MANGANESE PEROXIDASE; CONSERVED TRYPTOPHAN; MOLECULAR-COMPLEXES; DIRECTED EVOLUTION; WATER MOLECULE	Iso-1-cytochrome c, as any other hemeprotein, is able to react with hydrogen peroxide and to engage in the peroxidase cycle. However, peroxidases are irreversibly inactivated by their substrate, hydrogen peroxide. The oxidative inactivation of hemeproteins is mechanism based and arises as the consequence of unproductive electron abstraction reactions. Protein elements, such as the porphyrin ring or the protein backbone, act as simultaneous and competing electron sources even in the presence of exogenous reducing substrates, leading to a decline in activity. It is hypothetically possible to alter the intramolecular electron transfer pathways by direct replacement of low redox potential residues around the active site; as a consequence, the inactivation process would be delayed or even suppressed. To demonstrate this hypothesis, a redox-inspired strategy was implemented until an iso-1-cytochrome c variant fully stable at catalytic concentrations of hydrogen peroxide was obtained. This variant, harboring the N52I,W59F,Y67F,K79A,F82G substitutions, preserved the catalytic performance of the parental protein but achieved a 15-fold higher total-turnover number. The phenotype of this variant was reflected in the stability of its electronic components, allowing identification of a protein-based radical intermediate mechanistically similar to Compound I of classical peroxidases. The results presented here clearly demonstrate that redox-inspired protein engineering is a useful tool for the rational modulation of intramolecular electron transfer networks.-Valderrama, B., Garcia-Arellano, H., Giansanti, S., Baratto, M. C., Pogni, R., Vazquez-Duhalt, R. Oxidative stabilization of iso-1-cytochrome c by redox-inspired protein engineering.	Natl Univ Mexico, Dept Cellular Engn & Biocatalysis, Inst Biotechnol, Cuernavaca, Morelos, Mexico; Univ Siena, Dept Chem, I-53100 Siena, Italy	Universidad Nacional Autonoma de Mexico; University of Siena	Valderrama, B (corresponding author), Univ Nacl Autonoma Mexico, Dept Med Mol & Bioproc, Inst Biotecnol, AP 510-3, Cuernavaca 62250, Morelos, Mexico.	brenda@ibt.unam.mx	Garcia-Arellano, Humberto/G-7516-2018; Vazquez-Duhalt, Rafael/AGO-6764-2022; Vazquez-Duhalt, Rafael/E-2751-2016	Garcia-Arellano, Humberto/0000-0002-7018-7080; Vazquez-Duhalt, Rafael/0000-0003-1612-2996; Vazquez-Duhalt, Rafael/0000-0003-1612-2996; Valderrama, Brenda/0000-0002-5510-9439				ALOISI GG, 1974, J CHEM SOC FARAD T 1, V70, P1908, DOI 10.1039/f19747001908; Ausubel F. M., 1999, SHORT PROTOCOLS MOL; BERGHUIS AM, 1994, J MOL BIOL, V235, P1326, DOI 10.1006/jmbi.1994.1086; BERGHUIS AM, 1994, J MOL BIOL, V236, P786, DOI 10.1006/jmbi.1994.1189; Black KM, 2001, BIOCHEM J, V359, P715, DOI 10.1042/0264-6021:3590715; BLUMBERG WE, 1968, J BIOL CHEM, V243, P1854; CAFFREY MS, 1993, ARCH BIOCHEM BIOPHYS, V304, P205, DOI 10.1006/abbi.1993.1340; Cherry JR, 1999, NAT BIOTECHNOL, V17, P379, DOI 10.1038/7939; Cutruzzola F, 1997, BIOCHEM J, V322, P35, DOI 10.1042/bj3220035; Davies M.J., 1997, RADICAL MEDIATED PRO; DAVIES MJ, 1988, BIOCHIM BIOPHYS ACTA, V964, P28, DOI 10.1016/0304-4165(88)90063-3; Estevam ML, 2004, J BIOL CHEM, V279, P39214, DOI 10.1074/jbc.M402093200; FOSTER R, 1960, TETRAHEDRON, V10, P96, DOI 10.1016/0040-4020(60)85012-0; Garcia-Arellano H, 2002, BIOCONJUGATE CHEM, V13, P1336, DOI 10.1021/bc025561p; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; Hawkins CL, 2001, BBA-BIOENERGETICS, V1504, P196, DOI 10.1016/S0005-2728(00)00252-8; Hiner ANP, 2001, EUR J BIOCHEM, V268, P3091, DOI 10.1046/j.1432-1327.2001.02208.x; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Karuzina II, 1999, FREE RADICAL BIO MED, V26, P620, DOI 10.1016/S0891-5849(98)00252-4; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; Lett CM, 1996, J BIOL CHEM, V271, P29088, DOI 10.1074/jbc.271.46.29088; LOUIE GV, 1989, J MOL BIOL, V210, P313, DOI 10.1016/0022-2836(89)90333-1; LOUIE GV, 1988, BIOCHEMISTRY-US, V27, P7870, DOI 10.1021/bi00420a043; LOUIE GV, 1988, J MOL BIOL, V199, P295, DOI 10.1016/0022-2836(88)90315-4; MCARTHUR KM, 1993, BIOCHIM BIOPHYS ACTA, V1202, P173, DOI 10.1016/0167-4838(93)90002-9; MILLER VP, 1995, J BIOL CHEM, V270, P18413, DOI 10.1074/jbc.270.31.18413; Miyazaki C, 2001, FEBS LETT, V509, P111, DOI 10.1016/S0014-5793(01)03127-1; Miyazaki-Imamura C, 2003, PROTEIN ENG, V16, P423, DOI 10.1093/protein/gzg054; Morawski B, 2001, BIOTECHNOL BIOENG, V76, P99, DOI 10.1002/bit.1149; Ostdal H, 1999, ARCH BIOCHEM BIOPHYS, V362, P105, DOI 10.1006/abbi.1998.0988; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; PIELAK GJ, 1985, NATURE, V313, P152, DOI 10.1038/313152a0; Pogni R, 2005, BIOCHEMISTRY-US, V44, P4267, DOI 10.1021/bi047474l; Pollock WBR, 1998, BIOCHEMISTRY-US, V37, P6124, DOI 10.1021/bi972188d; PRUTZ WA, 1990, NATO ADV SCI I A-LIF, V197, P389; Qian SY, 2002, BIOCHEM J, V363, P281, DOI 10.1042/0264-6021:3630281; SCHEJTER A, 1996, OXIDATION STATE DEPE, P335; SCHWEINGRUBER ME, 1979, J BIOL CHEM, V254, P4132; SCOTT RA, 1996, CYTOCHROME C MULTIDI; Stuchebrukhov AA, 2003, THEOR CHEM ACC, V110, P291, DOI 10.1007/s00214-003-0462-2; Valderrama B, 2005, J MOL CATAL B-ENZYM, V35, P41, DOI 10.1016/j.molcatb.2005.05.003; Valderrama B, 2002, CHEM BIOL, V9, P555, DOI 10.1016/S1074-5521(02)00149-7; Vazquez-Duhalt R, 1999, J MOL CATAL B-ENZYM, V7, P241, DOI 10.1016/S1381-1177(99)00033-8; Villegas JA, 2000, CHEM BIOL, V7, P237, DOI 10.1016/S1074-5521(00)00098-3; [No title captured]	47	31	32	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1233	+		10.1096/fj.05-4173fje	http://dx.doi.org/10.1096/fj.05-4173fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16720736				2022-12-28	WOS:000240210300036
J	Boesten, LSM; Zadelaar, ASM; van Nieuwkoop, A; Hu, L; Jonkers, J; de Water, BV; Gijbels, MJJ; van der Made, I; de Winther, MPJ; Havekes, LM; van Vlijmen, BJM				Boesten, Lianne S. M.; Zadelaar, A. Susanne M.; van Nieuwkoop, Anita; hu, Lii Hu; Jonkers, Jos; de Water, Bob van; Gijbels, Marion J. J.; van der Made, Ingeborg; de Winther, Menno P. J.; Havekes, Louis M.; van Vlijmen, Bart J. M.			Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE-deficient mice	FASEB JOURNAL			English	Article						genetically altered mice; tumor suppressor gene; proliferation; apoptosis	CELL-PROLIFERATION; GENE; PLAQUE; RB; INACTIVATION; RESTENOSIS; ACTIVATION; EXPRESSION; P27(KIP1); PARADIGM	The cellular composition of an atherosclerotic lesion is determined by cell infiltration, proliferation, and apoptosis. The tumor suppressor gene retinoblastoma (Rb) has been shown to regulate both cell proliferation and cell death in many cell types. To study the role of macrophage Rb in the development of atherosclerosis, we used apoE-deficient mice with a macrophage-restricted deletion of Rb (Rb-del mice) and control littermates (Rb-fl mice). After 12 wk feeding a cholesterol-rich diet, the Rbdel mice showed a 51% increase in atherosclerotic lesion area with a 39% increase in the relative number of advanced lesions. Atherosclerotic lesions showed a 13% decrease in relative macrophage area and a 46% increase in relative smooth muscle cell area, reflecting the more advanced state of the lesions. The increase in atherosclerosis was independent of in vitro macrophage modified lipoprotein uptake or cytokine production. Whereas macrophage-restricted Rb deletion did not affect lesional macrophage apoptosis, a clear 2.6-fold increase in lesional macrophage proliferation was observed. These studies demonstrate that macrophage Rb is a suppressing factor in the progression of atherosclerosis by reducing macrophage proliferation.	CO TNO Qual Life, Dept Gen Internal Med, Leiden Univ Med Ctr, Gaubius Lab, NL-2310 CE Leiden, Netherlands; Leiden Univ Med Ctr, Dept Cardiol, Leiden, Netherlands; Leiden Univ Med Ctr, Ctr Hemostasis & Thrombosis Res, Dept Hematol, Leiden, Netherlands; Netherlands Canc Inst, Amsterdam, Netherlands; Leiden Amsterdam Ctr Drug Res, Div Toxicol, Leiden, Netherlands; Cardiovasc Res Inst, Dept Mol Genet, Maastricht, Netherlands; Maastricht Univ, Dept Pathol, Maastricht, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Netherlands Cancer Institute; Leiden University; Leiden University - Excl LUMC; Maastricht University; Maastricht University	Boesten, LSM (corresponding author), CO TNO Qual Life, Dept Gen Internal Med, Leiden Univ Med Ctr, Gaubius Lab, Zernikedreef 9,POB 2215, NL-2310 CE Leiden, Netherlands.	lsmboesten@diac-leiden.nl	de Winther, Menno/E-8721-2012; Jonkers, Jos/AAG-3246-2019	Jonkers, Jos/0000-0002-9264-9792; de Winther, Menno/0000-0002-4038-6636				Bennett MR, 1998, CIRC RES, V82, P704, DOI 10.1161/01.RES.82.6.704; Bergh G, 1999, BLOOD, V94, P1971; Boesten LSM, 2005, CARDIOVASC RES, V66, P179, DOI 10.1016/j.cardiores.2005.01.001; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Dickson BC, 2003, CARDIOVASC PATHOL, V12, P237, DOI 10.1016/S1054-8807(03)00072-3; Diez-Juan A, 2004, BLOOD, V103, P158, DOI 10.1182/blood-2003-07-2319; Diez-Juan A, 2001, FASEB J, V15, P1989, DOI 10.1096/fj.01-0130com; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; El-Omar Magdi M., 2001, Curr Interv Cardiol Rep, V3, P296; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; Fuster V, 1996, HAEMOSTASIS, V26, P269; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kanters E, 2003, J CLIN INVEST, V112, P1176, DOI 10.1172/JCI18580; Kockx M, 1999, BLOOD, V93, P2991; Kockx MM, 1998, AM J PATHOL, V152, P885; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Marino S, 2000, GENE DEV, V14, P994; Merched AJ, 2004, CIRCULATION, V110, P3830, DOI 10.1161/01.CIR.0000148681.01282.89; Merched AJ, 2003, ARTERIOSCL THROM VAS, V23, P1608, DOI 10.1161/01.ATV.0000084825.88022.53; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; NISHINA PM, 1990, J LIPID RES, V31, P859; O'Brien KD, 2005, ARTERIOSCL THROM VAS, V25, P785, DOI 10.1161/01.ATV.0000158383.65277.2b; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5; Smith RC, 1997, CIRCULATION, V96, P1899, DOI 10.1161/01.CIR.96.6.1899; van der Hoeven BL, 2005, INT J CARDIOL, V99, P9, DOI 10.1016/j.ijcard.2004.01.021; van Vlijmen BJM, 2001, CIRC RES, V88, P780, DOI 10.1161/hh0801.089261; Vooijs M, 1998, ONCOGENE, V17, P1, DOI 10.1038/sj.onc.1202169; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	40	24	26	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					953	+		10.1096/fj.05-4530fje	http://dx.doi.org/10.1096/fj.05-4530fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585057				2022-12-28	WOS:000240157700019
J	Huang, D; Shi, FD; Jung, S; Pien, GC; Wang, J; Salazar-Mather, TP; He, TT; Weaver, JT; Ljunggren, HG; Biron, CA; Littman, DR; Ransohoff, RM				Huang, Deren; Shi, Fu-Dong; Jung, Steffen; Pien, Gary C.; Wang, Jintang; Salazar-Mather, Thais P.; He, Toby T.; Weaver, Jennifer T.; Ljunggren, Hans-Gustaf; Biron, Christine A.; Littman, Dan R.; Ransohoff, Richard M.			The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system	FASEB JOURNAL			English	Article						autoimmune disease; chemokine; chemokine receptor; NK; T cell	NATURAL-KILLER-CELLS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; FRACTALKINE RECEPTOR CX(3)CR1; T-CELLS; TARGETED DELETION; CUTTING EDGE; MICE LACKING; IFN-GAMMA; BRAIN; NATALIZUMAB	Leukocyte trafficking to the central nervous system (CNS), regulated in part by chemokines, determines severity of the demyelinating diseases multiple sclerosis ( MS) and experimental autoimmune encephalomyelitis ( EAE). To examine chemokine receptor CX3CR1 in EAE, we studied CX3CR1(GFP/GFP) mice, in which CX3CR1 targeting by insertion of Green Fluorescent Protein (GFP) allowed tracking of CX3CR1+ cells in CX3CR1(+/GFP) animals and cells destined to express CX3CR1 in CX3CR1(GFP/GFP) knockouts. NK cells were markedly reduced in the inflamed CNS of CX3CR1-deficient mice with EAE, whereas recruitment of T cells, NKT cells and monocyte/macrophages to the CNS during EAE did not require CX3CR1. Impaired recruitment of NK cells in CX3CR1(GFP/GFP) mice was associated with increased EAE-related mortality, nonremitting spastic paraplegia and hemorrhagic inflammatory lesions. The absence of CD1d did not affect the severity of EAE in CX3CR1(GFP/GFP) mice, arguing against a role for NKT cells. Accumulation of NK cells in livers of wild-type (WT) and CX3CR1(GFP/GFP) mice with cytomegalovirus hepatitis was equivalent, indicating that CX3CL1 mediated chemoattraction of NK cells was relatively specific for the CNS. These results are the first to define a chemokine that governs NK cell migration to the CNS, and the findings suggest novel therapeutic manipulation of CX3CR1+ NK cells.	Cleveland Clin Fdn, Neuroinflammat Res Ctr, Dept Neurosci NC30, Lerner Res Inst, Cleveland, OH 44195 USA; Barrow Neurol Inst, Phoenix, AZ 85013 USA; NYU, Med Ctr, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Med Ctr, Howard Hughes Med Inst, New York, NY 10016 USA; Brown Univ, Div Biol & Med, Dept Mol Microbiol & Immunol, Providence, RI 02912 USA; Huddinge Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden	Cleveland Clinic Foundation; Barrow Neurological Institute; New York University; Howard Hughes Medical Institute; New York University; Brown University; Karolinska Institutet	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Neuroinflammat Res Ctr, Dept Neurosci NC30, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	ransohr@ccf.org	Jung, Steffen/K-1409-2012	Jung, Steffen/0000-0003-4290-5716	NCI NIH HHS [R01 CA041268] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041268] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bielekova B, 2004, J NEUROIMMUNOL, V154, P211; Campbell JJ, 2001, J IMMUNOL, V166, P6477, DOI 10.4049/jimmunol.166.11.6477; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chapman GA, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-15-j0004.2000; Cook DN, 2001, MOL CELL BIOL, V21, P3159, DOI 10.1128/MCB.21.9.3159-3165.2001; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Engelhardt B, 2005, TRENDS IMMUNOL, V26, P485, DOI 10.1016/j.it.2005.07.004; Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899; Fort MM, 1998, J IMMUNOL, V161, P3256; French AR, 2004, ARTHRITIS RES THER, V6, P8, DOI 10.1186/ar1034; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haskell CA, 2001, J CLIN INVEST, V108, P679, DOI 10.1172/JCI12976; Hong SM, 1999, IMMUNOL REV, V169, P31, DOI 10.1111/j.1600-065X.1999.tb01304.x; Huang DR, 2000, IMMUNOL REV, V177, P52, DOI 10.1034/j.1600-065X.2000.17709.x; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; Hughes PM, 2002, GLIA, V37, P314, DOI 10.1002/glia.10037; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Infante-Duarte C, 2005, FASEB J, V19, P1902, DOI 10.1096/fj.05-3832fje; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Jahng AW, 2001, J EXP MED, V194, P1789, DOI 10.1084/jem.194.12.1789; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847; Lee IF, 2004, J IMMUNOL, V172, P937, DOI 10.4049/jimmunol.172.2.937; Li ZQ, 2005, J IMMUNOL, V174, P5187, DOI 10.4049/jimmunol.174.9.5187; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nishiyori A, 1998, FEBS LETT, V429, P167, DOI 10.1016/S0014-5793(98)00583-3; Ogasawara K, 2004, IMMUNITY, V20, P757, DOI 10.1016/j.immuni.2004.05.008; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Pien GC, 2000, J IMMUNOL, V165, P4787, DOI 10.4049/jimmunol.165.9.4787; Poirot L, 2004, P NATL ACAD SCI USA, V101, P8102, DOI 10.1073/pnas.0402065101; Ransohoff RM, 2005, NAT NEUROSCI, V8, P1275, DOI 10.1038/nn1005-1275; Salazar-Mather TP, 2000, J CLIN INVEST, V105, P985, DOI 10.1172/JCI9232; Salazar-Mather TP, 1998, J EXP MED, V187, P1, DOI 10.1084/jem.187.1.1; Sandborn WJ, 2005, NEW ENGL J MED, V353, P1912, DOI 10.1056/NEJMoa043335; Schwaeble WJ, 1998, FEBS LETT, V439, P203, DOI 10.1016/S0014-5793(98)01384-2; Shi FD, 2000, NAT IMMUNOL, V1, P245, DOI 10.1038/79792; Shi FD, 2000, J IMMUNOL, V165, P3099, DOI 10.4049/jimmunol.165.6.3099; Shi FD, 2001, TRENDS IMMUNOL, V22, P97, DOI 10.1016/S1471-4906(00)01821-4; Sunnemark D, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-17; Tsai HH, 2002, CELL, V110, P373, DOI 10.1016/S0092-8674(02)00838-3; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Umehara H, 2001, TRENDS IMMUNOL, V22, P602, DOI 10.1016/S1471-4906(01)02051-8; Xu W, 2005, J NEUROIMMUNOL, V163, P24, DOI 10.1016/j.jneuroim.2005.02.011; Zhang BN, 1997, J EXP MED, V186, P1677, DOI 10.1084/jem.186.10.1677; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	55	222	229	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					896	905		10.1096/fj.05-5465com	http://dx.doi.org/10.1096/fj.05-5465com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675847				2022-12-28	WOS:000240157700012
J	Liu, CJ; Kong, W; Ilalov, K; Yu, S; Xu, K; Prazak, L; Fajardo, M; Sehgal, B; Di Cesare, PE				Liu, Chuan-ju; Kong, Wei; Ilalov, Kiril; Yu, Shuang; Xu, Ke; Prazak, Lisa; Fajardo, Marc; Sehgal, Bantoo; Di Cesare, Paul E.			ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein	FASEB JOURNAL			English	Article						degradation; arthritis; COMP	MULTIPLE EPIPHYSEAL DYSPLASIA; MYOBLAST DIFFERENTIATION; THROMBOSPONDIN MOTIFS; RHEUMATOID-ARTHRITIS; ARTICULAR-CARTILAGE; BONE METABOLISM; SYNOVIAL-FLUID; SERUM MARKERS; CELL-LINE; PSEUDOACHONDROPLASIA	Degradative fragments of cartilage oligomeric matrix protein (COMP) have been observed in arthritic patients. The physiological enzyme(s) that degrade COMP, however, remain unknown. We performed a yeast two-hybrid screen (Y2H) to search for proteins that associate with COMP to identify an interaction partner that might degrade it. One screen using the epidermal growth factor (EGF) domain of COMP as bait led to the discovery of ADAMTS-7. Rat ADAMTS-7 is composed of 1595 amino acids, and this protein exhibits higher expression in the musculoskeletal tissues. COMP binds directly to ADAMTS-7 in vitro and in native articular cartilage. ADAMTS-7 selectively interacts with the EGF repeat domain but not with the other three functional domains of COMP, whereas the four C-terminal TSP motifs of ADAMTS-7 are required and sufficient for association with COMP. The recombinant catalytic domain and intact ADAMTS-7 are capable of digesting COMP in vitro. The enzymatic activity of ADAMTS-7 requires the presence of Zn2+ and appropriate pH (7.5-9.5), and the concentration of ADAMTS-7 in cartilage and synovium of patients with rheumatoid arthritis is significantly increased as compared to normal cartilage and synovium. ADAMTS-7 is the first metalloproteinase found to bind directly to and degrade COMP.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA	New York University; Yale University	Liu, CJ (corresponding author), NYU, Sch Med, Dept Orthopaed Surg, 301 E 17th St, New York, NY 10003 USA.	Chuanju.liu@med.nyu.edu; pedicesare@aol.com	Liu, Chuan-ju/AAT-8165-2021	Xu, Ke Kate/0000-0002-2453-4475; liu, chuanju/0000-0002-7181-8032	NIAMS NIH HHS [R03 AR052022, AR052022-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR052022] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bevitt DJ, 2003, BBA-GENE STRUCT EXPR, V1626, P83, DOI 10.1016/S0167-4781(03)00047-2; BRIGGS MD, 1993, GENOMICS, V18, P656, DOI 10.1016/S0888-7543(05)80369-6; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Chen AL, 2004, J ORTHOP RES, V22, P1188, DOI 10.1016/j.orthres.2004.02.013; CHEN FHT, 2004, 50 ANN M ORTH RES SO; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Collins-Racie LA, 2004, MATRIX BIOL, V23, P219, DOI 10.1016/j.matbio.2004.05.004; Di Cesare PE, 2000, J ORTHOPAED RES, V18, P713, DOI 10.1002/jor.1100180506; Di Cesare PE, 1999, J ORTHOPAED RES, V17, P437; Di Cesare PE, 2002, MATRIX BIOL, V21, P461, DOI 10.1016/S0945-053X(02)00015-X; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DiCesare PE, 1996, J ORTHOPAED RES, V14, P946, DOI 10.1002/jor.1100140615; DiCesare PE, 1997, FEBS LETT, V412, P249, DOI 10.1016/S0014-5793(97)00789-8; Dickinson SC, 2003, MATRIX BIOL, V22, P267, DOI 10.1016/S0945-053X(03)00034-9; Duke J, 2003, APOPTOSIS, V8, P191, DOI 10.1023/A:1022926811397; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; HECHT JT, 1993, GENOMICS, V18, P661, DOI 10.1016/S0888-7543(05)80370-2; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Hecht JT, 2001, MATRIX BIOL, V20, P251, DOI 10.1016/S0945-053X(01)00136-6; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kraus VB, 2002, ARTHRITIS RHEUM-US, V46, P420, DOI 10.1002/art.10124; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Liu CJ, 2001, J BIOL CHEM, V276, P18925, DOI 10.1074/jbc.M101606200; LLAMAZARES M, 2003, J BIOL CHEM, V31, P31; Lohmander LS, 1999, ARTHRITIS RHEUM, V42, P534, DOI 10.1002/1529-0131(199904)42:3<534::AID-ANR19>3.0.CO;2-J; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; MANSSON B, 1995, J CLIN INVEST, V95, P1071, DOI 10.1172/JCI117753; Martel-Pelletier J, 2001, BEST PRACT RES CL RH, V15, P805, DOI 10.1053/berh.2001.0195; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Misumi K, 2002, EQUINE VET J, V34, P602, DOI 10.2746/042516402776180205; Mittaz L, 2004, BIOL REPROD, V70, P1096, DOI 10.1095/biolreprod.103.023911; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; Neidhart M, 1997, BRIT J RHEUMATOL, V36, P1151; Neidhart M, 1996, J RHEUMATOL, V23, P476; Ozbek S, 2002, EMBO J, V21, P5960, DOI 10.1093/emboj/cdf628; Petersson IF, 1998, BRIT J RHEUMATOL, V37, P46; POOLE RA, 1993, JOINT CARTILAGE DEGR; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Salzet M, 2002, CURR PHARM DESIGN, V8, P493, DOI 10.2174/1381612023395664; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SAXNE T, 1992, BRIT J RHEUMATOL, V31, P583; Somerville RPT, 2004, J BIOL CHEM, V279, P35159, DOI 10.1074/jbc.M402380200; Stracke JO, 2000, FEBS LETT, V478, P52, DOI 10.1016/S0014-5793(00)01819-6; Susic S, 1997, CLIN GENET, V51, P219; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2	64	109	121	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					988	+		10.1096/fj.05-3877fje	http://dx.doi.org/10.1096/fj.05-3877fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16585064	Green Accepted			2022-12-28	WOS:000240157700031
J	Liao, H; Hyman, MC; Lawrence, DA; Pinsky, DJ				Liao, Hui; Hyman, Matthew C.; Lawrence, Daniel A.; Pinsky, David J.			Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1 alpha, and C/EBP alpha	FASEB JOURNAL			English	Article						C/EBP alpha overexpression; hypoxia sensitivity; HRE-1 and HRE-2 motifs; PAI-1 transcription	INDUCIBLE FACTOR-I; ENHANCER-BINDING-PROTEIN; ISCHEMIA/REPERFUSION INJURY; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; RESPONSE ELEMENTS; EXPRESSION; ACTIVATOR; FAMILY; GROWTH	Hypoxia, as occurs during tissue ischemia, tips the natural anticoagulant/procoagulant balance of the endovascular wall to favor activation of coagulation. Plasminogen activator inhibitor-1 (PAI-1) is an important factor suppressing fibrinolysis under conditions of low oxygen tension. We previously reported that hypoxia induced PAI-1 mRNA and antigen expression in murine macrophages secondary to increased de novo transcription as well as increased mRNA stability. We now show in RAW264.7 murine macrophages that the transcription factors early growth response gene-1 (Egr-1), hypoxia-inducible factor-1 alpha (HIF-1 alpha), and CCAAT/enhancer binding protein cl (C/EBP alpha) are quickly activated in hypoxia and are responsible for transcription and expression of PAI-1. Murine PAI-1 promoter constructs, including Egr, HIF-1 alpha, and/or C/EBP alpha binding sites, were transfected into RAW 264.7 murine macrophages. To identify the relative importance of each of these putative hypoxia-responsive elements, cells were exposed to normobaric hypoxia, and transcriptional activity was recorded. At 16 h of hypoxic exposure, murine PAW promoter deletion constructs that included Egr, HIF-1 alpha, and/or C/EBP alpha binding sites demonstrated increased transcriptional activity. Mutation of each of these three murine PAI-1 promoter sites (or a combination of them) resulted in a marked reduction in hypoxia sensitivity as detected by transcriptional analysis. Functional data obtained using P-32-labeled Egr, HIF-1 alpha response element (HRE), and C/EBP alpha oligonucleotides revealed induction of DNA binding activity in nuclear extracts from hypoxic RAW cells, with supershift analysis confirming activation of Egr-1, HIF-1 alpha, or C/EBP alpha. ChIP analysis confirmed the authenticity of these interactions as each of these transcription factors binds to chromatin under hypoxic conditions. Further, the induction of PAI-1 by Egr-I, HIF-1 alpha, or C/EBP alpha was replicated in primary peritoneal macrophages. These data suggest that although HIF-1 alpha appears to dominate the PAI-1 transcriptional response in hypoxia, Egr-1 and C/EBP alpha greatly augment this response and can do so independent of HIF-1 alpha or each other. These studies are relevant to ischemic up-regulation of the PAI-1 gene and consequent accrual of microvascular thrombus under ischemic conditions.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Pinsky, DJ (corresponding author), Univ Michigan Hlth Syst, 7220 MSRB III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dpinsky@umich.edu		Lawrence, Daniel/0000-0003-3126-1935; Hyman, Matthew/0000-0002-4050-6925	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059488] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59377, HL59488] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Al-Sarraj A, 2005, J CELL BIOCHEM, V94, P153, DOI 10.1002/jcb.20305; Banks MF, 2005, J APPL PHYSIOL, V98, P732, DOI 10.1152/japplphysiol.00821.2004; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; Cao CZ, 2006, EMBO J, V25, P1860, DOI 10.1038/sj.emboj.7601082; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fujita T, 2004, J CLIN INVEST, V113, P1615, DOI 10.1172/JCI200419225; Gorlach A, 2003, THROMB HAEMOSTASIS, V89, P926; HAMER JD, 1981, BRIT J SURG, V68, P166, DOI 10.1002/bjs.1800680308; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ishiyama T, 2003, CANCER SCI, V94, P757, DOI 10.1111/j.1349-7006.2003.tb01515.x; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; Jung F, 2000, CIRC RES, V86, P319, DOI 10.1161/01.RES.86.3.319; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kietzmann T, 2003, THROMB HAEMOSTASIS, V89, P666; Kietzmann T, 2003, BLOOD, V101, P907, DOI 10.1182/blood-2002-06-1693; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Liu CT, 1998, CANCER GENE THER, V5, P3; Liu Q, 2004, BLOOD, V104, P3993, DOI 10.1182/blood-2004-03-1017; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MALONE PC, 1977, MED HYPOTHESES, V3, P189, DOI 10.1016/0306-9877(77)90005-6; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; Okada K, 2000, J BIOL CHEM, V275, P21468, DOI 10.1074/jbc.M002682200; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; PINSKY DJ, 1995, THROMB HAEMOSTASIS, V74, P58; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; Samoylenko A, 2001, BLOOD, V97, P2657, DOI 10.1182/blood.V97.9.2657; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Thake CD, 2004, AVIAT SPACE ENVIR MD, V75, P811; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zagorska A, 2004, ACTA BIOCHIM POL, V51, P563, DOI 10.18388/abp.2004_3545; Zhang QZ, 2004, J CELL PHYSIOL, V199, P89, DOI 10.1002/jcp.10452; Zhang QZ, 2003, J INVEST DERMATOL, V121, P1005, DOI 10.1046/j.1523-1747.2003.12564.x	65	93	97	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					935	949		10.1096/fj.06-6285com	http://dx.doi.org/10.1096/fj.06-6285com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197388	Green Submitted			2022-12-28	WOS:000244686400030
J	Rayment, SJ; Ralevic, V; Barrett, DA; Cordell, R; Alexander, SPH				Rayment, Sarah J.; Ralevic, Vera; Barrett, David A.; Cordell, Rebecca; Alexander, Stephen P. H.			A novel mechanism of vasoregulation: ADP-induced relaxation of the porcine isolated coronary artery is mediated via adenosine release	FASEB JOURNAL			English	Article						RT-PCR; adenosine A(2A) receptor; purine release; adenine nucleotides	ADENINE-NUCLEOTIDES; CYCLIC-AMP; EXTRACELLULAR ATP; P2Y(1) RECEPTOR; A(2A) RECEPTORS; P2 RECEPTORS; GUINEA-PIG; INVOLVEMENT; NEUROTRANSMISSION; 5'-NUCLEOTIDASE	In this study, we have investigated the mechanism of ADP-induced relaxation of porcine coronary artery (PCA) rings. The P2Y receptor agonists ADP and ADP beta S produced concentration-dependent relaxation of endothelium-denuded PCA smooth muscle with pD(2) values of 5.3 and 4.9, respectively. RT-polymerase chain reaction (RT-PCR) and immunoblotting demonstrated mRNA and protein expression of P2Y(1) and A(2)A adenosine receptors in the PCA. The nonselective P2 antagonist PPADS or the P2Y(1)-selective antagonist MRS2179 failed to alter ADP- or ADP beta S-induced relaxations. Relaxations to ADP were, however, blocked by the A2A adenosine receptor-selective antagonists ZM241385 and SCH58261 (apparent pK(B) values of 9.2 and 8.9, respectively). We excluded roles for direct occupancy of A(2)A adenosine receptors by ADP or ADP beta S as well as metabolism to adenosine as mechanisms for ADP-evoked relaxations. However, ADP responses were significantly enhanced in the presence of the ENT1 nucleoside transporter inhibitors dipyridamole and NBTI and were significantly inhibited by adenosine deaminase, indicating a role for extracellular adenosine. Suprafusion of [H-3]-adenine-labeled PCA segments showed that ADP induced the release of a number of purines, including adenosine. These data suggest that ADP mediates relaxation of the PCA via a novel mechanism that involves adenine nucleotide-evoked adenosine release and the subsequent activation of A(2A) receptors.	Univ Nottingham, Sch Med, Sch Biomed Sci, Queens Med Ctr, Nottingham NG7 2UH, England; Univ Nottingham, Sch Pharm, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Alexander, SPH (corresponding author), Univ Nottingham, Sch Med, Sch Biomed Sci, Queens Med Ctr, Nottingham NG7 2UH, England.	steve.alexander@nottingham.ac.uk	Alexander, Steve P/B-8105-2009; Barrett, David A/C-9922-2011	Alexander, Steve P/0000-0003-4417-497X; Barrett, David A/0000-0001-6900-9474; Rayment, Sarah/0000-0002-5293-5815; Ralevic, Vera/0000-0002-5252-280X; Cordell, Rebecca Lynne/0000-0002-3775-0193				Abbracchio MP, 2003, TRENDS PHARMACOL SCI, V24, P52, DOI 10.1016/S0165-6147(02)00038-X; Alexander S. P. H., 1999, British Journal of Pharmacology, V128, p182P; Alexander SPH, 2006, BRIT J PHARMACOL, V147, pS1; Alexander SPH, 2001, EUR J PHARMACOL, V411, P205, DOI 10.1016/S0014-2999(00)00899-2; Anwar Z, 1999, BRIT J PHARMACOL, V128, P465, DOI 10.1038/sj.bjp.0702792; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Blaylock N A, 1991, J Neural Transm Suppl, V34, P99; Boarder MR, 1998, TRENDS PHARMACOL SCI, V19, P99, DOI 10.1016/S0165-6147(98)01170-5; Bodor ET, 2003, MOL PHARMACOL, V64, P1210, DOI 10.1124/mol.64.5.1210; Cadogan AK, 1997, J NEUROCHEM, V69, P1131; Camaioni E, 1998, J MED CHEM, V41, P183, DOI 10.1021/jm970433l; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; CORR L, 1994, J CARDIOVASC PHARM, V23, P709, DOI 10.1097/00005344-199405000-00004; CRACK BE, 1995, BRIT J PHARMACOL, V114, P475, DOI 10.1111/j.1476-5381.1995.tb13251.x; Cristalli G, 2001, MED RES REV, V21, P105, DOI 10.1002/1098-1128(200103)21:2<105::AID-MED1002>3.0.CO;2-U; Hasan AZMA, 2000, J CARDIOVASC PHARM, V35, P322, DOI 10.1097/00005344-200002000-00022; KEEF KD, 1992, J PHARMACOL EXP THER, V260, P592; King BF, 1998, J PHARMACOL EXP THER, V285, P1005; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Kuo L, 2001, DRUG DEVELOP RES, V52, P350, DOI 10.1002/ddr.1134; Leon C, 1997, FEBS LETT, V403, P26, DOI 10.1016/S0014-5793(97)00022-7; Marala RB, 1998, J PHARMACOL EXP THER, V286, P1051; Marteau F, 2003, MOL PHARMACOL, V64, P104, DOI 10.1124/mol.64.1.104; Moro S, 1998, J MED CHEM, V41, P1456, DOI 10.1021/jm970684u; Ohkubo S, 1998, N-S ARCH PHARMACOL, V358, P153, DOI 10.1007/PL00005237; Ohkubo S, 2000, BRIT J PHARMACOL, V129, P291, DOI 10.1038/sj.bjp.0703053; Opgaard OS, 1997, BASIC RES CARDIOL, V92, P168; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; Qi AD, 2001, MOL PHARMACOL, V60, P1375, DOI 10.1124/mol.60.6.1375; Ralevic V, 1998, PHARMACOL REV, V50, P413; Schrier SM, 2002, BIOCHEM PHARMACOL, V63, P1119, DOI 10.1016/S0006-2952(01)00939-X; Schrier SM, 2001, BIOCHEM PHARMACOL, V61, P417, DOI 10.1016/S0006-2952(00)00573-6; Sevigny J, 1997, BBA-GEN SUBJECTS, V1334, P73, DOI 10.1016/S0304-4165(96)00079-7; SHINOZUKA K, 1994, BRIT J PHARMACOL, V113, P1203, DOI 10.1111/j.1476-5381.1994.tb17125.x; Simonsen U, 1997, BRIT J PHARMACOL, V120, P411, DOI 10.1038/sj.bjp.0700918; Sperlagh B, 2003, BRIT J PHARMACOL, V139, P623, DOI 10.1038/sj.bjp.0705285; Sprague RS, 1998, AM J PHYSIOL-HEART C, V275, pH1726, DOI 10.1152/ajpheart.1998.275.5.H1726; Ting N, 2000, N-S ARCH PHARMACOL, V361, P327, DOI 10.1007/s002109900198; TODOROV LD, 1994, J PHARMACOL EXP THER, V268, P985; von Kugelgen I, 2006, PHARMACOL THERAPEUT, V110, P415, DOI 10.1016/j.pharmthera.2005.08.014; VONKUGELGEN I, 1992, N-S ARCH PHARMACOL, V346, P187, DOI 10.1007/BF00165300; Waldo GL, 2004, MOL PHARMACOL, V65, P426, DOI 10.1124/mol.65.2.426; Westfall TD, 1996, BRIT J PHARMACOL, V117, P867, DOI 10.1111/j.1476-5381.1996.tb15273.x; Yegutkin G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/sj.bjp.0703136; Zimmermann H, 2001, DRUG DEVELOP RES, V52, P44, DOI 10.1002/ddr.1097; Zocchi C, 1996, J PHARMACOL EXP THER, V276, P398	47	22	22	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					577	585		10.1096/fj.06-7050com	http://dx.doi.org/10.1096/fj.06-7050com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17167068				2022-12-28	WOS:000244686300030
J	Blazquez, C; Carracedo, A; Barrado, L; Real, PJ; Fernandez-Luna, JL; Velasco, G; Malumbres, M; Guzman, M				Blazquez, Cristina; Carracedo, Arkaitz; Barrado, Lucia; Jose Real, Pedro; Fernandez-Luna, Jose Luis; Velasco, Guillermo; Malumbres, Marcos; Guzman, Manuel			Cannabinoid receptors as novel targets for the treatment of melanoma	FASEB JOURNAL			English	Article						G protein-coupled receptor; antitumoral drug; experimental therapeutics; cell proliferation	ACTIVATED PROTEIN-KINASE; GLIOBLASTOMA-MULTIFORME; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; INDUCED APOPTOSIS; TUMOR-GROWTH; IN-VIVO; CANCER; CB1; STIMULATION	Melanoma causes the greatest number of skin cancer-related deaths worldwide. Despite intensive research, prevention and early detection are the only effective measures against melanoma, so new therapeutic strategies are necessary for the management of this devastating disease. Here, we evaluated the efficacy of cannabinoid receptor agonists, a new family of potential antitumoral compounds, at skin melanoma. Human melanomas and melanoma cell lines express CB1 and CB2 cannabinoid receptors. Activation of these receptors decreased growth, proliferation, angiogenesis and metastasis, and increased apoptosis, of melanomas in mice. Cannabinoid antimelanoma activity was independent of the immune status of the animal, could be achieved without overt psychoactive effects and was selective for melanoma cells vs. normal melanocytes. Cannabinoid antiproliferative action on melanoma cells was due, at least in part, to cell cycle arrest at the G1-S transition via inhibition of the prosurvival protein Akt and hypophosphorylation of the pRb retinoblastoma protein tumor suppressor. These findings may contribute to the design of new chemotherapeutic strategies for the management of melanoma.	Univ Complutense Madrid, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain; Ctr Nacl Invest Oncol, Cell Div, Madrid, Spain; Ctr Nacl Invest Oncol, Canc Grp, Madrid, Spain; Marques Valdecilla Univ Hosp, Unit Mol Genet, Santander, Spain	Complutense University of Madrid; Hospital Universitario Marques de Valdecilla (HUMV)	Guzman, M (corresponding author), Univ Complutense Madrid, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain.	mgp@bbm1.ucm.es	Real, Pedro J./ABH-3493-2021; Velasco, Guillermo/AAU-9189-2020; Real, Pedro J./K-2994-2014; Velasco, Guillermo/H-5260-2012; Carracedo, Arkaitz/F-7029-2011; Malumbres, Marcos/E-8834-2011	Velasco, Guillermo/0000-0002-1994-2386; Real, Pedro J./0000-0001-7968-5353; Velasco, Guillermo/0000-0002-1994-2386; Carracedo, Arkaitz/0000-0001-5957-1260; Malumbres, Marcos/0000-0002-0829-6315; Guzman, Manuel/0000-0001-7475-118X				Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Bifulco M, 2002, NAT MED, V8, P547, DOI 10.1038/nm0602-547; Bifulco M, 2001, FASEB J, V15, P2745, DOI 10.1096/fj.01-0320fje; Blazquez C, 2004, CANCER RES, V64, P5617, DOI 10.1158/0008-5472.CAN-03-3927; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637; Bouaboula M, 1996, EUR J BIOCHEM, V237, P704, DOI 10.1111/j.1432-1033.1996.0704p.x; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; Chan PC, 1996, FUND APPL TOXICOL, V30, P109, DOI 10.1006/faat.1996.0048; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; Chudnovsky Y, 2005, J CLIN INVEST, V115, P813, DOI 10.1172/JCI200524808; del Pulgar T, 2000, BIOCHEM J, V347, P369, DOI 10.1042/bj3470369; del Pulgar TG, 2002, J BIOL CHEM, V277, P36527, DOI 10.1074/jbc.M205797200; del Pulgar TG, 2002, BIOCHEM J, V363, P183, DOI 10.1042/0264-6021:3630183; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Grotenhermen F, 2003, CLIN PHARMACOKINET, V42, P327, DOI 10.2165/00003088-200342040-00003; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Guzman M, 2006, BRIT J CANCER, V95, P197, DOI 10.1038/sj.bjc.6603236; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hall W, 2005, LANCET ONCOL, V6, P35, DOI 10.1016/S1470-2045(05)70024-3; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Iversen L, 2005, CURR OPIN PHARMACOL, V5, P69, DOI 10.1016/j.coph.2004.08.010; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; McAllister SD, 2005, J NEURO-ONCOL, V74, P31, DOI 10.1007/s11060-004-5950-2; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; MUNSON AE, 1975, J NATL CANCER I, V55, P597, DOI 10.1093/jnci/55.3.597; National Cancer Institute, SEER CANC STAT REV 1; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Samson MT, 2003, J IMMUNOL, V170, P4953, DOI 10.4049/jimmunol.170.10.4953; Sanchez C, 2001, CANCER RES, V61, P5784; Sanchez C, 1998, MOL PHARMACOL, V54, P834, DOI 10.1124/mol.54.5.834; Segal NH, 2003, J CLIN ONCOL, V21, P1775, DOI 10.1200/JCO.2003.10.108; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Thompson JF, 2005, LANCET, V365, P687, DOI 10.1016/S0140-6736(05)17951-3; Tramer MR, 2001, BMJ-BRIT MED J, V323, P16, DOI 10.1136/bmj.323.7303.16; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451	47	194	206	4	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2633	+		10.1096/fj.06-6638fje	http://dx.doi.org/10.1096/fj.06-6638fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065222				2022-12-28	WOS:000242490700048
J	Angata, T; Hayakawa, T; Yamanaka, M; Varki, A; Nakamura, M				Angata, Takashi; Hayakawa, Toshiyuki; Yamanaka, Masahiro; Varki, Ajit; Nakamura, Mitsuru			Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates	FASEB JOURNAL			English	Article						innate immunity; paired receptors; gene conversion; DAP12; great apes	IMMUNOGLOBULIN-LIKE RECEPTORS; GENE; CELL; INNATE; RECOGNITION; EXPRESSION; CLONING; CD33; ENGAGEMENT; P75/AIRM1	Immune receptors that show high mutual sequence similarity and have antagonizing signaling properties are called paired receptors, and are believed to fine-tune immune responses. Siglecs are sialic acid-recognizing receptors of the immunoglobulin (Ig) superfamily expressed on immune cells. Human Siglec-5, encoded by SIGLEC5 gene, has four extracellular Ig-like domains and a cytosolic inhibitory motif. We discovered human Siglec-14 with three Ig-like domains, encoded by the SIGLEC14 gene, adjacent to SIGLEC5. Human Siglec-14 has almost complete sequence identity with human Siglec-5 at the first two Ig-like domains, shows a glycan binding preference similar to that of human Siglec-5, and associates with the activating adapter protein DAP12. Thus, Siglec-14 and Siglec-5 appear to be the first glycan binding paired receptors. Near-complete sequence identity of the amino-terminal part of human Siglec-14 and Siglec-5 indicates partial gene conversion between SIGLEC14 and SIGLEC5. Remarkably, SIGLEC14 and SIGLEC5 in other primates also show evidence of gene conversions within each lineage. Evidently, balancing the interactions between Siglec-14, Siglec-5 and their common ligand(s) had selective advantage during the course of evolution. The "essential arginine" critical for sialic acid recognition in both Siglec-14 and Siglec-5 is present in humans but mutated in almost all great ape alleles.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058568, Japan; Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	National Institute of Advanced Industrial Science & Technology (AIST); University of California System; University of California San Diego; University of California System; University of California San Diego	Angata, T (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, 1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.	takashi-angata@aist.go.jp			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200; Angata T, 2001, J BIOL CHEM, V276, P40282, DOI 10.1074/jbc.M105926200; Angata T, 2001, J BIOL CHEM, V276, P45128, DOI 10.1074/jbc.M108573200; Angata T, 2004, P NATL ACAD SCI USA, V101, P13251, DOI 10.1073/pnas.0404833101; Arase H, 2002, MICROBES INFECT, V4, P1505, DOI 10.1016/S1286-4579(02)00033-3; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Avril T, 2005, J BIOL CHEM, V280, P19843, DOI 10.1074/jbc.M502041200; Blasius AL, 2006, BLOOD, V107, P2474, DOI 10.1182/blood-2005-09-3746; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8633, DOI 10.1074/jbc.275.12.8633; Brinkman-Vand der Linden ECM, 2003, MOL CELL BIOL, V23, P4199, DOI 10.1128/MCB.23.12.4199-4206.2003; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; Connolly NP, 2002, BRIT J HAEMATOL, V119, P221, DOI 10.1046/j.1365-2141.2002.03808.x; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker PR, 2005, CURR OPIN PHARMACOL, V5, P431, DOI 10.1016/j.coph.2005.03.003; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Gunturi A, 2004, IMMUNOL RES, V30, P29, DOI 10.1385/IR:30:1:029; Haile-Selassie Y, 2001, NATURE, V412, P178, DOI 10.1038/35084063; Hayakawa T, 2005, SCIENCE, V309, P1693, DOI 10.1126/science.1114321; Hayakawa T, 2001, P NATL ACAD SCI USA, V98, P11399, DOI 10.1073/pnas.191268198; Jones C, 2003, MOL MICROBIOL, V49, P1213, DOI 10.1046/j.1365-2958.2003.03634.x; Jukes T., 1969, MAMMALIAN PROTEIN ME, P21; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; Lanier LL, 2000, IMMUNOL TODAY, V21, P611, DOI 10.1016/S0167-5699(00)01745-X; Lanier LL, 2001, CURR OPIN IMMUNOL, V13, P326, DOI 10.1016/S0952-7915(00)00222-3; Lock K, 2004, IMMUNOBIOLOGY, V209, P199, DOI 10.1016/j.imbio.2004.04.007; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; Muchmore EA, 1998, AM J PHYS ANTHROPOL, V107, P187, DOI 10.1002/(SICI)1096-8644(199810)107:2<187::AID-AJPA5>3.3.CO;2-M; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Sonnenburg JL, 2004, GLYCOBIOLOGY, V14, P339, DOI 10.1093/glycob/cwh039; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; Vilches C, 2002, ANNU REV IMMUNOL, V20, P217, DOI 10.1146/annurev.immunol.20.092501.134942; Vitale C, 2001, P NATL ACAD SCI USA, V98, P5764, DOI 10.1073/pnas.091097198; Vitale C, 1999, P NATL ACAD SCI USA, V96, P15091, DOI 10.1073/pnas.96.26.15091; von Gunten S, 2005, BLOOD, V106, P1423, DOI 10.1182/blood-2004-10-4112; Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055; Yotsumoto K, 2003, J EXP MED, V198, P223, DOI 10.1084/jem.20021825; ZHANG J, 2006, IN PRESS BLOOD	45	116	125	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					1964	1973		10.1096/fj.06-5800com	http://dx.doi.org/10.1096/fj.06-5800com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012248				2022-12-28	WOS:000241156900004
J	Nijenhuis, T; van der Eerden, BCJ; Zugel, U; Steinmeyer, A; Weinans, H; Hoenderop, JGJ; van Leeuwen, JPTM; Bindels, RJM				Nijenhuis, Tom; van der Eerden, Bram C. J.; Zuegel, Ulrich; Steinmeyer, Andreas; Weinans, Harrie; Hoenderop, Joost G. J.; van Leeuwen, Johannes P. T. M.; Bindels, Rene J. M.			The novel vitamin D analog ZK191784 as an intestine-specific vitamin D antagonist	FASEB JOURNAL			English	Article						TRPV5; TRPV6; Ca2+ homeostasis; 1,25(OH)(2)D-3	1-ALPHA,25-DIHYDROXYVITAMIN D-3 ANALOG; CA2+ TRANSPORT PROTEINS; CALCIUM-ABSORPTION; CHANNEL; TRPV5; DIFFERENTIATION; HYPERABSORPTION; TAMOXIFEN; BETA; MICE	Vitamin D [1,25(OH) D-2(3)] plays a crucial role in Ca2+ homeostasis by stimulating Ca2+ (re) absorption and bone turnover. The 1,25(OH)(2)D-3 analog ZK191784 was recently developed to dissociate the therapeutic immunomodulatory activity from the hypercalcemic side effects of 1,25(OH)(2)D-3 and contains a structurally modified side chain characterized by a 22,23-double bond, 24R-hydroxy group, 25-cyclopropyl ring, and 5-butyloxazole unit. We investigated the effect of ZK191784 on Ca2+ homeostasis and the regulation of Ca2+ transport proteins in wild-type (WT) mice and mice lacking the renal epithelial Ca2+ channel TRPV5 (TRPV5(-/-)). The latter display hypercalciuria, hypervitaminosis D, increased intestinal expression of the epithelial Ca2+ channel TRPV6, the Ca2+-binding protein calbindin-D-9K, and intestinal Ca2+ hyperabsorption. ZK191784 normalized the Ca2+ hyperabsorption and the expression of intestinal Ca2+ transport proteins in TRPV5(-/-) mice. Furthermore, the compound decreased intestinal Ca2+ absorption in WT mice and reduced 1,25(OH)(2)D-3-dependent Ca-45(2+) uptake by Caco-2 cells, substantiating a 1,25(OH)(2)D-3-antagonistic action of ZK191784 in the intestine. ZK191784 increased renal TRPV5 and calbindin-D-28K expression and decreased urine Ca2+ excretion in WT mice. Both 1,25(OH)(2)D-3 and ZK191784 enhanced transcellular Ca2+ transport in primary cultures of rabbit connecting tubules and cortical collecting ducts, indicating a 1,25(OH)(2)D-3-agonistic effect in kidney. ZK191784 enhanced bone TRPV6 mRNA levels and 1,25(OH)(2)D-3 as well as ZK191784 stimulated secretion of the bone formation marker osteocalcin in rat osteosarcoma cells, albeit to a different extent. In conclusion, ZK191784 is a synthetic 1,25(OH)(2)D-3 ligand displaying a unique tissue-specific profile when administered in vivo. Because ZK191784 acts as an intestine-specific 1,25(OH)(2)D-3 antagonist, this compound will be associated with less hypercalcemic side effects compared with the 1,25(OH)(2)D-3 analogs currently used in clinical practice.	Radboud Univ Nijmegen Med Ctr, Dept Physiol, Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Erasmus MC, Dept Internal Med & Orthoped, Rotterdam, Netherlands; Schering AG, Res Business Area Med Chem, Berlin, Germany	Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus MC; Schering AG	Bindels, RJM (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Physiol, Ctr Mol Life Sci, POB 9101, NL-6500 HB Nijmegen, Netherlands.	r.bindels@ncmls.ru.nl	Nijenhuis, Tom/L-4547-2015; van Leeuwen, Johannes/D-5015-2014; Hoenderop, Joost G.J./H-8047-2014; Bindels, René JM/B-9824-2013; Nijenhuis, Tom/ABE-5194-2021; van der Eerden, Bram CJ/I-7496-2012	Nijenhuis, Tom/0000-0002-4375-7236; van Leeuwen, Johannes/0000-0002-2282-4006; Hoenderop, Joost G.J./0000-0002-1816-8544; Bindels, René JM/0000-0003-1167-1339; Nijenhuis, Tom/0000-0002-4375-7236; van der Eerden, Bram CJ/0000-0003-4403-6497; Weinans, Harrie/0000-0002-2275-6170				BINDELS RJM, 1991, AM J PHYSIOL, V261, pF799, DOI 10.1152/ajprenal.1991.261.5.F799; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Fujishima T, 2003, BIOORGAN MED CHEM, V11, P3621, DOI 10.1016/S0968-0896(03)00371-7; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Grese TA, 1997, P NATL ACAD SCI USA, V94, P14105, DOI 10.1073/pnas.94.25.14105; HEWISON M, 1992, J ENDOCRINOL, V132, P173, DOI 10.1677/joe.0.1320173; Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004; Hoenderop JGJ, 2004, KIDNEY INT, V66, P1082, DOI 10.1111/j.1523-1755.2004.00858.x; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2001, J AM SOC NEPHROL, V12, P1342, DOI 10.1681/ASN.V1271342; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Ji Y, 2004, CANCER RES, V64, P370, DOI 10.1158/0008-5472.CAN-03-3029; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; Mathieu C, 2002, TRENDS MOL MED, V8, P174, DOI 10.1016/S1471-4914(02)02294-3; McDowell N, 1999, SEMIN CELL DEV BIOL, V10, P311, DOI 10.1006/scdb.1999.0307; Miura D, 1999, J BIOL CHEM, V274, P16392, DOI 10.1074/jbc.274.23.16392; Nijenhuis T, 2005, J CLIN INVEST, V115, P1651, DOI 10.1172/JCI24134; Nijenhuis T, 2004, J AM SOC NEPHROL, V15, P549, DOI 10.1097/01.ASN.0000113318.56023.B6; Nijenhuis T, 2003, J AM SOC NEPHROL, V14, P2731, DOI 10.1097/01.ASN.0000094081.78893.E8; Norman AW, 2002, STEROIDS, V67, P457, DOI 10.1016/S0039-128X(01)00167-2; Ozono K, 1999, J BIOL CHEM, V274, P32376, DOI 10.1074/jbc.274.45.32376; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Renkema KY, 2005, J AM SOC NEPHROL, V16, P3188, DOI 10.1681/ASN.2005060632; Slatopolsky E, 2002, BLOOD PURIFICAT, V20, P109, DOI 10.1159/000046993; Smith EA, 2000, J ENDOCRINOL, V165, P163, DOI 10.1677/joe.0.1650163; Suda T, 2003, J CELL BIOCHEM, V88, P259, DOI 10.1002/jcb.10331; van Abel M, 2005, KIDNEY INT, V68, P1708, DOI 10.1111/j.1523-1755.2005.00587.x; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; van der Eerden BCJ, 2005, P NATL ACAD SCI USA, V102, P17507, DOI 10.1073/pnas.0505789102; van Leeuwen JPTM, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P1571; WOOD CM, 2001, TARGET ORGAN TOXICIT, V1, P1; Zugel U, 2002, J INVEST DERMATOL, V119, P1434, DOI 10.1046/j.1523-1747.2002.19623.x	34	14	15	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2171	+		10.1096/fj.06-5515fje	http://dx.doi.org/10.1096/fj.06-5515fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012263				2022-12-28	WOS:000241156900059
J	Yogev-Falach, M; Bar-Am, O; Amit, T; Weinreb, O; Youdim, MBH				Yogev-Falach, Merav; Bar-Am, Orit; Amit, Tamar; Weinreb, Orly; Youdim, Moussa B. H.			A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing	FASEB JOURNAL			English	Article						amyloid precursor protein; alpha-secretase; acetylcholinesterase inhibitor; Alzheimer disease	AMYLOID PRECURSOR PROTEIN; ANTI-PARKINSON DRUG; CHOLINESTERASE-INHIBITORS; ALZHEIMERS-DISEASE; KINASE-C; ACETYLCHOLINESTERASE INHIBITORS; RESPONSIVE ELEMENT; RASAGILINE; EXPRESSION; DERIVATIVES	The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on multiple targets has stimulated the development of the bifunctional drug ladostigil (TV3326) [(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate]. Ladostigil combines the neuroprotective effects of the antiparkinson drug rasagiline, a selective monoamine oxidase (MAO)-B inhibitor, with the cholinesterase (ChE) inhibitory activity of rivastigmine in a single molecule, as a potential treatment for Alzheimer's disease (AD) and Lewy Body disease. Here, we assessed the dual effects of lodostigil in terms of the molecular mechanism of neuroprotection and amyloid precursor protein (APP) regulation/processing by using an apoptotic model of neuroblastoma SK-N-SH cells. Ladostigil dose-dependently decreased cell death via inhibition of the cleavage and prevention of caspase-3 activation (IC50 = 1.05 mu M) through a mechanism related to regulation of the Bcl-2 family proteins, which resulted in reduced levels of Bad and Bax and induced levels of Bcl-2 gene and protein expression. We have also followed APP regulation/processing and found that ladostigil markedly decreased apoptotic-induced levels of holo-APP protein without altering APP mRNA levels, suggesting a posttranscriptional mechanism. In addition, the drug-elevated phosphorylated protein kinase C (pPKC) levels and stimulated the release of the nonamyloidogenic alpha-secretase proteolytic pathway. Similar to ladostigil, its S-isomer, TV3279, which is a ChE inhibitor but lacks MAO inhibitory activity, exerted neuroprotective properties and regulated APP processing, indicating that these effects are independent of MAO inhibition.	Technion Israel Inst Technol, Dept Pharmacol, Rappaport Family Inst Res Med Sci, Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Eve Topf Ctr Excellence Neurodegenerat Dis Res, Rappaport Family Inst Res Med Sci, Fac Med, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Dept Pharmacol, Rappaport Family Inst Res Med Sci, Fac Med, POB 9697, IL-31096 Haifa, Israel.	youdim@tx.technion.ac.il						Akao Y, 2002, J NEUROCHEM, V82, P913, DOI 10.1046/j.1471-4159.2002.01047.x; Ba F, 2003, J NEUROSCI METH, V123, P11, DOI 10.1016/S0165-0270(02)00324-2; Bar-Am O, 2005, FASEB J, V19, P1899, DOI 10.1096/fj.05-3794fje; Bar-Am O, 2004, J NEUROCHEM, V89, P1119, DOI 10.1111/j.1471-4159.2004.02425.x; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1978, CANCER RES, V38, P3751; Calderon FH, 1998, MOL PSYCHIATR, V3, P247, DOI 10.1038/sj.mp.4000383; Chong YH, 1996, LIFE SCI, V59, P545, DOI 10.1016/0024-3205(96)00335-9; Coyle J, 2001, BIOL PSYCHIAT, V49, P289, DOI 10.1016/S0006-3223(00)01101-X; DeKosky ST, 2002, ANN NEUROL, V51, P145, DOI 10.1002/ana.10069; Francis PT, 2005, TRENDS PHARMACOL SCI, V26, P104, DOI 10.1016/j.tips.2004.12.010; Francis PT, 1999, J NEUROL NEUROSUR PS, V66, P137, DOI 10.1136/jnnp.66.2.137; Giacobini E, 2004, PHARMACOL RES, V50, P433, DOI 10.1016/j.phrs.2003.11.017; Greig NH, 2005, P NATL ACAD SCI USA, V102, P17213, DOI 10.1073/pnas.0508575102; Joseph JA, 2005, NEUROCHEM RES, V30, P927, DOI 10.1007/s11064-005-6967-4; Lahiri DK, 1996, J MOL NEUROSCI, V7, P41, DOI 10.1007/BF02736847; Maruyama W, 2003, NEUROSCI LETT, V341, P233, DOI 10.1016/S0304-3940(03)00211-8; Maruyama W, 2000, ADV RES NEURODEGENER, V8, P171; MARUYAMA W, 2000, ANN NY ACAD SCI, V939, P320; Mazzucchelli M, 2003, J NEURAL TRANSM, V110, P935, DOI 10.1007/s00702-003-0006-x; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Pakaski M, 2003, CNS NEUROL DISORD-DR, V2, P163, DOI 10.2174/1568007033482869; Racchi M, 2001, MOL PSYCHIATR, V6, P520, DOI 10.1038/sj.mp.4000878; Racchi M, 2004, PHARMACOL RES, V50, P441, DOI 10.1016/j.phrs.2003.12.027; Rogers JT, 2004, CURR DRUG TARGETS, V5, P535, DOI 10.2174/1389450043345272; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Shaw KTY, 2001, P NATL ACAD SCI USA, V98, P7605, DOI 10.1073/pnas.131152998; Sterling J, 2002, J MED CHEM, V45, P5260, DOI 10.1021/jm020120c; von Bernhardi R, 2003, NEUROBIOL DIS, V14, P447, DOI 10.1016/j.nbd.2003.08.014; Wadia JS, 1998, J NEUROSCI, V18, P932; Weinreb O, 2004, FASEB J, V18, P1471, DOI 10.1096/fj.04-1916fje; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q; Weinstock M, 2000, ADV RES NEURODEGENER, V8, P157; Yang L, 2002, NEUROSCI RES, V42, P261, DOI 10.1016/S0168-0102(02)00005-6; YI H, 2005, IN PRESS J NEURAL T; Yogev-Falach M, 2003, FASEB J, V17, P2325, DOI 10.1096/fj.03-0078fje; Yogev-Falach M, 2002, FASEB J, V16, P1674, DOI 10.1096/fj.02-0198fje; Youdim MBH, 2005, TRENDS PHARMACOL SCI, V26, P27, DOI 10.1016/j.tips.2004.11.007; Youdim MBH, 2002, MECH AGEING DEV, V123, P1081, DOI 10.1016/S0047-6374(01)00391-8; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; YOUDIM MBH, 2001, DRUGS PREVENT CELL D, V86; Zhang HY, 2004, NEUROSCI LETT, V360, P21, DOI 10.1016/j.neulet.2004.01.055; Zimmermann M, 2004, J NEUROCHEM, V90, P1489, DOI 10.1111/j.1471-4159.2004.02680.x	46	80	83	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2177	+		10.1096/fj.05-4910fje	http://dx.doi.org/10.1096/fj.05-4910fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935943				2022-12-28	WOS:000241156900063
J	Zanardo, RCO; Brancaleone, V; Distrutti, E; Fiorucci, S; Cirino, G; Wallace, JL				Zanardo, Renata C. O.; Brancaleone, Vincenzo; Distrutti, Eleonora; Fiorucci, Stefano; Cirino, Giuseppe; Wallace, John L.			Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation	FASEB JOURNAL			English	Article						CNS; H2S donor; leukocyte adhesion	RAT; ADHESION; INHIBITION; DAMAGE; BLOOD	Hydrogen sulfide (H2S) is increasingly recognized as an important signaling molecule in the cardiovascular and nervous systems. Recently, H2S donors were reported to induce neutrophil apoptosis and to suppress expression of some leukocyte and endothelial adhesion molecules. Using rats, we examined the possibility that H2S is an endogenous regulator of key inflammatory events at the leukocyte-endothelial interface. Via intravital microscopy, we observed that H2S donors (NaHS and Na2S) inhibited aspirin-induced leukocyte adherence in mesenteric venules (ED50 of 5.0 mu mol/kg for Na2S), likely via activation of ATP-sensitive K+ (K-ATP) channels. Inhibition of endogenous H2S synthesis elicited leukocyte adherence. Leukocyte infiltration in an air pouch model was also suppressed by H2S donors (NaHS, Lawesson's reagent, and N-acetylcysteine; ED50 of 42.7, 1.3, and 29.9 mu mol/kg, respectively) and exacerbated by inhibition of endogenous H2S synthesis. Carrageenan-induced paw edema was suppressed by H2S donors (NaHS and Na2S; ED(50)s of 35 and 28 mu mol/kg, respectively) to the same extent as by diclofenac and enhanced by an inhibitor of H2S synthesis. Suppression of edema formation by H2S donors was mimicked by a K-ATP channel agonist and reversed by an antagonist of this channel. These results suggest that endogenous H2S is an important mediator of acute inflammation, acting at the leukocyte-endothelium interface. These findings have important implications for anti-inflammatory drug development.	Univ Calgary, Dept Pharmacol & Therapeut, Inflammat Res Network, Calgary, AB T2N 4N1, Canada; Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; Univ Perugia, Div Gastroenterol & Hepatol, I-06100 Perugia, Italy	University of Calgary; University of Naples Federico II; University of Perugia	Wallace, JL (corresponding author), Univ Calgary, Dept Pharmacol & Therapeut, Inflammat Res Network, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	wallacej@ucalgary.ca	Fiorucci, Stefano/I-1251-2012; Wallace, John/AAL-3763-2021	brancaleone, vincenzo/0000-0002-0063-659X; Cirino, Giuseppe/0000-0003-3954-4083				Abe K, 1996, J NEUROSCI, V16, P1066; ANTUNES E, 1990, BRIT J PHARMACOL, V101, P986, DOI 10.1111/j.1476-5381.1990.tb14193.x; ASAKO H, 1992, GASTROENTEROLOGY, V103, P146, DOI 10.1016/0016-5085(92)91107-F; Bhatia M, 2005, FASEB J, V19, P623, DOI 10.1096/fj.04-3023fje; Bhatia M, 2005, BRIT J PHARMACOL, V145, P141, DOI 10.1038/sj.bjp.0706186; Boehning D, 2003, ANNU REV NEUROSCI, V26, P105, DOI 10.1146/annurev.neuro.26.041002.131047; Distrutti E, 2006, J PHARMACOL EXP THER, V316, P325, DOI 10.1124/jpet.105.091595; Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060; Fujii K, 2005, ANTIOXID REDOX SIGN, V7, P788, DOI 10.1089/ars.2005.7.788; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; Kamath AF, 2006, BLOOD, V107, P591, DOI 10.1182/blood-2005-06-2506; Li L, 2005, FASEB J, V19, P1196, DOI 10.1096/fj.04-3583fje; Mariggio MA, 1998, IMMUNOPHARM IMMUNOT, V20, P399, DOI 10.3109/08923979809034822; Mok YYP, 2004, BRIT J PHARMACOL, V143, P881, DOI 10.1038/sj.bjp.0706014; Moore PK, 2003, TRENDS PHARMACOL SCI, V24, P609, DOI 10.1016/j.tips.2003.10.007; Richardson CJ, 2000, CLIN CHIM ACTA, V293, P115, DOI 10.1016/S0009-8981(99)00245-4; Searcy DG, 1998, J EXP ZOOL, V282, P310, DOI 10.1002/(SICI)1097-010X(19981015)282:3<310::AID-JEZ4>3.0.CO;2-P; SEDGWICK AD, 1985, BRIT J EXP PATHOL, V66, P455; SMITH SB, 1977, BIOCHEM J, V162, P453, DOI 10.1042/bj1620453; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; WALLACE JL, 1990, AM J PHYSIOL, V259, pG462, DOI 10.1152/ajpgi.1990.259.3.G462; Wallace JL, 1999, BRIT J PHARMACOL, V126, P1200, DOI 10.1038/sj.bjp.0702420; WALLACE JL, 1991, GASTROENTEROLOGY, V100, P878, DOI 10.1016/0016-5085(91)90259-N; WALLACE JL, 1993, AM J PHYSIOL, V265, pG993, DOI 10.1152/ajpgi.1993.265.5.G993; Wallace JL, 2003, FUND CLIN PHARMACOL, V17, P11, DOI 10.1046/j.1472-8206.2003.00125.x; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Weiss N, 2002, ARTERIOSCL THROM VAS, V22, P34, DOI 10.1161/hq1201.100456; Whiteman M, 2005, BIOCHEM BIOPH RES CO, V326, P794, DOI 10.1016/j.bbrc.2004.11.110; Whiteman M, 2004, J NEUROCHEM, V90, P765, DOI 10.1111/j.1471-4159.2004.02617.x; Zhao WM, 2002, AM J PHYSIOL-HEART C, V283, pH474, DOI 10.1152/ajpheart.00013.2002	30	688	746	2	113	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2118	+		10.1096/fj.06-6270fje	http://dx.doi.org/10.1096/fj.06-6270fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16912151				2022-12-28	WOS:000241156900023
J	Wang, L; Mukhopadhyay, D; Xu, XL				Wang, Ling; Mukhopadhyay, Debabrata; Xu, Xiaolei			C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis	FASEB JOURNAL			English	Article						NRP-1; VPF/ VEGF; endothelial cells; zebrafish; PDZ-domain	DOMAIN-CONTAINING PROTEIN; GROWTH-FACTOR RECEPTOR-2; VASCULAR DEVELOPMENT; PDZ DOMAINS; WILD-TYPE; ZEBRAFISH; EXPRESSION; GENE; NEUROPILIN; RECOGNITION	Initially, it was thought that there was no intracellular signaling mediated by NRP-1 alone in response to its ligands. However, the emerging data from our group as well as others suggest that the signaling through NRP-1 actually promotes angiogenesis and is mediated through its C-terminal domain and downstream molecules such as phosphoinositide 3-kinase. Hence, understanding the signal transduction pathways mediated by NRP-1 and identification of its downstream molecules are of importance. By using both in vivo zebrafish model and in vitro tissue culture system, we have shown that the C-terminal three amino acids of NRP-1 (SEA-COOH) are required for NRP-1-mediated angiogenesis. Furthermore, knocking down of RGS-GAIP-interacting protein C terminus (GIPC) in zebrafish, which is associated with C-terminal domain of NRP-1, exhibits similar vasculature phenotypes to those from NRP-1 null. Specific and effective silencing of GIPC in vascular endothelium results in inhibition of NRP-1-mediated migration. In both cases as described, PDZ domain of GIPC is responsible for its function. Taken together, our data suggest a novel role of GIPC in angiogenesis and vessel formation and also support our hypothesis that NRP-1 can facilitate downstream signaling to promote angiogenesis through GIPC.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Ctr Canc, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Mukhopadhyay, D (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW,Gugg 1401A, Rochester, MN 55905 USA.	mukhopadhyay.debabrata@mayo.edu; xu.xiaolei@mayo.edu			NCI NIH HHS [CA-78383] Funding Source: Medline; NHLBI NIH HHS [HL-072178, HL-70567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078383, R01CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072178, R01HL070567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bovenkamp DE, 2004, GENE EXPR PATTERNS, V4, P361, DOI 10.1016/j.modgep.2004.01.014; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Cai HB, 1999, J NEUROSCI, V19, P6519; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Childs S, 2002, DEVELOPMENT, V129, P973; Couffinhal T, 1997, AM J PATHOL, V150, P1673; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fouquet B, 1997, DEV BIOL, V183, P37, DOI 10.1006/dbio.1996.8495; Haffter P, 1996, DEVELOPMENT, V123, P1; Hajdu-Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Inoue M, 1998, CIRCULATION, V98, P2108, DOI 10.1161/01.CIR.98.20.2108; Isogai S, 2001, DEV BIOL, V230, P278, DOI 10.1006/dbio.2000.9995; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kennedy MB, 1998, BRAIN RES REV, V26, P243, DOI 10.1016/S0165-0173(97)00043-X; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Liao W, 1997, DEVELOPMENT, V124, P381; Lyons MS, 1998, DEV DYNAM, V212, P133, DOI 10.1002/(SICI)1097-0177(199805)212:1<133::AID-AJA12>3.0.CO;2-8; Murga M, 2005, BLOOD, V105, P1992, DOI 10.1182/blood-2004-07-2598; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; THISSE C, 1993, DEVELOPMENT, V119, P1203; Wang L, 2003, J BIOL CHEM, V278, P48848, DOI 10.1074/jbc.M310047200; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yu HH, 2004, GENE EXPR PATTERNS, V4, P371, DOI 10.1016/j.modgep.2004.01.011; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820	53	92	99	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1513	+		10.1096/fj.05-5504fje	http://dx.doi.org/10.1096/fj.05-5504fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16754745				2022-12-28	WOS:000240266000035
J	Bouhy, D; Malgrange, B; Multon, S; Poirrier, AL; Scholtes, F; Schoenen, J; Franzen, R				Bouhy, Delphine; Malgrange, Brigitte; Multon, Sylvie; Poirrier, Anne-Lise; Scholtes, Felix; Schoenen, Jean; Franzen, Rachelle			Delayed GM-CSF treatment stimulates axonal regeneration and functional recovery in paraplegic rats via an increased BDNF expression by endogenous macrophages	FASEB JOURNAL			English	Article						spinal cord injury; axonal regrowth; cytokine; neurotrophin	SPINAL-CORD-INJURY; NECROSIS-FACTOR-ALPHA; NEUROTROPHIC FACTOR; COMPRESSION-INJURY; LOCOMOTOR RECOVERY; UP-REGULATION; BRAIN; PROMOTE; CELLS; TRANSPLANTATION	Macrophages (monocytes/microglia) could play a critical role in central nervous system repair. We have previously found a synchronism between the regression of spontaneous axonal regeneration and the deactivation of macrophages 3-4 wk after a compression-injury of rat spinal cord. To explore whether reactivation of endogenous macrophages might be beneficial for spinal cord repair, we have studied the effects of granulocyte-macrophage colony stimulating factor (GM-CSF) in the same paraplegia model and in cell cultures. There was a significant, though transient, improvement of locomotor recovery after a single delayed intraperitoneal injection of 2 mu g GM-CSF, which also increased significantly the expression of Cr3 and brain-derived neurotrophic factor ( BDNF) by macrophages at the lesion site. At longer survival delays, axonal regeneration was significantly enhanced in GMCSF-treated rats. In vitro, BV2 microglial cells expressed higher levels of BDNF in the presence of GM-CSF and neurons cocultured with microglial cells activated by GM-CSF generated more neurites, an effect blocked by a BDNF antibody. These experiments suggest that GM-CSF could be an interesting treatment option for spinal cord injury and that its beneficial effects might be mediated by BDNF.-Bouhy, D., Malgrange, B., Multon, S., Poirrier, A. L., Scholtes, F., Schoenen, J., Franzen, R. Delayed GM-CSF treatment stimulates axonal regeneration and functional recovery in paraplegic rats via an increased BDNF expression by endogenous macrophages.	Univ Liege, Res Ctr Cellular & Mol Neurobiol, B-4000 Cointe Ougree, Belgium	University of Liege	Franzen, R (corresponding author), Univ Liege, Res Ctr Cellular & Mol Neurobiol, Tour Pathol B36,1er Etage,Local 1-4A, B-4000 Cointe Ougree, Belgium.	rfranzen@ulg.ac.be	malgrange, brigitte/A-4887-2019; Malgrange, Brigitte/F-8384-2010	malgrange, brigitte/0000-0002-8957-2528; Poirrier, Anne-Lise/0000-0002-1247-2334				Ankeny DP, 2001, EXP NEUROL, V170, P85, DOI 10.1006/exnr.2001.7699; Barouch R, 2001, J NEUROIMMUNOL, V112, P72, DOI 10.1016/S0165-5728(00)00408-2; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bomstein Y, 2003, J NEUROIMMUNOL, V142, P10, DOI 10.1016/S0165-5728(03)00260-1; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; Brook GA, 1998, J NEUROSCI RES, V53, P51, DOI 10.1002/(SICI)1097-4547(19980701)53:1<51::AID-JNR6>3.0.CO;2-I; BUNGE RP, 1993, ADV NEUROL, V59, P75; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; COLLINS HL, 1992, EUR J IMMUNOL, V22, P1447, DOI 10.1002/eji.1830220617; DELREE P, 1989, J NEUROSCI RES, V23, P198, DOI 10.1002/jnr.490230210; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Franzen R, 2004, NEUROSCI LETT, V361, P76, DOI 10.1016/j.neulet.2003.12.018; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.0.CO;2-J; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Guner H, 2003, INT J GYNECOL OBSTET, V83, P317, DOI 10.1016/S0020-7292(03)00296-0; Ha Y, 2005, J NEUROSURG-SPINE, V2, P55, DOI 10.3171/spi.2005.2.1.0055; Hashimoto M, 2005, NEUROREPORT, V16, P99, DOI 10.1097/00001756-200502080-00004; Hauben E, 2003, TRENDS PHARMACOL SCI, V24, P7, DOI 10.1016/S0165-6147(02)00013-5; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Ikeda O, 2001, ACTA NEUROPATHOL, V102, P239; KAMEGAI M, 1990, BRAIN RES, V532, P323, DOI 10.1016/0006-8993(90)91775-C; Kannan Y, 2000, NEUROIMMUNOMODULAT, V8, P132, DOI 10.1159/000054273; Kim JK, 2004, NEUROREPORT, V15, P2161, DOI 10.1097/00001756-200410050-00003; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; Koda M, 2004, J NEUROTRAUM, V21, P329, DOI 10.1089/089771504322972112; Lacroix S, 2002, J COMP NEUROL, V454, P213, DOI 10.1002/cne.10407; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; Lu J, 2002, BRAIN, V125, P14, DOI 10.1093/brain/awf014; Mabon PJ, 2000, EXP NEUROL, V166, P52, DOI 10.1006/exnr.2000.7488; Mamounas LA, 2000, J NEUROSCI, V20, P771, DOI 10.1523/JNEUROSCI.20-02-00771.2000; MARTIN D, 1992, J NEUROSCI RES, V32, P539, DOI 10.1002/jnr.490320409; McLay RN, 1997, BRAIN, V120, P2083, DOI 10.1093/brain/120.11.2083; Nakajima K, 2001, J NEUROSCI RES, V65, P322, DOI 10.1002/jnr.1157; Park HC, 2005, TISSUE ENG, V11, P913, DOI 10.1089/ten.2005.11.913; Plant GW, 2003, J NEUROTRAUM, V20, P1, DOI 10.1089/08977150360517146; Poirrier AL, 2004, J NEUROSCI RES, V75, P253, DOI 10.1002/jnr.10852; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Saada A, 1996, J CELL BIOL, V133, P159, DOI 10.1083/jcb.133.1.159; Schwartz M, 1999, NEUROSURGERY, V44, P1041, DOI 10.1097/00006123-199905000-00057; Shibata A, 2003, J NEUROIMMUNOL, V142, P112, DOI 10.1016/S0165-5728(03)00253-4; STERN AC, 1992, INFECTION, V20, pS124, DOI 10.1007/BF01705031; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Verdu E, 2003, GLIA, V42, P275, DOI 10.1002/glia.10217; Watanabe T, 1999, J NEUROTRAUM, V16, P255, DOI 10.1089/neu.1999.16.255; Wu HH, 2003, CANCER-AM CANCER SOC, V98, P2410, DOI 10.1002/cncr.11810; You SW, 2003, RESTOR NEUROL NEUROS, V21, P39; YOUNG W, 1994, ANN NY ACAD SCI, V743, P241, DOI 10.1111/j.1749-6632.1994.tb55796.x; Zylinska K, 1999, Pituitary, V2, P211, DOI 10.1023/A:1009905427902	55	85	87	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1239	+		10.1096/fj.05-4382fje	http://dx.doi.org/10.1096/fj.05-4382fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636109				2022-12-28	WOS:000240210300038
J	Flourakis, M; Van Coppenolle, F; Lehen'kyi, V; Beck, B; Skryma, R; Prevarskaya, N				Flourakis, Matthieu; Van Coppenolle, Fabien; Lehen'kyi, V'yacheslav; Beck, Benjamin; Skryma, Roman; Prevarskaya, Natalia			Passive calcium leak via translocon is a first step for iPLA(2)-pathway regulated store operated channels activation	FASEB JOURNAL			English	Article						calcium leak; store-operated channels; translocon; iPLA2, calcium homeostasis	ENDOPLASMIC-RETICULUM; ER MEMBRANE; PROTEIN TRANSLOCATION; PERMEABILITY; MESSENGER; INFLUX; CELLS; PORE	Calcium concentration within the endoplasmic reticulum ( ER) plays an essential role in cell physiopathology. One of the most enigmatic mechanisms responsible for Ca2+ concentration in the ER is passive calcium leak. Previous studies have shown that the translocon complex is permeable to calcium. However, the involvement of the translocon in the passive calcium leak has not been directly demonstrated. Furthermore, the question whether the passive store depletion via the translocon could activate SOC ( store operated channels) replenishing the ER, remains still unresolved. In this study, for the first time, we show that thapsigargin and calcium chelators deplete ER via translocon. Indeed, using confocal imaging, we demonstrate that when the number of opened translocons was lowered neither thapsigargin nor calcium chelators could induce ER store depletion. We also demonstrate that calcium leakage occurring via the translocon activates store-operated current, which is, by its kinetic and pharmacology, similar to that evoked by thapsigargin and EGTA ( but not IP3), thus highlighting our hypothesis that calcium leakage via the translocon is a first step for activation of the specific iPLA2-regulated SOC. As the translocon is present in yeast and mammalian cells, our findings suggest that translocon-related calcium signaling is a common phenomenon.	Univ Sci & Technol Lille, Lab Physiol Cellulaire, INSERM U800, F-59655 Villeneuve Dascq, France; Univ Lille 1, F-59655 Villeneuve Dascq, France; Equipe Labellisee Ligue Natl Contre Canc, Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille	Flourakis, M (corresponding author), Univ Sci & Technol Lille, Lab Physiol Cellulaire, INSERM U800, Batiment SN3, F-59655 Villeneuve Dascq, France.	flourakismatt@yahoo.fr; fabien.vancoppenolle@univ-lille1.fr; natacha.prevarskaya@univ-lille1.fr	LEHEN'KYI, V'yacheslav/AAJ-6008-2020	LEHEN'KYI, V'yacheslav/0000-0003-0806-8766; Beck, Benjamin/0000-0001-8162-7566; Flourakis, Matthieu/0000-0002-5366-9125; Prevarskaya, natacha/0000-0003-0316-197X				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BOLOTINA VM, 2004, SCI STKE, pPE34; Gregory RB, 1999, BIOCHEM J, V341, P401, DOI 10.1042/0264-6021:3410401; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Heritage D, 2001, J BIOL CHEM, V276, P22655, DOI 10.1074/jbc.M102409200; Hofer AM, 1996, FASEB J, V10, P302, DOI 10.1096/fasebj.10.2.8641563; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; Ioannou M, 1998, MOL PHARMACOL, V53, P1089; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kaneko M, 2003, LIFE SCI, V74, P199, DOI 10.1016/j.lfs.2003.09.007; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; Potter MD, 2002, J BIOL CHEM, V277, P23314, DOI 10.1074/jbc.M202559200; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Roy A, 2003, J BIOL CHEM, V278, P4397, DOI 10.1074/jbc.M207295200; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Van Coppenolle F, 2004, J CELL SCI, V117, P4135, DOI 10.1242/jcs.01274; Vanden Abeele F, 2004, J BIOL CHEM, V279, P30326, DOI 10.1074/jbc.M400106200	25	71	71	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1215	+		10.1096/fj.05-5254fje	http://dx.doi.org/10.1096/fj.05-5254fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16611832				2022-12-28	WOS:000240210300030
J	Li, R; Soosairajah, J; Harari, D; Citri, A; Price, J; Ng, HL; Morton, CJ; Parker, MW; Yarden, Y; Bernard, O				Li, Rong; Soosairajah, Juliana; Harari, Daniel; Citri, Ami; Price, John; Ng, Hooi Ling; Morton, Craig J.; Parker, Michael W.; Yarden, Yosef; Bernard, Ora			Hsp90 increases LIM kinase activity by promoting its homo-dimerization	FASEB JOURNAL			English	Article						Rho-GTPases; actin dynamics; half-life; transphosphorylation	ACTIN DYNAMICS; CHAPERONE COMPLEX; PROTEIN; COFILIN; PHOSPHORYLATION; CANCER; DOMAIN; ERBB-2/HER2; ACTIVATION; REGULATOR	LIM kinase 1 (LIMK1) is a serine protein kinase that regulates the actin cytoskeleton by phosphorylation and inactivation of actin depolymerizing factor cofilin. LIMK1 activity is regulated by the Rho-GTPases via their serine/threonine kinase effectors Rho-kinase and p21-activated kinases 1 and 4 that phosphorylate LIMK1 on threonine 508 in its activation loop. The purpose of this study was to elucidate the pathway leading to the stability of LIMK1, a protein with a half-life of similar to 20 h. Because the half-life of kinase-dead LIMK1 is only 4 h, it is suggestive that trans- or auto-phosphorylation is responsible for the stabilization of LIMK1. Using known Hsp90 inhibitors, we have shown that the half-life of LIMK1 in cells depends on the presence of active Hsp90. Furthermore, endogenous LIMK1 coimmunoprecipitated with endogenous Hsp90 and this interaction promoted LIMK1 homodimer formation as seen by cross-linking experiments. Hsp90 binds LIMK1 via a recognition sequence within the LIMK1 kinase domain, homologous to that of ErbB-2. Mutation of a proline residue within this sequence to glutamic acid reduces its interaction with Hsp90, inhibits homodimer formation, and reduces its half-life to 4 h. These findings implicate Hsp90 in the stabilization of LIMK1 by promoting homodimer formation and transphosphorylation.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Ben Gurion Univ Negev, Bioinformat Support Unit, IL-84105 Beer Sheva, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	St. Vincent's Institute of Medical Research; Walter & Eliza Hall Institute; Ben Gurion University; Weizmann Institute of Science	Bernard, O (corresponding author), St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	obernard@svi.edu.au	Morton, Craig/GON-8638-2022; Parker, Michael W/F-9069-2013; Citri, Ami/R-8973-2019; YARDEN, YOSEF/K-1467-2012	Morton, Craig/0000-0001-5452-5193; Parker, Michael W/0000-0002-3101-1138; Citri, Ami/0000-0002-9914-0278; Price, John/0000-0002-8244-1023				Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Birkenfeld J, 2003, BIOCHEM J, V369, P45, DOI 10.1042/BJ20021152; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Citri A, 2004, EMBO REP, V5, P1165, DOI 10.1038/sj.embor.7400300; Citri A, 2004, CELL CYCLE, V3, P51; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Foletta VC, 2004, EXP CELL RES, V294, P392, DOI 10.1016/j.yexcr.2003.11.024; Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060; Gohla A, 2002, CURR BIOL, V12, P1704, DOI 10.1016/S0960-9822(02)01184-3; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hiraoka J, 1996, FEBS LETT, V399, P117, DOI 10.1016/S0014-5793(96)01303-8; Ikebe C, 1997, GENOMICS, V46, P504, DOI 10.1006/geno.1997.5060; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Murphy PJM, 2003, J BIOL CHEM, V278, P34764, DOI 10.1074/jbc.M304469200; NUNOUE K, 1995, ONCOGENE, V11, P701; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Xu WP, 2005, NAT STRUCT MOL BIOL, V12, P120, DOI 10.1038/nsmb885; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100	28	39	44	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1218	+		10.1096/fj.05-5258fje	http://dx.doi.org/10.1096/fj.05-5258fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16641196				2022-12-28	WOS:000240210300031
J	Schmelter, M; Ateghang, B; Helmig, S; Wartenberg, M; Sauer, H				Schmelter, Maike; Ateghang, Bernadette; Helmig, Simone; Wartenberg, Maria; Sauer, Heinrich			Embryonic stem cells utilize reactive oxygen species as transducers of mechanical strain-induced cardiovascular differentiation	FASEB JOURNAL			English	Article							LAMINAR SHEAR-STRESS; KAPPA-B ACTIVATION; CARDIOMYOCYTE DIFFERENTIATION; TRANSCRIPTION FACTOR; NAD(P)H OXIDASE; CARDIAC-HYPERTROPHY; OXIDATIVE STRESS; CYCLIC STRAIN; IN-VITRO; STRETCH	Growing stem cells are subjected to mechanical forces, which may initiate differentiation programs. Mechanical strain stimulated cardiovascular differentiation of mouse embryonic stem (ES) cells as evaluated by quantification of contracting cardiac foci and capillary areas, respectively. Mechanical strain rapidly elevated intracellular reactive oxygen species (ROS). After 24 h up-regulation of NADPH oxidase subunits p22-phox, p47-phox, p67-phox, and Nox-4 as well as Nox-1 and Nox-4 mRNA was observed. In parallel, mechanical strain increased hypoxia-inducible factor-1 alpha (HIF-1 alpha) and vascular endothelial growth factor (VEGF) mRNA and protein as well as MEF2C and GATA-4 mRNA, which are involved in cardiovascular development. Furthermore, phosphorylation of extracellular-regulated kinase 1,2 (ERK1,2), p38, and c-jun N-terminal kinase (c-Jun NH2-terminal kinase (JNK)) was observed. Stimulation of cardiovascular commitment, HIF-1 alpha, VEGF, and MEF2C expression as well as MAPK activation were abolished by free radical scavengers, whereas GATA-4 expression was increased. Cardiomyogenesis was inhibited by the p38 inhibitor SB203580, the ERK1,2 inhibitor UO126, and the JNK inhibitor SP600125. Vasculogenesis/ angiogenesis was blunted following inhibition of ERK1,2 and JNK, whereas p38 inhibition was ineffective. Our data outline a role of ROS as mechanotransducing molecules in mechanical strain-stimulated cardiovascular differentiation of ES cells, and point toward a microenvironment of elevated ROS required for signaling cascades initiating cardiovascular differentiation programs.	Univ Giessen, Dept Physiol, D-35392 Giessen, Germany; GKSS Res Inst, Dept Cell Biol, Teltow, Germany	Justus Liebig University Giessen; Helmholtz Association; Helmholtz-Zentrum Geesthacht - Zentrum fur Material- und Kustenforschung	Sauer, H (corresponding author), Univ Giessen, Dept Physiol, Aulweg 129, D-35392 Giessen, Germany.	heinrich.sauer@physiologie.med.uni-giessen.de						Aikawa R, 2001, BIOCHEM BIOPH RES CO, V289, P901, DOI 10.1006/bbrc.2001.6068; Ali MH, 2002, CRIT CARE MED, V30, pS198, DOI 10.1097/00003246-200205001-00005; ALI MH, 2004, AM J PHYSL LUNG CELL; Amma H, 2005, BRIT J PHARMACOL, V145, P364, DOI 10.1038/sj.bjp.0706182; Benjamin M., 2003, European Journal of Morphology, V41, P3, DOI 10.1076/ejom.41.1.3.28102; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Chen QH, 2003, J VASC SURG, V37, P660, DOI 10.1067/mva.2003.95; Cowan DB, 2003, ARTERIOSCL THROM VAS, V23, P1754, DOI 10.1161/01.ATV.0000093546.10162.B2; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; Epstein ND, 2003, CELL, V112, P147, DOI 10.1016/S0092-8674(03)00037-0; Grepin C, 1997, DEVELOPMENT, V124, P2387; Griendling KK, 2004, HEART, V90, P491, DOI 10.1136/hrt.2003.029397; Griendling KK, 1999, CIRC RES, V85, P562, DOI 10.1161/01.RES.85.6.562; Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C; Heil M, 2004, CIRC RES, V95, P449, DOI 10.1161/01.RES.0000141145.78900.44; Heng BC, 2004, CARDIOVASC RES, V62, P34, DOI 10.1016/j.cardiores.2003.12.022; Hescheler J, 2002, Methods Mol Biol, V185, P169; Hescheler J, 1999, CELLS TISSUES ORGANS, V165, P153, DOI 10.1159/000016695; Hwang J, 2003, CIRC RES, V93, P1225, DOI 10.1161/01.RES.0000104087.29395.66; HWOARD AB, 1997, AM J PHYSIOL, V272, pC421; Illi B, 2005, CIRC RES, V96, P501, DOI 10.1161/01.RES.0000159181.06379.63; Li YH, 2004, AM J PHYSIOL-HEART C, V287, pH1712, DOI 10.1152/ajpheart.00124.2004; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Liu MY, 2000, J APPL PHYSIOL, V89, P2078, DOI 10.1152/jappl.2000.89.5.2078; Moore KA, 2005, DEV DYNAM, V232, P268, DOI 10.1002/dvdy.20237; Murfee WL, 2004, ANN BIOMED ENG, V32, P1662, DOI 10.1007/s10439-004-7819-0; Na L, 2003, BIRTH DEFECTS RES A, V67, P174, DOI 10.1002/bdra.10030; Nonaka S, 2002, NATURE, V418, P96, DOI 10.1038/nature00849; Park YM, 2004, BIOCHEM BIOPH RES CO, V313, P812, DOI 10.1016/j.bbrc.2003.11.173; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Reckova M, 2003, CIRC RES, V93, P77, DOI 10.1161/01.RES.0000079488.91342.B7; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; Sauer H, 1999, J CELL BIOCHEM, V75, P710, DOI 10.1002/(SICI)1097-4644(19991215)75:4<710::AID-JCB16>3.0.CO;2-Z; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Sauer H, 2005, EXP CELL RES, V304, P380, DOI 10.1016/j.yexcr.2004.11.026; Sauer H, 2004, EXP CELL RES, V294, P313, DOI 10.1016/j.yexcr.2003.10.032; Sauer H, 2000, FEBS LETT, V476, P218, DOI 10.1016/S0014-5793(00)01747-6; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Skalak Thomas C., 1996, Microcirculation (Philadelphia), V3, P143, DOI 10.3109/10739689609148284; Sorescu Dan, 2002, Congest Heart Fail, V8, P132, DOI 10.1111/j.1527-5299.2002.00717.x; Sun HY, 2005, AM J PHYSIOL-HEART C, V288, pH1900, DOI 10.1152/ajpheart.01244.2003; Taber LA, 2001, ANNU REV BIOMED ENG, V3, P1, DOI 10.1146/annurev.bioeng.3.1.1; Tenhunen O, 2004, J BIOL CHEM, V279, P24852, DOI 10.1074/jbc.M314317200; Torres M, 2003, BIOFACTORS, V17, P287, DOI 10.1002/biof.5520170128; TURNER CH, 1995, AM J PHYSIOL, V269, P438; Ushio-Fukai M, 2004, MOL CELL BIOCHEM, V264, P85, DOI 10.1023/B:MCBI.0000044378.09409.b5; Voronov DA, 2004, DEV BIOL, V272, P339, DOI 10.1016/j.ydbio.2004.04.033; Voronov DA, 2002, DEV DYNAM, V224, P413, DOI 10.1002/dvdy.10121; Wang DS, 2001, ENDOTHELIUM-NEW YORK, V8, P283, DOI 10.3109/10623320109090806; Wartenberg M, 2001, FASEB J, V15, P995, DOI 10.1096/fj.00-0350com; Waters CM, 2004, AM J PHYSIOL-LUNG C, V287, pL484, DOI 10.1152/ajplung.00161.2004; Wu R, 2004, J HYPERTENS, V22, P793, DOI 10.1097/00004872-200404000-00023; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yamamoto K, 1999, J BIOL CHEM, V274, P21840, DOI 10.1074/jbc.274.31.21840; Yamamoto K, 2005, AM J PHYSIOL-HEART C, V288, pH1915, DOI 10.1152/ajpheart.00956.2004; Zhao M, 1999, MOL CELL BIOL, V19, P21	56	208	221	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1182	+		10.1096/fj.05-4723fje	http://dx.doi.org/10.1096/fj.05-4723fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16636108				2022-12-28	WOS:000240210300019
J	Zhang, M; Haapasalo, A; Kim, DY; Ingano, LAM; Pettingell, WH; Kovacs, DM				Zhang, Mei; Haapasalo, Annakaisa; Kim, Doo Yeon; Ingano, Laura A. MacKenzie; Pettingell, Warren H.; Kovacs, Dora M.			Presenilin/gamma-secretase activity regulates protein clearance from the endocytic recycling compartment	FASEB JOURNAL			English	Article						amyloid precursor protein; transferrin; trafficking; Alzheimer's disease; neurodegeneration	AMYLOID PRECURSOR PROTEIN; SPORADIC ALZHEIMERS-DISEASE; P75 NEUROTROPHIN RECEPTOR; HAMSTER OVARY CELLS; TRANS-GOLGI NETWORK; GAMMA-SECRETASE; PLASMA-MEMBRANE; BETA-SECRETASE; E-CADHERIN; INTRACELLULAR DOMAIN	The presenilin (PS)/gamma-secretase complex proteolytically cleaves more than 20 different proteins in addition to the amyloid precursor protein (APP). These substrates are almost exclusively type I membrane proteins. Many undergo internalization from the cell surface followed by degradation or recycling back to the plasma membrane through the endocytic recycling compartment (ERC). Evidence shows that the PSs also regulate intracellular trafficking of APP and its C-terminal fragments (CTFs). To investigate whether PS/gamma-secretase activity is required for normal endosomal recycling, we performed live cell imaging experiments with fluorescently labeled transferrin, reported to specifically traffic through the ERC. By using pharmacological gamma-secretase inhibitors or cell lines lacking functional PS/gamma-secretase, here we show that PS/gamma-secretase activity is required for clearance of transferrin from the ERC. Interestingly, lack of PS/gamma-secretase function also resulted in the accumulation of APP and APP-CTFs in the ERC in addition to the cell surface. Familial Alzheimer's disease mutations in APP-CTFs did not affect endocytic recycling of these proteins. Our results suggest that PS/gamma-secretase activity is required for normal endosomal recycling of soluble and membrane- associated proteins through the ERC and propose a new mechanism by which impaired PS/gamma-secretase function may eventually contribute to neurodegeneration.	Synta Pharmaceut Corp, Lexington, MA 02421 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp,Dept Neurol,MIND, Neurobiol Dis Lab,Genet & Aging Res Unit, Charlestown, MA USA	Harvard University; Massachusetts General Hospital	Kovacs, DM (corresponding author), Synta Pharmaceut Corp, 45 Hartwell Ave, Lexington, MA 02421 USA.	dora_kovacs@hms.harvard.edu		Haapasalo, Annakaisa/0000-0003-0959-2957				Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; Beglopoulos V, 2004, J BIOL CHEM, V279, P46907, DOI 10.1074/jbc.M409544200; Bishop NE, 2003, INT REV CYTOL, V232, P1, DOI 10.1016/S0074-7696(03)32001-7; Brodsky F M, 1992, Trends Cell Biol, V2, P109, DOI 10.1016/0962-8924(92)90015-F; Bronfman FC, 2003, J NEUROSCI, V23, P3209; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Cam JA, 2004, J BIOL CHEM, V279, P29639, DOI 10.1074/jbc.M313893200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cataldo AM, 2004, J NEUROPATH EXP NEUR, V63, P821, DOI 10.1093/jnen/63.8.821; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Catalucci A, 2003, RIV NEURORADIOL, V16, P23, DOI 10.1177/19714009030160S102; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; Chyung JH, 2003, J BIOL CHEM, V278, P51035, DOI 10.1074/jbc.M304989200; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Daugherty BL, 2001, TRAFFIC, V2, P908, DOI 10.1034/j.1600-0854.2001.21206.x; DE SB, 1999, NATURE, V398, P518; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Deb S, 2000, BRIT J PSYCHIAT, V176, P468, DOI 10.1192/bjp.176.5.468; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Grant B, 2001, NAT CELL BIOL, V3, P573, DOI 10.1038/35078549; Grbovic OM, 2003, J BIOL CHEM, V278, P31261, DOI 10.1074/jbc.M304122200; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; HYMAN BT, 1995, ARCH NEUROL-CHICAGO, V52, P373, DOI 10.1001/archneur.1995.00540280059019; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kaether C, 2004, J CELL BIOL, V167, P809, DOI 10.1083/jcb.200410090; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kim DY, 2005, J BIOL CHEM, V280, P23251, DOI 10.1074/jbc.M412938200; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Lah JJ, 1997, J NEUROSCI, V17, P1971; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Leem JY, 2002, NEUROBIOL DIS, V11, P64, DOI 10.1006/nbdi.2002.0546; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Ling Y, 2003, INT J BIOCHEM CELL B, V35, P1505, DOI 10.1016/S1357-2725(03)00133-X; Lock JG, 2005, MOL BIOL CELL, V16, P1744, DOI 10.1091/mbc.E04-10-0867; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Mathews PM, 2002, J BIOL CHEM, V277, P36415, DOI 10.1074/jbc.M205208200; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; PASTERNAK SH, 2003, J BIOL CHEM; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Rechards M, 2003, TRAFFIC, V4, P553, DOI 10.1034/j.1600-0854.2003.t01-1-00114.x; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047; Seto ES, 2002, GENE DEV, V16, P1314, DOI 10.1101/gad.989602; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Takahashi RH, 2002, HISTOL HISTOPATHOL, V17, P239, DOI 10.14670/HH-17.239; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Torp R, 2003, NEUROSCIENCE, V120, P291, DOI 10.1016/S0306-4522(03)00320-8; Uemura K, 2003, J NEUROSCI RES, V74, P184, DOI 10.1002/jnr.10753; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VETRIVEL KS, 2004, J BIOL CHEM; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; Wang H, 2004, J BIOL CHEM, V279, P40560, DOI 10.1074/jbc.M404345200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong HK, 2005, J BIOL CHEM, V280, P23009, DOI 10.1074/jbc.M414648200; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; YAMASHIRO DJ, 1984, J CELL BIOCHEM, V26, P231, DOI 10.1002/jcb.240260404; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu WH, 2004, INT J BIOCHEM CELL B, V36, P2531, DOI 10.1016/j.biocel.2004.05.010; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898; Zuk PA, 1999, J BIOL CHEM, V274, P22303, DOI 10.1074/jbc.274.32.22303	96	48	49	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1176	+		10.1096/fj.05-5531fje	http://dx.doi.org/10.1096/fj.05-5531fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16645046				2022-12-28	WOS:000240210300017
J	Bacabac, RG; Smit, TH; Van Loon, JJWA; Doulabi, BZ; Helder, M; Klein-Nulend, J				Bacabac, Rommel G.; Smit, Theo H.; Van Loon, Jack J. W. A.; Doulabi, Behrouz Zandieh; Helder, Marco; Klein-Nulend, Jenneke			Bone cell responses to high-frequency vibration stress: does the nucleus oscillate within the cytoplasm?	FASEB JOURNAL			English	Article						osteoblasts; mechanical loading; NO; prostaglandin; COX-2	NITRIC-OXIDE; SHEAR-STRESS; MECHANICAL STRAIN; LOW-MAGNITUDE; MECHANOTRANSDUCTION; EXERCISE; RATS; OSTEOPENIA	Mechanosensing by cells directs changes in bone mass and structure in response to the challenges of mechanical loading. Low-amplitude, high-frequency loading stimulates bone growth by enhancing bone formation and inhibiting disuse osteoporosis. However, how bone cells sense vibration stress is unknown. Hence, we investigated bone cell responses to vibration stress at a wide frequency range (5-100 Hz). We used NO and prostaglandin E(2) (PGE(2)) release, and COX-2 mRNA expression as parameters for bone cell response since these molecules regulate bone adaptation to mechanical loading. NO release positively correlated whereas PGE2 release negatively correlated to the maximum acceleration rate of the vibration stress. COX-2 mRNA expression increased in a frequency-dependent manner, which relates to increased NO release at high frequencies, confirming our previous results. The negatively correlated release of NO and PGE2 suggests that these signaling molecules play different roles in bone adaptation to high-frequency loading. The maximum acceleration rate is proportional to omega(3) (frequency = omega/2 pi), which is commensurate with the Stokes-Einstein relation for modeling cell nucleus motion within the cytoplasm due to vibration stress. Correlations of NO and PGE(2) with the maximum acceleration rate then relate to nucleus oscillations, providing a physical basis for cellular mechano-sensing of high-frequency loading.	Univ Amsterdam, ACTA, Dept Oral Cell Biol, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Phys & Med Technol, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Dutch Expt Support Ctr, NL-1081 HV Amsterdam, Netherlands	Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Klein-Nulend, J (corresponding author), Univ Amsterdam, ACTA, Dept Oral Cell Biol, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	j.kleinnulend@vumc.nl	Smit, Theodoor/AAX-6657-2020; Smit, Theodoor H/C-5512-2009; Bacabac, Rommel G./F-8605-2012; van Loon, Jack JJWA/A-4250-2013; Smit, Theo/N-7534-2019	Smit, Theo/0000-0002-8906-7433; Zandieh Doulabi, Behrouz/0000-0002-0290-3241; van Loon, Jack/0000-0001-9051-6016; Bacabac, Rommel G./0000-0001-6148-6268				Bacabac RG, 2004, BIOCHEM BIOPH RES CO, V315, P823, DOI 10.1016/j.bbrc.2004.01.138; Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021-9290(00)00231-1; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; Buttery L. D. K., 1995, Bone (New York), V17, P560, DOI 10.1016/8756-3282(96)87796-9; CHOW JWM, 1994, AM J PHYSIOL, V267, P287; Cook S D, 2001, Spine J, V1, P246, DOI 10.1016/S1529-9430(01)00086-9; Forwood MR, 1996, J BONE MINER RES, V11, P1688; Fox SW, 1996, AM J PHYSIOL-ENDOC M, V270, pE955, DOI 10.1152/ajpendo.1996.270.6.E955; Frost HM, 2003, ANAT REC PART A, V275A, P1081, DOI 10.1002/ar.a.10119; Guilak F, 2000, BIOCHEM BIOPH RES CO, V269, P781, DOI 10.1006/bbrc.2000.2360; Hara S, 2001, CALCIFIED TISSUE INT, V68, P23, DOI 10.1007/BF02684999; Honda A, 2003, J APPL PHYSIOL, V95, P1032, DOI 10.1152/japplphysiol.00781.2002; Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116; JONES DB, 1991, BIOMATERIALS, V12, P101, DOI 10.1016/0142-9612(91)90186-E; Kamm RD, 2000, ASME INT C MECH BIOL, V242, P1; Karcher H, 2003, BIOPHYS J, V85, P3336, DOI 10.1016/S0006-3495(03)74753-5; Klein-Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270; KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223-001-1025-y; Mancini L, 1998, BIOCHEM BIOPH RES CO, V243, P785, DOI 10.1006/bbrc.1998.8175; Midura RJ, 2005, MED ENG PHYS, V27, P285, DOI 10.1016/j.medengphy.2004.12.014; Nagano T, 1999, LUMINESCENCE, V14, P283, DOI 10.1002/(SICI)1522-7243(199911/12)14:6<283::AID-BIO572>3.0.CO;2-G; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01-0166com; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012; Rubin CT, 2001, DRUG DISCOV TODAY, V6, P848, DOI 10.1016/S1359-6446(01)01872-4; Taaffe DR, 1997, J BONE MINER RES, V12, P255, DOI 10.1359/jbmr.1997.12.2.255; Tanaka SM, 2003, J BIOMECH, V36, P73, DOI 10.1016/S0021-9290(02)00245-2; Turner CH, 1996, AM J PHYSIOL-ENDOC M, V270, pE634, DOI 10.1152/ajpendo.1996.270.4.E634; TURNER CH, 1995, AM J PHYSIOL, V269, P438; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Warden SJ, 2004, BONE, V34, P261, DOI 10.1016/j.bone.2003.11.011; WEBSTER SSJ, 2001, BONE MECH HDB, P68; Wolff J, 1892, GESETZ TRANSFORMATIO	36	93	102	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					858	864		10.1096/fj.05-4966.com	http://dx.doi.org/10.1096/fj.05-4966.com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16675843				2022-12-28	WOS:000240157700008
J	Qin, HW; Wilson, CA; Lee, SJ; Benveniste, EN				Qin, Hongwei; Wilson, Cynthia A.; Lee, Sun Jung; Benveniste, Etty N.			IFN-beta-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia	FASEB JOURNAL			English	Article						macrophages; microglia	CYTOKINE SIGNALING SOCS; NF-KAPPA-B; IMMUNE-SYSTEM; TRANSCRIPTION; GAMMA; TRANSDUCTION; ACTIVATION; SUPPRESSOR; INDUCTION; INHIBITOR	Costimulation between T cells and antigenpresenting cells is required for adaptive immune responses. CD40, a costimulatory molecule, is expressed in macrophages and microglia. The aberrant expression of CD40 is involved in human diseases including multiple sclerosis, rheumatoid arthritis, and Alzheimer's disease. CD40 expression is induced by a variety of stimuli, including IFN-gamma and lipopolysaccharide (LPS). In this study, we describe the molecular basis by which IFN-beta, a cytokine with immunomodulatory properties, regulates CD40 gene expression. IFN-beta induces CD40 expression in macrophages and microglia at the transcriptional level, and GAS elements in the CD40 promoter are required for IFN-beta-induced CD40 promoter activity. The critical role of signal transducers and activators of transcription-1 alpha (STAT-1 alpha) in this response was confirmed by utilizing primary microglia from STAT-1 alpha deficient mice. IFN-beta induces suppressor of cytokine signaling-1 (SOCS-1) gene expression, which inhibits cytokine signaling by inhibiting activation of STAT proteins. The ectopic expression of SOCS-1 abrogates IFN-beta-mediated STAT-1 alpha activation and inhibits IFN-beta-induced CD40 expression. IFN-beta-induced recruitment of STAT-1 alpha and RNA Pol II and permissive histone modifications on the CD40 promoter are also inhibited by SOCS-1 overexpression. These novel results indicate that IFN-beta-induced SOCS-1 plays an important role in the negative regulation of IFN-beta-induced CD40 gene expression.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Benveniste, EN (corresponding author), Univ Alabama, Dept Cell Biol, 1918 Univ Blvd,MCLM 395, Birmingham, AL 35294 USA.	tika@uab.edu			NIADDK NIH HHS [AM20614] Funding Source: Medline; NIAMS NIH HHS [AR-48311] Funding Source: Medline; NINDS NIH HHS [NS-45290, NS-36765] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036765, R01NS045290] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Bartholome EJ, 2001, J INTERF CYTOK RES, V21, P495, DOI 10.1089/10799900152434367; Belardelli F, 2002, CYTOKINE GROWTH F R, V13, P119, DOI 10.1016/S1359-6101(01)00022-3; Benveniste EN, 2004, BRAIN BEHAV IMMUN, V18, P7, DOI 10.1016/j.bbi.2003.09.001; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Comabella M, 2002, J NEUROIMMUNOL, V126, P205, DOI 10.1016/S0165-5728(02)00064-4; Cooney RN, 2002, SHOCK, V17, P83, DOI 10.1097/00024382-200202000-00001; Dhib-Jalbut S, 1997, MULT SCLER J, V3, P397, DOI 10.1177/135245859700300609; Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9; Ding YZ, 2003, J IMMUNOL, V170, P1383, DOI 10.4049/jimmunol.170.3.1383; Elliott J, 2004, TRENDS IMMUNOL, V25, P434, DOI 10.1016/j.it.2004.05.012; Floris S, 2002, J NEUROIMMUNOL, V127, P69, DOI 10.1016/S0165-5728(02)00098-X; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Hebenstreit D, 2003, J IMMUNOL, V171, P5901, DOI 10.4049/jimmunol.171.11.5901; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Ilangumaran S, 2004, SEMIN IMMUNOL, V16, P351, DOI 10.1016/j.smim.2004.08.015; Jegalian AG, 2002, J BIOL CHEM, V277, P2345, DOI 10.1074/jbc.M105575200; Johnston JA, 2003, NAT IMMUNOL, V4, P507, DOI 10.1038/ni0603-507; Jones J, 2005, VIROLOGY, V331, P106, DOI 10.1016/j.virol.2004.10.013; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Karaghiosoff M, 2003, NAT IMMUNOL, V4, P471, DOI 10.1038/ni910; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Kim MO, 2002, J NEUROCHEM, V81, P1361, DOI 10.1046/j.1471-4159.2002.00949.x; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lin RT, 1999, MOL CELL BIOL, V19, P959; Losman JA, 1999, J IMMUNOL, V162, P3770; LU HT, 1995, J EXP MED, V182, P1517, DOI 10.1084/jem.182.5.1517; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Mostecki J, 2005, J BIOL CHEM, V280, P2596, DOI 10.1074/jbc.M408938200; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Nguyen VT, 2002, J BIOL CHEM, V277, P13796, DOI 10.1074/jbc.M111906200; NORRIS JG, 1993, J NEUROIMMUNOL, V45, P137; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Qin HW, 2005, BLOOD, V106, P3114, DOI 10.1182/blood-2005-02-0759; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Shrikant P, 1996, J IMMUNOL, V156, P1307; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Sporri B, 2001, BLOOD, V97, P221, DOI 10.1182/blood.V97.1.221; Stevenson NJ, 2004, J IMMUNOL, V173, P3243, DOI 10.4049/jimmunol.173.5.3243; Teige I, 2003, J IMMUNOL, V170, P4776, DOI 10.4049/jimmunol.170.9.4776; Travagli J, 2004, J BIOL CHEM, V279, P35183, DOI 10.1074/jbc.M403223200; WANG RK, 2000, P SOC PHOTO-OPT INS, V1, P12; Wesemann DR, 2004, NAT IMMUNOL, V5, P199, DOI 10.1038/ni1025; Wesemann DR, 2002, J IMMUNOL, V169, P2354, DOI 10.4049/jimmunol.169.5.2354; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200	51	63	66	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					985	+		10.1096/fj.05-5493fje	http://dx.doi.org/10.1096/fj.05-5493fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571771				2022-12-28	WOS:000240157700030
J	Leonard, MO; Kieran, NE; Howell, K; Burne, MJ; Varadarajan, R; Dhakshinamoorthy, S; Porter, AG; O'Farrelly, C; Rabb, H; Taylor, CT				Leonard, Martin O.; Kieran, Niamh E.; Howell, Katherine; Burne, Melissa J.; Varadarajan, Raghu; Dhakshinamoorthy, Saravanakumar; Porter, Alan G.; O'Farrelly, Cliona; Rabb, Hamid; Taylor, Cormac T.			Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury	FASEB JOURNAL			English	Article						antioxidant response element; hypoxia; ischemic preconditioning; NQO1	NITRIC-OXIDE; MOLECULAR-MECHANISMS; IDENTIFICATION; PROTECTION; HYPOXIA; PATHWAY; KINASE; INDUCTION; RESPONSES; STRESS	Tissue reoxygenation following hypoxia is associated with ischemia-reperfusion injury (IRI) and may signal the development of ischemic preconditioning, an adaptive state that is protective against subsequent IRI. Here we used microarray RNA analysis of in vivo and in vitro models of IRI to delineate the underlying molecular mechanisms. Microarray analysis of renal tissue after ischemia-reperfusion revealed a number of highly up-regulated antioxidant genes including aldehyde dehydrogenases (ALDH1A1 and ALDH1A7), glutathione S-transferases (GSTM5, GSTA2 and GSTP1), and NAD(P) H quinone oxidoreductase (NQO1). The transcription factor NF-E2-related factor-2 (Nrf2), a master regulator of this antioxidant response, is also elevated in IRI. Furthermore, microarray analysis of renal epithelial cells exposed to hypoxia/reoxygenation identified Nrf2 to be up-regulated on reoxygenation. We also reveal a reoxygenationspecific nuclear accumulation of Nrf2 protein and subsequent activation of a NQO1 promoter reporter construct. Attenuating reactive oxygen species (ROS) in reoxygenation using the antioxidant N-acetyl cysteine results in inhibition of Nrf-2 activation. mRNA levels for Nrf2-dependent genes were detected in human liver biopsy 1 h after transplantation. These results indicate that reoxygenation-dependent Nrf-2 activity facilitates ischemic preconditioning through the induction of antioxidant gene expression and that ROS may be critical in signaling this event.	Univ Coll Dublin, Sch Med & Med Sci, Conway Inst Biomol & Biomed Res, Dublin 2, Ireland; Univ Coll Dublin, St Vincents Univ Hosp, Educ & Res Ctr, Dublin 2, Ireland; Johns Hopkins Univ Hosp, Div Nephrol, Baltimore, MD 21205 USA; Inst Mol & Cell Biol, Singapore, Singapore	University College Dublin; University College Dublin; Saint Vincent's University Hospital; Johns Hopkins University; Johns Hopkins Medicine; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Leonard, MO (corresponding author), Univ Coll Dublin, Sch Med & Med Sci, Conway Inst Biomol & Biomed Res, Dublin 2, Ireland.	martin.leonard@ucd.ie	Leonard, Martin/AAI-2223-2020	Taylor, Cormac/0000-0002-0946-1247; O'Farrelly, Cliona/0000-0002-0616-2874	PHS HHS [R01 N100K] Funding Source: Medline; Wellcome Trust Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); Wellcome Trust(Wellcome TrustEuropean Commission)		Bolli R, 2000, CIRC RES, V87, P972, DOI 10.1161/01.RES.87.11.972; Bonventre JV, 2002, CURR OPIN NEPHROL HY, V11, P43, DOI 10.1097/00041552-200201000-00007; Cutrin JC, 2002, FREE RADICAL BIO MED, V33, P1200, DOI 10.1016/S0891-5849(02)01017-1; Dhakshinamoorthy S, 2004, J BIOL CHEM, V279, P20096, DOI 10.1074/jbc.M312492200; Eisen A, 2004, ATHEROSCLEROSIS, V172, P201, DOI 10.1016/S0021-9150(03)00238-7; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; GLAZIER SS, 1994, J CEREBR BLOOD F MET, V14, P545, DOI 10.1038/jcbfm.1994.68; Griffiths JR, 1999, BRIT J RADIOL, V72, P627, DOI 10.1259/bjr.72.859.10624317; Hotter G, 1996, BIOCHEM BIOPH RES CO, V222, P27, DOI 10.1006/bbrc.1996.0692; Husted Thomas L, 2005, Curr Opin Investig Drugs, V6, P508; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Kaeffer N, 1997, CIRCULATION, V96, P2311; Kharbanda RK, 2001, CIRCULATION, V103, P1624, DOI 10.1161/01.CIR.103.12.1624; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Leonard MO, 2005, J IMMUNOL, V174, P2250, DOI 10.4049/jimmunol.174.4.2250; Leonard MO, 2004, METHOD ENZYMOL, V381, P511; Leonard MO, 2003, J BIOL CHEM, V278, P40296, DOI 10.1074/jbc.M302560200; Leonard MO, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015795.74094.91; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; Mathers J, 2004, BIOCHEM SOC SYMP, V71, P157, DOI 10.1042/bss0710157; Mocanu MM, 2002, J MOL CELL CARDIOL, V34, P661, DOI 10.1006/jmcc.2002.2006; Moens AL, 2005, INT J CARDIOL, V100, P179, DOI 10.1016/j.ijcard.2004.04.013; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nayeem MA, 1997, AM J PHYSIOL-HEART C, V273, pH861, DOI 10.1152/ajpheart.1997.273.2.H861; Node K, 1997, CIRCULATION, V96, P1257, DOI 10.1161/01.CIR.96.4.1257; Park KM, 2003, J BIOL CHEM, V278, P27256, DOI 10.1074/jbc.M301778200; Peralta C, 1996, BIOCHEM BIOPH RES CO, V229, P264, DOI 10.1006/bbrc.1996.1790; Rabb H, 1997, KIDNEY INT, V51, P1463, DOI 10.1038/ki.1997.200; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Sun JZ, 1996, J CLIN INVEST, V97, P562, DOI 10.1172/JCI118449; Tang XL, 2002, AM J PHYSIOL-HEART C, V282, pH281, DOI 10.1152/ajpheart.2002.282.1.H281; Therade-Matharan S, 2004, AM J PHYSIOL-REG I, V287, pR1037, DOI 10.1152/ajpregu.00048.2004; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Tong HY, 2000, CIRC RES, V87, P309, DOI 10.1161/01.RES.87.4.309; Varadarajan R, 2004, TRANSPLANTATION, V78, P250, DOI 10.1097/01.tp.0000128188.45553.8c; WEINBERG JM, 1991, KIDNEY INT, V39, P476, DOI 10.1038/ki.1991.58; YELLON DM, 1995, J MOL CELL CARDIOL, V27, P1023, DOI 10.1016/0022-2828(95)90071-3; Zheng Z, 2003, CURR MOL MED, V3, P361, DOI 10.2174/1566524033479717	42	208	221	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2624	+		10.1096/fj.06-5097fje	http://dx.doi.org/10.1096/fj.06-5097fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17142801				2022-12-28	WOS:000242490700045
J	Qian, H; Martin, RJ; Robertson, AP				Qian, Hai; Martin, Richard J.; Robertson, Alan P.			Pharmacology of N-, L-, and B-subtypes of nematode nAChR resolved at the single-channel level in Ascaris suum	FASEB JOURNAL			English	Article						anthelmintic; levamisole; nicotinic; ACh receptor; patch-clamp	NICOTINIC ACETYLCHOLINE-RECEPTORS; HUMAN HOOKWORM INFECTIONS; LEVAMISOLE RESISTANCE; GENE ENCODES; PYRANTEL; PARAHERQUAMIDE; ANTHELMINTICS; METHYRIDINE; EFFICACY; SUBUNIT	Pharmacological experiments on Ascaris suum have demonstrated the presence of three (N-, L-, and B-) subtypes of cholinergic receptor mediating contraction of body wall muscle in parasitic nematodes (1). In the present study, these ionotropic acetylcholine (ACh) receptors (nAChRs) were activated by levamisole and bephenium under patch-clamp conditions and competitively antagonized by paraherquamide and 2-desoxoparaherquamide. A number of recordings exhibited three separate current amplitude levels, indicating the presence of small, intermediate, and large conductance subtypes of receptor. The mean conductance of the small conductance subtype, G(25), was 22 +/- 1 pS; the intermediate conductance channel, G(35), was 33 +/- 1 pS; and the large conductance channel, G(45), was 45 +/- 1 pS. The small channel was not antagonized significantly by paraherquamide and was identified as the N- subtype. The intermediate channel was preferentially activated by levamisole rather than bephenium and antagonized by paraherquamide: the intermediate channel was identified as the L- subtype. The large conductance channel was preferentially activated by bephenium, antagonized more by 2-desoxoparaherquamde than by paraherquamide and was identified as the B- subtype. These observations reveal that the three channel subtypes have different selectivity for cholinergic anthelmintics. The different selectivity of these compounds should be considered when dealing with drug resistant infections.	Iowa State Univ, Dept Biomed Sci, Coll Vet Med, Ames, IA 50011 USA	Iowa State University	Martin, RJ (corresponding author), Iowa State Univ, Dept Biomed Sci, Coll Vet Med, 2008, Ames, IA 50011 USA.	rjmartin@iastate.edu	Martin, Richard John/A-1783-2011	Martin, Richard John/0000-0003-2422-1847	NIAID NIH HHS [R01 AI47194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047194] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albonico M, 2002, T ROY SOC TROP MED H, V96, P685, DOI 10.1016/S0035-9203(02)90352-4; Blaxter Mark L., 2001, P1, DOI 10.1079/9780851994239.0001; COLQUHOUN D, 1982, BRIT J PHARMACOL, V75, P77, DOI 10.1111/j.1476-5381.1982.tb08759.x; Culetto E, 2004, J BIOL CHEM, V279, P42476, DOI 10.1074/jbc.M404370200; Fleming JT, 1997, J NEUROSCI, V17, P5843; Hoekstra R, 1997, MOL BIOCHEM PARASIT, V84, P179, DOI 10.1016/S0166-6851(96)02793-4; HOLLAND CV, 1989, PARASITOLOGY, V99, P275, DOI 10.1017/S003118200005873X; Horton J, 2003, TRENDS PARASITOL, V19, P527, DOI 10.1016/j.pt.2003.09.007; Jones AK, 2004, BIOESSAYS, V26, P39, DOI 10.1002/bies.10377; Levandoski MM, 2005, INT J PARASITOL, V35, P925, DOI 10.1016/j.ijpara.2005.03.007; Martin RJ, 2004, INT J PARASITOL, V34, P1083, DOI 10.1016/j.ijpara.2004.04.014; Martin RJ, 1998, INT J PARASITOL, V28, P849, DOI 10.1016/S0020-7519(98)00048-4; Martin RJ, 2003, BRIT J PHARMACOL, V140, P1068, DOI 10.1038/sj.bjp.0705528; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; Reynoldson JA, 1997, ACTA TROP, V68, P301, DOI 10.1016/S0001-706X(97)00106-X; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; Robertson AP, 1999, FASEB J, V13, P749, DOI 10.1096/fasebj.13.6.749; Robertson AP, 2002, J PHARMACOL EXP THER, V302, P853, DOI 10.1124/jpet.102.034272; ROBERTSON SJ, 1993, BRIT J PHARMACOL, V108, P170, DOI 10.1111/j.1476-5381.1993.tb13458.x; ROBERTSON SJ, 1993, PESTIC SCI, V37, P293, DOI 10.1002/ps.2780370310; Sacko M, 1999, T ROY SOC TROP MED H, V93, P195, DOI 10.1016/S0035-9203(99)90306-1; Touroutine D, 2005, J BIOL CHEM, V280, P27013, DOI 10.1074/jbc.M502818200; Towers PR, 2005, J NEUROCHEM, V93, P1, DOI 10.1111/j.1471-4159.2004.02951.x; *WHO, 2000, COMM DIS CONTR SCHIS; Wiley LJ, 1997, MOL BIOCHEM PARASIT, V90, P415, DOI 10.1016/S0166-6851(97)00179-5; YAMAZAKI M, 1981, TETRAHEDRON LETT, V22, P135, DOI 10.1016/0040-4039(81)80168-2; Zinser EW, 2002, J VET PHARMACOL THER, V25, P241, DOI 10.1046/j.1365-2885.2002.00423.x	27	58	62	4	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2606	+		10.1096/fj.06-6264fje	http://dx.doi.org/10.1096/fj.06-6264fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17056760				2022-12-28	WOS:000242490700039
J	Sobke, ACS; Selimovic, D; Orlova, V; Hassan, M; Chavakis, T; Athanasopoulos, AN; Schubert, U; Hussain, M; Thiel, G; Preissner, KT; Herrmann, M				Sobke, Astrid C. S.; Selimovic, Dennis; Orlova, Valeria; Hassan, Mohamed; Chavakis, Triantafyllos; Athanasopoulos, Athanasios N.; Schubert, Uwe; Hussain, Muzaffar; Thiel, Gerald; Preissner, Klaus T.; Herrmann, Mathias			The extracellular adherence protein from Staphylococcus aureus abrogates angiogenic responses of endothelial cells by blocking Ras activation	FASEB JOURNAL			English	Article						proliferation; sprouting; tissue factor; ERK1/2; Akt/PKB	NOSOCOMIAL INFECTIONS; KINASE PATHWAY; BINDING; PLATELET-FACTOR-4; PROLIFERATION; ENDOSTATIN; EXPRESSION; IDENTIFICATION; CULTURE; PHASE	The extracellular adherence protein (Eap), a broad-spectrum adhesin secreted by Staphylococcus aureus, was previously shown to curb acute inflammatory responses, presumably through its binding to endothelial cell (EC) ICAM-1. Examining the effect of Eap on endothelial function in more detail, we here show that, in addition, Eap functions as a potent angiostatic agent. Concomitant treatment of EC with purified Eap resulted in the complete blockage of the mitogenic and sprouting responses elicited by vascular endothelial growth factor (VEGF) 165 or basic fibroblast growth factor (bFGF). Moreover, the induction of tissue factor and decay-accelerating factor were repressed by Eap, as determined by qRT-polymerase chain reaction (qRT-PCR), with a corresponding reduction in Egr-1 protein up-regulation seen. This angiostatic activity was accompanied by a corresponding inhibition in ERK1/2 phosphorylation, while activation of p38 was not affected. Inhibition occurred downstream of tyrosine kinase receptor activation, as comparable effects were seen on TPA-induced ERK1/2 phosphorylation. Similar to previously described angiostatic agents like angiopoietin-1 or the 16-kDa prolactin fragment, Eap blockage of the Ras/Raf/MEK/ERK cascade was localized by pull-down assay at the level of Ras activation. Eap's combined anti-inflammmatory and antiangiogenic properties render this bacterial protein not only an important virulence factor during S. aureus infection but open new perspectives for therapeutic applications in pathological neovascularization.	Univ Saarland Hosp, Inst Med Microbiol & Hyg, D-66421 Homburg, Germany; Univ Saarland Hosp, Clin Operat Dent & Periodontol, D-66421 Homburg, Germany; Heidelberg Univ, Dept Internal Med 1, Heidelberg, Germany; Univ Giessen, Inst Biochem, Giessen, Germany; Univ Hosp Munster, Inst Med Microbiol, Munster, Germany; Univ Saarland Hosp, Dept Med Biochem & Mol Biol, Homburg, Germany; Univ Dusseldorf, Dept Dermatol, D-4000 Dusseldorf, Germany	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; University of Munster; Universitatsklinikum des Saarlandes; Heinrich Heine University Dusseldorf	Sobke, ACS (corresponding author), Univ Saarland Hosp, Inst Med Microbiol & Hyg, D-66421 Homburg, Germany.	astrid.sobke@gmx.de	Herrmann, Mathias/B-6475-2013; Orlova, Valeria V/C-6065-2014; Chavakis, Triantafyllos/ABE-8845-2020; Hassan, Mohamed/AHE-7565-2022	Herrmann, Mathias/0000-0003-2638-2257; Orlova, Valeria V/0000-0002-1169-2802; 				Athanasopoulos AN, 2006, BLOOD, V107, P2720, DOI 10.1182/blood-2005-08-3140; Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728; Chen YH, 2003, BIOCHEM BIOPH RES CO, V310, P804, DOI 10.1016/j.bbrc.2003.09.081; Cho CH, 2004, AM J PHYSIOL-HEART C, V286, pH1881, DOI 10.1152/ajpheart.00786.2003; Chu CL, 2004, BIOCHEM J, V379, P331, DOI 10.1042/BJ20031082; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; D'Angelo G, 1999, MOL ENDOCRINOL, V13, P692, DOI 10.1210/me.13.5.692; DAVIET I, 1989, BIOCHEM BIOPH RES CO, V158, P584, DOI 10.1016/S0006-291X(89)80089-0; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Edwards R, 2004, CURR OPIN INFECT DIS, V17, P91, DOI 10.1097/00001432-200404000-00004; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; Fujigaki Y, 1998, J PATHOL, V184, P436; Gaetzner S, 2005, MATRIX BIOL, V23, P557, DOI 10.1016/j.matbio.2004.10.001; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; Goerke C, 2005, INFECT IMMUN, V73, P3415, DOI 10.1128/IAI.73.6.3415-3421.2005; Goerke C, 2004, INT J MED MICROBIOL, V294, P195, DOI 10.1016/j.ijmm.2004.06.013; Gupta K, 1999, Angiogenesis, V3, P147, DOI 10.1023/A:1009018702832; Haggar A, 2004, INFECT IMMUN, V72, P6164, DOI 10.1128/IAI.72.10.6164-6167.2004; Harraghy N, 2005, MICROBIOL-SGM, V151, P1789, DOI 10.1099/mic.0.27902-0; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; Howdieshell TR, 2001, J SURG RES, V96, P173, DOI 10.1006/jsre.2001.6089; Hussain M, 2001, CLIN DIAGN LAB IMMUN, V8, P1271, DOI 10.1128/CDLI.8.6.1271-1276.2001; Hussain M, 2001, J BACTERIOL, V183, P6778, DOI 10.1128/JB.183.23.6778-6786.2001; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jahreis A, 2000, BRIT J DERMATOL, V142, P680, DOI 10.1046/j.1365-2133.2000.03412.x; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x; Lee LY, 2002, J CLIN INVEST, V110, P1461, DOI 10.1172/JC1200216318; Mason JC, 2002, AM J PHYSIOL-CELL PH, V282, pC578, DOI 10.1152/ajpcell.00339.2001; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; Naik MU, 2003, BLOOD, V102, P2108, DOI 10.1182/blood-2003-04-1114; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Nissen NN, 1998, AM J PATHOL, V152, P1445; Pascu C, 1996, CURR MICROBIOL, V32, P201, DOI 10.1007/s002849900036; Perollet C, 1998, BLOOD, V91, P3289, DOI 10.1182/blood.V91.9.3289.3289_3289_3299; Pittet D, 1999, INFECT CONT HOSP EP, V20, P37, DOI 10.1086/501554; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Ridyard MS, 2003, J BIOL CHEM, V278, P13803, DOI 10.1074/jbc.M210245200; Roberts DM, 2004, MOL CELL BIOL, V24, P10515, DOI 10.1128/MCB.24.24.10515-10528.2004; Sachais BS, 2004, SEMIN THROMB HEMOST, V30, P351, DOI 10.1055/s-2004-831048; Sassa Y, 2002, GRAEF ARCH CLIN EXP, V240, P1003, DOI 10.1007/s00417-002-0576-6; Schaberg DR, 1991, AM J MED S3B, V16, P72; SCHOR AM, 1986, MICROVASC RES, V32, P21, DOI 10.1016/0026-2862(86)90041-5; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; Sulpice E, 2002, BLOOD, V100, P3087, DOI 10.1182/blood.V100.9.3087; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Yashima R, 2001, J CELL PHYSIOL, V188, P201, DOI 10.1002/jcp.1107; YOUSIF Y, 1994, APMIS, V102, P891, DOI 10.1111/j.1699-0463.1994.tb05250.x; Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231	54	15	15	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2621	+		10.1096/fj.06-5764fje	http://dx.doi.org/10.1096/fj.06-5764fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077291				2022-12-28	WOS:000242490700044
J	Alvarez, A; Ibiza, S; Hernandez, C; Alvarez-Barrientos, A; Esplugues, JV; Calatayud, S				Alvarez, Angeles; Ibiza, Sales; Hernandez, Carlos; Alvarez-Barrientos, Alberto; Esplugues, Juan V.; Calatayud, Sara			Gastrin induces leukocyte-endothelial cell interactions in vivo and contributes to the inflammation caused by Helicobacter pylori	FASEB JOURNAL			English	Article						CCK-2 receptors; gastrin-releasing peptide	CHOLECYSTOKININ RECEPTORS; SOMATOSTATIN ANALOGS; CHEMOTACTIC ACTIVITY; B/GASTRIN RECEPTORS; SURFACE-PROTEINS; P-SELECTIN; CCK; ADHESION; RELEASE; MECHANISMS	Gastric mucosal inflammation causes hypergastrinemia, and gastrin receptors have been detected in several leukocyte types. We have analyzed whether gastrin affects the leukocyte-endothelial cell interactions in vivo by monitoring leukocyte rolling, adhesion, and emigration in rat mesenteric venules using intravital microscopy. Mesenteric superfusion with exogenous gastrin increased these processes in a concentration-and time-dependent manner, effects prevented by the cholecystokinin (CCK)-2 receptor antagonists (proglumide, L-365,260) but not by the CCK-1 receptor antagonist devazepide. A similar response was induced by exogenous CCK or endogenously released gastrin. CCK-2 receptors were localized in mesenteric macrophages and polymorphonuclear leukocytes. This effect of gastrin is not modulated by somatostatin and is independent of the endogenous release of histamine. To analyze whether hypergastrinemia elicited by Helicobacter pylori ( HP) modulates the inflammation induced by the germ, rats were chronically administered with an extract of a CagA+/VacA+ strain of HP. This protocol increased gastrinemia and induced an inflammatory response in the rat mesentery. Blockade of CCK-2 receptors attenuated this response and induced a qualitative change in the leukocyte infiltrate suggestive of a receding inflammatory process. Our results reveal a new proinflammatory role of gastrin that seems to contribute to the maintenance of the inflammation elicited by HP components.	Univ Valencia, Fac Med, Dept Farmacol, Valencia 46010, Spain; Univ Valencia, Fac Med, Unidad Mixta CNIC UVEG, Valencia 46010, Spain; Fdn Ctr Nacl Invest Cardiovasc, Cytometry Unit, Madrid, Spain	University of Valencia; University of Valencia; Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Esplugues, JV (corresponding author), Univ Valencia, Fac Med, Dept Farmacol, Avd Blasco Ibanez 15, Valencia 46010, Spain.	juan.v.esplugues@uv.es	Calatayud, Sara/ABB-9665-2021; Esplugues, Juan/ABC-1488-2021; SAEZ, CARLOS HERNANDEZ/M-3029-2014; Alvarez-Barrientos, Alberto/L-9299-2014	Calatayud, Sara/0000-0001-9675-2423; SAEZ, CARLOS HERNANDEZ/0000-0001-8536-429X; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Esplugues Mota, Juan Vicente/0000-0001-8205-021X; Ibiza, Sales/0000-0002-0132-2971; Ibiza, Sales/0000-0002-5748-382X; Alvarez, Angeles/0000-0002-2301-9746				Alvarez A, 2004, BLOOD, V104, P402, DOI 10.1182/blood-2003-08-2974; Alvarez A, 2002, CIRC RES, V91, P1142, DOI 10.1161/01.RES.0000046018.23605.3E; ASAKO H, 1994, J CLIN INVEST, V93, P1508, DOI 10.1172/JCI117129; Beales I, 1997, GASTROENTEROLOGY, V113, P465, DOI 10.1053/gast.1997.v113.pm9247465; Blandizzi C, 1999, EUR J PHARMACOL, V373, P71, DOI 10.1016/S0014-2999(99)00212-5; Brzozowski T, 1999, DIGESTION, V60, P22, DOI 10.1159/000007585; Calatayud S, 1999, BRIT J PHARMACOL, V127, P1111, DOI 10.1038/sj.bjp.0702649; Carrasco M, 1997, REGUL PEPTIDES, V70, P135, DOI 10.1016/S0167-0115(97)00025-6; Cong B, 2003, WORLD J GASTROENTERO, V9, P1273, DOI 10.3748/wjg.v9.i6.1273; CRAIG PM, 1992, GUT, V33, P1020, DOI 10.1136/gut.33.8.1020; DECKTOR DL, 1989, J PHARMACOL EXP THER, V249, P1; DeLaFuente M, 1996, PEPTIDES, V17, P219, DOI 10.1016/0196-9781(95)02133-7; DelaFuente M, 1997, J ENDOCRINOL, V153, P475, DOI 10.1677/joe.0.1530475; Dial EJ, 1996, GASTROENTEROLOGY, V110, P801, DOI 10.1053/gast.1996.v110.pm8608890; Dib K, 2000, FRONT BIOSCI-LANDMRK, V5, pD438, DOI 10.2741/Pathology; Dockray G, 2005, PFLUG ARCH EUR J PHY, V449, P344, DOI 10.1007/s00424-004-1347-5; Doong ML, 1998, BRIT J PHARMACOL, V124, P1123, DOI 10.1038/sj.bjp.0701937; Elizalde I, 1997, J CLIN INVEST, V100, P996, DOI 10.1172/JCI119650; ENGSTRAND L, 1995, FEMS IMMUNOL MED MIC, V10, P265; GABOURY JP, 1995, J IMMUNOL, V154, P804; Glatzle J, 2003, J PHYSIOL-LONDON, V550, P657, DOI 10.1113/jphysiol.2003.041673; GRAHAM DY, 1993, SCAND J GASTROENTERO, V28, P690, DOI 10.3109/00365529309098274; Haribabu B, 2000, J EXP MED, V192, P433, DOI 10.1084/jem.192.3.433; Helyes Z, 2001, BRIT J PHARMACOL, V134, P1571, DOI 10.1038/sj.bjp.0704396; Iwata N, 1996, BLOOD, V88, P2683, DOI 10.1182/blood.V88.7.2683.bloodjournal8872683; Jones GE, 2000, J LEUKOCYTE BIOL, V68, P593; Juanola C, 1998, AM J PHYSIOL-GASTR L, V275, pG63, DOI 10.1152/ajpgi.1998.275.1.G63; KARALIS K, 1994, J CLIN INVEST, V93, P2000, DOI 10.1172/JCI117193; KARALIS K, 1995, ENDOCRINOLOGY, V136, P4133, DOI 10.1210/en.136.9.4133; KELLY SM, 1993, DIGEST DIS SCI, V38, P129, DOI 10.1007/BF01296784; KUROSE I, 1994, GASTROENTEROLOGY, V107, P70, DOI 10.1016/0016-5085(94)90062-0; Lehmann FS, 1996, AM J PHYSIOL-GASTR L, V270, pG783, DOI 10.1152/ajpgi.1996.270.5.G783; Ley K, 2002, IMMUNOL REV, V186, P8, DOI 10.1034/j.1600-065X.2002.18602.x; LICHTENBERGER LM, 1995, GASTROENTEROLOGY, V108, P320, DOI 10.1016/0016-5085(95)90056-X; Liu Y, 2005, J CLIN PATHOL, V58, P927, DOI 10.1136/jcp.2003.010710; MAI UEH, 1991, J CLIN INVEST, V87, P894, DOI 10.1172/JCI115095; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; MATHISON R, 1995, J PHARMACOL EXP THER, V273, P337; MEZEY E, 1992, SCIENCE, V258, P1662, DOI 10.1126/science.1333642; Morisset J, 2000, AM J PHYSIOL-GASTR L, V279, pG148, DOI 10.1152/ajpgi.2000.279.1.G148; MOSS SF, 1992, LANCET, V340, P930, DOI 10.1016/0140-6736(92)92816-X; NIELSEN H, 1992, GUT, V33, P738, DOI 10.1136/gut.33.6.738; Niggli V, 2003, INT J BIOCHEM CELL B, V35, P1619, DOI 10.1016/S1357-2725(03)00144-4; ODUM L, 1994, GUT, V35, P615, DOI 10.1136/gut.35.5.615; Piqueras L, 2000, CIRCULATION, V102, P2118, DOI 10.1161/01.CIR.102.17.2118; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Sacerdote P, 1988, Peptides, V9 Suppl 1, P29, DOI 10.1016/0196-9781(88)90219-7; SACERDOTE P, 1991, PEPTIDES, V12, P167, DOI 10.1016/0196-9781(91)90184-Q; Scheiman JM, 1997, GUT, V40, P720, DOI 10.1136/gut.40.6.720; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; Schmitz F, 2001, REGUL PEPTIDES, V101, P25, DOI 10.1016/S0167-0115(01)00281-6; WAGNER S, 1994, AM J GASTROENTEROL, V89, P1211; WALSH JH, 1994, GUT PEPTIDES BIOCH P, P75; Wang L, 1998, BRAIN RES, V791, P157, DOI 10.1016/S0006-8993(98)00091-2; Wank SA, 1998, AM J PHYSIOL-GASTR L, V274, pG607, DOI 10.1152/ajpgi.1998.274.4.G607; Weigert N, 1996, GASTROENTEROLOGY, V110, P147, DOI 10.1053/gast.1996.v110.pm8536851; YOSHIDA N, 1993, GASTROENTEROLOGY, V105, P1431, DOI 10.1016/0016-5085(93)90148-6	57	16	16	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2396	+		10.1096/fj.05-5696fje	http://dx.doi.org/10.1096/fj.05-5696fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17015411				2022-12-28	WOS:000241702600032
J	Spruill, LS; McDermott, PJ				Spruill, Laura S.; McDermott, Paul J.			Regulation of c-jun mRNA expression in adult cardiocytes by MAP kinase interacting kinase-1 (MNK1)	FASEB JOURNAL			English	Article						cardiac hypertrophy; translation; eIF4E; protein synthesis; mRNA stability	INITIATION-FACTOR 4E; ELECTRICALLY STIMULATED CONTRACTION; ACTIVATED PROTEIN-KINASES; GENE-EXPRESSION; SYNTHESIS RATES; FACTOR EIF-4E; PHOSPHORYLATION; TRANSLATION; EIF4E; MECHANISMS	Hypertrophic growth of adult myocardium is associated with increased expression of the early response gene c-jun. The purpose of this study was to determine whether eukaryotic initiation factor (elF) 4E (eIF4E) regulates translational efficiency of c-jun mRNA as measured by flux into polysomes. Adult feline cardiomyocytes in primary culture were treated with 0.2 mu M 12-O-tetradecanoylphorbol 13-acetate (TPA), and c-jun mRNA was quantified in total, monosome, and polysome fractions by real-time polymerase chain reaction. After 1 h, TPA increased total c-jun mRNA by 10.5-fold. The corresponding flux into polysomes was significantly lower (5-fold). Adenoviral-mediated overexpression of either eIF4E or a nonphosphorylatable mutant (S209/A) did not affect total c-jun mRNA or its flux between monosomes and polysomes. Similar results were obtained following overexpression of the eIF4E kinase Mnk1. Thus, translational efficiency of c-jun mRNA was not affected by changes in activity or amount of eIF4E. In contrast, a kinase-deficient Mnk1 mutant significantly reduced total c-jun mRNA from 9.8-fold to 6.0-fold while flux between monosomes and polysomes remained constant. The decrease in total c-jun mRNA resulted from increased decay of c-jun mRNA incorporated into the polysomes. We conclude that Mnk1 activity stabilizes c-jun mRNA in polysomes independent of eIF4E phosphorylation.	Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Charleston, SC 29403 USA; Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	McDermott, PJ (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Strom Thurmond Biomed Res Bldg,Rm 303,114 Dohty, Charleston, SC 29403 USA.	mcdermp@musc.edu			NHLBI NIH HHS [P01 HL-48788] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berenji K, 2005, AM J PHYSIOL-HEART C, V289, pH8, DOI 10.1152/ajpheart.01303.2004; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; Davuluri RV, 2000, GENOME RES, V10, P1807, DOI 10.1101/gr.GR-1460R; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Hannan RD, 2003, CLIN EXP PHARMACOL P, V30, P517, DOI 10.1046/j.1440-1681.2003.03873.x; IVESTER CT, 1995, J BIOL CHEM, V270, P21950, DOI 10.1074/jbc.270.37.21950; IVESTER CT, 1993, AM J PHYSIOL, V265, pH666; KATO S, 1995, AM J PHYSIOL-HEART C, V268, pH2495; Kayahara M, 2005, MOL CELL BIOL, V25, P3784, DOI 10.1128/MCB.25.9.3784-3792.2005; Kim-Mitsuyama S, 2006, GENE THER, V13, P348, DOI 10.1038/sj.gt.3302670; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; MADER S, 1995, MOL CELL BIOL, V15, P4990; MARINO TA, 1985, AM J PHYSIOL, V249, pH371, DOI 10.1152/ajpheart.1985.249.2.H371; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; McKinsey TA, 2005, J CLIN INVEST, V115, P538, DOI 10.1172/JCI200524144; Morgan HE, 1997, MOL CELL BIOCHEM, V176, P145, DOI 10.1023/A:1006855818855; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nadruz W, 2004, AM J PHYSIOL-HEART C, V286, pH760, DOI 10.1152/ajpheart.00430.2003; Nadruz W, 2003, CIRC RES, V92, P243, DOI 10.1161/01.RES.0000053184.94618.97; Nagatomo Y, 1999, AM J PHYSIOL-HEART C, V277, pH2176; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Ramirez CV, 2002, J MOL BIOL, V318, P951, DOI 10.1016/S0022-2836(02)00162-6; Saghir AN, 2001, BIOCHEM J, V356, P557, DOI 10.1042/0264-6021:3560557; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; Taimor G, 2004, AM J PHYSIOL-HEART C, V286, pH2369, DOI 10.1152/ajpheart.00741.2003; Tourriere H, 2002, BIOCHIMIE, V84, P821, DOI 10.1016/S0300-9084(02)01445-1; Tuxworth WJ, 2004, BIOCHEM J, V378, P73, DOI 10.1042/BJ20031027; Tuxworth WJ, 1999, AM J PHYSIOL-HEART C, V277, pH1273, DOI 10.1152/ajpheart.1999.277.4.H1273; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Wada H, 1996, J BIOL CHEM, V271, P8359, DOI 10.1074/jbc.271.14.8359; Wagner RA, 2004, J MOL CELL CARDIOL, V37, P1159, DOI 10.1016/j.yjmcc.2004.09.003; Wang LJ, 2000, AM J PHYSIOL-HEART C, V278, pH1056, DOI 10.1152/ajpheart.2000.278.4.H1056; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Zhao MM, 2004, PHYSIOL GENOMICS, V19, P93, DOI 10.1152/physiolgenomics.00040.2004; Zuberek J, 2003, RNA, V9, P52, DOI 10.1261/rna.2133403; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	48	8	8	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2133	+		10.1096/fj.06-6245fje	http://dx.doi.org/10.1096/fj.06-6245fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16940435				2022-12-28	WOS:000241156900033
J	Irvine, KM; Burns, CJ; Wilks, AF; Su, S; Hume, DA; Sweet, MJ				Irvine, Katharine M.; Burns, Christopher J.; Wilks, Andrew F.; Su, Stephen; Hume, David A.; Sweet, Matthew J.			A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations	FASEB JOURNAL			English	Article						fms; imatinib mesylate; inflammation; BMM; TEPM	COLONY-STIMULATING FACTOR; FACTOR-I RECEPTOR; OF-FUNCTION MUTATIONS; T-CELL PROLIFERATION; GROWTH-FACTOR; C-FMS; TYROSINE KINASE; BACTERIAL LIPOPOLYSACCHARIDE; MONONUCLEAR PHAGOCYTES; SIGNAL-TRANSDUCTION	CSF-1 regulates macrophage differentiation, survival, and function, and is an attractive therapeutic target for chronic inflammation and malignant diseases. Here we describe the effects of a potent and selective inhibitor of CSF-1R -CYC10268 -on CSF1R-dependent signaling. In in vitro kinase assays, CYC10268 was active in the low nanomolar range and showed selectivity over other kinases such as Ab1 and Kit. CYC10268 blocked survival mediated by CSF-1R in primary murine bone marrow-derived macrophages (BMM) and in the factor-dependent cell line Ba/ F3, in which the CSF-1R was ectopically expressed. CYC10268 also inhibited CSF-1 regulated signaling (Akt, ERK-1/ 2), gene expression (urokinase plasminogen activator, toll-like receptor 9, and apolipoprotein E), and priming of LPS-inducible cytokine production in BMM. In thioglycollate-elicited peritoneal macrophages (TEPM), which survive in the absence of exogenous CSF-1, CYC10268 impaired LPS-induced cytokine production and regulated expression of known CSF-1 target genes. These observations support the conclusion that TEPM are CSF-1 autocrine and that CSF-1 plays a central role in macrophage effector functions during inflammation. CSF-1R inhibitors such as CYC10268 provide a powerful tool to dissect the role of the CSF-1/ CSF-1R signaling system in a range of biological systems and have potential for a number of therapeutic applications.	Univ Queensland, Cooperat Res Ctr Chron Inflammatory Dis, Brisbane, Qld, Australia; Univ Queensland, Special Res Ctr Funct & Appl Genom, Inst Mol Biosci, Brisbane, Qld, Australia; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld, Australia	University of Queensland; University of Queensland; University of Queensland	Sweet, MJ (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	m.sweet@imb.uq.edu.au	Hume, David A/C-7695-2013; Sweet, Matthew J/F-2229-2011; Wilks, Andrew F/R-5542-2019; Irvine, Katharine M/A-5559-2011	Sweet, Matthew J/0000-0002-0406-8139; Irvine, Katharine M/0000-0002-6716-1605; Hume, David/0000-0002-2615-1478; Burns, Christopher/0000-0002-4463-4916; Wilks, Andrew F/0000-0002-8554-2399				Agrawal S, 2002, TRENDS MOL MED, V8, P114, DOI 10.1016/S1471-4914(01)02264-X; Aharinejad S, 2004, CANCER RES, V64, P5378, DOI 10.1158/0008-5472.CAN-04-0961; Aharinejad S, 2002, CANCER RES, V62, P5317; Arora A, 2005, J PHARMACOL EXP THER, V315, P971, DOI 10.1124/jpet.105.084145; BACCARINI M, 1992, J IMMUNOL, V149, P2656; Balabanov S, 2005, ANN NY ACAD SCI, V1044, P168, DOI 10.1196/annals.1349.022; Bischof RJ, 2000, CLIN EXP IMMUNOL, V119, P361; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; BURNS CJ, 2003, Patent No. 03099796; Campbell IK, 2000, J LEUKOCYTE BIOL, V68, P144; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; CHAMBERS SK, 1995, CANCER RES, V55, P1578; Chan J, 1998, BLOOD, V92, P1423, DOI 10.1182/blood.V92.4.1423.416k31_1423_1431; Chapoval AI, 1998, J LEUKOCYTE BIOL, V63, P245, DOI 10.1002/jlb.63.2.245; CHEN BDM, 1986, J IMMUNOL, V137, P563; CHODAKEWITZ JA, 1990, J IMMUNOL, V144, P2190; Conway JG, 2005, P NATL ACAD SCI USA, V102, P16078, DOI 10.1073/pnas.0502000102; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood-2004-10-3967; Dey A, 2000, MOL BIOL CELL, V11, P3835, DOI 10.1091/mbc.11.11.3835; Dietz AB, 2004, BLOOD, V104, P1094, DOI 10.1182/blood-2003-12-4266; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DOYLE AG, 1992, INFECT IMMUN, V60, P1465, DOI 10.1128/IAI.60.4.1465-1472.1992; EVANS R, 1992, J LEUKOCYTE BIOL, V51, P93, DOI 10.1002/jlb.51.1.93; Fabbro D, 2002, PHARMACOL THERAPEUT, V93, P79, DOI 10.1016/S0163-7258(02)00179-1; Fixe P, 1997, EUR CYTOKINE NETW, V8, P91; Goyal A, 2002, AM J RESP CELL MOL, V26, P224, DOI 10.1165/ajrcmb.26.2.4640; Guidez F, 1998, MOL CELL BIOL, V18, P3851, DOI 10.1128/MCB.18.7.3851; GUILBERT LJ, 1984, J IMMUNOL METHODS, V73, P17, DOI 10.1016/0022-1759(84)90027-9; Hamilton JA, 2003, J LEUKOCYTE BIOL, V73, P702, DOI 10.1189/jlb.0103037; Hamilton JA, 1997, IMMUNOL TODAY, V18, P313, DOI 10.1016/S0167-5699(97)01084-0; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; HUME DA, 1988, J IMMUNOL, V141, P3405; Isbel NM, 2001, NEPHROL DIAL TRANSPL, V16, P1638, DOI 10.1093/ndt/16.8.1638; KACINSKI BM, 1991, ONCOGENE, V6, P941; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; Kamdar SJ, 1996, CELL IMMUNOL, V174, P165, DOI 10.1006/cimm.1996.0306; Klebl FH, 2001, J PATHOL, V195, P609, DOI 10.1002/path.991; Krieg AM, 2001, CURR OPIN MOL THER, V3, P15; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lenda DM, 2003, J IMMUNOL, V170, P3254, DOI 10.4049/jimmunol.170.6.3254; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin EY, 2002, J MAMMARY GLAND BIOL, V7, P147, DOI 10.1023/A:1020399802795; Moss ST, 2000, IMMUNOBIOLOGY, V202, P18, DOI 10.1016/S0171-2985(00)80048-0; Murray LJ, 2003, CLIN EXP METASTAS, V20, P757, DOI 10.1023/B:CLIN.0000006873.65590.68; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Okada S, 1998, J IMMUNOL, V160, P2590; Okazaki T, 2005, J IMMUNOL, V174, P7531, DOI 10.4049/jimmunol.174.12.7531; Paul S, 2003, CURR OPIN MOL THER, V5, P553; Roth P, 1997, J IMMUNOL, V158, P3874; Sapi E, 1999, P SOC EXP BIOL MED, V220, P1, DOI 10.1046/j.1525-1373.1999.d01-1.x; Seggewiss R, 2005, BLOOD, V105, P2473, DOI 10.1182/blood-2004-07-2527; Sester DP, 1999, J IMMUNOL, V163, P6541; Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200; SHERR CJ, 1992, CIBA F SYMP, V170, P209; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Stewart C C, 1994, Immunol Ser, V60, P3; STEWART CC, 1975, J EXP MED, V141, P1114, DOI 10.1084/jem.141.5.1114; Sudo T, 1995, ONCOGENE, V11, P2469; Sweeney KJ, 2003, SURG J R COLL SURG E, V1, P177, DOI 10.1016/S1479-666X(03)80100-2; Sweet MJ, 2002, J IMMUNOL, V168, P392, DOI 10.4049/jimmunol.168.1.392; Taylor JR, 2006, ONCOGENE, V25, P147, DOI 10.1038/sj.onc.1209007; Toy EP, 2001, GYNECOL ONCOL, V80, P194, DOI 10.1006/gyno.2000.6070; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; Uden M, 1999, ONCOGENE, V18, P3846, DOI 10.1038/sj.onc.1202743; Utsunomiya Y, 1996, CLIN EXP IMMUNOL, V106, P286, DOI 10.1046/j.1365-2249.1996.d01-831.x; Wang HW, 2005, BLOOD, V105, P1135, DOI 10.1182/blood-2004-01-0027; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WiktorJedrzejczak W, 1996, PHYSIOL REV, V76, P927, DOI 10.1152/physrev.1996.76.4.927; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WING EJ, 1986, J IMMUNOL, V137, P2768; Yee LD, 2000, ANTICANCER RES, V20, P4379	82	68	70	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1921	+		10.1096/fj.06-5848fje	http://dx.doi.org/10.1096/fj.06-5848fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877523				2022-12-28	WOS:000240267000031
J	Motzkus, D; Schulz-Maronde, S; Heitland, A; Schulz, A; Forssmann, WG; Jubner, M; Maronde, E				Motzkus, Dirk; Schulz-Maronde, Sandra; Heitland, Aleksandra; Schulz, Axel; Forssmann, Wolf-Georg; Juebner, Martin; Maronde, Erik			The novel beta-defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo	FASEB JOURNAL			English	Article						antimicrobial peptide; LAL-assay; RAW264.7; TNF-alpha; murine sepsis model	HUMAN AIRWAY EPITHELIA; TUMOR-NECROSIS-FACTOR; ANTIMICROBIAL PEPTIDES; BINDING-PROTEIN; ANTIBACTERIAL PEPTIDES; HUMAN BETA-DEFENSIN-3; CATHELICIDIN FAMILY; CATIONIC PEPTIDE; EXPRESSION; CELLS	Defensins are a family of secreted antimicrobial peptides proposed to directly interfere with bacterial membranes. Here we show a functional analysis of the novel beta-defensin DEFB123. A peptide comprising the beta-defensin core region was synthesized and used for our analysis. Like other beta-defensins, DEFB123 exerted antimicrobial activity against a broad spectrum of Gram-positive and Gram-negative bacteria, which was assessed by microbroth dilution assay and radial diffusion zone assay. In addition, the peptide showed lipopolysaccharide (LPS)-binding activity in a Limulus amoebocyte lysate (LAL) assay. Moreover, DEFB123 prevented LPS-induced tumor necrosis factor (TNF)alpha secretion in a murine monocyte cell line (RAW264.7). Accordingly, DEFB123 abolished LPS-mediated MAPK induction in these cells. Protection against LPS-mediated effects was then investigated in a murine model of acute sepsis. Our experiments show that synthetic beta-defensin DEFB123 prevents LPS-induced mortality in C57BL/ 6 mice in a therapeutic approach. We propose that the physiological role of beta-defensins may include interference with LPS-action on macrophages, a function formerly thought to be restricted to the family of cathelicidins, a structurally unrelated group of antimicrobial peptides. -Motzkus, D., Schulz-Maronde, S., Heitland, A., Schulz, A., Forssmann, W.-G., Jubner, M., and Maronde, E. The novel beta-defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo.	IPF PharmaCeut, Hannover, Germany		Maronde, E (corresponding author), Goethe Univ Frankfurt, Inst Anat 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	e.maronde@em.uni-frankfurt.de	Maronde, Erik/J-1915-2019	Maronde, Erik/0000-0002-5574-6323				Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854; Ciornei CD, 2005, ANTIMICROB AGENTS CH, V49, P2845, DOI 10.1128/AAC.49.7.2845-2850.2005; Davidson DJ, 2004, J IMMUNOL, V172, P1146, DOI 10.4049/jimmunol.172.2.1146; Frolich O, 2001, BIOL REPROD, V64, P1072, DOI 10.1095/biolreprod64.4.1072; Garcia JRC, 2001, CELL TISSUE RES, V306, P257, DOI 10.1007/s004410100433; Gough M, 1996, INFECT IMMUN, V64, P4922, DOI 10.1128/IAI.64.12.4922-4927.1996; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hertz CJ, 2001, J IMMUNOL, V166, P2444, DOI 10.4049/jimmunol.166.4.2444; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Hoover DM, 2002, J BIOL CHEM, V277, P37647, DOI 10.1074/jbc.M203907200; Jerala R, 2004, CURR TOP MED CHEM, V4, P1173, DOI 10.2174/1568026043388079; Jia HP, 2001, GENE, V263, P211; Krause A, 2003, PROTEIN SCI, V12, P143, DOI 10.1110/ps.0213603; Krisanaprakornkit S, 2000, INFECT IMMUN, V68, P2907, DOI 10.1128/IAI.68.5.2907-2915.2000; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Maronde E, 1999, J NEUROSCI, V19, P3326; McCray PB, 1997, AM J RESP CELL MOL, V16, P343, DOI 10.1165/ajrcmb.16.3.9070620; Mignon A, 1999, AM J RESP CRIT CARE, V159, P1308, DOI 10.1164/ajrccm.159.4.9712012; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; Mukhopadhyay S, 2004, IMMUNOLOGY, V112, P521, DOI 10.1111/j.1365-2567.2004.01941.x; Nagaoka I, 2002, CLIN DIAGN LAB IMMUN, V9, P972, DOI 10.1128/CDLI.9.5.972-982.2002; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; *NAT COMM CLIN LAB, 2000, M2A7 NAT COMM CLIN L; Niyonsaba F, 2004, IMMUNOLOGY, V111, P273, DOI 10.1111/j.0019-2805.2004.01816.x; Niyonsaba F, 2001, EUR J IMMUNOL, V31, P1066, DOI 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#; Niyonsaba F, 2002, IMMUNOLOGY, V106, P20, DOI 10.1046/j.1365-2567.2002.01398.x; OSTERHOFF C, 1994, BIOL REPROD, V50, P516, DOI 10.1095/biolreprod50.3.516; PIERS KL, 1994, ANTIMICROB AGENTS CH, V38, P2311, DOI 10.1128/AAC.38.10.2311; RITTENHOUSE J, 1984, ANAL BIOCHEM, V138, P442, DOI 10.1016/0003-2697(84)90836-4; Rodriguez-Jimenez FJ, 2003, GENOMICS, V81, P175, DOI 10.1016/S0888-7543(02)00034-4; Ryan LK, 2003, PEPTIDES, V24, P1785, DOI 10.1016/j.peptides.2003.09.021; Schultz J, 2005, STRENGTH COND J, V27, P28; Schulz A, 2005, BIOPOLYMERS, V80, P34, DOI 10.1002/bip.20193; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; Scott MG, 1999, INFECT IMMUN, V67, P6445; Scott MG, 2000, J IMMUNOL, V164, P549, DOI 10.4049/jimmunol.164.2.549; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; SZEWCZYK B, 1985, ANAL BIOCHEM, V150, P403, DOI 10.1016/0003-2697(85)90528-7; Tan NS, 2000, FASEB J, V14, P1801, DOI 10.1096/fj.99-0866com; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Vora P, 2004, J IMMUNOL, V173, P5398, DOI 10.4049/jimmunol.173.9.5398; Wain HM, 2004, NUCLEIC ACIDS RES, V32, pD255, DOI 10.1093/nar/gkh072; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yenugu S, 2004, ENDOCRINOLOGY, V145, P3165, DOI 10.1210/en.2003-1698; Yenugu S, 2003, BIOCHEM J, V372, P473, DOI 10.1042/BJ20020225; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4; Zhou CX, 2004, NAT CELL BIOL, V6, P458, DOI 10.1038/ncb1127	55	66	75	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1701	+		10.1096/fj.05-4970fje	http://dx.doi.org/10.1096/fj.05-4970fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790530				2022-12-28	WOS:000240266600020
J	Tentori, L; Leonetti, C; Scarsella, M; Muzi, A; Mazzon, E; Vergati, M; Forini, O; Lapidus, R; Xu, WZ; Dorio, AS; Zhang, J; Cuzzocrea, S; Graziani, G				Tentori, Lucio; Leonetti, Carlo; Scarsella, Marco; Muzi, Alessia; Mazzon, Emanuela; Vergati, Matteo; Forini, Olindo; Lapidus, Rena; Xu, Weizheng; Dorio, Annalisa Susanna; Zhang, Jie; Cuzzocrea, Salvatore; Graziani, Grazia			Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma	FASEB JOURNAL			English	Article						chemotherapy; cancer; diarrhea; mucositis	PHASE-I TRIAL; CANCER RESISTANCE PROTEIN; NITRO-N-NITROSOGUANIDINE; MISMATCH REPAIR SYSTEM; BASE EXCISION-REPAIR; COLORECTAL-CANCER; TOPOISOMERASE-I; MICROSATELLITE INSTABILITY; ANTITUMOR-ACTIVITY; MALIGNANT GLIOMA	Poly(ADP-ribose) polymerase ( PARP) inhibitors enhance the antitumor activity of the topoisomerase I inhibitor irinotecan (CPT-11), which is used to treat advanced colorectal carcinoma. Since PARP inhibitors sensitize tumor cells also to the methylating agent temozolomide (TMZ) and clinical trials are evaluating CPT-11 in combination with TMZ, we tested whether the PARP inhibitor GPI 15427 (10-(4-methyl-piperazin-1-ylmethyl)-2H- 7-oxa-1,2-diaza-benzo[de]anthracen-3-one) increases the efficacy of CPT-11 + TMZ against colon cancer. Moreover, due to the ability of PARP inhibitors to avoid cell death consequent to PARP-1 overactivation, we evaluated whether oral administration of GPI 15427 provides protection from the dose-limiting intestinal toxicity of CPT-11. The results of colony formation assay indicated that GPI 15427 increased the antiproliferative effects (combination index < 1) of TMZ + SN-38 (the active metabolite of CPT-11) against colon cancer cells. Accordingly, GPI 15427 (40 mg/kg/day x 5 days per os) in combination with TMZ (10 mg/kg/day x 5 days) + CPT-11 (4 mg/kg/day x 5 days) significantly reduced the growth of tumor xenografts. Oral administration of GPI 15427 (40 mg/kg/ q2 x 3 days) prevented intestinal injury and diarrhea induced by CPT-11 (30 mg/kg/day + 3 days) reducing inflammation and PARP-1 overactivation, as evidenced by immunohistochemical staining of intestinal tissue with antipoly(ADP-ribose) antibody ( Ab). In conclusion, the PARP inhibitor represents a novel strategy to enhance the antitumor efficacy and reduce toxicity of chemotherapy in colon cancer.	Univ Roma Tor Vergata, Dept Neurosci, I-00133 Rome, Italy; Inst Canc Res Regina Elena, Expt Clin Lab, Rome, Italy; Univ Messina, Dept Clin & Expt Med & Pharmacol, I-98100 Messina, Italy; IRCCS, Ctr Neurol Bonino Pulejo, Messina, Italy; MGI Pharma, Baltimore, MD USA	University of Rome Tor Vergata; University of Messina; IRCCS Bonino Pulejo	Graziani, G (corresponding author), Univ Roma Tor Vergata, Dept Neurosci, Via Montpellier 1, I-00133 Rome, Italy.	graziani@uniroma2.it	Leonetti, Carlo/B-2860-2018; Mazzon, Emanuela/AAL-4334-2020; Graziani, Grazia/G-5747-2012; Scarsella, Marco/AAA-1486-2020	Leonetti, Carlo/0000-0002-3526-7827; Graziani, Grazia/0000-0002-0221-768X; TENTORI, LUCIO/0000-0002-7691-527X; mazzon, emanuela/0000-0002-5073-717X; Muzi, Alessia/0000-0001-6946-3888; Scarsella, Marco/0000-0002-3386-9664				Bakondi E, 2002, J HISTOCHEM CYTOCHEM, V50, P91, DOI 10.1177/002215540205000110; Benson AB, 2004, J CLIN ONCOL, V22, P2918, DOI 10.1200/jco.2004.04.132; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; Cuzzocrea S, 2005, PHARMACOL RES, V52, P72, DOI 10.1016/j.phrs.2005.02.016; Cuzzocrea S, 2000, FASEB J, V14, P1061, DOI 10.1096/fasebj.14.9.1061; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; Fedier A, 2004, INT J ONCOL, V24, P1039; Fittkau M, 2004, J CANCER RES CLIN, V130, P388, DOI 10.1007/s00432-004-0557-8; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; GIBSON NW, 1986, CANCER RES, V46, P4995; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Houghton PJ, 2000, CLIN CANCER RES, V6, P4110; Idogawa M, 2005, GASTROENTEROLOGY, V128, P1919, DOI 10.1053/j.gastro.2005.03.007; Jacob S, 2001, CANCER RES, V61, P6555; Jones Suzanne F, 2003, Oncology (Williston Park), V17, P41; KOI M, 1994, CANCER RES, V54, P4308; Magrini R, 2002, INT J CANCER, V101, P23, DOI 10.1002/ijc.10565; Malanga M, 2004, J BIOL CHEM, V279, P5244, DOI 10.1074/jbc.C300437200; Mazzon E, 2002, BIOCHEM PHARMACOL, V64, P327, DOI 10.1016/S0006-2952(02)01075-4; Miknyoczki SJ, 2003, MOL CANCER THER, V2, P371; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Patel VJ, 2000, CLIN CANCER RES, V6, P4154; Pourquier P, 2001, CANCER RES, V61, P53; Quinn JA, 2005, J CLIN ONCOL, V23, P7178, DOI 10.1200/JCO.2005.06.502; Rajendra R, 2003, CANCER RES, V63, P3228; Rasheed ZA, 2003, ONCOGENE, V22, P7296, DOI 10.1038/sj.onc.1206935; Reardon DA, 2005, CANCER-AM CANCER SOC, V104, P1478, DOI 10.1002/cncr.21316; Roth RB, 2002, CANCER RES, V62, P656; Rowley PT, 2005, ANNU REV MED, V56, P539, DOI 10.1146/annurev.med.56.061704.135235; Saliba F, 1998, J CLIN ONCOL, V16, P2745, DOI 10.1200/JCO.1998.16.8.2745; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Tentori L, 2005, PHARMACOL RES, V52, P25, DOI 10.1016/j.phrs.2005.02.010; Tentori L, 2005, INT J ONCOL, V27, P525; Tentori L, 2005, INT J ONCOL, V26, P415; Tentori L, 2003, CLIN CANCER RES, V9, P5370; Tentori L, 2002, BLOOD, V99, P2241, DOI 10.1182/blood.V99.6.2241; TENTORI L, 2004, MED CHEM REV ONLINE, V1, P144; Trivedi RN, 2005, CANCER RES, V65, P6394, DOI 10.1158/0008-5472.CAN-05-0715; UMAR A, 1994, J BIOL CHEM, V269, P14367; Wagner LM, 2004, CLIN CANCER RES, V10, P840, DOI 10.1158/1078-0432.CCR-03-0175; Wedge SR, 1996, BRIT J CANCER, V73, P482, DOI 10.1038/bjc.1996.85; Xu-Welliver M, 2002, CARCINOGENESIS, V23, P823, DOI 10.1093/carcin/23.5.823; Yung TMC, 2004, J BIOL CHEM, V279, P39686, DOI 10.1074/jbc.M402729200	48	85	90	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1709	+		10.1096/fj.06-5916fje	http://dx.doi.org/10.1096/fj.06-5916fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16809434				2022-12-28	WOS:000240266600023
J	Ohmori, T; Mimuro, J; Takano, K; Madoiwa, S; Kashiwakura, Y; Ishiwata, A; Niimura, M; Mitomo, K; Tabata, T; Hasegawa, M; Ozawa, K; Sakata, Y				Ohmori, Tsukasa; Mimuro, Jun; Takano, Katsuhiro; Madoiwa, Seiji; Kashiwakura, Yuji; Ishiwata, Akira; Niimura, Masanori; Mitomo, Katsuyuki; Tabata, Toshiaki; Hasegawa, Mamoru; Ozawa, Keiya; Sakata, Yoichi			Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ib alpha promoter: in vivo model for platelet-targeting gene therapy	FASEB JOURNAL			English	Article						hemophilia A; lentiviral vector; stem cell transplantation	FACTOR-VIII GENE; HEMATOPOIETIC STEM-CELLS; HEMOPHILIA-A; PLASMINOGEN-ACTIVATOR; PHENOTYPIC CORRECTION; CD34(+) CELLS; THROMBOPOIETIN; INDUCTION; INTEGRIN; TRANSDUCTION	Platelets release several mediators that modify vascular integrity and hemostasis. In the present study, we developed a technique for efficient transgene expression in platelets in vivo and examined whether this targeted-gene-product delivery system using a platelet release reaction could be exploited for clinical applications. Analysis of luciferase reporter gene constructs driven by platelet-specific promoters (the GPIIb, GPIb alpha, and GPVI) revealed that the GPIb alpha promoter was the most potent in the megakaryoblastic cell line UT-7/TPO and human CD34(+)-derived megakaryocytes. Transduction of UT-7/TPO; CD34(+)-derived megakaryocytes; and c-Kit(+), ScaI(+), and Lineage(-) (KSL) murine hematopoietic stem cells with a simian immunodeficiency virus (SIV)-based lentiviral vector carrying eGFP resulted in efficient, dose-dependent expression of eGFP, and the GPIb alpha promoter seemed to bestow megakaryocytic-specific expression. Transplantation of KSL cells transduced with SIV vector containing eGFP into mice showed that there was preferable expression of eGFP in platelets driven by the GPIb alpha promoter [7-11% for the cytomeglovirus (CMV) promoter, 16-27% for the GPIb alpha promoter]. Furthermore, transplantation of ex vivo-transduced KSL cells by SIV vector carrying human factorVIII (hFVIII) driven by the GPIb alpha promoter induced the production of detectable transcripts of the hFVIII gene and the hFVIII antigen in bone marrow and spleen for at least 90 days and partially corrected the hemophilia A phenotype. Platelet-targeting gene therapy using SIV vectors appears to be promising for gene therapy approaches toward not only inherited platelet diseases but also other hemorrhagic disorders such as hemophilia A.	Jichi Med Sch, Ctr Mol Med, Res Div Cell & Mol Med, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Div Hematol, Dept Med, Minami Kawachi, Tochigi 3290498, Japan; DNAVEC Corp, Ibaraki, Japan; Jichi Med Sch, Ctr Mol Med, Res Div Genet Therapeut, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University; Jichi Medical University; DNAVEC Corporation; Jichi Medical University	Sakata, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Res Div Cell & Mol Med, Minami Kawachi, Tochigi 3290498, Japan.	yoisaka@jichi.ac.jp		OHMORI, TSUKASA/0000-0001-5082-6394				Afshar-Kharghan V, 1999, BLOOD, V94, P186, DOI 10.1182/blood.V94.1.186.413k19_186_191; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Fang J, 2005, BLOOD, V106, P2671, DOI 10.1182/blood-2004-12-4619; Flaumenhaft R, 2003, ARTERIOSCL THROM VAS, V23, P1152, DOI 10.1161/01.ATV.0000075965.88456.48; Haas DL, 2000, MOL THER, V2, P71, DOI 10.1006/mthe.2000.0094; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; High K, 2005, J THROMB HAEMOST, V3, P1682, DOI 10.1111/j.1538-7836.2005.01460.x; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; Holmes ML, 2002, J BIOL CHEM, V277, P48333, DOI 10.1074/jbc.M206127200; HOYER LW, 1994, NEW ENGL J MED, V330, P38, DOI 10.1056/NEJM199401063300108; Kikuchi J, 2004, J GENE MED, V6, P1049, DOI 10.1002/jgm.609; Komatsu N, 1996, BLOOD, V87, P4552, DOI 10.1182/blood.V87.11.4552.bloodjournal87114552; KONKLE BA, 1990, J BIOL CHEM, V265, P19833; Kootstra NA, 2003, MOL THER, V7, P623, DOI 10.1016/S1525-0016(03)00073-X; Kufrin D, 2003, BLOOD, V102, P926, DOI 10.1182/blood-2003-01-0054; Lepage A, 2000, BLOOD, V96, P4169, DOI 10.1182/blood.V96.13.4169.h8004169_4169_4177; LIND P, 1995, EUR J BIOCHEM, V232, P19, DOI 10.1111/j.1432-1033.1995.tb20776.x; Lozier J, 2004, SEMIN HEMATOL, V41, P287, DOI 10.1053/j.seminhematol.2004.07.005; Madoiwa S, 2004, J THROMB HAEMOST, V2, P754, DOI 10.1111/j.1538-7933.2004.00671.x; Majka M, 1999, J CLIN INVEST, V104, P1739, DOI 10.1172/JCI7779; Mimuro J, 2001, GENE THER, V8, P1690, DOI 10.1038/sj.gt.3301579; Moayeri M, 2005, MOL THER, V12, P1034, DOI 10.1016/j.ymthe.2005.09.007; Moayeri M, 2004, MOL THER, V10, P892, DOI 10.1016/j.ymthe.2004.08.006; Mostoslavsky G, 2005, MOL THER, V11, P932, DOI 10.1016/j.ymthe.2005.01.005; Nakajima T, 2000, HUM GENE THER, V11, P1863, DOI 10.1089/10430340050129486; Nakauchi H, 2001, ANN NY ACAD SCI, V938, P18; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; Rendu F, 2001, PLATELETS, V12, P261, DOI 10.1080/09537100120068170; Sun B, 2003, PLATELETS, V14, P225, DOI 10.1080/0953710031000118858; Tropel P, 1997, BLOOD, V90, P2995, DOI 10.1182/blood.V90.8.2995; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; Wahlers A, 2001, GENE THER, V8, P477, DOI 10.1038/sj.gt.3301426; Wilcox DA, 2000, BLOOD, V95, P3645; Wilcox DA, 2003, J THROMB HAEMOST, V1, P2477, DOI 10.1111/j.1538-7836.2003.00534.x; Wilcox DA, 2003, J THROMB HAEMOST, V1, P2300, DOI 10.1046/j.1538-7836.2003.00476.x; Woods NB, 2002, LEUKEMIA, V16, P563, DOI 10.1038/sj.leu.2402447; Yarovoi HV, 2003, BLOOD, V102, P4006, DOI 10.1182/blood-2003-05-1519	38	43	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1522	+		10.1096/fj.05-5161fje	http://dx.doi.org/10.1096/fj.05-5161fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16723382				2022-12-28	WOS:000240266000038
J	Selby, CC				Selby, Cecily Cannan			Does bias in science hold women back?	FASEB JOURNAL			English	Article									NYU, Steinhardt Sch Educ, New York, NY USA	New York University	Selby, CC (corresponding author), 1 E 66th St, New York, NY 10021 USA.	selbyc@aol.com						*AM AC ART SCI, 1978, DAEDALUS, V103; EINSTEIN A, 1934, WORLD SEE IT, P290; EISENHART MA, 1998, WOMENS SCI LEARNING, P281; FRUTON J. F., 1990, MEMOIRS SERIES, V191, P473; GEORGI H, 1999, NAT AC SCI WHO SCI F; GLADFELTER E, 2002, AGASSIZS LEGACY SCI, P437; Holton G, 1999, ANN NY ACAD SCI, V869, P78, DOI 10.1111/j.1749-6632.1999.tb08357.x; HOLTON G, 2001, PROPOSAL DEV TESTING, P14; HUBBARD R, 1976, IDEOLOGY NATURAL SCI, P363; KELLER EF, 1975, SEX SCI INQUIRY, P233; Medawar P. B., 1979, ADVICE YOUNG SCI; MEDAWAR PB, 1974, HOPE PROGR; *NAT SCI BOARD, 2004, SCI ENG IND; NEGROPONTE N, 2003, TECHNOL REV, V106, P34; Popper K, 1983, REALISM AIM SCI POST; Popper K. R., 1963, CONJECTURES REFUTAT; SCHIEBINGER LL, 1999, FEMINISM CHANGED SCI; Selby, 2006, NEW YORK ACAD SC MAY, P10; SELBY CC, 2006, IN PRESS J COLL SCI; SEYMOUR E, 1997, TALKING LEAVING UNDE; VALIAN V, 1998, WHY SLOW ADVANCEMENT; 2000, MIT FACULTY NEWS LET	22	2	2	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1284	1287		10.1096/fj.06-0703ufm	http://dx.doi.org/10.1096/fj.06-0703ufm			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816101				2022-12-28	WOS:000240266000003
J	Sun, XL; He, GQ; Song, WH				Sun, Xiulian; He, Guiqiong; Song, Weihong			BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome	FASEB JOURNAL			English	Article						BACE2; theta-secretase; Alzheimer; Down syndrome; Trisomy 21	AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; TRANSCRIPTIONAL REGULATION; ENZYMATIC-ACTIVITY; ASPARTYL PROTEASE; CRYSTAL-STRUCTURE; CLEAVING ENZYME; GENE-EXPRESSION; GENOME SCREEN; KNOCKOUT MICE	Amyloid beta protein (A beta), the major component of neuritic plaques in Alzheimer's disease (AD), is derived from APP by sequential cleavages of beta- and gamma-secretases. Beta-site APP cleaving enzyme 1 (BACE1) is the major beta-secretase in vivo. Beta-site APP cleaving enzyme 2 (BACE2) is the homologue of BACE1. The majority of people with Down syndrome (DS), also called Trisomy 21 syndrome, will develop AD neuropathology after middle age. We and others have shown that APP C99, the major beta-secretase product, and A beta are markedly increased in DS. Since BACE2 is located on chromosome 21, it is speculated that BACE2 may play a role in AD pathogenesis in DS. In this report we found that BACE2 cleaves APP at a novel theta site downstream of the alpha site, abolishing A beta production. Overexpression of BACE2 by lentivirus markedly reduced A beta production in primary neurons derived from Swedish mutant APP transgenic mice. Despite an extra copy of the BACE2 gene in DS and the increase of its transcription, BACE2 protein levels are unchanged. Our data clearly demonstrate that BACE2, as a novel theta-secretase to cleave APP within the A beta domain, is not involved in the AD pathogenesis of DS patients; instead, therapeutic interventions that potentiate BACE2 may prevent AD pathogenesis.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Grad Program Neurosci, Vancouver, BC V6T 1Z3, Canada; Chongqing Univ Med Sci, Dept Human Anat, Chongqing, Peoples R China	University of British Columbia; University of British Columbia; Chongqing Medical University	Song, WH (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	weihong@interchange.ubc.ca	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Basi G, 2003, J BIOL CHEM, V278, P31512, DOI 10.1074/jbc.M300169200; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Blacker D, 2003, HUM MOL GENET, V12, P23, DOI 10.1093/hmg/ddg007; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Charlwood J, 2001, J BIOL CHEM, V276, P16739, DOI 10.1074/jbc.M009361200; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Cruts M, 2001, NEUROSCI LETT, V313, P105, DOI 10.1016/S0304-3940(01)02234-0; DE SB, 1999, NATURE, V398, P518; Dittgen T, 2004, P NATL ACAD SCI USA, V101, P18206, DOI 10.1073/pnas.0407976101; Dominguez D, 2005, J BIOL CHEM, V280, P30797, DOI 10.1074/jbc.M505249200; Down J. T., 1866, LONDON HOSP REPORTS, V3, P259; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDIN LR, 1993, GENET EPIDEMIOL, V10, P449, DOI 10.1002/gepi.1370100620; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HESTON LL, 1991, AM J MED GENET, V40, P449, DOI 10.1002/ajmg.1320400415; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Hong L, 2002, BIOCHEMISTRY-US, V41, P10963, DOI 10.1021/bi026232n; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Hussain I, 2001, J BIOL CHEM, V276, P23322, DOI 10.1074/jbc.M101069200; JACOBS PA, 1959, LANCET, V1, P710; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; LEJEUNE J., 1959, BULL ACAD NATL MED [PARIS], V143, P256; Li Y, 2006, FASEB J, V20, P285, DOI 10.1096/fj.05-4986com; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Myers A, 2002, AM J MED GENET, V114, P235, DOI 10.1002/ajmg.10183; Myllykangas L, 2005, J NEUROL SCI, V236, P17, DOI 10.1016/j.jns.2005.04.008; Nicolaou M, 2001, NEUROGENETICS, V3, P203; Ostermann N, 2006, J MOL BIOL, V355, P249, DOI 10.1016/j.jmb.2005.10.027; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PODLISNY MB, 1987, SCIENCE, V238, P669, DOI 10.1126/science.2960019; Qing H, 2004, FASEB J, V18, P1571, DOI 10.1096/fj.04-1994fje; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Solans A, 2000, CYTOGENET CELL GENET, V89, P177, DOI 10.1159/000015608; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Sun XL, 2006, FASEB J, V20, P1361, DOI 10.1096/fj.05-5628com; Sun XL, 2005, FASEB J, V19, P739, DOI 10.1096/fj.04-3426com; Van Dam D, 2003, EUR J NEUROSCI, V17, P388, DOI 10.1046/j.1460-9568.2003.02444.x; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108; Zhou WH, 2006, MOL CELL BIOL, V26, P3353, DOI 10.1128/MCB.26.9.3353-3364.2006	66	122	130	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1369	1376		10.1096/FJ.05-5632COM	http://dx.doi.org/10.1096/FJ.05-5632COM			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816112				2022-12-28	WOS:000240266000014
J	Tancevski, I; Wehinger, A; Schgoer, W; Eller, P; Cuzzocrea, S; Foeger, B; Patsch, JR; Ritsch, A				Tancevski, Ivan; Wehinger, Andreas; Schgoer, Wilfried; Eller, Philipp; Cuzzocrea, Salvatore; Foeger, Bernhard; Patsch, Josef R.; Ritsch, Andreas			Aspirin regulates expression and function of scavenger receptor-BI in macrophages: studies in primary human macrophages and in mice	FASEB JOURNAL			English	Article						SR-BI; PPAR; KO mice; NF-kappa B	FACTOR-KAPPA-B; SR-BI; CELL-PROLIFERATION; CHOLESTEROL; INHIBITION; PROTEIN; IDENTIFICATION; SALICYLATES; ACTIVATION; PLASMA	Scavenger receptor class B type I (SR-BI) has been shown to be expressed in human atherosclerotic plaque macrophages, where it is believed to reduce atherosclerosis by promoting cholesterol efflux. In this study we investigated the influence of aspirin and other NSAIDs on SR-BI expression and function in cultured human macrophages as well as in different mouse strains. Incubation of human macrophages with 0.5 mmol/l aspirin resulted in increased SR-BI protein expression and increased uptake of HDL-associated [H-3]cholesteryl oleate without changes of SR-BI mRNA levels. In contrast, using 5 mmol/l of aspirin, SR-BI expression and function were significantly decreased. Sodium salicylate exerted similar effects on SR-BI expression, whereas no effects were observed using known COX1/2 inhibitors ibuprofen and naproxen, respectively. In in vivo studies low-dose aspirin treatment (6 mg/kg(.)day) induced SR-BI expression in wildtype and PPAR-alpha knockout mice, respectively, whereas the opposite effect was observed upon high-dose aspirin treatment (60 mg/kg(.)day) in these animals. We could show that COX-independent effects of aspirin were able to enhance expression of SR-BI in macrophages in a post-transcriptional, PPAR-alpha independent	Innsbruck Med Univ, Dept Internal Med, A-6020 Innsbruck, Austria; Univ Messina, Dipartimento Clin & Sperimentale Med & Farmacol, Ctr Studio & Trattamento Neurol Lungodegenti, Fac Med & Chirurg, Messina, Italy	Medical University of Innsbruck; University of Messina	Ritsch, A (corresponding author), Innsbruck Med Univ, Dept Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.	andreas.ritsch@uibk.ac.at	Tancevski, Ivan/AID-5169-2022	Tancevski, Ivan/0000-0001-5116-8960; Ritsch, Andreas/0000-0002-0417-5161				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Awtry EH, 2000, CIRCULATION, V101, P1206, DOI 10.1161/01.CIR.101.10.1206; Bell E, 2003, DIABETES, V52, P2731, DOI 10.2337/diabetes.52.11.2731; CALVO D, 1993, J BIOL CHEM, V268, P18929; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Connelly MA, 2004, CURR OPIN LIPIDOL, V15, P287, DOI 10.1097/00041433-200406000-00008; CRONSTEIN BN, 1995, ANNU REV PHARMACOL, V35, P449, DOI 10.1146/annurev.pa.35.040195.002313; Cronstein BN, 1999, P NATL ACAD SCI USA, V96, P6377, DOI 10.1073/pnas.96.11.6377; Cuzzocrea S, 2004, LAB INVEST, V84, P1643, DOI 10.1038/labinvest.3700185; Cyrus T, 2002, CIRCULATION, V106, P1282, DOI 10.1161/01.CIR.0000027816.54430.96; de la Llera-Moya M, 2001, J LIPID RES, V42, P1969; de Winther MPJ, 2005, ARTERIOSCL THROM VAS, V25, P904, DOI 10.1161/01.ATV.0000160340.72641.87; Dichtl W, 1999, CIRC RES, V84, P1085, DOI 10.1161/01.RES.84.9.1085; Garcia-Martinez JM, 2003, BIOCHEM PHARMACOL, V65, P209, DOI 10.1016/S0006-2952(02)01511-3; Hirano K, 1999, CIRC RES, V85, P108; Jans DM, 2004, J CARDIOVASC PHARM, V43, P462, DOI 10.1097/00005344-200403000-00019; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Kagawa A, 1999, J BIOL CHEM, V274, P34111, DOI 10.1074/jbc.274.48.34111; Kaser S, 2001, METABOLISM, V50, P723, DOI 10.1053/meta.2001.23307; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Martel-Pelletier J, 2004, ARTHRITIS RHEUM-US, V50, P3925, DOI 10.1002/art.20632; Matasic R, 2000, IMMUNOLOGY, V101, P53, DOI 10.1046/j.1365-2567.2000.00065.x; Mouithys-Mickalad A, 2004, BIOCHEM BIOPH RES CO, V325, P1122, DOI 10.1016/j.bbrc.2004.10.155; PATSCH JR, 1974, J LIPID RES, V15, P356; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; Planaguma A, 2002, FASEB J, V16, P1937, DOI 10.1096/fj.02-0224fje; Ranganathan S, 2003, BIOCHEM BIOPH RES CO, V301, P143, DOI 10.1016/S0006-291X(02)02987-X; RECALDE HR, 1984, J IMMUNOL METHODS, V69, P71, DOI 10.1016/0022-1759(84)90278-3; Ritsch A, 2004, J LIPID RES, V45, P214, DOI 10.1194/jlr.M300353-JLR200; Silver DL, 2004, REV ENDOCR METAB DIS, V5, P327, DOI 10.1023/B:REMD.0000045104.38104.8e; Tancevski I, 2005, J MOL MED, V83, P927, DOI 10.1007/s00109-005-0695-8; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Van Eck M, 2004, AM J PATHOL, V165, P785, DOI 10.1016/S0002-9440(10)63341-X; Vinals M, 2005, CARDIOVASC RES, V66, P141, DOI 10.1016/j.cardiores.2004.12.024; Voisard R, 2001, CIRCULATION, V103, P1688, DOI 10.1161/01.CIR.103.12.1688; Yesilaltay A, 2005, CURR OPIN LIPIDOL, V16, P147, DOI 10.1097/01.mol.0000162319.54795.e5	40	16	17	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1328	1335		10.1096/fj.05-5368com	http://dx.doi.org/10.1096/fj.05-5368com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816107				2022-12-28	WOS:000240266000009
J	Blanke, S; Jackle, H				Blanke, Stephen; Jaeckle, Herbert			Novel guanine nucleotide exchange factor GEFmeso of Drosophila melanogaster interacts with ral and rho GTPase Cdc42	FASEB JOURNAL			English	Article						DH domain; gastrulation; DRal activity	ACTIVATING PROTEIN; STRUCTURAL BASIS; DBL FAMILY; IDENTIFICATION; EFFECTOR; EXOCYST; ARF; MECHANISMS; HOMOLOGY; PATHWAY	This article reports the identification and characterization of a DBL-like guanine nucleotide exchange factor (GEF) in Drosophila, called GEFmeso, as a novel binding target of the Ras-like GTPase Ral. Previous studies suggested that some aspects of Ral activity, which is involved in multiple cellular processes, are mediated through regulation of Rho GTPases. Here we show in vitro association of GEFmeso with the GTP-bound active form of Ral and the nucleotide-free form of the Rho GTPase Cdc42. GEFmeso fails to bind to other Rho GTPases, showing that Cdc42 is a specific interaction partner of this GEF. Unlike Ral and Cdc42, which are ubiquitously expressed, GEFmeso exerts distinct spatio-temporal expression patterns during embryonic development, suggesting a tissue-restricted function of the GEF in vivo. Based on previous observations that mutations in Cdc42 or overexpression of mutant alleles of Cdc42 lead to distinct effects on wing development, the effects of overexpression of dominant-negative and activated versions of Ral on wing development were analyzed. In addition, GEFmeso overexpression studies as well as RNAi experiments were performed. The results suggest that Ral, GEFmeso and Cdc42 act in the same developmental pathway and that GEFmeso mediates activation of Cdc42 in response to activated Ral in the context of Drosophila wing development. -Blanke, S., Jackle, H. Novel guanine nucleotide exchange factor GEFmeso of Drosophila melanogaster interacts with Ral and Rho GTPase Cdc42.	Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, D-37077 Gottingen, Germany	Max Planck Society	Jackle, H (corresponding author), Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, Fassberg 11, D-37077 Gottingen, Germany.	vp-bms@gv.mpg.de						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Baron M, 2000, MOL GEN GENET, V264, P98, DOI 10.1007/s004380000287; Bhullar RP, 1996, BBA-MOL CELL RES, V1311, P181, DOI 10.1016/0167-4889(96)00002-X; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; EMKEY R, 1991, J BIOL CHEM, V266, P9703; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Frankel P, 2005, EMBO J, V24, P54, DOI 10.1038/sj.emboj.7600497; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Geneva JL, 2000, DEV BIOL, V221, P181, DOI 10.1006/dbio.2000.9671; Gildea JJ, 2002, CANCER RES, V62, P982; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Mirey G, 2003, MOL CELL BIOL, V23, P1112, DOI 10.1128/MCB.23.3.1112-1124.2003; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Park SH, 1995, ONCOGENE, V11, P2349; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Sawamoto K, 1999, J CELL BIOL, V146, P361, DOI 10.1083/jcb.146.2.361; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VAN AL, 1997, GENE DEV, V11, P2295; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	42	9	9	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					683	691		10.1096/fj.05-5376com	http://dx.doi.org/10.1096/fj.05-5376com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581976				2022-12-28	WOS:000240130900014
J	Dirkx, AEM; Egbrink, MGAO; Castermans, K; van der Schaft, DWJ; Thijssen, VLJL; Dings, RPM; Kwee, L; Mayo, KH; Wagstaff, J; Steege, JCABT; Griffioen, AW				Dirkx, Anita E. M.; Egbrink, Mirjam G. A. oude; Castermans, Karolien; van der Schaft, Daisy W. J.; Thijssen, Victor L. J. L.; Dings, Ruud P. M.; Kwee, Lucy; Mayo, Kevin H.; Wagstaff, John; Steege, Jessica C. A. Bouma-ter; Griffioen, Arjan W.			Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors	FASEB JOURNAL			English	Article						angiogenesis; endothelial adhesion molecules; anginex; endostatin	ADHESION MOLECULE-1 EXPRESSION; FIBROBLAST-GROWTH-FACTOR; TRANSENDOTHELIAL MIGRATION; HUMAN MALIGNANCIES; IN-VITRO; BREAST; CANCER; IMMUNOTHERAPY; ANGIOSTATIN; INHIBITOR	Tumor escape from immunity, as well as the failure of several anti-cancer vaccination and cellular immunotherapy approaches, is suggested to be due to the angiogenesis-mediated suppression of endothelial cell (EC) adhesion molecules involved in leukocyte-vessel wall interactions. We hypothesized that inhibition of angiogenesis would overcome this escape from immunity. We investigated this in vivo by means of intravital microscopy and ex vivo by immunohistochemistry in two mouse tumor models. Angiogenesis inhibitors anginex, endostatin, and angiostatin, and the chemotherapeutic agent paclitaxel were found to significantly stimulate leukocyte-vessel wall interactions by circumvention of EC anergy in vivo, i.e., by the up-regulation of endothelial adhesion molecules in tumor vessels. This was confirmed by in vitro studies of cultured EC at the protein and mRNA levels. The new angiostatic designer peptide anginex was most potent at overcoming EC anergy; the enhanced leuko cyte-vessel interactions led to an increase in the numbers of tumor infiltrating leukocytes. While anginex inhibited tumor growth and microvessel density significantly, the amount of infiltrated leukocytes (CD45), as well as the number of CD8(+) cytotoxic T lymphocytes, was enhanced markedly. The current results suggest that immunotherapy strategies can be improved by combination with anti-angiogenesis. -Dirkx, A. E. M., oude Egbrink, M. G. A., Castermans, K., van der Schaft, D. W. J., Thijssen, V. L. J. L., Dings, R. P. M., Kwee, L., Mayo, K. H., Wagstaff, J., Bouma-ter Steege, J. C. A., Griffioen, A. W. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.	Maastricht Univ & Univ Hosp, Dept Internal Med, Res Inst Growth & Dev GROW, Angiogenesis Lab, Maastricht, Netherlands; Maastricht Univ & Univ Hosp, Dept Pathol, Res Inst Growth & Dev GROW, Angiogenesis Lab, Maastricht, Netherlands; Maastricht Univ & Univ Hosp, Maastricht, Netherlands; Maastricht Univ, Cardiovasc Res Inst Maastricht, Microcirculat Lab, Dept Physiol, Maastricht, Netherlands; Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; University of Minnesota System; University of Minnesota Twin Cities	Griffioen, AW (corresponding author), Univ Hosp Maastricht, Dept Pathol, POB 5800, NL-6202 AZ Maastricht, Netherlands.	aw.griffioen@path.unimaas.nl	Egbrink, Mirjam oude/AAZ-7305-2020; Dings, Ruud/R-3772-2019; Thijssen, Victor LJL/B-2792-2009; Dings, Ruud/C-6188-2008	Dings, Ruud/0000-0001-7686-1331; Thijssen, Victor LJL/0000-0002-6146-1842; Wagstaff, John/0000-0002-1140-5981	NATIONAL CANCER INSTITUTE [R01CA096090] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-96090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed B, 2003, INT J CANCER, V105, P20, DOI 10.1002/ijc.11010; Bocci G, 2002, CANCER RES, V62, P6938; Bouma-ter-Steege JCA, 2004, CLIN CANCER RES, V10, P7171; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; CREAMER D, 2003, ANGIOGENESIS, V5, P231; Demaria S, 2001, CLIN CANCER RES, V7, P3025; Dings RPM, 2003, CANCER RES, V63, P382; Dirkx AEM, 2003, CANCER RES, V63, P2322; Dvorak HF, 2005, J THROMB HAEMOST, V3, P1835, DOI 10.1111/j.1538-7836.2005.01361.x; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Griffioen AW, 1997, CANCER J - FRANCE, V10, P249; Griffioen AW, 1996, CANCER RES, V56, P1111; Griffioen AW, 1999, INT J CANCER, V80, P315, DOI 10.1002/(SICI)1097-0215(19990118)80:2<315::AID-IJC23>3.0.CO;2-L; Griffioen AW, 1996, BLOOD, V88, P667, DOI 10.1182/blood.V88.2.667.bloodjournal882667; GRIFFIOEN AW, 2001, BIOCHEM J, P233; Hellwig SMM, 1997, CANCER LETT, V120, P203, DOI 10.1016/S0304-3835(97)00310-8; JANSSEN GHGW, 1994, AM J PHYSIOL, V267, pH1199, DOI 10.1152/ajpheart.1994.267.3.H1199; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kisker O, 2001, CANCER RES, V61, P7669; KUSAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P1070, DOI 10.1016/0006-291X(91)91529-L; Leek RD, 1996, CANCER RES, V56, P4625; Luo JY, 1998, BIOCHEM BIOPH RES CO, V245, P906, DOI 10.1006/bbrc.1998.8529; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Nair S, 2003, BLOOD, V102, P964, DOI 10.1182/blood-2002-12-3738; Niethammer AG, 2002, NAT MED, V8, P1369, DOI 10.1038/nm794; Nooijen PTGA, 1998, AM J PATHOL, V152, P679; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PIALI L, 1995, J EXP MED, V181, P811, DOI 10.1084/jem.181.2.811; Reiss Y, 1998, EUR J IMMUNOL, V28, P3086, DOI 10.1002/(SICI)1521-4141(199810)28:10<3086::AID-IMMU3086>3.3.CO;2-Q; Ribas A, 2003, J CLIN ONCOL, V21, P2415, DOI 10.1200/JCO.2003.06.041; Rosenberg SA, 2004, NEW ENGL J MED, V350, P1461, DOI 10.1056/NEJMcibr045001; Satchi-Fainaro R, 2005, CANCER CELL, V7, P251, DOI 10.1016/j.ccr.2005.02.007; SLAAF DW, 1982, INT J MICROCIRC, V1, P121; TEICHER BA, 1992, CANCER RES, V52, P6702; Thijssen VLJL, 2004, EXP CELL RES, V299, P286, DOI 10.1016/j.yexcr.2004.06.014; Tromp SC, 2000, INT IMMUNOL, V12, P671, DOI 10.1093/intimm/12.5.671; van der Schaft DWJ, 2002, FASEB J, V16, P1991, DOI 10.1096/fj.02-0509fje; WAHL ML, 2005, J CELL BIOCH; Wei YQ, 2000, NAT MED, V6, P1160, DOI 10.1038/80506; YAMAOKA M, 1993, CANCER RES, V53, P5233; Zhang H, 2002, AM J PATHOL, V160, P2219, DOI 10.1016/S0002-9440(10)61169-8; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	44	195	200	2	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					621	630		10.1096/fj.05-4493com	http://dx.doi.org/10.1096/fj.05-4493com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581970				2022-12-28	WOS:000240130900008
J	Mager, DE; Wan, RQ; Brown, M; Cheng, AW; Wareski, P; Abernethy, DR; Mattson, MP				Mager, Donald E.; Wan, Ruiqian; Brown, Martin; Cheng, Aiwu; Wareski, Przemyslaw; Abernethy, Darrell R.; Mattson, Mark P.			Caloric restriction and intermittent fasting alter spectral measures of heart rate and blood pressure variability in rats	FASEB JOURNAL			English	Article; Proceedings Paper	34th Annual Meeting of the Society-for-Neuroscience	OCT 23-27, 2004	San Diego, CA	Soc Neurosci		blood pressure; heart rate; autonomic nervous system; nutrition	SYMPATHETIC NERVOUS-SYSTEM; DIETARY RESTRICTION; PAROXETINE; AGE; METABOLISM; RESISTANCE; DISEASE; GLUCOSE; RISK	Dietary restriction (DR) has been shown to increase life span, delay or prevent age-associated diseases, and improve functional and metabolic cardiovascular risk factors in rodents and other species. To investigate the effects of DR on beat-to-beat heart rate and diastolic blood pressure variability (HRV and DPV) in male Sprague-Dawley rats, we implanted telemetric transmitters and animals were maintained on either intermittent fasting (every other day feeding) or calorie-restricted (40% caloric reduction) diets. Using power spectral analysis, we evaluated the temporal profiles of the low- and high-frequency oscillatory components in heart rate and diastolic blood pressure signals to assess cardiac autonomic activity. Body weight, heart rate, and systolic and diastolic blood pressure were all found to decrease in response to DR. Both methods of DR produced decreases in the low-frequency component of DPV spectra, a marker for sympathetic tone, and the high-frequency component of HRV spectra, a marker for parasympathetic activity, was increased. These parameters required at least 1 month to become maximal, but returned toward baseline values rapidly once rats resumed ad libitum diets. These results suggest an additional cardiovascular benefit of DR that merits further studies of this potential effect in humans.-Mager, D. E., Wan, R., Brown, M., Cheng, A., Wareski, P., Abernethy, D. R., Mattson, M. P. Caloric restriction and intermittent fasting alter spectral measures of heart rate and blood pressure variability in rats.	NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA; NIA, Clin Invest Lab, Intramural Res Program, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Mattson, MP (corresponding author), NIA, Neurosci Lab, Intramural Res Program, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	mattsonm@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE ON AGING [Z01AG000315, ZIAAG000315] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Camm AJ, 1996, CIRCULATION, V93, P1043; CERUTTI C, 1991, AM J PHYSIOL, V261, pH1292, DOI 10.1152/ajpheart.1991.261.4.H1292; Chung HY, 2001, ANN NY ACAD SCI, V928, P327; CRAFT N, 1995, AM J PHYSIOL-HEART C, V268, pH1441, DOI 10.1152/ajpheart.1995.268.4.H1441; Duan WZ, 2004, ANN NEUROL, V55, P590, DOI 10.1002/ana.20075; Duan WZ, 2003, ENDOCRINOLOGY, V144, P2446, DOI 10.1210/en.2002-0113; Duan WZ, 2001, J NEUROCHEM, V76, P619, DOI 10.1046/j.1471-4159.2001.00071.x; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Heilbronn LK, 2005, AM J CLIN NUTR, V81, P69; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Liao DP, 1997, AM J EPIDEMIOL, V145, P696, DOI 10.1093/aje/145.8.696; MALLIANI A, 1991, CIRCULATION, V84, P482, DOI 10.1161/01.CIR.84.2.482; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Mattison JA, 2003, EXP GERONTOL, V38, P35, DOI 10.1016/S0531-5565(02)00146-8; Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007; Nakagawa T, 2002, DIABETES-METAB RES, V18, P185, DOI 10.1002/dmrr.290; Pahlavani MA, 2000, FRONT BIOSCI-LANDMRK, V5, pD580, DOI 10.2741/Pahlavani; Spaulding CC, 1997, MECH AGEING DEV, V93, P87, DOI 10.1016/S0047-6374(96)01824-6; THOMAS J, 1993, J GERONTOL, V48, pB151, DOI 10.1093/geronj/48.4.B151; Tucker P, 1997, J CLIN PSYCHOPHARM, V17, P370; Vega VL, 2004, SHOCK, V22, P248, DOI 10.1097/01.shk.0000133590.09659.a1; Wan RQ, 2003, FASEB J, V17, P1133, DOI 10.1096/fj.02-0996fje; Wan RQ, 2003, J NUTR, V133, P1921, DOI 10.1093/jn/133.6.1921; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Yeragani VK, 1999, NEUROPSYCHOBIOLOGY, V40, P124, DOI 10.1159/000026608; YOUNG JB, 1977, SCIENCE, V196, P1473, DOI 10.1126/science.867049; YOUNG JB, 1982, J CHRON DIS, V35, P879, DOI 10.1016/0021-9681(82)90118-7	30	167	169	0	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2006	20	6					631	637		10.1096/fj.05-5263com	http://dx.doi.org/10.1096/fj.05-5263com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	078UW	16581971				2022-12-28	WOS:000240130900009
J	Wong, CH; Mruk, DD; Lee, WM; Cheng, CY				Wong, Ching-Hang; Mruk, Dolores D.; Lee, Will M.; Cheng, C. Yan			Targeted and reversible disruption of the blood-testis barrier by an FSH mutant-occludin peptide conjugate	FASEB JOURNAL			English	Article						spermatogenesis; light junction; adherens junction; ectoplasmic specialization; serfoli-germ cell interactions; male contraception	FOLLICLE-STIMULATING-HORMONE; GERM CELL-INTERACTIONS; IN-VIVO; JUNCTION DYNAMICS; TIGHT JUNCTIONS; SERTOLI-CELLS; CARBOHYDRATE RESIDUES; SIGNAL-TRANSDUCTION; RECEPTOR-BINDING; RAT TESTIS	The blood-testis barrier (BTB) is one of the tightest blood-tissue barriers in mammals. As such, it poses a challenge to deliver any drugs to the seminiferous epithelium of the testis, such as a nonhormonal male contraceptive. To circumvent this problem, a genetically engineered follicle-stimulating hormone (FSH) mutant protein was produced in Spodoptera furgiperda (Sf)-9 insect cells to serve as a testis-specific carrier. Subsequently, a 22-amino acid peptide corresponding to the second extracellular loop of occludin, which was known to disrupt BTB integrity in vivo, was inserted to the FSH mutant by polymerase chain reaction (PCR), as well as chemical cross-linking. This molecule was found to have negligible hormonal activity but was still capable of binding to FSH receptors, which are restricted to Sertoli cells in mammals. When this FSH mutant-occludin peptide conjugate was administered to adult rats at 40 mu g/adult rat (similar to 300 gm b.w.) via intraperitoneally (i.p.) injection, it induced transient and reversible disruption of the BTB, while at 150 mu g/rat, it induced partial germ cell loss from the testis, particularly elongating/elongate spermatids. Most importantly, this effect was limited to the BTB without compromising the TJ-barrier integrity or cell adhesion in epithelia of other organs, such as kidney, liver, and small intestine. In summary, the use of an FSH mutant-occludin peptide conjugate is a feasible nanodevice to transiently compromise the BTB.	Populat Council, Ctr Biomed Res, New York, NY 10021 USA; Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China	Population Council; University of Hong Kong	Cheng, CY (corresponding author), Populat Council, Ctr Biomed Res, 1230 York Ave, New York, NY 10021 USA.	y-cheng@popcby.rockefeller.edu	Lee, Will M/D-2357-2009	Cheng, C Yan/0000-0003-3117-3791	NICHD NIH HHS [U01 HD045908-04, U01 HD045908, U54 HD029990, U01 HD045908-01, U01 HD045908-02, U01 HD045908-03, U54 HD029990-110007] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD029990] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD045908] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baccetti B, 1998, FASEB J, V12, P1045, DOI 10.1096/fasebj.12.11.1045; Balda MS, 2000, SEMIN CELL DEV BIOL, V11, P281, DOI 10.1006/scdb.2000.0177; Bart J, 2002, LANCET ONCOL, V3, P357, DOI 10.1016/S1470-2045(02)00776-3; BISHOP LA, 1995, ENDOCRINOLOGY, V136, P2635, DOI 10.1210/en.136.6.2635; BISHOP LA, 1994, MOL ENDOCRINOL, V8, P722, DOI 10.1210/me.8.6.722; Cheng CY, 2002, PHYSIOL REV, V82, P825, DOI 10.1152/physrev.00009.2002; Chung NPY, 2001, BIOL REPROD, V65, P1340, DOI 10.1095/biolreprod65.5.1340; COLOMA TAS, 1990, J BIOL CHEM, V265, P5037; Dias JA, 1998, BIOL REPROD, V58, P1331, DOI 10.1095/biolreprod58.6.1331; Dym M, 1970, Biology Reprod., V3, P308; FLACK MR, 1994, J BIOL CHEM, V269, P14015; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Ghabriel MN, 2004, J COMP PATHOL, V131, P52, DOI 10.1016/j.jcpa.2004.01.004; GRIMA J, 1992, MOL CELL ENDOCRINOL, V89, P127, DOI 10.1016/0303-7207(92)90219-V; GRISWOLD MD, 1995, J STEROID BIOCHEM, V53, P215, DOI 10.1016/0960-0760(95)00049-6; Griswold MD, 1998, SEMIN CELL DEV BIOL, V9, P411, DOI 10.1006/scdb.1998.0203; KEENE JL, 1989, J BIOL CHEM, V264, P4769; Kondoh M, 2005, MOL PHARMACOL, V67, P749, DOI 10.1124/mol.104.008375; Lee NPY, 2003, ENDOCRINOLOGY, V144, P3114, DOI 10.1210/en.2002-0167; LINDAUSHEPARD B, 1994, ENDOCRINOLOGY, V135, P1235, DOI 10.1210/en.135.3.1235; MEANS AR, 1980, ANNU REV PHYSIOL, V42, P59, DOI 10.1146/annurev.ph.42.030180.000423; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Moroi S, 1998, AM J PHYSIOL-CELL PH, V274, pC1708, DOI 10.1152/ajpcell.1998.274.6.C1708; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Rose MP, 2000, ENDOCR REV, V21, P5, DOI 10.1210/er.21.1.5; Sairam MR, 2001, ARCH MED RES, V32, P601, DOI 10.1016/S0188-4409(01)00328-9; SETCHELL BP, 1980, J ANDROL, V1, P3; SILVESTRINI B, 1990, CLIN CHEM, V36, P277; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Ulloa-Aguirre A, 2003, BIOL REPROD, V69, P379, DOI 10.1095/biolreprod.103.016915; Ulloa-Aguirre A, 1999, ENDOCRINE, V11, P205, DOI 10.1385/ENDO:11:3:205; VALOVE FM, 1994, ENDOCRINOLOGY, V135, P2657, DOI 10.1210/en.135.6.2657; VanItallie CM, 1997, J CELL SCI, V110, P1113; WAHLSTROM T, 1983, J CLIN ENDOCR METAB, V57, P825, DOI 10.1210/jcem-57-4-825; Walker WH, 2005, REPRODUCTION, V130, P15, DOI 10.1530/rep.1.00358; Wong CH, 2005, CURR TOP DEV BIOL, V71, P263, DOI 10.1016/S0070-2153(05)71008-5; Wong CH, 2005, ENDOCRINOLOGY, V146, P1893, DOI 10.1210/en.2004-1464; Wong CH, 2004, J CELL SCI, V117, P783, DOI 10.1242/jcs.00900; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399	40	38	41	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					438	448		10.1096/fj.05-4144com	http://dx.doi.org/10.1096/fj.05-4144com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17167075	Green Accepted			2022-12-28	WOS:000244686300017
J	Daub, K; Langer, H; Seizer, P; Stellos, K; May, AE; Goyal, P; Bigalke, B; Schonberger, T; Geisler, T; Siegel-Axel, D; Oostendorp, RAJ; Lindemann, S; Gawaz, M				Daub, Karin; Langer, Harald; Seizer, Peter; Stellos, Konstantinos; May, Andreas E.; Goyal, Pankaj; Bigalke, Boris; Schoenberger, Tanja; Geisler, Tobias; Siegel-Axel, Dorothea; Oostendorp, Robert A. J.; Lindemann, Stephan; Gawaz, Meinrad			Platelets induce differentiation of human CD34(+) progenitor cells into foam cells and endothelial cells	FASEB JOURNAL			English	Article						atherothrombosis; vascular lesion; statins; stem cells; matrix metalloproteinases	COA REDUCTASE INHIBITORS; PPAR-ALPHA; MACROPHAGE ACTIVATION; MMP-9 SECRETION; MATRIX-METALLOPROTEINASE-9; INFLAMMATION; ADHESION; STATINS; MICE	Recruitment of human CD34(+) progenitor cells toward vascular lesions and differentiation into vascular cells has been regarded as a critical initial step in atherosclerosis. Previously we found that adherent platelets represent potential mediators of progenitor cell homing besides their role in thrombus formation. On the other hand, foam cell formation represents a key process in atherosclerotic plaque formation. To investigate whether platelets are involved in progenitor cell recruitment and differentiation into endothelial cells and foam cells, we examined the interactions of platelets and CD34(+) progenitor cells. Cocultivation experiments showed that human platelets recruit CD34(+) progenitor cells via the specific adhesion receptors P-selectin/PSGL-1 and beta(1)- and beta(2)-integrins. Furthermore, platelets were found to induce differentiation of CD34(+) progenitor cells into mature foam cells and endothelial cells. Platelet-induced foam cell generation could be prevented partially by HMG coenzyme A reductase inhibitors via reduction of matrix metalloproteinase-9 (MMP-9) secretion. Finally, agonists of peroxisome proliferator-activated receptor-alpha and -gamma attenuated platelet-induced foam cell generation and production of MMP-9. The present study describes a potentially important mechanism of platelet-induced foam cell formation and generation of endothelium in atherogenesis and atheroprogression. The understanding and modulation of these mechanisms may offer new treatment strategies for patients at high risk for atherosclerotic diseases. - Daub, K., Langer, H., Seizer, P., Stellos, K., May, A. E., Goyal, P., Bigalke, B., Schonberger, T., Geisler, T., Siegel-Axel, D., Oostendorp, R. A. J., Lindemann, S., Gawaz, M. Platelets induce differentiation of human CD34(+) progenitor cells into foam cells and endothelial cells.	Univ Klinikum Tubingen, Med Klin 3, D-72076 Tubingen, Germany; Univ Munich, Inst Prevent Cardiovasc Dis, Munich, Germany; Tech Univ Munich, Med Klin 3, Klinikum Rechts Isar, Munich, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Munich; Technical University of Munich	Gawaz, M (corresponding author), Univ Klinikum Tubingen, Med Klin 3, Otfried Muller Str 10, D-72076 Tubingen, Germany.	meinrad.gawaz@med.uni-tuebingen.de	Oostendorp, Robert A. J./K-9841-2018; Stellos, Konstantinos/G-8873-2011; Stellos, Konstantinos/AAF-2711-2020; Stellos, Konstantinos/ABH-1523-2021; Goyal, Pankaj/C-3567-2012; Geisler, Tobias/AAO-4472-2020	Oostendorp, Robert A. J./0000-0002-4947-0412; Stellos, Konstantinos/0000-0002-0194-0825				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bellosta S, 1998, ARTERIOSCL THROM VAS, V18, P1671, DOI 10.1161/01.ATV.18.11.1671; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; De Meyer GRY, 2002, CIRC RES, V90, P1197, DOI 10.1161/01.RES.0000020017.84398.61; Galt SW, 2001, CIRC RES, V89, P509, DOI 10.1161/hh1801.096339; Gawaz M, 2005, J CLIN INVEST, V115, P3378, DOI 10.1172/JCI27196; Gawaz M, 2004, CARDIOVASC RES, V61, P498, DOI 10.1016/j.cardiores.2003.11.036; Heiss C, 2005, J AM COLL CARDIOL, V45, P1441, DOI 10.1016/j.jacc.2004.12.074; Hristov M, 2003, ARTERIOSCL THROM VAS, V23, P1185, DOI 10.1161/01.ATV.0000073832.49290.B5; Jans DM, 2004, J CARDIOVASC PHARM, V43, P462, DOI 10.1097/00005344-200403000-00019; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; Korporaal SJA, 2005, ARTERIOSCL THROM VAS, V25, P867, DOI 10.1161/01.ATV.0000158381.02640.4b; Langer H, 2006, CIRC RES, V98, pE2, DOI 10.1161/01.RES.0000201285.87524.9e; Li AC, 2004, J CLIN INVEST, V114, P1564, DOI 10.1172/JCI200418730; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; Massberg S, 2005, CIRCULATION, V112, P1180, DOI 10.1161/CIRCULATIONAHA.105.539221; Massberg S, 2006, J EXP MED, V203, P1221, DOI 10.1084/jem.20051772; Ott I, 2005, FASEB J, V19, P992, DOI 10.1096/fj.04-3219fje; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Relou IAM, 2003, CELL MOL LIFE SCI, V60, P961, DOI 10.1007/s00018-003-2249-y; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Schmidt R, 2006, CIRCULATION, V113, P834, DOI 10.1161/CIRCULATIONAHA.105.568162; Schmidt-Lucke C, 2005, CIRCULATION, V111, P2981, DOI 10.1161/CIRCULATIONAHA.104.504340; Schonbeck U, 2004, CIRCULATION, V109, P18, DOI 10.1161/01.CIR.0000129505.34151.23; Shashkin P, 2005, CURR PHARM DESIGN, V11, P3061, DOI 10.2174/1381612054865064; Shu H, 2000, BIOCHEM BIOPH RES CO, V267, P345, DOI 10.1006/bbrc.1999.1968; Turner NA, 2005, FASEB J, V19, P804, DOI 10.1096/fj.04-2852fje; Urbich C, 2005, KIDNEY INT, V67, P1672, DOI 10.1111/j.1523-1755.2005.00261.x; Werner N, 2005, NEW ENGL J MED, V353, P999, DOI 10.1056/NEJMoa043814; Wong BM, 2001, J LEUKOCYTE BIOL, V69, P959; Xu QB, 2006, NAT CLIN PRACT CARD, V3, P94, DOI 10.1038/ncpcardio0396	31	165	170	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2559	+		10.1096/fj.06-6265fje	http://dx.doi.org/10.1096/fj.06-6265fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077283				2022-12-28	WOS:000242490700023
J	de Lange, P; Farina, P; Moreno, M; Ragni, M; Lombardi, A; Silvestri, E; Burrone, L; Lanni, A; Goglia, F				de Lange, Pieter; Farina, Paola; Moreno, Maria; Ragni, Maurizio; Lombardi, Assunta; Silvestri, Elena; Burrone, Lavinia; Lanni, Antonia; Goglia, Fernando			Sequential changes in the signal transduction responses of skeletal muscle following food deprivation	FASEB JOURNAL			English	Article						mitochondria; fatty acid oxidation; UCP3; fasting	FATTY-ACID OXIDATION; ACTIVATED PROTEIN-KINASE; ACETYL-COA CARBOXYLASE; UNCOUPLING PROTEIN-3; METABOLIC SYNDROME; GENE-EXPRESSION; PPAR-DELTA; RAT; UCP3; INCREASES	Coping with reduced energy sources entails drastic morphological and functional changes in skeletal muscle, but the sequence of events required classification. We found that gastrocnemius muscle from food-deprived rats shows acute rises in peroxisome proliferator activated receptor (PPAR) gamma coactivator (PGC) -1 alpha/PPAR delta nuclear protein and myosin heavy chain (MHC) Ib protein, while type I fibers accumulate and the muscle tissue appears redder. AMP levels, phosphorylation of both AMP-activated protein kinase (AMPK) and its downstream target acetyl coenzyme A carboxylase (ACC) are induced within 6 h. Rapidly increased MyoD mRNA levels are followed by an increase in uncoupling protein (UCP) 3 (UCP3) transcription. Increased serum fatty acid levels coincide with increases in mitochondrial UCP3 protein levels and fatty acid oxidation. Accompanying this is a decrease in AMPK phophorylation, reversible upon nicotinic acid treatment, indicating that fatty acids may modulate this kinase's activity after the metabolic challenges posed by food deprivation.	Seconda Univ Studi Napoli, Dipartimento Sci Vita, I-81100 Caserta, Italy; Univ Studi Sannio, Dipartimento Sci Biol & Ambientali, Benevento, Italy; Univ Naples Federico II, Dipartimento Sci Biol, Naples, Italy	Universita della Campania Vanvitelli; University of Sannio; University of Naples Federico II	Lanni, A (corresponding author), Seconda Univ Studi Napoli, Dipartimento Sci Vita, Via Vivaldi 43, I-81100 Caserta, Italy.	antonia.lanni@unina2.it; goglia@unisannio.it	Ragni, Maurizio/AAB-1527-2020; de Lange, Pieter/GXA-3052-2022	Ragni, Maurizio/0000-0001-6548-741X; Silvestri, Elena/0000-0002-0592-9033; GOGLIA, Fernando/0000-0003-0468-9645; MORENO, Maria/0000-0002-6218-5501				Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955; BELKHOU R, 1991, NUTR RES, V11, P365, DOI 10.1016/S0271-5317(05)80312-4; Bezaire V, 2005, FASEB J, V19, P977, DOI 10.1096/fj.04-2765fje; Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CHALLET E, 1995, PHARMACOL BIOCHEM BE, V50, P405, DOI 10.1016/0091-3057(94)00287-S; Clark H, 2004, EUR J BIOCHEM, V271, P2215, DOI 10.1111/j.1432-1033.2004.04151.x; de Lange P, 2003, FASEB J, V17, P350, DOI 10.1096/fj.03-0342fje; Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195; GAHILL GF, 1976, CLIN ENDOCRINOL META, V5, P397; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; Gonzalez AA, 2004, AM J PHYSIOL-REG I, V287, pR1270, DOI 10.1152/ajpregu.00409.2004; GOODMAN MN, 1980, AM J PHYSIOL, V239, pE277; Hardie D. Grahame, 1994, Seminars in Cell Biology, V5, P409, DOI 10.1006/scel.1994.1048; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Kaushik VK, 2001, AM J PHYSIOL-ENDOC M, V281, pE335, DOI 10.1152/ajpendo.2001.281.2.E335; Kyrolainen H, 2003, MED SCI SPORT EXER, V35, P45, DOI 10.1249/01.MSS.0000046149.03322.BB; Leverve XM, 2003, DIABETES METAB, V29, pS88; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Luquet S, 2004, BIOCHIMIE, V86, P833, DOI 10.1016/j.biochi.2004.09.024; MacLellan JD, 2005, DIABETES, V54, P2343, DOI 10.2337/diabetes.54.8.2343; Matsuda J, 1997, FEBS LETT, V418, P200, DOI 10.1016/S0014-5793(97)01381-1; Moreno M, 2003, FASEB J, V17, P1112, DOI 10.1096/fj.02-0839fje; MUNDAY MR, 1991, BIOCHEM J, V280, P733, DOI 10.1042/bj2800733; Noma T, 2001, BIOCHEM J, V358, P225, DOI 10.1042/0264-6021:3580225; OGILVIE RW, 1990, STAIN TECHNOL, V65, P231, DOI 10.3109/10520299009105613; Pilegaard H, 2003, DIABETES, V52, P657, DOI 10.2337/diabetes.52.3.657; Putman CT, 2003, J PHYSIOL-LONDON, V551, P169, DOI 10.1113/jphysiol.2003.04069; RANDLE PJ, 1963, LANCET, V1, P785; Schrauwen P, 2004, INT J OBESITY, V28, P824, DOI 10.1038/sj.ijo.0802629; Solanes G, 2003, MOL ENDOCRINOL, V17, P1944, DOI 10.1210/me.2002-0395; Son C, 2001, ENDOCRINOLOGY, V142, P4189, DOI 10.1210/en.142.10.4189; Suwa M, 2003, J APPL PHYSIOL, V95, P960, DOI 10.1152/japplphysiol.00349.2003; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Van der Lee KAJM, 2001, J LIPID RES, V42, P1752; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; WITTERS LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P413, DOI 10.1006/abbi.1994.1058; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622	40	66	77	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14								10.1096/fj.06-6025fje	http://dx.doi.org/10.1096/fj.06-6025fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065218				2022-12-28	WOS:000242490700030
J	Lash, GE; Otun, HA; Innes, BA; Kirkley, M; De Oliveira, L; Searle, RF; Robson, SC; Bulmer, JN				Lash, Gendie E.; Otun, Harry A.; Innes, Barbara A.; Kirkley, Maureen; De Oliveira, Leandro; Searle, Roger F.; Robson, Stephen C.; Bulmer, Judith N.			Interferon-gamma inhibits extravillous trophoblast cell invasion by a mechanism that involves both changes in apoptosis and protease levels	FASEB JOURNAL			English	Article						IFN-gamma; uNK cells	NATURAL-KILLER-CELLS; TRANSCRIPTIONAL SUPPRESSION; GENE-EXPRESSION; GROWTH-FACTORS; PLACENTAL BED; LYMPHOCYTES; PREGNANCY; INTERLEUKIN-12; GELATINASE; CYTOKINES	Background: Extravillous trophoblast cell (EVT) invasion of decidua and inner third of the myometrium is critical for a successful pregnancy. Many decidual factors are likely to play a role in regulating this process, including uterine natural killer (uNK) cell-derived cytokines. Hypotheses: 1) uNK cells are a major source of IFN gamma (IFN-gamma) and 2) IFN-gamma inhibits EVT invasion via an increase in EVT apoptosis and/or a decrease in active protease levels. Methods: Total decidual and uNK cells from 8-10 wk and 12-14 wk gestational age were cultured. IFN-gamma mRNA (real-time RT-polymerase chain reaction) and protein levels (FastQuant multicytokine analysis) were determined. EVT invasion in the presence of IFN-gamma or anti- IFN-gamma-neutralizing antibodies was assessed. Trophoblast apoptosis and proliferation was assessed in explants by immunohistochemistry for M30 and Ki67. Substrate zymography was performed to determine levels of secreted MMP2, MMP9, and uPA. Results: mRNA and protein for IFN-gamma was detected in both total decidual and uNK cell fractions. Trophoblast invasion was inhibited by IFN-gamma. The level of M30-positive EVT was increased in the presence of IFN-gamma whereas levels of secreted MMP2 were decreased. Conclusions: uNK cells are a source of IFN-gamma within early human pregnancy decidua. Mechanisms of IFN-gamma inhibition of EVT invasion include both increased EVT apoptosis and reduced levels of active proteases.-Lash, G. E., Otun, H. A., Innes, B. A., Kirkley, M., De Oliveira, L., Searle, R. F., Robson, S. C., Bulmer, J. N. Interferon-gamma inhibits extravillous trophoblast cell invasion by a mechanism that involves both changes in apoptosis and protease levels.	Newcastle Univ, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Newcastle Univ, Sch Clin & Lab Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Newcastle Univ, Sch Med Educ Dev, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Lash, GE (corresponding author), Newcastle Univ, Sch Surg & Reprod Sci, 3rd Floor,William Leech Bldg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	g.e.lash@ncl.ac.uk	Lash, Gendie/AAI-4116-2021; De Oliveira, Leandro/G-3476-2012	De Oliveira, Leandro/0000-0002-8422-9907; Lash, Gendie/0000-0002-3606-1361	Biotechnology and Biological Sciences Research Council [S19967] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Adams EJ, 1999, J CLIN PATHOL, V52, P75, DOI 10.1136/jcp.52.1.75; Ain R, 2003, DEV BIOL, V260, P176, DOI 10.1016/S0012-1606(03)00210-0; Ashkar AA, 2000, J EXP MED, V192, P259, DOI 10.1084/jem.192.2.259; Ball E, 2006, J PATHOL, V208, P535, DOI 10.1002/path.1927; BROSENS I, 1967, J PATHOL BACTERIOL, V93, P569, DOI 10.1002/path.1700930218; Bulmer JN, 2005, MOL IMMUNOL, V42, P511, DOI 10.1016/j.molimm.2004.07.035; Cohen M, 2006, PLACENTA, V27, P783, DOI 10.1016/j.placenta.2005.08.006; Craven CM, 1998, PLACENTA, V19, P241, DOI 10.1016/S0143-4004(98)90055-8; Gohji K, 1998, UROL RES, V26, P33, DOI 10.1007/s002400050020; GOHJI K, 1994, INT J CANCER, V58, P380, DOI 10.1002/ijc.2910580313; Goldman-Wohl DS, 2000, MOL HUM REPROD, V6, P535, DOI 10.1093/molehr/6.6.535; GRAHAM CH, 1994, EXP CELL RES, V214, P93, DOI 10.1006/excr.1994.1237; Graham CH, 1996, AM J OBSTET GYNECOL, V175, P555; Guimond MJ, 1998, J EXP MED, V187, P217, DOI 10.1084/jem.187.2.217; HAIMOVICI F, 1991, BIOL REPROD, V44, P69, DOI 10.1095/biolreprod44.1.69; HUJANEN ES, 1991, INT J CANCER, V47, P576, DOI 10.1002/ijc.2910470416; Jokhi PP, 1997, CYTOKINE, V9, P126, DOI 10.1006/cyto.1996.0146; Jones RK, 1997, BIOL REPROD, V57, P1217, DOI 10.1095/biolreprod57.5.1217; Kam EPY, 1999, HUM REPROD, V14, P2131, DOI 10.1093/humrep/14.8.2131; Karmakar S, 2004, J BIOL CHEM, V279, P55297, DOI 10.1074/jbc.M407013200; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Kitaya K, 2003, FERTIL STERIL, V79, P730, DOI 10.1016/S0015-0282(02)04818-5; Knupfer MM, 2001, ANTICANCER RES, V21, P3989; Lash GE, 2005, BIOL REPROD, V73, P374, DOI 10.1095/biolreprod.105.040337; Lash GE, 1999, PLACENTA, V20, P661, DOI 10.1053/plac.1999.0427; LASH GE, 2006, IN PRESS J LEUK BIOL; LASH GE, 2006, IN PRESS PLACENTA; Li XF, 2001, J CLIN ENDOCR METAB, V86, P1823, DOI 10.1210/jc.86.4.1823; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Marzusch K, 1997, HUM REPROD, V12, P921; Otun HA, 2003, PLACENTA, V24, pA67; PAULESU L, 1994, J REPROD IMMUNOL, V27, P37, DOI 10.1016/0165-0378(94)90013-2; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408; Pijnenborg R, 2000, MOL HUM REPROD, V6, P635, DOI 10.1093/molehr/6.7.635; PIJNENBORG R, 1991, BRIT J OBSTET GYNAEC, V98, P648, DOI 10.1111/j.1471-0528.1991.tb13450.x; PIJNENBORG R, 1980, PLACENTA, V1, P3, DOI 10.1016/S0143-4004(80)80012-9; Qin HW, 1998, J IMMUNOL, V161, P6664; Saito S, 1999, CLIN EXP IMMUNOL, V117, P550; van der Loos CM, 2001, J HISTOCHEM CYTOCHEM, V49, P699, DOI 10.1177/002215540104900604; van der Meer A, 2004, MOL HUM REPROD, V10, P189, DOI 10.1093/molehr/gah032; Vassiliadou N, 1998, BIOL REPROD, V58, P982, DOI 10.1095/biolreprod58.4.982; Vigano P, 2001, MOL HUM REPROD, V7, P971, DOI 10.1093/molehr/7.10.971; von Rango U, 2003, FERTIL STERIL, V79, P1176, DOI 10.1016/S0015-0282(02)04829-X; Wilczynski JR, 2002, MEDIAT INFLAMM, V11, P105, DOI 10.1080/09629350220131962	45	122	132	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2512	2518		10.1096/fj.06-6616com	http://dx.doi.org/10.1096/fj.06-6616com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17142800				2022-12-28	WOS:000242490700011
J	Nakahara, S; Saito, T; Kondo, N; Moriwaki, K; Noda, K; Ihara, S; Takahashi, M; Ide, Y; Gu, JG; Inohara, H; Katayama, T; Tohyama, M; Kubo, T; Taniguchi, N; Miyoshi, E				Nakahara, Susumu; Saito, Takashi; Kondo, Nami; Moriwaki, Kenta; Noda, Katsuhisa; Ihara, Shinji; Takahashi, Motoko; Ide, Yoshihito; Gu, Jianguo; Inohara, Hidenori; Katayama, Taiichi; Tohyama, Masaya; Kubo, Takeshi; Taniguchi, Naoyuki; Miyoshi, Eiji			A secreted type of beta 1,6 N-acetylglucosaminyltransferase V (GnT-V), a novel angiogenesis inducer, is regulated by gamma-secretase	FASEB JOURNAL			English	Article						glycosylation; presenilin-1; tumor metastasis; proteases	ASPARAGINE-LINKED OLIGOSACCHARIDES; AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; SIGNALING PATHWAY; CELL-LINE; CLEAVAGE; PRESENILIN-1; EXPRESSION; METASTASIS; NICASTRIN	Glycosyltransferases are present in the Golgi apparatus in a membrane-bound form and are released from cells after cleavage by certain proteases. beta 1,6- N-Acetylglucosaminyltransferase V (GnT-V), which is cleaved and secreted from the cells, is involved in the biosynthesis of beta 1-6GlcNAc branching on N-glycans and has been implicated in tumor progression and metastasis. We recently reported that a secreted type of GnT-V soluble (GnT-V) itself could promote angiogenesis, which is completely different from its original function as a glycosyltransferase, and this might play a role in tumor invasion. In this study, to explore the molecular basis for this functional glycosyltransferase secretion, its cleavage site was examined and the protease(s) involved in that cleavage were identified. The NH2-terminal protein sequence of purified soluble GnT-V (similar to 100 kDa) from GnT-V-overexpressed cells revealed that its terminus started at His(31), located at the boundary position between the transmembrane and stem regions. This secretion was not inhibited by a single amino acid mutation at the cleavage site (Leu(29), Leu(30) to Asp, His31 to Ala), but specifically inhibited by addition of DFK-167, a gamma-secretase inhibitor, suggesting that gamma-secretase is a plausible protease for secretion processing. In addition, transfection of the gene of familial Alzheimer's disease (flavin adenine dinucleotide) -linked presenilin-1, a component of gamma-secretase, increased the secretion rate of endogenous GnT-V; the secretion of soluble GnT-V (similar to 100 kDa) was completely inhibited in presenilin-1/2 double-deficient cells, which have no gamma-secretase activity. Collectively, these results demonstrate that Golgi-resident GnT-V is cleaved at the transmembrane region by gamma-secretase, and this might control tumor angiogenesis through a novel pathway.-Nakahara, S., Saito, T., Kondo, N., Moriwaki, K., Noda, K., Ihara, S., Takahashi, M., Ide, Y., Gu, J., Inohara, H., Katayama, T., Tohyama, M., Kubo, T., Taniguchi, N., Miyoshi, E. A secreted type of beta 1,6 N-acetylglucosaminyltransferase V (GnT-V), a novel angiogenesis inducer, is regulated by gamma-secretase.	Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Otolaryngol & Sensory Organ Surg, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Res Inst Microbial Dis, Dept Dis Gylcom, Suita, Osaka 5650871, Japan; Hamamatsu Univ Sch Med, Dept Anat, Shizuoka, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Hamamatsu University School of Medicine	Miyoshi, E (corresponding author), Osaka Univ, Grad Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	miyoshi34@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; Saito, Takashi/G-2563-2015; Taniguchi, Naoyuki/I-4182-2014; Gu, Jianguo/ABC-9257-2020; Ihara, Shinji/AAH-6730-2019; Takahashi, Motoko/I-3154-2013	Saito, Takashi/0000-0002-9659-9251; Taniguchi, Naoyuki/0000-0001-5889-5968; Moriwaki, Kenta/0000-0002-8724-4715; Takahashi, Motoko/0000-0002-2112-6142				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DE SB, 1999, NATURE, V398, P518; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 2001, NAT CELL BIOL, V3, pE221, DOI 10.1038/ncb1001-e221; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; El-Battari A, 2003, GLYCOBIOLOGY, V13, P941, DOI 10.1093/glycob/cwg117; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Granovsky M, 2000, NAT MED, V6, P306; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Ishibashi K, 2002, BBA-GENE STRUCT EXPR, V1576, P335, DOI 10.1016/S0167-4781(02)00393-7; KAPLAN HA, 1983, J BIOL CHEM, V258, P1505; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Kitazume-Kawaguchi S, 1999, GLYCOBIOLOGY, V9, P1397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai MT, 2003, J BIOL CHEM, V278, P22475, DOI 10.1074/jbc.M300974200; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; MIYAZAKI J, 1989, GENE, V79, P269; MIYOSHI E, 1995, J BIOL CHEM, V270, P6216, DOI 10.1074/jbc.270.11.6216; MIYOSHI E, 1993, CANCER RES, V53, P3899; Murata K, 2000, CLIN CANCER RES, V6, P1772; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Nakahara S, 2003, MOL CANCER THER, V2, P1207; Pierce M, 1997, GLYCOCONJUGATE J, V14, P623, DOI 10.1023/A:1018592627696; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; Saito T, 2002, J BIOL CHEM, V277, P17002, DOI 10.1074/jbc.M200521200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Siman R, 2003, J NEUROCHEM, V84, P1143, DOI 10.1046/j.1471-4159.2003.01616.x; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Taniguchi N, 1999, BBA-MOL BASIS DIS, V1455, P287, DOI 10.1016/S0925-4439(99)00066-6; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yanagi M, 2001, J GASTROEN HEPATOL, V16, P1282, DOI 10.1046/j.1440-1746.2001.02612.x	48	27	27	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2451	2459		10.1096/fj.05-5066com	http://dx.doi.org/10.1096/fj.05-5066com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17142794				2022-12-28	WOS:000242490700005
J	Smith, AJ; Chappell, AE; Buret, AG; Barrett, KE; Dong, H				Smith, Anders J.; Chappell, Alfred E.; Buret, Andre G.; Barrett, Kim E.; Dong, Hui			5-hydroxytryptamine contributes significantly to a reflex pathway by which the duodenal mucosa protects itself from gastric acid injury	FASEB JOURNAL			English	Article						acid-stimulated 5-HT release; duodenal mucosal bicarbonate secretion; cytoplasmic Ca2+ signaling; Na+ /Ca2(+) exchanger	INTESTINAL EPITHELIAL-CELLS; CA2+-DEPENDENT K+ CHANNEL; BICARBONATE SECRETION; CL-SECRETION; RAT COLON; SIGNALING PATHWAYS; CHLORIDE SECRETION; SEROTONIN RELEASE; 5-HT4 RECEPTORS; HCO3-SECRETION	Although duodenal mucosal bicarbonate secretion (DMBS) is currently accepted as an important defense mechanism against acid-induced duodenal injury, the mechanism and the regulation of DMBS are largely unknown. 5-HT may regulate DMBS, but little is known about its physiological relevance in DMBS and the underlying mechanism(s). Thus, the aims of the present study were to demonstrate the role of 5-HT in acid-stimulated DMBS and to further elucidate the precise mechanisms involved in this process. Luminal acid stimulation significantly increased 5-HT release from the duodenal mucosa (P < 0.01). SB204070, a selective 5-HT4 receptor antagonist, dose-dependently reduced luminal acid-stimulated HCO3- secretion of mice in vivo. In Ussing chamber studies, 5-HT-induced I-sc and DMBS were abolished by removal of extracellular Ca2+, and significantly attenuated by pharmacological blockade of the Na+/Ca2+ exchanger (NCX), intermediate Ca2+-activated K+ channels (IKCa), or cystic fibrosis transmembrane conductance regulator (CFTR). 5-HT increased cytoplasmic free calcium ([Ca2+](cyt)) in SCBN cells, a duodenal epithelial cell line, and knockdown of NCX1 proteins with a specific siRNA greatly decreased this 5-HT-mediated Ca2+ signaling. Taken together, our data suggest that 5-HT plays a physiological role in acid-stimulated DMBS via a Ca2+ signaling pathway, in which the plasma membrane NCX transporter as well as IKCa and CFTR channels may be involved.-Smith, A. J., Chappell, A. E., Buret, A. G., Barrett, K. E., Dong, H. 5-Hydroxytryptamine (5-HT) contributes significantly to a reflex pathway by which the duodenal mucosa protects itself from gastric acid injury.	Univ Calif San Diego, Sch Med, Div Gastroenterol, Dept Med, La Jolla, CA 92093 USA; Univ Calgary, Dept Biol, Calgary, AB T2N 1N4, Canada	University of California System; University of California San Diego; University of Calgary	Dong, H (corresponding author), Univ Calif San Diego, Sch Med, Div Gastroenterol, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	h2dong@ucsd.edu	Barrett, Kim Elaine/AAE-7762-2019; Barrett, Kim/AAE-2794-2022	Barrett, Kim Elaine/0000-0002-6704-998X; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033491, T32DK007202] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33491-18, T32 DK007202] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen P M, 1988, FEMS Microbiol Immunol, V1, P19; Banner SE, 1996, EUR J PHARMACOL, V308, P181, DOI 10.1016/0014-2999(96)00296-8; Barrett KE, 1997, AM J PHYSIOL-CELL PH, V272, pC1069, DOI 10.1152/ajpcell.1997.272.4.C1069; BOHME M, 1991, PFLUG ARCH EUR J PHY, V419, P144, DOI 10.1007/BF00373000; Buresi MC, 2001, AM J PHYSIOL-GASTR L, V281, pG323, DOI 10.1152/ajpgi.2001.281.2.G323; Cuthbert AW, 1999, AM J PHYSIOL-CELL PH, V277, pC111, DOI 10.1152/ajpcell.1999.277.1.C111; Day J, 2005, AM J SURG, V190, P736, DOI 10.1016/j.amjsurg.2005.07.012; Devor DC, 1998, AM J PHYSIOL-CELL PH, V274, pC138, DOI 10.1152/ajpcell.1998.274.1.C138; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL785, DOI 10.1152/ajplung.1996.271.5.L785; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; Dong H, 2005, AM J PHYSIOL-GASTR L, V288, pG457, DOI 10.1152/ajpgi.00381.2004; Flemstrom G, 2001, NEWS PHYSIOL SCI, V16, P23; Frings M, 1999, PFLUG ARCH EUR J PHY, V439, P39, DOI 10.1007/s004240051125; FUJIMIYA M, 1991, HISTOCHEMISTRY, V95, P217; Furukawa O, 2004, AM J PHYSIOL-GASTR L, V286, pG102, DOI 10.1152/ajpgi.00092.2003; Gaginella TS, 1995, SEROTONIN GASTROINTE; GERSHON MD, 1994, PHYSL GASTROINTESTIN, V1, P381; Gill RK, 2005, GASTROENTEROLOGY, V128, P962, DOI 10.1053/j.gastro.2005.02.011; Hogan DL, 1997, GASTROENTEROLOGY, V113, P533, DOI 10.1053/gast.1997.v113.pm9247473; HOGAN DL, 1994, ALIMENT PHARM THER, V8, P475; ISENBERG JI, 1987, NEW ENGL J MED, V316, P374, DOI 10.1056/NEJM198702123160704; ISENBERG JI, 1990, J INTERN MED, V228, P113, DOI 10.1111/j.1365-2796.1990.tb01482.x; Ito H, 2000, EUR J PHARMACOL, V409, P195, DOI 10.1016/S0014-2999(00)00851-7; Keely SJ, 2000, ANN NY ACAD SCI, V915, P67; KELLUM J, 1983, AM J PHYSIOL, V245, pG824, DOI 10.1152/ajpgi.1983.245.6.G824; KELLUM JM, 1984, J SURG RES, V36, P172, DOI 10.1016/0022-4804(84)90084-2; Kim MS, 2001, GASTROENTEROLOGY, V121, P1400, DOI 10.1053/gast.2001.29567; Kocks S, 2002, PFLUG ARCH EUR J PHY, V445, P390, DOI 10.1007/s00424-002-0947-1; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; Ning Y, 2004, CLIN EXP PHARMACOL P, V31, P424, DOI 10.1111/j.1440-1681.2004.04015.x; Pang G, 1996, GASTROENTEROLOGY, V111, P8, DOI 10.1053/gast.1996.v111.pm8698229; Repishti M, 2001, AM J PHYSIOL-GASTR L, V281, pG159, DOI 10.1152/ajpgi.2001.281.1.G159; RESNICK RH, 1962, GASTROENTEROLOGY, V42, P48; Safsten B, 2004, GASTROENTEROLOGY, V126, pA62; Schultheiss G, 2003, J MEMBRANE BIOL, V195, P183, DOI 10.1007/s00232-003-0618-y; Schultheiss G, 2000, ANN NY ACAD SCI, V915, P260; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; SEIDLER U, 1994, AM J PHYSIOL, V266, pG759, DOI 10.1152/ajpgi.1994.266.5.G759; Seip G, 2001, EXP PHYSIOL, V86, P461, DOI 10.1113/eph8602243; Shigekawa M, 2001, CIRC RES, V88, P864, DOI 10.1161/hh0901.090298; SJOLUND K, 1983, GASTROENTEROLOGY, V85, P1120; Tran VS, 2004, ANN NY ACAD SCI, V1014, P179, DOI 10.1196/annals.1294.019; Tuo BG, 2004, AM J PHYSIOL-GASTR L, V286, pG444, DOI 10.1152/ajpgi.00105.2003; Tuo BG, 2003, GASTROENTEROLOGY, V125, P805, DOI 10.1016/S0016-5085(03)01045-X; VAJANAPHANICH M, 1995, J CLIN INVEST, V96, P386, DOI 10.1172/JCI118046; VALLE JD, 2003, TXB GASTROENTEROLOGY, V1, P1321; Van Eylen F, 2001, CELL CALCIUM, V30, P191, DOI 10.1054/ceca.2001.0223	47	20	20	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2486	2495		10.1096/fj.06-6391com	http://dx.doi.org/10.1096/fj.06-6391com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17142798				2022-12-28	WOS:000242490700009
J	Berbee, JFP; van der Hoogt, CC; Kleemann, R; Schippers, EF; Kitchens, RL; van Dissel, JT; Bakker-Woudenberg, IAJM; Havekes, LM; Rensen, PCN				Berbee, Jimmy F. P.; van der Hoogt, Caroline C.; Kleemann, Robert; Schippers, Emile F.; Kitchens, Richard L.; van Dissel, Jaap T.; Bakker-Woudenberg, Irma A. J. M.; Havekes, Louis M.; Rensen, Patrick C. N.			Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in Gram-negative sepsis	FASEB JOURNAL			English	Article						inflammation; lipoprotein; macrophage; TNF-alpha; transgenic mice	TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTOR-4; HIGH-DENSITY-LIPOPROTEINS; FACTOR-ALPHA; TRANSGENIC MICE; IMMUNE-RESPONSE; ANIMAL-MODELS; LDL RECEPTOR; HOST-DEFENSE; APOC-I	Gram-negative sepsis is a major death cause in intensive care units. Accumulating evidence indicates the protective role of plasma lipoproteins such as high-density lipoprotein (HDL) in sepsis. It has recently been shown that septic HDL is almost depleted from apolipoprotein CI (apoCI), suggesting that apoCI may be a protective factor in sepsis. Sequence analysis revealed that apoCI possesses a highly conserved consensus KVKEKLK binding motif for lipopolysaccharide (LPS), an outer-membrane component of Gram-negative bacteria. Through avid binding to LPS involving this motif, apoCI improved the presentation of LPS to macrophages in vitro and in mice, thereby stimulating the inflammatory response to LPS. Moreover, apoCI dose-dependently increased the early inflammatory response to Klebsiella pneumoniae-induced pneumonia, reduced the number of circulating bacteria, and protected mice against fatal sepsis. Our data support the hypothesis that apoCI is a physiological protector against infection by enhancing the early inflammatory response to LPS and suggest that timely increase of apoCI levels could be used to efficiently prevent and treat early sepsis.	Leiden Univ, Dept Biomed Res, TNO Qual Life, Med Ctr, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Vasc Surg, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands; Univ Texas, SW Med Ctr, Dept Internal Med, Div Infect Dis, Dallas, TX USA; Erasmus MC, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Erasmus University Rotterdam; Erasmus MC	Rensen, PCN (corresponding author), Leiden Univ, Med Ctr, Dept Endocrinol & Metab, C4-R81,Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.	p.c.n.rensen@lumc.nl	Rensen, Patrick C.N./D-7176-2018	Rensen, Patrick C.N./0000-0002-8455-4988	NIAID NIH HHS [AI045896] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045896] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; BAGBY GJ, 1991, J INFECT DIS, V163, P83, DOI 10.1093/infdis/163.1.83; Bakker-Woudenberg IAJM, 2003, J MICROBIOL METH, V54, P295, DOI 10.1016/S0167-7012(03)00118-0; Barlage S, 2001, J LIPID RES, V42, P281; Berbee JFP, 2005, J LIPID RES, V46, P297, DOI 10.1194/jlr.M400301-JLR200; Bernheiden M, 2001, J ENDOTOXIN RES, V7, P447, DOI 10.1179/096805101101533061; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Branger J, 2004, INFECT IMMUN, V72, P788, DOI 10.1128/IAI.72.2.788-794.2004; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; Cohn JS, 2003, ATHEROSCLEROSIS, V169, P63, DOI 10.1016/S0021-9150(03)00139-4; CROSS AS, 1993, INFECT IMMUN, V61, P2741, DOI 10.1128/IAI.61.7.2741-2747.1993; de Bont N, 2000, EUR J CLIN INVEST, V30, P818; de Haas CJC, 1999, INFECT IMMUN, V67, P2790, DOI 10.1128/IAI.67.6.2790-2796.1999; Deitch EA, 1998, SHOCK, V9, P1, DOI 10.1097/00024382-199801000-00001; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; Echtenacher B, 2001, INFECT IMMUN, V69, P7271, DOI 10.1128/IAI.69.12.7172-7276.2001; Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1197, DOI 10.1164/rccm.200204-302OC; FLEGEL WA, 1993, INFECT IMMUN, V61, P5140, DOI 10.1128/IAI.61.12.5140-5146.1993; HAGBERG L, 1984, INFECT IMMUN, V46, P839, DOI 10.1128/IAI.46.3.839-844.1984; HARRIS HW, 1990, J CLIN INVEST, V86, P696, DOI 10.1172/JCI114765; Harris HW, 2000, J ENDOTOXIN RES, V6, P421, DOI 10.1177/09680519000060060301; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; Jong MC, 1996, J CLIN INVEST, V98, P2259, DOI 10.1172/JCI119036; Kleemann R, 2003, BLOOD, V101, P545, DOI 10.1182/blood-2002-06-1762; LARRICK JW, 1994, J IMMUNOL, V152, P231; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; MASTROENI P, 1991, MICROB PATHOGENESIS, V11, P33, DOI 10.1016/0882-4010(91)90091-N; Moore TA, 2003, SHOCK, V20, P309, DOI 10.1097/01.shk.0000087203.34916.45; Mullarkey M, 2003, J PHARMACOL EXP THER, V304, P1093, DOI 10.1124/jpet.102.044487; Nara C, 2004, J MED MICROBIOL, V53, P727, DOI 10.1099/jmm.0.45592-0; Netea MG, 2003, TRENDS IMMUNOL, V24, P254, DOI 10.1016/S1471-4906(03)00079-6; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; REHM SR, 1980, J CLIN INVEST, V66, P194, DOI 10.1172/JCI109844; Rensen PCN, 1997, J LIPID RES, V38, P1070; Rensen PCN, 1997, J CLIN INVEST, V99, P2438, DOI 10.1172/JCI119427; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Santo SMSE, 2005, J LIPID RES, V46, P1097, DOI 10.1194/jlr.C500007-JLR200; Schurr JR, 2005, INFECT IMMUN, V73, P532, DOI 10.1128/IAI.73.1.532-545.2005; Shachter NS, 1996, J CLIN INVEST, V98, P846, DOI 10.1172/JCI118857; Solomon SB, 2006, J INFECT DIS, V193, P634, DOI 10.1086/500147; Troelstra A, 1997, INFECT IMMUN, V65, P2272, DOI 10.1128/IAI.65.6.2272-2277.1997; van Dissel JT, 1998, LANCET, V351, P950, DOI 10.1016/S0140-6736(05)60606-X; Van Oosten MV, 2001, J BIOL CHEM, V276, P8820, DOI 10.1074/jbc.M009915200; vanderPoll T, 1997, AM J RESP CRIT CARE, V155, P603, DOI 10.1164/ajrccm.155.2.9032201; VANFURTH R, 1994, J INFECT DIS, V170, P234, DOI 10.1093/infdis/170.1.234; VANREE JH, 1995, BIOCHEM J, V305, P905, DOI 10.1042/bj3050905; Wang MJ, 1999, IMMUNOLOGY, V98, P90; Wang XR, 2002, J IMMUNOL, V168, P810, DOI 10.4049/jimmunol.168.2.810; WEINBERG RB, 1994, J LIPID RES, V35, P2212; WESTENDORP RGJ, 1995, J INFECT DIS, V171, P1057, DOI 10.1093/infdis/171.4.1057; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6; WOODS JP, 1988, INFECT IMMUN, V56, P1950, DOI 10.1128/IAI.56.8.1950-1955.1988	56	62	63	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2162	+		10.1096/fj.05-5639fje	http://dx.doi.org/10.1096/fj.05-5639fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935938				2022-12-28	WOS:000241156900053
J	Dimitrov, S; Lange, T; Benedict, C; Nowell, MA; Jones, SA; Scheller, J; Rose-John, S; Born, J				Dimitrov, Stoyan; Lange, Tanja; Benedict, Christian; Nowell, Mari A.; Jones, Simon A.; Scheller, Juergen; Rose-John, Stefan; Born, Jan			Sleep enhances IL-6 trans-signaling in humans	FASEB JOURNAL			English	Article						neuroimmunology; cytokine receptors; cytokines; hormones	NECROSIS-FACTOR-ALPHA; INTERLEUKIN-6 RECEPTOR; CYTOKINE PRODUCTION; GROWTH-HORMONE; IMMUNE-SYSTEM; PLASMA-LEVELS; SERUM; MODEL; DEPRIVATION; PERFORMANCE	Sleep is commonly considered to support immune defense. The underlying sleep-immune interaction appears to rely critically on cytokines, like interleukin-6 (IL-6), that combine effects on immune and neuronal functions. The IL-6 signal is conveyed in two ways: it stimulates a restricted group of (mostly immune) cells via membrane-bound IL-6 receptors (mIL-6R) by forming a complex with soluble IL-6R (sIL-6R), and it stimulates (via membrane-bound gp130) a great variety of other cell types-a process termed trans-signaling. Focusing on the receptor side of IL-6 signaling, we examined the effect of sleep on sIL-6R plasma concentrations, mIL-6R expression, plasma sgp130, and numbers of IL-6-producing monocytes in healthy humans who were tested during a regular sleep-wake cycle and 24 h of wakefulness while blood was sampled repeatedly. Sleep strongly enhanced concentrations of sIL-6R, exceeding wake levels by 70% at the end of sleep. This rise was due to an increase in the PC (proteolytic cleavage) rather than the DS (differentially spliced) variant of sIL-6R. Sleep did not affect IL-6-producing monocytes, mIL-6R density, or sgp130 concentrations. The selective increase in sIL-6R implicates an enhanced trans-signaling capacity whereby sleep distinctly widens the profile of IL-6 actions, enabling an integrated influence on brain and peripheral organs.	Med Univ Lubeck, Dept Neuroendocrinol, D-23538 Lubeck, Germany; Med Univ Lubeck, Dept Internal Med, D-23538 Lubeck, Germany; Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff, Wales; Univ Kiel, Dept Biochem, Kiel, Germany	University of Lubeck; University of Lubeck; Cardiff University; University of Kiel	Born, J (corresponding author), Med Univ Lubeck, Dept Neuroendocrinol, Ratzeburger Allee 160,Haus 23A, D-23538 Lubeck, Germany.	born@kfg.uni-luebeck.de	Benedict, Christian/K-2190-2017; Jones, Simon Arnett/Q-7017-2018; Lange, Tanja/Z-1688-2018; Born, Jan/K-2596-2016; Rose-John, Stefan/A-7998-2010	Benedict, Christian/0000-0002-8911-4068; Jones, Simon Arnett/0000-0001-7297-9711; Dimitrov, Stoyan/0000-0002-1184-1441; Lange, Tanja/0000-0001-8309-2112; Nowell, Mari/0000-0003-0053-0127; Born, Jan/0000-0002-1847-6248; Rose-John, Stefan/0000-0002-7519-3279				Adamopoulos S, 2002, AM HEART J, V144, P359, DOI 10.1067/mhj.2002.124052; Balschun D, 2004, FASEB J, V18, P1788, DOI 10.1096/fj.04-1625fje; Brattsand R, 1996, ALIMENT PHARM THERAP, V10, P81, DOI 10.1046/j.1365-2036.1996.22164025.x; Bryant PA, 2004, NAT REV IMMUNOL, V4, P457, DOI 10.1038/nri1369; Chen CK, 2004, ASIAN J CONTROL, V6, P130, DOI 10.1111/j.1934-6093.2004.tb00191.x; Cichy J, 1997, J IMMUNOL, V159, P5648; Ciftci TU, 2004, CYTOKINE, V28, P87, DOI 10.1016/j.cyto.2004.07.003; Cutolo M, 2003, ANN RHEUM DIS, V62, P593, DOI 10.1136/ard.62.7.593; Dimitrov S, 2004, BRAIN BEHAV IMMUN, V18, P341, DOI 10.1016/j.bbi.2003.08.004; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Franchimont N, 2005, ARTHRITIS RHEUM, V52, P84, DOI 10.1002/art.20727; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Gaillard JP, 1999, EUR CYTOKINE NETW, V10, P337; Guan ZW, 2005, BRAIN BEHAV IMMUN, V19, P526, DOI 10.1016/j.bbi.2005.01.005; Haack M, 2002, PSYCHONEUROENDOCRINO, V27, P921, DOI 10.1016/S0306-4530(02)00006-9; Horiuchi S, 1998, IMMUNOLOGY, V95, P360, DOI 10.1046/j.1365-2567.1998.00622.x; Hu J, 2003, BRAIN BEHAV IMMUN, V17, P498, DOI 10.1016/j.bbi.2003.03.001; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Irwin M, 2002, BRAIN BEHAV IMMUN, V16, P503, DOI 10.1016/S0889-1591(02)00003-X; Janke W., 1978, EIGENSCHAFTSWORTERLI; Jones R. A. C., 2001, Integrated Pest Management Reviews, V6, P15, DOI 10.1023/A:1020494604184; Jones SA, 2005, J INTERF CYTOK RES, V25, P241, DOI 10.1089/jir.2005.25.241; Krueger JM, 2003, ANN NY ACAD SCI, V992, P9, DOI 10.1111/j.1749-6632.2003.tb03133.x; Krueger JM, 1999, J SLEEP RES, V8, P53; Lenkei R, 1998, CYTOMETRY, V33, P188, DOI 10.1002/(SICI)1097-0320(19981001)33:2<188::AID-CYTO13>3.0.CO;2-Q; Majde JA, 2005, J ALLERGY CLIN IMMUN, V116, P1188, DOI 10.1016/j.jaci.2005.08.005; Marshall L, 2002, INT REV NEUROBIOL, V52, P93; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; McLoughlin RM, 2004, J IMMUNOL, V172, P5676, DOI 10.4049/jimmunol.172.9.5676; McLoughlin RM, 2005, P NATL ACAD SCI USA, V102, P9589, DOI 10.1073/pnas.0501794102; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; MOJON A, 1992, CHRONOBIOL INT, V9, P403, DOI 10.3109/07420529209064552; Nowell MA, 2003, J IMMUNOL, V171, P3202, DOI 10.4049/jimmunol.171.6.3202; Obal F, 2004, SLEEP MED REV, V8, P367, DOI 10.1016/j.smrv.2004.03.005; Petrovsky N, 2001, IMMUNOL CELL BIOL, V79, P350, DOI 10.1046/j.1440-1711.2001.01029.x; Petrovsky N, 1997, J IMMUNOL, V158, P5163; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; Redwine L, 2000, J CLIN ENDOCR METAB, V85, P3597, DOI 10.1210/jc.85.10.3597; Rose-John S, 2004, IMMUNITY, V20, P2, DOI 10.1016/S1074-7613(04)00003-2; Rose-John S, 2003, ACTA BIOCHIM POL, V50, P603; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SCHOBITZ B, 1995, FASEB J, V9, P659, DOI 10.1096/fasebj.9.8.7768358; Schroers A, 2005, PROTEIN SCI, V14, P783, DOI 10.1110/ps.041117105; Seres J, 2004, NEUROIMMUNOMODULAT, V11, P316, DOI 10.1159/000079412; Shearer WT, 2001, J ALLERGY CLIN IMMUN, V107, P165, DOI 10.1067/mai.2001.112270; SOTHERN RB, 1995, J ALLERGY CLIN IMMUN, V95, P1029, DOI 10.1016/S0091-6749(95)70104-4; Spath-Schwalbe E, 1998, J CLIN ENDOCR METAB, V83, P1573, DOI 10.1210/jc.83.5.1573; SPATHSCHWALBE E, 1994, J CLIN ENDOCR METAB, V79, P1212, DOI 10.1210/jc.79.4.1212; Sutherland ER, 2005, J ALLERGY CLIN IMMUN, V116, P1179, DOI 10.1016/j.jaci.2005.09.028; Tancredi V, 2000, J NEUROCHEM, V75, P634, DOI 10.1046/j.1471-4159.2000.0750634.x; Van Cauter E, 2000, GROWTH HORM IGF RES, V10, P57; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P2119, DOI 10.1210/jc.2003-031562; Vgontzas AN, 2005, NEUROIMMUNOMODULAT, V12, P131, DOI 10.1159/000084844; Vgontzas AN, 1999, J CLIN ENDOCR METAB, V84, P2603, DOI 10.1210/jc.84.8.2603; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P4409, DOI 10.1210/jc.2003-031929	56	81	82	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2174	+		10.1096/fj.06-5754fje	http://dx.doi.org/10.1096/fj.06-5754fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16912152				2022-12-28	WOS:000241156900061
J	Bjork, K; Saarikoski, ST; Arlinde, C; Kovanen, L; Osei-Hyiaman, D; Ubaldi, M; Reimers, M; Hyytia, P; Heilig, M; Sommer, WH				Bjork, K.; Saarikoski, S. T.; Arlinde, C.; Kovanen, L.; Osei-Hyiaman, D.; Ubaldi, M.; Reimers, M.; Hyytia, P.; Heilig, M.; Sommer, W. H.			Glutathione-S-transferase expression in the brain: possible role in ethanol preference and longevity	FASEB JOURNAL			English	Article						alcoholism; aging; animal model; microarray; haplotype	ALCOHOL-CONSUMPTION; ANTIOXIDANT SYSTEM; OXIDATIVE STRESS; ANIMAL-MODELS; GENETIC MODEL; RAT LINES; DETOXICATION; ASSOCIATION; ENZYMES; ALPHA	Identification of genes that are differentially expressed in rats bidirectionally selected for alcohol preference might reveal biological mechanisms underlying alcoholism or related phenotypes. Microarray analysis from medial prefrontal cortex (mPFC), a key brain region for drug reward, indicated increased expression of glutathione-S-transferases of the alpha (Gsta4) and mu (Gstm1-5) classes in ethanol-preferring AA rats compared with nonpreferring ANA rats. Real-time RT polymerase chain reaction (RT-PCR) analysis demonstrated similar to 2-fold higher Gsta4 transcript levels in several brain regions of ethanol-naive AA compared with ANA rats. Differences in mRNA levels were accompanied by differential levels of GSTA4 protein. We identified a novel haplotype variant in the rat Gsta4 gene, defined here as var3. Allele frequencies of var3 were markedly different between AA and ANA rats, 52% and 100%, respectively. Gsta4 expression was strongly correlated with the gene dose of var3, with similar to 60% of the variance in expression accounted for by genotype at this locus. The contribution of glutathione S-transferase expression to the ethanol-preferring phenotype is presently unclear. It could, however, underlie observed differences in life span between AA and ANA lines, prompting a utility of this animal model in aging research. - Bjork, K., Saarikoski, S. T., Arlinde, C., Kovanen, L., Osei-Hyiaman, D., Ubaldi, M., Reimers, M., Hyytia, P., Heilig, M. Sommer, W. H. Glutathione-S-transferase expression in the brain: possible role in ethanol preference and longevity.	NIAAA, Lab Clin & Translat Studies, NCI, NIH, Bethesda, MD USA; NIAAA, Lab Physiol Studies, NCI, NIH, Bethesda, MD USA; NIAAA, Mol Pharmacol Lab, NCI, NIH, Bethesda, MD USA; Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki, Finland; Univ Camerino, Dept Expt Med & Publ Hlth, I-62032 Camerino, Italy	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Karolinska Institutet; Finland National Institute for Health & Welfare; University of Camerino	Sommer, WH (corresponding author), NIAAA, Lab Clin & Translat Studies, NCI, NIH, 10 Center Dr,B 10,R 15330, Bethesda, MD USA.	wolfgang.sommer@mail.nih.gov	Sommer, Wolfgang H./I-4809-2019	Sommer, Wolfgang H./0000-0002-5903-6521; Osei-Hyiaman, Douglas/0000-0002-2725-5519; Hyytia, Petri/0000-0002-0284-1298; Ubaldi, Massimo/0000-0002-4089-2483; Kovanen, Leena/0000-0002-3552-124X	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000487, ZIAAA000487] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; [Anonymous], 1988, STAT POWER ANAL BEHA; Aoyama K, 2006, NAT NEUROSCI, V9, P119, DOI 10.1038/nn1609; Arlinde C, 2004, PHARMACOGENOMICS J, V4, P208, DOI 10.1038/sj.tpj.6500243; Awasthi YC, 2004, FREE RADICAL BIO MED, V37, P607, DOI 10.1016/j.freeradbiomed.2004.05.033; Baez S, 1997, BIOCHEM J, V324, P25, DOI 10.1042/bj3240025; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Brown-Borg HM, 2005, EXP GERONTOL, V40, P115, DOI 10.1016/j.exger.2004.11.004; Carr LG, 1998, ALCOHOL CLIN EXP RES, V22, P884, DOI 10.1097/00000374-199806000-00017; Cicero T.J., 1979, BIOCH PHARM ETHANOL, V2, P533; COMMANDEUR JNM, 1995, PHARMACOL REV, V47, P271; Covolo L, 2005, CANCER CAUSE CONTROL, V16, P831, DOI 10.1007/s10552-005-2302-2; de Leon J, 2005, J CLIN PSYCHOPHARM, V25, P448, DOI 10.1097/01.jcp.0000177546.34799.af; Desmots F, 2002, J BIOL CHEM, V277, P17892, DOI 10.1074/jbc.M112351200; Edenberg HJ, 2005, GENES BRAIN BEHAV, V4, P20, DOI 10.1111/j.1601-183X.2004.00091.x; Engle MR, 2004, TOXICOL APPL PHARM, V194, P296, DOI 10.1016/j.taap.2003.10.001; Engracia V, 2003, AM J MED GENET A, V123A, P257, DOI 10.1002/ajmg.a.20364; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; FEY GH, 1991, BIOCHIMIE, V73, P47, DOI 10.1016/0300-9084(91)90073-A; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; HANSSON AC, 2006, NEUROPSYCHOPHARMACOL; Harada S, 2001, BIOCHEM BIOPH RES CO, V281, P267, DOI 10.1006/bbrc.2001.4347; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396; HOLM S, 1979, SCAND J STAT, V6, P65; Hovatta I, 2005, NATURE, V438, P662, DOI 10.1038/nature04250; Hyytia P, 1999, N-S ARCH PHARMACOL, V360, P391, DOI 10.1007/s002109900070; JOHNSON JA, 1993, J NEUROSCI, V13, P2013; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Liang TB, 2004, ALCOHOL CLIN EXP RES, V28, P1622, DOI 10.1097/01.ALC.0000145686.79141.57; Martinez-Lara E, 2003, NEUROBIOL AGING, V24, P501, DOI 10.1016/S0197-4580(02)00139-2; McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40; Moller C, 1997, ALCOHOL CLIN EXP RES, V21, P656, DOI 10.1111/j.1530-0277.1997.tb03818.x; MONTOLIU C, 1995, J NEUROCHEM, V65, P2561; Moreau Y, 2003, TRENDS GENET, V19, P570, DOI 10.1016/j.tig.2003.08.006; Muller MM, 2006, P NATL ACAD SCI USA, V103, P14250, DOI 10.1073/pnas.0606668103; Murphy JM, 2002, BEHAV GENET, V32, P363, DOI 10.1023/A:1020266306135; Nordmann R, 1987, Alcohol Alcohol Suppl, V1, P75; Okubo T, 2003, ALCOHOL CLIN EXP RES, V27, p68S, DOI 10.1097/01.ALC.0000078616.63296.41; Pae CU, 2004, PSYCHIAT GENET, V14, P147, DOI 10.1097/00041444-200409000-00005; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Reddy SK, 1999, NEUROTOXICOLOGY, V20, P977; Reimers M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-166; Reimers M, 2005, METHODS, V37, P219, DOI 10.1016/j.ymeth.2005.09.002; Rodd ZA, 2004, PHARMACOL BIOCHEM BE, V79, P439, DOI 10.1016/j.pbb.2004.08.018; Saba L, 2006, MAMM GENOME, V17, P669, DOI 10.1007/s00335-005-0190-0; Salinas AE, 1999, CURR MED CHEM, V6, P279; Sarviharju M, 2004, ALCOHOL CLIN EXP RES, V28, P93, DOI 10.1097/01.ALC.0000106305.80993.6F; SeguraAguilar J, 1997, J BIOL CHEM, V272, P5727, DOI 10.1074/jbc.272.9.5727; Shao L, 2005, BIOL PSYCHIAT, V58, P879, DOI 10.1016/j.biopsych.2005.04.052; Shin Y, 2003, BRAIN RES, V968, P102, DOI 10.1016/S0006-8993(02)04279-8; SINCLAIR JD, 1989, EXPERIENTIA, V45, P798, DOI 10.1007/BF01954055; Sommer W, 2001, MOL PSYCHIATR, V6, P103, DOI 10.1038/sj.mp.4000823; Sommer WH, 2005, ADDICT BIOL, V10, P71, DOI 10.1080/13556210412331327821; STENBERG G, 1992, BIOCHEM J, V284, P313, DOI 10.1042/bj2840313; Toba G, 2000, GENE, V253, P179, DOI 10.1016/S0378-1119(00)00246-8; Wang JF, 2004, J NEUROCHEM, V88, P1477, DOI 10.1046/j.1471-4159.2003.02276.x; Yang YS, 2002, TOXICOL APPL PHARM, V182, P105, DOI 10.1006/taap.2002.9450	58	34	34	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1826	1835		10.1096/fj.06-5896com	http://dx.doi.org/10.1096/fj.06-5896com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940154				2022-12-28	WOS:000240267000010
J	Savinov, AY; Rozanov, DV; Strongin, AY				Savinov, Alexei Y.; Rozanov, Dmitri V.; Strongin, Alex Y.			Mechanistic insights into targeting T cell membrane proteinase to promote islet beta-cell rejuvenation in type 1 diabetes	FASEB JOURNAL			English	Article						IDDM; monoclonal antibody; CD44; MT1-MMP	MATRIX-METALLOPROTEINASE CLEAVES; CD44; MT1-MMP; MICE; ACTIVATION; INHIBITOR; REVERSAL; PRINOMASTAT; COLLAGENASE; PROTEOLYSIS	It has been well established that invasionpromoting membrane type-1 matrix metalloproteinase (MT1-MMP), a multifunctional membrane-tethered enzyme, functions in cancer cells as a mediator of pericellular proteolysis and directly cleaves several cell surface receptors, including CD44. In this report, we confirm that adhesion of diabetogenic T cells promotes the activation of endogenous MT1-MMP. Activated protease then cleaves CD44 in adherent T cells. We have validated that the T cell CD44 receptor is critical for the adhesion of diabetogenic insulin-specific, CD8-positive, K-d-restricted cells to the matrix as well as for the subsequent transmigration of the adherent T cells through the endothelium and homing of the transmigrated T cells into the pancreatic islets. We have determined that the inhibition of MT1-MMP by low dosages of AG3340 (a subnanomolar range hydroxamate inhibitor of MMPs that has been widely tested in cancer patients) inhibited both T cell MT1-MMP activity and MT1-MMP- dependent shedding of CD44, immobilized T cells on the endothelium, repressed the homing of diabetogenic T cells into the pancreatic islets, reduced insulitis and mononuclear cell infiltration, and promoted either the recovery or the rejuvenation of the functional insulin-producing beta cells in diabetic NOD mice with freshly developed type I diabetes (IDDM). We believe our data constitute a mechanistic and substantive rationale for clinical trials of selected MT1-MMP inhibitors in the therapy of IDDM in humans. - Savinov, A. Y., Rozanov, D. V., Strongin, A. Y. Mechanistic insights into targeting T cell membrane proteinase to promote islet beta-cell rejuvenation in type 1 diabetes.	Burnham Inst Med Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Strongin, AY (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NATIONAL CANCER INSTITUTE [R01CA077470, R01CA083017] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NCI NIH HHS [CA83017, CA77470] Funding Source: Medline; NCRR NIH HHS [RR020843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ablamunits V, 1999, CLIN EXP IMMUNOL, V115, P260, DOI 10.1046/j.1365-2249.1999.00802.x; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Annabi B, 2005, CLIN EXP METASTAS, V22, P429, DOI 10.1007/s10585-005-2669-1; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bissett D, 2005, J CLIN ONCOL, V23, P842, DOI 10.1200/JCO.2005.03.170; Chong AS, 2006, SCIENCE, V311, P1774, DOI 10.1126/science.1123510; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ezaki T, 2001, AM J PATHOL, V158, P2043, DOI 10.1016/S0002-9440(10)64676-7; Griffioen A W, 2000, IDrugs, V3, P336; Hande KR, 2004, CLIN CANCER RES, V10, P909, DOI 10.1158/1078-0432.CCR-0981-3; Holmbeck K, 2004, J CELL PHYSIOL, V200, P11, DOI 10.1002/jcp.20065; Homann D, 2004, CLIN IMMUNOL, V112, P202, DOI 10.1016/j.clim.2004.03.020; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Lee MH, 2002, PROTEIN SCI, V11, P2493, DOI 10.1110/ps.0216202; Luo ZR, 2005, TRANSPLANTATION, V79, P1091, DOI 10.1097/01.TP.0000161223.54452.A2; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nakamura H, 2004, CANCER RES, V64, P876, DOI 10.1158/0008-5472.CAN-03-3502; Nishio J, 2006, SCIENCE, V311, P1775, DOI 10.1126/science.1124004; Pomerleau DP, 2005, DIABETES, V54, P1603, DOI 10.2337/diabetes.54.5.1603; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Savinov AY, 2005, J BIOL CHEM, V280, P27755, DOI 10.1074/jbc.M506016200; Savinov AY, 2003, J EXP MED, V197, P643, DOI 10.1084/jem.20021378; Savinov AY, 2001, J IMMUNOL, V167, P6637, DOI 10.4049/jimmunol.167.11.6637; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suenaga N, 2005, ONCOGENE, V24, P859, DOI 10.1038/sj.onc.1208258; Suri A, 2006, SCIENCE, V311, P1778, DOI 10.1126/science.1123500; TRAISMAN HS, 1973, CLIN PEDIATR, V12, P357, DOI 10.1177/000992287301200612; Weiss L, 2000, P NATL ACAD SCI USA, V97, P285, DOI 10.1073/pnas.97.1.285; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wong FS, 1996, J EXP MED, V183, P67, DOI 10.1084/jem.183.1.67; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465; Zhou YP, 2005, DIABETES, V54, P2612, DOI 10.2337/diabetes.54.9.2612; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	41	11	11	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1793	1801		10.1096/fj.06-6207com	http://dx.doi.org/10.1096/fj.06-6207com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940151				2022-12-28	WOS:000240267000007
J	Nakayama, M; Iida, M; Koseki, H; Ohara, O				Nakayama, Manabu; Iida, Midori; Koseki, Haruhiko; Ohara, Osamu			A gene-targeting approach for functional characterization of KIAA genes encoding extremely large proteins	FASEB JOURNAL			English	Article						comprehensive analysis; functional genomics; human genome project; KO mice	UNIDENTIFIED HUMAN GENES; EGF-LIKE MOTIFS; COMPLETE SEQUENCES; CDNA-CLONES; IN-VITRO; CODING SEQUENCES; MOUSE GENOME; BRAIN; PREDICTION; CODE	Given that thousands of genes exist in the mammalian genome, criteria are needed to prioritize their functional analysis and to decrease the likelihood of producing gene-targeted mice that lack overt phenotypes. Initial analysis efforts are likely to be fruitful if focused on genes encoding large proteins, since at least some large proteins serve as frameworks for intricate assembly of protein complexes, and their inactivation would render definitive, observable phenotypes. Here, we describe the functional characterization of the murine homologues of five human KIAA genes (KIAA1409, KIAA1440, KIAA1447, KIAA1768, and KIAA1276) that encode large proteins. Gene-targeted mice had phenotypic and developmental defects resulting from the functional deletion of three of these five genes. Mice with targeted disruption of KIAA1409 lacked the ability to drink, and those with targeted disruption of KIAA1447 displayed hind leg motor dysfunction. Disruption of KIAA1440 led to embryonic lethality at the blastocyst stage. The high success rate of our approach demonstrates the rationale for the genome-wide functional examination of large proteins in mice using reverse genetics.	Chiba Univ, Grad Sch Pharmaceut Sci, Kausa DNA Re Inst, Dept Human Genome Technol, Chiba, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Lab Phamacogenom, Dept Human Genome Technol, Chiba, Japan; RIKEN, Inst Phys & Chem Res, Res Ctr Allergy & Immunol, Lab Dev Genet, Yokohama, Kanagawa, Japan; RIKEN, Inst Phys & Chem Res, Res Ctr Allergy & Immunol, Lab Immunogenom, Yokohama, Kanagawa, Japan	Chiba University; Chiba University; RIKEN; RIKEN	Nakayama, M (corresponding author), 2-6-7 Kazusa Kamatari, Chiba 2920818, Japan.	nmanabu@kazusa.or.jp	Koseki, Haruhiko/I-3825-2014; Ohara, Osamu/A-9119-2012; Ohara, Osamu/G-5448-2015	Koseki, Haruhiko/0000-0001-8424-5854; Ohara, Osamu/0000-0002-3328-9571				Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; Festing MFW, 1999, MAMM GENOME, V10, P836, DOI 10.1007/s003359901099; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Joyner AL, 2000, GENE TARGETING PRACT; Kikuno R, 2004, NUCLEIC ACIDS RES, V32, pD502, DOI 10.1093/nar/gkh035; Luo GB, 1998, P NATL ACAD SCI USA, V95, P10769, DOI 10.1073/pnas.95.18.10769; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Mitsui K, 2002, BIOCHEM BIOPH RES CO, V290, P1260, DOI 10.1006/bbrc.2002.6338; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Nagase T, 2000, DNA RES, V7, P143, DOI 10.1093/dnares/7.2.143; Nagase T, 2000, DNA RES, V7, P273; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; Nagase T, 2000, DNA RES, V7, P347, DOI 10.1093/dnares/7.6.347; Nakajima D, 2001, MOL BRAIN RES, V94, P85; Nakayama M, 2002, GENOME RES, V12, P1773, DOI 10.1101/gr.406902; Nakayama M, 2002, MOL CELL NEUROSCI, V20, P563, DOI 10.1006/mcne.2002.1146; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; Ohara O, 1997, DNA Res, V4, P53, DOI 10.1093/dnares/4.1.53; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Silva AJ, 1997, NEURON, V19, P755, DOI 10.1016/S0896-6273(00)80958-7; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Suzuki Y, 2003, DNA RES, V10, P263, DOI 10.1093/dnares/10.6.263; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Van der Weyden L, 2002, PHYSIOL GENOMICS, V11, P133, DOI 10.1152/physiolgenomics.00074.2002; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	31	24	28	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1718	+		10.1096/fj.06-5952fje	http://dx.doi.org/10.1096/fj.06-5952fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807365				2022-12-28	WOS:000240266600026
J	Wirth, HP; Yang, MQ; Sanabria-Valentin, E; Berg, DE; Dubois, A; Blaser, MJ				Wirth, Hans-Peter; Yang, Manqiao; Sanabria-Valentin, Edgardo; Berg, Douglas E.; Dubois, Andre; Blaser, Martin J.			Host Lewis phenotype-dependent Helicobacter pylori Lewis antigen expression in rhesus monkeys	FASEB JOURNAL			English	Article						bacterial pathogenesis; evolution; genetics; colonization; phase variation	BLOOD-GROUP ANTIGENS; EXPERIMENTAL-INFECTION; MONOCLONAL-ANTIBODIES; FUCOSYL-TRANSFERASE; NONHUMAN-PRIMATES; GENETIC DIVERSITY; PHASE VARIATION; MOUSE MODEL; O ANTIGEN; LIPOPOLYSACCHARIDE	Both human and H. pylori populations are polymorphic for the expression of Lewis antigens. Using an experimental H. pylori challenge of rhesus monkeys of differing Lewis phenotypes, we aimed to determine whether H. pylori populations adapt their Lewis phenotypes to those of their hosts. After inoculation of four monkeys with a mixture of seven strains identified by RAPD-polymerase chain reaction, H. pylori Lewis expression was followed in 86 isolates obtained over 40 wk. Host Lewis(a/b) secretion status was characterized by immunological assays. Fingerprints of the predominating strain (J166) were identical in all four animals after 40 wk, but its Lewis phenotype had substantial variability in individual hosts. At 40 wk, J166 populations from two Lewis(a-b+) animals predominantly expressed Lewis(y). In contrast, J166 populations had switched to a Lewis(x) dominant phenotype in the two Lewis(a+b-) animals; a frame shift in futC, regulating conversion of Lewis(x) to Lewis(y), accounted for the phenotypic switch. The results indicate that individual cells in H. pylori populations can change Lewis phenotypes during long-term colonization of natural hosts to resemble those of their hosts, providing evidence for host selection for bacterial phenotypes.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; VA Med Ctr, New York, NY 10016 USA; Univ Zurich, Sch Med, Div Gastroenterol, Zurich, Switzerland; Vanderbilt Univ, Sch Med, Div Infect Dis, Nashville, TN USA; VA Med Ctr, Nashville, TN USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO USA; Uniformed Serv Univ Hlth Sci, Dept Med, Div Digest Dis, Lab Gastrointestinal & Liver Studies, Bethesda, MD 20814 USA	New York University; New York University; University of Zurich; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Washington University (WUSTL); Washington University (WUSTL); Uniformed Services University of the Health Sciences - USA	Blaser, MJ (corresponding author), NYU, Sch Med, Dept Med, 550 1St Ave, New York, NY 10016 USA.	martin.blaser@med.nyu.edu			NCI NIH HHS [R01 CA082312-06, R01 CA082312, R01 CA82312] Funding Source: Medline; NIAID NIH HHS [AI38166] Funding Source: Medline; NIDDK NIH HHS [P30 DK052574, R01DK53707, P30DK52574, DK53727] Funding Source: Medline; NIGMS NIH HHS [GM63270, R01 GM063270] Funding Source: Medline; CGH CDC HHS [GH070098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053707, P30DK052574, R01DK053727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CGH CDC HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P5137, DOI 10.1093/nar/20.19.5137; AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P6221, DOI 10.1093/nar/20.23.6221; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Amano K, 1997, CLIN DIAGN LAB IMMUN, V4, P540, DOI 10.1128/CDLI.4.5.540-544.1997; Appelmelk BJ, 1999, INFECT IMMUN, V67, P5361, DOI 10.1128/IAI.67.10.5361-5366.1999; Appelmelk BJ, 1998, INFECT IMMUN, V66, P70, DOI 10.1128/IAI.66.1.70-76.1998; Appelmelk BJ, 1996, INFECT IMMUN, V64, P2031, DOI 10.1128/IAI.64.6.2031-2040.1996; Aras RA, 2003, P NATL ACAD SCI USA, V100, P13579, DOI 10.1073/pnas.1735481100; Aras RA, 2003, J INFECT DIS, V188, P486, DOI 10.1086/377098; ASPINALL GO, 1994, CARBOHYDR LETT, V0001; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2489, DOI 10.1021/bi951852s; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2498, DOI 10.1021/bi951853k; Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI [10.1172/JCI200420925, 10.1172/JCI20925]; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; CHAN NWC, 1995, GLYCOBIOLOGY, V5, P683, DOI 10.1093/glycob/5.7.683; Claeys D, 1998, GASTROENTEROLOGY, V115, P340, DOI 10.1016/S0016-5085(98)70200-8; DAVIDSON JS, 1992, GASTROENTEROLOGY, V103, P1552, DOI 10.1016/0016-5085(92)91177-6; Dubois A, 1999, GASTROENTEROLOGY, V116, P90, DOI 10.1016/S0016-5085(99)70232-5; Dubois A, 1996, INFECT IMMUN, V64, P2885, DOI 10.1128/IAI.64.8.2885-2891.1996; Dubois A, 1998, J GASTROENTEROL, V33, P18, DOI 10.1007/PL00009961; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; Falush D, 2001, P NATL ACAD SCI USA, V98, P15056, DOI 10.1073/pnas.251396098; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; Gibson JR, 1998, LETT APPL MICROBIOL, V26, P399, DOI 10.1046/j.1472-765X.1998.00361.x; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; HARRIS PA, 1991, MONOGRAPH DADE ED, P22; Heneghan MA, 2000, INFECT IMMUN, V68, P937, DOI 10.1128/IAI.68.2.937-941.2000; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Israel DA, 2001, P NATL ACAD SCI USA, V98, P14625, DOI 10.1073/pnas.251551698; Kuipers EJ, 2000, J INFECT DIS, V181, P273, DOI 10.1086/315173; Kurtenkov O, 1999, FEMS IMMUNOL MED MIC, V24, P227, DOI 10.1111/j.1574-695X.1999.tb01287.x; LEVIN BR, 1981, GENETICS, V99, P1; Linden S, 2004, BIOCHEM J, V379, P765, DOI 10.1042/BJ20031557; Linden S, 2002, GASTROENTEROLOGY, V123, P1923, DOI 10.1053/gast.2002.37076; LINDEN S, 2003, GASTROENTEROLOGY, V124, pW885; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; MOLLICONE R, 1985, LAB INVEST, V53, P219; Monteiro MA, 2000, EUR J BIOCHEM, V267, P305, DOI 10.1046/j.1432-1327.2000.01007.x; Monteiro MA, 1998, J BIOL CHEM, V273, P11533, DOI 10.1074/jbc.273.19.11533; MURATA K, 1992, AM J CLIN PATHOL, V98, P67, DOI 10.1093/ajcp/98.1.67; Negrini R, 1996, GASTROENTEROLOGY, V111, P655, DOI 10.1053/gast.1996.v111.pm8780570; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Rasko DA, 2000, J BIOL CHEM, V275, P4988, DOI 10.1074/jbc.275.7.4988; SAKAMOTO J, 1989, CANCER RES, V49, P745; Salama N, 2000, P NATL ACAD SCI USA, V97, P14668, DOI 10.1073/pnas.97.26.14668; Salaun L, 2004, MICROBIOL-SGM, V150, P817, DOI 10.1099/mic.0.26993-0; SHERBURNE R, 1995, INFECT IMMUN, V63, P4564, DOI 10.1128/IAI.63.12.4564-4568.1995; SimoonsSmit IM, 1996, J CLIN MICROBIOL, V34, P2196, DOI 10.1128/JCM.34.9.2196-2200.1996; Socha WW, 1995, J MED PRIMATOL, V24, P282, DOI 10.1111/j.1600-0684.1995.tb00182.x; SOCHA WW, 1983, BLOOD GROUPS PRIMATE, P128; Solnick JV, 2004, P NATL ACAD SCI USA, V101, P2106, DOI 10.1073/pnas.0308573100; Solnick JV, 2001, INFECT IMMUN, V69, P6887, DOI 10.1128/IAI.69.11.6887-6892.2001; Takata T, 2002, INFECT IMMUN, V70, P3073, DOI 10.1128/IAI.70.6.3073-3079.2002; Taylor DE, 1998, GASTROENTEROLOGY, V115, P1113, DOI 10.1016/S0016-5085(98)70082-4; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TORRADO J, 1989, AM J CLIN PATHOL, V91, P249, DOI 10.1093/ajcp/91.3.249; Wang G, 1999, MOL MICROBIOL, V31, P1265, DOI 10.1046/j.1365-2958.1999.01268.x; Wang G, 2000, MOL MICROBIOL, V36, P1187, DOI 10.1046/j.1365-2958.2000.01934.x; Webb GF, 2002, P NATL ACAD SCI USA, V99, P3135, DOI 10.1073/pnas.042685799; Wirth HP, 1997, GASTROENTEROLOGY, V113, P1091, DOI 10.1053/gast.1997.v113.pm9322503; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996; Wirth HP, 1998, INFECT IMMUN, V66, P4856, DOI 10.1128/IAI.66.10.4856-4866.1998; Wirth HP, 1999, J LAB CLIN MED, V133, P488, DOI 10.1016/S0022-2143(99)90026-4; Yokota SI, 1998, INFECT IMMUN, V66, P3006, DOI 10.1128/IAI.66.6.3006-3011.1998	66	28	32	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1534	+		10.1096/fj.05-5529fje	http://dx.doi.org/10.1096/fj.05-5529fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16720729	Green Accepted			2022-12-28	WOS:000240266000042
J	Rege, TA; Hagood, JS				Rege, Tanya A.; Hagood, James S.			Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis	FASEB JOURNAL			English	Review						neurite outgrowth; tumor suppressor; GPI anchor; wound healing	LUNG FIBROBLAST SUBPOPULATIONS; HUMAN OVARIAN-CANCER; MICROVASCULAR ENDOTHELIAL-CELLS; SURFACE GLYCOPROTEIN THY-1; GLOMERULAR MESANGIAL CELLS; DIFFERENTIAL EXPRESSION; NEURITE OUTGROWTH; MOLECULE THY-1; GROWTH-FACTOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR	Thy-1 (CD90) is a 25-37 kDa glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed on many cell types, including T cells, thymocytes, neurons, endothelial cells, and fibroblasts. Activation of Thy- 1 can promote T cell activation, and this role of Thy- 1 is reviewed elsewhere. Thy- 1 also affects numerous nonimmunologic biological processes, including cellular adhesion, neurite outgrowth, tumor growth, migration, and cell death. In reviewing the nonimmunologic functions of Thy- 1, we discuss the phenotype of the Thy- 1 null mouse, signaling pathways modulated by Thy- 1, the role of the GPI anchor in Thy- 1 localization to lipid rafts and signaling, and regulation of Thy- 1 expression. Thy- 1 is an important regulator of cell-cell and cell-matrix interactions, with important roles in nerve regeneration, metastasis, inflammation, and fibrosis.	Univ Alabama, Dept Pediat & Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Med Sci Training Program, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Hagood, JS (corresponding author), Univ Alabama, Dept Pediat & Cell Biol, VH 648A,1670 Univ Blvd, Birmingham, AL 35294 USA.	jhagood@peds.uab.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015490] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS049674] Funding Source: NIH RePORTER; NCRR NIH HHS [C06 RR 15490] Funding Source: Medline; NHLBI NIH HHS [HL065348] Funding Source: Medline; NINDS NIH HHS [NS49674] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeysinghe HR, 2005, CANCER GENET CYTOGEN, V161, P151, DOI 10.1016/j.cancergencyto.2005.02.014; Abeysinghe HR, 2004, CANCER GENET CYTOGEN, V149, P1, DOI 10.1016/S0165-4608(03)00234-6; Abeysinghe HR, 2003, CANCER GENET CYTOGEN, V143, P125, DOI 10.1016/S0165-4608(02)00855-5; AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; ALMQVIST P, 1988, J BIOL CHEM, V263, P12709; Avalos AM, 2004, J BIOL CHEM, V279, P39139, DOI 10.1074/jbc.M403439200; Avalos AM, 2002, BIOL RES, V35, P231, DOI 10.4067/S0716-97602002000200015; BARBONI E, 1995, J CELL SCI, V108, P487; Barbosa J., 1991, MAT CONT, V1, P3; Barker TH, 2004, J BIOL CHEM, V279, P23510, DOI 10.1074/jbc.M402169200; Barker TH, 2004, EXP CELL RES, V295, P488, DOI 10.1016/j.yexcr.2004.01.026; Barlow JZ, 2000, J COMP NEUROL, V421, P215, DOI 10.1002/(SICI)1096-9861(20000529)421:2<215::AID-CNE7>3.0.CO;2-U; Barlow JZ, 2002, NEUROSCIENCE, V111, P837, DOI 10.1016/S0306-4522(02)00023-4; Beissert S, 1998, J IMMUNOL, V161, P5296; Borrello MA, 1996, CELL IMMUNOL, V173, P198, DOI 10.1006/cimm.1996.0268; Brugger B, 2004, J BIOL CHEM, V279, P7530, DOI 10.1074/jbc.M310207200; BUKOVSKY A, 1983, IMMUNOLOGY, V48, P587; Chen CH, 2005, J CELL BIOCHEM, V94, P684, DOI 10.1002/jcb.20341; Choi J, 2005, BIOCHEM BIOPH RES CO, V331, P557, DOI 10.1016/j.bbrc.2005.04.006; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; DERDAK S, 1992, AM J PHYSIOL, V263, pL283, DOI 10.1152/ajplung.1992.263.2.L283; Desmouliere A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x; Devasahayam M, 1999, GLYCOBIOLOGY, V9, P1381, DOI 10.1093/glycob/9.12.1381; DOHERTY P, 1993, J CELL BIOL, V122, P181, DOI 10.1083/jcb.122.1.181; DREYER EB, 1995, P NATL ACAD SCI USA, V92, P11195, DOI 10.1073/pnas.92.24.11195; Durrheim GA, 2001, CELL BIOL INT, V25, P33, DOI 10.1006/cbir.2000.0675; FREIMUTH WW, 1978, J IMMUNOL, V120, P1651; FRIES KM, 1994, CLIN IMMUNOL IMMUNOP, V72, P283, DOI 10.1006/clin.1994.1144; Fujita N, 1997, EXP CELL RES, V232, P400, DOI 10.1006/excr.1997.3505; Fujita N, 1996, INT J CANCER, V66, P544; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Haeryfar SMM, 2004, J IMMUNOL, V173, P3581, DOI 10.4049/jimmunol.173.6.3581; Hagood JS, 2005, AM J PATHOL, V167, P365, DOI 10.1016/S0002-9440(10)62982-3; Hagood JS, 2002, AM J RESP CELL MOL, V26, P702, DOI 10.1165/ajrcmb.26.6.4547; Hagood JS, 2001, CHEST, V120, p64S, DOI 10.1378/chest.120.1_suppl.S64; Hagood JS, 1999, AM J PHYSIOL-LUNG C, V277, pL218, DOI 10.1152/ajplung.1999.277.1.L218; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HE HT, 1991, J EXP MED, V173, P515, DOI 10.1084/jem.173.2.515; Henke RC, 1997, J NEUROSCI RES, V49, P655, DOI 10.1002/(SICI)1097-4547(19970915)49:6<655::AID-JNR1>3.3.CO;2-0; Hollrigel GS, 1998, P ROY SOC B-BIOL SCI, V265, P63, DOI 10.1098/rspb.1998.0265; HUEBER AO, 1994, J EXP MED, V179, P785, DOI 10.1084/jem.179.3.785; Hueber AO, 1997, CURR BIOL, V7, P705, DOI 10.1016/S0960-9822(06)00300-9; JOHNSON RJ, 1990, AM J PATHOL, V136, P369; KEMSHEAD JT, 1982, BRAIN RES, V236, P451, DOI 10.1016/0006-8993(82)90727-2; Koumas L, 2003, AM J PATHOL, V163, P1291, DOI 10.1016/S0002-9440(10)63488-8; Kukulansky T, 1999, J IMMUNOL, V162, P5993; Leis M, 2004, J GEN VIROL, V85, P1995, DOI 10.1099/vir.0.79818-0; Leyton L, 1999, MOL IMMUNOL, V36, P755, DOI 10.1016/S0161-5890(99)00086-3; Leyton L, 2001, CURR BIOL, V11, P1028, DOI 10.1016/S0960-9822(01)00262-7; Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812; Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Mayeux-Portas V, 2000, CURR BIOL, V10, P68, DOI 10.1016/S0960-9822(99)00278-X; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Mosley K, 2000, VIRCHOWS ARCH, V436, P567, DOI 10.1007/s004289900167; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; NarisawaSaito M, 1996, J CELL PHYSIOL, V168, P705; NarisawaSaito M, 1996, CLIN EXP IMMUNOL, V106, P86, DOI 10.1046/j.1365-2249.1996.d01-800.x; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; Pei Y, 2004, EXP EYE RES, V79, P705, DOI 10.1016/j.exer.2004.08.002; PENNEY DP, 1992, ANAT RECORD, V232, P432, DOI 10.1002/ar.1092320312; PHIPPS RP, 1990, EUR J IMMUNOL, V20, P1723, DOI 10.1002/eji.1830200815; PHIPPS RP, 1989, AM J RESP CELL MOL, V1, P65, DOI 10.1165/ajrcmb/1.1.65; PRESL J, 1986, BIOL REPROD, V34, P159, DOI 10.1095/biolreprod34.1.159; Saalbach A, 1999, CELL TISSUE RES, V298, P307, DOI 10.1007/s004419900079; Saalbach A, 2000, J INVEST DERMATOL, V115, P882, DOI 10.1046/j.1523-1747.2000.00104.x; Saalbach A, 2005, ONCOGENE, V24, P4710, DOI 10.1038/sj.onc.1208559; Saalbach A, 1996, J INVEST DERMATOL, V106, P1314, DOI 10.1111/1523-1747.ep12349035; Saalbach A, 2002, MICROVASC RES, V64, P86, DOI 10.1006/mvre.2002.2401; Saalbach A, 1998, ARCH DERMATOL RES, V290, P360, DOI 10.1007/s004030050318; SALEH M, 1989, J NEUROIMMUNOL, V23, P203, DOI 10.1016/0165-5728(89)90052-0; Sato T, 1996, KIDNEY INT, V49, P403, DOI 10.1038/ki.1996.59; Sato T, 1997, KIDNEY INT, V51, P173, DOI 10.1038/ki.1997.21; Schlamp CL, 2001, MOL VIS, V7, P192; Seki M, 2002, NEUROSCI LETT, V329, P185, DOI 10.1016/S0304-3940(02)00654-7; SEKI T, 1985, P NATL ACAD SCI USA, V82, P6657, DOI 10.1073/pnas.82.19.6657; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SILVERA MR, 1995, J INTERF CYTOK RES, V15, P63, DOI 10.1089/jir.1995.15.63; SILVERA MR, 1994, LYMPHOKINE CYTOK RES, V13, P277; Simon PD, 1999, DEV BRAIN RES, V117, P219, DOI 10.1016/S0165-3806(99)00123-6; STOHL W, 1977, J IMMUNOL, V119, P422; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TIVERON MC, 1992, NATURE, V355, P745, DOI 10.1038/355745a0; TIVERON MC, 1994, J CELL SCI, V107, P1783; Wang XS, 2004, J NEUROL SCI, V220, P59, DOI 10.1016/j.jns.2004.02.004; Wetzel A, 2004, J IMMUNOL, V172, P3850, DOI 10.4049/jimmunol.172.6.3850; White ES, 2003, J PATHOL, V201, P343, DOI 10.1002/path.1446; WILLIAMS AF, 1982, SCIENCE, V216, P696, DOI 10.1126/science.6177036; XUE GP, 1991, DEVELOPMENT, V112, P161; XUE GP, 1992, J NEUROCHEM, V58, P430, DOI 10.1111/j.1471-4159.1992.tb09740.x; XUE GP, 1990, DEVELOPMENT, V109, P815; YAMAMOTO T, 1987, KIDNEY INT, V32, P514, DOI 10.1038/ki.1987.240; Zhou Y, 2004, AM J PATHOL, V165, P659, DOI 10.1016/S0002-9440(10)63330-5	93	249	266	2	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1045	1054		10.1096/fj.05-5460rev	http://dx.doi.org/10.1096/fj.05-5460rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770003				2022-12-28	WOS:000240210300004
J	Kolonin, MG; Sun, J; Do, KA; Vidal, CI; Ji, Y; Baggerly, KA; Pasqualini, R; Arap, W				Kolonin, Mikhail G.; Sun, Jessica; Do, Kim-Anh; Vidal, Claudia I.; Ji, Yuan; Baggerly, Keith A.; Pasqualini, Renata; Arap, Wadih			Synchronous selection of homing peptides for multiple tissues by in vivo phage display	FASEB JOURNAL			English	Article						vascular; receptor; ligand; combinatorial peptide library; phage display	PLACENTAL-LACTOGEN; EXTRACELLULAR DOMAIN; PRL RECEPTOR; PROLACTIN; MOUSE; VASCULATURE; EXPRESSION; ISLETS; TARGET	In vivo phage display is a technology used to reveal organ-specific vascular ligand-receptor systems in animal models and, recently, in patients, and to validate them as potential therapy targets. Here, we devised an efficient approach to simultaneously screen phage display libraries for peptides homing to any number of tissues without the need for an individual subject for each target tissue. We tested this approach in mice by selecting homing peptides for six different organs in a single screen and prioritizing them by using software compiled for statistical validation of peptide biodistribution specificity. We identified a number of motif-containing biological candidates for ligands binding to organ-selective receptors based on similarity of the selected peptide motifs to mouse proteins. To demonstrate that this methodology can lead to targetable ligand-receptor systems, we validated one of the pancreas-homing peptides as a mimic peptide of natural prolactin receptor ligands. This new comprehensive strategy for screening phage libraries in vivo provides an advantage over the conventional approach because multiple organs internally control for organ selectivity of each other in the successive rounds of selection. It may prove particularly relevant for patient studies, allowing efficient high-throughput selection of targeting ligands for multiple organs in a single screen.	Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Pasqualini, R (corresponding author), 1515 Holcombe Blvd, Houston, TX 77030 USA.	rpasqual@mdanderson.org; warap@mdanderson.org		Kolonin, Mikhail/0000-0002-3743-7869	NATIONAL CANCER INSTITUTE [U54CA090810, P50CA090270, P30CA016672, R33CA103030, R21CA111853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067683] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672, CA90270, CA111853, CA103030, CA90810] Funding Source: Medline; NIDDK NIH HHS [DK67683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BRELJE TC, 1993, ENDOCRINOLOGY, V132, P879, DOI 10.1210/en.132.2.879; Brelje TC, 2002, J HISTOCHEM CYTOCHEM, V50, P365, DOI 10.1177/002215540205000308; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Carlin BP, 1996, STAT MED, V15, P1093, DOI 10.1002/(SICI)1097-0258(19960615)15:11<1093::AID-SIM231>3.0.CO;2-0; Elkins PA, 2000, NAT STRUCT BIOL, V7, P808, DOI 10.1038/79047; Freemark M, 2002, ENDOCRINOLOGY, V143, P1378, DOI 10.1210/en.143.4.1378; Gelman A, 1996, Stat Methods Med Res, V5, P339, DOI 10.1177/096228029600500402; Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249; Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049; Kolonin M, 2001, CURR OPIN CHEM BIOL, V5, P308, DOI 10.1016/S1367-5931(00)00207-6; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Kolonin MG, 2002, P NATL ACAD SCI USA, V99, P13055, DOI 10.1073/pnas.162468499; KOLONIN MG, 2003, GENETICS ANGIOGENESI; Krebs LT, 2000, GENE DEV, V14, P1343; Lee KE, 2003, BIOINFORMATICS, V19, P90, DOI 10.1093/bioinformatics/19.1.90; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; Pasqualini R, 2000, CANCER RES, V60, P722; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PASQUALINI R, 2001, PHAGE DISPLAY LAB MA; Pentz RD, 2003, HASTINGS CENT REP, V33, P20, DOI 10.2307/3527910; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Vasavada RC, 2000, J BIOL CHEM, V275, P15399, DOI 10.1074/jbc.275.20.15399; Wang YF, 1997, MOL ENDOCRINOL, V11, P1353, DOI 10.1210/me.11.9.1353; Wiemers DO, 2003, ENDOCRINOLOGY, V144, P313, DOI 10.1210/en.2002-220724; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zurita AJ, 2004, CANCER RES, V64, P435, DOI 10.1158/0008-5472.CAN-03-2675	30	111	127	2	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					979	+		10.1096/fj.05-5186fje	http://dx.doi.org/10.1096/fj.05-5186fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16581960				2022-12-28	WOS:000240157700028
J	Menne, J; Park, JK; Agrawal, R; Lindschau, C; Kielstein, JT; Kirsch, T; Marx, A; Muller, D; Bahlmann, FH; Meier, M; Bode-Boger, SM; Haller, H; Fliser, D				Menne, Jan; Park, Joon-Keun; Agrawal, Rahul; Lindschau, Carsten; Kielstein, Jan T.; Kirsch, Torsten; Marx, Axel; Muller, Dominik; Bahlmann, Ferdinand H.; Meier, Matthias; Bode-Boeger, Stefanie M.; Haller, Hermann; Fliser, Danilo			Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers	FASEB JOURNAL			English	Article						angiotensin II; protein kinase C; asymmetric dimethylarginine; lercanidipine	PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE SYNTHASE; STAGE RENAL-DISEASE; ANGIOTENSIN-II; ASYMMETRICAL DIMETHYLARGININE; ENDOTHELIAL-CELLS; GROWTH-FACTOR; HUMAN RENIN; TNF-ALPHA	Long-acting third-generation dihydropyridine calcium channel blockers (CCBs) improve endothelial dysfunction and prevent cardiovascular events in humans, but their cellular and molecular mechanisms of tissue protection are not elucidated in detail. We assessed organ (renal) protection by the highly lipophilic CCB lercanidipine in a double-transgenic rat (dTGR) model with overexpression of human renin and angiotensinogen genes. We randomly treated dTGR with lercanidipine (2.5 mg/ kg/ day; n = 20) or vehicle (n = 20) for 3 wk. Furthermore, we explored the influence of lercanidipine on protein kinase C (PKC) signaling in vivo and in vitro using endothelial and vascular smooth muscle cell cultures. Cumulative mortality was 60% in untreated dTGR, whereas none of the lercanidipine-treated animals died (P < 0.001). We found significantly less albuminuria and improved renal function in lercanidipine-treated dTGR (both P < 0.05). Lercanidipine treatment also significantly (P < 0.05) reduced blood levels of the endogenous NOS inhibitor asymmetric dimethylarginine. On histological examination, we observed significantly less tissue inflammation and fibrosis in lercanidipine-treated animals (both P < 0.05). Lercanidipine significantly inhibited angiotensin (ANG) I-mediated PKC-alpha and -delta activation in vivo and in vitro, partly due to reduced intracellular calcium flux. As a result, lercanidipine improved endothelial cell permeability in vitro. Lercanidipine prevents tissue injury and improves survival in a model of progressive organ damage. These effects may result, at least in part, from inhibition of tissue inflammation as well as improved NO bioavailability. Modulation of PKC activity may be an important underlying intracellular mechanism.	Hannover Med Sch, Dept Internal Med, D-30625 Hannover, Germany; Berlin Chem AG, Berlin, Germany; Klinikum Charite, Franz Vollhard Clin, Berlin, Germany; Univ Magdeburg, Inst Clin Pharmacol, D-39106 Magdeburg, Germany	Hannover Medical School; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Otto von Guericke University	Menne, J (corresponding author), Hannover Med Sch, Dept Internal Med, Carl Neuberg Str 1, D-30625 Hannover, Germany.	janmenne@gmx.de	Kielstein, Jan T./I-2956-2019; Kirsch, Torsten/B-7773-2015; Lindschau, Carsten/G-1798-2011; Lindschau, Carsten/AAE-6721-2020	Kielstein, Jan T./0000-0001-8110-9064; Kirsch, Torsten/0000-0002-0751-5432; Lindschau, Carsten/0000-0003-1960-099X; Bode-Boger, Stefanie/0000-0002-5132-6591; Muller, Dominik N/0000-0003-3650-5644				BERK BC, 1987, J BIOL CHEM, V262, P5057; Berkels R, 2003, PHARMACOLOGY, V69, P171, DOI 10.1159/000073659; Boger RH, 1998, CIRCULATION, V98, P1842, DOI 10.1161/01.CIR.98.18.1842; Bohlender J, 1997, HYPERTENSION, V29, P428, DOI 10.1161/01.HYP.29.1.428; Braz JC, 2004, NAT MED, V10, P248, DOI 10.1038/nm1000; Chang YJ, 2002, J BIOL CHEM, V277, P7118, DOI 10.1074/jbc.M109924200; Cominacini L, 1999, J HYPERTENS, V17, P1837, DOI 10.1097/00004872-199917121-00009; Cooke JP, 2004, CIRCULATION, V109, P1813, DOI 10.1161/01.CIR.0000126823.07732.D5; Dayoub H, 2003, CIRCULATION, V108, P3042, DOI 10.1161/01.CIR.0000101924.04515.2E; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Grossman E, 2004, PROG CARDIOVASC DIS, V47, P34, DOI 10.1016/j.pcad.2004.04.006; Hahn HS, 2003, CIRC RES, V93, P1111, DOI 10.1161/01.RES.0000105087.79373.17; HALLER H, 1994, HYPERTENSION, V23, P848, DOI 10.1161/01.HYP.23.6.848; HALLER H, 1993, AM J KIDNEY DIS, V21, P26; Haller H, 1998, LANCET, V351, P945; HALLER H, 1994, KIDNEY INT, V46, P1653, DOI 10.1038/ki.1994.465; Hempel A, 1997, CIRC RES, V81, P363, DOI 10.1161/01.RES.81.3.363; Hempel A, 1999, CIRCULATION, V99, P2523, DOI 10.1161/01.CIR.99.19.2523; Hilgers KF, 1996, KIDNEY BLOOD PRESS R, V19, P254, DOI 10.1159/000174085; Hisayama T, 1999, Nihon Yakurigaku Zasshi, V114 Suppl 1, p86P; ISHIDOYA S, 1995, KIDNEY INT, V47, P1285, DOI 10.1038/ki.1995.183; Kielstein JT, 2004, CIRCULATION, V109, P172, DOI 10.1161/01.CIR.0000105764.22626.B1; Kielstein JT, 1999, J AM SOC NEPHROL, V10, P594; Kilian K, 2004, J BIOL CHEM, V279, P34472, DOI 10.1074/jbc.M405916200; Leiper J, 2002, P NATL ACAD SCI USA, V99, P13527, DOI 10.1073/pnas.212269799; Luft FC, 1999, HYPERTENSION, V33, P212, DOI 10.1161/01.HYP.33.1.212; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Martens-Lobenhoffer J, 2003, J CHROMATOGR B, V798, P231, DOI 10.1016/j.jchromb.2003.09.050; Menne J, 2004, DIABETES, V53, P2101, DOI 10.2337/diabetes.53.8.2101; Mervaala E, 2000, HYPERTENSION, V35, P587, DOI 10.1161/01.HYP.35.2.587; Muth JN, 2001, CIRCULATION, V103, P140; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oriji GK, 1999, PROSTAG LEUKOTR ESS, V61, P113, DOI 10.1054/plef.1999.0079; Orth SR, 1996, KIDNEY INT, V49, P868, DOI 10.1038/ki.1996.120; Osicka TM, 2001, CLIN SCI, V100, P249, DOI 10.1042/CS20000194; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Ruschitzka F, 1999, J Hypertens Suppl, V17, pS25; Sabbatini M, 2000, J PHARMACOL EXP THER, V294, P948; Taddei S, 2003, HYPERTENSION, V41, P950, DOI 10.1161/01.HYP.0000063361.70525.3C; Valkonen VP, 2001, LANCET, V358, P2127, DOI 10.1016/S0140-6736(01)07184-7; Woo CH, 2005, AM J PHYSIOL-LUNG C, V288, pL307, DOI 10.1152/ajplung.00105.2004; Yoo JH, 2001, ATHEROSCLEROSIS, V158, P425, DOI 10.1016/S0021-9150(01)00444-0; Zhang L, 2004, J BIOL CHEM, V279, P28315, DOI 10.1074/jbc.C400115200; Zoccali C, 2001, LANCET, V358, P2113, DOI 10.1016/S0140-6736(01)07217-8	44	17	17	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					994	996		10.1096/fj.05-4087fje	http://dx.doi.org/10.1096/fj.05-4087fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16597674				2022-12-28	WOS:000240157700033
